PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Khan, D; Sharathchandra, A; Ponnuswamy, A; Grover, R; Das, S				Khan, D.; Sharathchandra, A.; Ponnuswamy, A.; Grover, R.; Das, S.			Effect of a natural mutation in the 5 ' untranslated region on the translational control of p53 mRNA	ONCOGENE			English	Article						p53 mRNA; translational control; SNP; IRES; PTB; internal initiation	CELL-CYCLE; ENTRY SITE; POLYMORPHISM; MECHANISM; BINDING; TP53; PTB	Tumor-suppressor protein p53, the 'guardian of the genome', is critical in maintaining cellular homeostasis and genomic stability. Earlier, we have reported the discovery of internal ribosome entry sites (IRESs) within the p53 mRNA that regulate the translation of the full length and its N-terminal-truncated isoform, Delta N-p53. Polypyrimidine tract-binding protein (PTB) is an IRES trans-acting factor that positively regulates the IRES activities of both p53 isoforms by relocating from nucleus to the cytoplasm during stress conditions. Here we have demonstrated the putative contact points of PTB on the p53 IRES RNA. Studies on mutations that occur naturally in the 5' untranslated region (5' UTR) in p53 mRNA were lacking. We have investigated a naturally occurring C-to-T single-nucleotide polymorphism (SNP) first reported in human melanoma tumors. This SNP is at position 119 in the 5' UTR of p53 mRNA and we demonstrate that it has consequences on the translational control of p53. Introduction of this SNP has led to decrease in cap-independent translation from p53 5' UTR in bicistronic reporter assay. Further, the effects of this SNP on cap-independent translation have been studied in the context of p53 cDNA as well. Interestingly, the 5' UTR with this SNP has shown reduced binding to PTB that can be corroborated to its weaker IRES activity. Previously, it has been shown that G2-M checkpoint, DNA-damaging stress and oncogenic insult favor IRES-mediated translation. Under similar conditions, we demonstrate that this SNP interferes with the enhancement of the IRES activity of the 5' UTR. Taken together, the results demonstrate for the first time that SNP in the 5' UTR of the p53 mRNA might have a role in translational control of this critical tumor-suppressor gene.	[Khan, D.; Sharathchandra, A.; Ponnuswamy, A.; Grover, R.; Das, S.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Das, S (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	sdas@mcbl.iisc.ernet.in		Khan, Debjit/0000-0001-5568-3361; Arandkar, Sharathchandra/0000-0001-6160-6338	CSIR, India; IFCPAR	CSIR, India(Council of Scientific & Industrial Research (CSIR) - India); IFCPAR	We are grateful to Professor Robin Fahraeus (INSERM, France) for sharing the pcDNA3-GFP-hp-p53-5' UTR-cDNA construct with us. Professor Julian Downward (London Research Institute, UK) and Professor Annapoorni Rangarajan (Department of Molecular Reproduction and Developmental Genetics, IISc) are duly acknowledged for sharing the pBabe-H-Ras<SUP>V12</SUP> construct and anti-Ras antibody. We thank Professor K Somasundaram for sharing the WWP-Luciferase construct and Professor KN Balaji for providing anti-caspase-3 antibody. We also thank the FACS facility (Division of Biological Sciences, IISc) headed by Dr Omana Joy for the acquisition of the flow-cytometric data. We thank the present and past SD Lab members for critical discussion of the work and Ranjitha Tatineni for her help with the phylogenetic analysis. DK and SA are supported by pre-doctoral fellowships from CSIR, India. This work was partly supported by an Indo-French grant from IFCPAR to SD.	ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; Bellodi C, 2010, CANCER RES, V70, P6026, DOI 10.1158/0008-5472.CAN-09-4730; Bhattacharyya Sankar, 2006, RNA Biol, V3, P60; Bourougaa K, 2010, MOL CELL, V38, P78, DOI 10.1016/j.molcel.2010.01.041; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Grover R, 2009, ONCOGENE, V28, P2766, DOI 10.1038/onc.2009.138; Grover R, 2008, CELL CYCLE, V7, P2189, DOI 10.4161/cc.7.14.6271; Grover R, 2011, RNA BIOL, V8, P132, DOI 10.4161/rna.8.1.14260; Hellman LM, 2007, NAT PROTOC, V2, P1849, DOI 10.1038/nprot.2007.249; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Lewis SM, 2007, MOL BIOL CELL, V18, P1302, DOI 10.1091/mbc.E06-06-0515; Li XX, 2005, J BIOL CHEM, V280, P24245, DOI 10.1074/jbc.M414637200; Lim YP, 2007, ONCOGENE, V26, P1517, DOI 10.1038/sj.onc.1209952; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Montanaro L, 2010, CANCER RES, V70, P4767, DOI 10.1158/0008-5472.CAN-09-4024; Pudi R, 2004, J BIOL CHEM, V279, P29879, DOI 10.1074/jbc.M403417200; Ray AJ, 2002, INFECT CONT HOSP EP, V23, P474, DOI 10.1086/502090; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Soto JL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-36; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Yang DQ, 2006, ONCOGENE, V25, P4613, DOI 10.1038/sj.onc.1209483	28	28	29	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4148	4159		10.1038/onc.2012.422	http://dx.doi.org/10.1038/onc.2012.422			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23027126				2022-12-28	WOS:000323748500010
J	Guan, D; Factor, D; Liu, Y; Wang, Z; Kao, HY				Guan, D.; Factor, D.; Liu, Yu; Wang, Z.; Kao, H-Y			The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein	ONCOGENE			English	Article						UHRF1; PML; ubiquitination; cell migration; capillary tube formation	HEMI-METHYLATED DNA; BREAST-CANCER; SRA DOMAIN; PML; LIGASE; RECOGNITION; GENE; ICBP90; ALPHA; ACETYLATION	The promyelocytic leukemia (PML) protein is a tumor suppressor originally identified in acute promyelocytic leukemia and implicated in tumorigenesis in multiple forms of cancer. Here, we demonstrate that the PML protein undergoes ubiquitination-mediated degradation facilitated by an E3 ligase UHRF1 (ubiquitin-like with PHD and RING finger domains 1), which is commonly upregulated in various human malignancies. Furthermore, UHRF1 negatively regulates PML protein accumulation in primary human umbilical vein endothelial cells (HUVECs), HEK 293 cells and cancer cells. Knockdown of UHRF1 upregulates whereas ectopic overexpression of UHRF1 downregulates protein abundance of endogenous or exogenous PML, doing so through its binding to the N-terminus of PML. Overexpression of wild-type UHRF1 shortens PML protein half-life and promotes PML polyubiquitination, whereas deletion of the RING domain or coexpression of the dominant-negative E2 ubiquitin-conjugating enzyme, E2D2, attenuates this modification to PML. Finally, knockdown of UHRF1 prolongs PML half-life and increases PML protein accumulation, yet inhibits cell migration and in vitro capillary tube formation, whereas co-knockdown of PML compromises this inhibitory effect. These findings suggest that UHRF1 promotes the turnover of PML protein, and thus targeting UHRF1 to restore PML-mediated tumor suppression represents a promising, novel, anticancer strategy.	[Guan, D.; Factor, D.; Liu, Yu; Kao, H-Y] Dept Biochem, Cleveland, OH 44106 USA; [Guan, D.; Factor, D.; Liu, Yu; Kao, H-Y] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Wang, Z.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; [Wang, Z.; Kao, H-Y] Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH USA; [Wang, Z.; Kao, H-Y] Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Kao, HY (corresponding author), Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxk43@cwru.edu		Factor, Daniel/0000-0002-3200-7560	NIH [R01 DK078965, HL093269]; Case Comprehensive Cancer Center Program in Aging and Energy Balance, NCI [P20 CA103767, CA127590];  [T32HD07104]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007104] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA127590, P50CA150964, P20CA103736] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093269] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062985, R01DK078965] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Case Comprehensive Cancer Center Program in Aging and Energy Balance, NCI; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr David Samols for his comments on the manuscript. D Factor is supported by training Grant T32HD07104. This project is supported by the NIH through R01 DK078965, HL093269 and Case Comprehensive Cancer Center Program in Aging and Energy Balance, NCI P20 CA103767 to H-Y Kao and CA127590 to Z Wang.	Alhosin M, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-41; Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Boutell C, 2005, J VIROL, V79, P12342, DOI 10.1128/JVI.79.19.12342-12354.2005; Canning M, 2004, J BIOL CHEM, V279, P38160, DOI 10.1074/jbc.M402885200; Cheng XW, 2012, J BIOL CHEM, V287, P23356, DOI 10.1074/jbc.M112.340505; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Daskalos A, 2010, CANCER, V117, P1027; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Felle M, 2011, NUCLEIC ACIDS RES, V39, P8355, DOI 10.1093/nar/gkr528; Gao CZ, 2008, MOL BIOL CELL, V19, P3020, DOI 10.1091/mbc.E07-11-1203; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hashimoto H, 2008, NATURE, V455, P826, DOI 10.1038/nature07280; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hu LL, 2011, CELL RES, V21, P1374, DOI 10.1038/cr.2011.124; Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878; Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jin W, 2010, BREAST CANCER RES TR, V123, P359, DOI 10.1007/s10549-009-0652-2; Khurana S, 2011, J BIOL CHEM, V286, P1850, DOI 10.1074/jbc.M110.162107; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li XL, 2011, INT J RADIAT BIOL, V87, P263, DOI 10.3109/09553002.2011.530335; Lim JH, 2011, J BIOL CHEM, V286, P44403, DOI 10.1074/jbc.M111.289512; Louria-Hayon I, 2009, CELL DEATH DIFFER, V16, P1156, DOI 10.1038/cdd.2009.31; Ma HH, 2012, P NATL ACAD SCI USA, V109, P4828, DOI 10.1073/pnas.1116349109; Nady N, 2011, J BIOL CHEM, V286, P24300, DOI 10.1074/jbc.M111.234104; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Rajakumara E, 2011, MOL CELL, V43, P275, DOI 10.1016/j.molcel.2011.07.006; Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07; Reineke EL, 2010, J BIOL CHEM, V285, P9485, DOI 10.1074/jbc.M109.063362; Reineke EL, 2009, INT J BIOL SCI, V5, P366; Sabatino L, 2012, ONCOGENE, V31, P5061, DOI 10.1038/onc.2012.3; Sarkari F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016598; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; TERRIS B, 1995, CANCER RES, V55, P1590; Un F, 2006, ANTICANCER RES, V26, P2761; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Unoki M, 2010, BRIT J CANCER, V103, P217, DOI 10.1038/sj.bjc.6605717; Unoki M, 2009, BRIT J CANCER, V101, P98, DOI 10.1038/sj.bjc.6605123; Unoki M, 2009, BIOCHEM PHARMACOL, V78, P1279, DOI 10.1016/j.bcp.2009.05.035; van Wijk SJL, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.55; Wang DY, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3017; Wang F, 2012, ANN SURG ONCOL, V19, P2753, DOI 10.1245/s10434-011-2194-1; Xie S, 2012, J MOL BIOL, V415, P318, DOI 10.1016/j.jmb.2011.11.012; Yan F, 2011, CANCER BIOTHER RADIO, V26, P183, DOI 10.1089/cbr.2010.0886; Yang GL, 2012, MED ONCOL, V29, P842, DOI 10.1007/s12032-011-9983-z; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008	53	48	52	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3819	3828		10.1038/onc.2012.406	http://dx.doi.org/10.1038/onc.2012.406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22945642	Green Accepted			2022-12-28	WOS:000323210200004
J	Villacorte, M; Suzuki, K; Hirasawa, A; Ohkawa, Y; Suyama, M; Maruyama, T; Aoki, D; Ogino, Y; Miyagawa, S; Terabayashi, T; Tomooka, Y; Nakagata, N; Yamada, G				Villacorte, M.; Suzuki, K.; Hirasawa, A.; Ohkawa, Y.; Suyama, M.; Maruyama, T.; Aoki, D.; Ogino, Y.; Miyagawa, S.; Terabayashi, T.; Tomooka, Y.; Nakagata, N.; Yamada, G.			beta-Catenin signaling regulates Foxa2 expression during endometrial hyperplasia formation	ONCOGENE			English	Article						uterine gland; Wnt/beta-catenin; Foxa2; cyclin; endometrial hyperplasia	CONDITIONAL LOSS; GENE-EXPRESSION; ALPHA-CATENIN; CANCER; UTERUS; MICE; MORPHOGENESIS; CARCINOMA; CYTODIFFERENTIATION; DIFFERENTIATION	The Wnt/beta-catenin signaling is essential for various organogenesis and is often implicated during tumorigenesis. Dysregulated beta-catenin signaling is associated with the formation of endometrial adenocarcinomas (EACs), which is considered as the common form of endometrial cancer in women. In the current study, we investigate the downstream target of Wnt/beta-catenin signaling in the uterine epithelia and the mechanism leading to the formation of endometrial hyperplasia. We report that conditional ablation and activation of beta-catenin in the uterine epithelia lead to aberrant epithelial structures and endometrial hyperplasia formation, respectively. We demonstrate that beta-catenin regulates Foxa2 with its candidate upstream region for the uterine epithelia. Furthermore, knockdown of Foxa2 leads to defects in cell cycle regulation, suggesting a possible function of Foxa2 in the control of cell proliferation. We also observe that beta-catenin and Foxa2 expression levels are augmented in the human specimens of complex atypical endometrial hyperplasia, which is considered to have a greater risk of progression to EACs. Thus, our study indicates that beta-catenin regulates Foxa2 expression, and this interaction is possibly essential to control cell cycle progression during endometrial hyperplasia formation. Altogether, the augmented expression levels of beta-catenin and Foxa2 are essential features during the formation of endometrial hyperplasia.	[Villacorte, M.; Suzuki, K.; Yamada, G.] Wakayama Med Univ, Dept Dev Genet, Inst Adv Med, Wakayama, Kansai 6418509, Japan; [Villacorte, M.; Suzuki, K.; Terabayashi, T.; Yamada, G.] Kumamoto Univ, Global COE Cell Fate Regulat Res & Educ Unit, Kumamoto, Japan; [Villacorte, M.; Suzuki, K.; Yamada, G.] Kumamoto Univ, Dept Organ Format, IMEG, Kumamoto, Japan; [Hirasawa, A.; Maruyama, T.; Aoki, D.] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo 160, Japan; [Ohkawa, Y.] Kyushu Univ, Fac Med, SSP Stem Cell Unit, Dept Epigenet,Inst Adv Study, Fukuoka 812, Japan; [Suyama, M.] Kyoto Univ, Dept Genome Informat, Ctr Genom Med, Grad Sch Med, Kyoto, Japan; [Ogino, Y.; Miyagawa, S.] Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi, Japan; [Tomooka, Y.] Tokyo Univ Sci, Dept Biol Sci & Technol, Chiba, Japan; [Tomooka, Y.] Tokyo Univ Sci, Tissue Engn Res Ctr, Chiba, Japan; [Nakagata, N.] Kumamoto Univ, CARD, Kumamoto, Japan	Wakayama Medical University; Kumamoto University; Kumamoto University; Keio University; Kyushu University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Tokyo University of Science; Tokyo University of Science; Kumamoto University	Yamada, G (corresponding author), Wakayama Med Univ, Dept Dev Genet, Inst Adv Med, 811-1 Kimiidera, Wakayama, Kansai 6418509, Japan.	gensan7@wakayama-med.ac.jp	Ohkawa, Yasuyuki/C-4087-2016; Tabelin, Mylah/AGG-4616-2022; Ohkawa, Yasuyuki/ABG-1839-2021; Aoki, Daisuke/E-6650-2014	Ohkawa, Yasuyuki/0000-0001-6440-9954; Tabelin, Mylah/0000-0002-6383-7049; Ohkawa, Yasuyuki/0000-0001-6440-9954; Terabayashi, Takeshi/0000-0001-7102-784X; Suyama, Mikita/0000-0001-9526-3193; Nakagata, Naomi/0000-0002-5737-9993	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [22132006]; National Institutes Health [R01ES016597-01A1]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016597] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [22132005, 23570085] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institutes Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs R Behringer, H Sasaki, M M Taketo, W Birchmeier, A Santin, R Nishinakamura, Y Yoshimura, T Kurita, N Shiraki, K Maehara, H Nishida-Fukuda, K Yoshinaga, MA Suico, S Ohta, A Murashima, L Liu, A Omori, M Harada and D Matsumaru for their constructive criticisms We also thank E Chun, Y Sakamoto, Y Yamakawa, T Seki, M Aoki, S Usuki, M Matsumuto, M Etoh, S Fujikawa, Y Endo, S Miyaji and T Iba for technical help. This work was supported by Grant-in-Aid for Scientific Research on Innovative Areas: molecular mechanisms for the establishment of Sex Differences (22132006), Global Center of Excellence program 'Cell Fate Regulation Research and Education Unit' and Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. This work was also supported by the National Institutes Health grant R01ES016597-01A1.	Armaiz-Pena GN, 2009, CLIN CANCER RES, V15, P2971, DOI 10.1158/1078-0432.CCR-08-2525; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERCHUCK A, 1995, CANCER, V76, P2034, DOI 10.1002/1097-0142(19951115)76:10+<2034::AID-CNCR2820761321>3.0.CO;2-U; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; CUNHA GR, 1976, INT REV CYTOL, V47, P137, DOI 10.1016/S0074-7696(08)60088-1; CUNHA GR, 1976, J EXP ZOOL, V196, P361, DOI 10.1002/jez.1401960310; Daikoku T, 2008, NAT MED, V14, P1192, DOI 10.1038/nm1108-1192; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Daikoku T, 2011, GYNECOL ONCOL, V122, P424, DOI 10.1016/j.ygyno.2011.04.022; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963; Fyles A, 2008, GYNECOL ONCOL, V108, P395, DOI 10.1016/j.ygyno.2007.10.033; Giannini A, 2004, EXP CELL RES, V295, P150, DOI 10.1016/j.yexcr.2003.12.012; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; Guzzo F, 2012, INT J GYNECOL PATHOL, V31, P211, DOI 10.1097/PGP.0b013e31823bb24d; Hanazono R, 1997, IN VITRO CELL DEV-AN, V33, P668; Hayashi K, 2006, BIOL REPROD, V74, P721, DOI 10.1095/biolreprod.105.049718; Huang WW, 2005, MOL ENDOCRINOL, V19, P669, DOI 10.1210/me.2004-0155; Jeong JW, 2009, ONCOGENE, V28, P31, DOI 10.1038/onc.2008.363; Jeong JW, 2010, BIOL REPROD, V83, P396, DOI 10.1095/biolreprod.109.083154; Kaestner KH, 2010, CURR OPIN GENET DEV, V20, P527, DOI 10.1016/j.gde.2010.06.005; Kawano Y, 2006, ONCOGENE, V25, P6528, DOI 10.1038/sj.onc.1209661; Kobayashi A, 2003, NAT REV GENET, V4, P969, DOI 10.1038/nrg1225; Kurita T, 2001, DEV BIOL, V240, P194, DOI 10.1006/dbio.2001.0458; Matias-Guiu X, 2001, HUM PATHOL, V32, P569, DOI 10.1053/hupa.2001.25929; Mo B, 2006, BIOL REPROD, V75, P387, DOI 10.1095/biolreprod.106.051870; Nei H, 1999, MOL CARCINOGEN, V25, P207, DOI 10.1002/(SICI)1098-2744(199907)25:3<207::AID-MC7>3.3.CO;2-W; Ojalvo LS, 2010, J IMMUNOL, V184, P702, DOI 10.4049/jimmunol.0902360; Perantoni AO, 2003, SEMIN CELL DEV BIOL, V14, P201, DOI 10.1016/S1084-9521(03)00022-3; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Sasaki H, 1996, GENES CELLS, V1, P59, DOI 10.1046/j.1365-2443.1996.04004.x; Scholten AN, 2003, J PATHOL, V201, P460, DOI 10.1002/path.1402; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Silverberg SG, 1999, ARCH PATHOL LAB MED, V123, P1035; Suzuki K, 2009, DEVELOPMENT, V136, P367, DOI 10.1242/dev.021295; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Wang YY, 2009, CLIN CANCER RES, V15, P5784, DOI 10.1158/1078-0432.CCR-09-0814; Williamson EA, 2006, ONCOGENE, V25, P1391, DOI 10.1038/sj.onc.1209170; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Yue XA, 2010, BRAIN RES, V1366, P27, DOI 10.1016/j.brainres.2010.10.032; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	42	39	40	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2013	32	29					3477	3482		10.1038/onc.2012.376	http://dx.doi.org/10.1038/onc.2012.376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22945641				2022-12-28	WOS:000322014900009
J	Rebocho, AP; Marais, R				Rebocho, A. P.; Marais, R.			ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers	ONCOGENE			English	Article						ARAF; BRAF; CRAF; protein complexes; paradoxical activation	B-RAF; C-RAF; HUMAN CANCER; WILD-TYPE; KINASE-ACTIVITY; ONCOGENIC RAS; MUTATIONS; MELANOMA; PHOSPHORYLATION; ACTIVATION	The RAF proteins are cytosolic protein kinases that regulate cell responses to extracellular signals. There are three RAF proteins in cells, ARAF, BRAF and CRAF, and recent studies have shown that the formation of complexes by these different isoforms has an important role in their activation, particularly in response to RAF inhibitors. Here, we investigated the role of ARAF in cancer cell signaling and examined the role of ARAF in mediating paradoxical activation of the MAPK pathway in cells treated with RAF inhibitors. We show that two mutations that occur in ARAF in cancer inactivate the kinase. We also show that ARAF is not functionally redundant with CRAF and cannot substitute for CRAF downstream of RAS. We further show that ARAF binds to and is activated by BRAF and that ARAF also forms complexes with CRAF. Critically, ARAF seems to stabilize BRAF: CRAF complexes in cells treated with RAF inhibitors and thereby regulate cell signaling in a subtle manner to ensure signaling efficiency.	[Rebocho, A. P.; Marais, R.] Inst Canc Res, Div Canc Biol, Signal Transduct Team, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marais, R (corresponding author), Univ Manchester, Paterson Inst Canc Res, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	Richard.Marais@picr.man.ac.uk		Marais, Richard/0000-0001-7484-4183	Fundacao para a Ciencia e Tecnologia [SFRH/BD/15904/2005]; Institute of Cancer Research; Cancer Research UK [C107/A10433]; Cancer Research UK [17240, 19279] Funding Source: researchfish	Fundacao para a Ciencia e Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Institute of Cancer Research; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	This work was funded by Fundacao para a Ciencia e Tecnologia (SFRH/BD/15904/2005), the Institute of Cancer Research and Cancer Research UK (Ref: C107/A10433). We thank Professor Caroline Springer for providing sorafenib and PD184352.	Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hu JC, 2011, P NATL ACAD SCI USA, V108, P6067, DOI 10.1073/pnas.1102554108; Karreth FA, 2011, CANCER DISCOV, V1, P128, DOI 10.1158/2159-8290.CD-10-0044; Lee JW, 2005, APMIS, V113, P54, DOI 10.1111/j.1600-0463.2005.apm1130108.x; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; McKay MM, 2011, CURR BIOL, V21, P563, DOI 10.1016/j.cub.2011.02.033; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Moretti S, 2009, BBA-MOL CELL RES, V1793, P1634, DOI 10.1016/j.bbamcr.2009.09.001; Packer LM, 2011, CANCER CELL, V20, P715, DOI 10.1016/j.ccr.2011.11.004; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	28	47	48	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3207	3212		10.1038/onc.2012.330	http://dx.doi.org/10.1038/onc.2012.330			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22926515				2022-12-28	WOS:000321004600011
J	Takahashi, R; Giannini, C; Sarkaria, JN; Schroeder, M; Rogers, J; Mastroeni, D; Scrable, H				Takahashi, R.; Giannini, C.; Sarkaria, J. N.; Schroeder, M.; Rogers, J.; Mastroeni, D.; Scrable, H.			p53 isoform profiling in glioblastoma and injured brain	ONCOGENE			English	Article						gliosis; regeneration; astrocytoma	NEURAL STEM-CELLS; ADULT MAMMALIAN BRAIN; HUMAN CANCERS; SPINAL-CORD; MUTANT P53; EXPRESSION; ASTROCYTES; TUMORS; ZONE; GENE	The tumor suppressor p53 has been found to be the most commonly mutated gene in human cancers; however, the frequency of p53 mutations varies from 10 to 70% across different cancer types. This variability can partly be explained by inactivating mechanisms aside from direct genomic polymorphisms. The p53 gene encodes 12 isoforms, some of which can modulate full-length p53 activity in cancer. In this study, we characterized p53 isoform expression patterns in glioblastoma, gliosis, non-tumor brain and neural progenitor cells by SDS-PAGE, immunoblot, mass spectrometry and reverse transcription-PCR. We found that the most consistently expressed isoform in glioblastoma, Delta 40p53, was uniquely expressed in regenerative processes, such as those involving neural progenitor cells and gliosis compared with tumor samples. Isoform profiling of glioblastoma tissues revealed the presence of both Delta 40p53 and full-length p53, neither of which were detected in non-tumor cerebral cortex. Upon xenograft propagation of tumors, p53 levels increased. The variability of overall p53 expression and relative levels of isoforms suggest fluctuations in subpopulations of cells with greater or lesser capacity for proliferation, which can change as the tumor evolves under different growth conditions.	[Takahashi, R.] Mayo Clin, Med Scientist Training Program, Rochester, MN 55905 USA; [Takahashi, R.; Scrable, H.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Giannini, C.] Mayo Clin, Dept Lab Med & Pathol, Div Anat Pathol, Rochester, MN 55905 USA; [Sarkaria, J. N.; Schroeder, M.] Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA; [Rogers, J.; Mastroeni, D.] Banner Sun Hlth Res Inst, Sun City, AZ USA; [Scrable, H.] Mayo Clin, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; [Scrable, H.] Mayo Clin, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Banner Research; Banner Health; Banner Sun Health Research Institute; Mayo Clinic; Mayo Clinic	Scrable, H (corresponding author), Mayo Clin, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	Scrable.Heidi@mayo.edu	Giannini, Caterina/AAB-7551-2022		PHS [R01AG026094]; Ellison Medical Research Foundation; NCI Cancer Center support grant; Robert and Arlene Kogod Center on Aging at Mayo Clinic; Mayo Brain Tumors SPORE; Mayo Clinic Medical Scientist Training Program; NATIONAL INSTITUTE ON AGING [R01AG026094] Funding Source: NIH RePORTER	PHS(United States Department of Health & Human ServicesUnited States Public Health Service); Ellison Medical Research Foundation(Lawrence Ellison Foundation); NCI Cancer Center support grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Robert and Arlene Kogod Center on Aging at Mayo Clinic; Mayo Brain Tumors SPORE; Mayo Clinic Medical Scientist Training Program; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We would like to thank our Mayo Clinic colleagues for their contributions, in particular, Dr Robert Jenkins for seminal discussions on the etiology of GBM and xenograft biology; Alissa Caron for preparing GBM patient tumor specimens; Dr John Black for CTX samples; Guido Gonzalez for obtaining LNZ308 cells; and Benjamin Madden and the Mayo Clinic Protein Chemistry and Proteomics Shared Resource core for mass spectrometry analysis. We are grateful to past and current members of the Scrable lab for their enduring enthusiasm and abilities, in particular Dr Erica Ungewitter for her invaluable help with p53 antibodies and the work she did as a graduate student that laid the foundation for subsequent studies on p53 in ESCs, and Dr Silvia Medrano, for passing on her expertise with mouse NSC culture and the role of p53 in adult stem cells. This work was supported by PHS award R01AG026094 and a Senior Scholar in Aging award from the Ellison Medical Research Foundation to HS Additional support came from an NCI Cancer Center support grant to the Mayo Clinic Cancer Center, the Robert and Arlene Kogod Center on Aging at Mayo Clinic, the Mayo Brain Tumors SPORE, and the Mayo Clinic Medical Scientist Training Program (RT).	Anensen N, 2006, CLIN CANCER RES, V12, P3985, DOI 10.1158/1078-0432.CCR-05-1970; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butler T, 2010, BLOOD REV, V24, P135, DOI 10.1016/j.blre.2010.03.004; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Carlson BL, 2011, CURR PROTOC PHARM, V52, P1; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Doetsch F, 1997, J NEUROSCI, V17, P5046; GARD AL, 1990, NEURON, V5, P615, DOI 10.1016/0896-6273(90)90216-3; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Globus J.H., 1944, J NEUROPATH EXP NEUR, V3, P1; Globus JH, 1942, ARCH PATHOL, V34, P674; Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784; GRITTI A, 2001, PROTOCOLS NEURAL CEL; Grover R, 2009, ONCOGENE, V28, P2766, DOI 10.1038/onc.2009.138; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Imura T, 2006, GLIA, V53, P277, DOI 10.1002/glia.20281; Imura T, 2003, J NEUROSCI, V23, P2824; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Khoury MP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000927; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Lang B, 2004, NEUROSCIENCE, V128, P775, DOI 10.1016/j.neuroscience.2004.06.033; Laywell ED, 1999, EXP NEUROL, V156, P430, DOI 10.1006/exnr.1999.7029; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Leonard BW, 2009, J COMP NEUROL, V515, P269, DOI 10.1002/cne.22040; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li W, 2006, PATHOLOGY, V38, P287, DOI 10.1080/00313020600817951; Machado-Silva A, 2010, SEMIN CANCER BIOL, V20, P57, DOI 10.1016/j.semcancer.2010.02.005; Marcel V, 2010, FEBS LETT, V584, P4463, DOI 10.1016/j.febslet.2010.10.005; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; Medrano S, 2009, NEUROBIOL AGING, V30, P483, DOI 10.1016/j.neurobiolaging.2007.07.016; Mills AA, 2005, GENE DEV, V19, P2091, DOI 10.1101/gad.1362905; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Philipova T, 2011, INT J ONCOL, V38, P843, DOI 10.3892/ijo.2010.884; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Robles AI, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001016; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sasaki T, 2006, AGING CELL, V5, P413, DOI 10.1111/j.1474-9726.2006.00235.x; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Ungewitter E, 2010, GENE DEV, V24, P2408, DOI 10.1101/gad.1987810; VAN MEIR EG, 1994, CANCER RES, V54, P649; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801	59	27	29	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3165	3174		10.1038/onc.2012.322	http://dx.doi.org/10.1038/onc.2012.322			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22824800	Green Accepted			2022-12-28	WOS:000321004600007
J	Vainchenker, W; Constantinescu, SN				Vainchenker, W.; Constantinescu, S. N.			JAK/STAT signaling in hematological malignancies	ONCOGENE			English	Review						JAK/STAT; hematological malignancies; leukemia	ERYTHROPOIETIN RECEPTOR ACTIVATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACQUIRED UNIPARENTAL DISOMY; CLASSICAL HODGKIN LYMPHOMA; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; OF-FUNCTION MUTATIONS; SOCS FAMILY-MEMBERS; THROMBOPOIETIN RECEPTOR; MYELOPROLIFERATIVE NEOPLASMS	The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Many of those receptors transmit anti-apoptotic, proliferative and differentiation signals, and their expression and functions are critical for the formation of blood lineages. Several cancers, including blood malignancies, have been associated with constitutive activation of members of the STAT family, which normally require JAK-mediated tyrosine phosphorylation for transcriptional activation. More recently, human myeloproliferative neoplasms were discovered to be associated with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2. Prompted by these observations, many studies have explored the possibility that JAKs, cytokine receptors, or other components of the JAK/STAT pathway are mutated or upregulated in several hematological malignancies. This has been observed in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma. Here we discuss the nature and respective contribution of mutations dysregulating the JAK/STAT pathway in hematological malignancies and present examples in which such mutations drive the disease, contribute to the phenotype, or provide a survival and proliferative advantage. JAK inhibitors are making their way into the therapeutic arsenal (for example, in myelofibrosis), and we discuss the possibility that other hematological diseases might benefit from treatment with these inhibitors in combination with other agents.	[Vainchenker, W.] INSERM, UMR Hematopoiese Normale & Pathol 1009, Villejuif, France; [Vainchenker, W.] Inst Gustave Roussy, UMR 1009, Villejuif, France; [Vainchenker, W.] Univ Paris Sud, UMR 1009, Villejuif, France; [Constantinescu, S. N.] Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium; [Constantinescu, S. N.] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Ludwig Institute for Cancer Research; Universite Catholique Louvain	Vainchenker, W (corresponding author), Inst Gustave Roussy PR 1, INSERM, UMR Hematopoiese Normale & Pathol 1009, 114 Rue Edouart Vaillant, F-94805 Villejuif, France.	verpre@igr.fr; stefan.constantinescu@bru.licr.org		Constantinescu, Stefan N./0000-0002-8599-2699; Vainchenker, William/0000-0003-4705-202X	Novartis Pharmaceuticals	Novartis Pharmaceuticals(Novartis)	Financial support for medical editorial and graphic design assistance was provided by Novartis Pharmaceuticals. We thank Matthew Hoelzle PhD, Daniel Hutta, PhD and Isabelle Plo PhD for their assistance with this manuscript.	Adelaide J, 2006, LEUKEMIA, V20, P536, DOI 10.1038/sj.leu.2404104; Akada H, 2010, BLOOD, V115, P3589, DOI 10.1182/blood-2009-04-215848; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Argetsinger LS, 2004, MOL CELL BIOL, V24, P4955, DOI 10.1128/MCB.24.11.4955-4967.2004; Bacher U, 2010, ANN HEMATOL, V89, P643, DOI 10.1007/s00277-010-0920-6; Baus D, 2009, LEUKEMIA, V23, P1885, DOI 10.1038/leu.2009.103; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Beekman R, 2012, BLOOD, V119, P5071, DOI 10.1182/blood-2012-01-406116; Beekman R, 2010, BLOOD, V115, P5131, DOI 10.1182/blood-2010-01-234120; Beer PA, 2008, BLOOD, V112, P141, DOI 10.1182/blood-2008-01-131664; Bersenev A, 2010, J CLIN INVEST, V120, P2058, DOI 10.1172/JCI42032; Besancenot R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000476; Bommert K, 2006, EUR J CANCER, V42, P1574, DOI 10.1016/j.ejca.2005.12.026; Boyd EM, 2010, BRIT J HAEMATOL, V149, P250, DOI 10.1111/j.1365-2141.2010.08083.x; Braggio E, 2010, INT J HEMATOL, V91, P87, DOI 10.1007/s12185-009-0459-2; Brender C, 2005, LEUKEMIA, V19, P209, DOI 10.1038/sj.leu.2403610; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brown RJ, 2005, NAT STRUCT MOL BIOL, V12, P814, DOI 10.1038/nsmb977; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cain JA, 2007, BLOOD, V109, P3906, DOI 10.1182/blood-2006-07-036335; Calabrese V, 2009, MOL CELL, V36, P754, DOI 10.1016/j.molcel.2009.09.044; Carbuccia N, 2009, LEUKEMIA, V23, P2183, DOI 10.1038/leu.2009.141; Chaligne R, 2008, LEUKEMIA, V22, P1557, DOI 10.1038/leu.2008.137; Chaligne R, 2009, LEUKEMIA, V23, P1186, DOI 10.1038/leu.2009.22; Chen E, 2010, CANCER CELL, V18, P524, DOI 10.1016/j.ccr.2010.10.013; Chen IM, 2012, BLOOD, V119, P3512, DOI 10.1182/blood-2011-11-394221; Chim CS, 2008, CLIN LYMPHOMA MYELOM, V8, P331, DOI 10.3816/CLM.2008.n.048; Choudhary C, 2005, INT J HEMATOL, V82, P93, DOI 10.1532/IJH97.05090; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Cirmena G, 2008, CANCER GENET CYTOGEN, V183, P105, DOI 10.1016/j.cancergencyto.2008.02.005; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; de Graaf CA, 2010, P NATL ACAD SCI USA, V107, P21689, DOI 10.1073/pnas.1016166108; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; Deshpande A, 2012, LEUKEMIA, V26, P708, DOI 10.1038/leu.2011.255; Ding F, 2004, BLOOD, V103, P4198, DOI 10.1182/blood-2003-10-3471; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Dupont S, 2007, BLOOD, V110, P1013, DOI 10.1182/blood-2006-10-054940; Dusa A, 2008, J BIOL CHEM, V283, P12941, DOI 10.1074/jbc.M709302200; Dusa A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011157; Elliott J, 2009, HAEMATOL-HEMATOL J, V94, P576, DOI 10.3324/haematol.2008.002352; Elliott NE, 2011, BLOOD, V118, P3911, DOI 10.1182/blood-2010-12-319467; Feener EP, 2004, MOL CELL BIOL, V24, P4968, DOI 10.1128/MCB.24.11.4968-4978.2004; Flex E, 2008, J EXP MED, V205, P751, DOI 10.1084/jem.20072182; Forbes LV, 2002, ONCOGENE, V21, P5981, DOI 10.1038/sj.onc.1205767; Gaikwad A, 2009, BRIT J HAEMATOL, V144, P930, DOI 10.1111/j.1365-2141.2008.07552.x; Garcon L, 2006, BLOOD, V108, P1551, DOI 10.1182/blood-2005-10-009514; Ghoreschi K, 2009, IMMUNOL REV, V228, P273, DOI 10.1111/j.1600-065X.2008.00754.x; Girardot M, 2010, BLOOD, V116, P437, DOI 10.1182/blood-2008-06-165985; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Grand FH, 2009, BLOOD, V113, P6182, DOI 10.1182/blood-2008-12-194548; Gross AW, 2006, J BIOL CHEM, V281, P2024, DOI 10.1074/jbc.M510493200; Guglielmelli P, 2011, BLOOD, V118, P5227, DOI 10.1182/blood-2011-06-363424; Guglielmelli P, 2011, BLOOD, V118, P2069, DOI 10.1182/blood-2011-01-330563; Haan C, 2011, CHEM BIOL, V18, P314, DOI 10.1016/j.chembiol.2011.01.012; Hantschel O, 2012, NAT CHEM BIOL, V8, P285, DOI [10.1038/NCHEMBIO.775, 10.1038/nchembio.775]; Harashima A, 2002, BLOOD, V100, P4440, DOI 10.1182/blood-2002-03-0864; Harrison C, 2012, BRIT J HAEMATOL, V157, P426, DOI 10.1111/j.1365-2141.2012.09108.x; Harrison C, 2012, NEW ENGL J MED, V366, P787, DOI 10.1056/NEJMoa1110556; Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908; Hertzberg L, 2010, BLOOD, V115, P1006, DOI 10.1182/blood-2009-08-235408; Hitchcock IS, 2008, BLOOD, V112, P2222, DOI 10.1182/blood-2008-01-134049; Hookham MB, 2007, BLOOD, V109, P4924, DOI 10.1182/blood-2006-08-039735; Hornakova T, 2011, HAEMATOL-HEMATOL J, V96, P845, DOI 10.3324/haematol.2010.036350; Hornakova T, 2009, J BIOL CHEM, V284, P6773, DOI 10.1074/jbc.M807531200; Hortner M, 2002, EUR J BIOCHEM, V269, P2516, DOI 10.1046/j.1432-1033.2002.02916.x; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Hussein K, 2009, LEUKEMIA, V23, P852, DOI 10.1038/leu.2008.371; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Irandoust MI, 2007, EMBO J, V26, P1782, DOI 10.1038/sj.emboj.7601640; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Ishida-Takahashi R, 2006, MOL CELL BIOL, V26, P4063, DOI 10.1128/MCB.01589-05; Ishikawa H, 2003, LEUKEMIA LYMPHOMA, V44, P1477, DOI 10.1080/1042819031000097339; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jegalian AG, 2002, J INTERF CYTOK RES, V22, P853, DOI 10.1089/107999002760274863; Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839; Jones AV, 2009, NAT GENET, V41, P446, DOI 10.1038/ng.334; Jost E, 2007, LEUKEMIA, V21, P505, DOI 10.1038/sj.leu.2404513; Kales SC, 2010, CANCER RES, V70, P4789, DOI 10.1158/0008-5472.CAN-10-0610; Kameda T, 2010, INT J HEMATOL, V92, P320, DOI 10.1007/s12185-010-0653-2; Kaminker JS, 2007, CANCER RES, V67, P465, DOI 10.1158/0008-5472.CAN-06-1736; Kanade SR, 2012, J BIOL CHEM, V287, P7313, DOI 10.1074/jbc.M111.331660; Kearney L, 2009, BLOOD, V113, P646, DOI 10.1182/blood-2008-08-170928; Kennedy JA, 2006, P NATL ACAD SCI USA, V103, P16930, DOI 10.1073/pnas.0604902103; Kilpivaara O, 2009, NAT GENET, V41, P455, DOI 10.1038/ng.342; Klampfl T, 2011, BLOOD, V118, P167, DOI 10.1182/blood-2011-01-331678; Kleppe M, 2011, HAEMATOL-HEMATOL J, V96, P1723, DOI 10.3324/haematol.2011.041921; Kleppe M, 2011, BLOOD, V117, P7090, DOI 10.1182/blood-2010-10-314286; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Knoops L, 2008, ONCOGENE, V27, P1511, DOI 10.1038/sj.onc.1210800; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kralovics R, 2002, EXP HEMATOL, V30, P229, DOI 10.1016/S0301-472X(01)00789-5; Krebs DL, 2000, J CELL SCI, V113, P2813; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lasho T, 2010, LEUKEMIA, V24, P1378, DOI 10.1038/leu.2010.109; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LEVY Y, 1991, J CLIN INVEST, V88, P696, DOI 10.1172/JCI115355; Li JA, 2010, BLOOD, V116, P1528, DOI 10.1182/blood-2009-12-259747; Li J, 2010, NEOPLASIA, V12, P28, DOI 10.1593/neo.91192; Liao W, 2011, CURR OPIN IMMUNOL, V23, P598, DOI 10.1016/j.coi.2011.08.003; Liu F, 2011, CANCER CELL, V19, P283, DOI 10.1016/j.ccr.2010.12.020; Liu X, 2011, J SIGNAL TRANSDUCT, V2011, DOI DOI 10.1155/2011/195239; LONGMORE G, 1993, LEUKEMIA, V7, pS113; Lu M, 2010, BLOOD, V116, P4284, DOI 10.1182/blood-2010-04-279125; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Lu XH, 2008, J BIOL CHEM, V283, P5258, DOI 10.1074/jbc.M707125200; Ma WL, 2009, J MOL DIAGN, V11, P49, DOI 10.2353/jmoldx.2009.080114; Malcovati L, 2009, BLOOD, V114, P3538, DOI 10.1182/blood-2009-05-222331; Malinge S, 2008, BLOOD, V112, P4220, DOI 10.1182/blood-2008-01-136366; Malinge S, 2007, BLOOD, V109, P2202, DOI 10.1182/blood-2006-09-045963; Marijanovic Z, 2006, BIOCHEM J, V397, P31, DOI 10.1042/BJ20060272; Marty C, 2010, BLOOD, V116, P783, DOI 10.1182/blood-2009-12-257063; Marubayashi S, 2010, J CLIN INVEST, V120, P3578, DOI 10.1172/JCI42442; Mead AJ, 2012, NEW ENGL J MED, V366, P967, DOI 10.1056/NEJMc1200349; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Moucadel V, 2005, J BIOL CHEM, V280, P13364, DOI 10.1074/jbc.M407326200; Mullally A, 2010, CANCER CELL, V17, P584, DOI 10.1016/j.ccr.2010.05.015; Mullighan CG, 2011, CLIN CANCER RES, V17, P396, DOI 10.1158/1078-0432.CCR-10-1203; Mullighan CG, 2009, NAT GENET, V41, P1243, DOI 10.1038/ng.469; Mullighan CG, 2009, P NATL ACAD SCI USA, V106, P9414, DOI 10.1073/pnas.0811761106; Murati A, 2005, LEUKEMIA, V19, P1692, DOI 10.1038/sj.leu.2403879; Nault JC, 2012, J HEPATOL, V56, P184, DOI 10.1016/j.jhep.2011.07.018; Navarro A, 2009, BLOOD, V114, P2945, DOI 10.1182/blood-2009-02-204842; Nebral K, 2009, LEUKEMIA, V23, P134, DOI 10.1038/leu.2008.306; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; Nguyen MHH, 2001, J BIOL CHEM, V276, P32704, DOI 10.1074/jbc.M103100200; Oh ST, 2010, BLOOD, V116, P988, DOI 10.1182/blood-2010-02-270108; Olcaydu D, 2009, NAT GENET, V41, P450, DOI 10.1038/ng.341; Ozawa Y, 2008, LEUKEMIA RES, V32, P893, DOI 10.1016/j.leukres.2007.11.032; Palvimo JJ, 2007, BIOCHEM SOC T, V35, P1405, DOI 10.1042/BST0351405; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Pardanani A, 2010, LEUKEMIA, V24, P1713, DOI 10.1038/leu.2010.163; Pardanani A, 2011, J CLIN ONCOL, V29, P789, DOI 10.1200/JCO.2010.32.8021; Pardanani AD, 2006, BLOOD, V108, P3472, DOI 10.1182/blood-2006-04-018879; Passamonti F, 2011, BLOOD, V117, P2813, DOI 10.1182/blood-2010-11-316810; Pecquet C, 2012, BLOOD, V119, P4625, DOI 10.1182/blood-2011-08-372524; Pecquet C, 2010, BLOOD, V115, P1037, DOI 10.1182/blood-2008-10-183558; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Plo I, 2009, J EXP MED, V206, P1701, DOI 10.1084/jem.20090693; Poitras JL, 2008, GENE CHROMOSOME CANC, V47, P884, DOI 10.1002/gcc.20585; Porcu M, 2012, BLOOD, V119, P4476, DOI 10.1182/blood-2011-09-379958; Qian H, 2007, CELL STEM CELL, V1, P671, DOI 10.1016/j.stem.2007.10.008; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Ramakrishnan V, 2010, AM J HEMATOL, V85, P675, DOI 10.1002/ajh.21785; Rambaldi A, 2010, BRIT J HAEMATOL, V150, P446, DOI 10.1111/j.1365-2141.2010.08266.x; Reddy J, 2005, ONCOGENE, V24, P732, DOI 10.1038/sj.onc.1208032; Reiter A, 2005, CANCER RES, V65, P2662, DOI 10.1158/0008-5472.CAN-04-4263; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Riera L, 2011, LEUKEMIA LYMPHOMA, V52, P1742, DOI 10.3109/10428194.2011.574757; Ritz O, 2009, BLOOD, V114, P1236, DOI 10.1182/blood-2009-03-209759; Royer Y, 2005, J BIOL CHEM, V280, P27251, DOI 10.1074/jbc.M501376200; Rudd C E, 2001, Sci STKE, V2001, ppe1; Russell LJ, 2009, BLOOD, V114, P2688, DOI 10.1182/blood-2009-03-208397; Santos FPS, 2010, BLOOD, V115, P1131, DOI 10.1182/blood-2009-10-246363; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Saur SJ, 2010, BLOOD, V115, P1254, DOI 10.1182/blood-2009-06-227033; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Scott LM, 2006, BLOOD, V108, P2435, DOI 10.1182/blood-2006-04-018259; Scuto A, 2011, LEUKEMIA, V25, P538, DOI 10.1038/leu.2010.289; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Shochat C, 2011, J EXP MED, V208, P901, DOI 10.1084/jem.20110580; Staerk J, 2005, J BIOL CHEM, V280, P41893, DOI 10.1074/jbc.C500358200; Staerk J, 2006, BLOOD, V107, P1864, DOI 10.1182/blood-2005-06-2600; Sternberg DW, 2004, J CLIN ONCOL, V22, P361, DOI 10.1200/JCO.2004.10.124; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Tefferi Ayalew, 2006, Hematology Am Soc Hematol Educ Program, P240; Tefferi A, 2012, BLOOD, V119, P2721, DOI 10.1182/blood-2011-11-395228; Tefferi A, 2012, NEW ENGL J MED, V366, P844, DOI 10.1056/NEJMe1115119; Teofili L, 2008, INT J CANCER, V123, P1586, DOI 10.1002/ijc.23694; Teofili L, 2007, BLOOD, V110, P354, DOI 10.1182/blood-2007-01-069237; Thomas C, 2011, CELL, V146, P621, DOI 10.1016/j.cell.2011.06.048; Tiedt R, 2008, BLOOD, V111, P3931, DOI 10.1182/blood-2007-08-107748; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Tomasson MH, 2008, BLOOD, V111, P4797, DOI 10.1182/blood-2007-09-113027; Tong W, 2004, J EXP MED, V200, P569, DOI 10.1084/jem.20040762; Touw IP, 2007, FRONT BIOSCI-LANDMRK, V12, P800, DOI 10.2741/2103; Ugo V, 2004, EXP HEMATOL, V32, P179, DOI 10.1016/j.exphem.2003.11.003; Ungureanu D, 2011, NAT STRUCT MOL BIOL, V18, P971, DOI 10.1038/nsmb.2099; Vainchenker W, 2008, SEMIN CELL DEV BIOL, V19, P385, DOI 10.1016/j.semcdb.2008.07.002; van de Geijn GJM, 2004, BLOOD, V104, P667, DOI 10.1182/blood-2003-08-2913; Van Roosbroeck K, 2011, BLOOD, V117, P4056, DOI 10.1182/blood-2010-06-291310; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557; Verstovsek S, 2011, J CLIN ONCOL, V29, P781, DOI 10.1200/JCO.2010.33.4508; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182/blood-2011-12-397554; Wang Q, 2000, BLOOD, V96, P2093; Warsch W, 2011, BLOOD, V117, P3409, DOI 10.1182/blood-2009-10-248211; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; WeberNordt RM, 1996, BLOOD, V88, P809; Weigert O, 2012, J EXP MED, V209, P259, DOI 10.1084/jem.20111694; Weniger MA, 2006, ONCOGENE, V25, P2679, DOI 10.1038/sj.onc.1209151; Wernig G, 2008, BLOOD, V111, P3751, DOI 10.1182/blood-2007-07-102186; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wrighton KH, 2011, NAT REV MOL CELL BIO, V12, P689, DOI 10.1038/nrm3213; Xia Z, 1998, CANCER RES, V58, P3173; Xiang ZF, 2008, BLOOD, V111, P4809, DOI 10.1182/blood-2007-05-090308; Yan DQ, 2012, BLOOD, V119, P3539, DOI 10.1182/blood-2011-03-345215; Yao ZJ, 2006, P NATL ACAD SCI USA, V103, P1000, DOI 10.1073/pnas.0507350103; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Yoshihara H, 2007, CELL STEM CELL, V1, P685, DOI 10.1016/j.stem.2007.10.020; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhou S, 2008, J BIOL CHEM, V283, P20137, DOI 10.1074/jbc.M801307200	222	345	368	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2601	2613		10.1038/onc.2012.347	http://dx.doi.org/10.1038/onc.2012.347			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22869151				2022-12-28	WOS:000319806700001
J	Al-Ansari, MM; Hendrayani, SF; Shehata, AI; Aboussekhra, A				Al-Ansari, M. M.; Hendrayani, S. F.; Shehata, A. I.; Aboussekhra, A.			p16(INK4A) Represses the paracrine tumor-promoting effects of breast stromal fibroblasts	ONCOGENE			English	Article						AUF1; breast cancer; cell nonautonomous tumor suppression; p16(INK4A); stromal fibroblasts	GENE-EXPRESSION; MOLECULAR CHARACTERIZATION; CANCER; SUPPRESSOR; MICROENVIRONMENT; CARCINOMAS; P21(WAF1/CIP1); INHIBITION; INDUCTION; INVASION	Cancer-associated fibroblasts (CAFs), the most abundant and probably the most active cellular component of breast cancer-associated stroma, promote carcinogenesis through paracrine effects; however, the molecular basis remains elusive. We have shown here that p16(INK4A) expression is reduced in 83% CAFs as compared with their normal adjacent counterparts cancer-free tissues isolated from the same patients. This decrease is mainly due to AUF1-dependent higher turnover of the CDKN2A mRNA in CAFs. Importantly, p16(INK4A) downregulation using specific siRNA activated breast fibroblasts and increased the expression/secretion levels of stromal cell-derived factor 1 (SDF-1) and matrix metalloproteinase (MMP)-2. Consequently, media conditioned with these cells stimulated the proliferation of epithelial cells. Furthermore, the migration/invasion of breast cancer cells was also enhanced in an SDF-1-dependent manner. This effect was mediated through inducing an epithelial-mesenchymal transition state. By contrast, increase in p16(INK4A) level through ectopic expression or AUF1 downregulation, reduced the secreted levels of SDF-1 and MMP-2 and suppressed the pro-carcinogenic effects of CAFs. In addition, p16(INK4A)-defective fibroblasts accelerated breast tumor xenograft formation and growth rate in mice. Importantly, tumors formed in the presence of p16(INK4A)-defective fibroblasts exhibited higher levels of active Akt, Cox-2, MMP-2 and MMP-9, showing their greater aggressiveness as compared with xenografts formed in the presence of p16(INK4A)-proficient fibroblasts. These results provide the first indication that p16(INK4A) downregulation in breast stromal fibroblasts is an important step toward their activation.	[Al-Ansari, M. M.; Hendrayani, S. F.; Aboussekhra, A.] Dept Mol Oncol, Riyadh, Saudi Arabia; [Shehata, A. I.] King Saud Univ, Dept Microbiol, Riyadh, Saudi Arabia	King Saud University	Aboussekhra, A (corresponding author), King Faisal Specialist Hosp & Res Ctr, DMO, MBC 03-66,POB 3354, Riyadh 11211, Saudi Arabia.	aboussekhra@kfshrc.edu.sa	Al-Ansari, Mysoon/K-1915-2013; Al-Ansari, Mysoon M/X-3875-2018	Al-Ansari, Mysoon/0000-0002-2501-691X; Al-Ansari, Mysoon M/0000-0002-2501-691X				Aboussekhra A, 2011, INT J DEV BIOL, V55, P841, DOI 10.1387/ijdb.113362aa; Al-Mohanna MA, 2007, NUCLEIC ACIDS RES, V35, P223, DOI 10.1093/nar/gkl1075; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Arendt LM, 2010, SEMIN CELL DEV BIOL, V21, P11, DOI 10.1016/j.semcdb.2009.10.003; Atienza JM, 2006, ASSAY DRUG DEV TECHN, V4, P597, DOI 10.1089/adt.2006.4.597; Bauer M, 2010, ONCOGENE, V29, P1732, DOI 10.1038/onc.2009.463; Bourhis XFDL, 1997, INT J CANCER, V71, P42, DOI 10.1002/(SICI)1097-0215(19970328)71:1<42::AID-IJC9>3.0.CO;2-3; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Chintala SK, 1997, ONCOGENE, V15, P2049, DOI 10.1038/sj.onc.1201382; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Gao MQ, 2010, J CELL SCI, V123, P3507, DOI 10.1242/jcs.072900; Hawsawi NM, 2008, CANCER RES, V68, P2717, DOI 10.1158/0008-5472.CAN-08-0192; Hu M, 2008, EUR J CANCER, V44, P2760, DOI 10.1016/j.ejca.2008.09.038; Hua M, 2009, P NATL ACAD SCI USA, V106, P3372, DOI 10.1073/pnas.0813306106; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kiaris H, 2005, CANCER RES, V65, P1627, DOI 10.1158/0008-5472.CAN-04-3791; Kim JB, 2005, TUMOR BIOL, V26, P173, DOI 10.1159/000086950; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Mazan-Mamczarz K, 2009, NUCLEIC ACIDS RES, V37, P204, DOI 10.1093/nar/gkn929; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; Ohtani Naoko, 2004, J Med Invest, V51, P146, DOI 10.2152/jmi.51.146; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; Sadlonova A, 2009, CANCER MICROENVIRON, V2, P9, DOI 10.1007/s12307-008-0017-0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shimoda M, 2010, SEMIN CELL DEV BIOL, V21, P19, DOI 10.1016/j.semcdb.2009.10.002; Singer CF, 2008, BREAST CANCER RES TR, V110, P273, DOI 10.1007/s10549-007-9725-2; Souza-Rodrigues E, 2007, PROTEOMICS, V7, P4102, DOI 10.1002/pmic.200700133; Sun P, 2010, J BIOL CHEM, V285, P27545, DOI 10.1074/jbc.M110.105767; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Trimis G, 2008, HUM MOL GENET, V17, P3596, DOI 10.1093/hmg/ddn252; Trimmer C, 2011, CANCER BIOL THER, V11, P383, DOI 10.4161/cbt.11.4.14101; vanRoozendaal KEP, 1996, INT J CANCER, V65, P120, DOI 10.1002/(SICI)1097-0215(19960103)65:1<120::AID-IJC20>3.0.CO;2-J; Wang WG, 2005, EMBO REP, V6, P158, DOI 10.1038/sj.embor.7400346; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	41	57	61	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2356	2364		10.1038/onc.2012.270	http://dx.doi.org/10.1038/onc.2012.270			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22751126	Green Published, hybrid			2022-12-28	WOS:000318683600012
J	Gong, C; Bauvy, C; Tonelli, G; Yue, W; Delomenie, C; Nicolas, V; Zhu, Y; Domergue, V; Marin-Esteban, V; Tharinger, H; Delbos, L; Gary-Gouy, H; Morel, AP; Ghavami, S; Song, E; Codogno, P; Mehrpour, M				Gong, C.; Bauvy, C.; Tonelli, G.; Yue, W.; Delomenie, C.; Nicolas, V.; Zhu, Y.; Domergue, V.; Marin-Esteban, V.; Tharinger, H.; Delbos, L.; Gary-Gouy, H.; Morel, A-P; Ghavami, S.; Song, E.; Codogno, P.; Mehrpour, M.			Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells	ONCOGENE			English	Article						breast cancer; autophagy; cancer stem-like/progenitor cell; Beclin 1	EPITHELIAL-MESENCHYMAL TRANSITION; IN-VITRO PROPAGATION; SELF-RENEWAL; IDENTIFICATION; INHIBITION; MODULATION; ACTIVATION; INDUCTION; SURVIVAL; GROWTH	Malignant breast tissue contains a rare population of multi-potent cells with the capacity to self-renew; these cells are known as cancer stem-like cells (CSCs) or tumor-initiating cells. Primitive mammary CSCs/progenitor cells can be propagated in culture as floating spherical colonies termed 'mammospheres'. We show here that the expression of the autophagy protein Beclin 1 is higher in mammospheres established from human breast cancers or breast cancer cell lines (MCF-7 and BT474) than in the parental adherent cells. As a result, autophagic flux is more robust in mammospheres. We observed that basal and starvation-induced autophagy flux is also higher in aldehyde dehydrogenase 1-positive (ALDH1(+)) population derived from mammospheres than in the bulk population. Beclin 1 is critical for CSC maintenance and tumor development in nude mice, whereas its expression limits the development of tumors not enriched with breast CSCs/progenitor cells. We found that decreased survival in autophagy-deficient cells (MCF-7 Atg7 knockdown cells) during detachment does not contribute to an ultimate deficiency in mammosphere formation. This study demonstrates that a prosurvival autophagic pathway is critical for CSC maintenance, and that Beclin 1 plays a dual role in tumor development.	[Gong, C.; Bauvy, C.; Tonelli, G.; Yue, W.; Codogno, P.; Mehrpour, M.] INSERM, Fac Pharm, U984, Chatenay Malabry, France; [Gong, C.; Zhu, Y.; Song, E.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Guangdong, Peoples R China; [Bauvy, C.; Tonelli, G.; Yue, W.; Delomenie, C.; Nicolas, V.; Domergue, V.; Marin-Esteban, V.; Tharinger, H.; Delbos, L.; Gary-Gouy, H.; Codogno, P.; Mehrpour, M.] Univ Paris 11, Fac Pharm, UMRS 996, F-92296 Chatenay Malabry, France; [Delomenie, C.; Nicolas, V.; Domergue, V.; Tharinger, H.; Delbos, L.; Gary-Gouy, H.] IFR 141 IPSIT, Fac Pharm, UMRS 996, Chatenay Malabry, France; [Marin-Esteban, V.] INSERM, Fac Pharm, UMRS 996, Chatenay Malabry, France; [Morel, A-P] INSERM, U520, F-69008 Lyon, France; [Ghavami, S.] Univ Manitoba, Dept Physiol, Winnipeg, MB, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Sun Yat Sen University; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Manitoba	Song, E (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, 107 Yanjiang West Rd, Guangzhou 510120, Guangdong, Peoples R China.	songerwei02@yahoo.com.cn; patrice.codogno@u-psud.fr; mehrpourmaryam@yahoo.fr	Marin-Esteban, Viviana/A-8856-2014; MOREL, Anne-Pierre/AAN-7072-2021; Mehrpour, Maryam/D-8640-2017; Ghavami, Saeid/Q-8918-2016; Ghavami, Saeid/GLT-0606-2022; Codogno, Patrice/G-1384-2013	Ghavami, Saeid/0000-0001-5948-508X; Codogno, Patrice/0000-0002-5492-3180; Delomenie, Claudine/0000-0002-6326-966X	INSERM; Universite Paris-Sud 11; PHC-PFCC programme francais de cooperation avec la Chine; INCa; ANR; National Natural Science Foundation of China [30830110, 30921140312, 30801376, 30972785, 81172524]; 973 Projects from Ministry of Science and Technology of China [2010CB912800, 2011CB504203, 2009CB521706]; Development of Important New Drugs from Ministry of Health of China [2011ZX09102-010-02]; Clinical Key Project of Public Health Administration of China; Sun Yat-sen University Training Project [11ykpy28, 11ykzd12]; Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University [KLB09001]; Parker B Francis Fellowship in Respiratory Disease	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Paris-Sud 11; PHC-PFCC programme francais de cooperation avec la Chine; INCa(Institut National du Cancer (INCA) France); ANR(French National Research Agency (ANR)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 973 Projects from Ministry of Science and Technology of China; Development of Important New Drugs from Ministry of Health of China; Clinical Key Project of Public Health Administration of China; Sun Yat-sen University Training Project; Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University; Parker B Francis Fellowship in Respiratory Disease	We thank B Levine for providing us with the MCF-7.beclin 1 cell line, M Jaattela and N Brady for providing the MCF-7 GFP-LC3 and the mCherry-GFP-LC3 cell lines, respectively. We thank A Hamai for his careful reading of our manuscript. We thank N Modjtahedi for helpful discussions. This work was supported by grants from INSERM, Universite Paris-Sud 11, PHC-PFCC programme francais de cooperation avec la Chine, INCa, ANR, the National Natural Science Foundation of China (30830110, 30921140312, 30801376, 30972785, 81172524), 973 Projects from Ministry of Science and Technology of China (2010CB912800, 2011CB504203, 2009CB521706), Development of Important New Drugs from Ministry of Health of China (2011ZX09102-010-02), Clinical Key Project of Public Health Administration of China, Sun Yat-sen University Training Project (11ykpy28,11ykzd12) and Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University (KLB09001). SG was supported with Parker B Francis Fellowship in Respiratory Disease.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gangemi R, 2009, CURR MED CHEM, V16, P1688, DOI 10.2174/092986709788186147; Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125; Ghavami S, 2012, AM J PHYSIOL-LUNG C, V302, pL420, DOI 10.1152/ajplung.00312.2011; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82; Mizushima N, 2011, COLD SPRING HARB SYM, VLXXVI, P3; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mortensen M, 2011, J EXP MED, V208, P455, DOI 10.1084/jem.20101145; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823; Singh SK, 2003, CANCER RES, V63, P5821; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Weidberg H, 2011, ANNU REV BIOCHEM, V80, P125, DOI 10.1146/annurev-biochem-052709-094552; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064	50	246	255	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2261	2272		10.1038/onc.2012.252	http://dx.doi.org/10.1038/onc.2012.252			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22733132	Green Published			2022-12-28	WOS:000318683600003
J	Sharma, A; Sen, JM				Sharma, A.; Sen, J. M.			Molecular basis for the tissue specificity of beta-catenin oncogenesis	ONCOGENE			English	Article						beta-catenin; hypocellular thymus; p53; apoptosis; intestinal adenoma; c-Myc	ACUTE LYMPHOBLASTIC-LEUKEMIA; T-CELL DEVELOPMENT; MULTIPLE INTESTINAL NEOPLASIA; IN-VIVO; MEDIATED TRANSCRIPTION; THYMOCYTE DEVELOPMENT; APC(MIN/+) MOUSE; GENE-EXPRESSION; APC DEFICIENCY; MYC DELETION	Wnt-beta-catenin-T-cell factor signaling is causally linked to c-myc-dependent tumorigenesis in mouse and human colon epithelial cells. By contrast, beta-catenin is not similarly associated with oncogenic transformation of other tissues, including T cells. The molecular basis for tissue specificity of beta-catenin-dependent oncogenesis is unknown. Here, we demonstrate that adenomatous polyposis coli mutant APC(Min/-) mice, which have increased expression of beta-catenin in all tissues, develop severe intestinal neoplasia, but fail to develop thymic lymphoma. Whereas beta-catenin-dependent signals elicit a proliferative response from intestinal cells, thymocytes experience oncogene-induced senescence (OIS), growth arrest and apoptosis. We demonstrate that the differential cellular response of thymocytes and intestinal epithelial cells is a direct consequence of the gene expression elicited by beta-catenin expression in each tissue. We find that whereas intestinal cells induce genes that promote proliferation thymocytes induce expression of genes associated with OIS, growth arrest and p53-dependent apoptosis. We correlate gene expression pattern with the role beta-catenin plays in the development of each tissue and suggest that susceptibility of transformation by beta-catenin is intimately related to its function during development. We propose that when oncogenes are used as signaling molecules, safety nets in the form of OIS, growth arrest and apoptosis prevent accidental transformation. Oncogene (2013) 32, 1901-1909; doi:10.1038/onc.2012.215; published online 11 June 2012	[Sharma, A.; Sen, J. M.] NIA, Lymphocyte Dev Unit, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sen, JM (corresponding author), NIA, Lymphocyte Dev Unit, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA.	Jyoti-Sen@NIH.GOV	Sharma, Archna/R-9377-2016	Sharma, Archna/0000-0003-4745-0220	National Institute on Aging; National Institutes of Health; NATIONAL INSTITUTE ON AGING [ZIAAG000772, ZIAAG000768, ZIAAG000771] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Q Yu for doing IP BrdU injections; R Wersto and the FACS facility team for cell sorting; the animal facility of National Institute on Aging for maintaining animals; S Luo and team for genotyping. This research was supported by Intramural Research Program of the National Institute on Aging and National Institutes of Health.	Bellei B, 2004, MODERN PATHOL, V17, P1275, DOI 10.1038/modpathol.3800181; CASTROP J, 1995, BLOOD, V86, P3050, DOI 10.1182/blood.V86.8.3050.bloodjournal8683050; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Ciofani M, 2006, IMMUNOL RES, V34, P117, DOI 10.1385/IR:34:2:117; Cole AM, 2010, EMBO MOL MED, V2, P472, DOI 10.1002/emmm.201000101; Coletta PL, 2004, BLOOD, V103, P1050, DOI 10.1182/blood-2003-03-0707; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Dorfman DM, 2003, AM J PATHOL, V162, P1539, DOI 10.1016/S0002-9440(10)64287-3; Gandhirajan RK, 2010, NEOPLASIA, V12, P326, DOI 10.1593/neo.91972; Gounari F, 2005, NAT IMMUNOL, V6, P800, DOI 10.1038/ni1228; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; Groen RWJ, 2008, CANCER RES, V68, P6969, DOI 10.1158/0008-5472.CAN-08-1322; Guo ZY, 2007, BLOOD, V109, P5463, DOI 10.1182/blood-2006-11-059071; Ignatenko NA, 2006, CANCER BIOL THER, V5, P1658, DOI 10.4161/cbt.5.12.3376; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017; LUONGO C, 1994, CANCER RES, V54, P5947; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Mulroy T, 2003, INT IMMUNOL, V15, P1485, DOI 10.1093/intimm/dxg146; Pajari AM, 2003, INT J CANCER, V106, P653, DOI 10.1002/ijc.11270; Polakis P, 2000, GENE DEV, V14, P1837; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Reed KR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-162; Reed KR, 2008, P NATL ACAD SCI USA, V105, P18919, DOI 10.1073/pnas.0805778105; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sansom OJ, 2005, ONCOGENE, V24, P8205, DOI 10.1038/sj.onc.1208956; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Serinsoz E, 2004, BRIT J HAEMATOL, V126, P313, DOI 10.1111/j.1365-2141.2004.05049.x; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521-4141(200101)31:1<285::AID-IMMU285>3.3.CO;2-4; Staal FJT, 2008, HAEMATOLOGICA, V93, P493, DOI 10.3324/haematol.12917; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tang XW, 2007, J CLIN INVEST, V117, P3753, DOI 10.1172/JCI32481; Tsutsui J, 1996, J BIOCHEM-TOKYO, V120, P1034; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Weerkamp F, 2006, LEUKEMIA, V20, P1197, DOI 10.1038/sj.leu.2404255; Wiman KG, 2010, ONCOGENE, V29, P4245, DOI 10.1038/onc.2010.188; Xu M, 2008, MOL CELL BIOL, V28, P1713, DOI 10.1128/MCB.01360-07; Xu M, 2009, J IMMUNOL, V182, P759, DOI 10.4049/jimmunol.182.2.759; Xu M, 2009, J IMMUNOL, V182, P751, DOI 10.4049/jimmunol.182.2.751; Xu YY, 2003, NAT IMMUNOL, V4, P1177, DOI 10.1038/ni1008; Xu YY, 2003, EUR J IMMUNOL, V33, P12, DOI 10.1002/immu.200390002; You L, 2008, MOL CANCER THER, V7, P1633, DOI 10.1158/1535-7163.MCT-08-0155; Young NP, 2010, P NATL ACAD SCI USA, V107, P10184, DOI 10.1073/pnas.1004796107; Yu Q, 2010, IMMUNOL RES, V47, P45, DOI 10.1007/s12026-009-8137-2	54	14	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 11	2013	32	15					1901	1909		10.1038/onc.2012.215	http://dx.doi.org/10.1038/onc.2012.215			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22689057	Green Accepted			2022-12-28	WOS:000317599900004
J	Castillo-Lluva, S; Tan, CT; Daugaard, M; Sorensen, PHB; Malliri, A				Castillo-Lluva, S.; Tan, C-T; Daugaard, M.; Sorensen, P. H. B.; Malliri, A.			The tumour suppressor HACE1 controls cell migration by regulating Rac1 degradation	ONCOGENE			English	Article						HACE1; Rac1; ubiquitylation; migration; HGF	LIGASE HACE1; GTPASE; PROTEINS	The small GTPase Rac1 is a key regulator of cell motility. Multiple mechanisms regulate Rac1 activity including its ubiquitylation and subsequent degradation. Here, we identify the tumour suppressor HACE1 (HECT domain and Ankyrin repeat Containing E3 ubiquitin-protein ligase 1) as an E3 ubiquitin ligase responsible for Rac1 degradation following activation by a migration stimulus. We show that HACE1 and Rac1 interaction is enhanced by hepatocyte growth factor (HGF) signalling, a Rac activator and potent stimulus of cell migration. Furthermore, HACE1 catalyses the poly-ubiquitylation of Rac1 at lysine 147 following its activation by HGF, resulting in its proteasomal degradation. This negative feedback mechanism likely restricts cell motility. Consistent with this, HACE1 depletion is accompanied by increased total Rac1 levels and accumulation of Rac1 in membrane ruffles. Moreover, HACE1-depletion enhances cell migration independently of growth factor stimulation, which may have significance for malignant conversion. A non-ubiquitylatable Rac1 rescues the migration defect of Rac1-null cells to a greater extent than wild-type Rac1. These findings identify HACE1 as an antagonist of cell migration through its ability to degrade active Rac1. Oncogene (2013) 32, 1735-1742; doi:10.1038/onc.2012.189; published online 21 May 2012	[Castillo-Lluva, S.; Tan, C-T; Malliri, A.] Univ Manchester, Cell Signalling Grp, Canc Res UK Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England; [Daugaard, M.; Sorensen, P. H. B.] Univ British Columbia, Dept Mol Oncol, BC Canc Res Ctr, Vancouver, BC V6T 1Z4, Canada; [Daugaard, M.; Sorensen, P. H. B.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z4, Canada	Cancer Research UK; University of Manchester; British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Malliri, A (corresponding author), Univ Manchester, Cell Signalling Grp, Canc Res UK Paterson Inst Canc Res, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	amalliri@picr.man.ac.uk	CASTILLO-LLUVA, SONIA/AAA-1776-2020; Daugaard, Mads/Y-6483-2018	Tan, Chong Teik/0000-0002-9503-8364; Castillo-LLuva, Sonia/0000-0001-5357-7178; Malliri, Angeliki/0000-0001-6848-090X; Daugaard, Mads/0000-0001-8383-055X	Cancer Research UK [C147/A12328]; Association for International Cancer Research grant [12-0037]; EMBO long-term fellowship; British Columbia Cancer Foundation; Danish Cancer Society Scientific Committee [R2-A189-B146]; Cancer Research UK [12937] Funding Source: researchfish; Worldwide Cancer Research [12-0037] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Association for International Cancer Research grant; EMBO long-term fellowship(European Molecular Biology Organization (EMBO)); British Columbia Cancer Foundation; Danish Cancer Society Scientific Committee; Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	This work was supported by Cancer Research UK grant number C147/A12328 and the Association for International Cancer Research grant number 12-0037 to AM. SCL was additionally supported by an EMBO long-term fellowship. Also this work was supported in part by funds to PHBS from the British Columbia Cancer Foundation through generous donations from Team Finn and other riders in the Ride to Conquer Cancer. MD was supported by The Danish Cancer Society Scientific Committee (grant number R2-A189-B146). We thank Dr Trusolino, Dr Sanchez-Madrid and Dr Vidali for reagents, Dr Hurlstone and Dr Wilkinson for critical reading of the manuscript.	Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Castillo-Lluva S, 2010, NAT CELL BIOL, V12, P1078, DOI 10.1038/ncb2112; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Doye A, 2006, METHOD ENZYMOL, V406, P447, DOI 10.1016/S0076-6879(06)06033-2; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Garcia-Mata R, 2006, METHOD ENZYMOL, V406, P425, DOI 10.1016/S0076-6879(06)06031-9; Gentile A, 2008, CANCER METAST REV, V27, P85, DOI 10.1007/s10555-007-9107-6; Hays JL, 2003, J BIOL CHEM, V278, P27456, DOI 10.1074/jbc.M210648200; Lynch EA, 2006, MOL BIOL CELL, V17, P2236, DOI 10.1091/mbc.E05-08-0779; Nethe M, 2010, J CELL SCI, V123, P1948, DOI 10.1242/jcs.062919; Oberoi TK, 2012, EMBO J, V31, P14, DOI 10.1038/emboj.2011.423; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Vidali L, 2006, MOL BIOL CELL, V17, P2377, DOI 10.1091/mbc.e05-10-0955; Visvikis O, 2008, FEBS J, V275, P386, DOI 10.1111/j.1742-4658.2007.06209.x; Zhang L, 2007, NAT MED, V13, P1060, DOI 10.1038/nm1621	19	57	60	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 28	2013	32	13					1735	1742		10.1038/onc.2012.189	http://dx.doi.org/10.1038/onc.2012.189			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614015				2022-12-28	WOS:000316855800013
J	Ciechomska, IA; Gabrusiewicz, K; Szczepankiewicz, AA; Kaminska, B				Ciechomska, I. A.; Gabrusiewicz, K.; Szczepankiewicz, A. A.; Kaminska, B.			Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporine A-induced cell death	ONCOGENE			English	Article						glioma; autophagy; endoplasmic reticulum stress; mTOR kinase	AP-1 TRANSCRIPTION FACTOR; IN-VIVO; INDUCED CYTOTOXICITY; SIGNALING PATHWAYS; ER STRESS; APOPTOSIS; THERAPY; INHIBITION; MECHANISMS; CANCER	Autophagy is a conserved, self-digestion process that is activated in response to nutrient limitation but acting also as an alternative death mechanism under certain conditions. It is accompanied by the progressive formation of vesicle structures from autophagosomes to autophagolysosomes orchestrated by autophagy effectors (Atg proteins) and modulators (that is, mTOR-mammalian target of rapamycin as a negative regulator). Malignant gliomas are highly resistant to current therapies that induce apoptosis, thus induction of the alternative cell death is an attractive strategy. We demonstrate that cyclosporine A (CsA, an immunophilin/calcineurin inhibitor) induces cell death with some apoptotic features but also accompanied by the appearance of numerous cytoplasmic vacuoles, immunostained for endoplasmic reticulum (ER) and autophagy markers. The induction of ER stress in glioma cells by CsA was evidenced by detection of unfolded protein response activation (phosphorylation of PERK, accumulation of IRE1 alpha) and accumulation of ER stress-associated proteins (BIP and CHOP). Formation of the acidic vesicular organelles, increase of autophagic vacuoles, GFP-LC3 punctation (microtubule-associated protein light chain 3) and LC3-II accumulation upon CsA treatment confirmed activation of autophagy. Decrease of phosphorylation of 4E-BP1, p70S6K1 and its downstream target S6 ribosomal protein demonstrate inhibition of mTOR signaling by CsA. Salubrinal and silencing of PERK and IRE1 alpha partially blocked CsA-induced accumulation of LC3-II. It suggests that ER stress precedes CsA-induced autophagy. Surprisingly, silencing of autophagy effectors ULK1, Atg5 or Atg7 increased the level of active caspases 3, 7 and PARP degradation in CsA-treated cells. Our results demonstrate that CsA induces both apoptosis and autophagy in malignant glioma cells via induction of ER stress and inhibition of mTOR/p70S6K1 pathway, however autophagy is cytoprotective in this context. Oncogene (2013) 32, 1518-1529; doi:10.1038/onc.2012.174; published online 14 May 2012	[Ciechomska, I. A.; Gabrusiewicz, K.; Kaminska, B.] Nencki Inst Expt Biol, Dept Cell Biol, Lab Transcript Regulat, PL-02093 Warsaw, Poland; [Szczepankiewicz, A. A.] Nencki Inst Expt Biol, Dept Neurophysiol, Lab Mol & Syst Neuromorphol, Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Ciechomska, IA (corresponding author), Nencki Inst Expt Biol, Dept Cell Biol, Lab Transcript Regulat, 3 Pasteur Str, PL-02093 Warsaw, Poland.	jcjech@nencki.gov.pl	Kaminska, Bozena/H-4592-2011; Kaminska, Bozena/B-2915-2014; Ciechomksa, Iwona/R-4706-2016	Kaminska, Bozena/0000-0002-2642-4616; Ciechomksa, Iwona/0000-0002-8068-0020; Szczepankiewicz, Andrzej/0000-0002-1502-3147; Gabrusiewicz, Konrad/0000-0001-7857-8062	Polish Ministry of Science and Higher Education [N N301 092036]	Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	We are grateful to Aviva M. Tolkovsky for her critical review of the manuscript. This work was supported by a grant N N301 092036 from The Polish Ministry of Science and Higher Education (IC).	Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Ciechomska I, 2005, INT J CANCER, V117, P59, DOI 10.1002/ijc.21153; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Ciechomska Iwona A., 2008, V445, P175, DOI 10.1007/978-1-59745-157-4_12; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Dunn IF, 2003, NEUROSURGERY, V52, P1411, DOI 10.1227/01.NEU.0000064808.27512.CF; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Ge PF, 2009, MED HYPOTHESES, V73, P45, DOI 10.1016/j.mehy.2008.11.047; Gijtenbeek JMM, 1999, J NEUROL, V246, P339, DOI 10.1007/s004150050360; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992; Jia WT, 2010, INT J BIOCHEM CELL B, V42, P2019, DOI 10.1016/j.biocel.2010.09.003; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kang CH, 2008, AUTOPHAGY, V4, P82, DOI 10.4161/auto.5154; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lefranc F, 2007, ONCOLOGIST, V12, P1395, DOI 10.1634/theoncologist.12-12-1395; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liu HY, 2009, J BIOL CHEM, V284, P31484, DOI 10.1074/jbc.M109.033936; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Mosieniak G, 1997, J NEUROCHEM, V68, P1142; Neufeld TP, 2010, CURR OPIN CELL BIOL, V22, P157, DOI 10.1016/j.ceb.2009.11.005; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Pallet N, 2008, AM J TRANSPLANT, V8, P2283, DOI 10.1111/j.1600-6143.2008.02396.x; Pallet N, 2008, AUTOPHAGY, V4, P783, DOI 10.4161/auto.6477; Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014; Pyrzynska B, 2000, J NEUROCHEM, V74, P42, DOI 10.1046/j.1471-4159.2000.0740042.x; Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030; Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yoon Hye Eun, 2009, Korean Journal of Internal Medicine, V24, P81, DOI 10.3904/kjim.2009.24.2.81; Zupanska A, 2005, NEUROCHEM INT, V47, P430, DOI 10.1016/j.neuint.2005.05.010	48	97	103	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 21	2013	32	12					1518	1529		10.1038/onc.2012.174	http://dx.doi.org/10.1038/onc.2012.174			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22580614				2022-12-28	WOS:000316456000005
J	Brune, M; Muller, M; Melino, G; Bierhaus, A; Schilling, T; Nawroth, PP				Brune, M.; Mueller, M.; Melino, G.; Bierhaus, A.; Schilling, T.; Nawroth, P. P.			Depletion of the receptor for advanced glycation end products (RAGE) sensitizes towards apoptosis via p53 and p73 posttranslational regulation	ONCOGENE			English	Article						RAGE; apoptosis; CD95; p53; p73	FACTOR-KAPPA-B; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR; BINDING-PROTEINS; CELL-SURFACE; EXPRESSION; MOUSE; CANCER; DEATH; INFLAMMATION	The receptor for advanced glycation endproduct (RAGE) is involved in diabetic complications and chronic inflammation, conditions known to affect the sensitivity towards apoptosis. Here, we studied the effect of genetically depleting RAGE on the susceptibility towards apoptosis. In murine osteoblastic cells, RAGE knockout increased both spontaneous and induced apoptosis. Decreased levels of B-cell lymphoma 2 protein and increased intrinsic apoptosis were observed in Rage(-/-) cells. Furthermore, loss of RAGE increased expression of the death receptor CD95 (Fas, Apo-1), CD95-dependent caspase activation and extrinsic apoptosis, whereas NF-kB-p65 nuclear translocation was diminished. Importantly, depletion of RAGE reduced the ubiquitination and degradation of p53 and p73 and increased their nuclear translocation. The increase of p53 and p73 transactivational activity was essential for the RAGE-dependent regulation of apoptosis, because knockdown of p53 and p73 significantly decreased apoptosis in RAGE-deficient but not in RAGE-expressing cells. Thus, the RAGE-mediated posttranslational regulation of p53 and p73 orchestrates a sequence of events culminating in control of intrinsic and extrinsic apoptosis signaling pathways. Oncogene (2013) 32, 1460-1468; doi:10.1038/onc.2012.150; published online 30 April 2012	[Brune, M.; Bierhaus, A.; Schilling, T.; Nawroth, P. P.] Heidelberg Univ, Dept Internal Med & Clin Chem 1, D-69120 Heidelberg, Germany; [Mueller, M.] Heidelberg Univ, Dept Internal Med 4, D-69120 Heidelberg, Germany; [Mueller, M.] Univ Regensburg, Dept Internal Med 1, D-93053 Regensburg, Germany; [Melino, G.] MRC, Toxicol Unit, Leicester, Leics, England; [Melino, G.] Univ Rome, Dept Expt Med & Biochem Sci, IDI IRCCS, Biochem Lab, Rome, Italy	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Regensburg; University of Leicester; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Sapienza University Rome	Brune, M (corresponding author), Heidelberg Univ, Dept Internal Med & Clin Chem 1, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	maik.brune@med.uni-heidelberg.de	Martina, Mueller-Schilling/R-4162-2016		Dietmar Hopp Stiftung 'Altern-Mobilitat erhalten, Regeneration ermoglichen'; Deutsche Forschungsgemeinschaft [SFB938]; Deutsche Forschungsgemeinschaft, Transregional Collaborative Research Centre [SFB/TRR77]; Tumorzentrum Heidelberg/Mannheim; Helmholtz Alliance on Immunotherapy of Cancer; Initiative and Networking Fund of the Helmholtz Association; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	Dietmar Hopp Stiftung 'Altern-Mobilitat erhalten, Regeneration ermoglichen'; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft, Transregional Collaborative Research Centre(German Research Foundation (DFG)); Tumorzentrum Heidelberg/Mannheim; Helmholtz Alliance on Immunotherapy of Cancer; Initiative and Networking Fund of the Helmholtz Association; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dr Subrata Biswas for isolation of MOC, Thomas Fleming for assistance with chromatin immunoprecipitation and electroporation, Dr Andreas Koch for assistance with flow cytometry, as well as Katja Lorenz and Petra Hill for expert technical assistance. This work was supported by a grant of the Dietmar Hopp Stiftung 'Altern-Mobilitat erhalten, Regeneration ermoglichen' to MB, PN, AB and TS, by a grant of the Deutsche Forschungsgemeinschaft SFB938 to AB and by the grant of the Deutsche Forschungsgemeinschaft, Transregional Collaborative Research Centre SFB/TRR77, the Tumorzentrum Heidelberg/Mannheim and the Helmholtz Alliance on Immunotherapy of Cancer funded by the Initiative and Networking Fund of the Helmholtz Association to MM.	Alikhani M, 2007, BONE, V40, P345, DOI 10.1016/j.bone.2006.09.011; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bentires-Alj M, 2001, ONCOGENE, V20, P2805, DOI 10.1038/sj.onc.1204343; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Bierhaus A, 2009, DIABETOLOGIA, V52, P2251, DOI 10.1007/s00125-009-1458-9; Borcsok I, 1998, J EXP MED, V188, P1563, DOI 10.1084/jem.188.9.1563; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Cheng B, 2011, EXP CLIN ENDOCR DIAB, V119, P480, DOI 10.1055/s-0031-1279714; Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030; Ding KH, 2006, BIOCHEM BIOPH RES CO, V340, P1091, DOI 10.1016/j.bbrc.2005.12.107; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Eggers K, 2011, EXP CLIN ENDOCR DIAB, V119, P353, DOI 10.1055/s-0030-1268426; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Gulcelik NE, 2011, EXP CLIN ENDOCR DIAB, V119, P414, DOI 10.1055/s-0030-1270466; Hiwatashi K, 2009, ANTICANCER RES, V29, P1287; Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kang R, 2011, AUTOPHAGY, V7, P442, DOI 10.4161/auto.7.4.14681; Kang R, 2011, AUTOPHAGY, V7, P91, DOI [10.4161/auto.7.1.13852, 10.1038/cdd.2009.149]; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kikuchi H, 2006, ONCOGENE, V25, P7608, DOI 10.1038/sj.onc.1209748; Lavrik IN, 2007, J BIOL CHEM, V282, P13664, DOI 10.1074/jbc.M700434200; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Mundt HM, 2010, BIOCHEM BIOPH RES CO, V396, P335, DOI 10.1016/j.bbrc.2010.04.093; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Paul RG, 1996, INT J BIOCHEM CELL B, V28, P1297, DOI 10.1016/S1357-2725(96)00079-9; RENSINGEHL A, 1995, J INFLAMM, V45, P161; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Seitz SJ, 2010, INT J CANCER, V126, P2049, DOI 10.1002/ijc.24861; Soro-Paavonen A, 2008, DIABETES, V57, P2461, DOI 10.2337/db07-1808; Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17; Stolzing A, 2010, CELLS TISSUES ORGANS, V191, P453, DOI 10.1159/000281826; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tsoporis JN, 2010, CIRC RES, V106, P93, DOI 10.1161/CIRCRESAHA.109.195834; Villa-Morales M, 2006, ONCOGENE, V25, P2022, DOI 10.1038/sj.onc.1209234; Zhou Z, 2006, J EXP MED, V203, P1067, DOI 10.1084/jem.20051947	44	10	10	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1460	1468		10.1038/onc.2012.150	http://dx.doi.org/10.1038/onc.2012.150			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22543586				2022-12-28	WOS:000316455600012
J	Ley, S; Weigert, A; Weichand, B; Henke, N; Mille-Baker, B; Janssen, RAJ; Brune, B				Ley, S.; Weigert, A.; Weichand, B.; Henke, N.; Mille-Baker, B.; Janssen, R. A. J.; Bruene, B.			The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages	ONCOGENE			English	Article						immunity; sphingolipids; cancer; nerve growth factor; trafficking	NERVE GROWTH-FACTOR; HUMAN MONOCYTES; BREAST-CANCER; RECEPTORS; SPHINGOSINE-1-PHOSPHATE; EXPRESSION; TRANSACTIVATION; INTERLEUKIN-10; PROGRESSION; DISEASE	Tumor-associated macrophages (TAMs) are a major supportive component within neoplasms. Mechanisms of macrophage (M(1)) attraction and differentiation to a tumor-promoting phenotype, which is characterized by pronounced interleukin (IL)-10 production, are under investigation. We report that supernatants of dying cancer cells induced substantial IL-10 release from primary human MOs, dependent on signaling through tyrosine kinase receptor A (TRKA or neurotrophic tyrosine kinase receptor type 1 (NTRK1)). Mechanistically, sphingosine-1-phosphate (SIP) release from apoptotic cancer cells triggered src-dependent shuttling of cytosolic TRKA to the plasma membrane via S1P receptor signaling. Plasma membrane-associated TRKA, which was activated by constitutively autocrine secreted nerve growth factor, used phosphatidylinositol 3-kinase (PI3K)/AKT and p38 mitogen-activated protein kinase (MAPK) signaling to induce IL-10. Interestingly, TRKA-dependent signaling was required for cytokine production by TAMs isolated from primary murine breast cancer tissue. Besides IL-10, this pathway initiated secretion of IL-6, tumor necrosis factor-alpha (TNF-alpha) and monocyte chemotactic protein-1 (MCP-1), indicating relevance in cancer-associated inflammation. Our findings highlight a fine-tuned regulatory system including S1P-dependent TRKA trafficking for executing TAM-like cell function in vitro as well as in vivo. Oncogene (2013) 32, 631-640; doi:10.1038/onc.2012.77; published online 12 March 2012	[Ley, S.; Weigert, A.; Weichand, B.; Henke, N.; Bruene, B.] Goethe Univ Frankfurt, Inst Biochem, I ZAFES, D-60590 Frankfurt, Germany; [Mille-Baker, B.] BioFocus Ltd, Leiden, Netherlands; [Janssen, R. A. J.] Galapagos BV, Leiden, Netherlands	Goethe University Frankfurt; Galapagos NV	Brune, B (corresponding author), Goethe Univ Frankfurt, Inst Biochem, I ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	bruene@pathobiochemie1.de	Weigert, Andreas/E-6540-2010	Weigert, Andreas/0000-0002-7529-1952	DFG [Br999, FOG 784, GRK 757]; Sander Foundation [2007.070.2]; Deutsche Krebshilfe [109599]	DFG(German Research Foundation (DFG)); Sander Foundation; Deutsche Krebshilfe(Deutsche Krebshilfe)	The work was supported by DFG (Br999, FOG 784, GRK 757), Sander Foundation (2007.070.2) and Deutsche Krebshilfe (109599). We are grateful to Yves-Alain Barde for sharing the HA-TRKA expression plasmid and thank Franz Josef Streb, Magarethe Wiebe and Karina Pfister for excellent technical assistance.	Adriaenssens E, 2008, CANCER RES, V68, P346, DOI 10.1158/0008-5472.CAN-07-1183; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Arevalo JC, 2006, CELL MOL LIFE SCI, V63, P1523, DOI 10.1007/s00018-006-6010-1; Barra V, 2011, CELL MOL LIFE SCI, V68, P1815, DOI 10.1007/s00018-010-0537-x; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bracci-Laudiero L, 2005, BLOOD, V106, P3507, DOI 10.1182/blood-2004-10-4055; Chung EY, 2007, IMMUNITY, V27, P952, DOI 10.1016/j.immuni.2007.11.014; Duong CQ, 2004, BBA-MOL CELL BIOL L, V1682, P112; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; El Zein N, 2010, CELL SIGNAL, V22, P1437, DOI 10.1016/j.cellsig.2010.05.012; Gregory CD, 2011, J PATHOL, V223, P177, DOI 10.1002/path.2792; Herr B, 2009, BLOOD, V114, P2140, DOI 10.1182/blood-2009-01-201889; Hughes JE, 2008, CIRC RES, V102, P950, DOI 10.1161/CIRCRESAHA.107.170779; Jung EJ, 2008, EXP MOL MED, V40, P276, DOI 10.3858/emm.2008.40.3.276; Karkoulias G, 2007, CELL SIGNAL, V19, P945, DOI 10.1016/j.cellsig.2006.11.003; Keul P, 2011, CIRC RES, V108, P314, DOI 10.1161/CIRCRESAHA.110.235028; Koh E, 2007, CELL SIGNAL, V19, P1328, DOI 10.1016/j.cellsig.2007.01.005; Kruttgen A, 2006, BRAIN PATHOL, V16, P304, DOI 10.1111/j.1750-3639.2006.00037.x; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Long JS, 2010, J BIOL CHEM, V285, P35957, DOI 10.1074/jbc.M110.117945; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Moises T, 2007, MOL NEUROBIOL, V35, P151, DOI 10.1007/s12035-007-8000-1; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Noga O, 2007, CLIN EXP ALLERGY, V37, P1701, DOI 10.1111/j.1365-2222.2007.02832.x; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; Sandilands E, 2007, EMBO REP, V8, P1162, DOI 10.1038/sj.embor.7401097; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schecterson LC, 2010, DEV NEUROBIOL, V70, P332, DOI 10.1002/dneu.20767; Toman RE, 2004, J CELL BIOL, V166, P381, DOI 10.1083/jcb.200402016; Tsuruda A, 2004, FEBS LETT, V560, P215, DOI 10.1016/S0014-5793(04)00115-2; van Es HHG, 2005, DRUG DISCOV TODAY, V10, P1385, DOI 10.1016/S1359-6446(05)03590-7; Wang WG, 2005, FASEB J, V19, P1731, DOI 10.1096/fj.05-3730fje; Weigert A, 2007, MOL BIOL CELL, V18, P3810, DOI 10.1091/mbc.E06-12-1096; Weigert A, 2010, BLOOD, V115, P3531, DOI 10.1182/blood-2009-10-243444; Weis N, 2009, MOL BIOL CELL, V20, P1280, DOI 10.1091/mbc.E08-10-1005; Wetter JA, 2009, J BIOMOL SCREEN, V14, P1134, DOI 10.1177/1087057109343809; Zweifel LS, 2005, NAT REV NEUROSCI, V6, P615, DOI 10.1038/nrn1727	40	27	30	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2013	32	5					631	640		10.1038/onc.2012.77	http://dx.doi.org/10.1038/onc.2012.77			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22410777				2022-12-28	WOS:000316164700010
J	Agarwal, N; Adhikari, AS; Iyer, SV; Hekmatdoost, K; Welch, DR; Iwakuma, T				Agarwal, N.; Adhikari, A. S.; Iyer, S. V.; Hekmatdoost, K.; Welch, D. R.; Iwakuma, T.			MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4	ONCOGENE			English	Article						MDM2; MTBP; ACTN4; filopodia; metastasis	ALPHA-ACTININ; GENE AMPLIFICATION; CANCER INVASION; METASTASIS; CARCINOMA; MOTILITY; MDM2; NETWORK; GROWTH	Murine double minute (MDM2) binding protein (MTBP) has been implicated in cancer progression. Here, we demonstrate one mechanism by which MTBP inhibits cancer metastasis. Overexpression of MTBP in human osteosarcoma cell lines lacking wildtype p53 did not alter primary tumor growth in mice, but significantly inhibited metastases. MTBP downregulation increased the migratory potential of MDM2(-/-)p53(-/-) mouse embryonic fibroblasts, suggesting that MTBP inhibited cell migration independently of the Mdm2-p53 pathway. Co-immunoprecipitation and mass spectrometric analysis identified alpha-actinin-4 (ACTN4) as an MTBP-interacting protein. Endogenous MTBP interacted with and partially colocalized with ACTN4. MTBP overexpression inhibited cell migration and filopodia formation mediated by ACTN4. Increased cell migration by MTBP downregulation was inhibited by concomitant downregulation of ACTN4. MTBP also inhibited ACTN4-mediated F-actin bundling. We furthermore demonstrated that nuclear localization of MTBP was dispensable for inhibiting ACTN4-mediated cell migration and filopodia formation. Thus, MTBP suppresses cell migration, at least partially, by inhibiting ACTN4 function. Our study not only provides a mechanism of metastasis suppression by MTBP, but also suggests MTBP as a potential biomarker for cancer progression. Oncogene (2013) 32, 462-470; doi:10.1038/onc.2012.69; published online 27 February 2012	[Agarwal, N.; Adhikari, A. S.; Iyer, S. V.; Hekmatdoost, K.; Iwakuma, T.] Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA USA; [Agarwal, N.; Iyer, S. V.; Welch, D. R.; Iwakuma, T.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66160 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Kansas; University of Kansas Medical Center	Iwakuma, T (corresponding author), Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66160 USA.	tiwakuma@kumc.edu	Welch, Danny R/B-7310-2009; Agarwal, Neeraj/F-2834-2016	Welch, Danny R/0000-0002-1951-4947; Agarwal, Neeraj/0000-0001-7163-1043	LCRC start-up; National Foundation for Cancer Research-Center for Metastasis Research;  [P20 RR020152-02];  [RSG-09-169-01-CSM]; NATIONAL CANCER INSTITUTE [R01CA134981] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020152] Funding Source: NIH RePORTER	LCRC start-up; National Foundation for Cancer Research-Center for Metastasis Research; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs Indu Kheterpal, Yuki Tochigi and Louis Marrero for their technical assistance. We also thank Ms Kristy-Le T Nguyen for her technical assistance and editing the manuscript. This work was supported by grants from P20 RR020152-02 (PLD), RSG-09-169-01-CSM (JI), LCRC start-up (TI) and National Foundation for Cancer Research-Center for Metastasis Research (DRW).	Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Agarwal N, 2011, CELL DEATH DIFFER, V18, P1208, DOI 10.1038/cdd.2010.189; Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296; Barbolina MV, 2008, LAB INVEST, V88, P602, DOI 10.1038/labinvest.2008.25; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brady M, 2005, MOL CELL BIOL, V25, P545, DOI 10.1128/MCB.25.2.545-553.2005; Chen XP, 2011, INT J BIOL MARKER, V26, P1, DOI 10.5301/JBM.2011.6267; Choi HS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-122; Hayashida Y, 2005, CANCER RES, V65, P8836, DOI 10.1158/0008-5472.CAN-05-0718; Hendrix MJC, 1996, CANCER METAST REV, V15, P507, DOI 10.1007/BF00054016; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Hurst DR, 2011, INT REV CEL MOL BIO, V286, P107, DOI 10.1016/B978-0-12-385859-7.00003-3; Iwakuma T, 2008, ONCOGENE, V27, P1813, DOI 10.1038/sj.onc.1210827; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Jia SF, 2002, ANTI-CANCER DRUG, V13, P155, DOI 10.1097/00001813-200202000-00007; Kikuchi S, 2008, CLIN CANCER RES, V14, P5348, DOI 10.1158/1078-0432.CCR-08-0075; Kirfel G, 2004, EUR J CELL BIOL, V83, P717, DOI 10.1078/0171-9335-00421; Koizumi T, 2010, UROLOGY, V75, P357, DOI 10.1016/j.urology.2009.09.037; Lindberg U, 2008, SEMIN CANCER BIOL, V18, P2, DOI 10.1016/j.semcancer.2007.10.002; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Menez J, 2004, ONCOGENE, V23, P2630, DOI 10.1038/sj.onc.1207347; Mierke CT, 2009, CELL BIOCHEM BIOPHYS, V53, P115, DOI 10.1007/s12013-009-9047-6; Mina LA, 2011, NAT REV CLIN ONCOL, V8, P325, DOI 10.1038/nrclinonc.2011.59; Mukhina S, 2007, DEV CELL, V13, P554, DOI 10.1016/j.devcel.2007.08.003; Odvody J, 2010, ONCOGENE, V29, P3287, DOI 10.1038/onc.2010.82; Quick Q, 2010, EXP CELL RES, V316, P1137, DOI 10.1016/j.yexcr.2010.02.011; Sen S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008427; Shao HS, 2010, J BIOL CHEM, V285, P2591, DOI 10.1074/jbc.M109.035790; Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012; Vignjevic D, 2008, SEMIN CANCER BIOL, V18, P12, DOI 10.1016/j.semcancer.2007.08.001; Vlatkovic N, 2011, CANCER-AM CANCER SOC, V117, P2939, DOI 10.1002/cncr.25864; Weins A, 2007, P NATL ACAD SCI USA, V104, P16080, DOI 10.1073/pnas.0702451104; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yamamoto S, 2009, MODERN PATHOL, V22, P499, DOI 10.1038/modpathol.2008.234	35	43	44	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					462	470		10.1038/onc.2012.69	http://dx.doi.org/10.1038/onc.2012.69			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22370640	Green Accepted			2022-12-28	WOS:000315551300007
J	Stebbing, J; Filipovic, A; Lit, LC; Blighe, K; Grothey, A; Xu, Y; Miki, Y; Chow, LW; Coombes, RC; Sasano, H; Shaw, JA; Giamas, G				Stebbing, J.; Filipovic, A.; Lit, L. C.; Blighe, K.; Grothey, A.; Xu, Y.; Miki, Y.; Chow, L. W.; Coombes, R. C.; Sasano, H.; Shaw, J. A.; Giamas, G.			LMTK3 is implicated in endocrine resistance via multiple signaling pathways	ONCOGENE			English	Article						LMTK3; breast cancer; estrogen receptor; endocrine resistance; HSPB8; oncogene	BREAST-CANCER CELLS; ESTROGEN-RECEPTOR-ALPHA; CYCLIN D1; IN-VITRO; EXPRESSION; KINASE; TUMORIGENESIS; RECURRENCE; ACTIVATION; TAMOXIFEN	Resistance to endocrine therapy in breast cancer is common. With the aim of discovering new molecular targets for breast cancer therapy, we have recently identified LMTK3 as a regulator of the estrogen receptor-alpha (ER alpha) and wished to understand its role in endocrine resistance. We find that inhibition of LMTK3 in a xenograft tamoxifen (Tam)-resistant (BT474) breast cancer mouse model results in re-sensitization to Tam as demonstrated by a reduction in tumor volume. A whole genome microarray analysis, using a BT474 cell line, reveals genes significantly modulated (positively or negatively) after LMTK3 silencing, including some that are known to be implicated in Tam resistance, notably c-MYC, HSPB8 and SIAH2. We show that LMTK3 is able to increase the levels of HSPB8 at a transcriptional and translational level thereby protecting MCF7 cells from Tam-induced cell death, by reducing autophagy. Finally, high LMTK3 levels at baseline in tumors are predictive for endocrine resistance; therapy does not lead to alteration in levels, whereas in patient's plasma samples, acquired LMTK3 gene amplification (copy number variation) was associated with relapse while receiving Tam. In aggregate, these data support a role for LMTK3 in both innate (intrinsic) and acquired (adaptive) endocrine resistance in breast cancer.	[Stebbing, J.; Filipovic, A.; Lit, L. C.; Grothey, A.; Xu, Y.; Coombes, R. C.; Giamas, G.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus, London W12 0NN, England; [Blighe, K.; Shaw, J. A.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Miki, Y.; Chow, L. W.; Sasano, H.] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 980, Japan; [Chow, L. W.] Comprehens Ctr Breast Dis, UNIMED Med Inst, Hong Kong, Hong Kong, Peoples R China	Imperial College London; University of Leicester; Tohoku University	Giamas, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England.	g.giamas@imperial.ac.uk	LIT, LEI CHENG/B-8875-2010; Giamas, Georgios/AAP-3487-2021; Lit, Lei Cheng/AAS-9778-2021	LIT, LEI CHENG/0000-0002-3210-4491; Lit, Lei Cheng/0000-0002-3210-4491; Coombes, Raoul Charles/0000-0002-4811-1100; Blighe, Kevin/0000-0002-6322-6571; Shaw, Jacqui/0000-0003-4227-503X; Giamas, Georgios/0000-0002-4417-2707; Stebbing, Justin/0000-0002-1117-6947	Grants for Targets (G4T) program of Bayer Healthcare; Cancer Research UK; UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant; R & E Girling and friends; Pink Ribbon Foundation; Imperial BRC; ECMC; MRC [MR/L000172/1] Funding Source: UKRI; Cancer Research UK [13462, 14549, 12011] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	Grants for Targets (G4T) program of Bayer Healthcare; Cancer Research UK(Cancer Research UK); UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant; R & E Girling and friends; Pink Ribbon Foundation; Imperial BRC; ECMC; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We would like to thank Champions Biotechnology, in particular David Sidransky and Elizabeth Bruckheimer for their expertise and help with the mouse xenograft model (Johns Hopkins, Baltimore, USA), P Trivedi for performing the immunohistochemistry staining (Imperial College) and Katsuhiko Ono for technical assistance (Tohoku University). We are grateful to Richard Szydlo (Imperial College) for statistical advice. We thank Martina Sperling for performing the Illumina microarray hybridizations. We thank Luisella Toschi, Anette Sommer, and Georg Beckmann (Bayer, Berlin, Germany) for their significant input in both the experimental design and analysis of the gene expression profiling experiments and the selection of cell lines, without which this work could not have been undertaken. The project was supported by a grant from the Grants for Targets (G4T) program of Bayer Healthcare. JS, JAS, RCC and GG are supported by grants from Cancer Research UK. This work has been supported by a UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant to GG. We thank R & E Girling and friends, Cancer Research UK and the Pink Ribbon Foundation for their support. This work was also supported by the Imperial BRC and ECMC.	Agoulnik IU, 2011, ONCOTARGET, V2, P321; Al-Azawi D, 2008, ONCOGENE, V27, P3021, DOI 10.1038/sj.onc.1210964; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Chanplakorn N, BREAST CANC RES TREA, V120, P639; Chow LWC, 2008, J STEROID BIOCHEM, V111, P13, DOI 10.1016/j.jsbmb.2008.04.004; Cook KL, 2011, EXPERT REV ANTICANC, V11, P1283, DOI [10.1586/ERA.11.111, 10.1586/era.11.111]; Cordera F, 2006, SEMIN ONCOL, V33, P631, DOI 10.1053/j.seminoncol.2006.08.020; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Dixon JM, 2005, CLIN EVID, p[13, 2226]; Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Giamas G, 2007, PHARMACOGENOMICS, V8, P1005, DOI 10.2217/14622416.8.8.1005; Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351; Giamas G, 2010, CELL SIGNAL, V22, P984, DOI 10.1016/j.cellsig.2010.01.011; Gonzalez-Malerva L, 2011, P NATL ACAD SCI USA, V108, P2058, DOI 10.1073/pnas.1018157108; Guo SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021467; Harrington WR, 2006, ENDOCRINOLOGY, V147, P3843, DOI 10.1210/en.2006-0358; Hu DG, 2009, MOL PHARMACOL, V76, P425, DOI 10.1124/mol.109.057380; Jansen MPHM, 2009, BREAST CANCER RES TR, V116, P263, DOI 10.1007/s10549-008-0125-z; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; Lange CA, 2011, ENDOCR-RELAT CANCER, V18, pC19, DOI 10.1530/ERC-11-0112; LASFARGUES EY, 1978, J NATL CANCER I, V61, P967; Li Y, 2010, NAT MED, V16, P214, DOI 10.1038/nm.2090; Liguori L, 2012, CELL CYCLE, V11, P569, DOI 10.4161/cc.11.3.19063; Miller TW, 2011, J CLIN ONCOL, V29, P4452, DOI 10.1200/JCO.2010.34.4879; Miller TW, CLIN CANC RES, V17, P2024; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Oshima T, 2011, BIOL PHARM BULL, V34, P54, DOI 10.1248/bpb.34.54; Paroni G, 2011, ONCOGENE; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Schafer JM, 2006, METH MOLEC MED, V120, P453; Shaw JA, 2012, GENOME RES, V22, P220, DOI 10.1101/gr.123497.111; Stebbing J, 2007, CLIN EVID, V2007; Stebbing J, 2007, PHARMACOGENOMICS, V8, P1, DOI 10.2217/14622416.8.1.1; Stebbing J, 2012, BREAST CANCER RES TR, V132, P537, DOI 10.1007/s10549-011-1622-z; Stone James C, 2011, Genes Cancer, V2, P320, DOI 10.1177/1947601911408082; Sun X, 2007, CELL STRESS CHAPERON, V12, P307, DOI 10.1379/CSC-276.1; Tobin NP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-417; Tomura H, 2005, CELL SIGNAL, V17, P1466, DOI 10.1016/j.cellsig.2005.06.002; Wang YZ, 2011, MOL ENDOCRINOL, V25, P72, DOI 10.1210/me.2010-0294; Wilson CG, 2011, FEBS LETT, V585, P2137, DOI 10.1016/j.febslet.2011.05.059; Xu J, 2012, BREAST CANC RES TREA; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Zhang Q, 2009, CANCER CELL, V16, P413, DOI 10.1016/j.ccr.2009.09.029	46	34	38	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2013	32	28					3371	3380		10.1038/onc.2012.343	http://dx.doi.org/10.1038/onc.2012.343			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22869149				2022-12-28	WOS:000321620200007
J	Cotrim, CZ; Fabris, V; Doria, ML; Lindberg, K; Gustafsson, JA; Amado, F; Lanari, C; Helguero, LA				Cotrim, C. Z.; Fabris, V.; Doria, M. L.; Lindberg, K.; Gustafsson, J-A; Amado, F.; Lanari, C.; Helguero, L. A.			Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells	ONCOGENE			English	Article						estrogen receptor beta; mammary gland; breast cancer; apoptosis; proliferation; ERK 1/2	ER-ALPHA; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; PROLIFERATION; LINE; PROTEIN; DIFFERENTIATION; GENISTEIN; APOPTOSIS; SURVIVAL	Two thirds of breast cancers express estrogen receptors (ER). ER alpha (ER alpha) mediates breast cancer cell proliferation, and expression of ER alpha is the standard choice to indicate adjuvant endocrine therapy. ERbeta (ER beta) inhibits growth in vitro; its effects in vivo have been incompletely investigated and its role in breast cancer and potential as alternative target in endocrine therapy needs further study. In this work, mammary epithelial (EpH4 and HC11) and breast cancer (MC4-L2) cells with endogenous ER alpha and ER beta expression and T47-D human breast cancer cells with recombinant ER beta (T47-DER beta) were used to explore effects exerted in vitro and in vivo by the ER beta agonists 2,3-bis (4-hydroxy-phenyl)-propionitrile (DPN) and 7-bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY). In vivo, ER beta agonists induced mammary gland hyperplasia and MC4-L2 tumour growth to a similar extent as the ER alpha agonist 4,4',4 ''-(4-propyl-(1H)-pyrazole-1,3,5-triyl) trisphenol (PPT) or 17 beta-estradiol (E2) and correlated with higher number of mitotic and lower number of apoptotic features. In vitro, in MC4-L2, EpH4 or HC11 cells incubated under basal conditions, ER beta agonists induced apoptosis measured as upregulation of p53 and apoptosis-inducible factor protein levels and increased caspase 3 activity, whereas PPT and E2 stimulated proliferation. However, when extracellular signal-regulated kinase 1 and 2 (ERK1/2) were activated by co-incubation with basement membrane extract or epidermal growth factor, induction of apoptosis by ER beta agonists was repressed and DPN induced proliferation in a similar way as E2 or PPT. In a context of active ERK1/2, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/RAC-alpha serine/threonine-protein kinase (AKT) signalling was necessary to allow proliferation stimulated by ER agonists. Inhibition of MEK1/2 with UO126 completely restored ER beta growth-inhibitory effects, whereas inhibition of PI3K by LY294002 inhibited ER beta-induced proliferation. These results show that the cellular context modulates ER beta growth-inhibitory effects and should be taken into consideration upon assessment of ER beta as target for endocrine treatment.	[Cotrim, C. Z.; Doria, M. L.; Helguero, L. A.] Univ Aveiro, Dept Chem, P-3810193 Aveiro, Portugal; [Fabris, V.; Lanari, C.] Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; [Lindberg, K.; Gustafsson, J-A; Helguero, L. A.] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Gustafsson, J-A] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Dept Biol & Biochem, Houston, TX USA; [Amado, F.] Univ Aveiro, Sch Hlth Sci, P-3800 Aveiro, Portugal	Universidade de Aveiro; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Karolinska Institutet; University of Houston System; University of Houston; Universidade de Aveiro	Helguero, LA (corresponding author), Univ Aveiro, Dept Chem, Campus Univ Santigo, P-3810193 Aveiro, Portugal.	luisa.helguero@ua.pt	Helguero, Luisa/B-1221-2013; Cruz e Silva, Odete/AAH-5595-2020; Amado, Francisco ML/M-5337-2015	Helguero, Luisa/0000-0001-8237-2390; Amado, Francisco ML/0000-0001-8256-1749; Cotrim, Candida Zita/0000-0002-2489-274X; Lanari, Claudia/0000-0003-0555-2309	Federal funds through Programa Operacional Tematico Factores de Competitividade (COMPETE); European Community Fund (FEDER); Fundacao para a Ciencia e Tecnologia (FCT) [PTDC/SAU-ONC/112671/2009]; Mass Spectrometry Unit at University of Aveiro; Swedish Cancer Fund; FCT	Federal funds through Programa Operacional Tematico Factores de Competitividade (COMPETE); European Community Fund (FEDER)(European Commission); Fundacao para a Ciencia e Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); Mass Spectrometry Unit at University of Aveiro; Swedish Cancer Fund; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	We are grateful to Dr Lars-Arne Haldosen for enlightening discussions related to this work, Dr Anders Strom for T47-DER beta human breast cancer cells and Dr Margaret Warner for chicken anti-ER beta 503 and rabbit anti-ER beta 2 antibodies. This work was supported by Federal funds through Programa Operacional Tematico Factores de Competitividade (COMPETE) with co-participation from the European Community Fund (FEDER) and national funds through Fundacao para a Ciencia e Tecnologia (FCT) under the project no. PTDC/SAU-ONC/112671/2009 (LAH); Project Ciencia 2008 through FCT; Mass Spectrometry Unit at University of Aveiro and Swedish Cancer Fund.	Aliaga A, 2004, NUCL MED BIOL, V31, P761, DOI 10.1016/j.nucmedbio.2004.02.011; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Ciarloni L, 2007, P NATL ACAD SCI USA, V104, P5455, DOI 10.1073/pnas.0611647104; Cotroneo MS, 2002, CARCINOGENESIS, V23, P1467, DOI 10.1093/carcin/23.9.1467; Forster C, 2002, P NATL ACAD SCI USA, V99, P15578, DOI 10.1073/pnas.192561299; Frasor J, 2003, ENDOCRINOLOGY, V144, P3159, DOI 10.1210/en.2002-0143; Green CA, 2008, HISTOPATHOLOGY, V53, P374, DOI 10.1111/j.1365-2559.2008.02968.x; Grober OMV, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-36; Hamilton-Burke W, 2010, AM J PATHOL, V177, P1079, DOI 10.2353/ajpath.2010.090886; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Helguero LA, 2008, CANCER RES, V68, P8695, DOI 10.1158/0008-5472.CAN-08-0788; Honma N, 2008, J CLIN ONCOL, V26, P3727, DOI 10.1200/JCO.2007.14.2968; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Jarvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5; Jensen EV, 2001, P NATL ACAD SCI USA, V98, P15197, DOI 10.1073/pnas.211556298; Lanari C, 2001, CANCER RES, V61, P293; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; Lindberg K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2865; Lindberg K, 2010, J CELL PHYSIOL, V222, P156, DOI 10.1002/jcp.21932; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Liu Y, 2008, P NATL ACAD SCI USA, V105, P2604, DOI 10.1073/pnas.0712085105; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; MERLO GR, 1994, ONCOGENE, V9, P443; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Migliaccio A, 2006, ANN NY ACAD SCI, V1089, P194, DOI 10.1196/annals.1386.006; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nilsson S, 2011, CLIN PHARMACOL THER, V89, P44, DOI 10.1038/clpt.2010.226; Novaro V, 2003, J CELL SCI, V116, P2975, DOI 10.1242/jcs.00523; Novelli F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2139; Rahal OM, 2011, ENDOCRINOLOGY, V152, P3409, DOI 10.1210/en.2011-1085; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Roger P, 2001, CANCER RES, V61, P2537; Sanchez M, 2010, TRENDS ENDOCRIN MET, V21, P104, DOI 10.1016/j.tem.2009.09.007; Shaaban AM, 2008, CLIN CANCER RES, V14, P5228, DOI 10.1158/1078-0432.CCR-07-4528; Shu XO, 2009, JAMA-J AM MED ASSOC, V302, P2437, DOI 10.1001/jama.2009.1783; Skliris GP, 2006, BRIT J CANCER, V95, P616, DOI 10.1038/sj.bjc.6603295; Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436; Soldati R, 2010, BREAST CANCER RES TR, V123, P709, DOI 10.1007/s10549-009-0659-8; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Su Y, 2009, CARCINOGENESIS, V30, P331, DOI 10.1093/carcin/bgn279; Walker VR, 2004, ILAR J, V45, P455, DOI 10.1093/ilar.45.4.455; Weitsman GE, 2006, BREAST CANCER RES TR, V100, P23, DOI 10.1007/s10549-006-9229-5; Williams C, 2008, ONCOGENE, V27, P1019, DOI 10.1038/sj.onc.1210712; Wu XL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2844	50	68	72	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2390	2402		10.1038/onc.2012.261	http://dx.doi.org/10.1038/onc.2012.261			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751110				2022-12-28	WOS:000318694900003
J	Ribeiro, JD; Morey, L; Mas, A; Gutierrez, A; Luis, NM; Mejetta, S; Richly, H; Benitah, SA; Keyes, WM; Di Croce, L				Ribeiro, J. D.; Morey, L.; Mas, A.; Gutierrez, A.; Luis, N. M.; Mejetta, S.; Richly, H.; Benitah, S. A.; Keyes, W. M.; Di Croce, L.			ZRF1 controls oncogene-induced senescence through the INK4-ARF locus	ONCOGENE			English	Article						chromatin; Polycomb; senescence; ZRF1	DEMETHYLASE JMJD3 CONTRIBUTES; DEPENDENT KINASE INHIBITORS; HUMAN EMBRYONAL CARCINOMA; TUMOR-SUPPRESSOR LOCUS; NEURONAL DIFFERENTIATION; INK4A-ARF LOCUS; TRANSCRIPTIONAL ACTIVATION; CELLULAR SENESCENCE; CELLS; RAS	The reactivation of the INK4-ARF locus, which is epigenetically repressed by Polycomb proteins in healthy cells, is a hallmark of senescence. One mechanism of reactivating Polycomb-silenced genes is mediated by the epigenetic factor ZRF1, which associates with ubiquitinated histone H2A. We show that cells undergoing senescence following oncogenic Ras expression have increased ZRF1 levels, and that this binds to the p15INK4b, ARF and p16INK4a promoters. Furthermore, ZRF1 depletion in oncogenic Ras-expressing cells restores proliferation by preventing Arf and p16Ink4a expression, consequently bypassing senescence. Thus, ZRF1 regulates the INK4-ARF locus during cellular proliferation and senescence, and alterations in ZRF1 may contribute to tumorigenesis. Oncogene (2013) 32, 2161-2168; doi:10.1038/onc.2012.241; published online 25 June 2012	[Ribeiro, J. D.; Morey, L.; Mas, A.; Gutierrez, A.; Luis, N. M.; Mejetta, S.; Richly, H.; Benitah, S. A.; Keyes, W. M.; Di Croce, L.] CRG, Dept Differentiat & Canc, Barcelona 08003, Spain; [Ribeiro, J. D.; Morey, L.; Mas, A.; Gutierrez, A.; Luis, N. M.; Mejetta, S.; Richly, H.; Benitah, S. A.; Keyes, W. M.; Di Croce, L.] UPF, Barcelona 08003, Spain; [Benitah, S. A.; Di Croce, L.] ICREA, Barcelona, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; ICREA	Di Croce, L (corresponding author), CRG, Dept Differentiat & Canc, Barcelona 08003, Spain.	luciano.dicroce@crg.es	Luis, Nuno/F-2405-2012; Ribeiro, Jose Dirceu D/I-7308-2012; Di Croce, Luciano/E-7759-2015; Aznar-Benitah, Salvador/F-4761-2016; Gutierrez, Arantxa/K-8213-2015; Luis, Nuno Miguel/ABD-9784-2020; Ribeiro, Joana/K-3357-2014	Luis, Nuno/0000-0001-5438-9638; Ribeiro, Jose Dirceu D/0000-0002-3387-5642; Di Croce, Luciano/0000-0003-3488-6228; Aznar-Benitah, Salvador/0000-0002-9059-5049; Gutierrez, Arantxa/0000-0001-9033-3834; Luis, Nuno Miguel/0000-0001-5438-9638; Ribeiro, Joana/0000-0003-2221-4002; Morey, Lluis/0000-0001-9851-4066; Keyes, William M./0000-0002-8917-2268	Spanish 'Ministerio de Educacion y Ciencia' (CONSOLIDER) [BFU2010-18692]; European Commission FP7 project 4DCellFate [277899]; AICR [10-0177]; Foundation for Science and Technology (FCT) Portugal [SFRH/BD/15908/2005]; CRG-Novartis fellowship; ICREA Funding Source: Custom; Worldwide Cancer Research [10-0177] Funding Source: researchfish	Spanish 'Ministerio de Educacion y Ciencia' (CONSOLIDER)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Commission FP7 project 4DCellFate; AICR; Foundation for Science and Technology (FCT) Portugal(Portuguese Foundation for Science and Technology); CRG-Novartis fellowship; ICREA(ICREA); Worldwide Cancer Research	We thank VA Raker for help in preparing the manuscript, and to the CRG Genomic Unit. This work was supported by grants from the Spanish 'Ministerio de Educacion y Ciencia' (CONSOLIDER and BFU2010-18692), from the European Commission FP7 project 4DCellFate (277899), and from AICR (10-0177) to LDC. JDR was supported by grant SFRH/BD/15908/2005 from Foundation for Science and Technology (FCT) Portugal and is a fellow of the Graduate Program in Areas of Basic and Applied Biology (GABBA), University of Oporto, Portugal; LM was supported by a post-doctoral CRG-Novartis fellowship.	Adams PD, 2009, MOL CELL, V36, P2, DOI 10.1016/j.molcel.2009.09.021; Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Cruickshanks HA, 2011, CURR OPIN GENET DEV, V21, P100, DOI 10.1016/j.gde.2010.10.007; Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ferbeyre G, 2000, GENE DEV, V14, P2015; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kotake Y, 2009, CANCER RES, V69, P1809, DOI 10.1158/0008-5472.CAN-08-2739; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; LOIS AF, 1995, CANCER RES, V55, P4010; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maertens GN, 2010, EMBO J, V29, P2553, DOI 10.1038/emboj.2010.129; Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Resto VA, 2000, CANCER RES, V60, P5529; Richly H, 2011, CELL CYCLE, V10, P745, DOI 10.4161/cc.10.5.14795; Richly H, 2010, NATURE, V468, P1124, DOI 10.1038/nature09574; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Simboeck E, 2011, BIOCHEM PHARMACOL, V82, P1361, DOI 10.1016/j.bcp.2011.07.084; Smith JC, 2007, J PROTEOME RES, V6, P3174, DOI 10.1021/pr070122r; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	40	22	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 25	2013	32	17					2161	2168		10.1038/onc.2012.241	http://dx.doi.org/10.1038/onc.2012.241			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22733129				2022-12-28	WOS:000318062800005
J	Kawabata, KC; Ehata, S; Komuro, A; Takeuchi, K; Miyazono, K				Kawabata, K. C.; Ehata, S.; Komuro, A.; Takeuchi, K.; Miyazono, K.			TGF-beta-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20	ONCOGENE			English	Article						B-cell lymphoma; apoptosis; TGF-beta; MS4A1/CD20; rituximab	BURKITT-LYMPHOMA; RITUXIMAB; INVOLVEMENT; RESISTANCE; EXPRESSION; ANTIBODIES; THERAPY; PROTEIN; LINES; NHL	Transforming growth factor-beta (TGF-beta) exhibits growth inhibitory effects on various types of tumor cells, including B-cell lymphoma cells. In the present study, the role of TGF-beta in the survival of Epstein-Barr virus-negative B-cell lymphoma Ramos cells was investigated. As TGF-beta-induced apoptosis of Ramos cells in vitro and in vivo, we attempted to identify novel target gene(s) responsible for their survival. Oligonucleotide microarray analysis and chromatin immunoprecipitation revealed that Smad proteins directly regulated the transcription of membrane-spanning 4-domains, subfamily A, member 1 (MS4A1), also known as CD20, in Ramos cells upon TGF-beta stimulation. In addition, immunohistochemical analysis using clinical samples from B-cell lymphoma patients showed an inverse correlation between the expression of MS4A1/CD20 and phosphorylation of Smad3. Although knockdown of MS4A1/CD20 in Ramos cells resulted in an increase of apoptotic cells, Ramos cells stably expressing MS4A1/CD20 were resistant to TGF-beta-induced apoptosis. This suggests that MS4A1/CD20 is responsible for TGF-beta-induced apoptosis of B-cell lymphoma cells. Moreover, downregulation of MS4A1/CD20 by TGF-beta attenuated the effects of the monoclonal anti-MS4A1/CD20 antibody, rituximab, on Ramos cells. Our findings suggest that the sensitivity of B-cell lymphoma cells to rituximab may be affected by TGF-beta signaling. Oncogene (2013) 32, 2096-2106; doi:10.1038/onc.2012.219; published online 4 June 2012	[Kawabata, K. C.; Ehata, S.; Komuro, A.; Miyazono, K.] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Tokyo 1130033, Japan; [Takeuchi, K.] Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Tokyo 170, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	; Takeuchi, Kengo/C-3614-2008	Ehata, Shogo/0000-0002-6740-9391; Takeuchi, Kengo/0000-0002-1599-5800	KAKENHI; Global Center of Excellence Program 'Integrative Life Science Based on the Study of Biosignaling Mechanisms' from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); Japan Society for the Promotion of Science (JSPS) Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signaling; Grants-in-Aid for Scientific Research [22112002] Funding Source: KAKEN	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Global Center of Excellence Program 'Integrative Life Science Based on the Study of Biosignaling Mechanisms' from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); Japan Society for the Promotion of Science (JSPS) Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signaling(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank D Koinuma (the University of Tokyo) and Y Morishita (the University of Tokyo) for technical assistance and H Miyoshi (RIKEN) for the lentiviral vectors. This work was supported by KAKENHI (Grants-in-Aid for Scientific Research on Innovative Areas 'Integrative Research on Cancer Microenvironment Network' (to KM) Grant-in-Aid for Young Scientists (to SE)) and the Global Center of Excellence Program 'Integrative Life Science Based on the Study of Biosignaling Mechanisms' from the Ministry of Education, Culture, Sports, Science and Technology (MEXT). This work was also supported by Japan Society for the Promotion of Science (JSPS) Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signaling'.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; Bellan C, 2005, BLOOD, V106, P1031, DOI 10.1182/blood-2005-01-0168; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blackford A, 2009, CLIN CANCER RES, V15, P4674, DOI 10.1158/1078-0432.CCR-09-0227; Daniel D, 2007, BLOOD, V110, P4037, DOI 10.1182/blood-2007-02-076075; Daniels I, 2008, BRIT J HAEMATOL, V142, P394, DOI 10.1111/j.1365-2141.2008.07193.x; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Ernst JA, 2005, BIOCHEMISTRY-US, V44, P15150, DOI 10.1021/bi0511078; Fujita M, 2000, PATHOL INT, V50, P696, DOI 10.1046/j.1440-1827.2000.01108.x; Gopal AK, 2004, BLOOD, V103, P3516, DOI 10.1182/blood-2003-08-2795; Goyama S, 2009, CANCER SCI, V100, P990, DOI 10.1111/j.1349-7006.2009.01152.x; Guikema JEJ, 2006, GENE CHROMOSOME CANC, V45, P808, DOI 10.1002/gcc.20345; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Ikushima H, 2012, CELL TISSUE RES, V347, P37, DOI 10.1007/s00441-011-1179-5; Inman GJ, 2000, J GEN VIROL, V81, P1567, DOI 10.1099/0022-1317-81-6-1567; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jaffe ES, 2009, HEMATOL-AM SOC HEMAT, V2009, P523, DOI DOI 10.1182/ASHEDUCATI0N-2009.1.523; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Lin HK, 2005, ONCOGENE, V24, P5693, DOI 10.1038/sj.onc.1208923; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Mancao C, 2005, BLOOD, V106, P4339, DOI 10.1182/blood-2005-06-2341; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; MYEROFF LL, 1995, CANCER RES, V55, P5545; Polyak MJ, 2002, BLOOD, V99, P3256, DOI 10.1182/blood.V99.9.3256; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; SHIRAMIZU B, 1991, BLOOD, V77, P1516; Spender LC, 2009, J BIOL CHEM, V284, P1435, DOI 10.1074/jbc.M808080200; Stolz C, 2009, LEUKEMIA LYMPHOMA, V50, P873, DOI 10.1080/10428190902878471; Sugimoto T, 2009, BIOCHEM BIOPH RES CO, V390, P48, DOI 10.1016/j.bbrc.2009.09.059; Suzuki E, 2007, ONCOGENE, V26, P6184, DOI 10.1038/sj.onc.1210448; Uchiyama S, 2010, CANCER SCI, V101, P201, DOI 10.1111/j.1349-7006.2009.01392.x; van Meerten T, 2009, NETH J MED, V67, P251; Vega MI, 2009, CLIN CANCER RES, V15, P6582, DOI 10.1158/1078-0432.CCR-09-1234; Witzig TE, 2005, J CLIN ONCOL, V23, P1103, DOI 10.1200/JCO.2005.12.052; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197	42	20	23	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2096	2106		10.1038/onc.2012.219	http://dx.doi.org/10.1038/onc.2012.219			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22665052				2022-12-28	WOS:000317919900011
J	Li, Z; Zhang, Y; Kim, WJ; Daaka, Y				Li, Z.; Zhang, Y.; Kim, W. J.; Daaka, Y.			PGE2 promotes renal carcinoma cell invasion through activated RalA	ONCOGENE			English	Article						renal cell carcinoma; cell invasion; inflammation; PGE2; Ral	PROTEIN-COUPLED RECEPTORS; PROSTAGLANDIN-E-RECEPTORS; CANCER; GROWTH; E-2; PATHWAY; GTPASE; PHARMACOLOGY; INFLAMMATION; PROGRESSION	Incidence of kidney cancer is on the rise, and a better understanding of molecular mechanisms involved in the cancer invasion and metastasis is required for the development of curative therapeutics. In this study, we report that the proinflammatory cytokine prostaglandin E2 (PGE2) induces the malignant SN12C, but not benign HK2 kidney cell invasion. The PGE2 increases SN12C cell invasion through a signal pathway that encompasses EP2 and EP4, Akt, small GTPase RalA and Ral . GTP inactivator RGC2. The results support the idea that targeted interference of EP2/EP4 signal to RalA . GTP may provide benefit to patients diagnosed with advanced kidney cancer. Oncogene (2013) 32, 1408-1415; doi:10.1038/onc.2012.161; published online 14 May 2012	[Li, Z.; Zhang, Y.; Kim, W. J.; Daaka, Y.] Univ Florida, Coll Med, Dept Urol, Gainesville, FL 32610 USA; [Li, Z.; Zhang, Y.; Kim, W. J.; Daaka, Y.] Univ Florida, Coll Med, Prostate Dis Ctr, Gainesville, FL 32610 USA; [Daaka, Y.] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Daaka, Y (corresponding author), Univ Florida, Coll Med, Dept Urol, CGRC Rm 462,2033 Mowry Rd, Gainesville, FL 32610 USA.	ydaaka@ufl.edu			US National Institutes of Health [R01 CA129155]; NATIONAL CANCER INSTITUTE [R01CA129155] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr A Saltiel for providing anti-RGC2 and anti-phospho-RGC2 antibodies and the NCI for providing the SN12C cancer cells. We also thank Ms E Grigson and Ms K Durst for editorial assistance, and Dr Z Nie for reading and commenting on the manuscript. This work was supported, in part, by US National Institutes of Health grant R01 CA129155 (to YD).	Asano T, 2002, CLIN CANCER RES, V8, P1157; Balkwill F, 2010, CLIN PHARMACOL THER, V87, P401, DOI 10.1038/clpt.2009.312; Biswas S, 2009, NAT REV CLIN ONCOL, V6, P478, DOI 10.1038/nrclinonc.2009.91; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Bukowski RM, 2009, CANCER-AM CANCER SOC, V115, P2273, DOI 10.1002/cncr.24226; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen XW, 2011, MOL BIOL CELL, V22, P141, DOI 10.1091/mbc.E10-08-0665; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DeWire SM, 2011, CIRC RES, V109, P205, DOI 10.1161/CIRCRESAHA.110.231308; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; Eruslanov E, 2011, INT IMMUNOPHARMACOL, V11, P848, DOI 10.1016/j.intimp.2011.01.033; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; HALBRUGGE M, 1990, J CHROMATOGR, V521, P335, DOI 10.1016/0021-9673(90)85057-3; Hao CM, 2008, ANNU REV PHYSIOL, V70, P357, DOI 10.1146/annurev.physiol.70.113006.100614; Hattori M, 2003, J BIOCHEM, V134, P479, DOI 10.1093/jb/mvg180; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Kim WJ, 2012, CANC LETT, V1820, P743; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Murai M, 2004, CURR OPIN UROL, V14, P229, DOI 10.1097/01.mou.0000135078.04721.f5; PUGH S, 1994, GUT, V35, P675, DOI 10.1136/gut.35.5.675; Salcedo R, 2003, BLOOD, V102, P1966, DOI 10.1182/blood-2002-11-3400; Schlesinger-Raab A, 2008, EUR J CANCER, V44, P2485, DOI 10.1016/j.ejca.2008.07.039; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Smith SC, 2009, UROL ONCOL-SEMIN ORI, V27, P42, DOI 10.1016/j.urolonc.2008.04.012; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Sun M, 2010, NAT REV UROL, V7, P327, DOI 10.1038/nrurol.2010.57; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wu JJ, 2011, J BIOL CHEM, V286, P33954, DOI 10.1074/jbc.M110.187344; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07; Young AN, 2006, UROLOGY, V67, P873, DOI 10.1016/j.urology.2005.11.042	36	29	32	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1408	1415		10.1038/onc.2012.161	http://dx.doi.org/10.1038/onc.2012.161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22580611	Green Accepted			2022-12-28	WOS:000316455600007
J	Griner, EM; Churchill, MEA; Brautigan, DL; Theodorescu, D				Griner, E. M.; Churchill, M. E. A.; Brautigan, D. L.; Theodorescu, D.			PKC alpha phosphorylation of RhoGDI2 at Ser31 disrupts interactions with Rac1 and decreases GDI activity	ONCOGENE			English	Article						RhoGDI2; phosphorylation; GTPase; PKC alpha	RHO-GTPASES; DISSOCIATION INHIBITOR; CARCINOMA-CELLS; BLADDER-CANCER; PROTEIN; METASTASIS; EXPRESSION; INVASION; IDENTIFICATION; ASSOCIATION	Rho family GTPases control a diverse range of cellular processes, and their deregulation has been implicated in human cancer. Guanine nucleotide dissociation inhibitors (GDIs) bind and sequester GTPases in the cytosol, restricting their actions. RhoGDI2 is a member of the GDI family that acts as a metastasis suppressor in a variety of cancer types; however, very little is known about the regulation of this protein. Here, we present a mechanism for inactivation of RhoGDI2 via protein kinase C (PKC) phosphorylation of Ser31 in a region that contacts GTPases. In cells, RhoGDI2 becomes rapidly phosphorylated at Ser31 in response to phorbol 12-myristate 13-acetate stimulation. Based on the effects of pharmacological inhibitors and knockdown by siRNA, we determine that conventional type PKC alpha is responsible for this phosphorylation. Phospho-mimetic S31E-RhoGDI2 exhibits reduced binding to Rac1 relative to wild type, with a concomitant failure to reduce levels of activated endogenous Rac1 or remove Rac1 from membranes. These results reveal a mechanism of downregulation of RhoGDI2 activity through PKC-mediated phosphorylation of Ser31. We hypothesize that this mechanism may serve to neutralize RhoGDI2 function in tumors that express RhoGDI2 and active PKCa. Oncogene (2013) 32, 1010-1017; doi:10.1038/onc.2012.124; published online 2 April 2012	[Griner, E. M.; Brautigan, D. L.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Ctr Cell Signaling, Charlottesville, VA USA; [Churchill, M. E. A.; Theodorescu, D.] Univ Colorado, Dept Pharmacol, Aurora, CO 80045 USA; [Churchill, M. E. A.; Theodorescu, D.] Univ Colorado, Ctr Comprehens Canc, Aurora, CO 80045 USA	University of Virginia; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Theodorescu, D (corresponding author), Univ Colorado, Ctr Comprehens Canc, Dept Surg & Pharmacol, 13001 E 17th Pl MS F-434, Aurora, CO 80045 USA.	dantheodorescu@ucdenver.edu	Churchill, Mair E. A./C-5549-2014	Churchill, Mair E. A./0000-0003-0862-235X	National Institutes of Health [CA143971]; Paul Mellon Urologic Cancer Institute (Charlottesville, VA); NATIONAL CANCER INSTITUTE [R01CA143971, P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079154] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Paul Mellon Urologic Cancer Institute (Charlottesville, VA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Myr-PKC alpha was a generous gift of Dr Marcelo G Kazanietz (University of Pennsylvania). This work was supported by National Institutes of Health grant CA143971 to DT. EMG was supported by the Paul Mellon Urologic Cancer Institute (Charlottesville, VA).	Aaltonen V, 2010, ANTICANCER RES, V30, P3995; Aaltonen V, 2006, J HISTOCHEM CYTOCHEM, V54, P795, DOI 10.1369/jhc.5A6839.2006; Abiatari I, 2009, MOL CANCER THER, V8, P1494, DOI 10.1158/1535-7163.MCT-08-0755; Boulter E, 2010, NAT CELL BIOL, V12, P477, DOI 10.1038/ncb2049; Cho HJ, 2009, CLIN CANCER RES, V15, P2612, DOI 10.1158/1078-0432.CCR-08-2192; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Dovas A, 2010, J BIOL CHEM, V285, P23294, DOI 10.1074/jbc.M109.098129; Gildea JJ, 2002, CANCER RES, V62, P6418; Golovanov AP, 2001, J MOL BIOL, V305, P121, DOI 10.1006/jmbi.2000.4262; Gorvel JP, 1998, FEBS LETT, V422, P269, DOI 10.1016/S0014-5793(98)00020-9; Griner EM, 2010, J BIOL CHEM, V285, P16931, DOI 10.1074/jbc.M109.099036; Harding MA, 2010, EUR J CANCER, V46, P1252, DOI 10.1016/j.ejca.2010.02.025; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; Koivunen J, 2004, CANCER RES, V64, P5693, DOI 10.1158/0008-5472.CAN-03-3511; Koren R, 2000, APPL IMMUNOHISTO M M, V8, P166, DOI 10.1097/00022744-200006000-00013; Lopez-Pedrera C, 2006, PROTEOMICS, V6, pS293, DOI 10.1002/pmic.200500384; Ma L, 2007, BRIT J HAEMATOL, V139, P217, DOI 10.1111/j.1365-2141.2007.06782.x; Moissoglu K, 2009, CANCER RES, V69, P2838, DOI 10.1158/0008-5472.CAN-08-1397; Niu HY, 2010, ONCOL REP, V24, P465, DOI 10.3892/or_00000880; Pervaiz S, 2001, ONCOGENE, V20, P6263, DOI 10.1038/sj.onc.1204840; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rex EB, 2010, MOL PHARMACOL, V78, P69, DOI 10.1124/mol.110.063727; Saito N, 2002, J BIOCHEM, V132, P683, DOI 10.1093/oxfordjournals.jbchem.a003274; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Siliceo M, 2006, J CELL SCI, V119, P141, DOI 10.1242/jcs.02722; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wu YM, 2009, P NATL ACAD SCI USA, V106, P5807, DOI 10.1073/pnas.0810094106	33	17	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					1010	1017		10.1038/onc.2012.124	http://dx.doi.org/10.1038/onc.2012.124			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22469974	Green Accepted			2022-12-28	WOS:000316523200008
J	Nasr, Z; Robert, F; Porco, JA; Muller, WJ; Pelletier, J				Nasr, Z.; Robert, F.; Porco, J. A., Jr.; Muller, W. J.; Pelletier, J.			eIF4F suppression in breast cancer affects maintenance and progression	ONCOGENE			English	Article						elF4E; elF4A; PyMT mouse model; breast cancer; pulmonary metastasis	INITIATION-FACTOR 4E; MAMMARY-TUMOR PROGRESSION; CELL-GROWTH; C-MYC; THERAPEUTIC SUPPRESSION; EPITHELIAL-CELLS; MOUSE MODEL; TSC GENES; TRANSLATION; EXPRESSION	Levels of eukaryotic initiation factor 4E (eIF4E) are frequently elevated in human cancers and in some instances have been associated with poor prognosis and outcome. Here we utilize transgenic and allograft breast cancer models to demonstrate that increased mammalian target of rapamycin (mTOR) signalling can be a significant contributor to breast cancer progression in vivo. Suppressing mTOR activity, as well as levels and activity of the downstream translation regulators, elF4E and elF4A, delayed breast cancer progression, onset of associated pulmonary metastasis in vivo and breast cancer cell invasion and migration in vitro. Translation of vascular endothelial growth factor (VEGF), matrix metallopeptidase 9 (MMP9) and cyclin D1 mRNAs, which encode products associated with the metastatic phenotype, is inhibited upon eIF4E suppression. Our results indicate that the mTOR/eIF4F axis is an important contributor to tumor maintenance and progression programs in breast cancer. Targeting this pathway may be of therapeutic benefit. Oncogene (2013) 32, 861-871; doi:10.1038/onc.2012.105; published online 9 April 2012	[Nasr, Z.; Robert, F.; Muller, W. J.; Pelletier, J.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Porco, J. A., Jr.] Boston Univ, Dept Chem, Ctr Chem Methodol & Lib Dev, Boston, MA 02215 USA; [Muller, W. J.; Pelletier, J.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; Boston University; McGill University	Pelletier, J (corresponding author), McGill Univ, McIntyre Med Sci Bldg,Room 810,3655 Promenade Sir, Montreal, PQ H3G 1Y6, Canada.	jerry.pelletier@mcgill.ca			Canadian Institutes of Health Research [MOP-89791, MOP-106530]; CRC Chair in Molecular Oncology; National Institutes of Health [GM-073855]; Canadian Cancer Society Research Institute (CCSRI) [17099]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM111625, R01GM073855] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); CRC Chair in Molecular Oncology; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	WJM is supported by the Canadian Institutes of Health Research (MOP-89791) and a CRC Chair in Molecular Oncology. JAP, Jr thanks the National Institutes of Health (GM-073855) for research support. This work was supported by the Canadian Institutes of Health Research (MOP-106530) and the Canadian Cancer Society Research Institute (CCSRI no. 17099) to JP.	Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531; Bordeleau ME, 2008, J CLIN INVEST, V118, P2651, DOI 10.1172/JCI34753; Bordeleau ME, 2006, NAT CHEM BIOL, V2, P213, DOI 10.1038/nchembio776; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Brown CJ, 2011, J MOL BIOL, V405, P736, DOI 10.1016/j.jmb.2010.10.045; Cencic R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005223; Chakraborty S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-163; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dong K, 2009, BREAST CANCER RES TR, V113, P443, DOI 10.1007/s10549-008-9956-x; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Graff JR, 2007, J CLIN INVEST, V117, P2638, DOI 10.1172/JCI32044; GRAFF JR, 1995, INT J CANCER, V60, P255; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Iliopoulos D, 2011, CANCER RES, V71, P3196, DOI 10.1158/0008-5472.CAN-10-3471; Jiang H, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-2; Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Knowles MA, 2003, BIOCHEM SOC T, V31, P597, DOI 10.1042/BST0310597; Ko SY, 2009, CLIN CANCER RES, V15, P4336, DOI 10.1158/1078-0432.CCR-08-2924; Konicek BW, 2011, CANCER RES, V71, P1849, DOI 10.1158/0008-5472.CAN-10-3298; Larsson O, 2007, CANCER RES, V67, P6814, DOI 10.1158/0008-5472.CAN-07-0752; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; Lin CJ, 2008, CANCER RES, V68, P5326, DOI 10.1158/0008-5472.CAN-07-5876; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Maglione JE, 2001, CANCER RES, V61, P8298; Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Pons B, 2011, INT J ONCOL, V39, P1337, DOI 10.3892/ijo.2011.1118; PRICE JE, 1990, CANCER RES, V50, P717; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Soni A, 2008, MOL CANCER THER, V7, P1782, DOI 10.1158/1535-7163.MCT-07-2357; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Weigelt B, 2011, ONCOGENE, V30, P3222, DOI 10.1038/onc.2011.42; Wendel HG, 2006, CANCER RES, V66, P7639, DOI 10.1158/0008-5472.CAN-06-0419; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wienecke R, 1997, ANN NEUROL, V42, P230, DOI 10.1002/ana.410420215; Xu ZF, 2009, LEUKEMIA RES, V33, P891, DOI 10.1016/j.leukres.2009.01.041; Zhou FF, 2011, MED ONCOL, V28, P1302, DOI 10.1007/s12032-010-9630-0; Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420	57	57	63	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2013	32	7					861	871		10.1038/onc.2012.105	http://dx.doi.org/10.1038/onc.2012.105			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22484424	Green Accepted			2022-12-28	WOS:000316581100006
J	De Marco, P; Bartella, V; Vivacqua, A; Lappano, R; Santolla, MF; Morcavallo, A; Pezzi, V; Belfiore, A; Maggiolini, M				De Marco, P.; Bartella, V.; Vivacqua, A.; Lappano, R.; Santolla, M. F.; Morcavallo, A.; Pezzi, V.; Belfiore, A.; Maggiolini, M.			Insulin-like growth factor-I regulates GPER expression and function in cancer cells	ONCOGENE			English	Article						cancer cells; ER alpha; GPER; IGF-I; signal transduction	PROTEIN-COUPLED RECEPTOR; BREAST-CANCER; ESTROGEN-RECEPTOR; GENE-EXPRESSION; FACTOR SYSTEM; SIGNALING SYSTEMS; CCN FAMILY; IGF-I; GPR30; 17-BETA-ESTRADIOL	Functional cross talk between insulin-like growth factor-I (IGF-I) system and estrogen signaling has been largely reported, although the underlying molecular mechanisms remain to be fully elucidated. As GPR30/GPER mediates rapid cell responses to estrogens, we evaluated the potential of IGF-I to regulate GPER expression and function in estrogen receptor (ER)alpha-positive breast (MCF-7) and endometrial (Ishikawa) cancer cells. We found that IGF-I transactivates the GPER promoter sequence and upregulates GPER mRNA and protein levels in both cells types. Similar data were found, at least in part, in carcinoma-associated fibroblasts. The upregulation of GPER expression by IGF-I involved the IGF-IR/PKC delta/ERK/c-fos/AP1 transduction pathway and required ER alpha, as ascertained by specific pharmacological inhibitors and gene-silencing. In both MCF-7 and Ishikawa cancer cells, the IGF-I-dependent cell migration required GPER and its main target gene CTGF, whereas the IGF-I-induced proliferation required both GPER and cyclin D1. Our data demonstrate that the IGF-I system regulates GPER expression and function, triggering the activation of a signaling network that leads to the migration and proliferation of cancer cells. Oncogene (2013) 32, 678-688; doi:10.1038/onc.2012.97; published online 19 March 2012	[De Marco, P.; Bartella, V.; Vivacqua, A.; Lappano, R.; Santolla, M. F.; Pezzi, V.; Maggiolini, M.] Univ Calabria, Dept Pharmacobiol, I-87030 Arcavacata Di Rende, CS, Italy; [Morcavallo, A.; Belfiore, A.] Magna Graecia Univ Catanzaro, Dept Hlth, Catanzaro, Italy	University of Calabria; Magna Graecia University of Catanzaro	Maggiolini, M (corresponding author), Univ Calabria, Dept Pharmacobiol, Via P Bucci, I-87030 Arcavacata Di Rende, CS, Italy.	marcellomaggiolini@yahoo.it	Pezzi, Vincenzo/AAL-4017-2020; Maggiolini, Marcello/Z-4729-2019; vivacqua, adele/I-2771-2015; Santolla, Maria Francesca/AAH-5481-2020; Belfiore, Antonino/B-4652-2011; Lappano, Rosamaria/Z-4857-2019	vivacqua, adele/0000-0001-5333-8396; Belfiore, Antonino/0000-0002-6181-4193; pezzi, Vincenzo/0000-0003-2311-2286; Santolla, Maria Francesca/0000-0002-4838-5953; Lappano, Rosamaria/0000-0002-9374-9701; Maggiolini, Marcello/0000-0002-7485-854X	Associazione Italiana per la Ricerca sul Cancro (AIRC) [8925/2009, 10625/2009]; Fondazione Cassa di Risparmio di Calabria e Lucania; Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) [PRIN 2008PK2WCW/2008, PRIN 2008BKRFBH_005]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio di Calabria e Lucania; Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR))	This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, project no. 8925/2009 to MM and project no. 10625/2009 to AB; project Calabria 2011 to AB and MM) (http://www.airc.it/), Fondazione Cassa di Risparmio di Calabria e Lucania and Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) (project PRIN 2008PK2WCW/2008 to MM and project PRIN 2008BKRFBH_005 to AB) (http://www.istruzione.it/).	Akekawatchai C, 2005, J BIOL CHEM, V280, P39701, DOI 10.1074/jbc.M509829200; Albanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Bai ZL, 2009, ARCH PHARM, V342, P133, DOI 10.1002/ardp.200800174; Baron S, 2007, J BIOL CHEM, V282, P11732, DOI 10.1074/jbc.M610079200; Belfiore A, 2007, CURR PHARM DESIGN, V13, P671, DOI 10.2174/138161207780249173; Belfiore A, 2008, J MAMMARY GLAND BIOL, V13, P381, DOI 10.1007/s10911-008-9099-z; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bradley LM, 2008, J STEROID BIOCHEM, V109, P185, DOI 10.1016/j.jsbmb.2007.10.006; Cascio S, 2007, J BIOL CHEM, V282, P3498, DOI 10.1074/jbc.M606244200; Chaqour B, 2006, J BIOL CHEM, V281, P20608, DOI 10.1074/jbc.M600214200; Cortez V, 2010, Minerva Ginecol, V62, P573; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Fagan D, 2008, J MAMMARY GLAND BIOL, V13, P423, DOI 10.1007/s10911-008-9098-0; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Gerdes MJ, 2006, CANCER RES, V66, P7578, DOI 10.1158/0008-5472.CAN-06-1247; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Holbourn KP, 2008, TRENDS BIOCHEM SCI, V33, P461, DOI 10.1016/j.tibs.2008.07.006; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kisfalvi K, 2009, CANCER RES, V69, P6539, DOI 10.1158/0008-5472.CAN-09-0418; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lann D, 2008, J MAMMARY GLAND BIOL, V13, P371, DOI 10.1007/s10911-008-9100-x; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Madeo A, 2010, CANCER RES, V70, P6036, DOI 10.1158/0008-5472.CAN-10-0408; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; Mawson A, 2005, MOL CELL ENDOCRINOL, V229, P161, DOI 10.1016/j.mce.2004.08.002; Mendoza RA, 2011, J ENDOCRINOL, V208, P1, DOI 10.1677/JOE-10-0235; Pandey DP, 2009, EMBO J, V28, P523, DOI 10.1038/emboj.2008.304; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pike MC, 2004, ONCOGENE, V23, P6379, DOI 10.1038/sj.onc.1207899; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Recchia AG, 2011, J BIOL CHEM, V286, P10773, DOI 10.1074/jbc.M110.172247; Rosenzweig SA, 2010, BIOCHEM PHARMACOL, V80, P1115, DOI 10.1016/j.bcp.2010.06.013; Rozengurt E, 2010, CLIN CANCER RES, V16, P2505, DOI 10.1158/1078-0432.CCR-09-2229; Sirianni R, 2008, ENDOCRINOLOGY, V149, P5043, DOI 10.1210/en.2007-1593; Smith HO, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2007.01.004; Song RXD, 2007, ENDOCRINOLOGY, V148, P4091, DOI 10.1210/en.2007-0240; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; Vivacqua A, 2009, MOL ENDOCRINOL, V23, P1815, DOI 10.1210/me.2009-0120; Young SH, 2010, BIOCHEM BIOPH RES CO, V401, P154, DOI 10.1016/j.bbrc.2010.09.036; Zhang G, 2010, CANCER GENET CYTOGEN, V200, P140, DOI 10.1016/j.cancergencyto.2010.04.007	54	73	76	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2013	32	6					678	688		10.1038/onc.2012.97	http://dx.doi.org/10.1038/onc.2012.97			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430216				2022-12-28	WOS:000315746700002
J	Kalvik, TV; Arnesen, T				Kalvik, T. V.; Arnesen, T.			Protein N-terminal acetyltransferases in cancer	ONCOGENE			English	Review						N-terminal acetylation; NAT; Naa10p; oncoprotein; tumor suppressor	ARF-LIKE GTPASE; SACCHAROMYCES-CEREVISIAE; ALPHA-ACETYLATION; IDENTIFICATION; EXPRESSION; HYPOXIA; YEAST; COMPLEX; HARD1; REQUIRES	The human N-terminal acetyltransferases (NATs) catalyze the transfer of acetyl moieties to the N-termini of 80-90% of all human proteins. Six NAT types are present in humans, NatA-NatF, each is composed of specific subunits and each acetylates a set of substrates defined by the N-terminal amino-acid sequence. NATs have been suggested to act as oncoproteins as well as tumor suppressors in human cancers, and NAT expression may be both elevated and decreased in cancer versus non-cancer tissues. Manipulation of NATs in cancer cells induced cell-cycle arrest, apoptosis or autophagy, implying that these enzymes target a variety of pathways. Of particular interest is hNaa10p (human ARD1), the catalytic subunit of the NatA complex, which was coupled to a number of signaling molecules including hypoxia inducible factor-1 alpha, beta-catenin/cyclin D1, TSC2/mammalian target of rapamycin, myosin light chain kinase, DNA methyltransferase1/E-cadherin and p21-activated kinase-interacting exchange factors (PIX)/Cdc42/Rac1. The variety of mechanistic links where hNaa10p acts as a NAT, a lysine acetyltransferase or displaying a non-catalytic role, provide insights to how hNaa10p may act as both a tumor suppressor and oncoprotein. Oncogene (2013) 32, 269-276; doi:10.1038/onc.2012.82; published online 5 March 2012	[Kalvik, T. V.; Arnesen, T.] Univ Bergen, Dept Mol Biol, N-5020 Bergen, Hordaland, Norway; [Arnesen, T.] Haukeland Hosp, Dept Surg, N-5021 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital	Arnesen, T (corresponding author), Univ Bergen, Dept Mol Biol, N-5020 Bergen, Hordaland, Norway.	Thomas.Arnesen@mbi.uib.no	Arnesen, Thomas/J-7139-2017; Arnesen, Thomas/Q-8117-2019	Arnesen, Thomas/0000-0002-3005-147X; Arnesen, Thomas/0000-0002-3005-147X				Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; Ametzazurra A, 2008, ONCOGENE, V27, P7296, DOI 10.1038/onc.2008.332; Arnesen T, 2005, FEBS LETT, V579, P6428, DOI 10.1016/j.febslet.2005.10.036; Arnesen T, 2006, ONCOGENE, V25, P4350, DOI 10.1038/sj.onc.1209469; Arnesen T, 2006, GENE, V371, P291, DOI 10.1016/j.gene.2005.12.008; Arnesen T, 2005, THYROID, V15, P1131, DOI 10.1089/thy.2005.15.1131; Arnesen T, 2005, BIOCHEM J, V386, P433, DOI 10.1042/BJ20041071; Arnesen T, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001074; Arnesen T, 2010, MOL CELL BIOL, V30, P1898, DOI 10.1128/MCB.01199-09; Arnesen T, 2009, P NATL ACAD SCI USA, V106, P8157, DOI 10.1073/pnas.0901931106; Arnesen Thomas, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-13; Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Behnia R, 2004, NAT CELL BIOL, V6, P405, DOI 10.1038/ncb1120; Behnia R, 2007, J CELL BIOL, V176, P255, DOI 10.1083/jcb.200607151; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; BROWN JL, 1976, J BIOL CHEM, V251, P1009; Caesar R, 2004, J BIOL CHEM, V279, P38532, DOI 10.1074/jbc.M402939200; Coulton AT, 2010, J CELL SCI, V123, P3235, DOI 10.1242/jcs.069971; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Evjenth R, 2009, J BIOL CHEM, V284, P31122, DOI 10.1074/jbc.M109.001347; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Fluge O, 2002, ONCOGENE, V21, P5056, DOI 10.1038/sj.onc.1205687; Forte GMA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001073; Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Gromyko D, 2010, INT J CANCER, V127, P2777, DOI 10.1002/ijc.25275; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Helbig AO, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-685; Helsens K, 2011, J PROTEOME RES, V10, P3578, DOI 10.1021/pr2002325; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; Hofmann I, 2006, J CELL SCI, V119, P1494, DOI 10.1242/jcs.02958; Hole K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024713; Hopfl G, 2004, AM J PHYSIOL-REG I, V286, pR608, DOI 10.1152/ajpregu.00538.2003; Hou FJ, 2007, J CELL BIOL, V177, P587, DOI 10.1083/jcb.200701043; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hua KT, 2011, CANCER CELL, V19, P218, DOI 10.1016/j.ccr.2010.11.010; Huang GL, 2010, WORLD J GASTROENTERO, V16, P2046, DOI 10.3748/wjg.v16.i16.2046; Hwang CS, 2010, SCIENCE, V327, P973, DOI 10.1126/science.1183147; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kuo HP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000590; Lee CF, 2010, J CLIN INVEST, V120, P2920, DOI 10.1172/JCI42275; Lim JH, 2008, CANCER RES, V68, P5177, DOI 10.1158/0008-5472.CAN-07-6234; Lim JH, 2006, CANCER RES, V66, P10677, DOI 10.1158/0008-5472.CAN-06-3171; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; Liu Z, 2009, INT J BIOCHEM CELL B, V41, P2528, DOI 10.1016/j.biocel.2009.08.009; Marmorstein R, 2004, METHOD ENZYMOL, V376, P106; Martin DT, 2007, CLIN CANCER RES, V13, P1480, DOI 10.1158/1078-0432.CCR-06-1716; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Murray-Rust TA, 2006, FEBS LETT, V580, P1911, DOI 10.1016/j.febslet.2006.02.012; Murthi A, 2005, GENETICS, V170, P1553, DOI 10.1534/genetics.105.043620; Pimenta-Marques A, 2008, DEV BIOL, V323, P197, DOI 10.1016/j.ydbio.2008.08.021; Plasman K, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.003301; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Polevoda B, 2003, J BIOL CHEM, V278, P30686, DOI 10.1074/jbc.M304690200; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Polevoda B, 2008, J CELL BIOCHEM, V103, P492, DOI 10.1002/jcb.21418; Polevoda Bogdan, 2009, BMC Proc, V3 Suppl 6, pS2, DOI 10.1186/1753-6561-3-S6-S2; Ren TT, 2008, CANCER LETT, V264, P83, DOI 10.1016/j.canlet.2008.01.028; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Rope AF, 2011, AM J HUM GENET, V89, P28, DOI 10.1016/j.ajhg.2011.05.017; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scott DC, 2011, SCIENCE, V334, P674, DOI 10.1126/science.1209307; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Seo JH, 2010, CANCER RES, V70, P4422, DOI 10.1158/0008-5472.CAN-09-3258; Setty SRG, 2004, NAT CELL BIOL, V6, P414, DOI 10.1038/ncb1121; Shin DH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007451; Song OK, 2003, J BIOL CHEM, V278, P38109, DOI 10.1074/jbc.C300355200; Starheim KK, 2008, BIOCHEM J, V415, P325, DOI 10.1042/BJ20080658; Starheim Kristian K, 2009, BMC Proc, V3 Suppl 6, pS3, DOI 10.1186/1753-6561-3-S6-S3; Starheim KK, 2009, MOL CELL BIOL, V29, P3569, DOI 10.1128/MCB.01909-08; Sugiura N, 2003, J BIOL CHEM, V278, P40113, DOI 10.1074/jbc.M301218200; Van Damme P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002169; Varshavsky A, 2011, PROTEIN SCI, V20, P1298, DOI 10.1002/pro.666; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Williams BC, 2003, CURR BIOL, V13, P2025, DOI 10.1016/j.cub.2003.11.018; Yi CH, 2007, J CELL BIOL, V179, P619, DOI 10.1083/jcb.200708090; Yi CH, 2011, CELL, V146, P607, DOI 10.1016/j.cell.2011.06.050; Yu M, 2009, CANCER INVEST, V27, P978, DOI 10.3109/07357900902769723; Yu M, 2009, ONCOL REP, V21, P909, DOI 10.3892/or_00000303; Zhou J, 2006, CANCER LETT, V237, P10, DOI 10.1016/j.canlet.2005.05.028	88	113	119	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					269	276		10.1038/onc.2012.82	http://dx.doi.org/10.1038/onc.2012.82			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22391571				2022-12-28	WOS:000314736600001
J	Wilting, SM; Snijders, PJF; Verlaat, W; Jaspers, A; van de Wiel, MA; van Wieringen, WN; Meijer, GA; Kenter, GG; Yi, Y; le Sage, C; Agami, R; Meijer, CJLM; Steenbergen, RDM				Wilting, S. M.; Snijders, P. J. F.; Verlaat, W.; Jaspers, A.; van de Wiel, M. A.; van Wieringen, W. N.; Meijer, G. A.; Kenter, G. G.; Yi, Y.; le Sage, C.; Agami, R.; Meijer, C. J. L. M.; Steenbergen, R. D. M.			Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis	ONCOGENE			English	Article						microRNA; squamous cell carcinoma; adenocarcinoma; CIN lesion; HPV; hsa-miR-9	TUMOR-SUPPRESSIVE MICRORNAS; HUMAN-PAPILLOMAVIRUS DNA; GENE-EXPRESSION; MIRNA EXPRESSION; CELL-LINES; HIGH-RISK; CANCER; METHYLATION; LESIONS; KERATINOCYTES	Little is known about the alterations in microRNA (miRNA) expression patterns during the consecutive stages of cervical cancer development and their association with chromosomal instability. In this study, miRNA expression in normal cervical squamous epithelium, high-grade precancerous lesions (cervical intraepithelial neoplasia (CIN2-3)), squamous cell carcinomas (SCCs) and adenocarcinomas (AdCAs) was integrated with previously generated chromosomal profiles of the same samples. Significantly differential expression during the consecutive stages of cervical SCC development was observed for 106 miRNAs. Of these differentially expressed miRNAs, 27 showed early transiently altered expression in CIN2-3 lesions only, 46 miRNAs showed late altered expression in SCCs only and 33 showed continuously altered expression in both CIN2-3 and SCCs. Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations. Functional analyses were performed for hsa-miR-9, representing a potential oncogene with increased expression linked to a chromosomal gain of 1q. Hsa-miR-9 overexpression was found to increase cell viability, anchorage-independent growth and migration in vitro. Upon organic raft culturing, hsa-miR-9 hampered differentiation and induced proliferation in all strata of the epithelial layer. These findings support a potential oncogenic function of hsa-miR-9 in cervical cancer. In summary, differential expression of 106 miRNAs, partly associated with chromosomal alterations, was observed during cervical SCC development. Altered expression of hsa-miR-9 associated with a chromosomal gain of chromosome 1q was shown to be functionally relevant, underlining the importance of deregulated miRNA expression in cervical carcinogenesis. Oncogene (2013) 32, 106-116; doi:10.1038/onc.2012.20; published online 13 February 2012	[Steenbergen, R. D. M.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Unit Mol Pathol, NL-1007 MB Amsterdam, Netherlands; [van de Wiel, M. A.; van Wieringen, W. N.] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [van de Wiel, M. A.; van Wieringen, W. N.] Vrije Univ Amsterdam, Dept Math, Amsterdam, Netherlands; [Kenter, G. G.] VU Univ Med Ctr Amsterdam, Dept Obstet & Gynaecol, Amsterdam, Netherlands; [Yi, Y.] Vanderbilt Univ Sch Med, Vanderbilt Ingram Canc Ctr, Div Genet Med, Nashville, TN USA; [le Sage, C.; Agami, R.] Netherlands Canc Inst, Div Gene Regulat, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vanderbilt University; Netherlands Cancer Institute	Steenbergen, RDM (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Pathol, Unit Mol Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	r.steenbergen@vumc.nl	agami, reuven/GOG-8289-2022; van de Wiel, Mark/F-6759-2013; van Wieringen, Wessel N/F-9850-2016	van Wieringen, Wessel N/0000-0002-5100-9123; Wilting, Saskia/0000-0002-2838-841X; Meijer, Gerrit/0000-0003-0330-3130; Steenbergen, Renske/0000-0002-2327-9839; van de Wiel, Mark/0000-0003-4780-8472; Agami, Reuven/0000-0002-2848-2473	V-ICI institute of the VU University Medical Center, Amsterdam, The Netherlands [CCA20085-04]; Dutch Cancer Society (KWF) [VU2010-4668]	V-ICI institute of the VU University Medical Center, Amsterdam, The Netherlands(Netherlands Government); Dutch Cancer Society (KWF)(KWF Kankerbestrijding)	This work was supported by the V-ICI institute of the VU University Medical Center, Amsterdam, The Netherlands (grant number CCA20085-04) and the Dutch Cancer Society (KWF, grant number VU2010-4668). We are grateful to Marlon van der Plas, Suzanne Snellenberg, Nour Makazaji and Tim Schutte for excellent technical assistance.	Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Botezatu A, 2011, MOL MED REP, V4, P121, DOI 10.3892/mmr.2010.394; Bray I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007850; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chim CS, 2011, J CELL MOL MED, V15, P2760, DOI 10.1111/j.1582-4934.2011.01274.x; Fu Y, 1989, PATHOLOGY UTERINE CE, P288; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; Guo LM, 2009, FEBS J, V276, P5537, DOI 10.1111/j.1742-4658.2009.07237.x; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Hildebrandt MAT, 2010, ONCOGENE, V29, P5724, DOI 10.1038/onc.2010.305; Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914; Hu XX, 2010, CANCER RES, V70, P1441, DOI 10.1158/0008-5472.CAN-09-3289; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Li BH, 2010, INT J GYNECOL CANCER, V20, P597, DOI 10.1111/IGC.0b013e3181d63170; Li Y, 2011, J PATHOL, V224, P484, DOI 10.1002/path.2873; Lionetti M, 2009, GENE CHROMOSOME CANC, V48, P521, DOI 10.1002/gcc.20660; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Manduchi E, 2000, BIOINFORMATICS, V16, P685, DOI 10.1093/bioinformatics/16.8.685; Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919; Mascaux C, 2009, EUR RESPIR J, V33, P352, DOI 10.1183/09031936.00084108; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; McKenna DJ, 2010, J VIROL, V84, P10644, DOI 10.1128/JVI.00703-10; Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10; Muralidhar B, 2007, J PATHOL, V212, P368, DOI 10.1002/path.2179; Muralidhar B, 2011, J PATHOL, V224, P496, DOI 10.1002/path.2898; Nuovo GJ, 2010, DIAGN MOL PATHOL, V19, P135, DOI 10.1097/PDM.0b013e3181c4daaa; Overmeer RM, 2009, J PATHOL, V219, P327, DOI 10.1002/path.2598; Pereira PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011780; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Rao QX, 2012, MED ONCOL, V29, P1242, DOI 10.1007/s12032-011-9830-2; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Steenbergen RDM, 1998, J VIROL, V72, P749, DOI 10.1128/JVI.72.1.749-757.1998; TASE T, 1989, INT J GYNECOL PATHOL, V8, P8, DOI 10.1097/00004347-198903000-00002; van Wieringen WN, 2009, BIOMETRICS, V65, P19, DOI 10.1111/j.1541-0420.2008.01052.x; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201; Wang X, 2009, RNA, V15, P637, DOI 10.1261/rna.1442309; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209; Wentzensen N, 2007, DIS MARKERS, V23, P315, DOI 10.1155/2007/678793; Wilting S, 2006, J PATHOL, V209, P220, DOI 10.1002/path.1966; Wilting SM, 2008, GENE CHROMOSOME CANC, V47, P890, DOI 10.1002/gcc.20590; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Wilting SM, 2009, CANCER RES, V69, P647, DOI 10.1158/0008-5472.CAN-08-2478; Winer RL, 2005, J INFECT DIS, V191, P731, DOI 10.1086/427557; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Yi YJ, 2005, GENOMICS, V85, P401, DOI 10.1016/j.ygeno.2004.11.011; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zielinski GD, 2001, BRIT J CANCER, V85, P398, DOI 10.1054/bjoc.2001.1926	60	117	122	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					106	116		10.1038/onc.2012.20	http://dx.doi.org/10.1038/onc.2012.20			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22330141				2022-12-28	WOS:000313029500011
J	Liu, Z; Li, Q; Li, K; Chen, L; Li, W; Hou, M; Liu, T; Yang, J; Lindvall, C; Bjorkholm, M; Jia, J; Xu, D				Liu, Z.; Li, Q.; Li, K.; Chen, L.; Li, W.; Hou, M.; Liu, T.; Yang, J.; Lindvall, C.; Bjorkholm, M.; Jia, J.; Xu, D.			Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells	ONCOGENE			English	Article						CSCs; EMT; gastric cancer; hTERT	TUMOR-INITIATING CELLS; INDUCED APOPTOSIS; GASTRIC-CANCER; BETA-CATENIN; EXPRESSION; SNAIL; GROWTH; CARCINOMA; SURVIVAL; METASTASIS	Telomerase activation through induction of telomerase reverse transcriptase (hTERT) contributes to malignant transformation by stabilizing telomeres. Clinical studies demonstrate that higher hTERT expression is associated with cancer progression and poor outcomes, but the underlying mechanism is unclear. Because epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) are key factors in cancer metastasis and relapse, and hTERT has been shown to exhibit multiple biological activities independently of its telomere-lengthening function, we address a potential role of hTERT in EMT and CSCs using gastric cancer (GC) as a model. hTERT overexpression promotes, whereas its inhibition suppresses, EMT and stemness of GC cells, respectively. Transforming growth factor (TGF)-beta 1 and beta-catenin-mediated EMT was abolished by small interfering RNA depletion of hTERT expression. hTERT interacts with beta-catenin, enhances its nuclear localization and transcriptional activity, and occupies the beta-catenin target vimentin promoter. All these hTERT effects were independent of its telomere-lengthening function or telomerase activity. hTERT and EMT marker expression correlates positively in GC samples. Mouse experiments demonstrate the in vivo stimulation of hTERT on cancer cell colonization. Collectively, hTERT stimulates EMT and induces stemness of cancer cells, thereby promoting cancer metastasis and recurrence. Thus, targeting hTERT may prevent cancer progression by inhibiting EMT and CSCs.	[Liu, Z.; Li, Q.; Chen, L.; Li, W.; Jia, J.] Shandong Univ, Sch Med, Chinese Minist Educ, Dept Microbiol,Key Lab Expt Teratol, Jinan 250012, Peoples R China; [Liu, Z.; Li, Q.; Chen, L.; Li, W.; Jia, J.] Shandong Univ, Hosp 2, Jinan 250012, Peoples R China; [Liu, Z.; Li, Q.; Liu, T.; Yang, J.; Bjorkholm, M.; Xu, D.] Karolinska Univ Hosp, Dept Med, Div Haematol, Stockholm, Sweden; [Liu, Z.; Li, Q.; Liu, T.; Yang, J.; Bjorkholm, M.; Xu, D.] Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden; [Liu, Z.; Li, Q.; Li, K.; Hou, M.; Liu, T.; Yang, J.; Bjorkholm, M.; Xu, D.] Karolinska Inst, Stockholm, Sweden; [Li, K.] Karolinska Univ Hosp, Dept Biosci & Nutr, Stockholm, Sweden; [Hou, M.] Karolinska Univ Hosp, Dept Women & Child Hlth, Stockholm, Sweden; [Lindvall, C.] Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, Grand Rapids, MI USA; [Xu, D.] Shandong Univ, Hosp 2, Cent Res Lab, Jinan 250012, Peoples R China	Shandong University; Shandong University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Van Andel Institute; Shandong University	Jia, J (corresponding author), Shandong Univ, Sch Med, Chinese Minist Educ, Dept Microbiol,Key Lab Expt Teratol, Jinan 250012, Peoples R China.	jiajihui@sdu.edu.cn; Dawei.Xu@ki.se		Hou, Mi/0000-0002-4573-7028; Xu, Dawei/0000-0003-3141-4524	National Basic Research Program of China [973 Program 2012CB911202]; Swedish Cancer Society; Swedish Research Council; Cancer Society in Stockholm; Swedish Child Cancer Society; Karolinska Institutet Foundations; National Natural Science Foundation of China [30770118, 30800406, 30972775, 81071721, 81000868, 81171536]; National Key Scientific Program of China [2007CB914801]; Science Foundation of Shandong Province [ZR2009CZ001, ZR2009CM002, BS2010YY040]	National Basic Research Program of China(National Basic Research Program of China); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Society in Stockholm; Swedish Child Cancer Society; Karolinska Institutet Foundations(Karolinska Institutet); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Scientific Program of China; Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	We thank Drs RA Weinberg (Massachusetts Institute of Technology), CM Counter (Duke University), JM Wong and K Collins (University of California, Berkeley), Y Cong (Beijing Normal University) and W Cui (Imperial College London) for retroviral vectors and plasmids. This study was supported by the National Basic Research Program of China (grant No. 973 Program 2012CB911202), the Swedish Cancer Society, the Swedish Research Council, Cancer Society in Stockholm, Swedish Child Cancer Society, the Karolinska Institutet Foundations, National Natural Science Foundation of China (No.: 30770118, 30800406, 30972775, 81071721, 81000868, 81171536), the National Key Scientific Program of China (2007CB914801) and the Science Foundation of Shandong Province (No.: ZR2009CZ001, ZR2009CM002 and BS2010YY040)	Boukamp P, 2007, EXP DERMATOL, V16, P71, DOI 10.1111/j.1600-0625.2006.00517.x; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Chen HP, 2009, MOL BIOTECHNOL, V41, P194, DOI 10.1007/s12033-008-9117-9; Cong YS, 2008, CELL RES, V18, P725, DOI 10.1038/cr.2008.74; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200; Domomt J, 2005, J CLIN ONCOL, V23, P3086, DOI 10.1200/JCO.2005.06.944; Dudognon C, 2004, ONCOGENE, V23, P7469, DOI 10.1038/sj.onc.1208029; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Gerrard L, 2005, STEM CELLS, V23, P124, DOI 10.1634/stemcells.2004-0102; Gertler R, 2004, J CLIN ONCOL, V22, P1807, DOI 10.1200/JCO.2004.09.160; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275; Hayry V, 2009, ENDOCR-RELAT CANCER, V16, P1211, DOI 10.1677/ERC-09-0049; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim MA, 2009, HISTOPATHOLOGY, V54, P442, DOI 10.1111/j.1365-2559.2009.03247.x; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Liu JP, 2010, AGEING RES REV, V9, P245, DOI 10.1016/j.arr.2010.03.002; Liu L, 2011, J PATHOL, V225, P203, DOI 10.1002/path.2914; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marian CO, 2010, CLIN CANCER RES, V16, P154, DOI 10.1158/1078-0432.CCR-09-2850; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ohali A, 2003, J CLIN ONCOL, V21, P3836, DOI 10.1200/JCO.2003.05.059; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Shay JW, 2007, J PATHOL, V211, P114, DOI 10.1002/path.2090; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Strong MA, 2011, MOL CELL BIOL, V31, P2369, DOI 10.1128/MCB.05312-11; Tabori U, 2006, J CLIN ONCOL, V24, P1522, DOI 10.1200/JCO.2005.04.2127; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Terrin L, 2008, CLIN CANCER RES, V14, P7444, DOI 10.1158/1078-0432.CCR-08-0478; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; van Zijl F, 2009, FUTURE ONCOL, V5, P1169, DOI [10.2217/fon.09.91, 10.2217/FON.09.91]; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Waldmann J, 2008, BRIT J CANCER, V99, P1900, DOI 10.1038/sj.bjc.6604755; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou LL, 2009, BIOCHEM BIOPH RES CO, V386, P739, DOI 10.1016/j.bbrc.2009.06.116	55	191	199	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2013	32	36					4203	4213		10.1038/onc.2012.441	http://dx.doi.org/10.1038/onc.2012.441			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045275				2022-12-28	WOS:000324168000002
J	Tripurani, SK; Cook, RW; Eldin, KW; Pangas, SA				Tripurani, S. K.; Cook, R. W.; Eldin, K. W.; Pangas, S. A.			BMP-specific SMADs function as novel repressors of PDGFA and modulate its expression in ovarian granulosa cells and tumors	ONCOGENE			English	Article						bone morphogenetic protein; platelet-derived growth factor; SMAD1; SMAD5; granulosa cell tumor	FACTOR-A-CHAIN; GROWTH-FACTORS; GENE-TRANSCRIPTION; RECEPTORS; BINDING; CANCER; PATHWAY; SP1	Platelet-derived growth factor alpha (PDGFA) is frequently upregulated in various cancers and thought to function as a key player in the development and progression of tumor growth by regulating aspects of cell proliferation, angiogenesis and metastasis. However, the mechanism by which it is upregulated is not fully understood. Previously, we demonstrated that conditional deletion of two transcription factors that signal for the bone morphogenetic proteins (Smad1 and Smad5) in ovarian granulosa cells causes metastatic granulosa cell tumors (GCTs) in female mice and phenocopies human juvenile GCTs (JGCTs). Smad1/5 double conditional knockout tumors, as well as human JGCTs, are highly vascularized, hemorrhagic and mitotically active. Expression analysis of these tumors and their metastases revealed a significant upregulation of key proliferation and pro-angiogenic factors such as Pdgfa, Pdgfb and Vegf. We examined whether these genes were direct targets of SMAD1 and SMAD5. Knockdown of SMAD1 and SMAD5 in mouse primary granulosa cells and a human GCT-derived cell line (COV434) resulted in upregulation of PDGFA, but not PDGFB nor VEGF. We identified several putative SMAD1/5-binding sites in the PDGFA promoter, and chromatin immunoprecipitation and reporter assays demonstrated that SMAD1/5 interact with the PDGFA promoter to regulate its activity. Further, SMAD1/5 antagonize the activity of the transcription factor Sp1, a well-known positive regulator of PDGFA, by inhibiting its occupancy at a key regulatory site on the proximal PDGFA promoter. Collectively, our studies establish that loss of SMAD1/5 leads to upregulation of PDGFA in ovarian granulosa cells, and that a novel regulatory interaction exists between the BR-SMADs and Sp1 in controlling PDGFA expression during granulosa cell tumorigenesis.	[Tripurani, S. K.; Cook, R. W.; Eldin, K. W.; Pangas, S. A.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Pangas, S. A.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Pangas, SA (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	spangas@bcm.edu		Pangas, Stephanie/0000-0001-5748-5844	Burroughs Wellcome Career award in Biomedical Sciences; NIH [CA138628]; NATIONAL CANCER INSTITUTE [R01CA138628] Funding Source: NIH RePORTER	Burroughs Wellcome Career award in Biomedical Sciences(Burroughs Wellcome Fund); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Burroughs Wellcome Career award in Biomedical Sciences and a NIH CA138628 to SAP. We thank Dr David Kaetzel (University of Kentucky) for the PDGFA luciferase plasmids, Drs An Zwijsen (Leuven University), Elizabeth Robertson (University of Oxford), and Richard R Behringer (MD Anderson Cancer Center) for mouse lines, and Dr Xin-Hua Feng (Baylor College of Medicine) for the flag-tagged SMAD1 and SMAD5 expression plasmids. We thank Rebecca James, Hermann Piard and Yuxuan Lin for technical assistance and Nadera Mansouri-Attia, Krishna Jagarlamudi for critical reading of the manuscript.	Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Chu S, 2008, GYNECOL ONCOL, V108, P182, DOI 10.1016/j.ygyno.2007.09.017; Edson MA, 2010, MOL ENDOCRINOL, V24, P1251, DOI 10.1210/me.2009-0461; Fei T, 2010, GENOME RES, V20, P36, DOI 10.1101/gr.092114.109; Fortin J, 2010, CELL SIGNAL, V22, P936, DOI 10.1016/j.cellsig.2010.01.019; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; George D, 2003, ADV EXP MED BIOL, V532, P141; Gonfloni S, 2009, NAT MED, V15, P1179, DOI 10.1038/nm.2033; Hoffmann AC, 2008, NEOPLASIA, V10, P674, DOI 10.1593/neo.08292; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Iwamori T, 2010, MOL CELL BIOL, V30, P2280, DOI 10.1128/MCB.01392-09; Kaetzel DM, 2003, CYTOKINE GROWTH F R, V14, P427, DOI 10.1016/S1359-6101(03)00051-0; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Kodach LL, 2008, GASTROENTEROLOGY, V134, P1332, DOI 10.1053/j.gastro.2008.02.059; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Middlebrook BS, 2009, ENDOCRINOLOGY, V150, P5208, DOI 10.1210/en.2009-0644; Morikawa M, 2011, NUCLEIC ACIDS RES, V39, P8712, DOI 10.1093/nar/gkr572; Pangas SA, 2004, J BIOL CHEM, V279, P32281, DOI 10.1074/jbc.M403212200; Pangas SA, 2008, MOL CELL BIOL, V28, P248, DOI 10.1128/MCB.01404-07; Pinkas H, 2008, MOL HUM REPROD, V14, P199, DOI 10.1093/molehr/gan011; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; Rocconi RP, 2008, REPROD SCI, V15, P673, DOI 10.1177/1933719108317584; Schumer ST, 2003, J CLIN ONCOL, V21, P1180, DOI 10.1200/JCO.2003.10.019; Shih AH, 2006, CANCER LETT, V232, P139, DOI 10.1016/j.canlet.2005.02.002; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Uhrbom L, 1998, CANCER RES, V58, P5275; Yamamoto S, 2008, MODERN PATHOL, V21, P115, DOI 10.1038/modpathol.3800984; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54; Zhang H, 2000, MOL HUM REPROD, V6, P146, DOI 10.1093/molehr/6.2.146	35	22	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3877	3885		10.1038/onc.2012.392	http://dx.doi.org/10.1038/onc.2012.392			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22964636	Green Accepted			2022-12-28	WOS:000323210200010
J	Gillis, LD; Lewis, SM				Gillis, L. D.; Lewis, S. M.			Decreased eIF3e/Int6 expression causes epithelial-to-mesenchymal transition in breast epithelial cells	ONCOGENE			English	Article						migration; metastasis; breast cancer; Snail1; Zeb2; translation initiation	MAMMARY-TUMOR VIRUS; TRANSLATION INITIATION; GENE-EXPRESSION; MIR-200 FAMILY; SNAIL; INT6; TRANSCRIPTION; PHOSPHORYLATION; PROGRESSION; INT6/EIF3E	eIF3e/Int6 is a component of the multi-subunit eIF3 complex, which binds directly to the 40S ribosome to facilitate ribosome recruitment to mRNA and hence protein synthesis. Reduced expression of eIF3e/Int6 has been found in up to 37% of human breast cancers, and expression of a truncated mutant version of the mouse eIF3e/Int6 protein leads to malignant transformation of normal mammary cells. These findings suggest that eIF3e/Int6 is a tumor suppressor; however, a recent study has reported that a reduction of eIF3e/Int6 expression in breast cancer cells leads to reduced translation of oncogenes, suggesting that eIF3e/Int6 may in fact have an oncogenic role in breast cancer. To gain a better understanding of the role of eIF3e/Int6 in breast cancer, we have examined the effects of decreased eIF3e/Int6 expression in an immortalized breast epithelial cell line, MCF-10A. Surprisingly, we find that decreased expression of eIF3e/Int6 causes breast epithelial cells to undergo epithelial-to-mesenchymal transition (EMT). We show that EMT induced by a decrease in eIF3e/Int6 expression imparts invasive and migratory properties to breast epithelial cells, suggesting that regulation of EMT by eIF3e/Int6 may have an important role in breast cancer metastasis. Furthermore, we show that reduced eIF3e/Int6 expression in breast epithelial cells causes a specific increase in the expression of the key EMT regulators Snail1 and Zeb2, which occurs at both the transcriptional and post-transcriptional levels. Together, our data indicate a novel role of eIF3e/Int6 in the regulation of EMT in breast epithelial cells and support a tumor suppressor role of eIF3e/Int6.	[Gillis, L. D.; Lewis, S. M.] Hotel Dieu Pavil, Atlantic Canc Res Inst, Moncton, NB E1C 8X3, Canada; [Lewis, S. M.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada; [Lewis, S. M.] Univ New Brunswick, Dept Biol, St John, NB E2L 4L5, Canada	Dalhousie University; University of New Brunswick	Lewis, SM (corresponding author), Hotel Dieu Pavil, Atlantic Canc Res Inst, 35 Providence St, Moncton, NB E1C 8X3, Canada.	stephenl@canceratl.ca	Lewis, Stephen/E-5533-2010	Lewis, Stephen/0000-0001-9537-5822	Canadian Breast Cancer Foundation-Atlantic Chapter; Canadian Institutes of Health Research-Regional [RSH-108667]	Canadian Breast Cancer Foundation-Atlantic Chapter; Canadian Institutes of Health Research-Regional	We thank Dr Craig McCormick for the generous gift of the retroviral transduction system used in this study, Dr Anirban Ghosh for advice on confocal immunofluorescence microscopy and Dr Martin Holcik for critical comments on the manuscript. This research was supported by a grant to SML from the Canadian Breast Cancer Foundation-Atlantic Chapter. SML is a Senior Scientist of the Beatrice Hunter Cancer Research Institute and a Canadian Institutes of Health Research-Regional Partnerships Program New Investigator (RSH-108667).	Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Beltran M, 2008, GENE DEV, V22, P756, DOI 10.1101/gad.455708; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Chiluiza D, 2011, J BIOL CHEM, V286, P31288, DOI 10.1074/jbc.M111.267294; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Evdokimova V, 2009, CELL CYCLE, V8, P2901, DOI 10.4161/cc.8.18.9537; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grzmil M, 2010, ONCOGENE, V29, P4080, DOI 10.1038/onc.2010.152; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; LeFebvre AK, 2006, J BIOL CHEM, V281, P22917, DOI 10.1074/jbc.M605418200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo DC, 2011, MOL CANCER RES, V9, P234, DOI 10.1158/1541-7786.MCR-10-0214; Mack DL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1742; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Morris C, 2007, EMBO REP, V8, P596, DOI 10.1038/sj.embor.7400955; PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323; Petz M, 2007, NUCLEIC ACIDS RES, V35, P2473, DOI 10.1093/nar/gkm096; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Raun R, MRNA FORMATION FUNCT, P305; SOULE HD, 1990, CANCER RES, V50, P6075; Suo J, 2011, ONCOGENE, V30, P724, DOI 10.1038/onc.2010.445; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhao TT, 2009, CELL DEATH DIFFER, V16, P244, DOI 10.1038/cdd.2008.146; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14; Zhou M, 2008, P NATL ACAD SCI USA, V105, P18139, DOI 10.1073/pnas.0801313105	40	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3598	3605		10.1038/onc.2012.371	http://dx.doi.org/10.1038/onc.2012.371			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22907435				2022-12-28	WOS:000322638400004
J	Bhattacharya, A; Schmitz, U; Wolkenhauer, O; Schoenherr, M; Raatz, Y; Kunz, M				Bhattacharya, A.; Schmitz, U.; Wolkenhauer, O.; Schoenherr, M.; Raatz, Y.; Kunz, M.			Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma	ONCOGENE			English	Article						microRNA; melanoma; metastasis; cell cycle	SUPPRESSES TUMORIGENICITY; MICRORNAS; EXPRESSION; GENES; METASTASIS; INHIBITION; MK-1775; PATHWAY; CHK1; P53	WEE1 kinase has been described as a major gate keeper at the G2 cell cycle checkpoint and to be involved in tumour progression in different malignant tumours. Here we analysed the expression levels of WEE1 in a series of melanoma patient samples and melanoma cell lines using immunoblotting, quantitative real-time PCR and immunohistochemistry. WEE1 expression was significantly downregulated in patient samples of metastatic origin as compared with primary melanomas and in melanoma cell lines of high aggressiveness as compared with cell lines of low aggressiveness. Moreover, there was an inverse correlation between the expression of WEE1 and WEE1-targeting microRNA miR-195. Further analyses showed that transfection of melanoma cell lines with miR-195 indeed reduced WEE1 mRNA and protein expression in these cells. Reporter gene analysis confirmed direct targeting of the WEE1 3' untranslated region (3'UTR) by miR-195. Overexpression of miR-195 in SK-Mel-28 melanoma cells was accompanied by WEE1 reduction and significantly reduced stress-induced G2-M cell cycle arrest, which could be restored by stable overexpression of WEE1. Moreover, miR-195 overexpression and WEE1 knockdown, respectively, increased melanoma cell proliferation. miR-195 overexpression also enhanced migration and invasiveness of melanoma cells. Taken together, the present study shows that WEE1 expression in malignant melanoma is directly regulated by miR-195. miR-195-mediated downregulation of WEE1 in metastatic lesions may help to overcome cell cycle arrest under stress conditions in the local tissue microenvironment to allow unrestricted growth of tumour cells.	[Bhattacharya, A.; Schoenherr, M.; Raatz, Y.; Kunz, M.] Univ Leipzig, Dept Dermatol Venereol & Allergol, D-04103 Leipzig, Germany; [Schmitz, U.; Wolkenhauer, O.] Univ Rostock, Dept Syst Biol & Bioinformat, D-18055 Rostock, Germany	Leipzig University; University of Rostock	Bhattacharya, A (corresponding author), Univ Leipzig, Dept Dermatol Venereol & Allergol, Philipp Rosenthal St 23-25, D-04103 Leipzig, Germany.	animesh.bhattacharya@medizin.uni-leipzig.de	Schmitz, Ulf/B-5400-2010	Schmitz, Ulf/0000-0001-5806-4662; Wolkenhauer, Olaf/0000-0001-6105-2937	Deutsche Forschungsgemeinschaft [KU 1320/5-1, WO 991/4-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank T Magin, Translational Centre for Regenerative Medicine (TRM), Division of Cell and Developmental Biology, University of Leipzig, for helpful advice and discussion. This work was supported by the Deutsche Forschungsgemeinschaft, grant number KU 1320/5-1 to MK and grant number WO 991/4-1 to WO.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Beck H, 2010, J CELL BIOL, V188, P629, DOI 10.1083/jcb.200905059; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashimoto O, 2003, MOL CARCINOGEN, V36, P171, DOI 10.1002/mc.10111; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hirai H, 2010, CANCER BIOL THER, V9, P514, DOI 10.4161/cbt.9.7.11115; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Jewell R, 2010, CLIN CANCER RES, V16, P5211, DOI 10.1158/1078-0432.CCR-10-1521; Bueno MJ, 2011, BBA-MOL BASIS DIS, V1812, P592, DOI 10.1016/j.bbadis.2011.02.002; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Levati L, 2009, INT J ONCOL, V35, P393, DOI 10.3892/ijo_00000352; Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800; Liu L, 2010, BIOCHEM BIOPH RES CO, V400, P236, DOI 10.1016/j.bbrc.2010.08.046; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mir SE, 2010, CANCER CELL, V18, P244, DOI 10.1016/j.ccr.2010.08.011; Muller DW, 2008, ONCOGENE, V27, P6698, DOI 10.1038/onc.2008.282; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Philippidou D, 2010, CANCER RES, V70, P4163, DOI 10.1158/0008-5472.CAN-09-4512; Qi JL, 2009, CELL CYCLE, V8, P3729, DOI 10.4161/cc.8.22.10033; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rai D, 2010, P NATL ACAD SCI USA, V107, P3111, DOI 10.1073/pnas.0910667107; Schultz J, 2008, CELL RES, V18, P549, DOI 10.1038/cr.2008.45; Swarbrick A, 2010, NAT MED, V16, P1134, DOI 10.1038/nm.2227; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Ujifuku K, 2010, CANCER LETT, V296, P241, DOI 10.1016/j.canlet.2010.04.013; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Wang F, 2005, ONCOGENE, V24, P3875, DOI 10.1038/sj.onc.1208546; Wang YL, 2001, CANCER RES, V61, P8211; Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919; Yoshida T, 2004, ANN ONCOL, V15, P252, DOI 10.1093/annonc/mdh073; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	40	77	82	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2013	32	26					3175	3183		10.1038/onc.2012.324	http://dx.doi.org/10.1038/onc.2012.324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22847610				2022-12-28	WOS:000321004600008
J	Zhang, J; Chen, QM				Zhang, J.; Chen, Q. M.			Far upstream element binding protein 1: a commander of transcription, translation and beyond	ONCOGENE			English	Review						FBP1; FUSE; cancer	FBP-INTERACTING REPRESSOR; P27(KIP1) MESSENGER-RNA; DNA HELICASE-V; C-MYC GENE; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGET; KH DOMAINS; FUSE; IDENTIFICATION; CANCER	The far upstream binding protein 1 (FBP1) was first identified as a DNA-binding protein that regulates c-Myc gene transcription through binding to the far upstream element (FUSE) in the promoter region 1.5 kb upstream of the transcription start site. FBP1 collaborates with TFIIH and additional transcription factors for optimal transcription of the c-Myc gene. In recent years, mounting evidence suggests that FBP1 acts as an RNA-binding protein and regulates mRNA translation or stability of genes, such as GAP43, p27(Kip) and nucleophosmin. During retroviral infection, FBP1 binds to and mediates replication of RNA from Hepatitis C and Enterovirus 71. As a nuclear protein, FBP1 may translocate to the cytoplasm in apoptotic cells. The interaction of FBP1 with p38/JTV-1 results in FBP1 ubiquitination and degradation by the proteasomes. Transcriptional and post-transcriptional regulations by FBP1 contribute to cell proliferation, migration or cell death. FBP1 association with carcinogenesis has been reported in c-Myc dependent or independent manner. This review summarizes biochemical features of FBP1, its mechanism of action, FBP family members and the involvement of FBP1 in carcinogenesis.	[Zhang, J.; Chen, Q. M.] Univ Arizona, Dept Pharmacol, Tucson, AZ 85724 USA	University of Arizona	Chen, QM (corresponding author), Univ Arizona, Dept Pharmacol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	qchen@email.arizona.edu			Arizona Biomedical Research Commission;  [NIH R01 HL 076530];  [R01 HL089958];  [R21ES017473];  [T32 ES007091]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076530, R01HL089958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007091, R21ES017473] Funding Source: NIH RePORTER	Arizona Biomedical Research Commission; ; ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We acknowledge the support of NIH R01 HL 076530, R01 HL089958, R21ES017473, T32 ES007091 and Arizona Biomedical Research Commission (QMC). We thank Dr Joseph Alpert and Joshua Strom for proof reading the manuscript.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Atanassov BS, 2011, EMBO REP, V12, P924, DOI 10.1038/embor.2011.140; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Balvay L, 2009, BBA-GENE REGUL MECH, V1789, P542, DOI 10.1016/j.bbagrm.2009.07.005; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; BAZAR L, 1995, ONCOGENE, V10, P2229; Benjamin LR, 2008, P NATL ACAD SCI USA, V105, P18296, DOI 10.1073/pnas.0803279105; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557; Bouchireb N, 1999, CHROMOSOME RES, V7, P577, DOI 10.1023/A:1009201914881; Braddock DT, 2002, NATURE, V415, P1051, DOI 10.1038/4151051a; Braddock DT, 2002, EMBO J, V21, P3476, DOI 10.1093/emboj/cdf352; Buchan JR, 2009, MOL CELL, V36, P932, DOI 10.1016/j.molcel.2009.11.020; Chien HL, 2011, J VIROL, V85, P4698, DOI 10.1128/JVI.01950-10; Chung HJ, 2006, MOL CELL BIOL, V26, P6584, DOI 10.1128/MCB.00754-06; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Corsini L, 2009, J BIOL CHEM, V284, P630, DOI 10.1074/jbc.M805395200; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; Danckwardt S, 2011, MOL CELL, V41, P298, DOI 10.1016/j.molcel.2010.12.032; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; de Nigris F, 2003, CELL CYCLE, V2, P325, DOI 10.4161/cc.2.4.414; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Duncan R, 1996, MOL CELL BIOL, V16, P2274; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Engidawork E, 2006, INT J ONCOL, V29, P721; Felty Q, 2011, CELL BIOL TOXICOL, V27, P49, DOI 10.1007/s10565-010-9170-6; Fukumoto M, 2011, CELL STRUCT FUNCT, V36, P57, DOI 10.1247/csf.10026; Gherzi R, 2010, WIRES RNA, V1, P230, DOI 10.1002/wrna.2; Giglia-Mari G, 2004, NAT GENET, V36, P714, DOI 10.1038/ng1387; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Guo QM, 2000, CANCER RES, V60, P5922; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He LS, 2000, NUCLEIC ACIDS RES, V28, P4558, DOI 10.1093/nar/28.22.4558; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Hsiao HH, 2010, BIOCHEMISTRY-US, V49, P4620, DOI 10.1021/bi9021445; Huang PN, 2011, NUCLEIC ACIDS RES, V39, P9633, DOI 10.1093/nar/gkr682; Huth JR, 2004, J MED CHEM, V47, P4851, DOI 10.1021/jm0497803; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; Jang M, 2009, ONCOGENE, V28, P1529, DOI 10.1038/onc.2009.11; Karst AM, 2011, GYNECOL ONCOL, V123, P5, DOI 10.1016/j.ygyno.2011.05.021; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; Ko HS, 2006, J BIOL CHEM, V281, P16193, DOI 10.1074/jbc.C600041200; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Kusik BW, 2010, DEV DYNAM, V239, P482, DOI 10.1002/dvdy.22190; Lasserre JP, 2009, J PROTEOME RES, V8, P5485, DOI 10.1021/pr900480f; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; Levens David, 2008, J Natl Cancer Inst Monogr, P41, DOI 10.1093/jncimonographs/lgn004; Liu JH, 2000, MOL CELL, V5, P331, DOI 10.1016/S1097-2765(00)80428-1; Liu JH, 2001, CELL, V104, P353, DOI 10.1016/S0092-8674(01)00223-9; Liu JH, 2006, EMBO J, V25, P2119, DOI 10.1038/sj.emboj.7601101; Liu JH, 2011, EMBO J, V30, P846, DOI 10.1038/emboj.2011.11; Malz M, 2009, HEPATOLOGY, V50, P1130, DOI 10.1002/hep.23051; Man TK, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-45; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Matsushita K, 2006, CANCER RES, V66, P1409, DOI 10.1158/0008-5472.CAN-04-4459; Matsushita K, 2009, FRONT BIOSCI-LANDMRK, V14, P3401, DOI 10.2741/3461; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Milosevic J, 2009, PROTEOMICS, V9, P1230, DOI 10.1002/pmic.200700604; Morrish F, 2009, ONCOGENE, V28, P2485, DOI 10.1038/onc.2009.112; NICOLAIDES NC, 1995, GENOMICS, V29, P329, DOI 10.1006/geno.1995.9997; Niforou Katerina N., 2008, Cancer Genomics & Proteomics, V5, P63; NISHIZAWA K, 1994, BIOCHEM BIOPH RES CO, V205, P1380, DOI 10.1006/bbrc.1994.2818; Olanich ME, 2011, ONCOGENE, V30, P77, DOI 10.1038/onc.2010.404; Page-McCaw PS, 1999, RNA, V5, P1548, DOI 10.1017/S1355838299991938; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Rabenhorst U, 2009, HEPATOLOGY, V50, P1121, DOI 10.1002/hep.23098; Rana S, 2008, EXPERT REV ANTICANC, V8, P1461, DOI 10.1586/14737140.8.9.1461; Singer S, 2009, CANCER RES, V69, P2234, DOI 10.1158/0008-5472.CAN-08-3338; Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395; Sportoletti P, 2008, BLOOD, V111, P3859, DOI 10.1182/blood-2007-06-098251; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Sully G, 2004, BIOCHEM J, V377, P629, DOI 10.1042/BJ20031484; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; TUTEJA N, 1993, NUCLEIC ACIDS RES, V21, P2323, DOI 10.1093/nar/21.10.2323; Valverde R, 2008, FEBS J, V275, P2712, DOI 10.1111/j.1742-4658.2008.06411.x; Vindigni A, 2001, NUCLEIC ACIDS RES, V29, P1061, DOI 10.1093/nar/29.5.1061; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Weber A, 2005, MOL CELL BIOL, V25, P147, DOI 10.1128/mcb.25.1.147-161.2005; Weber A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-369; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; Williams BY, 2000, FEBS LETT, V470, P207, DOI 10.1016/S0014-5793(00)01320-X; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Xiao JY, 2009, CELL CYCLE, V8, P889, DOI 10.4161/cc.8.6.7898; Xu SG, 2010, J CANCER RES CLIN, V136, P1545, DOI 10.1007/s00432-010-0812-0; Yan S, 2009, CANCER RES, V69, P3283, DOI 10.1158/0008-5472.CAN-08-0367; Zhang L, 2011, CURR DRUG METAB, V12, P455, DOI 10.2174/138920011795495303; Zhang ZB, 2008, J VIROL, V82, P5761, DOI 10.1128/JVI.00064-08; Zheng YH, 2011, INT J BIOCHEM CELL B, V43, P1641, DOI 10.1016/j.biocel.2011.08.001; Zubaidah RM, 2008, PROTEOMICS, V8, P5086, DOI 10.1002/pmic.200800322	99	73	77	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2907	2916		10.1038/onc.2012.350	http://dx.doi.org/10.1038/onc.2012.350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22926519	Green Accepted			2022-12-28	WOS:000320369700001
J	Heo, K; Kim, JS; Kim, K; Kim, H; Choi, J; Yang, K; An, W				Heo, K.; Kim, J-S; Kim, K.; Kim, H.; Choi, J.; Yang, K.; An, W.			Cell-penetrating H4 tail peptides potentiate p53-mediated transactivation via inhibition of G9a and HDAC1	ONCOGENE			English	Article						p53; histone; transcription; acetylation; methylation	TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL REGULATION; CANCER-CELLS; COMPLEX; PROTEIN; RECRUITMENT; TRANSDUCTION; ACTIVATION; REPRESSION; PHYSIOLOGY	Histone acetylation has a central role in establishing an active chromatin environment. The functional contribution of histone acetylation to chromatin transcription is accomplished by a dominant action of histone acetyltransferases over repressive histone-modifying activities at gene promoters; misregulation of these dynamic events can lead to various diseases. Here, we describe the synthesis and characterization of transducible peptides derived from histone H4 N-terminal tail as a molecular tool to establish and maintain the active state of p53 target genes. Cellular experiments demonstrate a distinct increase in p53 transactivation by acetylated H4 tail peptides, but only a modest change by unmodified H4 tail peptides. The molecular basis underlying the observed effects involves the selective interaction of the tail peptides with G9a histone methyltransferase and histone deacetylase 1 (HDAC1) and the disruption of their occupancy at p53 target promoters. Furthermore, treatment of xenograft models and cancer cell lines with the tail peptides sharply decline tumor cell growth and enhances apoptosis in response to DNA damage. These results indicate that H4 tail peptide mimics upregulate p53 transcription pathway and may be used as a novel strategy for anticancer therapy.	[Heo, K.; Kim, K.; Kim, H.; Choi, J.; An, W.] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; [Heo, K.; Kim, J-S; Yang, K.] Dongnam Inst Radiol & Med Sci DIRAMS, Res Ctr, Pusan, South Korea; [Kim, H.] Harvard Univ, Sch Med, Dept Pediat,Dana Farber Canc Inst,Childrens Hosp, Dept Pediat Oncol,Div Hematol Oncol, Boston, MA 02115 USA	University of Southern California; Korea Institute of Radiological & Medical Sciences; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	An, W (corresponding author), Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, 1450 Biggy St NRT6507, Los Angeles, CA 90089 USA.	woojinan@usc.edu		Heo, Kyu/0000-0001-8833-4731	National Institutes of Health [R01GM84209]; American Cancer Society [RSG DMC1005001]; DIRAMS from the Ministry of Education, Science and Technology [50595-2012]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084209] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); DIRAMS from the Ministry of Education, Science and Technology; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Michael Stallcup and Mr Dan Gerke for the gift of pSG5-FLAG-G9a and G9a shRNA constructs. The technical assistance of Drs Balachandra Hegde and Ralph Langen in circular dichroism analysis is greatly acknowledged. We also thank Dr Jing Huang for p53K373me2 antibody. This work was supported by R01GM84209 to WA from the National Institutes of Health, RSG DMC1005001 to WA from the American Cancer Society and DIRAMS (50595-2012) to KH from the Ministry of Education, Science and Technology.	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Harada Y, 2010, CANCER RES, V70, P5829, DOI 10.1158/0008-5472.CAN-10-0255; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Heo K, 2008, MOL CELL, V30, P86, DOI 10.1016/j.molcel.2008.02.029; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Muntean AG, 2009, AM J PATHOL, V175, P1353, DOI 10.2353/ajpath.2009.081142; Nishiyama A, 2008, FEBS LETT, V582, P1501, DOI 10.1016/j.febslet.2008.03.044; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Spannhoff A, 2009, CHEMMEDCHEM, V4, P1568, DOI 10.1002/cmdc.200900301; Spotswood HT, 2002, J CLIN INVEST, V110, P577, DOI 10.1172/JCI200216547; Stimson L, 2009, ANN ONCOL, V20, P1293, DOI 10.1093/annonc/mdn792; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191	33	14	15	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2013	32	20					2510	2520		10.1038/onc.2012.273	http://dx.doi.org/10.1038/onc.2012.273			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22751130				2022-12-28	WOS:000319274300002
J	Lang, JY; Shi, Y; Chin, YE				Lang, J-Y; Shi, Y.; Chin, Y. E.			Reprogramming cancer cells: back to the future	ONCOGENE			English	Editorial Material							PLURIPOTENT STEM-CELLS; C-MYC; HYBRIDOMAS; DEATH	Reprogramming healthy somatic cells into induced pluripotent stem cells (iPSCs) with four defined factors (Oct4, Sox2, c-Myc and Klf4) has been intensively investigated. However, reprogramming diseased cells such as cancer cells has fallen much behind. In this issue of Oncogene, Zhang et al. demonstrated that reprogrammed sarcoma cells with defined factors, as well as Nanog and Lin28, lost their tumorigenicity and dedifferentiated to mesenchymal stem cells (MSC) and hematopoietic stem cell (HSC)-like cells that can be terminally differentiated into mature connective tissues and red blood cells, suggesting sarcoma cells may be reversed back to a stage of common ancestor iPSC bifurcating for HSC and MSC ontogeny. It may, therefore, provide a novel strategy for cancer treatment via ancestor pluripotency induction	[Lang, J-Y; Shi, Y.; Chin, Y. E.] Chinese Acad Sci, Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci,Shanghai Inst Biol Sci,Lab Stem Cel, Shanghai 200025, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Chin, YE (corresponding author), Chinese Acad Sci, Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci,Shanghai Inst Biol Sci,Lab Stem Cel, 225 South Chongqing Rd, Shanghai 200025, Peoples R China.	yechin@sibs.ac.cn	Shi, Yufang/AAE-4431-2020	Shi, Yufang/0000-0001-8964-319X				BERNS EMJJ, 1992, CANCER RES, V52, P1107; Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845; Chang G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010320; Choi SM, 2011, BLOOD, V118, P1801, DOI 10.1182/blood-2011-03-340620; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Hu KJ, 2011, BLOOD, V117, pE109, DOI 10.1182/blood-2010-07-298331; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; Muller LUW, 2009, MOL THER, V17, P947, DOI 10.1038/mt.2009.72; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Ramos-Mejia V, 2012, TRENDS MOL MED, V18, P245, DOI 10.1016/j.molmed.2012.04.001; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307	18	15	17	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2247	2248		10.1038/onc.2012.349	http://dx.doi.org/10.1038/onc.2012.349			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22869153				2022-12-28	WOS:000318683600001
J	Sagiv, A; Biran, A; Yon, M; Simon, J; Lowe, SW; Krizhanovsky, V				Sagiv, A.; Biran, A.; Yon, M.; Simon, J.; Lowe, S. W.; Krizhanovsky, V.			Granule exocytosis mediates immune surveillance of senescent cells	ONCOGENE			English	Article						cellular senescence; perforin; liver fibrosis	NATURAL-KILLER-CELLS; ACTIVATED STELLATE CELLS; PERFORIN-DEFICIENT MICE; CELLULAR SENESCENCE; LIVER FIBROSIS; TUMOR-SUPPRESSOR; GRANZYME-B; NK CELLS; T-CELLS; CYTOTOXICITY	Senescence is a stable cell cycle arrest program that contributes to tumor suppression, organismal aging and certain wound healing responses. During liver fibrosis, for example, hepatic stellate cells initially proliferate and secrete extracellular matrix components that produce fibrosis; however, these cells eventually senesce and are cleared by immune cells, including natural killer (NK) cells. Here, we examine how NK cells target senescent cells and assess the impact of this process on liver fibrosis. We show that granule exocytosis, but not death-receptor-mediated apoptosis, is required for NK-cell-mediated killing of senescent cells. This pathway bias is due to upregulation of the decoy death receptor, Dcr2, an established senescence marker that attenuates NK-mediated cell death. Accordingly, mice with defects in granule exocytosis accumulate senescent stellate cells and display more liver fibrosis in response to a fibrogenic agent. Our results thus provide new insights into the immune surveillance of senescent cells and reveal how granule exocytosis has a protective role against liver fibrosis. Oncogene (2013) 32, 1971-1977; doi:10.1038/onc.2012.206; published online 2 July 2012	[Sagiv, A.; Biran, A.; Krizhanovsky, V.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Yon, M.; Simon, J.; Lowe, S. W.; Krizhanovsky, V.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Yon, M.] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508 Sao Paulo, Brazil; [Simon, J.; Lowe, S. W.] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Weizmann Institute of Science; Cold Spring Harbor Laboratory; Universidade de Sao Paulo; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Lowe, SW (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA.	lowes@mskcc.org; valery.krizhanovsky@weizmann.ac.il	Krizhanovsky, Valery/D-1336-2010	Krizhanovsky, Valery/0000-0002-3977-5482	Binational Israel-USA Science foundation; National Institutes of Health [AG16379]; Israel Science Foundation; Abisch-Frenkel foundation; Simms/Mann Family foundation; EU; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R56AG016379, R01AG016379] Funding Source: NIH RePORTER	Binational Israel-USA Science foundation(US-Israel Binational Science Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Israel Science Foundation(Israel Science Foundation); Abisch-Frenkel foundation; Simms/Mann Family foundation; EU(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We gratefully acknowledge O Mandelboim from Hadassah Medical Center for providing us with primary human NK cells; D Sabah-Israel for editorial suggestions; members of the Lowe and Krizhanovsky laboratories for stimulating discussions; K Lehet, L Bianco and the CSHL animal facility for help with animals; T Berkutzki from the Histology Facility at the Weizmann Institute for assistance with histology. This work was supported by a Binational Israel-USA Science foundation (VK and SWL) and grant AG16379 from the National Institutes of Health (SWL). VK was supported by Israel Science Foundation, Abisch-Frenkel foundation, Simms/Mann Family foundation and Marie Curie RG grant from EU FP7. VK is an incumbent of The Karl and Frances Korn Career Development Chair. SWL is a Howard Hughes Medical Institute investigator and Geoffrey Beene Chair for Cancer Biology (MSKCC).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Arnon TI, 2006, SEMIN CANCER BIOL, V16, P348, DOI 10.1016/j.semcancer.2006.07.005; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bottino C, 2005, TRENDS IMMUNOL, V26, P221, DOI 10.1016/j.it.2005.02.007; Chahroudi A, 2003, METHODS, V31, P120, DOI 10.1016/S1046-2023(03)00121-X; Chan CW, 2008, CELL DEATH DIFFER, V15, P58, DOI 10.1038/sj.cdd.4402235; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404; Choy JC, 2003, MODERN PATHOL, V16, P460, DOI 10.1097/01.MP.0000067424.12280.BC; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Colucci S, 2009, LEUKEMIA, V23, P2139, DOI 10.1038/leu.2009.136; Cullen SP, 2008, CELL DEATH DIFFER, V15, P251, DOI 10.1038/sj.cdd.4402244; Davis ID, 2007, CLIN CANCER RES, V13, P3630, DOI 10.1158/1078-0432.CCR-07-0410; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Guo JS, 2007, SEMIN LIVER DIS, V27, P413, DOI 10.1055/s-2007-991517; Hanna J, 2003, BLOOD, V102, P1569, DOI 10.1182/blood-2003-02-0517; Hayakawa Y, 2006, SEMIN IMMUNOL, V18, P176, DOI 10.1016/j.smim.2006.03.005; Ishiyama K, 2006, HEPATOLOGY, V43, P362, DOI 10.1002/hep.21035; Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Krizhanovsky V, 2008, COLD SH Q B, V73, P513, DOI 10.1101/sqb.2008.73.048; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Melhem A, 2006, J HEPATOL, V45, P60, DOI 10.1016/j.jhep.2005.12.025; Miyazaki H, 2004, J CLIN PATHOL, V57, P1292, DOI 10.1136/jcp.2003.015495; MONTEL AH, 1995, CELL IMMUNOL, V166, P236, DOI 10.1006/cimm.1995.9974; Muhanna N, 2007, CLIN EXP IMMUNOL, V148, P338, DOI 10.1111/j.1365-2249.2007.03353.x; Muta H, 2000, J IMMUNOL, V165, P5105, DOI 10.4049/jimmunol.165.9.5105; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Ogata K, 1997, CLIN IMMUNOL IMMUNOP, V84, P269, DOI 10.1006/clin.1997.4401; Park O, 2009, HEPATOLOGY, V49, P1683, DOI 10.1002/hep.22813; Pinkoski MJ, 2000, AM J PHYSIOL-GASTR L, V278, pG354, DOI 10.1152/ajpgi.2000.278.3.G354; Pitiyage GN, 2011, J PATHOL, V223, P604, DOI 10.1002/path.2839; Radaeva S, 2006, GASTROENTEROLOGY, V130, P435, DOI 10.1053/j.gastro.2005.10.055; Rukavina D, 1998, BLOOD, V92, P2410, DOI 10.1182/blood.V92.7.2410.2410_2410_2420; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Soriani A, 2009, BLOOD, V113, P3503, DOI 10.1182/blood-2008-08-173914; Street SEA, 2001, BLOOD, V97, P192, DOI 10.1182/blood.V97.1.192; Takeda K, 2005, BLOOD, V105, P2082, DOI 10.1182/blood-2004-08-3262; vandenBroek MF, 1996, J EXP MED, V184, P1781, DOI 10.1084/jem.184.5.1781; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yawalkar N, 2001, BRIT J DERMATOL, V144, P1133, DOI 10.1046/j.1365-2133.2001.04222.x	51	138	145	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 11	2013	32	15					1971	1977		10.1038/onc.2012.206	http://dx.doi.org/10.1038/onc.2012.206			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22751116	Green Published, hybrid			2022-12-28	WOS:000317599900011
J	Mackintosh, C; Garcia-Dominguez, DJ; Ordonez, JL; Ginel-Picardo, A; Smith, PG; Sacristan, MP; de Alava, E				Mackintosh, C.; Garcia-Dominguez, D. J.; Ordonez, J. L.; Ginel-Picardo, A.; Smith, P. G.; Sacristan, M. P.; de Alava, E.			WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells	ONCOGENE			English	Article						MLN4924; Ewing sarcoma; WEE1; cyclin A; cyclin E; P27	NEDD8-ACTIVATING ENZYME-INHIBITOR; UBIQUITIN LIGASE; BETA-TRCP; CANCER-CELLS; DEGRADATION; PHOSPHORYLATION; P27(KIP1); KINASES; P27; COMPLEX	Ewing sarcoma (ES) is an aggressive bone and soft tissue tumor of children and young adults in which finding effective new targeted therapies is imperative. Here, we report an in-depth preclinical study of the investigational cullin-RING ubiquitin ligase (CRL) inhibitor MLN4924 in ES, as we have recently demonstrated the implication of a CRL component in the ES pathogenesis. First, our results support a high sensitivity of ES cells to MLN4924 growth inhibition both in vitro (14 ES cell lines tested, median IC50 = 81 nM) and in tumor xenografts (tumor regression achieved with 60 mg/kg BID, subcutaneously, n = 9). Second, we report a dual mechanism of action of MLN4924 in ES cells: while a wide range of MLN4924 concentrations (similar to 30-300 nM) trigger a G2 arrest that can only be rescued by WEE1 kinase inhibition or depletion, saturating doses of the drug (>300 nM) cause a delay in S-phase progression concomitant with unbalanced CDK2-Cyclin E and CDK2-Cyclin A relative levels (accumulation of the first and depletion of the latter). The aberrant presence of CDC6 in the nucleus at late S-phase cell cycle stage confirmed the loss of CDK2-Cyclin A-specific functions. Remarkably, other mechanisms explored (P27 accumulation and DNA damage signaling pathways) were found unable to explain MLN4924 effects, strengthening the specificity of our findings and suggesting the absence of functionality of some CRL substrates accumulated in response to MLN4924. This study renders a rationale for clinical trials and contributes molecular mechanisms for a better understanding of this promising antitumoral agent. Oncogene (2013) 32, 1441-1451; doi:10.1038/onc.2012.153; published online 28 May 2012	[Mackintosh, C.; Garcia-Dominguez, D. J.; Ordonez, J. L.; de Alava, E.] IBSAL Ctr Invest Canc IBMCC USAL CSIC, Mol Pathol Program, Salamanca 37007, Spain; [Ginel-Picardo, A.] Ctr Invest Canc IBMCC USAL CSIC, Lab 1, Salamanca, Spain; [Smith, P. G.] Millennium Pharmaceut Inc, Discovery, Cambridge, MA USA; [Sacristan, M. P.] Ctr Invest Canc IBMCC USAL CSIC, Dept Mol & Genet, Salamanca 37007, Spain; [de Alava, E.] IBSAL Univ Hosp Salamanca, Dept Pathol, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC)	Mackintosh, C (corresponding author), IBSAL Ctr Invest Canc IBMCC USAL CSIC, Mol Pathol Program, Campus Miguel de Unamuno S-N, Salamanca 37007, Spain.	cmackintosh@usal.es; edealava@usal.es	Sacristan, Maria/Y-4923-2019; Garcia, Daniel Jose/B-5366-2016; de Alava, Enrique/GOH-0368-2022; Garcia, Daniel Jose/X-6857-2019; Sacristán, María P/A-9587-2016; IBIS, SARCOMAS/O-1893-2015; Ordóñez, José Luis/B-6069-2017	Sacristan, Maria/0000-0003-2314-8430; Garcia, Daniel Jose/0000-0001-8150-2747; de Alava, Enrique/0000-0001-8400-046X; Sacristán, María P/0000-0003-2314-8430; Ordóñez, José Luis/0000-0002-3791-4215; Mackintosh, Carlos/0000-0002-6786-9558	Maria Garcia Estrada Foundation; Ministry of Economy and Competitiveness of Spain-FEDER [PI081828, RD06/0020/0059, PI1100018]; Ministry of Economy and Competitiveness of Spain-FEDER (ISCIII_postdoc grant) [CD06/00001]; European Commission [278742 EUROSARC]	Maria Garcia Estrada Foundation; Ministry of Economy and Competitiveness of Spain-FEDER; Ministry of Economy and Competitiveness of Spain-FEDER (ISCIII_postdoc grant); European Commission(European CommissionEuropean Commission Joint Research Centre)	We thank Cristina Teodosio and Martin Perez de Andres for their kind help in flow cytometry studies. Daniel J Garcia-Dominguez is supported by a grant from the Maria Garcia Estrada Foundation. Research in Enrique de Alava's lab is also supported by the Ministry of Economy and Competitiveness of Spain-FEDER (PI081828, RD06/0020/0059, PI1100018, ISCIII_postdoc grant CD06/00001) and the European Commission (FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC).	Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Bernstein M, 2006, ONCOLOGIST, V11, P503, DOI 10.1634/theoncologist.11-5-503; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Duda DM, 2008, CELL, V134, P995, DOI 10.1016/j.cell.2008.07.022; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Haeusler J, 2010, CANCER-AM CANCER SOC, V116, P443, DOI 10.1002/cncr.24740; Jia LJ, 2011, NEOPLASIA, V13, P561, DOI 10.1593/neo.11420; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Liao H, 2011, MOL CELL PROTEOMICS, DOI [10.1074/mcp.M111.009183, DOI 10.1074/mcp.M111.009183]; Lin JJ, 2010, CANCER RES, V70, P10310, DOI 10.1158/0008-5472.CAN-10-2062; Mackintosh C, 2012, ONCOGENE, V31, P1287, DOI 10.1038/onc.2011.317; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Milhollen MA, 2011, CANCER RES, V71, P3042, DOI 10.1158/0008-5472.CAN-10-2122; Milhollen MA, 2010, BLOOD, V116, P1515, DOI 10.1182/blood-2010-03-272567; Mir SE, 2010, CANCER CELL, V18, P244, DOI 10.1016/j.ccr.2010.08.011; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Paolinelli R, 2009, NAT STRUCT MOL BIOL, V16, P412, DOI 10.1038/nsmb.1583; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Smith MA, 2012, PEDIATR BLOOD CANCER, V59, P246, DOI 10.1002/pbc.23357; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Susaki E, 2007, CELL CYCLE, V6, P3015, DOI 10.4161/cc.6.24.5087; Swords RT, 2010, BLOOD, V115, P3796, DOI 10.1182/blood-2009-11-254862; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wei DP, 2012, CANCER RES, V72, P282, DOI 10.1158/0008-5472.CAN-11-2866; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	40	52	53	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1441	1451		10.1038/onc.2012.153	http://dx.doi.org/10.1038/onc.2012.153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22641220				2022-12-28	WOS:000316455600010
J	Cagnol, S; Rivard, N				Cagnol, S.; Rivard, N.			Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition	ONCOGENE			English	Article						ERK; KRAS; BRAF; DUSP; intestinal epithelial cells; colorectal cancer	INTESTINAL EPITHELIAL-CELLS; PROTEIN-TYROSINE PHOSPHATASES; COLON-CARCINOMA CELLS; MAP KINASE-ACTIVITY; COLORECTAL-CANCER; SPATIOTEMPORAL REGULATION; REGULATED KINASE; CELLULAR-TRANSFORMATION; PROTEASOMAL DEGRADATION; MESENCHYMAL TRANSITION	Gain-of-function mutations in KRAS and BRAF genes are found in up to 50% of colorectal cancers. These mutations result in the activation of the BRAF/MEK signaling pathway culminating in the stimulation of ERK1/2 mitogen-activated protein kinases. Upon activation, ERK1/2 translocate from the cytoplasm to the nucleus. This process has been shown to be required for the induction of many cellular responses, although the molecular mechanisms regulating ERK nuclear function, especially under oncogenic stimulation, remain to be explored. Herein, we examined the spatiotemporal regulation of ERK1/2 activity upon oncogenic activation of KRAS(G12V) and BRAF(V600E) in normal intestinal epithelial crypt cells (IECs). Results demonstrate that expression of these oncogenes markedly stimulated ERK1/2 activities and morphologically transformed IECs. Importantly however, ERK phosphorylation was not observed in the nucleus, but restricted to the cytoplasm of KRAS(G12V)- and BRAF(V600E)-transformed IECs. The absence of nuclear ERK phosphorylation was due to a vanadate-sensitive phosphatase activity. Nuclear ERK dephosphorylation was found to be tightly correlated with the rapid expression of DUSP4 phosphatase induced in an MEK-dependent manner. In addition, MEK-dependent phosphorylation of T361, T363, S390 and S395 residues highly stabilized DUSP4 protein. Finally, in human colorectal cancer cells, ERK1/2 activities were also confined to the cytoplasm and treatment with pervanadate reactivated ERK1/2 in the nucleus. Accordingly, DUSP4 mRNAs were found to be highly expressed, in an MEK-dependent manner, in all colorectal cancer cells analyzed. These findings indicate that DUSP4 functions as part of a negative feedback mechanism in the control of the duration and magnitude of nuclear ERK activation during intestinal tumorigenesis. Oncogene (2013) 32, 564-576; doi:10.1038/onc.2012.88; published online 19 March 2012	[Cagnol, S.; Rivard, N.] Univ Sherbrooke, Fac Med & Sci Sante, CIHR Team Digest Epithelium, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med & Sci Sante, CIHR Team Digest Epithelium, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada.	Nathalie.Rivard@USherbrooke.ca			Canadian Institutes of Health and Research [MT-14405]; Canadian Research Chair in Colorectal Cancer and Inflammatory Cell Signaling	Canadian Institutes of Health and Research(Canadian Institutes of Health Research (CIHR)); Canadian Research Chair in Colorectal Cancer and Inflammatory Cell Signaling	We thank Pierre Pothier for critical reading of the manuscript, and Anne Vezina and Etienne Lemieux for their technical assistance. This research was supported by a grant from the Canadian Institutes of Health and Research to NR (MT-14405). NR is a recipient of a Canadian Research Chair in Colorectal Cancer and Inflammatory Cell Signaling.	Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; Andreolas C, 2008, INT J CANCER, V122, P1745, DOI 10.1002/ijc.23309; Armstrong SP, 2009, MOL ENDOCRINOL, V23, P510, DOI 10.1210/me.2008-0333; Avruch J, 2007, BBA-MOL CELL RES, V1773, P1150, DOI 10.1016/j.bbamcr.2006.11.006; Bergeron S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-271; Brami-Cherrier K, 2005, J NEUROSCI, V25, P11444, DOI 10.1523/JNEUROSCI.1711-05.2005; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Cagnol S, 2006, APOPTOSIS, V11, P337, DOI 10.1007/s10495-006-4065-y; Caunt CJ, 2008, J BIOL CHEM, V283, P26612, DOI 10.1074/jbc.M801500200; Caunt CJ, 2008, J BIOL CHEM, V283, P6241, DOI 10.1074/jbc.M706624200; Caunt CJ, 2006, TRENDS ENDOCRIN MET, V17, P276, DOI 10.1016/j.tem.2006.07.008; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Gaedcke J, 2010, GENE CHROMOSOME CANC, V49, P1024, DOI 10.1002/gcc.20811; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Katagiri C, 2005, J BIOL CHEM, V280, P14716, DOI 10.1074/jbc.M500200200; Komatsu K, 2005, GASTROENTEROLOGY, V129, P577, DOI 10.1053/j.gastro.2005.06.003; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Kucharska A, 2009, CELL SIGNAL, V21, P1794, DOI 10.1016/j.cellsig.2009.07.015; Lemieux E, 2009, INT J CANCER, V125, P1575, DOI 10.1002/ijc.24485; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lin YW, 2006, J BIOL CHEM, V281, P915, DOI 10.1074/jbc.M508720200; Liu J, 2007, ONCOGENE, V26, P1954, DOI 10.1038/sj.onc.1209994; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mattison CP, 2000, GENE DEV, V14, P1229; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; Nandan MO, 2008, GASTROENTEROLOGY, V134, P120, DOI 10.1053/j.gastro.2007.10.023; Nishimura T, 2008, TUMOR BIOL, V29, P343, DOI 10.1159/000176044; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Peng DJ, 2010, CELL CYCLE, V9, P4650, DOI 10.4161/cc.9.23.13957; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Simoneau M, 2011, CELL SIGNAL, V23, P269, DOI 10.1016/j.cellsig.2010.09.011; Smakman N, 2005, BBA-REV CANCER, V1756, P103, DOI 10.1016/j.bbcan.2005.07.001; Smith ER, 2004, J CELL BIOL, V164, P689, DOI 10.1083/jcb.200312028; Vakiani E, 2011, J PATHOL, V223, P219, DOI 10.1002/path.2796; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Voisin L, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-337; Volmat V, 2001, J CELL SCI, V114, P3433; Yeh JJ, 2009, MOL CANCER THER, V8, P834, DOI 10.1158/1535-7163.MCT-08-0972; Yuen ST, 2002, CANCER RES, V62, P6451	53	61	64	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2013	32	5					564	576		10.1038/onc.2012.88	http://dx.doi.org/10.1038/onc.2012.88			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22430215				2022-12-28	WOS:000316164700004
J	Yeramian, A; Moreno-Bueno, G; Dolcet, X; Catasus, L; Abal, M; Colas, E; Reventos, J; Palacios, J; Prat, J; Matias-Guiu, X				Yeramian, A.; Moreno-Bueno, G.; Dolcet, X.; Catasus, L.; Abal, M.; Colas, E.; Reventos, J.; Palacios, J.; Prat, J.; Matias-Guiu, X.			Endometrial carcinoma: molecular alterations involved in tumor development and progression	ONCOGENE			English	Review						endometrial carcinoma; genetics; microsatellite instability; molecular alterations; beta-catenin; apoptosis; chromosomal instability	GENE-EXPRESSION PROFILES; DIFFERENT HISTOLOGIC TYPES; FOLATE BINDING-PROTEIN; MIXED MULLERIAN TUMORS; K-RAS MUTATIONS; MICROSATELLITE INSTABILITY; BETA-CATENIN; MICROARRAY ANALYSIS; MATRIX METALLOPROTEINASE-2; PROMOTER HYPERMETHYLATION	In the western world, endometrial carcinoma (EC) is the most common cancer of the female genital tract. The annual incidence has been estimated at 10-20 per 100 000 women. Two clinicopathological variants are recognized: the estrogen related (type I, endometrioid) and the non-estrogen related (type II, non-endometrioid).The clinicopathological differences are paralleled by specific genetic alterations, with type I showing microsatellite instability and mutations in phosphatase and tensin homologue deleted on chromosome 70, PIK3CA, K-RAS and CTNNB1 (beta-catenin), and type II exhibiting TP53 mutations and chromosomal instability. Some non-endometrioid carcinomas probably arise from pre-existing endometrioid carcinomas as a result of tumor progression and, not surprisingly, some tumors exhibit combined or mixed features at the clinical, pathological and molecular levels. In EC, apoptosis resistance may have a role in tumor progression. Understanding pathogenesis at the molecular level is essential in identifying biomarkers for successful targeted therapies. In this review, the genetic changes of endometrial carcinogenesis are discussed in the light of the morphological features of the tumors and their precursors. Oncogene (2013) 32, 403-413; doi: 10.1038/onc.2012.76; published online 19 March 2012	[Yeramian, A.; Dolcet, X.; Matias-Guiu, X.] Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Pathol & Mol Genet, IRBLLEIDA, Lleida, Spain; [Yeramian, A.; Dolcet, X.; Matias-Guiu, X.] Univ Lleida, Hosp Univ Arnau de Vilanova, Res Lab, IRBLLEIDA, Lleida, Spain; [Moreno-Bueno, G.] UAM, CSIC UAM, IdiPAZ Inst Invest Sanitaria La Paz, Inst Invest Biomed Alberto Sols,Dept Bioquim, Madrid, Spain; [Moreno-Bueno, G.] Fdn MD Anderson Canc Ctr, Madrid, Spain; [Catasus, L.; Prat, J.] Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Inst Invest Biorned IBB SantPau, Dept Pathol, Barcelona, Spain; [Abal, M.] Complejo Hosp Santiago de Compostela, Oncol Res Lab, Santiago De Compostela, Spain; [Colas, E.; Reventos, J.] Vail dHebron Res Inst, Biomed Res Unit, Barcelona, Spain; [Colas, E.; Reventos, J.] Univ Hosp, Barcelona, Spain; [Palacios, J.] Hosp Univ Virgen del Rocio, Dept Pathol, Seville, Spain; [Palacios, J.] Inst Biomed Sevilla IBIS, Seville, Spain	Universitat de Lleida; University Hospital Arnau de Vilanova; Universitat de Lleida; University Hospital Arnau de Vilanova; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Texas System; UTMD Anderson Cancer Center; Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; Complexo Hospitalario Universitario de Santiago de Compostela; University of Barcelona; Hospital Clinic de Barcelona; Virgen del Rocio University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS)	Matias-Guiu, X (corresponding author), Hosp Arnau Vilanova, Dept Pathol & Mol Genet, Ave Alcalde Rovira Roure 80, Lleida 25198, Spain.	xmatias@arnau.scs.es	matias-guiu, xavier/C-3039-2009; yeramian, andree/B-5936-2009; Yeramian, Andree/P-6724-2019; Moreno-Bueno, Gema/K-9354-2016; Catasus, Lluis/K-4620-2013; Palacios, Jose/AAV-3765-2020; Catasus, Luis/G-6811-2011; Dolcet, Xavi/B-5665-2009; Prat, Jaime/G-4679-2011	matias-guiu, xavier/0000-0002-7201-6605; yeramian, andree/0000-0002-9569-6316; Moreno-Bueno, Gema/0000-0002-5030-6687; Catasus, Lluis/0000-0001-6075-6238; Dolcet, Xavi/0000-0003-1921-0449; Abal Posada, Miguel/0000-0003-3533-7781	FIS [PI100922, PI080410, 2009SGR794, RD06/0020/1034, RD06/0020/0013, RD06/0020/0058, RD06/0020/0015]; Fundacion Mutua Madrilena [AP75732010]; Fundacion Asociacion Espanola contra el Cancer; programa de intensificacion de Is investigacion, Instituto Carlos III; Programa Juan de la Cierva, Ministerio de Ciencia e Innovacion [JCI-2008-1969]	FIS(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); Fundacion Asociacion Espanola contra el Cancer; programa de intensificacion de Is investigacion, Instituto Carlos III; Programa Juan de la Cierva, Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This work was supported by grants from FIS PI100922, Fundacion Mutua Madrilena AP75732010, FIS PI080410, 2009SGR794, RD06/0020/1034, RD06/0020/0013, RD06/0020/0058, RD06/0020/0015, Fundacion Asociacion Espanola contra el Cancer and programa de intensificacion de Is investigacion, Instituto Carlos III. AY holds a postdoctoral fellowship from Programa Juan de la Cierva, Ministerio de Ciencia e Innovacion (JCI-2008-1969).	Allard JE, 2007, GYNECOL ONCOL, V107, P52, DOI 10.1016/j.ygyno.2007.05.018; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Bignotti E, 2008, BRIT J CANCER, V99, P768, DOI 10.1038/sj.bjc.6604546; Blechschmidt K, 2007, DIAGN MOL PATHOL, V16, P222, DOI 10.1097/PDM.0b013e31806219ae; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Bussaglia E, 2000, HUM PATHOL, V31, P312, DOI 10.1016/S0046-8177(00)80244-0; Cao QJ, 2004, INT J GYNECOL PATHOL, V23, P321, DOI 10.1097/01.pgp.0000139646.32997.3a; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.3.CO;2-9; Catasus L, 1998, LAB INVEST, V78, P1439; Catasus L, 1998, HUM PATHOL, V29, P1160, DOI 10.1016/S0046-8177(98)90430-0; Catasus L, 2008, MODERN PATHOL, V21, P131, DOI 10.1038/modpathol.3800992; Catasus L, 2010, MODERN PATHOL, V23, P694, DOI 10.1038/modpathol.2010.44; Catasus L, 2009, MODERN PATHOL, V22, P522, DOI 10.1038/modpathol.2009.5; Chen YH, 2011, EXP MOL PATHOL, V91, P373, DOI 10.1016/j.yexmp.2011.04.005; Dainty LA, 2007, GYNECOL ONCOL, V105, P563, DOI 10.1016/j.ygyno.2006.10.063; Dedes KJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001538; Dolcet X, 2005, LAB INVEST, V85, P885, DOI 10.1038/labinvest.3700286; Dolcet X, 2006, J BIOL CHEM, V281, P22118, DOI 10.1074/jbc.M601350200; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; Dutt A, 2008, P NATL ACAD SCI USA, V105, P8713, DOI 10.1073/pnas.0803379105; Espinosa I, 2010, AM J SURG PATHOL, V34, P1708, DOI 10.1097/PAS.0b013e3181f32168; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fukuchi T, 1998, CANCER RES, V58, P3526; Gatius S, 2011, MODERN PATHOL, V24, P1500, DOI 10.1038/modpathol.2011.110; Guan B, 2011, AM J SURG PATHOL, V35, P625, DOI 10.1097/PAS.0b013e318212782a; Hayes MP, 2010, GYNECOL ONCOL, V116, P286, DOI 10.1016/j.ygyno.2009.11.012; Hayes MP, 2009, GYNECOL ONCOL, V113, P370, DOI 10.1016/j.ygyno.2008.12.021; Huvila J, 2009, INT J GYNECOL CANCER, V19, P1226, DOI 10.1111/IGC.0b013e3181b33be0; Kobayashi K, 1999, JPN J CANCER RES, V90, P55, DOI 10.1111/j.1349-7006.1999.tb00665.x; KOBAYASHI K, 1995, GENE CHROMOSOME CANC, V14, P128, DOI 10.1002/gcc.2870140207; Lagarda H, 2001, J PATHOL, V193, P193, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH769>3.0.CO;2-9; Lax SF, 2000, CANCER-AM CANCER SOC, V88, P814, DOI 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.3.CO;2-L; Llaurado M, 2012, INT J CANCER, V130, P1532, DOI 10.1002/ijc.26148; Llobet D, 2008, ONCOGENE, V27, P2513, DOI 10.1038/sj.onc.1210924; Llobet D, 2010, EUR J CANCER, V46, P836, DOI 10.1016/j.ejca.2009.12.025; Llobet D, 2009, J CLIN PATHOL, V62, P777, DOI 10.1136/jcp.2008.056101; Llobet D, 2011, AM J PATHOL, V178, P1529, DOI 10.1016/j.ajpath.2010.12.041; Lopez-Garcia MA, 2010, SEMIN DIAGN PATHOL, V27, P274, DOI 10.1053/j.semdp.2010.09.005; Machin P, 2002, HUM PATHOL, V33, P206, DOI 10.1053/hupa.2002.30723; Matias-Guiu X, 2001, HUM PATHOL, V32, P569, DOI 10.1053/hupa.2001.25929; Matias-Guiu X, 2010, SEMIN DIAGN PATHOL, V27, P197, DOI 10.1053/j.semdp.2010.08.001; Maxwell GL, 2005, CLIN CANCER RES, V11, P4056, DOI 10.1158/1078-0432.CCR-04-2001; McCluggage WG, 2002, INT J GYNECOL CANCER, V12, P687, DOI 10.1046/j.1525-1438.2002.01151.x; Milam MR, 2007, AM J OBSTET GYNECOL, V196, P247, DOI 10.1016/j.ajog.2006.10.872; Monge M, 2007, CANCER RES, V67, P6753, DOI 10.1158/0008-5472.CAN-06-4487; Monge M, 2009, J PROTEOME RES, V8, P4676, DOI 10.1021/pr900390t; Montserrat N, 2012, HUM PATHOL, V43, P632, DOI 10.1016/j.humpath.2011.06.021; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Moreno-Bueno G, 2006, CLIN CANCER RES, V12, P3865, DOI 10.1158/1078-0432.CCR-06-0284; Morrison C, 2006, J CLIN ONCOL, V24, P2376, DOI 10.1200/JCO.2005.03.4827; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620; Palacios J, 2001, VIRCHOWS ARCH, V193, P193; Pallares J, 2004, J PATHOL, V204, P569, DOI 10.1002/path.1666; Pallares J, 2008, MODERN PATHOL, V21, P691, DOI 10.1038/modpathol.2008.38; Pallares J, 2009, AM J PATHOL, V174, P287, DOI 10.2353/ajpath.2009.080552; Pijnenborg JMA, 2006, GYNECOL ONCOL, V100, P397, DOI 10.1016/j.ygyno.2005.09.056; Pijnenborg JMA, 2005, J PATHOL, V205, P597, DOI 10.1002/path.1738; Pijnenborg JMA, 2004, INT J GYNECOL CANCER, V14, P947, DOI 10.1111/j.1048-891X.2004.014534.x; Pijnenborg JMA, 2004, GYNECOL ONCOL, V94, P550, DOI 10.1016/j.ygyno.2004.05.020; Planaguma J, 2004, CANCER RES, V64, P8846, DOI 10.1158/0008-5472.CAN-04-2066; Planaguma J, 2011, HUM PATHOL, V42, P57, DOI 10.1016/j.humpath.2010.01.025; Pollock PM, 2007, ONCOGENE, V26, P7158, DOI 10.1038/sj.onc.1210529; Prat J, 2007, PATHOLOGY, V39, P72, DOI 10.1080/00313020601136153; Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850; Risinger JI, 2003, CANCER RES, V63, P6; RISINGER JI, 1993, CANCER RES, V53, P5100; Romero-Perez L, HMGA2 EPITHELI UNPUB; Rudd ML, 2011, CLIN CANCER RES, V17, P1331, DOI 10.1158/1078-0432.CCR-10-0540; Santacana M, 2012, HISTOPATHOLOGY, V60, P460, DOI 10.1111/j.1365-2559.2011.04106.x; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shedden KA, 2005, CLIN CANCER RES, V11, P2123, DOI 10.1158/1078-0432.CCR-04-2061; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; SHERMAN ME, 1995, HUM PATHOL, V26, P1268, DOI 10.1016/0046-8177(95)90204-X; Soslow RA, 2010, SEMIN DIAGN PATHOL, V27, P261, DOI 10.1053/j.semdp.2010.09.003; Tafe LJ, 2010, MODERN PATHOL, V23, P781, DOI 10.1038/modpathol.2010.41; Tashiro H, 1997, AM J PATHOL, V150, P177; Tashiro H, 1997, CANCER RES, V57, P3935; Tritz D, 1997, HUM PATHOL, V28, P607, DOI 10.1016/S0046-8177(97)90084-8; Urick ME, 2011, CANCER RES, V71, P4061, DOI 10.1158/0008-5472.CAN-11-0549; Velasco A, 2006, HUM PATHOL, V37, P1465, DOI 10.1016/j.humpath.2006.05.007; Velasco A, 2011, HUM PATHOL, V42, P185, DOI 10.1016/j.humpath.2010.08.001; Wiegand KC, 2011, J PATHOL, V224, P328, DOI 10.1002/path.2911; Yao YY, 2010, INT J GYNECOL OBSTET, V110, P125, DOI 10.1016/j.ijgo.2010.03.020; Yeramian A, 2011, LAB INVEST, V91, P859, DOI 10.1038/labinvest.2011.58	87	122	129	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					403	413		10.1038/onc.2012.76	http://dx.doi.org/10.1038/onc.2012.76			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22430211	Green Published			2022-12-28	WOS:000315551300001
J	Liu, YN; Yin, JJ; Abou-Kheir, W; Hynes, PG; Casey, OM; Fang, L; Yi, M; Stephens, RM; Seng, V; Sheppard-Tillman, H; Martin, P; Kelly, K				Liu, Y-N; Yin, J. J.; Abou-Kheir, W.; Hynes, P. G.; Casey, O. M.; Fang, L.; Yi, M.; Stephens, R. M.; Seng, V.; Sheppard-Tillman, H.; Martin, P.; Kelly, K.			MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms	ONCOGENE			English	Article						prostate cancer; EMT; SLUG; miR-1; miR-200	EPITHELIAL-MESENCHYMAL TRANSITION; DOWN-REGULATION; TGF-BETA; PROSTATE; INVASION; ZEB1; METASTASIS; REPRESSION; CADHERIN; FAMILY	Epithelial-mesenchymal transition (EMT) is a developmental program of signaling pathways that determine commitment to epithelial and mesenchymal phenotypes. In the prostate, EMT processes have been implicated in benign prostatic hyperplasia and prostate cancer progression. In a model of Pten- and TP53-null prostate adenocarcinoma that progresses via transforming growth factor beta-induced EMT, mesenchymal transformation is characterized by plasticity, leading to various mesenchymal lineages and the production of bone. Here we show that SLUG is a major regulator of mesenchymal differentiation. As microRNAs (miRs) are pleiotropic regulators of differentiation and tumorigenesis, we evaluated miR expression associated with tumorigenesis and EMT. Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. We demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Thus, SLUG and miR-1/miR-200 act in a self-reinforcing regulatory loop, leading to amplification of EMT. Depletion of Slug inhibited EMT during tumorigenesis, whereas forced expression of miR-1 or miR-200 inhibited both EMT and tumorigenesis in human and mouse model systems. Various miR targets were analyzed, and our findings suggest that miR-1 has roles in regulating EMT and mesenchymal differentiation through Slug and functions in tumor-suppressive programs by regulating additional targets. Oncogene (2013) 32, 296-306; doi:10.1038/onc.2012.58; published online 27 February 2012	[Liu, Y-N; Yin, J. J.; Abou-Kheir, W.; Hynes, P. G.; Casey, O. M.; Fang, L.; Seng, V.; Sheppard-Tillman, H.; Martin, P.; Kelly, K.] NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA; [Yi, M.; Stephens, R. M.] NCI, Adv Biomed Comp Ctr, FCRDC, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kelly, K (corresponding author), NCI, Cell & Canc Biol Branch, NIH, 37 Convent Dr,Room 1068, Bethesda, MD 20892 USA.	kellyka@mail.nih.gov	Abou-Kheir, Wassim/AAP-2587-2020; Liu, Yen-Nien/AAW-4698-2021; Tillman, Heather/N-2526-2018	Abou-Kheir, Wassim/0000-0001-9719-9324; Tillman, Heather/0000-0002-9623-2812; Yi, Ming/0000-0001-9098-1364	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, USA; NATIONAL CANCER INSTITUTE [ZIABC010802] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the support of the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, USA. We thank Dr Chi-Ping Day, Dr Yvona Ward and Ross Lake for assistance.	Abou-Kheir WG, 2010, STEM CELLS, V28, P2129, DOI 10.1002/stem.538; Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Alonso-Magdalena P, 2009, P NATL ACAD SCI USA, V106, P2859, DOI 10.1073/pnas.0812666106; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Ao MF, 2006, CANCER RES, V66, P8007, DOI 10.1158/0008-5472.CAN-05-4451; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Day CP, 2009, PIGM CELL MELANOMA R, V22, P283, DOI 10.1111/j.1755-148X.2009.00545.x; Ganem NJ, 2004, J CELL BIOL, V166, P473, DOI 10.1083/jcb.200404012; Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hansel DE, 2006, AM J SURG PATHOL, V30, P1316, DOI 10.1097/01.pas.0000209838.92842.bf; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Jaggi M, 2006, PROSTATE, V66, P193, DOI 10.1002/pros.20334; Jones E, 2009, EXPERT OPIN THER TAR, V13, P227, DOI [10.1517/14728220802705696, 10.1517/14728220802705696 ]; Lambertini E, 2009, CELL MOL LIFE SCI, V66, P3641, DOI 10.1007/s00018-009-0149-5; Liu YN, 2011, MOL CELL BIOL, V32, P941; Martin P, 2011, AM J PATHOL, V179, P422, DOI 10.1016/j.ajpath.2011.03.035; Molchadsky A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003707; Nasser MW, 2008, J BIOL CHEM, V283, P33394, DOI 10.1074/jbc.M804788200; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Suzuki H, 2011, CANCER RES, V71, P5646, DOI 10.1158/0008-5472.CAN-11-1076; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Torreggiani E, 2012, J CELL MOL MED, V16, P740, DOI 10.1111/j.1582-4934.2011.01352.x; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Ward Y, 2011, CANCER RES, V71, P7301, DOI 10.1158/0008-5472.CAN-11-2381; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wikstrom P, 1998, PROSTATE, V37, P19, DOI 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07; Zhu M, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r77	34	236	242	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					296	306		10.1038/onc.2012.58	http://dx.doi.org/10.1038/onc.2012.58			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370643	Green Accepted			2022-12-28	WOS:000314736600004
J	Sun, H; Jiang, L; Luo, X; Jin, W; He, Q; An, J; Lui, K; Shi, J; Rong, R; Su, W; Lucchesi, C; Liu, Y; Sheikh, MS; Huang, Y				Sun, H.; Jiang, L.; Luo, X.; Jin, W.; He, Q.; An, J.; Lui, K.; Shi, J.; Rong, R.; Su, W.; Lucchesi, C.; Liu, Y.; Sheikh, M. S.; Huang, Y.			Potential tumor-suppressive role of monoglyceride lipase in human colorectal cancer	ONCOGENE			English	Article						monoglyceride lipase; gene expression; Akt; phosphatidylinositides; colorectal cancer	COLON-CANCER; APOPTOSIS; GENETICS; PROTEIN; PATHWAY; CELLS	Human monoglyceride lipase (MGL) is a recently identified lipase and very little is known about its regulation and function in cellular regulatory processes, particularly in context to human malignancy. In this study, we investigated the regulation and function of MGL in human cancer(s) and report that MGL expression was either absent or reduced in the majority of primary colorectal cancers. Immunohistochemical studies showed that reduction of MGL expression in the colorectal tumor tissues predominantly occurred in the cancerous epithelial cells. MGL was found to reside in the core surface of a cellular organelle named 'lipid body'. Furthermore, it was found to interact selectively with a number of phospholipids, including phosphatidic acid and phosphoinositol(3,4,5)P3, phosphoinositol(3,5)P2, phosphoinositol(3,4)P2 and several other phosphoinositides, and among all phosphoinositides analyzed, its interaction with P1(3,4,5)P3 was found to be the strongest. In addition, overexpression of MGL suppressed colony formation in tumor cell lines and knockdown of MGL resulted in increased Akt phosphorylation. Taken together, our results suggest that MGL plays a negative regulatory role in phosphatidylinositol-3 kinase/Akt signaling and tumor cell growth. Oncogene (2013) 32, 234-241; doi:10.1038/onc.2012.34; published online 20 February 2012	[Sun, H.; Jiang, L.; Luo, X.; Jin, W.; He, Q.; An, J.; Lui, K.; Shi, J.; Rong, R.; Su, W.; Lucchesi, C.; Liu, Y.; Sheikh, M. S.; Huang, Y.] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu		Lui, Ki/0000-0002-1690-4616; Liu, Yusen/0000-0002-0994-0109; Liu, Yuxin/0000-0002-0623-2561	NIH [DK062136, CA121850]; NATIONAL CANCER INSTITUTE [R01CA121850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062136] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH Grants DK062136 and CA121850 to YH.	Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999; Duan RD, 2006, J FOOD NUTR S2, V50, P45; Dueck DA, 1996, MOL CELL BIOCHEM, V162, P97; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Huang Y, 2001, CANCER RES, V61, P6918; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Kennedy BP, 1998, CANCER RES, V58, P500; Li J, 2010, AM J PHYSIOL-CELL PH, V298, pC251, DOI 10.1152/ajpcell.00221.2009; LIU C, 2005, PATHOLOGIC BASIS DIS, P797; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Prevost N, 2009, BLOOD, V113, P447, DOI 10.1182/blood-2008-06-162032; Rong R, 2005, ONCOGENE, V24, P4867, DOI 10.1038/sj.onc.1208660; Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	16	34	37	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2013	32	2					234	241		10.1038/onc.2012.34	http://dx.doi.org/10.1038/onc.2012.34			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349814	Green Accepted			2022-12-28	WOS:000314075500011
J	Formosa, A; Lena, AM; Markert, EK; Cortelli, S; Miano, R; Mauriello, A; Croce, N; Vandesompele, J; Mestdagh, P; Finazzi-Agro, E; Levine, AJ; Melino, G; Bernardini, S; Candi, E				Formosa, A.; Lena, A. M.; Markert, E. K.; Cortelli, S.; Miano, R.; Mauriello, A.; Croce, N.; Vandesompele, J.; Mestdagh, P.; Finazzi-Agro, E.; Levine, A. J.; Melino, G.; Bernardini, S.; Candi, E.			DNA methylation silences miR-132 in prostate cancer	ONCOGENE			English	Article						prostate cancer; miRNAs; miR-132; methylation; methylation-specific PCR; anoikis	MICRORNA EXPRESSION; TUMOR-SUPPRESSOR; CELL-ADHESION; GROWTH-FACTOR; EPIGENETICS; METASTASIS; HYPERMETHYLATION; CARCINOMA; APOPTOSIS; PROMOTES	Silencing of microRNAs (miRNAs) by promoter CpG island methylation may be an important mechanism in prostate carcinogenesis. To screen for epigenetically silenced miRNAs in prostate cancer (PCa), we treated prostate normal epithelial and carcinoma cells with 5-aza-2'-deoxycytidine (AZA) and subsequently examined expression changes of 650 miRNAs by megaplex stemloop reverse transcription-quantitative PCR. After applying a selection strategy, we analyzed the methylation status of CpG islands upstream to a subset of miRNAs by methylation-specific PCR. The CpG islands of miR-18b, miR-132, miR-34b/c, miR-148a, miR-450a and miR-542-3p showed methylation patterns congruent with their expression modulations in response to AZA. Methylation analysis of these CpG islands in a panel of 50 human prostate carcinoma specimens and 24 normal controls revealed miR-132 to be methylated in 42% of human cancer cases in a manner positively correlated to total Gleason score and tumor stage. Expression analysis of miR-132 in our tissue panel confirmed its downregulation in methylated tumors. Re-expression of miR-132 in PC3 cells induced cell detachment followed by cell death (anoikis). Two pro-survival proteins-heparin-binding epidermal growth factor and TALIN2-were confirmed as direct targets of miR-132. The results of this study point to miR-132 as a methylation-silenced miRNA with an antimetastatic role in PCa controlling cellular adhesion. Oncogene (2013) 32, 127-134; doi:10.1038/onc.2012.14; published online 6 February 2012	[Formosa, A.; Cortelli, S.; Croce, N.; Bernardini, S.] Univ Roma Tor Vergata, Dept Internal Med, Rome, Italy; [Lena, A. M.; Melino, G.; Candi, E.] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; [Lena, A. M.; Melino, G.; Candi, E.] Univ Roma Tor Vergata, Biochem Lab IDI IRCCS, Rome, Italy; [Markert, E. K.] Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA; [Miano, R.; Finazzi-Agro, E.] Univ Roma Tor Vergata, Policlin Tor Vergata, Div Urol, Dept Surg, Rome, Italy; [Mauriello, A.] Univ Roma Tor Vergata, Dept Biopathol & Image Diagnost, Rome, Italy; [Vandesompele, J.; Mestdagh, P.] Ghent Univ Hosp, Ctr Med Genet Ghent, Ghent, Belgium; [Vandesompele, J.] Biogazelle, Zwijnaarde, Belgium; [Levine, A. J.] Canc Inst New Jersey, New Brunswick, NJ USA	University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; Institute for Advanced Study - USA; University of Rome Tor Vergata; Policlin Tor Vergata; University of Rome Tor Vergata; Ghent University; Ghent University Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Bernardini, S (corresponding author), Univ Rome, Dept Internal Med, I-00133 Rome, Italy.	bernards@uniroma2.it; candi@uniroma2.it	Agrò, Enrico Finazzi/N-7969-2018; MAURIELLO, ALESSANDRO/K-4705-2016; Lena, Anna Maria/AAI-5042-2020; Vandesompele, Jo/W-3411-2018	Agrò, Enrico Finazzi/0000-0002-0308-8824; MAURIELLO, ALESSANDRO/0000-0002-7351-5676; Vandesompele, Jo/0000-0001-6274-0184; Mestdagh, Pieter/0000-0001-7821-9684; Miano, Roberto/0000-0003-2445-1204	MIUR-PRIN; Min Sal onc_ord [26/07]; ISS e Min Sal [ACC12]; RF07 [55, 57]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	MIUR-PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Min Sal onc_ord; ISS e Min Sal; RF07; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from MIUR-PRIN08, Min Sal onc_ord 26/07, RF07#55 to GM, and ISS e Min Sal ACC12 and RF07#57 to GM and EC.	Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186; Bartkowiak D, 1999, CYTOMETRY, V37, P191, DOI 10.1002/(SICI)1097-0320(19991101)37:3<191::AID-CYTO5>3.0.CO;2-U; Boissier S, 1997, CANCER RES, V57, P3890; Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; Cooper CS, 2009, BRIT J CANCER, V100, P240, DOI 10.1038/sj.bjc.6604771; Cooper CR, 2000, PROSTATE CANCER P D, V3, P6, DOI 10.1038/sj.pcan.4500387; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; Fabbri M, 2010, ADV GENET, V70, P87, DOI [10.1016/S0065-2660(10)70004-3, 10.1016/B978-0-12-380866-0.60004-6]; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Gougelet A, 2011, INT J CANCER, V129, P680, DOI 10.1002/ijc.25715; Kalimutho M, 2011, BRIT J CANCER, V104, P1770, DOI 10.1038/bjc.2011.82; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Lages E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020600; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CELL CYCLE, V6, P1455; Matsunaga S, 2007, ANTICANCER RES, V27, P927; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Miyamoto S, 2007, ANTICANCER RES, V27, P3713; Monkley SJ, 2001, BIOCHEM BIOPH RES CO, V286, P880, DOI 10.1006/bbrc.2001.5497; Nelson WG, 2009, ENDOCRINOLOGY, V150, P3991, DOI 10.1210/en.2009-0573; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299; Park JY, 2010, CANCER CONTROL, V17, P245, DOI 10.1177/107327481001700405; Pavicic W, 2011, MOL MED, V17, P726, DOI 10.2119/molmed.2010.00239; Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Sakamoto S, 2010, CANCER RES, V70, P1885, DOI 10.1158/0008-5472.CAN-09-2833; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Torring N, 2000, ANTICANCER RES, V20, P91; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Wong TS, 2008, INT J CANCER, V123, P251, DOI 10.1002/ijc.23583; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yoon S, 2010, FEBS LETT, V584, P4048, DOI 10.1016/j.febslet.2010.08.025; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang SY, 2011, CARCINOGENESIS, V32, P1183, DOI 10.1093/carcin/bgr105; Zhang X, 2008, NAT CELL BIOL, V10, P1062, DOI 10.1038/ncb1765	44	117	128	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					127	134		10.1038/onc.2012.14	http://dx.doi.org/10.1038/onc.2012.14			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22310291				2022-12-28	WOS:000313029500013
J	Ma, G; Yasunaga, J; Fan, J; Yanagawa, S; Matsuoka, M				Ma, G.; Yasunaga, J.; Fan, J.; Yanagawa, S.; Matsuoka, M.			HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells	ONCOGENE			English	Article						HTLV-1; HBZ; Tax; DAPLE; Wnt signaling pathway; Wnt5a	NF-KAPPA-B; VIRUS TYPE-1; BETA-CATENIN; SIGNALING PATHWAY; TGF-BETA; TRANSCRIPTION FACTOR; VIRAL TRANSCRIPTION; BINDING PROTEIN; ISOMERASE PIN1; IN-VIVO	Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia (ATL). HTLV-1 bZIP factor (HBZ), the viral gene transcribed from the antisense strand, is consistently expressed in ATL cells and promotes their proliferation. In this study, we found that a Wnt pathway-related protein, disheveled-associating protein with a high frequency of leucine residues (DAPLE), interacts with both HTLV-1 Tax and HBZ. In the presence of DAPLE, Tax activated canonical Wnt signaling. Conversely, HBZ markedly suppressed canonical Wnt activation induced by either Tax/DAPLE or beta-catenin. As a mechanism of HBZ-mediated Wnt suppression, we found that HBZ targets lymphoid enhancer-binding factor 1, one of the key transcription factors of the pathway, and impairs its DNA-binding ability. We also observed that the canonical Wnt pathway was not activated in HTLV-1-infected cells, whereas the representative of noncanonical Wnt ligand, Wnt5a, which antagonizes canonical Wnt signaling, was overexpressed. HBZ was able to induce Wnt5a transcription by enhancing its promoter activity through the TGF-beta pathway. Importantly, knocking down of Wnt5a in ATL cells repressed cellular proliferation and migration. Our results implicate novel roles of HBZ in ATL leukemogenesis through dysregulation of both the canonical and noncanonical Wnt pathways.	[Ma, G.; Yasunaga, J.; Fan, J.; Matsuoka, M.] Kyoto Univ, Inst Virus Res, Lab Virus Control, Kyoto 6068507, Japan; [Yanagawa, S.] Kyoto Univ, Inst Virus Res, Lab Gene Anal, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Yasunaga, J (corresponding author), Kyoto Univ, Inst Virus Res, Lab Virus Control, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	jyasunag@virus.kyoto-u.ac.jp		Matsuoka, Masao/0000-0002-0473-754X; Yasunaga, Jun-ichirou/0000-0002-7939-2080	Ministry of Education, Science, Sports, and Culture of Japan; Takeda Science Foundation; Grants-in-Aid for Scientific Research [22114003, 221S0001] Funding Source: KAKEN	Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank H Miyoshi for providing lentiviral packaging vectors and L Kingsbury for proofreading of this manuscript. This work was supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan to MM, and a grant from the Takeda Science Foundation to JY.	Arnold J, 2008, BLOOD, V112, P3788, DOI 10.1182/blood-2008-04-154286; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Badiglian L, 2009, ONCOL REP, V21, P313, DOI 10.3892/or_00000223; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; Clerc I, 2008, J BIOL CHEM, V283, P23903, DOI 10.1074/jbc.M803116200; Da Forno PD, 2008, CLIN CANCER RES, V14, P5825, DOI 10.1158/1078-0432.CCR-07-5104; Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200; Driessens G, 2011, J IMMUNOL, V186, P784, DOI 10.4049/jimmunol.1001562; Fan J, 2005, CANCER RES, V65, P6927, DOI 10.1158/0008-5472.CAN-04-3495; Franchini G, 2003, INT J HEMATOL, V78, P280, DOI 10.1007/BF02983552; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Groen RWJ, 2008, CANCER RES, V68, P6969, DOI 10.1158/0008-5472.CAN-08-1322; Hagiya K, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-19; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Katoh M, 2009, INT J MOL MED, V23, P763, DOI 10.3892/ijmm_00000190; Klemm F, 2011, CARCINOGENESIS, V32, P434, DOI 10.1093/carcin/bgq269; Kuo YL, 2006, EMBO J, V25, P1741, DOI 10.1038/sj.emboj.7601054; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Lemasson I, 2007, J VIROL, V81, P1543, DOI 10.1128/JVI.00480-06; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; McDonald SL, 2009, BRIT J CANCER, V101, P209, DOI 10.1038/sj.bjc.6605174; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Oshita A, 2003, GENES CELLS, V8, P1005, DOI 10.1111/j.1365-2443.2003.00692.x; Peloponese JM, 2009, J VIROL, V83, P3238, DOI 10.1128/JVI.01824-08; Pise-Masison CA, 2009, BLOOD, V113, P4016, DOI 10.1182/blood-2008-08-175901; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Roarty K, 2007, DEVELOPMENT, V134, P3929, DOI 10.1242/dev.008250; Saito M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-19; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; Satou Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001274; Shackelford J, 2003, P NATL ACAD SCI USA, V100, P15572, DOI 10.1073/pnas.2636947100; Shibamoto S, 1998, GENES CELLS, V3, P659; Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Sukarawan W, 2010, AM J PATHOL, V176, P461, DOI 10.2353/ajpath.2010.090478; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; Tezuka N, 2007, BIOCHEM BIOPH RES CO, V356, P648, DOI 10.1016/j.bbrc.2007.03.019; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Uren A, 2005, CANCER RES, V65, P6199, DOI 10.1158/0008-5472.CAN-05-0455; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Watashi K, 2008, J VIROL, V82, P9928, DOI 10.1128/JVI.01017-08; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015; Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496; Yanagawa S, 2000, FEBS LETT, V474, P189, DOI 10.1016/S0014-5793(00)01601-X; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Zhao TJ, 2011, BLOOD, V118, P1865, DOI 10.1182/blood-2010-12-326199; Zhao T, 2009, BLOOD, V113, P2755, DOI 10.1182/blood-2008-06-161729; Zhi HJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002025	61	51	54	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2013	32	36					4222	4230		10.1038/onc.2012.450	http://dx.doi.org/10.1038/onc.2012.450			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045287	Green Submitted			2022-12-28	WOS:000324168000004
J	Chowdhry, S; Zhang, Y; McMahon, M; Sutherland, C; Cuadrado, A; Hayes, JD				Chowdhry, S.; Zhang, Y.; McMahon, M.; Sutherland, C.; Cuadrado, A.; Hayes, J. D.			Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity	ONCOGENE			English	Article						Nrf2; beta-TrCP; GSK-3; oxidative stress; drug resistance; ubiquitylation	TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT RESPONSE ELEMENT; GLYCOGEN-SYNTHASE KINASE-3; OXIDATIVE STRESS; HEME OXYGENASE-1; KEAP1 GENE; PROTEASOMAL DEGRADATION; NEGATIVE REGULATION; MAP KINASES; E3 LIGASE	Identification of regulatable mechanisms by which transcription factor NF-E2 p45-related factor 2 (Nrf2) is repressed will allow strategies to be designed that counter drug resistance associated with its upregulation in tumours that harbour somatic mutations in Kelch-like ECH-associated protein-1 (Keap1), a gene that encodes a joint adaptor and substrate receptor for the Cul3-Rbx1/Roc1 ubiquitin ligase. We now show that mouse Nrf2 contains two binding sites for beta-transducin repeat-containing protein (beta-TrCP), which acts as a substrate receptor for the Skp1-Cul1-Rbx1/Roc1 ubiquitin ligase complex. Deletion of either binding site in Nrf2 decreased beta-TrCP-mediated ubiquitylation of the transcription factor. The ability of one of the two beta-TrCP-binding sites to serve as a degron could be both increased and decreased by manipulation of glycogen synthase kinase-3 (GSK-3) activity. Biotinylated-peptide pull-down assays identified DSGIS(338) and DSAPGS(378) as the two beta-TrCP-binding motifs in Nrf2. Significantly, our pull-down assays indicated that beta-TrCP binds a phosphorylated version of DSGIS more tightly than its non-phosphorylated counterpart, whereas this was not the case for DSAPGS. These data suggest that DSGIS, but not DSAPGS, contains a functional GSK-3 phosphorylation site. Activation of GSK-3 in Keap1-null mouse embryonic fibroblasts (MEFs), or in human lung A549 cells that contain mutant Keap1, by inhibition of the phosphoinositide 3-kinase (PI3K)-protein kinase B (PKB)/Akt pathway markedly reduced endogenous Nrf2 protein and decreased to 10-50% of normal the levels of mRNA for prototypic Nrf2-regulated enzymes, including the glutamate-cysteine ligase catalytic and modifier subunits, glutathione S-transferases Alpha-1 and Mu-1, haem oxygenase-1 and NAD(P)H:quinone oxidoreductase-1. Pre-treatment of Keap1(-/-) MEFs or A549 cells with the LY294002 PI3K inhibitor or the MK-2206 PKB/Akt inhibitor increased their sensitivity to acrolein, chlorambucil and cisplatin between 1.9-fold and 3.1-fold, and this was substantially attenuated by simultaneous pre-treatment with the GSK-3 inhibitor CT99021.	[Chowdhry, S.; Zhang, Y.; McMahon, M.; Hayes, J. D.] Univ Dundee, Ninewells Hosp & Med Sch, Jacqui Wood Canc Ctr, Div Canc Res, Dundee DD1 9SY, Scotland; [Sutherland, C.] Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Div Cardiovasc & Diabet Med, Dundee DD1 9SY, Scotland; [Cuadrado, A.] Inst Invest Sanitaria Paz IdiPAZ, Dept Bioquim, Madrid, Spain; [Cuadrado, A.] Inst Invest Sanitaria Paz IdiPAZ, Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Inst Invest Biomed Alberto Sols UAM CSIC, Madrid, Spain	University of Dundee; University of Dundee; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Hayes, JD (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Jacqui Wood Canc Ctr, Div Canc Res, James Arrott Dr, Dundee DD1 9SY, Scotland.	j.d.hayes@dundee.ac.uk	McMahon, Michael J/F-7070-2010; chowdhry, sudhir/R-8310-2016	McMahon, Michael J/0000-0001-8615-9351; chowdhry, sudhir/0000-0002-8511-5717; Cuadrado, Antonio/0000-0002-4039-7140; Hayes, John/0000-0002-2927-5548; Sutherland, Calum/0000-0003-4398-7434; Cuadrado, Antonio/0000-0002-3444-9012; Zhang, Yiguo/0000-0003-3910-2779	Tenovus Scotland [T07/39]; Association for International Cancer Research [09-0254]; Cancer Research UK [C4909/A9990, C4909/A13786]; Biotechnology and Biological Sciences Research Council [C18727] Funding Source: researchfish; Cancer Research UK [13786] Funding Source: researchfish	Tenovus Scotland; Association for International Cancer Research; Cancer Research UK(Cancer Research UK); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK)	We are very grateful to Professor Masayuki Yamamoto for supplying Keap1-null MEFs, and thank Dr Akira Kikuchi for the gift of the pCGN/GSK-3 beta<SUP>Delta 9</SUP> and pCGN/GSK-3 beta<SUP>Y216F</SUP> expression plasmids. We thank Professor Ronald T Hay and Dr David W Meek for valuable advice in establishing the peptide pull-down assay, and Dr Albena T Dinkova-Kostova and Professor C Roland Wolf for helpful suggestions. We gratefully acknowledge Tenovus Scotland (T07/39), the Association for International Cancer Research (09-0254) and Cancer Research UK (C4909/A9990; C4909/A13786) for funding this work.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alam J, 2000, J BIOL CHEM, V275, P27694; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Finlay D, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-15; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221; Higgins LG, 2009, TOXICOL APPL PHARM, V237, P267, DOI 10.1016/j.taap.2009.03.005; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Hwang YP, 2008, TOXICOL APPL PHARM, V231, P318, DOI 10.1016/j.taap.2008.04.019; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jiang T, 2010, CANCER RES, V70, P5486, DOI 10.1158/0008-5472.CAN-10-0713; Kaidanovich-Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi M, 2009, MOL CELL BIOL, V29, P493, DOI 10.1128/MCB.01080-08; Konstantinopoulos PA, 2011, CANCER RES, V71, P5081, DOI 10.1158/0008-5472.CAN-10-4668; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; MacLeod AK, 2009, CARCINOGENESIS, V30, P1571, DOI 10.1093/carcin/bgp176; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; McMahon M, 2010, P NATL ACAD SCI USA, V107, P18838, DOI 10.1073/pnas.1007387107; McMahon M, 2006, J BIOL CHEM, V281, P24756, DOI 10.1074/jbc.M601119200; Meyer L, 2007, BLOOD, V109, P5215, DOI 10.1182/blood-2006-10-055350; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; Muscarella LA, 2011, EPIGENETICS-US, V6, P710, DOI 10.4161/epi.6.6.15773; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Putters J, 2011, CELL SIGNAL, V23, P641, DOI 10.1016/j.cellsig.2010.11.015; Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204-10; Rojo AI, 2008, MOL CELL NEUROSCI, V39, P125, DOI 10.1016/j.mcn.2008.06.007; Rojo AI, 2008, J NEUROCHEM, V105, P192, DOI 10.1111/j.1471-4159.2007.05124.x; Rojo AI, 2012, FREE RADICAL BIO MED, V52, P473, DOI 10.1016/j.freeradbiomed.2011.11.003; Rushworth SA, 2005, J IMMUNOL, V175, P4408, DOI 10.4049/jimmunol.175.7.4408; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Seo E, 2009, CELL SIGNAL, V21, P43, DOI 10.1016/j.cellsig.2008.09.009; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Sun Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006588; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tong KI, 2007, MOL CELL BIOL, V27, P7511, DOI 10.1128/MCB.00753-07; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsuchiya Y, 2011, MOL CELL BIOL, V31, P4500, DOI 10.1128/MCB.05663-11; Wang R, 2008, BIOCHEM BIOPH RES CO, V373, P151, DOI 10.1016/j.bbrc.2008.06.004; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yoo NJ, 2012, HISTOPATHOLOGY, V60, P943, DOI 10.1111/j.1365-2559.2012.04178.x; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang YG, 2006, BIOCHEM J, V399, P373, DOI 10.1042/BJ20060725; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zipper LM, 2000, BIOCHEM BIOPH RES CO, V278, P484, DOI 10.1006/bbrc.2000.3830	62	391	411	4	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2013	32	32					3765	3781		10.1038/onc.2012.388	http://dx.doi.org/10.1038/onc.2012.388			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22964642	Green Accepted, hybrid, Green Submitted			2022-12-28	WOS:000322904400011
J	Aprelikova, O; Palla, J; Hibler, B; Yu, X; Greer, YE; Yi, M; Stephens, R; Maxwell, GL; Jazaeri, A; Risinger, JI; Rubin, JS; Niederhuber, J				Aprelikova, O.; Palla, J.; Hibler, B.; Yu, X.; Greer, Y. E.; Yi, M.; Stephens, R.; Maxwell, G. L.; Jazaeri, A.; Risinger, J. I.; Rubin, J. S.; Niederhuber, J.			Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility	ONCOGENE			English	Article						cancer-associated fibroblasts; endometrial cancer; microRNA; miR-148a; WNT10B	NUCLEAR BETA-CATENIN; STROMAL CELLS; HUMAN BREAST; GASTRIC-CANCER; ENDOMETRIAL; MICRORNAS; DNA; CARCINOMAS; EXPRESSION; ABNORMALITIES	The tumor microenvironment has an important role in cancer progression. Here we show that miR-148a is downregulated in 15 out of 16 samples (94%) of cancer-associated fibroblasts (CAFs) compared with matched normal tissue fibroblasts (NFs) established from patients with endometrial cancer. Laser-capture microdissection of stromal cells from normal tissue and endometrial cancer confirmed this observation. Treatment of cells with 5-aza-deoxycytidine stimulated the expression of miR-148a in the majority of CAFs implicating DNA methylation in the regulation of miR-148a expression. Investigation of miR-148a function in fibroblasts demonstrated that conditioned media (CM) from CAFs overexpressing miR-148a significantly impaired the migration of five endometrial cancer cell lines without affecting their growth rates in co-culture experiments. Among predicted miR-148a target genes are two WNT family members, WNT1 and WNT10B. Activation of the WNT/b-catenin pathway in CAFs was confirmed by microarray analysis of gene expression and increased activity of the SuperTOPFlash luciferase reporter. We found elevated levels of WNT10B protein in CAFs and its level decreased when miR-148a was re-introduced by lentiviral infection. The 3'-UTR of WNT10B, cloned downstream of luciferase cDNA, suppressed luciferase activity when co-expressed with miR-148a indicating that WNT10B is a direct target of miR-148a. In contrast to the effect of miR-148a, WNT10B stimulated migration of endometrial cancer cell lines. Our findings have defined a molecular mechanism in the tumor microenvironment that is a novel target for cancer therapy.	[Aprelikova, O.; Palla, J.; Hibler, B.; Yu, X.; Niederhuber, J.] Canc & Cell Biol Branch, Bethesda, MD USA; [Greer, Y. E.; Rubin, J. S.] NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; [Yi, M.; Stephens, R.] SAIC Inc, Frederick, MD USA; [Maxwell, G. L.] Walter Reed Army Med Ctr, US Mil Canc Inst, Washington, DC 20307 USA; [Jazaeri, A.] Univ Virginia, Charlottesville, VA USA; [Risinger, J. I.] Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, Grand Rapids, MI USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of Virginia; Michigan State University; Michigan State University College of Human Medicine	Aprelikova, O (corresponding author), NCI, Bldg 37,Rm 1042,9000 Rockville Pike, Bethesda, MD 20892 USA.	apreliko@mail.nih.gov; rubinj@mail.nih.gov	Jazaeri, Amir/I-3458-2015; Greer, Yoshimi/K-2155-2019	Jazaeri, Amir/0000-0003-4335-4151; Yi, Ming/0000-0001-9098-1364	Intramural Research Program of National Institutes of Health; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010251] Funding Source: NIH RePORTER	Intramural Research Program of National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Julie Oliver, Tracy Litzi, and Shelley Hoover for help with laser capture microdissection, Dr Xin Wei Wang (NCI) for the WNT10B expression vector and Dr Randall Moon (University of Washington) for the SuperTOPFlash and SuperFOPFlash constructs. This work was supported by the Intramural Research Program of National Institutes of Health, National Cancer Institute, and Center for Cancer Research.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Cardone A, 1997, PANMINERVA MED, V39, P174; Carmon KS, 2008, MOL CANCER RES, V6, P1017, DOI 10.1158/1541-7786.MCR-08-0039; Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595; Di Leva G, 2010, TRENDS MOL MED, V16, P257, DOI 10.1016/j.molmed.2010.04.001; Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200; Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508; Hanoun N, 2010, CLIN CHEM, V56, P1107, DOI 10.1373/clinchem.2010.144709; Hecht JL, 2006, J CLIN ONCOL, V24, P4783, DOI 10.1200/JCO.2006.06.7173; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Jiang L, 2008, CANCER RES, V68, P9900, DOI 10.1158/0008-5472.CAN-08-1319; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kellermann MG, 2008, ORAL ONCOL, V44, P509, DOI 10.1016/j.oraloncology.2007.07.001; Kiaris H, 2005, CANCER RES, V65, P1627, DOI 10.1158/0008-5472.CAN-04-3791; Kikuchi A, 2008, CANCER SCI, V99, P202, DOI 10.1111/j.1349-7006.2007.00675.x; Klapholz-Brown Z, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000945; Konopka B, 2007, J CANCER RES CLIN, V133, P361, DOI 10.1007/s00432-006-0179-4; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Nagendra DC, MOL CARCINOG, DOI DOI 10.1002/MC.20850); Olson P, 2009, GENE DEV, V23, P2152, DOI 10.1101/gad.1820109; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Qin LM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-320; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Saegusa M, 2001, J PATHOL, V194, P59, DOI 10.1002/path.856; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Scholten AN, 2003, J PATHOL, V201, P460, DOI 10.1002/path.1402; Sneddon JB, 2006, P NATL ACAD SCI USA, V103, P14842, DOI 10.1073/pnas.0606857103; Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1; Tchemitsa O, 2010, J PATHOL, V222, P310, DOI 10.1002/path.2759; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Walter K, 2008, CANCER BIOL THER, V7, P882, DOI 10.4161/cbt.7.6.5869; Wei J, 2011, ARTHRITIS RHEUM-US, V63, P1707, DOI 10.1002/art.30312; Yi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003288; Yoshikawa H, 2007, MOL BIOL CELL, V18, P4292, DOI 10.1091/mbc.E06-10-0889; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714	50	95	100	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3246	3253		10.1038/onc.2012.351	http://dx.doi.org/10.1038/onc.2012.351			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22890324	Green Accepted			2022-12-28	WOS:000321301600004
J	Pan, Y; Zhang, Q; Atsaves, V; Yang, H; Claret, FX				Pan, Y.; Zhang, Q.; Atsaves, V.; Yang, H.; Claret, F. X.			Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways	ONCOGENE			English	Article						nasopharyngeal carcinoma; Epstein-Barr virus-associated malignancy; cisplatin; ultraviolet radiation; ionizing radiation; RPPA	DOMAIN-BINDING PROTEIN-1; CELL-CYCLE CHECKPOINTS; HOMOLOGOUS RECOMBINATION; RAD51 PROTEIN; ACTIVATION; EXPRESSION; CISPLATIN; INHIBITION; OVEREXPRESSION; CONTRIBUTES	Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus-associated malignancy most common in East Asia and Africa. Radiotherapy and cisplatin-based chemotherapy are the main treatment options. Unfortunately, disease response to concurrent chemoradiotherapy varies among patients with NPC, and many cases are resistant to cisplatin. Increased DNA damage repair is one of the mechanisms contributing to this resistance. Jab1/CSN5 is a multifunctional protein that participates in controlling cell proliferation and the stability of multiple proteins. Jab1 overexpression has been found to correlate with poor prognosis in several tumor types. However, the biological significance of Jab1 activity in response to cancer treatment is unclear. In this study, we used three NPC cell lines (CNE1, CNE2 and HONE1) to investigate the hypothesis that Jab1 positively regulates the DNA repair protein Rad51 and, in turn, cellular response to treatment with DNA-damaging agents such as cisplatin, ionizing radiation (IR) and ultraviolet (UV) radiation. We found that Jab1 was overexpressed in two relatively cisplatin-, IR- and UV-resistant NPC cell lines, and knocking down its expression conferred sensitivity to cisplatin, IR and UV radiation. By contrast, exogenous Jab1 expression enhanced the resistance of NPC cells to cisplatin, IR and UV radiation. Moreover, we provide a mechanism by which Jab1 positively regulated Rad51 through p53-dependent pathway, and increased ectopic expression of Rad51 conferred cellular resistance to cisplatin, IR and UV radiation in Jab1-deficient cells. Taken together, our findings suggest that Jab1 has an important role in the cellular response to cisplatin and irradiation by regulating DNA damage and repair pathways. Therefore, Jab1 is a novel biomarker for predicting the outcome of patients with NPC who are treated with DNA-damaging agents.	[Pan, Y.; Zhang, Q.; Atsaves, V.; Claret, F. X.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Pan, Y.; Yang, H.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510275, Guangdong, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; Sun Yat Sen University	Claret, FX (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.	fxclaret@mdanderson.org	atsaves, vasileios/ABA-1599-2021; Claret, Francois X/R-2104-2016; Pan, Yunbao/J-9016-2013	Claret, Francois X/0000-0003-4629-6495; Pan, Yunbao/0000-0002-6311-2945; atsaves, vasileios/0000-0002-9234-4657	China Scholarship Council [2010638087]; National Cancer Institute [RO1-CA90853]; NCI Cancer Center Support Grant [CA16672]; National Natural Science Foundation of China [81071837, 30670627]; Natural Science Foundation of Guangdong Province, China [9251008901000005, 06021210]; Scientific and Technological Project of Guangdong, China [2008A030201009, 2010B050700016]; NATIONAL CANCER INSTITUTE [R01CA090853, P30CA016672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148] Funding Source: NIH RePORTER	China Scholarship Council(China Scholarship Council); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Scientific and Technological Project of Guangdong, China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Zahid H Siddik, Do Youn Oh for helpful discussions and Ronald Glaser for kindly providing HONE1 cells. This work was supported by a fellowship from the China Scholarship Council (2010638087 to YP) and a grant from the National Cancer Institute (RO1-CA90853 to FXC). The University of Texas MD Anderson Functional Proteomics Core Facility is supported by an NCI Cancer Center Support Grant (CA16672); the National Natural Science Foundation of China (81071837; 30670627); Natural Science Foundation of Guangdong Province, China (9251008901000005; 06021210) and Scientific and Technological Project of Guangdong, China (2008A030201009; 2010B050700016 to HY). We thank Kate J Newberry and Sunita Patterson for editing the manuscript.	Arias-Lopez C, 2006, EMBO REP, V7, P219, DOI 10.1038/sj.embor.7400587; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Cheung BW, 2005, CANCER RES, V65, P1450, DOI 10.1158/0008-5472.CAN-04-0567; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Cruet-Hennequart S, 2009, CELL CYCLE, V8, P3039; Davies MA, 2009, CLIN CANCER RES, V15, P7538, DOI 10.1158/1078-0432.CCR-09-1985; Dmitrieva NI, 2011, P NATL ACAD SCI USA, V108, P20796, DOI 10.1073/pnas.1114677108; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feng ZZ, 2010, CANCER LETT, V297, P190, DOI 10.1016/j.canlet.2010.05.011; Hannay JAF, 2007, MOL CANCER THER, V6, P1650, DOI 10.1158/1535-7163.MCT-06-0636; Hui EP, 2009, J CLIN ONCOL, V27, P242, DOI 10.1200/JCO.2008.18.1545; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Kouvaraki MA, 2006, CANCER RES, V66, P8581, DOI 10.1158/0008-5472.CAN-06-0975; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le QT, 2003, INT J RADIAT ONCOL, V56, P1046, DOI 10.1016/S0360-3016(03)00117-2; Lee JH, 2010, ONCOGENE, V29, P1431, DOI 10.1038/onc.2009.438; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lo KW, 2012, SEMIN CANCER BIOL, V22, P79, DOI 10.1016/j.semcancer.2011.12.011; Ma W, 2012, ONCOGENE, V31, P1024, DOI 10.1038/onc.2011.300; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pabla N, 2011, J BIOL CHEM, V286, P10411, DOI 10.1074/jbc.M110.210989; Pan YB, 2012, CANCER RES, V72, P1890, DOI 10.1158/0008-5472.CAN-11-3472; Pedram A, 2009, MOL BIOL CELL, V20, P3374, DOI 10.1091/mbc.E09-01-0085; Qing Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002148; Raderschall E, 2002, CANCER RES, V62, P219; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Revet I, 2011, P NATL ACAD SCI USA, V108, P8663, DOI 10.1073/pnas.1105866108; Russell JS, 2003, CANCER RES, V63, P7377; Shackleford TJ, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-26; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Spano JP, 2003, EUR J CANCER, V39, P2121, DOI 10.1016/S0959-8049(03)00367-8; Tian L, 2010, ONCOGENE, V29, P6125, DOI 10.1038/onc.2010.345; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Yip KW, 2005, CLIN CANCER RES, V11, P8131, DOI 10.1158/1078-0432.CCR-05-1266; Zhang QX, 2005, FEBS LETT, V579, P3932, DOI 10.1016/j.febslet.2005.06.012	44	57	60	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2756	2766		10.1038/onc.2012.294	http://dx.doi.org/10.1038/onc.2012.294			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22797071	Green Accepted			2022-12-28	WOS:000319808000007
J	Luwor, RB; Baradaran, B; Taylor, LE; Iaria, J; Nheu, TV; Amiry, N; Hovens, CM; Wang, B; Kaye, AH; Zhu, HJ				Luwor, R. B.; Baradaran, B.; Taylor, L. E.; Iaria, J.; Nheu, T. V.; Amiry, N.; Hovens, C. M.; Wang, B.; Kaye, A. H.; Zhu, H-J			Targeting Stat3 and Smad7 to restore TGF-beta cytostatic regulation of tumor cells in vitro and in vivo	ONCOGENE			English	Article						EGFR; TGF-beta Stat3; Smad7; cancer	EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; FACTOR RECEPTOR EGFR; BREAST-CANCER-CELLS; WILD-TYPE EGFR; LUNG-CANCER; SIGNAL TRANSDUCERS; CDDO-IMIDAZOLIDE; ACTIVATION; FAMILY	Transforming Growth Factor-beta (TGF-beta) and Epidermal Growth Factor (EGF) signaling pathways are both independently implicated as key regulators in tumor formation and progression. Here, we report that the tumor-associated overexpression of epidermal growth factor receptor (EGFR) desensitizes TGF-beta signaling and its cytostatic regulation through specific and persistent Stat3 activation and Smad7 induction in vivo. In human tumor cell lines, reduction of TGF-beta-mediated Smad2 phosphorylation, nuclear translocation and Smad3 target gene activation were observed when EGFR was overexpressed, but not in cells that expressed EGFR at normal levels. We identified Stat3, which is activated specifically and persistently by overexpressed EGFR, as a key signaling molecule responsible for the reduced TGF-beta sensitivity. Stable knockdown of Stat3 using small hairpin RNA(shRNA) in Head and Neck (HN5) and Epidermoid (A431) tumor cell lines resulted in reduced growth compared with control shRNA-transfected cells when grown as subcutaneous tumor xenografts. Furthermore, xenografts with Stat3 knockdown displayed increased Smad3 transcriptional activity, increased Smad2 phosphorylation and decreased Smad7 expression compared with control xenografts in vivo. Consistently, Smad7 mRNA and protein expression was also significantly reduced when EGFR activity was blocked by a specific tyrosine kinase inhibitor, AG1478, or in Stat3 knockdown tumors. Similarly, Smad7 knockdown also resulted in enhanced Smad3 transcriptional activity in vivo. Importantly, there was no uptake of subcutaneous HN5 xenografts with Smad7 knockdown. Taken together, we demonstrate here that targeting Stat3 or Smad7 for knockdown results in resensitization of TGF-beta's cytostatic regulation in vivo. Overall, these results establish EGFR/Stat3/Smad7/TGF-beta signaling axis driving tumor growth, which can be targeted therapeutically.	[Luwor, R. B.; Taylor, L. E.; Iaria, J.; Nheu, T. V.; Hovens, C. M.; Wang, B.; Kaye, A. H.; Zhu, H-J] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Melbourne, Vic 3050, Australia; [Baradaran, B.] Tabriz Univ Med Sci, Dept Immunol, Tabriz, Iran; [Amiry, N.; Hovens, C. M.] Epworth Med Fdn, Australian Prostate Canc Res Ctr, Richmond, Vic, Australia	Royal Melbourne Hospital; University of Melbourne; Tabriz University of Medical Science; Epworth Medical Foundation	Zhu, HJ (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Melbourne, Vic 3050, Australia.	hongjian@unimelb.edu.au	Baradaran, Behzad/AAQ-5177-2020	Baradaran, Behzad/0000-0002-8642-6795; Hovens, Christopher/0000-0002-0610-1289; Luwor, Rodney/0000-0002-3020-4245; Zhu, Hong-Jian/0000-0002-1478-995X; Kaye, Andrew Henry/0000-0001-5049-8861	National Health and Medical Research Council (NHMRC); University of Melbourne	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); University of Melbourne(University of Melbourne)	This work was supported by grants from the National Health and Medical Research Council (NHMRC) to H-JZ. RBL is a recipient of the Winter and Glover Fellowship for Cancer Research from the University of Melbourne.	Albanell J, 2001, CANCER RES, V61, P6500; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Burgess AW, 2008, GROWTH FACTORS, V26, P263, DOI 10.1080/08977190802312844; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Das P, 1999, CYTOKINE GROWTH F R, V10, P179, DOI 10.1016/S1359-6101(99)00014-3; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ettinger DS, 2006, ONCOLOGIST, V11, P358, DOI 10.1634/theoncologist.11-4-358; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; HOWE PH, 1993, J BIOL CHEM, V268, P21448; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Iacopetta BJ, 1999, J PATHOL, V187, P428, DOI 10.1002/(SICI)1096-9896(199903)187:4<428::AID-PATH264>3.0.CO;2-A; Itman C, 2009, DEV DYNAM, V238, P1688, DOI 10.1002/dvdy.21995; Janmaat ML, 2003, CLIN CANCER RES, V9, P2316; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kuang CZ, 2006, P NATL ACAD SCI USA, V103, P1858, DOI 10.1073/pnas.0508977103; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Liby K, 2006, CLIN CANCER RES, V12, P4288, DOI 10.1158/1078-0432.CCR-06-0215; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Luwor RB, 2001, CANCER RES, V61, P5355; Luwor RB, GROWTH FACTORS, V29, P211; Luwor RB, 2008, J CLIN NEUROSCI, V15, P845, DOI 10.1016/j.jocn.2008.01.003; Massague J, 2000, GENE DEV, V14, P627; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Nagane M, 2001, J NEUROSURG, V95, P472, DOI 10.3171/jns.2001.95.3.0472; Normanno N, 2006, J CELL PHYSIOL, V207, P420, DOI 10.1002/jcp.20588; OSBORNE CK, 1985, CANCER RES, V45, P584; Place AE, 2003, CLIN CANCER RES, V9, P2798; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sehgal PB, 2008, SEMIN CELL DEV BIOL, V19, P329, DOI 10.1016/j.semcdb.2008.07.003; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Tenney R, 2005, J CELL PHYSIOL, V202, P160, DOI 10.1002/jcp.20100; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Wild R, 2006, MOL CANCER THER, V5, P104, DOI 10.1158/1535-7163.MCT-05-0259; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424; Zhu Hong-Jian, 2001, Molecular Cell Biology Research Communications, V4, P321, DOI 10.1006/mcbr.2001.0301	51	57	61	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2433	2441		10.1038/onc.2012.260	http://dx.doi.org/10.1038/onc.2012.260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751114	Green Published, hybrid			2022-12-28	WOS:000318694900007
J	Wang, Y; Moncayo, G; Morin, P; Xue, G; Grzmil, M; Lino, MM; Clement-Schatlo, V; Frank, S; Merlo, A; Hemmings, BA				Wang, Y.; Moncayo, G.; Morin, P., Jr.; Xue, G.; Grzmil, M.; Lino, M. M.; Clement-Schatlo, V.; Frank, S.; Merlo, A.; Hemmings, B. A.			Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme	ONCOGENE			English	Article						glioblastoma multiforme (GBM); MerTK; invasiveness; apoptosis; actomyosin contractility	STEM-LIKE CELLS; MYOSIN-II; SIGNALING PATHWAY; APOPTOTIC CELLS; GLIOMA INVASION; NDR KINASE; C-MER; CANCER; IDENTIFICATION; EXPRESSION	The infiltration of glioma cells into adjacent tissue is one of the major obstacles in the therapeutic management of malignant brain tumours, in most cases precluding complete surgical resection. Consequently, malignant glioma patients almost invariably experience tumour recurrences. Within the brain, glioma cells migrate rapidly either amoeboidly or mesenchymally to invade surrounding structures, in dependence on the extracellular environment. In addition, radiotherapy, frequently applied as adjuvant therapeutic modality, may enhance tumour cell mobility. Here, we show that the receptor tyrosine kinase Mer (MerTK) is overexpressed in glioblastoma multiforme (GBM) and that this is accompanied with increased invasive potential. MerTK expression is maintained in primary GBM-derived tumour spheres under stem cell culture conditions but diminishes significantly in serum-containing cultures with concomitant downregulation of Nestin and Sox2. Depletion of MerTK disrupts the rounded morphology of glioma cells and decreases their invasive capacity. Furthermore, the expression and phosphorylation of myosin light chain 2 are strongly associated with MerTK activity, indicating that the effect of MerTK on glionna cell invasion is mediated by actomyosin contractility. Finally, DNA damage robustly triggers the upregulation and phosphorylation of MerTK, which protects cells from apoptosis. This effect is strongly impaired upon MerTK depletion or overexpression of an inactive MerTK mutant. Collectively, our data suggests that MerTK is a novel therapeutic target in the treatment of the malignant gliomas. Oncogene (2013) 32, 872-882; doi:10.1038/onc.2012.104; published online 2 April 2012	[Wang, Y.; Moncayo, G.; Morin, P., Jr.; Xue, G.; Grzmil, M.; Hemmings, B. A.] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Lino, M. M.; Merlo, A.] Univ Basel, Dept Res & Surg, Mol Neurooncol Lab, Basel, Switzerland; [Clement-Schatlo, V.] Univ Hosp Geneva, Dept Clin Neurosci, Div Neurosurg, Geneva, Switzerland; [Clement-Schatlo, V.] Univ Geneva, Geneva, Switzerland; [Frank, S.] Univ Basel, Dept Neuropathol, Inst Pathol, Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; University of Basel; University of Geneva; University of Geneva; University of Basel	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	brian.hemmings@fmi.ch		Grzmil, Michal/0000-0002-7866-8145	Oncosuisse CCRP Grant [KFP OCS-01613-12-2004]; Swiss National Science Foundation [SNF 31003A_130838]	Oncosuisse CCRP Grant; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	We thank Sandrine Bichet and Hubertus Kohler for helping with immunohistochemistry and FACS experiments, respectively, Susanne Schenk for the generation of the MerTK monoclonal antibody, Douglass Vollrath for the pcDNA3.1(-)-MerTK construct, Janis Liebetanz and Doriano Fabbro for the GST-hMerTK (amino acids 536-999) construct and Patrick King for editing the manuscript. This research was funded by Oncosuisse CCRP Grant KFP OCS-01613-12-2004. G Xue is supported by the Swiss National Science Foundation SNF 31003A_130838. The FMI is part of the Novartis Research Foundation.	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beadle C, 2008, MOL BIOL CELL, V19, P3357, DOI 10.1091/mbc.E08-03-0319; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Clement V, 2010, NAT METHODS, V7, P224, DOI [10.1038/nmeth.1430, 10.1038/NMETH.1430]; Cohen PL, 2002, J EXP MED, V196, P135, DOI 10.1084/jem.20012094; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Duncan JL, 2003, ADV EXP MED BIOL, V533, P165; Ek S, 2002, CANCER RES, V62, P4398; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Graham DK, 2006, CLIN CANCER RES, V12, P2662, DOI 10.1158/1078-0432.CCR-05-2208; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; Grzmil M, 2011, CANCER RES, V71, P2392, DOI 10.1158/0008-5472.CAN-10-3112; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Gyorffy B, 2007, J INVEST DERMATOL, V127, P394, DOI 10.1038/sj.jid.5700543; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hambardzumyan D, 2006, CANCER CELL, V10, P454, DOI 10.1016/j.ccr.2006.11.008; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hergovich A, 2007, MOL CELL, V25, P625, DOI 10.1016/j.molcel.2007.01.020; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Ling L, 1996, J BIOL CHEM, V271, P18355, DOI 10.1074/jbc.271.31.18355; LING L, 1995, MOL CELL BIOL, V15, P6582; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; McCord AM, 2009, CLIN CANCER RES, V15, P5145, DOI 10.1158/1078-0432.CCR-09-0263; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nakada M, 2007, CELL MOL LIFE SCI, V64, P458, DOI 10.1007/s00018-007-6342-5; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Rao JY, 2004, CURR CANCER DRUG TAR, V4, P345, DOI 10.2174/1568009043332998; Rogers AEJ, 2012, ONCOGENE, V31, P4171, DOI 10.1038/onc.2011.588; Ropolo M, 2009, MOL CANCER RES, V7, P383, DOI 10.1158/1541-7786.MCR-08-0409; Sather S, 2007, BLOOD, V109, P1026, DOI 10.1182/blood-2006-05-021634; Strick DJ, 2009, INVEST OPHTH VIS SCI, V50, P2427, DOI 10.1167/iovs.08-3058; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vichalkovski A, 2008, CURR BIOL, V18, P1889, DOI 10.1016/j.cub.2008.10.060; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632; Wu YM, 2004, CANCER RES, V64, P7311, DOI 10.1158/0008-5472.CAN-04-0972; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Zhai GG, 2006, J NEURO-ONCOL, V76, P227, DOI 10.1007/s11060-005-6499-4; Zhang M, 2005, INVEST OPHTH VIS SCI, V46, P4130, DOI 10.1167/iovs.05-0164	49	53	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2013	32	7					872	882		10.1038/onc.2012.104	http://dx.doi.org/10.1038/onc.2012.104			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469987	hybrid			2022-12-28	WOS:000316581100007
J	Kang, JM; Park, S; Kim, SJ; Hong, HY; Jeong, J; Kim, HS; Kim, SJ				Kang, J. M.; Park, S.; Kim, S. J.; Hong, H. Y.; Jeong, J.; Kim, H-S; Kim, S-J			CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-beta signaling	ONCOGENE			English	Article						TGF-beta; smad; CBL; breast cancer; tumorigenesis	GROWTH-FACTOR-BETA; ACQUIRED UNIPARENTAL DISOMY; II RECEPTOR; C-CBL; CANCER CELLS; TYROSINE KINASES; NUCLEAR IMPORT; SMAD3; MUTATIONS; TRANSCRIPTION	Casitas B-lineage lymphoma (CBL) protein family functions as multifunctional adaptor proteins and E3 ubiquitin ligases that are implicated as regulators of signaling in various cell types. Recent discovery revealed mutations of proto-oncogenic CBL in the linker region and RING finger domain in human acute myeloid neoplasm, and these transforming mutations induced carcinogenesis. However, the adaptor function of CBL mediated signaling pathway during tumorigenesis has not been well characterized. Here, we show that CBL is highly expressed in breast cancer cells and significantly inhibits transforming growth factor-beta (TGF-beta) tumor suppressive activity. Knockdown of CBL expression resulted in the increased expression of TGF-beta target genes, PAI-I and CDK inhibitors such as p15(INK4b) and p21(Cip1). Furthermore, we demonstrate that CBL is frequently overexpressed in human breast cancer tissues, and the loss of CBL decreases the tumorigenic activity of breast cancer cells in vivo. CBL directly binds to Smad3 through its proline-rich motif, thereby preventing Smad3 from interacting with Smad4 and blocking nuclear translocation of Smad3. CBL-b, one of CBL protein family, also interacted with Smad3 and knockdown of both CBL and CBL-b further enhanced TGF-beta transcriptional activity. Our findings provide evidence for a previously undescribed mechanism by which oncogenic CBL can block TGF-beta tumor suppressor activity. Oncogene (2012) 31, 5123-5131; doi:10.1038/onc.2012.18; published online 6 February 2012	[Kang, J. M.; Park, S.; Kim, S. J.; Kim, S-J] CHA Univ, Dept Biomed Sci, Seoul 135081, South Korea; [Hong, H. Y.; Kim, S-J] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Lab Cell Regulat & Carcinogenesis, Inchon, South Korea; [Jeong, J.] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Surg, Seoul, South Korea; [Kim, H-S; Kim, S-J] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA	Pochon Cha University; Gachon University; Yonsei University; Yonsei University Health System; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Kim, SJ (corresponding author), CHA Univ, Dept Biomed Sci, 605 Yeoksam 1 Dong, Seoul 135081, South Korea.	kimsj@cha.ac.kr		Kim, Staci J./0000-0001-9932-255X; Kang, Jin Muk/0000-0002-7949-9160	National Research Foundation grant of Korea [20090081756, 2011-0014281]; Korea government	National Research Foundation grant of Korea(National Research Foundation of Korea); Korea government(Korean Government)	This work was supported by a National Research Foundation grant of Korea (20090081756 and 2011-0014281) funded by the Korea government. We thank H Kim, W Joo, Y Kim and J Park for their technical supporting.	Bisogna M, 2001, CANCER GENET CYTOGEN, V125, P131, DOI 10.1016/S0165-4608(00)00367-8; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Dunbar AJ, 2008, CANCER RES, V68, P10349, DOI 10.1158/0008-5472.CAN-08-2754; Falanga V, 2004, WOUND REPAIR REGEN, V12, P320, DOI 10.1111/j.1067-1927.2004.012316.x; Grand FH, 2009, BLOOD, V113, P6182, DOI 10.1182/blood-2008-12-194548; Hansson MD, 2008, ANAL BIOCHEM, V375, P373, DOI 10.1016/j.ab.2007.12.005; Inoue Y, 2009, J CELL BIOCHEM, V108, P285, DOI 10.1002/jcb.22252; Jin W, 2005, P NATL ACAD SCI USA, V102, P16239, DOI 10.1073/pnas.0503137102; Jin W, 2007, CANCER RES, V67, P9869, DOI 10.1158/0008-5472.CAN-07-0436; Jin W, 2010, CARCINOGENESIS, V31, P1939, DOI 10.1093/carcin/bgq180; Knight JF, 2008, BRIT J CANCER, V99, P1849, DOI 10.1038/sj.bjc.6604774; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Lahn M, 2006, SMAD SIGNAL TRANSDUC, P415; Lee BI, 2001, CANCER RES, V61, P931; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Li LY, 2004, MOL CELL BIOL, V24, P856, DOI 10.1128/MCB.24.2.856-864.2004; Loh ML, 2009, BLOOD, V114, P1859, DOI 10.1182/blood-2009-01-198416; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Pennock S, 2008, MOL CELL BIOL, V28, P3020, DOI 10.1128/MCB.01809-07; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Tan YHC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008972; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Wan M, 2005, AM J PATHOL, V166, P1379, DOI 10.1016/S0002-9440(10)62356-5; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200	32	31	34	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5123	5131		10.1038/onc.2012.18	http://dx.doi.org/10.1038/onc.2012.18			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22310290				2022-12-28	WOS:000312449800001
J	Maslov, AY; Lee, M; Gundry, M; Gravina, S; Strogonova, N; Tazearslan, C; Bendebury, A; Suh, Y; Vijg, J				Maslov, A. Y.; Lee, M.; Gundry, M.; Gravina, S.; Strogonova, N.; Tazearslan, C.; Bendebury, A.; Suh, Y.; Vijg, J.			5-Aza-2 '-deoxycytidine-induced genome rearrangements are mediated by DNMT1	ONCOGENE			English	Article						DNA methylation; 5-aza-2 '-deoxycytidine; mutations; genome rearrangements; DNMT1	BASE EXCISION-REPAIR; DNA METHYLTRANSFERASE; MASS-SPECTROMETRY; CANCER-CELLS; POLY(ADP-RIBOSE) POLYMERASE; MYELODYSPLASTIC SYNDROME; MAMMALIAN-CELLS; IN-VIVO; DEMETHYLATION; METHYLATION	Observations that genome-wide DNA hypomethylation induces genome instability and tumors in animals caution against the indiscriminate use of demethylating agents, such as 5-aza-2'-deoxycytidine (5-Aza-dC). Using primary mouse embryonic fibroblasts harboring a lacZ mutational reporter construct that allows the quantification and characterization of a wide range of mutational events, we found that, in addition to demethylation, treatment with 5-Aza-dC induces gamma-H2AX expression, a marker for DNA breaks, and both point mutations and genome rearrangements. To gain insight into the source of these mutations, we first tested the hypothesis that the mutagenic effect of 5-Aza-dC may be directly mediated through the DNA methyltransferase 1 (DNMT1) covalently trapped in 5-Aza-dC-substituted DNA. Knockdown of DNMT1 resulted in increased resistance to the cytostatic effects of 5-Aza-dC, delayed onset of g-H2AX expression and a significant reduction in the frequency of genome rearrangements. There was no effect on the 5-Aza-dC-induced point mutations. An alternative mechanism for 5-Aza-dC-induced demethylation and genome rearrangements via activation-induced cytidine deaminase (AID) followed by base excision repair (BER) was found not to be involved. That is, 5-Aza-dC treatment did not significantly induce AID expression and inhibition of BER did not reduce the frequency of genome rearrangements. Thus, our results indicate that the formation of DNMT1 adducts is the prevalent mechanism of 5-Aza-dC-induced genome rearrangements, although hypomethylation per se may still contribute. As the therapeutic effects of 5-Aza-dC greatly depend on the presence of DNMT1, the expression level of DNA methyltransferases in tumors may serve as a prognostic factor for the efficacy of 5-Aza-dC treatment. Oncogene (2012) 31, 5172--5179; doi:10.1038/onc.2012.9; published online 20 February 2012	[Maslov, A. Y.; Lee, M.; Gundry, M.; Gravina, S.; Strogonova, N.; Tazearslan, C.; Bendebury, A.; Suh, Y.; Vijg, J.] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA; [Suh, Y.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Suh, Y.] Guangdong Med Coll, Inst Aging Res, Dongguan, Peoples R China	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Guangdong Medical University	Maslov, AY (corresponding author), Albert Einstein Coll Med, Dept Genet, 1301 Morris Pk Ave, Bronx, NY 10461 USA.	alex.maslov@einstein.yu.edu; yousin.suh@einstein.yu.edu; jan.vijg@einstein.yu.edu	Gundry, Michael/AAE-7670-2020; Maslov, Alexander/AAH-3788-2019	Gundry, Michael/0000-0003-3654-1741; 	NIH [P01 AG017242, R01 AG024391]; Ellison/AFAR; NATIONAL INSTITUTE ON AGING [R01AG024391, P01AG017242] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison/AFAR; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by NIH Grant P01 AG017242 to JV and YS; R01 AG024391 to YS. CT is a recipient of Ellison/AFAR postdoctoral fellowship.	Allinson SL, 2003, ACTA BIOCHIM POL, V50, P169; AMACHER DE, 1987, MUTAT RES, V176, P123, DOI 10.1016/0027-5107(87)90259-4; Bhutani N, 2011, CELL, V146, P866, DOI 10.1016/j.cell.2011.08.042; BOERRIGTER METI, 1995, NATURE, V377, P657, DOI 10.1038/377657a0; CHABOT GG, 1983, BIOCHEM PHARMACOL, V32, P1327, DOI 10.1016/0006-2952(83)90293-9; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Dolle MET, 2002, GENOME RES, V12, P1732, DOI 10.1101/gr.125502; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fandy TE, 2009, CURR MED CHEM, V16, P2075, DOI 10.2174/092986709788612738; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Fisher AEO, 2007, MOL CELL BIOL, V27, P5597, DOI 10.1128/MCB.02248-06; Fritz EL, 2010, GENE DEV, V24, P2107, DOI 10.1101/gad.1963010; Garcia Ana Maria, 2007, Methods Mol Biol, V371, P267; Hernandez R, 1997, CYTOGENET CELL GENET, V76, P196, DOI 10.1159/000134548; Hoglund A, 2009, BLOOD, V113, P4281, DOI 10.1182/blood-2008-10-183475; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kelecsenyi Z, 2000, MUTAGENESIS, V15, P25, DOI 10.1093/mutage/15.1.25; Kuo HK, 2007, CANCER RES, V67, P8248, DOI 10.1158/0008-5472.CAN-07-1038; LANDOLPH JR, 1982, CANCER RES, V42, P817; Langer F, 2005, LEUKEMIA RES, V29, P325, DOI 10.1016/j.leukres.2004.08.004; Larijani M, 2005, MOL IMMUNOL, V42, P599, DOI 10.1016/j.molimm.2004.09.007; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Masaoka A, 2009, DNA REPAIR, V8, P1290, DOI 10.1016/j.dnarep.2009.08.004; Nakano T, 2009, J BIOL CHEM, V284, P27065, DOI 10.1074/jbc.M109.019174; Obeid S, 2010, EMBO J, V29, P1738, DOI 10.1038/emboj.2010.64; Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogstad DK, 2009, CHEM RES TOXICOL, V22, P1194, DOI 10.1021/tx900131u; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229; Sandhu SK, 2010, EUR J CANCER, V46, P9, DOI 10.1016/j.ejca.2009.10.021; Sczepanski JT, 2010, P NATL ACAD SCI USA, V107, P22475, DOI 10.1073/pnas.1012860108; Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; ZIMMERMANN FK, 1984, MUTAT RES, V139, P21, DOI 10.1016/0165-7992(84)90116-7	42	36	39	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5172	5179		10.1038/onc.2012.9	http://dx.doi.org/10.1038/onc.2012.9			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22349820	Green Accepted			2022-12-28	WOS:000312449800006
J	Hsu, YL; Hou, MF; Kuo, PL; Huang, YF; Tsai, EM				Hsu, Y-L; Hou, M-F; Kuo, P-L; Huang, Y-F; Tsai, E-M			Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/Snail signaling pathway	ONCOGENE			English	Article						breast cancer; osteoblasts; CXCL5; cancer progression	EPITHELIAL-MESENCHYMAL TRANSITIONS; ACTIVATED PROTEIN-KINASE; SNAIL; EXPRESSION; GROWTH; CELLS; MECHANISMS; DISEASE; GENE; MSK	The skeleton is the most common metastatic site for breast cancer, with bone metastasis causing pain as well as risk of pathological fractures. Interaction between tumors and the bone microenvironment creates a vicious cycle that accelerates both bone destruction and cancer progression. This study is the first to analyze the soluble factors secreted by breast tumor-associated osteoblasts (TAOBs), which are responsible for promoting cancer progression. The addition of CXCL5 (chemokine (C-X-C motif) ligand 5), present in large amounts in TAOB-condition medium (TAOB-CM), mimicked the inductive effect of TAOB-CM on breast cancer epithelial-mesenchymal transition, migration and invasion. In contrast, inhibition of CXCL5 in OBs decreased TAOB-mediated cancer progression. Inducement of MCF-7 and MDA-MB-231 cancer progression by TAOB-derived CXCL5 is associated with increased Raf/MEK/ERK activation, and mitogen-and stress-activated protein kinase 1 (MSK1) and Elk-1 phosphorylation, as well as Snail upregulation. Activation of Elk-1 facilitates recruitment of phosphorylated MSK1, which in turn enhances histone H3 acetylation and phosphorylation (serine 10) of Snail promoter, resulting in Snail enhancement and E-cadherin downregulation. Moreover, mice treated with anti-CXCL5 antibodies showed decreased metastasis of 4T1 breast cancer cells. Our study suggests that inhibition of CXCL5-mediated ERK/Snail signaling is an attractive therapeutic target for treating metastases in breast cancer patients.	[Hsu, Y-L; Tsai, E-M] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan; [Hou, M-F; Kuo, P-L; Huang, Y-F] Kaohsiung Med Univ, Coll Med, Inst Clin Med, Kaohsiung 807, Taiwan; [Hou, M-F; Kuo, P-L; Huang, Y-F] Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung, Taiwan; [Kuo, P-L] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan; [Tsai, E-M] Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Hsu, YL (corresponding author), Kaohsiung Med Univ, Coll Med, Grad Inst Med, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.	hsuyl326@gmail.com		Huang, Ya-Fang/0000-0002-7790-8071; Hou, Ming-Feng/0000-0001-6030-9702	National Science Council of Taiwan [NSC 99-2320-B-037-017-MY3]; Excellence for Cancer Research Center Grant, the Department of Health, Executive Yuan, Taipei, Taiwan [DOH101-TD-C-111-002]; Kaohsiung Medical University Hospital [KMUH 99-9I04]; Kaohsiung Medical University Research Foundation [KMUER008]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Excellence for Cancer Research Center Grant, the Department of Health, Executive Yuan, Taipei, Taiwan; Kaohsiung Medical University Hospital; Kaohsiung Medical University Research Foundation	This study is supported by grants from the National Science Council of Taiwan (NSC 99-2320-B-037-017-MY3), the Excellence for Cancer Research Center Grant, the Department of Health, Executive Yuan, Taipei, Taiwan (DOH101-TD-C-111-002), the Kaohsiung Medical University Hospital (KMUH 99-9I04) and the Kaohsiung Medical University Research Foundation (KMUER008).	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Besnard A, 2011, J NEUROSCI, V31, P14296, DOI 10.1523/JNEUROSCI.2890-11.2011; Bieche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cassinat B, 2011, MOL CELL BIOL, V31, P1409, DOI 10.1128/MCB.00756-10; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Chen Y, 2011, J BIOL CHEM, V286, P42575, DOI 10.1074/jbc.M111.294595; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Espino PS, 2006, CANCER RES, V66, P4610, DOI 10.1158/0008-5472.CAN-05-4251; Georges S, 2009, CYTOKINE GROWTH F R, V20, P29, DOI 10.1016/j.cytogfr.2008.11.005; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu YL, 2011, J BIOL CHEM, V286, P37335, DOI 10.1074/jbc.M111.256156; Jorda M, 2007, EXP CELL RES, V313, P2389, DOI 10.1016/j.yexcr.2007.04.001; Kuo PL, 2011, J CELL PHYSIOL, V226, P1224, DOI 10.1002/jcp.22445; Kuo PL, 2011, J IMMUNOL, V186, P1521, DOI 10.4049/jimmunol.1002940; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134; Pacheco-Rodriguez G, 2009, J IMMUNOL, V182, P1270, DOI 10.4049/jimmunol.182.3.1270; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Van't Veer LJ, 2003, NAT MED, V9, P999, DOI 10.1038/nm0803-999b; Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yuen HF, 2011, J PATHOL, V224, P78, DOI 10.1002/path.2859; Zhang HM, 2008, NUCLEIC ACIDS RES, V36, P2594, DOI 10.1093/nar/gkn099	38	97	104	1	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4436	4447		10.1038/onc.2012.444	http://dx.doi.org/10.1038/onc.2012.444			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23045282				2022-12-28	WOS:000324404200012
J	Shum, CKY; Lau, ST; Tsoi, LLS; Chan, LK; Yam, JWP; Ohira, M; Nakagawara, A; Tam, PKH; Ngan, ESW				Shum, C. K. Y.; Lau, S. T.; Tsoi, L. L. S.; Chan, L. K.; Yam, J. W. P.; Ohira, M.; Nakagawara, A.; Tam, P. K. H.; Ngan, E. S. W.			Kruppel-like factor 4 (KLF4) suppresses neuroblastoma cell growth and determines non-tumorigenic lineage differentiation	ONCOGENE			English	Article						differentiation; regression; neuroblastoma	CREST STEM-CELLS; BREAST-CANCER; CHILDHOOD NEUROBLASTOMA; GENE AMPLIFICATION; PROGNOSTIC-FACTORS; SERUM FERRITIN; EXPRESSION; PROGRESSION; TUMORS; MYCN	Neuroblastoma (NB) is an embryonal tumor and possesses a unique propensity to exhibit either a spontaneous regression or an unrestrained growth. However, the underlying mechanism for this paradoxical clinical outcome remains largely unclear. Quantitative RT-PCR analysis on 102 primary NB tumors revealed that lower Kruppel-like factor 4 (KLF4) expression is frequently found in the unfavorable NB (Mann-Whitney test, P = 0.027). In particular with the high-risk factors such as age of patient 41 year, MYCN amplification and low TRKA expression, the decreased expression of KLF4 was significantly associated with an unfavorable NB outcome. Despite knockdown of KLF4 alone is not sufficient to increase tumorigenicity of NB cells in vivo, stable expression of KLF4 short hairpin RNA in Be(2)-C cells significantly promoted growth of NB cells and inhibited cell differentiation toward fibromuscular lineage. In concordant with these observations, overexpression of KLF4 in SH-SY-5Y cells profoundly suppressed cell proliferation by direct upregulation of cell-cycle inhibitor protein p21(WAF1/CIP1), and knocking down p21(WAF1/CIP1) could partially rescue the suppressive effect of KLF4. Importantly, KLF4 overexpressing cells have lost their neuroblastic phenotypes, they were epithelial-like, strongly substrate-adherent, expressing smooth muscle marker and became non-tumorigenic, suggesting that KLF4 expression is crucial for lineage determination of NB cells, probably, favoring spontaneous tumor regression. Subsequent global gene expression profiling further revealed that transforming growth factor beta (TGF beta) and cell-cycle pathways are highly dysregulated upon KLF4 overexpression, and myogenic modulators, MEF2A and MYOD1 were found significantly upregulated. Taken together, we have demonstrated that KLF4 contributes to the favorable disease outcome by directly mediating the growth and lineage determination of NB cells.	[Shum, C. K. Y.; Lau, S. T.; Tsoi, L. L. S.; Tam, P. K. H.; Ngan, E. S. W.] Univ Hong Kong, Dept Surg, Pokfulam, Hong Kong, Peoples R China; [Chan, L. K.; Yam, J. W. P.] Univ Hong Kong, Dept Pathol, Pokfulam, Hong Kong, Peoples R China; [Ohira, M.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Chiba 2608717, Japan; [Tam, P. K. H.; Ngan, E. S. W.] Univ Hong Kong, Li Ka Shing Fac Med, Ctr Reprod Dev & Growth, Pokfulam, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Chiba Cancer Center; University of Hong Kong	Ngan, ESW (corresponding author), Univ Hong Kong, Dept Surg, Fac Med Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	engan@hku.hk	Ngan, Elly/N-1543-2019; Kong, Chan Lo/AAI-9300-2020; /C-4405-2009; Yam, Judy Wai Ping/C-4454-2009	Ngan, Elly/0000-0002-0022-7999; Kong, Chan Lo/0000-0003-3082-1013; /0000-0001-6231-3035; Yam, Judy Wai Ping/0000-0002-5637-121X	University of Hong Kong; Hong Kong Research Grants Council [HKU773909]; Hong Kong Children Cancer Foundation	University of Hong Kong(University of Hong Kong); Hong Kong Research Grants Council(Hong Kong Research Grants Council); Hong Kong Children Cancer Foundation	This study was funded by seed funding grant for basic research from the University of Hong Kong, General Research Grant HKU773909 from the Hong Kong Research Grants Council and research grant from Hong Kong Children Cancer Foundation to ESWN.	Acosta S, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-12; Akaogi K, 2009, ONCOGENE, V28, P2894, DOI 10.1038/onc.2009.151; Beppu Y, 2005, CANCER RES, V65, P4775, DOI 10.1158/0008-5472.CAN-04-3332; Biagiotti T, 2006, STEM CELLS, V24, P443, DOI 10.1634/stemcells.2004-0264; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRESLOW N, 1971, CANCER RES, V31, P2098; Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Chen JK, 2011, CELL RES, V21, P205, DOI 10.1038/cr.2010.172; Chen SY, 2006, J BIOL CHEM, V281, P1765, DOI 10.1074/jbc.M507771200; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; Feinberg MW, 2007, EMBO J, V26, P4138, DOI 10.1038/sj.emboj.7601824; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; HANN HWL, 1985, CANCER RES, V45, P2843; Iehara T, 2006, BRIT J CANCER, V94, P1510, DOI 10.1038/sj.bjc.6603149; Iraci N, 2011, CANCER RES, V71, P404, DOI 10.1158/0008-5472.CAN-10-2627; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Janoueix-Lerosey I, 2010, ONCOGENE, V29, P1566, DOI 10.1038/onc.2009.518; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Kaneko M, 2002, J PEDIAT HEMATOL ONC, V24, P613, DOI 10.1097/00043426-200211000-00004; Katz JP, 2002, DEVELOPMENT, V129, P2619; Keshelava N, 2001, CANCER RES, V61, P6185; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Mahller YY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004235; Marzi F, 2007, CANCER RES, V67, P2402, DOI 10.1158/0008-5472.CAN-06-3208; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; Michels E, 2007, GENE CHROMOSOME CANC, V46, P1098, DOI 10.1002/gcc.20496; Mosse YP, 2007, GENE CHROMOSOME CANC, V46, P936, DOI 10.1002/gcc.20477; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Peterson S, 2004, ONCOGENE, V23, P213, DOI 10.1038/sj.onc.1206980; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SHUSTER JJ, 1992, AM J CLIN ONCOL-CANC, V15, P295, DOI 10.1097/00000421-199208000-00004; SILBER JH, 1991, CANCER RES, V51, P1426; Tang XX, 2000, P NATL ACAD SCI USA, V97, P10936, DOI 10.1073/pnas.190123297; Tomioka N, 2008, ONCOGENE, V27, P441, DOI 10.1038/sj.onc.1210661; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Tweddle DA, 2001, CANCER RES, V61, P8; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260; Yori JL, 2010, J BIOL CHEM, V285, P16854, DOI 10.1074/jbc.M110.114546; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	57	24	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4086	4099		10.1038/onc.2012.437	http://dx.doi.org/10.1038/onc.2012.437			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23045286				2022-12-28	WOS:000323748500004
J	Maicas, M; Vazquez, I; Vicente, C; Garcia-Sanchez, MA; Marcotegui, N; Urquiza, L; Calasanz, MJ; Odero, MD				Maicas, M.; Vazquez, I.; Vicente, C.; Garcia-Sanchez, M. A.; Marcotegui, N.; Urquiza, L.; Calasanz, M. J.; Odero, M. D.			Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription	ONCOGENE			English	Article						EVI1; promoter; AML; RUNX1; ELK1	POINT MUTATIONS; ETS FAMILY; EXPRESSION; DIFFERENTIATION; ONCOGENE; CELLS; PHOSPHORYLATION; ACTIVATION; GATA-1; DOMAIN	The EVI1 gene (3q26) codes for a transcription factor with important roles in normal hematopoiesis and leukemogenesis. High expression of EVI1 is a negative prognostic indicator of survival in acute myeloid leukemia (AML) irrespective of the presence of 3q26 rearrangements. However, the only known mechanisms that lead to EVI1 overexpression are 3q aberrations, and the MLL-ENL oncoprotein, which activates the transcription of EVI1 in hematopoietic stem cells. Our aim was to characterize the functional promoter region of EVI1, and to identify transcription factors involved in the regulation of this gene. Generation of seven truncated constructs and luciferase reporter assays allowed us to determine a 318-bp region as the minimal promoter region of EVI1. Site-directed mutagenesis and chromatin immunoprecipitation (ChIP) assays identified RUNX1 and ELK1 as putative transcription factors of EVI1. Furthermore, knockdown of RUNX1 and ELK1 led to EVI1 downregulation, and their overexpression to upregulation of EVI1. Interestingly, in a series of patient samples with AML at diagnosis, we found a significant positive correlation between EVI1 and RUNX1 at protein level. Moreover, we identified one of the roles of RUNX1 in the activation of EVI1 during megakaryocytic differentiation. EVI1 knockdown significantly inhibited the expression of megakaryocytic markers after treating K562 cells with TPA, as happens when knocking down RUNX1. In conclusion, we define the minimal promoter region of EVI1 and demonstrate that RUNX1 and ELK1, two proteins with essential functions in hematopoiesis, regulate EVI1 in AML. Furthermore, our results show that one of the mechanisms by which RUNX1 regulates the transcription of EVI1 is by acetylation of the histone H3 on its promoter region. This study opens new directions to further understand the mechanisms of EVI1 overexpressing leukemias. Oncogene (2013) 32, 2069-2078; doi:10.1038/onc.2012.222; published online 11 June 2012	[Maicas, M.; Vazquez, I.; Vicente, C.; Garcia-Sanchez, M. A.; Marcotegui, N.; Urquiza, L.; Odero, M. D.] Univ Navarra, CIMA, Div Oncol, Genet Lab, Pamplona 31008, Spain; [Maicas, M.; Calasanz, M. J.; Odero, M. D.] Univ Navarra, Dept Genet, Pamplona 31008, Spain	University of Navarra; University of Navarra	Odero, MD (corresponding author), Univ Navarra, CIMA, Div Oncol, Genet Lab, C Pio 12,55, Pamplona 31008, Spain.	modero@unav.es	Calasanz, MJ/R-5813-2016; Vicente, Carmen/AAA-7098-2021; Maicas, Miren/A-9836-2017; Garcia-Sanchez, Asuncion/AAE-8611-2019; Vázquez, Iria/AAD-4092-2020; Odero/ABG-9860-2020	Calasanz, MJ/0000-0002-0374-3008; Vicente, Carmen/0000-0002-3363-3459; Maicas, Miren/0000-0003-1404-5552; Garcia-Sanchez, Asuncion/0000-0002-9655-4918; Vázquez, Iria/0000-0003-0027-6384; Odero/0000-0002-8858-2054	Ministerio Educacion y Ciencia [AP2007-03879]; Ministerio Ciencia e Innovacion [PI081687]; Departamento Salud del Gobierno de Navarra [14/2008]; ISCIII-RTICC [RD06/0020/0078]; Fundacion para la Investigacion Medica Aplicada y UTE (Spain)	Ministerio Educacion y Ciencia(Spanish Government); Ministerio Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Departamento Salud del Gobierno de Navarra; ISCIII-RTICC(Instituto de Salud Carlos III); Fundacion para la Investigacion Medica Aplicada y UTE (Spain)	We thank Dr Hipskind (Hannover Medical School, Germany) for the plasmid pCDNA3-ELK1, Dr Zhang (Department of Molecular and Experimental Medicine, La Jolla, CA, USA) for the plasmid pFlagCMV2-AML1B (Addgene plasmid 12504), and Dr Arenas and Dr Guruceaga (Department of Proteomics, Genomics and Bioinformatics, CIMA) for technical support. This work was supported by Ministerio Educacion y Ciencia (AP2007-03879), Ministerio Ciencia e Innovacion (PI081687), Departamento Salud del Gobierno de Navarra (14/2008), ISCIII-RTICC (RD06/0020/0078) and Fundacion para la Investigacion Medica Aplicada y UTE (Spain).	Arai S, 2011, BLOOD, V117, P6304, DOI 10.1182/blood-2009-07-234310; Aytekin M, 2005, GENE, V356, P160, DOI 10.1016/j.gene.2005.04.032; Biggs JR, 2006, MOL CELL BIOL, V26, P7420, DOI 10.1128/MCB.00597-06; Bingemann SC, 2009, FEBS J, V276, P6810, DOI 10.1111/j.1742-4658.2009.07398.x; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Fernandez-Alvarez A, 2010, J BIOL CHEM, V285, P11765, DOI 10.1074/jbc.M109.067447; Fujiwara T, 2009, MOL CELL, V36, P667, DOI 10.1016/j.molcel.2009.11.001; Gaidzik VI, 2011, J CLIN ONCOL, V29, P1364, DOI 10.1200/JCO.2010.30.7926; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Goldfarb AN, 2009, J CELL BIOCHEM, V107, P377, DOI 10.1002/jcb.22142; Goyama S, 2008, CELL STEM CELL, V3, P207, DOI 10.1016/j.stem.2008.06.002; Groschel S, 2010, J CLIN ONCOL, V28, P2101, DOI 10.1200/JCO.2009.26.0646; Haas K, 2008, GENE CHROMOSOME CANC, V47, P288, DOI 10.1002/gcc.20532; Langabeer SE, 2002, GENE CHROMOSOME CANC, V34, P24, DOI 10.1002/gcc.10031; Laricchia-Robbio L, 2006, MOL CELL BIOL, V26, P7658, DOI 10.1128/MCB.00363-06; Laricchia-Robbio L, 2009, CANCER RES, V69, P1633, DOI 10.1158/0008-5472.CAN-08-2562; Lugthart S, 2008, BLOOD, V111, P4329, DOI 10.1182/blood-2007-10-119230; Mikhail FM, 2006, J CELL PHYSIOL, V207, P582, DOI 10.1002/jcp.20538; Nucifora G, 2006, GENE, V368, P1, DOI 10.1016/j.gene.2005.09.020; Oakford PC, 2010, LEUKEMIA RES, V34, P1203, DOI 10.1016/j.leukres.2010.03.029; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pencovich N, 2011, BLOOD, V117, pE1, DOI 10.1182/blood-2010-07-295113; Senyuk V, 2007, CANCER RES, V67, P5658, DOI 10.1158/0008-5472.CAN-06-3962; Shimizu S, 2002, BIOCHEM BIOPH RES CO, V292, P609, DOI 10.1006/bbrc.2002.6693; Terui K, 2000, TOHOKU J EXP MED, V192, P259, DOI 10.1620/tjem.192.259; Vazquez I, 2011, HAEMATOL-HEMATOL J, V96, P1448, DOI 10.3324/haematol.2011.040535; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wieser R, 2007, GENE, V396, P346, DOI 10.1016/j.gene.2007.04.012; Yasar D, 2010, CANCER GENET CYTOGEN, V197, P122, DOI 10.1016/j.cancergencyto.2009.11.018; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679; Zhang L, 2003, J BIOL CHEM, V278, P33097, DOI 10.1074/jbc.M303972200	35	13	13	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2069	2078		10.1038/onc.2012.222	http://dx.doi.org/10.1038/onc.2012.222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22689058				2022-12-28	WOS:000317919900008
J	Jin, W; Wu, K; Li, YZ; Yang, WT; Zou, B; Zhang, F; Zhang, J; Wang, KK				Jin, W.; Wu, K.; Li, Y-Z; Yang, W-T; Zou, B.; Zhang, F.; Zhang, J.; Wang, K-K			AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia	ONCOGENE			English	Article						cathepsin G; AML1-ETO; t(8;21) AML	FUSION PROTEIN; NEUTROPHIL ELASTASE; GENE-EXPRESSION; EMBRYONIC LETHALITY; TRANSCRIPTION; DIFFERENTIATION; APOPTOSIS; CELLS; PU.1; PROMOTER	Although the significance of cathepsin G (CTSG) in host defense has been intensively investigated, little is known about its potential roles in granulopoiesis or leukemogenesis. We report here that CTSG is directly targeted and suppressed by AML1-ETO in t(8;21) acute myeloid leukemia (AML). Luciferase assays demonstrate that the CTSG promoter is strongly transactivated by AML1 and the AML1-dependent transactivation is suppressed by AML1-ETO. We also define a novel regulatory mechanism by which AML1-ETO-mediated transrepression requires both AML1-ETO and AML1 binding at adjacent sites, instead of the replacement of AML1 by AML1-ETO, and wild-type AML1 binding is a prerequisite for the repressive effect caused by AML1-ETO. Further evidence shows that CTSG, as a hematopoietic serine protease, can degrade AML1-ETO both in vitro and in vivo. Restoration of CTSG induces partial differentiation, growth inhibition and apoptosis in AML1-ETO-positive cells. In addition to t(8; 21) AML, CTSG downregulation is observed in AML patients with other cytogenetic/genetic abnormalities that potentially interrupt normal AML1 function, that is, inv(16) and EVI1 overexpression. Thus, the targeting and suppression of CTSG by AML1-ETO in t(8; 21) AML may provide a mechanism for leukemia cells to escape from the intracellular surveillance system by preventing degradation of foreign proteins. Oncogene (2013) 32, 1978-1987; doi:10.1038/onc.2012.204; published online 28 May 2012	[Jin, W.; Wu, K.; Li, Y-Z; Yang, W-T; Zou, B.; Zhang, F.; Zhang, J.; Wang, K-K] SJTU SM, Ruijin Hosp, State Key Lab Med Genom, Shanghai 200025, Peoples R China; [Jin, W.; Wu, K.; Li, Y-Z; Yang, W-T; Zou, B.; Zhang, F.; Zhang, J.; Wang, K-K] SJTU SM, Ruijin Hosp, Shanghai Inst Hematol, Shanghai 200025, Peoples R China; [Zhang, J.] Chinese Acad Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Zhang, J.] SJTU SM, Shanghai 200025, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Wang, KK (corresponding author), SJTU SM, Ruijin Hosp, State Key Lab Med Genom, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China.	kankanwang@shsmu.edu.cn		Wu, Kang/0000-0002-9024-795X	Ministry of Science and Technology Grants of China [2009CB825607, 2012AA02A211, 2011CB910202]; National Natural Science Foundation Grants of China [31171257, 90919059, 30971623]	Ministry of Science and Technology Grants of China; National Natural Science Foundation Grants of China(National Natural Science Foundation of China (NSFC))	We thank Dr Lubbert M for providing the AML1-ETO-inducible cell line, U937-A/E9/14/18. This work was supported in part by the Ministry of Science and Technology Grants of China (2009CB825607, 2012AA02A211 and 2011CB910202) and National Natural Science Foundation Grants of China (31171257, 90919059 and 30971623).	Biggs JR, 2001, P NATL ACAD SCI USA, V98, P3814, DOI 10.1073/pnas.071057398; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; Corsello SM, 2009, BLOOD, V113, P6193, DOI 10.1182/blood-2008-07-166090; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; Dunne J, 2006, ONCOGENE, V25, P6067, DOI 10.1038/sj.onc.1209638; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Frank R, 1995, ONCOGENE, V11, P2667; Gardini A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000275; Garwicz D, 1998, BLOOD, V92, P1415, DOI 10.1182/blood.V92.4.1415.416k28_1415_1422; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Howcroft TK, 2005, J IMMUNOL, V174, P2106, DOI 10.4049/jimmunol.174.4.2106; Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674; Igney FH, 2002, J LEUKOCYTE BIOL, V71, P907; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Kadkol SS, 2004, J MOL DIAGN, V6, P22, DOI 10.1016/S1525-1578(10)60487-4; Kitareewan S, 2007, J NATL CANCER I, V99, P41, DOI 10.1093/jnci/djk004; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Korkmaz B, 2008, BIOCHIMIE, V90, P227, DOI 10.1016/j.biochi.2007.10.009; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Laricchia-Robbio L, 2009, CANCER RES, V69, P1633, DOI 10.1158/0008-5472.CAN-08-2562; Lausen J, 2006, ONCOGENE, V25, P1349, DOI 10.1038/sj.onc.1209181; Lennartsson A, 2005, GENE, V356, P193, DOI 10.1016/j.gene.2005.05.004; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Okumura AJ, 2008, BLOOD, V112, P1392, DOI 10.1182/blood-2007-11-124735; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Piazza F, 2000, BLOOD, V96, P1358, DOI 10.1182/blood.V96.4.1358.h8001358_1358_1365; Puissant A, 2010, LEUKEMIA, V24, P115, DOI 10.1038/leu.2009.233; Senyuk V, 2007, CANCER RES, V67, P5658, DOI 10.1158/0008-5472.CAN-06-3962; Shimada H, 2002, LEUKEMIA, V16, P874, DOI 10.1038/sj.leu.2402465; Tomasson MH, 2008, BLOOD, V111, P4797, DOI 10.1182/blood-2007-09-113027; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Uchida H, 1997, J IMMUNOL, V158, P2251; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang KK, 2010, CANCER CELL, V17, P186, DOI 10.1016/j.ccr.2009.12.045; Wang L, 2007, CELL DEATH DIFFER, V14, P306, DOI 10.1038/sj.cdd.4401996; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wingender E, 2008, BRIEF BIOINFORM, V9, P326, DOI 10.1093/bib/bbn016; Wouters BJ, 2009, BLOOD, V113, P3088, DOI 10.1182/blood-2008-09-179895; Yang G, 2007, ONCOGENE, V26, P91, DOI 10.1038/sj.onc.1209760; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhou GB, 2007, BLOOD, V109, P3441, DOI 10.1182/blood-2006-06-032250	51	20	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1978	1987		10.1038/onc.2012.204	http://dx.doi.org/10.1038/onc.2012.204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22641217				2022-12-28	WOS:000317599900012
J	Ye, Y; Tian, H; Lange, AR; Yearsley, K; Robertson, FM; Barsky, SH				Ye, Y.; Tian, H.; Lange, A. R.; Yearsley, K.; Robertson, F. M.; Barsky, S. H.			The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin	ONCOGENE			English	Article						calpain-mediated proteolysis; E-cadherin fragments; spheroidgenesis; lymphovascular emboli	INFLAMMATORY BREAST-CANCER; P120 CATENIN; BETA-CATENIN; DOWN-REGULATION; CELL-ADHESION; CLEAVAGE; PROTEINS; GTPASE; GROWTH; DOMAIN	The genesis and unique properties of the lymphovascular tumor embolus are poorly understood largely because of the absence of an experimental model that specifically reflects this important step of tumor progression. The lymphovascular tumor embolus is a blastocyst-like structure resistant to chemotherapy, efficient at metastasis and overexpressing E-cadherin (E-cad). Conventional dogma has regarded E-cad as a metastasis-suppressor gene involved in epithelial-mesenchymal transition. However, within the lymphovascular embolus, E-cad and its proteolytic processing by calpain and other proteases have a dominant oncogenic rather than suppressive role in metastasis formation and tumor cell survival. Studies using a human xenograft model of inflammatory breast cancer, MARY-X, demonstrated the equivalence of xenograft-generated spheroids with lymphovascular emboli in vivo with both structures demonstrating E-cad overexpression and specific proteolytic processing. Western blot revealed full-length (FL) E-cad (120 kDa) and four fragments: E-cad/NTF1 (100 kDa), E-cad/NTF2 (95 kDa), E-cad/NTF3 (85 kDa) and E-cad/NTF4 (80 kDa). Compared with MARY-X, only E-cad/NTF1 was present in the spheroids. E-cad/NTF1 was produced by calpain, E-cad/NTF2 by gamma-secretase and E-cad/NTF3 by a matrix metalloproteinase (MMP). Spheroidgenesis and lymphovascular emboli formation are the direct result of calpain-mediated cleavage of E-cad and the generation of E-cad/NTF1 from membrane-associated E-cad rather than the de novo presence of either E-cad/NTF1 or E-cad/CTF1. E-cad/NTF1 retained the p120ctn-binding site but lost both the beta-catenin and alpha-binding sites, facilitating its disassembly from traditional cadherin-based adherens junctions and its 360 degrees distribution around the embolus. This calpain-mediated proteolysis of E-cad generates the formation of the lymphovascular embolus and is responsible for its unique properties of increased homotypic adhesion, apoptosis resistance and budding. Oncogene (2013) 32, 1702-1713; doi:10.1038/onc.2012.180; published online 14 May 2012	[Ye, Y.; Tian, H.; Lange, A. R.; Barsky, S. H.] Univ Nevada, Sch Med, Dept Pathol, Reno, NV 89557 USA; [Yearsley, K.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Robertson, F. M.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Robertson, F. M.] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA; [Barsky, S. H.] Whittemore Peterson Inst, Reno, NV USA; [Barsky, S. H.] Nevada Canc Inst, Las Vegas, NV USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; University System of Ohio; Ohio State University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Diego	Barsky, SH (corresponding author), Univ Nevada, Sch Med, Dept Pathol, Whittemore Peterson Inst, 1 Manville Med Bldg,Reno 0350, Reno, NV 89557 USA.	sbarsky@medicine.nevada.edu			Department of Defense Breast Cancer Research Program [BC990959, BC024258, BC053405]; American Airlines-Susan G Komen for the Cure Promise [KG081287-02]; University of Nevada Vasco A Salvadorini Endowment	Department of Defense Breast Cancer Research Program(United States Department of Defense); American Airlines-Susan G Komen for the Cure Promise(Susan G. Komen Breast Cancer Foundation); University of Nevada Vasco A Salvadorini Endowment	We thank Dr John J Hasenau, Dr Walter F Mandeville, Patricia L Atkins and Jared H Smith of Laboratory Animal Medicine for their veterinarian and technical assistance with the maintenance of the MARY-X xenografts. This work was supported by the Department of Defense Breast Cancer Research Program Grants BC990959, BC024258 and BC053405, the American Airlines-Susan G Komen for the Cure Promise Grant KG081287-02 and the University of Nevada Vasco A Salvadorini Endowment.	Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; Albini A, 2010, CURR OPIN CELL BIOL, V22, P677, DOI 10.1016/j.ceb.2010.08.017; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Beronja S, 2005, J CELL BIOL, V169, P635, DOI 10.1083/jcb.200410081; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Chun J, 2009, CELL HOST MICROBE, V5, P47, DOI 10.1016/j.chom.2008.11.009; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Ferber EC, 2008, J BIOL CHEM, V283, P12691, DOI 10.1074/jbc.M708887200; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GOPALAKRISHNA R, 1985, ANAL BIOCHEM, V148, P413, DOI 10.1016/0003-2697(85)90247-7; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P13936; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hajra KM, 2002, CANCER RES, V62, P1613; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Ito K, 1999, ONCOGENE, V18, P7080, DOI 10.1038/sj.onc.1203191; Kanazawa C, 2003, BIOCHEM BIOPH RES CO, V309, P848, DOI 10.1016/j.bbrc.2003.08.078; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Langevin J, 2005, DEV CELL, V9, P365, DOI 10.1016/j.devcel.2005.07.013; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lebart MC, 2006, FEBS J, V273, P3415, DOI 10.1111/j.1742-4658.2006.05350.x; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Messaritou G, 2009, J CELL SCI, V122, P4042, DOI 10.1242/jcs.044305; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Quigley JP, 1998, CELL, V94, P281, DOI 10.1016/S0092-8674(00)81470-1; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Robertson FM, 2010, J BIOMOL SCREEN, V15, P820, DOI 10.1177/1087057110376541; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; Silvera D, 2009, CELL CYCLE, V8, P3091, DOI 10.4161/cc.8.19.9637; Silvera D, 2009, NAT CELL BIOL, V11, P903, DOI 10.1038/ncb1900; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Tomlinson JS, 2001, CANCER RES, V61, P5231; Toyoshima M, 2007, CANCER RES, V67, P5162, DOI 10.1158/0008-5472.CAN-06-2756; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; van IJzendoorn SCD, 2006, J CELL SCI, V119, P1679, DOI 10.1242/jcs.02948; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; Wakabayashi T, 2008, PHYSIOLOGY, V23, P194, DOI 10.1152/physiol.00009.2008; Wells A, 2005, INT REV CYTOL, V245, P1, DOI 10.1016/S0074-7696(05)45001-9; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xiao Y, 2011, ONCOGENE, V30, P287, DOI 10.1038/onc.2010.405; Xiao Y, 2008, AM J PATHOL, V173, P561, DOI 10.2353/ajpath.2008.071214; Ye Y, 2010, ANTICANCER RES, V30, P3903; Zhang XM, 2004, J BIOL CHEM, V279, P43027, DOI 10.1074/jbc.M402264200	51	32	36	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1702	1713		10.1038/onc.2012.180	http://dx.doi.org/10.1038/onc.2012.180			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22580607				2022-12-28	WOS:000316855800010
J	Du, W; Wright, BM; Li, X; Finke, J; Rini, BI; Zhou, M; He, H; Lal, P; Welford, SM				Du, W.; Wright, B. M.; Li, X.; Finke, J.; Rini, B. I.; Zhou, M.; He, H.; Lal, P.; Welford, S. M.			Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; macrophage migration inhibitory factor; MIF; src; p27; autocrine signaling	HYPOXIA-INDUCIBLE FACTORS; FACTOR MIF; GASTRIC-CANCER; UP-REGULATION; EXPRESSION; ACTIVATION; GENE; SRC; ANGIOGENESIS; PROGNOSIS	The macrophage migration inhibitory factor (MIF) is a hypoxia regulated gene that has a variety of tumorigenic functions. In clear cell renal carcinoma (CCRC), hypoxic signaling is constitutively active because of the frequent loss of function of the von Hippel-Lindau tumor suppressor protein. We therefore sought to assess the expression of MIF in CCRC and its biological functions. We stained tumor tissue microarrays comprising sections of 128 CCRC tumors and found MIF to be moderately or highly expressed in >98%. MIF expression was further found to be dramatically elevated in blood plasma of individuals with CCRC compared with healthy controls, suggesting that measurement of MIF levels in the blood may have utility as a diagnostic marker in CCRC. At a functional level, MIF has been reported to engage the CD74 and CD44 receptors and induce signal transduction. In CCRC cell lines, depletion of MIF, CD74 or CD44 by small hairpin RNA led to a significant reduction in growth rate, and clonogenic survival, coinciding with the degree of knockdown. Interruption of the MIF pathway also decreased tumorigenic potential. Biochemically, we found that in CCRC cells MIF signaling leads to activation of the mitogen-activated protein kinase pathway and to Src phosphorylation, which is critical for regulation of p27. Together, our studies establish MIF as a protumorigenic signaling molecule that functions in an autocrine fashion to promote renal cell carcinoma and may be useful as a minimally invasive marker of disease status. Oncogene (2013) 32, 1469-1474; doi:10.1038/onc.2012.143; published online 30 April 2012	[Du, W.; Wright, B. M.; Li, X.; Welford, S. M.] Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; [Finke, J.] Dept Mol Med, Cleveland, OH USA; [Rini, B. I.] Dept Solid Tumor Oncol, Cleveland, OH USA; [Zhou, M.; He, H.] Cleveland Clin Fdn, Dept Anat Pathol & Canc Biol, Cleveland, OH 44195 USA; [Lal, P.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA	Case Western Reserve University; Cleveland Clinic Foundation; University of Pennsylvania	Welford, SM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, BRB325,10900 Euclid Ave, Cleveland, OH 44106 USA.	scott.welford@case.edu			RSG from the American Cancer Society [121762-RSG-12-097-01-CCG];  [CA147387];  [P30CA43703]; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER	RSG from the American Cancer Society; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by CA147387, and by an RSG from the American Cancer Society (121762-RSG-12-097-01-CCG) to SMW. We thank Drs Amato Giaccia and Haifeng Yang for cell lines. Flow cytometry was performed in the CASE Comprehensive Cancer Center Cytometry and Microscopy Core facility, which is supported by P30CA43703.	American Cancer Society, 2011, CANC FACTS FIG 2011; Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011; Bach JP, 2008, ONCOLOGY-BASEL, V75, P127, DOI 10.1159/000155223; Bacher M, 2003, AM J PATHOL, V162, P11, DOI 10.1016/S0002-9440(10)63793-5; Baugh JA, 2006, BIOCHEM BIOPH RES CO, V347, P895, DOI 10.1016/j.bbrc.2006.06.148; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; He XX, 2006, GUT, V55, P797, DOI 10.1136/gut.2005.078113; He XX, 2009, MOL MED, V15, P1, DOI 10.2119/molmed.2008.00107; Hira E, 2005, CANCER, V103, P588, DOI 10.1002/cncr.20818; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koong AC, 2000, CANCER RES, V60, P883; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Legendre H, 2003, MODERN PATHOL, V16, P491, DOI 10.1097/01.MP.0000068235.45178.C1; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Li GQ, 2009, WORLD J GASTROENTERO, V15, P5541, DOI 10.3748/wjg.15.5541; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Lue H, 2007, ONCOGENE, V26, P5046, DOI 10.1038/sj.onc.1210318; Lue HQ, 2006, CELL SIGNAL, V18, P688, DOI 10.1016/j.cellsig.2005.06.013; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meyer-Siegler KL, 2002, CANCER-AM CANCER SOC, V94, P1449, DOI 10.1002/cncr.10354; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Nguyen MT, 2003, J IMMUNOL, V170, P3337, DOI 10.4049/jimmunol.170.6.3337; Onodera S, 2002, J BIOL CHEM, V277, P7865, DOI 10.1074/jbc.M106020200; Schrader J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-464; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Welford SM, 2006, GENE DEV, V20, P3366, DOI 10.1101/gad.1471106; Xia HHX, 2009, CANCER-AM CANCER SOC, V115, P5441, DOI 10.1002/cncr.24609	36	28	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1469	1474		10.1038/onc.2012.143	http://dx.doi.org/10.1038/onc.2012.143			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22543583				2022-12-28	WOS:000316455600013
J	Zhou, C; Licciulli, S; Avila, JL; Cho, M; Troutman, S; Jiang, P; Kossenkov, AV; Showe, LC; Liu, Q; Vachani, A; Albelda, SM; Kissil, JL				Zhou, C.; Licciulli, S.; Avila, J. L.; Cho, M.; Troutman, S.; Jiang, P.; Kossenkov, A. V.; Showe, L. C.; Liu, Q.; Vachani, A.; Albelda, S. M.; Kissil, J. L.			The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis	ONCOGENE			English	Article						Ras; Rac1; Rac1b; lung cancer; mouse model	CELL-SURVIVAL; CANCER; EXPRESSION; GTPASES; VARIANT; RHO; PROGRESSION; ACTIVATION; ADHESION; ISOFORM	Rac1b, an alternative splice form of Rac1, has been previously shown to be upregulated in colon and breast cancer cells, suggesting an oncogenic role for Rac1b in these cancers. Our analysis of NSCLC tumor and matched normal tissue samples indicates Rac1b is upregulated in a significant fraction of lung tumors in correlation with mutational status of K-ras. To directly assess the oncogenic potential of Rac1b in vivo, we employed a mouse model of lung adenocarcinoma, in which the expression of Rac1b can be conditionally activated specifically in the lung. Although expression of Rac1b alone is insufficient to drive tumor initiation, the expression of Rac1b synergizes with an oncogenic allele of K-ras resulting in increased cellular proliferation and accelerated tumor growth. Finally, we show that in contrast to our previous findings demonstrating a requirement for Rac1 in K-ras-driven cell proliferation, Rac1b is not required in this context. Given the partially overlapping spectrum of downstream effectors regulated by Rac1 and Rac1b, our findings further delineate the signaling pathways downstream of Rac1 that are required for K-ras driven tunnorigenesis. Oncogene (2013) 32, 903-909; doi:10.1038/onc.2012.99; published online 19 March 2012	[Zhou, C.; Licciulli, S.; Avila, J. L.; Cho, M.; Troutman, S.; Kossenkov, A. V.; Showe, L. C.; Liu, Q.; Kissil, J. L.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; [Avila, J. L.; Kissil, J. L.] Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; [Jiang, P.] Wistar Inst Anat & Biol, Anim Transgen Core Facil, Philadelphia, PA 19104 USA; [Vachani, A.; Albelda, S. M.] Univ Penn, Sch Med, Thorac Oncol Res Lab, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; The Wistar Institute; University of Pennsylvania	Kissil, JL (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	jkissil@wistar.org			 [CA124495]; NATIONAL CANCER INSTITUTE [R01CA124495, P30CA010815] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024693] Funding Source: NIH RePORTER	; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Derek Radisky for sharing the pEYFP-C1-mRac1b vector and members of the Kissil and Albelda labs for technical assistance. We thank the Wistar Transgenics and Animal core facilities. This work was supported by Grant CA124495 (JLK).	Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Esufali S, 2007, CANCER RES, V67, P2469, DOI 10.1158/0008-5472.CAN-06-2843; Fiegen D, 2004, J BIOL CHEM, V279, P4743, DOI 10.1074/jbc.M310281200; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Lozano E, 2008, J CELL SCI, V121, P933, DOI 10.1242/jcs.016121; Matos P, 2005, EXP CELL RES, V305, P292, DOI 10.1016/j.yexcr.2004.12.029; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Orlichenko L, 2010, J BIOL CHEM, V285, P19153, DOI 10.1074/jbc.M109.099382; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118	20	74	75	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2013	32	7					903	909		10.1038/onc.2012.99	http://dx.doi.org/10.1038/onc.2012.99			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22430205	Green Accepted			2022-12-28	WOS:000316581100010
J	Veldhoen, RA; Banman, SL; Hemmerling, DR; Odsen, R; Simmen, T; Simmonds, AJ; Underhill, DA; Goping, IS				Veldhoen, R. A.; Banman, S. L.; Hemmerling, D. R.; Odsen, R.; Simmen, T.; Simmonds, A. J.; Underhill, D. A.; Goping, I. S.			The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis	ONCOGENE			English	Article						autophagy; paclitaxel; apoptosis	PROGRAMMED CELL-DEATH; BREAST-CANCER; RAT-LIVER; ANTIMITOTIC DRUGS; GENE-EXPRESSION; CARCINOMA-CELLS; MITOTIC BLOCK; MICROTUBULES; LYSOSOMES; FUSION	Anti-mitotic agents such as paclitaxel and docetaxel are widely used for the treatment of breast, ovarian and lung cancers. Although paclitaxel induces apoptosis, this drug also modulates autophagy. How autophagy affects paclitaxel activity, is unclear. We discovered that paclitaxel inhibited autophagy through two distinct mechanisms dependent on cell cycle stage. In mitotic cells, paclitaxel blocked activation of the class III phosphatidyl inositol 3 kinase, Vps34, a critical initiator of autophagosome formation. In non-mitotic paclitaxel-treated cells, autophagosomes were generated but their movement and maturation was inhibited. Chemically or genetically blocking autophagosome formation diminished paclitaxel-induced cell death suggesting that autophagosome accumulation sensitized cells to paclitaxel toxicity. In line with these observations, we identified that primary breast tumors that expressed diminished levels of autophagy-initiating genes were resistant to taxane therapy, identifying possible mechanisms and prognostic markers of clinical chemotherapeutic resistance. Oncogene (2013) 32, 736-746; doi:10.1038/onc.2012.92; published online 19 March 2012	[Veldhoen, R. A.; Banman, S. L.; Odsen, R.; Goping, I. S.] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; [Hemmerling, D. R.] Concordia Univ Coll, Dept Biol & Environm Sci, Edmonton, AB, Canada; [Simmen, T.; Simmonds, A. J.] Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; [Underhill, D. A.; Goping, I. S.] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada	University of Alberta; Concordia University - Canada; University of Alberta; University of Alberta	Goping, IS (corresponding author), Univ Alberta, Dept Biochem, Fac Med & Dent, Edmonton, AB T6G 2H7, Canada.	igoping@ualberta.ca	Veldhoen, Richard/M-8168-2019	Veldhoen, Richard/0000-0003-4643-2960; Simmonds, Andrew/0000-0001-7165-9302; Underhill, Darrell/0000-0003-0957-7407	Canadian Breast Cancer Foundation; Alberta Cancer Foundation/Alberta Innovates-Health Solutions [25011]	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Alberta Cancer Foundation/Alberta Innovates-Health Solutions	This work was supported by operating grants from the Canadian Breast Cancer Foundation and Alberta Cancer Foundation/Alberta Innovates-Health Solutions (project #25011) awarded to ISG. We thank Dr Junying Yuan for the kind gift of the anti-phospho T159 Vps34 antibody. We thank the Gaping lab, Simmen lab and Signal Transduction Research Group for valuable discussions. Owing to journal reference restraints, we apologize to those investigators whose work was not cited.	Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; APLIN A, 1992, J CELL PHYSIOL, V152, P458, DOI 10.1002/jcp.1041520304; ARSTILA AU, 1974, EXP CELL RES, V87, P249, DOI 10.1016/0014-4827(74)90477-7; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Craik AC, 2010, ONCOGENE, V29, P5381, DOI 10.1038/onc.2010.272; Czernick M, 2009, BIOCHEM BIOPH RES CO, V379, P145, DOI 10.1016/j.bbrc.2008.12.025; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; Derry WB, 1998, CANCER RES, V58, P1177; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x; Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200; Furuya T, 2010, MOL CELL, V38, P500, DOI 10.1016/j.molcel.2010.05.009; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gorka M, 2005, ANTI-CANCER DRUG, V16, P777; Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kimura S, 2008, CELL STRUCT FUNCT, V33, P109, DOI 10.1247/csf.08005; Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Liu LY, 2009, CELL CYCLE, V8, P1616, DOI 10.4161/cc.8.10.8577; MARZELLA L, 1980, EXP CELL RES, V128, P291, DOI 10.1016/0014-4827(80)90065-8; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; Paglin S, 2001, CANCER RES, V61, P439; PFEIFER U, 1978, J CELL BIOL, V78, P152, DOI 10.1083/jcb.78.1.152; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Xi GM, 2011, CANCER LETT, V307, P141, DOI 10.1016/j.canlet.2011.03.026; Xie R, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-89; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	40	92	95	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					736	746		10.1038/onc.2012.92	http://dx.doi.org/10.1038/onc.2012.92			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430212				2022-12-28	WOS:000315746700007
J	Calhabeu, F; Hayashi, S; Morgan, JE; Relaix, F; Zammit, PS				Calhabeu, F.; Hayashi, S.; Morgan, J. E.; Relaix, F.; Zammit, P. S.			Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells	ONCOGENE			English	Article						alveolar rhabdomyosarcoma; PAX3/FOXO1A; PAX7/FOXO1A; MyoD; myogenin; satellite cell	PAX3-FKHR FUSION PROTEIN; SKELETAL-MUSCLE; SATELLITE CELLS; PROGENITOR CELLS; MYOGENIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; FAMILY-MEMBERS; IN-VIVO; PAX3; EXPRESSION	Rhabdomyosarcoma (RMS) is the commonest soft-tissue sarcoma in childhood and is characterized by expression of myogenic proteins, including the transcription factors MyoD and myogenin. There are two main subgroups, embryonal RMS and alveolar RMS (ARMS). Most ARMS are associated with chromosomal translocations that have breakpoints in introns of either PAX3 or PAX7, and FOXO1A. These translocations create chimeric transcription factors termed PAX3/FOXO1A and PAX7/FOXO1A respectively. Upon ectopic PAX3/FOXO1A expression, together with other genetic manipulation in mice, both differentiating myoblasts and satellite cells (the resident stem cells of postnatal muscle) can give rise to tumours with ARMS characteristics. As PAX3 and PAX7 are part of transcriptional networks that regulate muscle stem cell function in utero and during early postnatal life, PAX3/FOXO1A and PAX7/FOXO1A may subvert normal PAX3 and PAX7 functions. Here we examined how PAX3/FOXO1A and PAX7/FOXO1A affect myogenesis in satellite cells. PAX3/FOXO1A or PAX7/FOXO1A inhibited myogenin expression and prevented terminal differentiation in nnurine satellite cells: the same effect as dominant-negative (DN) Pax3 or Pax7 constructs. The transcription of MyoD-target genes myogenin and muscle creatine kinase were suppressed by PAX3/FOXO1A or PAX7/FOXO1A in C2C12 myogenic cells again as seen with Pax3/7DN. PAX3/FOXO1A or PAX7/FOXO1A did not inhibit the transcriptional activity of MyoD by perturbing MyoD expression, localization, phosphorylation or interaction with E-proteins. Chromatin immunoprecipitation on the myogenin promoter showed that PAX3/FOXO1A or PAX7/FOXO1A did not prevent MyoD from binding. However, PAX3/FOXO1A or PAX7/FOXO1A reduced occupation of the myogenin promoter by RNA polynnerase II and decreased acetylation of histone H4, but did not directly bind to the myogenin promoter. Together, these observations reveal that PAX3/FOXO1A and PAX7/FOXO1A act to prevent myogenic differentiation via suppression of the transcriptional activation of MyoD-target genes. Oncogene (2013) 32, 651-662; doi:10.1038/onc.2012.73; published online 18 June 2012	[Calhabeu, F.; Zammit, P. S.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Hayashi, S.; Relaix, F.] Univ Paris 06, INSERM, UMR S 787,Fac Med Pitie Salpetriere, Myol Grp,Avenir Team Mouse Mol Genet, Paris, France; [Morgan, J. E.] UCL Inst Child Hlth, Dubowitz Neuromuscular Ctr, London, England	University of London; King's College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of London; University College London	Zammit, PS (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	peter.zammit@kcl.ac.uk	Zammit, peter/GXV-7746-2022	Hayashi, Shinichiro/0000-0001-5553-7698; zammit, peter/0000-0001-9562-3072; Relaix, Frederic/0000-0003-1270-1472	Association of International Cancer Research [07-0151]; Wellcome Trust [085137/Z/08/Z]; Medical Research Council; OPTISTEM European Commission [223098]; Wellcome Trust; INSERM Avenir Program; AFM; INCa; LNCC; ARC; FP7 ENDOSTEM [241440]	Association of International Cancer Research; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); OPTISTEM European Commission; Wellcome Trust(Wellcome Trust); INSERM Avenir Program(Institut National de la Sante et de la Recherche Medicale (Inserm)); AFM(Association Francaise contre les Myopathies); INCa(Institut National du Cancer (INCA) France); LNCC; ARC(Australian Research Council); FP7 ENDOSTEM	We thank Frederic Barr for PAX3-FOXO1A and PAX7-FOXO1A, and Stephen Tapscott for pcIBabe-MyoD similar to E12 and pC52-MCK-luciferase. We acknowledge colleagues who shared antibodies through the Developmental Studies Hybridoma Bank maintained by the University of Iowa. FC was funded by the Association of International Cancer Research (07-0151). The laboratory of PSZ is also supported by The Wellcome Trust (085137/Z/08/Z), The Medical Research Council and OPTISTEM (Grant 223098) from the European Commission FP7. JEM is supported by a Wellcome Trust University Award. The laboratory of FR is supported by the INSERM Avenir Program, AFM, INCa, LNCC, ARC and FP7 ENDOSTEM (Grant 241440).	Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Bajard L, 2006, GENE DEV, V20, P2450, DOI 10.1101/gad.382806; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315; Bennicelli JL, 1999, ONCOGENE, V18, P4348, DOI 10.1038/sj.onc.1202812; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Collins CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004475; Cui S, 1999, PATHOL INT, V49, P62, DOI 10.1046/j.1440-1827.1999.00825.x; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Dilworth FJ, 2004, P NATL ACAD SCI USA, V101, P11593, DOI 10.1073/pnas.0404192101; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Finckenstein FG, 2008, ONCOGENE, V27, P2004, DOI 10.1038/sj.onc.1210835; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Gnocchi VF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005205; GUO K, 1995, MOL CELL BIOL, V15, P3823; Gurney JG, 1999, CANC INCIDENCE SURVI, P111; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hettmer S, 2010, NAT MED, V16, P171, DOI 10.1038/nm0210-171; Horst D, 2006, INT J DEV BIOL, V50, P47, DOI 10.1387/ijdb.052111dh; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; L'honore A, 2007, MOL BIOL CELL, V18, P1992, DOI 10.1091/mbc.E06-09-0867; Lagha M, 2008, GENE DEV, V22, P1828, DOI 10.1101/gad.477908; Lepper C, 2009, NATURE, V460, P627, DOI 10.1038/nature08209; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; Miller PJ, 2007, BBA-GEN SUBJECTS, V1770, P1450, DOI 10.1016/j.bbagen.2007.06.016; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nishijo K, 2009, FASEB J, V23, P2681, DOI 10.1096/fj.08-128116; Ono Y, 2010, DEV BIOL, V337, P29, DOI 10.1016/j.ydbio.2009.10.005; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Relaix F, 2004, GENE DEV, V18, P1088, DOI 10.1101/gad.301004; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Russo S, 1998, J CELL SCI, V111, P691; Saccone V, 2010, ORGANOGENESIS, V6, P48, DOI 10.4161/org.6.1.11293; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Scuoppo C, 2007, EXP CELL RES, V313, P2308, DOI 10.1016/j.yexcr.2007.02.037; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Weintraub M, 1997, Sarcoma, V1, P135, DOI 10.1080/13577149778218; Yang ZH, 2009, GENE DEV, V23, P694, DOI 10.1101/gad.1765109; Zammit PS, 2006, J CELL SCI, V119, P1824, DOI 10.1242/jcs.02908; Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958	58	45	47	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2013	32	5					651	662		10.1038/onc.2012.73	http://dx.doi.org/10.1038/onc.2012.73			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22710712				2022-12-28	WOS:000316164700012
J	Wang, Z; Yuan, H; Roth, M; Stark, JM; Bhatia, R; Chen, WY				Wang, Z.; Yuan, H.; Roth, M.; Stark, J. M.; Bhatia, R.; Chen, W. Y.			SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells	ONCOGENE			English	Article						chronic myelogenous leukemia; BCR-ABL; SIRT1; DNA damage repair; mutation; acquired resistance	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; DOUBLE-STRAND BREAKS; DNA-DAMAGE; CLINICAL RESISTANCE; STRESS-RESPONSE; ERROR-PRONE; C-ABL; IMATINIB; REPAIR	BCR-ABL transforms bone marrow progenitor cells and promotes genome instability, leading to development of chronic myelogenous leukemia (CML). The tyrosine kinase inhibitor imatinib effectively treats CML, but acquired resistance can develop because of BCR-ABL mutations. Mechanisms for acquisition of BCR-ABL mutations are not fully understood. Using a novel culture model of CML acquired resistance, we show that inhibition of SIRT1 deacetylase by small molecule inhibitors or gene knockdown blocks acquisition of BCR-ABL mutations and relapse of CML cells on tyrosine kinase inhibitors. SIRT1 knockdown also suppresses de novo genetic mutations of hypoxanthine phosphoribosyl transferase gene in CML and non-CML cells upon treatment with DNA damaging agent cannptothecin. Although SIRT1 can enhance cellular DNA damage response, it alters functions of DNA repair machineries in CML cells and stimulates activity of error-prone DNA damage repair, in association with acquisition of genetic mutations. These results reveal a previously unrecognized role of SIRT1 for promoting mutation acquisition in cancer, and have implication for targeting SIRT1 to overcome CML drug resistance. Oncogene (2013) 32, 589-598; doi:10.1038/onc.2012.83; published online 12 March 2012	[Wang, Z.; Yuan, H.; Roth, M.; Stark, J. M.; Chen, W. Y.] City Hope Natl Med Ctr, Dept Canc Biol, Beckman Res Inst, Duarte, CA 91010 USA; [Bhatia, R.] City Hope Natl Med Ctr, Div Hematopoiet Stem Cell & Leukemia Res, Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Chen, WY (corresponding author), City Hope Natl Med Ctr, Dept Canc Biol, Beckman Res Inst, Duarte, CA 91010 USA.	wechen@coh.org	Chen, WenYong/D-6748-2012	Chen, WenYong/0000-0001-6913-5729; Bhatia, Ravi/0000-0001-5740-2316	US Department of Defense [W81XWH-06-1-0268]; STOPCANCER Foundation; V-Foundation; National Cancer Institute, NIH [R01 CA143421];  [R01 CA95684];  [R01 CA120954]; NATIONAL CANCER INSTITUTE [P30CA033572, R01CA095684, R01CA120954, R01CA143421] Funding Source: NIH RePORTER	US Department of Defense(United States Department of Defense); STOPCANCER Foundation; V-Foundation; National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the following Grants: W81XWH-06-1-0268 from the US Department of Defense, a career development award from the STOPCANCER Foundation, a translational research grant from the V-Foundation and R01 CA143421 from the National Cancer Institute, NIH to WYC. RB was supported by R01 CA95684, and JMS was supported by R01 CA120954. The core facilities used in this study were supported by NCI P30 CA033572.	Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034; Brady N, 2003, CANCER RES, V63, P1798; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Dinkelmann M, 2009, NAT STRUCT MOL BIOL, V16, P808, DOI 10.1038/nsmb.1639; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Fiskus W, 2006, CLIN CANCER RES, V12, P5869, DOI 10.1158/1078-0432.CCR-06-0980; Gaymes TJ, 2006, MOL CANCER RES, V4, P563, DOI 10.1158/1541-7786.MCR-06-0111; Gaymes TJ, 2002, CANCER RES, V62, P2791; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guarente L, 2007, COLD SPRING HARB SYM, V72, P483, DOI 10.1101/sqb.2007.72.024; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Issa JPJ, 1997, CANCER RES, V57, P1678; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Koschmieder S, 2011, MYELOID LEUKEMIA BAS, P69; Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; O'Hagan HM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000155; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Perrotti D, 2010, J CLIN INVEST, V120, P2254, DOI 10.1172/JCI41246; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Quintas-Cardama A, 2011, LEUKEMIA, V25, P226, DOI 10.1038/leu.2010.276; Rass E, 2009, NAT STRUCT MOL BIOL, V16, P819, DOI 10.1038/nsmb.1641; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Slupianek A, 2006, DNA REPAIR, V5, P243, DOI 10.1016/j.dnarep.2005.10.005; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; von Bubnoff N, 2006, BLOOD, V108, P1328, DOI 10.1182/blood-2005-12-010132; Wang B, 2011, ONCOGENE, V30, P907, DOI 10.1038/onc.2010.468; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; Xie AY, 2009, NAT STRUCT MOL BIOL, V16, P814, DOI 10.1038/nsmb.1640; Yu CR, 2003, CANCER RES, V63, P2118; Yuan HF, 2012, BLOOD, V119, P1904, DOI 10.1182/blood-2011-06-361691; Yuan HF, 2010, J BIOL CHEM, V285, P5085, DOI 10.1074/jbc.M109.039206; Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029; Zhang B, 2010, CANCER CELL, V17, P427, DOI 10.1016/j.ccr.2010.03.011	58	73	76	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					589	598		10.1038/onc.2012.83	http://dx.doi.org/10.1038/onc.2012.83			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22410779	Green Accepted			2022-12-28	WOS:000316164700006
J	Yasaei, H; Gilham, E; Pickles, JC; Roberts, TP; O'Donovan, M; Newbold, RF				Yasaei, H.; Gilham, E.; Pickles, J. C.; Roberts, T. P.; O'Donovan, M.; Newbold, R. F.			Carcinogen-specific mutational and epigenetic alterations in INK4A, INK4B and p53 tumour-suppressor genes drive induced senescence bypass in normal diploid mammalian cells	ONCOGENE			English	Article						oncogene/stress-induced senescence; chemical carcinogen; ionizing radiation; Syrian hamster dermal cells; cell transformation assay	CELLULAR SENESCENCE; HUMAN CANCER; CHEEK-POUCH; P16(INK4A)/CDKN2A ALTERATIONS; DIOL EPOXIDE; LUNG-TUMORS; HAMSTER P16; RAS; IMMORTALIZATION; METHYLATION	Immortalization (senescence bypass) is a critical rate-limiting step in the malignant transformation of mammalian somatic cells. Human cells must breach at least two distinct senescence barriers to permit unfettered clonal evolution during cancer development: (1) stress- or oncogene-induced premature senescence (SIPS/OIS), mediated via the p16-Rb and/or ARF-p53-p21 tumour-suppressive pathways, and (2) replicative senescence triggered by telomere shortening. In contrast, because their telomerase is constitutively active, cells from small rodents possess only the SIPS/OIS barrier, and are therefore useful for studying SIPS/OIS bypass in isolation. Dermal fibroblasts from the Syrian hamster (SHD cells) are exceptionally resistant to spontaneous SIPS bypass, but it can be readily induced following exposure to a wide range of chemical and physical carcinogens. Here we show that a spectrum of carcinogen-specific mutational and epigenetic alterations involving the INK4A (p16), p53 and INK4B (p15) genes are associated with induced SIPS bypass. With ionizing radiation, immortalization is invariably accompanied by efficient biallelic deletion of the complete INK4/CDKN2 locus. In comparison, SHD cells immortalized by the powerful polycyclic hydrocarbon carcinogen benzo(a)pyrene display transversion point mutations in the DNA-binding domain of p53 coupled with INK4 alterations such as loss of expression of p15. Epimutational silencing of p16 is the primary event associated with immortalization by nickel, a human non-genotoxic carcinogen. As SIPS/OIS bypass is a prerequisite for the immortalization of normal diploid human epithelial cells, our results with the SHD model will provide a basis for delineating combinations of key molecular changes underpinning this important event in human carcinogenesis. Oncogene (2013) 32, 171-179; doi:10.1038/onc.2012.45; published online 12 March 2012	[Yasaei, H.; Gilham, E.; Pickles, J. C.; Roberts, T. P.; Newbold, R. F.] Brunel Univ, Sch Hlth Sci & Social Care, Inst Canc Genet & Pharmacogen, Div Biosci, Uxbridge UB8 3PH, Middx, England; [O'Donovan, M.] AstraZeneca R&D, Safety Assessment Grp, Macclesfield, Cheshire, England	Brunel University; AstraZeneca	Newbold, RF (corresponding author), Brunel Univ, Sch Hlth Sci & Social Care, Inst Canc Genet & Pharmacogen, Div Biosci, Kingston Lane, Uxbridge UB8 3PH, Middx, England.	robert.newbold@brunel.ac.uk	Yasaei, Hemad/A-6351-2014; Roberts, Terry/A-8211-2014	Pickles, Jessica/0000-0001-7888-1723	(UK) National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) [G0800697/1]; UK BBSRC-CASE Studentship; Unilever Plc.; AstraZeneca; National Centre for the Replacement [NC/K500045/1, G0800697/1] Funding Source: researchfish	(UK) National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs); UK BBSRC-CASE Studentship; Unilever Plc.; AstraZeneca(AstraZeneca); National Centre for the Replacement	This work was fully funded by triennial Project Grant to RFN and MUD (ID G0800697/1) from the (UK) National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). JCP is funded by a UK BBSRC-CASE Studentship award with Unilever Plc. EG was funded by a grant from AstraZeneca. We acknowledge Mrs Alison Marriott and Dr Rana Hasan for their expert technical assistance. We dedicate this article to colleagues Professor Philip D Lawley (1927-2011) who pioneered research into the reaction of alkylating carcinogens with DNA; and to Steven Pash (1955-2011) who assisted expertly with the generation of hamster cell cultures.	Arita A, 2009, METALLOMICS, V1, P222, DOI 10.1039/b903049b; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Camacho CV, 2010, CARCINOGENESIS, V31, P1889, DOI 10.1093/carcin/bgq153; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chang KW, 2000, CARCINOGENESIS, V21, P1441, DOI 10.1093/carcin/21.7.1441; Chang KW, 1996, CARCINOGENESIS, V17, P595, DOI 10.1093/carcin/17.3.595; CHANG KW, 1994, CANCER RES, V54, P3878; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Creton S, 2012, MUTAGENESIS, V27, P93, DOI 10.1093/mutage/ger053; Csepregi A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-317; Florl AR, 2003, GENE CHROMOSOME CANC, V37, P141, DOI 10.1002/gcc.10192; Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270; GimenezConti IB, 1996, MOL CARCINOGEN, V16, P197, DOI 10.1002/(SICI)1098-2744(199608)16:4<197::AID-MC3>3.0.CO;2-D; Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784; Grafstrom E, 2005, CLIN CANCER RES, V11, P2991, DOI 10.1158/1078-0432.CCR-04-1731; Haga K, 2007, CANCER SCI, V98, P147, DOI 10.1111/j.1349-7006.2006.00373.x; Hanaoka M, 2005, BIOCHEM BIOPH RES CO, V333, P1249, DOI 10.1016/j.bbrc.2005.06.034; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; LACONI S, 1995, CANCER RES, V55, P2560; Lam TK, 2009, ANN EPIDEMIOL, V19, P546, DOI 10.1016/j.annepidem.2009.03.003; LEGROS Y, 1992, GENE, V112, P247, DOI 10.1016/0378-1119(92)90384-2; Li JN, 2004, CARCINOGENESIS, V25, P263, DOI 10.1093/carcin/bgh007; Li JN, 2003, BIOCHEM BIOPH RES CO, V304, P241, DOI 10.1016/S0006-291X(03)00577-1; Li J, 2008, MOL CARCINOGEN, V47, P733, DOI 10.1002/mc.20424; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Liu ZP, 2005, CANCER RES, V65, P2583, DOI 10.1158/0008-5472.CAN-04-3675; Muscarella P, 2001, GENE, V278, P235, DOI 10.1016/S0378-1119(01)00728-4; NEWBOLD RF, 1977, MUTAT RES, V43, P101, DOI 10.1016/0027-5107(77)90136-1; NEWBOLD RF, 1976, NATURE, V261, P52, DOI 10.1038/261052a0; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NEWBOLD RF, 1980, NATURE, V283, P596, DOI 10.1038/283596a0; Newbold RF, 2005, INTRO CELLULAR MOL B, P170; Odell A, 2010, AGING-US, V2, P160, DOI 10.18632/aging.100129; OREFFO VIC, 1993, CARCINOGENESIS, V14, P451, DOI 10.1093/carcin/14.3.451; Peters G, 2008, NAT STRUCT MOL BIOL, V15, P1133, DOI 10.1038/nsmb1108-1133; POPESCU NC, 1995, CYTOGENET CELL GENET, V68, P71, DOI 10.1159/000133893; Raschke S, 2005, GENE CHROMOSOME CANC, V42, P58, DOI 10.1002/gcc.20119; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; Seluanov A, 2008, AGING CELL, V7, P813, DOI 10.1111/j.1474-9726.2008.00431.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sikora E, 2011, AGEING RES REV, V10, P146, DOI 10.1016/j.arr.2010.10.002; TROTT DA, 1995, CARCINOGENESIS, V16, P193, DOI 10.1093/carcin/16.2.193; Whibley C, 2010, J BIOL CHEM, V285, P11326, DOI 10.1074/jbc.M109.064444; Windhofer F, 2008, MUTAT RES-FUND MOL M, V638, P56, DOI 10.1016/j.mrfmmm.2007.08.016; Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X	50	41	43	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					171	179		10.1038/onc.2012.45	http://dx.doi.org/10.1038/onc.2012.45			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22410783	Bronze			2022-12-28	WOS:000314075500005
J	Kan, CY; Wen, VW; Pasquier, E; Jankowski, K; Chang, M; Richards, LA; Kavallaris, M; MacKenzie, KL				Kan, C-Y; Wen, V. W.; Pasquier, E.; Jankowski, K.; Chang, M.; Richards, L. A.; Kavallaris, M.; MacKenzie, K. L.			Endothelial cell dysfunction and cytoskeletal changes associated with repression of p16(INK4a) during immortalization	ONCOGENE			English	Article						endothelial cell; p16(INK4a); TERT; immortalization; cytoskeleton; morphogenesis	MOLECULAR-WEIGHT TROPOMYOSINS; MAMMARY EPITHELIAL-CELLS; MALIGNANT-TRANSFORMATION; REPLICATIVE SENESCENCE; ACTIN CYTOSKELETON; CYCLE PROGRESSION; 4 ANGIOSARCOMAS; TELOMERE; VIMENTIN; EXPRESSION	The immortalization process is a fundamental step in the development of most (if not all) human cancers, including the aggressive endothelial cell (EC)-derived malignancy angiosarcoma. Inactivation of the tumor suppressor p16(INK4a) and the development of multiple chromosomal abnormalities are features of angiosarcoma that are recapitulated during telomerase-mediated immortalization of human ECs in vitro. The present study used a panel of telomerase-immortalized bone marrow EC (BMEC) lines to define the consequences of inactivation of p16(INK4a) on EC function and to identify molecular changes associated with repression of p16(INK4a). In a comparison of two immortalized BMEC mass cultures and six clones, the cell lines that repressed p16(INK4a) showed a higher rate of proliferation and an impaired ability to undergo morphogenic differentiation and form vessel-like structures in vitro. Proteomic comparison of a p16(INK4a)-negative and a p16(INK4a)-positive BMEC mass culture at early-and late-passage time points following transduction with telomerase reverse transcriptase (hTERT) revealed altered expression of cytoskeletal proteins, including vimentin and a-tropomyosin (alpha Tm), in the immortal cells. Immunoblot analyses of a panel of 11 immortal clones showed that cells that lacked p16(INK4a) expression tended to accumulate more dramatic changes in these cytoskeletal proteins than cells that retained p16(INK4a) expression. This corresponded with aberrant cytoskeletal architectures among p16(INK4a)-negative clones, which featured thicker actin stress fibers and less fluid membrane ruffles than p16(INK4a)-positive cells. A direct link between p16(INK4a) repression and defective EC function was confirmed by analysis of normal cells transfected with small interfering RNA (siRNA) targeting p16(INK4a). siRNA-mediated repression of p16(INK4a) significantly impaired random motility and vessel formation in vitro. This report is the first to demonstrate that ECs that repress the expression of p16(INK4a) are prone to defects in motility, morphogenesis and cytoskeletal organization. These defects are likely to reflect alterations that occur during the development of EC-derived malignancies.	[Kan, C-Y; Wen, V. W.; Jankowski, K.; Richards, L. A.; MacKenzie, K. L.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Canc Cell Dev Grp, Randwick, NSW 2031, Australia; [Pasquier, E.; Chang, M.; Kavallaris, M.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Tumour Biol & Targeting Program, Randwick, NSW 2031, Australia; [Kavallaris, M.] Univ New S Wales, Australian Ctr Nanomed, Randwick, NSW 2031, Australia	Children's Cancer Institute; University of New South Wales Sydney; Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney	MacKenzie, KL (corresponding author), Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, Canc Cell Dev Grp, POB 81, Randwick, NSW 2031, Australia.	k.mackenzie@unsw.edu.au	Mackenzie, Karen/F-1310-2011; Pasquier, Eddy/A-8112-2018; MacKenzie, Karen/N-5849-2019; Kavallaris, Maria/J-5240-2014	Pasquier, Eddy/0000-0003-2824-5002; MacKenzie, Karen/0000-0003-2996-1617; Chang, Melissa/0000-0001-6311-3414	National Health and Medical Research Council [510378, 568611]; New South Wales Cancer Council [07-14]; Cancer Institute New South Wales [07-CDF-1/23, 07/ECF/1-21]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); New South Wales Cancer Council(Cancer Council New South Wales); Cancer Institute New South Wales	We thank Dr Galina Schevzov and Professor Peter Gunning for provision of the Tm antibody and helpful discussion. Children's Cancer Institute Australia for Medical Research is affiliated with the University of New South Wales and Sydney Children's Hospital. This research was facilitated by access to the Australian Proteome Analysis Facility established under the Australian Government's Major National Research Facilities Program. Funding: National Health and Medical Research Council (KLM Career Development Award ID no. 510378; MK Senior Research Fellowship ID no. 568611), New South Wales Cancer Council (KLM ID no. 07-14) and Cancer Institute New South Wales (KLM Career Development and Support Fellowship ID no. 07-CDF-1/23; EP Early Career Research Fellowship ID no. 07/ECF/1-21).	Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alhaja Elena, 2004, Angiogenesis, V7, P323, DOI 10.1007/s10456-005-0368-9; Baumhoer D, 2005, GYNECOL ONCOL, V97, P348, DOI 10.1016/j.ygyno.2004.12.046; Bell CD, 2003, MICROSC RES TECHNIQ, V60, P165, DOI 10.1002/jemt.10254; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chen J, 2006, AM J PHYSIOL-HEART C, V290, pH1575, DOI 10.1152/ajpheart.00364.2005; Chinnam M, 2011, CURR TOP DEV BIOL, V94, P129, DOI 10.1016/B978-0-12-380916-2.00005-X; Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Eckes B, 1998, J CELL SCI, V111, P1897; Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906; Franzen B, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.162; GILBENSO R, 1994, GENE CHROMOSOME CANC, V10, P210, DOI 10.1002/gcc.2870100311; Gunning PW, 2005, TRENDS CELL BIOL, V15, P333, DOI 10.1016/j.tcb.2005.04.007; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara E, 1996, MOL CELL BIOL, V16, P859; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Houle F, 2007, J CELL SCI, V120, P3666, DOI 10.1242/jcs.003251; Hsiao RS, 1997, ANTICANCER RES, V17, P827; Huang B, 2009, CARDIOVASC RES, V83, P536, DOI 10.1093/cvr/cvp154; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Hughes JAI, 2003, GLIA, V42, P25, DOI 10.1002/glia.10174; Ivaska J, 2007, EXP CELL RES, V313, P2050, DOI 10.1016/j.yexcr.2007.03.040; Jacobs JJL, 2004, CURR BIOL, V14, P2302, DOI 10.1016/j.cub.2004.12.025; KINDBLOM LG, 1991, VIRCHOWS ARCH A, V419, P439, DOI 10.1007/BF01605079; Koch M, 2008, J SURG ONCOL, V97, P321, DOI 10.1002/jso.20973; Kouvroukoglou S, 2000, BIOMATERIALS, V21, P1725, DOI 10.1016/S0142-9612(99)00205-7; Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; MacKenzie KL, 2002, ONCOGENE, V21, P4200, DOI 10.1038/sj.onc.1205425; MANDAHL N, 1990, GENE CHROMOSOME CANC, V1, P315, DOI 10.1002/gcc.2870010410; Milyavsky M, 2007, CANCER CELL, V11, P133, DOI 10.1016/j.ccr.2006.11.022; Minamino T, 2002, CIRCULATION, V105, P1541, DOI 10.1161/01.CIR.0000013836.85741.17; Minamino T, 2004, CURR VASC PHARMACOL, V2, P141, DOI 10.2174/1570161043476393; Nishio K, 2001, HISTOCHEM CELL BIOL, V116, P321, DOI 10.1007/s004180100325; Nylund R, 2004, PROTEOMICS, V4, P1359, DOI 10.1002/pmic.200300773; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Pasquier E, 2010, MOL CANCER THER, V9, P1408, DOI 10.1158/1535-7163.MCT-09-0894; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Schevzov G, 2005, J HISTOCHEM CYTOCHEM, V53, P557, DOI 10.1369/jhc.4A6505.2005; Schuborg C, 1998, CANCER GENET CYTOGEN, V100, P52, DOI 10.1016/S0165-4608(97)00012-5; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Soler D, 2005, GENE CHROMOSOME CANC, V44, P339, DOI 10.1002/gcc.20244; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Tannapfel A, 2001, J HEPATOL, V35, P62, DOI 10.1016/S0168-8278(01)00046-0; Urashima M, 1999, BRIT J CANCER, V79, P1032, DOI 10.1038/sj.bjc.6690165; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; Verrills NM, 2006, PROTEOMICS, V6, P1681, DOI 10.1002/pmic.200500417; Wagner M, 2001, EXP GERONTOL, V36, P1327, DOI 10.1016/S0531-5565(01)00105-X; WANG E, 1985, J CELL BIOL, V100, P1466, DOI 10.1083/jcb.100.5.1466; Wang FL, 1996, CANCER RES, V56, P3634; Weihrauch M, 2002, HUM PATHOL, V33, P884, DOI 10.1053/hupa.2002.126880; Wen VW, 2006, CANCER RES, V66, P10691, DOI 10.1158/0008-5472.CAN-06-0979; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhang JC, 2002, P NATL ACAD SCI USA, V99, P12224, DOI 10.1073/pnas.192668299; Zheng Q, 2008, INT J CANCER, V122, P78, DOI 10.1002/ijc.23025; Zu YL, 2001, APPL IMMUNOHISTO M M, V9, P24, DOI 10.1097/00022744-200103000-00006	62	12	12	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	46					4815	4827		10.1038/onc.2011.645	http://dx.doi.org/10.1038/onc.2011.645			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22310292	Green Published, hybrid			2022-12-28	WOS:000311210700002
J	Li, Y; Deng, C; Hu, X; Patel, B; Fu, X; Qiu, Y; Brand, M; Zhao, K; Huang, S				Li, Y.; Deng, C.; Hu, X.; Patel, B.; Fu, X.; Qiu, Y.; Brand, M.; Zhao, K.; Huang, S.			Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis	ONCOGENE			English	Article						TAL1/SCL; LSD1; H3K4 demethylation; serine phosphorylation; epigenetic regulation; leukemogenesis	T-CELL LEUKEMIA; CHROMOSOME-TRANSLOCATION; GENE-EXPRESSION; SCL GENE; TRANSCRIPTION; DIFFERENTIATION; PHOSPHORYLATION; PROLIFERATION; DEMETHYLASE; DISRUPTION	TAL1/SCL is a hematopoietic-specific oncogene and its activity is regulated by associated transcriptional co-activators and corepressors. Dysregulation of TAL1 activity has been associated with T-cell leukemogenesis. However, it remains unclear how the interactions between TAL1 and corepressors versus co-activators are properly regulated. Here, we reported that protein kinase A (PKA)-mediated phosphorylation regulates TAL1 interaction with the lysine-specific demethylase (LSD1) that removes methyl group from methylated Lys 4 on histone H3 tails. Phosphorylation of serine 172 in TAL1 specifically destabilizes the TAL1-LSD1 interaction leading to promoter H3K4 hypermethylation and activation of target genes that have been suppressed in normal and malignant hematopoiesis. Knockdown of TAL1 or LSD1 led to a derepression of the TAL1 target genes in T-cell acute lymphoblast leukemia (T-ALL) Jurkat cells, which is accompanied by elevating promoter H3K4 methylation. Similarly, treatment of PKA activator forskolin resulted in derepression of target genes by reducing its interaction with LSD1 while PKA inhibitor H89 represses them by suppressing H3K4 methylation levels. Consistent with the dual roles of TAL1 in transcription, TAL1-associated LSD1 is decreased while recruitment of hSET1 is increased at the TAL1 targets during erythroid differentiation. This process is accompanied by a dramatic increase in H3K4 methylation. Thus, our data revealed a novel interplay between PKA phosphorylation and TAL1-mediated epigenetic regulation that regulates hematopoietic transcription and differentiation programs during hematopoiesis and leukemogenesis. Oncogene (2012) 31, 5007-5018; doi:10.1038/onc.2012.8; published online 6 February 2012	[Li, Y.; Hu, X.; Fu, X.] Jilin Univ, Coll Life Sci, Changchun 130023, Peoples R China; [Qiu, Y.] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Qiu, Y.; Huang, S.] Univ Florida, Coll Med, Shands Canc Ctr, Gainesville, FL 32610 USA; [Brand, M.] Ottawa Hosp, Sprott Ctr Stem Cell Res, Res Inst, Ottawa, ON, Canada; [Zhao, K.] NHLBI, Syst Biol Ctr, NIH, Bethesda, MD 20892 USA; [Li, Y.; Deng, C.; Hu, X.; Patel, B.; Huang, S.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	Jilin University; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Ottawa; Ottawa Hospital Research Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University System of Florida; University of Florida	Huang, S (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.	sumingh@ufl.edu	Li, Ying/L-7292-2019	, Yi/0000-0002-3282-6072	National Institute of Health [R01HL090589, R01HL091929, R01HL091929-01A1S1, R01HL095674]; NIH [5T32-CA9126-34]; Intramural Research programs, National Heart Lung Blood Institute and National Institute of Health; NATIONAL CANCER INSTITUTE [T32CA009126] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090589, ZICHL006058, ZIAHL005801, R01HL095674, ZIAHL006031, R01HL091929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056009] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research programs, National Heart Lung Blood Institute and National Institute of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to members of the Huang laboratory for their suggestions and comments. This work was supported by grants from the National Institute of Health (SH, R01HL090589, R01HL091929 and R01HL091929-01A1S1-the ARRA Administrative supplement; YQ, R01HL095674). BP is supported by NIH T32 training grant (5T32-CA9126-34). KZ is supported by the Intramural Research programs, National Heart Lung Blood Institute and National Institute of Health.	APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; Begley CG, 1999, BLOOD, V93, P2760; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Cai Y, 2009, BIOCHEM BIOPH RES CO, V390, P295, DOI 10.1016/j.bbrc.2009.09.111; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Martinez MC, 2006, BLOOD, V108, P3012, DOI 10.1182/blood-2006-04-019109; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; Condorelli GL, 1996, CANCER RES, V56, P5113; Cui KR, 2009, CELL STEM CELL, V4, P80, DOI 10.1016/j.stem.2008.11.011; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Demers C, 2007, MOL CELL, V27, P573, DOI 10.1016/j.molcel.2007.06.022; Dey S, 2010, MOL CELL BIOL, V30, P2181, DOI 10.1128/MCB.01441-09; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Hansson A, 2003, BIOCHEM BIOPH RES CO, V312, P1073, DOI 10.1016/j.bbrc.2003.11.030; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109; Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105; Hu X, 2009, EPIGENETICS-US, V4, P257, DOI 10.4161/epi.4.6.9711; Hu X, 2009, P NATL ACAD SCI USA, V106, P10141, DOI 10.1073/pnas.0900437106; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Izraeli S, 2004, BRIT J HAEMATOL, V126, P3, DOI 10.1111/j.1365-2141.2004.04986.x; Kassouf MT, 2010, GENOME RES, V20, P1064, DOI 10.1101/gr.104935.110; Kusy S, 2010, J EXP MED, V207, P2141, DOI 10.1084/jem.20100745; Lacombe J, 2010, BLOOD, V115, P792, DOI 10.1182/blood-2009-01-201384; Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06; Li XG, 2010, BLOOD, V115, P2028, DOI 10.1182/blood-2009-07-236059; Linggi BE, 2005, J CELL BIOCHEM, V96, P938, DOI 10.1002/jcb.20604; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; Palamarchuk A, 2005, CANCER RES, V65, P4515, DOI 10.1158/0008-5472.CAN-05-0751; Palii CG, 2011, EMBO J, V30, P494, DOI 10.1038/emboj.2010.342; Palomero T, 2006, BLOOD, V108, P986, DOI 10.1182/blood-2005-08-3482; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRASAD KSS, 1995, J BIOL CHEM, V270, P11603, DOI 10.1074/jbc.270.19.11603; Prasad KSS, 1997, J BIOL CHEM, V272, P11457; Robb L, 1997, BIOESSAYS, V19, P607, DOI 10.1002/bies.950190711; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039; Sanchez MJ, 2001, DEVELOPMENT, V128, P4815; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; Scoumanne A, 2007, J BIOL CHEM, V282, P15471, DOI 10.1074/jbc.M701023200; Shank-Calvo JA, 2006, ONCOGENE, V25, P3023, DOI 10.1038/sj.onc.1209326; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Song SH, 2007, MOL CELL, V28, P810, DOI 10.1016/j.molcel.2007.09.025; Tremblay M, 2003, J BIOL CHEM, V278, P12680, DOI 10.1074/jbc.M209870200; Tripic T, 2009, BLOOD, V113, P2191, DOI 10.1182/blood-2008-07-169417; WADMAN IA, 1994, ONCOGENE, V9, P3713; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050	59	51	53	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					5007	5018		10.1038/onc.2012.8	http://dx.doi.org/10.1038/onc.2012.8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22310283	Green Accepted			2022-12-28	WOS:000311888600005
J	Sangwan, M; McCurdy, SR; Livne-bar, I; Ahmad, M; Wrana, JL; Chen, D; Bremner, R				Sangwan, M.; McCurdy, S. R.; Livne-bar, I.; Ahmad, M.; Wrana, J. L.; Chen, D.; Bremner, R.			Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation	ONCOGENE			English	Article						chemoprevention; retinoblastoma; Cdk; E2f; p107	CELL-CYCLE INHIBITION; FUNCTIONALLY ANTAGONIZE; DNA-BINDING; RB; P107; PROLIFERATION; APOPTOSIS; CANCER; SUPPRESSOR; PRB	RB+/- individuals develop retinoblastoma and, subsequently, many other tumors. The Rb relatives p107 and p130 protect the tumor-resistant Rb-/- mouse retina. Determining the mechanism underlying this tumor suppressor function may expose novel strategies to block Rb pathway cancers. p107/p130 are best known as E2f inhibitors, but here we implicate E2f-independent Cdk2 inhibition as the critical p107 tumor suppressor function in vivo. Like p107 loss, deleting p27 or inactivating its Cdk inhibitor (CKI) function (p27(CK-)) cooperated with Rb loss to induce retinoblastoma. Genetically, p107 behaved like a CKI because inactivating Rb and one allele each of p27 and p107 was tumorigenic. Although Rb loss induced canonical E2f targets, unexpectedly p107 loss did not further induce these genes, but instead caused post-transcriptional Skp2 induction and Cdk2 activation. Strikingly, Cdk2 activity correlated with tumor penetrance across all the retinoblastoma models. Therefore, Rb restrains E2f, but p107 inhibits cross talk to Cdk. While removing either E2f2 or E2f3 genes had little effect, removing only one E2f1 allele blocked tumorigenesis. More importantly, exposing retinoblastoma-prone fetuses to small molecule inhibitors of E2f (HLM006474) or Cdk (R547) for merely 1 week dramatically inhibited subsequent tumorigenesis in adult mice. Protection was achieved without disrupting normal proliferation. Thus, exquisite sensitivity of the cell-of-origin to E2f and Cdk activity can be exploited to prevent Rb pathway-induced cancer in vivo without perturbing normal cell division. These data suggest that E2f inhibitors, never before tested in vivo, or CKIs, largely disappointing as therapeutics, may be effective preventive agents. Oncogene (2012) 31, 5019-5028; doi:10.1038/onc.2011.654; published online 30 January 2012	[Sangwan, M.; McCurdy, S. R.; Livne-bar, I.; Ahmad, M.; Chen, D.; Bremner, R.] Univ Toronto, Toronto Western Res Inst, Univ Hlth Network, Dept Ophthalmol & Visual Sci, Toronto, ON M5T 2S8, Canada; [Sangwan, M.; McCurdy, S. R.; Livne-bar, I.; Ahmad, M.; Chen, D.; Bremner, R.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5T 2S8, Canada; [Wrana, J. L.] Univ Toronto, Dept Mol Genet, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Bremner, R (corresponding author), Univ Toronto, Toronto Western Res Inst, Univ Hlth Network, Dept Ophthalmol & Visual Sci, Room Mc6-424,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	dchen@uhnres.utoronto.ca; rbremner@uhnres.utoronto.ca	Chen, Danian/GXV-7996-2022; Bremner, Rod/I-6490-2012; Wrana, Jeffrey/F-8857-2013	Bremner, Rod/0000-0001-9184-7212; Chen, Danian/0000-0002-6916-2978	Canadian Institutes for Health Research (CIHR); Foundation Fighting Blindness Canada; Ontario Institute for Cancer Research through Government of Ontario; Terry Fox Research Institute; CIHR	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Foundation Fighting Blindness Canada; Ontario Institute for Cancer Research through Government of Ontario; Terry Fox Research Institute; CIHR(Canadian Institutes of Health Research (CIHR))	We thank Arnaud Besson and James Roberts for sharing p27<SUP>CK-/CK-</SUP> mice, and Fred Dick, Gustavo Leone and Philippe Monnier for comments. This project was funded by grants to RB from the Canadian Institutes for Health Research (CIHR), Foundation Fighting Blindness Canada, Ontario Institute for Cancer Research through funding provided by the Government of Ontario and the Terry Fox Research Institute. MS, MA and SRM were supported in part by fellowships from a CIHR training program.	Balmer A, 2006, ONCOGENE, V25, P5341, DOI 10.1038/sj.onc.1209622; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Black EP, 2003, CANCER RES, V63, P3716; Boquoi A, 2009, CANCER PREV RES, V2, P800, DOI 10.1158/1940-6207.CAPR-09-0053; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Buttitta LA, 2007, DEV CELL, V12, P631, DOI 10.1016/j.devcel.2007.02.020; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen D, 2007, PLOS BIOL, V5, P1504, DOI 10.1371/journal.pbio.0050179; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chibazakura T, 2004, P NATL ACAD SCI USA, V101, P4465, DOI 10.1073/pnas.0400655101; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Conkrite K, 2011, GENE DEV, V25, P1734, DOI 10.1101/gad.17027411; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; DePinto W, 2006, MOL CANCER THER, V5, P2644, DOI 10.1158/1535-7163.MCT-06-0355; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Kelloff GJ, 2006, CLIN CANCER RES, V12, P3661, DOI 10.1158/1078-0432.CCR-06-1104; Lara MF, 2008, MOL CARCINOGEN, V47, P209, DOI 10.1002/mc.20376; Lara MF, 2008, MOL CARCINOGEN, V47, P105, DOI 10.1002/mc.20367; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Lindor NM, 2008, J NATL CANC I MONOGR, V38, P1, DOI DOI 10.1093/JNCIMONOGRAPHS/LGN001; Ma YH, 2008, CANCER RES, V68, P6292, DOI 10.1158/0008-5472.CAN-08-0121; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; McClellan KA, 2007, MOL CELL BIOL, V27, P4825, DOI 10.1128/MCB.02100-06; Montigiani S, 2003, ONCOGENE, V22, P4943, DOI 10.1038/sj.onc.1206495; Ng AK, 2010, SEMIN RADIAT ONCOL, V20, P67, DOI 10.1016/j.semradonc.2009.09.002; Padmakumar VC, 2009, MOL CELL BIOL, V29, P2582, DOI 10.1128/MCB.00952-08; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Rodier G, 2005, J CELL BIOL, V168, P55, DOI 10.1083/jcb.200404146; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yu CL, 2009, JNCI-J NATL CANCER I, V101, P581, DOI 10.1093/jnci/djp046; Zhang JK, 2004, CELL CYCLE, V3, P952; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	51	43	45	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					5019	5028		10.1038/onc.2011.654	http://dx.doi.org/10.1038/onc.2011.654			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22286767	Green Accepted			2022-12-28	WOS:000311888600006
J	Louie, E; Chen, XF; Coomes, A; Ji, K; Tsirka, S; Chen, E				Louie, E.; Chen, X. F.; Coomes, A.; Ji, K.; Tsirka, S.; Chen, El			Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis	ONCOGENE			English	Article						breast cancer; brain metastasis; neurotrophin-3; protein signature; HER2 positive; HER2 signaling	CENTRAL-NERVOUS-SYSTEM; OF-THE-LITERATURE; CARCINOMA-CELLS; E-CADHERIN; FACTOR RECEPTOR-2; EXPRESSION; MODEL; TRANSITION; LUNG; OVEREXPRESSION	Metastasis, which remains incompletely characterized at the molecular and biochemical levels, is a highly specific process. Despite the ability of disseminated cancer cells to intravasate into distant tissues, it has been long recognized that only a limited subset of target organs develop clinically overt metastases. Therefore, subsequent adaptation of disseminated cancer cells to foreign tissue microenvironment determines the metastatic latency and tissue tropism of these cells. As a result, studying interactions between the disseminated cancer cells and the adjacent stromal cells will provide a better understanding of what constitutes a favorable or unfavorable microenvironment for disseminated cancer cells in a tissue-specific manner. Previously, we reported a protein signature of brain metastasis showing increased ability of brain metastatic breast cancer cells to counteract oxidative stress. In this study, we showed that another protein from the brain metastatic protein signature, neurotrophin-3 (NT-3), has a dual function of regulating the metastatic growth of metastatic breast cancer cells and reducing the activation of immune response in the brain. More importantly, increased NT-3 secretion in metastatic breast cancer cells results in a reversion of mesenchymal-like (EMT) state to epithelial-like (MET) state and vice versa. Ectopic expression of NT-3 in EMT-like breast cancer cells reduces their migratory ability and increases the expression of HER2 (human epidermal growth factor receptor 2) and E-cadherin at the cell-cell junction. In addition, both endogenous and ectopic expression of NT-3 reduced the number of fully activated cytotoxic microglia. In summary, NT-3 appears to promote growth of metastatic breast cancer cells in the brain by facilitating the re-epithelialization of metastatic breast cancer cells and downmodulating the cytotoxic response of microglia. Most importantly, our results provide new insights into the latency and development of central nervous system macrometastases in patients with HER2-positive breast tumors and provide mechanistic rationale to target HER2 signaling for HER2-positive breast cancer brain metastasis.	[Louie, E.; Chen, X. F.; Coomes, A.; Ji, K.; Tsirka, S.; Chen, El] SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Louie, E (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, BST 8-125, Stony Brook, NY 11794 USA.	emily@pharm.stonybrook.edu	Tsirka, Stella/AAD-4018-2019		Susan Komen Foundation; Mary Anita Conroy Memorial Breast Cancer Fund from the Manhasset Women's Coalition Against Breast Cancer;  [R01NS42168]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI091175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042168] Funding Source: NIH RePORTER	Susan Komen Foundation(Susan G. Komen Breast Cancer Foundation); Mary Anita Conroy Memorial Breast Cancer Fund from the Manhasset Women's Coalition Against Breast Cancer; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants to EIC from the Susan Komen Foundation and the Mary Anita Conroy Memorial Breast Cancer Fund from the Manhasset Women's Coalition Against Breast Cancer. S Tsirka and K Ji were supported by R01NS42168.	Adriaenssens E, 2008, CANCER RES, V68, P346, DOI 10.1158/0008-5472.CAN-07-1183; Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; Cameron D, 2008, BREAST CANCER RES TR, V112, P533, DOI 10.1007/s10549-007-9885-0; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chaffer CL, 2005, CLIN EXP METASTAS, V22, P115, DOI 10.1007/s10585-005-5141-3; Chang EL, 2003, ONCOLOGIST, V8, P398, DOI 10.1634/theoncologist.8-5-398; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; Cho S, 2007, CURR NEUROPHARMACOL, V5, P19, DOI 10.2174/157015907780077105; Choi YH, 2009, ANN ONCOL, V20, P1337, DOI 10.1093/annonc/mdp003; Descamps S, 2001, CANCER RES, V61, P4337; Elkabes S, 1996, J NEUROSCI, V16, P2508; Fitzgerald DP, 2008, CLIN EXP METASTAS, V25, P799, DOI 10.1007/s10585-008-9193-z; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; He BP, 2006, MOL MED, V12, P161, DOI 10.2119/2006-00033.He; Hondermarck H, 2008, AM J PATHOL, V172, P865, DOI 10.2353/ajpath.2008.080008; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Jung S, 2002, J CANCER RES CLIN, V128, P469, DOI 10.1007/s00432-002-0366-x; Kim JW, 2004, CANCER LETT, V213, P203, DOI 10.1016/j.canlet.2004.03.042; Kirsch David G, 2005, Clin Breast Cancer, V6, P115, DOI 10.3816/CBC.2005.n.013; Klos KJ, 2004, NEUROLOGIST, V10, P31, DOI 10.1097/01.nrl.0000106922.83090.71; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Kwon HC, ONKOLOGIE, V33, P146; Lin NU, 2008, J CLIN ONCOL, V26, P1993, DOI 10.1200/JCO.2007.12.3588; Louie E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2773; Lu X, 2007, J MAMMARY GLAND BIOL, V12, P153, DOI 10.1007/s10911-007-9047-3; MacDonald IC, 2002, BIOESSAYS, V24, P885, DOI 10.1002/bies.10156; Matsumura H, 2000, BIOCHEM BIOPH RES CO, V269, P513, DOI 10.1006/bbrc.2000.2332; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Menon MB, 2009, CELL MOTIL CYTOSKEL, V66, P1041, DOI 10.1002/cm.20418; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Montel V, 2005, AM J PATHOL, V166, P1565, DOI 10.1016/S0002-9440(10)62372-3; Nathoo N, 2005, J CLIN PATHOL, V58, P237, DOI 10.1136/jcp.2003.013623; Ohno Shinji, 2004, Breast Cancer, V11, P27, DOI 10.1007/BF02967997; Ohsawa K, 2004, J NEUROCHEM, V88, P844, DOI 10.1046/j.1471-4159.2003.02213.x; Oltean S, 2006, P NATL ACAD SCI USA, V103, P14116, DOI 10.1073/pnas.0603090103; Palmieri D, 2007, CANCER RES, V67, P4190, DOI 10.1158/0008-5472.CAN-06-3316; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Piccirilli M, 2007, TUMORI, V93, P150; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Puduvalli V K, 2001, Curr Oncol Rep, V3, P467, DOI 10.1007/s11912-001-0067-7; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; Tomasevic Z, 2009, J BUON, V14, P225; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215; Tzeng SF, 2005, J NEUROSCI RES, V81, P666, DOI 10.1002/jnr.20586; Vanhecke E, 2011, CLIN CANCER RES, V17, P1741, DOI 10.1158/1078-0432.CCR-10-1890; Vincan E, 2005, DIFFERENTIATION, V73, P142, DOI 10.1111/j.1432-0436.2005.00015.x; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7; Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87; Yarrow JC, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-21; Yates CC, 2007, BRIT J CANCER, V96, P1246, DOI 10.1038/sj.bjc.6603700; Yonemori K, 2010, CANCER-AM CANCER SOC, V116, P302, DOI 10.1002/cncr.24735	54	70	70	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4064	4077		10.1038/onc.2012.417	http://dx.doi.org/10.1038/onc.2012.417			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23001042	Green Accepted			2022-12-28	WOS:000323748500002
J	Shi, XB; Xue, L; Ma, AH; Tepper, CG; Gandour-Edwards, R; Kung, HJ; White, RWD				Shi, X-B; Xue, L.; Ma, A-H; Tepper, C. G.; Gandour-Edwards, R.; Kung, H-J; White, R. W. deVere			Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen; androgen receptor; miRNA; tumor suppressor	GROUP PROTEIN I(Y); DNA METHYLATION; MICRORNA GENES; EXPRESSION; P53; HYPERMETHYLATION; CARCINOMA; APOPTOSIS; INTERACT; THERAPY	Although prostate cancer (CaP) is the most frequently diagnosed malignant tumor in American men, the mechanisms underlying the development and progression of CaP remain largely unknown. Recent studies have shown that downregulation of the microRNA miR-124 occurs in several types of human cancer, suggesting a tumor suppressive function of miR-124. Until now, however, it has been unclear whether miR-124 is associated with CaP. In the present study, we completed a series of experiments to understand the functional role of miR-124 in CaP. We detected the expression level of miR-124 in clinical CaP tissues, evaluated the influence of miR-124 on the growth of CaP cells and investigated the mechanism underlying the dysregulation of miR-124. We found that (i) miR-124 directly targets the androgen receptor (AR) and subsequently induces an upregulation of p53; (ii) miR-124 is significantly downregulated in malignant prostatic cells compared to benign cells, and DNA methylation causes the reduced expression of miR-124; and (iii) miR-124 can inhibit the growth of CaP cells in vitro and in vivo. Data from this study revealed that loss of miR-124 expression is a common event in CaP, which may contribute to the pathogenesis of CaP. Our studies also suggest that miR-124 is a potential tumor suppressive gene in CaP, and restoration of miR-124 expression may represent a novel strategy for CaP therapy.	[Shi, X-B; Xue, L.; White, R. W. deVere] Univ Calif Davis, Sch Med, Dept Urol, Sacramento, CA 95817 USA; [Ma, A-H; Tepper, C. G.; Kung, H-J] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Gandour-Edwards, R.] Univ Calif Davis, Sch Med, Dept Pathol, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	White, RWD (corresponding author), Univ Calif Davis, Sch Med, Dept Urol, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA.	rwdeverewhite@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013		NIH [1RO1CA136597]; Department of Defense [PCRP PC080488]; LANIE Foundation; NCI [CA136597]; DOD [PC080488]; NATIONAL CANCER INSTITUTE [P30CA093373, R01CA136597, R01CA165263, R01CA092069] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); LANIE Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NIH 1RO1CA136597 (R deVere White), Department of Defense PCRP PC080488 (R deVere White) and The LANIE Foundation. We thank Dr Mukta Webber for providing the RWPE-1 cell line and Dr Johng Rhim for the pRNS-1-1 cell line. We are also grateful to Dr Melanie C Bradnam for her editorial assistance and Stephanie Soares for critically reading the manuscript. This work was supported by NCI grant (no. CA136597) and DOD grant (no. PC080488).	Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Baroukh N, 2007, J BIOL CHEM, V282, P19575, DOI 10.1074/jbc.M611841200; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cao XW, 2007, GENE DEV, V21, P531, DOI 10.1101/gad.1519207; Chang BL, 2007, CANCER RES, V67, P4098, DOI 10.1158/0008-5472.CAN-06-4570; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; Davis BN, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-18; Frasca F, 2006, CANCER RES, V66, P2980, DOI 10.1158/0008-5472.CAN-05-2637; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Furuta M, CARCINOGENESIS, V31, P766; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; GRAFF JR, 1995, CANCER RES, V55, P5195; Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; Koivisto P, 1997, CANCER RES, V57, P314; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim JTE, 2005, P NATL ACAD SCI USA, V102, P5156, DOI 10.1073/pnas.0501203102; Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065; Lou W, 1999, CANCER RES, V59, P2329; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015; Matsuyama H, 2003, PROSTATE, V54, P103, DOI 10.1002/pros.10173; Mazar J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024922; Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421; Perinchery G, 1999, INT J ONCOL, V14, P495; Pierantoni GM, 2006, CELL DEATH DIFFER, V13, P1554, DOI 10.1038/sj.cdd.4401839; Qi J, CANC CELL, V18, P23; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162; Sadar MD, 2011, CANCER RES, V71, P1208, DOI 10.1158/0008-5472.CAN_10-3398; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Shi XB, 1996, DIAGN MOL PATHOL, V5, P271, DOI 10.1097/00019606-199612000-00008; Shi XB, 2008, J CELL MOL MED, V12, P1456, DOI 10.1111/j.1582-4934.2008.00420.x; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391; Takaha N, 2002, CANCER RES, V62, P647; TAMIMI Y, 1993, CANCER RES, V53, P5512; Tepper CG, 2002, CANCER RES, V62, P6606; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Walton TJ, 2008, PROSTATE, V68, P210, DOI 10.1002/pros.20673; White RD, 1997, EUR UROL, V31, P1; Woodson K, 2004, CANCER LETT, V205, P181, DOI 10.1016/j.canlet.2003.11.027; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yu XP, 2005, ANN NY ACAD SCI, V1061, P77, DOI 10.1196/annals.1336.009	54	134	147	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4130	4138		10.1038/onc.2012.425	http://dx.doi.org/10.1038/onc.2012.425			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23069658	hybrid, Green Accepted			2022-12-28	WOS:000323748500008
J	Boreddy, SR; Srivastava, SK				Boreddy, S. R.; Srivastava, S. K.			Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model	ONCOGENE			English	Article						NF kappa B; TGF-beta; RKIP; Snail; metastasis; apoptosis	NF-KAPPA-B; CANCER-CELLS; E-CADHERIN; TGF-BETA; SMAD PATHWAYS; AKT INHIBITOR; EXPRESSION; APOPTOSIS; KINASE; ACTIVATION	Deguelin is known to suppress the growth of cancer cells; however, its anti-metastatic effects have not been studied so far in any cancer model. In the present study, we aimed to evaluate the anti-metastatic potential of deguelin in vivo and in tumor growth factor-beta 1 (TGF beta 1)-stimulated cells. Our results demonstrate that tumor growth, peritoneal dissemination and liver/lung metastasis of orthotopically implanted PanC-1-luc cells were significantly reduced in deguelin-treated mice along with the induction of apoptosis. Furthermore, deguelin-treated tumors showed increased epithelial signature such as increased expression of E-Cadherin and cytokeratin-18 and decreased expression of Snail. Similar observations were made when PanC-1, COLO-357 and L3.6pl cells were treated in vitro with deguelin. Moreover, E-cadherin was transcriptionally upregulated and accumulated in the membrane fraction of deguelin-treated cells, as indicated by increased interaction of E-Cadherin with beta-catenin. TGF beta 1-induced downregulation of E-Cadherin and upregulation of Snail were abrogated by deguelin treatment. In addition, deguelin inhibited TGF beta 1-induced Smad3 phosphorylation and Smad4 nuclear translocation in PanC-1 cells. Furthermore, when TGF beta 1-induced nuclear factor kappa B (NF kappa B) activation was inhibited, TGF beta 1-induced Snail upregulation or E-Cadherin downregulation was blocked. Deguelin also significantly downregulated the constitutive phosphorylation and DNA binding of NF kappa B in a dose-dependent manner. Interestingly, overexpression of either NF kappa B or Snail completely abrogated deguelin-mediated epithelial-to-mesenchymal transition (EMT) inhibition, whereas overexpression of NF kappa B but not Snail rescued cells from deguelin-induced apoptosis. Hence, deguelin targets NF kappa B to induce reversal of EMT and apoptosis but downstream effectors might be different for both processes. Taken together, our results suggest that deguelin suppresses both pancreatic tumor growth and metastasis by inducing apoptosis and inhibiting EMT.	Texas Tech Univ, Hlth Sci Ctr, Dept Biomed Sci, Amarillo, TX 79106 USA; [Srivastava, S. K.] Texas Tech Univ, Hlth Sci Ctr, Canc Biol Ctr, Amarillo, TX 79106 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo	Srivastava, SK (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biomed Sci, ARB, 1406 Coulter,Suite 1103, Amarillo, TX 79106 USA.	Sanjay.Srivastava@ttuhsc.edu	Srivastava, Sanjay K./AAE-7635-2020		National Cancer Institute [CA106953, CA129038]; NATIONAL CANCER INSTITUTE [R01CA106953, R01CA129038] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to acknowledge National Cancer Institute for supporting the present study in part by R01 grants CA106953 and CA129038 (to SKS). The technical assistance of Kartick C Pramanik, Prabodh K Kandala and Parul Gupta in the in vivo experiment is greatly appreciated. We would also like to thank Dr Thomas L Brown (Wright State University, Dayton, OH, USA), Dr Ming H Wang (Texas Tech Health Sciences Center, Amarillo, TX, USA), Dr Fazlul H Sarkar (Wayne State University, Detroit, MI, USA), Dr Paul Chiao (MD Anderson Cancer Center, Houston, TX, USA), Dr Frank C Marini (MD Anderson Cancer Center, Houston, TX, USA) and Dr Ming-Sound Tsao (University of Toronto, Toronto, Ontario, Canada) for providing the cell lines.	Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158/0008-5472.CAN-09-4598; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Baritaki S, 2009, ONCOGENE, V28, P3573, DOI 10.1038/onc.2009.214; Batra S, 2010, MOL CANCER THER, V9, P1596, DOI 10.1158/1535-7163.MCT-09-1146; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Boreddy SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025799; Boreddy SR, 2011, CLIN CANCER RES, V17, P1784, DOI 10.1158/1078-0432.CCR-10-1891; Brinck U, 2004, ANTICANCER RES, V24, P2237; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cates JMM, 2009, PANCREAS, V38, pE1, DOI 10.1097/MPA.0b013e3181878b7f; Chen Y, 2009, INT J HEMATOL, V89, P618, DOI 10.1007/s12185-009-0307-4; Dell'Eva R, 2007, CARCINOGENESIS, V28, P404, DOI 10.1093/carcin/bgl162; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Ito S, 2010, LEUKEMIA RES, V34, P352, DOI 10.1016/j.leukres.2009.09.003; Javle MM, 2007, ANN SURG ONCOL, V14, P3527, DOI 10.1245/s10434-007-9540-3; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kandala PK, 2012, J BIOL CHEM, V287, P28745, DOI 10.1074/jbc.M112.351379; Kang HW, DIG DIS SCI; Lee HY, 2005, J NATL CANCER I, V97, P1695, DOI 10.1093/jnci/dji377; Lee H, 2010, ONCOL REP, V24, P957, DOI 10.3892/or_00000942; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Murillo G, 2002, EUR J CANCER, V38, P2446, DOI 10.1016/S0959-8049(02)00192-2; Murillo G, 2009, CANCER PREV RES, V2, P942, DOI 10.1158/1940-6207.CAPR-08-0232; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oh SH, 2007, J NATL CANCER I, V99, P949, DOI 10.1093/jnci/djm007; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Pramanik KC, ANTIOXID REDOX SIGNA; Sahu RP, 2009, JNCI-J NATL CANCER I, V101, P176, DOI 10.1093/jnci/djn470; Salahshor S, 2008, MODERN PATHOL, V21, P271, DOI 10.1038/modpathol.3800990; Shah AN, 2007, ANN SURG ONCOL, V14, P3629, DOI 10.1245/s10434-007-9583-5; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tang HH, 2010, FEBS LETT, V584, P662, DOI 10.1016/j.febslet.2009.12.051; Udeani GO, 2001, CANCER CHEMOTH PHARM, V47, P263, DOI 10.1007/s002800000187; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Weinel RJ, 1996, INT J PANCREATOL, V19, P25; Wu K, 2009, CRIT REV IMMUNOL, V29, P241, DOI 10.1615/CritRevImmunol.v29.i3.40; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yan Y, 2005, NEOPLASIA, V7, P1053, DOI 10.1593/neo.05532; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	47	55	60	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3980	3991		10.1038/onc.2012.413	http://dx.doi.org/10.1038/onc.2012.413			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22986522	Green Accepted			2022-12-28	WOS:000323748100006
J	Jones, RM; Mortusewicz, O; Afzal, I; Lorvellec, M; Garcia, P; Helleday, T; Petermann, E				Jones, R. M.; Mortusewicz, O.; Afzal, I.; Lorvellec, M.; Garcia, P.; Helleday, T.; Petermann, E.			Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress	ONCOGENE			English	Article						Cyclin E; replication fork; origin firing; DNA damage; homologous recombination	DNA-DAMAGE RESPONSE; ONCOGENE-INDUCED SENESCENCE; GENOMIC INSTABILITY; HUMAN-CELLS; S-PHASE; FORK PROGRESSION; MAMMALIAN-CELLS; ANTICANCER BARRIER; CANCER DEVELOPMENT; TUMOR SUPPRESSION	It has become increasingly clear that oncogenes not only provide aberrant growth signals to cells but also cause DNA damage at replication forks (replication stress), which activate the ataxia telangiectasia mutated (ATM)/p53-dependent tumor barrier. Here we studied underlying mechanisms of oncogene-induced replication stress in cells overexpressing the oncogene Cyclin E. Cyclin E overexpression is associated with increased firing of replication origins, impaired replication fork progression and DNA damage that activates RAD51-mediated recombination. By inhibiting replication initiation factors, we show that Cyclin E-induced replication slowing and DNA damage is a consequence of excessive origin firing. A significant amount of Cyclin E-induced replication slowing is due to interference between replication and transcription, which also underlies the activation of homologous recombination. Our data suggest that Cyclin E-induced replication stress is caused by deregulation of replication initiation and increased interference between replication and transcription, which results in impaired replication fork progression and DNA damage triggering the tumor barrier or cancer-promoting mutations.	[Jones, R. M.; Afzal, I.; Petermann, E.] Univ Birmingham, Inst Biomed Res, Coll Med & Dent Sci, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England; [Mortusewicz, O.] Univ Oxford, Dept Oncol, Gray Inst Radiat Oncol & Biol, Oxford, England; [Lorvellec, M.; Garcia, P.] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect, Birmingham B15 2TT, W Midlands, England; [Helleday, T.] Karolinska Inst, Dept Med Biochem & Biophys, Sci Life Lab, Div Translat Med & Chem Biol, S-17121 Stockholm, Sweden	University of Birmingham; University of Oxford; University of Birmingham; Karolinska Institutet	Helleday, T (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Sci Life Lab, Div Translat Med & Chem Biol, S-17121 Stockholm, Sweden.	thomas.helleday@scilifelab.se; e.petermann@bham.ac.uk	Petermann, Eva/AAR-3368-2021; Garcia, Paloma/AFO-2595-2022	Petermann, Eva/0000-0002-5746-213X; Helleday, Thomas/0000-0002-7384-092X; Jones, Rebecca M/0000-0002-5310-8475; Garcia, Paloma/0000-0001-5582-8575; Lorvellec, Maelle/0000-0002-7566-1415	EMBO; Cancer Research UK	EMBO(European Molecular Biology Organization (EMBO)); Cancer Research UK(Cancer Research UK)	OM is supported by an EMBO Long-Term Fellowship. We thank Cancer Research UK for supporting this work financially, Dr Anastasia Zlatanou for cells and materials and Dr Agnieszka Gambus for helpful discussions.	Akli S, 2007, CANCER RES, V67, P7212, DOI 10.1158/0008-5472.CAN-07-0599; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Dereli-Oz A, 2011, MOL ONCOL, V5, P308, DOI 10.1016/j.molonc.2011.05.002; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Fang Y, 2004, EMBO J, V23, P3164, DOI 10.1038/sj.emboj.7600315; Gan WJ, 2011, GENE DEV, V25, P2041, DOI 10.1101/gad.17010011; Garcia P, 2000, ONCOGENE, V19, P1820, DOI 10.1038/sj.onc.1203494; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Gilbert DM, 2007, CHROMOSOMA, V116, P341, DOI 10.1007/s00412-007-0105-9; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gottipati P, 2008, MOL CELL BIOL, V28, P154, DOI 10.1128/MCB.00816-07; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; JACKSON DA, 1995, EXP CELL RES, V220, P62, DOI 10.1006/excr.1995.1292; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Kawabata T, 2011, MOL CELL, V41, P543, DOI 10.1016/j.molcel.2011.02.006; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Lorvellec M, 2010, STEM CELLS, V28, P1751, DOI 10.1002/stem.496; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mechali M, 2010, NAT REV MOL CELL BIO, V11, P728, DOI 10.1038/nrm2976; Montagnoli A, 2008, NAT CHEM BIOL, V4, P357, DOI 10.1038/nchembio.90; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Nimonkar AV, 2011, GENE DEV, V25, P350, DOI 10.1101/gad.2003811; Petermann E, 2006, MOL CELL BIOL, V26, P3319, DOI 10.1128/MCB.26.8.3319-3326.2006; Petermann E, 2010, P NATL ACAD SCI USA, V107, P16090, DOI 10.1073/pnas.1005031107; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Sorensen CS, 2004, CELL CYCLE, V3, P941; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Thomson AM, 2010, J CELL BIOL, V188, P209, DOI 10.1083/jcb.200911037; Tuduri S, 2010, CELL CYCLE, V9, P1886, DOI 10.4161/cc.9.10.11539; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Zlatanou A, 2011, MOL CELL, V43, P649, DOI 10.1016/j.molcel.2011.06.023	50	156	156	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3744	3753		10.1038/onc.2012.387	http://dx.doi.org/10.1038/onc.2012.387			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22945645				2022-12-28	WOS:000322904400009
J	Kalari, S; Jung, M; Kernstine, KH; Takahashi, T; Pfeifer, GP				Kalari, S.; Jung, M.; Kernstine, K. H.; Takahashi, T.; Pfeifer, G. P.			The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells	ONCOGENE			English	Article						DNA methylation; small cell lung cancer; differentiation; epigenetics	TUMOR-SUPPRESSOR GENE; CPG ISLAND; EPIGENETIC INACTIVATION; MOLECULAR-GENETICS; EXPRESSION; FAMILY; IDENTIFICATION; AMPLIFICATION; HYPERMETHYLATION; NEUROBLASTOMA	Small cell lung cancer (SCLC) is a disease characterized by aggressive clinical behavior and lack of effective therapy. Owing to its tendency for early dissemination, only a third of patients have limited-stage disease at the time of diagnosis. SCLC is thought to derive from pulmonary neuroendocrine cells. Although several molecular abnormalities in SCLC have been described, there are relatively few studies on epigenetic alterations in this type of tumor. Here, we have used methylation profiling with the methylated-CpG island recovery assay in combination with microarrays and conducted the first genome-scale analysis of methylation changes that occur in primary SCLC and SCLC cell lines. Among the hundreds of tumor-specifically methylated genes discovered, we identified 73 gene targets that are methylated in >77% of primary SCLC tumors, most of which have never been linked to aberrant methylation in tumors. These methylated targets have potential for biomarker development for early detection and therapeutic management of SCLC. SCLC cell lines had a greater number of hypermethylated genes than primary tumors. Gene ontology analysis indicated a significant enrichment of methylated genes functioning as transcription factors and in processes of neuronal differentiation. Motif analysis of tumor-specific methylated regions identified enrichment of binding sites for several neural cell fate-specifying transcription factors including NEUROD1, HAND1, ZNF423 and REST. We hypothesize that two potential mechanisms, loss of cell fate-determining transcription factors by methylation of their promoters and functional inactivation of their corresponding genomic-binding sites by DNA methylation, can promote a differentiation defect of neuroendocrine cells thus enhancing the ability of tumor progenitor cells to transition toward SCLC.	[Kalari, S.; Jung, M.; Pfeifer, G. P.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [Kernstine, K. H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Surg, Duarte, CA 91010 USA; [Takahashi, T.] Nagoya Univ, Grad Sch Med, Div Mol Carcinogenesis, Nagoya, Aichi 4648601, Japan	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Nagoya University	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA.	gpfeifer@coh.org	Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001	National Institutes of Health grant [CA084469]; NATIONAL CANCER INSTITUTE [R01CA084469] Funding Source: NIH RePORTER	National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Steven Bates for culturing SCLC cell lines. This work was supported by the National Institutes of Health grant CA084469 to GPP and by generous funds from an anonymous donor.	Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032; Coulson JM, 2000, CANCER RES, V60, P1840; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Fischer B, 2007, CANCER TREAT REV, V33, P391, DOI 10.1016/j.ctrv.2007.01.006; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Hahn MA, 2008, CANCER RES, V68, P10280, DOI 10.1158/0008-5472.CAN-08-1957; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Holzel M, 2010, CELL, V142, P218, DOI 10.1016/j.cell.2010.06.004; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; Kalari S, 2010, ADV GENET, V70, P277, DOI [10.1016/B978-0-12-380866-0.60010-1, 10.1016/S0065-2660(10)70010-9]; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Kreisler A, 2010, ONCOGENE, V29, P5828, DOI 10.1038/onc.2010.321; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lee NH, 2007, HYPERTENSION, V50, P1126, DOI 10.1161/HYPERTENSIONAHA.107.093138; Lerman MI, 2000, CANCER RES, V60, P6116; Linhart C, 2008, GENOME RES, V18, P1180, DOI 10.1101/gr.076117.108; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Majumder S, 2006, CELL CYCLE, V5, P1929, DOI 10.4161/cc.5.17.2982; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Modi S, 2000, ONCOGENE, V19, P4632, DOI 10.1038/sj.onc.1203815; Neptune ER, 2008, J BIOL CHEM, V283, P21160, DOI 10.1074/jbc.M708692200; Park KS, 2011, CELL CYCLE, V10, P2806, DOI 10.4161/cc.10.16.17012; Piper M, 2010, J NEUROSCI, V30, P9127, DOI 10.1523/JNEUROSCI.6167-09.2010; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Qureshi IA, 2010, CELL CYCLE, V9, P4477, DOI 10.4161/cc.9.22.13973; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105; Rauch TA, 2010, METHODS, V52, P213, DOI 10.1016/j.ymeth.2010.03.004; Rauch Tibor A., 2009, V507, P65, DOI 10.1007/978-1-59745-522-0_6; Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Sattler M, 2003, SEMIN ONCOL, V30, P57, DOI 10.1053/sonc.2003.50019; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941; SUTHERLAND K, 2011, TLS TIMES LIT S 0422, P19; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; TAKAHASHI T, 1989, CANCER RES, V49, P2683; Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109; Toedling J, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-221; Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Warming S, 2006, MOL CELL BIOL, V26, P6913, DOI 10.1128/MCB.02255-05; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wu XW, 2010, CANCER RES, V70, P2718, DOI 10.1158/0008-5472.CAN-09-3631; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	55	48	48	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3559	3568		10.1038/onc.2012.362	http://dx.doi.org/10.1038/onc.2012.362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22907430	Green Accepted			2022-12-28	WOS:000322220800009
J	Lu, X; Liu, DP; Xu, Y				Lu, X.; Liu, D. P.; Xu, Y.			The gain of function of p53 cancer mutant in promoting mammary tumorigenesis	ONCOGENE			English	Article						p53 mutant; gain of function; genetic instability	BREAST-CANCER; GENETIC INSTABILITY; EPITHELIAL-CELLS; TRANSGENIC MICE; MOUSE MODEL; DNA-DAMAGE; STEM-CELL; ATM; CARCINOGENESIS; PROTEIN	Tumor suppressor p53 is critical for suppressing all types of human cancers, including breast cancer. The p53 gene is somatically mutated in over half of all human cancers. The majority of the p53 mutations are missense mutations, leading to the expression of the full-length p53 mutants. Several hotspot mutations, including R175H, are frequently detected in human breast cancer. P53 cancer mutants not only lose tumor suppression activity but, more problematically, also gain new oncogenic activities. Despite correlation of the expression of p53 cancer mutants and the poor prognosis of human breast cancer patients, the roles of p53 cancer mutants in promoting breast cancer remain unclear. We used the humanized p53 cancer mutant knock-in (R175H) mice and mouse mammary tumor virus (MMTV)-Wnt-1 transgenic (mWnt-1) mice to specifically address the gain of function of R175H in promoting breast cancer. Although both R175H/R175HmWnt-1(R175HmWnt-1) and p53(-/-) mWnt-1 mice died from mammary tumor at the same kinetics, which was much earlier than mWnt-1 mice, most of the R175HmWnt-1 mice developed multiple mammary tumors per mouse, whereas p53(-/-) mWnt-1 and mWnt-1 mice mostly developed one tumor per mouse. The multiple mammary tumors arose in the same R175HmWnt-1 mouse exhibited different histological characters. Moreover, R175H gain-of-function mutant expands the mammary epithelial stem cells (MESCs) that give rise to the mammary tumors. As ATM suppresses the expansion of MESCs, the inactivation of ATM by R175H in mammary epithelial cells (MECs) could contribute to the expansion of MESCs in R175HmWnt-1 mice. These findings provide the basis for R175H to promote the initiation of breast cancer by expanding MESCs.	[Lu, X.; Liu, D. P.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X	NIH [R01 CA94254]; DOD Breast Cancer Research Program [W81XWH-08-1-0381]; NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Breast Cancer Research Program(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Yi Li for the MMTV-Wnt-1 mice. This work was supported by grants from the NIH (R01 CA94254) and DOD Breast Cancer Research Program (W81XWH-08-1-0381) to YX.	Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Bowen TJ, 2005, CANCER RES, V65, P8736, DOI 10.1158/0008-5472.CAN-05-1598; Cabioglu N, 2009, J AM COLL SURGEONS, V208, P67, DOI 10.1016/j.jamcollsurg.2008.09.001; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; Gallagher WM, 1999, ONCOGENE, V18, P3608, DOI 10.1038/sj.onc.1202937; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Haupt S, 2009, CANCER RES, V69, P4818, DOI 10.1158/0008-5472.CAN-08-4010; Hussain SP, 2000, MUTAT RES-REV MUTAT, V462, P311, DOI 10.1016/S1383-5742(00)00015-6; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kalo E, 2007, MOL CELL BIOL, V27, P8228, DOI 10.1128/MCB.00374-07; Kitamura T, 2009, CANCER RES, V69, P7681, DOI 10.1158/0008-5472.CAN-09-2133; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Lin SCJ, 2004, CANCER RES, V64, P3525, DOI 10.1158/0008-5472.CAN-03-3524; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Lu S, 2006, CARCINOGENESIS, V27, P848, DOI 10.1093/carcin/bgi302; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Reddy JP, 2010, P NATL ACAD SCI USA, V107, P3728, DOI 10.1073/pnas.0910665107; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978-1-59745-019-5_11; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531; Weissenbacher TM, 2010, BREAST CANCER RES TR, V122, P27, DOI 10.1007/s10549-010-0917-9; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Xu Y, 2006, NAT REV IMMUNOL, V6, P261, DOI 10.1038/nri1804	36	34	35	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2013	32	23					2900	2906		10.1038/onc.2012.299	http://dx.doi.org/10.1038/onc.2012.299			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22824795	Green Accepted			2022-12-28	WOS:000320369100010
J	Chevet, E; Fessart, D; Delom, F; Mulot, A; Vojtesek, B; Hrstka, R; Murray, E; Gray, T; Hupp, T				Chevet, E.; Fessart, D.; Delom, F.; Mulot, A.; Vojtesek, B.; Hrstka, R.; Murray, E.; Gray, T.; Hupp, T.			Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development	ONCOGENE			English	Review						AGR2; PDI; endoplasmic reticulum; secretome; p53; tumour	ENDOPLASMIC-RETICULUM PROTEIN; XENOPUS CEMENT GLAND; ESTROGEN-RECEPTOR; PANCREATIC-CANCER; OVARIAN-CANCER; HIPPO PATHWAY; HUMAN HOMOLOG; PDI FAMILY; CYCLIN D1; AGR2	Clinical studies have defined the core 'genetic blueprint' of a cancer cell, but this information does not necessarily predict the cancer phenotype. Signalling hubs that mediate such phenotype have been identified largely using OMICS platforms that measure dynamic molecular changes within the cancer cell landscape. The pro-oncogenic protein anterior gradient 2 (AGR2) is a case in point; AGR2 has been shown using a range of expression platforms to be involved in asthma, inflammatory bowel disease, cell transformation, cancer drug resistance and metastatic growth. AGR2 protein is also highly overexpressed in a diverse range of human cancers and can be secreted and detected in extracellular fluids, thus representing a compelling pro-oncogenic signalling intermediate in human cancer. AGR2 belongs to the protein disulphide isomerase family with all the key features of an endoplasmic reticulum-resident protein-this gives clues into how it might function as an oncoprotein through the regulation of protein folding, maturation and secretion that can drive metastatic cell growth. In this review, we will describe the known aspects of AGR2 molecular biology, including gene structure and regulation, emerging protein interaction networks and how its subcellular localization mediates its biological functions. We will finally review the cases of AGR2 expression in human cancers, the pathophysiological consequences of AGR2 overexpression, its potential role as a tumour biomarker that predicts the response to therapy and how the AGR2 pathway might form the basis for drug discovery programmes aimed at targeting protein folding/maturation pathways that mediate secretion and metastasis.	[Chevet, E.; Mulot, A.] INSERM, U1053, Bordeaux, France; [Chevet, E.; Mulot, A.] Univ Bordeaux Segalen, Bordeaux, France; [Fessart, D.; Delom, F.] Univ Bordeaux Segalen, Ctr Rech Cardiothorac Bordeaux, Bordeaux, France; [Fessart, D.; Delom, F.] INSERM, Ctr Rech Cardiothorac Bordeaux, Bordeaux, France; [Vojtesek, B.; Hrstka, R.; Murray, E.] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Brno, Czech Republic; [Murray, E.; Gray, T.; Hupp, T.] Univ Edinburgh, Canc Res Ctr, Inst Genet & Mol Med, Signal Transduct Labs P53, Edinburgh, Midlothian, Scotland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); Masaryk Memorial Cancer Institute; University of Edinburgh	Chevet, E (corresponding author), INSERM, U1053, Bordeaux, France.	eric.chevet@inserm.fr; vojtesek@mou.cz; ted.hupp@ed.ac.uk	chevet, eric/E-4992-2016; Delom, Frederic/J-2782-2014; FESSART, Delphine/J-2784-2014; Hrstka, Roman/AAM-4430-2020	chevet, eric/0000-0001-5855-4522; Delom, Frederic/0000-0002-4600-7633; FESSART, Delphine/0000-0001-7566-5670; Hrstka, Roman/0000-0002-6139-2664	INSERM; INCa; Ligue contre le Cancer; Association pour la Recherche sur le Cancer; Chaire mixte Inserm-Univ. Bordeaux; GACR [P301/10/1615]; IGA MZ CR [NT/13794-4/2012]; European Regional Development Fund [RECAMO CZ.1.05/2.1.00/03.0101]; Cancer Research UK; MRC; BBSRC	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); INCa(Institut National du Cancer (INCA) France); Ligue contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Chaire mixte Inserm-Univ. Bordeaux; GACR(Grant Agency of the Czech Republic); IGA MZ CR; European Regional Development Fund(European Commission); Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We apologize to authors whose work has not been cited here owing to space limitations. This work was supported by grants from INSERM, INCa, Ligue contre le Cancer, Association pour la Recherche sur le Cancer (EC), Ligue contre le Cancer and a Chaire mixte Inserm-Univ. Bordeaux (FD), GACR number P301/10/1615 (RH), IGA MZ CR number NT/13794-4/2012 (BV) and by the European Regional Development Fund (RECAMO CZ.1.05/2.1.00/03.0101) (BV, RH, EM), and Cancer Research UK, MRC and BBSRC (TH).	Aberger F, 1998, MECH DEVELOP, V72, P115, DOI 10.1016/S0925-4773(98)00021-5; Adam GC, 2002, MOL CELL PROTEOMICS, V1, P828, DOI 10.1074/mcp.T200007-MCP200; Adam GC, 2002, NAT BIOTECHNOL, V20, P805, DOI 10.1038/nbt714; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Bambang IF, 2013, ONCOGENE, V32, P1240, DOI 10.1038/onc.2012.149; Benham AM, 2012, ANTIOXID REDOX SIGN, V16, P781, DOI 10.1089/ars.2011.4439; Bradley L, 1996, DEVELOPMENT, V122, P2739; Bu HJ, 2011, PROSTATE, V71, P575, DOI 10.1002/pros.21273; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; Clarke DJ, 2011, J AM SOC MASS SPECTR, V22, P1432, DOI 10.1007/s13361-011-0155-3; Dong AW, 2011, J BIOL CHEM, V286, P18301, DOI 10.1074/jbc.M110.215707; Dumartin L, 2011, CANCER RES, V71, P7091, DOI 10.1158/0008-5472.CAN-11-1367; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fourtouna A, 2009, CURR CHEM BIOL, V3, P124; Fraser JA, 2010, J BIOL CHEM, V285, P37762, DOI 10.1074/jbc.M110.143099; Gray TA, 2012, J IMMUNOL METHODS, V378, P20, DOI 10.1016/j.jim.2012.01.013; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Gupta A, 2012, J BIOL CHEM, V287, P4773, DOI 10.1074/jbc.M111.301531; Hengel SM, 2011, J PROTEOME RES, V10, P4567, DOI 10.1021/pr2004117; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Hrstka R, 2010, ONCOGENE, V29, P4838, DOI 10.1038/onc.2010.228; Jessop CE, 2009, J CELL SCI, V122, P4287, DOI 10.1242/jcs.059154; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; Komiya T, 1999, BBA-GENE STRUCT EXPR, V1444, P434, DOI 10.1016/S0167-4781(99)00010-X; Komuta M, 2012, HEPATOLOGY, V55, P1876, DOI 10.1002/hep.25595; Kozlov G, 2010, FEBS J, V277, P3924, DOI 10.1111/j.1742-4658.2010.07793.x; Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200; Kumar A, 2007, SCIENCE, V318, P772, DOI 10.1126/science.1147710; Lepreux S, 2011, LIVER INT, V31, P322, DOI 10.1111/j.1478-3231.2010.02438.x; Li SR, 2012, DEVELOPMENT, V139, P2500, DOI 10.1242/dev.079699; Liu D, 2005, CANCER RES, V65, P3796, DOI 10.1158/0008-5472.CAN-04-3823; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Maslon MM, 2010, J MOL BIOL, V404, P418, DOI 10.1016/j.jmb.2010.09.035; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Norgaard P, 2001, BIOCHEM J, V358, P269, DOI 10.1042/0264-6021:3580269; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67; Park K, 2011, EXP MOL MED, V43, P91, DOI 10.3858/emm.2011.43.2.011; Park SW, 2009, P NATL ACAD SCI USA, V106, P6950, DOI 10.1073/pnas.0808722106; Persson S, 2005, MOL PHYLOGENET EVOL, V36, P734, DOI 10.1016/j.ympev.2005.04.002; Petek E, 2000, CYTOGENET CELL GENET, V89, P141, DOI 10.1159/000015594; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; Raykhel I, 2007, J CELL BIOL, V179, P1193, DOI 10.1083/jcb.200705180; Schroeder BW, 2012, AM J RESP CELL MOL, V47, P178, DOI 10.1165/rcmb.2011-0421OC; Sive H, 1996, DEV DYNAM, V205, P265, DOI 10.1002/(SICI)1097-0177(199603)205:3<265::AID-AJA7>3.0.CO;2-G; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Sweeny L, 2012, EXP CELL RES, V318, P1788, DOI 10.1016/j.yexcr.2012.04.022; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson DA, 1997, J STEROID BIOCHEM, V62, P143, DOI 10.1016/S0960-0760(97)00029-0; Thompson DA, 1998, BIOCHEM BIOPH RES CO, V251, P111, DOI 10.1006/bbrc.1998.9440; Tian CH, 2008, CELL RES, V18, P458, DOI 10.1038/cr.2007.112; Vanderlaag KE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2586; Varghese S, 2012, GASTROENTEROLOGY, V142, P435, DOI 10.1053/j.gastro.2012.01.013; Vendrell JA, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2158; Vivekanandan P, 2009, HUM PATHOL, V40, P293, DOI 10.1016/j.humpath.2008.08.003; Wang X, 2011, CELL, V145, P1023, DOI 10.1016/j.cell.2011.05.026; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Wilson CL, 2006, ENDOCR-RELAT CANCER, V13, P617, DOI 10.1677/erc.1.01165; Worrall Erin G, 2009, J Chem Biol, V2, P113, DOI 10.1007/s12154-009-0019-5; Worralll EG, 2010, J MOL BIOL, V398, P414, DOI 10.1016/j.jmb.2010.03.023; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang JS, 2005, GENE CHROMOSOME CANC, V43, P249, DOI 10.1002/gcc.20188; Zhang YX, 2010, CANCER RES, V70, P240, DOI 10.1158/0008-5472.CAN-09-2904; Zhao F, 2010, DEV BIOL, V338, P268, DOI 10.1016/j.ydbio.2009.12.008; Zheng W, 2006, GENES IMMUN, V7, P11, DOI 10.1038/sj.gene.6364263; Zweitzig DR, 2007, MOL CELL BIOCHEM, V306, P255, DOI 10.1007/s11010-007-9562-y	78	104	106	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2499	2509		10.1038/onc.2012.346	http://dx.doi.org/10.1038/onc.2012.346			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22945652				2022-12-28	WOS:000319274300001
J	Garcia, I; Crowther, AJ; Gama, V; Miller, CR; Deshmukh, M; Gershon, TR				Garcia, I.; Crowther, A. J.; Gama, V.; Miller, C. Ryan; Deshmukh, M.; Gershon, T. R.			Bax deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation	ONCOGENE			English	Article						Bax; CGNPs; cerebellar neurogenesis; medulloblastoma; SmoA1 transgenic mouse	PROGRAMMED CELL-DEATH; KNOCK-OUT MICE; SONIC HEDGEHOG; NERVOUS-SYSTEM; POSTNATAL-DEVELOPMENT; TUMOR SUPPRESSORS; GRANULE CELLS; BCL-2 FAMILY; MOUSE MODEL; DAP-KINASE	Neurogenesis requires negative regulation through differentiation of progenitors or their programmed cell death (PCD). Growth regulation is particularly important in the postnatal cerebellum, where excessive progenitor proliferation promotes medulloblastoma, the most common malignant brain tumor in children. We present evidence that PCD operates alongside differentiation to regulate cerebellar granule neuron progenitors (CGNPs) and to prevent medulloblastoma. Here, we show that genetic deletion of pro-apoptotic Bax disrupts regulation of cerebellar neurogenesis and promotes medulloblastoma formation. In Bax(-/-) mice, the period of neurogenesis was extended into the third week of postnatal life, and ectopic neurons and progenitors collected in the molecular layer of the cerebellum and adjacent tectum. Importantly, genetic deletion of Bax in medulloblastoma-prone ND2:SmoA1 transgenic mice greatly accelerated tumorigenesis. Bax-deficient medulloblastomas exhibited strikingly distinct pathology, with reduced apoptosis, increased neural differentiation and tectal migration. Comparing Bax(-/-) and Bax(-/-) medulloblastomas, we were able to identify upregulation of Bcl-2 and nuclear exclusion of p27 as tumorigenic changes that are required to mitigate the tumor suppressive effect of Bax. Studies on human tumors confirmed the importance of modulating Bax in medulloblastoma pathogenesis. Our results demonstrate that Bax-dependent apoptosis regulates postnatal cerebellar neurogenesis, suppresses medulloblastoma formation and imposes selective pressure on tumors that form. Functional resistance to Bax-mediated apoptosis, required for medulloblastoma tumorigenesis, may be a tumor-specific vulnerability to be exploited for therapeutic benefit.	[Garcia, I.; Crowther, A. J.; Miller, C. Ryan; Gershon, T. R.] Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA; [Gama, V.; Deshmukh, M.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; [Miller, C. Ryan] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Div Neuropathol, Chapel Hill, NC 27599 USA; [Miller, C. Ryan; Deshmukh, M.; Gershon, T. R.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Miller, C. Ryan; Deshmukh, M.; Gershon, T. R.] Univ N Carolina, Sch Med, Ctr Neurosci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Gershon, TR (corresponding author), Univ N Carolina, Sch Med, Dept Neurol, 170 Manning Dr CB7025, Chapel Hill, NC 27599 USA.	gershont@neurology.unc.edu	, Pathology Services Core/CEZ-2246-2022; Gershon, Timothy/H-5398-2019; Miller, Ryan/B-9365-2008	Gershon, Timothy/0000-0001-7034-6400; Miller, Ryan/0000-0002-0096-8762; Crowther, Andrew/0000-0001-9269-6188; Gama, Vivian/0000-0002-1201-1394	National Cancer Institute [3P30CA016086]; National Institute of Environmental Health Sciences [3P30ES010126]; Department of Defense [W81XWH-09-2-0042]; UNC University Cancer Research Fund (UCRF); Clinical Investigator award from the Damon Runyon Cancer Research Foundation [CI-45-09]; St Baldrick's Foundation; Morgan Adams Foundation; Matthew Larson Brain Tumor Foundation; NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS077978] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Department of Defense(United States Department of Defense); UNC University Cancer Research Fund (UCRF); Clinical Investigator award from the Damon Runyon Cancer Research Foundation; St Baldrick's Foundation; Morgan Adams Foundation; Matthew Larson Brain Tumor Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank James Olson, Fred Hutchinson Cancer Research Center for generously sharing ND2:SmoA1 mice; and Mervi Eeva, Jackie Kylander and Stephanie Cohen in the UNC Translational Pathology Laboratory (TPL) for expert technical assistance. The UNC TPL is supported, in part, by grants from the National Cancer Institute (3P30CA016086), National Institute of Environmental Health Sciences (3P30ES010126), Department of Defense (W81XWH-09-2-0042), and the UNC University Cancer Research Fund (UCRF). CRM is supported in part by a Clinical Investigator award from the Damon Runyon Cancer Research Foundation (CI-45-09). TRG is supported by a Scholar Award from the St Baldrick's Foundation. Major portions of this work were supported by the Morgan Adams Foundation and the Matthew Larson Brain Tumor Foundation.	Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Ayrault O, 2009, MOL CANCER RES, V7, P33, DOI 10.1158/1541-7786.MCR-08-0369; Bhatia B, 2010, CELL CYCLE, V9, P4307, DOI 10.4161/cc.9.21.13441; Bolduc ME, 2011, DEV MED CHILD NEUROL, V53, P409, DOI 10.1111/j.1469-8749.2011.03929.x; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Dicou E, 2009, INT J DEV NEUROSCI, V27, P299, DOI 10.1016/j.ijdevneu.2009.02.005; Fan HB, 2001, J COMP NEUROL, V436, P82; Gershon TR, 2006, CURR NEUROL NEUROSCI, V6, P200, DOI 10.1007/s11910-006-0006-y; Gershon TR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007491; Guenebeaud C, 2010, MOL CELL, V40, P863, DOI 10.1016/j.molcel.2010.11.021; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; Heine VM, 2009, J CLIN INVEST, V119, P267, DOI 10.1172/JCI36376; Jung AR, 2008, J NEUROSCI, V28, P2941, DOI 10.1523/JNEUROSCI.3897-07.2008; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kessler JD, 2009, GENE DEV, V23, P157, DOI 10.1101/gad.1759909; Kim WR, 2007, J NEUROSCI, V27, P14392, DOI 10.1523/JNEUROSCI.3903-07.2007; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lindsten T, 2005, NEUROSCIENTIST, V11, P10, DOI 10.1177/1073858404269267; Lindsten T, 2003, J NEUROSCI, V23, P11112; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; Machold R, 2005, NEURON, V48, P17, DOI 10.1016/j.neuron.2005.08.028; Matei V, 2005, DEV DYNAM, V234, P633, DOI 10.1002/dvdy.20551; Noguchi KK, 2008, CELL DEATH DIFFER, V15, P1582, DOI 10.1038/cdd.2008.97; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Packer RJ, 2008, J CHILD NEUROL, V23, P1122, DOI 10.1177/0883073808320758; Parathath SR, 2010, CELL CYCLE, V9, P4013, DOI 10.4161/cc.9.19.13325; Pfaff E, 2010, J CLIN ONCOL, V28, P5188, DOI 10.1200/JCO.2010.31.1670; Preusser M, 2011, ANN NEUROL, V70, P9, DOI 10.1002/ana.22425; Sato T, 2008, MOL CELL NEUROSCI, V39, P569, DOI 10.1016/j.mcn.2008.08.003; Tanaka S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005922; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Valerie AW, 1999, CURR BIOL, V9, P445; Wang H, 2008, BIOCHEM BIOPH RES CO, V370, P594, DOI 10.1016/j.bbrc.2008.03.152; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0	39	20	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2304	2314		10.1038/onc.2012.248	http://dx.doi.org/10.1038/onc.2012.248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22710714	Green Submitted, Green Accepted			2022-12-28	WOS:000318683600007
J	Kallunki, T; Olsen, OD; Jaattela, M				Kallunki, T.; Olsen, O. D.; Jaattela, M.			Cancer-associated lysosomal changes: friends or foes?	ONCOGENE			English	Review						Lysosome; Cancer; metastasis; cell death	HUMAN CATHEPSIN-B; EXTRACELLULAR-MATRIX PROTEINS; HEPARANASE INHIBITOR PI-88; PROTON PUMP INHIBITORS; VACUOLAR H+-ATPASE; BREAST-CANCER; CYSTEINE CATHEPSINS; ACID SPHINGOMYELINASE; CELL-DEATH; V-ATPASES	Rapidly dividing and invasive cancer cells are strongly dependent on effective lysosomal function. Accordingly, transformation and cancer progression are characterized by dramatic changes in lysosomal volume, composition and cellular distribution. Depending on one's point of view, the cancer-associated changes in the lysosomal compartment can be regarded as friends or foes. Most of them are clearly transforming as they promote invasive growth, angiogenesis and drug resistance. The same changes can, however, strongly sensitize cells to lysosomal membrane permeabilization and thereby to lysosome-targeting anti-cancer drugs. In this review we compile our current knowledge on cancer-associated changes in lysosomal composition and discuss the consequences of these alterations to cancer progression and the possibilities they can bring to cancer therapy. Oncogene (2013) 32, 1995-2004; doi:10.1038/onc.2012.292; published online 9 July 2012	[Jaattela, M.] Danish Canc Soc, Res Ctr, DK-2100 Copenhagen, Denmark; [Jaattela, M.] Danish Canc Soc, Res Ctr, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Danish Cancer Society	Jaattela, M (corresponding author), Danish Canc Soc, Res Ctr, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	mj@cancer.dk	Jäättelä, Marja/AAT-7932-2021	Jäättelä, Marja/0000-0001-5950-7111; Kallunki, Tuula/0000-0002-8571-383X	Danish Cancer Society; Danish Medical Research Council; Danish National Research Foundation; European Commission FP7 APO-SYS network; Association for International Cancer Research; Meyer Foundation; Lundbeck Foundation; Novo Nordisk Foundation; Worldwide Cancer Research [11-0226] Funding Source: researchfish	Danish Cancer Society(Danish Cancer Society); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish National Research Foundation(Danmarks Grundforskningsfond); European Commission FP7 APO-SYS network; Association for International Cancer Research; Meyer Foundation; Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Worldwide Cancer Research	The authors' own work has been supported by grants from the Danish Cancer Society, the Danish Medical Research Council, the Danish National Research Foundation, the European Commission FP7 APO-SYS network, the Association for International Cancer Research, the Meyer Foundation, the Lundbeck Foundation and the Novo Nordisk Foundation.	Abboud-Jarrous G, 2008, J BIOL CHEM, V283, P18167, DOI 10.1074/jbc.M801327200; Adams-Cioaba MA, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1204; Al-Shamahi A, 2009, IDRUGS, V12, P799; Basche M, 2006, CLIN CANCER RES, V12, P5471, DOI 10.1158/1078-0432.CCR-05-2423; Beckham TH, 2012, INT J CANCER, V131, P2034, DOI 10.1002/ijc.27480; Benavides F, 2012, MOL CARCINOGEN, V51, P352, DOI 10.1002/mc.20792; Benes P, 2008, CRIT REV ONCOL HEMAT, V68, P12, DOI 10.1016/j.critrevonc.2008.02.008; Benes P, 2006, CANCER LETT, V239, P46, DOI 10.1016/j.canlet.2005.07.030; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Boudreau F, 2007, FASEB J, V21, P3853, DOI 10.1096/fj.07-8113com; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Braulke T, 2009, BBA-MOL CELL RES, V1793, P605, DOI 10.1016/j.bbamcr.2008.10.016; Brubaker KD, 2003, J BONE MINER RES, V18, P222, DOI 10.1359/jbmr.2003.18.2.222; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; Canals D, 2011, BRIT J PHARMACOL, V163, P694, DOI 10.1111/j.1476-5381.2011.01279.x; Carpinteiro A, 2008, CANCER LETT, V264, P1, DOI 10.1016/j.canlet.2008.02.020; Ceru S, 2010, J BIOL CHEM, V285, P10078, DOI 10.1074/jbc.M109.034793; Corvo I, 2009, MOL BIOCHEM PARASIT, V167, P41, DOI 10.1016/j.molbiopara.2009.04.005; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Davidson D, 2007, GYNECOL ONCOL, V104, P311, DOI 10.1016/j.ygyno.2006.08.045; De Milito A, 2010, INT J CANCER, V127, P207, DOI 10.1002/ijc.25009; Dennemarker J, 2010, ONCOGENE, V29, P1611, DOI 10.1038/onc.2009.466; Dredge K, 2011, BRIT J CANCER, V104, P635, DOI 10.1038/bjc.2011.11; Dumitru CA, 2006, ONCOGENE, V25, P5612, DOI 10.1038/sj.onc.1209568; Duncan EM, 2008, CELL, V135, P284, DOI 10.1016/j.cell.2008.09.055; Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Fehrenbacher N, 2008, CANCER RES, V68, P6623, DOI 10.1158/0008-5472.CAN-08-0463; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Gerasimenko JV, 2001, CURR BIOL, V11, pR971, DOI 10.1016/S0960-9822(01)00577-2; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Gocheva V, 2010, BIOL CHEM, V391, P937, DOI 10.1515/BC.2010.080; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Grabowska UB, 2005, CURR OPIN DRUG DISC, V8, P619; Groth-Pedersen L, CANC LETT; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hantschel M, 2000, CELL STRESS CHAPERON, V5, P438, DOI 10.1379/1466-1268(2000)005<0438:HPMEOP>2.0.CO;2; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Hernandez A, 2010, RECENT PAT ANTI-CANC, V5, P88, DOI 10.2174/157489210790936216; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Huss M, 2009, J EXP BIOL, V212, P341, DOI 10.1242/jeb.024067; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Ishidoh K, 1995, BIOCHEM BIOPH RES CO, V217, P624, DOI 10.1006/bbrc.1995.2820; Janvier K, 2005, MOL BIOL CELL, V16, P4231, DOI 10.1091/mbc.E05-03-0213; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Jenkins RW, 2009, CELL SIGNAL, V21, P836, DOI 10.1016/j.cellsig.2009.01.026; Joyce JA, 2004, CELL CYCLE, V3, P1516, DOI 10.4161/cc.3.12.1289; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Katunuma N, 2002, ADV ENZYME REGUL, V42, P159, DOI 10.1016/S0065-2571(01)00060-7; Katunuma N, 2011, P JPN ACAD B-PHYS, V87, P29, DOI 10.2183/pjab.87.29; Kim K, 1998, INT J CANCER, V79, P324, DOI 10.1002/(SICI)1097-0215(19980821)79:4<324::AID-IJC4>3.3.CO;2-N; Kirkegaard T, 2010, NATURE, V463, P549, DOI 10.1038/nature08710; Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kolter T, 2010, FEBS LETT, V584, P1700, DOI 10.1016/j.febslet.2009.10.021; Kornhuber J, 2010, CELL PHYSIOL BIOCHEM, V26, P9, DOI 10.1159/000315101; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kuester D, 2008, PATHOL RES PRACT, V204, P491, DOI 10.1016/j.prp.2008.04.010; Lankelma JM, 2010, LIFE SCI, V86, P225, DOI 10.1016/j.lfs.2009.11.016; Le Gall C, 2007, CANCER RES, V67, P9894, DOI 10.1158/0008-5472.CAN-06-3940; Leto G, 2004, CLIN EXP METASTAS, V21, P91, DOI 10.1023/B:CLIN.0000024740.44602.b7; Leto G, 2010, BIOL CHEM, V391, P655, DOI 10.1515/BC.2010.069; Li JP, 2008, ANTI-CANCER AGENT ME, V8, P64, DOI 10.2174/187152008783330824; Liaudet-Coopman E, 2006, CANCER LETT, V237, P167, DOI 10.1016/j.canlet.2005.06.007; Linke T, 2001, BIOL CHEM, V382, P283, DOI 10.1515/BC.2001.035; LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386; Liu CJ, 2009, J HEPATOL, V50, P958, DOI 10.1016/j.jhep.2008.12.023; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; Maeda I, 1999, INT J CANCER, V81, P700, DOI 10.1002/(SICI)1097-0215(19990531)81:5<700::AID-IJC5>3.3.CO;2-4; Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159; Marchetti D, 2003, INT J CANCER, V104, P167, DOI 10.1002/ijc.10930; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Matarrese P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-207; Miao HQ, 2006, CURR MED CHEM, V13, P2101, DOI 10.2174/092986706777935230; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Miyagi T, 2008, P JPN ACAD B-PHYS, V84, P407, DOI 10.2183/pjab.84.407; Mobius W, 2003, TRAFFIC, V4, P222; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Morgan AJ, 2011, BIOCHEM J, V439, P349, DOI 10.1042/BJ20110949; Nagaraj NS, 2007, TOXICOL LETT, V170, P134, DOI 10.1016/j.toxlet.2007.02.014; Ni XY, 2006, TRAFFIC, V7, P889, DOI 10.1111/j.1600-0854.2006.00429.x; Nishisho T, 1916, MOL CANCER RES, V9, P845; Norrby K, 2006, APMIS, V114, P79, DOI 10.1111/j.1600-0463.2006.apm_235.x; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269; Otero-Rey EM, 2008, ORAL ONCOL, V44, P193, DOI 10.1016/j.oraloncology.2007.02.011; Ozbayraktar Fatma Betul Kavun, 2009, Biotechnology Journal, V4, P1028, DOI 10.1002/biot.200800322; Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Pena-Llopis S, 2011, EMBO J, V30, P3242, DOI 10.1038/emboj.2011.257; Perez-Sayans M, 2009, CANCER TREAT REV, V35, P707, DOI 10.1016/j.ctrv.2009.08.003; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Pryor PR, 2009, BBA-MOL CELL RES, V1793, P615, DOI 10.1016/j.bbamcr.2008.12.022; Quintanilla-Dieck MJ, 2008, J INVEST DERMATOL, V128, P2281, DOI 10.1038/jid.2008.63; Quiros RM, 2006, CANCER-AM CANCER SOC, V106, P532, DOI 10.1002/cncr.21648; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Rebbaa A, 2009, ANTICANCER RES, V29, P4473; Reczek D, 2007, CELL, V131, P770, DOI 10.1016/j.cell.2007.10.018; REID TR, 1989, J BIOL CHEM, V264, P4583; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Ruckhaberle E, 2009, CLIMACTERIC, V12, P502, DOI 10.3109/13697130902939913; Saddoughi Sahar A., 2008, V49, P413, DOI 10.1007/978-1-4020-8831-5_16; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; SAITOH O, 1992, J BIOL CHEM, V267, P5700; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Scaringi L, 2004, INT J IMMUNOPATH PH, V17, P331, DOI 10.1177/039463200401700313; Schneede A, 2011, J CELL MOL MED, V15, P280, DOI 10.1111/j.1582-4934.2009.00973.x; Schurigt U, 2008, BIOL CHEM, V389, P1067, DOI 10.1515/BC.2008.115; Seelan RS, 2000, GENE CHROMOSOME CANC, V29, P137, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1018>3.0.CO;2-E; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Settembre C, 2011, AUTOPHAGY, V7, P1379, DOI 10.4161/auto.7.11.17166; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Sevenich L, 2011, ONCOGENE, V30, P54, DOI 10.1038/onc.2010.387; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shafat I, 2006, J BIOL CHEM, V281, P23804, DOI 10.1074/jbc.M602762200; Shafat I, 2011, J CELL MOL MED, V15, P1857, DOI 10.1111/j.1582-4934.2010.01190.x; Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402; SHIRAISHI N, 1986, CANCER LETT, V30, P251, DOI 10.1016/0304-3835(86)90049-2; SLOANE BF, 1994, J CELL SCI, V107, P373; Spugnini EP, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-44; Strojnik T, 2005, CANCER DETECT PREV, V29, P448, DOI 10.1016/j.cdp.2005.07.006; Sugimoto Y, 2009, J MED CHEM, V52, P798, DOI 10.1021/jm801265e; Sullivan S, 2009, INT J CANCER, V125, P54, DOI 10.1002/ijc.24275; Toei M, 2010, BIOCHEMISTRY-US, V49, P4715, DOI 10.1021/bi100397s; Tomoo K, 2010, CURR TOP MED CHEM, V10, P696, DOI 10.2174/156802610791113441; Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Uemura T, 2009, ONCOGENE, V28, P1218, DOI 10.1038/onc.2008.471; van der Goot FG, 2006, TRENDS CELL BIOL, V16, P514, DOI 10.1016/j.tcb.2006.08.003; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2008, BIOCHIMIE, V90, P380, DOI 10.1016/j.biochi.2007.10.004; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Victor BC, 2007, BIOL CHEM, V388, P1131, DOI 10.1515/BC.2007.150; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Walz M, 2007, EXP DERMATOL, V16, P715, DOI 10.1111/j.1600-0625.2007.00579.x; Wang B, 2006, J BIOL CHEM, V281, P6020, DOI 10.1074/jbc.M509134200; Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697; Withana NP, 2012, CANCER RES, V72, P1199, DOI 10.1158/0008-5472.CAN-11-2759; Yan SQ, 2003, BIOL CHEM, V384, P845, DOI 10.1515/BC.2003.095; Yogalingam G, 2008, DEV CELL, V15, P74, DOI 10.1016/j.devcel.2008.05.005; Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937	152	190	192	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					1995	2004		10.1038/onc.2012.292	http://dx.doi.org/10.1038/onc.2012.292			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22777359				2022-12-28	WOS:000317919900001
J	Fan, S; Niu, Y; Tan, N; Wu, Z; Wang, Y; You, H; Ke, R; Song, J; Shen, Q; Wang, W; Yao, G; Shu, H; Lin, H; Yao, M; Zhang, Z; Gu, J; Qin, W				Fan, S.; Niu, Y.; Tan, N.; Wu, Z.; Wang, Y.; You, H.; Ke, R.; Song, J.; Shen, Q.; Wang, W.; Yao, G.; Shu, H.; Lin, H.; Yao, M.; Zhang, Z.; Gu, J.; Qin, W.			LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump	ONCOGENE			English	Article						breast cancer; LASS2; V-ATPase; acidic tumor microenvironment; multidrug resistance	RESISTANT CELL-LINES; DRUG-RESISTANCE; ANTICANCER AGENTS; P-GLYCOPROTEIN; H+-ATPASES; KAPPA-B; EXPRESSION; LYSOSOMES; APOPTOSIS; THERAPY	A main obstacle to overcome during the treatment of tumors is drug resistance to chemotherapy; emerging studies indicate that a key factor contributing to this problem is the acidic tumor microenvironment. Here, we found that LASS2 expression was significantly lower in drug-resistant Michigan Cancer Foundation-7/adriamycin (MCF-7/ADR) human breast cancer cells than the drug-sensitive MCF-7 cells, and low expression of LASS2 was associated with poor prognosis in patients with breast cancer. Our results showed that the overexpression of LASS2 in MCF-7/ADR cells increased the chemosensitivity to multiple chemotherapeutic agents, including doxorubicin (Dox), whereas LASS2 knockdown in MCF-7 cells decreased the chemosensitivity. Cell-cycle analysis revealed a corresponding increase in apoptosis in the LASS2-overexpressing cells following Dox exposure, showing that the overexpression of LASS2 increased the susceptibility to Dox cytotoxicity. This effect was mediated by a significant increase in pH(e) (extracellular pH) and lysosomal pH, and more Dox entered the cells and stayed in the nuclei of cells. In nude mice, the combination of LASS2 overexpression and Dox significantly inhibited the growth of xenografts. Our findings suggest that LASS2 is involved in chemotherapeutic outcomes and low LASS2 expression may predict chemoresistance. Oncogene ( 2013) 32, 1682-1690; doi:10.1038/onc.2012.183; published online 14 May 2012	[Fan, S.; Niu, Y.; Wu, Z.; You, H.; Ke, R.; Song, J.; Shen, Q.; Wang, W.; Yao, G.; Shu, H.; Lin, H.; Zhang, Z.; Gu, J.; Qin, W.] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai 200032, Peoples R China; [Fan, S.] Jiangsu Normal Univ, Sch Life Sci, Dept Biotechnol, Xuzhou, Peoples R China; [Tan, N.] Guangdong Med Coll, Key Lab Med Mol Diag, Zhanjiang, Guangdong, Peoples R China; [Wang, Y.] Xuzhou Med Coll, Affiliated City Hosp, Dept Oncol, Xuzhou, Peoples R China; [Yao, M.] Shanghai Jiao Tong Univ, Sch Med, Dept Expt Pathol, Shanghai Canc Inst,Renji Hosp, Shanghai 200032, Peoples R China	Shanghai Jiao Tong University; Jiangsu Normal University; Guangdong Medical University; Xuzhou Medical University; Shanghai Jiao Tong University	Qin, W (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, 25-2200 Xietu Rd, Shanghai 200032, Peoples R China.	wxqin@sjtu.edu.cn	Ke, Rough/AAM-9687-2021; niu, yd/C-5030-2009	Fan, Shaohua/0000-0003-1878-5902; Zhang, Zhi-gang/0000-0001-8965-223X; Niu, Yongdong/0000-0002-5392-3736	National Key Basic Research Program of China [2009CB521803]; National Key Sci-Tech Special Project of China [2012ZX10002011-004]; National Natural Science Foundation of China [30973492, 81030038]	National Key Basic Research Program of China(National Basic Research Program of China); National Key Sci-Tech Special Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We are grateful to Shenglin Huang, Jun Li and Jie Chen for the kind suggestions and technical assistance. This work was supported by grants from the National Key Basic Research Program of China ( 2009CB521803), National Key Sci-Tech Special Project of China (2012ZX10002011-004) and National Natural Science Foundation of China (30973492 and 81030038).	Andreetta C, 2009, ANN ONCOL, V20, P265, DOI 10.1093/annonc/mdn592; Ben-Batalla I, 2010, J CLIN INVEST, V120, P4289, DOI 10.1172/JCI42015; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; COLEY HM, 1993, BRIT J CANCER, V67, P1316, DOI 10.1038/bjc.1993.244; Cruciat CM, 2010, SCIENCE, V327, P459, DOI 10.1126/science.1179802; Dai Y, 2009, AM J TRANSL RES, V1, P1; De Milito A, 2007, CANCER RES, V67, P5408, DOI 10.1158/0008-5472.CAN-06-4095; Ding J, 2010, NAT CELL BIOL, V12, P390, DOI 10.1038/ncb2039; Erez-Roman R, 2010, BIOCHEM BIOPH RES CO, V391, P219, DOI 10.1016/j.bbrc.2009.11.035; Fais S, 2007, CANCER RES, V67, P10627, DOI 10.1158/0008-5472.CAN-07-1805; Furu M, 2011, ONCOGENE, V30, P4015, DOI 10.1038/onc.2011.108; Generali D, 2006, ENDOCR-RELAT CANCER, V13, P921, DOI 10.1677/erc.1.01216; GERVASONI JE, 1991, CANCER RES, V51, P4955; Gerweck LE, 1996, CANCER RES, V56, P1194; Gong YP, 2003, J BIOL CHEM, V278, P50234, DOI 10.1074/jbc.M306606200; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; Jiffar T, 2011, ONCOGENE, V30, P3163, DOI 10.1038/onc.2011.39; Kawasaki K, 2009, CANCER GENE THER, V16, P65, DOI 10.1038/cgt.2008.58; Larsen AK, 2000, PHARMACOL THERAPEUT, V85, P217, DOI 10.1016/S0163-7258(99)00073-X; Lou PJ, 2006, INT J CANCER, V119, P2692, DOI 10.1002/ijc.22098; Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008-5472.CAN-04-3822; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; MA LD, 1992, BIOCHEM BIOPH RES CO, V182, P675, DOI 10.1016/0006-291X(92)91785-O; Mahoney BP, 2003, BIOCHEM PHARMACOL, V66, P1207, DOI 10.1016/S0006-2952(03)00467-2; National Comprehensive Cancer Network, 2011, NCCN CLIN PRACT GUID; Ottewell PD, 2008, JNCI-J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240; Ouar Z, 2003, BIOCHEM J, V370, P185, DOI 10.1042/BJ20021411; Pan H, 2001, GENOMICS, V77, P58, DOI 10.1006/geno.2001.6614; Petrangolini G, 2006, J PHARMACOL EXP THER, V318, P939, DOI 10.1124/jpet.106.103481; Raghunand N, 1999, BRIT J CANCER, V80, P1005, DOI 10.1038/sj.bjc.6690455; Raghunand N, 1999, BIOCHEM PHARMACOL, V57, P1047, DOI 10.1016/S0006-2952(99)00021-0; Rojas JD, 2006, AM J PHYSIOL-HEART C, V291, pH1147, DOI 10.1152/ajpheart.00166.2006; Schiffmann S, 2009, CARCINOGENESIS, V30, P745, DOI 10.1093/carcin/bgp061; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Thussbas C, 2006, J CLIN ONCOL, V24, P3747, DOI 10.1200/JCO.2005.04.8587; Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Wojtkowiak JW, 2011, MOL PHARMACEUT, V8, P2032, DOI 10.1021/mp200292c; Wulfing P, 2004, BRIT J CANCER, V91, P434, DOI 10.1038/sj.bjc.6601889; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022; You HY, 2009, CANCER LETT, V280, P110, DOI 10.1016/j.canlet.2009.02.023; Zhao YJ, 2011, HEPATOLOGY, V53, P493, DOI 10.1002/hep.24079	45	77	80	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1682	1690		10.1038/onc.2012.183	http://dx.doi.org/10.1038/onc.2012.183			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22580606				2022-12-28	WOS:000316855800008
J	Kufe, DW				Kufe, D. W.			MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches	ONCOGENE			English	Review						MUC1; breast cancer; oncoprotein; signaling pathways; targeted agents	GROWTH-FACTOR RECEPTOR; CARCINOMA-ASSOCIATED ANTIGEN; MUCIN 1 ONCOPROTEIN; BETA-CATENIN; CYCLIN D1; C-SRC; PHOSPHOINOSITIDE 3-KINASE; PROGNOSTIC-SIGNIFICANCE; MONOCLONAL-ANTIBODY; METASTATIC BREAST	Mucin 1 (MUC1) is a heterodimeric protein formed by two subunits that is aberrantly overexpressed in human breast cancer and other cancers. Historically, much of the early work on MUC1 focused on the shed mucin subunit. However, more recent studies have been directed at the transmembrane MUC1-C-terminal subunit (MUC1-C) that functions as an oncoprotein. MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor tyrosine kinases at the cell membrane and contributes to activation of the PI3K -> AKT and mitogen-activated protein kinase kinase (MEK)-> extracellular signal-regulated kinase (ERK) pathways. MUC1-C also localizes to the nucleus where it activates the Wnt/beta-catenin, signal transducer and activator of transcription (STAT) and NF (nuclear factor)-kappa B RelA pathways. These findings and the demonstration that MUC1-C is a druggable target have provided the experimental basis for designing agents that block MUC1-C function. Notably, inhibitors of the MUC1-C subunit have been developed that directly block its oncogenic function and induce death of breast cancer cells in vitro and in xenograft models. On the basis of these findings, a first-in-class MUC1-C inhibitor has entered phase I evaluation as a potential agent for the treatment of patients with breast cancers who express this oncoprotein. Oncogene (2013) 32, 1073-1081; doi:10.1038/onc.2012.158; published online 14 May 2012	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, DW (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute [CA97098]; NATIONAL CANCER INSTITUTE [R01CA166480, R01CA097098] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work has been supported by Grant CA97098 awarded by the National Cancer Institute.	ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; ABE M, 1990, J CELL PHYSIOL, V143, P226, DOI 10.1002/jcp.1041430205; ABE M, 1989, CANCER RES, V49, P2834; Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Arlen PM, 2006, CLIN BREAST CANCER, V7, P176, DOI 10.3816/CBC.2006.n.032; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bieche I, 1997, CANCER GENET CYTOGEN, V98, P75, DOI 10.1016/S0165-4608(96)00410-4; Bitler BG, 2010, J CELL SCI, V123, P1716, DOI 10.1242/jcs.062661; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Gaemers IC, 2001, J BIOL CHEM, V276, P6191, DOI 10.1074/jbc.M009449200; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GILLETT C, 1994, CANCER RES, V54, P1812; Gulley J, 2011, SOC IMMUNOTHER CANC, P56; Gulley JL, 2008, CLIN CANCER RES, V14, P3060, DOI 10.1158/1078-0432.CCR-08-0126; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; HAYES DF, 1985, J CLIN INVEST, V75, P1671, DOI 10.1172/JCI111875; He C, 2002, J BIOL CHEM, V277, P38284, DOI 10.1074/jbc.M104646200; Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152; Hoppler S, 2007, J CELL SCI, V120, P385, DOI 10.1242/jcs.03363; Horn G, 2009, EXP CELL RES, V315, P1490, DOI 10.1016/j.yexcr.2009.02.011; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang L, 2003, CANCER BIOL THER, V2, P702; Ibrahim NK, 2011, CLIN CANCER RES, V17, P6822, DOI 10.1158/1078-0432.CCR-11-1151; Jin CN, 2010, INT J ONCOL, V37, P61, DOI 10.3892/ijo_00000653; Joshi MD, 2009, MOL CANCER THER, V8, P3056, DOI 10.1158/1535-7163.MCT-09-0646; Kato K, 2007, AM J PHYSIOL-LUNG C, V293, pL686, DOI 10.1152/ajplung.00423.2006; Khodarev N, 2010, ONCOGENE, V29, P920, DOI 10.1038/onc.2009.391; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kinlough CL, 2006, J BIOL CHEM, V281, P12112, DOI 10.1074/jbc.M512996200; Kinlough CL, 2004, J BIOL CHEM, V279, P53071, DOI 10.1074/jbc.M409360200; Kondo S, 2007, J VIROL, V81, P1554, DOI 10.1128/JVI.02222-06; Kosugi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028234; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; KUFE D, 2009, CANCER BIOL THER, V8, P1201; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lacunza E, 2010, CANCER GENET CYTOGEN, V201, P102, DOI 10.1016/j.cancergencyto.2010.05.015; Lagow EL, 2002, J CELL BIOCHEM, V86, P759, DOI 10.1002/jcb.10261; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Li Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019102; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Merlin J, 2011, ONCOGENE, V30, P2514, DOI 10.1038/onc.2010.631; MERLO GR, 1989, CANCER RES, V49, P6966; Mohebtash M, 2008, AM SOC CLIN ONC BREA; Mohebtash M, 2011, CLIN CANCER RES, V17, P7164, DOI 10.1158/1078-0432.CCR-11-0649; PANDEY P, 1995, CANCER RES, V55, P4000; Pegram MD, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2409; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Pochampalli MR, 2007, CANCER RES, V67, P6591, DOI 10.1158/0008-5472.CAN-06-4518; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Rajabi H, 2012, PROSTATE, V72, P1659, DOI 10.1002/pros.22519; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Rajabi Hasan, 2010, Genes Cancer, V1, P62; Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Ren J, 2006, MOL CANCER RES, V4, P873, DOI 10.1158/1541-7786.MCR-06-0204; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Thompson EJ, 2006, MOL CANCER RES, V4, P489, DOI 10.1158/1541-7786.MCR-06-0038; Udhayakumar G, 2007, MOL CARCINOGEN, V46, P807, DOI 10.1002/mc.20311; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Woo JK, 2012, ONCOGENE, V31, P2187, DOI 10.1038/onc.2011.410; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yao MY, 2011, LUNG, V189, P453, DOI 10.1007/s00408-011-9327-y; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zaretsky JZ, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-57; Zhou YC, 2011, MOL PHARMACOL, V79, P886, DOI 10.1124/mol.110.070797	103	258	269	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1073	1081		10.1038/onc.2012.158	http://dx.doi.org/10.1038/onc.2012.158			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22580612	Bronze, Green Accepted			2022-12-28	WOS:000316428800001
J	Sarek, G; Ma, L; Enback, J; Jarviluoma, A; Moreau, P; Haas, J; Gessain, A; Koskinen, PJ; Laakkonen, P; Ojala, PM				Sarek, G.; Ma, L.; Enback, J.; Jarviluoma, A.; Moreau, P.; Haas, J.; Gessain, A.; Koskinen, P. J.; Laakkonen, P.; Ojala, P. M.			Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas	ONCOGENE			English	Article						KSHV; lymphoma; p53; apoptosis; viral lytic replication; hypoxia	PRIMARY EFFUSION LYMPHOMA; NF-KAPPA-B; HUMAN-HERPESVIRUS-8; EXPRESSION; HYPOXIA; ANTAGONISTS; ACTIVATION; PATHWAY; GENE; PHOSPHORYLATION	Primary effusion lymphomas (PELs) are aggressive Kaposi's sarcoma herpesvirus (KSHV)-induced malignancies with median survival time <6 months post-diagnosis. Mutations in the TP53 gene seldom occur in PELs, suggesting that genetic alterations in the TP53 are not selected during PEL progression. We have reported that p53 reactivation by an inhibitor of the p53-MDM2 interaction, Nutlin-3, induces selective and massive apoptosis in PEL cells leading to efficient anti-tumor activity in a subcutaneous xenograft model for PEL. Here, we show compelling anti-tumor activity of Nutlin-3 in the majority of intraperitoneal PEL xenografts in vivo. Interestingly, our results demonstrate that spontaneous induction of viral lytic replication in tumors could drastically attenuate the p53-dependent apoptotic response to Nutlin-3. Moreover, viral reactivation compromised p53-dependent apoptosis in PEL cells treated with genotoxic anti-cancer agents doxorubicin and etoposide. We have recently demonstrated that the Ser/Thr kinases Pim 1 and 3 are required to trigger induction of the lytic replication cascade of KSHV. We have now assessed the ability of a novel Pim kinase inhibitor to restore the Nutlin-3-induced cytotoxicity in lytic PEL cells. PEL cells induced to lytic replication by phorbol esters showed 50% inhibition of active viral replication following treatment with the Pim kinase inhibitor. Importantly, co-treatment of these cells with the kinase inhibitor and Nutlin-3 resulted in a robust restoration of the Nutlin-3-induced cell death. These results highlight the potential impact of activation of viral lytic replication on disease progression and response to treatment in KSHV-induced lymphomas. Oncogene (2013) 32,1091-1098; doi:10.1038/onc.2012.118; published online 2 April 2012	[Sarek, G.; Ma, L.; Ojala, P. M.] Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; [Sarek, G.; Ma, L.; Enback, J.; Laakkonen, P.; Ojala, P. M.] Univ Helsinki, Res Programs Unit, Biomedicum Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland; [Jarviluoma, A.] Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; [Moreau, P.] Univ Blaise Pascal, Univ Clermont Ferrand 2, SEESIB, CNRS, Aubiere, France; [Haas, J.] Univ Edinburgh, Sch Biomed Sci, Divison Pathway Med, Edinburgh, Midlothian, Scotland; [Haas, J.] Univ Munich, Max Von Pettenkofer Inst, Munich, Germany; [Gessain, A.] Inst Pasteur, Dept Virol, Unite Epidemiol & Physiopathol Virus Oncogenes, Paris, France; [Koskinen, P. J.] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Gessain, A.] Abo Akad Univ, Turku, Finland; [Laakkonen, P.] K Albin Johansson Fdn, Helsinki, Finland; [Ojala, P. M.] Finnish Canc Inst, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); University of Edinburgh; University of Munich; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Turku; Abo Akademi University	Laakkonen, P (corresponding author), Univ Helsinki, Res Programs Unit, POB 63, FIN-00014 Helsinki, Finland.	Pirjolaakkonen@helsinki.fi; Paivi.Ojala@helsinki.fi	Koskinen, Päivi J/G-8939-2014; Ojala, Paivi M/J-3266-2014; Moreau, Pascale/M-9020-2016	Moreau, Pascale/0000-0001-6527-7586; Laakkonen, Pirjo/0000-0002-9620-095X; Ojala, Paivi/0000-0001-9065-1832; Koskinen, Paivi/0000-0002-6864-4457	European Union [LSHC-CT-2005-018704]; Helsinki Biomedical Graduate School; Finnish Cultural Foundation; Paulo Foundation; K Albin Johansson Foundation; Maud Kuistila Memorial Foundation; University of Helsinki Funds; Biomedicum Helsinki Foundation; MRC [G0501453] Funding Source: UKRI; Medical Research Council [G0501453] Funding Source: researchfish; Cancer Foundation Finland sr [130134] Funding Source: researchfish	European Union(European Commission); Helsinki Biomedical Graduate School; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Paulo Foundation; K Albin Johansson Foundation; Maud Kuistila Memorial Foundation; University of Helsinki Funds; Biomedicum Helsinki Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Cancer Foundation Finland sr	We thank M Laiho for reagents, discussions and critical review of this manuscript; C Boshoff for valuable comments; E Cesarman for providing the BC-3/NF-kappa B-luc cell line; D Ganem for anti-RTA antibody; and B Chandran for anti-ORF59 and anti-LANA antibodies. J Barlund, S Vartia and P Kivinen are acknowledged for excellent technical assistance. This work was supported by grants from the Academy of Finland (PMO, PL), Finnish Cancer Foundations (PMO, PL), Sigrid Juselius Foundation (PMO), University of Helsinki Foundations (PMO), and from the European Union (FP6 INCA project LSHC-CT-2005-018704) to PMO, AJ, GS and LM were supported by the University of Helsinki Graduate Program in Biotechnology and Molecular Biology. JE was supported by the Helsinki Biomedical Graduate School. GS was also supported by Finnish Cultural Foundation, Paulo Foundation, K Albin Johansson Foundation, Maud Kuistila Memorial Foundation, University of Helsinki Funds and Biomedicum Helsinki Foundation.	Ablashi DV, 2002, CLIN MICROBIOL REV, V15, P439, DOI 10.1128/CMR.15.3.439-464.2002; Akue-Gedu R, 2009, J MED CHEM, V52, P6369, DOI 10.1021/jm901018f; Boulanger E, 2005, J CLIN ONCOL, V23, P4372, DOI 10.1200/JCO.2005.07.084; Boulanger E, 2003, AM J HEMATOL, V73, P143, DOI 10.1002/ajh.10341; Brown HJ, 2005, ANTIVIR THER, V10, P745; Carbone A, 1998, BRIT J HAEMATOL, V102, P1081, DOI 10.1046/j.1365-2141.1998.00877.x; Casper C, 2008, REV MED VIROL, V18, P321, DOI 10.1002/rmv.583; Cesarman E, 1996, AM J PATHOL, V149, P53; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chandran B, 1998, VIROLOGY, V249, P140, DOI 10.1006/viro.1998.9316; Cheng F, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000324; Crum-Cianflone NF, 2006, AIDS, V20, P1567, DOI 10.1097/01.aids.0000237381.92303.61; Davis DA, 2001, BLOOD, V97, P3244, DOI 10.1182/blood.V97.10.3244; Davis DA, 2007, CANCER RES, V67, P7003, DOI 10.1158/0008-5472.CAN-07-0939; Dittmer DP, 2003, CANCER RES, V63, P2010; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Grossmann C, 2008, VIROLOGY, V375, P94, DOI 10.1016/j.virol.2007.12.044; Haque M, 2003, J VIROL, V77, P6761, DOI 10.1128/JVI.77.12.6761-6768.2003; Hocqueloux L, 2001, AIDS, V15, P280, DOI 10.1097/00002030-200101260-00023; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Katano H, 2000, VIROLOGY, V269, P335, DOI 10.1006/viro.2000.0196; Kedes DH, 1997, J CLIN INVEST, V99, P2082, DOI 10.1172/JCI119380; Keller SA, 2006, BLOOD, V107, P3295, DOI 10.1182/blood-2005-07-2730; Keller SA, 2000, BLOOD, V96, P2537; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lalezari JP, 1996, ADV EXP MED BIOL, V394, P105; LEACH FS, 1993, CANCER RES, V53, P2231; Loncaster JA, 2001, CANCER RES, V61, P6394; Luppi M, 2005, LEUKEMIA, V19, P473, DOI 10.1038/sj.leu.2403646; MATTHEWS T, 1988, REV INFECT DIS, V10, pS490; Morotti A, 2006, AM J HEMATOL, V81, P938, DOI 10.1002/ajh.20732; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Nakamura H, 2003, J VIROL, V77, P4205, DOI 10.1128/JVI.77.7.4205-4220.2003; Nicholas J, 2005, J INTERF CYTOK RES, V25, P373, DOI 10.1089/jir.2005.25.373; Petre CE, 2007, J VIROL, V81, P1912, DOI 10.1128/JVI.01757-06; Qin Z, 2011, LEUKEMIA, V25, P1598, DOI 10.1038/leu.2011.144; Santio NM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-279; Sarek G, 2006, BLOOD, V107, P725, DOI 10.1182/blood-2005-06-2534; Sarek G, 2007, J CLIN INVEST, V117, P1019, DOI 10.1172/JCI30945; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Simonelli C, 2003, J CLIN ONCOL, V21, P3948, DOI 10.1200/JCO.2003.06.013; Stuhmer T, 2005, BLOOD, V106, P3609, DOI 10.1182/blood-2005-04-1489; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Varjosalo M, 2008, CELL, V133, P537, DOI 10.1016/j.cell.2008.02.047; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wies E, 2009, J BIOL CHEM, V284, P8525, DOI 10.1074/jbc.M809252200	48	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1091	1098		10.1038/onc.2012.118	http://dx.doi.org/10.1038/onc.2012.118			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22469985				2022-12-28	WOS:000316428800003
J	Baumgartner, F; Woess, C; Pedit, V; Tzankov, A; Labi, V; Villunger, A				Baumgartner, F.; Woess, C.; Pedit, V.; Tzankov, A.; Labi, V.; Villunger, A.			Minor cell-death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf	ONCOGENE			English	Article						apoptosis; BH3-only proteins; Bad; Bmf; hematopoiesis; cancer	GLUCOCORTICOID-INDUCED APOPTOSIS; BCL-2 PROTEINS; BH3 DOMAINS; BIM; HOMEOSTASIS; PUMA; SUPPRESSION; ACTIVATION; RECEPTOR; COMPLEX	Proapoptotic Bcl-2 family members of the Bcl-2 homology (BH)3-only subgroup are critical for the establishment and maintenance of tissue homeostasis and can mediate apoptotic cell death in response to developmental cues or exogenously induced forms of cell stress. On the basis of the biochemical experiments as well as genetic studies in mice, the BH3-only proteins Bad and Bmf have been implicated in different proapoptotic events such as those triggered by glucose- or trophic factor-deprivation, glucocorticoids, or histone deacetylase inhibition, as well as suppression of B-cell lymphomagenesis upon aberrant expression of c-Myc. To address possible redundancies in cell death regulation and tumor suppression, we generated compound mutant mice lacking both genes. Our studies revealed lack of redundancy in most paradigms of lymphocyte apoptosis tested in tissue culture. Only spontaneous cell death of thymocytes kept in low glucose or that of pre-B cells deprived of cytokines was significantly delayed when both genes were lacking. Of note, despite these minor apoptosis defects we observed compromised lymphocyte homeostasis in vivo that affected mainly the B-cell lineage. Long-term follow-up revealed significantly reduced latency to spontaneous tumor formation in aged mice when both genes were lacking. Together our study suggests that Bad and Bmf co-regulate lymphocyte homeostasis and limit spontaneous transformation by mechanisms that may not exclusively be linked to the induction of lymphocyte apoptosis. Oncogene (2013) 32, 621-630; doi:10.1038/onc.2012.78; published online 19 March 2012	[Baumgartner, F.; Woess, C.; Pedit, V.; Labi, V.; Villunger, A.] Med Univ Innsbruck, Bioctr, Div Dev Immunol, A-6020 Innsbruck, Austria; [Tzankov, A.] Univ Basel, Inst Pathol, Basel, Switzerland	Medical University of Innsbruck; University of Basel	Villunger, A (corresponding author), Med Univ Innsbruck, Bioctr, Div Dev Immunol, A-6020 Innsbruck, Austria.	andreas.villunger@i-med.ac.at	Tzankov, Alexandar/H-5656-2019; Labi, Verena/V-2766-2019	Tzankov, Alexandar/0000-0002-1100-3819; Labi, Verena/0000-0001-7538-1520; Klepsch, Victoria/0000-0003-4146-4664	Tiroler Krebshilfe; Tiroler Wissenschaftsfond (TWF); Austrian Science Fund, FWF [Y212-B12, P23510-B19, SFB021]; Integrated Center for Research and Therapy (IFTZ) of the Innsbruck Medical University; Austrian Academy of Science (OAW); Austrian Science Fund (FWF) [P 23510] Funding Source: researchfish	Tiroler Krebshilfe; Tiroler Wissenschaftsfond (TWF); Austrian Science Fund, FWF(Austrian Science Fund (FWF)); Integrated Center for Research and Therapy (IFTZ) of the Innsbruck Medical University; Austrian Academy of Science (OAW); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank A Strasser and the late S Korsemeyer for the mice and reagents. I Gaggl for mouse genotyping, C Soratroi for technical assistance, K Rossi for animal care and G Bock for cell sorting. This work was supported by grants from the 'Tiroler Krebshilfe' to FB and CW, the 'Tiroler Wissenschaftsfond' (TWF) to VL, as well as the Austrian Science Fund, FWF (Y212-B12; P23510-B19; SFB021) to AV and the Integrated Center for Research and Therapy (IFTZ) of the Innsbruck Medical University to AV and FB. CW is a recipient of a DOC-fFORTE doctoral fellowship sponsored by the Austrian Academy of Science (OAW).	Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Erlacher M, 2006, J EXP MED, V203, P2939, DOI 10.1084/jem.20061552; Frenzel A, 2010, BLOOD, V115, P995, DOI 10.1182/blood-2009-03-212670; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Gramantieri L, 2009, CLIN CANCER RES, V15, P5073, DOI 10.1158/1078-0432.CCR-09-0092; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hubner A, 2010, MOL CELL BIOL, V30, P98, DOI 10.1128/MCB.01155-09; Kelly PN, 2010, CELL DEATH DIFFER, V17, P1655, DOI 10.1038/cdd.2010.43; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Labi V, 2008, J EXP MED, V205, P641, DOI 10.1084/jem.20071658; Lee JW, 2004, CARCINOGENESIS, V25, P1371, DOI 10.1093/carcin/bgh145; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Pinon JD, 2008, ONCOGENE, V27, pS41, DOI 10.1038/onc.2009.42; Ploner C, 2008, LEUKEMIA, V22, P370, DOI 10.1038/sj.leu.2405039; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Teo K, 2007, BJU INT, V100, P691, DOI 10.1111/j.1464-410X.2007.07001.x; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang P, 2012, DIABETES-METAB RES, V28, P109, DOI 10.1002/dmrr.1291; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhao YX, 2008, J BIOL CHEM, V283, P36344, DOI 10.1074/jbc.M803580200	33	12	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					621	630		10.1038/onc.2012.78	http://dx.doi.org/10.1038/onc.2012.78			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22430207	Green Accepted			2022-12-28	WOS:000316164700009
J	Origanti, S; Cai, SR; Munir, AZ; White, LS; Piwnica-Worms, H				Origanti, S.; Cai, S-R; Munir, A. Z.; White, L. S.; Piwnica-Worms, H.			Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells	ONCOGENE			English	Article						cell cycle; checkpoints; apoptosis; cancer	ONCOGENE-INDUCED SENESCENCE; S-PHASE; POTENT INHIBITOR; CDK INHIBITORS; DEFECTIVE P53; CHECKPOINT; UCN-01; CDC25A; 7-HYDROXYSTAUROSPORINE; PHOSPHORYLATION	Cell cycle checkpoints ensure genome integrity and are frequently compromised in human cancers. A therapeutic strategy being explored takes advantage of checkpoint defects in p53-deficient tumors in order to sensitize them to DNA-damaging agents by eliminating Chk1-mediated checkpoint responses. Using mouse models, we demonstrated that p21 is a key determinant of how cells respond to the combination of DNA damage and Chk1 inhibition (combination therapy) in normal cells as well as in tumors. Loss of p21 sensitized normal cells to the combination therapy much more than did p53 loss and the enhanced lethality was partially blocked by CDK inhibition. In addition, basal pools of p21 (p53 independent) provided p53 null cells with protection from the combination therapy. Our results uncover a novel p53-independent function for p21 in protecting cells from the lethal effects of DNA damage followed by Chk1 inhibition. As p21 levels are low in a significant fraction of colorectal tumors, they are predicted to be particularly sensitive to the combination therapy. Results reported in this study support this prediction. Oncogene (2013) 32, 577-588; doi:10.1038/onc.2012.84; published online 19 March 2012	[Origanti, S.; Cai, S-R; Munir, A. Z.; White, L. S.; Piwnica-Worms, H.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Origanti, S.; Cai, S-R; Munir, A. Z.; White, L. S.; Piwnica-Worms, H.] Washington Univ, Sch Med, BRIGHT Inst, St Louis, MO 63110 USA; [Piwnica-Worms, H.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 South Euclid Ave, St Louis, MO 63110 USA.	hpiwnica@wustl.edu	Piwnica-Worms, Helen/C-5214-2012	Origanti, Sofia/0000-0002-6953-0160	NIH [GM047017]; KOMEN Foundation; Washington University [P50 CA94056]; NATIONAL CANCER INSTITUTE [P50CA094056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047017] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); KOMEN Foundation(Susan G. Komen Breast Cancer Foundation); Washington University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr B Vogelstein for providing the HCT116 cell lines. This study was supported in part by NIH GM047017, the KOMEN Foundation and P50 CA94056 to the Molecular Imaging Center at Washington University. HP-W is a Research Professor of the American Cancer Society.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Eastman A, 2004, J CELL BIOCHEM, V91, P223, DOI 10.1002/jcb.10699; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fikaris AJ, 2006, J BIOL CHEM, V281, P34759, DOI 10.1074/jbc.M606737200; Fracasso PM, 2011, CANCER CHEMOTH PHARM, V67, P1225, DOI 10.1007/s00280-010-1410-1; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kohn EA, 2003, CANCER RES, V63, P31; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Levesque AA, 2008, MOL CANCER THER, V7, P252, DOI 10.1158/1535-7163.MCT-07-2066; Levesque AA, 2007, CARCINOGENESIS, V28, P13, DOI 10.1093/carcin/bgl214; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Perez RP, 2006, CLIN CANCER RES, V12, P7079, DOI 10.1158/1078-0432.CCR-06-0197; Raynaud FI, 2004, MOL CANCER THER, V3, P353; Rodriguez R, 2006, MOL BIOL CELL, V17, P402, DOI 10.1091/mbc.E05-07-0594; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Tapia C, 2006, AM J SURG PATHOL, V30, P83, DOI 10.1097/01.pas.0000183572.94140.43; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tse AN, 2007, CLIN CANCER RES, V13, P591, DOI 10.1158/1078-0432.CCR-06-1424; Cespedes MV, 2007, AM J PATHOL, V170, P1077, DOI 10.2353/ajpath.2007.060773; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	39	48	49	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					577	588		10.1038/onc.2012.84	http://dx.doi.org/10.1038/onc.2012.84			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22430210	Green Accepted, Green Submitted			2022-12-28	WOS:000316164700005
J	Kim, JH; Yu, S; Chen, JD; Kong, AN				Kim, J-H; Yu, S.; Chen, J. D.; Kong, A. N.			The nuclear cofactor RAC3/AIB1/SRC-3 enhances Nrf2 signaling by interacting with transactivation domains	ONCOGENE			English	Article						Nrf2; RAC3/SRC-3; HO-1	STEROID-RECEPTOR COACTIVATOR-1; ELECTROPHILE RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; CREB-BINDING-PROTEIN; INDUCIBLE EXPRESSION; OXIDATIVE STRESS; THYROID-HORMONE; GENE; AIB1; ANTIOXIDANT	Nuclear factor erythroid 2-related factor 2 (Nrf2, NM 006164, 605 AA) is essential for the antioxidant responsive element (ARE)-mediated expression of a group of detoxifying antioxidant genes that detoxify carcinogens and protect against oxidative stress. Several proteins have been identified as Nrf2-interacting molecules. In this study, we found that the overexpression of receptor-associated coactivator 3 (RAC3)/AIB-1/steroid receptor coactivator-3, a nuclear coregulator and oncogene frequently amplified in human breast cancers, induced heme oxygenase-1 (HO-1) through Nrf2 transactivation in HeLa cells. Next, we determined the interaction between RAC3 and Nrf2 proteins using a co-immunoprecipitation assay and fluorescence resonance energy transfer analysis. The results showed that RAC3 bound directly to the Nrf2 protein in the nucleus. Subsequently, we identified the interacting domains of Nrf2 and RAC3 using a gintathione S-transferase pull-down assay. The results showed that both the N-terminal RAC3-pasB and C-terminal RAC3-R3B3 domains were tightly bound to the Neh4 and Neh5 transactivation domains. Furthermore, chromatin immunoprecipitation showed that RAC3 bound tightly to the ARE enhancer region of the HO-1 promoter via Nrf2 binding. These data suggest that Nrf2 activation is modulated and directly controlled through interactions with the RAC3 protein in HeLa cells. Oncogene (2013) 32, 514-527; doi:10.1038/onc.2012.59; published online 27 February 2012	[Kim, J-H; Kong, A. N.] Rutgers State Univ, Grad Program Pharmaceut Sci, Piscataway, NJ 08854 USA; [Kim, J-H; Yu, S.; Kong, A. N.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA; [Chen, J. D.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kong, AN (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd,Room 228, Piscataway, NJ 08854 USA.	KongT@pharmacy.rutgers.edu	yu, Siwang/AAL-8059-2020; Kong, Ah-Ng Tony/AAX-2828-2020	Yu, Siwang/0000-0002-3336-202X; Kim, Jung Hwan/0000-0002-2975-4899	NIH [R01 NIH R01-CA-94828]; NATIONAL CANCER INSTITUTE [R01CA094828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005022] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Jianjie Ma (Department of Physiology and Biophysics, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA) for help with confocal microscopy. This study was supported by NIH Grant R01 NIH R01-CA-94828.	Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arimura A, 2004, J BIOL CHEM, V279, P31105, DOI 10.1074/jbc.M404428200; Blank V, 2008, J MOL BIOL, V376, P913, DOI 10.1016/j.jmb.2007.11.074; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Han SJ, 2006, MOL ENDOCRINOL, V20, P45, DOI 10.1210/me.2005-0310; Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henke RT, 2004, CLIN CANCER RES, V10, P6134, DOI 10.1158/1078-0432.CCR-04-0561; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kong ANT, 2001, DRUG METAB REV, V33, P255, DOI 10.1081/DMR-120000652; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, P NATL ACAD SCI USA, V101, P9751, DOI 10.1073/pnas.0403620101; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li C, 2007, MOL CELL BIOL, V27, P1296, DOI 10.1128/MCB.00336-06; LI Y, 1993, J BIOL CHEM, V268, P21454; Lin W, 2006, J BIOCHEM MOL BIOL, V39, P304; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McMahon M, 2001, CANCER RES, V61, P3299; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sakakura C, 2000, INT J CANCER, V89, P217; Shen GX, 2004, J BIOL CHEM, V279, P23052, DOI 10.1074/jbc.M401368200; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Vollrath V, 2006, BIOCHEM J, V395, P599, DOI 10.1042/BJ20051518; Wang Y, 2002, CANCER-AM CANCER SOC, V95, P2346, DOI 10.1002/cncr.10963; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Wu XY, 2001, J BIOL CHEM, V276, P23962, DOI 10.1074/jbc.M101041200; Xie D, 2005, HUM PATHOL, V36, P777, DOI 10.1016/j.humpath.2005.05.007; Xu FP, 2007, CANCER LETT, V245, P69, DOI 10.1016/j.canlet.2005.12.030; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Ying H, 2005, MOL CELL BIOL, V25, P7687, DOI 10.1128/MCB.25.17.7687-7695.2005; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003; Zhu M, 2001, BIOCHEM BIOPH RES CO, V289, P212, DOI 10.1006/bbrc.2001.5944	55	67	70	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					514	527		10.1038/onc.2012.59	http://dx.doi.org/10.1038/onc.2012.59			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22370642	Green Accepted			2022-12-28	WOS:000315551300012
J	van der Weyden, L; Rust, AG; McIntyre, RE; Robles-Espinoza, CD; Velasco-Herrera, MD; Strogantsev, R; Ferguson-Smith, AC; McCarthy, S; Keane, TM; Arends, MJ; Adams, DJ				van der Weyden, L.; Rust, A. G.; McIntyre, R. E.; Robles-Espinoza, C. D.; Velasco-Herrera, M. del Castillo; Strogantsev, R.; Ferguson-Smith, A. C.; McCarthy, S.; Keane, T. M.; Arends, M. J.; Adams, D. J.			Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity	ONCOGENE			English	Article						p53; Jdp2; transposon; heterozygosity; lymphoma; mice	RETROVIRAL INSERTIONAL MUTAGENESIS; JUN DIMERIZATION PROTEIN-2; AP-1 REPRESSOR PROTEIN; WILD-TYPE P53; BREAST-CANCER; CELL; MUTATIONS; GENES; SUPPRESSION; PROGRESSION	We performed a genetic screen in mice to identify candidate genes that are associated with leukaemogenesis in the context of Trp53 heterozygosity. To do this we generated Trp53 heterozygous mice carrying the T2/Onc transposon and SB11 transposase alleles to allow transposon-mediated insertional mutagenesis to occur. From the resulting leukaemias/lymphomas that developed in these mice, we identified nine loci that are potentially associated with tumour formation in the context of Trp53 heterozygosity, including AB041803 and the Jun dimerization protein 2 (Jdp2). We show that Jdp2 transcriptionally regulates the Trp53 promoter, via an atypical AP-1 site, and that Jdp2 expression negatively regulates Trp53 expression levels. This study is the first to identify a genetic mechanism for tumour formation in the context of Trp53 heterozygosity. Oncogene (2013) 32, 397-402; doi:10.1038/onc.2012.56; published online 27 February 2012	[van der Weyden, L.; Rust, A. G.; McIntyre, R. E.; Robles-Espinoza, C. D.; Velasco-Herrera, M. del Castillo; McCarthy, S.; Keane, T. M.; Adams, D. J.] Wellcome Trust Sanger Inst, Cambridge, England; [Strogantsev, R.; Ferguson-Smith, A. C.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England; [Arends, M. J.] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England	Wellcome Trust Sanger Institute; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Adams, DJ (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton CB10 1HH, Cambs, England.	da1@sanger.ac.uk	van der Weyden, Louise/AAV-5711-2021; Robles-Espinoza, Carla Daniela/L-2560-2019	van der Weyden, Louise/0000-0002-0645-1879; Robles-Espinoza, Carla Daniela/0000-0003-3277-7466; Adams, David/0000-0001-9490-0306; Del Castillo Velasco Herrera, Martin/0000-0001-5956-0211; Rust, Alistair/0000-0001-7287-192X; Ferguson-Smith, Anne/0000-0002-7608-5894; McCarthy, Shane/0000-0002-2715-4187	Cancer Research UK; Wellcome Trust; Kay Kendall Leukaemia Fund; Consejo Nacional de Ciencia y Tecnologia (CONACYT); MRC [G0800024] Funding Source: UKRI; Cancer Research UK [14356, 13031] Funding Source: researchfish; Medical Research Council [G0800024] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Kay Kendall Leukaemia Fund; Consejo Nacional de Ciencia y Tecnologia (CONACYT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	DJA was supported by Cancer Research UK and the Wellcome Trust. LvdW was supported by the Kay Kendall Leukaemia Fund. CDRE was supported by Consejo Nacional de Ciencia y Tecnologia (CONACYT) and the Wellcome Trust. MJA and REM were supported by Cancer Research UK.	Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bitton-Worms K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-54; Collier LS, 2009, CANCER RES, V69, P8429, DOI 10.1158/0008-5472.CAN-09-1760; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Dail M, 2010, P NATL ACAD SCI USA, V107, P5106, DOI 10.1073/pnas.1001064107; de Ridder J, 2006, PLOS COMPUT BIOL, V2, P1530, DOI 10.1371/journal.pcbi.0020166; Demarest RM, 2008, ONCOGENE, V27, P5082, DOI 10.1038/onc.2008.222; Donehower LA, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001081; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Dube N, 2008, CELL SIGNAL, V20, P1608, DOI 10.1016/j.cellsig.2008.05.006; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giguere A, 2011, GENE CHROMOSOME CANC, V50, P228, DOI 10.1002/gcc.20848; Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784; Gutierrez A, 2011, J EXP MED, V208, P1595, DOI 10.1084/jem.20101691; Iwasaki M, 2010, BIOCHEM BIOPH RES CO, V400, P413, DOI 10.1016/j.bbrc.2010.08.092; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; Nakade K, 2009, J BIOL CHEM, V284, P10808, DOI 10.1074/jbc.M808333200; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Pan J, 2010, ONCOGENE, V29, P6245, DOI 10.1038/onc.2010.355; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Rasmussen MH, 2009, NUCLEIC ACIDS RES, V37, P4657, DOI 10.1093/nar/gkp469; Robles AI, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001016; Sedlacek Z, 1998, BRIT J CANCER, V77, P1034, DOI 10.1038/bjc.1998.172; Severson EA, 2009, MOL BIOL CELL, V20, P1916, DOI 10.1091/mbc.E08-10-1014; Stewart M, 2007, CANCER RES, V67, P5126, DOI 10.1158/0008-5472.CAN-07-0433; Trbusek M, 2011, J CLIN ONCOL, V29, P2703, DOI 10.1200/JCO.2011.34.7872; Uren AG, 2005, ONCOGENE, V24, P7656, DOI 10.1038/sj.onc.1209043; Uren AG, 2008, CELL, V133, P727, DOI 10.1016/j.cell.2008.03.021; Uren AG, 2009, NAT PROTOC, V4, P789, DOI 10.1038/nprot.2009.64; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Wang SW, 2011, CURR PHARM DESIGN, V17, P2278, DOI 10.2174/138161211797052394; Xu YH, 2010, INT J BIOL MARKER, V25, P136, DOI 10.1177/172460081002500303; Zheng BH, 2002, CANCER BIOL THER, V1, P433, DOI 10.4161/cbt.1.4.24	42	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					397	402		10.1038/onc.2012.56	http://dx.doi.org/10.1038/onc.2012.56			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370638	Green Published, hybrid			2022-12-28	WOS:000314736600013
J	Schafer, H; Struck, B; Feldmann, EM; Bergmann, F; Grage-Griebenow, E; Geismann, C; Ehlers, S; Altevogt, P; Sebens, S				Schaefer, H.; Struck, B.; Feldmann, E-M; Bergmann, F.; Grage-Griebenow, E.; Geismann, C.; Ehlers, S.; Altevogt, P.; Sebens, S.			TGF-beta 1-dependent L1CAM expression has an essential role in macrophage-induced apoptosis resistance and cell migration of human intestinal epithelial cells	ONCOGENE			English	Article						colon cancer; inflammatory bowel disease; CD171; cellular microenvironment	INFLAMMATORY-BOWEL-DISEASE; PANCREATIC DUCTAL ADENOCARCINOMA; OVARIAN-CARCINOMA CELLS; ULCERATIVE-COLITIS; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; COLONIC MACROPHAGES; PROTEASOME ACTIVITY; ADHESION MOLECULE; UP-REGULATION	Patients with chronic inflammatory bowel disease (IBD) have an increased risk to develop colorectal cancer (CRC) particularly after long duration of the disease. Chronic inflammation of the intestinal mucosa is characterized by a marked enrichment of immune cells such as macrophages as well as by high expression of cytokines and growth factors including transforming growth factor-beta 1 (TGF-beta 1). The adhesion molecule L1CAM mediates chemoresistance and migration of tumor cells and is elevated in CRC tissues being associated with metastatic spread and poor prognosis for the patients. In this study, we examine the role of TGF-beta 1-induced L1CAM expression and macrophages in malignant transformation of intestinal epithelial cells. We demonstrate that TGF-beta 1 stimulation leads to a Slug-dependent upregulation of L1CAM expression already in the colonic intestinal epithelial cell line NCM460 thereby enhancing cell motility and apoptosis resistance. Accordingly, NCM460 cells acquired a migratory and apoptosis-resistant phenotype if transfected with L1CAM. Immunohistochemistry of colonic biopsies revealed considerable L1CAM expression in intestinal epithelial cells in tissues from IBD patients but not in normal colonic tissues. Moreover, L1CAM expression increased with duration of disease being associated with the presence of CD33+ macrophages. Coculture with macrophages generated from monocyte colony-stimulating factor (MCSF)-treated monocytes led to the upregulation of Slug and L1CAM in NCM460 cells thereby elevating cell motility and apoptosis resistance. Pharmacological inhibition of TGF-beta 1 signalling abolished expression of Slug and L1CAM in cocultured NCM460 cells resulting in decreased cell migration and apoptosis resistance. In conclusion, these data provide new insights into the mechanisms by which IBD promotes malignant transformation of intestinal epithelial cells and underscore the role of L1CAM and macrophages in this scenario. Oncogene (2013) 32, 180-189; doi:10.1038/onc.2012.44; published online 20 February 2012	[Schaefer, H.; Struck, B.; Feldmann, E-M; Grage-Griebenow, E.; Geismann, C.] UKSH, Lab Mol Gastroenterol & Hepatol, Dept Internal Med 1, D-24105 Kiel, Germany; [Struck, B.; Feldmann, E-M; Grage-Griebenow, E.; Geismann, C.; Sebens, S.] UKSH, Inst Expt Med, Dept Internal Med 1, D-24105 Kiel, Germany; [Bergmann, F.] Heidelberg Univ, Dept Pathol, Heidelberg, Germany; [Ehlers, S.] Forschungszentrum, Dept Mol Infect Biol, Borstel, Germany; [Altevogt, P.] German Canc Res Ctr, Dept Translat Immunol D015, Heidelberg, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Sebens, S (corresponding author), UKSH, Inst Expt Med, Dept Internal Med 1, Campus Kiel,Arnold Heller Str 3,Haus 6, D-24105 Kiel, Germany.	mueerkoe@1med.uni-kiel.de	Geismann, Claudia/AAX-8158-2021; Sebens, Susanne/C-1222-2010; Ehlers, Stefan/B-4075-2010; Schäfer, Heiner/C-1055-2011	Geismann, Claudia/0000-0003-0640-9256; 	German Research Society DFG [Scha677/9-1, SE-1831/2-1]; German Cluster of Excellence 'Inflammation at Interfaces'	German Research Society DFG(German Research Foundation (DFG)); German Cluster of Excellence 'Inflammation at Interfaces'	Excellent technical assistance by Dagmar Leisner, Erika Kuhlenhauser, Christina Trabandt and Maike Witt-Ramdohr, statistical advice by Jurgen Hedderich and funding by the German Research Society DFG (Scha677/9-1 and SE-1831/2-1) as well as the German Cluster of Excellence 'Inflammation at Interfaces' are acknowledged.	Arlt A, 2009, ONCOGENE, V28, P3983, DOI 10.1038/onc.2009.264; Arlt MJE, 2006, CANCER RES, V66, P936, DOI 10.1158/0008-5472.CAN-05-1818; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P975, DOI 10.1053/gast.1996.v110.pm8613031; Bergmann F, 2010, ONCOL REP, V24, P909, DOI 10.3892/or_00000936; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; BULL DM, 1977, J CLIN INVEST, V59, P966, DOI 10.1172/JCI108719; Clovel T, 2007, INFLAMM BOWEL DIS, V13, P1153, DOI 10.1002/ibd.20174; Ellenrieder V, 2002, J GASTROINTEST CANC, V31, P61, DOI 10.1385/IJGC:31:1-3:61; Ellenrieder V, 2001, CANCER RES, V61, P4222; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Gavert N, 2011, MOL CANCER RES, V9, P14, DOI 10.1158/1541-7786.MCR-10-0406; Geismann C, 2011, INT J ONCOL, V38, P257, DOI 10.3892/ijo_00000846; Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493; GOLDER JP, 1983, GASTROENTEROLOGY, V84, P795; Grage-Griebenow E, 2001, EUR J IMMUNOL, V31, P48; Herszenyi L, 2007, DIGEST DIS, V25, P267, DOI 10.1159/000103898; Hosui A, 2009, J EXP MED, V206, P819, DOI 10.1084/jem.20080003; Huszar M, 2006, HUM PATHOL, V37, P1000, DOI 10.1016/j.humpath.2006.03.014; Huszar M, 2010, J PATHOL, V220, P551, DOI 10.1002/path.2673; Kaifi JT, 2007, MODERN PATHOL, V20, P1183, DOI 10.1038/modpathol.3800955; Kamada N, 2005, J IMMUNOL, V175, P6900, DOI 10.4049/jimmunol.175.10.6900; Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990; Lawrance IC, 2001, INFLAMM BOWEL DIS, V7, P16, DOI 10.1097/00054725-200102000-00003; Matsumoto S, 2010, J IMMUNOL, V184, P1543, DOI 10.4049/jimmunol.0801217; Min JK, 2010, CLIN CANCER RES, V16, P3571, DOI 10.1158/1078-0432.CCR-09-3075; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Rahimi R, 2002, MED SCI MONITOR, V13, pPI13; Rezaie A, 2006, ANN NY ACAD SCI, V1091, P110, DOI 10.1196/annals.1378.060; Roessner A, 2008, PATHOL RES PRACT, V204, P511, DOI 10.1016/j.prp.2008.04.011; Rogler G, 1998, CLIN EXP IMMUNOL, V112, P205; Rogler G, 1997, EUR J GASTROEN HEPAT, V9, P893, DOI 10.1097/00042737-199709000-00013; Schiechl G, 2011, J CLIN INVEST, V121, P1692, DOI 10.1172/JCI42540; Schniewind B, 2007, ONCOGENE, V26, P4850, DOI 10.1038/sj.onc.1210272; Sebens S, 2011, J BIOL CHEM, V286, P40911, DOI 10.1074/jbc.M111.274902; Smith PD, 2001, J IMMUNOL, V167, P2651, DOI 10.4049/jimmunol.167.5.2651; Smith PD, 2005, IMMUNOL REV, V206, P149, DOI 10.1111/j.0105-2896.2005.00288.x; Smythies LE, 2005, J CLIN INVEST, V115, P66, DOI 10.1172/JCI200519229; Stadnicki A, 2009, INT IMMUNOPHARMACOL, V9, P761, DOI 10.1016/j.intimp.2009.02.014; Stoeck A, 2007, GYNECOL ONCOL, V104, P461, DOI 10.1016/j.ygyno.2006.08.038; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Verreck FAW, 2006, J LEUKOCYTE BIOL, V79, P285, DOI 10.1189/jlb.0105015; Wiercinska-Drapalo A, 2001, CYTOKINE, V14, P343, DOI 10.1006/cyto.2001.0901; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Xie JL, 2008, WORLD J GASTROENTERO, V14, P378, DOI 10.3748/wjg.14.378; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	47	38	38	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					180	189		10.1038/onc.2012.44	http://dx.doi.org/10.1038/onc.2012.44			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349829				2022-12-28	WOS:000314075500006
J	Smith, AL; Iwanaga, R; Drasin, DJ; Micalizzi, DS; Vartuli, RL; Tan, AC; Ford, HL				Smith, A. L.; Iwanaga, R.; Drasin, D. J.; Micalizzi, D. S.; Vartuli, R. L.; Tan, A-C; Ford, H. L.			The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer	ONCOGENE			English	Article						Six1; miRNA; TGF-beta; epithelial-to-mesenchymal transition; tumor-initiating cell	EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; MICRORNA CLUSTER; CARCINOMA CELLS; OVEREXPRESSION; METASTASIS; MECHANISM; PROTEIN; GROWTH; LUNG	The role of TGF-beta signaling in tumorigenesis is paradoxical: it can be tumor suppressive or tumor promotional, depending on context. The metastatic regulator, Six1, was recently shown to mediate this switch, providing a novel means to explain this elusive 'TGF-beta paradox'. Herein, we identify a mechanism by which Six1 activates the tumor promotional arm of TGF-beta signaling, via its ability to upregulate the miR-106b-25 microRNA cluster, and further identify a novel function for this cluster of microRNAs. Although expression of the miR-106b-25 cluster is known to overcome TGF-beta-mediated growth suppression via targeting p21 and BIM, we demonstrate for the first time that this same cluster can additionally target the inhibitory Smad7 protein, resulting in increased levels of the TGF-beta type I receptor and downstream activation of TGF-beta signaling. We further show that the miR-106b-25 cluster is sufficient to induce an epithelial-to-mesenchymal transition and a tumor initiating cell phenotype, and that it is required downstream of Six1 to induce these phenotypes. Finally, we demonstrate a significant correlation between miR-106b, Six1, and activated TGF-beta signaling in human breast cancers, and further show that high levels of miR-106b and miR-93 in breast tumors significantly predicts shortened time to relapse. These findings expand the spectrum of oncogenic functions of miR-106b-25, and may provide a novel molecular explanation, through the Six1 regulated miR-106b-25 cluster, by which TGF-beta signaling shifts from tumor suppressive to tumor promoting. Oncogene (2012) 31, 5162-5171; doi:10.1038/onc.2012.11; published online 30 January 2012	[Ford, H. L.] Univ Colorado Anschutz Med Campus, Dept Obstet & Gynecol, Program Mol Biol, Med Scientist Training Program, Aurora, CO 80045 USA; [Tan, A-C] Univ Colorado Anschutz Med Campus, Dept Med, Aurora, CO 80045 USA; [Ford, H. L.] Univ Colorado Anschutz Med Campus, Dept Biochem & Mol Genet, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Ford, HL (corresponding author), Univ Colorado Anschutz Med Campus, Dept Obstet & Gynecol, Program Mol Biol, Med Scientist Training Program, 12700 E 19th St,RC2,Rm 3100C, Aurora, CO 80045 USA.	heide.ford@ucdenver.edu	Reever, Larson/H-9685-2019; Tan, Aik Choon/A-3135-2011	Reever, Larson/0000-0002-5692-4793; Tan, Aik Choon/0000-0003-2955-8369; Micalizzi, Douglas/0000-0002-0306-9914	National Cancer Institute [2ROI-CA095277]; American Cancer Society [RSG-07-183-01-DDC]; Department of Defense Breast Cancer Research Program [W81XWH-10-1-0296, W81XWH-06-1-0757]; NATIONAL CANCER INSTITUTE [R01CA095277, P30CA046934] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Department of Defense Breast Cancer Research Program(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by grants from the National Cancer Institute (2ROI-CA095277) and The American Cancer Society (no. RSG-07-183-01-DDC) to HLF. ALS is funded by a predoctoral fellowship from the Department of Defense Breast Cancer Research Program (W81XWH-10-1-0296). DSM was funded by a predoctoral fellowship from the Department of Defense Breast Cancer Research Program (W81XWH-06-1-0757).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Brett JO, 2011, AGING-US, V3, P108, DOI 10.18632/aging.100285; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Chopra VS, 2006, BIOESSAYS, V28, P445, DOI 10.1002/bies.20401; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Ho J, 2011, J AM SOC NEPHROL, V22, P1053, DOI 10.1681/ASN.2010080841; Hu YL, 2010, NUCLEIC ACIDS RES, V38, P5472, DOI 10.1093/nar/gkq337; Inman GJ, 2011, CURR OPIN GENET DEV, V21, P93, DOI 10.1016/j.gde.2010.12.004; Jorgensen S, 2010, METHODS, V52, P375, DOI 10.1016/j.ymeth.2010.07.002; Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Li ZH, 2011, EMBO J, V30, P823, DOI 10.1038/emboj.2011.2; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Micalizzi DS, 2010, CANCER RES, V70, P10371, DOI 10.1158/0008-5472.CAN-10-1354; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Qian S, 2008, BIOCHEM BIOPH RES CO, V377, P668, DOI 10.1016/j.bbrc.2008.10.052; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Yan XH, 2011, BIOCHEM J, V434, P1, DOI 10.1042/BJ20101827; Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018	35	227	248	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5162	5171		10.1038/onc.2012.11	http://dx.doi.org/10.1038/onc.2012.11			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22286770	Green Accepted			2022-12-28	WOS:000312449800005
J	Babbio, F; Pistore, C; Curti, L; Castiglioni, I; Kunderfranco, P; Brino, L; Oudet, P; Seiler, R; Thalman, GN; Roggero, E; Sarti, M; Pinton, S; Mello-Grand, M; Chiorino, G; Catapano, CV; Carbone, GM; Bonapace, IM				Babbio, F.; Pistore, C.; Curti, L.; Castiglioni, I.; Kunderfranco, P.; Brino, L.; Oudet, P.; Seiler, R.; Thalman, G. N.; Roggero, E.; Sarti, M.; Pinton, S.; Mello-Grand, M.; Chiorino, G.; Catapano, C. V.; Carbone, G. M.; Bonapace, I. M.			The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression	ONCOGENE			English	Article						prostate cancer; epigenetics; UHRF1; EZH2; Suv39H1	TUMOR-SUPPRESSOR GENE; DNA METHYLATION; PERICENTROMERIC HETEROCHROMATIN; TRANSCRIPTION FACTOR; CPG ISLAND; E-CADHERIN; CELLS; REPRESSION; EXPRESSION; EZH2	Epigenetic silencing of tumour suppressor genes is an important mechanism involved in cell transformation and tumour progression. The Set and RING-finger-associated domain-containing protein UHRF1 might be an important link between different epigenetic pathways. Here, we report that UHRF1 is frequently overexpressed in human prostate tumours and has an important role in prostate cancer pathogenesis and progression. Analysis of human prostate cancer samples by microarrays and immunohistochemistry showed increased expression of UHRF1 in about half of the cases. Moreover, UHRF1 expression was associated with reduced overall survival after prostatectomy in patients with organ-confined prostate tumours (P<0.0001). UHRF1 expression was negatively correlated with several tumour suppressor genes and positively with the histone methyltransferase (HMT) EZH2 both in prostate tumours and cell lines. UHRF1 knockdown reduced proliferation, clonogenic capability and anchorage-independent growth of prostate cancer cells. Depletion of UHRF1 resulted in reactivation of several tumour suppressor genes. Gene reactivation upon UHRF1 depletion was associated with changes in histone H3K9 methylation, acetylation and DNA methylation, and impaired binding of the H3K9 HMT Suv39H1 to the promoter of silenced genes. Co-immunoprecipitation experiments showed direct interaction between UHRF1 and Suv39H1. Our data support the notion that UHRF1, along with Suv39H1 and DNA methyltransferases, contributes to epigenetic gene silencing in prostate tumours. This could represent a parallel and convergent pathway to the H3K27 methylation catalyzed by EZH2 to synergistically promote inactivation of tumour suppressor genes. Deregulated expression of UHRF1 is involved in the prostate cancer pathogenesis and might represent a useful marker to distinguish indolent cancer from those at high risk of lethal progression.	[Babbio, F.; Pistore, C.; Castiglioni, I.; Bonapace, I. M.] Univ Insubria, Dept Struct & Funct Biol, I-21052 Busto Arsizio, Varese, Italy; [Curti, L.; Kunderfranco, P.; Sarti, M.; Pinton, S.; Catapano, C. V.; Carbone, G. M.] IOR, Bellinzona, Switzerland; [Curti, L.; Kunderfranco, P.; Roggero, E.; Sarti, M.; Pinton, S.; Catapano, C. V.; Carbone, G. M.] Oncol Inst So Switzerland IOSI, Bellinzona, Switzerland; [Brino, L.; Oudet, P.; Bonapace, I. M.] ULP, INSERM U596, UMR CNRS 7104, IGBMC,Dept Biol Canc, Strasbourg, France; [Brino, L.; Oudet, P.] Canc Pole Grand Est, Tranfected Cell Array Platform, Strasbourg, France; [Seiler, R.; Thalman, G. N.] Univ Bern, Inselspital, Dept Urol, Urol Res Lab, CH-3010 Bern, Switzerland; [Mello-Grand, M.; Chiorino, G.] Fondo Edo Tempia, Lab Canc Genom, Biella, Italy	University of Insubria; Institute of Oncology Research (IOR); Universita della Svizzera Italiana; Institute of Oncology Research (IOR); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Bern; University Hospital of Bern	Bonapace, IM (corresponding author), Univ Insubria, Dept Struct & Funct Biol, Via A da Giussano 12, I-21052 Busto Arsizio, Varese, Italy.	pina.carbone@irb.unisi.ch; ian.bonapace@uninsubria.it	Kunderfranco, Paolo/ABH-9294-2020; Kunderfranco, Paolo/J-7636-2016; Chiorino, Giovanna/K-5037-2016; Kunderfranco, Paolo/GUQ-8968-2022	Kunderfranco, Paolo/0000-0001-7477-8710; Kunderfranco, Paolo/0000-0003-3636-3391; Chiorino, Giovanna/0000-0002-9502-6400; Kunderfranco, Paolo/0000-0001-7477-8710; BONAPACE, IAN MARC/0000-0001-6580-8893; Catapano, Carlo V./0000-0002-7079-557X; Seiler, Roland/0000-0002-3529-2088; Brino, laurent/0000-0002-9036-1461; Castiglioni, Ilaria/0000-0003-1165-7844	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-10742]; Fondazione Cariplo 'Progetto Nobel'; Oncosuisse [OCS-01913-08]; Swiss National Science Foundation [FNS-31003A-118113]; Ticino Foundation for Cancer Research; Fondazione Compagnia di San Paolo; Universite de Strasbourg; Region Alsace; Conseil General du Bas Rhin; Communaute Urbaine de Strasbourg; Canceropole du Grand Est, France; Institut National du Cancer (INCa); Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariplo 'Progetto Nobel'(Fondazione Cariplo); Oncosuisse; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Ticino Foundation for Cancer Research; Fondazione Compagnia di San Paolo(Compagnia di San Paolo); Universite de Strasbourg; Region Alsace(Region Grand-Est); Conseil General du Bas Rhin; Communaute Urbaine de Strasbourg; Canceropole du Grand Est, France(Region Grand-Est); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC)	We acknowledge Benoit Fischer, Laure Froidevaux and Amelie Weiss from the High-Throughput Screening facility (IGBMC) for their contribution to the project; Martina Mandruzzato and Giada Tamolli for their collaboration as undergraduate students; Dr Giampaolo Perletti for reviewing the manuscript and Professor Gianfranco Badaracco for constant support. Grant support: This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) project No IG-10742 and Fondazione Cariplo 'Progetto Nobel' to IMB and by Oncosuisse (OCS-01913-08), the Swiss National Science Foundation (FNS-31003A-118113) and Ticino Foundation for Cancer Research to GMC, and the Fondazione Compagnia di San Paolo to GC. Further support is acknowledged from the Universite de Strasbourg, Region Alsace, Conseil General du Bas Rhin, Communaute Urbaine de Strasbourg, Canceropole du Grand Est, France, Institut National du Cancer (INCa) and Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC).	Abdulkadir SA, 2005, ANN NY ACAD SCI, V1059, P33, DOI 10.1196/annals.1339.018; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bastian PJ, 2007, EUR UROL, V51, P665, DOI 10.1016/j.eururo.2006.08.008; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Cangemi R, 2008, ONCOGENE, V27, P2877, DOI 10.1038/sj.onc.1210953; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t; Chuang TD, 2010, J BIOL CHEM, V285, P23598, DOI 10.1074/jbc.M109.098301; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Jeronimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643; Jeronimo C, 2011, EUR UROL, V60, P753, DOI 10.1016/j.eururo.2011.06.035; Kawano Y, 2009, BRIT J CANCER, V100, P1165, DOI 10.1038/sj.bjc.6604976; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Koizume S, 2002, NUCLEIC ACIDS RES, V30, P4770, DOI 10.1093/nar/gkf593; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037; Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547; Li QA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013732; Meilinger D, 2009, EMBO REP, V10, P1259, DOI 10.1038/embor.2009.201; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Napoli S, 2009, EMBO J, V28, P1708, DOI 10.1038/emboj.2009.139; Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Papait R, 2008, MOL BIOL CELL, V19, P3554, DOI 10.1091/mbc.E07-10-1059; Papait R, 2007, MOL BIOL CELL, V18, P1098, DOI 10.1091/mbc.E06-09-0874; Park JY, 2007, CANCER DETECT PREV, V31, P359, DOI 10.1016/j.cdp.2007.09.002; Perry AS, 2010, NAT REV UROL, V7, P668, DOI 10.1038/nrurol.2010.185; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Prtilo A, 2005, J UROLOGY, V174, P1814, DOI 10.1097/01.ju.0000176796.47988.64; Raha T, 2005, PLOS BIOL, V3, P221, DOI 10.1371/journal.pbio.0030044; Richiardi L, 2009, J CLIN ONCOL, V27, P3161, DOI 10.1200/JCO.2008.18.2485; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Unoki M, 2009, BRIT J CANCER, V101, P98, DOI 10.1038/sj.bjc.6605123; Unoki M, 2009, BIOCHEM PHARMACOL, V78, P1279, DOI 10.1016/j.bcp.2009.05.035; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Yang YJ, 2010, NUCLEIC ACIDS RES, V38, P382, DOI 10.1093/nar/gkp991; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498	50	91	100	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	46					4878	4887		10.1038/onc.2011.641	http://dx.doi.org/10.1038/onc.2011.641			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22330138				2022-12-28	WOS:000311210700008
J	Yang, S; Li, Y; Gao, J; Zhang, T; Li, S; Luo, A; Chen, H; Ding, F; Wang, X; Liu, Z				Yang, S.; Li, Y.; Gao, J.; Zhang, T.; Li, S.; Luo, A.; Chen, H.; Ding, F.; Wang, X.; Liu, Z.			MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1	ONCOGENE			English	Article						miR-34a; miR-34c; breast cancer; metastasis	NEGATIVE FEEDBACK LOOP; C-MET EXPRESSION; MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; DOWN-REGULATION; INHIBITS MIGRATION; MIR-34A; FAMILY; METHYLATION	MicroRNAs have key roles in tumor metastasis. Here, we describe the regulation and function of miR-34a and miR-34c (miR-34a/c) in breast cancer metastasis. Expression analysis verified that miR-34a/c expression is significantly decreased in metastatic breast cancer cells and human primary breast tumors with lymph node metastases. Overexpression of miR-34a/c could inhibit breast cancer cell migration and invasion in vitro and distal pulmonary metastasis in vivo. Further studies revealed that Fos-related antigen 1 (Fra-1 or Fosl1) is a downstream target of miR-34a/c as miR-34a/c bound directly to the 3'untranslated region of Fra-1, subsequently reducing both the mRNA and protein levels of Fra-1. Silencing of Fra-1 recapitulated the effects of miR-34a/c overexpression, whereas enforced expression of Fra-1 reverses the suppressive effects of miR-34a/c. Moreover, significant downregulation of miR-34a in metastatic breast cancer tissues was found to be inversely correlated with Fra-1 expression. Our results demonstrate that miR-34a/c functions as a metastasis suppressor to regulate breast cancer migration and invasion through targeting Fra-1 oncogene and suggest a therapeutic application of miR-34 in breast cancer.	[Yang, S.; Li, Y.; Zhang, T.; Li, S.; Luo, A.; Chen, H.; Ding, F.; Liu, Z.] Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst & Hosp, Beijing 100021, Peoples R China; [Yang, S.; Li, Y.; Gao, J.; Zhang, T.; Li, S.; Luo, A.; Chen, H.; Ding, F.; Wang, X.; Liu, Z.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Gao, J.; Wang, X.] Chinese Acad Med Sci, Dept Abdominal Surg, Canc Inst & Hosp, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS	Wang, X (corresponding author), Chinese Acad Med Sci, Dept Abdominal Surg, Canc Inst & Hosp, Beijing 100021, Peoples R China.	xiangw@vip.sina.com; liuzh@cicams.ac.cn	Yang, Shouhui/M-5374-2017	Wang, Xiang/0000-0002-1522-9532; Li, Sheng/0000-0001-8080-9712	National Basic Research Program of China [2011CB504205]; National Natural Science Foundation of China [91019009, 81021061]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Ziqiang Zhang, Yongquan Wang and Zhiyuan Wu for providing technical support. This work was supported by the National Basic Research Program of China (2011CB504205) and National Natural Science Foundation of China (91019009, 81021061).	Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen L, 2009, CANCER RES, V69, P8853, DOI 10.1158/0008-5472.CAN-09-1636; Chiappetta G, 2000, CLIN CANCER RES, V6, P4300; Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033; Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Debinski W, 2005, MOL CANCER RES, V3, P237; Ellsworth RE, 2008, BREAST CANCER RES TR, V107, P259, DOI 10.1007/s10549-007-9547-2; Ellsworth RE, 2003, CANCER EPIDEM BIOMAR, V12, P915; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gee HE, 2008, NATURE, V455, DOI 10.1038/nature07362; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guessous F, 2010, CELL CYCLE, V9, P1031, DOI 10.4161/cc.9.6.10987; Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hwang CI, 2011, P NATL ACAD SCI USA, V108, P14240, DOI 10.1073/pnas.1017536108; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Li N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035; Li Y, 2010, CANCER RES, V70, P7894, DOI 10.1158/0008-5472.CAN-10-1675; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Lv Xiao-Bin, 2011, Chin J Cancer, V30, P821, DOI 10.5732/cjc.011.10289; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Mackiewicz M, 2011, BREAST CANCER RES TR, V130, P663, DOI 10.1007/s10549-011-1690-0; Migliore C, 2008, CANCER RES, V68, P10128, DOI 10.1158/0008-5472.CAN-08-2148; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Mudduluru G, 2011, ONCOGENE, V30, P2888, DOI 10.1038/onc.2011.13; NAGAI H, 1995, CANCER RES, V55, P1752; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Osborne RJ, 2000, CANCER RES, V60, P3706; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Sayan AE, 2011, ONCOGENE, V25, P8; Serewko MM, 2002, CANCER RES, V62, P3759; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538; Sun F, 2008, FEBS LETT, V582, P1564, DOI 10.1016/j.febslet.2008.03.057; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877; Tkach V, 2003, ONCOGENE, V22, P5045, DOI 10.1038/sj.onc.1206570; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Usui A, 2012, CANCER-AM CANCER SOC, V118, P3387, DOI 10.1002/cncr.26652; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; WINQVIST R, 1995, CANCER RES, V55, P2660; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860; Yu FY, 2012, J BIOL CHEM, V287, P465, DOI 10.1074/jbc.M111.280768; Zajchowski DA, 2001, CANCER RES, V61, P5168	67	176	181	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4294	4303		10.1038/onc.2012.432	http://dx.doi.org/10.1038/onc.2012.432			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23001043				2022-12-28	WOS:000324168000011
J	Sunaga, N; Kaira, K; Imai, H; Shimizu, K; Nakano, T; Shames, DS; Girard, L; Soh, J; Sato, M; Iwasaki, Y; Ishizuka, T; Gazdar, AF; Minna, JD; Mori, M				Sunaga, N.; Kaira, K.; Imai, H.; Shimizu, K.; Nakano, T.; Shames, D. S.; Girard, L.; Soh, J.; Sato, M.; Iwasaki, Y.; Ishizuka, T.; Gazdar, A. F.; Minna, J. D.; Mori, M.			Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer	ONCOGENE			English	Article						NSCLC; KRAS; EREG; therapeutic target	EPIDERMAL-GROWTH-FACTOR; COPY NUMBER GAINS; SIGNALING PATHWAY; RAS ONCOGENE; EXPRESSION; MUTATIONS; EGFR; ACTIVATION; RESISTANCE; GEFITINIB	KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer (NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a significant challenge in NSCLC therapy. We recently identified epiregulin (EREG) as one of several putative transcriptional targets of oncogenic KRAS signaling in both KRAS-mutant NSCLC cells and immortalized bronchial epithelial cells expressing ectopic mutant KRAS. In the current study, we found that EREG is overexpressed in NSCLCs harboring KRAS, BRAF or EGFR mutations compared with NSCLCs with wild-type KRAS/BRAF/EGFR. Small interfering RNAs (siRNAs) targeting mutant KRAS, but not an siRNA targeting wild-type KRAS, significantly reduced EREG expression in KRAS-mutant and EREG-overexpressing NSCLC cell lines. In these cell lines, EREG expression was downregulated by MEK and ERK inhibitors. Importantly, EREG expression significantly correlated with KRAS expression or KRAS copy number in KRAS-mutant NSCLC cell lines. Further expression analysis using 89 NSCLC specimens showed that EREG was predominantly expressed in NSCLCs with pleural involvement, lymphatic permeation or vascular invasion and in KRAS-mutant adenocarcinomas. In addition, multivariate analysis revealed that EREG expression is an independent prognostic marker and EREG overexpression in combination with KRAS mutations was associated with an unfavorable prognosis for lung adenocarcinoma patients. In KRAS-mutant and EREG overexpressing NSCLC cells, siRNA-mediated EREG silencing inhibited anchorage-dependent and -independent growth and induced apoptosis. Our findings suggest that oncogenic KRAS-induced EREG overexpression contributes to an aggressive phenotype and could be a promising therapeutic target in oncogenic KRAS-driven NSCLC.	[Sunaga, N.; Kaira, K.; Imai, H.; Iwasaki, Y.; Ishizuka, T.; Mori, M.] Gunma Univ, Sch Med, Dept Med & Mol Sci, Maebashi, Gunma 3718511, Japan; [Shimizu, K.; Nakano, T.] Gunma Univ, Sch Med, Maebashi, Gunma 3718511, Japan; [Shames, D. S.] Genentech Inc, Oncol Diagnost, San Francisco, CA 94080 USA; [Shames, D. S.; Girard, L.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Girard, L.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Soh, J.; Gazdar, A. F.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Minna, J. D.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Sato, M.] Nagoya Univ, Grad Sch Med, Dept Resp Med, Showa Ku, Nagoya, Aichi 4648601, Japan; [Soh, J.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg, Kita Ku, Okayama, Japan	Gunma University; Gunma University; Roche Holding; Genentech; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Nagoya University; Okayama University	Sunaga, N (corresponding author), Gunma Univ, Sch Med, Dept Canc & Thorac Med & Mol Sci, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.	nsunaga@showa.gunma-u.ac.jp	Soh, Junichi/AAV-1053-2020; Sato, MITSUO/I-7280-2014; Soh, Junichi/AAT-7095-2021; Imai, Hisao/AAB-7248-2021	Soh, Junichi/0000-0001-8532-7915; Sato, MITSUO/0000-0001-5458-9576; Soh, Junichi/0000-0001-8532-7915; Imai, Hisao/0000-0003-3097-4255	Japan Society for the Promotion of Science [23591134]; SPORE [P50CA70907]; DOD PROSPECT, Texas Higher Education Coordinating Board Advanced Technology Program [01001901392003]; Gillson Longenbaugh Foundation; NASA Specialized Center of Research [NNJ05HD36G]; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23591134] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); SPORE; DOD PROSPECT, Texas Higher Education Coordinating Board Advanced Technology Program; Gillson Longenbaugh Foundation; NASA Specialized Center of Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grants-in-Aid for Scientific Research (C) (grant #23591134) from the Japan Society for the Promotion of Science. Funding for this work also came from SPORE (P50CA70907); DOD PROSPECT, Texas Higher Education Coordinating Board Advanced Technology Program (grant #01001901392003); Gillson Longenbaugh Foundation; NASA Specialized Center of Research (grant #NNJ05HD36G). We thank Drs Yoshio Tomizawa, Noriko Yanagitani, Hironobu Iijima, Takeshi Hisada, Mitsuyoshi Utsugi of the Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan for technical support and critical advices. We also thank Drs Kenneth Huffman and Victor Stastny of the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center at Dallas for kind assistance.	Baba I, 2000, CANCER RES, V60, P6886; Cho MC, 2008, BIOCHEM BIOPH RES CO, V377, P832, DOI 10.1016/j.bbrc.2008.10.053; Chu EK, 2005, AM J RESP CELL MOL, V32, P373, DOI 10.1165/rcmb.2004-0266OC; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Draper BK, 2003, J CELL BIOCHEM, V89, P1126, DOI 10.1002/jcb.10584; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Gandhi J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004576; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Gazdar AF, 2008, CANCER PREV RES, V1, P156, DOI 10.1158/1940-6207.CAPR-08-0080; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Hu K, 2009, ORAL ONCOL, V45, P156, DOI 10.1016/j.oraloncology.2008.04.009; Imai H, 2010, INT J IMMUNOPATH PH, V23, P153, DOI 10.1177/039463201002300114; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kaira K, 2010, J CLIN ONCOL, V28, P3746, DOI 10.1200/JCO.2009.27.4662; Kris MG, 2011, J CLIN ONCOL, V29; Larsen JE, 2011, CLIN CHEST MED, V32, P703, DOI 10.1016/j.ccm.2011.08.003; Lee S, 2009, INT J ONCOL, V34, P161, DOI 10.3892/ijo_00000138; Lindvall C, 2003, CANCER RES, V63, P1743; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Morita S, 2009, CLIN CANCER RES, V15, P4493, DOI 10.1158/1078-0432.CCR-09-0391; Nicholson BE, 2004, CANCER RES, V64, P7813, DOI 10.1158/0008-5472.CAN-04-0826; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Phelps RM, 1996, J CELL BIOCHEM, P32; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Regales L, 2009, J CLIN INVEST, V119, P3000, DOI 10.1172/JCI38746; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Soh J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007464; Suda K, 2010, CANCER METAST REV, V29, P49, DOI 10.1007/s10555-010-9209-4; Sun MH, 2009, CLIN CANCER RES, V15, P4829, DOI 10.1158/1078-0432.CCR-08-2921; Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941; Sunaga N, 2012, INT J CANCER, V130, P1733, DOI 10.1002/ijc.26164; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Takahashi M, 2003, CIRCULATION, V108, P2524, DOI 10.1161/01.CIR.0000096482.02567.8C; Thogersen VB, 2001, CANCER RES, V61, P6227; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; Wang XY, 2009, MOL CARCINOGEN, V48, P1, DOI 10.1002/mc.20449; Yamamoto H, 2008, CANCER RES, V68, P6913, DOI 10.1158/0008-5472.CAN-07-5084; Zhang J, 2008, CANCER PREV RES, V1, P201, DOI 10.1158/1940-6207.CAPR-08-0014; Zhao M, 2009, BIOCHEM BIOPH RES CO, V387, P239, DOI 10.1016/j.bbrc.2009.06.128; Zhu ZW, 2000, BIOCHEM BIOPH RES CO, V273, P1019, DOI 10.1006/bbrc.2000.3033	47	42	44	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4034	4042		10.1038/onc.2012.402	http://dx.doi.org/10.1038/onc.2012.402			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22964644	Green Accepted			2022-12-28	WOS:000323748100012
J	Budiu, RA; Elishaev, E; Brozick, J; Lee, M; Edwards, RP; Kalinski, P; Vlad, AM				Budiu, R. A.; Elishaev, E.; Brozick, J.; Lee, M.; Edwards, R. P.; Kalinski, P.; Vlad, A. M.			Immunobiology of human mucin 1 in a preclinical ovarian tumor model	ONCOGENE			English	Article						ovarian cancer; MUC1; Kras; Pten; dendritic cells	CARCINOMA-ASSOCIATED ANTIGEN; MAJOR HISTOCOMPATIBILITY COMPLEX; REGULATORY T-CELLS; MOUSE MODEL; MOLECULAR-CLONING; GENE-EXPRESSION; CANCER; MICE; TOLERANCE; PTEN	Epithelial ovarian cancer is an aggressive malignancy, with a low 5-year median survival. Continued improvement on the development of more effective therapies depends in part on the availability of adequate preclinical models for in vivo testing of treatment efficacy. Mucin 1 (MUC1) glycoprotein is a tumor-associated antigen overexpressed in ovarian cancer cells, making it a potential target for immune therapy. To create a preclinical mouse model for MUC1-positive ovarian tumors, we generated triple transgenic (Tg) mice that heterozygously express human MUC1(+/+) as a transgene, and carry the conditional K-rasG12D oncoallele (loxP-Stop-loxP-K-ras(G12D/+)) and the floxed Pten gene (Pten/(loxP/loxP)). Injection of Cre recombinase-encoding adenovirus (AdCre) in the ovarian bursa of triple (MUC1KrasPten) Tg mice triggers ovarian tumors that, in analogy to human ovarian cancer, express strongly elevated MUC1 levels. The tumors metastasize loco-regionally and are accompanied by high serum MUC1, closely mimicking the human disease. Compared with the KrasPten mice with tumors, the MUC1KrasPten mice show increased loco-regional metastasis and augmented accumulation of CD4+Foxp3+ immune-suppressive regulatory T cells. Vaccination of MUC1KrasPten mice with type 1 polarized dendritic cells (DC1) loaded with a MUC1 peptide (DC1-MUC1) can circumvent tumor-mediated immune suppression in the host, activate multiple immune effector genes and effectively prolong survival. Our studies report the first human MUC1-expressing, orthotopic ovarian tumor model, reveal novel MUC1 functions in ovarian cancer biology and demonstrate its suitability as a target for immune-based therapies.	[Budiu, R. A.; Elishaev, E.; Edwards, R. P.; Vlad, A. M.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA; [Budiu, R. A.; Brozick, J.; Lee, M.; Edwards, R. P.; Vlad, A. M.] Magee Womens Res Inst, Pittsburgh, PA USA; [Elishaev, E.] Univ Pittsburgh, Med Ctr, Dept Pathol, Magee Womens Hosp, Pittsburgh, PA 15213 USA; [Kalinski, P.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Kalinski, P.] Univ Pittsburgh, Sch Med, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15213 USA; [Kalinski, P.; Vlad, A. M.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Vlad, AM (corresponding author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Magee Womens Res Inst, Room B403,204 Craft Ave, Pittsburgh, PA 15213 USA.	vladam@upmc.edu	Brozick, Joan/AAA-5785-2019		Department of Defense Ovarian Cancer Academy Award; Pennsylvania Department of Health; Scaife Foundation; NIH/NCI [1 R01 CA163462-01]; NATIONAL CANCER INSTITUTE [R01CA163462] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER	Department of Defense Ovarian Cancer Academy Award; Pennsylvania Department of Health; Scaife Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We would like to thank Dr Daniela Dinulescu for discussion on various aspects of the mouse model, Dr Olivera Finn for critical review of the paper and Julia Thaller for technical assistance with histology work. This study was supported by the Department of Defense Ovarian Cancer Academy Award, Pennsylvania Department of Health, Scaife Foundation and NIH/NCI 1 R01 CA163462-01 (to AMV).	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Allavena P, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/547179; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; Beatty PL, 2007, J IMMUNOL, V179, P735, DOI 10.4049/jimmunol.179.2.735; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Boyd J, 2005, NEW ENGL J MED, V352, P2240, DOI 10.1056/NEJMcibr051024; Brayman Melissa, 2004, Reprod Biol Endocrinol, V2, P4, DOI 10.1186/1477-7827-2-4; Budiu RA, 2011, CANCER IMMUNOL IMMUN, V60, P975, DOI 10.1007/s00262-011-1010-x; Budiu RA, 2009, DIS MODEL MECH, V2, P593, DOI 10.1242/dmm.002535; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Chen DS, 2000, BREAST CANCER RES TR, V60, P107, DOI 10.1023/A:1006332009414; Connolly DC, 2003, CANCER RES, V63, P1389; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Fan HY, 2009, CANCER RES, V69, P6463, DOI 10.1158/0008-5472.CAN-08-3363; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Giermasz AS, 2009, CANCER IMMUNOL IMMUN, V58, P1329, DOI 10.1007/s00262-008-0648-5; Hiltbold EM, 2000, J IMMUNOL, V165, P3730, DOI 10.4049/jimmunol.165.7.3730; HO SB, 1993, CANCER RES, V53, P641; IOANNIDES CG, 1993, J IMMUNOL, V151, P3693; JEROME KR, 1993, J IMMUNOL, V151, P1654; Kandalaft LE, 2011, J CLIN ONCOL, V29, P925, DOI 10.1200/JCO.2009.27.2369; Karam AK, 2010, NAT REV CLIN ONCOL, V7, P335, DOI 10.1038/nrclinonc.2010.44; KOTERA Y, 1994, CANCER RES, V54, P2856; Kryczek I, 2007, CANCER RES, V67, P8900, DOI 10.1158/0008-5472.CAN-07-1866; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; Matzuk MM, 2005, NAT MED, V11, P24, DOI 10.1038/nm0105-24; Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004; Mullany LK, 2011, ONCOGENE, V30, P3522, DOI 10.1038/onc.2011.70; Odunsi K, 2008, AM J REPROD IMMUNOL, V59, P62, DOI 10.1111/j.1600-0897.2007.00560.x; Palucka K, 2011, J IMMUNOL, V186, P1325, DOI 10.4049/jimmunol.0902539; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Reinartz S, 2012, EUR J CANCER, V48, P1558, DOI 10.1016/j.ejca.2011.07.004; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rowse GJ, 1998, CANCER RES, V58, P315; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Rustin GJS, 2004, CLIN CANCER RES, V10, P3919, DOI 10.1158/1078-0432.CCR-03-0787; Ryan SO, 2009, BIOL CHEM, V390, P611, DOI 10.1515/BC.2009.070; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Shan WW, 2009, CELL CYCLE, V8, P731, DOI 10.4161/cc.8.5.7848; SPICER AP, 1991, J BIOL CHEM, V266, P15099; Tanwar PS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020715; Theriault C, 2011, GYNECOL ONCOL, V121, P434, DOI 10.1016/j.ygyno.2011.02.020; Tinder TL, 2008, J IMMUNOL, V181, P3116, DOI 10.4049/jimmunol.181.5.3116; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Vlad AM, 2002, J EXP MED, V196, P1435, DOI 10.1084/jem.20020493; Vlad AM, 2006, IMMUNOL RES, V36, P229, DOI 10.1385/IR:36:1:229; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang DH, 2006, AM J PATHOL, V169, P258, DOI 10.2353/ajpath.2006.060036	58	24	24	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2013	32	32					3664	3675		10.1038/onc.2012.397	http://dx.doi.org/10.1038/onc.2012.397			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22964632	Green Accepted			2022-12-28	WOS:000322904400002
J	Kang, DW; Hwang, WC; Park, MH; Ko, GH; Ha, WS; Kim, KS; Lee, YC; Choi, KY; Min, DS				Kang, D. W.; Hwang, W. C.; Park, M. H.; Ko, G-H; Ha, W-S; Kim, K-S; Lee, Y-C; Choi, K-Y; Min, D. S.			Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NF kappa B and suppresses invasion of gastric cancer cells	ONCOGENE			English	Article						phospholipase D1; Helicobacter pylori; CagA; gastric cancer; NF kappa B; rebamipide	TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; C-MET; ACTIVATION; PATHWAY; SECRETION; PROTEIN; MATRIX-METALLOPROTEINASE-9; PROLIFERATION; MECHANISMS	Infection with cagA-positive Helicobacter pylori is a risk factor for the development of severe gastritis and gastric cancer (GC). CagA protein is injected into gastric epithelial cells and deregulates a variety of cellular signaling molecules. Phospholipase D (PLD) is elevated in many different types of human cancers and has been implicated as a critical factor in inflammation and carcinogenesis. In this study, we show that infection with cagA-positive H. pylori in GC cells significantly induces PLD1 expression via CagA-dependent activation of nuclear factor kappa B (NF kappa B). Interestingly, the level of PLD1 protein and I kappa B alpha phosphorylation is aberrantly upregulated in H. pylori-infected human GC tissues. Infection with cagA-positive H. pylori and expression of CagA enhanced the binding of NF kappa B to the PLD1 promoter, and two functional NF kappa B-binding sites were identified within the PLD1 promoter. Rebamipide, a mucosal-protective antiulcer agent, abolished H. pylori cagA-induced PLD1 expression via inhibition of binding of NF kappa B to the PLD1 promoter, and also inhibited PLD activity. Moreover, rebamipide suppressed H. pylori-induced matrix metalloproteinase-9, interleukin-8 and activation-induced cytidine deaminase expression as well as invasion of GC cells through downregulation of PLD1. Our data suggest that H. pylori cagA targets PLD1 for invasion of GC cells, and rebamipide might contribute to the antitumorigenic effect of GC cells via inhibition of the H. pylori cagA-NF kappa B-PLD1 signaling pathway.	[Kang, D. W.; Hwang, W. C.; Park, M. H.; Min, D. S.] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; [Ko, G-H] Gyeongsang Natl Univ, Sch Med, Dept Pathol, Jinju, Gyeongnam, South Korea; [Ha, W-S] Gyeongsang Natl Univ, Sch Med, Dept Surg, Jinju, Gyeongnam, South Korea; [Kim, K-S; Lee, Y-C] Dong A Univ, Dept Biotechnol, Pusan, South Korea; [Choi, K-Y; Min, D. S.] Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea; [Choi, K-Y; Min, D. S.] Yonsei Univ, Dept Biotechnol, Seoul 120749, South Korea	Pusan National University; Gyeongsang National University; Gyeongsang National University; Dong A University; Yonsei University; Yonsei University	Min, DS (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.	minds@pusan.ac.kr	Park, Min Hi/AAL-9880-2020		Translational Research Center for Protein Function Control, NSF, South Korea [2009-0092960]; National Research Foundation of Korea (NRF) grant; Korea government (MEST) [2012002009]; National R&D program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea grant [0920050]	Translational Research Center for Protein Function Control, NSF, South Korea; National Research Foundation of Korea (NRF) grant(National Research Foundation of Korea); Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); National R&D program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea grant	This work was supported by a grant from the Translational Research Center for Protein Function Control, NSF (2009-0092960), South Korea and a National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST; no. 2012002009) and by the National R&D program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea grant 0920050. We are most grateful to Dr DaiHyun Yu (Otsuka Pharmaceutical Co. Ltd. Otsuka International Asia Arab Division, Korea) for his helpful suggestions and generous comments.	ARAKAWA T, 1995, DIGEST DIS SCI, V40, P2469, DOI 10.1007/BF02063257; Arakawa T, 2005, DIGEST DIS SCI, V50, pS3, DOI 10.1007/s10620-005-2800-9; Arakawa T, 1998, DIGEST DIS SCI, V43, p5S; BLASER MJ, 1995, CANCER RES, V55, P2111; Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102; Buti L, 2011, P NATL ACAD SCI USA, V108, P9238, DOI 10.1073/pnas.1106200108; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chen G, 1997, BIOCHEM BIOPH RES CO, V239, P626, DOI 10.1006/bbrc.1997.7485; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200; Gozgit JM, 2007, BRIT J CANCER, V97, P809, DOI 10.1038/sj.bjc.6603926; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hatakeyama M, 2008, ONCOGENE, V27, P7047, DOI 10.1038/onc.2008.353; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Huang JQ, 2003, GASTROENTEROLOGY, V125, P1636, DOI 10.1053/j.gastro.2003.08.033; Huang P, 2007, EXPERT OPIN THER TAR, V11, P707, DOI 10.1517/14728222.11.5.707; Jones NL, 1999, INFECT IMMUN, V67, P4237, DOI 10.1128/IAI.67.8.4237-4242.1999; Kang DW, 2008, J BIOL CHEM, V283, P4094, DOI 10.1074/jbc.M707416200; Kang DW, 2011, CANCER RES, V71, P293, DOI 10.1158/0008-5472.CAN-10-2463; Kang DW, 2011, INT J CANCER, V128, P805, DOI 10.1002/ijc.25402; Kang DW, 2010, EXP MOL MED, V42, P555, DOI 10.3858/emm.2010.42.8.056; Kang DW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012109; Kang DW, 2010, CANCER LETT, V294, P125, DOI 10.1016/j.canlet.2010.01.031; Kang DW, 2010, CANCER RES, V70, P4233, DOI 10.1158/0008-5472.CAN-09-3470; Kishimoto S, 2000, DIGEST DIS SCI, V45, P1608, DOI 10.1023/A:1005525313856; Knoepp SM, 2008, MOL PHARMACOL, V74, P574, DOI 10.1124/mol.107.040105; Lamb A, 2009, EMBO REP, V10, P1242, DOI 10.1038/embor.2009.210; Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540; Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Oliveira MJ, 2006, J BIOL CHEM, V281, P34888, DOI 10.1074/jbc.M607067200; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peek Jr RM, 2005, SCI STKE, V2005, P14, DOI [10.1126/stke.2772005pe14, DOI 10.1126/STKE.2772005PE14]; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peek RM, 1999, CANCER RES, V59, P6124; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Rieder G, 2005, GASTROENTEROLOGY, V128, P1229, DOI 10.1053/j.gastro.2005.02.064; Rudi J, 1998, J CLIN INVEST, V102, P1506, DOI 10.1172/JCI2808; SHARMA SA, 1995, INFECT IMMUN, V63, P1681, DOI 10.1128/IAI.63.5.1681-1687.1995; Shibata W, 2006, J PATHOL, V210, P306, DOI 10.1002/path.2040; Sier CFM, 1996, BRIT J CANCER, V74, P413, DOI 10.1038/bjc.1996.374; Snider Jared L, 2009, J Carcinog, V8, P7, DOI 10.4103/1477-3163.50892; Su WJ, 2009, FUTURE ONCOL, V5, P1477, DOI [10.2217/fon.09.110, 10.2217/FON.09.110]; Suzuki M, 2009, CELL HOST MICROBE, V5, P23, DOI 10.1016/j.chom.2008.11.010; Tarnawski A, 2005, BIOCHEM BIOPH RES CO, V334, P207, DOI 10.1016/j.bbrc.2005.05.204; Wang HY, 2011, FEMS IMMUNOL MED MIC, V63, P82, DOI 10.1111/j.1574-695X.2011.00833.x; Wei JX, 2010, GASTROENTEROLOGY, V139, P1333, DOI 10.1053/j.gastro.2010.06.018; Yamane T, 1998, DIGEST DIS SCI, V43, p207S; Yoshida N, 1996, DIGEST DIS SCI, V41, P1139, DOI 10.1007/BF02088229; Zhang XY, 2002, DIAGN MOL PATHOL, V11, P135, DOI 10.1097/00019606-200209000-00002	58	34	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3531	3542		10.1038/onc.2012.358	http://dx.doi.org/10.1038/onc.2012.358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22890316				2022-12-28	WOS:000322220800006
J	Gery, S; Koeffler, HP				Gery, S.; Koeffler, H. P.			Role of the adaptor protein LNK in normal and malignant hematopoiesis	ONCOGENE			English	Review						cytokine signaling; LNK; hematopoiesis	GENOME-WIDE ASSOCIATION; MYELOPROLIFERATIVE NEOPLASMS; CELIAC-DISEASE; SELF-RENEWAL; GLUCOSE-HOMEOSTASIS; SIGNAL-TRANSDUCTION; PROGENITOR CELLS; DEFICIENT MICE; BLOOD-PRESSURE; STEM-CELLS	The signal transduction pathways, orchestrating the differentiation of hematopoietic stem and progenitor cells in response to cytokine stimulation, are strictly controlled by networks of feedback loops, highly selective protein interactions and finely tuned on/off switches. In hematological malignancies, the aberrant activation of signaling pathways is usually associated with mutations in tyrosine kinases. Recently, the role of negative signaling regulators is increasingly being recognized as an alternative mechanism involved in diseases such as leukemias and myeloproliferative neoplasms (MPNs). The adaptor protein LNK (Src homology 2 (SH2)B3) is a negative regulator of cytokine signaling that has an essential, nonredundant role in normal hematopoiesis. Indeed, LNK-deficient mice show marked expansion of early hematopoietic precursors, more mature myeloid and B-lineage lymphoid cells, as well as enhanced hematopoietic reconstitution. Murine models show that loss of LNK enhances the development of MPNs and may have a role in additional pathologies. LNK mutations were recently identified in patients with MPNs, and studies in animal models and hematopoietic cell lines suggest that LNK controls the aberrant signaling pathways induced by activated oncogenic kinases. In addition, genome-wide studies show that LNK is associated with autoimmune and cardiovascular disorders. These findings have implications for the future study of hematopoiesis, as well as for the development of novel stem cell and disease-specific therapies.	[Gery, S.; Koeffler, H. P.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; [Koeffler, H. P.] Natl Univ Singapore, Canc Sci Inst, Natl Canc Inst, Singapore 117548, Singapore	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National University of Singapore	Gery, S (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	gerys@cshs.org			NIH [R01CA026038-32, U54CA143930]; A * STAR Grant; Mary Barry Foundation; NATIONAL CANCER INSTITUTE [U54CA143930, R01CA026038] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); A * STAR Grant(Agency for Science Technology & Research (A*STAR)); Mary Barry Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study is supported in part by the NIH grants R01CA026038-32 and U54CA143930, as well as A * STAR Grant and the Mary Barry Foundation.	Ahlenius H, 2012, J NEUROSCI, V32, P5151, DOI 10.1523/JNEUROSCI.0474-12.2012; Alcina A, 2010, GENES IMMUN, V11, P439, DOI 10.1038/gene.2010.30; Baran-Marszak F, 2010, BLOOD, V116, P5961, DOI 10.1182/blood-2009-12-256768; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Bersenev A, 2008, J CLIN INVEST, V118, P2832, DOI 10.1172/JCI35808; Bersenev A, 2010, J CLIN INVEST, V120, P2058, DOI 10.1172/JCI42032; Buza-Vidas N, 2006, GENE DEV, V20, P2018, DOI 10.1101/gad.385606; Coenen MJH, 2009, HUM MOL GENET, V18, P4195, DOI 10.1093/hmg/ddp365; Devalliere J, 2011, BIOCHEM PHARMACOL, V82, P1391, DOI 10.1016/j.bcp.2011.06.023; Dhe-Sirano D, 2004, NAT STRUCT MOL BIOL, V11, P968, DOI 10.1038/nsmb829; Dravid G, 2011, MOL THER, V19, P768, DOI 10.1038/mt.2010.281; Ema H, 2005, DEV CELL, V8, P907, DOI 10.1016/j.devcel.2005.03.019; Eriksson N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034442; Gateva V, 2009, NAT GENET, V41, P1228, DOI 10.1038/ng.468; Gery S, 2007, BLOOD, V110, P3360, DOI 10.1182/blood-2007-05-089326; Gery S, 2009, J LEUKOCYTE BIOL, V85, P957, DOI 10.1189/jlb.0908575; Gery S, 2009, EXP HEMATOL, V37, P585, DOI 10.1016/j.exphem.2009.01.009; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Gueller S, 2008, BIOCHEM J, V415, P241, DOI 10.1042/BJ20080102; Gueller S, 2011, EXP HEMATOL, V39, P591, DOI 10.1016/j.exphem.2011.02.001; Gueller S, 2010, J LEUKOCYTE BIOL, V88, P699, DOI 10.1189/jlb.0309185; Ha JS, 2011, AM J HEMATOL, V86, P866, DOI 10.1002/ajh.22107; He XQ, 2000, MOL IMMUNOL, V37, P603, DOI 10.1016/S0161-5890(00)00070-5; Hu JJ, 2005, J BIOL CHEM, V280, P18943, DOI 10.1074/jbc.M414157200; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; Hunt KA, 2008, NAT GENET, V40, P395, DOI 10.1038/ng.102; Hurtado C, 2011, LEUKEMIA RES, V35, P1537, DOI 10.1016/j.leukres.2011.07.009; Jatiani Shashidhar S, 2010, Genes Cancer, V1, P979, DOI 10.1177/1947601910397187; Jiang J, 2012, J CLIN INVEST, V122, P2079, DOI 10.1172/JCI59719; Jin Y, 2012, NAT GENET, V44, P676, DOI 10.1038/ng.2272; Kamei N, 2010, STEM CELLS, V28, P365, DOI 10.1002/stem.243; Koren-Michowitz M, HAEMATOLOGICA; Koren-Michowitz M, 2010, BLOOD, V116; Kurzer JH, 2006, MOL CELL BIOL, V26, P6381, DOI 10.1128/MCB.00570-06; Kwon SM, 2009, CIRC RES, V104, P969, DOI 10.1161/CIRCRESAHA.108.192856; Lasho TL, 2011, LEUKEMIA, V25, P1056, DOI 10.1038/leu.2011.45; Lasho TL, 2010, NEW ENGL J MED, V363, P1189, DOI 10.1056/NEJMc1006966; Lavrikova EY, 2011, PEDIATR DIABETES, V12, P127, DOI 10.1111/j.1399-5448.2010.00656.x; Levy D, 2009, NAT GENET, V41, P677, DOI 10.1038/ng.384; Li M, 2006, ENDOCRINOLOGY, V147, P2163, DOI 10.1210/en.2005-1313; Li YJ, 2000, J IMMUNOL, V164, P5199, DOI 10.4049/jimmunol.164.10.5199; Lin DC, BLOOD; Looi CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023640; Matsumoto T, 2010, J EXP MED, V207, P2207, DOI 10.1084/jem.20100321; Maures TJ, 2007, TRENDS ENDOCRIN MET, V18, P38, DOI 10.1016/j.tem.2006.11.007; McMullin MF, 2011, AM J HEMATOL, V86, P962, DOI 10.1002/ajh.22154; Morris DL, 2010, ENDOCRINOLOGY, V151, P3643, DOI 10.1210/en.2010-0254; Newton-Cheh C, 2009, NAT GENET, V41, P666, DOI 10.1038/ng.361; Nobuhisa I, 2003, MOL CELL BIOL, V23, P8486, DOI 10.1128/MCB.23.23.8486-8494.2003; Oh ST, 2010, BLOOD, V116, P988, DOI 10.1182/blood-2010-02-270108; Pardanani A, 2010, LEUKEMIA, V24, P1713, DOI 10.1038/leu.2010.163; Seita J, 2007, P NATL ACAD SCI USA, V104, P2349, DOI 10.1073/pnas.0606238104; Simon C, 2008, BLOOD, V112, P1039, DOI 10.1182/blood-2008-05-154849; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smyth DJ, 2008, NEW ENGL J MED, V359, P2767, DOI 10.1056/NEJMoa0807917; Takaki S, 2002, J EXP MED, V195, P151, DOI 10.1084/jem.20011170; Takizawa H, 2006, BLOOD, V107, P2968, DOI 10.1182/blood-2005-05-2138; Takizawa H, 2008, EXP HEMATOL, V36, P897, DOI 10.1016/j.exphem.2008.02.004; Takizawa H, 2010, J CLIN INVEST, V120, P179, DOI 10.1172/JCI39503; Tefferi A, 2011, J CLIN ONCOL, V29, P573, DOI 10.1200/JCO.2010.29.8711; Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Tong W, 2005, BLOOD, V105, P4604, DOI 10.1182/blood-2004-10-4093; Tong W, 2004, J EXP MED, V200, P569, DOI 10.1084/jem.20040762; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; Wan MF, 2006, J SURG RES, V136, P53, DOI 10.1016/j.jss.2006.07.004; Wang TC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026433; Zahn JM, 2010, BLOOD, V116; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhernakova A, 2010, AM J HUM GENET, V86, P970, DOI 10.1016/j.ajhg.2010.05.004	72	27	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2013	32	26					3111	3118		10.1038/onc.2012.435	http://dx.doi.org/10.1038/onc.2012.435			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	23045270				2022-12-28	WOS:000321004600001
J	Sorokin, AV; Chen, J				Sorokin, A. V.; Chen, J.			MEMO1, a new IRS1-interacting protein, induces epithelial-mesenchymal transition in mammary epithelial cells	ONCOGENE			English	Article						MEMO1; IRS1; EMT; Snail1; breast cancer	INSULIN-RECEPTOR SUBSTRATE-1; NF-KAPPA-B; PLECKSTRIN-HOMOLOGY DOMAIN; GLYCOGEN-SYNTHASE KINASE-3; HUMAN PANCREATIC-CANCER; GROWTH-FACTOR RECEPTOR; E-CADHERIN; BREAST-CANCER; IRS PROTEINS; SIGNAL-TRANSDUCTION	MEMO1 (mediator of ErbB2-driven cell motility 1) regulates HER2-dependent cell migration. Increased MEMO1 expression is associated with cancer aggressiveness. Here, we found that MEMO1 is also involved in breast carcinogenesis via regulating insulin-like growth factor-I receptor-dependent signaling events. We showed that MEMO1 binds to insulin receptor substrate 1, activates the downstream PI3K/Akt signaling pathway, leads to upregulation of Snail1 and thereby triggers the epithelial-mesenchymal transition (EMT) program. In addition, MEMO1 overexpression is accompanied by growth factor-independent proliferation, anchorage-independent growth in soft agar, and enhanced metastatic potential. Together, these findings suggest that MEMO1 acts as an oncogene and is a potential therapeutic target for cancer treatment.	[Sorokin, A. V.; Chen, J.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Chen, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jchen8@mdanderson.org			Era of Hope Research award [W81XWH-09-1-0409]; Department of Defense [W81XWH-05-1-0470]; MD Anderson's Cancer Center Support Grant [CA016672]	Era of Hope Research award; Department of Defense(United States Department of Defense); MD Anderson's Cancer Center Support Grant	We thank all our colleagues in the Chen laboratory for insightful discussions and technical assistance. We thank Dr Douglas Yee at the University of Minnesota for sharing hIRS2 cDNA and Dr Cosima Baldari at the University of Siena (Italy) for sharing ShcA(p66) cDNA. This work was supported in part by an Era of Hope Research award to JC (W81XWH-09-1-0409). JC is also a recipient of an Era of Hope Scholar award from the Department of Defense (W81XWH-05-1-0470). This work was supported by MD Anderson's Cancer Center Support Grant (CA016672).	Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Backer JM, 1997, EUR J BIOCHEM, V245, P91, DOI 10.1111/j.1432-1033.1997.t01-1-00091.x; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; Boissan M, 2005, AM J PATHOL, V167, P869, DOI 10.1016/S0002-9440(10)62058-5; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Cantarini MC, 2006, HEPATOLOGY, V44, P446, DOI 10.1002/hep.21272; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dearth RK, 2006, MOL CELL BIOL, V26, P9302, DOI 10.1128/MCB.00260-06; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Fagiani E, 2007, CANCER RES, V67, P3064, DOI 10.1158/0008-5472.CAN-06-2301; Gibson SL, 2007, CELL CYCLE, V6, P631, DOI 10.4161/cc.6.6.3987; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hanke S, 2009, MOL CELL PROTEOMICS, V8, P519, DOI 10.1074/mcp.M800407-MCP200; Hannafon BN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2839; Hellawell GO, 2002, CANCER RES, V62, P2942; Hemi R, 2002, J BIOL CHEM, V277, P8961, DOI 10.1074/jbc.M109391200; Hoang CD, 2004, CANCER RES, V64, P7479, DOI 10.1158/0008-5472.CAN-04-1898; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kalinina T, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-295; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim HJ, 2007, MOL CELL BIOL, V27, P3165, DOI 10.1128/MCB.01315-06; Kornmann M, 1998, CANCER RES, V58, P4250; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mardilovich K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-14; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Meira M, 2009, J CELL SCI, V122, P787, DOI 10.1242/jcs.032094; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pelicci G, 1996, ONCOGENE, V13, P633; Qiu C, 2008, J BIOL CHEM, V283, P2734, DOI 10.1074/jbc.M703523200; Ravikumar S, 2007, CANCER RES, V67, P9266, DOI 10.1158/0008-5472.CAN-07-2088; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Szabolcs M, 2009, AM J PATHOL, V174, P276, DOI 10.2353/ajpath.2009.080086; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; White MF, 2006, CAN J PHYSIOL PHARM, V84, P725, DOI 10.1139/Y06-008; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zaoui K, 2008, J CELL BIOL, V183, P401, DOI 10.1083/jcb.200805107; Zaoui K, 2010, P NATL ACAD SCI USA, V107, P18517, DOI 10.1073/pnas.1000975107; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	57	47	47	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3130	3138		10.1038/onc.2012.327	http://dx.doi.org/10.1038/onc.2012.327			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22824790				2022-12-28	WOS:000321004600003
J	Das, S; Bryan, K; Buckley, PG; Piskareva, O; Bray, IM; Foley, N; Ryan, J; Lynch, J; Creevey, L; Fay, J; Prenter, S; Koster, J; van Sluis, P; Versteeg, R; Eggert, A; Schulte, JH; Schramm, A; Mestdagh, P; Vandesompele, J; Speleman, F; Stallings, RL				Das, S.; Bryan, K.; Buckley, P. G.; Piskareva, O.; Bray, I. M.; Foley, N.; Ryan, J.; Lynch, J.; Creevey, L.; Fay, J.; Prenter, S.; Koster, J.; van Sluis, P.; Versteeg, R.; Eggert, A.; Schulte, J. H.; Schramm, A.; Mestdagh, P.; Vandesompele, J.; Speleman, F.; Stallings, R. L.			Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs	ONCOGENE			English	Article						miRNA; methylation; tumor suppressor; neuroblastoma; SOX2	TUMOR-SUPPRESSOR; PROMOTES TRANSFORMATION; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; RETINOIC ACID; EXPRESSION; METHYLATION; GENE; DIFFERENTIATION; PATTERNS	MicroRNAs (miRNAs) contribute to the pathogenesis of many forms of cancer, including the pediatric cancer neuroblastoma, but the underlying mechanisms leading to altered miRNA expression are often unknown. Here, a novel integrated approach for analyzing DNA methylation coupled with miRNA and mRNA expression data sets identified 67 epigenetically regulated miRNA in neuroblastoma. A large proportion (42%) of these miRNAs was associated with poor patient survival when underexpressed in tumors. Moreover, we demonstrate that this panel of epigenetically silenced miRNAs targets a large set of genes that are overexpressed in tumors from patients with poor survival in a highly redundant manner. The genes targeted by the epigenetically regulated miRNAs are enriched for a number of biological processes, including regulation of cell differentiation. Functional studies involving ectopic overexpression of several of the epigenetically silenced miRNAs had a negative impact on neuroblastoma cell viability, providing further support to the concept that inactivation of these miRNAs is important for neuroblastoma disease pathogenesis. One locus, miR-340, induced either differentiation or apoptosis in a cell context dependent manner, indicating a tumor suppressive function for this miRNA. Intriguingly, it was determined that miR-340 is upregulated by demethylation of an upstream genomic region that occurs during the process of neuroblastoma cell differentiation induced by all-trans retinoic acid (ATRA). Further biological studies of miR-340 revealed that it directly represses the SOX2 transcription factor by targeting of its 30-untranslated region, explaining the mechanism by which SOX2 is downregulated by ATRA. Although SOX2 contributes to the maintenance of stem cells in an undifferentiated state, we demonstrate that miR-340-mediated downregulation of SOX2 is not required for ATRA induced differentiation to occur. In summary, our results exemplify the dynamic nature of the miRNA epigenome and identify a remarkable network of miRNA/mRNA interactions that significantly contribute to neuroblastoma disease pathogenesis.	[Das, S.; Bryan, K.; Buckley, P. G.; Piskareva, O.; Bray, I. M.; Foley, N.; Ryan, J.; Lynch, J.; Creevey, L.; Fay, J.; Prenter, S.; Stallings, R. L.] Royal Coll Surgeons Ireland, Dept Mol & Cellular Therapeut, Dublin 2, Ireland; [Das, S.; Bryan, K.; Buckley, P. G.; Piskareva, O.; Bray, I. M.; Foley, N.; Ryan, J.; Lynch, J.; Creevey, L.; Fay, J.; Prenter, S.; Stallings, R. L.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland; [Koster, J.; van Sluis, P.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Eggert, A.; Schulte, J. H.; Schramm, A.] Univ Childrens Hosp, Essen, Germany; [Mestdagh, P.; Vandesompele, J.; Speleman, F.] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium	Royal College of Surgeons - Ireland; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; University of Amsterdam; Academic Medical Center Amsterdam; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ghent University; Ghent University Hospital	Stallings, RL (corresponding author), Royal Coll Surgeons Ireland, Dept Mol & Cellular Therapeut, York House,York St, Dublin 2, Ireland.	rstallings@rcsi.ie	Versteeg, Rogier/AAQ-1765-2020; Vandesompele, Jo/W-3411-2018; Eggert, Angelika/AAE-6907-2022; Schulte, Johannes H/G-3981-2010; Schulte, Johannes H./V-2474-2018; Koster, Jan/C-5934-2008; Schramm, Alexander/G-5688-2010; Stallings, Raymond/A-7213-2008; speleman, frank/AAR-5184-2020	Vandesompele, Jo/0000-0001-6274-0184; Eggert, Angelika/0000-0003-3476-8184; Koster, Jan/0000-0002-0890-7585; Schramm, Alexander/0000-0001-7670-7529; speleman, frank/0000-0002-6628-8559; Versteeg, Rogier/0000-0001-7172-0388; Fay, Joanna/0000-0001-6294-2886; Mestdagh, Pieter/0000-0001-7821-9684; Schulte, Johannes Hubertus/0000-0003-0671-1201; Bryan, Kenneth/0000-0002-9550-8354	Science Foundation Ireland [07/IN.1/B1776]; Children's Medical and Research Foundation; NIH [5R01CA127496]; NATIONAL CANCER INSTITUTE [R01CA127496] Funding Source: NIH RePORTER	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Children's Medical and Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from Science Foundation Ireland (07/IN.1/B1776), Children's Medical and Research Foundation and NIH (5R01CA127496).	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bray I, 2011, CANCER LETT, V303, P56, DOI 10.1016/j.canlet.2011.01.016; Bray I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007850; Buckley PG, 2011, INT J CANCER, V128, P2296, DOI 10.1002/ijc.25584; Buckley PG, 2010, CLIN CANCER RES, V16, P2971, DOI 10.1158/1078-0432.CCR-09-3215; Buechner J, 2011, BRIT J CANCER, V105, P296, DOI 10.1038/bjc.2011.220; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Das S, 2010, CANCER RES, V70, P7874, DOI 10.1158/0008-5472.CAN-10-1534; Decock A, 2011, EPIGENETICS-US, V6, P962, DOI 10.4161/epi.6.8.16516; Gomez-Mateo MD, 2011, GENE CHROMOSOME CANC, V50, P374, DOI 10.1002/gcc.20859; Dudziec E, 2011, CLIN CANCER RES, V17, P1287, DOI 10.1158/1078-0432.CCR-10-2017; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Foley NH, 2011, CELL DEATH DIFFER, V18, P1089, DOI 10.1038/cdd.2010.172; Foley NH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-83; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fujita S, 2008, BIOINFORMATICS, V24, P303, DOI 10.1093/bioinformatics/btm589; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938; Girgert R, 1997, J NEURO-ONCOL, V31, P93, DOI 10.1023/A:1005789516322; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hoebeeck J, 2009, CANCER LETT, V273, P336, DOI 10.1016/j.canlet.2008.08.019; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jankowski MP, 2006, NEUROSCIENCE, V143, P501, DOI 10.1016/j.neuroscience.2006.09.010; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Kunej T, 2011, MUTAT RES-FUND MOL M, V717, P77, DOI 10.1016/j.mrfmmm.2011.03.008; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lopez-Serra P., 2011, ONCOGENE; Lynch J, 2012, CARCINOGENESIS, V33, P976, DOI 10.1093/carcin/bgs114; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429; Mestdagh P, 2010, MOL CELL, V40, P762, DOI 10.1016/j.molcel.2010.11.038; Murphy DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008154; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Patel M, 2010, STEM CELL REV REP, V6, P367, DOI 10.1007/s12015-010-9123-8; Saetrom P, 2007, NUCLEIC ACIDS RES, V35, P2333, DOI 10.1093/nar/gkm133; Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104; Schulte JH, 2010, INT J CANCER, V127, P2374, DOI 10.1002/ijc.25436; SIDELL N, 1982, J NATL CANCER I, V68, P589; Stallings RL, 2010, EXPERT OPIN THER TAR, V14, P951, DOI 10.1517/14728222.2010.510136; Stallings RL, 2011, SEMIN CANC BIOL; Stevanovic M, 2003, MOL BIOL REP, V30, P127, DOI 10.1023/A:1023961009869; Tivnan A, 2010, ANTICANCER RES, V30, P4391; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Vogt M, 2011, VIRCHOWS ARCH, V458, P313, DOI 10.1007/s00428-010-1030-5; Wang YC, 2010, CARCINOGENESIS, V31, P1516, DOI 10.1093/carcin/bgq107; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860; Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919; Yang QW, 2007, CLIN CANCER RES, V13, P3191, DOI 10.1158/1078-0432.CCR-06-2846; Yang QW, 2004, CANCER RES, V64, P4531, DOI 10.1158/0008-5472.CAN-04-0956; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147	56	65	68	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2927	2936		10.1038/onc.2012.311	http://dx.doi.org/10.1038/onc.2012.311			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797059	Green Accepted			2022-12-28	WOS:000320369700003
J	Krajewska, M; Heijink, AM; Bisselink, YJWM; Seinstra, RI; Sillje, HHW; de Vries, EGE; van Vugt, MATM				Krajewska, M.; Heijink, A. M.; Bisselink, Y. J. W. M.; Seinstra, R. I.; Sillje, H. H. W.; de Vries, E. G. E.; van Vugt, M. A. T. M.			Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination	ONCOGENE			English	Article						Wee1; homologous recombination; DNA repair; cell cycle checkpoint; MK-1775	CYCLIN-DEPENDENT KINASES; DNA-DAMAGE CHECKPOINT; DOUBLE-STRAND-BREAK; CELL-CYCLE; END RESECTION; REGULATORY MECHANISM; MAMMALIAN-CELLS; REPAIR; PHOSPHORYLATION; RECOVERY	In response to DNA breaks, the 'DNA damage response' provokes a cell cycle arrest to facilitate DNA repair. Recent findings have indicated that cells can respond to DNA damage throughout the cell cycle, except during mitosis. Specifically, various mitotic kinases, including Cdk1, Aurora A and Plk1, were shown to inactivate key DNA damage checkpoint proteins when cells enter mitosis. Aberrant activation of mitotic kinases during interphase could therefore modulate cellular responses to DNA damage. In this study, our aim was to determine how aberrant activation of Cdk1 affects the cellular responses to DNA damage. We used Wee1 inhibition, using MK-1775, to force Cdk1 activation, which did not cause cytotoxicity in non-transformed cells. Instead, it accelerated mitotic entry and caused radio sensitization in p53-defective cancer cells, but not in p53-proficient cancer cells. Interestingly, we showed that Wee1 inhibition leads to elevation of Cdk1 activity in interphase cells. When we subsequently analyzed DNA damage responses in cells with forced Cdk1 activation, we observed a marked reduction of 53BP1 at sites of DNA damage along with an increase in g-H2AX staining after irradiation, indicative of defective DNA repair. Indeed, when DNA repair was analyzed using in vivo endonuclease-induced homologous recombination (HR) assays, compromised DNA repair after Wee1 inhibition was confirmed. This defect in HR was accompanied by increased phosphorylation of BRCA2 at the Cdk1 phosphorylation site S3291. Taken together, our results indicate that Wee1 inhibition leads to forced Cdk1 activation in interphase cells, which interferes with normal DNA damage responses.	[Krajewska, M.; Heijink, A. M.; Bisselink, Y. J. W. M.; Seinstra, R. I.; de Vries, E. G. E.; van Vugt, M. A. T. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands; [Sillje, H. H. W.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	van Vugt, MATM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	m.vugt@umcg.nl	Krajewska, Malgorzata/AAH-1158-2021	Heijink, Anne Margriet/0000-0001-9229-0575; Krajewska, Malgorzata/0000-0002-2243-5924; de Vries, Elisabeth/0000-0002-8949-7425	NWO-VENI grant [916.76.062]	NWO-VENI grant	This work was supported by a NWO-VENI grant (916.76.062) to MATMVV. We thank Drs Maria Jasin, Jeff Parvin, Reuven Agami, James Ferrell Jr and Vera Gorbunova for generously supplying materials, Dr Gerben Vader for critically reading the manuscript and members of the Medical Oncology laboratory for helpful discussions.	Adams Bret R, 2010, Aging (Albany NY), V2, P582; Cerqueira A, 2009, J CELL BIOL, V187, P773, DOI 10.1083/jcb.200903033; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Crescenzi E, 2005, CLIN CANCER RES, V11, P8158, DOI 10.1158/1078-0432.CCR-05-1042; Dominguez-Kelly R, 2011, J CELL BIOL, V194, P567, DOI 10.1083/jcb.201101047; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enserink JM, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-11; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; HARPER JW, 1993, CELL, V75, P805; Hirai H, 2010, CANCER BIOL THER, V9, P514, DOI 10.4161/cbt.9.7.11115; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Huertas P, 2008, NATURE, V455, P689, DOI 10.1038/nature07215; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Johnson N, 2009, MOL CELL, V35, P327, DOI 10.1016/j.molcel.2009.06.036; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Lee SE, 2000, COLD SPRING HARB SYM, V65, P303, DOI 10.1101/sqb.2000.65.303; Leijen S, 2010, CURR CLIN PHARMACOL, V5, P186, DOI 10.2174/157488410791498824; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARVIN J, 2011, J VIS EXP, V48, pE2468; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pomerening JR, 2008, MOL BIOL CELL, V19, P3426, DOI 10.1091/mbc.E08-02-0172; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Scully R, 2005, ONCOGENE, V24, P2871, DOI 10.1038/sj.onc.1208609; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; van Vugt MATM, 2010, CELL CYCLE, V9, P2097, DOI 10.4161/cc.9.11.11840; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	41	92	93	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2013	32	24					3001	3008		10.1038/onc.2012.296	http://dx.doi.org/10.1038/onc.2012.296			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797065				2022-12-28	WOS:000320369700010
J	Ezponda, T; Popovic, R; Shah, MY; Martinez-Garcia, E; Zheng, Y; Min, DJ; Will, C; Neri, A; Kelleher, NL; Yu, J; Licht, JD				Ezponda, T.; Popovic, R.; Shah, M. Y.; Martinez-Garcia, E.; Zheng, Y.; Min, D-J; Will, C.; Neri, A.; Kelleher, N. L.; Yu, J.; Licht, J. D.			The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer	ONCOGENE			English	Article						MMSET; histone methylation; epithelial-mesenchymal transition; invasion; prostate cancer	MULTIPLE-MYELOMA; GENE-EXPRESSION; MODIFICATION PATTERNS; UP-REGULATION; PREDICT RISK; MMSET; PROTEIN; CLASSIFICATION; IDENTIFICATION; CHARACTERIZES	Epigenetic deregulation of gene expression has a role in the initiation and progression of prostate cancer (PCa). The histone methyltransferase MMSET/WHSC1 (Multiple Myeloma SET domain) is overexpressed in a number of metastatic tumors, but its mechanism of action has not been defined. In this work, we found that PCa cell lines expressed significantly higher levels of MMSET compared with immortalized, non-transformed prostate cells. Knockdown experiments showed that, in metastatic PCa cell lines, dimethylation of lysine 36 and trimethylation of lysine 27 on histone H3 (H3K36me2 and H3K27me3, respectively) depended on MMSET expression, whereas depletion of MMSET in benign prostatic cells did not affect chromatin modifications. Knockdown of MMSET in DU145 and PC-3 tumor cells decreased cell proliferation, colony formation in soft agar and strikingly diminished cell migration and invasion. Conversely, overexpression of MMSET in immortalized, non-transformed RWPE-1 cells promoted cell migration and invasion, accompanied by an epithelial-mesenchymal transition (EMT). Among a panel of EMT-promoting genes analyzed, TWIST1 expression was strongly activated in response to MMSET. Chromatin immunoprecipitation analysis demonstrated that MMSET binds to the TWIST1 locus and leads to an increase in H3K36me2, suggesting a direct role of MMSET in the regulation of this gene. Depletion of TWIST1 in MMSET-overexpressing RWPE-1 cells blocked cell invasion and EMT, indicating that TWIST1 was a critical target of MMSET, responsible for the acquisition of an invasive phenotype. Collectively, these data suggest that MMSET has a role in PCa pathogenesis and progression through epigenetic regulation of metastasis-related genes.	[Ezponda, T.; Popovic, R.; Shah, M. Y.; Martinez-Garcia, E.; Min, D-J; Will, C.; Kelleher, N. L.; Yu, J.; Licht, J. D.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA; [Zheng, Y.; Kelleher, N. L.] Northwestern Univ, Dept Chem, Dept Mol Biosci, Evanston, IL USA; [Zheng, Y.; Kelleher, N. L.] Northwestern Univ, Chem Life Proc Inst, Evanston, IL USA; [Neri, A.] Univ Milan, Dept Med Sci, Fdn Ist Ricovero & Cura Carattere Sci Policlin, Hematol Ctr Trapianti Midollo Osseo 1, Milan, Italy	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; University of Milan	Licht, JD (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Feinberg Sch Med, Lurie 5-123,303 E Super St, Chicago, IL 60611 USA.	j-licht@northwestern.edu	Neri, Antonino/I-9690-2014; Licht, Jonathan/AAL-9184-2020; Ezponda, Teresa/AAA-5040-2020; Zheng, Yupeng/B-3782-2014; Licht, Jonathan/L-4239-2019	Neri, Antonino/0000-0001-9047-5912; Licht, Jonathan/0000-0002-3942-1369; Ezponda, Teresa/0000-0003-3682-7125; Zheng, Yupeng/0000-0002-3351-5161	Fundacion Alfonso Martin Escudero fellowship; Ruth Kirschstein National Research Service Award [F32HL099177]; Associazione Italiana Ricerca sul Cancro (AIRC); NIH [K99/R00CA129565]; U.S. Department of Defense [W81XWH-09-1-0193]; American Cancer Society [RSG-12-085-01, R01GM067193, RO1CA123204]; Leukemia and Lymphoma Society Specialized Center of Research Award; Physical Sciences Oncology Center grant [U54CA143869]; NATIONAL CANCER INSTITUTE [R01CA123204, U54CA143869, K99CA129565, P30CA060553] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL099177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067193] Funding Source: NIH RePORTER	Fundacion Alfonso Martin Escudero fellowship; Ruth Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Defense(United States Department of Defense); American Cancer Society(American Cancer Society); Leukemia and Lymphoma Society Specialized Center of Research Award(Leukemia and Lymphoma Society); Physical Sciences Oncology Center grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a Fundacion Alfonso Martin Escudero fellowship (T.E.), a Ruth Kirschstein National Research Service Award F32HL099177 (R.P.), the Associazione Italiana Ricerca sul Cancro (AIRC) (A.N.), NIH K99/R00CA129565 (J.Y.), the U.S. Department of Defense W81XWH-09-1-0193 (J.Y.), a Research Scholar Award RSG-12-085-01 from the American Cancer Society (J.Y.), R01GM067193 (N.L.K.), RO1CA123204 (J.D.L.) a Leukemia and Lymphoma Society Specialized Center of Research Award (J.D.L.) and Physical Sciences Oncology Center grant U54CA143869 (J.D.L. and N.L.K.).	Agnelli L, 2005, J CLIN ONCOL, V23, P7296, DOI 10.1200/JCO.2005.01.3870; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; Bianco-Miotto T, CANC EPIDEMIOL BIOMA, V19, P2611; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brito JLR, 2009, HAEMATOL-HEMATOL J, V94, P78, DOI 10.3324/haematol.13426; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Daigle SR, CANC CELL, V20, P53; Garcia BA, 2007, NAT PROTOC, V2, P933, DOI 10.1038/nprot.2007.106; Garlisi CG, 2001, AM J RESP CELL MOL, V24, P90, DOI 10.1165/ajrcmb.24.1.4224; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Hudlebusch HR, CLIN CANC RES, V17, P2919; Hudlebusch HR, CANC RES, V71, P4226; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeronimo C, 2011, EUR UROL, V60, P753, DOI 10.1016/j.eururo.2011.06.035; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kassambara A, 2009, BIOCHEM BIOPH RES CO, V379, P840, DOI 10.1016/j.bbrc.2008.12.093; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kim JY, 2008, MOL CELL BIOL, V28, P2023, DOI 10.1128/MCB.02130-07; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674; Lennartsson A, 2009, BBA-GEN SUBJECTS, V1790, P863, DOI 10.1016/j.bbagen.2008.12.006; Li J, 2008, NEURO-ONCOLOGY, V10, P45, DOI 10.1215/15228517-2007-036; Li Y, 2009, J BIOL CHEM, V284, P34283, DOI 10.1074/jbc.M109.034462; Lombardi L, 2007, GENE CHROMOSOME CANC, V46, P226, DOI 10.1002/gcc.20404; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood-2007-06-092122; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Morishita M, 2011, BBA-REV CANCER, V1816, P158, DOI 10.1016/j.bbcan.2011.05.004; Okabe H, 2001, CANCER RES, V61, P2129; Perry AS, 2010, NAT REV UROL, V7, P668, DOI 10.1038/nrurol.2010.185; Schulz WA, 2006, J CELL MOL MED, V10, P100, DOI 10.1111/j.1582-4934.2006.tb00293.x; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toyokawa G, 2011, NEOPLASIA, V13, P887, DOI 10.1593/neo.11048; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Volkel P, 2007, BIOCHIMIE, V89, P1, DOI 10.1016/j.biochi.2006.07.009; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143	52	95	103	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2882	2890		10.1038/onc.2012.297	http://dx.doi.org/10.1038/onc.2012.297			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22797064	Green Accepted			2022-12-28	WOS:000320369100008
J	Malek, SN				Malek, S. N.			The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia	ONCOGENE			English	Review						CLL; genomic copy number aberrations; gene mutations	TELANGIECTASIA MUTATED GENE; TREATMENT-FREE SURVIVAL; TUMOR-SUPPRESSOR LOCUS; TERM-FOLLOW-UP; CHROMOSOME 13Q14; CLL PATIENTS; DISEASE PROGRESSION; CLONAL EVOLUTION; NOTCH1 MUTATIONS; TP53 MUTATION	Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional chemotherapy treatment approaches. CLL as a disease entity is defined by a relatively parsimonious set of diagnostic criteria and therefore likely constitutes an umbrella term for multiple related illnesses. Of the enduring fundamental biological processes that affect the biology and clinical behavior of CLL, few are as central to the pathogenesis of CLL as recurrent acquired genomic copy number aberrations (aCNA) and recurrent gene mutations. Here, a state-of-the-art overview of the pathological anatomy of the CLL genome is presented, including detailed descriptions of the anatomy of aCNA and gene mutations. Data from SNP array profiling and large-scale sequencing of large CLL cohorts, as well as stimulated karyotyping, are discussed. This review is organized by discussions of the anatomy, underlying pathomechanisms and clinical significance of individual genomic lesions and recurrent gene mutations. Finally, gaps in knowledge regarding the biological and clinical effects of recurrent genomic aberrations or gene mutations on CLL are outlined to provide critical stimuli for future research.	Univ Michigan, Div Hematol & Oncol, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Malek, SN (corresponding author), Univ Michigan, Div Hematol & Oncol, Dept Internal Med, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	smalek@med.umich.edu			NIH; Leukemia and Lymphoma Society of America; Lymphoma Research Foundation; National Institutes of Health [R01 CA136537-01]; Translational Research Program of the Leukemia and Lymphoma Society of America; Scholars in Clinical Research Program of the Leukemia and Lymphoma Society of America; CLL collaborative grant from the Lymphoma Research Foundation; National Institutes of Health through the University of Michigan's Cancer Center Support Grant [5 P30 CA46592]; National Institutes of Health through the University of Michigan's Oncology Research Training Grant [T32 CA 009357-30]; NATIONAL CANCER INSTITUTE [R01CA136537, R01CA171972, P30CA046592, T32CA009357] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); Lymphoma Research Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Translational Research Program of the Leukemia and Lymphoma Society of America; Scholars in Clinical Research Program of the Leukemia and Lymphoma Society of America; CLL collaborative grant from the Lymphoma Research Foundation; National Institutes of Health through the University of Michigan's Cancer Center Support Grant; National Institutes of Health through the University of Michigan's Oncology Research Training Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr Malek's work has been funded by the NIH, the Leukemia and Lymphoma Society of America and the Lymphoma Research Foundation. He has received honoraria from Roche and Teva.; This research is supported by the National Institutes of Health through R01 CA136537-01 (SM), the Translational Research Program of the Leukemia and Lymphoma Society of America (SM), the Scholars in Clinical Research Program of the Leukemia and Lymphoma Society of America (SM) and a CLL collaborative grant from the Lymphoma Research Foundation. This research is supported (in part) by the National Institutes of Health through the University of Michigan's Cancer Center Support Grant (5 P30 CA46592) and Oncology Research Training Grant (T32 CA 009357-30). I am grateful for services provided by the microarray core of the University of Michigan Comprehensive Cancer Center.	Augereau A, 2011, BLOOD, V118, P1316, DOI 10.1182/blood-2010-07-295774; Austen B, 2005, BLOOD, V106, P3175, DOI 10.1182/blood-2004-11-4516; Austen B, 2007, J CLIN ONCOL, V25, P5448, DOI 10.1200/JCO.2007.11.2649; Balatti V, 2012, BLOOD, V119, P329, DOI 10.1182/blood-2011-10-386144; Best OG, 2009, LEUKEMIA, V23, P212, DOI 10.1038/leu.2008.260; Braggio E, 2012, LEUKEMIA, V26, P1698, DOI 10.1038/leu.2012.14; Britt-Compton B, 2012, LEUKEMIA, V26, P826, DOI 10.1038/leu.2011.281; Brown JR, 2008, LEUKEMIA, V22, P1966, DOI 10.1038/leu.2008.222; Brown JR, 2012, LEUKEMIA, V26, P1710, DOI 10.1038/leu.2012.33; Brown JR, 2012, CLIN CANCER RES, V18, P3791, DOI 10.1158/1078-0432.CCR-11-2342; Brugat T, 2010, BLOOD, V116, P239, DOI 10.1182/blood-2009-12-257618; Bullrich F, 1996, BLOOD, V88, P3109, DOI 10.1182/blood.V88.8.3109.bloodjournal8883109; Bullrich F, 1999, CANCER RES, V59, P24; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Castro JE, 2009, LEUKEMIA, V23, P1779, DOI 10.1038/leu.2009.133; Cejkova S, 2009, EUR J HAEMATOL, V82, P133, DOI 10.1111/j.1600-0609.2008.01177.x; Dal Bo M, 2011, GENE CHROMOSOME CANC, V50, P633, DOI 10.1002/gcc.20885; Decker S, 2012, BLOOD, V119, P997, DOI 10.1182/blood-2011-06-359075; Del Giudice I, 2012, HAEMATOL-HEMATOL J, V97, P437, DOI 10.3324/haematol.2011.060129; Dicker F, 2009, LEUKEMIA, V23, P117, DOI 10.1038/leu.2008.274; Dicker F, 2006, BLOOD, V108, P3152, DOI 10.1182/blood-2006-02-005322; Dohner H, 1997, LEUKEMIA, V11, pS19; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; Dreger P, 2010, BLOOD, V116, P2438, DOI 10.1182/blood-2010-03-275420; ELROUBY S, 1993, BLOOD, V82, P3452; Fabbri G, 2011, J EXP MED, V208, P1389, DOI 10.1084/jem.20110921; Fazi C, 2011, BLOOD, V118, P6618, DOI 10.1182/blood-2011-05-357251; Fegan C, 1995, LEUKEMIA, V9, P2003; GAHRTON G, 1980, BLOOD, V56, P640; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gonzalez D, 2011, J CLIN ONCOL, V29, P2223, DOI 10.1200/JCO.2010.32.0838; Grubor V, 2009, BLOOD, V113, P1294, DOI 10.1182/blood-2008-05-158865; Gunnarsson R, 2010, LEUKEMIA, V24, P211, DOI 10.1038/leu.2009.187; Gunnarsson R, 2011, HAEMATOL-HEMATOL J, V96, P1161, DOI 10.3324/haematol.2010.039768; Haferlach C, 2007, LEUKEMIA, V21, P2442, DOI 10.1038/sj.leu.2404935; Hammarsund M, 2004, FEBS LETT, V556, P75, DOI 10.1016/S0014-5793(03)01371-1; Heerema NA, 2010, CANCER GENET CYTOGEN, V203, P134, DOI 10.1016/j.cancergencyto.2010.07.128; Herling M, 2009, BLOOD, V114, P4675, DOI 10.1182/blood-2009-03-208256; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Huh Y, 2011, AM J CLIN PATHOL, V135, P686, DOI 10.1309/AJCPOEFP3SLX6HXJ; Johnson GG, 2009, CANCER RES, V69, P5210, DOI 10.1158/0008-5472.CAN-09-0627; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; Kalachikov S, 1997, GENOMICS, V42, P369, DOI 10.1006/geno.1997.4747; Kanduri M, 2010, BLOOD, V115, P296, DOI 10.1182/blood-2009-07-232868; Kapanadze B, 2000, GENOMICS, V70, P327, DOI 10.1006/geno.2000.6386; Kay NE, 2010, CANCER GENET CYTOGEN, V203, P161, DOI 10.1016/j.cancergencyto.2010.09.003; Kitamura E, 2000, ONCOGENE, V19, P5772, DOI 10.1038/sj.onc.1203978; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Knight SJL, 2012, LEUKEMIA, V26, P1564, DOI 10.1038/leu.2012.13; Kujawski L, 2008, BLOOD, V112, P1993, DOI 10.1182/blood-2007-07-099432; Lanasa MC, 2011, LEUKEMIA, V25, P1459, DOI 10.1038/leu.2011.117; Lehmann S, 2008, CANCER-AM CANCER SOC, V112, P1296, DOI 10.1002/cncr.23270; Lia M, 2012, BLOOD, V119, P2981, DOI 10.1182/blood-2011-09-381814; Lin TT, 2010, BLOOD, V116, P1899, DOI 10.1182/blood-2010-02-272104; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; LIU Y, 1993, P NATL ACAD SCI USA, V90, P8697, DOI 10.1073/pnas.90.18.8697; Lopez C, 2012, GENE CHROMOSOME CANC, V51, P881, DOI 10.1002/gcc.21972; Lozanski G, 2012, LEUKEMIA LYMPHOMA, V53, P1743, DOI 10.3109/10428194.2012.668683; Mabuchi H, 2001, CANCER RES, V61, P2870; Malcikova J, 2009, BLOOD, V114, P5307, DOI 10.1182/blood-2009-07-234708; Malek S, ASCO ED BOOK 2010 RE, P263; Martin-Subero J, 2007, LEUKEMIA, V21, P1532, DOI 10.1038/sj.leu.2404695; Mayr C, 2006, BLOOD, V107, P742, DOI 10.1182/blood-2005-05-2093; Migliazza A, 2001, BLOOD, V97, P2098, DOI 10.1182/blood.V97.7.2098; Mohr J, 2011, BLOOD, V117, P1622, DOI 10.1182/blood-2010-08-300160; Mosca L, 2010, CLIN CANCER RES, V16, P5641, DOI 10.1158/1078-0432.CCR-10-0151; Muthusamy N, 2011, CANCER GENET-NY, V204, P77, DOI 10.1016/j.cancergen.2010.12.006; Neilson JR, 1997, LEUKEMIA, V11, P1929, DOI 10.1038/sj.leu.2400819; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nguyen-Khac F, 2011, AM J BLOOD RES, V1, P13; Ouillette P, 2012, GENES CHROM IN PRESS; Ouillette P, 2008, CANCER RES, V68, P1012, DOI 10.1158/0008-5472.CAN-07-3105; Ouillette P, 2011, CLIN CANCER RES, V17, P6778, DOI 10.1158/1078-0432.CCR-11-0785; Ouillette P, 2011, BLOOD, V118, P3051, DOI 10.1182/blood-2010-12-327858; Ouillette P, 2010, CLIN CANCER RES, V16, P835, DOI 10.1158/1078-0432.CCR-09-2534; Palamarchuk A, 2010, BLOOD, V115, P3916, DOI 10.1182/blood-2009-10-249367; Parikh SA, 2011, BLOOD, V118, P2062, DOI 10.1182/blood-2011-01-329177; Parker H, 2011, LEUKEMIA, V25, P489, DOI 10.1038/leu.2010.288; PETERSON LC, 1992, GENE CHROMOSOME CANC, V4, P273, DOI 10.1002/gcc.2870040402; Pettitt AR, 2012, J CLIN ONCOL, V30, P1647, DOI 10.1200/JCO.2011.35.9695; Pfeifer D, 2007, BLOOD, V109, P1202, DOI 10.1182/blood-2006-07-034256; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Put N, 2009, GENE CHROMOSOME CANC, V48, P843, DOI 10.1002/gcc.20691; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Raveche ES, 2007, BLOOD, V109, P5079, DOI 10.1182/blood-2007-02-071225; Rigolin GM, 2012, BLOOD, V119, P2310, DOI 10.1182/blood-2011-11-395269; Roos G, 2008, BLOOD, V111, P2246, DOI 10.1182/blood-2007-05-092759; Rosenwald A, 2004, BLOOD, V104, P1428, DOI 10.1182/blood-2003-09-3236; Rossi D, 2012, BLOOD, V119, P2854, DOI 10.1182/blood-2011-12-395673; Rossi D, 2012, BLOOD, V119, P521, DOI 10.1182/blood-2011-09-379966; Rossi D, 2011, BLOOD, V118, P6904, DOI 10.1182/blood-2011-08-373159; Rossi D, 2009, CLIN CANCER RES, V15, P995, DOI 10.1158/1078-0432.CCR-08-1630; Rossi S, 2010, BLOOD, V116, P945, DOI 10.1182/blood-2010-01-263889; Saddler C, 2008, BLOOD, V111, P1584, DOI 10.1182/blood-2007-09-112698; Saiya-Cork K, 2011, CLIN CANCER RES, V17, P2679, DOI 10.1158/1078-0432.CCR-10-2058; Sampath D, 2012, BLOOD, V119, P1162, DOI 10.1182/blood-2011-05-351510; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Shanafelt TD, 2008, J CLIN ONCOL, V26, pE5, DOI 10.1200/JCO.2008.16.7874; Shanafelt TD, 2006, J CLIN ONCOL, V24, P4634, DOI 10.1200/JCO.2006.06.9492; Shedden K, 2012, LEUKEMIA, V26, P1108, DOI 10.1038/leu.2011.361; Sorror ML, 2008, J CLIN ONCOL, V26, P4912, DOI 10.1200/JCO.2007.15.4757; Spaner DE, 2012, LEUKEMIA, V26, P1144, DOI 10.1038/leu.2011.329; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; STILGENBAUER S, 1993, BLOOD, V81, P2118; Stilgenbauer S, 2007, HAEMATOLOGICA, V92, P1242, DOI 10.3324/haematol.10720; Stilgenbauer S, 2009, J CLIN ONCOL, V27, P3994, DOI 10.1200/JCO.2008.21.1128; Tam CS, 2009, BLOOD, V114, P957, DOI 10.1182/blood-2009-03-210591; Trbusek M, 2011, J CLIN ONCOL, V29, P2703, DOI 10.1200/JCO.2011.34.7872; Tsimberidou AM, 2009, CANCER-AM CANCER SOC, V115, P373, DOI 10.1002/cncr.23993; UESHIMA Y, 1985, INT J CANCER, V36, P287, DOI 10.1002/ijc.1985.36.3.287; Van Den Neste E, 2007, LEUKEMIA, V21, P1715, DOI 10.1038/sj.leu.2404764; Visone R, 2009, BLOOD, V114, P3872, DOI 10.1182/blood-2009-06-229211; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Zainuddin N, 2011, LEUKEMIA RES, V35, P272, DOI 10.1016/j.leukres.2010.08.023; Zenz T, 2010, LEUKEMIA, V24, P2072, DOI 10.1038/leu.2010.208; Zenz T, 2008, BLOOD, V112, P3322, DOI 10.1182/blood-2008-04-154070; Zenz T, 2010, J CLIN ONCOL, V28, P4473, DOI 10.1200/JCO.2009.27.8762; Zenz T, 2009, BLOOD, V114, P2589, DOI 10.1182/blood-2009-05-224071; Zhang X, 2011, LEUKEMIA, V25, P1908, DOI 10.1038/leu.2011.163	124	38	39	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2013	32	23					2805	2817		10.1038/onc.2012.411	http://dx.doi.org/10.1038/onc.2012.411			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	23001040	Green Accepted			2022-12-28	WOS:000320369100001
J	Tang, Y; Horikawa, I; Ajiro, M; Robles, AI; Fujita, K; Mondal, AM; Stauffer, JK; Zheng, ZM; Harris, CC				Tang, Y.; Horikawa, I.; Ajiro, M.; Robles, A. I.; Fujita, K.; Mondal, A. M.; Stauffer, J. K.; Zheng, Z-M; Harris, C. C.			Downregulation of splicing factor SRSF3 induces p53 beta, an alternatively spliced isoform of p53 that promotes cellular senescence	ONCOGENE			English	Article						SRSF3; p53; isoform; cellular senescence; alternative splicing	PRE-MESSENGER-RNA; SR PROTEIN-PHOSPHORYLATION; ONCOGENE-INDUCED SENESCENCE; FACTOR SRP20; EXPRESSION; GENE; SF2/ASF; BINDING; PLURIPOTENCY; REQUIRES	Most human pre-mRNA transcripts are alternatively spliced, but the significance and fine-tuning of alternative splicing in different biological processes is only starting to be understood. SRSF3 (SRp20) is a member of a highly conserved family of splicing factors that have critical roles in key biological processes, including tumor progression. Here, we show that SRSF3 regulates cellular senescence, a p53-mediated process to suppress tumorigenesis, through TP53 alternative splicing. Downregulation of SRSF3 was observed in normal human fibroblasts undergoing replicative senescence, and was associated with the upregulation of p53 beta, an alternatively spliced isoform of p53 that promotes p53-mediated senescence. Knockdown of SRSF3 by short interfering RNA ( siRNA) in early-passage fibroblasts induced senescence, which was associated with elevated expression of p53 beta at mRNA and protein levels. Knockdown of p53 partially rescued SRSF3-knockdown-induced senescence, suggesting that SRSF3 acts on p53-mediated cellular senescence. RNA pulldown assays demonstrated that SRSF3 binds to an alternatively spliced exon uniquely included in p53b mRNA through the consensus SRSF3-binding sequences. RNA crosslinking and immunoprecipitation assays ( CLIP) also showed that SRSF3 in vivo binds to endogenous p53 pre-mRNA at the region containing the p53 beta-unique exon. Splicing assays using a transfected TP53 minigene in combination with siRNA knockdown of SRSF3 showed that SRSF3 functions to inhibit the inclusion of the p53 beta-unique exon in splicing of p53 pre-mRNA. These data suggest that downregulation of SRSF3 represents an endogenous mechanism for cellular senescence that directly regulates the TP53 alternative splicing to generate p53 beta. This study uncovers the role for general splicing machinery in tumorigenesis, and suggests that SRSF3 is a direct regulator of p53.	[Tang, Y.; Horikawa, I.; Robles, A. I.; Fujita, K.; Mondal, A. M.; Harris, C. C.] NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Ajiro, M.; Zheng, Z-M] NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Stauffer, J. K.] NCI, Canc & Inflammat Program, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bldg 37,Room 3068,37 Convent Dr, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov	Tang, Yizhe/A-8682-2014	Tang, Yizhe/0000-0001-5354-478X; Zheng, Zhi-Ming/0000-0001-5547-7912; Robles, Ana/0000-0001-5019-4374	Intramural Research Program of the NIH; NCI; NATIONAL CANCER INSTITUTE [ZIABC011496, ZIASC010357, ZIABC005795] Funding Source: NIH RePORTER	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the NIH, NCI. We thank the NIH Fellows Editorial Board for improving the readability of the manuscript.	Anko ML, 2010, NAT STRUCT MOL BIOL, V17, P962, DOI 10.1038/nsmb.1862; Akgul C, 2004, CELL MOL LIFE SCI, V61, P2189, DOI 10.1007/s00018-004-4001-7; Aubol BE, 2011, BIOCHEMISTRY-US, V50, P6888, DOI 10.1021/bi2007993; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Celotto AM, 2001, GENETICS, V159, P599; Chen WY, 2001, GENE CHROMOSOME CANC, V32, P281, DOI 10.1002/gcc.1191; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Ebrahimi M, 2008, ORAL ONCOL, V44, P156, DOI 10.1016/j.oraloncology.2007.01.014; Ezponda T, 2010, CLIN CANCER RES, V16, P4113, DOI 10.1158/1078-0432.CCR-10-0076; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fujita K, 2010, NAT CELL BIOL, V12, P1205, DOI 10.1038/ncb2123; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gabut M, 2011, CELL, V147, P132, DOI 10.1016/j.cell.2011.08.023; Garcia-Alai MM, 2008, PROTEIN SCI, V17, P1671, DOI 10.1110/ps.036996.108; Goldschneider D, 2006, NUCLEIC ACIDS RES, V34, P5603, DOI 10.1093/nar/gkl619; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; He X, 2011, ONCOGENE, V30, P356, DOI 10.1038/onc.2010.426; He XL, 2004, CLIN CANCER RES, V10, P4652, DOI 10.1158/1078-0432.CCR-03-0439; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Jia R, 2010, INT J BIOL SCI, V6, P806; Jia R, 2009, J VIROL, V83, P167, DOI 10.1128/JVI.01719-08; Jiang K, 2009, ENDOCRINOLOGY, V150, P2087, DOI 10.1210/en.2008-0818; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Jumaa H, 1997, MOL CELL BIOL, V17, P3116, DOI 10.1128/MCB.17.6.3116; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Kang JG, 2011, J VIROL, V85, P2620, DOI 10.1128/JVI.02144-10; Kanj SS, 2006, VIROLOGY, V345, P280, DOI 10.1016/j.virol.2005.09.060; Kannan K, 2011, P NATL ACAD SCI USA, V108, P9172, DOI 10.1073/pnas.1100489108; Karni R, 2008, P NATL ACAD SCI USA, V105, P15323, DOI 10.1073/pnas.0801376105; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Khoury Marie P, 2011, Genes Cancer, V2, P453, DOI 10.1177/1947601911408893; Klinck R, 2008, CANCER RES, V68, P657, DOI 10.1158/0008-5472.CAN-07-2580; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lanigan F, 2011, ONCOGENE, V30, P2901, DOI 10.1038/onc.2011.34; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Majerciak V, 2006, J BIOL CHEM, V281, P28365, DOI 10.1074/jbc.M603095200; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Olshavsky NA, 2010, CANCER RES, V70, P3975, DOI 10.1158/0008-5472.CAN-09-3468; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; Rajan P, 2008, BIOCHEM SOC T, V36, P505, DOI 10.1042/BST0360505; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Salomonis N, 2010, P NATL ACAD SCI USA, V107, P10514, DOI 10.1073/pnas.0912260107; Sanford JR, 1999, GENE DEV, V13, P1513, DOI 10.1101/gad.13.12.1513; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sciabica KS, 2003, EMBO J, V22, P1608, DOI 10.1093/emboj/cdg166; Sen S, 2009, MOL CELL BIOL, V29, P871, DOI 10.1128/MCB.01709-08; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shaw SD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000854; Shen HH, 2006, GENE DEV, V20, P1755, DOI 10.1101/gad.1422106; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WynfordThomas D, 1996, J PATHOL, V180, P118, DOI 10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I; Xi LQ, 2008, NUCLEIC ACIDS RES, V36, P6535, DOI 10.1093/nar/gkn697; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zheng ZM, 2004, J BIOMED SCI, V11, P278, DOI 10.1159/000077096; Zhong XY, 2009, GENE DEV, V23, P482, DOI 10.1101/gad.1752109; Zhu J, 2000, GENE DEV, V14, P3166, DOI 10.1101/gad.189500	75	99	101	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2792	2798		10.1038/onc.2012.288	http://dx.doi.org/10.1038/onc.2012.288			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22777358	Green Accepted			2022-12-28	WOS:000319808000010
J	Del Vecchio, CA; Giacomini, CP; Vogel, H; Jensen, KC; Florio, T; Merlo, A; Pollack, JR; Wong, AJ				Del Vecchio, C. A.; Giacomini, C. P.; Vogel, H.; Jensen, K. C.; Florio, T.; Merlo, A.; Pollack, J. R.; Wong, A. J.			EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms	ONCOGENE			English	Article						EGFRvIII; glioblastoma; HDAC; methylation; amplification	GROWTH-FACTOR RECEPTOR; HISTONE DEACETYLASE INHIBITORS; TUMOR-INITIATING CELLS; TRICHOSTATIN-A; IN-VIVO; LUNG CARCINOMAS; HDAC INHIBITORS; BREAST-CANCER; VALPROIC ACID; BRAIN-TUMORS	Amplification and rearrangements of the epidermal growth factor receptor (EGFR) gene are frequently found in glioblastoma multiforme (GBM). The most common variant is EGFR variant III (EGFRvIII). Research suggests that EGFRvIII could be a marker for a cancer stem cell or tumor-initiating population. If amplification and rearrangement are early events in tumorigenesis, this implies that they should be preserved throughout the tumor. However, in primary GBM, EGFRvIII expression is focal and sporadic. Unexpectedly, we found EGFR amplification and rearrangement throughout the tumor, including regions with no EGFRvIII expression, suggesting that mechanisms exist to modulate EGFRvIII expression even in the presence of high gene amplification. To study this phenomenon, we characterized three GBM cell lines with endogenous EGFRvIII. EGFRvIII expression was heterogeneous, with both positive and negative populations maintaining the genetic alterations, akin to primary tumors. Furthermore, EGFRvIII defined a hierarchy where EGFRvIII-positive cells gave rise to additional positive and negative cells. Only cells that had recently lost EGFRvIII expression could re-express EGFRvIII, providing an important buffer for maintaining EGFRvIII-positive cell numbers. Epigenetic mechanisms had a role in maintaining heterogeneous EGFRvIII expression. Demethylation induced a 20-60% increase in the percentage of EGFRvIII-positive cells, indicating that some cells could re-express EGFRvIII. Surprisingly, inhibition of histone deacetylation resulted in a 50-80% reduction in EGFRvIII expression. Collectively, this data demonstrates that EGFR amplification and rearrangement are early events in tumorigenesis and EGFRvIII follows a model of hierarchical expression. Furthermore, EGFRvIII expression is restricted by epigenetic mechanisms, suggesting that drugs that modulate the epigenome might be used successfully in glioblastoma tumors.	[Del Vecchio, C. A.; Wong, A. J.] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA; [Del Vecchio, C. A.; Giacomini, C. P.; Pollack, J. R.; Wong, A. J.] Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA; [Giacomini, C. P.; Vogel, H.; Jensen, K. C.; Pollack, J. R.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; [Jensen, K. C.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; [Florio, T.] Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy; [Merlo, A.] Univ Basel, Lab Mol Neurooncol, Dept Clin & Biol Sci, Basel, Switzerland	Stanford University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Genoa; University of Basel	Wong, AJ (corresponding author), Stanford Univ, Med Ctr, Dept Neurosurg, Canc Biol Program, 1201 Welch Rd,MSLS P108, Stanford, CA 94305 USA.	ajwong@stanford.edu	Florio, Tullio/A-2211-2012; FLORIO, TULLIO/ABG-3182-2020	Florio, Tullio/0000-0002-2394-996X; Vogel, Otto Hannes/0000-0002-0960-3508; Del Vecchio Fitz, Catherine/0000-0002-9554-411X; Jensen, Kristin/0000-0003-1177-9104	National Defense Science and Engineering Graduate Research Fellowship; National Science Foundation Graduate Research Fellowship; NIH [CA124832, RC2 CA14891]; Lucille Packard Children's Foundation; National Brain Tumor Foundation; NATIONAL CANCER INSTITUTE [R01CA124832, R01CA069495, RC2CA148491] Funding Source: NIH RePORTER	National Defense Science and Engineering Graduate Research Fellowship; National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lucille Packard Children's Foundation; National Brain Tumor Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Neethan Lobo, Dr Siddhartha Mitra, Dr A Hunter Shain and the Stanford FACS facility for technical advice. Additionally, we thank Dana Bangs and Dr Athena Cherry at the Stanford Cytogenetics Laboratory for their assistance with FISH staining and analysis. This work was supported by the National Defense Science and Engineering Graduate Research Fellowship, the National Science Foundation Graduate Research Fellowship, NIH Grants CA124832, RC2 CA14891, the Lucille Packard Children's Foundation and a research grant from the National Brain Tumor Foundation.	Aldape KD, 2004, J NEUROPATH EXP NEUR, V63, P700, DOI 10.1093/jnen/63.7.700; Ayuso-Sacido A, 2010, J NEURO-ONCOL, V97, P323, DOI 10.1007/s11060-009-0035-x; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bialer M, 2007, NEUROTHERAPEUTICS, V4, P130, DOI 10.1016/j.nurt.2006.11.007; Biernat W, 2004, BRAIN PATHOL, V14, P131, DOI 10.1111/j.1750-3639.2004.tb00045.x; BIGNER SH, 1990, CANCER RES, V50, P8017; Camphausen K, 2005, INT J CANCER, V114, P380, DOI 10.1002/ijc.20774; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Frederick L, 2000, NEURO-ONCOLOGY, V2, P159, DOI 10.1093/neuonc/2.3.159; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1988, CANCER RES, V48, P2231; Jones G, 2001, CANCER RES, V61, P4978; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Nagane M, 2001, J NEUROSURG, V95, P472, DOI 10.3171/jns.2001.95.3.0472; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; Porter KR, 2010, NEURO-ONCOLOGY, V12, P520, DOI 10.1093/neuonc/nop066; Schulte A, 2012, CLIN CANCER RES, V18, P1901, DOI 10.1158/1078-0432.CCR-11-3084; Shabason JE, 2011, J CELL MOL MED, V15, P2735, DOI 10.1111/j.1582-4934.2011.01296.x; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Solomon DA, 2009, CANCER RES, V69, P5630, DOI 10.1158/0008-5472.CAN-09-1055; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Stockhausen MT, 2011, EXP CELL RES, V317, P1513, DOI 10.1016/j.yexcr.2011.04.001; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Svechnikova I, 2008, INT J ONCOL, V32, P821; Tan JH, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-5; Tang CK, 2000, CANCER RES, V60, P3081; Thomas C, 2001, ACTA NEUROPATHOL, V101, P605; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vogt N, 2004, P NATL ACAD SCI USA, V101, P11368, DOI 10.1073/pnas.0402979101; VONHOFF DD, 1991, CANCER RES, V51, P6273; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Witusik-Perkowska M, 2011, J NEURO-ONCOL, V102, P395, DOI 10.1007/s11060-010-0352-0; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 2008, J CLIN ONCOL S, V26, P2002; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	45	80	82	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2670	2681		10.1038/onc.2012.280	http://dx.doi.org/10.1038/onc.2012.280			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22797070	Bronze			2022-12-28	WOS:000319806700008
J	Xie, Y; Tobin, LA; Camps, J; Wangsa, D; Yang, J; Rao, M; Witasp, E; Awad, KS; Yoo, N; Ried, T; Kwong, KF				Xie, Y.; Tobin, L. A.; Camps, J.; Wangsa, D.; Yang, J.; Rao, M.; Witasp, E.; Awad, K. S.; Yoo, N.; Ried, T.; Kwong, K. F.			MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells	ONCOGENE			English	Article						microRNA; cancer; XIAP	MODULATES MULTIDRUG-RESISTANCE; X-LINKED INHIBITOR; TARGETING BCL2; SUPPRESSES TUMORIGENICITY; STRUCTURAL BASIS; DOWN-REGULATION; UP-REGULATION; LUNG-CANCER; MIR-24; GENE	MicroRNAs have been implicated as important mediators of cancer cell homeostasis, and accumulating data suggest compelling roles for them in the apoptosis pathway. X-linked inhibitor of apoptosis protein (XIAP) is a potent caspase inhibitor and an important barrier to apoptotic cell death, but the mechanisms that determine the diverse range of XIAP expression seen in cancer remains unclear. In this study, we present evidence that miR-24 directly targets the 3'UTR of the XIAP messenger RNA (mRNA) to exert translational repression. Using a heuristic algorithm of bioinformatics analysis and in vitro screening, we identified miR-24 as a candidate regulator of XIAP expression. Array comparative genomic hybridization and spectral karyotype analysis reveal that genomic copy number loss at the miR-24 locus is concordant with the loss of endogenous miR-24 in cancer cells. Using a luciferase construct of the XIAP 3'UTR, we showed that miR-24 specifically coordinates to the XIAP mRNA. Interference with miR-24's binding of the critical seed region, resulting from site-directed mutagenesis of the 3'UTR, significantly abrogated miR-24's effects on XIAP expression. Moreover, miR-24 overexpression can overcome apoptosis resistance in cancer cells via downregulation of XIAP expression, and the resulting cancer cell death induced by tumor necrosis factor-related apoptosis-inducing ligand is executed by the canonical caspase-mediated apoptosis pathway. In summary, our data suggest a novel mechanism by which miR-24 directly modulates XIAP expression level and consequently the apoptosis threshold in cancer cells.	[Xie, Y.; Tobin, L. A.; Yang, J.; Rao, M.; Witasp, E.; Yoo, N.; Kwong, K. F.] NCI, Sect Thorac Oncol, Surg Branch, NIH, Bethesda, MD 20892 USA; [Camps, J.; Wangsa, D.; Ried, T.] NCI, Clin Genet Branch, NIH, Bethesda, MD 20892 USA; [Witasp, E.] Swedish Chem Agcy, Sundbyberg, Sweden; [Awad, K. S.] NCI, Dept Crit Care Med, NIH Clin Ctr, NIH, Bethesda, MD 20892 USA; [Kwong, K. F.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kwong, KF (corresponding author), NCI, Sect Thorac Oncol, Surg Branch, NIH, 10 Ctr Dr,MSC 1201, Bethesda, MD 20892 USA.	kwongk2@mail.nih.gov	Camps, Jordi/AAG-3080-2020; Yang, Jianhui/GQO-8030-2022	Camps, Jordi/0000-0002-3165-3640; 	National Institutes of Health; NIH; NATIONAL CANCER INSTITUTE [ZIABC011046, ZIABC010833] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Steven A Rosenberg for reviewing the manuscript. This work was supported by the National Institutes of Health, Intramural Research Program (TR and KFK) and NIH Postdoctoral Cancer Research Training Awards (YX, JC, EW and KSA).	Adair SJ, 2009, CANCER IMMUNOL IMMUN, V58, P589, DOI 10.1007/s00262-008-0582-6; Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025; Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008-5472.CAN-10-2754; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bao L, 2011, CANCER IMMUNOL IMMUN, V60, P1299, DOI 10.1007/s00262-011-1037-z; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chhabra R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005848; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Dean EJ, 2007, CANCER TREAT REV, V33, P203, DOI 10.1016/j.ctrv.2006.11.002; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Diakos C, 2010, BLOOD, V116, P4885, DOI 10.1182/blood-2009-02-206706; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Geering B, 2011, BLOOD, V117, P5953, DOI 10.1182/blood-2010-11-322206; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Holcik M, 2003, ANN NY ACAD SCI, V1010, P249, DOI 10.1196/annals.1299.043; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kang HG, 2008, CANCER GENET CYTOGEN, V180, P6, DOI 10.1016/j.cancergencyto.2007.07.021; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Ku G, 2008, HUM GENE THER, V19, P17, DOI 10.1089/hum.2007.1226; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lal A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001864; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lal A, 2009, NAT STRUCT MOL BIOL, V16, P492, DOI 10.1038/nsmb.1589; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Liu L, 2010, BIOCHEM BIOPH RES CO, V400, P236, DOI 10.1016/j.bbrc.2010.08.046; Macville M, 1999, CANCER RES, V59, P141; Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292; Mashima T, 2005, DRUG RESIST UPDATE, V8, P339, DOI 10.1016/j.drup.2005.11.001; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Niederer F, 2012, ARTHRITIS RHEUM-US, V64, P1771, DOI 10.1002/art.34334; Padilla-Nash HM, 2006, NAT PROTOC, V1, P3129, DOI 10.1038/nprot.2006.358; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Riley A, 2010, NUCLEIC ACIDS RES, V38, P4665, DOI 10.1093/nar/gkq241; Saini S, 2011, CANCER RES, V71, P6208, DOI 10.1158/0008-5472.CAN-11-0073; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Tonon G, 2004, CANCER GENET CYTOGEN, V152, P15, DOI 10.1016/j.cancergencyto.2003.10.007; Ulybina YM, 2011, TUMORI, V97, P248, DOI 10.1700/667.7794; Walker JC, 2009, GENE DEV, V23, P1046, DOI 10.1101/gad.1777709; Wang BB, 2006, MOL CELL, V22, P553, DOI 10.1016/j.molcel.2006.03.034; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang Q, 2008, BLOOD, V111, P588, DOI 10.1182/blood-2007-05-092718; Wang XY, 2009, BRAIN RES BULL, V80, P268, DOI 10.1016/j.brainresbull.2009.08.006; Yoon S, 2010, FEBS LETT, V584, P4048, DOI 10.1016/j.febslet.2010.08.025; Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3; Zhu W, 2010, INT J CANCER, V127, P2520, DOI 10.1002/ijc.25260	59	74	77	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2442	2451		10.1038/onc.2012.258	http://dx.doi.org/10.1038/onc.2012.258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22733138	Green Accepted			2022-12-28	WOS:000318694900008
J	Li, A; Zhang, C; Gao, S; Chen, F; Yang, C; Luo, R; Xiao, H				Li, A.; Zhang, C.; Gao, S.; Chen, F.; Yang, C.; Luo, R.; Xiao, H.			TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice	ONCOGENE			English	Article						TIP30; lung adenocarcinoma; EGFR signaling; tumor suppressor	EPIDERMAL-GROWTH-FACTOR; BRONCHIOALVEOLAR STEM-CELLS; FACTOR RECEPTOR; TARGETED THERAPIES; TUMOR-METASTASIS; MUTANT P53; C-MYC; K-RAS; CANCER; EXPRESSION	Lung adenocarcinoma, the most common type of human non-small cell lung cancer (NSCLC), frequently overexpresses epidermal growth factor receptor (EGFR). However, the mechanisms underlying EGFR overexpression are not completely understood. Recent studies have identified that decreased expression of TIP30 (30kDa HIV-1 Tat interacting protein) is associated with the metastasis of human NSCLCs, but a causative relationship between TIP30 deficiency and NSCLC development remains unclear. We show here that Tip30 deletion leads to spontaneous development of lung adenomas and adenocarcinomas in mice. Lung tumor development was preceded by aberrant expansion of bronchioalveolar stem/progenitor and alveolar type II (AT2) cells, and also increased expression of EGFR and its downstream signaling factors in the lung of Tip30(-/-) mice. Moreover, TIP30 knockdown in human lung adenocarcinoma cells resulted in prolonged EGFR activity in early endosomes, delayed EGFR degradation, increased EGFR nuclear localization, leading to upregulated pAKT and pERK1/2 expression. Importantly, in human lung adenocarcinomas, low TIP30 expression correlates with prolonged patient overall and post-progression survival times. Together, these results suggest that TIP30 functions as a tumor suppressor to inhibit EGFR cytoplasmic and nuclear signaling and suppress adenocarcinogenesis in the lung, and highlight the potential of therapeutic strategies aiming at inhibiting EGFR signaling for patients with low TIP30-expression lung adenocarcinoma.	[Li, A.; Zhang, C.; Gao, S.; Chen, F.; Yang, C.; Xiao, H.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Li, A.; Chen, F.; Luo, R.] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Zhang, C.] Michigan State Univ, Genet Program, E Lansing, MI 48824 USA; [Gao, S.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Southern Medical University - China; Michigan State University; Michigan State University	Luo, R (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Oncol, 1838 North Guangzhou Rd, Guangzhou 510515, Guangdong, Peoples R China.	luorc01@163.com; xiaoh@msu.edu	Zhang, Chengliang/E-6943-2016	Zhang, Chengliang/0000-0003-3798-4157; Zhang, Chengliang/0000-0001-6999-4670	NIDDK, NIH [RO1 DK066110-01, W81XWH-08-1-0377]; DOD [RO1 DK066110-01, W81XWH-08-1-0377]; Nanfang Hospital, China; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066110] Funding Source: NIH RePORTER	NIDDK, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DOD(United States Department of Defense); Nanfang Hospital, China; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to Jill Pecha for backcrossing Tip30 knockout gene into Balb/c mice, Ying Qin and Zuguo Li for histological examination of preneoplastic lesions and tumors, Eran Andrechek and Inez Yuwanita for helping patient survival analysis, and Sandra Z Haslam for critical reading of the manuscript. This work was supported by grants RO1 DK066110-01 and W81XWH-08-1-0377 (to HX) from NIDDK, NIH and DOD. AL is partly supported by a fellowship from Nanfang Hospital, China.	Berger AH, 2010, NAT GENET, V42, P216, DOI 10.1038/ng.527; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bitler BG, 2010, J CELL SCI, V123, P1716, DOI 10.1242/jcs.062661; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Chen V, 2010, CELL CYCLE, V9, P4941, DOI 10.4161/cc.9.24.14230; Chen X, 2006, DIGEST DIS SCI, V55, P2219; Ehrhardt A, 2001, BRIT J CANCER, V84, P813, DOI 10.1054/bjoc.2000.1676; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fong S, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-23; Gazdar AF, 2008, CANCER PREV RES, V1, P156, DOI 10.1158/1940-6207.CAPR-08-0080; Ito M, 2003, CANCER RES, V63, P8763; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jiang C, 2004, J BIOL CHEM, V279, P27781, DOI 10.1074/jbc.M401809200; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; King FW, 2004, MOL CELL BIOL, V24, P7091, DOI 10.1128/MCB.24.16.7091-7101.2004; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Morimoto M, 2009, DEV BIOL, V325, P171, DOI 10.1016/j.ydbio.2008.10.013; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Pecha J, 2007, ONCOGENE, V26, P7423, DOI 10.1038/sj.onc.1210548; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; RUSCH V, 1993, CANCER RES, V53, P2379; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Sun S, 2007, J CLIN INVEST, V117, P2740, DOI 10.1172/JCI31809; Tchou-Wong KM, 2002, AM J RESP CELL MOL, V27, P186, DOI 10.1165/ajrcmb.27.2.4799; Tong X, 2009, AM J PATHOL, V174, P1931, DOI 10.2353/ajpath.2009.080846; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Yanagi S, 2007, J CLIN INVEST, V117, P2929, DOI 10.1172/JCI31854; Yang CH, 2008, J CLIN ONCOL, V26, P2745, DOI 10.1200/JCO.2007.15.6695; Zhang CL, 2011, J BIOL CHEM, V286, P9373, DOI 10.1074/jbc.M110.207720; Zhang CL, 2010, CANCER RES, V70, P10224, DOI 10.1158/0008-5472.CAN-10-3057; Zhao J, 2008, HEPATOLOGY, V48, P265, DOI 10.1002/hep.22280; Zhao J, 2007, HUM PATHOL, V38, P293, DOI 10.1016/j.humpath.2006.08.005	42	26	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2273	2281		10.1038/onc.2012.253	http://dx.doi.org/10.1038/onc.2012.253			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22733137	Green Accepted			2022-12-28	WOS:000318683600004
J	Huang, JM; Nagatomo, I; Suzuki, E; Mizuno, T; Kumagai, T; Berezov, A; Zhang, H; Karlan, B; Greene, MI; Wang, Q				Huang, J-M; Nagatomo, I.; Suzuki, E.; Mizuno, T.; Kumagai, T.; Berezov, A.; Zhang, H.; Karlan, B.; Greene, M. I.; Wang, Q.			YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14	ONCOGENE			English	Article						ovarian cancer; YAP; PTPN14; EGFR; survivin; erlotinib	YES-ASSOCIATED PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; WW DOMAIN; HIPPO PATHWAY; TRANSCRIPTIONAL COACTIVATOR; SIZE-CONTROL; ORGAN SIZE; TGF-BETA; GROWTH; TAZ	The Yes-associated protein (YAP) is a transcriptional factor involved in tissue development and tumorigenesis. Although YAP has been recognized as a key element of the Hippo signaling pathway, the mechanisms that regulate YAP activities remain to be fully characterized. In this study, we demonstrate that the non-receptor type protein tyrosine phosphatase 14 (PTPN14) functions as a negative regulator of YAP. We show that YAP forms a protein complex with PTPN14 through the WW domains of YAP and the PPXY motifs of PTPN14. In addition, PTPN14 inhibits YAP-mediated transcriptional activities. Knockdown of YAP sensitizes cancer cells to various anti-cancer agents, such as cisplatin, the EGFR tyrosine kinase inhibitor erlotinib and the small-molecule antagonist of survivin, S12. YAP-targeted modalities may be used in combination with other cancer drugs to achieve maximal therapeutic effects. Oncogene (2013) 32, 2220-2229; doi:10.1038/onc.2012.231; published online 11 June 2012	[Huang, J-M; Karlan, B.; Wang, Q.] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Womens Canc Program, Los Angeles, CA USA; [Nagatomo, I.; Kumagai, T.; Zhang, H.; Greene, M. I.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Suzuki, E.; Mizuno, T.; Berezov, A.; Greene, M. I.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of Pennsylvania; Pennsylvania Medicine; Cedars Sinai Medical Center	Greene, MI (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, 36th Hamilton Walk,252 John Morgan Bldg, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu; qiang.wang@cshs.org	Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049	Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute of the Cedars-Sinai Medical Center; Donna and Jesse Garber Award for Cancer Research; National Cancer Institute [R01CA089481, R01 CA055306]; Breast Cancer Research Foundation; Abramson Family Cancer Research Institute at the University of Pennsylvania; Abramson Cancer Center [P30CA016520]; CEET [ES013508-04]; NATIONAL CANCER INSTITUTE [R01CA055306, R01CA089481, P30CA016520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute of the Cedars-Sinai Medical Center; Donna and Jesse Garber Award for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; Abramson Family Cancer Research Institute at the University of Pennsylvania; Abramson Cancer Center; CEET; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work has been supported by funds from the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute of the Cedars-Sinai Medical Center (QW), the Donna and Jesse Garber Award for Cancer Research (QW), R01CA089481 and R01 CA055306 from the National Cancer Institute (MIG), the Breast Cancer Research Foundation, and the Abramson Family Cancer Research Institute at the University of Pennsylvania (MIG). We thank these investigators for providing plasmids Masato Ogata (murine PTPN14/ PEZ), Joan Brugge (YAP), Kunliang Guan (Gal4- TEAD4) and Marius Sudol (LATS1). We thank Dr Chao-Xing Yuan for performing proteomics analysis at the proteomics core facility at the University of Pennsylvania. The Proteomics Core was supported by grant P30CA016520 (Abramson Cancer Center) and by grant ES013508-04 (CEET). We also thank the members of the Women's Cancer Program (Cedars-Sinai) and the Greene laboratory (UPenn) for helpful discussion.	Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Andersen J, 2010, DANCING TIMES, V100, P55; Barr AJ, 2006, PROTEINS, V63, P1132, DOI 10.1002/prot.20958; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Berezov A, 2012, ONCOGENE, V31, P1938, DOI 10.1038/onc.2011.377; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cao XW, 2008, GENE DEV, V22, P3320, DOI 10.1101/gad.1726608; Carlucci A, 2008, J BIOL CHEM, V283, P10919, DOI 10.1074/jbc.M707248200; Carlucci A, 2010, J BIOL CHEM, V285, P39260, DOI 10.1074/jbc.M110.174706; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; Fernandez LA, 2011, ONCOGENE, P29; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Laczmanska I, 2011, ACTA BIOCHIM POL, V58, P467; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Niedergethmann M, 2007, BRIT J CANCER, V97, P1432, DOI 10.1038/sj.bjc.6604031; Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905; Ogata M, 1999, J BIOL CHEM, V274, P20717, DOI 10.1074/jbc.274.29.20717; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Poernbacher I, 2012, CURR BIOL, V22, P389, DOI 10.1016/j.cub.2012.01.019; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Urtasun R, 2011, HEPATOLOGY, V54, P2149, DOI 10.1002/hep.24587; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wadham C, 2000, J CELL SCI, V113, P3117; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Webb C, 2011, BIOCHEMISTRY-US, V50, P3300, DOI 10.1021/bi2001888; Wu ZZ, 2010, BIOCHEM PHARMACOL, V80, P262, DOI 10.1016/j.bcp.2010.03.029; Wyatt L, 2007, J CELL BIOL, V178, P1223, DOI 10.1083/jcb.200705035; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yoneda T, 2006, DNA CELL BIOL, V25, P530, DOI 10.1089/dna.2006.25.530; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	64	114	119	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2220	2229		10.1038/onc.2012.231	http://dx.doi.org/10.1038/onc.2012.231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689061	Green Accepted			2022-12-28	WOS:000318062800011
J	Mihlan, S; Reiss, C; Thalheimer, P; Herterich, S; Gaetzner, S; Kremerskothen, J; Pavenstadt, HJ; Lewandrowski, U; Sickmann, A; Butt, E				Mihlan, S.; Reiss, C.; Thalheimer, P.; Herterich, S.; Gaetzner, S.; Kremerskothen, J.; Pavenstaedt, H. J.; Lewandrowski, U.; Sickmann, A.; Butt, E.			Nuclear import of LASP-1 is regulated by phosphorylation and dynamic protein-protein interactions	ONCOGENE			English	Article						LASP-1; nucleo-cytoplasmatic shuttling; phosphatase 2B; ZO-2; LPP	BINDING-PROTEINS; CELL-MIGRATION; OVARIAN-CANCER; ACTIN-BINDING; LIM; DOMAIN; TRANSCRIPTION; LOCALIZATION; ZO-2; CAMP	LASP-1 is a multidomain protein predominantly localized at focal contacts, where it regulates cytoskeleton dynamics and cell migration. However, in different tumor entities, a nuclear LASP-1 accumulation is observed, thought to have an important role in cancer progression. Until now, the molecular mechanisms that control LASP-1 nuclear import were not elucidated. Here, we identified a novel LASP-1-binding partner, zona occludens protein 2 (ZO-2), and established its role in the signal transduction pathway of LASP-1 nucleo-cytoplasmatic shuttling. Phosphorylation of LASP-1 by PKA at serine 146 induces translocation of the LASP-1/ZO-2 complex from the cytoplasm to the nucleus. Interaction occurs within the carboxyterminal proline-rich motif of ZO-2 and the SH3 domain in LASP-1. In situ proximity ligation assay confirmed the direct binding between LASP-1 and ZO-2 and visualized the shuttling. Nuclear export is mediated by Crm-1 and a newly identified nuclear export signal in LASP-1. Finally, dephosphorylation of LASP-1 by phosphatase PP2B is suggested to relocalize the protein back to focal contacts. In summary, we define a new pathway for LASP-1 in tumor progression. Oncogene (2013) 32, 2107-2113; doi:10.1038/onc.2012.216; published online 4 June 2012	[Mihlan, S.; Reiss, C.; Thalheimer, P.; Herterich, S.; Gaetzner, S.; Butt, E.] Univ Clin Wuerzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; [Kremerskothen, J.; Pavenstaedt, H. J.] Univ Hosp Muenster, Div Mol Nephrol, Dept Internal Med D, Munster, Germany; [Lewandrowski, U.; Sickmann, A.] Leibniz Inst Analyt Wissensch ISAS eV, Dept Bioanalyt, Dortmund, Germany; [Sickmann, A.] Ruhr Univ Bochum, Med Proteome Ctr, Bochum, Germany	University of Wurzburg; University of Munster; Dortmund University of Technology; Leibniz Institut fur Analytische Wissenschaften (ISAS); Ruhr University Bochum	Butt, E (corresponding author), Univ Clin Wuerzburg, Inst Clin Biochem & Pathobiochem, Grombuehlstr 12, D-97080 Wurzburg, Germany.	butt@klin-biochem.uni-wuerzburg.de	Sickmann, Albert/A-1010-2011	Sickmann, Albert/0000-0002-2388-5265	DFG [BU 740/6-2, RE 3183/1-1, SFB 688 A2]; Innovative Medizinische Forschung, University Hospital Munster [KR110904]; Ministerium fur Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen	DFG(German Research Foundation (DFG)); Innovative Medizinische Forschung, University Hospital Munster; Ministerium fur Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen	We thank Dr Viacheslav Nikolaev for his help with confocal microscopy. This work was supported by grants from the DFG (BU 740/6-2 to EB, RE 3183/1-1 to CR, SFB 688 A2 to SG) the Innovative Medizinische Forschung, University Hospital Munster (KR110904 to JK) and the Ministerium fur Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen (UL and AS).	Balda MS, 2009, BBA-BIOMEMBRANES, V1788, P761, DOI 10.1016/j.bbamem.2008.11.024; Betanzos A, 2004, EXP CELL RES, V292, P51, DOI 10.1016/j.yexcr.2003.08.007; Butt E, 2003, J BIOL CHEM, V278, P15601, DOI 10.1074/jbc.M209009200; Call GS, 1942, BIOCHEM BIOPH RES CO, V404, P780; Chew CS, 2002, J CELL SCI, V115, P4787, DOI 10.1242/jcs.00174; Chew CS, 2008, AM J PHYSIOL-GASTR L, V288, pG376; CHIYOMARU T, 2010, UROL ONCOL; Dimova I, 2009, TUMORI, V95, P357; Ferraro E, 2007, NUCLEIC ACIDS RES, V35, pW451, DOI 10.1093/nar/gkm296; Frietsch JJ, 2010, BRIT J CANCER, V102, P1645, DOI 10.1038/sj.bjc.6605685; Grunewald TGP, 2007, BRIT J CANCER, V96, P296, DOI 10.1038/sj.bjc.6603545; Grunewald TGP, 2006, EXP CELL RES, V312, P974, DOI 10.1016/j.yexcr.2005.12.016; Grunewald TGP, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-31; Grunewald TGP, 2007, BMC CANCER, V7, P1, DOI 10.1186/1471-2407-7-198; Hammarstrom A, 1996, BIOCHEMISTRY-US, V35, P12723, DOI 10.1021/bi961149j; Huerta M, 2007, MOL BIOL CELL, V18, P4826, DOI 10.1091/mbc.E07-02-0109; Keicher C, 2004, BIOCHEM BIOPH RES CO, V324, P308, DOI 10.1016/j.bbrc.2004.08.235; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; LEREA KM, 1991, BIOCHEMISTRY-US, V30, P6819, DOI 10.1021/bi00242a003; Li B, 2004, J BIOL CHEM, V279, P20401, DOI 10.1074/jbc.M310304200; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Merkle D, 2011, CELL SIGNAL, V23, P507, DOI 10.1016/j.cellsig.2010.08.017; Nakagawa H, 2006, FEBS LETT, V580, P3223, DOI 10.1016/j.febslet.2006.04.082; Oka T, 2002, BIOCHEM J, V432, P461; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Traenka C, 2010, CANCER RES, V70, P8003, DOI 10.1158/0008-5472.CAN-10-0592; Traenka J, 2009, THROMB HAEMOSTASIS, V102, P520, DOI 10.1160/TH09-03-0143; Traweger A, 2003, J BIOL CHEM, V278, P2692, DOI 10.1074/jbc.M206821200; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Zhang H, 2009, PHYSIOL GENOMICS, V38, P372, DOI 10.1152/physiolgenomics.00048.2009; Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739; Zheng B, 2009, FEBS J, V276, P2669, DOI 10.1111/j.1742-4658.2009.06986.x	34	46	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2107	2113		10.1038/onc.2012.216	http://dx.doi.org/10.1038/onc.2012.216			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22665060				2022-12-28	WOS:000317919900012
J	Kuroda, I; Inukai, T; Zhang, X; Kikuchi, J; Furukawa, Y; Nemoto, A; Akahane, K; Hirose, K; Honna-Oshiro, H; Goi, K; Kagami, K; Yagita, H; Tauchi, T; Maeda, Y; Sugita, K				Kuroda, I.; Inukai, T.; Zhang, X.; Kikuchi, J.; Furukawa, Y.; Nemoto, A.; Akahane, K.; Hirose, K.; Honna-Oshiro, H.; Goi, K.; Kagami, K.; Yagita, H.; Tauchi, T.; Maeda, Y.; Sugita, K.			BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia	ONCOGENE			English	Article						Philadelphia chromosome-positive leukemia; tumor necrosis factor-related apoptosis-inducing ligand; BCR-ABL	ACUTE LYMPHOBLASTIC-LEUKEMIA; STEM-CELL TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; IMATINIB; INHIBITOR; SURVEILLANCE; METASTASIS; MECHANISMS; INITIATION	Allogeneic stem cell transplantation (allo-SCT) is a potentially curative therapy for chronic myeloid leukemia and Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia, and the graft-vs-leukemia (GVL) effect can eradicate residual leukemia after allo-SCT. Ph(+) leukemia cells frequently express death-inducing receptors (DR4 and DR5) for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is one of the cytotoxic ligands expressed on cytotoxic T cells and natural killer cells mediating the GVL effect. Here we demonstrate that imatinib specifically downregulated DR4 and DR5 expression in cell lines and clinical samples of Ph(+) leukemia. Second-generation tyrosine kinase inhibitors (dasatinib and nilotinib) and short hairpin RNA against bcr-abl also downregulated DR4 and DR5 expression in Ph(+) leukemia cells, and transfection of bcr-abl into a Ph(-) leukemia cell line induced DR4 and DR5 expression, which was abrogated by imatinib treatment. Accordingly, Ph(+) leukemia cells that had been pretreated with imatinib showed resistance to the pro-apoptotic activity of recombinant human soluble TRAIL. These observations demonstrate that BCR-ABL is critically involved in the leukemia-specific expression of DR4 and DR5 and in the susceptibility of Ph(+) leukemia to TRAIL-mediated anti-leukemic activity, providing new insight into the mechanisms of the tumor-specific cytotoxic activities of TRAIL. Oncogene (2013) 32, 1670-1681; doi:10.1038/onc.2012.186; published online 4 June 2012	[Kuroda, I.; Inukai, T.; Zhang, X.; Nemoto, A.; Akahane, K.; Hirose, K.; Honna-Oshiro, H.; Goi, K.; Kagami, K.; Sugita, K.] Univ Yamanashi, Dept Pediat, Sch Med, Chuo, Yamanashi 4093898, Japan; [Kikuchi, J.; Furukawa, Y.] Jichi Med Sch, Ctr Mol Med, Simotsuke, Tochigi, Japan; [Yagita, H.] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; [Tauchi, T.] Tokyo Med Univ, Dept Internal Med 1, Tokyo 1608402, Japan; [Maeda, Y.] Kinki Univ, Sch Med, Div Hematol, Dept Internal Med, Osaka 589, Japan	University of Yamanashi; Juntendo University; Tokyo Medical University; Kindai University (Kinki University)	Inukai, T (corresponding author), Univ Yamanashi, Dept Pediat, Sch Med, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan.	tinukai@yamanashi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418	Ministry of Education, Science and Culture, Japan	Ministry of Education, Science and Culture, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The authors thank technological supports by Masako Abe. This work was supported in part by research grants from the Ministry of Education, Science and Culture, Japan.	Akahane K, 2010, EXP HEMATOL, V38, P885, DOI 10.1016/j.exphem.2010.06.014; Arico M, 2000, NEW ENGL J MED, V342, P998, DOI 10.1056/NEJM200004063421402; Carpenter PA, 2007, BLOOD, V109, P2791, DOI 10.1182/blood-2006-04-019836; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fielding AK, 2010, BLOOD, V116, P3409, DOI 10.1182/blood-2010-01-242750; Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221; Hehlmann R, 2007, LANCET, V370, P342, DOI 10.1016/S0140-6736(07)61165-9; Hess G, 2005, J CLIN ONCOL, V23, P7583, DOI 10.1200/JCO.2005.01.3110; Hirase C, 2009, LEUKEMIA RES, V33, P450, DOI 10.1016/j.leukres.2008.07.023; Hirose K, 2010, BLOOD, V116, P962, DOI 10.1182/blood-2009-09-244673; INUKAI T, 1993, BRIT J HAEMATOL, V85, P823; Jabbour E, 2010, LEUKEMIA, V24, P6, DOI 10.1038/leu.2009.193; Jabbour E, 2011, BLOOD, V117, P1822, DOI 10.1182/blood-2010-07-293977; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kolb HJ, 2008, BLOOD, V112, P4371, DOI 10.1182/blood-2008-03-077974; Kolb HJ, 2004, BLOOD, V103, P767, DOI 10.1182/blood-2003-02-0342; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Nimmanapalli R, 2001, CLIN CANCER RES, V7, P350; Olavarria E, 2007, BLOOD, V110, P4614, DOI 10.1182/blood-2007-04-082990; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PRETI HA, 1994, AM J MED, V97, P60, DOI 10.1016/0002-9343(94)90049-3; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Savani BN, 2005, BONE MARROW TRANSPL, V36, P1009, DOI 10.1038/sj.bmt.1705167; Schmaltz C, 2002, NAT MED, V8, P1433, DOI 10.1038/nm797; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tiribelli M, 2009, LEUKEMIA RES, V33, P174, DOI 10.1016/j.leukres.2008.03.031; Uckun FM, 1998, CANCER-AM CANCER SOC, V83, P2030, DOI 10.1002/(SICI)1097-0142(19981101)83:9<2030::AID-CNCR21>3.0.CO;2-Q; Uno K, 2003, BLOOD, V101, P3658, DOI 10.1182/blood-2002-06-1770; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Yoshimitsu M, 2008, INT J HEMATOL, V88, P331, DOI 10.1007/s12185-008-0150-z; Zhang XC, 2011, LEUKEMIA RES, V35, P940, DOI 10.1016/j.leukres.2011.03.016	41	6	8	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1670	1681		10.1038/onc.2012.186	http://dx.doi.org/10.1038/onc.2012.186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22665066				2022-12-28	WOS:000316855800007
J	Lee, PC; Lee, HJ; Kakadiya, R; Sanjiv, K; Su, TL; Lee, TC				Lee, P-C; Lee, H-J; Kakadiya, R.; Sanjiv, K.; Su, T-L; Lee, T-C			Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity	ONCOGENE			English	Article						DNA crosslinking agents; nnultidrug resistance; Src/nuclear EGFR cascade; DNA repair; DNA-PK nuclear translocation	GROWTH-FACTOR RECEPTOR; DEPENDENT PROTEIN-KINASE; HAMSTER OVARY CELLS; STRAND BREAK REPAIR; IN-VITRO; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; HUMAN CANCER; TUMOR-CELLS; SRC	We synthesized several novel bifunctional alkylating derivatives of 3a-aza-cyclopenta[a]indene (BO-1012, BO-1005, BO-1099 and BO-1101) that are potent DNA interstrand crosslinking agents. In in vitro cytotoxicity assay, these compounds were more cytotoxic to multidrug-resistant (MDR) cells, such as KBvin10, KBtax50 and CEM/VBL, than their parental cells. Using a xenograft model, BO-1012, at a dose of 5 mg/kg, partially suppressed the growth of parental KB cells but completely suppressed the growth of KBvin10 cells in nude mice. In exploring the possible mechanism, we found that DNA double-strand break (DSB) repair activity in MDR cells, KBvin10 and CEM/VBL, was significantly reduced compared with their parental cells, KB and CEM. Reduced DSB repair activity in KBvin10 cells was likely due to a defect in nuclear translocation of DNA-dependent protein kinase (DNA-PK), a component of the non-homologous end-joining repair machinery. Furthermore, BO-1012-induced DNA-PK translocation from the cytosol into the nucleus in KB cells is associated with the activation of the Src/nuclear epidermal growth factor receptor (EGFR) cascade, which is defective in MDR cells. As knockdown of P-glycoprotein (P-gp) by siRNA reactivated the Src/nuclear EGFR cascade, DNA-PK translocation and DNA repair activity in MDR cells, overexpression of P-gp attenuates the activity of DNA DSB repair through suppression of Src/nuclear EGFR cascade. Therefore, DNA interstrand crosslinking agents may have potential therapeutic use against P-gp-overexpressing MDR cells. Oncogene (2013) 32, 1144-1154; doi:10.1038/onc.2012.133; published online 23 April 2012	[Lee, P-C; Lee, H-J; Kakadiya, R.; Sanjiv, K.; Su, T-L; Lee, T-C] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Lee, P-C; Lee, T-C] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Lee, TC (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.	tlsu@ibms.sinica.edu.tw; bmtcl@ibms.sinica.edu.tw			Academia Sinica [AS-96-TP-B06, AS-100-TP-B13]; National Science Councils, Taiwan (ROC) [NSC-100-2325-B-001-003]	Academia Sinica(Academia Sinica - Taiwan); National Science Councils, Taiwan (ROC)	We thank Dr Ling-Hui Yih for helpful suggestions and critical comments. This work was supported by grants from the Academia Sinica (AS-96-TP-B06 and AS-100-TP-B13) and the National Science Councils (NSC-100-2325-B-001-003), Taiwan (ROC).	Aleshin A, 2010, NEOPLASIA, V12, P599, DOI 10.1593/neo.10328; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bell SE, 1998, BRIT J CANCER, V78, P1464, DOI 10.1038/bjc.1998.708; Bergman AM, 2003, BRIT J CANCER, V88, P1963, DOI 10.1038/sj.bjc.6601011; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Borowski E, 2005, ACTA BIOCHIM POL, V52, P609; Bradshaw JM, 2010, CELL SIGNAL, V22, P1175, DOI 10.1016/j.cellsig.2010.03.001; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; Chaniyara R, 2011, BIOORGAN MED CHEM, V19, P275, DOI 10.1016/j.bmc.2010.11.030; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dittmann K, 2011, RADIOTHER ONCOL, V99, P317, DOI 10.1016/j.radonc.2011.06.001; Dittmann K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-69; Egloff AM, 2008, SEMIN ONCOL, V35, P286, DOI 10.1053/j.seminoncol.2008.03.008; ERBA E, 1995, INT J CANCER, V62, P170, DOI 10.1002/ijc.2910620211; FORD JM, 1990, PHARMACOL REV, V42, P155; Friedmann BJ, 2006, MOL CANCER THER, V5, P209, DOI 10.1158/1535-7163.MCT-05-0239; Frosina G, 2009, MOL CANCER RES, V7, P989, DOI 10.1158/1541-7786.MCR-09-0030; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; GUPTA RS, 1985, CANCER TREAT REP, V69, P515; Hall MD, 2011, J MED CHEM, V54, P5878, DOI 10.1021/jm2006047; Hall MD, 2009, TRENDS PHARMACOL SCI, V30, P546, DOI 10.1016/j.tips.2009.07.003; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; He SN, 2010, INT J MOL SCI, V11, P3039, DOI 10.3390/ijms11093039; Huo LF, 2010, P NATL ACAD SCI USA, V107, P16125, DOI 10.1073/pnas.1000743107; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Juang SH, 2007, MOL CANCER THER, V6, P193, DOI 10.1158/1535-7163.MCT-06-0482; Kakadiya R, 2009, BIOORGAN MED CHEM, V17, P5614, DOI 10.1016/j.bmc.2009.06.018; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kimura Y, 2004, MICROBIOL-SGM, V150, P631, DOI 10.1099/mic.0.26786-0; Lage H, 2006, CURR DRUG TARGETS, V7, P813, DOI 10.2174/138945006777709566; Lai KC, 2008, MOL CANCER RES, V6, P1431, DOI 10.1158/1541-7786.MCR-08-0141; Lee CH, 2010, METHODS MOL BIOL, V596, P325, DOI 10.1007/978-1-60761-416-6_14; Lee PC, 2010, NEOPLASIA, V12, P376, DOI 10.1593/neo.10110; LEE TC, 1994, CANCER RES, V54, P1660; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834; Medunjanin S, 2010, MOL BIOL CELL, V21, P1620, DOI 10.1091/mbc.E09-08-0724; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Miyagawa K, 2008, CANCER SCI, V99, P187, DOI 10.1111/j.1349-7006.2007.00644.x; Norgaard JM, 1998, BRIT J HAEMATOL, V100, P534, DOI 10.1046/j.1365-2141.1998.00593.x; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Pan GD, 2009, WORLD J GASTROENTERO, V15, P431, DOI 10.3748/wjg.15.431; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; RONINSON IB, 1992, BIOCHEM PHARMACOL, V43, P95, DOI 10.1016/0006-2952(92)90666-7; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Szumiel I, 2006, CELL SIGNAL, V18, P1537, DOI 10.1016/j.cellsig.2006.03.010; Takara K, 2006, CURR PHARM DESIGN, V12, P273, DOI 10.2174/138161206775201965; Turk D, 2009, CANCER RES, V69, P8293, DOI 10.1158/0008-5472.CAN-09-2422; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yih LH, 2006, CANCER RES, V66, P2098, DOI 10.1158/0008-5472.CAN-05-2308	62	19	19	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2013	32	9					1144	1154		10.1038/onc.2012.133	http://dx.doi.org/10.1038/onc.2012.133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22525278				2022-12-28	WOS:000316428800008
J	Alikhani, N; Ferguson, RD; Novosyadlyy, R; Gallagher, EJ; Scheinman, EJ; Yakar, S; LeRoith, D				Alikhani, N.; Ferguson, R. D.; Novosyadlyy, R.; Gallagher, E. J.; Scheinman, E. J.; Yakar, S.; LeRoith, D.			Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model	ONCOGENE			English	Article						dyslipidemia; mammary tumor; ApoE; metastasis; Akt	PROSTATE-CANCER CELLS; RICH LIPID RAFTS; BREAST-CANCER; CHOLESTEROL; PROGRESSION; INSULIN; RISK; MICE; SENSITIVITY; CARCINOMA	Dyslipidemia has been associated with an increased risk for developing cancer. However, the implicated mechanisms are largely unknown. To explore the role of dyslipidemia in breast cancer growth and metastasis, we used the apolipoprotein E (ApoE) knockout mice (ApoE(-/-)), which exhibit marked dyslipidemia, with elevated circulating cholesterol and triglyceride levels in the setting of normal glucose homeostasis and insulin sensitivity. Non-metastatic Met-1 and metastatic Mvt-1 mammary cancer cells derived from MM1V-PyVmT/FVB-N transgenic mice and c-Myc/vegf tumor explants respectively, were injected into the mammary fat pad of ApoE(-/-) and wild-type (WT) females consuming a high-fat/high-cholesterol diet and tumor growth was evaluated. ApoE(-/-) mice exhibited increased tumor growth and displayed a greater number of spontaneous metastases to the lungs. Furthermore, intravenous injection of Mvt-1 cells resulted in a greater number of pulmonary metastases in the lungs of ApoE(-/-) mice compared with WT controls. To unravel the molecular mechanism involved in enhanced tumor growth in ApoE(-/-) mice, we studied the response of Mvt-1 cells to cholesterol in vitro. We found that cholesterol increased Akt(S473) phosphorylation in Mvt-1 cells as well as cellular proliferation, whereas cholesterol depletion in the cell membrane abrogated Akt(S473) phosphorylation induced by exogenously added cholesterol. Furthermore, in vivo administration of BKM120, a small-molecule inhibitor of phosphatidylinositol 3-kinase (PI3K), alleviated dyslipidemia-induced tumor growth and metastasis in Mvt-1 model with a concomitant decrease in PI3K/Akt signaling. Collectively, we suggest that the hypercholesterolennic milieu in the ApoE(-/-) mice is a favorable setting for mammary tumor growth and metastasis. Oncogene (2013) 32, 961-967; doi:10.1038/onc.2012.113; published online 2 April 2012	[Alikhani, N.; Ferguson, R. D.; Novosyadlyy, R.; Gallagher, E. J.; Yakar, S.; LeRoith, D.] Mt Sinai Sch Med, Samuel Bronfman Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA; [Scheinman, E. J.; LeRoith, D.] CRIR, Diabet & Metab Clin Res Ctr Excellence, Haifa, Israel	Icahn School of Medicine at Mount Sinai; Rambam Health Care Campus	LeRoith, D (corresponding author), Mt Sinai Sch Med, Samuel Bronfman Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA.	derek.leroith@mssm.edu			ADA mentor-based postdoctoral fellowship award [7-08-MN-33]; National Cancer Institute [RO1CA128799]; Israel Cancer Association; NATIONAL CANCER INSTITUTE [R01CA128799] Funding Source: NIH RePORTER	ADA mentor-based postdoctoral fellowship award; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Israel Cancer Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by ADA mentor-based postdoctoral fellowship award 7-08-MN-33 and National Cancer Institute Grant RO1CA128799, both to DLR. We thank Novartis for providing us with BKM120 compound. In addition, partial support was from the Israel Cancer Association to DLR.	Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/0008-5472.CAN-07-0288; ALEXOPOULOS CG, 1987, CANCER-AM CANCER SOC, V60, P3065, DOI 10.1002/1097-0142(19871215)60:12<3065::AID-CNCR2820601234>3.0.CO;2-Q; Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824; Bianchini F, 2002, LANCET ONCOL, V3, P565, DOI 10.1016/S1470-2045(02)00849-5; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Caldieri G, 2010, TRENDS CELL BIOL, V20, P64, DOI 10.1016/j.tcb.2009.10.006; Cauley JA, 2003, J WOMENS HEALTH, V12, P749, DOI 10.1089/154099903322447710; Chae YK, 2011, CANCER INVEST, V29, P585, DOI 10.3109/07357907.2011.616252; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dansky HM, 1999, ARTERIOSCL THROM VAS, V19, P1960, DOI 10.1161/01.ATV.19.8.1960; Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751; DeStefani E, 1997, NUTR CANCER, V29, P83, DOI 10.1080/01635589709514606; Edidin M, 2003, NAT REV MOL CELL BIO, V4, P414, DOI 10.1038/nrm1102; FAVROT MC, 1984, BIOMED PHARMACOTHER, V38, P55; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fierz Y, 2010, DIABETES, V59, P686, DOI 10.2337/db09-1291; Freeman MR, 2010, ONCOGENE, V29, P3745, DOI 10.1038/onc.2010.132; Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724; Gallagher EJ, 2011, ENDOCRINOLOGY, V152, P2546, DOI 10.1210/en.2011-0231; Gallagher EJ, 2010, CURR DIABETES REP, V10, P93, DOI 10.1007/s11892-010-0101-y; Giovannucci E, 2007, INT J CANCER, V121, P1571, DOI 10.1002/ijc.22788; Graziani SR, 2002, GYNECOL ONCOL, V85, P493, DOI 10.1006/gyno.2002.6654; Halton JM, 1998, CANCER, V83, P379, DOI 10.1002/(SICI)1097-0142(19980715)83:2<379::AID-CNCR24>3.0.CO;2-P; Hu J, 2012, ANN ONCOL, V23, P491, DOI 10.1093/annonc/mdr155; Kawashima Y, 2009, DIABETOLOGIA, V52, P1434, DOI 10.1007/s00125-009-1378-8; Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959; Mandal CC, 2011, J BIOL CHEM, V286, P11314, DOI 10.1074/jbc.M110.193714; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Mondul Alison M, 2011, Cancer Epidemiol, V35, pe6, DOI 10.1016/j.canep.2010.11.005; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; Patra SK, 2008, BBA-REV CANCER, V1785, P182, DOI 10.1016/j.bbcan.2007.11.002; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Platz EA, 2008, INT J CANCER, V123, P1693, DOI 10.1002/ijc.23715; Platz EA, 2006, JNCI-J NATL CANCER I, V98, P1819, DOI 10.1093/jnci/djj499; Sekine Y, 2009, CANCER EPIDEMIOL, V33, P16, DOI 10.1016/j.canep.2009.04.004; Xue F, 2007, AM J CLIN NUTR, V86, p823S, DOI 10.1093/ajcn/86.3.823S; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhuang LY, 2005, J CLIN INVEST, V115, P959; Zhuang LY, 2002, CANCER RES, V62, P2227; ZIELINSKI CC, 1988, J CANCER RES CLIN, V114, P514, DOI 10.1007/BF00391503	40	93	98	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					961	967		10.1038/onc.2012.113	http://dx.doi.org/10.1038/onc.2012.113			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22469977	Green Accepted			2022-12-28	WOS:000316523200003
J	Lorca, T; Castro, A				Lorca, T.; Castro, A.			The Greatwall kinase: a new pathway in the control of the cell cycle	ONCOGENE			English	Review						Greatwall; PP2A; cyclin B-Cdc2; mitosis; mRNA; checkpoint	PROTEIN PHOSPHATASE 2A; XENOPUS EGG EXTRACTS; IN-VIVO; MITOSIS; DROSOPHILA; ENTRY; MASTL; EXIT; THROMBOCYTOPENIA; PROGRESSION	New data have recently established that protein phosphorylation during mitosis is the result of a controlled balance between kinase and phosphatase activities and that, as for mitotic kinases, phosphatases are also regulated during cell division. This regulation is at least in part induced by the activation of the Greatwall (Gwl) kinase at mitotic entry. Activated Gwl phosphorylates its substrates cAMP-regulated phospho protein 19 (Arpp19) and alpha-endosulfine (ENSA), promoting their binding to and the inhibition of PP2A. Interestingly, besides the role of the Gwl-Arpp19/ENSA in the control of mitotic division, new data in yeast support the involvement of this pathway in mRNA stabilization during G(o) program initiation, although in this case the phosphatase PP2A appears not to be implicated. Finally, Gwl activity has been shown to be required for DNA checkpoint recovery. These new findings support the view that Gwl, Arpp19 and ENSA could function as the core of a new signalization pathway that, by targeting different final substrates, could participate in a variety of physiological functions. Oncogene (2013) 32, 537-543; doi:10.1038/onc.2012.79; published online 2 April 2012	Univ Montpellier 2, Ctr Rech Biochim Macromol, CNRS UMR 5237, F-34293 Montpellier 5, France; Univ Montpellier I, Ctr Rech Biochim Macromol, CNRS UMR 5237, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Castro, A (corresponding author), Univ Montpellier 2, Ctr Rech Biochim Macromol, CNRS UMR 5237, IFR 122, 1919 Route Mende, F-34293 Montpellier 5, France.	thierry.lorca@crbm.cnrs.fr; anna.castro@crbm.cnrs.fr	CASTRO, ANNA/F-4350-2010	CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924	'Agence Nationale de la Recherche' (Programme Blanc); Ligue Nationale Contre le Cancer' (Equipe Labelissee)	'Agence Nationale de la Recherche' (Programme Blanc)(French National Research Agency (ANR)); Ligue Nationale Contre le Cancer' (Equipe Labelissee)	We thank A Burgess and K Hached for comments and suggestions on the manuscript. Research in the laboratory of TL and AC has received funding from the 'Agence Nationale de la Recherche' (Programme Blanc) and from The Ligue Nationale Contre le Cancer' (Equipe Labelissee).	Archambault V, 2007, PLOS GENET, V3, P2163, DOI 10.1371/journal.pgen.0030200; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Castilho PV, 2009, MOL BIOL CELL, V20, P4777, DOI 10.1091/mbc.E09-07-0643; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Gandhi MJ, 2003, HUM HERED, V55, P66, DOI 10.1159/000071812; Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Johnson HJ, 2009, EXP HEMATOL, V37, P901, DOI 10.1016/j.exphem.2009.05.005; Lorca T, 2010, J CELL SCI, V123, P2281, DOI 10.1242/jcs.064527; Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028; Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689; Mochida S, 2009, EMBO J, V28, P2777, DOI 10.1038/emboj.2009.238; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Peng AM, 2011, J BIOL CHEM, V286, P28996, DOI 10.1074/jbc.M111.257121; Peng AM, 2010, CELL CYCLE, V9, P4364, DOI 10.4161/cc.9.21.13632; Rangone H, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002225; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Talarek N, 2010, MOL CELL, V38, P345, DOI 10.1016/j.molcel.2010.02.039; Vigneron S, 2011, MOL CELL BIOL, V31, P2262, DOI 10.1128/MCB.00753-10; Vigneron S, 2009, EMBO J, V28, P2786, DOI 10.1038/emboj.2009.228; Voets E, 2010, CELL CYCLE, V9, P3591, DOI 10.4161/cc.9.17.12832; Von Stetina JR, 2008, DEVELOPMENT, V135, P3697, DOI 10.1242/dev.025114; Wang P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002227; WhiteCooper H, 1996, GENETICS, V144, P1097, DOI 10.1534/genetics.112.1097.test; Woods WS, 2007, J BIOL CHEM, V282, P34555, DOI 10.1074/jbc.M705283200; Yamamoto TM, 2011, MOL BIOL CELL, V22, P2157, DOI 10.1091/mbc.E11-01-0008; Yong Z, 2008, MOL BIOL CELL, V19, P1317, DOI 10.1091/mbc.E07-11-1099; Yu JT, 2006, MOL CELL, V22, P83, DOI 10.1016/j.molcel.2006.02.022; Yu JT, 2004, J CELL BIOL, V164, P487, DOI 10.1083/JCB.200310059	33	45	45	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					537	543		10.1038/onc.2012.79	http://dx.doi.org/10.1038/onc.2012.79			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22469975	Green Published			2022-12-28	WOS:000316164700001
J	Falco, A; Festa, M; Basile, A; Rosati, A; Pascale, M; Florenzano, F; Nori, SL; Nicolin, V; Di Benedetto, M; Vecchione, ML; Arra, C; Barbieri, A; De Laurenzi, V; Turco, MC				Falco, A.; Festa, M.; Basile, A.; Rosati, A.; Pascale, M.; Florenzano, F.; Nori, S. L.; Nicolin, V.; Di Benedetto, M.; Vecchione, M. L.; Arra, C.; Barbieri, A.; De Laurenzi, V.; Turco, M. C.			BAG3 controls angiogenesis through regulation of ERK phosphorylation	ONCOGENE			English	Article						BAG3; angiogenesis; tumour	HEAT-SHOCK FACTOR-1; CANCER-CELLS; NEUROBLASTOMA-CELLS; SIGNALING PATHWAY; INDUCED APOPTOSIS; GENE-EXPRESSION; PROTEIN; LEUKEMIA; STRESS; COMPLEX	BAG3 is a co-chaperone of the heat shock protein (Hsp) 70, is expressed in many cell types upon cell stress, however, its expression is constitutive in many tumours. We and others have previously shown that in neoplastic cells BAG3 exerts an antiapoptotic function thus favoring tumour progression. As a consequence we have proposed BAG3 as a target of antineoplastic therapies. Here we identify a novel role for BAG3 in regulation of neo-angiogenesis and show that its downregulation results in reduced angiogenesis therefore expanding the role of BAG3 as a therapeutical target. In brief we show that BAG3 is expressed in endothelial cells and is essential for the interaction between ERK and its phosphatase DUSP6, as a consequence its removal results in reduced binding of DUSP6 to ERK and sustained ERK phosphorylation that in turn determines increased levels of p21 and p15 and cell-cycle arrest in the G1 phase. Oncogene (2012) 31, 5153-5161; doi:10.1038/onc.2012.17; published online 6 February 2012	[Falco, A.; Festa, M.; Basile, A.; Rosati, A.; Pascale, M.; Nori, S. L.; Turco, M. C.] Univ Salerno, Dept Pharmaceut & Biomed Sci FARMABIOMED, I-84084 Fisciano, SA, Italy; [Falco, A.; Festa, M.; Basile, A.; Rosati, A.; Pascale, M.; De Laurenzi, V.; Turco, M. C.] Univ Salerno, BIOUNIVERSA Srl, I-84084 Fisciano, SA, Italy; [Florenzano, F.] IRCSS Fdn Santa Lucia, Rome, Italy; [Florenzano, F.] European Brain Res Inst Rita Levi Montalcini, Rome, Italy; [Nicolin, V.] Univ Trieste, Clin Dept Biomed, I-34127 Trieste, Italy; [Di Benedetto, M.; Vecchione, M. L.] Univ Naples Federico II, Clin & Expt Med Dept, Naples, Italy; [Arra, C.; Barbieri, A.] Pascale Tumor Inst, Anim Facil, Naples, Italy; [De Laurenzi, V.] Univ G dAnnunzio, Fdn G DAnnunzio, Dept Biomed Sci, Chieti, Italy; [De Laurenzi, V.] Ctr Studi Invecchiamento CeSI, Chieti, Italy	University of Salerno; University of Salerno; IRCCS Santa Lucia; University of Trieste; University of Naples Federico II; G d'Annunzio University of Chieti-Pescara	Turco, MC (corresponding author), Univ Salerno, Dept Pharmaceut & Biomed Sci FARMABIOMED, I-84084 Fisciano, SA, Italy.	mcturco@unisa.it	Barbieri, Antonio/AAG-8961-2019; TURCO, Maria Caterina/AAC-5282-2022; De Laurenzi, Vincenzo/K-7471-2016	Barbieri, Antonio/0000-0002-7788-6167; TURCO, Maria Caterina/0000-0002-7835-359X; Arra, Claudio/0000-0003-3162-2091; Basile, Anna/0000-0002-4523-8202; Rosati, Alessandra/0000-0001-6675-0857; Nicolin, Vanessa/0000-0002-5665-6493; De Laurenzi, Vincenzo/0000-0002-7506-1743	AIRC; Ministero Sanita' grant	AIRC(Fondazione AIRC per la ricerca sul cancro); Ministero Sanita' grant	This work was supported by AIRC and Ministero Sanita' grants to VDL.	Ammirante M, 2010, P NATL ACAD SCI USA, V107, P7497, DOI 10.1073/pnas.0907696107; Basile A, 2011, J MED CHEM, V54, P1391, DOI 10.1021/jm101435r; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Bodart JFL, 2010, J CELL BIOCHEM, V109, P850, DOI 10.1002/jcb.22477; Bonelli P, 2004, LEUKEMIA, V18, P358, DOI 10.1038/sj.leu.2403219; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Canepa ET, 2007, IUBMB LIFE, V59, P419, DOI 10.1080/15216540701488358; Cesaro E, 2010, LEUKEMIA, V24, P1204, DOI 10.1038/leu.2010.68; Chiappetta G, 2007, J CLIN ENDOCR METAB, V92, P1159, DOI 10.1210/jc.2006-1712; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Doong H, 2003, J BIOL CHEM, V278, P28490, DOI 10.1074/jbc.M209682200; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Festa M, 2011, AM J PATHOL, V178, P2504, DOI 10.1016/j.ajpath.2011.02.002; Franceschelli S, 2008, J CELL PHYSIOL, V215, P575, DOI 10.1002/jcp.21397; Gentilella A, 2008, ONCOGENE, V27, P5011, DOI 10.1038/onc.2008.142; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Guedez L, 2003, AM J PATHOL, V162, P1431, DOI 10.1016/S0002-9440(10)64276-9; Homma S, 2006, AM J PATHOL, V169, P761, DOI 10.2353/ajpath.2006.060250; Jacobs AT, 2009, J BIOL CHEM, V284, P9176, DOI 10.1074/jbc.M808656200; Jung SE, 2010, BRAIN RES, V1349, P1, DOI 10.1016/j.brainres.2010.06.043; Jurek A, 2009, J BIOL CHEM, V284, P4626, DOI 10.1074/jbc.M808490200; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Liu P, 2009, FEBS LETT, V583, P401, DOI 10.1016/j.febslet.2008.12.032; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Norrby K, 2006, J CELL MOL MED, V10, P588, DOI 10.1111/j.1582-4934.2006.tb00423.x; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Rosati A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.24; Rosati A, 2009, LEUKEMIA, V23, P823, DOI 10.1038/leu.2009.23; Rosati A, 2007, INT J BIOCHEM CELL B, V39, P1337, DOI 10.1016/j.biocel.2007.03.007; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Tabuchi Y, 2007, CANCER LETT, V246, P149, DOI 10.1016/j.canlet.2006.02.011; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Valdez BC, 2008, LEUKEMIA RES, V32, P1684, DOI 10.1016/j.leukres.2008.01.016; Wainwright LJ, 2001, P NATL ACAD SCI USA, V98, P9396, DOI 10.1073/pnas.161288698; Wang HQ, 2009, BRIT J PHARMACOL, V158, P1405, DOI 10.1111/j.1476-5381.2009.00455.x	41	34	35	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5153	5161		10.1038/onc.2012.17	http://dx.doi.org/10.1038/onc.2012.17			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22310281				2022-12-28	WOS:000312449800004
J	Schonerr, C; Ruuth, K; Kamaraj, S; Wang, CL; Yang, HL; Combaret, V; Djos, A; Martinsson, T; Christensen, JG; Palmer, RH; Hallberg, B				Schonerr, C.; Ruuth, K.; Kamaraj, S.; Wang, C-L; Yang, H-L; Combaret, V.; Djos, A.; Martinsson, T.; Christensen, J. G.; Palmer, R. H.; Hallberg, B.			Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; anaplastic lymphoma kinase; ALK; MYCN; transcription factor	N-MYC; TYROSINE KINASE; ACTIVATING MUTATIONS; LUNG-CANCER; C-MET; EXPRESSION; INHIBITOR; PROTEIN; CRIZOTINIB; RECEPTOR	Neuroblastoma is a neural crest-derived embryonal tumour of the postganglionic sympathetic nervous system and a disease with several different chromosomal gains and losses, which include MYCN-amplified neuroblastoma on chromosome 2, deletions of parts of the chromosomes 1p and 11q, gain of parts of 17q and triploidy. Recently, activating mutations of the ALK (Anaplastic Lymphoma Kinase) RTK (Receptor Tyrosine Kinase) gene have been described in neuroblastoma. A meta-analysis of neuroblastoma cases revealed that ALK mutations (49 of 709 cases) in relation to genomic subtype were most frequently observed in MYCN amplified tumours (8.9%), correlating with a poor clinical outcome. MYCN proteins target proliferation and apoptotic pathways, and have an important role in the progression of neuroblastoma. Here, we show that both wild-type and gain-of-function mutants in ALK are able to stimulate transcription at the MYCN promoter and initiate mRNA transcription of the MYCN gene in both neuronal and neuroblastoma cell lines. Further, this stimulation of MYCN gene transcription and de novo MYCN protein expression is abrogated by specific ALK inhibitors, such as crizotinib (PF-2341066), NVP-TAE684, and by small interfering RNA to ALK resulting in a decrease in proliferation rate. Finally, co-transfection of ALK gain-of-function mutations together with MYCN leads to an increase in transformation potential. Taken together, our results indicate that ALK signalling regulates initiation of transcription of the MYCN gene providing a possible explanation for the poor clinical outcome observed when MYCN is amplified together with activated ALK. Oncogene (2012) 31, 5193 - 5200; doi:10.1038/onc.2012.12; published online 30 January 2012	[Schonerr, C.; Ruuth, K.; Kamaraj, S.; Palmer, R. H.; Hallberg, B.] Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden; [Wang, C-L; Yang, H-L] Beijing Forestry Univ, Coll Life Sci & Biotechnol, Beijing, Peoples R China; [Combaret, V.] Ctr Leon Berard, FNCLCC, Lab Rech Translat, F-69373 Lyon, France; [Djos, A.; Martinsson, T.] Univ Gothenburg, Dept Clin Genet, Gothenburg, Sweden; [Christensen, J. G.] La Jolla Labs, Global Res & Dev, Dept Res Pharmacol, La Jolla, CA USA	Umea University; Beijing Forestry University; UNICANCER; Centre Leon Berard; University of Gothenburg	Palmer, RH (corresponding author), Umea Univ, Dept Mol Biol, Bldg 6L, S-90187 Umea, Sweden.	Ruth.Palmer@molbiol.umu.se; Bengt.Hallberg@molbiol.umu.se	Martinsson, Tommy/J-4140-2013; sattu, kamaraj/L-7247-2015	Martinsson, Tommy/0000-0002-9403-3123; sattu, kamaraj/0000-0002-3559-8423; Djos, Anna/0000-0002-5250-2163	Swedish Cancer Society [BH 08-0597]; Children's Cancer Foundation [BH 08/084, RHP 08/074]; Swedish Research Council [RHP 621-2003-3399]; Lions Cancer Society; Association for International Cancer Research [RHP 08-0177]; Umea	Swedish Cancer Society(Swedish Cancer Society); Children's Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Lions Cancer Society; Association for International Cancer Research; Umea	We thank Marc Vigny and Arturo Sala for support and the pGL2-N-myc-luc plasmid, respectively. Crizotinib was a generous gift from Pfizer and the neuroblastoma cell lines were from Valerie Combaret, Centre Leon Berard, France under MTA. This work has been supported by grants from the Swedish Cancer Society (BH 08-0597), the Children's Cancer Foundation (BH 08/084; RHP 08/074), the Swedish Research Council (RHP 621-2003-3399), Lions Cancer Society, Umea, Association for International Cancer Research (RHP 08-0177). SK is a Children's Cancer Foundation fellow (NBCNSPDHEL09/002). RHP is a Swedish Cancer Foundation Research Fellow.	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Berthier A, 2011, HUM PATHOL, V42, P301, DOI 10.1016/j.humpath.2010.07.024; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brognard J, 2011, CURR OPIN GENET DEV, V21, P4, DOI 10.1016/j.gde.2010.10.012; Butrynski JE, 2010, NEW ENGL J MED, V363, P1727, DOI 10.1056/NEJMoa1007056; Caren H, 2008, BIOCHEM J, V416, P153, DOI 10.1042/BJ20081834; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365; COMBARET V, 1995, INT J CANCER, V61, P185, DOI 10.1002/ijc.2910610208; De Brouwer S, 2010, CLIN CANCER RES, V16, P4353, DOI 10.1158/1078-0432.CCR-09-2660; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Goodman LA, 1997, CLIN EXP METASTAS, V15, P130, DOI 10.1023/A:1018448710006; Gualdrini F, 2010, ONCOTARGET, V1, P278; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Hallberg Bengt, 2011, F1000 Med Rep, V3, P21, DOI 10.3410/M3-21; Hallberg B, 2010, NEW ENGL J MED, V363, P1760, DOI 10.1056/NEJMe1010404; Hatzi E, 2000, ADV EXP MED BIOL, V476, P239; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; Johnsen JI, 2008, ONCOGENE, V27, P2910, DOI 10.1038/sj.onc.1210938; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li YJ, 2011, NEOPLASIA, V13, P1, DOI 10.1593/neo.101120; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Martinsson T, 2011, CANCER RES, V71, P98, DOI 10.1158/0008-5472.CAN-10-2366; Michels E, 2007, GENE CHROMOSOME CANC, V46, P1098, DOI 10.1002/gcc.20496; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; OBRIG TG, 1971, J BIOL CHEM, V246, P174; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Schleiermacher G, 2003, CANCER GENET CYTOGEN, V141, P32, DOI 10.1016/S0165-4608(02)00644-1; Schonherr C, 2010, ONCOGENE, V29, P2817, DOI 10.1038/onc.2010.27; Schonherr C, 2011, BIOCHEM J, V440, P405, DOI 10.1042/BJ20101796; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Tartari CJ, 2008, J BIOL CHEM, V283, P3743, DOI 10.1074/jbc.M706067200; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Yang HL, 2007, J EXP ZOOL PART B, V308B, P269, DOI 10.1002/jez.b.21146; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	49	70	70	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	50					5193	5200		10.1038/onc.2012.12	http://dx.doi.org/10.1038/onc.2012.12			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22286764				2022-12-28	WOS:000312449800008
J	Bakker, ERM; Hoekstra, E; Franken, PF; Helvensteijn, W; van Deurzen, CHM; van Veelen, W; Kuipers, EJ; Smits, R				Bakker, E. R. M.; Hoekstra, E.; Franken, P. F.; Helvensteijn, W.; van Deurzen, C. H. M.; van Veelen, W.; Kuipers, E. J.; Smits, R.			beta-Catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer	ONCOGENE			English	Article						beta-catenin; APC; intestinal cancer; mammary tumor	FAMILIAL ADENOMATOUS POLYPOSIS; MOUSE MODEL; INTESTINAL TUMORS; SOMATIC MUTATION; ONCOGENIC KRAS; PROGRESSION; GENE; HETEROZYGOSITY; INSTABILITY; ACTIVATION	Apc-driven tumor formation in patients and Apc-mutant mouse models is generally attributed to increased levels of beta-catenin signaling. We and others have proposed that a specific level of b-catenin signaling is required to successfully initiate tumor formation, and that each tissue prefers different dosages of signaling. This is illustrated by APC genotype - tumor phenotype correlations in cancer patients, and by the different tumor phenotypes displayed by different Apc-mutant mouse models. Apc1638N mice, associated with intermediate b-catenin signaling, characteristically develop intestinal tumors (< 10) and extra-intestinal tumors, including cysts and desmoids. Apc1572T mice associated with lower levels of b-catenin signaling are free of intestinal tumors, but instead develop mammary tumors. Although the concept of b-catenin signaling dosage and its impact on tumor growth among tissues is gaining acceptance, it has not been formally proven. Additionally, alternative explanations for Apc-driven tumor formation have been proposed. To obtain direct evidence for the dominant role of b-catenin dosage in tumor formation and tissue-specific tumor predisposition, we crossed Apc1638N mice with heterozygous b-catenin knockout mice, thereby reducing b-catenin levels. Whereas all the Apc1638N; Ctnnb1(+/+) mice developed gastrointestinal tumors, none were present in the Apc1638N; Ctnnb1(-/-) mice. Incidence of other Apc1638N-associated lesions, including desmoids and cysts, was strongly reduced as well. Interestingly, Apc1638N; Ctnnb1(-/-) females showed an increased incidence of mammary tumors, which are normally rarely observed in Apc1638N mice, and the histological composition of the tumors resembled that of Apc1572T-related tumors. Hereby, we provide in vivo genetic evidence confirming the dominant role of b-catenin dosage in tumor formation and in dictating tumor predisposition among tissues in Apc-driven cancer.	[Bakker, E. R. M.; Hoekstra, E.; Helvensteijn, W.; van Veelen, W.; Kuipers, E. J.; Smits, R.] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, NL-3015 CE Rotterdam, Netherlands; [Franken, P. F.; van Deurzen, C. H. M.] Erasmus MC Univ Med Ctr, Dept Pathol, NL-3015 CE Rotterdam, Netherlands; [Kuipers, E. J.] Erasmus MC Univ Med Ctr, Dept Internal Med, NL-3015 CE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Smits, R (corresponding author), Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.	m.j.m.smits@erasmusmc.nl	Hoekstra, Elmer/P-5440-2014; Kuipers, Ernst J/H-3293-2019	Hoekstra, Elmer/0000-0001-8840-8294; Kuipers, Ernst J/0000-0002-0633-3098				Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Albuquerque C, 2011, BBA-REV CANCER, V1816, P219, DOI 10.1016/j.bbcan.2011.07.005; Albuquerque C, 2010, GENE CHROMOSOME CANC, V49, P746, DOI 10.1002/gcc.20786; Athineos D, 2010, ONCOGENE, V29, P2585, DOI 10.1038/onc.2010.5; Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816; Crabtree M, 2003, ONCOGENE, V22, P4257, DOI 10.1038/sj.onc.1206471; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fodde R, 2010, J PATHOL, V221, P239, DOI 10.1002/path.2718; Gaspar C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000547; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Incassati A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2723; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Leedham SJ, 2012, GUT, DOI [10.1136/gutjnl-2011-301601, DOI 10.1136/GUTJNL-2011-301601)]; Lewis A, 2012, J PATHOL, V226, P73, DOI 10.1002/path.2972; Mahmoud NN, 1999, CANCER RES, V59, P353; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Nathke I, 2006, NAT REV CANCER, V6, P967, DOI 10.1038/nrc2010; Obrador-Hevia A, 2010, J PATHOL, V221, P57, DOI 10.1002/path.2685; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Schneikert J, 2011, HUM MOL GENET, V20, P3554, DOI 10.1093/hmg/ddr273; Shoemaker AR, 1997, CANCER RES, V57, P1999; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; van Veelen W, 2011, GUT, V60, P1204, DOI 10.1136/gut.2010.233460	33	25	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2013	32	38					4579	4585		10.1038/onc.2012.449	http://dx.doi.org/10.1038/onc.2012.449			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23045279	Green Submitted			2022-12-28	WOS:000324831300014
J	Maglic, D; Zhu, S; Fry, EA; Taneja, P; Kai, F; Kendig, RD; Sugiyama, T; Miller, LD; Willingham, MC; Inoue, K				Maglic, D.; Zhu, S.; Fry, E. A.; Taneja, P.; Kai, F.; Kendig, R. D.; Sugiyama, T.; Miller, L. D.; Willingham, M. C.; Inoue, K.			Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer	ONCOGENE			English	Article						Dmp1 (Dmtf1); breast cancer; loss of heterozygosity; relapse-free survival; Ki67; prognostic marker	TRANSCRIPTION FACTOR DMP1; MDM2 PROTEIN EXPRESSION; CELL-CYCLE ARREST; GENE-EXPRESSION; ARF; P53; HETEROZYGOSITY; LOCALIZATION; MUTATIONS; ACTIVATOR	Our recent study showed critical roles of Dmp1 as a sensor of oncogenic Ras, HER2/neu signaling and activation of the Arf-p53 pathway. To elucidate the role of human DMP1 (hDMP1) in breast cancer, one hundred and ten pairs of human breast cancer specimen were studied for the alterations of the hDMP1-ARF-Hdm2-p53 pathway with follow up of clinical outcomes. Loss of heterozygosity (LOH) of the hDMP1 locus was found in 42% of human breast carcinomas, while that of INK4a/ARF and p53 were found in 20 and 34%, respectively. Hdm2 amplification was found in 13% of the same sample, which was found independently of LOH for hDMP1. Conversely, LOH for hDMP1 was found in mutually exclusive fashion with that of INK4a/ARF and p53, and was associated with low Ki67 index and diploid karyotype. Consistently, LOH for hDMP1 was associated with luminal A category and longer relapse-free survival, while that of p53 was associated with non-luminal A and shorter survival. Thus, loss of hDMP1 could define a new disease category associated with prognosis of breast cancer patients. Human breast epithelial cells/cancer cells with wild-type p53 were sensitive to growth inhibition by activated Dmp1: ER while those that delete p14(ARF) or p53, and/or Hdm2 amplification showed partial or nearly complete resistance, indicating that p53 is a critical target for hDMP1 to exhibit its biological activity.	[Maglic, D.; Zhu, S.; Fry, E. A.; Taneja, P.; Kai, F.; Kendig, R. D.; Sugiyama, T.; Willingham, M. C.; Inoue, K.] Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC 27157 USA; [Maglic, D.; Fry, E. A.; Taneja, P.; Kai, F.; Kendig, R. D.; Sugiyama, T.; Miller, L. D.; Inoue, K.] Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC 27157 USA; [Maglic, D.; Zhu, S.; Inoue, K.] Wake Forest Univ Hlth Sci, Dept Grad Program Mol Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Inoue, K (corresponding author), Wake Forest Univ Hlth Sci, Dept Pathol, Med Ctr Blvd,2102 Gray Bldg, Winston Salem, NC 27157 USA.	kinoue@triad.rr.com		Miller, Lance/0000-0003-3799-2528	ACS [RSG-07-207-01-MGO]; NIH/NCI [5R01CA106314]; WFUHS [20595]; Susan G Komen Foundation [KG080179]; DOD [BC100907]; NATIONAL CANCER INSTITUTE [R01CA106314] Funding Source: NIH RePORTER	ACS(American Cancer Society); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WFUHS; Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to R Weinberg for HMEC cells; C Sherr, and M Roussel for plasmid DNAs. We thank G Hawkins and Abdoulaye Diallo for LOH analyses of breast cancer samples. We also thank G Kucera for providing information on human breast cancer patients' samples, Guangchao Sui, Tim Kute for helpful discussions, Guorui Deng, and Jordan Chapman for technical assistance. K Inoue is supported by ACS RSG-07-207-01-MGO, NIH/NCI 5R01CA106314, and by Director's Challenge Award #20595 from WFUHS. P Taneja was supported by the Susan G Komen Foundation postdoctoral fellowship KG080179. D Maglic has been supported by DOD pre-doctoral fellowship BC100907.	BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bodner SM, 1999, GENE, V229, P223, DOI 10.1016/S0378-1119(98)00591-5; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Frazier DP, 2012, CANCER RES, V72, P1740, DOI 10.1158/0008-5472.CAN-11-2410; Gasco M, 2003, HUM MUTAT, V21, P301, DOI 10.1002/humu.10173; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407; Inoue K, 2007, ONCOGENE, V26, P4329, DOI 10.1038/sj.onc.1210226; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Inoue K, 2000, GENE DEV, V14, P1797; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Inoue K, 2008, CANCER RES, V68, P4487, DOI 10.1158/0008-5472.CAN-07-6791; Kristjansson AK, 1997, ANTICANCER RES, V17, P93; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Mallakin A, 2006, ONCOGENE, V25, P7703, DOI 10.1038/sj.onc.1209750; Mallakin A, 2007, CANCER CELL, V12, P381, DOI 10.1016/j.ccr.2007.08.034; Mallakin A, 2010, INT J CANCER, V126, P1403, DOI 10.1002/ijc.24938; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; Masood S, 2005, CLIN LAB MED, V25, P809, DOI 10.1016/j.cll.2005.08.012; Ross JS, 2003, AM J CLIN PATHOL, V120, P822, DOI 10.1309/6CQ7AXQ6WHHBXUWH; Ross JS, 2005, MOL ONCOLOGY BREAST; Shetty A, 2005, BRIT J CANCER, V93, P1295, DOI 10.1038/sj.bjc.6602829; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Smeets SJ, 2011, CLIN CANCER RES, V17, P4959, DOI 10.1158/1078-0432.CCR-11-0462; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Sugiyama T, 2008, EXPERT REV MOL DIAGN, V8, P435, DOI 10.1586/14737159.8.4.435; Taneja P, 2010, CLIN MED INSIGHTS-ON, V4, P15; Taneja P, 2010, CANCER RES, V70, P9084, DOI 10.1158/0008-5472.CAN-10-0159; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Turbin DA, 2006, MODERN PATHOL, V19, P69, DOI 10.1038/modpathol.3800484; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wasielewski M, 2006, BREAST CANCER RES TR, V99, P97, DOI 10.1007/s10549-006-9186-z; Wiesner FG, 2009, BREAST, V18, P135, DOI 10.1016/j.breast.2009.02.009	37	21	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4120	4129		10.1038/onc.2012.423	http://dx.doi.org/10.1038/onc.2012.423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23045280	Green Accepted			2022-12-28	WOS:000323748500007
J	Quintavalle, C; Donnarumma, E; Iaboni, M; Roscigno, G; Garofalo, M; Romano, G; Fiore, D; De Marinis, P; Croce, CM; Condorelli, G				Quintavalle, C.; Donnarumma, E.; Iaboni, M.; Roscigno, G.; Garofalo, M.; Romano, G.; Fiore, D.; De Marinis, P.; Croce, C. M.; Condorelli, G.			Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells	ONCOGENE			English	Article						glioblastoma; TRAIL; therapy; microRNA; treatment; apoptosis	GROWTH IN-VIVO; MICRORNA SIGNATURES; MONOCLONAL-ANTIBODY; DEATH RECEPTORS; DOWN-REGULATION; STEM-CELLS; GLIOBLASTOMA; EXPRESSION; RESISTANCE; TARGETS	Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in treatments, survival of patients remains poor. To define novel pathways that regulate susceptibility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in glioma, we have performed genome-wide expression profiling of microRNAs (miRs). We show that in TRAIL-resistant glioma cells, levels of different miRs are increased, and in particular, miR-30b/c and -21. We demonstrate that these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. T98G-sensitive cells treated with miR-21 or -30b/c become resistant to TRAIL. Furthermore, we demonstrate that miR-30b/c and miR-21 target respectively the 30 untranslated region of caspase-3 and TAp63 mRNAs, and that those proteins mediate some of the effects of miR-30 and -21 on TRAIL resistance, even in human glioblastoma primary cells and in lung cancer cells. In conclusion, we show that high expression levels of miR-21 and -30b/c are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets for TRAIL resistance in glioma.	[Quintavalle, C.; Iaboni, M.; Roscigno, G.; Fiore, D.; Condorelli, G.] Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol, I-80131 Naples, Italy; [Quintavalle, C.; Iaboni, M.; Roscigno, G.; Condorelli, G.] CNR, IEOS, I-80125 Naples, Italy; [Donnarumma, E.; Romano, G.] Fdn IRCCS SDN, Naples, Italy; [Garofalo, M.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [De Marinis, P.] Osped Antonio Cardarelli, Neurosurg Unit, Naples, Italy; [Condorelli, G.] Univ Naples Federico II, Fac Sci Biotechnol, Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Antonio Cardarelli Hospital; University of Naples Federico II	Condorelli, G (corresponding author), Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol, Via Pansini,5,Ed 19 A,2 Floor, I-80131 Naples, Italy.	gecondor@unina.it	Young, Richard A/F-6495-2012; Quintavalle, Cristina/AHH-9379-2022; Condorelli, Gerolama/AAC-3472-2022; Fiore, Danilo/A-6002-2019	Young, Richard A/0000-0001-8855-8647; Condorelli, Gerolama/0000-0003-0177-8829; Fiore, Danilo/0000-0003-3004-6862; Roscigno, Giuseppina/0000-0002-5359-6376	Associazione Italiana Ricerca sul Cancro, AIRC [10620]; MERIT [RBNE08E8CZ_002]; 'Federazione Italiana Ricerca sul Cancro' (FIRC); MERIT project Fellowship	Associazione Italiana Ricerca sul Cancro, AIRC(Fondazione AIRC per la ricerca sul cancro); MERIT; 'Federazione Italiana Ricerca sul Cancro' (FIRC)(Fondazione AIRC per la ricerca sul cancro); MERIT project Fellowship	This work was partially supported by funds from Associazione Italiana Ricerca sul Cancro, AIRC to GC (grant n.ro 10620), and MERIT (RBNE08E8CZ_002) to GC. CQ and MI are supported by the 'Federazione Italiana Ricerca sul Cancro' (FIRC) Post-Doctoral Research Fellowship. GR is supported by a MERIT project Fellowship.	Balyasnikova IV, 2011, CANCER LETT, V310, P148, DOI 10.1016/j.canlet.2011.06.029; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Garofalo M, 2008, ONCOGENE, V27, P3845, DOI 10.1038/onc.2008.6; Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170; Garofalo M, 2010, CELL DEATH DIFFER, V17, P200, DOI 10.1038/cdd.2009.105; Garofalo M, 2007, INT J CANCER, V120, P1215, DOI 10.1002/ijc.22495; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Garofalo M, 2008, CURR OPIN PHARMACOL, V8, P661, DOI 10.1016/j.coph.2008.06.005; Gaur AB, 2011, NEURO-ONCOLOGY, V13, P580, DOI 10.1093/neuonc/nor033; Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Incoronato M, 2010, CANCER RES, V70, P3638, DOI 10.1158/0008-5472.CAN-09-3341; Joglekar MV, 2009, ISLETS, V1, P137, DOI 10.4161/isl.1.2.9578; Kwak HJ, 2011, ONCOGENE, V30, P2433, DOI 10.1038/onc.2010.620; Lakomy R, 2011, CANCER SCI, V102, P2186, DOI 10.1111/j.1349-7006.2011.02092.x; Li Jun-cai, 2010, Xibei Zhiwu Xuebao, V30, P30; Li N, 2012, CANCER RES, V72, P154, DOI 10.1158/0008-5472.CAN-11-2484; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malzkorn B, 2010, BRAIN PATHOL, V20, P539, DOI 10.1111/j.1750-3639.2009.00328.x; Moore LM, 2010, EXPERT OPIN THER TAR, V14, P1247, DOI 10.1517/14728222.2010.527334; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Plummer R, 2007, CLIN CANCER RES, V13, P6187, DOI 10.1158/1078-0432.CCR-07-0950; Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96; Quintavalle C, 2010, CELL DEATH DIFFER, V17, P1908, DOI 10.1038/cdd.2010.65; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Tran B, 2010, J CLIN NEUROSCI, V17, P417, DOI 10.1016/j.jocn.2009.09.004; Trarbach T, 2010, BRIT J CANCER, V102, P506, DOI 10.1038/sj.bjc.6605507; Unterkircher T, 2011, CLIN CANCER RES, V17, P4019, DOI 10.1158/1078-0432.CCR-11-0075; Walczak H, 2000, CANCER RES, V60, P3051; Younes A, 2010, BRIT J CANCER, V103, P1783, DOI 10.1038/sj.bjc.6605987; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Zanca C, 2008, J CELL MOL MED, V12, P2416, DOI 10.1111/j.1582-4934.2008.00283.x; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	42	80	84	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4001	4008		10.1038/onc.2012.410	http://dx.doi.org/10.1038/onc.2012.410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22964638				2022-12-28	WOS:000323748100008
J	Scales, TME; Jayo, A; Obara, B; Holt, MR; Hotchin, NA; Berditchevski, F; Parsons, M				Scales, T. M. E.; Jayo, A.; Obara, B.; Holt, M. R.; Hotchin, N. A.; Berditchevski, F.; Parsons, M.			alpha 3 beta 1 integrins regulate CD151 complex assembly and membrane dynamics in carcinoma cells within 3D environments	ONCOGENE			English	Article						alpha 3 integrin; CD151; migration; protrusion; actin cytoskeleton; 3D ECM	LAMININ-BINDING INTEGRINS; TETRASPANIN CD151; TRANSMEMBRANE-4 SUPERFAMILY; CLINICAL-SIGNIFICANCE; ADHESION DYNAMICS; PROTEIN COMPLEXES; GENE-EXPRESSION; RAC ACTIVATION; BREAST-CANCER; IN-VIVO	Integrins are extracellular matrix (ECM) receptors that are key players in the regulation of tumour cell invasion. The laminin-binding integrin alpha 3 beta 1 has previously been shown to regulate adhesion and migration of carcinoma cells in part through co-operative signalling with the tetraspanin family of transmembrane proteins. However, the spatial and temporal regulation of crosstalk between these families of transmembrane proteins in intact cells remains poorly understood. Here we have used fluorescence resonance energy transfer (FRET) to demonstrate for the first time that alpha 3 beta 1 and the tetraspanin CD151 directly associate at the front and retracting rear of polarised migrating breast carcinoma cells in both two-dimentional (2D) and three-dimentional (3D) matrices. Furthermore, localised alpha 3 beta 1-CD151 binding correlates with lower CD151 homodimerisation in cells migrating on laminin or within matrigel. Loss of alpha 3 beta 1 integrin leads to increased CD151 homodimer formation, increased activation of Rho GTPase, loss of cell polarity and decreased invasion in 3D ECM. As a result, alpha 3-silenced cells show decreased actin-based membrane protrusion and retraction in both 2D and 3D environments. These data demonstrate that associations between alpha 3 beta 1 and CD151 occur dynamically within discrete subcellular compartments and act to establish local GTPase signalling to promote tumour cell invasion. These novel findings shed light on the complex crosstalk and switching between receptor complexes in response to different extracellular cues during cell invasion in 3D environments.	[Scales, T. M. E.; Jayo, A.; Holt, M. R.; Parsons, M.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Obara, B.] Univ Oxford, Oxford E Res Ctr, Oxford, England; [Obara, B.] Univ Oxford, Oxford Ctr Integrat Syst Biol, Oxford, England; [Hotchin, N. A.] Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England; [Berditchevski, F.] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England	University of London; King's College London; University of Oxford; University of Oxford; Cancer Research UK; University of Birmingham; University of Birmingham	Parsons, M (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, Room 3-22B,New Hunts House,Guys Campus, London SE1 1UL, England.	maddy.parsons@kcl.ac.uk	Jayo, Asier/A-8419-2015; Jayo, Asier/A-2359-2010; Jayo, Asier/AAE-5895-2021; Parsons, Maddy/B-2203-2013	Jayo, Asier/0000-0002-9899-8723; Jayo, Asier/0000-0002-9899-8723; Jayo, Asier/0000-0002-9899-8723; Parsons, Maddy/0000-0002-2021-8379; Holt, Mark/0000-0001-7775-8539; Obara, Boguslaw/0000-0003-4084-7778; Hotchin, Neil/0000-0002-1844-7607	Cancer Research UK; Wellcome Trust; Biotechnology and Biological Sciences Research Council; Engineering and Physical Sciences Research Council; Royal Society University Research Fellowship; MRC [MR/J000647/1] Funding Source: UKRI; Medical Research Council [MR/J000647/1] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Royal Society University Research Fellowship(Royal Society of London); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We would like to thank Simon Ameer-Beg and Daniel Matthews for technical assistance and support with the multiphoton FLIM. This research was funded by grants from Cancer Research UK (to MP, FB and NH), the Wellcome Trust (to NH), the Biotechnology and Biological Sciences Research Council and Engineering and Physical Sciences Research Council (to BO) and a Royal Society University Research Fellowship (to MP).	Ang J, 2004, CANCER EPIDEM BIOMAR, V13, P1717; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Baldwin G, 2008, J BIOL CHEM, V283, P35445, DOI 10.1074/jbc.M806394200; Berditchevski F, 2001, J BIOL CHEM, V276, P41165, DOI 10.1074/jbc.M104041200; Calderwood DA, 2004, J BIOL CHEM, V279, P28889, DOI 10.1074/jbc.M402161200; Carmona-Fontaine C, 2008, NATURE, V456, P957, DOI 10.1038/nature07441; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015; Frank DE, 2004, J CELL SCI, V117, P1351, DOI 10.1242/jcs.01003; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Hashida H, 2003, BRIT J CANCER, V89, P158, DOI 10.1038/sj.bjc.6601015; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kazarov AR, 2002, J CELL BIOL, V158, P1299, DOI 10.1083/jcb.200204056; Latysheva N, 2006, MOL CELL BIOL, V26, P7707, DOI 10.1128/MCB.00849-06; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; Liu L, 2007, J BIOL CHEM, V282, P31631, DOI 10.1074/jbc.M701165200; Matthews HK, 2008, DEVELOPMENT, V135, P1771, DOI 10.1242/dev.017350; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; Mitchell K, 2010, CANCER RES, V70, P6359, DOI 10.1158/0008-5472.CAN-09-4283; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; Morton PE, 2011, METHODS MOL BIOL, V769, P403, DOI 10.1007/978-1-61779-207-6_27; Nakamura T, 2006, METHOD ENZYMOL, V406, P315, DOI 10.1016/S0076-6879(06)06023-X; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKADA T, 1994, CLIN EXP METASTAS, V12, P305, DOI 10.1007/BF01753837; Parsons M, 2005, MOL CELL BIOL, V25, P1680, DOI 10.1128/MCB.25.5.1680-1695.2005; Parsons M, 2008, J CELL SCI, V121, P265, DOI 10.1242/jcs.018440; Ramirez NE, 2011, J CLIN INVEST, V121, P226, DOI 10.1172/JCI42328; Reynolds LE, 2008, J CLIN INVEST, V118, P965, DOI 10.1172/JCI33538; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Sadej R, 2009, MOL CANCER RES, V7, P787, DOI 10.1158/1541-7786.MCR-08-0574; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sarmiento C, 2008, J CELL BIOL, V180, P1245, DOI 10.1083/jcb.200708123; Sterk LMT, 2002, J CELL SCI, V115, P1161; Stipp CS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001355; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Takeda Y, 2011, BLOOD, V118, P464, DOI 10.1182/blood-2010-08-302240; Tokuhara T, 2001, CLIN CANCER RES, V7, P4109; Turner FE, 2006, J BIOL CHEM, V281, P21321, DOI 10.1074/jbc.M509731200; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Wang ZM, 1999, J CELL SCI, V112, P2925; Winterwood NE, 2006, MOL BIOL CELL, V17, P2707, DOI 10.1091/mbc.E05-11-1042; Worth DC, 2008, INT J BIOCHEM CELL B, V40, P2397, DOI 10.1016/j.biocel.2008.04.008; Worth DC, 2010, J CELL BIOL, V189, P369, DOI 10.1083/jcb.200912014; Yanez-Mo M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004; Yang XWH, 2008, CANCER RES, V68, P3204, DOI 10.1158/0008-5472.CAN-07-2949; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou H, 2005, J BIOL CHEM, V280, P10624, DOI 10.1074/jbc.M411900200; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	57	15	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3965	3979		10.1038/onc.2012.415	http://dx.doi.org/10.1038/onc.2012.415			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22986527				2022-12-28	WOS:000323748100005
J	Sundqvist, A; Zieba, A; Vasilaki, E; Hidalgo, CH; Soderberg, O; Koinuma, D; Miyazono, K; Heldin, CH; Landegren, U; ten Dijke, P; van Dam, H				Sundqvist, A.; Zieba, A.; Vasilaki, E.; Hidalgo, C. Herrera; Soderberg, O.; Koinuma, D.; Miyazono, K.; Heldin, C-H; Landegren, U.; ten Dijke, P.; van Dam, H.			Specific interactions between Smad proteins and AP-1 components determine TGF beta-induced breast cancer cell invasion	ONCOGENE			English	Article						invasion; spheroids; TGF beta; AP-1; Smad; PLA	GROWTH-FACTOR-BETA; MAMMARY-GLAND DEVELOPMENT; MESENCHYMAL TRANSITION; COLORECTAL CANCERS; PROXIMITY LIGATION; TUMOR-SUPPRESSOR; IN-SITU; TUMORIGENESIS; TRANSCRIPTION; PATHWAYS	Deregulation of the transforming growth factor beta (TGF beta) signal transduction cascade is functionally linked to cancer. In early phases, TGFb acts as a tumor suppressor by inhibiting tumor cell proliferation, whereas in late phases, it can act as a tumor promoter by stimulating tumor cell invasion and metastasis. Smad transcriptional effectors mediate TGF beta responses, but relatively little is known about the Smad-containing complexes that are important for epithelial-mesenchymal transition and invasion. In this study, we have tested the hypothesis that specific members of the AP-1 transcription factor family determine TGF beta signaling specificity in breast cancer cell invasion. Using a 3D model of collagen-embedded spheroids of MCF10A-MII premalignant human breast cancer cells, we identified the AP-1 transcription factor components c-Jun, JunB, c-Fos and Fra1 as essential factors for TGF beta-induced invasion and found that various mesenchymal and invasion-associated TGF beta-induced genes are co-regulated by these proteins. In situ proximity ligation assays showed that TGF beta signaling not only induces complexes between Smad3 and Smad4 in the nucleus but also complexes between Smad2/3 and Fra1, whereas complexes between Smad3, c-Jun and JunB could already be detected before TGF beta stimulation. Finally, chromatin immunoprecipitations showed that c-Jun, JunB and Fra1, but not c-Fos, are required for TGF beta-induced binding of Smad2/3 to the mmp-10 and pai-1 promoters. Together these results suggest that in particular formation of Smad2/3-Fra1 complexes may reflect activation of the Smad/AP-1-dependent TGF beta-induced invasion program.	[Sundqvist, A.; Vasilaki, E.; Hidalgo, C. Herrera; Miyazono, K.; Heldin, C-H; ten Dijke, P.; van Dam, H.] Uppsala Univ, Sci Life Lab, Ludwig Inst Canc Res, Uppsala, Sweden; [Zieba, A.; Soderberg, O.; Landegren, U.] Uppsala Univ, Rudbeck Lab, Sci Life Lab, Dept Immunol Genet & Pathol, Uppsala, Sweden; [Koinuma, D.; Miyazono, K.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan; [ten Dijke, P.; van Dam, H.] Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University; University of Tokyo; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Dam, H (corresponding author), Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol Cell Biol, POB 9600, NL-2300 RC Leiden, Netherlands.	vdam@lumc.nl	Dijke, Peter ten/AAG-4660-2021; Landegren, Ulf D/A-8197-2019; Koinuma, Daizo/Y-8716-2018; Söderberg, Ola/O-5130-2017; Vasilaki, Eleftheria/AAY-6392-2020	Dijke, Peter ten/0000-0002-7234-342X; Koinuma, Daizo/0000-0001-5611-2122; Söderberg, Ola/0000-0003-2883-1925; van Dam, Hans/0000-0002-8307-4325	Swedish Cancerfonden [090773]; Netherlands Centre for Biomedical Genetics	Swedish Cancerfonden; Netherlands Centre for Biomedical Genetics	We thank our colleagues, in particular Aris Moustakas and Masato Morikawa, for their valuable discussion and help with experiments. This work was supported by the Swedish Cancerfonden (090773) and the Netherlands Centre for Biomedical Genetics.	Baan B, 2010, MOL CELL PROTEOMICS, V9, P1982, DOI 10.1074/mcp.M110.000943; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Dzwonek J, 2009, MOL CANCER RES, V7, P1342, DOI 10.1158/1541-7786.MCR-08-0558; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Heldin CH, 2012, CELL TISSUE RES, V347, P21, DOI 10.1007/s00441-011-1190-x; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Laverty HG, 2009, CYTOKINE GROWTH F R, V20, P305, DOI 10.1016/j.cytogfr.2009.07.002; Leary RJ, 2008, P NATL ACAD SCI USA, V105, P16224, DOI 10.1073/pnas.0808041105; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441-011-1201-y; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Parvani JG, 2011, J MAMMARY GLAND BIOL, V16, P127, DOI 10.1007/s10911-011-9207-3; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Sundqvist A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3066; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Verde P, 2007, CELL CYCLE, V6, P2633, DOI 10.4161/cc.6.21.4850; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396; Wakefield LM, 2001, J MAMMARY GLAND BIOL, V6, P67, DOI 10.1023/A:1009568532177; Wiercinska E, 2011, BREAST CANCER RES TR, V128, P657, DOI 10.1007/s10549-010-1147-x; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	41	69	70	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2013	32	31					3606	3615		10.1038/onc.2012.370	http://dx.doi.org/10.1038/onc.2012.370			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22926518				2022-12-28	WOS:000322638400005
J	Gebeshuber, CA; Martinez, J				Gebeshuber, C. A.; Martinez, J.			miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling	ONCOGENE			English	Article						breast cancer; IGF2; miR-100	II MESSENGER-RNA; GENE-EXPRESSION; CANCER; INSULIN; MICRORNAS; CELLS; TUMOR	Dysregulation of micro RNAs is crucially implicated in tumorigenesis. We detected downregulation of miR-100 in breast cancer cells, leading to an upregulation of the proliferation- and survival-promoting oncogene insulin-like growth factor (IGF) 2. Stable overexpression of miR-100 strongly reduced IGF2 expression and inhibited tumor growth. In invasive human breast tumors, miR-100 was reduced about fourfold as compared with benign patient samples, whereas IGF2 was strongly enhanced. MiR-100 has also been shown to suppress other proteins of the IGF/mammalian target of rapamycin (mTOR) signaling cascade in different human tumors. Our results reveal miR-100 as a context-dependent master regulator of the IGF/mTOR pathway and a potential target for therapeutic approaches.	[Gebeshuber, C. A.; Martinez, J.] Austrian Acad Sci, Inst Mol Biotechnol, A-1010 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Gebeshuber, CA (corresponding author), Med Univ Vienna, Dept Pathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	christoph.gebeshuber@meduniwien.ac.at; javier.martinez@imba.oeaw.ac.at		Gebeshuber, Christoph A/0000-0003-3293-4572; Martinez, Javier/0000-0001-9152-7323	FWF; Austrian Government's GENAU program; IMBA	FWF(Austrian Science Fund (FWF)); Austrian Government's GENAU program; IMBA	We thank Albin Rudisch and Marlies Schlauf for technical assistance and Florian Grebien and Wolfgang Sommergruber for critical comments on the manuscript. CG was funded from the FWF and the Austrian Government's GENAU program. JM was funded by the IMBA.	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bazzini AA, SCIENCE, V336, P233; Burns JL, 2001, DEVELOPMENT, V128, P3819; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Giani C, 1996, BREAST CANCER RES TR, V41, P43, DOI 10.1007/BF01807035; Hausser J, 2009, NUCLEIC ACIDS RES, V37, pW266, DOI 10.1093/nar/gkp412; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jones RA, 2007, ONCOGENE, V26, P1636, DOI 10.1038/sj.onc.1209955; Kauppinen S, 2006, HANDB EXP PHARM, V173, P405; McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Pacher M, 2007, CARCINOGENESIS, V28, P49, DOI 10.1093/carcin/bgl091; Pollak M, 2008, BEST PRACT RES CL EN, V22, P625, DOI 10.1016/j.beem.2008.08.004; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Romero-Cordoba S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031904; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880; Tovar V, 2010, J HEPATOL, V52, P550, DOI 10.1016/j.jhep.2010.01.015; WILLISON K, 1991, TRENDS GENET, V7, P107, DOI 10.1016/0168-9525(91)90441-R	26	69	75	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2013	32	27					3306	3310		10.1038/onc.2012.372	http://dx.doi.org/10.1038/onc.2012.372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22926517				2022-12-28	WOS:000321301600010
J	Costa, C; Santos, M; Martinez-Fernandez, M; Duenas, M; Lorz, C; Garcia-Escudero, R; Paramio, JM				Costa, C.; Santos, M.; Martinez-Fernandez, M.; Duenas, M.; Lorz, C.; Garcia-Escudero, R.; Paramio, J. M.			E2F1 loss induces spontaneous tumour development in Rb-deficient epidermis	ONCOGENE			English	Article						skin; pRb; E2F1; p53; hair follicle; Wnt signalling	HAIR FOLLICLE MORPHOGENESIS; MOUSE SKIN CARCINOGENESIS; BETA-CATENIN ACTIVATION; EPITHELIAL STEM-CELLS; BLADDER-CANCER; RETINOBLASTOMA FAMILY; EXPRESSION PROFILES; TRANSGENIC MODEL; S-PHASE; PROLIFERATION	The specific ablation of Rb1 gene in epidermis (Rb-F/F; K14cre) promotes proliferation and altered differentiation but does not produce spontaneous tumour development. These phenotypic changes are associated with increased expression of E2F members and E2F-dependent transcriptional activity. Here, we have focused on the possible dependence on E2F1 gene function. We have generated mice that lack Rb1 in epidermis in an inducible manner (RbF/F; K14creER(TM)). These mice are indistinguishable from those lacking pRb in this tissue in a constitutive manner (Rb-F/F; K14cre). In an E2F1-null background (Rb-F/F; K14creER(TM); and E2F1(-/-) mice), the phenotype due to acute Rb1 loss is not ameliorated by E2F1 loss, but rather exacerbated, indicating that pRb functions in epidermis do not rely solely on E2F1. On the other hand, Rb-F/F; K14creER(TM); E2F1(-/-) mice develop spontaneous epidermal tumours of hair follicle origin with high incidence. These tumours, which retain a functional p19(arf)/p53 axis, also show aberrant activation of beta-catenin/Wnt pathway. Gene expression studies revealed that these tumours display relevant similarities with specific human tumours. These data demonstrate that the Rb/E2F1 axis exerts essential functions not only in maintaining epidermal homoeostasis, but also in suppressing tumour development in epidermis, and that the disruption of this pathway may induce tumour progression through specific alteration of developmental programs.	[Costa, C.; Santos, M.; Martinez-Fernandez, M.; Duenas, M.; Lorz, C.; Garcia-Escudero, R.; Paramio, J. M.] CIEMAT, Mol Oncol Unit, Dept Basic Res, E-28040 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Paramio, JM (corresponding author), CIEMAT, Mol Oncol Unit, Dept Basic Res, Ed 70A,Ave Complutense 40, E-28040 Madrid, Spain.	jesusm.paramio@ciemat.es	Costa, Clotilde/L-6850-2015; Lorz, Corina/E-3651-2016; Paramio, Jesus M/M-8482-2014; Santos, Mirentxu/AAA-1727-2020; Garcia-Escudero, Ramon/A-2735-2012	Lorz, Corina/0000-0001-8214-9076; Paramio, Jesus M/0000-0001-7520-3177; Garcia-Escudero, Ramon/0000-0001-5640-6542; Costa, Clotilde/0000-0001-7327-2259; Duenas, Marta/0000-0003-0857-9726	Ministerio de Ciencia e Innovacion (MICINN) [SAF2006-0121, SAF2011-26122C02-01, JCI-2010-06167]; Comunidad Autonoma de Madrid Oncocycle Program Grant [S2006/BIO-0232, CAM P2010/BMD-2470]; Ministerio de Sanidad y Consumo grant [SCIII-RETIC RD06/0020/0029]; Fundacion Sandra Ibarra	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Comunidad Autonoma de Madrid Oncocycle Program Grant; Ministerio de Sanidad y Consumo grant; Fundacion Sandra Ibarra	Ministerio de Ciencia e Innovacion (MICINN) grants SAF2006-0121, SAF2011-26122C02-01 and JCI-2010-06167, Comunidad Autonoma de Madrid Oncocycle Program Grant S2006/BIO-0232 and: CAM P2010/BMD-2470, Ministerio de Sanidad y Consumo grant ISCIII-RETIC RD06/0020/0029 and from Fundacion Sandra Ibarra to JMP. The excellent technical support by Pilar Hernandez in histology and the personnel of the CIEMAT Animal Facility are specially acknowledged.	Ahmad I, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.7; Ahmad I, 2011, ONCOGENE, V30, P178, DOI 10.1038/onc.2010.399; Ahmad I, 2012, DIS MODEL MECH, V5, P323, DOI 10.1242/dmm.008888; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Brandt WD, 2009, CANCER METAST REV, V28, P291, DOI 10.1007/s10555-009-9187-6; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen R, 2007, NAT METHODS, V4, P879, DOI 10.1038/nmeth1107-879; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Chong JL, 2009, MOL CELL BIOL, V29, P414, DOI 10.1128/MCB.01161-08; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Doglioni C, 2003, AM J PATHOL, V163, P2277, DOI 10.1016/S0002-9440(10)63585-7; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Haegebarth A, 2009, AM J PATHOL, V174, P715, DOI 10.2353/ajpath.2009.080758; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lara MF, 2008, MOL CARCINOGEN, V47, P209, DOI 10.1002/mc.20376; Lara MF, 2008, MOL CARCINOGEN, V47, P105, DOI 10.1002/mc.20367; Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977; Li MM, 2012, MOL CELL, V46, P30, DOI 10.1016/j.molcel.2012.01.020; Lo Celso C, 2004, DEVELOPMENT, V131, P1787, DOI 10.1242/dev.01052; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lopez RG, 2009, NAT CELL BIOL, V11, P1181, DOI 10.1038/ncb1960; Lorz C, 2010, STEM CELL REV REP, V6, P162, DOI 10.1007/s12015-010-9139-0; Lorz C, 2010, METHODS MOL BIOL, V585, P1, DOI 10.1007/978-1-60761-380-0_1; Lorz C, 2009, CURR MOL MED, V9, P355, DOI 10.2174/156652409787847227; Lowry WE, 2005, GENE DEV, V19, P1596, DOI 10.1101/gad.1324905; Martinez-Cruz AB, 2008, CANCER RES, V68, P683, DOI 10.1158/0008-5472.CAN-07-3049; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OGUIN WM, 1992, J INVEST DERMATOL, V98, P24, DOI 10.1111/1523-1747.ep12494172; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Rabbani F, 1999, J NATL CANCER I, V91, P874, DOI 10.1093/jnci/91.10.874; Rabbani F, 2000, UROL CLIN N AM, V27, P83, DOI 10.1016/S0094-0143(05)70237-8; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Ruiz S, 2005, CANCER RES, V65, P9678, DOI 10.1158/0008-5472.CAN-05-1853; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Ruiz S, 2004, DEV DYNAM, V230, P410, DOI 10.1002/dvdy.20065; Ruiz S, 2006, CELL CYCLE, V5, P625, DOI 10.4161/cc.5.6.2580; Russell JL, 2006, ONCOGENE, V25, P867, DOI 10.1038/sj.onc.1209120; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Santos M, 2008, MOL CARCINOGEN, V47, P815, DOI 10.1002/mc.20426; Segrelles C, 2008, MOL BIOL CELL, V19, P137, DOI 10.1091/mbc.E07-08-0764; Segrelles C, 2007, CANCER RES, V67, P10879, DOI 10.1158/0008-5472.CAN-07-2564; Shin K, 2011, NATURE, V472, P110, DOI 10.1038/nature09851; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	67	17	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2937	2951		10.1038/onc.2012.316	http://dx.doi.org/10.1038/onc.2012.316			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22890321				2022-12-28	WOS:000320369700004
J	Zhu, Y; Zhao, T; Itasaka, S; Zeng, L; Yeom, CJ; Hirota, K; Suzuki, K; Morinibu, A; Shinomiya, K; Ou, G; Yoshimura, M; Hiraoka, M; Harada, H				Zhu, Y.; Zhao, T.; Itasaka, S.; Zeng, L.; Yeom, C. J.; Hirota, K.; Suzuki, K.; Morinibu, A.; Shinomiya, K.; Ou, G.; Yoshimura, M.; Hiraoka, M.; Harada, H.			Involvement of decreased hypoxia-inducible factor 1 activity and resultant G(1)-S cell cycle transition in radioresistance of perinecrotic tumor cells	ONCOGENE			English	Article						radiation therapy; radioresistance; tumor microenvironments; hypoxia; hypoxia-inducible factor 1 (HIF-1)	DOUBLE-STRAND BREAKS; SOLID TUMORS; DNA-DAMAGE; FACTOR-I; IONIZING-RADIATION; MAMMALIAN-CELLS; STRESS-RESPONSE; CANCER-THERAPY; HISTONE H2AX; EXPRESSION	Cancer patients often suffer from local tumor recurrence after radiation therapy. Some intracellular and extracellular factors, such as activity of hypoxia-inducible factor 1 (HIF-1), cell cycle status and oxygen availability, have been suggested to affect DNA damage responses and eventual radioresistant characteristics of cancer cells. But when, where, and how these factors affect one another and induce cellular radioresistance is largely unknown. Here, we analyzed mechanistic and spatio-temporal relationships among them in highly heterogeneous tumor microenvironments. Experiments in vitro demonstrated that a decrease in the glucose concentration reduced the transcriptional activity of HIF-1 and expression of a downstream gene for the cell cycle regulator p27(Kip1) even under hypoxic conditions. Then, the proportion of cells in the radioresistant S phase increased, whereas that radiosensitive G(1) phase decreased, significantly. Immunohistochemical analyses showed that cancer cells in perinecrotic hypoxic regions, which should be under low-glucose conditions, expressed little HIF-1 alpha, and therefore, were mainly in S phase and less damaged by radiation treatment. Continuous administration of glucagon, which increases the blood glucose concentration and so improves glucose availability in perinecrotic hypoxic regions, induced HIF-1 alpha expression and increased radiation-induced DNA damage. Taken all together, these results indicate that cancer cells in perinecrotic regions, which would be under low-glucose and hypoxic conditions, obtain radioresistance by decreasing the level of both HIF-1 activity and p27(Kip1) expression, and adjusting their cell cycle to the radioresistant S phase. Oncogene (2013) 32, 2058-2068; doi:10.1038/onc.2012.223; published online 18 June 2012	[Zhu, Y.; Zhao, T.; Zeng, L.; Yeom, C. J.; Morinibu, A.; Shinomiya, K.; Harada, H.] Kyoto Univ, Grp Radiat & Tumor Biol, Career Path Promot Unit Young Life Scientists, Kyoto, Japan; [Zhu, Y.; Zhao, T.; Itasaka, S.; Zeng, L.; Ou, G.; Yoshimura, M.; Hiraoka, M.] Kyoto Univ, Dept Radiat Oncol & Image Appl Therapy, Grad Sch Med, Kyoto, Japan; [Zhu, Y.] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing, Peoples R China; [Zhao, T.; Itasaka, S.] Fourth Mil Med Univ, Dept Radiat Med, Xian, Shaanxi, Peoples R China; [Hirota, K.] Kyoto Univ, Kyoto Univ Hosp, Dept Anesthesia, Kyoto, Japan; [Suzuki, K.] Nagasaki Univ, Grad Sch Biomed Sci, Div Radiat Biol, Dept Radiol & Radiat Biol, Nagasaki 852, Japan	Kyoto University; Kyoto University; Chongqing Medical University; Air Force Military Medical University; Kyoto University; Nagasaki University	Harada, H (corresponding author), Kyoto Univ, Grp Radiat & Tumor Biol, Career Path Promot Unit Young Life Scientists, Sakyo Ku, Yoshida Konoe Cho, Kyoto, Japan.	hharada@kuhp.kyoto-u.ac.jp	; Hirota, Kiichi/E-9181-2010	Yuxi, Zhu/0000-0001-7563-505X; Hirota, Kiichi/0000-0003-1110-0827	Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) from the Japan Society for the Promotion of Science (JSPS), Japan [LS071]; Program for Promotion of Fundamental Studies in Health Science from the National Institute of Biomedical Innovation (NIBIO), Japan [09-25]; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [21791184, 22791190]; Sagawa Foundation for the Promotion of Cancer Research; International Science and Technology Cooperation Project of China and Japan [2010DFA31900]; Grants-in-Aid for Scientific Research [24659695] Funding Source: KAKEN	Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) from the Japan Society for the Promotion of Science (JSPS), Japan; Program for Promotion of Fundamental Studies in Health Science from the National Institute of Biomedical Innovation (NIBIO), Japan; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Sagawa Foundation for the Promotion of Cancer Research; International Science and Technology Cooperation Project of China and Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Masahiro Inoue for discussions and Dr GL Semenza for the plasmid pcDNA3-HIF-1 alpha-CA, which expresses the constitutively active mutant form of HIF-1 alpha (HIF-1 alpha-CA). This study was supported by the Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) from the Japan Society for the Promotion of Science (JSPS), Japan to HH (No. LS071), by the Program for Promotion of Fundamental Studies in Health Science from the National Institute of Biomedical Innovation (NIBIO), Japan to HH (No. 09-25), by Grants-in-aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan to HH (No. 21791184). and SI (No. 22791190), by the Sagawa Foundation for the Promotion of Cancer Research to HH, and by the International Science and Technology Cooperation Project of China and Japan to ZL and HH (No. 2010DFA31900).	Aebersold DM, 2001, CANCER RES, V61, P2911; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Box AH, 2004, CARCINOGENESIS, V25, P2325, DOI 10.1093/carcin/bgh274; BROWN JM, 1993, BRIT J CANCER, V67, P1163, DOI 10.1038/bjc.1993.220; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Brown JM, 1998, CANCER RES, V58, P1408; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DESCHNER EE, 1959, RADIAT RES, V11, P115, DOI 10.2307/3570739; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Gorski DH, 1999, CANCER RES, V59, P3374; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; Harada H, 2009, BRIT J CANCER, V100, P747, DOI 10.1038/sj.bjc.6604939; Harada H, 2007, BIOCHEM BIOPH RES CO, V360, P791, DOI 10.1016/j.bbrc.2007.06.149; Harada H, 2005, MOL IMAGING, V4, P182; Harada H, 2006, FEBS LETT, V580, P5718, DOI 10.1016/j.febslet.2006.09.025; Harada H, 2009, J BIOL CHEM, V284, P5332, DOI 10.1074/jbc.M806653200; Irie Nobuyuki, 2004, Brain Tumor Pathol, V21, P1, DOI 10.1007/BF02482169; Ishikawa H, 2004, INT J RADIAT ONCOL, V60, P513, DOI 10.1016/j.ijrobp.2004.03.025; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kizaka-Kondoh S, 2003, CANCER SCI, V94, P1021, DOI 10.1111/j.1349-7006.2003.tb01395.x; Kizaka-Kondoh S, 2009, CANCER SCI, V100, P1366, DOI 10.1111/j.1349-7006.2009.01195.x; Kizaka-Kondoh S, 2009, ADV DRUG DELIVER REV, V61, P623, DOI 10.1016/j.addr.2009.01.006; Li XC, 2008, CLIN SCI, V114, P591, DOI 10.1042/CS20070257; Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555-007-9066-y; Moeller BJ, 2004, CELL CYCLE, V3, P1107; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; PALCIC B, 1984, RADIAT RES, V100, P328, DOI 10.2307/3576354; Pryde F, 2005, J CELL SCI, V118, P2043, DOI 10.1242/jcs.02336; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2011, AM J PHYSIOL-CELL PH, V301, pC550, DOI 10.1152/ajpcell.00176.2011; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; SINCLAIR WK, 1968, RADIAT RES, V33, P620, DOI 10.2307/3572419; Sobhanifar S, 2005, CANCER RES, V65, P7259, DOI 10.1158/0008-5472.CAN-04-4480; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; TERASIMA T, 1963, BIOPHYS J, V3, P11, DOI 10.1016/S0006-3495(63)86801-0; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAUPEL P, 1989, CANCER RES, V49, P6449; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Webb GC, 2002, DIABETES, V51, P398, DOI 10.2337/diabetes.51.2.398; Zeng LH, 2008, CANCER SCI, V99, P2327, DOI 10.1111/j.1349-7006.2008.00943.x	51	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2013	32	16					2058	2068		10.1038/onc.2012.223	http://dx.doi.org/10.1038/onc.2012.223			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22710721	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000317919900007
J	Shi, G; DiRenzo, D; Qu, C; Barney, D; Miley, D; Konieczny, SF				Shi, G.; DiRenzo, D.; Qu, C.; Barney, D.; Miley, D.; Konieczny, S. F.			Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia	ONCOGENE			English	Article						Mist1; pancreatic cancer; lineage tracing; signaling pathways; 3D tissue culture	TRANSCRIPTION FACTOR MIST1; PANCREATIC INTRAEPITHELIAL NEOPLASIA; K-RAS ONCOGENE; CANCER; MICE; INDUCTION; ADENOCARCINOMA; PROGRESSION; TRANSDIFFERENTIATION; TRANSFORMATION	Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers owing to a number of characteristics including difficulty in establishing early diagnosis and the absence of effective therapeutic regimens. A large number of genetic alterations have been ascribed to PDAC with mutations in the KRAS2 proto-oncogene thought to be an early event in the progression of disease. Recent lineage-tracing studies have shown that acinar cells expressing mutant Kras(G12D) are induced to transdifferentiate, generating duct-like cells through a process known as acinar-ductal metaplasia (ADM). ADM lesions then convert to precancerous pancreatic intraepithelial neoplasia (PanIN) that progresses to PDAC over time. Thus, understanding the earliest events involved in ADM/PanIN formation would provide much needed information on the molecular pathways that are instrumental in initiating this disease. As studying the transition of acinar cells to metaplastic ductal cells in vivo is complicated by analysis of the entire organ, an in vitro three dimensional (3D) culture system was used to model ADM outside the animal. Kras(G12D)-expressing acinar cells rapidly underwent ADM in 3D culture, forming ductal cysts that silenced acinar genes and activated duct genes, characteristics associated with in vivo ADM/PanIN lesions. Analysis of downstream KRAS signaling events established a critical importance for the Raf/MEK/ERK pathway in ADM induction. In addition, forced expression of the acinar-restricted transcription factor Mist1, which is critical to acinar cell organization, significantly attenuated Kras(G12D)-induced ADM/PanIN formation. These results suggest that maintaining MIST1 activity in Kras(G12D)-expressing acinar cells can partially mitigate the transformation activity of oncogenic KRAS. Future therapeutics that target both the MAPK pathway and Mist1 transcriptional networks may show promising efficacy in combating this deadly disease. Oncogene (2013) 32, 1950-1958; doi:10.1038/onc.2012.210; published online 4 June 2012	[Konieczny, S. F.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Konieczny, S. F.] Purdue Univ, Purdue Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Konieczny, SF (corresponding author), Purdue Univ, Dept Biol Sci, Hansen Life Sci Res Bldg,201 South Univ St, W Lafayette, IN 47907 USA.	sfk@purdue.edu	Shi, Guanglu/G-1641-2013	Shi, Guanglu/0000-0001-5562-111X	NIH [CA124586, DK55489]; CTSI Predoctoral Fellowship; Phi Beta Psi Sorority for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA124586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055489] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CTSI Predoctoral Fellowship; Phi Beta Psi Sorority for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Judy Hallett of the Purdue Center for Cancer Research Transgenic Mouse Core Facility for generating the transgenic mouse strains used in this study and David Hess and Anju Karki for critical reading of the manuscript. This work was supported by grants to SFK (NIH CA124586, NIH DK55489 and the Phi Beta Psi Sorority for Cancer Research) and to DD (CTSI Predoctoral Fellowship).	ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Brembeck FH, 2003, CANCER RES, V63, P2005; Brune K, 2006, AM J SURG PATHOL, V30, P1067; Calhoun ES, 2003, AM J PATHOL, V163, P1255, DOI 10.1016/S0002-9440(10)63485-2; Carriere C, 2007, P NATL ACAD SCI USA, V104, P4437, DOI 10.1073/pnas.0701117104; Carriere C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027725; Carriere C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068; De Corte V, 2002, EMBO J, V21, P6781, DOI 10.1093/emboj/cdf680; Detlefsen S, 2005, VIRCHOWS ARCH, V447, P800, DOI 10.1007/s00428-005-0032-1; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Heid I, 2011, GASTROENTEROLOGY, V141, P719, DOI 10.1053/j.gastro.2011.04.043; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Houbracken I, 2011, GASTROENTEROLOGY, V141, P731, DOI 10.1053/j.gastro.2011.04.050; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Jean-Paul D, 2008, P NATL ACAD SCI USA, V105, P18907, DOI 10.1073/pnas.0810111105; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jensen JN, 2005, GASTROENTEROLOGY, V128, P728, DOI 10.1053/j.gastro.2004.12.008; Kowalik AS, 2007, AM J PHYSIOL-GASTR L, V292, pG1123, DOI 10.1152/ajpgi.00512.2006; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Maitra A, 2005, ADV ANAT PATHOL, V12, P81, DOI 10.1097/01.pap.0000155055.14238.25; Malka D, 2002, GUT, V51, P849, DOI 10.1136/gut.51.6.849; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; Ramsey VG, 2007, DEVELOPMENT, V134, P211, DOI 10.1242/dev.02700; Ray KC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016786; Rovira M, 2008, GASTROENTEROLOGY, V135, P1301, DOI 10.1053/j.gastro.2008.06.049; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Shi CJ, 2009, MOL CANCER RES, V7, P230, DOI 10.1158/1541-7786.MCR-08-0206; Shi GL, 2009, GASTROENTEROLOGY, V136, P1368, DOI 10.1053/j.gastro.2008.12.066; Siveke JT, 2007, CANCER CELL, V12, P266, DOI 10.1016/j.ccr.2007.08.002; Strobel O, 2007, GASTROENTEROLOGY, V133, P1999, DOI 10.1053/j.gastro.2007.09.009; Tuveson DA, 2006, CANCER RES, V66, P242, DOI 10.1158/0008-5472.CAN-05-2305; Wagner M, 1998, GASTROENTEROLOGY, V115, P1254, DOI 10.1016/S0016-5085(98)70098-8; Zhu LQ, 2007, AM J PATHOL, V171, P263, DOI 10.2353/ajpath.2007.061176; Zhu LQ, 2004, MOL CELL BIOL, V24, P2673, DOI 10.1128/MCB.24.7.2673-2681.2004	47	96	97	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1950	1958		10.1038/onc.2012.210	http://dx.doi.org/10.1038/onc.2012.210			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22665051	Green Accepted			2022-12-28	WOS:000317599900009
J	Lopez-Lago, MA; Posner, S; Thodima, VJ; Molina, AM; Motzer, RJ; Chaganti, RSK				Lopez-Lago, M. A.; Posner, S.; Thodima, V. J.; Molina, A. M.; Motzer, R. J.; Chaganti, R. S. K.			Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression	ONCOGENE			English	Article						kidney cancer; metastasis; neutrophil	COMPARATIVE GENOMIC HYBRIDIZATION; GENE-EXPRESSION; NUDE-MICE; CANCER METASTASIS; MELANOMA-CELLS; BREAST-CANCER; INTERLEUKIN-8; GROWTH; IL-8; INFILTRATION	The mechanism by which renal cell carcinoma (RCC) colonizes the lung microenvironment during metastasis remains largely unknown. To investigate this process, we grafted human RCC cells with varying lung metastatic potential in mice. Gene expression profiling of the mouse lung stromal compartment revealed a signature enriched for neutrophil-specific functions that was induced preferentially by poorly metastatic cells. Analysis of the gene expression signatures of tumor cell lines showed an inverse correlation between metastatic activity and the levels of a number of chemokines, including CXCL5 and IL8. Enforced depletion of CXCL5 and IL8 in these cell lines enabled us to establish a functional link between lung neutrophil infiltration, secretion of chemokines by cancer cells and metastatic activity. We further show that human neutrophils display a higher cytotoxic activity against poorly metastatic cells compared with highly metastatic cells. Together, these results support a model in which neutrophils recruited to the lung by tumor-secreted chemokines build an antimetastatic barrier with loss of neutrophil chemokines in tumor cells acting as a critical rate-limiting step during lung metastatic seeding. Oncogene (2013) 32, 1752-1760; doi: 10.1038/onc.2012.201; published online 4 June 2012	[Lopez-Lago, M. A.; Posner, S.; Thodima, V. J.; Chaganti, R. S. K.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; [Molina, A. M.; Motzer, R. J.; Chaganti, R. S. K.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	chagantr@mskcc.org		Motzer, Robert/0000-0001-6925-2327	National Cancer Institute [CA-121327]; V-Foundation; Syms kidney cancer award; NATIONAL CANCER INSTITUTE [R01CA121327] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); V-Foundation; Syms kidney cancer award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by research grants from the National Cancer Institute (CA-121327), the V-Foundation and a Syms kidney cancer award. We thank Marco Seandel and Eric Pamer for critical reading of the manuscript. The MSKCC Genomics Core Facility provided expert assistance in performing the gene expression profiling assays. R Chaganti is a Board member and a paid consultant of Cancer Genetics Inc., Rutherford, NJ, USA.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bellocq A, 1998, AM J PATHOL, V152, P83; Bissig H, 1999, AM J PATHOL, V155, P267, DOI 10.1016/S0002-9440(10)65120-6; Buonocore S, 2008, J LEUKOCYTE BIOL, V84, P713, DOI 10.1189/jlb.0108075; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Dakhova O, 2009, CLIN CANCER RES, V15, P3979, DOI 10.1158/1078-0432.CCR-08-1899; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Di Carlo E, 2001, BLOOD, V97, P339, DOI 10.1182/blood.V97.2.339; EBERT T, 1990, CANCER RES, V50, P5531; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Finak G, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1608; Foekens JA, 2003, CANCER RES, V63, P337; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gorbachev AV, 2007, J IMMUNOL, V178, P2278, DOI 10.4049/jimmunol.178.4.2278; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Jensen HK, 2009, J CLIN ONCOL, V27, P4709, DOI 10.1200/JCO.2008.18.9498; Jiang F, 2000, CANCER RES, V60, P6503; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kondo T, 2004, J UROLOGY, V171, P2171, DOI 10.1097/01.ju.0000127726.25609.87; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Lee LF, 2000, J IMMUNOL, V164, P2769, DOI 10.4049/jimmunol.164.5.2769; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; Lopez-Lago MA, 2010, CANC RES; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; McAllister SS, 2010, J CLIN ONCOL, V28, P4022, DOI 10.1200/JCO.2010.28.4257; Miyazaki H, 2006, CANCER RES, V66, P4279, DOI 10.1158/0008-5472.CAN-05-4398; Monti P, 2003, CANCER RES, V63, P7451; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; MURPHY GP, 1973, JNCI-J NATL CANCER I, V50, P1013, DOI 10.1093/jnci/50.4.1013; NAITO S, 1989, CLIN EXP METASTAS, V7, P381, DOI 10.1007/BF01753659; NAITO S, 1986, CANCER RES, V46, P4109; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Ostrand-Rosenberg S, 2008, CURR OPIN GENET DEV, V18, P11, DOI 10.1016/j.gde.2007.12.007; PAGET S, 1989, CANCER METAST REV, V8, P98; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Schaider H, 2003, INT J CANCER, V103, P335, DOI 10.1002/ijc.10775; SINGH RK, 1994, CANCER RES, V54, P3242; Speetjens FM, 2008, CLIN CANCER RES, V14, P2276, DOI 10.1158/1078-0432.CCR-07-4045; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Takahashi H, 2005, IMMUNOL LETT, V98, P189, DOI 10.1016/j.imlet.2004.11.012; Talmadge JE, 2007, CANCER METAST REV, V26, P373, DOI 10.1007/s10555-007-9072-0; Tan XJ, 2008, INT J CANCER, V123, P1080, DOI 10.1002/ijc.23637; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wong YF, 2007, ONCOGENE, V26, P1971, DOI 10.1038/sj.onc.1209986	50	98	105	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2013	32	14					1752	1760		10.1038/onc.2012.201	http://dx.doi.org/10.1038/onc.2012.201			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22665059	Green Accepted			2022-12-28	WOS:000317043900002
J	Liu, Z; Zanata, SM; Kim, J; Peterson, MA; Di Vizio, D; Chirieac, LR; Pyne, S; Agostini, M; Freeman, MR; Loda, M				Liu, Z.; Zanata, S. M.; Kim, J.; Peterson, M. A.; Di Vizio, D.; Chirieac, L. R.; Pyne, S.; Agostini, M.; Freeman, M. R.; Loda, M.			The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation	ONCOGENE			English	Article						USP2a; DUB; EGFR; endocytosis	EPIDERMAL-GROWTH-FACTOR; DEUBIQUITINATING ENZYME USP2A; RECEPTOR TYROSINE KINASES; CLATHRIN-COATED PITS; DOWN-REGULATION; PROSTATE-CANCER; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; LUNG-CANCER; CELL-GROWTH	Ubiquitination of epidermal growth factor receptor (EGFR) is required for downregulation of the receptor by endocytosis. Impairment of this pathway results in constitutively active EGFR, which is associated with carcinogenesis, particularly in lung cancer. We previously demonstrated that the deubiquitinating enzyme ubiquitin-specific protease 2a (USP2a) has oncogenic properties. Here, we show a new role for USP2a as a regulator of EGFR endocytosis. USP2a localizes to early endosomes and associates with EGFR, stabilizing the receptor, which retains active downstream signaling. HeLa cells transiently expressing catalytically active, but not mutant (MUT), USP2a show increased plasma membrane-localized EGFR, as well as decreased internalized and ubiquitinated EGFR. Conversely, USP2a silencing reverses this phenotype. Importantly, USP2a prevents the degradation of MUT in addition to wild-type EGFR. Finally, we observed that USP2a and EGFR proteins are coordinately overexpressed in non-small cell lung cancers. Taken together, our data indicate that USP2a antagonizes EGFR endocytosis and thus amplifies signaling activity from the receptor. Our findings suggest that regulation of deubiquitination could be exploited therapeutically in cancers overexpressing EGFR. Oncogene (2013) 32, 1660-1669; doi:10.1038/onc.2012.188; published online 18 June 2012	[Liu, Z.; Zanata, S. M.; Peterson, M. A.; Chirieac, L. R.; Pyne, S.; Agostini, M.; Loda, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Liu, Z.; Zanata, S. M.; Peterson, M. A.; Chirieac, L. R.; Pyne, S.; Agostini, M.; Loda, M.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02215 USA; [Liu, Z.; Loda, M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Zanata, S. M.] Univ Fed Parana, Dept Basic Pathol, BR-80060000 Curitiba, Parana, Brazil; [Zanata, S. M.] Univ Fed Parana, Dept Cell Biol, BR-80060000 Curitiba, Parana, Brazil; [Kim, J.; Di Vizio, D.; Freeman, M. R.] Childrens Hosp, Urol Dis Res Ctr, Boston, MA 02115 USA; [Kim, J.; Di Vizio, D.; Freeman, M. R.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Freeman, M. R.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Loda, M.] Kings Coll London, Div Canc Studies, London WC2R 2LS, England	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Universidade Federal do Parana; Universidade Federal do Parana; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of London; King's College London	Loda, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, DA1536,450 Brookline Ave, Boston, MA 02215 USA.	Massimo_loda@dfci.harvard.edu	Chirieac, Lucian R./AAD-2030-2019; Agostini, Michelle/AAD-6610-2022; Zanata, Silvio/AAC-9670-2021; Agostini, Michelle/I-1275-2012	Agostini, Michelle/0000-0002-3648-337X; Zanata, Silvio/0000-0003-2818-6954; 	National Cancer Institute [RO1CA131945, PO1CA89021, P50 CA90381]; Prostate Cancer Foundation; CAPES, Brazil [3665/10-0]; NATIONAL CANCER INSTITUTE [P50CA090381, R01CA131945, P01CA089021, R00CA131472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087806] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Prostate Cancer Foundation; CAPES, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Tomas Kirchhausen for AMSH constructs, Mihee Ji and Erik McCauley for technical assistance, Jane Hayward for help with preparation of the figures, Giulio Draetta and Richard J Flavin for critical reading of the manuscript. This work was supported by the National Cancer Institute (RO1CA131945, PO1CA89021, P50 CA90381 and the Prostate Cancer Foundation). SMZ was supported by CAPES (no. 3665/10-0), Brazil.	Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Agromayor M, 2006, J BIOL CHEM, V281, P23083, DOI 10.1074/jbc.M513803200; Allende-Vega N, 2010, ONCOGENE, V29, P432, DOI 10.1038/onc.2009.330; Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; Amit I, 2004, GENE DEV, V18, P1737, DOI 10.1101/gad.294904; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Benassi B, 2012, CANCER DISCOV, V2, P236, DOI 10.1158/2159-8290.CD-11-0219; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Bunn PA, 2002, SEMIN ONCOL, V29, P38, DOI 10.1053/sonc.2002.35646; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CERNY T, 1986, BRIT J CANCER, V54, P265, DOI 10.1038/bjc.1986.172; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; de Araujo Mariana Eca Guimaraes, 2008, V424, P317, DOI 10.1007/978-1-60327-064-9_25; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gousseva N, 2003, GENE EXPRESSION, V11, P163, DOI 10.3727/000000003108749053; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Haslekas C, 2005, MOL BIOL CELL, V16, P5832, DOI 10.1091/mbc.E05-05-0456; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Komada Masayuki, 2008, Curr Drug Discov Technol, V5, P78, DOI 10.2174/157016308783769469; Lenferink AEG, 1997, BIOCHEM J, V327, P859; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin HJ, 2000, MOL CELL BIOL, V20, P6568, DOI 10.1128/MCB.20.17.6568-6578.2000; Love KR, 2007, NAT CHEM BIOL, V3, P697, DOI 10.1038/nchembio.2007.43; Ma YM, 2007, J BIOL CHEM, V282, P9805, DOI 10.1074/jbc.M611635200; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Metzig M, 2011, INT J CANCER, V129, P607, DOI 10.1002/ijc.26124; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mizuno E, 2006, TRAFFIC, V7, P1017, DOI 10.1111/j.1600-0854.2006.00452.x; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Niendorf S, 2007, MOL CELL BIOL, V27, P5029, DOI 10.1128/MCB.01566-06; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Priolo C, 2006, CANCER RES, V66, P8625, DOI 10.1158/0008-5472.CAN-06-1374; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Saksena S, 2007, TRENDS BIOCHEM SCI, V32, P561, DOI 10.1016/j.tibs.2007.09.010; Sakurada A, 2006, CLIN LUNG CANCER, V7, pS138, DOI 10.3816/CLC.2006.s.005; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Shi Y, 2011, J BIOL CHEM, V286, P38960, DOI 10.1074/jbc.M111.231498; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Stuffers S, 2009, EXP CELL RES, V315, P1619, DOI 10.1016/j.yexcr.2008.10.013; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Urbe S, 2006, BIOCHEM SOC T, V34, P754, DOI 10.1042/BST0340754; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	61	47	48	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 28	2013	32	13					1660	1669		10.1038/onc.2012.188	http://dx.doi.org/10.1038/onc.2012.188			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22710717	Green Accepted			2022-12-28	WOS:000316855800006
J	Pierotti, MA; Berrino, F; Gariboldi, M; Melani, C; Mogavero, A; Negri, T; Pasanisi, P; Pilotti, S				Pierotti, M. A.; Berrino, F.; Gariboldi, M.; Melani, C.; Mogavero, A.; Negri, T.; Pasanisi, P.; Pilotti, S.			Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects	ONCOGENE			English	Review						metformin; AMPK; mTORC; energetic metabolism; cancer treatment; chemoprevention	ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; ABERRANT CRYPT FOCI; EARLY BREAST-CANCER; HIGH-ENERGY DIET; BCL-X-L; IN-VIVO; PANCREATIC-CANCER; DIABETIC-PATIENTS; LIFE-SPAN	Understanding the complexity of cancer and of the underlying regulatory networks provides a new paradigm that tackles cancer development and treatment through a system biology approach, contemporarily acting on various intersecting pathways. Cancer cell metabolism is an old pathogenetic issue that has recently gained new interest as target for therapeutic approaches. More than 70 years ago, Warburg discovered that malignant cells generally have altered metabolism with high rates of glucose uptake and increased glycolysis, even under aerobic condition. Observational studies have provided evidence that impaired metabolism, obesity, hyperglycemia and hyperinsulinemia may have a role in cancer development, progression and prognosis, and actually diabetic and obese patients have increased cancer risk. On the other hand, caloric restriction has been shown to prolong life span and reduce cancer incidence in several animal models, having an impact on different metabolic pathways. Metformin, an antidiabetic drug widely used for over 40 years, mimics caloric restriction acting on cell metabolism at multiple levels, reducing all energy-consuming processes in the cells, including cell proliferation. By overviewing molecular mechanisms of action, epidemiological evidences, experimental data in tumor models and early clinical study results, this review provides information supporting the promising use of metformin in cancer prevention and treatment. Oncogene (2013) 32, 1475-1487; doi:10.1038/onc.2012.181; published online 4 June 2012	[Pierotti, M. A.; Melani, C.] Ist Nazl Tumori, Fdn IRCCS, Sci Directorate, I-20133 Milan, Italy; [Berrino, F.; Pasanisi, P.] Ist Nazl Tumori, Fdn IRCCS, Dept Predict & Prevent Med, I-20133 Milan, Italy; [Gariboldi, M.; Mogavero, A.] Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Mol Med, I-20133 Milan, Italy; [Gariboldi, M.; Mogavero, A.] Fdn Ist FIRC Oncol Mol, Milan, Italy; [Negri, T.; Pilotti, S.] Ist Nazl Tumori, Fdn IRCCS, Dept Pathol, Lab Mol Pathol, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; Fondazione IRCCS Istituto Nazionale Tumori Milan	Pierotti, MA (corresponding author), Ist Nazl Tumori, Fdn IRCCS, Sci Directorate, Via Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it	Pasanisi, Patrizia/F-4908-2017; Melani, Cecilia/C-2756-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Berrino, Franco/AAC-2364-2020; Gariboldi, Manuela/K-4744-2016	Pasanisi, Patrizia/0000-0001-6278-3491; Melani, Cecilia/0000-0003-2734-739X; Pierotti, Marco Alessandro/0000-0002-7431-8332; Berrino, Franco/0000-0002-4858-1866; Negri, Tiziana/0000-0002-3528-7115; Gariboldi, Manuela/0000-0001-8406-165X	Ministero dell'Universita e della Ricerca [DO11/002]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [R10/029]	Ministero dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Ministero dell'Universita e della Ricerca with the MIUR 5 x 1000 grant no. DO11/002 and by the Associazione Italiana per la Ricerca sul Cancro (AIRC grant no. R10/029). MAP would like to thank Dr Mathias Christian Zohoungbogbo who first introduced him to metformin. The authors wish to thank Dr Daniela Majerna for editorial assistance.	Algire C, 2011, ONCOGENE, V30, P1174, DOI 10.1038/onc.2010.483; Algire C, 2008, ENDOCR-RELAT CANCER, V15, P833, DOI 10.1677/ERC-08-0038; Algire C, 2010, ENDOCR-RELAT CANCER, V17, P351, DOI 10.1677/ERC-09-0252; Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Anisimov VN, 2008, CELL CYCLE, V7, P2769, DOI 10.4161/cc.7.17.6625; Anisimov VN, 2005, EXP GERONTOL, V40, P685, DOI 10.1016/j.exger.2005.07.007; Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824; Basen-Engquist K, 2011, CURR ONCOL REP, V13, P71, DOI 10.1007/s11912-010-0139-7; Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024; Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Bodmer M, 2012, AM J GASTROENTEROL, V107, P620, DOI 10.1038/ajg.2011.483; Bodmer M, 2012, CANCER EPIDEM BIOMAR, V21, P280, DOI 10.1158/1055-9965.EPI-11-0992-T; Bodmer M, 2010, DIABETES CARE, V33, P1304, DOI 10.2337/dc09-1791; Bosco JLF, 2011, CANCER EPIDEM BIOMAR, V20, P101, DOI 10.1158/1055-9965.EPI-10-0817; Bowker SL, 2010, DIABETOLOGIA, V53, P1631, DOI 10.1007/s00125-010-1750-8; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Campagnoli C, 2012, CLIN BREAST CANCER, V12, P175, DOI 10.1016/j.clbc.2012.03.004; Campbell IW, 2007, METFORMIN GOLD STAND, P77; Cantrell LA, 2010, GYNECOL ONCOL, V116, P92, DOI 10.1016/j.ygyno.2009.09.024; Carling D, 2011, NAT CHEM BIOL, V7, P512, DOI [10.1038/nchembio.610, 10.1038/NCHEMBIO.610]; Cazzaniga M, 2009, CANCER EPIDEM BIOMAR, V18, P701, DOI 10.1158/1055-9965.EPI-08-0871; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; Chiacchiera F, 2010, CELL CYCLE, V9, P1091, DOI 10.4161/cc.9.6.11035; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6; Currie CJ, 2012, DIABETES CARE, V35, P299, DOI 10.2337/dc11-1313; DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157; Detaille D, 2002, BIOCHEM PHARMACOL, V63, P1259, DOI 10.1016/S0006-2952(02)00858-4; Donadon V, 2009, WORLD J GASTROENTERO, V15, P2506, DOI 10.3748/wjg.15.2506; Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Feng ZH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001057; Fontana L, 2007, JAMA-J AM MED ASSOC, V297, P986, DOI 10.1001/jama.297.9.986; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Frenzel A, 2009, APOPTOSIS, V14, P584, DOI 10.1007/s10495-008-0300-z; Galluzzi L, 2010, AGING-US, V2, P535, DOI 10.18632/aging.100202; Garrett CR, 2012, BRIT J CANCER, V106, P1374, DOI 10.1038/bjc.2012.71; Giannarelli R, 2003, DIABETES METAB, V29, pS28; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Goodwin PJ, 2011, BREAST CANCER RES TR, V126, P215, DOI 10.1007/s10549-010-1224-1; Goodwin PJ, 2008, CLIN BREAST CANCER, V8, P501, DOI 10.3816/CBC.2008.n.060; Gotlieb WH, 2008, GYNECOL ONCOL, V110, P246, DOI 10.1016/j.ygyno.2008.04.008; Green AS, 2010, BLOOD, V116, P4262, DOI 10.1182/blood-2010-02-269837; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hadad SM, 2010, J CLIN ONCOL, V28; Hadad S, 2011, BREAST CANCER RES TR, V128, P783, DOI 10.1007/s10549-011-1612-1; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Home PD, 2010, DIABETOLOGIA, V53, P1838, DOI 10.1007/s00125-010-1804-y; Hosono K, 2010, CANCER PREV RES, V3, P1077, DOI 10.1158/1940-6207.CAPR-10-0186; Hosono K, 2010, MOL CARCINOGEN, V49, P662, DOI 10.1002/mc.20637; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Hursting SD, 2007, CURR CANCER DRUG TAR, V7, P484; Iliopoulos D, 2011, CANCER RES, V71, P3196, DOI 10.1158/0008-5472.CAN-10-3471; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Isakovic A, 2007, CELL MOL LIFE SCI, V64, P1290, DOI 10.1007/s00018-007-7080-4; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jiralerspong S, 2009, J CLIN ONCOL, V27, P3297, DOI 10.1200/JCO.2009.19.6410; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kim J, 2011, ANNU REV BIOCHEM, V80, P1001, DOI 10.1146/annurev-biochem-062209-094414; Kisfalvi K, 2009, CANCER RES, V69, P6539, DOI 10.1158/0008-5472.CAN-09-0418; Kourelis TV, 2012, MED ONCOL, V29, P1314, DOI 10.1007/s12032-011-9846-7; Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380; Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394; Lee MS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-20; Leontieva OV, 2010, CELL CYCLE, V9, P4323, DOI 10.4161/cc.9.21.13584; Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; MacKenzie MJ, 2012, INVEST NEW DRUG, V30, P647, DOI 10.1007/s10637-010-9570-8; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Martin-Castillo B, 2010, ANN ONCOL, V21, P187, DOI 10.1093/annonc/mdp494; Martin-Castillo B, 2010, CELL CYCLE, V9, P1057, DOI 10.4161/cc.9.6.10994; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P4208, DOI 10.4161/cc.10.24.18487; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1271, DOI 10.4161/cc.10.8.15330; MATTHAEI S, 1993, ENDOCRINOLOGY, V133, P304, DOI 10.1210/en.133.1.304; McCarthy A, 2009, J PATHOL, V219, P306, DOI 10.1002/path.2599; Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Monami M, 2011, DIABETES CARE, V34, P129, DOI 10.2337/dc10-1287; Monami M, 2009, ACTA DIABETOL, V46, P279, DOI 10.1007/s00592-008-0083-2; Muti P, 2009, CELL CYCLE, V8, P2661, DOI 10.4161/cc.8.16.9226; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Ning JY, 2010, MOL ENDOCRINOL, V24, P1218, DOI 10.1210/me.2009-0474; Niraula S, 2010, CANC RES S, V70, P104; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Oliveras-Ferraros C, 2011, CELL CYCLE, V10, P1144, DOI 10.4161/cc.10.7.15210; Oliveria SA, 2008, DIABETES METAB SYND, V2, P47, DOI 10.1016/j.dsx.2007.11.002; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Phoenix KN, 2009, BREAST CANCER RES TR, V113, P101, DOI 10.1007/s10549-008-9916-5; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175; Rattan R, 2011, NEOPLASIA, V13, P483, DOI 10.1593/neo.11148; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Roberts DL, 2010, ANNU REV MED, V61, P301, DOI 10.1146/annurev.med.080708.082713; Rozengurt E, 2010, CLIN CANCER RES, V16, P2505, DOI 10.1158/1078-0432.CCR-09-2229; Saito S, 2009, CANCER RES, V69, P4225, DOI 10.1158/0008-5472.CAN-08-2689; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Segal ED, 2011, BIOCHEM BIOPH RES CO, V414, P694, DOI 10.1016/j.bbrc.2011.09.134; Shu Y, 2007, J CLIN INVEST, V117, P1422, DOI 10.1172/JCI30558; Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49; Tomimoto A, 2008, CANCER SCI, V99, P2136, DOI 10.1111/j.1349-7006.2008.00933.x; Tzvetkov MV, 2009, CLIN PHARMACOL THER, V86, P299, DOI 10.1038/clpt.2009.92; Vazquez-Martin A, 2010, CURR MOL MED, V10, P674, DOI 10.2174/156652410792630625; Vazquez-Martin A, 2011, DRUG RESIST UPDATE, V14, P212, DOI 10.1016/j.drup.2011.04.003; Vazquez-Martin A, 2011, CELL CYCLE, V10, P1499, DOI 10.4161/cc.10.9.15423; Vazquez-Martin A, 2011, ONCOL REP, V25, P135, DOI 10.3892/or_00001052; Vazquez-Martin A, 2010, CELL CYCLE, V9, P3807, DOI 10.4161/cc.9.18.13131; Vazquez-Martin A, 2011, BREAST CANCER RES TR, V126, P355, DOI 10.1007/s10549-010-0924-x; Vazquez-Martin A, 2009, J CLIN ONCOL, V27, pE207, DOI 10.1200/JCO.2009.24.5456; Vazquez-Martin A, 2009, CELL CYCLE, V8, P88, DOI 10.4161/cc.8.1.7499; Vigneri P, 2009, ENDOCR-RELAT CANCER, V16, P1103, DOI 10.1677/ERC-09-0087; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P4047, DOI 10.4161/cc.10.23.18151; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Yea SS, 2011, SCIENCE, V332, P1270, DOI 10.1126/science.1208071; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zakikhani M, 2010, BREAST CANCER RES TR, V123, P271, DOI 10.1007/s10549-010-0763-9; Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081; Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625; Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377; Zeqiraj E, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000126; Zhou KX, 2011, NAT GENET, V43, P117, DOI 10.1038/ng.735; Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18; Zhuang YX, 2011, MOL CANCER RES, V9, P603, DOI 10.1158/1541-7786.MCR-10-0343	145	153	161	1	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1475	1487		10.1038/onc.2012.181	http://dx.doi.org/10.1038/onc.2012.181			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22665053				2022-12-28	WOS:000316456000001
J	Jagan, I; Fatehullah, A; Deevi, RK; Bingham, V; Campbell, FC				Jagan, I.; Fatehullah, A.; Deevi, R. K.; Bingham, V.; Campbell, F. C.			Rescue of glandular dysmorphogenesis in PTEN-deficient colorectal cancer epithelium by PPAR gamma-targeted therapy	ONCOGENE			English	Article						PTEN; cdc42; epithelium; morphogenesis	PLECKSTRIN HOMOLOGY DOMAIN; POLARITY PROTEIN PAR6; SPINDLE ORIENTATION; GLYCOGEN-SYNTHASE; TUMOR-SUPPRESSOR; CELL-POLARITY; RHO-GTPASES; CDC42 GEF; DUAL ROLE; KINASE B	Disruption of glandular architecture associates with poor clinical outcome in high-grade colorectal cancer (CRC). Phosphatase and tensin homolog deleted on chromosome ten (PTEN) regulates morphogenic growth of benign MDCK (Madin Darby Canine Kidney) cells through effects on the Rho-like GTPase cdc42 (cell division cycle 42). This study investigates PTEN-dependent morphogenesis in a CRC model. Stable short hairpin RNA knockdown of PTEN in Caco-2 cells influenced expression or localization of cdc42 guanine nucleotide exchange factors and inhibited cdc42 activation. Parental Caco-2 cells formed regular hollow gland-like structures (glands) with a single central lumen, in three-dimensional (3D) cultures. Conversely, PTEN-deficient Caco-2 ShPTEN cells formed irregular glands with multiple abnormal lumens as well as intra-and/or intercellular vacuoles evocative of the high-grade CRC phenotype. Effects of targeted treatment were investigated. Phosphatidinylinositol 3-kinase (PI3K) modulating treatment did not affect gland morphogenesis but did influence gland number, gland size and/or cell size within glands. As PTEN may be regulated by the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR gamma), cultures were treated with the PPAR gamma ligand rosiglitazone. This treatment enhanced PTEN expression, cdc42 activation and rescued dysmorphogenesis by restoring single lumen formation in Caco-2 ShPTEN glands. Rosiglitazone effects on cdc42 activation and Caco-2 ShPTEN gland development were attenuated by cotreatment with GW9662, a PPAR gamma antagonist. Taken together, these studies show PTEN-cdc42 regulation of lumen formation in a 3D model of human CRC glandular morphogenesis. Treatment by the PPAR gamma ligand rosiglitazone, but not PI3K modulators, rescued colorectal glandular dysmorphogenesis of PTEN deficiency. Oncogene (2013) 32, 1305-1315; doi:10.1038/onc.2012.140; published online 30 April 2012	[Jagan, I.; Fatehullah, A.; Deevi, R. K.; Bingham, V.; Campbell, F. C.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland	Queens University Belfast	Campbell, FC (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	f.c.campbell@qub.ac.uk		Campbell, Frederick/0000-0002-0363-9964	Wellcome Trust [WT081232MA]; Department for Education and Learning, Northern Ireland	Wellcome Trust(Wellcome TrustEuropean Commission); Department for Education and Learning, Northern Ireland	We gratefully acknowledge the support of the Wellcome Trust (WT081232MA) and the Department for Education and Learning, Northern Ireland for financial support. We are greatly indebted to Dr T Waldman, Georgetown University, USA, for supply of PTEN<SUP>+/+</SUP> HCT116 and PTEN <SUP>-/-</SUP> HCT116 cells, to Dr Pietro DiCamilli, Howard Hughes Medical Institute, Yale, for his generous provision of anti-human Tuba antibody, to Dr Estelle McLean for technical help, to Dr James Murray for the gift of PI-103 and to S Church for assistance with all imaging.	Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aoki K, 2005, MOL BIOL CELL, V16, P2207, DOI 10.1091/mbc.e04-10-0904; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Balciunaite E, 2001, BIOCHEM J, V358, P281, DOI 10.1042/0264-6021:3580281; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Carracedo A, 2011, CANCER RES, V71, P629, DOI 10.1158/0008-5472.CAN-10-2488; Cho YB, 2009, HEPATO-GASTROENTEROL, V56, P1335; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Deevi R, 2011, BRIT J CANCER, V105, P1313, DOI 10.1038/bjc.2011.384; Donev IS, 2011, CLIN CANCER RES, V17, P2260, DOI 10.1158/1078-0432.CCR-10-1993; Durgan J, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.174235; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Gunaratne J, 2011, J BIOL CHEM, V286, P18093, DOI 10.1074/jbc.M111.221184; Guruswamy S, 2008, INT J CANCER, V122, P25, DOI 10.1002/ijc.23031; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Itoh T, 2006, BBA-MOL CELL BIOL L, V1761, P897, DOI 10.1016/j.bbalip.2006.06.015; Jaffe AB, 2008, J CELL BIOL, V183, P625, DOI 10.1083/jcb.200807121; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johnson K, 2003, NAT CELL BIOL, V5, P12, DOI 10.1038/ncb0103-12; Kong M, 2000, J BIOL CHEM, V275, P36035, DOI 10.1074/jbc.M005621200; Lee C, 2004, CANCER RES, V64, P6906, DOI 10.1158/0008-5472.CAN-04-1767; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mitsushima M, 2009, MOL CELL BIOL, V29, P2816, DOI 10.1128/MCB.01713-08; Nassif NT, 2004, ONCOGENE, V23, P617, DOI 10.1038/sj.onc.1207059; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; PELZ C, 1989, J CELL BIOCHEM, V39, P197, DOI 10.1002/jcb.240390211; Pertz O, 2010, J CELL SCI, V123, P1841, DOI 10.1242/jcs.064345; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Pruitt WM, 2003, BBA-MOL CELL RES, V1640, P61, DOI 10.1016/S0167-4889(03)00002-8; Qin Y, 2010, J CELL BIOL, V189, P661, DOI 10.1083/jcb.201002097; Raynaud FI, 2009, MOL CANCER THER, V8, P1725, DOI 10.1158/1535-7163.MCT-08-1200; Rodriguez-Fraticelli AE, 2010, J CELL BIOL, V189, P725, DOI 10.1083/jcb.201002047; Salazar MA, 2003, J BIOL CHEM, V278, P49031, DOI 10.1074/jbc.M308104200; Sawai H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-56; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Seargent JM, 2004, BRIT J PHARMACOL, V143, P933, DOI 10.1038/sj.bjp.0705973; Shao J, 2007, CARCINOGENESIS, V28, P2476, DOI 10.1093/carcin/bgm186; Sinha S, 2008, CELL SIGNAL, V20, P1927, DOI 10.1016/j.cellsig.2008.05.002; Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tan I, 2008, CELL, V135, P123, DOI 10.1016/j.cell.2008.09.018; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Teresi RE, 2008, HUM MOL GENET, V17, P919, DOI 10.1093/hmg/ddm364; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Wang H, 2010, P NATL ACAD SCI USA, V107, P5142, DOI 10.1073/pnas.0912524107; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002	65	16	19	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1305	1315		10.1038/onc.2012.140	http://dx.doi.org/10.1038/onc.2012.140			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543585	Green Accepted			2022-12-28	WOS:000316454500011
J	Heijmans, J; Buller, NVJA; Hoff, E; Dihal, AA; van der Poll, T; van Zoelen, MAD; Bierhaus, A; Biemond, I; Hardwick, JCH; Hommes, DW; Muncan, V; van den Brink, GR				Heijmans, J.; Buller, N. V. J. A.; Hoff, E.; Dihal, A. A.; van der Poll, T.; van Zoelen, M. A. D.; Bierhaus, A.; Biemond, I.; Hardwick, J. C. H.; Hommes, D. W.; Muncan, V.; van den Brink, G. R.			Rage signalling promotes intestinal tumourigenesis	ONCOGENE			English	Article						intestinal adenoma; ApcMin; Rage; MyD88	MOUSE MODEL; INFLAMMATION; COLON; COLITIS; PROTEIN; CANCER; RECEPTOR; HMGB1	Development of colon cancer is a multistep process that is regulated by intrinsic and extrinsic cellular signals. Extrinsic factors include molecular patterns that are derived from either pathogens (PAMPs) or cellular damage (DAMPs). These molecules can promote tumourigenesis by activation of the innate immune system, but the individual contribution of ligands and their receptors remains elusive. The receptor for advanced glycation end products (Rage) is a pattern recognition receptor that binds multiple ligands derived from a damaged cell environment such as Hmgb1 and S100 protein. Here we show that Rage signalling has a critical role in sporadic development of intestinal adenomas, as Apc(Min/+) Rage(-/-) mice are protected against tumourigenesis. Oncogene (2013) 32, 1202-1206; doi:10.1038/onc.2012.119; published online 2 April 2012	[Heijmans, J.; Buller, N. V. J. A.; Muncan, V.; van den Brink, G. R.] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 BK Amsterdam, North Holland, Netherlands; [Heijmans, J.; Buller, N. V. J. A.; Hoff, E.; Dihal, A. A.; Biemond, I.; Hardwick, J. C. H.; Hommes, D. W.; Muncan, V.; van den Brink, G. R.] Leiden Univ, Dept Gastroenterol & Hepatol, Med Ctr, Leiden, Netherlands; [van der Poll, T.; van Zoelen, M. A. D.] Univ Amsterdam, Acad Med Ctr, Ctr Expt Mol Med, NL-1105 BK Amsterdam, North Holland, Netherlands; [Bierhaus, A.] Heidelberg Univ, Dept Med & Clin Chem 1, Heidelberg, Germany; [van den Brink, G. R.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 BK Amsterdam, North Holland, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; Ruprecht Karls University Heidelberg; University of Amsterdam; Academic Medical Center Amsterdam	Heijmans, J (corresponding author), Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, Meibergdreef 69-71, NL-1105 BK Amsterdam, North Holland, Netherlands.	j.heijmans@amc.nl; g.r.vandenbrink@amc.nl	Biemond, Izak/A-3540-2016; Hardwick, James/J-4862-2013	Biemond, Izak/0000-0002-3137-7527; Heijmans, Jarom/0000-0001-9615-7851; Hardwick, James/0000-0002-9575-5099				Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030; EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; Fukata M, 2011, INFLAMM BOWEL DIS, V17, P1464, DOI 10.1002/ibd.21527; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He M, 2011, EMBO REP, V12, P358, DOI 10.1038/embor.2011.28; Heijmans J. N.V., 2010, BIOCHIM BIOPHYS ACTA, V1822, P9; Heijmans J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022620; Kang HJ, 2009, LAB INVEST, V89, P948, DOI 10.1038/labinvest.2009.47; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Sakaguchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023132; Salama I, 2008, EJSO-EUR J SURG ONC, V34, P357, DOI 10.1016/j.ejso.2007.04.009; Turovskaya O, 2008, CARCINOGENESIS, V29, P2035, DOI 10.1093/carcin/bgn188; van Zoelen MA, 2011, CRIT CARE, V15, DOI 10.1186/cc9990; Volp K, 2006, GUT, V55, P234, DOI 10.1136/gut.2004.062729; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296	26	44	45	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1202	1206		10.1038/onc.2012.119	http://dx.doi.org/10.1038/onc.2012.119			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22469986				2022-12-28	WOS:000316428800014
J	Chiu, CF; Ho, MY; Peng, JM; Hung, SW; Lee, WH; Liang, CM; Liang, SM				Chiu, C-F; Ho, M-Y; Peng, J-M; Hung, S-W; Lee, W-H; Liang, C-M; Liang, S-M			Raf activation by Ras and promotion of cellular metastasis require phosphorylation of prohibitin in the raft domain of the plasma membrane	ONCOGENE			English	Article						prohibitin; Akt; Raf-1; metastasis; invasion	CANCER-CELLS; ROLES; REPRESSION; TISSUE	Prohibitin (PHB) is indispensable for Ras-induced Raf-1 activation, cell migration and growth; however, the exact role of PHB in the molecular pathogenesis of cancer metastasis remains largely unexamined. Here, we found a positive correlation between plasma membrane-associated PHB and the clinical stages of cancer. The level of PHB phosphorylated at threonine 258 (T258) and tyrosine 259 (Y259) in human cancer-cell membranes correlated with the invasiveness of cancer cells. Overexpression of phosphorylated PHB (phospho-PHB) in the lipid-raft domain of the cell membrane enhanced cell migration/invasion through PI3K/Akt and Raf-1/ERK activation. It also enhanced epithelial-mesenchynnal transition, matrix metalloproteinase-2 activity and invasiveness of cancer cells in vitro. Immunoprecipitation analysis demonstrated that phospho-PHB associated with Raf-1, Akt and Ras in the membrane and was essential for the activation of Raf-1 signaling by Ras. Mice implanted with cancer cells stably overexpressing PHB in the plasma membrane showed enlarged cervical tumors, enhanced metastasis and shorter survival time compared with mice implanted with cancer cells without PHB overexpression. Dephosphorylation of PHB at T258 by site-directed mutagenesis diminished the in vitro and in vivo effects of PHB. These results suggest that increase in phospho-PHB T258 in the raft domain of the plasma membrane has a role in the Ras-driven activation of PI3K/Akt and Raf-1/ERK-signaling cascades and results in the promotion of cancer metastasis. Oncogene (2013) 32, 777-787; doi:10.1038/onc.2012.86; published online 12 March 2012	[Chiu, C-F; Liang, S-M] Natl Cheng Kung Univ, Inst Biotechnol, Coll Biosci & Biotechnol, Tainan 70101, Taiwan; [Chiu, C-F; Hung, S-W; Liang, S-M] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 11529, Taiwan; [Ho, M-Y; Peng, J-M; Liang, C-M; Liang, S-M] Acad Sinica, Genom Res Ctr, Taipei 11529, Taiwan; [Lee, W-H] Taipei Med Univ, Shuang Ho Hosp, Dept Pathol, Taipei, Taiwan; [Liang, C-M] Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan	National Cheng Kung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Taipei Medical University; Shuang Ho Hospital; Academia Sinica - Taiwan	Liang, SM (corresponding author), Acad Sinica, Agr Biotechnol Res Ctr, 128 Acad Rd,Sec 2, Taipei 11529, Taiwan.	cmliang@gate.sinica.edu.tw; smyang@gate.sinica.edu.tw		Liang, Shu-Mei/0000-0001-8926-4747; Chiu, Ching-Feng/0000-0001-5591-0288	National Science Council, Taiwan [NSC 96-2313-B-001-005-MY3, NSC 99-2313-B-001-004-MY3]; Academia Sinica	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Academia Sinica(Academia Sinica - Taiwan)	This work was supported by the National Science Council, Taiwan (grants NSC 96-2313-B-001-005-MY3 and NSC 99-2313-B-001-004-MY3 to Shu-Mei Liang), and Academia Sinica (to Shu-Mei Liang and Chi-Ming Liang). We thank Chi-Ying Huang of National Yang Ming University, Taiwan for designing phosphorylated peptides to make antibodies against phospho-PHB. We also thank Shu-Chen Shen and Tzu-Wen Tai of the Scientific Instrument Center, Academia Sinica for their assistance with confocal microscopy analyses and flow cytometric analysis.	Ande SR, 2009, BBA-MOL CELL RES, V1793, P1372, DOI 10.1016/j.bbamcr.2009.05.008; Ande SR, 2010, BIOCHEM CELL BIOL, V88, P553, DOI [10.1139/O09-177, 10.1139/o09-177]; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Dart DA, 2009, ENDOCR-RELAT CANCER, V16, P1157, DOI 10.1677/ERC-09-0028; DELLORCO RT, 1997, BREAST J, V3, P85; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Han EKH, 2008, ANTICANCER RES, V28, P957; Huang Q, 2006, CANCER RES, V66, P5807, DOI 10.1158/0008-5472.CAN-06-0077; Kang XD, 2008, J GASTROENTEROL, V43, P618, DOI 10.1007/s00535-008-2208-3; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Matallanas David, 2011, Genes Cancer, V2, P232, DOI 10.1177/1947601911407323; Maurer G, 2011, ONCOGENE, V30, P3477, DOI 10.1038/onc.2011.160; Mishra S, 2006, J CELL MOL MED, V10, P353, DOI 10.1111/j.1582-4934.2006.tb00404.x; Mishra S, 2010, FEBS J, V277, P3937, DOI 10.1111/j.1742-4658.2010.07809.x; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nock NL, 2010, ENERG BALANCE CANCER, V1, P129, DOI 10.1007/978-1-4419-5515-9_5; Patel N, 2010, P NATL ACAD SCI USA, V107, P2503, DOI 10.1073/pnas.0910649107; Peng XJ, 2006, CANCER RES, V66, P7361, DOI 10.1158/0008-5472.CAN-06-1004; Rajalingam K, 2005, CELL CYCLE, V4, P1503, DOI 10.4161/cc.4.11.2142; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; SATOH T, 1992, J BIOL CHEM, V267, P24149; Sievers C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012735; Ummanni R, 2008, CANCER LETT, V266, P171, DOI 10.1016/j.canlet.2008.02.047; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wu TF, 2007, ANTICANCER RES, V27, P895; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	29	55	61	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					777	787		10.1038/onc.2012.86	http://dx.doi.org/10.1038/onc.2012.86			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22410782				2022-12-28	WOS:000315746700011
J	Shchors, K; Nozawa, H; Xu, J; Rostker, F; Swigart-Brown, L; Evan, G; Hanahan, D				Shchors, K.; Nozawa, H.; Xu, J.; Rostker, F.; Swigart-Brown, L.; Evan, G.; Hanahan, D.			Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis	ONCOGENE			English	Article						tumor; metalloproteinase; invasion; cathepsin; Myc; interleukin-1 beta	MATRIX-METALLOPROTEINASE INHIBITORS; LYSOSOMAL CYSTEINE PROTEASES; CAPILLARY ENDOTHELIAL-CELLS; MARROW-DERIVED CELLS; CATHEPSIN-B; ANGIOGENIC SWITCH; PHASE-III; MULTISTAGE TUMORIGENESIS; MALIGNANT PROGRESSION; EXTRACELLULAR-MATRIX	Despite their apparent success in pre-clinical trials, metalloproteinase (MMP) inhibitors proved to be inefficacious in clinical settings. In an effort to understand the underlying causes of this unanticipated outcome, we modeled the consequences of long-term MMP inhibition by removing one of the major players in tumorigenesis, MMP9, in two complimentary mouse models of pancreatic neuroendocrine carcinogenesis: Myc;BclXI and RIP1-Tag2. By employing gel zymography and a fluoregenic solution assay, we first established that MMP9 is expressed and activated in Myc;BclXI tumors in an interleukin-1 beta-dependent manner. The genetic deletion of MMP9 in Myc;BclXI mice impairs tumor angiogenesis and growth analogous to its absence in the RIP1-Tag2 model. Notably, tumors that developed in the context of MMP9-deficient backgrounds in both models were markedly more invasive than their typical wild-type counterparts, and expressed elevated levels of pro-invasive cysteine cathepsin B. The increased invasion of MMP9-deficient tumors was associated with a switch in the spectrum of inflammatory cells at the tumor margins, involving homing of previously undetected, cathepsin-B expressing CD11b;Gr1-positive cells to the invasive fronts. Thus, plasticity in the tumor inflammatory compartment is partially responsible for changes in the expression pattern of tumor-associated proteases, and may contribute to the compensatory effects observed on MMP inhibition, hence accounting for the heightened tumor progression described in late stage clinical trials. Oncogene (2013) 32, 502-513; doi:10.1038/onc.2012.60; published online 5 March 2012	[Shchors, K.; Hanahan, D.] Swiss Fed Inst Technol Lausanne EPFL, Sch Life Sci, Swiss Inst Expt Canc Res, CH-1015 Lausanne, Switzerland; [Shchors, K.; Xu, J.; Rostker, F.; Swigart-Brown, L.; Evan, G.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Nozawa, H.; Hanahan, D.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shchors, K (corresponding author), Swiss Fed Inst Technol Lausanne EPFL, Sch Life Sci, Swiss Inst Expt Canc Res, SV2818,Stn 19, CH-1015 Lausanne, Switzerland.	ksenya.shchors@epfl.ch			NCI; EPLF [F32-CA106039]; Cancer Research UK [12077] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [F32CA106039] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EPLF; Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the NCI and by core support from EPLF to DH. KS is a recipient of F32-CA106039. We are extremely grateful to Dr Zena Werb (UCSF) providing the MMP9-deficient animal model. Special thanks to Drs Johanna Joyce and Vasilena Gocheva (MSKCC) for providing cathepsin activity probe, antibodies and experimental protocols. We are grateful to Dr Elizabeth Allen and Dr Masahiro Inoue for providing Sutent-treated RT2 samples and RT2;RipCre;VEGFA FL/FL samples, respectively. We are grateful to Drs Lisa Coussens, Luisa Iruela-Arrispe (UCLA), Enrico Giraudo (U of Torino) for helpful discussions and advice. We are grateful to Mr Jeffrey A Kasten (EPFL) for critical reading of the paper. Authors also would like to acknowledge the Bioimaging and Optics platform (PT-BIOP) and the Histology Core Facility at EPFL for their services.	Ahn GO, 2008, CANCER CELL, V13, P193, DOI 10.1016/j.ccr.2007.11.032; Apte RN, 2006, EUR J CANCER, V42, P751, DOI 10.1016/j.ejca.2006.01.010; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Batist G, 2002, ANN ONCOL, V13, P1259, DOI 10.1093/annonc/mdf195; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bissett D, 2005, J CLIN ONCOL, V23, P842, DOI 10.1200/JCO.2005.03.170; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; Chesler L, 2007, CANCER RES, V67, P9435, DOI 10.1158/0008-5472.CAN-07-1316; Chintala SK, 1999, INT J DEV NEUROSCI, V17, P495, DOI 10.1016/S0736-5748(99)00010-6; Chun MGH, 2010, P NATL ACAD SCI USA, V107, P17268, DOI 10.1073/pnas.1012705107; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Creemers LB, 1998, MATRIX BIOL, V16, P575, DOI 10.1016/S0945-053X(98)90068-3; Czyzewska J, 2008, FOLIA HISTOCHEM CYTO, V46, P57, DOI 10.2478/v10042-008-0007-6; DALETFUMERON V, 1993, FEBS LETT, V332, P251, DOI 10.1016/0014-5793(93)80643-9; Deryugina EI, 2010, BBA-MOL CELL RES, V1803, P103, DOI 10.1016/j.bbamcr.2009.09.017; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Elaraj DM, 2006, CLIN CANCER RES, V12, P1088, DOI 10.1158/1078-0432.CCR-05-1603; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Geraghty P, 2007, J IMMUNOL, V178, P5871, DOI 10.4049/jimmunol.178.9.5871; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Grimm J, 2005, P NATL ACAD SCI USA, V102, P14404, DOI 10.1073/pnas.0503920102; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HERRON GS, 1986, J BIOL CHEM, V261, P2810; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kamat AA, 2006, CLIN CANCER RES, V12, P1707, DOI 10.1158/1078-0432.CCR-05-2338; Kirschke H, 1997, J CANCER RES CLIN, V123, P402, DOI 10.1007/s004320050078; Kruger A, 2001, CANCER RES, V61, P1272; LAH TT, 1989, CLIN EXP METASTAS, V7, P461, DOI 10.1007/BF01753666; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; Lee HT, 2004, J BIOL CHEM, V279, P32325, DOI 10.1074/jbc.M405208200; Levicar N, 2003, ACTA NEUROCHIR, V145, P825, DOI 10.1007/s00701-003-0097-z; Levin VA, 2006, J NEURO-ONCOL, V78, P295, DOI 10.1007/s11060-005-9098-5; Littlepage LE, 2010, CANCER RES, V70, P2224, DOI 10.1158/0008-5472.CAN-09-3515; Lockwood CJ, 2006, AM J PATHOL, V168, P445, DOI 10.2353/ajpath.2006.050082; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; McCawley LJ, 2008, AM J PATHOL, V173, P1528, DOI 10.2353/ajpath.2008.080132; MELCHIORI A, 1992, CANCER RES, V52, P2353; Moore MJ, 2003, J CLIN ONCOL, V21, P3296, DOI 10.1200/JCO.2003.02.098; Mountain DJH, 2007, AM J PHYSIOL-CELL PH, V292, pC867, DOI 10.1152/ajpcell.00161.2006; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871; Pavlaki M, 2003, CANCER METAST REV, V22, P177, DOI 10.1023/A:1023047431869; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Raymond L, 2006, J CELL PHYSIOL, V207, P683, DOI 10.1002/jcp.20608; Sekhon HS, 2008, LUNG CANCER, V60, P347, DOI 10.1016/j.lungcan.2007.10.028; Shchors K, 2006, GENE DEV, V20, P2527, DOI 10.1101/gad.1455706; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Sillanpaa S, 2007, GYNECOL ONCOL, V104, P296, DOI 10.1016/j.ygyno.2006.09.004; Sounni NE, 2010, DIS MODEL MECH, V3, P317, DOI 10.1242/dmm.003863; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Tazawa H, 2003, AM J PATHOL, V163, P2221, DOI 10.1016/S0002-9440(10)63580-8; Turk V, 2002, ADV ENZYME REGUL, V42, P285, DOI 10.1016/S0065-2571(01)00034-6; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; van Kempen LCL, 2006, EUR J CANCER, V42, P728, DOI 10.1016/j.ejca.2006.01.004; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	71	41	42	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					502	513		10.1038/onc.2012.60	http://dx.doi.org/10.1038/onc.2012.60			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391572	Green Published			2022-12-28	WOS:000315551300011
J	Jung, MJ; Rho, JK; Kim, YM; Jung, JE; Jin, YB; Ko, YG; Lee, JS; Lee, SJ; Lee, JC; Park, MJ				Jung, M-J; Rho, J-K; Kim, Y-M; Jung, J. E.; Jin, Y. B.; Ko, Y-G; Lee, J-S; Lee, S-J; Lee, J. C.; Park, M-J			Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells	ONCOGENE			English	Article						non-small cell lung cancer; cancer stern cell; CXCR4; PI3K/PTEN/Akt/mTOR signaling; STAT3 signaling; tumorigenicity	GROWTH-FACTOR; CHEMOKINE RECEPTOR-4; TUMOR-GROWTH; EXPRESSION; IDENTIFICATION; ACTIVATION; A549; PROLIFERATION; POPULATION; INVASION	The hypothesis of cancer stem cells has been proposed to explain the therapeutic failure in a variety of cancers including lung cancers. Previously, we demonstrated acquisition of epithelial-mesenchymal transition, a feature highly reminiscent of cancer stem-like cells, in gefitinib-resistant A549 cells (A549/GR). Here, we show that A549/GR cells contain a high proportion of CXCR4+ cells that are responsible for having high potential of self-renewal activity in vitro and tumorigenicity in vivo. A549/GR cells exhibited strong sphere-forming activity and high CXCR4 expression and SDF-1 alpha secretion compared with parent cells. Pharmacological inhibition (AMD3100) and/or siRNA transfection targeting CXCR4 significantly suppressed sphere-forming activity in A549 and A549/GR cells, and in various non-small cell lung cancer (NSCLC) cell lines. A549/GR cells showed enhanced Akt, mTOR and STAT3 (Y705) phosphorylation. Pharmacological inhibition of phosphatidyl inositol 3-kinase or transfection with wild-type PTEN suppressed phosphorylation of Akt, mTOR and STAT3 (Y705), sphere formation, and CXCR4 expression in A549/GR cells, whereas mutant PTEN enhanced these events. Inhibition of STAT3 by WP1066 or siSTAT3 significantly suppressed the sphere formation, but not CXCR4 expression, indicating that STAT3 is a downstream effector of CXCR4-mediated signaling. FACS-sorted CXCR4+ A549/GR cells formed many large spheres, had self-renewal capacity, demonstrated radiation resistance in vitro and exhibited stronger tumorigenic potential in vivo than CXCR4 cells. Lentiviral-transduction of CXCR4 enhanced sphere formation and tumorigenicity in H460 and A549 cells, whereas introduction of siCXCR4 suppressed these activities in A549/GR cells. Our data indicate that CXCR4 NSCLC cells are strong candidates for tumorigenic stem-like cancer cells that maintain sternness through a CXCR4-medated STAT3 pathway and provide a potential therapeutic target for eliminating these malignant cells in NSCLC. Oncogene (2013) 32, 209-221; doi:10.1038/onc.2012.37; published online 27 February 2012	[Jung, M-J; Kim, Y-M; Jung, J. E.; Lee, J-S; Park, M-J] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea; [Jung, M-J; Kim, Y-M; Ko, Y-G] Korea Univ, Coll Life Sci & Biotechnol, Seoul, South Korea; [Rho, J-K] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul 138736, South Korea; [Jin, Y. B.] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 139706, South Korea; [Lee, S-J] Hanyang Univ, Dept Chem, Seoul 133791, South Korea; [Lee, S-J] Hanyang Univ, Res Inst Nat Sci, Seoul 133791, South Korea; [Lee, J. C.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul 138736, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; University of Ulsan; Asan Medical Center; Korea Institute of Radiological & Medical Sciences; Hanyang University; Hanyang University; University of Ulsan; Asan Medical Center	Park, MJ (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Res, 215-4 Gongneung Dong, Seoul 139706, South Korea.	jclee@amc.seoul.kr; mjpark@kcch.re.kr	Lee, Jae Cheol/AAA-2678-2021		Mid-career Researcher Program through NRF [2009-0086438]; Nuclear Research and Development Program of Korea Science and Engineering foundation; Korean government (MEST) [2011-0030604]	Mid-career Researcher Program through NRF(National Research Foundation of Korea); Nuclear Research and Development Program of Korea Science and Engineering foundation; Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by the Mid-career Researcher Program through NRF grant (2009-0086438) and the Nuclear Research and Development Program of Korea Science and Engineering foundation funded by the Korean government (MEST) (2011-0030604).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Belperio JA, 2004, CHEST, V125, p156S, DOI 10.1378/chest.125.5_suppl.156S; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Cho HH, 2006, STEM CELLS DEV, V15, P853, DOI 10.1089/scd.2006.15.853; Ehtesham M, 2009, CANCER LETT, V274, P305, DOI 10.1016/j.canlet.2008.09.034; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Furusato B, 2010, PATHOL INT, V60, P497, DOI 10.1111/j.1440-1827.2010.02548.x; Gilbert CA, 2009, J CELL BIOCHEM, V108, P1031, DOI 10.1002/jcb.22350; Gutova M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000243; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389; Kato M, 2003, BREAST CANCER RES, V5, pR144, DOI 10.1186/bcr627; Kijima T, 2002, CANCER RES, V62, P6304; Kim J, 2005, J CLIN ONCOL, V23, P2744, DOI 10.1200/JCO.2005.07.078; Krohn A, 2009, CANCER LETT, V280, P65, DOI 10.1016/j.canlet.2009.02.005; Lam WK, 2007, RESPIROLOGY, V12, P471, DOI 10.1111/j.1440-1843.2007.01105.x; Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Na IK, 2008, HUM PATHOL, V39, P1751, DOI 10.1016/j.humpath.2008.04.017; Nickel W, 2010, CURR OPIN BIOTECH, V21, P621, DOI 10.1016/j.copbio.2010.06.004; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Park CM, 2006, CANCER RES, V66, P8511, DOI 10.1158/0008-5472.CAN-05-4340; Pfeiffer M, 2009, BRIT J CANCER, V100, P1949, DOI 10.1038/sj.bjc.6605068; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Santer FR, 2006, CANCER RES, V66, P3024, DOI 10.1158/0008-5472.CAN-05-2013; Schimanski CC, 2006, BRIT J CANCER, V95, P210, DOI 10.1038/sj.bjc.6603251; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Su LP, 2005, CLIN CANCER RES, V11, P8273, DOI 10.1158/1078-0432.CCR-05-0537; Sung JM, 2008, BIOCHEM BIOPH RES CO, V371, P163, DOI 10.1016/j.bbrc.2008.04.038; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Teng Y, 2010, BIOCHEM BIOPH RES CO, V392, P373, DOI 10.1016/j.bbrc.2010.01.028; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499	44	154	159	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					209	221		10.1038/onc.2012.37	http://dx.doi.org/10.1038/onc.2012.37			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22370645				2022-12-28	WOS:000314075500009
J	Barbarulo, A; Iansante, V; Chaidos, A; Naresh, K; Rahemtulla, A; Franzoso, G; Karadimitris, A; Haskard, DO; Papa, S; Bubici, C				Barbarulo, A.; Iansante, V.; Chaidos, A.; Naresh, K.; Rahemtulla, A.; Franzoso, G.; Karadimitris, A.; Haskard, D. O.; Papa, S.; Bubici, C.			Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma	ONCOGENE			English	Article						PARP14; c-Jun N-terminal kinase; survival; multiple myeloma; apoptosis	N-TERMINAL KINASE; GENE-EXPRESSION; CELL-LINES; APOPTOSIS; JNK; LYMPHOMA; PROLIFERATION; SUPPRESSION; ACTIVATION; CARCINOMA	Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM). Jun N-terminal kinase (JNK) signaling has been implicated in MM pathogenesis, but its function is unclear. To elucidate the role of JNK in MM, we evaluated the specific functions of the two major JNK proteins, JNK1 and JNK2. We show here that JNK2 is constitutively activated in a panel of MM cell lines and primary tumors. Using loss-of-function studies, we demonstrate that JNK2 is required for the survival of myeloma cells and constitutively suppresses JNK1-mediated apoptosis by affecting expression of poly(ADP-ribose) polymerase (PARP) 14, a key regulator of B-cell survival. Strikingly, we found that PARP14 is highly expressed in myeloma plasma cells and associated with disease progression and poor survival. Overexpression of PARP14 completely rescued myeloma cells from apoptosis induced by JNK2 knockdown, indicating that PARP14 is critically involved in JNK2-dependent survival. Mechanistically, PARP14 was found to promote the survival of myeloma cells by binding and inhibiting JNK1. Moreover, inhibition of PARP14 enhances the sensitization of MM cells to anti-myeloma agents. Our findings reveal a novel regulatory pathway in myeloma cells through which JNK2 signals cell survival via PARP14, and identify PARP14 as a potential therapeutic target in myeloma.	[Barbarulo, A.; Franzoso, G.; Bubici, C.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Sect Inflammat & Signal Transduct, London, England; [Iansante, V.; Papa, S.] Fdn Liver Res, Inst Hepatol, Cell Signalling & Canc Lab, London WC1E 6HX, England; [Chaidos, A.; Rahemtulla, A.; Karadimitris, A.] Imperial Coll Healthcare NHS Trust, Ctr Haematol, London, England; [Chaidos, A.; Naresh, K.; Rahemtulla, A.; Karadimitris, A.; Haskard, D. O.] Univ London Imperial Coll Sci Technol & Med, London, England; [Naresh, K.] Imperial Coll Healthcare NHS Trust, Dept Histopathol, London, England; [Haskard, D. O.] Imperial Coll Healthcare NHS Trust, Natl Heart & Lung Inst, British Heart Fdn, Vasc Sci Unit, London, England	Imperial College London; University of London; University College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of London; University College London	Papa, S (corresponding author), Fdn Liver Res, Inst Hepatol, Cell Signalling & Canc Lab, 69-75 Chenies Mews, London WC1E 6HX, England.	s.papa@researchinliver.org.uk; c.bubici@imperial.ac.uk	Papa, Salvatore/J-9413-2012; Franzoso, Guido/GRR-8628-2022	Papa, Salvatore/0000-0002-8369-6538; Franzoso, Guido/0000-0002-0778-988X; Naresh, Kikkeri N/0000-0003-3807-3638; Iansante, Valeria/0000-0002-4369-3375; Chaidos, Aristeidis/0000-0003-1453-8576; Bubici, Concetta/0000-0002-8074-4661	NIH [R01 CA084040, R01 CA098583]; Cancer Research UK [C26587/A8839]; Kay Kendall Leukemia Fund [KKL443]; Italian Association for Cancer Research [8557]; Foundation for Liver Research; NATIONAL CANCER INSTITUTE [R01CA084040, R01CA098583] Funding Source: NIH RePORTER; Cancer Research UK [15115] Funding Source: researchfish	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research UK(Cancer Research UK); Kay Kendall Leukemia Fund; Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Foundation for Liver Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK)	We are grateful to S Chokshi, R Williams and J Dyson for critical comments on the manuscript. We also thank D Trono (Ecole Polytechnique Federale de Lausanne, Switzerland) for the pWPI lentiviral vector and M Johns (Imperial College) for the human PARP14 cDNA; H Cooksley, A Riva (Institute of Hepatology), and PM Choy, MH Lam and V Patel (MSc students) for technical support. GF receives funding from NIH grants R01 CA084040 and R01 CA098583 and Cancer Research UK grant C26587/A8839. DOH receives professorial support from the British Heart Foundation. This study was primarily supported by a research grant from Kay Kendall Leukemia Fund (KKL443) to CB, and in part by grants from Italian Association for Cancer Research (Start-up 8557) and the Foundation for Liver Research to S.P.	Ahmed SU, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007305; Anbalagan M, 2012, INT J CANCER, V130, P1967, DOI 10.1002/ijc.26207; Anderson KC, 2011, ANNU REV PATHOL-MECH, V6, P249, DOI 10.1146/annurev-pathol-011110-130249; Aravind L, 2001, TRENDS BIOCHEM SCI, V26, P273, DOI 10.1016/S0968-0004(01)01787-X; Bardwell AJ, 2009, J BIOL CHEM, V284, P13165, DOI 10.1074/jbc.M900080200; Blonska M, 2007, IMMUNITY, V26, P55, DOI 10.1016/j.immuni.2006.11.008; Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06; Bogoyevitch MA, 2010, BBA-PROTEINS PROTEOM, V1804, P463, DOI 10.1016/j.bbapap.2009.11.002; Bost F, 1999, MOL CELL BIOL, V19, P1938; Brune V, 2008, J EXP MED, V205, P2251, DOI 10.1084/jem.20080809; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chen NY, 2001, CANCER RES, V61, P3908; Cho SH, 2011, P NATL ACAD SCI USA, V108, P15972, DOI 10.1073/pnas.1017082108; Cho SH, 2009, BLOOD, V113, P2416, DOI 10.1182/blood-2008-03-144121; Cui J, 2005, J BIOL CHEM, V280, P9913, DOI 10.1074/jbc.M412165200; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Ford J, 2008, CELL CYCLE, V7, P3091, DOI 10.4161/cc.7.19.6799; Gangopadhyay NN, 2011, CANCER INVEST, V29, P608, DOI 10.3109/07357907.2011.621916; Geest CR, 2009, J LEUKOCYTE BIOL, V86, P237, DOI 10.1189/jlb.0209097; Goenka S, 2006, P NATL ACAD SCI USA, V103, P4210, DOI 10.1073/pnas.0506981103; Goenka S, 2007, J BIOL CHEM, V282, P18732, DOI 10.1074/jbc.M611283200; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hideshima T, 2003, ONCOGENE, V22, P8797, DOI 10.1038/sj.onc.1206919; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood-2002-06-1874; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Kajiguchi T, 2006, CANCER SCI, V97, P540, DOI 10.1111/j.1349-7006.2006.00199.x; Ke HN, 2010, CANCER RES, V70, P3080, DOI 10.1158/0008-5472.CAN-09-2923; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim KH, 2010, BIOMAT PROP PROD DEV, P149; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Naresh KN, 2006, J CLIN PATHOL, V59, P903, DOI 10.1136/jcp.2004.020610; Nitta RT, 2011, ONCOGENE, V30, P234, DOI 10.1038/onc.2010.414; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Raab MS, 2009, LANCET, V374, P324, DOI 10.1016/S0140-6736(09)60221-X; Rajkumar SV, 2011, NAT REV CLIN ONCOL, V8, P479, DOI 10.1038/nrclinonc.2011.63; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Spanoudakis E, 2009, BLOOD, V113, P2498, DOI 10.1182/blood-2008-06-161281; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Witzig TE, 1999, BRIT J HAEMATOL, V104, P131, DOI 10.1046/j.1365-2141.1999.01136.x; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yanagawa T, 2007, CANCER RES, V67, P8682, DOI 10.1158/0008-5472.CAN-07-1586; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yoon CH, 2012, ONCOGENE, V31, P4655, DOI 10.1038/onc.2011.634; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zhan FH, 2007, BLOOD, V109, P1692, DOI 10.1182/blood-2006-07-037077; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458	53	84	92	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2013	32	36					4231	4242		10.1038/onc.2012.448	http://dx.doi.org/10.1038/onc.2012.448			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045269	Green Accepted			2022-12-28	WOS:000324168000005
J	Koyama-Nasu, R; Nasu-Nishimura, Y; Todo, T; Ino, Y; Saito, N; Aburatani, H; Funato, K; Echizen, K; Sugano, H; Haruta, R; Matsui, M; Takahashi, R; Manabe, E; Oda, T; Akiyama, T				Koyama-Nasu, R.; Nasu-Nishimura, Y.; Todo, T.; Ino, Y.; Saito, N.; Aburatani, H.; Funato, K.; Echizen, K.; Sugano, H.; Haruta, R.; Matsui, M.; Takahashi, R.; Manabe, E.; Oda, T.; Akiyama, T.			The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells	ONCOGENE			English	Article						cancer stem cells; cell cycle; cyclin D2; glioblastoma	CANCER; PROLIFERATION; PATHWAYS; GLIOMAS; ORIGIN; TUMORS; BRAIN; LINES	Cancer stem cells are believed to be responsible for tumor initiation and development. Much current research on human brain tumors is focused on the stem-like properties of glioblastoma stem cells (GSCs). However, little is known about the molecular mechanisms of cell cycle regulation that discriminate between GSCs and differentiated glioblastoma cells. Here we show that cyclin D2 is the cyclin that is predominantly expressed in GSCs and suppression of its expression by RNA interference causes G1 arrest in vitro and growth retardation of GSCs xenografted into immunocompromised mice in vivo. We also demonstrate that the expression of cyclin D2 is suppressed upon serum-induced differentiation similar to what was observed for the cancer stem cell marker CD133. Taken together, our results demonstrate that cyclin D2 has a critical role in cell cycle progression and the tumorigenicity of GSCs.	[Koyama-Nasu, R.; Nasu-Nishimura, Y.; Funato, K.; Echizen, K.; Sugano, H.; Haruta, R.; Matsui, M.; Takahashi, R.; Manabe, E.; Oda, T.; Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1100032, Japan; [Todo, T.; Ino, Y.; Saito, N.] Tokyo Univ Hosp, Dept Neurosurg, Bunkyo Ku, Tokyo 113, Japan; [Aburatani, H.] Univ Tokyo, Genome Sci Div, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1100032, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1100032, Japan.	akiyama@iam.u-tokyo.ac.jp		Funato, Kosuke/0000-0003-2437-1116; Todo, Tomoki/0000-0003-0523-8010	Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks); Integrative Research on Cancer Microenvironment Network; Takeda Science Foundation; MEXT, Japan; Grants-in-Aid for Scientific Research [25670138] Funding Source: KAKEN	Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks); Integrative Research on Cancer Microenvironment Network; Takeda Science Foundation(Takeda Science Foundation (TSF)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks), Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Research on Cancer Microenvironment Network), Takeda Science Foundation and in part by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.	Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793; [Anonymous], 2008, NATURE, V455, P1061; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Kowalczyk A, 2004, J CELL BIOL, V167, P209, DOI 10.1083/jcb.200404181; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lottaz C, 2010, CANCER RES, V70, P2030, DOI 10.1158/0008-5472.CAN-09-1707; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Singh SK, 2003, CANCER RES, V63, P5821; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Walzlein JH, 2008, STEM CELLS, V26, P2945, DOI 10.1634/stemcells.2008-0307; Zhang X, 2005, J CLIN NEUROSCI, V12, P166, DOI 10.1016/j.jocn.2004.03.036	17	40	41	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2013	32	33					3840	3845		10.1038/onc.2012.399	http://dx.doi.org/10.1038/onc.2012.399			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22964630				2022-12-28	WOS:000323210200006
J	Romeo, Y; Moreau, J; Zindy, PJ; Saba-El-Leil, M; Lavoie, G; Dandachi, F; Baptissart, M; Borden, KLB; Meloche, S; Roux, PP				Romeo, Y.; Moreau, J.; Zindy, P-J; Saba-El-Leil, M.; Lavoie, G.; Dandachi, F.; Baptissart, M.; Borden, K. L. B.; Meloche, S.; Roux, P. P.			RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth	ONCOGENE			English	Article						Melanoma; BRAF; MAPK; RSK; mTOR	PROTEIN-KINASE PATHWAY; INITIATION-FACTOR 4E; TRANSLATION INITIATION; B-RAF; DEPENDENT TRANSLATION; MOLECULAR-MECHANISMS; TUBEROUS SCLEROSIS; CELL-PROLIFERATION; S6 KINASE; PHOSPHORYLATION	The Ras/mitogen-activated protein kinase (MAPK) signalling cascade regulates various biological functions, including cell growth, proliferation and survival. As such, this pathway is often deregulated in cancer, including melanomas, which frequently harbour activating mutations in the NRAS and BRAF oncogenes. Hyperactive MAPK signalling is known to promote protein synthesis, but the mechanisms by which this occurs remain poorly understood. Here, we show that expression of oncogenic forms of Ras and Raf promotes the constitutive activation of the mammalian target of rapamycin (mTOR). Using pharmacological inhibitors and RNA interference, we find that the MAPK-activated protein kinase RSK (p90 ribosomal S6 kinase) is partly required for these effects. Using melanoma cell lines carrying activating BRAF mutations, we show that ERK/RSK signalling regulates assembly of the translation initiation complex and polysome formation, as well as the translation of growth-related messenger RNAs containing a 50-terminal oligopyrimidine (TOP) motif. Accordingly, we find that RSK inhibition abrogates tumour growth in mice. Our findings indicate that RSK may be a valuable therapeutic target for the treatment of tumours characterized by deregulated MAPK signalling, such as melanoma.	[Romeo, Y.; Moreau, J.; Zindy, P-J; Saba-El-Leil, M.; Lavoie, G.; Dandachi, F.; Baptissart, M.; Borden, K. L. B.; Meloche, S.; Roux, P. P.] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada; [Borden, K. L. B.; Roux, P. P.] Univ Montreal, Fac Med, Dept Pathol & Cell Biol, Montreal, PQ H3C 3J7, Canada; [Meloche, S.] Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Roux, PP (corresponding author), Univ Montreal, IRIC Univ Montreal, POB 6128,Stn Ctr Ville, Montreal, PQ H3C 3J7, Canada.	philippe.roux@umontreal.ca	Romeo, Yves/AAC-1669-2021; Roux, Philippe P./J-3996-2012	Roux, Philippe P./0000-0002-5962-0250	Canadian Cancer Society Research Institute; Cancer Research Society; Natural Sciences and Engineering Research Council of Canada; Human Frontier Science Programme (HFSP); FRSQ; NATIONAL CANCER INSTITUTE [R01CA080728, R01CA098571] Funding Source: NIH RePORTER	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Research Society; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Human Frontier Science Programme (HFSP)(Human Frontier Science Program); FRSQ(Fonds de la Recherche en Sante du Quebec); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Canadian Cancer Society Research Institute (PPR), the Cancer Research Society (PPR and SM), and the Natural Sciences and Engineering Research Council of Canada (PPR). We thank Dr Nahum Sonenberg for the phospho-4E-BP1 antibody. PP Roux holds a Canada Research Chair in Signal Transduction and Proteomics and a Career Development Award from the Human Frontier Science Programme (HFSP). K Borden and S Meloche hold Canada Research Chairs in Molecular Biology of the Cell Nucleus, and in Cellular Signalling, respectively. IRIC core facilities are supported by the FRSQ.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; Bilanges B, 2007, MOL CELL BIOL, V27, P5746, DOI 10.1128/MCB.02136-06; Buxade M, 2008, FRONT BIOSCI-LANDMRK, V13, P5359, DOI 10.2741/3086; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Caron E, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.68; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Carriere A, 2008, FRONT BIOSCI-LANDMRK, V13, P4258, DOI 10.2741/3003; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Eisenmann KM, 2003, CANCER RES, V63, P8330; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Fecher LA, 2008, CURR OPIN ONCOL, V20, P183, DOI 10.1097/CCO.0b013e3282f5271c; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gaestel M, 2008, FRONT BIOSCI, V13, P6050, DOI 10.2741/3136; Gray-Schopfer VC, 2005, CANCER METAST REV, V24, P165, DOI 10.1007/s10555-005-5865-1; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Jacinto E, 2008, IUBMB LIFE, V60, P483, DOI 10.1002/iub.56; Karbowniczek M, 2008, J INVEST DERMATOL, V128, P980, DOI 10.1038/sj.jid.5701074; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Max X, 2008, CELL, V133, P303, DOI 10.1016/j.cell.2008.02.031; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Meyuhas O, 2009, PROG MOL BIOL TRANSL, V90, P109, DOI 10.1016/S1877-1173(09)90003-5; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; O'Reilly KE, 2009, CLIN CANCER RES, V15, P2872, DOI 10.1158/1078-0432.CCR-08-2336; Old WM, 2009, MOL CELL, V34, P115, DOI 10.1016/j.molcel.2009.03.007; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Romeo Y, 2011, EXPERT OPIN THER TAR, V15, P5, DOI 10.1517/14728222.2010.531014; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Scheier B, 2011, IMMUNOTHERAPY-UK, V3, P1461, DOI [10.2217/IMT.11.136, 10.2217/imt.11.136]; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yamashita R, 2008, NUCLEIC ACIDS RES, V36, P3707, DOI 10.1093/nar/gkn248; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026	50	43	43	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2917	2926		10.1038/onc.2012.312	http://dx.doi.org/10.1038/onc.2012.312			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797077	Green Accepted			2022-12-28	WOS:000320369700002
J	Koese, M; Rentero, C; Kota, BP; Hoque, M; Cairns, R; Wood, P; de Muga, SV; Reverter, M; Alvarez-Guaita, A; Monastyrskaya, K; Hughes, WE; Swarbrick, A; Tebar, F; Daly, RJ; Enrich, C; Grewal, T				Koese, M.; Rentero, C.; Kota, B. P.; Hoque, M.; Cairns, R.; Wood, P.; Vila de Muga, S.; Reverter, M.; Alvarez-Guaita, A.; Monastyrskaya, K.; Hughes, W. E.; Swarbrick, A.; Tebar, F.; Daly, R. J.; Enrich, C.; Grewal, T.			Annexin A6 is a scaffold for PKC alpha to promote EGFR inactivation	ONCOGENE			English	Article						annexin A6; scaffold; PKC alpha; EGF receptor	EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-C; FACTOR RECEPTOR PHOSPHORYLATION; INTRACELLULAR TRAFFICKING; CHOLESTEROL TRANSPORT; MEMBRANE-BINDING; CARCINOMA-CELLS; 79 AKAP79; CANCER; VI	Protein kinase C alpha (PKC alpha) can phosphorylate the epidermal growth factor receptor (EGFR) at threonine 654 (T654) to inhibit EGFR tyrosine phosphorylation (pY-EGFR) and the associated activation of downstream effectors. However, upregulation of PKC alpha in a large variety of cancers is not associated with EGFR inactivation, and factors determining the potential of PKC alpha to downregulate EGFR are yet unknown. Here, we show that ectopic expression of annexin A6 (AnxA6), a member of the Ca2+ and phospholipid-binding annexins, strongly reduces pY-EGFR levels while augmenting EGFR T654 phosphorylation in EGFR overexpressing A431, head and neck and breast cancer cell lines. Reduced EGFR activation in AnxA6 expressing A431 cells is associated with reduced EGFR internalization and degradation. RNA interference (RNAi)-mediated PKC alpha knockdown in AnxA6 expressing A431 cells reduces T654-EGFR phosphorylation, but restores EGFR tyrosine phosphorylation, clonogenic growth and EGFR degradation. These findings correlate with AnxA6 interacting with EGFR, and elevated AnxA6 levels promoting PKC alpha membrane association and interaction with EGFR. Stable expression of the cytosolic N-terminal mutant AnxA6(1-175), which cannot promote PKC alpha membrane recruitment, does not increase T654-EGFR phosphorylation or the association of PKC alpha with EGFR. AnxA6 overexpression does not inhibit tyrosine phosphorylation of the T654A EGFR mutant, which cannot be phosphorylated by PKC alpha. Most strikingly, stable plasma membrane anchoring of AnxA6 is sufficient to recruit PKC alpha even in the absence of EGF or Ca2+. In summary, AnxA6 is a new PKC alpha scaffold to promote PKC alpha-mediated EGFR inactivation through increased membrane targeting of PKC alpha and EGFR/PKC alpha complex formation.	[Koese, M.; Kota, B. P.; Hoque, M.; Cairns, R.; Wood, P.; Grewal, T.] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Rentero, C.; Vila de Muga, S.; Reverter, M.; Alvarez-Guaita, A.; Tebar, F.; Enrich, C.] Univ Barcelona, Fac Med, Dept Biol Cellular Immunol & Neurociencies, IDIBAPS, Barcelona 08036, Spain; [Monastyrskaya, K.] Univ Bern, Dept Clin Res, Urol Res Lab, Bern, Switzerland; [Hughes, W. E.; Swarbrick, A.; Daly, R. J.] St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	University of Sydney; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Bern; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Enrich, C (corresponding author), Univ Barcelona, Fac Med, Dept Biol Cellular, Casanova 143, Barcelona 08036, Spain.	enrich@ub.edu; thomas.grewal@sydney.edu.au	Rentero Alfonso, Carles/L-4430-2017; Hoque, Monira/AAN-5715-2020; Köse, Meryem/K-7399-2013; Tebar, Francesc/H-1498-2015; Swarbrick, Alexander/E-6107-2010	Rentero Alfonso, Carles/0000-0003-4684-0278; Köse, Meryem/0000-0002-3391-3418; Tebar, Francesc/0000-0002-9522-9726; Swarbrick, Alexander/0000-0002-3051-5676; Hughes, William/0000-0002-7149-3987; Alvarez-Guaita, Anna/0000-0002-9248-2275; Enrich, Carlos/0000-0003-0382-2993; Daly, Roger/0000-0002-5739-8027; Grewal, Thomas/0000-0002-7937-8887; Monastyrskaya, Katia/0000-0003-2042-1139; Cairns, Rose/0000-0002-8946-5079	National Health and Medical Research Council of Australia (NHMRC) [510293, 510294]; University of Sydney [2010-02681]; Consolider-Ingenio from Ministerio de Innovacion, Ciencia y Tecnologia [CSD2009-00016]; Fundacio Marato TV3 (Barcelona, Spain) [PI040236]; NHMRC; National Heart Foundation (NHF)/NHMRC postgraduate scholarship; Beatriu de Pinos fellowship (Generalitat de Catalunya); Ministerio de Educacion y Ciencia, Spain; Ministerio de Innovacion, Ciencia y Tecnologia; Cancer Institute NSW; National Breast Cancer Foundation; (FPI mobility Program) at the laboratory of TG (Sydney, Australia);  [BFU2009-10335];  [BFU2009-13526]	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney(University of Sydney); Consolider-Ingenio from Ministerio de Innovacion, Ciencia y Tecnologia; Fundacio Marato TV3 (Barcelona, Spain); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation (NHF)/NHMRC postgraduate scholarship; Beatriu de Pinos fellowship (Generalitat de Catalunya)(Generalitat de Catalunya); Ministerio de Educacion y Ciencia, Spain(Spanish Government); Ministerio de Innovacion, Ciencia y Tecnologia; Cancer Institute NSW; National Breast Cancer Foundation; (FPI mobility Program) at the laboratory of TG (Sydney, Australia); ; 	This study was supported by grants to TG from the National Health and Medical Research Council of Australia (NHMRC; 510293, 510294) and the University of Sydney (2010-02681). CE is supported by BFU2009-10335, Consolider-Ingenio CSD2009-00016 from Ministerio de Innovacion, Ciencia y Tecnologia and PI040236 from Fundacio Marato TV3 (Barcelona, Spain). FT is supported by BFU2009-13526. RJD and AS would like to acknowledge funding from the NHMRC. PW is a recipient of a co-funded National Heart Foundation (NHF)/NHMRC postgraduate scholarship. CR is grateful to the Beatriu de Pinos fellowship (Generalitat de Catalunya). SV is thankful to Ministerio de Educacion y Ciencia, Spain, (FPI mobility Program) for a short-term fellowship at the laboratory of TG (Sydney, Australia). MR and AA are supported by fellowships from Ministerio de Innovacion, Ciencia y Tecnologia. AS is supported by Early Career Fellowships from the Cancer Institute NSW and the National Breast Cancer Foundation.	Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Assender JW, 2007, J CLIN PATHOL, V60, P1216, DOI 10.1136/jcp.2006.041616; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; BOWEN S, 1991, J BIOL CHEM, V266, P1162; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Collazos A, 2011, BIOCHEM J, V438, P535, DOI 10.1042/BJ20110521; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Cubells L, 2008, J BIOL CHEM, V283, P10174, DOI 10.1074/jbc.M706618200; Cubells L, 2007, TRAFFIC, V8, P1568, DOI 10.1111/j.1600-0854.2007.00640.x; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P4080, DOI 10.1073/pnas.82.12.4080; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; Dubois T, 1996, BBA-MOL CELL RES, V1313, P290, DOI 10.1016/0167-4889(96)00102-4; Enrich C, 2011, BBA-MOL CELL RES, V1813, P935, DOI 10.1016/j.bbamcr.2010.09.015; FABBRO D, 1986, CANCER RES, V46, P2720; Faux MC, 1999, BIOCHEM J, V343, P443, DOI 10.1042/0264-6021:3430443; Ferguson KM, 2008, ANNU REV BIOPHYS, V37, P353, DOI 10.1146/annurev.biophys.37.032807.125829; Frankel LB, 2007, BREAST CANCER RES TR, V104, P165, DOI 10.1007/s10549-006-9399-1; Freye-Minks C, 2003, BIOCHEMISTRY-US, V42, P620, DOI 10.1021/bi026742h; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Gold MG, 2011, P NATL ACAD SCI USA, V108, P6426, DOI 10.1073/pnas.1014400108; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; Grewal T, 2005, ONCOGENE, V24, P5809, DOI 10.1038/sj.onc.1208743; Grewal T, 2006, CURR SIGNAL TRANSD T, V1, P147, DOI 10.2174/157436206777012066; Grewal T, 2010, INT J BIOCHEM CELL B, V42, P580, DOI 10.1016/j.biocel.2009.12.020; Grewal T, 2009, CELL SIGNAL, V21, P847, DOI 10.1016/j.cellsig.2009.01.031; Groves JT, 2010, NAT STRUCT MOL BIOL, V17, P659, DOI 10.1038/nsmb.1844; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Johannsdottir HK, 2006, INT J CANCER, V119, P1052, DOI 10.1002/ijc.21934; Kheifets V, 2007, PHARMACOL RES, V55, P467, DOI 10.1016/j.phrs.2007.04.014; Kheifets V, 2006, J BIOL CHEM, V281, P23218, DOI 10.1074/jbc.M602075200; Kim J, 2011, ONCOGENE, V30, P323, DOI 10.1038/onc.2010.415; KING CS, 1986, J BIOL CHEM, V261, P73; Lanzetti L, 2008, TRAFFIC, V9, P2011, DOI 10.1111/j.1600-0854.2008.00816.x; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; Llado A, 2008, MOL BIOL CELL, V19, P17, DOI 10.1091/mbc.E07-05-0411; LUND KA, 1990, J BIOL CHEM, V265, P20517; McNulty DE, 2011, J BIOL CHEM, V286, P15010, DOI 10.1074/jbc.M111.227694; Minashima T, 2012, J BIOL CHEM, V287, P14803, DOI 10.1074/jbc.M111.297861; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Monastyrskaya K, 2009, J BIOL CHEM, V284, P17227, DOI 10.1074/jbc.M109.004457; MORRISON P, 1993, J BIOL CHEM, V268, P15536; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Pierga JY, 2007, BRIT J CANCER, V96, P341, DOI 10.1038/sj.bjc.6603483; Pines G, 2010, FEBS LETT, V584, P2699, DOI 10.1016/j.febslet.2010.04.019; Podszywalow-Bartnicka P, 2010, J CELL BIOCHEM, V111, P168, DOI 10.1002/jcb.22685; Pons M, 2001, FEBS LETT, V501, P69, DOI 10.1016/S0014-5793(01)02635-7; Prevostel C, 2000, J CELL SCI, V113, P2575; Rentero C, 2006, CELL SIGNAL, V18, P1006, DOI 10.1016/j.cellsig.2005.08.008; Reverter M, 2011, MOL BIOL CELL, V22, P4108, DOI 10.1091/mbc.E11-04-0332; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; RON D, 1994, J BIOL CHEM, V269, P21395; Sakwe AM, 2011, EXP CELL RES, V317, P823, DOI 10.1016/j.yexcr.2010.12.008; Santiskulvong C, 2007, CELL SIGNAL, V19, P1348, DOI 10.1016/j.cellsig.2007.01.006; Schmitz-Peiffer C, 1998, BIOCHEM J, V330, P675, DOI 10.1042/bj3300675; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007; Stern KA, 2007, MOL CELL BIOL, V27, P888, DOI 10.1128/MCB.02356-05; Stewart JR, 2005, MOL CANCER THER, V4, P726, DOI 10.1158/1535-7163.MCT-05-0013; Strzelecka-Kiliszek A, 2008, J CELL BIOCHEM, V104, P418, DOI 10.1002/jcb.21632; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; Timpson P, 2007, CANCER RES, V67, P9304, DOI 10.1158/0008-5472.CAN-07-0798; Tonetti DA, 2003, BRIT J CANCER, V88, P1400, DOI 10.1038/sj.bjc.6600923; de Muga SV, 2009, ONCOGENE, V28, P363, DOI 10.1038/onc.2008.386; Wang XQ, 2007, CANCER RES, V67, P9986, DOI 10.1158/0008-5472.CAN-07-1300; Warren CM, 2006, CELL SIGNAL, V18, P923, DOI 10.1016/j.cellsig.2005.12.007; Xu TR, 2004, FEBS LETT, V570, P20, DOI 10.1016/j.febslet.2004.05.080	74	48	50	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2858	2872		10.1038/onc.2012.303	http://dx.doi.org/10.1038/onc.2012.303			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22797061				2022-12-28	WOS:000320369100006
J	Ortiz-Padilla, C; Gallego-Ortega, D; Browne, BC; Hochgrafe, F; Caldon, CE; Lyons, RJ; Croucher, DR; Rickwood, D; Ormandy, CJ; Brummer, T; Daly, RJ				Ortiz-Padilla, C.; Gallego-Ortega, D.; Browne, B. C.; Hochgraefe, F.; Caldon, C. E.; Lyons, R. J.; Croucher, D. R.; Rickwood, D.; Ormandy, C. J.; Brummer, T.; Daly, R. J.			Functional characterization of cancer-associated Gab1 mutations	ONCOGENE			English	Article						signal transduction; protein phosphorylation; mammary; breast cancer	EPITHELIAL MORPHOGENESIS DOWNSTREAM; RECEPTOR TYROSINE KINASE; HUMAN BREAST-CANCER; DOCKING PROTEIN; MET RECEPTOR; SCAFFOLDING ADAPTER; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-PROLIFERATION; PHOSPHATASE SHP-2; GENE-EXPRESSION	Grb2-associated binder 1 (Gab1) is a docking protein that transduces signals from a variety of tyrosine kinases, including Met and the epidermal growth factor receptor (EGFR). Although the related protein Gab2 is strongly implicated in human cancer, a role for Gab1 has been less clear. However, a screen for gene mutations in breast cancer identified two somatic mutations in Gab1, Y83C and T387N. In this paper we describe the functional characterization of these Gab1 mutants. MCF-10A immortalized mammary epithelial cells overexpressing Gab1 Y83C and T387N exhibited a more elongated, fibroblastic phenotype compared with wild-type Gab1 controls. Expression of Gab1 or the mutants promoted epidermal growth factor (EGF)-independent proliferation in monolayer culture to a similar degree. However, in Matrigel culture, both mutants enhanced the formation of acini exhibiting an aberrant, branched morphology. In addition, expression of the mutants modestly increased Erk activation. The two mutants also enhanced branching morphogenesis in a different mammary epithelial cell line, HC11. To gain further insights into the mechanism of action of these mutations, we mapped Gab1 phosphorylation sites by mass spectrometry. This detected phosphorylation of T387 but; not Y83. Cellular stimulation with EGF or hepatocyte growth factor (HGF) led to a transient, or sustained, induction of T387 phosphorylation, respectively. As T387 corresponds in position to Gab2 T391, which suppresses Gab2 signaling in a phosphorylation-dependent manner, these data support a model in which the T387N mutation abrogates negative-feedback regulation of Gab1. Interrogation of publically-available databases revealed additional cancer-associated mutations at, or in close proximity to, identified serine/threonine phosphorylation sites in other docking proteins. These data indicate that aberrant Gab1 signaling can directly contribute to breast cancer progression, and that negative feedback sites in docking proteins can be targeted by oncogenic mutations.	[Ortiz-Padilla, C.; Gallego-Ortega, D.; Browne, B. C.; Hochgraefe, F.; Caldon, C. E.; Lyons, R. J.; Croucher, D. R.; Rickwood, D.; Ormandy, C. J.; Daly, R. J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; [Brummer, T.] Univ Freiburg, Ctr Biol Syst Anal ZBSA, D-79106 Freiburg, Germany; [Brummer, T.] Univ Freiburg, Inst Biol 3, D-79106 Freiburg, Germany; [Brummer, T.] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, D-79106 Freiburg, Germany; [Ormandy, C. J.; Daly, R. J.] Univ New S Wales, St Vincents Hosp, Sch Clin, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of Freiburg; University of Freiburg; University of Freiburg; St Vincents Hospital Sydney; University of New South Wales Sydney	Daly, RJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	r.daly@garvan.org.au	Brummer, Tilman/AAA-9428-2020; Caldon, Liz/C-1559-2009; Gallego-Ortega, David/AAK-9067-2020; Ormandy, Chris/G-4165-2014; Brummer, Tilman/B-6218-2016	Brummer, Tilman/0000-0003-4387-7905; Caldon, Liz/0000-0003-1392-3472; Gallego-Ortega, David/0000-0002-2347-7835; Brummer, Tilman/0000-0003-4387-7905; Croucher, David/0000-0003-4965-8674; Daly, Roger/0000-0002-5739-8027; Ormandy, Christopher/0000-0002-2504-7919	National Health and Medical Research Council of Australia; Cancer Institute New South Wales Early Career Fellowships; New South Wales Cancer Council; Banque Nationale de Paris-Paribas Australia; German Research Foundation (DFG) through the Emmy-Noether-Program [CRC850, EXC294]; National Breast Cancer Foundation [NC-12-24, PF-12-06] Funding Source: researchfish	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute New South Wales Early Career Fellowships; New South Wales Cancer Council(Cancer Council New South Wales); Banque Nationale de Paris-Paribas Australia; German Research Foundation (DFG) through the Emmy-Noether-Program(German Research Foundation (DFG)); National Breast Cancer Foundation	This work was supported by the National Health and Medical Research Council of Australia. CEC and DRC are recipients of Cancer Institute New South Wales Early Career Fellowships. DG-O is a National Breast Cancer Foundation and Cure Cancer Australia Fellow. CJO is supported by New South Wales Cancer Council and Banque Nationale de Paris-Paribas Australia. TB is supported by the German Research Foundation (DFG) through the Emmy-Noether-Program, CRC850 and EXC294 BIOSS.	Abella JV, 2010, J CELL SCI, V123, P1306, DOI 10.1242/jcs.062570; Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Arnaud M, 2004, J IMMUNOL, V173, P3962, DOI 10.4049/jimmunol.173.6.3962; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bocanegra M, 2010, ONCOGENE, V29, P774, DOI 10.1038/onc.2009.364; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Brummer T, 2008, EMBO J, V27, P2305, DOI 10.1038/emboj.2008.159; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chernoff KA, 2009, CLIN CANCER RES, V15, P4288, DOI 10.1158/1078-0432.CCR-09-0280; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Eulenfeld R, 2009, J CELL SCI, V122, P55, DOI 10.1242/jcs.037226; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Fleuren EDG, 2010, INT J CANCER, V127, P1486, DOI 10.1002/ijc.25172; Gual P, 2001, ONCOGENE, V20, P156, DOI 10.1038/sj.onc.1204047; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; JANES PW, 1994, ONCOGENE, V9, P3601; Juric D, 2007, J CLIN ONCOL, V25, P1341, DOI 10.1200/JCO.2006.09.3534; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Landgraf KE, 2008, BIOCHEMISTRY-US, V47, P12260, DOI 10.1021/bi801683k; Laramee M, 2007, J BIOL CHEM, V282, P7758, DOI 10.1074/jbc.M611327200; Lee SH, 2007, PATHOLOGY, V39, P326, DOI 10.1080/00313020701329773; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Mood K, 2006, MOL BIOL CELL, V17, P3717, DOI 10.1091/mbc.E06-03-0244; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; SOULE HD, 1990, CANCER RES, V50, P6075; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Xian W, 2005, J CELL BIOL, V171, P663, DOI 10.1083/jcb.200505098; Yu CF, 2001, J BIOL CHEM, V276, P32552, DOI 10.1074/jbc.M104493200; Zatkova A, 2006, GENE CHROMOSOME CANC, V45, P798, DOI 10.1002/gcc.20344	42	25	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 23	2013	32	21					2696	2702		10.1038/onc.2012.271	http://dx.doi.org/10.1038/onc.2012.271			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22751113				2022-12-28	WOS:000319806700011
J	Couts, KL; Anderson, EM; Gross, MM; Sullivan, K; Ahn, NG				Couts, K. L.; Anderson, E. M.; Gross, M. M.; Sullivan, K.; Ahn, N. G.			Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions	ONCOGENE			English	Article						B-Raf; melanoma; microRNAs; microarray; U0126	BRAF MUTATIONS; EXPRESSION; CLUSTER; CANCER; GENES; LINES; PROLIFERATION; SUPPRESSION; PROGRESSION; SIGNATURES	Over two-thirds of melanomas have activating mutations in B-Raf, leading to constitutive activation of the B-Raf/MKK/ERK signaling pathway. The most prevalent mutation, B-RafV600E, promotes cancer cell behavior through mechanisms that are still incompletely defined. Here, we used a sensitive microarray profiling platform to compare microRNA (miRNA) expression levels between primary melanocytes and B-RafV600E-positive melanoma cell lines, and between melanoma cells treated in the presence and absence of an MKK1/2 inhibitor. We identified a network of >20 miRNAs deregulated by B-Raf/MKK/ERK in melanoma cells, the majority of which modulate the expression of key cancer regulatory genes and functions. Importantly, miRNAs within the network converge on protein regulation and cancer phenotypes, suggesting that these miRNAs might function combinatorially. We show that miRNAs augment effects on protein repression and cell invasion when co-expressed, and gene-specific latency and interference effects between miRNAs were also observed. Thus, B-Raf/MKK/ERK controls key aspects of cancer cell behavior and gene expression by modulating a network of miRNAs with cross-regulatory functions. The findings highlight the potential for complex interactions between coordinately regulated miRNAs within a network. Oncogene (2013) 32, 1959-1970; doi:10.1038/onc.2012.209; published online 2 July 2012	[Couts, K. L.; Ahn, N. G.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Anderson, E. M.; Gross, M. M.; Sullivan, K.] Dharmacon Inc, Lafayette, CO USA; [Ahn, N. G.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Ahn, NG (corresponding author), Univ Colorado, Dept Chem & Biochem, HHMI, Campus Box 215, Boulder, CO 80309 USA.	natalie.ahn@colorado.edu			NIH [R01-CA118972, T32-GM008759]; NATIONAL CANCER INSTITUTE [R01CA118972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008759] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are indebted to Meenhard Herlyn for melanoma cell lines used throughout these studies, and to Judith Leopold-Sebolt for a generous gift of CI-1040. We thank SwitchGear Genomics for providing 3'UTR constructs. Finally, we thank Thermo Fisher Scientific investigators Amanda Birmingham, Annaleen Vermeulen and Barbara Robertson for many helpful discussions. This study was financially supported by NIH R01-CA118972 (NGA) and NIH T32-GM008759 (KLC).	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Argast GM, 2009, ONCOGENE, V28, P2697, DOI 10.1038/onc.2009.133; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Caramuta S, 2010, J INVEST DERMATOL, V130, P2062, DOI 10.1038/jid.2010.63; Chan E, 2011, CELL CYCLE, V10, P1845, DOI 10.4161/cc.10.11.15777; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen JM, 2010, AM J PATHOL, V176, P2520, DOI 10.2353/ajpath.2010.091061; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Edlundh-Rose E, 2006, MELANOMA RES, V16, P471, DOI 10.1097/01.cmr.0000232300.22032.86; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56; Hingorani SR, 2003, CANCER RES, V63, P5198; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Igoucheva O, 2009, BIOCHEM BIOPH RES CO, V379, P790, DOI 10.1016/j.bbrc.2008.12.152; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Koo HM, 2002, P NATL ACAD SCI USA, V99, P3052, DOI 10.1073/pnas.052707699; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mills CN, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-104; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Papadopoulos GL, 2009, NUCLEIC ACIDS RES, V37, pD155, DOI 10.1093/nar/gkn809; Paroo Z, 2009, CELL, V139, P112, DOI 10.1016/j.cell.2009.06.044; Philippidou D, 2010, CANCER RES, V70, P4163, DOI 10.1158/0008-5472.CAN-09-4512; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Saetrom P, 2007, NUCLEIC ACIDS RES, V35, P2333, DOI 10.1093/nar/gkm133; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	41	41	42	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1959	1970		10.1038/onc.2012.209	http://dx.doi.org/10.1038/onc.2012.209			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22751131	Green Published, hybrid			2022-12-28	WOS:000317599900010
J	Li, N; Zoubeidi, A; Beraldi, E; Gleave, ME				Li, N.; Zoubeidi, A.; Beraldi, E.; Gleave, M. E.			GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer	ONCOGENE			English	Article						ER stress; GRP78; clusterin; cancer; retrotranslocation; apoptosis	UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; CELL-SURVIVAL; N-GLYCANASE; INDUCED APOPTOSIS; OXIDATIVE STRESS; CHAPERONE GRP78; EXPRESSION; GENE; SUPPRESSION	Expression of clusterin (CLU) closely correlates with the regulation of apoptosis in cancer. Although endoplasmic reticulum (ER) stress-induced upregulation and retrotranslocation of cytoplasmic CLU (presecretory (psCLU) and secreted (sCLU) forms) has been linked to its anti-apoptotic properties, mechanisms mediating these processes remain undefined. Here, we show using human prostate cancer cells that GRP78 (Bip) associates with CLU under ER stress conditions to facilitate its retrotranslocation and redistribution to the mitochondria. Many ER stress inducers, including thapsigargin, MG132 or paclitaxel, increased expression levels of GRP78 and CLU, as well as post-translationally modified hypoglycosylated CLU forms. ER stress increased association between GRP78 and CLU, which led to increased cytoplasmic CLU levels, while reducing sCLU levels secreted into the culture media. GRP78 stabilized CLU protein and its hypoglycosylated forms, in particular after paclitaxel treatment. Moreover, subcellular fractionation and confocal microscopy with CLUGFP indicated that GRP78 increased stress-induced CLU retrotranslocation from the ER with co-localized redistribution to the mitochondria, thereby reducing stress-induced apoptosis by cooperatively stabilizing mitochondrial membrane integrity. GRP78 silencing reduced CLU protein, but not mRNA levels, and enhanced paclitaxel-induced cell apoptosis. Taken together, these findings reveal novel dynamic interactions between GRP78 and CLU under ER stress conditions that govern CLU trafficking and redistribution to the mitochondria, elucidating how GRP78 and CLU cooperatively promote survival during treatment stress in prostate cancer. Oncogene (2013) 32, 1933-1942; doi:10.1038/onc.2012.212; published online 11 June 2012	[Li, N.; Zoubeidi, A.; Beraldi, E.; Gleave, M. E.] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC V5Z 3J5, Canada	University of British Columbia	Gleave, ME (corresponding author), Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, 2660 Oak St, Vancouver, BC V5Z 3J5, Canada.	m.gleave@ubc.ca		Gleave, Martin/0000-0003-4235-0167				Afshar N, 2005, MOL CELL BIOL, V25, P8844, DOI 10.1128/MCB.25.20.8844-8853.2005; Ammar H, 2008, J BIOL CHEM, V283, P12851, DOI 10.1074/jbc.M800403200; Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; Carver JA, 2003, IUBMB LIFE, V55, P661, DOI 10.1080/15216540310001640498; Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426; de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534; Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200; Gleave M, 2005, WORLD J UROL, V23, P38, DOI 10.1007/s00345-004-0474-0; Graves TK, 2001, J CELL SCI, V114, P3685; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Hayashi T, 2009, TRENDS CELL BIOL, V19, P81, DOI 10.1016/j.tcb.2008.12.002; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Kapron JT, 1997, PROTEIN SCI, V6, P2120; Katiyar S, 2005, MOL BIOL CELL, V16, P4584, DOI 10.1091/mbc.E05-04-0345; Kim N, 2012, J CELL PHYSIOL, V227, P1157, DOI 10.1002/jcp.22836; Lamoureux F, 2011, CANCER RES, V71, P5838, DOI 10.1158/0008-5472.CAN-11-0994; Lee DH, 2011, BIOCHEM BIOPH RES CO, V408, P541, DOI 10.1016/j.bbrc.2011.04.054; Leung SYL, 2000, PROSTATE, V44, P156, DOI 10.1002/1097-0045(20000701)44:2<156::AID-PROS8>3.0.CO;2-8; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Miyake H, 2000, CANCER RES, V60, P2547; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Nizard P, 2007, TRAFFIC, V8, P554, DOI 10.1111/j.1600-0854.2007.00549.x; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Shental-Bechor D, 2009, CURR OPIN STRUC BIOL, V19, P524, DOI 10.1016/j.sbi.2009.07.002; Shiota M, 2011, MOL CANCER RES, V9, P1755, DOI 10.1158/1541-7786.MCR-11-0379; Shu CV, 2008, J CELL PHYSIOL, V215, P627, DOI 10.1002/jcp.21340; Stanley P., 2009, ESSENTIALS GLYCOBIOL, V1; Sun FC, 2006, BIOCHEM J, V396, P31, DOI 10.1042/BJ20051916; Suzuki T, 2007, ARCH BIOCHEM BIOPHYS, V468, P1, DOI 10.1016/j.abb.2007.09.004; Trougakos IP, 2009, ADV CANCER RES, V104, P171, DOI 10.1016/S0065-230X(09)04009-3; Trougakos IP, 2009, CLIN CANCER RES, V15, P48, DOI 10.1158/1078-0432.CCR-08-1805; Trougakos IP, 2009, CANCER RES, V69, P403, DOI 10.1158/0008-5472.CAN-08-2912; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; Tsutsumi S, 2006, ONCOGENE, V25, P1018, DOI 10.1038/sj.onc.1209139; Wacker I, 1997, J CELL SCI, V110, P1453; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yerbury JJ, 2005, BIOCHEMISTRY-US, V44, P10914, DOI 10.1021/bi050764x; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291; Zoubeidi A, 2010, CLIN CANCER RES, V16, P1088, DOI 10.1158/1078-0432.CCR-09-2917; Zoubeidi A, 2010, MOL CANCER RES, V8, P119, DOI 10.1158/1541-7786.MCR-09-0277	49	75	77	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 11	2013	32	15					1933	1942		10.1038/onc.2012.212	http://dx.doi.org/10.1038/onc.2012.212			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22689054				2022-12-28	WOS:000317599900007
J	Sher, YP; Chang, CM; Juo, CG; Chen, CT; Hsu, JL; Lin, CY; Han, Z; Shiah, SG; Hung, MC				Sher, Y-P; Chang, C-M; Juo, C-G; Chen, C-T; Hsu, J. L.; Lin, C-Y; Han, Z.; Shiah, S-G; Hung, M-C			Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth	ONCOGENE			English	Article						ovarian cancer; anti-angiogenesis; VISA; gene therapy	EXPRESSION; CANCER; SURVIVIN; DELIVERY; CELLS; YEAST; 5-FLUOROURACIL; ANGIOGENESIS; CHEMOTHERAPY; CISPLATIN	There are currently no effective therapies for cancer patients with advanced ovarian cancer, therefore developing an efficient and safe strategy is urgent. To ensure cancer-specific targeting, efficient delivery, and efficacy, we developed an ovarian cancer-specific construct (Survivin-VISA-hEndoyCD) composed of the cancer specific promoter survivin in a transgene amplification vector (VISA; VP16-GAL4-WPRE integrated systemic amplifier) to express a secreted human endostatin-yeast cytosine deaminase fusion protein (hEndoyCD) for advanced ovarian cancer treatment. hEndoyCD contains an endostatin domain that has tumor-targeting ability for anti-angiogenesis and a cytosine deaminase domain that converts the prodrug 5-fluorocytosine (5-FC) into the chemotherapeutic drug, 5-fluorouracil. Survivin-VISA-hEndoyCD was found to be highly specific, selectively express secreted hEndoyCD from ovarian cancer cells, and induce cancer-cell killing in vitro and in vivo in the presence of 5-FC without affecting normal cells. In addition, Survivin-VISA-hEndoyCD plus 5-FC showed strong synergistic effects in combination with cisplatin in ovarian cancer cell lines. Intraperitoneal (i.p.) treatment with Survivin-VISA-hEndoyCD coupled with liposome attenuated tumor growth and prolonged survival in mice bearing advanced ovarian tumors. Importantly, there was virtually no severe toxicity when hEndoyCD is expressed by Survivin-VISA plus 5-FC compared with CMV plus 5-FC. Thus, the current study demonstrates an effective cancer-targeted gene therapy that is worthy of development in clinical trials for treating advanced ovarian cancer. Oncogene (2013) 32, 1082-1090; doi:10.1038/onc.2012.134; published online 7 May 2012	[Sher, Y-P; Chang, C-M; Hung, M-C] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Lin, C-Y] China Med Univ Hosp, Div Hematol & Oncol, Taichung, Taiwan; [Sher, Y-P; Lin, C-Y] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Hung, M-C] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Juo, C-G] Chang Gung Univ, Mol Med Res Ctr, Tao Yuan, Taiwan; [Shiah, S-G] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Chen, C-T; Hsu, J. L.; Han, Z.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hsu, J. L.; Hung, M-C] Asia Univ, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; Chang Gung University; National Health Research Institutes - Taiwan; University of Texas System; UTMD Anderson Cancer Center; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Shiah, Shine-Gwo/D-2087-2010	Hung, Mien-Chie/0000-0003-4317-4740; 	National Science Council [NSC100-3112-B-039-003]; Private University [N5C99-2314-B-039-029-MY3, NSC99-2632-B]; Department of Health Cancer Research Center of Excellence [DOH99-TD-C-111-005]; Sister Institution Fund of China Medical University and Hospital; University of Texas MD Anderson Cancer Center	National Science Council(Ministry of Science and Technology, Taiwan); Private University; Department of Health Cancer Research Center of Excellence; Sister Institution Fund of China Medical University and Hospital; University of Texas MD Anderson Cancer Center	This work was supported by grants from National Science Council (NSC100-3112-B-039-003), Private University (N5C99-2314-B-039-029-MY3 to Y-PS and NSC99-2632-B to M-CH), Department of Health Cancer Research Center of Excellence (DOH99-TD-C-111-005), and The Sister Institution Fund of China Medical University and Hospital and The University of Texas MD Anderson Cancer Center.	Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chen CT, 2011, MOL CANCER THER, V10, P1327, DOI 10.1158/1535-7163.MCT-10-1117; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dixelius J, 2002, CANCER RES, V62, P1944; Erbs P, 2000, CANCER RES, V60, P3813; Glover CPJ, 2002, MOL THER, V5, P509, DOI 10.1006/mthe.2002.0588; Gunther Michael, 2005, Curr Med Chem Anticancer Agents, V5, P157, DOI 10.2174/1568011053174855; Hydzik Catherine, 2009, Oncology (Williston Park), V23, P15; Iyer M, 2001, P NATL ACAD SCI USA, V98, P14595, DOI 10.1073/pnas.251551098; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kievit E, 1999, CANCER RES, V59, P1417; Kim YM, 2000, CANCER RES, V60, P5410; KISH JA, 1988, AM J CLIN ONCOL-CANC, V11, P553, DOI 10.1097/00000421-198810000-00009; Lang JY, 2011, CANCER CELL, V20, P341, DOI 10.1016/j.ccr.2011.07.017; Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634; Markman M, 2009, CANCER J, V15, P105, DOI 10.1097/PPO.0b013e31819e31f2; Miller DS, 2009, J CLIN ONCOL, V27, P2686, DOI 10.1200/JCO.2008.19.2963; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; OLSON TA, 1994, CANCER RES, V54, P276; Ou-Yang F, 2006, CANCER RES, V66, P378, DOI 10.1158/0008-5472.CAN-05-1578; Parsons SL, 1996, EUR J SURG ONCOL, V22, P237, DOI 10.1016/S0748-7983(96)80009-6; Pisano R, 2005, J PHARMACEUT BIOMED, V38, P738, DOI 10.1016/j.jpba.2005.01.039; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Sher YP, 2009, ONCOGENE, V28, P3286, DOI 10.1038/onc.2009.187; Sim BKL, 2000, CANCER METAST REV, V19, P181, DOI 10.1023/A:1026551202548; Subramanian IV, 2006, CANCER RES, V66, P4319, DOI 10.1158/0008-5472.CAN-05-3297; Sui L, 2002, INT J ONCOL, V21, P315; Tanaka T, 2001, ANTICANCER RES, V21, P2463; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Xie XM, 2009, MOL CANCER THER, V8, P2375, DOI 10.1158/1535-7163.MCT-09-0056; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; YU DH, 1993, CANCER RES, V53, P891; Zaffaroni N, 2005, J CELL MOL MED, V9, P360, DOI 10.1111/j.1582-4934.2005.tb00361.x; Zhang LQ, 2003, CANCER RES, V63, P4552; Zhang M, 2003, CANCER RES, V63, P658; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	40	19	20	0	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1082	1090		10.1038/onc.2012.134	http://dx.doi.org/10.1038/onc.2012.134			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22562248				2022-12-28	WOS:000316428800002
J	Yang, H; Liu, Y; Bai, F; Zhang, JY; Ma, SH; Liu, J; Xu, ZD; Zhu, HG; Ling, ZQ; Ye, D; Guan, KL; Xiong, Y				Yang, H.; Liu, Y.; Bai, F.; Zhang, J-Y; Ma, S-H; Liu, J.; Xu, Z-D; Zhu, H-G; Ling, Z-Q; Ye, D.; Guan, K-L; Xiong, Y.			Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation	ONCOGENE			English	Article						TET; 5-hydroxymethylation; DNA methylation; cancer biomarker	MAFFUCCI SYNDROME; IDH2 MUTATIONS; OLLIER DISEASE; MAMMALIAN DNA; 5-HYDROXYMETHYLCYTOSINE; 5-CARBOXYLCYTOSINE; CONVERSION; PROTEINS; CANCERS	The TET (ten eleven translocation) family of alpha-ketoglutarate (alpha-KG)-dependent dioxygenases catalyzes the sequential oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formyleytosine and 5-carboxylcytosine, leading to eventual DNA demethylation. The TET2 gene is a bona fide tumor suppressor frequently mutated in leukemia, and TET enzyme activity is inhibited in IDH1/2-mutated tumors by the oncometabolite 2-hydroxyglutarate, an antagonist of alpha-KG, linking 5mC oxidation to cancer development. We report here that the levels of 5hmC are dramatically reduced in human breast, liver, lung, pancreatic and prostate cancers when compared with the matched surrounding normal tissues. Associated with the 5hmC decrease is the substantial reduction of the expression of all three TET genes, revealing a possible mechanism for the reduced 5hmC in cancer cells. The decrease of 5hmC was also observed during tumor development in different genetically engineered mouse models. Together, our results identify 5hmC as a biomarker whose decrease is broadly and tightly associated with tumor development. Oncogene (2013) 32, 663-669; doi:10.1038/onc.2012.67;published online 5 March 2012	[Yang, H.; Zhang, J-Y; Ma, S-H; Ye, D.; Guan, K-L; Xiong, Y.] Fudan Univ, Mol & Cell Biol Lab, Inst Biomed Sci, Shanghai 200433, Peoples R China; [Yang, H.; Ma, S-H; Xiong, Y.] Fudan Univ, Coll Life Sci, Shanghai 200433, Peoples R China; [Liu, Y.; Liu, J.; Xu, Z-D; Zhu, H-G] Fudan Univ, Dept Pathol, Shanghai 200433, Peoples R China; [Liu, Y.; Liu, J.; Xu, Z-D; Zhu, H-G; Guan, K-L] Fudan Univ, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Bai, F.; Xiong, Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [Ling, Z-Q] Zhejiang Prov Canc Hosp, Zhejiang Canc Res Inst, Zhejiang Canc, Hangzhou, Zhejiang, Peoples R China; [Guan, K-L] Univ Calif San Diego, Dept Pharmacol, Moores Canc Ctr, La Jolla, CA 92093 USA	Fudan University; Fudan University; Fudan University; Fudan University; University of North Carolina; University of North Carolina Chapel Hill; Zhejiang Cancer Hospital; University of California System; University of California San Diego	Ye, D (corresponding author), Fudan Univ, Mol & Cell Biol Lab, Inst Biomed Sci, Shanghai 200433, Peoples R China.	yedan@fudan.edu.cn; kuguan@ucsd.edu; yxiong@email.unc.edu	Guan, Kun-Liang/ADK-7088-2022; Yang, Hui/AAM-4564-2021; Yang, Hui/ABG-0952-2022	Yang, Hui/0000-0002-2865-5311	MOST [2009CB918401, 2011CB910600]; NSFC [30600112, 30871255, 31071192]; 985 Program; Shanghai key project [09JC1402300]; Shanghai Leading Academic Discipline Project [B110]; NIH; NATIONAL CANCER INSTITUTE [P30CA016086, R01CA163834] Funding Source: NIH RePORTER	MOST; NSFC(National Natural Science Foundation of China (NSFC)); 985 Program; Shanghai key project; Shanghai Leading Academic Discipline Project(Shanghai Leading Academic Discipline Project); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Fudan MCB laboratory for discussions and support throughout this study, and Eric Oermann for reading the manuscript. This work was supported by MOST 973 (No. 2009CB918401, No. 2011CB910600), NSFC (Grant No. 30600112, 30871255, 31071192). This work was also supported by the 985 Program, Shanghai key project (Grant No. 09JC1402300), the Shanghai Leading Academic Discipline Project (project number B110), and NIH grants (to YX and KLG).	Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Haffner MC, 2011, ONCOTARGET, V2, P627; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hemerly JP, 2010, EUR J ENDOCRINOL, V163, P747, DOI 10.1530/EJE-10-0473; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Langemeijer SMC, 2009, NAT GENET, V41, P838, DOI 10.1038/ng.391; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Mullighan CG, 2009, NAT GENET, V41, P766, DOI 10.1038/ng0709-766; Murugan AK, 2010, BIOCHEM BIOPH RES CO, V393, P555, DOI 10.1016/j.bbrc.2010.02.095; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	22	422	437	2	138	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2013	32	5					663	669		10.1038/onc.2012.67	http://dx.doi.org/10.1038/onc.2012.67			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22391558	Green Published, Green Accepted			2022-12-28	WOS:000316164700013
J	Shi, Y; Frost, P; Hoang, B; Yang, Y; Fukunaga, R; Gera, J; Lichtenstein, A				Shi, Y.; Frost, P.; Hoang, B.; Yang, Y.; Fukunaga, R.; Gera, J.; Lichtenstein, A.			MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; rapamycin; mTOR inhibitors; c-myc; IRES activity; MNK kinases	INTERNAL RIBOSOME ENTRY; INITIATION-FACTOR 4E; MAMMALIAN TARGET; CYCLIN D1; ENHANCED SENSITIVITY; PROTEIN-SYNTHESIS; BINDING-PROTEIN; SITE FUNCTION; AKT ACTIVITY; N-TERMINI	When mTOR inhibitor rapalogs prevent cap-dependent translation of cell-cycle proteins like c-myc, continuing tumor cell growth depends on cap-independent translation, which is mediated by internal ribosome entry sites (IRESes) located in the 5'-UTR (untranslated region) of transcripts. To investigate if rapalog-induced activation of MNK kinases had a role in such IRES activity, we studied multiple myeloma (MM) cells. Rapamycin (RAP)-activated MNK1 kinase activity in MM cell lines and primary specimens by a mitogen-activated protein kinase-dependent mechanism. Pharmacological inhibition of MNK activity or genetic silencing of MNK1 prevented a rapalog-induced upregulation of c-myc IRES activity. Although RAP, used alone, had little effect on myc protein expression, when combined with a MNK inhibitor, myc protein expression was abrogated. In contrast, there was no inhibition of myc RNA, consistent with an effect on myc translation. In a RAP-resistant MM cell lines as well as a resistant primary MM specimen, co-exposure to a MNK inhibitor or MNK1 knockdown significantly sensitized cells for RAP-induced cytoreduction. Studies in MNK-null murine embryonic fibroblasts additionally supported a role for MNK kinases in RAP-induced myc IRES stimulation. These results indicate that MNK kinase activity has a critical role in the fail-safe mechanism of IRES-dependent translation when mTOR is inhibited. As kinase activity also regulated sensitivity to RAP, the data also provide a rationale for therapeutically targeting MNK kinases for combined treatment with mTOR inhibitors. Oncogene (2013) 32, 190-197; doi:10.1038/onc.2012.43; published online 27 February 2012	[Shi, Y.; Frost, P.; Hoang, B.; Yang, Y.; Fukunaga, R.; Gera, J.; Lichtenstein, A.] Univ Calif Los Angeles, Med Ctr, Dept Med, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA 90024 USA; [Shi, Y.; Frost, P.; Hoang, B.; Yang, Y.; Fukunaga, R.; Gera, J.; Lichtenstein, A.] Univ Calif Los Angeles, Med Ctr, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Shi, Y.; Frost, P.; Hoang, B.; Yang, Y.; Fukunaga, R.; Gera, J.; Lichtenstein, A.] Osaka Univ Pharmaceut Sci, Dept Biochem, Biochem Lab, Takatsuki, Osaka, Japan	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Osaka University of Pharmaceutical Sciences	Lichtenstein, A (corresponding author), W LA VA Hosp, W111H,11301 Wilshire Blvd,Bldg 500,Rm 4237, Los Angeles, CA 90073 USA.	alan.lichtenstein@med.va.gov	Fukunaga, Rikiro/CAG-2891-2022	Gera, Joseph/0000-0002-2908-6894; Frost, Patrick/0000-0003-3348-5983	Veteran's Administration; Multiple Myeloma Research Foundation; Department of Defense; NIH [RO1 CA109312, RO1 CA111448]; Grants-in-Aid for Scientific Research [24590105] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [R01CA109312, R01CA111448, R01CA168700, R01CA132778] Funding Source: NIH RePORTER	Veteran's Administration(US Department of Veterans Affairs); Multiple Myeloma Research Foundation; Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the UCLA Jonsson Comprehensive Cancer Center vector core lab for assistance in generating the lentiviral shRNA vectors. This work was supported by research funds of the Veteran's Administration, the Multiple Myeloma Research Foundation and the Department of Defense and NIH Grants RO1 CA109312 and RO1 CA111448.	Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Chrestensen CA, 2007, J BIOL CHEM, V282, P4243, DOI 10.1074/jbc.M607368200; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Farag SS, 2009, LEUKEMIA RES, V33, P1475, DOI 10.1016/j.leukres.2009.01.039; Frost P, 2004, BLOOD, V104, P4181, DOI 10.1182/blood-2004-03-1153; Frost P, 2009, MOL CANCER THER, V8, P83, DOI 10.1158/1535-7163.MCT-08-0254; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Ogata A, 1997, J IMMUNOL, V159, P2212; Paquette RL, 1990, ONCOGENE, V5, P1569; Parra JL, 2005, J BIOL CHEM, V280, P37623, DOI 10.1074/jbc.M508356200; Parra-Palau JL, 2003, J BIOL CHEM, V278, P44197, DOI 10.1074/jbc.M302398200; Paulin FEM, 1996, ONCOGENE, V13, P505; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Ross G, 2006, J NEUROCHEM, V97, P79, DOI 10.1111/j.1471-4159.2006.03704.x; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Shi YJ, 2002, CANCER RES, V62, P5027; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wang XR, 2007, MOL CELL BIOL, V27, P7405, DOI 10.1128/MCB.00760-07; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Zhu Y, 2002, NEUROSCIENCE, V110, P191, DOI 10.1016/S0306-4522(01)00522-X	32	19	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					190	197		10.1038/onc.2012.43	http://dx.doi.org/10.1038/onc.2012.43			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22370634	Green Accepted			2022-12-28	WOS:000314075500007
J	Ferguson, J; Arozarena, I; Ehrhardt, M; Wellbrock, C				Ferguson, J.; Arozarena, I.; Ehrhardt, M.; Wellbrock, C.			Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion	ONCOGENE			English	Article						melanoma; MEK; SRC; MMP-2; invasion; combination therapy	MMP-2 EXPRESSION; FACTOR RECEPTOR; KINASE; MIGRATION; ACTIVATION; DASATINIB; ADHESION; PROTEIN; RESISTANCE; INTEGRIN	The RAS-RAF-MEK-ERK pathway is deregulated in over 90% of malignant melanomas, and targeting MEK as a central kinase of this pathway is currently tested in clinical trials. However, dose-limiting side effects are observed, and MEK inhibitors that sufficiently reduce ERK activation in patients show a low clinical response. Apart from dose limitations, a reason for the low response to MEK targeting drugs is thought to be the upregulation of counteracting signalling cascades as a direct response to MEK inhibition. Therefore, understanding the biology of melanoma cells and the effects of MEK inhibition on these cells will help to identify new combinatorial approaches that are more potent and allow for lower concentrations of the drug being used. We have discovered that in melanoma cells MEK inhibition by selumetinib (AZD6244, ARRY-142886) or PD184352, while efficiently suppressing proliferation, stimulates increased invasiveness. Inhibition of MEK suppresses actin-cortex contraction and increases integrin-mediated adhesion. Most importantly, and surprisingly, MEK inhibition results in a significant increase in matrix metalloproteases (MMP)-2 and membrane-type 1-MMP expression. All together, MEK inhibition in melanoma cells induces a 'mesenchymal' phenotype that is characterised by protease-driven invasion. This mode of invasion is dependent on integrin-mediated adhesion, and because SRC kinases are the main regulators of this process, the SRC kinase inhibitor, saracatinib (AZD0530), completely abolished the MEK inhibitor-induced invasion. Moreover, the combination of saracatinib and selumetinib effectively suppressed the growth and invasion of melanoma cells in a 3D environment, suggesting that combined inhibition of MEK and SRC is a promising approach to improve the efficacy of targeting the ERK/MAP kinase pathway in melanoma. Oncogene (2013) 32, 86-96; doi:10.1038/onc.2012.25; published online 6 February 2012	[Ferguson, J.; Arozarena, I.; Ehrhardt, M.; Wellbrock, C.] Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Wellbrock, C (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	Claudia.Wellbrock@manchester.ac.uk	Arozarena, Imanol/A-5981-2017	Arozarena, Imanol/0000-0001-6349-2442; Wellbrock, Claudia/0000-0002-3825-6381	Cancer Research UK [C11591/A10202]	Cancer Research UK(Cancer Research UK)	We thank Astra Zeneca (Macclesfield) for providing us with selumetinib and saracatinib, John Humphries (Manchester) for providing help, advice and the reagents (MB13) for the integrin analyses, Chistoph Ballestrem (Manchester) for the vinculin antibody and Stephen Taylor (Manchester) for support with microscopy. This work was funded by Cancer Research UK (grant no C11591/A10202).	AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bass MD, 2008, J CELL BIOL, V181, P1013, DOI 10.1083/jcb.200711129; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Buettner R, 2008, MOL CANCER RES, V6, P1766, DOI 10.1158/1541-7786.MCR-08-0169; Carragher NO, 2006, ONCOGENE, V25, P5726, DOI 10.1038/sj.onc.1209582; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Dong MY, 2010, ANTICANCER RES, V30, P4405; Dummer R, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.9033; Eustace AJ, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-53; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Fornier MN, 2011, ANN ONCOL, V22, P2575, DOI 10.1093/annonc/mdr018; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Friedl P, 1998, MICROSC RES TECHNIQ, V43, P369, DOI 10.1002/(SICI)1097-0029(19981201)43:5<369::AID-JEMT3>3.0.CO;2-6; Geissinger E, 2002, CANCER RES, V62, P4820; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Green TP, 2009, MOL ONCOL, V3, P248, DOI 10.1016/j.molonc.2009.01.002; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Homsi J, 2009, MELANOMA RES, V19, P167, DOI 10.1097/CMR.0b013e328304974c; Huang JH, 2003, J BIOL CHEM, V278, P48367, DOI 10.1074/jbc.M308213200; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Itoh Y, 2006, IUBMB LIFE, V58, P589, DOI 10.1080/15216540600962818; Johnson ML, 2011, J THORAC ONCOL, V6, P1128, DOI 10.1097/JTO.0b013e3182161508; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kluger HM, 2011, CANCER-AM CANCER SOC, V117, P2202, DOI 10.1002/cncr.25766; Lee JH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-116; Lee SH, 2010, ONCOGENE, V29, P5182, DOI 10.1038/onc.2010.251; Meierjohann S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-201; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Pullikuth AK, 2010, MOL CELL BIOL, V30, P3233, DOI 10.1128/MCB.01178-09; Puzanov I, 2011, MOL ONCOL, V5, P116, DOI 10.1016/j.molonc.2011.01.005; Renouf DJ, 2010, INVEST NEW DRUGS; Sabeh F, 2009, J CELL BIOL, V185, P11, DOI 10.1083/jcb.200807195; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Tower GB, 2002, BBA-MOL BASIS DIS, V1586, P265, DOI 10.1016/S0925-4439(01)00105-3; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Wellbrock C, 2000, EUR J BIOCHEM, V267, P3513, DOI 10.1046/j.1432-1327.2000.01378.x; Wellbrock C, 2010, BIOCHEM PHARMACOL, V80, P561, DOI 10.1016/j.bcp.2010.03.019; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yang JY, 2010, CANCER RES, V70, P4709, DOI 10.1158/0008-5472.CAN-09-4524; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zheng YH, 2009, MOL CELL, V35, P11, DOI 10.1016/j.molcel.2009.06.013	52	51	53	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					86	96		10.1038/onc.2012.25	http://dx.doi.org/10.1038/onc.2012.25			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22310287	Green Accepted, Bronze			2022-12-28	WOS:000313029500009
J	Freije, A; Ceballos, L; Coisy, M; Barnes, L; Rosa, M; De Diego, E; Blanchard, JM; Gandarillas, A				Freije, A.; Ceballos, L.; Coisy, M.; Barnes, L.; Rosa, M.; De Diego, E.; Blanchard, J. M.; Gandarillas, A.			Cyclin E drives human keratinocyte growth into differentiation	ONCOGENE			English	Article						skin; stem cells; DNA damage; MYCER; cell size; endoreplication	DEPENDENT KINASE INHIBITOR; EPIDERMAL STEM-CELLS; XENOPUS EGG EXTRACTS; C-MYC; DNA-DAMAGE; TERMINAL DIFFERENTIATION; INVOLUCRIN SYNTHESIS; CHEMICAL INHIBITORS; CANCER DEVELOPMENT; G2/M TRANSITION	Human epidermis is continuously exposed to environmental mutagenic hazard and is the most frequent target of human cancer. How the epidermis coordinates proliferation with differentiation to maintain homeostasis, even in hyperproliferative conditions, is unclear. For instance, overactivation of the proto-oncogene MYC in keratinocytes stimulates differentiation. Here we explore the cell cycle regulation as proliferating human keratinocytes commit to terminal differentiation upon loss of anchorage or overactivation of MYC. The S-phase of the cell cycle is deregulated as mitotic regulators are inhibited in the onset of differentiation. Experimental inhibition of mitotic kinase cdk1 or kinases of the mitosis spindle checkpoint Aurora B or Polo-like Kinase, triggered keratinocyte terminal differentiation. Furthermore, hyperactivation of the cell cycle by overexpressing the DNA replication regulator Cyclin E induced mitosis failure and differentiation. Inhibition of Cyclin E by shRNAs attenuated the induction of differentiation by MYC. In addition, we present evidence that Cyclin E induces DNA damage and the p53 pathway. The results provide novel clues for the mechanisms committing proliferative keratinocytes to differentiate, with implications for tissue homeostasis maintenance, HPV amplification and tumorigenesis. Oncogene (2012) 31, 5180--5192; doi:10.1038/onc.2012.22; published online 20 February 2012	[Freije, A.; Ceballos, L.; Rosa, M.; Gandarillas, A.] Fdn Marques de Valdecilla IFIMAV FMDV, Res & Training Inst, Cell Cycle Stem Cell Fate & Canc Lab, Santander 39011, Spain; [Freije, A.; Ceballos, L.; Rosa, M.; Gandarillas, A.] Univ Cantabria, Dept Mol Biol, E-39005 Santander, Spain; [Coisy, M.; Barnes, L.; Blanchard, J. M.; Gandarillas, A.] Inst Genet Mol Montpellier CNRS UMPII, Montpellier, France; [De Diego, E.] HUMV, Serv Cirugia Pediat, Santander, Spain; [Gandarillas, A.] Inst Univ Rech Clin, Inserm ADR Languedoc Roussillon, Lab Dermatol Mol, UPRES EA 3754, Montpellier, France	Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; Centre National de la Recherche Scientifique (CNRS); Hospital Universitario Marques de Valdecilla (HUMV); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Gandarillas, A (corresponding author), Fdn Marques de Valdecilla IFIMAV FMDV, Res & Training Inst, Cell Cycle Stem Cell Fate & Canc Lab, Av Herrera Oria S-N, Santander 39011, Spain.	ifimav.agandarillas@fmdv.org	Rosa-Garrido, Manuel/AAE-4188-2019	Rosa-Garrido, Manuel/0000-0002-2169-3972	ARC (France); INSERM (Spain); ISCIII (Spain); ISCIII; FMDV-IFIMAV; La Ligue contre le cancer (France); Instituto de Salud Carlos III (ISCIII-Programa Regiones Emergentes); Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias; Spain) [PI080890]	ARC (France); INSERM (Spain); ISCIII (Spain)(Instituto de Salud Carlos III); ISCIII(Instituto de Salud Carlos III); FMDV-IFIMAV; La Ligue contre le cancer (France); Instituto de Salud Carlos III (ISCIII-Programa Regiones Emergentes); Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias; Spain)(Instituto de Salud Carlos III)	We are especially grateful to Jean-Claude Rossi and Javier Leon for their strong support. We thank Bruno Amati, Pierre Roux and Jonathon Pines for providing DNA constructs, J. Leon for reagents, Anne Blangy, Vjeko Dulic, Veronique Baldin and Thierry Lorca for technical advice, Daniel Fisher for helpful suggestions, Kathy Brooks and Maria Aramburu for technical support at flow cytometry, J. Leon and Philippe Pasero for critical reading of the manuscript, and Anna Solinis and Diana Solinis for reviewing the English writing. Human skin biopsies were provided with consent by St Jean and Hopital La Peronye (Montpellier, France) and by the Chirurgical Paediatric Service of Hospital Marques de Valdecilla (EdD; HMDV, Santander, Spain). MC was a recipient of a predoctoral fellowship from ARC (France). AG belongs to the INSERM (France) and the FMDV-IFIMAV (Spain) and was financially supported by the INSERM and the ISCIII (Spain). AF and LC were employed by FMDV-IFIMAV and supported by the ISCIII, MR was recipient of a postdoctoral contract by the FMDV-IFIMAV. This work was funded by ARC (AG; France), La Ligue contre le cancer (JMB; France), and Instituto de Salud Carlos III (AG; ISCIII-Programa Regiones Emergentes and Fondo de Investigaciones Sanitarias PI080890; Spain).	ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Beer S, 2004, PLOS BIOL, V2, P1785, DOI 10.1371/journal.pbio.0020332; Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; Coudreuse D, 2010, NATURE, V468, P1074, DOI 10.1038/nature09543; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908; Gadea BB, 2005, MOL BIOL CELL, V16, P1305, DOI 10.1091/mbc.E04-10-0891; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; Gandarillas A, 2000, ONCOGENE, V19, P3278, DOI 10.1038/sj.onc.1203630; Garcia P, 2000, ONCOGENE, V19, P1820, DOI 10.1038/sj.onc.1203494; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser P, 2004, MOL CANCER RES, V2, P96; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Iglesias-Ara A, 2010, ONCOGENE, V29, P5579, DOI 10.1038/onc.2010.296; Itahana Koji, 2007, Methods Mol Biol, V371, P21; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kleinberger-Doron N, 1998, EXP CELL RES, V241, P340, DOI 10.1006/excr.1998.4061; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Krasinska L, 2008, CELL CYCLE, V7, P1702, DOI 10.4161/cc.7.12.6101; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Lilly MA, 2005, ONCOGENE, V24, P2765, DOI 10.1038/sj.onc.1208610; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; Munoz-Alonso MJ, 2012, J CELL PHYSIOL, V227, P2069, DOI 10.1002/jcp.22935; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Noya F, 2001, J VIROL, V75, P6121, DOI 10.1128/JVI.75.13.6121-6134.2001; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Perez de Castro I, 2008, CURR OPIN PHARMACOL, V8, P375, DOI 10.1016/j.coph.2008.06.013; Planchais S, 1997, PLANT J, V12, P191, DOI 10.1046/j.1365-313X.1997.12010191.x; Planchais S, 2000, FEBS LETT, V476, P78, DOI 10.1016/S0014-5793(00)01675-6; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Rosania GR, 1999, P NATL ACAD SCI USA, V96, P4797, DOI 10.1073/pnas.96.9.4797; Schellmann S, 2005, INT J DEV BIOL, V49, P579, DOI 10.1387/ijdb.051983ss; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Simpson CL, 2010, METHODS MOL BIOL, V585, P127, DOI 10.1007/978-1-60761-380-0_10; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; Swift LP, 2006, CANCER RES, V66, P4863, DOI 10.1158/0008-5472.CAN-05-3410; Taylor S, 2008, CURR OPIN CELL BIOL, V20, P77, DOI 10.1016/j.ceb.2007.11.008; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Ullah Z, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-10; Watt FM, 2008, NAT REV CANCER, V8, P234, DOI 10.1038/nrc2328; Watt FM, 2006, CURR OPIN GENET DEV, V16, P518, DOI 10.1016/j.gde.2006.08.006; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; Whittaker SR, 2007, CELL CYCLE, V6, P3114, DOI 10.4161/cc.6.24.5142; Yin XY, 2001, CANCER RES, V61, P6487; Zanet J, 2005, J CELL SCI, V118, P1693, DOI 10.1242/jcs.02298; Zanet J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015701	65	32	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5180	5192		10.1038/onc.2012.22	http://dx.doi.org/10.1038/onc.2012.22			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22349815				2022-12-28	WOS:000312449800007
J	Zhao, J; Ramos, R; Demma, M				Zhao, J.; Ramos, R.; Demma, M.			CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation	ONCOGENE			English	Article						CDK8; E2F1; tumor suppressor; phosphorylation; transcriptional regulation	POSITIVE REGULATOR; COLORECTAL-CANCER; CELL-CYCLE; BETA; MEDIATOR; SUPPRESSES; PROTEIN; KINASE; WNT; PRB	Activation of the Wnt/beta-catenin pathway is a critical step in the development of colorectal cancers. A key mediator of this activation is the recently described oncogene CDK8, which is amplified in a large number of colorectal tumors. CDK8 affects beta-catenin activation by interaction of the CDK8 submodule of the mediator complex with beta-catenin/TCF transcriptional complex, and by CDK8 interacting with and phosphorylating E2F1, which acts as a repressor of beta-catenin/TCF transcriptional activity. The amino-acid residue in E2F1 that CDK8 phosphorylates and how this phosphorylation impacts E2F1 activity in general is not known. Here, we describe that CDK8 phosphorylates serine 375 in E2F1 both in vitro and in cells, and that phosphorylation of this residue is required for E2F1 interaction with CDK8, and that the phosphorylation is dependent on CDK8 kinase activity. The phosphorylation of S375 by CDK8 regulates E2F1 ability to repress transcription of beta-catenin/TCF-dependent genes, as well as activation of E2F1-dependent genes. This regulation is due to inactivation of E2F1 transcriptional activation, and not to the interference of E2F1's ability to bind to E2F1-binding sites in various promoters or to interact with DP1.	[Zhao, J.] Dept Late Stage Analyt, Union, NJ USA; [Ramos, R.] Merck Res Labs, Dept Vitro Cell Pharmacol, Rahway, NJ USA; [Demma, M.] Merck Res Labs, Dept Oncol, Boston, MA 02115 USA	Merck & Company; Merck & Company	Demma, M (corresponding author), Merck Res Labs, Dept Oncol, BMB 9-107,33 Ave Louis Pasteur, Boston, MA 02115 USA.	Mark.Demma@merck.com						Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Donner AJ, 2010, NAT STRUCT MOL BIOL, V17, P194, DOI 10.1038/nsmb.1752; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Firestein R, 2010, INT J CANCER, V126, P2863, DOI 10.1002/ijc.24908; Firestein R, 2009, CANCER RES, V69, P7899, DOI 10.1158/0008-5472.CAN-09-1704; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Galbraith MD, 2010, TRANSCR-AUSTIN, V1, P4, DOI 10.4161/trns.1.1.12373; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ji JY, 2010, CONTEMP CANCER RES, P23, DOI 10.1007/978-1-4419-1770-6_2; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kim S, 2006, J BIOL CHEM, V281, P14066, DOI 10.1074/jbc.M602696200; Knuesel MT, 2009, GENE DEV, V23, P439, DOI 10.1101/gad.1767009; Knuesel MT, 2009, MOL CELL BIOL, V29, P650, DOI 10.1128/MCB.00993-08; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Meyer KD, 2008, EMBO J, V27, P1447, DOI 10.1038/emboj.2008.78; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Nair JS, 2009, MOL BIOL CELL, V20, P2218, DOI 10.1091/mbc.E08-08-0885; Ohantani K, 1994, MOL CELL BIOL, V14, P1603; PEEPER DS, 1995, ONCOGENE, V10, P39; Rickert P, 1999, ONCOGENE, V18, P1093, DOI 10.1038/sj.onc.1202399; Taatjes DJ, 2010, TRENDS BIOCHEM SCI, V35, P315, DOI 10.1016/j.tibs.2010.02.004; Tago K, 2000, GENE DEV, V14, P1741; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Wu Z, 2011, ONCOGENE, V30, P3979, DOI 10.1038/onc.2011.129; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Xu W, 2011, J GENET GENOMICS, V38, P439, DOI 10.1016/j.jgg.2011.09.002; Zhang J, 2010, J NEUROSCI, V30, P5219, DOI 10.1523/JNEUROSCI.5628-09.2010	42	42	45	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3520	3530		10.1038/onc.2012.364	http://dx.doi.org/10.1038/onc.2012.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22945643				2022-12-28	WOS:000322220800005
J	Das, TK; Sangodkar, J; Negre, N; Narla, G; Cagan, RL				Das, T. K.; Sangodkar, J.; Negre, N.; Narla, G.; Cagan, R. L.			Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors	ONCOGENE			English	Article						Sin3a; Ret; Src; Rho; wingless; Drosophila	GENE-EXPRESSION PATTERNS; HISTONE DEACETYLASE; BETA-CATENIN; TRANSCRIPTIONAL REPRESSION; LUNG ADENOCARCINOMA; FUNCTIONAL-ROLE; CANCER; COMPLEX; GROWTH; PROGRESSION	Chromatin remodeling proteins regulate multiple aspects of cell homeostasis, making them ideal candidates for misregulation in transformed cells. Here, we explore Sin3A, a member of the Sin3 family of proteins linked to tumorigenesis that are thought to regulate gene expression through their role as histone deacetylases (HDACs). We identified Drosophila Sin3a as an important mediator of oncogenic Ret receptor in a fly model of Multiple Endocrine Neoplasia Type 2. Reducing Drosophila Sin3a activity led to metastasis-like behavior and, in the presence of Diap1, secondary tumors distant from the site of origin. Genetic and Chip-Seq analyses identified previously undescribed Sin3a targets including genes involved in cell motility and actin dynamics, as well as signaling pathways including Src, Jnk and Rho. A key Sin3a oncogenic target, PP1B, regulates stability of beta-Catenin/Armadillo: the outcome is to oppose T-cell factor (TCF) function and Wg/Wnt pathway signaling in both fly and mammalian cancer cells. Reducing Sin3A strongly increased the invasive behavior of A549 human lung adenocarcinoma cells. We show that Sin3A is downregulated in a variety of human tumors and that Src, JNK, RhoA and PP1B/beta-Catenin are regulated in a manner analogous to our Drosophila models. Our data suggest that Sin3A influences a specific step of tumorigenesis by regulating a module of genes involved in cell invasion. Tumor progression may commonly rely on such 'modules of invasion' under the control of broad transcriptional regulators.	[Das, T. K.; Cagan, R. L.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA; [Sangodkar, J.; Narla, G.] Mt Sinai Sch Med, Dept Genet, New York, NY 10029 USA; [Negre, N.] Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA; [Narla, G.] Mt Sinai Sch Med, Div Hematol Oncol, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Chicago; Icahn School of Medicine at Mount Sinai	Cagan, RL (corresponding author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, Box 1020,1 Gustave Levy Pl, New York, NY 10029 USA.	Ross.Cagan@mssm.edu	Narla, Goutham/AAZ-5710-2020; Cagan, Ross Leigh/AAV-9528-2021	Narla, Goutham/0000-0003-4098-4203; Cagan, Ross/0000-0001-5297-450X; Negre, Nicolas/0000-0001-9727-3416	NIH/NCI [R01-CA084309, R01-CA109730]; American Cancer Society [120886-PFM-11-137-01-DDC]; NATIONAL CANCER INSTITUTE [R01CA109730, R01CA170495, R01CA084309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM082773] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Cagan Lab for sharing reagents, information, and helpful advice and Justin Graves for providing help mapping UAS-dRet<SUP>MEN2</SUP> transgenic flies. This work was supported by NIH/NCI grants R01-CA084309 and R01-CA109730 to RC and American Cancer Society Fellowship grant 120886-PFM-11-137-01-DDC to TD.	Ahn YH, 2011, MOL CELL BIOL, V31, P4270, DOI 10.1128/MCB.05562-11; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Blauwkamp TA, 2008, EMBO J, V27, P1436, DOI 10.1038/emboj.2008.80; Brachmann CB, 2000, CURR BIOL, V10, P547, DOI 10.1016/S0960-9822(00)00474-7; Cadigan KM, 2012, CURR TOP DEV BIOL, V98, P1, DOI 10.1016/B978-0-12-386499-4.00001-X; Castellone MD, 2009, CANCER RES, V69, P1867, DOI 10.1158/0008-5472.CAN-08-1982; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; David G, 2008, P NATL ACAD SCI USA, V105, P4168, DOI 10.1073/pnas.0710285105; Difeo A, 2008, CANCER RES, V68, P965, DOI 10.1158/0008-5472.CAN-07-2604; Duman-Scheel M, 2004, P NATL ACAD SCI USA, V101, P3857, DOI 10.1073/pnas.0400526101; Ellison-Zelski SJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-263; Farias EF, 2010, P NATL ACAD SCI USA, V107, P11811, DOI 10.1073/pnas.1006737107; Foglietti C, 2006, J BIOL CHEM, V281, P17968, DOI 10.1074/jbc.M511945200; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Geuking P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007709; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasegawa T, 2008, ONCOGENE, V27, P5684, DOI 10.1038/onc.2008.182; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Hurst DR, 2009, CLIN EXP METASTAS, V26, P89, DOI 10.1007/s10585-008-9216-9; Iwashita T, 1996, ONCOGENE, V12, P481; Janic A, 2010, SCIENCE, V330, P1824, DOI 10.1126/science.1195481; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lafon-Hughes L, 2008, MUTAT RES-REV MUTAT, V658, P191, DOI 10.1016/j.mrrev.2008.01.008; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nascimento EM, 2011, NAT CELL BIOL, V13, P1395, DOI 10.1038/ncb2385; Negre N, 2011, NATURE, V471, P527, DOI 10.1038/nature09990; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pile LA, 2003, J BIOL CHEM, V278, P37840, DOI 10.1074/jbc.M305996200; Pile LA, 2002, MOL CELL BIOL, V22, P4965, DOI 10.1128/MCB.22.14.4965-4976.2002; Plaza-Menacho I, 2006, TRENDS GENET, V22, P627, DOI 10.1016/j.tig.2006.09.005; Polette M, 2007, CELLS TISSUES ORGANS, V185, P61, DOI 10.1159/000101304; Rao G, 1996, ONCOGENE, V12, P1165; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Read RD, 2005, GENETICS, V171, P1057, DOI 10.1534/genetics.104.038018; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Samant RS, 2006, CANCER LETT, V235, P260, DOI 10.1016/j.canlet.2005.04.032; Sancho R, 2009, EMBO J, V28, P1843, DOI 10.1038/emboj.2009.153; Sangodkar J, 2009, EUR J CANCER, V45, P666, DOI 10.1016/j.ejca.2008.11.009; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Suzuki H, 2008, LUNG CANCER, V59, P24, DOI 10.1016/j.lungcan.2007.08.002; Teng DHF, 1997, CANCER RES, V57, P4177; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; van Oevelen C, 2008, MOL CELL, V32, P359, DOI 10.1016/j.molcel.2008.10.015; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733; Zhang YX, 2005, NUCLEIC ACIDS RES, V33, P6024, DOI 10.1093/nar/gki903	67	45	45	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2013	32	26					3184	3197		10.1038/onc.2012.326	http://dx.doi.org/10.1038/onc.2012.326			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22890320	Green Accepted			2022-12-28	WOS:000321004600009
J	Loffler, H; Fechter, A; Liu, FY; Poppelreuther, S; Kramer, A				Loeffler, H.; Fechter, A.; Liu, F. Y.; Poppelreuther, S.; Kraemer, A.			DNA damage-induced centrosome amplification occurs via excessive formation of centriolar satellites	ONCOGENE			English	Article						DNA damage; centrosome amplification; centriolar satellites; Chk1	CHROMOSOMAL INSTABILITY; GENOME MAINTENANCE; MAMMALIAN-CELLS; DUPLICATION; CHECKPOINT; INVOLVEMENT; INDUCTION; RADIATION; INTEGRITY; PATHWAY	Centrosome amplification is a frequent phenomenon in malignancies and may facilitate tumorigenesis by promoting chromosomal instability. On the other hand, a centrosome inactivation checkpoint comprising centrosome amplification leading to elimination of cells by mitotic catastrophe has been described in response to DNA damage by ionizing radiation or cytostatic drugs. So far, the exact nature of DNA damage-induced centrosome amplification, which might be overduplication or fragmentation of existing centrosomes, has been controversial. To solve this controversy, we have established a method to distinguish between these two possibilities using A549 cells expressing photoconvertible CETN2-Dendra2. In response to various DNA-damaging treatments, centrosome amplification but not fragmentation was observed. Moreover, centrosome amplification was preceded by excessive formation of centrin-containing centriolar satellites, which were identified as de novo-generated atypical centrin dots staining positive for centriolar satellite markers but negative or only weakly positive for other established centrosomal markers, and which could be verified as centriolar satellites using immunogold electron microscopy. In line with this notion, disruption of dynein-mediated recruitment of centrosomal proteins via centriolar satellites suppressed centrosome amplification after DNA damage, and excessive formation of centriolar satellites could be inhibited by interference with Chk1, a known mediator of centrosome amplification in response to DNA damage. In conclusion, we provide a model in which a Chk1-mediated DNA damage checkpoint induces excessive formation of centriolar satellites constituting assembly platforms for centrosomal proteins, which subsequently leads to centrosome amplification.	[Loeffler, H.; Fechter, A.; Liu, F. Y.; Kraemer, A.] German Canc Res Ctr, Clin Cooperat Unit Mol Hematol Oncol, D-69120 Heidelberg, Germany; [Loeffler, H.; Fechter, A.; Liu, F. Y.; Kraemer, A.] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany; [Poppelreuther, S.] Carl Zeiss Applicat Ctr, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Carl Zeiss AG	Kramer, A (corresponding author), German Canc Res Ctr, Clin Cooperat Unit Mol Hematol Oncol, D-69120 Heidelberg, Germany.	a.kraemer@dkfz.de			Deutsche Krebshilfe [108560]	Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Birgit Hub and Sigrid Heil for excellent technical assistance, and Andrew M Fry, Andreas Merdes, Jeffrey L Salisbury and Richard B Vallee for important reagents. This work was supported by the Deutsche Krebshilfe (grant 108560).	Barenz F, 2011, EUR J CELL BIOL, V90, P983, DOI 10.1016/j.ejcb.2011.07.007; Bourke E, 2010, ONCOGENE, V29, P616, DOI 10.1038/onc.2009.340; Bourke E, 2007, EMBO REP, V8, P603, DOI 10.1038/sj.embor.7400962; Boutros R, 2007, CANCER RES, V67, P11557, DOI 10.1158/0008-5472.CAN-07-2415; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; FETNER RH, 1965, EXP CELL RES, V37, P429, DOI 10.1016/0014-4827(65)90190-4; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gurskaya NG, 2006, NAT BIOTECHNOL, V24, P461, DOI 10.1038/nbt1191; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Heilig CE, 2010, J CELL MOL MED, V14, P895, DOI 10.1111/j.1582-4934.2009.00905.x; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; KOBAYASHI T, 1978, BIOCHEM BIOPH RES CO, V81, P1313, DOI 10.1016/0006-291X(78)91279-2; Kodani A, 2010, MOL BIOL CELL, V21, P3376, DOI 10.1091/mbc.E10-05-0430; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kramer A, 2005, LEUKEMIA, V19, P1142, DOI 10.1038/sj.leu.2403780; Kramer A, 2004, CELL CYCLE, V3, P1390, DOI 10.4161/cc.3.11.1252; Kubo A, 2003, J CELL SCI, V116, P919, DOI 10.1242/jcs.00282; Kubo A, 1999, J CELL BIOL, V147, P969, DOI 10.1083/jcb.147.5.969; Leidel S, 2005, NAT CELL BIOL, V7, P115, DOI 10.1038/ncb1220; LEVIS AG, 1963, EXP CELL RES, V31, P448, DOI 10.1016/0014-4827(63)90026-0; Loffler H, 2007, CELL CYCLE, V6, P2541; Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008; Loffler H, 2011, CANCER RES, V71, P2129, DOI 10.1158/0008-5472.CAN-10-2684; Lopes CAM, 2011, J CELL SCI, V124, P600, DOI 10.1242/jcs.077156; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; Prosser SL, 2009, MOL CELL BIOL, V29, P1760, DOI 10.1128/MCB.01124-08; Robinson HMR, 2007, CELL CYCLE, V6, P982, DOI 10.4161/cc.6.8.4111; SATO C, 1983, J CELL BIOL, V96, P776, DOI 10.1083/jcb.96.3.776; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Stevens NR, 2010, DEV CELL, V19, P913, DOI 10.1016/j.devcel.2010.11.010; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; White RA, 2000, MICROSC RES TECHNIQ, V49, P451, DOI 10.1002/(SICI)1097-0029(20000601)49:5<451::AID-JEMT7>3.0.CO;2-9; Yih LH, 2006, CANCER RES, V66, P2098, DOI 10.1158/0008-5472.CAN-05-2308; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zyss D, 2009, TRENDS CELL BIOL, V19, P334, DOI 10.1016/j.tcb.2009.04.001	36	43	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2013	32	24					2963	2972		10.1038/onc.2012.310	http://dx.doi.org/10.1038/onc.2012.310			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22824794				2022-12-28	WOS:000320369700006
J	Ng, T; Irshad, S; Stebbing, J				Ng, T.; Irshad, S.; Stebbing, J.			BRCA1 mutations and luminal-basal transformation	ONCOGENE			English	Editorial Material							DIFFERENTIATION; PROLIFERATION; EXPRESSION; TARGET; BREAST	The multifunctional roles of BRCA1 include its ability to regulate transcriptional processes that control differentiation at multiple levels, as well as functioning as a tumor suppressor. Data herein demonstrate that germline mutations in Brca1 impair luminal cell lineage and mammary development, with its deficiency converting ER-positive luminal tumors into basal-like cancers. Heterozygous mutations in Brca1 lead to downregulation of a number of luminal differentiation genes, explaining how it suppresses basal-like tumors, also highlighting its importance outside of its known highly publicized role in DNA repair.	[Ng, T.; Irshad, S.] Kings Coll London, Richard Dimbleby Dept Canc Res, Randall Div, London WC2R 2LS, England; [Ng, T.; Irshad, S.] Kings Coll London, Div Canc Studies, London WC2R 2LS, England; [Ng, T.; Irshad, S.] Kings Coll London, Breakthrough Breast Canc Res Unit, London WC2R 2LS, England; [Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Dept Med Oncol, London W12 0NN, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; Imperial College London	Stebbing, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Med Oncol, Hammersmith Campus, London W12 0NN, England.	j.stebbing@imperial.ac.uk	Irshad, Sheeba/ABE-9417-2021	Irshad, Sheeba/0000-0002-4419-7162; Stebbing, Justin/0000-0002-1117-6947; Ng, Tony/0000-0003-3894-5619	Cancer Research UK [14549, 16463] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; Breast Cancer Now [KCL-Q1] Funding Source: researchfish; Department of Health [NIHR-RP-011-053] Funding Source: Medline	Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Breast Cancer Now; Department of Health		Bai F, 2013, ONCOGENE, V32, P2715, DOI 10.1038/onc.2012.293; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Coene ED, 2011, J CELL BIOL, V192, P497, DOI 10.1083/jcb.201004136; Deans AJ, 2006, CANCER RES, V66, P8219, DOI 10.1158/0008-5472.CAN-05-3945; Drost R, 2011, CANCER CELL, V20, P797, DOI 10.1016/j.ccr.2011.11.014; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Kubista M, 2002, ONCOGENE, V21, P4747, DOI 10.1038/sj.onc.1205580; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593; Pei XH, 2009, CANCER CELL, V15, P389, DOI 10.1016/j.ccr.2009.03.004; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Taghavi N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-138; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61	16	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2712	2714		10.1038/onc.2012.379	http://dx.doi.org/10.1038/onc.2012.379			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22926516				2022-12-28	WOS:000319808000002
J	Akbay, EA; Pena, CG; Ruder, D; Michel, JA; Nakada, Y; Pathak, S; Multani, AS; Chang, S; Castrillon, DH				Akbay, E. A.; Pena, C. G.; Ruder, D.; Michel, J. A.; Nakada, Y.; Pathak, S.; Multani, A. S.; Chang, S.; Castrillon, D. H.			Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis	ONCOGENE			English	Article						endometrial cancer; shelterin; p53; telomeres; pot1a; mouse models	CELL-LINE; CANCER; DYSFUNCTION; COMPLEX; LENGTH; TRANSLOCATIONS; INSTABILITY; MUTATIONS; CARCINOMA; PTEN	Type II endometrial cancer (EMCA) represents only 10% of all EMCAs, but accounts for 40% of EMCA-related mortality. Previous studies of human tumors have shown an association between Type II tumors and damaged telomeres. We hypothesized that the lack of murine Type II EMCA models is due to the extremely long telomeres in laboratory mouse strains. We previously showed that telomerase-null mice with critically short telomeres developed endometrial lesions histologically resembling endometrial intraepithelial carcinoma (EIC), the accepted precursor for Type II EMCA. However, these mice did not develop invasive endometrial adenocarcinoma, and instead succumbed prematurely to multi-organ failure. Here, we modeled critical telomere attrition by conditionally inactivating Pot1a, a component of the shelterin complex that stabilizes telomeres, within endometrial epithelium. Inactivation of Pot1a by itself did not stimulate endometrial carcinogenesis, and did not result in detectable DNA damage or apoptosis in endometrium. However, simultaneous inactivation of Pot1a and p53 resulted in EIC-like lesions by 9 months indistinguishable from those seen in late generation telomerase-null mice. These lesions progressed to invasive endometrial adenocarcinomas as early as 9 months of age with metastatic disease in 100% of the animals by 15 months. These tumors were poorly differentiated endometrial adenocarcinomas with prominent nuclear atypia, resembling human Type II cancers. Furthermore, these tumors were aneuploid with double-stranded DNA breaks and end-to-end telomere fusions and most were tetraploid or near-tetraploid. These studies lend further support to the hypothesis that telomeric instability has a critical role in Type II endometrial carcinogenesis and provides an intriguing in-vivo correlate to recent studies implicating telomere-dependent tetraploidization as an important mechanism in carcinogenesis. Oncogene (2013) 32, 2211-2219; doi:10.1038/onc.2012.232; published online 11 June 2012	[Akbay, E. A.; Pena, C. G.; Ruder, D.; Michel, J. A.; Nakada, Y.; Castrillon, D. H.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Akbay, E. A.; Pena, C. G.; Ruder, D.; Michel, J. A.; Nakada, Y.; Castrillon, D. H.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Pathak, S.] Univ Texas MD Anderson Canc Ctr, Cellular Genet Lab, Houston, TX 77030 USA; [Multani, A. S.] Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA; [Chang, S.] Yale Univ, Sch Med, Dept Lab Med & Pathol, New Haven, CT USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Yale University	Castrillon, DH (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pathol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	diego.castrillon@utsouthwestern.edu		Akbay, Esra/0000-0002-4149-2529; Ruder, Dennis/0000-0001-7605-111X	MD Anderson Molecular Cytogenetics Core for cytogenetic services (under Cancer Center Support) [NCI CA016672]; NCI [RO1CA129037]; Michal and Betty Kadoorie Cancer Genetic Research Program; NIH [NCI R01CA137181, NCI U01CA141576]; Cancer Prevention Research Institute of Texas [RP100550]; NATIONAL CANCER INSTITUTE [R01CA129037, P30CA016672, R01CA137181, U01CA141576] Funding Source: NIH RePORTER	MD Anderson Molecular Cytogenetics Core for cytogenetic services (under Cancer Center Support); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Michal and Betty Kadoorie Cancer Genetic Research Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Florence Sibetya for help with the ploidy analyses, Teresa Gallardo for technical assistance, and the MD Anderson Molecular Cytogenetics Core for cytogenetic services (under Cancer Center Support Grant NCI CA016672). SC acknowledges support from the NCI (RO1CA129037) and the Michal and Betty Kadoorie Cancer Genetic Research Program. This work was supported by grants to DHC from the NIH (NCI R01CA137181, NCI U01CA141576) and the Cancer Prevention Research Institute of Texas (RP100550).	Akbay EA, 2008, AM J PATHOL, V173, P536, DOI 10.2353/ajpath.2008.071179; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Baerlocher GM, 2004, METHOD CELL BIOL, V75, P719; Batista LFZ, 2009, CANCER CELL, V15, P455, DOI 10.1016/j.ccr.2009.05.006; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Bunch JT, 2005, MOL CELL BIOL, V25, P5567, DOI 10.1128/mcb.25.13.5567-5578.2005; Cirisano FD, 1999, GYNECOL ONCOL, V74, P385, DOI 10.1006/gyno.1999.5505; Clement PB, 2004, ADV ANAT PATHOL, V11, P117, DOI 10.1097/00125480-200405000-00001; Contreras CM, 2010, DIS MODEL MECH, V3, P181, DOI 10.1242/dmm.004440; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Davoli T, 2010, CELL, V141, P81, DOI 10.1016/j.cell.2010.01.031; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2009, SCIENCE, V326, P948, DOI 10.1126/science.1170633; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Deng YB, 2008, NAT REV CANCER, V8, P450, DOI 10.1038/nrc2393; DePinho RA, 2003, J CLIN INVEST, V111, pS9; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Friel Anne M, 2010, Front Biosci (Elite Ed), V2, P882; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Guo X, 2007, EMBO J, V26, P4709, DOI 10.1038/sj.emboj.7601893; HARKER WG, 1983, CANCER RES, V43, P4943; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Hockemeyer D, 2008, GENE DEV, V22, P1773, DOI 10.1101/gad.1679208; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kendellen MF, 2009, MOL CELL BIOL, V29, P5611, DOI 10.1128/MCB.00286-09; Kim TH, 2010, J ONCOL, V2010, DOI 10.1155/2010/139087; Lax S F, 2002, Zentralbl Gynakol, V124, P10; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; MacDonald ND, 2000, CANCER RES, V60, P1750; Meyer LA, 2009, CANCER CONTROL, V16, P14, DOI 10.1177/107327480901600103; Multani AS, 2000, NEOPLASIA, V2, P339, DOI 10.1038/sj.neo.7900105; NOUMOFF JS, 1988, GYNECOL ONCOL, V31, P217, DOI 10.1016/0090-8258(88)90297-1; Okuda T, 2010, OBSTET GYNECOL INT, V2010, DOI 10.1155/2010/984013; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Pradhan M, 2006, MODERN PATHOL, V19, P1227, DOI 10.1038/modpathol.3800641; Qi L, 2005, NAT CELL BIOL, V7, P706, DOI 10.1038/ncb1276; Rai R, 2011, NAT STRUCT MOL BIOL, V18, P1400, DOI 10.1038/nsmb.2172; RISINGER JI, 1993, CANCER RES, V53, P5100; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Savage SA, 2008, AM J HUM GENET, V82, P501, DOI 10.1016/j.ajhg.2007.10.004; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Soliman PT, 2007, OBSTET GYN CLIN N AM, V34, P701, DOI 10.1016/j.ogc.2007.09.003; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tashiro H, 1997, AM J PATHOL, V150, P177; Thanasoula M, 2010, CURR BIOL, V20, P521, DOI 10.1016/j.cub.2010.01.046; Ueda SM, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.08.075; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037	56	22	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2211	2219		10.1038/onc.2012.232	http://dx.doi.org/10.1038/onc.2012.232			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689059	Green Published, hybrid			2022-12-28	WOS:000318062800010
J	Coppola, V; Musumeci, M; Patrizii, M; Cannistraci, A; Addario, A; Maugeri-Sacca, M; Biffoni, M; Francescangeli, F; Cordenonsi, M; Piccolo, S; Memeo, L; Pagliuca, A; Muto, G; Zeuner, A; De Maria, R; Bonci, D				Coppola, V.; Musumeci, M.; Patrizii, M.; Cannistraci, A.; Addario, A.; Maugeri-Sacca, M.; Biffoni, M.; Francescangeli, F.; Cordenonsi, M.; Piccolo, S.; Memeo, L.; Pagliuca, A.; Muto, G.; Zeuner, A.; De Maria, R.; Bonci, D.			BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition	ONCOGENE			English	Article						prostate cancer; BTG2; microRNA; basal and luminal phenotype; EMT	TRANSLOCATION GENE-2 PROTEIN; STEM-CELLS; INDUCED DIFFERENTIATION; CYCLE REGULATOR; CANCER CELLS; IN-VIVO; CARCINOMA; MICRORNAS; P63; INVASION	Prostate cancer is one of the leading causes of cancer-related death in men. Despite significant advances in prostate cancer diagnosis and management, the molecular events involved in the transformation of normal prostate cells into cancer cells have not been fully understood. It is generally accepted that prostate cancer derives from the basal compartment while expressing luminal markers. We investigated whether downregulation of the basal protein B-cell translocation gene 2 (BTG2) is implicated in prostate cancer transformation and progression. Here we show that BTG2 loss can shift normal prostate basal cells towards luminal markers expression, a phenotype also accompanied by the appearance of epithelial-mesenchymal transition (EMT) traits. We also show that the overexpression of microRNA (miR)-21 suppresses BTG2 levels and promotes the acquisition of luminal markers and EMT in prostate cells. Furthermore, by using an innovative lentiviral vector able to compete with endogenous mRNA through the overexpression of the 3'-untranslated region of BTG2, we demonstrate that in prostate tumor cells, the levels of luminal and EMT markers can be reduced by derepression of BTG2 from microRNA-mediated control. Finally, we show that the loss of BTG2 expression confers to non-tumorigenic prostate cells ability to grow in an orthotopic murine model, thus demonstrating the central role of BTG2 downregulaton in prostate cancer biology. Oncogene (2013) 32, 1843-1853; doi: 10.1038/onc.2012.194; published online 21 May 2012	[Coppola, V.; Musumeci, M.; Patrizii, M.; Cannistraci, A.; Addario, A.; Biffoni, M.; Francescangeli, F.; Pagliuca, A.; Zeuner, A.; Bonci, D.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Maugeri-Sacca, M.; De Maria, R.] Regina Elena Inst Canc Res, Rome, Italy; [Cordenonsi, M.; Piccolo, S.] Univ Padua, Sch Med, Dept Histol Microbiol & Med Biotechnol, Padua, Italy; [Memeo, L.] Mediterranean Inst Oncol, Dept Expt Oncol, Catania, Italy; [Muto, G.] S Giovanni Bosco Hosp, Dept Urol, Turin, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Padua; Mediterranean Institute of Oncology	De Maria, R (corresponding author), Regina Elena Inst Canc Res, Rome, Italy.	demaria@ifo.it; desiree.bonci@iss.it	Coppola, Valeria/K-5120-2016; Pagliuca, Alfredo/AAI-3689-2020; Zeuner, Ann/K-8607-2016; Francescangeli, Federica/K-6500-2016; Cordenonsi, Michelangelo/K-7692-2016; Bonci, Desiree/K-6488-2016; De Maria, Ruggero/S-6385-2019; Maugeri-Saccà, Marcello/K-2350-2014; Addario, Antonio/AAC-4707-2022; Biffoni, Mauro/J-8318-2016; Zeuner, Ann/A-8529-2010	Coppola, Valeria/0000-0002-5745-2572; Francescangeli, Federica/0000-0002-1086-5265; Cordenonsi, Michelangelo/0000-0002-8253-5724; Bonci, Desiree/0000-0002-2472-5140; De Maria, Ruggero/0000-0003-2255-0583; Maugeri-Saccà, Marcello/0000-0003-2287-9581; Addario, Antonio/0000-0001-8527-8738; Biffoni, Mauro/0000-0002-1304-9060; Zeuner, Ann/0000-0002-8295-3715; PICCOLO, STEFANO/0000-0002-2037-0004; Musumeci, Maria/0000-0001-6680-8158; Muto, Giovanni/0000-0003-3593-6450; Memeo, Lorenzo/0000-0003-4251-7203; pagliuca, alfredo/0000-0002-8703-2077	Italian Health Ministry; Italy-USA microRNA program; Italian Association for Cancer Research (AIRC); Fondazione Roma	Italian Health Ministry(Ministry of Health, Italy); Italy-USA microRNA program; Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma(Fondazione RomaEuropean Commission)	We thank F. Tirone and L. Leonardi for providing non-commercial His-tagged anti-BTG2 antibody, S. Soddu for kindly providing pSUPER-p53plasmid for p53 interference, T. Merlino for manuscript editing, and G. Loreto for graphical assistance. This work was supported by the Italian Health Ministry with 'Under forty researchers 2007' and Italy-USA microRNA program to DB, and by the Italian Association for Cancer Research (AIRC) and 'Fondazione Roma' support to RDM.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Bonkhoff H, 1996, PROSTATE, V28, P98; BONKHOFF H, 1994, PROSTATE, V24, P114, DOI 10.1002/pros.2990240303; Buganim Y, 2010, CANCER RES, V70, P2274, DOI 10.1158/0008-5472.CAN-09-2661; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cecchinelli B, 2006, MOL CELL BIOL, V26, P4746, DOI 10.1128/MCB.00959-05; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hao YB, 2011, CANCER INVEST, V29, P318, DOI 10.3109/07357907.2011.554477; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hu XD, 2011, BIOCHEM BIOPH RES CO, V404, P903, DOI 10.1016/j.bbrc.2010.12.064; Jalava SE, 2012, ONCOGENE, V31, P4460, DOI 10.1038/onc.2011.624; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kawakubo H, 2006, CANCER RES, V66, P7075, DOI 10.1158/0008-5472.CAN-06-0379; Kawamura-Tsuzuku J, 2004, ONCOGENE, V23, P6630, DOI 10.1038/sj.onc.1207890; Lam JS, 2006, UROL ONCOL-SEMIN ORI, V24, P131, DOI 10.1016/j.urolonc.2005.11.038; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Lim IK, 2006, J CANCER RES CLIN, V132, P417, DOI 10.1007/s00432-006-0080-1; Liu M, 2009, CELL RES, V19, P828, DOI 10.1038/cr.2009.72; Maitland Norman J., 2011, Hormones & Cancer, V2, P47, DOI 10.1007/s12672-010-0058-y; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Melamed J, 2002, TISSUE CELL, V34, P28, DOI 10.1054/tice.2001.0220; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; NAGLE RB, 1987, CANCER RES, V47, P281; Passeri D, 2006, MOL CELL BIOL, V26, P5023, DOI 10.1128/MCB.01360-05; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159; SHERWOOD ER, 1990, J UROLOGY, V143, P167, DOI 10.1016/S0022-5347(17)39903-2; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Signoretti S, 2005, P NATL ACAD SCI USA, V102, P11355, DOI 10.1073/pnas.0500165102; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Tokar EJ, 2005, DIFFERENTIATION, V73, P463, DOI 10.1111/j.1432-0436.2005.00047.x; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Webber MM, 1997, PROSTATE, V30, P58; Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246	52	74	76	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2013	32	14					1843	1853		10.1038/onc.2012.194	http://dx.doi.org/10.1038/onc.2012.194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22614007				2022-12-28	WOS:000317043900010
J	Herroon, MK; Rajagurubandara, E; Rudy, DL; Chalasani, A; Hardaway, AL; Podgorski, I				Herroon, M. K.; Rajagurubandara, E.; Rudy, D. L.; Chalasani, A.; Hardaway, A. L.; Podgorski, I.			Macrophage cathepsin K promotes prostate tumor progression in bone	ONCOGENE			English	Article						cathepsin K; macrophages; osteoclasts; bone metastasis; prostate cancer; inflammation	MONOCYTE CHEMOATTRACTANT PROTEIN-1; RESISTANT ACID-PHOSPHATASE; CARCINOMA CELL-LINE; BREAST-CANCER; IN-VITRO; MATRIX-METALLOPROTEINASE; OSTEOCLAST; RESORPTION; EXPRESSION; INHIBITOR	Bone marrow macrophages (BMMs) share common progenitors with osteoclasts and are critical components of bone-tumor microenvironment; however, their function in prostate tumor growth in the skeleton has not been explored. BMMs are the major source of inflammatory factors and proteases, including cysteine protease cathepsin K (CTSK). In this study, utilizing mice deficient in CTSK, we demonstrate the critical involvement of this potent collagenase in tumor progression in bone. We present the evidence that tumor growth and progression in the bone are impaired in the absence of CTSK. Most importantly, we show for the first time that BMM-supplied CTSK may be involved in CCL2- and COX-2-driven pathways that contribute to tumor progression in bone. Together, our data unravel novel roles for CTSK in macrophage-regulated processes, and provide evidence for close interplay between inflammatory, osteolytic and tumor cell-driven events in the bone-tumor microenvironment. Oncogene (2013) 32, 1580-1593; doi:10.1038/onc.2012.166; published online 21 May 2012	[Herroon, M. K.; Rajagurubandara, E.; Rudy, D. L.; Chalasani, A.; Hardaway, A. L.; Podgorski, I.] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; [Podgorski, I.] Karmanos Canc Inst, Detroit, MI USA	Wayne State University; Barbara Ann Karmanos Cancer Institute	Podgorski, I (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield,Rm 6304, Detroit, MI 48201 USA.	ipodgors@med.wayne.edu			DOD [PC074031, PC030325]; Wayne State University;  [MICR: P30 CA 22453]; NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER	DOD(United States Department of Defense); Wayne State University; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge Dr Lisa Coussens (UCSF, CA) for providing breeding pairs of immuno-deficient (FVB/N/N5, Rag-1 <SUP>/</SUP> , Cat K <SUP>/</SUP> (WT)) and (FVB/N/N5, Rag-1 <SUP>/</SUP> , Cat K<SUP>-/-</SUP> (CTSK KO)) mice, as well as immuno-competent (FVB/N/N5 Cat K<SUP>+/+</SUP> (WT)) and (FVB/N/N5 Cat K<SUP>-/-</SUP> (CTSK KO)) mice used in this study. We also thank Dr Bonnie Sloane for providing CTSB antibodies, Dr Kamiar Moin and the Microscopy, Imaging and Cytometry Resources Core for assistance with confocal and conventional light microscopy analyses, and Dr Karin list for critical review of this manuscript. Grant support was provided by DOD PC074031, DOD PC030325, Wayne State University start-up fund and MICR: P30 CA 22453.	Abedinpour P, 2011, PROSTATE, V71, P813, DOI 10.1002/pros.21297; Andresen C., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P148; Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110; BALEY PA, 1995, J STEROID BIOCHEM, V52, P403, DOI 10.1016/0960-0760(95)00001-G; Bar-Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Boyce BF, 2009, CRIT REV EUKAR GENE, V19, P171, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.10; Bromme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661 , 10.1517/13543780902832661]; Brubaker KD, 2003, J BONE MINER RES, V18, P222, DOI 10.1359/jbmr.2003.18.2.222; Buhling F, 2001, J PATHOL, V195, P375; Chao TY, 2010, CLIN CHIM ACTA, V411, P1553, DOI 10.1016/j.cca.2010.06.027; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Conti I, 2004, SEMIN CANCER BIOL, V14, P149, DOI 10.1016/j.semcancer.2003.10.009; Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078-0432.CCR-06-0269; Cross AK, 1999, GLIA, V28, P183, DOI 10.1002/(SICI)1098-1136(199912)28:3<183::AID-GLIA2>3.0.CO;2-3; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Desmarais S, 2009, BIOL CHEM, V390, P941, DOI 10.1515/BC.2009.092; Galvez BG, 2005, J BIOL CHEM, V280, P1292, DOI 10.1074/jbc.M408673200; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Jensen AB, 2010, CLIN BREAST CANCER, V10, P452, DOI 10.3816/CBC.2010.n.059; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kawashima M, 2009, MOD RHEUMATOL, V19, P192, DOI 10.1007/s10165-008-0149-6; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020; Kiviranta R, 2001, J BONE MINER RES, V16, P1444, DOI 10.1359/jbmr.2001.16.8.1444; Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015; Lean JM, 2000, BONE, V27, P29, DOI 10.1016/S8756-3282(00)00306-9; Lee RJ, 2010, CLIN GENITOURIN CANC, V8, P29, DOI 10.3816/CGC.2010.n.005; Lee RJ, 2011, BONE, V48, P88, DOI 10.1016/j.bone.2010.05.038; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386; Loberg RD, 2007, NEOPLASIA, V9, P556, DOI 10.1593/neo.07307; Lu Y, 2007, CANCER RES, V67, P3646, DOI 10.1158/0008-5472.CAN-06-1210; Lynch CC, 2011, BONE, V48, P44, DOI 10.1016/j.bone.2010.06.007; Mancini A, 2007, J CELL BIOCHEM, V101, P425, DOI 10.1002/jcb.21191; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marquis RW, 2001, J MED CHEM, V44, P1380, DOI 10.1021/jm000481x; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; McCabe NP, 2008, CLIN EXP METASTAS, V25, P581, DOI 10.1007/s10585-008-9175-1; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; Miyamoto K, 2009, BIOCHEM BIOPH RES CO, V383, P373, DOI 10.1016/j.bbrc.2009.04.020; Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988; MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427; Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298; Navone NM, 1997, CLIN CANCER RES, V3, P2493; New DC, 2003, ACTA BIOCH BIOPH SIN, V35, P779; Nonomura N, 2011, BJU INT, V107, P1918, DOI 10.1111/j.1464-410X.2010.09804.x; Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011; Podgorski I, 2005, NEOPLASIA, V7, P207, DOI 10.1593/neo.04349; Podgorski I, 2009, FUTURE MED CHEM, V1, P21, DOI 10.4155/FMC.09.4; Podgorski I, 2009, AM J PATHOL, V175, P1255, DOI 10.2353/ajpath.2009.080906; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Porta C, 2007, ADV EXP MED BIOL, V604, P67, DOI 10.1007/978-0-387-69116-9_5; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; Qian BZ, 2011, NATURE; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Roato I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003627; Robichaud J, 2008, J MED CHEM, V51, P6410, DOI 10.1021/jm800610j; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Saftig P, 2000, ADV EXP MED BIOL, V477, P293; Saylor PJ, 2011, J CLIN ONCOL, V29, P3705, DOI 10.1200/JCO.2010.34.4994; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; Shiirevnyamba A, 2011, BRIT J CANCER, V104, P505, DOI 10.1038/sj.bjc.6606070; Singh B, 2007, ONCOGENE, V26, P3789, DOI 10.1038/sj.onc.1210154; Smith MR, 2008, UROL ONCOL-SEMIN ORI, V26, P420, DOI 10.1016/j.urolonc.2007.11.004; Smith MR, 2007, UROLOGY, V70, P315, DOI 10.1016/j.urology.2007.03.071; Smith MR, 2006, J CLIN ONCOL, V24, P2723, DOI 10.1200/JCO.2005.03.7804; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tanaka S, 2006, GUT, V55, P54, DOI 10.1136/gut.2004.059824; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Valsecchi ME, 2009, CLIN BREAST CANCER, V9, P225, DOI 10.3816/CBC.2009.n.038; Weischenfeldt J, 2008, CSH PROTOC, V2008, DOI DOI 10.1101/PDB.PROT5080; Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200; Wilson TJ, 2008, BBA-REV CANCER, V1785, P85, DOI 10.1016/j.bbcan.2007.11.001; Wolf M, 2008, INT J BIOCHEM CELL B, V40, P1185, DOI 10.1016/j.biocel.2007.12.009; Yoon DS, 2010, STEM CELLS DEV, V19, P1523, DOI 10.1089/scd.2009.0393; Zenger S, 2007, BONE, V41, P820, DOI 10.1016/j.bone.2007.07.010; Zhang J, 2010, CYTOKINE GROWTH F R, V21, P41, DOI 10.1016/j.cytogfr.2009.11.009; Zhau HE, 2008, CLIN EXP METASTAS, V25, P601, DOI 10.1007/s10585-008-9183-1	83	52	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1580	1593		10.1038/onc.2012.166	http://dx.doi.org/10.1038/onc.2012.166			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22614014	Green Accepted			2022-12-28	WOS:000316456000011
J	Mythreye, K; Knelson, EH; Gatza, CE; Gatza, ML; Blobe, GC				Mythreye, K.; Knelson, E. H.; Gatza, C. E.; Gatza, M. L.; Blobe, G. C.			T beta RIII/beta-arrestin2 regulates integrin alpha 5 beta 1 trafficking, function, and localization in epithelial cells	ONCOGENE			English	Article						integrin alpha 5 beta 1; beta-arrestin2; TGF-beta; betaglycan	TGF-BETA RECEPTOR; FOCAL ADHESION KINASE; CANCER; BETAGLYCAN; PROTEIN; ALPHA-V-BETA-3; EXPRESSION; MEMBRANE; BINDING; INVASIVENESS	The type III TGF-beta receptor (T beta RIII) is a ubiquitous co-receptor for TGF-beta superfamily ligands with roles in suppressing cancer progression, in part through suppressing cell motility. Here we demonstrate that T beta RIII promotes epithelial cell adhesion to fibronectin in a beta-arrestin2 dependent and TGF-beta/BMP independent manner by complexing with active integrin alpha 5 beta 1, and mediating beta-arrestin2-dependent alpha 5 beta 1 internalization and trafficking to nascent focal adhesions. T beta RIII-mediated integrin alpha 5 beta 1 trafficking regulates cell adhesion and fibronectin fibrillogenesis in epithelial cells, as well as alpha 5 localization in breast cancer patients. We further demonstrate that increased T beta RIII expression correlates with increased alpha 5 localization at sites of cell-cell adhesion in breast cancer patients, while higher T beta RIII expression is a strong predictor of overall survival in breast cancer patients. These data support a novel, clinically relevant role for T beta RIII in regulating integrin alpha 5 localization, reveal a novel crosstalk mechanism between the integrin and TGF-beta superfamily signaling pathways and identify beta-arrestin2 as a regulator of alpha 5 beta 1 trafficking. Oncogene (2013) 32, 1416-1427; doi:10.1038/onc.2012.157; published online 7 May 2012	[Mythreye, K.; Gatza, C. E.; Blobe, G. C.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27708 USA; [Knelson, E. H.; Blobe, G. C.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; [Gatza, M. L.] Duke Univ, Med Ctr, Duke IGSP, Durham, NC 27708 USA	Duke University; Duke University; Duke University	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med, B354 LSRC,Box 91004 DUMC, Durham, NC 27708 USA.	blobe001@mc.duke.edu	Blobe, Gerard/AAJ-5945-2020; Karthikeyan, Mythreye/ABC-7345-2020	Blobe, Gerard/0000-0002-4274-8901; Karthikeyan, Mythreye/0000-0001-5478-0098; Knelson, Erik/0000-0003-4087-2017; Gatza, Michael/0000-0001-6796-7791	NIH Grants [R01-CA135006, R01-CA136786]; Komen for the Cure Grants [KG090154, SAC100002]; Department of Defense grant [W81 XWH-09-1-0265]; NATIONAL CANCER INSTITUTE [R01CA136786, R01CA135006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER	NIH Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Komen for the Cure Grants; Department of Defense grant(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We sincerely thank Sue Craig and Martin Humphries for generously providing us with SNAKA51, L. Attisano for BMPRII construct, Tam How and Alisha Holtzhausen for technical help in generation of the ratT beta RIII-T841A plasmid and plasmid purifications respectively, Duke University Light Microscopy facility for help in training individuals with the use of the TIRFM and confocal microscopes. This work was supported in part by NIH Grants R01-CA135006 and R01-CA136786 (GCB), Komen for the Cure Grants KG090154 and SAC100002 (GCB) and Department of Defense grant W81 XWH-09-1-0265 (KM).	AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Bilandzic M, 2011, MOL CELL ENDOCRINOL, V28; Bilandzic M, 2009, MOL ENDOCRINOL, V23, P539, DOI 10.1210/me.2008-0300; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; BRETSCHER MS, 1992, EMBO J, V11, P383, DOI 10.1002/j.1460-2075.1992.tb05066.x; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Clark K, 2005, J CELL SCI, V118, P291, DOI 10.1242/jcs.01623; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DeFea KA, 2007, ANNU REV PHYSIOL, V69, P535, DOI 10.1146/annurev.physiol.69.022405.154804; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; Finger EC, 2008, CARCINOGENESIS, V29, P528, DOI 10.1093/carcin/bgm289; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Gordon KJ, 2008, CARCINOGENESIS, V29, P252, DOI 10.1093/carcin/bgm249; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hempel N, 2007, CANCER RES, V67, P5231, DOI 10.1158/0008-5472.CAN-07-0035; Kirkbride KC, 2008, J BIOL CHEM, V283, P7628, DOI 10.1074/jbc.M704883200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; Lee NY, 2009, MOL BIOL CELL, V20, P4362, DOI 10.1091/mbc.E09-07-0539; Lee-Hoeflich ST, 2004, EMBO J, V23, P4792, DOI 10.1038/sj.emboj.7600418; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Molteni R, 2009, BLOOD, V114, P1073, DOI 10.1182/blood-2008-10-183699; Morgan MR, 2009, IUBMB LIFE, V61, P731, DOI 10.1002/iub.200; Mythreye K, 2009, CELL SIGNAL, V8; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; PARSONS JT, 1994, J CELL SCI, P109; Pellinen T, 2006, J CELL SCI, V119, P3723, DOI 10.1242/jcs.03216; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Roberts MS, 2004, MOL CELL BIOL, V24, P1505, DOI 10.1128/MCB.24.4.1505-1515.2004; Robertson D, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-13; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Toutant M, 2002, MOL CELL BIOL, V22, P7731, DOI 10.1128/MCB.22.22.7731-7743.2002; Turley RS, 2007, CANCER RES, V67, P1090, DOI 10.1158/0008-5472.CAN-06-3117; White DP, 2007, J CELL BIOL, V177, P515, DOI 10.1083/jcb.200609004; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; You HJ, 2007, CARCINOGENESIS, V28, P2491, DOI 10.1093/carcin/bgm195; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	53	19	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1416	1427		10.1038/onc.2012.157	http://dx.doi.org/10.1038/onc.2012.157			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22562249	Green Accepted			2022-12-28	WOS:000316455600008
J	Bambang, IF; Lee, YK; Richardson, DR; Zhang, D				Bambang, I. F.; Lee, Y. K.; Richardson, D. R.; Zhang, D.			Endoplasmic reticulum protein 29 regulates epithelial cell integrity during the mesenchymal-epithelial transition in breast cancer cells	ONCOGENE			English	Article						ERp29; tight junctions; cell polarity; mesenchymal-epithelial transition; epithelial morphogenesis	E-CADHERIN EXPRESSION; TIGHT JUNCTIONS; METASTATIC PROGRESSION; TUMOR PROGRESSION; UP-REGULATION; LIGHT-CHAIN; MYOSIN-II; POLARITY; COMPLEX; ERP29	The epithelial-mesenchymal transition (EMT) correlates with disruption of cell-cell adhesion, loss of cell polarity and development of epithelial cell malignancy. Identifying novel molecules that inhibit EMT has profound potential for developing mechanism-based therapeutics. We previously demonstrated that the endoplasmic reticulum protein 29 (ERp29) is a novel factor that can drive mesenchymal-epithelial transition (MET) and induce cell growth arrest in MDA-MB-231 cells. Here, we show that ERp29 is an important molecule in establishing epithelial cell integrity during the MET. We demonstrate that ERp29 regulates MET in a cell context-dependent manner. ERp29 overexpression induced a complete MET in mesenchymal MDA-MB-231 cells through downregulating the expression of transcriptional repressors (for example, Slug, Snai1, ZEB2 and Twist) of E-cadherin. In contrast, overexpression of ERp29 induces incomplete MET in basal-like BT549 cells in which the expression of EMT-related markers (for example, vimentin; cytokeratin 19 (CK19) and E-cadherin) and the transcriptional repressors of E-cadherin were not altered. However, ERp29 overexpression in both cell-types resulted in loss of filamentous stress fibers, formation of cortical actin and restoration of an epithelial phenotype. Mechanistic studies revealed that overexpression of ERp29 in both cell-types upregulated the expression of TJ proteins (zonula-occludens-1 (ZO-1) and occludin) and the core apical-basal polarity proteins (Par3 and Scribble) at the membrane to enhance cell-cell contact and cell polarization. Knockdown of ERp29 in the epithelial MCF-7 cells decreased the expression of these proteins, leading to the disruption of cell-cell adhesion. Taken together, ERp29 is a novel molecule that regulates MET and epithelial cell integrity in breast cancer cells. Oncogene (2013) 32, 1240-1251; doi:10.1038/onc.2012.149; published online 30 April 2012	[Bambang, I. F.; Zhang, D.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore 117595, Singapore; [Bambang, I. F.; Lee, Y. K.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117595, Singapore; [Richardson, D. R.; Zhang, D.] Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia; [Richardson, D. R.; Zhang, D.] Univ Sydney, Bosch Inst, Iron Metab & Chelat Program, Sydney, NSW 2006, Australia	National University of Singapore; National University of Singapore; University of Sydney; University of Sydney	Zhang, D (corresponding author), Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia.	d.richardson@med.usyd.edu.au; daohai.zhang@sydney.edu.au		Richardson, Des/0000-0002-5506-3274; Richardson, Des/0000-0003-0960-6415	National Health and Medical Research Council of Australia; Agency of Science, Technology and Research-Biomedical Research Council in Singapore (A*STAR-BMRC) [07/1/21/19/496]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Agency of Science, Technology and Research-Biomedical Research Council in Singapore (A*STAR-BMRC)(Agency for Science Technology & Research (A*STAR))	DRR thanks the National Health and Medical Research Council of Australia for a Senior Principal Research Fellowship. This research was performed in DZ's laboratory in the National University of Singapore and was sponsored by an Individual Research Grant awarded to DZ from the Agency of Science, Technology and Research-Biomedical Research Council in Singapore (A*STAR-BMRC 07/1/21/19/496).	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bambang IF, 2009, LAB INVEST, V89, P1229, DOI 10.1038/labinvest.2009.87; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Baryshev M, 2006, BIOCHEM BIOPH RES CO, V340, P617, DOI 10.1016/j.bbrc.2005.12.052; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; Chaffer CL, 2005, CLIN EXP METASTAS, V22, P115, DOI 10.1007/s10585-005-5141-3; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Coradini D, 2011, ACTA PHARMACOL SIN, V32, P552, DOI 10.1038/aps.2011.20; Das S, 2009, MOL BIOL CELL, V20, P2593, DOI 10.1091/mbc.E08-07-0790; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Farmaki E, 2011, BBA-MOL CELL RES, V1813, P1165, DOI 10.1016/j.bbamcr.2011.03.003; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gao DM, 2012, LAB INVEST, V92, P200, DOI 10.1038/labinvest.2011.163; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; Gibson MC, 2003, CURR OPIN CELL BIOL, V15, P747, DOI 10.1016/j.ceb.2003.10.008; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hunter MP, 2010, AM J PHYSIOL-CELL PH, V299, pC21, DOI 10.1152/ajpcell.00543.2009; IMHOF BA, 1983, CELL, V35, P667, DOI 10.1016/0092-8674(83)90099-5; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Katoh K, 2001, AM J PHYSIOL-CELL PH, V280, pC1669, DOI 10.1152/ajpcell.2001.280.6.C1669; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Martin TA, 2004, EUR J CANCER, V40, P2717, DOI 10.1016/j.ejca.2004.08.008; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Qi L, 2012, MED ONCOL, V29, P721, DOI 10.1007/s12032-011-9929-5; Ren XD, 2004, J CELL SCI, V117, P3511, DOI 10.1242/jcs.01205; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Ross DT, 2001, DIS MARKERS, V17, P99, DOI 10.1155/2001/850531; Rothenberg SM, 2010, CANCER RES, V70, P2158, DOI 10.1158/0008-5472.CAN-09-3458; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Shnyder SD, 2008, J PROTEOME RES, V7, P3364, DOI 10.1021/pr800126n; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Tanos B, 2008, ONCOGENE, V27, P6939, DOI 10.1038/onc.2008.345; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Watanabe T, 2007, MOL BIOL CELL, V18, P605, DOI 10.1091/mbc.E06-07-0590; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zen K, 2009, ONCOGENE, V28, P2910, DOI 10.1038/onc.2009.148; Zhang DH, 2010, EXP CELL RES, V316, P3522, DOI 10.1016/j.yexcr.2010.08.014	64	27	30	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1240	1251		10.1038/onc.2012.149	http://dx.doi.org/10.1038/onc.2012.149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543584				2022-12-28	WOS:000316454500005
J	Hennigan, RF; Moon, CA; Parysek, LM; Monk, KR; Morfini, G; Berth, S; Brady, S; Ratner, N				Hennigan, R. F.; Moon, C. A.; Parysek, L. M.; Monk, K. R.; Morfini, G.; Berth, S.; Brady, S.; Ratner, N.			The NF2 tumor suppressor regulates microtubule-based vesicle trafficking via a novel Rac, MLK and p38(SAPK) pathway	ONCOGENE			English	Article						merlin; NF2; Rac; trafficking; exocytosis	FAST AXONAL-TRANSPORT; MEDIATES CONTACT INHIBITION; HUMAN SCHWANNOMA CELLS; NEUROFIBROMATOSIS TYPE-2; PLASMA-MEMBRANE; P21-ACTIVATED KINASE; SIGNALING PATHWAY; ERM PROTEINS; MERLIN; RECEPTOR	Neurofibromatosis type 2 patients develop schwannomas, meningiomas and ependymomas resulting from mutations in the tumor suppressor gene, NF2, encoding a membrane-cytoskeleton adapter protein called merlin. Merlin regulates contact inhibition of growth and controls the availability of growth factor receptors at the cell surface. We tested if microtubule-based vesicular trafficking might be a mechanism by which merlin acts. We found that schwannoma cells, containing merlin mutations and constitutive activation of the Rho/Rac family of GTPases, had decreased intracellular vesicular trafficking relative to normal human Schwann cells. In Nf2-/- mouse Schwann (SC4) cells, re-expression of merlin as well as inhibition of Rac or its effector kinases, MLK and p38(SAPK), each increased the velocity of Rab6 positive exocytic vesicles. Conversely, an activated Rac mutant decreased Rab6 vesicle velocity. Vesicle motility assays in isolated squid axoplasm further demonstrated that both mutant merlin and active Rac specifically reduce anterograde microtubule-based transport of vesicles dependent upon the activity of p38(SAPK) kinase. Taken together, our data suggest loss of merlin results in the Rac-dependent decrease of anterograde trafficking of exocytic vesicles, representing a possible mechanism controlling the concentration of growth factor receptors at the cell surface. Oncogene (2013) 32, 1135-1143; doi:10.1038/onc.2012.135; published online 23 April 2012	[Hennigan, R. F.; Moon, C. A.; Ratner, N.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Parysek, L. M.] Univ Cincinnati, Sch Med, Dept Cell & Canc Biol, Cincinnati, OH USA; [Monk, K. R.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Morfini, G.; Berth, S.; Brady, S.] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL USA; [Morfini, G.; Berth, S.; Brady, S.; Ratner, N.] Marine Biol Lab, Woods Hole, MA 02543 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Washington University (WUSTL); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Marine Biological Laboratory - Woods Hole	Hennigan, RF (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, 240 Albert Sabin Way, Cincinnati, OH 45229 USA.	Robert.Hennigan@cchmc.org	Morfini, Gerardo/AAP-8070-2021	Morfini, Gerardo/0000-0001-6059-5518; RATNER, NANCY/0000-0001-5030-9354	NIH [R01 CA118032, R01 NS23868]; MBL research fellowships; NATIONAL CANCER INSTITUTE [R01CA118032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023868] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MBL research fellowships; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH R01 CA118032 (to NR), and MBL research fellowships (to NR and GM), NIH R01 NS23868 (to SIB). We thank Atira Dudley Hardiman for assistance with growth and transfection of human cells, Jamie M Walker for expert technical assistance and Dr Yi Zheng for critical reading of the manuscript.	Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Ammoun S, 2011, NAT REV NEUROL, V7, P392, DOI 10.1038/nrneurol.2011.82; Avruch J, 2007, BBA-MOL CELL RES, V1773, P1150, DOI 10.1016/j.bbamcr.2006.11.006; Bensenor LB, 2010, P NATL ACAD SCI USA, V107, P7311, DOI 10.1073/pnas.0907389107; Best A, 1996, J BIOL CHEM, V271, P3756; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Bosco DA, 2010, NAT NEUROSCI, V13, P1396, DOI 10.1038/nn.2660; Bosco EE, 2010, ONCOGENE, V29, P2540, DOI 10.1038/onc.2010.20; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1985, CELL MOTIL CYTOSKEL, V5, P81, DOI 10.1002/cm.970050203; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cole BK, 2008, MOL CELL BIOL, V28, P1274, DOI 10.1128/MCB.01139-07; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Edelstein A., 2010, COMPUTER CONTROL MIC; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gerst JE, 1999, CELL MOL LIFE SCI, V55, P707, DOI 10.1007/s000180050328; Giovannini M, 2000, GENE DEV, V14, P1617; Grigoriev I, 2007, DEV CELL, V13, P305, DOI 10.1016/j.devcel.2007.06.010; Hennigan RF, 2010, MOL CELL BIOL, V30, P54, DOI 10.1128/MCB.00248-09; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lallemand D, 2009, ONCOGENE, V28, P854, DOI 10.1038/onc.2008.427; Lerdrup M, 2006, J CELL SCI, V119, P85, DOI 10.1242/jcs.02707; Lerdrup M, 2007, MOL BIOL CELL, V18, P3656, DOI 10.1091/mbc.e07-01-0025; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; MACCOLLIN M, 1993, JAMA-J AM MED ASSOC, V270, P2316, DOI 10.1001/jama.270.19.2316; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; McClatchey AI, 2009, TRENDS CELL BIOL, V19, P198, DOI 10.1016/j.tcb.2009.02.006; Morfini G, 2006, NAT NEUROSCI, V9, P907, DOI 10.1038/nn1717; Morfini GA, 2009, J NEUROSCI, V29, P12776, DOI 10.1523/JNEUROSCI.3463-09.2009; Morfini GA, 2009, NAT NEUROSCI, V12, P864, DOI 10.1038/nn.2346; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muranen T, 2007, HUM MOL GENET, V16, P1742, DOI 10.1093/hmg/ddm122; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nakai Y, 2006, J NEUROSCI, V26, P3390, DOI 10.1523/JNEUROSCI.4865-05.2006; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTKOWSKI JL, 1995, NAT MED, V1, P80, DOI 10.1038/nm0195-80; Sampo B, 2003, NEURON, V37, P611, DOI 10.1016/S0896-6273(03)00058-8; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Woodcock SA, 2010, CURR BIOL, V20, P669, DOI 10.1016/j.cub.2010.02.033; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	54	13	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2013	32	9					1135	1143		10.1038/onc.2012.135	http://dx.doi.org/10.1038/onc.2012.135			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22525268	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000316428800007
J	Martineau, Y; Azar, R; Bousquet, C; Pyronnet, S				Martineau, Y.; Azar, R.; Bousquet, C.; Pyronnet, S.			Anti-oncogenic potential of the eIF4E-binding proteins	ONCOGENE			English	Review						protein synthesis; elF4E; 4E-BP; mTOR	INITIATION-FACTOR 4E; CAP-DEPENDENT TRANSLATION; FACTOR 4E-BINDING PROTEIN-1; SERINE/THREONINE KINASE PIM-2; SMALL-MOLECULE INHIBITION; REPRESSOR PHAS-I; MESSENGER-RNA; BINDING PROTEIN; EIF4E PHOSPHORYLATION; MAMMALIAN TARGET	The elF4E-binding proteins (4E-BPs) are inhibitors of protein synthesis that sequester the mRNA cap-binding protein elF4E and consequently block cell growth and proliferation. In most tumors however, their inhibitory function is compromised by major oncogenic signaling pathways. Recently, thanks to the generation of mouse genetic models, considerable progress has been made in elucidating the involvement of 4E-BPs and their unique target, elF4E, in the process of carcinogenesis. Increasing evidence indicates that an 'addiction' to protein synthesis emerges in cancer cells, highlighting the potential that 4E-BPs have as targets for therapeutics. In this review, we summarize the biochemical function, regulation and anti-oncogenic activity of the 4E-BPs. Oncogene (2013) 32, 671-677; doi:10.1038/onc.2012.116; published online 16 April 2012	[Martineau, Y.; Azar, R.; Bousquet, C.; Pyronnet, S.] Univ Toulouse, CRCT, INSERM UMR 1037, F-31432 Toulouse, France; [Azar, R.] Lebanese Univ, Fac Pharm, Dept Clin Pharm, Hadath, Lebanon; [Pyronnet, S.] Ctr Hosp Toulouse, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Lebanese University; CHU de Toulouse	Pyronnet, S (corresponding author), Univ Toulouse, CHU Rangueil, INSERM UMR 1037, CRCT, BP 84225, F-31432 Toulouse, France.	stephane.pyronnet@inserm.fr	Pyronnet, Stéphane/P-2419-2014; Martineau, Yvan/G-2387-2017; Bousquet, Corinne/P-2917-2014	Martineau, Yvan/0000-0002-0575-4085; Bousquet, Corinne/0000-0002-2501-0593	La Ligue Contre le Cancer; Fondation pour la Recherche Medicale (FRM); Association pour la Recherche contre le Cancer (ARC)	La Ligue Contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR))	The author's work was supported by grants from La Ligue Contre le Cancer to SP, the Fondation pour la Recherche Medicale (FRM) Post-Doc fellow program (YM) and the Association pour la Recherche contre le Cancer (ARC) PhD fellow program (RA).	Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Azar R, 2008, CELL MOL LIFE SCI, V65, P3110, DOI 10.1007/s00018-008-8418-2; Azar R, 2009, EMBO J, V28, P3514, DOI 10.1038/emboj.2009.291; Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Braunstein S, 2009, MOL CELL BIOL, V29, P5645, DOI 10.1128/MCB.00711-09; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Caron S, 2004, MOL CELL BIOL, V24, P4920, DOI 10.1128/MCB.24.11.4920-4928.2004; Cencic R, 2011, P NATL ACAD SCI USA, V108, P1046, DOI 10.1073/pnas.1011477108; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Constantinou C, 2008, BIOL CELL, V100, P279, DOI 10.1042/BC20070121; Cormier P, 2001, DEV BIOL, V232, P275, DOI 10.1006/dbio.2001.0206; Dobrikov M, 2011, MOL CELL BIOL, V31, P2947, DOI 10.1128/MCB.05589-11; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gong JP, 2009, J SURG RES, V153, P17, DOI 10.1016/j.jss.2008.03.033; Gosselin P, 2011, NUCLEIC ACIDS RES, V39, P3496, DOI 10.1093/nar/gkq1306; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; Holzmann K, 2000, BIOCHEM BIOPH RES CO, V267, P339, DOI 10.1006/bbrc.1999.1973; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Jacobson BA, 2006, CANCER RES, V66, P4256, DOI 10.1158/0008-5472.CAN-05-2879; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Joshi B, 2004, EUR J BIOCHEM, V271, P2189, DOI 10.1111/j.1432-1033.2004.04149.x; Kleijn M, 2002, FEBS LETT, V532, P319, DOI 10.1016/S0014-5793(02)03694-3; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Le Bouffant R, 2006, J CELL BIOCHEM, V99, P126, DOI 10.1002/jcb.20856; Lee VHY, 2008, FEBS J, V275, P2185, DOI 10.1111/j.1742-4658.2008.06372.x; Li QY, 1999, MOL CELL BIOL, V19, P7336; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Liu GM, 2002, J BIOL CHEM, V277, P8810, DOI 10.1074/jbc.M110477200; Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436-6453.2005; MADER S, 1995, MOL CELL BIOL, V15, P4990; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Murata T, 2006, J BIOL CHEM, V281, P20788, DOI 10.1074/jbc.M600563200; Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; Orton KC, 2004, J BIOL CHEM, V279, P38649, DOI 10.1074/jbc.M407337200; Oulhen N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005070; Paku KS, 2012, BIOCHEM J, V441, P237, DOI 10.1042/BJ20101481; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Petroulakis E, 2009, CANCER CELL, V16, P439, DOI 10.1016/j.ccr.2009.09.025; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rolli-Derkinderen M, 2003, J BIOL CHEM, V278, P18859, DOI 10.1074/jbc.M211696200; Rom E, 1998, J BIOL CHEM, V273, P13104, DOI 10.1074/jbc.273.21.13104; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Salaun P, 2003, DEV BIOL, V255, P428, DOI 10.1016/S0012-1606(02)00099-4; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Shveygert M, 2010, MOL CELL BIOL, V30, P5160, DOI 10.1128/MCB.00448-10; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Tamburini J, 2009, BLOOD, V114, P1618, DOI 10.1182/blood-2008-10-184515; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Teleman AA, 2005, GENE DEV, V19, P1844, DOI 10.1101/gad.341505; Tettweiler G, 2005, GENE DEV, V19, P1840, DOI 10.1101/gad.1311805; Topisirovic I, 2009, MOL CELL BIOL, V29, P1152, DOI 10.1128/MCB.01532-08; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yamaguchi S, 2008, CELL METAB, V7, P269, DOI 10.1016/j.cmet.2008.01.008	83	67	70	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2013	32	6					671	677		10.1038/onc.2012.116	http://dx.doi.org/10.1038/onc.2012.116			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22508483				2022-12-28	WOS:000315746700001
J	Murfuni, I; Nicolai, S; Baldari, S; Crescenzi, M; Bignami, M; Franchitto, A; Pichierri, P				Murfuni, I.; Nicolai, S.; Baldari, S.; Crescenzi, M.; Bignami, M.; Franchitto, A.; Pichierri, P.			The WRN and MUS81 proteins limit cell death and genome instability following oncogene activation	ONCOGENE			English	Article						RecQ helicases; replication fork arrest; genome instability; Werner syndrome	DNA-DAMAGE RESPONSE; WERNERS-SYNDROME PROTEIN; REPLICATION FORK; S-PHASE; HOMOLOGOUS RECOMBINATION; SYNTHETIC LETHALITY; CANCER DEVELOPMENT; HELICASE ACTIVITY; DEPENDENT MANNER; DOWN-REGULATION	Oncogene-induced replication stress is recognized as the primary cause of accumulation of DNA damage and genome instability in precancerous cells. Although the molecular mechanisms responding to such type of replication perturbation are not fully characterized, it has been speculated that their dysfunction may enhance genonne instability and accelerate tumor progression. Here, we show that the WRN protein, a member of the human RecQ helicases, is necessary to sustain replication fork progression in response to oncogene-induced replication stress. Loss of WRN affects cell cycle progression and results in enhanced accumulation of double-strand breaks and instability at common fragile sites in cells experiencing oncogene-induced replication stress. Moreover, we demonstrate that double-strand breaks, observed upon oncogene over-expression, depend on the MUS81 endonuclease, which represents a parallel pathway collaborating with WRN to prevent cell death. Overall, our findings give insights into the mechanisms protecting replication forks in cells experiencing oncogene-induced replication stress, and identify factor\s that, when mutated or dysfunctional, may enhance genome instability in precancerous cells. In addition, because concomitant depletion of WRN and MUS81 causes synthetic sickness in cells growing under oncogene-induced replication stress, our results support the possibility of targeting cancer cells with an impaired replication fork recovery pathway by a specific inactivation of the other parallel pathway. Oncogene (2013) 32, 610-620; doi:10.1038/onc.2012.80; published online 12 March 2012	[Murfuni, I.; Nicolai, S.; Bignami, M.; Pichierri, P.] Ist Super Sanita, Sect Expt & Computat Carcinogenesis, I-00161 Rome, Italy; [Baldari, S.; Franchitto, A.] Ist Super Sanita, Sect Mol Epidemiol, Dept Environm & Primary Prevent, I-00161 Rome, Italy; [Crescenzi, M.] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Franchitto, A (corresponding author), Ist Super Sanita, Dept Primary Prevent, Sect Expt Carcinogenesis, Viale Regina Elena 299, I-00161 Rome, Italy.	annapaola.franchitto@iss.it; pietro.pichierri@iss.it	Pichierri, Pietro/AAA-5476-2021; Crescenzi, Marco/J-3603-2018; Baldari, Silvia/AAA-5959-2021; Franchitto, Annapaola/K-7564-2016	Pichierri, Pietro/0000-0002-2702-3523; Crescenzi, Marco/0000-0003-0156-1494; Baldari, Silvia/0000-0001-7982-9468; Franchitto, Annapaola/0000-0003-4232-4727	Association for International Cancer Research [07-497]; Associazione ltaliana per la Ricerca sul Cancro (AIRC) [IG 9294, IG 4400]	Association for International Cancer Research; Associazione ltaliana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We are grateful to Dr Pavel Janscak for providing the siRNAs and antibody against RECQ5. We also thank Drs D Toniolo and M Rocchi for providing bacterial artificial chromosomes for FISH analysis. This work was supported by a grant from the Association for International Cancer Research (Grant 07-497) to PP. and by grants from Associazione ltaliana per la Ricerca sul Cancro (AIRC) to PP. (IG 9294) and A.F. (IG 4400).	Aggarwal M, 2011, P NATL ACAD SCI USA, V108, P1525, DOI 10.1073/pnas.1006423108; Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103; Allen C, 2011, J MOL CELL BIOL, V3, P4, DOI 10.1093/jmcb/mjq049; Ammazzalorso F, 2010, EMBO J, V29, P3156, DOI 10.1038/emboj.2010.205; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bohr VA, 2008, TRENDS BIOCHEM SCI, V33, P609, DOI 10.1016/j.tibs.2008.09.003; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Doe CL, 2002, J BIOL CHEM, V277, P32753, DOI 10.1074/jbc.M202120200; Duker NJ, 2002, AM J MED GENET, V115, P125, DOI 10.1002/ajmg.10688; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Franchitto A, 2002, HUM MOL GENET, V11, P2447, DOI 10.1093/hmg/11.20.2447; Franchitto A, 2003, CANCER RES, V63, P3289; Franchitto A, 2008, J CELL BIOL, V183, P241, DOI 10.1083/jcb.200803173; Friedel AM, 2009, CURR OPIN CELL BIOL, V21, P237, DOI 10.1016/j.ceb.2009.01.017; Froget B, 2008, MOL BIOL CELL, V19, P445, DOI 10.1091/mbc.E07-07-0728; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hanada K, 2007, NAT STRUCT MOL BIOL, V14, P1096, DOI 10.1038/nsmb1313; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Liontos M, 2007, CANCER RES, V67, P10899, DOI 10.1158/0008-5472.CAN-07-2837; Lopez-Contreras AJ, 2010, DNA REPAIR, V9, P1249, DOI 10.1016/j.dnarep.2010.09.012; Mao FJ, 2010, CANCER RES, V70, P6548, DOI 10.1158/0008-5472.CAN-10-0475; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; OLIVE PL, 1991, CANCER RES, V51, P4671; Petermann E, 2010, NAT REV MOL CELL BIO, V11, P683, DOI 10.1038/nrm2974; Pichierri P, 2003, ONCOGENE, V22, P1491, DOI 10.1038/sj.onc.1206169; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; Pichierri P, 2011, AGING-US, V3, P311, DOI 10.18632/aging.100293; Pirzio LM, 2008, J CELL BIOL, V180, P305, DOI 10.1083/jcb.200705126; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; Robinson K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005951; Roseaulin L, 2008, EMBO J, V27, P1378, DOI 10.1038/emboj.2008.65; Rossi ML, 2010, DNA REPAIR, V9, P331, DOI 10.1016/j.dnarep.2009.12.011; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Schwendener S, 2010, J BIOL CHEM, V285, P15739, DOI 10.1074/jbc.M110.110478; Sidorova JM, 2008, CELL CYCLE, V7, P796, DOI 10.4161/cc.7.6.5566; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Trowbridge K, 2007, GENETICS, V176, P1993, DOI 10.1534/genetics.106.070060; Walther A, 2008, GUT, V57, P941, DOI 10.1136/gut.2007.135004; Wechsler T, 2011, NATURE, V471, P642, DOI 10.1038/nature09790; Wu F, 2011, CANCER SCI, V102, P472, DOI 10.1111/j.1349-7006.2010.01790.x; Wu F, 2010, ANTICANCER RES, V30, P5011; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5	54	35	37	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					610	620		10.1038/onc.2012.80	http://dx.doi.org/10.1038/onc.2012.80			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22410776				2022-12-28	WOS:000316164700008
J	Li, X; Stevens, PD; Yang, H; Gulhati, P; Wang, W; Evers, BM; Gao, T				Li, X.; Stevens, P. D.; Yang, H.; Gulhati, P.; Wang, W.; Evers, B. M.; Gao, T.			The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer	ONCOGENE			English	Article						PHLPP; USP46; Akt; deubiquitination; tumor suppressor	PROTEIN-KINASE-C; E3 LIGASE; PHOSPHATASE; GLIOBLASTOMA; ACTIVATION; STABILITY; APOPTOSIS; FEEDBACK; PTEN	PH domain leucine-rich-repeats protein phosphatase (PHLPP) is a family of Ser/Thr protein phosphatases that serve as tumor suppressors by negatively regulating Akt. Our recent studies have demonstrated that the ubiquitin proteasome pathway has an important role in the downregulation of PHLPP in colorectal cancer. In this study, we show that the deubiquitinase USP46 stabilizes the expression of both PHLPP isoforms by reducing the rate of PHLPP degradation. USP46 binds to PHLPP and directly removes the polyubiquitin chains from PHLPP in vitro and in cells. Increased USP46 expression correlates with decreased ubiquitination and upregulation of PHLPP proteins in colon cancer cells, whereas knockdown of USP46 has the opposite effect. Functionally, USP46-mediated stabilization of PHLPP and the subsequent inhibition of Akt result in a decrease in cell proliferation and tumorigenesis of colon cancer cells in vivo. Moreover, reduced USP46 protein level is found associated with poor PHLPP expression in colorectal cancer patient specimens. Taken together, these results indentify a tumor suppressor role of USP46 in promoting PHLPP expression and inhibiting Akt signaling in colon cancer. Oncogene (2013) 32, 471-478; doi:10.1038/onc.2012.66; published online 5 March 2012	[Li, X.; Stevens, P. D.; Gulhati, P.; Wang, W.; Evers, B. M.; Gao, T.] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; [Yang, H.] Taizhou Hosp, Dept Oncol, Taizhou, Peoples R China; [Gulhati, P.; Evers, B. M.] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA; [Gulhati, P.] Univ Texas Med Branch, MD PhD Program, Galveston, TX 77555 USA; [Gao, T.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Texas System; University of Texas Medical Branch Galveston; University of Kentucky	Gao, T (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	tianyan.gao@uky.edu			NIH [R01CA133429]; American Cancer Society [RSG0822001TBE, P20CA1530343, R01DK48498]; NATIONAL CANCER INSTITUTE [P20CA150343, R01CA133429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048498] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Wade Harper (Harvard Medical School) for providing USP46, USP7 and USP16 expression plasmids, and Dr Hui-Kuan Lin (University of Texas MD Anderson Cancer Center) for providing His-tagged ubiquitin construct. The Biostatistic Core at the Markey Cancer Center (University of Kentucky) provided assistant with the statistical analysis in our study. This work was supported by NIH R01CA133429 (TG), American Cancer Society RSG0822001TBE (TG), P20CA1530343 (UK GI SPORE) and R01DK48498 (BME).	Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kowalski JR, 2011, J NEUROSCI, V31, P1341, DOI 10.1523/JNEUROSCI.4765-10.2011; Li X, 2011, EMBO REP, V12, P818, DOI 10.1038/embor.2011.106; Li X, 2009, MOL CELL BIOL, V29, P6192, DOI 10.1128/MCB.00681-09; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Liu JY, 2011, J BIOL CHEM, V286, P6510, DOI 10.1074/jbc.M110.183087; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017; REINER A, 1990, CANCER RES, V50, P7057; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Shimizu K, 2010, MOL BIOSYST, V6, P38, DOI 10.1039/b911410f; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Warfel NA, 2011, J BIOL CHEM, V286, P19777, DOI 10.1074/jbc.M111.237081; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065	24	73	75	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					471	478		10.1038/onc.2012.66	http://dx.doi.org/10.1038/onc.2012.66			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391563	Green Accepted			2022-12-28	WOS:000315551300008
J	Psallidas, I; Stathopoulos, GT; Maniatis, NA; Magkouta, S; Moschos, C; Karabela, SP; Kollintza, A; Simoes, DCM; Kardara, M; Vassiliou, S; Papiris, SA; Roussos, C; Kalomenidis, I				Psallidas, I.; Stathopoulos, G. T.; Maniatis, N. A.; Magkouta, S.; Moschos, C.; Karabela, S. P.; Kollintza, A.; Simoes, D. C. M.; Kardara, M.; Vassiliou, S.; Papiris, S. A.; Roussos, C.; Kalomenidis, I.			Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion	ONCOGENE			English	Article						osteopontin; pleural effusion; cancer; inflammation; angiogenesis	TUMOR PROGRESSION; OSTEOPONTIN ISOFORMS; LUNG-CANCER; IN-VIVO; MACROPHAGES; METASTASIS; INFLAMMATION; INVASION; GROWTH; CELLS	Secreted phosphoprotein-1 (SPP1) promotes cancer cell survival and regulates tumor-associated angiogenesis and inflammation, both central to the pathogenesis of malignant pleural effusion (MPE). Here, we examined the impact of tumor- and host-derived SPP1 in MPE formation and explored the mechanisms by which the cytokine exerts its effects. We used a syngeneic murine model of lung adenocarcinoma-induced MPE. To dissect the effects of tumor- versus host-derived SPP1, we intrapleurally injected wild-type and SPP1-knockout C57/BL/6 mice with either wild-type or SPP1-deficient syngeneic lung cancer cells. We demonstrated that both tumor- and host-derived SPP1 promoted pleural fluid accumulation and tumor dissemination in a synergistic manner (P<0.001). SPP1 of host origin elicited macrophage recruitment into the cancer-affected pleural cavity and boosted tumor angiogenesis, whereas tumor-derived SPP1 curtailed cancer cell apoptosis in vivo. Moreover, the cytokine directly promoted vascular hyper-permeability independently of vascular endothelial growth factor. In addition, SPP1 of tumor and host origin differentially affected the expression of proinflammatory and angiogenic mediators in the tumor microenvironment. These results suggest that SPP1 of tumor and host origin impact distinct aspects of MPE pathobiology to synergistically promote pleural fluid formation and pleural tumor progression. SPP1 may present an attractive target of therapeutic interventions for patients with MPE. Oncogene (2013) 32, 528-535; doi:10.1038/onc.2012.57; published online 27 February 2012	[Psallidas, I.; Stathopoulos, G. T.; Maniatis, N. A.; Magkouta, S.; Moschos, C.; Karabela, S. P.; Kollintza, A.; Simoes, D. C. M.; Kardara, M.; Papiris, S. A.; Roussos, C.; Kalomenidis, I.] Evangelismos Med Ctr, Athens Med Sch, Dept Crit Care & Pulm Serv 1, Marianthi Simou Lab, Athens, Greece; [Psallidas, I.; Moschos, C.; Papiris, S. A.; Kalomenidis, I.] Attikon Hosp, Athens Med Sch, Dept Pulm Med 2, Haidari, Greece; [Stathopoulos, G. T.] Univ Patras, Sch Med, Dept Physiol, Rion, Greece; [Vassiliou, S.] Euaggelismos Hosp, Dept Hematol & Lymphomas, Athens, Greece	Evangelismos Hospital; National & Kapodistrian University of Athens; University Hospital Attikon; University of Patras	Psallidas, I (corresponding author), Athens Med Sch, Dept Crit Care & Pulm Serv 1, Marianthi Simou Lab, 3 Ploutarhou St, Athens 10675, Greece.	jpsallidas@med.uoa.gr	Stathopoulos, Georgios/AAE-6884-2020; Kalomenidis, Ioannis/AAD-7521-2019; PAPIRIS, SPYROS/AAD-1825-2020; Stathopoulos, Georgios/D-6576-2013	Stathopoulos, Georgios/0000-0002-9215-6461; Psallidas, Ioannis/0000-0001-7284-0111; Simoes, Davina Camargo Madeira/0000-0002-7262-1784	'Thorax' Foundation (Athens, Greece); GlaxoSmithKline [12 000]	'Thorax' Foundation (Athens, Greece); GlaxoSmithKline(GlaxoSmithKline)	We thank Dr A Marantidou and Z Kollia for professional veterinarian and animal care assistance, respectively. We also thank L Liaw (Maine Medical Center Research Institute) for permission to use the Spp1 +1+ and Spp1-/- mice. This work was supported by the 'Thorax' Foundation (Athens, Greece) and by a research grant by GlaxoSmithKline (funding 12 000 to IP). GlaxoSmithKline had no involvement in study design, collection, analysis and interpretation of data, writing of the report and in the decision to submit the report for publication. IP and IK had full control of all of the data in this study and take complete responsibility for the integrity of the data and the accuracy of the data analysis.	Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; Bourassa B, 2004, CELL IMMUNOL, V227, P1, DOI 10.1016/j.cellimm.2004.01.001; Burdo TH, 2007, J LEUKOCYTE BIOL, V81, P1504, DOI 10.1189/jlb.1106711; Burgers JA, 2008, EUR RESPIR J, V32, P1321, DOI 10.1183/09031936.00165607; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Crawford HC, 1998, CANCER RES, V58, P5206; Cui R, 2009, LUNG CANCER, V63, P368, DOI 10.1016/j.lungcan.2008.06.020; Dai J, 2009, ONCOGENE, V28, P3412, DOI 10.1038/onc.2009.189; Dai JX, 2010, CANCER IMMUNOL IMMUN, V59, P355, DOI 10.1007/s00262-009-0754-z; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Dickson PV, 2007, CLIN CANCER RES, V13, P3942, DOI 10.1158/1078-0432.CCR-07-0278; Du XL, 2009, GYNECOL ONCOL, V115, P371, DOI 10.1016/j.ygyno.2009.08.029; Ivanov SV, 2009, BIOCHEM BIOPH RES CO, V382, P514, DOI 10.1016/j.bbrc.2009.03.042; Kalomenidis I, 2011, RESPIROLOGY, V16, P1020, DOI 10.1111/j.1440-1843.2011.02023.x; Krump-Konvalinkova V, 2001, LAB INVEST, V81, P1717, DOI 10.1038/labinvest.3780385; Liaw L, 1998, J CLIN INVEST, V101, P1468; Mason CK, 2008, MOL CANCER THER, V7, P548, DOI 10.1158/1535-7163.MCT-07-2251; Moschos C, 2009, RESPIROLOGY, V14, P716, DOI 10.1111/j.1440-1843.2009.01536.x; Moschos C, 2009, NEOPLASIA, V11, P298, DOI 10.1593/neo.81480; Nemoto H, 2001, J BONE MINER RES, V16, P652, DOI 10.1359/jbmr.2001.16.4.652; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Psallidas I, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-56; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Roberts ME, 2010, THORAX, V65, P32, DOI 10.1136/thx.2010.136994; Rodrigues LR, 2007, CANCER EPIDEM BIOMAR, V16, P1087, DOI 10.1158/1055-9965.EPI-06-1008; Shevde LA, 2010, CURR MOL MED, V10, P71, DOI 10.2174/156652410791065381; Shinohara ML, 2008, P NATL ACAD SCI USA, V105, P7235, DOI 10.1073/pnas.0802301105; Sica A., 2010, Experimental Oncology, V32, P153; Stathopoulos GT, 2008, JNCI-J NATL CANCER I, V100, P1464, DOI 10.1093/jnci/djn325; Stathopoulos GT, 2008, AM J RESP CRIT CARE, V178, P50, DOI 10.1164/rccm.200710-1513OC; Stathopoulos GT, 2007, CANCER RES, V67, P9825, DOI 10.1158/0008-5472.CAN-07-1064; Stathopoulos GT, 2010, AM J RESP CRIT CARE, V182, P1273, DOI 10.1164/rccm.201001-0001OC; Stathopoulos GT, 2006, AM J RESP CELL MOL, V34, P142, DOI 10.1165/rcmb.2005-0130OC; Van Meter MEM, 2011, J GEN INTERN MED, V26, P70, DOI 10.1007/s11606-010-1472-0; Wai PY, 2006, SURGERY, V140, P132, DOI 10.1016/j.surg.2006.02.005; Wai PY, 2005, CARCINOGENESIS, V26, P741, DOI 10.1093/carcin/bgi027; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Yamamoto Y, 1998, INFECT IMMUN, V56, P370; Yano S, 2000, AM J PATHOL, V157, P1893, DOI 10.1016/S0002-9440(10)64828-6; Zhao W, 2010, J BIOL CHEM, V285, P20452, DOI 10.1074/jbc.M110.110312	42	37	37	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					528	535		10.1038/onc.2012.57	http://dx.doi.org/10.1038/onc.2012.57			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22370646				2022-12-28	WOS:000315551300013
J	Kamiyama, H; Suzuki, K; Maeda, T; Koizumi, K; Miyaki, Y; Okada, S; Kawamura, YJ; Samuelsson, JK; Alonso, S; Konishi, F; Perucho, M				Kamiyama, H.; Suzuki, K.; Maeda, T.; Koizumi, K.; Miyaki, Y.; Okada, S.; Kawamura, Y. J.; Samuelsson, J. K.; Alonso, S.; Konishi, F.; Perucho, M.			DNA demethylation in normal colon tissue predicts predisposition to multiple cancers	ONCOGENE			English	Article						DNA demethylation; colon cancer; synchronous; metachronous; epigenetics	COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; LINE-1 HYPOMETHYLATION; METHYLATION; TUMORS; FIELD; MUCOSA; AGE; GUIDELINES; MUTATIONS	Some colon cancer (CC) patients present synchronous cancers at diagnosis and others develop metachronous neoplasms, but the risk factors are unclear for non-hereditary CC. We showed previously that global DNA demethylation increased with aging and correlated with genomic damage in CC, and we show now that preferentially associates to CCs with wild-type p53. This study aimed to elucidate the extent of DNA hypomethylation in patients with single and multiple CC, its relationship with aging, and its potential as predictive tool. We compared by real-time methylation-specific PCR the relative demethylation level (RDL) of long interspersed nucleotide element-1 (LINE-1) sequences in matched cancer tissues and non-cancerous colonic mucosa (NCM) from patients with single and multiple right-sided CCs. Although no RDL difference was found in NCM from single CC patients and healthy volunteers (P = 0.5), there was more demethylation (higher RDL) in NCM from synchronous cancer patients (P = 1.1 x 10(-5)) multiple CCs also were more demethylated than single CCs (P = 0.0014). High NCM demethylation was predictive for metachronous neoplasms (P = 0.003). In multivariate logistic regression analyses RDL was the only independent predictor for metachronous (P = 0.02) and multiple (P = 4.9 x 10(-5)) tumors. The higher LINE-1 demethylation in NCM from patients with multiple (synchronous and metachronous) tumors (P = 9.6 x 10(-7)) was also very significant in patients with tumors without (P = 3.8 x 10(-6)), but not with (P = 0.16) microsatellite instability. NCM demethylation increased with aging in patients with single tumors, but decreased in those with multiple tumors. Moreover, the demethylation difference between patients with single vs multiple tumors appeared higher in younger (P = 3.6 x 10(-4)) than in older (P = 0.0016) patients. These results predict that LINE-1 hypomethylation in NCM can be used as an epigenetic predictive biomarker for multiple CC risk. The stronger association of demethylation in NCM with multiple CC risk from younger patients also suggests an inherited predisposition for the apparent field cancerization effect of somatic demethylation. Oncogene (2012) 31, 5029-5037; doi:10.1038/onc.2011.652; published online 6 February 2012	[Kamiyama, H.; Suzuki, K.; Maeda, T.; Okada, S.; Kawamura, Y. J.; Konishi, F.] Jichi Med Univ, Saitama Med Ctr, Dept Surg, Saitama, Japan; [Koizumi, K.; Miyaki, Y.] Hamamatsu Univ Sch Med, Dept Surg 1, Hamamatsu, Shizuoka 4313192, Japan; [Samuelsson, J. K.; Perucho, M.] Sanford Burnham Med Res Inst SBMRI, La Jolla, CA 92037 USA; [Samuelsson, J. K.; Alonso, S.; Perucho, M.] Inst Predict & Personalized Med Canc IMPPC, Barcelona, Spain; [Perucho, M.] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain	Jichi Medical University; Hamamatsu University School of Medicine; Sanford Burnham Prebys Medical Discovery Institute; ICREA	Suzuki, K (corresponding author), Jichi Med Univ, Saitama Med Ctr, Dept Surg, Saitama, Japan.	ksuzbnhm@omiya.jichi.ac.jp; mperucho@sanfordburnham.org	Alonso, Sergio/GVR-8346-2022; Alonso, Sergio/G-5145-2011	Alonso, Sergio/0000-0001-6497-892X; Perucho, Manuel/0000-0002-2169-2662	Ministry of Education, Culture, Science, Sports, and Technology of Japan; NIH [R37 CA63585]; Spanish Ministry of Science and Innovation [FIS PI09/02444]; ICREA Funding Source: Custom; NATIONAL CANCER INSTITUTE [R37CA063585] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [21591710] Funding Source: KAKEN	Ministry of Education, Culture, Science, Sports, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); ICREA(ICREA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by grants from the Ministry of Education, Culture, Science, Sports, and Technology of Japan, NIH grant R37 CA63585 and from the Spanish Ministry of Science and Innovation (FIS PI09/02444).	Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94; Belshaw NJ, 2010, CARCINOGENESIS, V31, P1158, DOI 10.1093/carcin/bgq077; Bouvier AM, 2008, EUR J CANCER, V44, P522, DOI 10.1016/j.ejca.2008.01.007; Braakhuis BJM, 2003, CANCER RES, V63, P1727; Brenner H, 2007, GUT, V56, P1585, DOI 10.1136/gut.2007.122739; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Estecio MRH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000399; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gonzalo V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008777; Horii J, 2008, CLIN BIOCHEM, V41, P1440, DOI 10.1016/j.clinbiochem.2008.08.089; Ibrahim AEK, 2011, GUT, V60, P499, DOI 10.1136/gut.2010.223602; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kawakami K, 2011, CANCER SCI, V102, P166, DOI 10.1111/j.1349-7006.2010.01776.x; KIM HG, 1994, AM J PATHOL, V145, P148; Konishi K, 2009, CANCER PREV RES, V2, P814, DOI 10.1158/1940-6207.CAPR-09-0054; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Menigatti M, 2009, ONCOGENE, V28, P899, DOI 10.1038/onc.2008.444; Nosho K, 2009, GASTROENTEROLOGY, V137, P1609, DOI 10.1053/j.gastro.2009.08.002; Ogino S, 2008, J NATL CANCER I, V100, P1734, DOI 10.1093/jnci/djn359; Paun BC, 2010, CANCER-AM CANCER SOC, V116, P4495, DOI 10.1002/cncr.25348; Perucho M, 1996, BIOL CHEM, V377, P675; Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5; R Core Team, 2020, R LANG ENV STAT COMP; Rex DK, 2006, GASTROENTEROLOGY, V130, P1865, DOI 10.1053/j.gastro.2006.03.013; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Sunami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018884; Suter CM, 2004, INT J COLORECTAL DIS, V19, P95, DOI 10.1007/s00384-003-0539-3; Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016; Suzuki K, 2003, GASTROENTEROLOGY, V125, P1330, DOI 10.1016/j.gastro.2003.07.006; Svrcek M, 2010, GUT, V59, P1516, DOI 10.1136/gut.2009.194787; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tsao JL, 2000, P NATL ACAD SCI USA, V97, P1236, DOI 10.1073/pnas.97.3.1236; Umar A, 2004, NAT REV CANCER, V4, P153, DOI 10.1038/nrc1278; Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142; Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Worthley DL, 2010, ONCOGENE, V29, P1653, DOI 10.1038/onc.2009.449; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9; Zeimet AG, 2011, GYNECOL ONCOL, V121, P24, DOI 10.1016/j.ygyno.2010.12.332	44	47	47	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					5029	5037		10.1038/onc.2011.652	http://dx.doi.org/10.1038/onc.2011.652			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22310288	Green Accepted			2022-12-28	WOS:000311888600007
J	Aoki, I; Higuchi, M; Gotoh, Y				Aoki, I.; Higuchi, M.; Gotoh, Y.			NEDDylation controls the target specificity of E2F1 and apoptosis induction	ONCOGENE			English	Article						apoptosis; cell cycle; E2F transcription factor; post-translational modification; NEDD8	DNA-DAMAGE; FAMILY-MEMBERS; CELL-CYCLE; TRANSCRIPTION; P73; NEDD8; DEGRADATION; ACTIVATION; PROTEINS; CHECKPOINT	The transcription factor E2F1 has pivotal roles in both cell proliferation and cell death, and is an important molecular target in cancer. Under proliferative conditions E2F1 induces the expression of genes that promote cell cycle progression, such as E2F2, whereas under proapoptotic conditions E2F1 induces expression of genes such as p73 that lead to apoptosis. The mechanism by which the apoptotic function of E2F1 is activated remains unclear, however. We now show that members of the E2F family are covalently conjugated with the ubiquitin-like modifier NEDD8. Overexpression of SENP8, a NEDD8-specific cysteine protease, resulted in deNEDDylation of E2F1 and promoted its transactivation activity at the p73 gene but not at the E2F2 gene. Knockdown of SENP8, on the other hand, attenuated p73 expression and apoptosis induced by E2F1 or by DNA damage. SENP8 also promoted the interaction between E2F1 and its cofactor Microcephalin 1, which is required for p73 induction. These results suggest that NEDDylation is a molecular trigger that modifies the target specificity of E2F1, and could have important implications for E2F1 regulation of apoptosis.	[Aoki, I.; Higuchi, M.; Gotoh, Y.] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan	University of Tokyo	Gotoh, Y (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ygotoh@iam.u-tokyo.ac.jp	Aoki, Ichiro/J-6578-2012	Aoki, Ichiro/0000-0001-5756-2723	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; CREST from the Japan Science and Technology Agency; Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan; Grants-in-Aid for Scientific Research [22123003] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); CREST from the Japan Science and Technology Agency(Core Research for Evolutional Science and Technology (CREST)); Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Elizabeth Nigh and colleagues for critical reading of the manuscript. This work was supported by Grants-in-Aid for Scientific Research (A) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, and by CREST from the Japan Science and Technology Agency. This work was also supported in part by the Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.	Biswas SC, 2005, J NEUROSCI, V25, P8349, DOI 10.1523/JNEUROSCI.1570-05.2005; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; DeGregori J, 2006, CURR MOL MED, V6, P739; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Engels IH, 2009, ANAL BIOCHEM, V390, P85, DOI 10.1016/j.ab.2009.03.035; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gao F, 2006, NAT CELL BIOL, V8, P1171, DOI 10.1038/ncb1483; Hallstrom TC, 2006, GENE DEV, V20, P613, DOI 10.1101/gad.1345006; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hughes TA, 2005, BIOCHEM BIOPH RES CO, V329, P1267, DOI 10.1016/j.bbrc.2005.02.102; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Inari A, 2004, J BIOL CHEM, V279, P30830, DOI 10.1074/jbc.M402403200; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Lin WC, 2001, GENE DEV, V15, P1833; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Martinez LA, 2010, MOL CELL BIOL, V30, P524, DOI 10.1128/MCB.00938-09; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183; Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rowland BD, 2006, CELL, V127, P871, DOI 10.1016/j.cell.2006.11.019; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; van den Heuvel S, 2008, NAT REV MOL CELL BIO, V9, P713, DOI 10.1038/nrm2469; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Watson IR, 2010, ONCOGENE, V29, P297, DOI 10.1038/onc.2009.314; Watson IR, 2006, J BIOL CHEM, V281, P34096, DOI 10.1074/jbc.M603654200; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Wu S, 2008, BIOCHEM BIOPH RES CO, V365, P75, DOI 10.1016/j.bbrc.2007.10.145; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang SZ, 2008, EMBO REP, V9, P907, DOI 10.1038/embor.2008.128	49	31	34	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3954	3964		10.1038/onc.2012.428	http://dx.doi.org/10.1038/onc.2012.428			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	23001041				2022-12-28	WOS:000323748100004
J	Kunkeaw, N; Jeon, SH; Lee, K; Johnson, BH; Tanasanvimon, S; Javle, M; Pairojkul, C; Chamgramol, Y; Wongfieng, W; Gong, B; Leelayuwat, C; Lee, YS				Kunkeaw, N.; Jeon, S. H.; Lee, K.; Johnson, B. H.; Tanasanvimon, S.; Javle, M.; Pairojkul, C.; Chamgramol, Y.; Wongfieng, W.; Gong, B.; Leelayuwat, C.; Lee, Y. S.			Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma	ONCOGENE			English	Article						nc886; cholangiocarcinoma; PKR; eIF2 alpha; NF-kappa B	GUANINE-NUCLEOTIDE EXCHANGE; INITIATION-FACTORS EIF-4E; UP-REGULATION; TRANSLATIONAL CONTROL; INCREASED EXPRESSION; CANCER CELLS; PKR ACTIVITY; VIRUS; INHIBITION; APOPTOSIS	We have recently identified nc886 (pre-miR-886 or vtRNA2-1) as a novel type of non-coding RNA that inhibits activation of protein kinase R (PKR). PKR's pro-apoptotic role through eukaryotic initiation factor 2 alpha (eIF2 alpha) phosphorylation is well established in the host defense against viral infection. Paradoxically, some cancer patients have elevated PKR activity; however, its cause and consequence are not understood. Initially, we evaluated the expression of nc886, PKR and eIF2 alpha in non-malignant cholangiocyte and cholangiocarcinoma (CCA) cells. nc886 is repressed in CCA cells and this repression is the cause of PKR's activation therein. nc886 alone is necessary and sufficient for suppression of PKR via direct physical interaction. Consistently, artificial suppression of nc886 in cholangiocyte cells activates the canonical PKR/eIF2 alpha cell death pathway, suggesting a potential significance of the nc886 suppression and the consequent PKR activation in eliminating pre-malignant cells during tumorigenesis. In comparison, active PKR in CCA cells does not induce phospho-eIF2 alpha nor apoptosis, but promotes the pro-survival nuclear factor-kappa B pathway. Thus, PKR has a dual life or death role during tumorigenesis. Similarly to the CCA cell lines, nc886 tends to be decreased but PKR tends to be activated in our clinical samples from CCA patients. Collectively from our data, we propose a tumor surveillance model for nc886's role in the PKR pathway during tumorigenesis.	[Kunkeaw, N.; Jeon, S. H.; Lee, K.; Johnson, B. H.; Lee, Y. S.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Kunkeaw, N.; Wongfieng, W.; Leelayuwat, C.] Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev, Med Diagnost Labs, Khon Kaen, Thailand; [Jeon, S. H.] Hallym Univ, Dept Life Sci, Chunchon, South Korea; [Tanasanvimon, S.] Chulalongkorn Univ, Fac Med, King Chulalongkorn Mem Hosp, Dept Med, Bangkok 10330, Thailand; [Tanasanvimon, S.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Javle, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Pairojkul, C.; Chamgramol, Y.; Leelayuwat, C.] Khon Kaen Univ, Fac Med, Liver Fluke & Cholangiocarcinoma Res Ctr, Khon Kaen, Thailand; [Gong, B.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; Khon Kaen University; Hallym University; Chulalongkorn University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Khon Kaen University; University of Texas System; University of Texas Medical Branch Galveston	Lee, YS (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, 7-138H Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	yslee@utmb.edu	Jeon, Sung Ho/B-9728-2009; , Alsevier/V-1974-2019	Piwphankum, Jirawut/0000-0001-6129-8830	National Cancer Institute [CA16672]; American Cancer Society [RSG-12-187-01-RMC]; Sealy Center for Cancer Biology at the University of Texas Medical Branch; Royal Golden Jubilee (RGJ) scholarship of Thailand Research Fund (TRF) [PHD/0105/2550]; Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2011-0022022]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Sealy Center for Cancer Biology at the University of Texas Medical Branch; Royal Golden Jubilee (RGJ) scholarship of Thailand Research Fund (TRF); Basic Science Research Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Sopit Wongkham, Dr Kanlayanee Sawanyawisuth and Ms Sirinapa Sribenja (Khon Kaen University) for CCA cells and helpful discussion; Dr Inhan Lee (miRcore, MI) for helpful advice; Research Histology Core Laboratory Facility, University of Texas, MD Anderson Cancer Center (funded by the National Cancer Institute Grant # CA16672) for tissue preparation and IHC. This work was supported by a Research Scholar Grant, RSG-12-187-01-RMC from the American Cancer Society to YSL, by start-up funding from the Sealy Center for Cancer Biology at the University of Texas Medical Branch to YSL, by the Royal Golden Jubilee (RGJ) scholarship (PHD/0105/2550) of Thailand Research Fund (TRF) to NK and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0022022) to SHJ.	Alisi A, 2011, J HEPATOL, V54, P956, DOI 10.1016/j.jhep.2010.08.016; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Basu S, 1997, CANCER RES, V57, P943; Beretta L, 1996, ONCOGENE, V12, P1593; Blalock WL, 2009, J CELL PHYSIOL, V221, P232, DOI 10.1002/jcp.21848; Datta B, 2000, BIOCHIMIE, V82, P95, DOI 10.1016/S0300-9084(00)00383-7; Fabian JR, 1998, PROTEIN EXPRES PURIF, V13, P16, DOI 10.1006/prep.1998.0860; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; Hiasa Y, 2003, AM J GASTROENTEROL, V98, P2528, DOI 10.1016/S0002-9270(03)01696-4; Hii SI, 2004, INT J CANCER, V109, P329, DOI 10.1002/ijc.11714; Ikegami T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000287; Jeon SH, 2012, FEBS LETT IN PRESS, DOI DOI 10.1016/J.FEBSLET.2012.07.076); Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lee K, 2011, RNA, V17, P1076, DOI 10.1261/rna.2701111; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; Li YJ, 2011, INT J MOL MED, V28, P215, DOI 10.3892/ijmm.2011.666; Lobo MVT, 2000, HISTOCHEM J, V32, P139, DOI 10.1023/A:1004091122351; Maruyama M, 2004, TRANSPLANTATION, V77, P446, DOI 10.1097/01.TP.0000110292.73873.25; Mounir Z, 2010, FUTURE ONCOL, V6, P643, DOI 10.2217/FON.10.45; Murad JM, 2005, BLOOD CELL MOL DIS, V34, P1, DOI 10.1016/j.bcmd.2004.08.025; Nandy C, 2009, J MOL BIOL, V388, P776, DOI 10.1016/j.jmb.2009.03.031; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Onori P, 2009, INT J CANCER, V125, P565, DOI 10.1002/ijc.24271; Pataer A, 2002, CANCER RES, V62, P2239; Pataer A, 2010, CLIN CANCER RES, V16, P5522, DOI 10.1158/1078-0432.CCR-10-0753; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Raught B, 1996, CANCER RES, V56, P4382; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Stadler PF, 2009, MOL BIOL EVOL, V26, P1975, DOI 10.1093/molbev/msp112; Tepsiri N, 2005, WORLD J GASTROENTERO, V11, P2748, DOI 10.3748/wjg.v11.i18.2748; Terada T, 2000, HUM PATHOL, V31, P817, DOI 10.1053/hupa.2000.8443; Treppendahl MB, 2012, BLOOD, V119, P206, DOI 10.1182/blood-2011-06-362541; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Yonglitthipagon P, 2010, INT J PARASITOL, V40, P1203, DOI 10.1016/j.ijpara.2010.05.002	47	52	56	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3722	3731		10.1038/onc.2012.382	http://dx.doi.org/10.1038/onc.2012.382			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22926522	Green Accepted			2022-12-28	WOS:000322904400007
J	Schepeler, T; Lamy, P; Hvidberg, V; Laurberg, JR; Fristrup, N; Reinert, T; Bartkova, J; Tropia, L; Bartek, J; Halazonetis, TD; Pan, CC; Borre, M; Dyrskjot, L; Orntoft, TF				Schepeler, T.; Lamy, P.; Hvidberg, V.; Laurberg, J. R.; Fristrup, N.; Reinert, T.; Bartkova, J.; Tropia, L.; Bartek, J.; Halazonetis, T. D.; Pan, C-C; Borre, M.; Dyrskjot, L.; Orntoft, T. F.			A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response	ONCOGENE			English	Article						bladder cancer; SNP array; DNA damage response; Timeless	ANTICANCER BARRIER; MAMMALIAN TIMELESS; TIPIN; CHECKPOINT; GENE; INSTABILITY; PROGRESSION; SIGNATURES; ONCOGENE; COMPLEX	One major challenge in cancer research is to understand the complex interplay between the DNA damage response (DDR), genomic integrity, and tumor development. To address these issues, we analyzed 43 bladder tumor genomes from 22 patients using single nucleotide polymorphism (SNP) arrays, and tissue expression of multiple DDR proteins, including Timeless and its interaction partner Tipin. The SNP profiles confirmed and extended known copy number alterations (CNAs) at high resolution, showed clustering of CNAs at nine common fragile sites, and revealed that most metachronous tumors were clonally related. The occurrence of many novel uniparental disomy regions (UPDs) was of potential functional importance in some tumors because UPDs spanned mutated FGFR3 and PIK3CA alleles, and also homozygous deletion of the CDKN2A tumor suppressor locus. The DDR signaling as evaluated by phospho-epitope-specific antibodies against Ser139-phosphorylated H2A histone family member X (gamma H2AX), ataxia telangiectasia mutated (ATM), and ATM- and Rad3-related (ATR) was commonly activated in tumors with both moderate and high extent of accumulated genomic aberrations, the latter tumors showing a more frequent loss of ATM expression. Strikingly, the tumor genomes exhibiting the most complex alterations were associated with a high Ki67-proliferation index, abundant Timeless but not Tipin expression, aberrant p53 expression, and homozygous CDKN2A deletions. Of clinical relevance, evaluation of a tissue microarray (TMA; n = 319) showed that abundant Timeless expression was associated with risk of progression to muscle-invasive disease (P<0.0005; hazard ratio, 2.4; 95% confidence interval, 1.6-3.8) and higher T stage (P<0.05). Univariate analysis confirmed this association (P = 0.006) in an independent cohort (n = 241) but statistical significance was not reached in a multivariate model. Overall, our results are consistent with DDR activation preceding the accumulation of genomic aberrations. Tumors with extensive genomic rearrangements were associated with inactivation of CDKN2A, excessive proliferation, and robust Timeless expression, the latter also correlating with the risk of disease progression. Moreover, we provide evidence to suggest that UPDs likely contribute to bladder tumorigenesis.	[Schepeler, T.; Lamy, P.; Hvidberg, V.; Laurberg, J. R.; Fristrup, N.; Reinert, T.; Dyrskjot, L.; Orntoft, T. F.] Aarhus Univ Hosp, Dept Mol Med, DK-8200 Aarhus N, Denmark; [Bartkova, J.; Bartek, J.] Danish Canc Soc, Res Ctr, Copenhagen, Denmark; [Tropia, L.; Halazonetis, T. D.] Univ Geneva, Dept Mol Biol, CH-1211 Geneva, Switzerland; [Bartek, J.] Palacky Univ, Inst Mol & Translat Med, CR-77147 Olomouc, Czech Republic; [Halazonetis, T. D.] Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; [Pan, C-C] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan; [Borre, M.] Aarhus Univ Hosp, Dept Urol, DK-8200 Aarhus N, Denmark	Aarhus University; Danish Cancer Society; University of Geneva; Palacky University Olomouc; University of Geneva; Taipei Veterans General Hospital; Aarhus University	Orntoft, TF (corresponding author), Aarhus Univ Hosp, Dept Mol Med, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark.	orntoft@ki.au.dk	Bartek, Jiri/G-5870-2014	Dyrskjot, Lars/0000-0001-7061-9851; Borre, Michael/0000-0002-1519-9185; Reinert, Thomas/0000-0003-4835-4804	John and Birthe Meyer Foundation; Danish Cancer Society; Danish National Research Foundation; Ministry of Technology and Science; Lundbeck Foundation; European Community's Seventh Framework program [201663]	John and Birthe Meyer Foundation; Danish Cancer Society(Danish Cancer Society); Danish National Research Foundation(Danmarks Grundforskningsfond); Ministry of Technology and Science; Lundbeck Foundation(Lundbeckfonden); European Community's Seventh Framework program(European Commission)	We thank The John and Birthe Meyer Foundation, the Danish Cancer Society, the Danish National Research Foundation, the Ministry of Technology and Science, the Lundbeck Foundation, and the European Community's Seventh Framework program (projects Infla-Care, Biomedreg, DDresponse, and Grant agreement no. 201663).	Aly A, 2011, J MOL CELL BIOL, V3, P66, DOI 10.1093/jmcb/mjq055; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Blaveri E, 2005, CLIN CANCER RES, V11, P7012, DOI 10.1158/1078-0432.CCR-05-0177; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Chou DM, 2006, P NATL ACAD SCI USA, V103, P18143, DOI 10.1073/pnas.0609251103; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Dereli-Oz A, 2011, MOL ONCOL, V5, P308, DOI 10.1016/j.molonc.2011.05.002; Dheekollu J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019596; Duggan BJ, 2004, J UROLOGY, V171, P419, DOI 10.1097/01.ju.0000100105.27708.6c; Fu A, 2011, MOL CARCINOG, V17, DOI [10.1002/mc.20862, DOI 10.1002/MC.20862)]; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gotter AL, 2007, J MOL BIOL, V366, P36, DOI 10.1016/j.jmb.2006.10.097; Hafner C, 2002, INT J CANCER, V101, P1, DOI 10.1002/ijc.10544; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Koed K, 2005, CANCER RES, V65, P34; Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821; Langbein S, 2002, LAB INVEST, V82, P639, DOI 10.1038/labinvest.3780458; Lapunzina P, 2011, BIOL CELL, V103, P303, DOI 10.1042/BC20110013; Le Tallec B, 2011, NAT STRUCT MOL BIOL, V18, P1421, DOI 10.1038/nsmb.2155; Letessier A, 2011, NATURE, V470, P120, DOI 10.1038/nature09745; Lindgren D, 2010, CANCER RES, V70, P3463, DOI 10.1158/0008-5472.CAN-09-4213; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Lu ML, 2002, CLIN CANCER RES, V8, P171; Martin SA, 2010, J PATHOL, V220, P281, DOI 10.1002/path.2631; McFarlane RJ, 2010, CELL CYCLE, V9, P700, DOI 10.4161/cc.9.4.10676; Mo L, 2007, J CLIN INVEST, V117, P314, DOI 10.1172/JCI30062; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Santarius T, 2010, GENE CHROMOSOME CANC, V49, P711, DOI 10.1002/gcc.20784; Schepeler Troels, 2007, J Mol Signal, V2, P6, DOI 10.1186/1750-2187-2-6; Smith-Roe SL, 2011, CELL CYCLE, V10, P1618, DOI 10.4161/cc.10.10.15613; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031; Takacova S, 2012, CANCER CELL, V21, P517, DOI 10.1016/j.ccr.2012.01.021; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Tuna M, 2009, TRENDS MOL MED, V15, P120, DOI 10.1016/j.molmed.2009.01.005; Unsal-Kacmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005; Unsal-Kacmaz K, 2007, MOL CELL BIOL, V27, P3131, DOI 10.1128/MCB.02190-06; Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Wu QO, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-16; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Yang XM, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M109.050237; Yoshizawa-Sugata N, 2007, J BIOL CHEM, V282, P2729, DOI 10.1074/jbc.M605596200; Zieger K, 2009, INT J CANCER, V125, P2095, DOI 10.1002/ijc.24619; Zieger K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-149	56	24	26	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3577	3586		10.1038/onc.2012.381	http://dx.doi.org/10.1038/onc.2012.381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22926521				2022-12-28	WOS:000322638400002
J	Gopisetty, G; Xu, J; Sampath, D; Colman, H; Puduvalli, VK				Gopisetty, G.; Xu, J.; Sampath, D.; Colman, H.; Puduvalli, V. K.			Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation	ONCOGENE			English	Article						CD133; glioma Stem Cell; Sp1; Myc; promoter methylation; epigenetic regulation	DNA METHYLATION; CPG METHYLATION; HEMATOPOIETIC STEM; CHROMOSOMAL-PROTEIN; FUNCTIONAL-ANALYSIS; EPITHELIAL-CELLS; GENE-EXPRESSION; BINDING-SITES; C-MYC; TRANSCRIPTION	Tumor stem cells, postulated to be the source cells for malignancies, have been identified in several cancers using cell-surface expression of markers including CD133, a pentaspan membrane protein. CD133+ve cells form neurospheres, exhibit self-renewal and differentiation, and are tumorigenic. However, despite its association with stem cells, a causal relationship of CD133 to tumorigenesis remains to be defined. Hypothesizing that specific epigenetic and transcription factors implicated in driving the stem cell state may concurrently regulate CD133 expression in stem cells, we analyzed the structure and regulation of CD133 promoter in glioma stem cells and glioma cell lines. Initially, a minimal promoter region was identified by analyzing the activity of CD133 promoter-driven luciferase-expressing 5'-and 3'-deletion-constructs upstream of the transcription start site. This region contained a CpG island that was hypermethylated in CD133-ve glioma stem cells (GSC) and glioma cells but unmethylated in CD133+ve ones. Of several predicted TF-binding sites in this region, the role of tandem Sp1 (-242 and -221) and two Myc (-541 and -25)-binding sites were examined. Overexpression of Sp1 or Myc increased CD133 minimal promoter-driven luciferase activity and CD133 levels in GSC and in glioma cell line. Mithramycin, a Sp1 inhibitor, decreased minimal promoter activity and downregulated CD133 levels in GSC. Gel-shift assays demonstrated direct binding of Sp1 to their predicted sites that was competitively inhibited by oligonucleotide-binding-site sequences and supershifted by anti-Sp1 confirming the interaction. Sp1 and Myc-antibody chromatin immunoprecipitation (ChIP) analysis in GSC showed enrichment of regions with Sp1 and Myc-binding sites. In CD133-ve cells, ChIP analysis showed binding of the methyl-DNA-binding proteins, MBD1, MBD2 and MeCP2 to the methylated CpG island and repression of transcription. These results demonstrate that Sp1 and Myc regulate CD133 transcription in GSC and that promoter methylation and methyl-DNA-binding proteins cause repression of CD133 by excluding transcription-factor binding.	[Gopisetty, G.; Xu, J.; Colman, H.; Puduvalli, V. K.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77035 USA; [Sampath, D.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77035 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Puduvalli, VK (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 431, Houston, TX 77035 USA.	vpuduval@mdanderson.org	Sampath, Deepa/T-5069-2019; Colman, Howard/L-5433-2019; Puduvalli, Vinay K/A-2411-2016; Sampath, Deepa/J-3298-2016; Gopisetty, Gopal/ABB-6470-2020	Sampath, Deepa/0000-0002-4366-8436	Gregory Jungeblut Brain Tumor Research Fund; Dr Marnie Rose Foundation; Chuoke Brain Tumor Fund; NATIONAL CANCER INSTITUTE [K24CA160777, P30CA016672] Funding Source: NIH RePORTER	Gregory Jungeblut Brain Tumor Research Fund; Dr Marnie Rose Foundation; Chuoke Brain Tumor Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the Gregory Jungeblut Brain Tumor Research Fund, The Dr Marnie Rose Foundation and the Chuoke Brain Tumor Fund for providing funding support for this project.	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; BEDNARIK DP, 1991, NEW BIOL, V3, P969; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Chen RH, 2010, CANCER CELL, V17, P362, DOI 10.1016/j.ccr.2009.12.049; Cheng LP, 2004, FEBS LETT, V565, P195, DOI 10.1016/j.febslet.2004.03.097; Clouaire T, 2010, NUCLEIC ACIDS RES, V38, P4620, DOI 10.1093/nar/gkq228; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Corbeil D, 2000, J BIOL CHEM, V275, P5512, DOI 10.1074/jbc.275.8.5512; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Elsaba TMA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010714; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marsden CG, 2009, METHODS MOL BIOL, V590, P363, DOI 10.1007/978-1-60327-378-7_23; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Neuzil J, 2007, BIOCHEM BIOPH RES CO, V355, P855, DOI 10.1016/j.bbrc.2007.01.159; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Parisi F, 2007, NUCLEIC ACIDS RES, V35, P1098, DOI 10.1093/nar/gkl1157; RAY BK, 1994, GENE, V147, P253, DOI 10.1016/0378-1119(94)90076-0; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Shmelkov SV, 2005, INT J BIOCHEM CELL B, V37, P715, DOI 10.1016/j.biocel.2004.08.010; Shmelkov SV, 2004, BLOOD, V103, P2055, DOI 10.1182/blood-2003-06-1881; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tabu K, 2008, CELL RES, V18, P1037, DOI 10.1038/cr.2008.270; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Weigmann A, 1997, P NATL ACAD SCI USA, V94, P12425, DOI 10.1073/pnas.94.23.12425; Wu DY, 2006, CELL RES, V16, P319, DOI 10.1038/sj.cr.7310040; Yi JM, 2008, CANCER RES, V68, P8094, DOI 10.1158/0008-5472.CAN-07-6208; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	50	50	52	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2013	32	26					3119	3129		10.1038/onc.2012.331	http://dx.doi.org/10.1038/onc.2012.331			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22945648	Green Accepted			2022-12-28	WOS:000321004600002
J	Carloni, V; Mazzocca, A; Mello, T; Galli, A; Capaccioli, S				Carloni, V.; Mazzocca, A.; Mello, T.; Galli, A.; Capaccioli, S.			Cell fusion promotes chemoresistance in metastatic colon carcinoma	ONCOGENE			English	Article						colon cancer therapy; RhoA; GTP-binding protein alpha 13; tetraspanin CD81/CD9; FOLFOX; ADAM10	TUMOR-CELLS; PROTEINS; OXALIPLATIN; CD81; FLUOROURACIL; LEUCOVORIN; ACTIVATION; FAMILY; BREAST; CANCER	Chemoresistance is an important concern in the treatment of metastatic colon cancer. It may emerge through selection of clones that are inherently resistant from the outset or through mechanisms acquired during treatment. Cell fusion represents an efficient means of rapid phenotypic evolution that make cells with new properties at a rate exceeding that achievable by random mutagenesis. Here, we first identified a number of proteins involved in cell fusion using a shotgun proteomics approach, then we investigated the role of these proteins namely tetraspanin CD81/CD9, ADAM10, GTP-binding protein alpha 13, radixin, myosin regulatory light chain and RhoA in the regulation of colon cancer cell fusion. We also found a previously unrecognized role of ADAM10, G alpha 13 and RhoA in promoting cell fusion. Finally, we show that the occurrence of cell fusion in a metastatic model of colon carcinoma causes the appearance of cells resistant to both 5-fluorouracil and oxaliplatin. These findings highlight the importance of cell fusion in cancer progression and raise significant implications for overcoming chemoresistance in metastatic colon cancer.	[Carloni, V.] Univ Florence, DENOthe, Dept Internal Med, Ctr Res Transfer & High Educ, I-50134 Florence, Italy; [Mazzocca, A.] Univ Bari, Sch Med, Dept Emergency & Organ Transplantat, Sect Internal Med Allergol & Clin Immunol, Bari, Italy; [Mello, T.; Galli, A.] Univ Florence, Dept Clin Pathophysiol, Gastroenterol Unit, I-50134 Florence, Italy; [Capaccioli, S.] Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy	University of Florence; Universita degli Studi di Bari Aldo Moro; University of Florence; University of Florence	Carloni, V (corresponding author), Univ Florence, DENOthe, Dept Internal Med, Ctr Res Transfer & High Educ, Largo Brambilla 3, I-50134 Florence, Italy.	v.carloni@dmi.unifi.it	Galli, Andrea/AAC-1623-2019; Mello, Tommaso/AAO-7831-2021; Mello, Tommaso/I-4715-2012	Mello, Tommaso/0000-0002-6192-6902; Mello, Tommaso/0000-0002-6192-6902; MAZZOCCA, Antonio/0000-0003-0940-7352; Galli, Andrea/0000-0001-5416-6290	Ente Cassa di Risparmio di Firenze	Ente Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze)	We thank Peter Altevogt and Joaquin Teixido for important reagents used in this study. This work was supported by grant from Ente Cassa di Risparmio di Firenze.	Alberts SR, 2005, J CLIN ONCOL, V23, P9243, DOI 10.1200/JCO.2005.07.740; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; BORST P, 1993, PHARMACOL THERAPEUT, V60, P289, DOI 10.1016/0163-7258(93)90011-2; Carloni V, 2004, ONCOGENE, V23, P1566, DOI 10.1038/sj.onc.1207287; Chen EH, 2005, SCIENCE, V308, P369, DOI 10.1126/science.1104799; COLE SPC, 1994, CANCER RES, V54, P5902; Duelli D, 2003, CANCER CELL, V3, P445, DOI 10.1016/S1535-6108(03)00114-4; Duelli D, 2007, NAT REV CANCER, V7, P968, DOI 10.1038/nrc2272; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; FORTUNA MB, 1990, CANCER LETT, V55, P109, DOI 10.1016/0304-3835(90)90019-T; FORTUNA MB, 1989, INT J CANCER, V44, P731, DOI 10.1002/ijc.2910440430; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Johansson CB, 2008, NAT CELL BIOL, V10, P575, DOI 10.1038/ncb1720; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Khatib AM, 2005, AM J PATHOL, V167, P749, DOI 10.1016/S0002-9440(10)62048-2; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lu X, 2009, CANCER RES, V69, P8536, DOI 10.1158/0008-5472.CAN-09-2159; Lu X, 2009, P NATL ACAD SCI USA, V106, P9385, DOI 10.1073/pnas.0900108106; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Mazzocca A, 2008, GASTROENTEROLOGY, V135, P244, DOI 10.1053/j.gastro.2008.03.024; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Paluch E, 2006, TRENDS CELL BIOL, V16, P5, DOI 10.1016/j.tcb.2005.11.003; Parthasarathy V, 2009, IMMUNOLOGY, V127, P237, DOI 10.1111/j.1365-2567.2008.02945.x; Pawelek JM, 2008, NAT REV CANCER, V8, P377, DOI 10.1038/nrc2371; Samimi G, 2005, CANCER CHEMOTH PHARM, V55, P1, DOI 10.1007/s00280-004-0819-9; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; Takeda Y, 2003, J CELL BIOL, V161, P945, DOI 10.1083/jcb.200212031; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; WAGHORNE C, 1988, CANCER RES, V48, P6109; WAKELING WF, 1994, CELL BIOL INT, V18, P207, DOI 10.1006/cbir.1994.1063; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720	35	50	50	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2649	2660		10.1038/onc.2012.268	http://dx.doi.org/10.1038/onc.2012.268			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22751128				2022-12-28	WOS:000319806700006
J	Scribner, KC; Behbod, F; Porter, WW				Scribner, K. C.; Behbod, F.; Porter, W. W.			Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s)	ONCOGENE			English	Article						SIM2s; breast cancer; DCIS; differentiation	CARCINOMA IN-SITU; MAMMARY-GLAND DEVELOPMENT; GENE-EXPRESSION PROFILES; LUMINAL CELL FATE; SINGLE-MINDED 2S; ABERRANT ACTIVATION; SONIC HEDGEHOG; DIFFERENTIATION; PATHWAY; NOTCH	Singleminded-2s (SIM2s) is a member of the bHLH/ PAS family of transcription factors and a key regulator of mammary epithelial cell differentiation. SIM2s is highly expressed in mammary epithelial cells and downregulated in human breast cancer. Loss of Sim2s causes aberrant mouse mammary ductal development, with features suggestive of malignant transformation, whereas overexpression of SIM2s promotes precocious alveolar differentiation in nulliparous mouse mammary glands, suggesting that SIM2s is required for establishing and enhancing mammary gland differentiation. To test the hypothesis that SIM2s regulates tumor cell differentiation, we analyzed SIM2s expression in human primary breast ductal carcinoma in situ (DCIS) samples and found that SIM2s is lost with progression from DCIS to invasive ductal cancer (IDC). Using a MCF10DCIS. COM progression model, we have shown that SIM2s expression is decreased in MCF10DCIS. COM cells compared with MCF10A cells, and reestablishment of SIM2s in MCF10DCIS. COM cells significantly inhibits growth and invasion both in vitro and in vivo. Analysis of SIM2s-MCF10DCIS. com tumors showed that SIM2s promoted a more differentiated tumor phenotype including the expression of a broad range of luminal markers (CSN2 (beta-casein), CDH1 (E-cadherin), and KER18 (keratin-18)) and suppressed genes associated with stem cell maintenance and a basal phenotype (SMO (smoothened), p63, SLUG (snail-2), KER14 (keratin-14) and VIM (vimentin)). Furthermore, loss of SIM2s expression in MCF10DCIS. COM xenografts resulted in a more invasive phenotype and increased lung metastasis likely due to an increase in Hedgehog signaling and matrix metalloproteinase expression. Together, these exciting new data support a role for SIM2s in promoting human breast tumor differentiation and maintaining epithelial integrity.	[Scribner, K. C.; Porter, W. W.] Texas A&M Univ, Coll Vet Med, Dept Integrat Biosci, College Stn, TX 77843 USA; [Behbod, F.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA	Texas A&M University System; Texas A&M University College Station; University of Kansas; University of Kansas Medical Center	Porter, WW (corresponding author), Texas A&M Univ, Coll Vet Med, Depertment Integrat Biosci, Mail Stop 4458, College Stn, TX 77843 USA.	wporter@cvm.tamu.edu			National Cancer Institute (NCI) [R01CA111551]; Department of Defence (DOD-CDMRP) [W81XWH-11-1-0158]; NCI [5R00CA127462-06]; NATIONAL CANCER INSTITUTE [R00CA127462, R01CA111551] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defence (DOD-CDMRP); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Daniel Medina (Baylor College of Medicine, Houston, TX, USA) for providing the MCF10DCIS.com cell line and the Histology Core Facility at Texas A&M University College of Veterinary Medicine & Biomedical Sciences for tissue preparation and hematoxylin and eosin staining. DCIS and IDC tissue sections were provided by the University of KansasCancer Center Biospecimen Share Resources at the University of KansasMedical Center. This work was supported by grants R01CA111551 from the National Cancer Institute (NCI) to WWP, W81XWH-11-1-0158 from the Department of Defence (DOD-CDMRP) to KCS and 5R00CA127462-06 from the NCI to FB.	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Bond J, 1996, ONCOGENE, V13, P2097; Burstein HJ, 2004, NEW ENGL J MED, V350, P1430, DOI 10.1056/NEJMra031301; Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409; Cocker R, 2007, MED HYPOTHESES, V69, P57, DOI 10.1016/j.mehy.2006.11.042; Cody HS, 2007, ANN SURG ONCOL, V14, P2179, DOI 10.1245/s10434-006-9300-9; de Biase D, 2010, VIRCHOWS ARCH, V456, P395, DOI 10.1007/s00428-010-0900-1; Du ZJ, 2010, CANCER SCI, V101, P2417, DOI 10.1111/j.1349-7006.2010.01700.x; Dubois-Marshall S, 2011, CLIN EXP METASTASIS; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Gustafson TL, 2009, ONCOGENE; Hettinger AM, 2001, BIOL REPROD, V65, P507, DOI 10.1095/biolreprod65.2.507; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Ioachim EE, 1998, ANTICANCER RES, V18, P1665; Kallergi G, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2896; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Kasperczyk H, 2009, FASEB J, V23, P21, DOI 10.1096/fj.08-111096; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Koodie L, 2010, AM J PATHOL, V177, P984, DOI 10.2353/ajpath.2010.090621; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07; LaMarca HL, 2010, STEM CELLS, V28, P535, DOI 10.1002/stem.297; Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230; Liu D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031251; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Maffuz A, 2006, J EXP CLIN CANC RES, V25, P223; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McDaniel SM, 2006, AM J PATHOL, V168, P608, DOI 10.2353/ajpath.2006.050677; Mendes O, 2005, CLIN EXP METASTAS, V22, P237, DOI 10.1007/s10585-005-8115-6; Metz RP, 2006, J BIOL CHEM, V281, P10839, DOI 10.1074/jbc.M508858200; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Moraes RC, 2007, DEVELOPMENT, V134, P1231, DOI 10.1242/dev.02797; Oakes SR, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1411; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Porter D, 2003, MOL CANCER RES, V1, P362; Schedin P, 2004, MOL CARCINOGEN, V41, P207, DOI 10.1002/mc.20058; Scribner KC, 2011, MOL ENDOCRINOL; Shekhar MPV, 2008, CANCER BIOL THER, V7, P1774, DOI 10.4161/cbt.7.11.6781; Sims JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018848; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Tait LR, 2007, INT J CANCER, V120, P2127, DOI 10.1002/ijc.22572; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Visbal AP, 2011, DEV BIOL, V352, P116, DOI 10.1016/j.ydbio.2011.01.025; Walsh LA, 2012, J CELL COMMUN SIGNAL, V6, P87, DOI 10.1007/s12079-011-0157-8; Wang C, 2011, J CANCER RES CLIN, V137, P985, DOI 10.1007/s00432-010-0963-z; Wellberg E, 2010, DEVELOPMENT, V137, P945, DOI 10.1242/dev.041657; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Witty Jean P., 1995, Molecular Biology of the Cell, V6, P1287; Yalcin-Ozuysal O, 2010, CELL DEATH DIFFER, V17, P1600, DOI 10.1038/cdd.2010.37; Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083; Yoo YA, 2011, CANCER RES, V71, P7061, DOI 10.1158/0008-5472.CAN-11-1338; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhou J, 2005, EMBO J, V24, P635, DOI 10.1038/sj.emboj.7600538; Zuo SG, 2012, J CANCER RES CLIN, V138, P1045, DOI 10.1007/s00432-012-1153-y	64	20	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 23	2013	32	21					2631	2639		10.1038/onc.2012.286	http://dx.doi.org/10.1038/onc.2012.286			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22777354	Green Accepted			2022-12-28	WOS:000319806700004
J	Herglotz, J; Kuvardina, ON; Kolodziej, S; Kumar, A; Hussong, H; Grez, M; Lausen, J				Herglotz, J.; Kuvardina, O. N.; Kolodziej, S.; Kumar, A.; Hussong, H.; Grez, M.; Lausen, J.			Histone arginine methylation keeps RUNX1 target genes in an intermediate state	ONCOGENE			English	Article						epigenetics; stem cell; histone modifications; poised state; RUNX1	HEMATOPOIETIC STEM-CELLS; CHROMATIN SIGNATURES; H3K4 METHYLATION; TRANSCRIPTION; POLYCOMB; LEUKEMIA; AML1; EXPRESSION; COMPLEX; BINDING	The coordinated recruitment of epigenetic regulators of gene expression by transcription factors such as RUNX1 (AML1, acute myeloid leukemia 1) is crucial for hematopoietic differentiation. Here, we identify protein arginine methyltransferase 6 (PRMT6) as a central functional component of a RUNX1 corepressor complex containing Sin3a and HDAC1 in human hematopoietic progenitor cells. PRMT6 is recruited by RUNX1 and mediates asymmetric histone H3 arginine-2 dimethylation (H3R2me2a) at megakaryocytic genes in progenitor cells. H3R2me2a keeps RUNX1 target genes in an intermediate state with concomitant H3K27me3 and H3K4me2 but not H3K4me3. Upon megakaryocytic differentiation PRMT6 binding is lost, the H3R2me2a mark decreases and a coactivator complex containing WDR5/MLL and p300/pCAF is recruited. This leads to an increase of H3K4me3 and H3K9ac, which result in augmented gene expression. Our results provide novel mechanistic insight into how RUNX1 activity in hematopoietic progenitor cells maintains differentiation genes in a suppressed state but poised for rapid transcriptional activation.	[Herglotz, J.; Kuvardina, O. N.; Kolodziej, S.; Kumar, A.; Hussong, H.; Grez, M.; Lausen, J.] Georg Speyer Haus, Inst Biomed Res, D-60596 Frankfurt, Hessen, Germany	Octapharma	Lausen, J (corresponding author), Georg Speyer Haus, Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Hessen, Germany.	lausen@em.uni-frankfurt.de			LOEWE initiatives Onkogene Signaltransduktion Frankfurt (OSF); LOEWE Center for Cell and Gene Therapy Frankfurt (CGT), Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK) [III L 4-518/55.004, III L 4-518/17004]; institutional funds of the Georg-Speyer-Haus; German Federal Ministry of Health (BMG); HMWK; Deutsche Forschungsgemeinschaft [SPP-1463, LA 1389/5-1]	LOEWE initiatives Onkogene Signaltransduktion Frankfurt (OSF); LOEWE Center for Cell and Gene Therapy Frankfurt (CGT), Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK); institutional funds of the Georg-Speyer-Haus; German Federal Ministry of Health (BMG); HMWK; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Reinhard Henschler of the Institute for Transfusion Medicine Frankfurt for providing hCD34+ cells. JL is supported by the LOEWE initiatives Onkogene Signaltransduktion Frankfurt (OSF), the LOEWE Center for Cell and Gene Therapy Frankfurt (CGT), Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK), III L 4-518/55.004 and III L 4-518/17004 and institutional funds of the Georg-Speyer-Haus. The Georg-Speyer-Haus is funded jointly by the German Federal Ministry of Health (BMG) and the HMWK. This project was supported by the Deutsche Forschungsgemeinschaft (SPP-1463, LA 1389/5-1).	Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Balint BL, 2005, MOL CELL BIOL, V25, P5648, DOI 10.1128/MCB.25.13.5648-5663.2005; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Ben-Ami O, 2009, P NATL ACAD SCI USA, V106, P238, DOI 10.1073/pnas.0811466106; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Cui KR, 2009, CELL STEM CELL, V4, P80, DOI 10.1016/j.stem.2008.11.011; de Laat W, 2008, CURR TOP DEV BIOL, V82, P117, DOI 10.1016/S0070-2153(07)00005-1; Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984; Elagib KE, 2007, CRIT REV EUKAR GENE, V17, P271, DOI 10.1615/CritRevEukarGeneExpr.v17.i4.20; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Goldfarb AN, 2009, J CELL BIOCHEM, V107, P377, DOI 10.1002/jcb.22142; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166; Hammoud SS, 2009, NATURE, V460, P473, DOI 10.1038/nature08162; Hannah R, 2011, EXP HEMATOL, V39, P531, DOI 10.1016/j.exphem.2011.02.009; Harada Y, 2009, J CELL PHYSIOL, V220, P16, DOI 10.1002/jcp.21769; Hoogenkamp M, 2007, MOL CELL BIOL, V27, P7425, DOI 10.1128/MCB.00905-07; Hoogenkamp M, 2009, BLOOD, V114, P299, DOI 10.1182/blood-2008-11-191890; Huang G, 2008, NAT GENET, V40, P51, DOI 10.1038/ng.2007.7; Hyllus D, 2007, GENE DEV, V21, P3369, DOI 10.1101/gad.447007; Iberg AN, 2008, J BIOL CHEM, V283, P3006, DOI 10.1074/jbc.C700192200; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Jiang HM, 2005, MOL CELL BIOL, V25, P10675, DOI 10.1128/MCB.25.24.10675-10683.2005; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kirmizis A, 2007, NATURE, V449, P928, DOI 10.1038/nature06160; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kowenz-Leutz E, 2010, EMBO J, V29, P1105, DOI 10.1038/emboj.2010.3; Lausen J, 2004, J BIOL CHEM, V279, P49281, DOI 10.1074/jbc.M407239200; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Mahajan MC, 2009, EXP HEMATOL, V37, P1143, DOI 10.1016/j.exphem.2009.07.001; Michaud-Levesque J, 2009, J BIOL CHEM, V284, P21338, DOI 10.1074/jbc.M109.005322; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; O'Malley BW, 2008, CURR OPIN CELL BIOL, V20, P310, DOI 10.1016/j.ceb.2008.04.005; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Orford K, 2008, DEV CELL, V14, P798, DOI 10.1016/j.devcel.2008.04.002; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Owen CJ, 2008, BLOOD, V112, P4639, DOI 10.1182/blood-2008-05-156745; Pencovich N, 2011, BLOOD, V117, pE1, DOI 10.1182/blood-2010-07-295113; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Satoh Y, 2008, J BIOL CHEM, V283, P30045, DOI 10.1074/jbc.M804768200; Shilatifard A, 2008, CURR OPIN CELL BIOL, V20, P341, DOI 10.1016/j.ceb.2008.03.019; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Wang L, 2009, BLOOD CELL MOL DIS, V43, P30, DOI 10.1016/j.bcmd.2009.03.005; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang W, 2010, BLOOD, V116, P254, DOI 10.1182/blood-2009-11-254664; Wilson NK, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt47; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Xu G, 2006, LEUKEMIA, V20, P1002, DOI 10.1038/sj.leu.2404223; Yu M, 2012, MOL CELL, V45, P330, DOI 10.1016/j.molcel.2011.11.032; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608	56	39	39	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2565	2575		10.1038/onc.2012.274	http://dx.doi.org/10.1038/onc.2012.274			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22777353				2022-12-28	WOS:000319274300008
J	Kent, OA; Fox-Talbot, K; Halusha, MK				Kent, O. A.; Fox-Talbot, K.; Halusha, M. K.			RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets	ONCOGENE			English	Article						miRNA; miR-143; miR-145; KRAS; RREB1; colorectal	ZINC-FINGER PROTEIN; HUMAN COLON-CANCER; COLORECTAL-CANCER; TRANSCRIPTION FACTOR; PROSTATE-CANCER; RAS; MICRORNAS; EXPRESSION; MICE; TUMORIGENESIS	A lack of expression of miR-143 and miR-145 has been demonstrated to be a frequent feature of colorectal tumors. Activating KRAS mutations have been reported in 30-60% of colorectal cancers and an inverse correlation between Kras and miR-143/145 expression has been observed. Previously, we have demonstrated that oncogenic Kras leads to repression of the miR-143/145 cluster in pancreatic cancer and is dependent on the Ras responsive element (RRE) binding protein (RREB1), which negatively regulates miR-143/145 expression. In the present study, we have found that RREB1 is overexpressed in colorectal adenocarcinoma tumors and cell lines, and the expression of the miR-143/145 primary transcript is inversely related to RREB1 expression. In colorectal cancer cell lines, the miR-143/145 cluster is repressed by RREB1 downstream of constitutively active KRAS. RREB1 is activated by the MAPK pathway and negatively represses the miR-143/145 promoter through interaction with two RREs. In addition, overexpression of miR-143 or miR-145 in HCT116 cells abrogates signaling through the MAPK, PI3K and JNK pathways by downregulation of both KRAS and RREB1 in addition to downregulation of a cohort of genes in the MAPK signaling cascade. These results establish a complex network of regulation through which the miR-143/145 cluster is able to modulate KRAS signaling in colorectal cancer.	[Kent, O. A.; Fox-Talbot, K.; Halusha, M. K.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Johns Hopkins University	Kent, OA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 720 Rutland Ave,Ross Res Bldg 632, Baltimore, MD 21205 USA.	kent@lunenfeld.ca		Halushka, Marc/0000-0002-7112-7389; Kent, Oliver/0000-0001-6494-4383	NIH [R01CA120185]; Doris Duke Foundation [2009040]; NATIONAL CANCER INSTITUTE [R01CA120185] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doris Duke Foundation(Doris Duke Charitable Foundation (DDCF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Joshua Mendell and Dr Anirban Maitra for helpful discussions and feedback during preparation of the manuscript. We thank Dr James Eshleman for kindly providing cell lines and Norman Barker for photography assistance. We would like to thank Dr Dan Durocher and members of the Durocher laboratory at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital Toronto for kindly providing laboratory space and reagents and helpful discussions during the review process of the manuscript. This work was supported in part through the NIH (R01CA120185) and by a Clinician Scientist Award to MKH from the Doris Duke Foundation Grant #: 2009040. OAK is a Life Sciences Research Foundation Fellow.	Adler V, 2005, BIOCHEMISTRY-US, V44, P10784, DOI 10.1021/bi050619j; Akao Y, 2006, ONCOL REP, V16, P845; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bissonnette M, 2000, CANCER RES, V60, P4602; Borralho PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023787; Borralho PM, 2009, FEBS J, V276, P6689, DOI 10.1111/j.1742-4658.2009.07383.x; Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Buzzi N, 2009, MOL CELL BIOCHEM, V328, P201, DOI 10.1007/s11010-009-0090-9; Calcagno SR, 2008, INT J CANCER, V122, P2462, DOI 10.1002/ijc.23383; Campbell PM, 2007, CANCER RES, V67, P2098, DOI 10.1158/0008-5472.CAN-06-3752; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Clape C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007542; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Date S, 2004, INT J MOL MED, V13, P637; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Feldmann G, 2008, GUT, V57, P1420, DOI 10.1136/gut.2007.148189; Gaspar C, 2008, AM J PATHOL, V172, P1363, DOI 10.2353/ajpath.2008.070851; Han SX, 2010, WORLD J GASTROENTERO, V16, P4541, DOI 10.3748/wjg.v16.i36.4541; Hao JM, 2010, J PATHOL, V220, P475, DOI 10.1002/path.2668; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kaiser S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r131; Keller JW, 2007, ONCOGENE, V26, P3051, DOI 10.1038/sj.onc.1210103; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kent OA, 2009, CANCER BIOL THER, V8, P2013, DOI 10.4161/cbt.8.21.9685; Kressner U, 1998, BRIT J CANCER, V77, P1848, DOI 10.1038/bjc.1998.307; Liu AW, 2011, CLIN CANCER RES, V17, P710, DOI 10.1158/1078-0432.CCR-10-0331; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Michael MZ, 2003, MOL CANCER RES, V1, P882; Mosakhani N, 2012, GENE CHROMOSOME CANC, V51, P1, DOI 10.1002/gcc.20925; Mukhopadhyay NK, 2007, MOL ENDOCRINOL, V21, P2056, DOI 10.1210/me.2006-0503; Ng EKO, 2009, BRIT J CANCER, V101, P699, DOI 10.1038/sj.bjc.6605195; Nitz MD, 2011, AM J PATHOL, V179, P477, DOI 10.1016/j.ajpath.2011.03.038; Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Sancho R, 2009, EMBO J, V28, P1843, DOI 10.1038/emboj.2009.153; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Thiagalingam A, 1996, MOL CELL BIOL, V16, P5335; Thiagalingam A, 1997, GENOMICS, V45, P630, DOI 10.1006/geno.1997.5001; Uren AG, 2008, CELL, V133, P727, DOI 10.1016/j.cell.2008.03.021; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Zhang L, 1999, NUCLEIC ACIDS RES, V27, P2947, DOI 10.1093/nar/27.14.2947; Zhang SL, 2003, ONCOGENE, V22, P2285, DOI 10.1038/sj.onc.1206257; Zhu HY, 2011, MOL CANCER RES, V9, P960, DOI 10.1158/1541-7786.MCR-10-0531	57	104	110	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2576	2585		10.1038/onc.2012.266	http://dx.doi.org/10.1038/onc.2012.266			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22751122	Green Accepted			2022-12-28	WOS:000319274300009
J	Yao, Z; Jones, AWE; Fassone, E; Sweeney, MG; Lebiedzinska, M; Suski, JM; Wieckowski, MR; Tajeddine, N; Hargreaves, IP; Yasukawa, T; Tufo, G; Brenner, C; Kroemer, G; Rahman, S; Szabadkai, G				Yao, Z.; Jones, A. W. E.; Fassone, E.; Sweeney, M. G.; Lebiedzinska, M.; Suski, J. M.; Wieckowski, M. R.; Tajeddine, N.; Hargreaves, I. P.; Yasukawa, T.; Tufo, G.; Brenner, C.; Kroemer, G.; Rahman, S.; Szabadkai, G.			PGC-1 beta mediates adaptive chemoresistance associated with mitochondrial DNA mutations	ONCOGENE			English	Article						CDDP; chemoresistance; mitochondrial biogenesis; PGC-1; Complex-I; mitochondrial DNA	CANCER; COACTIVATORS; RESISTANCE; FAMILY; NEURODEGENERATION; PGC-1-ALPHA; BIOGENESIS; REGULATOR; CISPLATIN; APOPTOSIS	Primary mitochondrial dysfunction commonly leads to failure in cellular adaptation to stress. Paradoxically, however, nonsynonymous mutations of mitochondrial DNA (mtDNA) are frequently found in cancer cells and may have a causal role in the development of resistance to genotoxic stress induced by common chemotherapeutic agents, such as cis-diammine-dichloroplatinum(II) (cisplatin, CDDP). Little is known about how these mutations arise and the associated mechanisms leading to chemoresistance. Here, we show that the development of adaptive chemoresistance in the A549 non-small-cell lung cancer cell line to CDDP is associated with the hetero- to homoplasmic shift of a nonsynonymous mutation in MT-ND2, encoding the mitochondrial Complex-I subunit ND2. The mutation resulted in a 50% reduction of the NADH: ubiquinone oxidoreductase activity of the complex, which was compensated by increased biogenesis of respiratory chain complexes. The compensatory mitochondrial biogenesis was most likely mediated by the nuclear co-activators peroxisome proliferator-activated receptor gamma co-activator-1 alpha (PGC-1 alpha) and PGC-1 beta, both of which were significantly upregulated in the CDDP-resistant cells. Importantly, both transient and stable silencing of PGC-1 beta re-established the sensitivity of these cells to CDDP-induced apoptosis. Remarkably, the PGC-1 beta-mediated CDDP resistance was independent of the mitochondrial effects of the co-activator. Altogether, our results suggest that partial respiratory chain defects because of mtDNA mutations can lead to compensatory upregulation of nuclear transcriptional co-regulators, in turn mediating resistance to genotoxic stress.	[Yao, Z.; Jones, A. W. E.; Szabadkai, G.] UCL, Consortium Mitochondrial Res, Dept Cell & Dev Biol, London WC1E 6BT, England; [Fassone, E.; Rahman, S.] UCL Inst Child Hlth, Clin & Mol Genet Unit, London, England; [Fassone, E.] Univ Milan, IRCCS Fdn Ca Granda, Osped Maggiore Policlin, Dino Ferrari Ctr,Dept Neurol Sci, Milan, Italy; [Sweeney, M. G.] Natl Hosp Neurol & Neurosurg, Neurogenet Unit, London, England; [Lebiedzinska, M.; Suski, J. M.; Wieckowski, M. R.] M Nencki Inst Expt Biol, Dept Biochem, PL-02093 Warsaw, Poland; [Tajeddine, N.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Hargreaves, I. P.] UCL, Inst Neurol, London, England; [Yasukawa, T.] UCL, Wolfson Inst Biomed Res, London, England; [Tufo, G.; Brenner, C.] Univ Paris 11, INSERM, UMR S 769, Chatenay Malabry, France; [Kroemer, G.] Inst Gustave Roussy, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France; [Kroemer, G.] Univ Paris 05, Fac Med, Paris, France	University of London; University College London; University of London; University College London; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; University of London; University College London; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Szabadkai, G (corresponding author), UCL, Consortium Mitochondrial Res, Dept Cell & Dev Biol, Gower St, London WC1E 6BT, England.	g.szabadkai@ucl.ac.uk	Yao, Zhi/B-9047-2013; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Suski, Jan/AAP-9727-2021; Lebiedzińska-Arciszewska, Magdalena/AAA-3279-2022; Rahman, Shamima/C-5232-2008; Yasukawa, Takehiro/AAP-1335-2020; Rahman, Shamima/M-7904-2019; Lebiedzińska-Arciszewska, Magdalena/AAC-5956-2021; YAO, Zhi/C-6096-2009; Hargreaves, Iain/AAJ-6757-2020	Yao, Zhi/0000-0001-6432-5734; KROEMER, Guido/0000-0002-9334-4405; Lebiedzińska-Arciszewska, Magdalena/0000-0002-2725-5551; Rahman, Shamima/0000-0003-2088-730X; Wieckowski, Mariusz/0000-0003-0789-4521; Yasukawa, Takehiro/0000-0001-9531-8780; Szabadkai, Gyorgy/0000-0002-3006-3577; Suski, Jan/0000-0001-5657-2655	Parkinson's UK [G-0905]; Medical Research Council (MRC-DTA); Polish Ministry of Science and Higher Education [NN407075137]; National Science Centre [DEC-2011/01/M/NZ3/02128]; Foundation for Polish Science; EU; European Regional Development Fund; Operational Programme "Innovative economy"; L'Oreal fellowship; Great Ormond Street Hospital Children's Charity; European Union (ApoSys); European Union (ArtForce); European Union (ChemoRes); Ligue contre le Cancer (Laboratoire labellise); Parkinson&quot;s UK [G-0905] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [V1220] Funding Source: researchfish	Parkinson's UK(Parkinson's UK); Medical Research Council (MRC-DTA); Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); National Science Centre(National Science Centre, Poland); Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); EU(European Commission); European Regional Development Fund(European Commission); Operational Programme "Innovative economy"; L'Oreal fellowship(L'Oreal Group); Great Ormond Street Hospital Children's Charity; European Union (ApoSys)(European CommissionEuropean Commission Joint Research Centre); European Union (ArtForce); European Union (ChemoRes); Ligue contre le Cancer (Laboratoire labellise); Parkinson&quot;s UK(Parkinson&apos;s UK); Great Ormond Street Hospital Childrens Charity	We thank the excellent technical help of M Rahman (UCL Biosciences Molecular Biology Unit), K Pearce (UCL Genomics), the access to the Arrayscan VTI HCS Reader and the help of G Keen, M Elrayess and J Staddon from Eisai Europe Ltd; Professors M Duchen, C Boshoff and JM Funes for reagents and advice; JW Taanman for providing the A549 rho0 cell line, and D Housenloy for the Akt antibodies. The work was supported by Parkinson's UK (G-0905) and the Medical Research Council (MRC-DTA) to GS, ZY and AJ MRW is supported by the Polish Ministry of Science and Higher Education under Grant NN407075137 and by the grant from the National Science Centre-decision number DEC-2011/01/M/NZ3/02128. JMS is a recipient of a PhD fellowship from the Foundation for Polish Science, EU, European Regional Development Fund and Operational Programme "Innovative economy". ML is recipient of a fellowship from the Foundation for Polish Science (Programme Start) and the L'Oreal fellowship (For Women in Science). SR is supported by Great Ormond Street Hospital Children's Charity. GK is supported by the European Union (ApoSys, ArtForce, ChemoRes) and the Ligue contre le Cancer (Laboratoire labellise).	Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bianchi K, 2006, CELL DEATH DIFFER, V13, P586, DOI 10.1038/sj.cdd.4401784; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Campanella M, 2009, BBA-BIOENERGETICS, V1787, P393, DOI 10.1016/j.bbabio.2009.02.023; Chandra D, 2011, BBA-BIOENERGETICS, V1807, P620, DOI 10.1016/j.bbabio.2010.10.023; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; CREWS S, 1979, NATURE, V277, P192, DOI 10.1038/277192a0; Cullen KJ, 2007, J BIOENERG BIOMEMBR, V39, P43, DOI 10.1007/s10863-006-9059-5; Di Re M, 2009, NUCLEIC ACIDS RES, V37, P5701, DOI 10.1093/nar/gkp614; Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI [10.1042/BSE0470115, 10.1042/bse0470115]; Efremov RG, 2010, NATURE, V465, P441, DOI 10.1038/nature09066; Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917; Galluzzi L, 2007, APOPTOSIS, V12, P803, DOI 10.1007/s10495-007-0720-1; Guerra F, 2011, HUM MOL GENET, V20, P2394, DOI 10.1093/hmg/ddr146; Guha M, 2010, MOL BIOL CELL, V21, P3578, DOI 10.1091/mbc.E10-03-0192; Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; Jones AWE, 2012, MITOCHONDRION, V12, P86, DOI 10.1016/j.mito.2011.09.009; Kajimura S, 2008, GENE DEV, V22, P1397, DOI 10.1101/gad.1666108; Kulawiec M, 2010, ENVIRON MOL MUTAGEN, V51, P427, DOI 10.1002/em.20582; Kulawiec M, 2009, CANCER BIOL THER, V8, P1378, DOI 10.4161/cbt.8.14.8751; Kwong JQ, 2007, J CELL BIOL, V179, P1163, DOI 10.1083/jcb.200704059; Lane N, 2011, BIOESSAYS, V16, P1; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lo S, 2005, INT J ONCOL, V27, P337; Mizutani S, 2009, CANCER SCI, V100, P1680, DOI 10.1111/j.1349-7006.2009.01238.x; Nakamaru-Ogiso E, 2010, FEBS LETT, V584, P883, DOI 10.1016/j.febslet.2010.01.004; Ohta S, 2006, ONCOGENE, V25, P4768, DOI 10.1038/sj.onc.1209602; Park CB, 2011, J CELL BIOL, V193, P809, DOI 10.1083/jcb.201010024; Ragan CI, 1988, MITOCHONDRIA PRACTIC, P79; Rahman S, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000411; Ruhanen H, 2010, BBA-MOL CELL RES, V1803, P931, DOI 10.1016/j.bbamcr.2010.04.008; Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019; Sen T, 2011, CANCER RES, V71, P1167, DOI 10.1158/0008-5472.CAN-10-1481; Spinazzola A, 2009, ADV EXP MED BIOL, V652, P69, DOI 10.1007/978-90-481-2813-6_6; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Suski JM, 2012, METHODS MOL BIOL, V810, P183, DOI 10.1007/978-1-61779-382-0_12; Traba J, 2012, CELL DEATH DIFFER, V19, P650, DOI 10.1038/cdd.2011.139; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002; Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05; Wallace DC, 2010, MITOCHONDRION, V10, P12, DOI 10.1016/j.mito.2009.09.006; Zechner C, 2010, CELL METAB, V12, P633, DOI 10.1016/j.cmet.2010.11.008	43	29	29	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2592	2600		10.1038/onc.2012.259	http://dx.doi.org/10.1038/onc.2012.259			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22777349				2022-12-28	WOS:000319274300011
J	Rodriguez-Blanco, J; Schilling, NS; Tokhunts, R; Giambelli, C; Long, J; Fei, DL; Singh, S; Black, KE; Wang, Z; Galimberti, F; Bejarano, PA; Elliot, S; Glassberg, MK; Nguyen, DM; Lockwood, WW; Lam, WL; Dmitrovsky, E; Capobianco, AJ; Robbins, DJ				Rodriguez-Blanco, J.; Schilling, N. S.; Tokhunts, R.; Giambelli, C.; Long, J.; Fei, D. Liang; Singh, S.; Black, K. E.; Wang, Z.; Galimberti, F.; Bejarano, P. A.; Elliot, S.; Glassberg, M. K.; Nguyen, D. M.; Lockwood, W. W.; Lam, W. L.; Dmitrovsky, E.; Capobianco, A. J.; Robbins, D. J.			The Hedgehog processing pathway is required for NSCLC growth and survival	ONCOGENE			English	Article						dispatched; lung cancer; hedgehog; hedgehog acyltransferase; skinny hedgehog	BASAL-CELL CARCINOMA; SMALL-MOLECULE MODULATION; HUMAN SONIC HEDGEHOG; LUNG-CANCER; SIGNALING PATHWAY; LONG-RANGE; CHROMOSOMAL IMBALANCES; ANIMAL DEVELOPMENT; GENE-EXPRESSION; HUMAN HOMOLOG	Considerable interest has been generated from the results of recent clinical trials using smoothened (SMO) antagonists to inhibit the growth of hedgehog (HH) signaling-dependent tumors. This interest is tempered by the discovery of SMO mutations mediating resistance, underscoring the rationale for developing therapeutic strategies that interrupt HH signaling at levels distinct from those inhibiting SMO function. Here, we demonstrate that HH-dependent non-small cell lung carcinoma (NSCLC) growth is sensitive to blockade of the HH pathway upstream of SMO, at the level of HH ligand processing. Individually, the use of different lentivirally delivered shRNA constructs targeting two functionally distinct HH-processing proteins, skinny hedgehog (SKN) or dispatched-1 (DISP-1), in NSCLC cell lines produced similar decreases in cell proliferation and increased cell death. Further, providing either an exogenous source of processed HH or a SMO agonist reverses these effects. The attenuation of HH processing, by knocking down either of these gene products, also abrogated tumor growth in mouse xenografts. Finally, we extended these findings to primary clinical specimens, showing that SKN is frequently overexpressed in NSCLC and that higher DISP-1 expression is associated with an unfavorable clinical outcome. Our results show a critical role for HH processing in HH-dependent tumors, identifies two potential druggable targets in the HH pathway, and suggest that similar therapeutic strategies could be explored to treat patients harboring HH ligand-dependent cancers.	[Rodriguez-Blanco, J.; Schilling, N. S.; Tokhunts, R.; Giambelli, C.; Long, J.; Fei, D. Liang; Singh, S.; Black, K. E.; Wang, Z.; Nguyen, D. M.; Capobianco, A. J.; Robbins, D. J.] Univ Miami, Dept Surg, Mol Oncol Program, Miami, FL 33136 USA; [Schilling, N. S.; Tokhunts, R.; Fei, D. Liang; Galimberti, F.; Dmitrovsky, E.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03756 USA; [Bejarano, P. A.] Univ Miami, Dept Pathol, Miami, FL 33136 USA; [Elliot, S.] Univ Miami, Dept Surg, Lab Sex & Gender Differences Hlth & Dis, Miami, FL 33136 USA; [Glassberg, M. K.] Univ Miami, Jackson Mem Hosp, Dept Med, Miami, FL 33136 USA; [Glassberg, M. K.] Univ Miami, Jackson Mem Hosp, Dept Surg, Miami, FL 33136 USA; [Nguyen, D. M.; Capobianco, A. J.; Robbins, D. J.] Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Miami, FL 33136 USA; [Lockwood, W. W.] NHGRI, Canc Genet Branch, Bethesda, MD 20892 USA; [Lam, W. L.] British Columbia Canc Res Ctr, Dept Integrat Biol, Vancouver, BC V5Z 1L3, Canada; [Dmitrovsky, E.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Lebanon, NH USA; [Dmitrovsky, E.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; [Robbins, D. J.] Univ Miami, Dept Biochem & Mol Biol, Miami, FL 33136 USA	University of Miami; Dartmouth College; University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); British Columbia Cancer Agency; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; University of Miami	Robbins, DJ (corresponding author), Univ Miami, Miller Sch Med, Sylvester Canc Ctr, 1042 RMSB,1600 NW 10th Ave, Miami, FL 33136 USA.	drobbins@med.miami.edu	Long, Jun/S-2382-2019; Rodriguez, Jezabel/B-7613-2019; Singh, Samer/H-8468-2013; LONG, JUN/N-7270-2015; Lockwood, William W/A-2879-2009; Wang, Zhiqiang/O-6810-2014	Long, Jun/0000-0002-8229-9653; Rodriguez, Jezabel/0000-0003-1839-6181; Singh, Samer/0000-0002-0921-1686; Fei, Dennis Liang/0000-0002-1953-0584; Capobianco, Anthony/0000-0002-3706-6797	NIH [GM64011, R03-CA132166, R01-CA087546, R01-CA111422]; Samuel Waxman Cancer Research Foundation; American Lung Association/LUNGevity Foundation;  [FICYT-POST10-27]; NATIONAL CANCER INSTITUTE [R01CA087546, R03CA132166, P30CA023108, R01CA111422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064011, R56GM064011] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation; American Lung Association/LUNGevity Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the NIH grants GM64011 (DJ Robbins), R03-CA132166 (E Dmitrovsky), R01-CA087546 (E Dmitrovsky) and R01-CA111422 (E Dmitrovsky); grants from the Samuel Waxman Cancer Research Foundation (E Dmitrovsky, A Capobianco); FICYT-POST10-27 (J Rodriguez-Blanco) and from the American Lung Association/LUNGevity Foundation (DJ Robbins). E Dmitrovsky is an American Cancer Society Professor supported by a generous gift from the FM Kirby Foundation.	Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Amanai K, 2001, DEVELOPMENT, V128, P5119; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Buglino JA, 2008, J BIOL CHEM, V283, P22076, DOI 10.1074/jbc.M803901200; Burke R, 1999, CELL, V99, P803, DOI 10.1016/S0092-8674(00)81677-3; Caspary T, 2002, CURR BIOL, V12, P1628, DOI 10.1016/S0960-9822(02)01147-8; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chen MH, 2004, GENE DEV, V18, P641, DOI 10.1101/gad.1185804; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dijkgraaf GJP, 2011, CANCER RES, V71, P435, DOI 10.1158/0008-5472.CAN-10-2876; Farzan SF, 2008, AM J PHYSIOL-GASTR L, V294, pG844, DOI 10.1152/ajpgi.00564.2007; Fei DL, 2010, CANCER RES, V70, P1981, DOI 10.1158/0008-5472.CAN-09-2898; Fernandez C, 2010, DEV NEUROSCI-BASEL, V32, P59, DOI 10.1159/000274458; Gialmanidis IP, 2009, LUNG CANCER, V66, P64, DOI 10.1016/j.lungcan.2009.01.007; Goetz JA, 2006, J BIOL CHEM, V281, P4087, DOI 10.1074/jbc.M511427200; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570; Kawakami T, 2002, DEVELOPMENT, V129, P5753, DOI 10.1242/dev.00178; Kohtz JD, 2001, DEVELOPMENT, V128, P2351; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lauth M, 2010, NAT STRUCT MOL BIOL, V17, P718, DOI 10.1038/nsmb.1833; Lee ES, 2008, CLIN CANCER RES, V14, P7397, DOI 10.1158/1078-0432.CCR-07-4937; Lee JD, 2001, CURR BIOL, V11, P1147, DOI 10.1016/S0960-9822(01)00323-2; LEGRAND C, 1992, J BIOTECHNOL, V25, P231, DOI 10.1016/0168-1656(92)90158-6; Liu X, 2009, CLIN CANCER RES, V15, P1177, DOI 10.1158/1078-0432.CCR-08-1355; Lockwood WW, 2010, PLOS MED, V7; Low JA, 2010, J CLIN ONCOL, V28, P5321, DOI 10.1200/JCO.2010.27.9943; Ma Y, 2002, CELL, V111, P63, DOI 10.1016/S0092-8674(02)00977-7; Ma Y, 2007, P NATL ACAD SCI USA, V104, P4089, DOI 10.1073/pnas.0606537104; Mann RK, 2004, ANNU REV BIOCHEM, V73, P891, DOI 10.1146/annurev.biochem.73.011303.073933; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Mas C, 2010, BIOCHEM PHARMACOL, V80, P712, DOI 10.1016/j.bcp.2010.04.016; Micchelli CA, 2002, DEVELOPMENT, V129, P843; Miura GI, 2006, DEV CELL, V10, P167, DOI 10.1016/j.devcel.2005.11.017; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Neal JW, 2010, CURR TREAT OPTION ON, V11, P36, DOI 10.1007/s11864-010-0120-6; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Petersen I, 1997, CANCER RES, V57, P2331; Petty WJ, 2005, J NATL CANCER I, V97, P1645, DOI 10.1093/jnci/dji371; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Quirk J, 1997, COLD SPRING HARB SYM, V62, P217; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Shen TL, 1999, HUM PATHOL, V30, P284, DOI 10.1016/S0046-8177(99)90006-0; Singh S, 2011, CANCER RES, V71, P4454, DOI 10.1158/0008-5472.CAN-10-2313; Singh S, 2009, HUM GENET, V125, P95, DOI 10.1007/s00439-008-0599-0; Sinha S, 2006, NAT CHEM BIOL, V2, P29, DOI 10.1038/nchembio753; Stanton BZ, 2010, MOL BIOSYST, V6, P44, DOI 10.1039/b910196a; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Tai ALS, 2004, CANCER, V100, P1918, DOI 10.1002/cncr.20190; Taylor FR, 2001, BIOCHEMISTRY-US, V40, P4359, DOI 10.1021/bi002487u; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yuan Z, 2007, ONCOGENE, V26, P1046, DOI 10.1038/sj.onc.1209860; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3	79	34	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2335	2345		10.1038/onc.2012.243	http://dx.doi.org/10.1038/onc.2012.243			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22733134	Green Accepted			2022-12-28	WOS:000318683600010
J	Bernard, H; Garmy-Susini, B; Ainaoui, N; Van Den Berghe, L; Peurichard, A; Javerzat, S; Bikfalvi, A; Lane, DP; Bourdon, JC; Prats, AC				Bernard, H.; Garmy-Susini, B.; Ainaoui, N.; Van Den Berghe, L.; Peurichard, A.; Javerzat, S.; Bikfalvi, A.; Lane, D. P.; Bourdon, J. C.; Prats, A-C			The p53 isoform, Delta 133p53 alpha, stimulates angiogenesis and tumour progression	ONCOGENE			English	Article						angiogenesis; p53; isoform; cancer; glioblastoma	EXPRESSION; DELTA-113P53; SURVIVAL; CANCER; GENE	The tumour suppressor p53, involved in DNA repair, cell cycle arrest and apoptosis, also inhibits blood vessel formation, that is, angiogenesis, a process strongly contributing to tumour development. The p53 gene expresses 12 different proteins (isoforms), including TAp53 (p53 (or p53 alpha), p53 beta and p53 gamma) and Delta 133p53 isoforms (Delta 133p53 alpha, Delta 133p53 beta and Delta 133p53 gamma). The Delta 133p53 alpha isoform was shown to modulate p53 transcriptional activity and is overexpressed in various human tumours. However, its role in tumour progression is still unexplored. In the present study, we examined the involvement of Delta 133p53 isoforms in tumoural angiogenesis and tumour growth in the highly angiogenic human glioblastoma U87. Our data show that conditioned media from U87 cells depleted for Delta 133p53 isoforms block endothelial cell migration and tubulogenesis without affecting endothelial cell proliferation in vitro. The Delta 133p53 depletion in U2OS osteosarcoma cells resulted in a similar angiogenesis blockade. Furthermore, using conditioned media from U87 cells ectopically expressing each Delta 133p53 isoform, we determined that Delta 133p53 alpha and Delta 133p53 gamma but not Delta 133p53 beta, stimulate angiogenesis. Our in vivo data using the chicken chorio-allantoic membrane and mice xenografts establish that angiogenesis and growth of glioblastoma U87 tumours are inhibited upon depletion of Delta 133p53 isoforms. By TaqMan low-density array, we show that alteration of expression ratio of Delta 133p53 and TAp53 isoforms differentially regulates angiogenic gene expression with Delta 133p53 isoforms inducing pro-angiogenic gene expression and repressing anti-angiogenic gene expression. Oncogene (2013) 32, 2150-2160; doi:10.1038/onc.2012.242; published online 25 June 2012	[Bernard, H.; Garmy-Susini, B.; Ainaoui, N.; Van Den Berghe, L.; Peurichard, A.; Prats, A-C] Univ Toulouse, Lab Translat Control & Gene Therapy Vasc Dis, Inst Malad Metab & Cardiovasc, UPS,TRADGENE,EA4554, Toulouse, France; [Bernard, H.; Lane, D. P.; Bourdon, J. C.] Univ Dundee, Dept Surg & Mol Oncol, Dundee, Scotland; [Garmy-Susini, B.] Fac Med Toulouse, INSERM, U1037, F-31073 Toulouse, France; [Van Den Berghe, L.] INSERM, U1048, F-31432 Toulouse, France; [Javerzat, S.; Bikfalvi, A.] INSERM, U920, Talence, France; [Javerzat, S.; Bikfalvi, A.] Univ Bordeaux 1, Angiogenesis & Canc Microenvironm Lab, F-33405 Talence, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Dundee; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Prats, AC (corresponding author), Univ Toulouse 3, Inst Malad Metab & Cardiovasc, Lab Translat Control & Gene Therapy Vasc Dis, TRADGENE,EA 4554, 1 Ave Jean Poulhes,BP 84225, F-31432 Toulouse 4, France.	Anne-Catherine.Prats@inserm.fr	VAN DEN BERGHE, Loïc/X-6705-2019; Prats, Anne-Catherine/E-5051-2016; Garmy-Susini, Barbara/B-9735-2014; Petibois, Cyril/L-9049-2014; JC, Bourdon/A-4439-2008	Prats, Anne-Catherine/0000-0002-5282-3776; Petibois, Cyril/0000-0001-9027-4192; JC, Bourdon/0000-0003-4623-9386; Lane, David/0000-0003-0551-3545; GARMY-SUSINI, Barbara/0000-0001-6100-2294	Association pour la Recherche sur le Cancer; Canceropole GSO; INCA; Fondation de l'Avenir; Association Francaise contre les Myopathies (AFM); Ligue Nationale Contre Le Cancer; ARC; Fondation pour la Recherche Medicale; AFM; Cancer Research UK [C8/A6613]	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Canceropole GSO; INCA(Institut National du Cancer (INCA) France); Fondation de l'Avenir; Association Francaise contre les Myopathies (AFM)(Association Francaise contre les Myopathies); Ligue Nationale Contre Le Cancer(Ligue nationale contre le cancer); ARC(Australian Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); AFM(Association Francaise contre les Myopathies); Cancer Research UK(Cancer Research UK)	We thank A Delluc-Clavieres and F Pujol for technical assistance, Y Barreira, S Legonidec (animal production and phenotyping facilities of ANEXPLO platform, Inserm US006), F Gross (Vector facility), J-J Maoret (GeT TQ plateau of the Genotoul Genome-Transcriptome platform), M Pucelle (CAM facility) and C Touriol (ABAE and HUVEC cells). This work was supported by grants from Association pour la Recherche sur le Cancer, Canceropole GSO, INCA, Fondation de l'Avenir, Association Francaise contre les Myopathies (AFM). HB had a fellowship from the Ligue Nationale Contre Le Cancer, then from the ARC. BGS had a postdoc fellowship from the Fondation pour la Recherche Medicale, NA had a thesis fellowship from AFM. DPL and JCB were supported by Cancer Research UK (grant number: C8/A6613).	Aoubala M, 2011, CELL DEATH DIFFER, V18, P248, DOI 10.1038/cdd.2010.91; Bossard C, 2004, CANCER RES, V64, P7507, DOI 10.1158/0008-5472.CAN-04-0287; Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Bourdon JC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2811; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Davidson WR, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-102; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Folkman Judah, 2006, Sci STKE, V2006, ppe35, DOI 10.1126/stke.3542006pe35; Fraisl P, 2009, DEV CELL, V16, P167, DOI 10.1016/j.devcel.2009.01.003; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Giuriato S, 2006, P NATL ACAD SCI USA, V103, P16266, DOI 10.1073/pnas.0608017103; Hagedorn M, 2005, P NATL ACAD SCI USA, V102, P1643, DOI 10.1073/pnas.0408622102; Jensen Mette Munk, 2008, BMC Med Imaging, V8, P16, DOI 10.1186/1471-2342-8-16; Khoury Marie P, 2011, Genes Cancer, V2, P453, DOI 10.1177/1947601911408893; Marcel V, 2010, ONCOGENE, V29, P2691, DOI 10.1038/onc.2010.26; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pal S, 2001, CANCER RES, V61, P6952; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Ravi R, 2000, GENE DEV, V14, P34; Saidi A, 2008, INT J CANCER, V122, P2187, DOI 10.1002/ijc.23313; Sirven A, 2001, MOL THER, V3, P438, DOI 10.1006/mthe.2001.0282; Teodoro JG, 2007, J MOL MED-JMM, V85, P1175, DOI 10.1007/s00109-007-0221-2; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Wong MLH, 2009, J CLIN NEUROSCI, V16, P1119, DOI 10.1016/j.jocn.2009.02.009	29	64	67	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2150	2160		10.1038/onc.2012.242	http://dx.doi.org/10.1038/onc.2012.242			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22733133	Green Submitted			2022-12-28	WOS:000318062800004
J	Perez-Benavente, B; Garcia, JL; Rodriguez, MS; Pineda-Lucena, A; Piechaczyk, M; de Mora, JF; Farras, R				Perez-Benavente, B.; Garcia, J. L.; Rodriguez, M. S.; Pineda-Lucena, A.; Piechaczyk, M.; Font de Mora, J.; Farras, R.			GSK3-SCFFBXW7 targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase	ONCOGENE			English	Article						JunB; G2 phase; ubiquitin-proteasome; NPM-ALK; GSK3; DDX11	LARGE-CELL-LYMPHOMA; CHRONIC MYELOID-LEUKEMIA; C-JUN; PROFILING REVEALS; TUMOR-SUPPRESSOR; HODGKIN-LYMPHOMA; EXPRESSION; TRANSCRIPTION; KINASE; ALK	JunB, an activator protein-1 (AP-1) transcription factor component, acts either as a tumor suppressor or as an oncogene depending on the cell context. In particular, JunB is strongly upregulated in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) where it enhances cell proliferation. Although its overexpression is linked to lymphomagenesis, the mechanisms whereby JunB promotes neoplastic growth are still largely obscure. Here, we show that JunB undergoes coordinated phosphorylation-dependent ubiquitylation during the G2 phase of the cell cycle. We characterized a critical consensus phosphodegron that controls JunB turnover and identified GSK3 and SCFFBXW7 as, respectively, the kinase and the E3 ubiquitin ligase responsible for its degradation in G2. Pharmacological or genetic inactivation of the GSK3-FBXW7-JunB axis induced accumulation of JunB in G2/M and entailed transcriptional repression of the DNA helicase DDX11, leading to premature sister chromatid separation. This abnormal phenotype due to dysregulation of the GSK3 beta/JunB/DDX11 pathway is phenocopied in ALK-positive ALCL. Thus, our results reveal a novel mechanism by which mitosis progression and chromatid cohesion are regulated through GSK3/SCFFBXW7-mediated proteolysis of JunB, and suggest that JunB proteolysis in G2 is an essential step in maintaining genetic fidelity during mitosis. Oncogene (2013) 32, 2189-2199; doi:10.1038/onc.2012.235; published online 18 June 2012	[Perez-Benavente, B.; Farras, R.] Ctr Invest Principe Felipe, Cytom Lab, Valencia 46012, Spain; [Garcia, J. L.] Univ Salamanca, Ctr Invest Canc, Hosp Univ Salamanca, Unidad Invest,IECSCYL,CSIC, E-37008 Salamanca, Spain; [Rodriguez, M. S.] CIC BioGUNE, Prote Unit, Bizkaia, Spain; [Pineda-Lucena, A.] Ctr Invest Principe Felipe, Struct Biochem Lab, Valencia 46012, Spain; [Piechaczyk, M.] Univ Montpellier I, Univ Montpellier 2, CNRS, UMR 5535,Inst Genet Mol Montpellier, Montpellier 2, France; [Font de Mora, J.] Ctr Invest Principe Felipe, Cellular & Mol Biol Lab, Valencia 46012, Spain	Prince Felipe Research Center; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; CIC bioGUNE; Prince Felipe Research Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Prince Felipe Research Center	Farras, R (corresponding author), Ctr Invest Principe Felipe, Cytom Lab, C EP Autopista del Saler 16, Valencia 46012, Spain.	rfarras@cipf.es	RODRIGUEZ, Manuel S./D-5439-2018; PIECHACZYK, Marc/E-7896-2013; Pineda-Lucena, Antonio/B-1320-2014; Farràs, Rosa/B-5180-2014; de Mora, Jaime Font/AAK-7591-2021; de Mora, Jaime Font/H-6304-2015	PIECHACZYK, Marc/0000-0003-1367-2597; Pineda-Lucena, Antonio/0000-0002-3532-8781; Farràs, Rosa/0000-0003-4931-1494; de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095; Perez-Benavente, Beatriz/0000-0001-9977-058X	Fondo de Investigaciones Sanitarias [PI08/1127]; Valencia's Regional Ministry of Health [AP007/11]; Spanish Ministry of Science and Innovation [SAF2009-08334]; Institute of Health Carlos III; Regional Ministry of Health; program 'Equipe Labellisee' of the French Ligue against Cancer	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Valencia's Regional Ministry of Health; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Institute of Health Carlos III(Instituto de Salud Carlos III); Regional Ministry of Health; program 'Equipe Labellisee' of the French Ligue against Cancer	We thank Sandra Gallach and Pablo Mateos for their excellent technical support and A Ferrando, TM Thomson, G Bossis and O Coux for fruitful discussions and critical reading of the manuscript. This research was supported by grants from the Fondo de Investigaciones Sanitarias (PI08/1127) and from Valencia's Regional Ministry of Health (AP007/11) to RF, from the Spanish Ministry of Science and Innovation (SAF2009-08334) to JFM. RF is supported by the Institute of Health Carlos III and by the Regional Ministry of Health. MP was supported by the program 'Equipe Labellisee' of the French Ligue against Cancer. We are grateful to B Vogelstein for providing DLD1 and DLD1<SUP>FBXW7-/-</SUP> cells, M Pagano for Flag-tagged SKP2, CDH1 and CDC20 constructs, O Sangfield for Flag-tagged FBXW7 alpha and FBXW7 gamma constructs, C Bonne-Andrea for Flag-tagged FBXW7 alpha(R465A), PK Vogt (Scripps Research Institute) for activated AKT and E Noguchi for DDX11.	Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Babaei-Jadidi R, 2011, J EXP MED, V208, P295, DOI 10.1084/jem.20100830; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; Bruchova H, 2002, LEUKEMIA LYMPHOMA, V43, P1289, DOI 10.1080/10428190290026358; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fadlelmola FM, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-2; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Farina A, 2008, J BIOL CHEM, V283, P20925, DOI 10.1074/jbc.M802696200; Farras R, 2008, MOL CELL BIOL, V28, P4173, DOI 10.1128/MCB.01620-07; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Inoue A, 2007, CELL CYCLE, V6, P1646, DOI 10.4161/cc.6.13.4411; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mussolin L, 2010, PEDIATR BLOOD CANCER, V55, P446, DOI 10.1002/pbc.22550; Nagel S, 2008, LEUKEMIA, V22, P387, DOI 10.1038/sj.leu.2405028; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Parish JL, 2006, J CELL SCI, V119, P4857, DOI 10.1242/jcs.03262; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Peters JM, 2008, GENE DEV, V22, P3089, DOI 10.1101/gad.1724308; Piccaluga PP, 2010, ADV HEMATOL, DOI DOI 10.1155/2010/345053; Piechaczyk M, 2008, BIOCHEM SOC T, V36, P864, DOI 10.1042/BST0360864; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rassidakis GZ, 2005, MODERN PATHOL, V18, P1365, DOI 10.1038/modpathol.3800419; Salaverria I, 2008, BRIT J HAEMATOL, V140, P516, DOI 10.1111/j.1365-2141.2007.06924.x; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Singh RR, 2009, CANCER RES, V69, P2550, DOI 10.1158/0008-5472.CAN-08-1808; Staber PB, 2007, BLOOD, V110, P3374, DOI 10.1182/blood-2007-02-071258; van der Lelij P, 2010, AM J HUM GENET, V86, P262, DOI 10.1016/j.ajhg.2010.01.008; Watanabe M, 2005, CANCER RES, V65, P7628, DOI 10.1158/0008-5472.CAN-05-0925; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Ye X, 2004, J BIOL CHEM, V279, P50110, DOI 10.1074/jbc.M409226200; Zettl A, 2004, AM J PATHOL, V164, P1837, DOI 10.1016/S0002-9440(10)63742-X	53	35	35	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2189	2199		10.1038/onc.2012.235	http://dx.doi.org/10.1038/onc.2012.235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22710716				2022-12-28	WOS:000318062800008
J	Jia, Y; Song, W; Zhang, F; Yan, J; Yang, Q				Jia, Y.; Song, W.; Zhang, F.; Yan, J.; Yang, Q.			Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway	ONCOGENE			English	Article						Brca1; PKB/Akt; Chk1; Rad51; HR	CYCLE CHECKPOINT; BRCA1; CANCER; BREAST; ACTIVATION; RAD51; CHK1	Brca1 deficiency leads to the development of breast cancer. We previously found that Brca1 deficiency activates the Akt oncogenic pathway. Reduced expression of Brca1 was highly correlated with increased activated Akt in human breast cancer samples. Furthermore, activation of Akt1 was involved in Brca1-deficiency-mediated tumorigenesis in mice. Defective homologous recombination (HR) is thought to be a major contributor to tumorigenesis in Brca1 deficiency. Here, we show that Akt1 promotes chromosome instability in Brca1-deficent cells. DNA breaks in Brca1-deficent cells are aberrantly joined into complex chromosome rearrangements by a process dependent on Akt1. Depletion of Akt1 increases HR in Brca1-mutant cells, which is rescued by expression of wild-type, but not mutant Akt1 with deletion of Brca1-binding domain. Mechanistically, activated Akt1 in Brca1-deficient cells impairs Chk1 nuclear localization and subsequently disrupts interaction of Chk1 and Rad51 leading to HR defects. Our results indicate that Brca1 deficiency might activate Akt1 contributing to tumorigenesis through regulation of the Chk1-Rad51 signaling. Oncogene (2013) 32, 1943-1949; doi:10.1038/onc.2012.211; published online 4 June 2012	[Jia, Y.; Song, W.; Zhang, F.; Yan, J.; Yang, Q.] Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO 63108 USA; [Jia, Y.] Harbin Med Univ, Affiliated Hosp 3, Colorectal Canc Surg Dept, Harbin, Peoples R China; [Yan, J.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA	Washington University (WUSTL); Harbin Medical University; University of Washington; University of Washington Seattle	Yang, Q (corresponding author), Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, 4511 Forest Pk, St Louis, MO 63108 USA.	qyang@wustl.edu			Susan G. Komen Foundation; Siteman Cancer Center Award; NIH [CA129440]; NATIONAL CANCER INSTITUTE [R01CA129440] Funding Source: NIH RePORTER	Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Siteman Cancer Center Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Chuxia Deng for providing the Brca1<SUP>WT</SUP> and Brca1<SUP>Delta 11/Delta 11</SUP> MEFs. We thank Buck Rogers and Xiaowei Wang for proof reading. This work is supported in part by grants from the Susan G. Komen Foundation (QY), Siteman Cancer Center Award (QY) and NIH CA129440 (QY).	Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2002, ENVIRON MOL MUTAGEN, V39, P171, DOI 10.1002/em.10069; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Xiang T, 2011, ONCOGENE, V30, P2443, DOI 10.1038/onc.2010.603; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yang O, 2004, ONCOGENE, V23, P3749, DOI 10.1038/sj.onc.1207462; Yang Q, 2005, MOL CELL BIOL, V25, P1070, DOI 10.1128/MCB.25.3.1070-1080.2005; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zeng SC, 2009, NAT CELL BIOL, V11, P616, DOI 10.1038/ncb1867	25	30	30	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1943	1949		10.1038/onc.2012.211	http://dx.doi.org/10.1038/onc.2012.211			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22665067	Green Accepted			2022-12-28	WOS:000317599900008
J	Das, CM; Taylor, P; Gireud, M; Singh, A; Lee, D; Fuller, G; Ji, L; Fangusaro, J; Rajaram, V; Goldman, S; Eberhart, C; Gopalakrishnan, V				Das, C. M.; Taylor, P.; Gireud, M.; Singh, A.; Lee, D.; Fuller, G.; Ji, L.; Fangusaro, J.; Rajaram, V.; Goldman, S.; Eberhart, C.; Gopalakrishnan, V.			The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation	ONCOGENE			English	Article						REST; proliferation; p27; USP37; deubiquitylase	CDK INHIBITOR P27; RESTRICTIVE SILENCER FACTOR; SCF-BETA-TRCP; NEURONAL DIFFERENTIATION; N-MYC; ONCOGENIC TRANSFORMATION; REGULATES PROTEOLYSIS; SUBTYPE SPECIFICATION; NEURAL DEVELOPMENT; TUMOR SUPPRESSORS	The RE1 silencing transcription factor (REST) is a repressor of neuronal differentiation and its elevated expression in neural cells blocks neuronal differentiation. In this study, we demonstrate a role for REST in the control of proliferation of medulloblastoma cells. REST expression decreased the levels of cyclin-dependent kinase (CDK)NIB/p27, a CDK inhibitor and a brake of cell proliferation in these cells. The reciprocal relationship between REST and p27 was validated in human tumor samples. REST knockdown in medulloblastoma cells derepessed a novel REST target gene encoding the deubiquitylase ubiquitin (Ub)-specific peptidase 37 (USP37). Ectopically expressed wild-type USP37 formed a complex with p27, promoted its deubiquitination and stabilization and blocked cell proliferation. Knockdown of REST and USP37 prevented p27 stabilization and blocked the diminution in proliferative potential that normally accompanied REST loss. Unexpectedly, wild-type USP37 expression also induced the expression of REST-target neuronal differentiation genes even though REST levels were unaffected. In contrast, a mutant of USP37 carrying a site-directed change in a conserved cysteine failed to rescue REST-mediated p27 destabilization, maintenance of cell proliferation and blockade to neuronal differentiation. Consistent with these findings, a significant correlation between USP37 and p27 was observed in patient tumors. Collectively, these findings provide a novel connection between REST and the proteasomal machinery in the control of p27 and cell proliferation in medulloblastoma cells. Oncogene (2013) 32, 1691-1701; doi:10.1038/onc.2012.182; published online 4 June 2012	[Das, C. M.; Taylor, P.; Gireud, M.; Singh, A.; Lee, D.; Gopalakrishnan, V.] Univ Texas MD Anderson Canc Ctr, Dept Pediat & Mol & Cellular Oncol, Houston, TX 77030 USA; [Fuller, G.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Ji, L.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Fangusaro, J.; Goldman, S.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Rajaram, V.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Eberhart, C.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Gopalakrishnan, V.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Gopalakrishnan, V.] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; [Gopalakrishnan, V.] Univ Texas MD Anderson Canc Ctr, Ctr Canc Epigenet, Houston, TX 77030 USA; [Gopalakrishnan, V.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Gopalakrishnan, V.] Univ Texas Houston, Grad Sch Biomed Sci, Program Neurosci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Gopalakrishnan, V (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pediat & Mol & Cellular Oncol, Unit 853, 1515 Holcombe Blvd, Houston, TX 77030 USA.	vgopalak@mdanderson.org	Lee, Dean Anthony/AAK-8443-2021	Lee, Dean Anthony/0000-0001-6693-5392; Gireud-Goss, Monica/0000-0001-5172-2351; Fuller, Gregory/0000-0001-9447-2647	American Cancer Center [RSG-09-273-01-DDC]; National Institutes of Neurological Disorders and Stroke [1R03NS077021]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R03NS077021, R01NS079715] Funding Source: NIH RePORTER	American Cancer Center; National Institutes of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the American Cancer Center (RSG-09-273-01-DDC) and the National Institutes of Neurological Disorders and Stroke (1R03NS077021) to VG.	Abrajano JJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007936; Abrajano JJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007665; Aguilera DG, 2009, J NEURO-ONCOL, V93, P303, DOI 10.1007/s11060-008-9788-x; Ayrault O, 2009, MOL CANCER RES, V7, P33, DOI 10.1158/1541-7786.MCR-08-0369; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Ballas N, 2005, CURR OPIN NEUROBIOL, V15, P500, DOI 10.1016/j.conb.2005.08.015; Bhatia B, 2010, CELL CYCLE, V9, P4307, DOI 10.4161/cc.9.21.13441; Bhatia B, 2010, CELL CYCLE, V9, P456, DOI 10.4161/cc.9.3.10532; Bhatia B, 2009, CANCER RES, V69, P7224, DOI 10.1158/0008-5472.CAN-09-1299; Blain SW, 2008, CELL CYCLE, V7, P892, DOI 10.4161/cc.7.7.5637; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chang L, 2011, MOL CANC RES; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032; Das CM, 2010, EUR J CANCER, V46, P2771, DOI 10.1016/j.ejca.2010.05.010; Eletr ZM, 2011, CELL BIOCHEM BIOPHYS, V60, P3, DOI 10.1007/s12013-011-9184-6; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Fuller GN, 2005, MOL CANCER THER, V4, P343; Gao ZL, 2011, J NEUROSCI, V31, P9772, DOI 10.1523/JNEUROSCI.1604-11.2011; Gopalakrishnan V, 2009, FUTUR NEUROL, V4, P317, DOI 10.2217/FNL.09.1; Goto T, 2004, DEV NEUROSCI-BASEL, V26, P208, DOI 10.1159/000082138; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Hara T, 2005, MOL CELL BIOL, V25, P9292, DOI 10.1128/MCB.25.21.9292-9303.2005; Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621; Hayes SD, 2010, NAT CELL BIOL, V12, P311, DOI 10.1038/ncb2043; Hsieh J, 2005, CURR OPIN CELL BIOL, V17, P664, DOI 10.1016/j.ceb.2005.09.002; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Juliandi B, 2010, CURR OPIN NEUROBIOL, V20, P408, DOI 10.1016/j.conb.2010.04.001; Kagalwala MN, 2008, COLD SH Q B, V73, P227, DOI 10.1101/sqb.2008.73.042; Kaldis P, 2007, CELL, V128, P241, DOI 10.1016/j.cell.2007.01.006; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Keller UB, 2007, EMBO J, V26, P2562, DOI 10.1038/sj.emboj.7601691; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Koff A, 2006, CANCER CELL, V9, P75, DOI 10.1016/j.ccr.2006.01.020; Kohyama J, 2010, J CELL BIOL, V189, P159, DOI 10.1083/jcb.200908048; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kotoshiba S, 2005, J BIOL CHEM, V280, P17694, DOI 10.1074/jbc.M500866200; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; Lu Z, 2010, CELL CYCLE, V9, P2400; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Masuda K, 2010, ONCOGENE, V29, P1798, DOI 10.1038/onc.2009.469; McFarlane C, 2010, CANCER RES, V70, P3329, DOI 10.1158/0008-5472.CAN-09-4152; Miyazawa K, 2000, J NEUROSCI, V20, P5756, DOI 10.1523/JNEUROSCI.20-15-05756.2000; Ooi L, 2007, NAT REV GENET, V8, P544, DOI 10.1038/nrg2100; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041; Peschiaroli A, 2010, ONCOGENE, V29, P1384, DOI 10.1038/onc.2009.430; Ravanpay AC, 2010, MOL CELL NEUROSCI, V44, P178, DOI 10.1016/j.mcn.2010.03.006; Reed SI, 2002, CELL CYCLE, V1, P389, DOI 10.4161/cc.1.6.261; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Singh A, 2011, CANCER-AM CANCER SOC, V117, P5189, DOI 10.1002/cncr.26145; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Spencer EM, 2006, NEUROBIOL DIS, V24, P41, DOI 10.1016/j.nbd.2006.04.020; Stegmeier F, 2007, P NATL ACAD SCI USA, V104, P8869, DOI 10.1073/pnas.0703268104; Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006; Sun YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003656; Todi S.V., 2011, TRENDS NEUROSCI; Tomasoni R, 2011, J CELL SCI, V124, P3174, DOI 10.1242/jcs.087551; Ungermannova D, 2005, J BIOL CHEM, V280, P30301, DOI 10.1074/jbc.M411103200; van Leuken RJ, 2008, CELL CYCLE, V7, P2710, DOI 10.4161/cc.7.17.6553; Wander SA, 2011, CLIN CANCER RES, V17, P12, DOI 10.1158/1078-0432.CCR-10-0752; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Westbrook TF, 2008, NATURE, V452, P370, DOI 10.1038/nature06780; Wilkinson KD, 2009, J CELL SCI, V122, P2325, DOI 10.1242/jcs.041046; Zindy F, 2006, P NATL ACAD SCI USA, V103, P11579, DOI 10.1073/pnas.0604727103	72	29	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 28	2013	32	13					1691	1701		10.1038/onc.2012.182	http://dx.doi.org/10.1038/onc.2012.182			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22665064	Green Accepted			2022-12-28	WOS:000316855800009
J	Palumbo, T; Faucz, FR; Azevedo, M; Xekouki, P; Iliopoulos, D; Stratakis, CA				Palumbo, T.; Faucz, F. R.; Azevedo, M.; Xekouki, P.; Iliopoulos, D.; Stratakis, C. A.			Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway	ONCOGENE			English	Article						microRNAs; growth-hormone producing adenomas; Carney complex; acromegaly; pituitary hyperplasia; protein kinase A	MCCUNE-ALBRIGHT-SYNDROME; CELL SELF-RENEWAL; CARNEY COMPLEX; MICRORNA GENES; BREAST-CANCER; BMI-1; EXPRESSION; ADENOMAS; PROLIFERATION; MUTATIONS	MicroRNAs (miRNAs) have been involved in the pathogenesis of different types of cancer; however, their function in pituitary tumorigenesis remains poorly understood. Cyclic-AMP-dependent protein kinase-defective pituitaries occasionally form aggressive growth-hormone (GH)-producing pituitary tumors in the background of hyperplasia caused by haploinsufficiency of the protein kinase's main regulatory subunit, PRKAR1A. The molecular basis for this development remains unknown. We have identified a 17-miRNA signature of pituitary tumors formed in the background of hyperplasia (caused in half of the cases by PRKAR1A-mutations). We selected two miRNAs on the basis of their functional screen analysis: inhibition of miR-26b expression and upregulation of miR-128 suppressed the colony formation ability and invasiveness of pituitary tumor cells. Furthermore, we identified that miR-26b and miR-128 affected pituitary tumor cell behavior through regulation of their direct targets, PTEN and BMI1, respectively. In addition, we found that miR-128 through BMI1 direct binding on the PTEN promoter affected PTEN expression levels and AKT activity in the pituitary tumor cells. Our in vivo data revealed that inhibition of miR-26b and overexpression of miR-128 could suppress pituitary GH3 tumor growth in xenografts. Taken together, we have identified a miRNA signature for GH-producing pituitary tumors and found that miR-26b and miR-128 regulate the activity of the PTEN-AKT pathway in these tumors. This is the first suggestion of the possible involvement of miRNAs regulating the PTEN-AKT pathway in GH-producing pituitary tumor formation in the context of hyperplasia or due to germline PRKAR1A defects. MiR-26b suppression and miR-128 upregulation could have therapeutic potential in GH-producing pituitary tumor patients. Oncogene (2013) 32, 1651-1659; doi: 10.1038/onc.2012.190; published online 21 May 2012	[Palumbo, T.; Iliopoulos, D.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA; [Palumbo, T.; Iliopoulos, D.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA; [Faucz, F. R.; Azevedo, M.; Xekouki, P.; Stratakis, C. A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet, Bethesda, MD USA; [Faucz, F. R.] Pontificia Univ Catolica Parana, Grp Adv Mol Invest, Grad Program Hlth Sci, Ctr Biol & Sci, Curitiba, Parana, Brazil	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Pontificia Universidade Catolica do Parana	Iliopoulos, D (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.	Dimitrios_iliopoulos@dfci.harvard.edu; stratakc@mail.nih.gov	Faucz, Fabio R/C-1607-2009; Iliopoulos, Dimitrios/AAE-9106-2019; Stratakis, Constantine/AAP-4745-2020; Xekouki, Paraskevi/AAM-2485-2021	Faucz, Fabio/0000-0001-7959-9842	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008920] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA HD008920-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Amaral FC, 2009, J CLIN ENDOCR METAB, V94, P320, DOI 10.1210/jc.2008-1451; Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798; Asa SL, 2002, NAT REV CANCER, V2, P836, DOI 10.1038/nrc926; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boikos Sosipatros A, 2006, Pituitary, V9, P203, DOI 10.1007/s11102-006-0265-2; Bossis I, 2004, J MED GENET, V41, P596, DOI 10.1136/jmg.2004.020214; Bottoni A, 2005, J CELL PHYSIOL, V204, P280, DOI 10.1002/jcp.20282; Bottoni A, 2007, J CELL PHYSIOL, V210, P370, DOI 10.1002/jcp.20832; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Farrell WE, 2011, J CLIN ENDOCR METAB, V96, pE1905, DOI 10.1210/jc.2011-1127; Galland F, 2006, J CLIN ENDOCR METAB, V91, P4957, DOI 10.1210/jc.2006-0561; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-10; Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Horvath A, 2010, HUM MUTAT, V31, P369, DOI 10.1002/humu.21178; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Incoronato M, 2010, CANCER RES, V70, P3638, DOI 10.1158/0008-5472.CAN-09-3341; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; KOVACS K, 1984, VIRCHOWS ARCH A, V403, P77, DOI 10.1007/BF00689340; Liu WL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-467; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Mai PL, 2007, J MED CASE REPORTS B, V1, P1; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Pack SD, 2005, GENE CHROMOSOME CANC, V43, P72, DOI 10.1002/gcc.20162; Pack SD, 2000, J CLIN ENDOCR METAB, V85, P3860, DOI 10.1210/jc.85.10.3860; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rahbari R, 2011, ANN SURG ONCOL, V18, P1158, DOI 10.1245/s10434-010-1359-7; Sinha AU, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-88; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Stilling G, 2010, ENDOCRINE, V38, P67, DOI 10.1007/s12020-010-9346-0; Stratakis CA, 2010, CLIN GENET, V78, P457, DOI 10.1111/j.1399-0004.2010.01406.x; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200	49	105	114	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1651	1659		10.1038/onc.2012.190	http://dx.doi.org/10.1038/onc.2012.190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614013	Green Accepted			2022-12-28	WOS:000316855800005
J	Reilly, PT; Teo, WL; Low, MJ; Amoyo-Brion, AA; Dominguez-Brauer, C; Elia, AJ; Berger, T; Greicius, G; Pettersson, S; Mak, TW				Reilly, P. T.; Teo, W. L.; Low, M. J.; Amoyo-Brion, A. A.; Dominguez-Brauer, C.; Elia, A. J.; Berger, T.; Greicius, G.; Pettersson, S.; Mak, T. W.			Lipocalin 2 performs contrasting, location-dependent roles in APCmin tumor initiation and progression	ONCOGENE			English	Article						NGAL; 24p3; iron; intestinal cancer	GELATINASE-ASSOCIATED LIPOCALIN; INTESTINAL TUMORIGENESIS; BREAST-CANCER; NEUTROPHIL LIPOCALIN; APC(MIN/+) MOUSE; GASTRIC-CANCER; BETA-CATENIN; IRON; NGAL; MICE	Evidence that lipocalin 2 (LCN2) is oncogenic has grown in recent years and comes from both animal models and expression analysis from a variety of human cancers. In the intestine, LCN2 is overexpressed in colitis patients and its overexpression is a negative prognostic indicator in colorectal cancer. Functionally, LCN2 has a number of different activities that may contribute to its oncogenic potential, including increasing matrix metalloproteinase activity, control of iron availability and stimulating inflammation. In this report, we examined APCmin intestinal tumorigenesis in an LCN2-deficient background. We found that the loss of LCN2 increased tumor multiplicity specifically in the duodenum, suggesting a potential tumor-suppressive activity. Concurrently, however, LCN2 increased the average small intestinal tumor size particularly in the distal small intestine. We found that this increase was correlated to tumor iron(II) content, suggesting that an iron-scavenging role is important for LCN2 oncogenic activity in the intestine. Oncogene (2013) 32, 1233-1239; doi:10.1038/onc.2012.159; published online 21 May 2012	[Reilly, P. T.; Teo, W. L.; Amoyo-Brion, A. A.; Greicius, G.; Pettersson, S.; Mak, T. W.] Natl Canc Ctr Singapore, Div Cellular & Mol Res, Singapore, Singapore; [Dominguez-Brauer, C.; Elia, A. J.; Berger, T.; Mak, T. W.] Univ Hlth Network, Campbell Family Canc Res Inst, Toronto, ON M5G 2C1+, Canada	National Cancer Centre Singapore (NCCS); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Mak, TW (corresponding author), Univ Hlth Network, Campbell Family Canc Res Inst, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1+, Canada.	tmak@uhnres.utoronto.ca	Berger, Thorsten/J-7632-2012; Pettersson, Sven/F-9511-2015	Greicius, Gediminas/0000-0001-8333-787X	National Cancer Centre Research Foundation, Singapore	National Cancer Centre Research Foundation, Singapore	We would like to acknowledge the National Cancer Centre Research Foundation, Singapore for financial support. We also thank Dr Ralph Bunte for helpful discussion as well as Dr Keith Rogers, Dr Seow Shih Wee, Mr Wong Jieshun, and Dr Annie-Gale Cambel for technical assistance.	Alpizar-Alpizar W, 2009, VIRCHOWS ARCH, V455, P225, DOI 10.1007/s00428-009-0825-8; Bachman MA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000622; Baltgalvis KA, 2008, J APPL PHYSIOL, V104, P1137, DOI 10.1152/japplphysiol.00955.2007; Bao GH, 2010, NAT CHEM BIOL, V6, P602, DOI [10.1038/nchembio.402, 10.1038/NCHEMBIO.402]; Barresi V, 2010, CLIN NEUROPATHOL, V29, P317; Barresi V, 2011, PATHOL RES PRACT, V207, P479, DOI 10.1016/j.prp.2011.05.012; Barresi V, 2010, ONCOL REP, V24, P305, DOI 10.3892/or_00000860; Bauer M, 2008, BREAST CANCER RES TR, V108, P389, DOI 10.1007/s10549-007-9619-3; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; Berger T, 2010, P NATL ACAD SCI USA, V107, P2995, DOI 10.1073/pnas.1000101107; Carlson M, 2002, GUT, V50, P501, DOI 10.1136/gut.50.4.501; Dale JC, 2002, AM J CLIN PATHOL, V117, P802, DOI 10.1309/2YT4-CMP3-KYW7-9RK1; de  Haar C, 2012, CARCINOGENESIS; Devireddy LR, 2010, CELL, V141, P1006, DOI 10.1016/j.cell.2010.04.040; Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027; Dove WF, 1997, CANCER RES, V57, P812; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Fischbach MA, 2006, P NATL ACAD SCI USA, V103, P16502, DOI 10.1073/pnas.0604636103; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Forbes A, 2009, GASTROENTEROLOGY, V137, pS47, DOI 10.1053/j.gastro.2009.08.013; Friedl A, 1999, HISTOCHEM J, V31, P433, DOI 10.1023/A:1003708808934; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Hata K, 2006, CANCER LETT, V239, P123, DOI 10.1016/j.canlet.2005.07.033; Hvidberg V, 2005, FEBS LETT, V579, P773, DOI 10.1016/j.febslet.2004.12.031; Kubben FJGM, 2007, EUR J CANCER, V43, P1869, DOI 10.1016/j.ejca.2007.05.013; Leng XH, 2009, CANCER RES, V69, P8579, DOI 10.1158/0008-5472.CAN-09-1934; Mori K, 2007, KIDNEY INT, V71, P967, DOI 10.1038/sj.ki.5002165; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Murphy EA, 2011, J INTERF CYTOK RES, V31, P219, DOI 10.1089/jir.2010.0051; Mutanen M, 2000, CARCINOGENESIS, V21, P1167, DOI 10.1093/carcin/21.6.1167; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; Nuntagowat C, 2010, CLIN EXP METASTAS, V27, P295, DOI 10.1007/s10585-010-9327-y; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Rodvold JJ, 2012, CANCER LETT, V316, P132, DOI 10.1016/j.canlet.2011.11.002; Ryon J, 2002, BIOCHEM J, V367, P271, DOI 10.1042/BJ20020026; Shen Zhe-zhu, 2003, Zhonghua Wai Ke Za Zhi, V41, P817; Sinnamon MJ, 2008, INT J EXP PATHOL, V89, P466, DOI 10.1111/j.1365-2613.2008.00621.x; Stoesz SP, 1998, INT J CANCER, V79, P565, DOI 10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.3.CO;2-6; Vinuesa E, 2008, AM J PHYSIOL-RENAL, V295, pF1554, DOI 10.1152/ajprenal.90250.2008; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Wang HJ, 2010, ANAT REC, V293, P1855, DOI 10.1002/ar.21230; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Xiao H, 2010, GASTROENTEROLOGY, V139, P574, DOI 10.1053/j.gastro.2010.04.043; Xu G, 2012, J BIOL CHEM, V287, P4808, DOI 10.1074/jbc.M111.275719; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zhang HH, 2007, J CLIN PATHOL, V60, P555, DOI 10.1136/jcp.2006.039297; Zhang JH, 2008, MOL ENDOCRINOL, V22, P1416, DOI 10.1210/me.2007-0420	50	16	16	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1233	1239		10.1038/onc.2012.159	http://dx.doi.org/10.1038/onc.2012.159			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22614012	Green Published			2022-12-28	WOS:000316454500004
J	Yu, YH; Chen, HA; Chen, PS; Cheng, YJ; Hsu, WH; Chang, YW; Chen, YH; Jan, Y; Hsiao, M; Chang, TY; Liu, YH; Jeng, YM; Wu, CH; Huang, MT; Su, YH; Hung, MC; Chien, MH; Chen, CY; Kuo, ML; Su, JL				Yu, Y-H; Chen, H-A; Chen, P-S; Cheng, Y-J; Hsu, W-H; Chang, Y-W; Chen, Y-H; Jan, Y.; Hsiao, M.; Chang, T-Y; Liu, Y-H; Jeng, Y-M; Wu, C-H; Huang, M-T; Su, Y-H; Hung, M-C; Chien, M-H; Chen, C-Y; Kuo, M-L; Su, J-L			MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol	ONCOGENE			English	Article						FOXC2; miR-520h; resveratrol; metastasis	PROTEIN PHOSPHATASE 2A; EPITHELIAL-MESENCHYMAL TRANSITION; KAPPA-B KINASE; TRANSCRIPTION FACTORS; COLORECTAL-CANCER; SIGNALING PATHWAY; TUMOR-SUPPRESSOR; EXPRESSION; CELL; METASTASIS	Resveratrol, a phytochemical found in various plants and Chinese herbs, is associated with multiple tumor-suppressing activities, has been tested in clinical trials. However, the molecular mechanisms involved in resveratrol-mediated tumor suppressing activities are not yet completely defined. Here, we showed that treatment with resveratrol inhibited cell mobility through induction of the mesenchymal-epithelial transition (MET) in lung cancer cells. We. also found that downregulation of FOXC2 (forkhead box C2) is critical for resveratrol-mediated suppression of tumor metastasis in an in vitro and in vivo models. We also identified a signal cascade, namely, resveratrol-vertical bar miRNA-520h-vertical bar PP2A/C-vertical bar Akt -> NF-kappa B -> FOXC2, in which resveratrol inhibited the expression of FOXC2 through regulation of miRNA-520h-mediated signal cascade. This study identified a new miRNA-520h-related signal cascade involved in resveratrol-mediated tumor suppression activity and provide the clinical significances of miR-520h, PP2A/C and FOXC2 in lung cancer patients. Our results indicated a functional link between resveratrol-mediated miRNA-520h regulation and tumor suppressing ability, and provide a new insight into the role of resveratrol-induced molecular and epigenetic regulations in tumor suppression. Oncogene (2013) 32, 431-443; doi:10.1038/onc.2012.74; published online 12 March 2012	[Yu, Y-H; Hsu, W-H] China Med Univ Hosp, Dept Internal Med, Div Pulm Med, Taichung, Taiwan; [Yu, Y-H; Hsu, W-H] China Med Univ Hosp, Div Crit Care Med, Taichung, Taiwan; [Yu, Y-H] China Med Univ, Grad Inst Clin Med Sci, Taichung 40402, Taiwan; [Chen, H-A; Wu, C-H; Huang, M-T; Su, Y-H; Chien, M-H] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Chen, H-A; Wu, C-H; Huang, M-T; Su, Y-H] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan; [Chen, P-S; Kuo, M-L] Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan; [Chen, P-S; Kuo, M-L] Natl Taiwan Univ, Angiogenesis Res Ctr, Taipei 10764, Taiwan; [Chen, P-S; Kuo, M-L] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; [Cheng, Y-J; Chang, T-Y; Hung, M-C; Su, J-L] China Med Univ, Coll Med, Grad Inst Canc Biol, Taichung 40402, Taiwan; [Chang, Y-W] Natl Yang Ming Univ, Grad Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Chen, Y-H; Liu, Y-H; Hung, M-C; Su, J-L] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Jan, Y.; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Jeng, Y-M] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan; [Chien, M-H] Taipei Med Univ, Wan Fang Hosp, Taipei, Taiwan; [Chen, C-Y] China Med Univ Hosp, Ctr Canc, Taichung, Taiwan; [Su, J-L] China Med Univ, Canc Biol & Drug Discovery PhD Degree Program, Taichung 40402, Taiwan; [Su, J-L] Asia Univ, Dept Biotechnol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; China Medical University Taiwan; National Yang Ming Chiao Tung University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; Taipei Medical University; Taipei Municipal WanFang Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan	Su, JL (corresponding author), China Med Univ, Coll Med, Grad Inst Canc Biol, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.	mhchien1976@gmail.com; jlsu@mail.cmu.edu.tw	Hsiao, Michael/U-6238-2019; Chen, Pai-Sheng/G-2130-2012; Hung, Mien-Chie/ABD-5911-2021	Hsiao, Michael/0000-0001-8529-9213; Chen, Pai-Sheng/0000-0003-0513-1467; Hung, Mien-Chie/0000-0003-4317-4740; Su, Yen-Hao/0000-0001-8288-3772; JENG, YUNG-MING/0000-0002-3878-4491; KUO, MIN-LIANG/0000-0002-7139-0144	National Science Council [NSC-2632-B-001-MY3, NSC 96-2320-B-004-MY2, NSC 97-2320-B-039-039-MY3, NSC 98-2815-C-039-082-B]; National Health Research Institutes Grant from Taiwan [NHRI-EX98-9712BC, NHRI-EX99-9712BC, NHRI-EX100-9712BC]; Department of Health, Executive Yuan Grant from Taiwan [DOH99-TD-G111-011]; China Medical University [CMU96-220, CMU97-077, CMU97-277, CMU-99-NTU-08, CMU100-TS-06, DMR-101-014]	National Science Council(Ministry of Science and Technology, Taiwan); National Health Research Institutes Grant from Taiwan; Department of Health, Executive Yuan Grant from Taiwan; China Medical University(China Medical University)	This work was partially supported by the National Science Council Grant (NSC-2632-B-001-MY3, NSC 96-2320-B-004-MY2, NSC 97-2320-B-039-039-MY3 and NSC 98-2815-C-039-082-B to J-LS); National Health Research Institutes Grant from Taiwan (NHRI-EX98-9712BC, NHRI-EX99-9712BC and NHRI-EX100-9712BC to J-LS); Department of Health, Executive Yuan Grant from Taiwan (DOH99-TD-G111-011 to J-LS); Grants from China Medical University (CMU96-220, CMU97-077 and CMU97-277 to J-LS; CMU-99-NTU-08, CMU100-TS-06 and DMR-101-014 to Y-HY).	Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433; Athar M, 2009, ARCH BIOCHEM BIOPHYS, V486, P95, DOI 10.1016/j.abb.2009.01.018; Aziz MH, 2006, MOL CANCER THER, V5, P1335, DOI 10.1158/1535-7163.MCT-05-0526; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Browne G, 2010, CELL CYCLE, V9, P886, DOI 10.4161/cc.9.5.10839; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Choi HK, 2006, CANCER LETT, V242, P198, DOI 10.1016/j.canlet.2005.11.005; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Gronning LM, 2002, MOL ENDOCRINOL, V16, P873, DOI 10.1210/me.16.4.873; Hader C, 2010, ONCOGENE, V29, P1031, DOI 10.1038/onc.2009.397; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hayashi H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002401; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Korpal M, 2008, RNA BIOL, V5, P115, DOI 10.4161/rna.5.3.6558; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Kuhn H, 2002, EUR RESPIR J, V20, P703, DOI 10.1183/09031936.02.00294502; Kume T, 2001, GENE DEV, V15, P2470, DOI 10.1101/gad.907301; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Li Q, 2009, AM J PHYSIOL-ENDOC M, V4, P965; Liao Y, 2004, CANCER RES, V64, P5938, DOI 10.1158/0008-5472.CAN-04-1533; Lu YB, 2005, J LEUKOCYTE BIOL, V78, P259, DOI 10.1189/jlb.0904498; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Matsuoka Y, 2003, BRIT J PHARMACOL, V138, P1303, DOI 10.1038/sj.bjp.0705182; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Ngan CY, 2007, BRIT J CANCER, V96, P986, DOI 10.1038/sj.bjc.6603651; Nishida N, 2011, ANN SURG ONCOL, V18, P535, DOI 10.1245/s10434-010-1274-y; PAGET S, 1989, CANCER METAST REV, V8, P98; Perrotti D, 2008, CANCER METAST REV, V27, P159, DOI 10.1007/s10555-008-9119-x; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Sano H, 2010, BIOCHEM BIOPH RES CO, V392, P201, DOI 10.1016/j.bbrc.2010.01.015; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Stewart JR, 1999, BIOCHEMISTRY-US, V38, P13244, DOI 10.1021/bi990875u; Stewart JR, 2000, BIOCHEM PHARMACOL, V60, P1355, DOI 10.1016/S0006-2952(00)00450-0; Su JL, 2010, CANCER RES, V70, P5096, DOI 10.1158/0008-5472.CAN-09-4148; Sun HZ, 2010, J ENDOCRINOL, V204, P311, DOI 10.1677/JOE-09-0270; Tili E, 2010, BIOCHEM PHARMACOL, V80, P2057, DOI 10.1016/j.bcp.2010.07.003; Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Topczewska JM, 2001, GENE DEV, V15, P2483, DOI 10.1101/gad.907401; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	54	101	110	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					431	443		10.1038/onc.2012.74	http://dx.doi.org/10.1038/onc.2012.74			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22410781				2022-12-28	WOS:000315551300004
J	Jan, M; Majeti, R				Jan, M.; Majeti, R.			Clonal evolution of acute leukemia genomes	ONCOGENE			English	Review						acute leukemia; genome; stem cells	ACUTE MYELOID-LEUKEMIA; BCR-ABL1 LYMPHOBLASTIC-LEUKEMIA; COPY NUMBER ALTERATIONS; STEM-CELLS; MUTATIONS; CANCER; TET2; ORIGINS; RELAPSE; ABNORMALITIES	In large part, cancer results from the accumulation of multiple mutations in a single cell lineage that are sequentially acquired and subject to an evolutionary process where selection drives the expansion of more fit subclones. Owing to the technical challenge of distinguishing and isolating distinct cancer subclones, many aspects of this clonal evolution are poorly understood, including the diversity of different subclones in an individual cancer, the nature of the subclones contributing to relapse, and the identity of pre-cancerous mutations. These issues are not just important to our understanding of cancer biology, but are also clinically important given the need to understand the nature of subclones responsible for the refractory and relapsed disease that cause significant morbidity and mortality in patients. Recently, advanced genomic techniques have been used to investigate clonal diversity and evolution in acute leukemia. Studies of pediatric acute lymphoblastic leukemia (ALL) demonstrated that in individual patients there are multiple genetic subclones of leukemia-initiating cells, with a complex clonal architecture. Separate studies also investigating pediatric ALL determined that the clonal basis of relapse was variable and complex, with relapse often evolving from a clone ancestral to the predominant de novo leukemia clone. Additional studies in both ALL and acute myeloid leukemia have identified pre-leukemic mutations in some individual cases. This review will highlight these recent reports investigating the clonal evolution of acute leukemia genomes and discuss the implications for clinical therapy. Oncogene (2013) 32, 135-140; doi:10.1038/onc.2012.48; published online 20 February 2012	[Jan, M.; Majeti, R.] Stanford Univ, Sch Med, Dept Med, Div Hematol,Canc Inst, Palo Alto, CA 94304 USA; [Jan, M.; Majeti, R.] Stanford Univ, Sch Med, Stanford Inst Stem Cell Biol & Regenerat Med, Palo Alto, CA 94304 USA; [Jan, M.; Majeti, R.] Stanford Univ, Sch Med, Program Canc Biol, Inst Canc, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University	Majeti, R (corresponding author), Stanford Univ, Stanford Inst Stem Cell Biol & Regenerat Med, Lokey Stem Cell Bldg,265 Campus Dr,G3021B, Stanford, CA 94305 USA.	rmajeti@stanford.edu		Majeti, Ravindra/0000-0002-5814-0984	Lucille P Markey Biomedical Research Fellowship; National Science Foundation; Burroughs Wellcome Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL099999] Funding Source: NIH RePORTER	Lucille P Markey Biomedical Research Fellowship; National Science Foundation(National Science Foundation (NSF)); Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We would like to acknowledge Ryan Corces-Zimmerman for critical review of the manuscript. MJ is supported by the Lucille P Markey Biomedical Research Fellowship and the National Science Foundation Graduate Research Fellowship. RM holds a career award for medical scientists from the Burroughs Wellcome Fund.	Abrahamsson AE, 2009, P NATL ACAD SCI USA, V106, P3925, DOI 10.1073/pnas.0900189106; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Bateman CM, 2010, BLOOD, V115, P3553, DOI 10.1182/blood-2009-10-251413; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Cloos J, 2006, LEUKEMIA, V20, P1217, DOI 10.1038/sj.leu.2404246; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Greaves Mel, 2003, Rev Clin Exp Hematol, V7, P233; Greaves Mel, 2009, Hematology Am Soc Hematol Educ Program, P3, DOI 10.1182/asheducation-2009.1.3; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jan M, 2011, P NATL ACAD SCI USA, V108, P5009, DOI 10.1073/pnas.1100551108; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kikushige Y, 2010, CELL STEM CELL, V7, P708, DOI 10.1016/j.stem.2010.11.014; Kuster L, 2011, BLOOD, V117, P2658, DOI 10.1182/blood-2010-03-275347; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Link DC, 2011, JAMA-J AM MED ASSOC, V305, P1568, DOI 10.1001/jama.2011.473; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Mrozek K, 2007, BLOOD, V109, P431, DOI 10.1182/blood-2006-06-001149; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; Nilsson L, 2002, BLOOD, V100, P259, DOI 10.1182/blood-2001-12-0188; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Schaub FX, 2010, BLOOD, V115, P2003, DOI 10.1182/blood-2009-09-245381; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; van Delft FW, 2011, BLOOD, V117, P6247, DOI 10.1182/blood-2010-10-314674; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Walter MJ, 2009, P NATL ACAD SCI USA, V106, P12950, DOI 10.1073/pnas.0903091106; Weissman I, 2005, JAMA-J AM MED ASSOC, V294, P1359, DOI 10.1001/jama.294.11.1359; Welch JS, 2011, JAMA-J AM MED ASSOC, V305, P1577, DOI 10.1001/jama.2011.497; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788; Yang JJ, 2008, BLOOD, V112, P4178, DOI 10.1182/blood-2008-06-165027	55	88	90	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					135	140		10.1038/onc.2012.48	http://dx.doi.org/10.1038/onc.2012.48			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349821	Green Accepted			2022-12-28	WOS:000314075500001
J	Wen, ZH; Su, YC; Lai, PL; Zhang, Y; Xu, YF; Zhao, A; Yao, GY; Jia, CH; Lin, J; Xu, S; Wang, L; Wang, XK; Liu, AL; Jiang, Y; Dai, YF; Bai, XC				Wen, Z-H; Su, Y-C; Lai, P-L; Zhang, Y.; Xu, Y-F; Zhao, A.; Yao, G-Y; Jia, C-H; Lin, J.; Xu, S.; Wang, L.; Wang, X-K; Liu, A-L; Jiang, Y.; Dai, Y-F; Bai, X-C			Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis	ONCOGENE			English	Article						mammalian target of rapamycin; arachidonic acid; breast cancer; tumorigenesis; angiogenesis	FATTY-ACIDS; PHOSPHOLIPASE A(2); CANCER PREVENTION; CELL-GROWTH; PATHWAY; METABOLISM; INHIBITION; EXPRESSION; ADHESION; MEDIATOR	The mammalian target of rapamycin (mTOR) signaling pathway is upregulated in the pathogenesis of many cancers. Arachidonic acid (AA) and its metabolites play critical role in the development of breast cancer, but the mechanisms through which AA promotes mammary tumorigenesis and progression are poorly understood. We found that the levels of AA and cytosolic phospholipase A2 (cPLA2) strongly correlated with the signaling activity of mTORC1 and mTORC2 as well as the expression levels of vascular epithelial growth factor (VEGF) in human breast tumor tissues. In cultured breast cancer cells, AA effectively activated both mTOR complex 1 (mTORC1) and mTORC2. Interestingly, AA-stimulated mTORC1 activation was independent of amino acids, phosphatidylinositol 3-kinase (PI3-K) and tuberous sclerosis complex 2 (TSC2), which suggests a novel mechanism for nnTORC1 activation. Further studies revealed that AA stimulated mTORC1 activity through destabilization of mTOR-raptor association in ras homolog enriched in brain (Rheb)-dependent mechanism. Moreover, we showed that AA-stimulated cell proliferation and angiogenesis required mTOR activity and that the effect of AA was mediated by lipoxygenase (LOX) but not cyclooxygenase-2 (COX-2). In animal models, AA-enhanced incidences of rat mammary tumorigenesis, tumor weights and angiogenesis were inhibited by rapamycin. Our findings suggest that AA is an effective intracellular stimulus of mTOR and that AA-activated mTOR plays critical roles in angiogenesis and tumorigenesis of breast cancer. Oncogene (2013) 32, 160-170; doi:10.1038/onc.2012.47; published online 20 February 2012	[Wen, Z-H; Su, Y-C; Lai, P-L; Zhang, Y.; Xu, Y-F; Jia, C-H; Lin, J.; Xu, S.; Wang, L.; Wang, X-K; Liu, A-L; Bai, X-C] So Med Univ, Sch Basic Med Sci, Dept Cell Biol, Guangzhou 510515, Guangdong, Peoples R China; [Zhao, A.; Dai, Y-F] Nanjing Med Univ, Ctr Metab Dis Res, Nanjing 201129, Jiangsu, Peoples R China; [Yao, G-Y] So Med Univ, Nanfang Hosp, Breast Ctr, Guangzhou 510515, Guangdong, Peoples R China; [Jiang, Y.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Dai, Y-F] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 201129, Jiangsu, Peoples R China	Southern Medical University - China; Nanjing Medical University; Southern Medical University - China; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Nanjing Medical University	Dai, YF (corresponding author), Nanjing Med Univ, Ctr Metab Dis Res, Nanjing 201129, Jiangsu, Peoples R China.	yifandai08@gmail.com; baixc15@smu.edu.cn		Bai, Xiaochun/0000-0001-9631-4781	State Key Development Program for Basic Research of China [2009CB 918904]; National Natural Sciences Foundation of China [30870955, 91029727, 30900555]; Program for New Century Excellent Talents in University [NCET-08-0646]; NATIONAL CANCER INSTITUTE [R01CA129821] Funding Source: NIH RePORTER	State Key Development Program for Basic Research of China(State Key Development Program for Basic Research of China); National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We greatly appreciate the gift of TSC2<SUP>+/+</SUP> and TSC2<SUP>-/-</SUP> MEFs from Dr David J Kwiatkowski (Brigham and Women's Hospital, Boston, MA, USA). This work was supported by The State Key Development Program for Basic Research of China (No. 2009CB 918904), National Natural Sciences Foundation of China (30870955, 91029727, 30900555) and Program for New Century Excellent Talents in University (NCET-08-0646).	Agrawal A, 2008, INT J CLIN PRACT, V62, P444, DOI 10.1111/j.1742-1241.2007.01668.x; Bai XC, 2007, SCIENCE, V318, P977, DOI 10.1126/science.1147379; Bai XC, 2010, CELL MOL LIFE SCI, V67, P239, DOI 10.1007/s00018-009-0163-7; BUZZARD CJ, 1993, CIRC RES, V72, P1023, DOI 10.1161/01.RES.72.5.1023; Cakir Y, 2002, INT J ONCOL, V21, P153; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Chen XX, 2006, CURR CANCER DRUG TAR, V6, P613, DOI 10.2174/156800906778742451; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Goberdhan DCI, 2010, CURR OPIN INVEST DR, V11, P1360; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Harizi H, 2008, TRENDS MOL MED, V14, P461, DOI 10.1016/j.molmed.2008.08.005; Holmes MD, 1999, JAMA-J AM MED ASSOC, V281, P914, DOI 10.1001/jama.281.10.914; Horn L, 2009, EXPERT OPIN THER TAR, V13, P675, DOI 10.1517/14728220902915567; Hyde CAC, 2009, INT IMMUNOPHARMACOL, V9, P701, DOI 10.1016/j.intimp.2009.02.003; Hynes NE, 2006, J MAMMARY GLAND BIOL, V11, P53, DOI 10.1007/s10911-006-9012-6; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jiang WG, 2006, PROSTAG LEUKOTR ESS, V74, P125, DOI 10.1016/j.plefa.2005.10.005; Kennett SB, 2004, J BIOL CHEM, V279, P3300, DOI 10.1074/jbc.M305734200; Kim C, 2008, BMB REP, V41, P555, DOI 10.5483/BMBRep.2008.41.8.555; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kuehn HS, 2011, J BIOL CHEM, V286, P391, DOI 10.1074/jbc.M110.164772; Li M, 2010, CELL SIGNAL, V22, P1469, DOI 10.1016/j.cellsig.2010.05.015; Linkous AG, 2010, JNCI-J NATL CANCER I, V102, P1398, DOI 10.1093/jnci/djq290; Martinez-Orozco R, 2010, EUR J CELL BIOL, V89, P476, DOI 10.1016/j.ejcb.2009.12.005; MCCORMICK DL, 1987, CANCER LETT, V37, P139, DOI 10.1016/0304-3835(87)90156-X; Menna C, 2010, CURR PHARM DESIGN, V16, P725, DOI 10.2174/138161210790883822; Meyer AM, 2004, CARCINOGENESIS, V25, P1517, DOI 10.1093/carcin/bgh150; Mieulet V, 2010, TRENDS MOL MED, V16, P329, DOI 10.1016/j.molmed.2010.05.001; Nakanishi M, 2006, BBA-MOL CELL BIOL L, V1761, P1335, DOI 10.1016/j.bbalip.2006.09.005; Navarro-Tito N, 2008, EXP CELL RES, V314, P3340, DOI 10.1016/j.yexcr.2008.08.018; Navarro-Tito N, 2010, INT J BIOCHEM CELL B, V42, P306, DOI 10.1016/j.biocel.2009.11.010; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Razanamahefa L, 2000, NUTR CANCER, V38, P274, DOI 10.1207/S15327914NC382_17; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Singh-Ranger G, 2008, BREAST CANCER RES TR, V109, P189, DOI 10.1007/s10549-007-9641-5; Thiebaut ACM, 2009, INT J CANCER, V124, P924, DOI 10.1002/ijc.23980; Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801; Weiser-Evans MCM, 2009, CANCER RES, V69, P1733, DOI 10.1158/0008-5472.CAN-08-3766; YAMASHITA SI, 1994, BRIT J CANCER, V69, P1166, DOI 10.1038/bjc.1994.229; Ye YN, 2005, CARCINOGENESIS, V26, P827, DOI 10.1093/carcin/bgi012; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Zhang BL, 2006, J BIOL CHEM, V281, P905, DOI 10.1074/jbc.M503945200; Zhang BL, 2005, CANCER RES, V65, P7283, DOI 10.1158/0008-5472.CAN-05-0633; Zhou L, 2002, J NUTR, V132, P2626, DOI 10.1093/jn/132.9.2626	50	66	71	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					160	170		10.1038/onc.2012.47	http://dx.doi.org/10.1038/onc.2012.47			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349822				2022-12-28	WOS:000314075500004
J	Ying, M; Liu, G; Shimada, H; Ding, W; May, WA; He, Q; Adams, GB; Wu, L				Ying, M.; Liu, G.; Shimada, H.; Ding, W.; May, W. A.; He, Q.; Adams, G. B.; Wu, L.			Human osteosarcoma CD49f(-) CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity	ONCOGENE			English	Article						osteosarcoma-initiating cells; self-renewal; tumorigenicity; lineage differentiation; osteosarcoma-forming cells; osteogenic differentiation	CANCER-STEM-CELLS; PROSPECTIVE IDENTIFICATION; INITIATING CELLS; TUMOR-GROWTH; EXPRESSION; DIFFERENTIATION; MARKERS; METASTASIS; EXPANSION; ANTIGEN	The biological relationships among self-renewal, tumorigenicity and lineage differentiation of human osteosarcoma-initiating cells (OSIC) remain elusive, making it difficult to identify and distinguish OSIC from osteosarcoma-forming cells (OSFC) for developing OSIC-targeted therapies. Using a new inverse-lineage tracking strategy coupled with serial human-to-mouse xenotransplantation, we identified a subpopulation of osteosarcoma cells with OSIC-like properties and sought to distinguish them from their progeny, OSFC. We found that serial transplantation of cells from different osteosarcoma cell lines and primary osteosarcoma tissues progressively increased the CD49f(+) subpopulation composing the bulk of the osteosarcoma mass. These CD49f(+) cells displayed characteristics of OSFC: limited in vivo tumorigenicity, weak lineage differentiation, more differentiated osteogenic feature and greater chemo-sensitivity. By contrast, their parental CD49f(-) CD133(+) cells had an inhibited osteogenic fate, together with OSIC-like properties of self-renewal, strong tumorigenicity and differentiation to CD49f(+) progeny. Hence, the CD49f(-)CD133(+) phenotype appears to identify OSIC-like cells that possess strong tumorigenicity correlated with an impaired osteogenic fate and the ability to initiate tumor growth through the generation of CD49f(+) progeny. These findings advance our understanding of OSIC-like properties and, for the first time, provide a much-needed distinction between OSIC and OSFC in this cancer.	[Ying, M.; Liu, G.; Shimada, H.; Ding, W.; Wu, L.] Childrens Hosp Los Angeles, Dept Pathol, Saban Res Inst, Los Angeles, CA 90027 USA; [Shimada, H.; May, W. A.; Adams, G. B.; Wu, L.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA; [May, W. A.] Childrens Hosp Los Angeles, Dept Pediat, Saban Res Inst, Los Angeles, CA 90027 USA; [He, Q.] Zhejiang Univ, Sch Pharmaceut Sci, Inst Pharmacol & Toxicol, Hangzhou 310003, Zhejiang, Peoples R China; [Adams, G. B.] Univ So Calif, Keck Sch Med, Ctr Stem Cell & Regenerat Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; Zhejiang University; University of Southern California	Wu, L (corresponding author), Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Pathol, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@usc.edu	Liu, Gang/B-7635-2012		National Institutes of Health [R01 CA120512, ARRA-R01CA120512]; NATIONAL CANCER INSTITUTE [R21CA137485, R01CA120512] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health (R01 CA120512 and ARRA-R01CA120512 to LW).	Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bakhshi S, 2010, EXPERT REV ANTICANC, V10, P271, DOI [10.1586/era.09.186, 10.1586/ERA.09.186]; Bomken S, 2010, BRIT J CANCER, V103, P439, DOI 10.1038/sj.bjc.6605821; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581-200810050-00005; Cox CV, 2007, BLOOD, V109, P674, DOI 10.1182/blood-2006-06-030445; Cox CV, 2004, BLOOD, V104, P2919, DOI 10.1182/blood-2004-03-0901; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dewan MZ, 2006, BIOMED PHARMACOTHER, V60, P273, DOI 10.1016/j.biopha.2006.06.004; Di Fiore R, 2009, J CELL PHYSIOL, V219, P301, DOI 10.1002/jcp.21667; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Ferrandina G, 2009, EXPERT OPIN THER TAR, V13, P823, DOI 10.1517/14728220903005616; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Joo KM, 2009, METHODS MOL BIOL, V568, P57, DOI 10.1007/978-1-59745-280-9_5; Kang HG, 2007, CANCER RES, V67, P3094, DOI 10.1158/0008-5472.CAN-06-3259; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee RH, 2009, BLOOD, V113, P816, DOI 10.1182/blood-2007-12-128702; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Luo P, 2010, ONCOGENE, V29, P2772, DOI 10.1038/onc.2010.50; Luo PH, 2007, STEM CELLS, V25, P2628, DOI 10.1634/stemcells.2007-0264; Majetl R, 2009, P NATL ACAD SCI USA, V106, P3396, DOI 10.1073/pnas.0900089106; Maxson S, 2008, J TISSUE ENG REGEN M, V2, P147, DOI 10.1002/term.76; Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Oda Y, 2006, MODERN PATHOL, V19, P738, DOI 10.1038/modpathol.3800587; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rountree CB, 2009, STEM CELLS, V27, P290, DOI 10.1634/stemcells.2008-0332; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850; Tirino V, 2011, FASEB J, V25, P2022, DOI 10.1096/fj.10-179036; Tirino V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003469; Wang L, 2011, INT J CANCER, V128, P294, DOI 10.1002/ijc.25331; Woodward WA, 2008, CANCER METAST REV, V27, P459, DOI 10.1007/s10555-008-9130-2; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338; Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917	47	23	25	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4252	4263		10.1038/onc.2012.438	http://dx.doi.org/10.1038/onc.2012.438			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045288	Green Accepted			2022-12-28	WOS:000324168000007
J	Guo, L; Liew, HP; Camus, S; Goh, AM; Chee, LL; Lunny, DP; Lane, EB; Lane, DP				Guo, L.; Liew, H. P.; Camus, S.; Goh, A. M.; Chee, L. L.; Lunny, D. P.; Lane, E. B.; Lane, D. P.			Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish	ONCOGENE			English	Article						mutant; p53 protein; DNA damage; ionizing radiation; zebrafish; stability	SMALL-MOLECULE INHIBITORS; MDM2; GAIN; ACTIVATION; PATHWAY; INSTABILITY; EXPRESSION; LIGASE; DOMAIN; P63	Mutant p53 proteins accumulate to high levels in human tumors and in preneoplastic lesions in the skin and fallopian tube. However examination of tissues from mice and fish that are homozygous for mutant p53 surprisingly showed that the protein was present only at low levels except in the tumors that arose in these animals. The mutant protein did accumulate, however, following treatment with ionizing radiation in the same tissues in which the wild-type protein is induced. Here we study in detail the accumulation of mutant and wild-type p53 proteins following ionizing radiation in zebrafish embryos. We found that the mutant protein was induced by lower levels of radiation and reached higher levels than the wild-type protein. Morpholino knockdown of the zebrafish homologs of Mdm2 and Mdm4 caused dramatic accumulation of mutant p53 protein. The most remarkable results were observed by examining p53 protein levels over an extended time course. Mutant p53 protein increased and persisted for days after irradiation and this was accompanied by persistent elevation of phosphorylated H2AX (gamma H2AX), implying that the resolution of DNA damage signaling in these embryos is severely compromised by mutations in p53. Thus mutation in p53 results in an exaggerated and persistent damage response, which could in turn drive the process of cancer development as high levels of mutant p53 can act as an oncoprotein to drive invasion and metastasis.	[Guo, L.; Liew, H. P.; Camus, S.; Goh, A. M.; Chee, L. L.; Lane, D. P.] Inst Biomed Sci, Lab P53, Singapore 138648, Singapore; [Lunny, D. P.; Lane, E. B.] Inst Biomed Sci, Epithelial Biol Lab, Singapore 138648, Singapore		Lane, DP (corresponding author), Inst Biomed Sci, Lab P53, 8A Biomed Grove,Immunos 06-06, Singapore 138648, Singapore.	dplane@p53lab.a-star.edu.sg		Lane, David/0000-0003-0551-3545	Biomedical Research Council of Singapore	Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR))	We thank Dr Hwang Le-Ann from the Molecular Antibody Unit at the Institute of Molecular and Cell Biology for providing us the ZFp53-5.1 and ZFp53-9.1 antibodies. The zebrafish tp53<SUP>m214k</SUP> mutant line was generously provided by Professor A Thomas Look (Dana Farber Cancer Institute, Boston, MA, USA). Adult zebrafish was processed and sectioned by the Biopolis Shared Facility Histology Unit. All the adult zebrafish were maintained by zebrafish facility at the Institute of Molecular and Cell Biology. This work was supported by the Biomedical Research Council of Singapore.	BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARTEK J, 1991, ONCOGENE, V6, P1699; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Ding K, 2006, J MED CHEM, V49, P3432, DOI 10.1021/jm051122a; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guo L, 2010, CELL CYCLE, V9, P1998, DOI 10.4161/cc.9.10.11732; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; Iyappan S, 2010, J BIOL CHEM, V285, P33065, DOI 10.1074/jbc.M110.115113; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee KC, 2008, ONCOGENE, V27, P629, DOI 10.1038/sj.onc.1210695; Li Y, 2007, ONCOGENE, V26, P2220, DOI 10.1038/sj.onc.1210311; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; MELTZER PS, 1994, J NATL CANCER I, V86, P1265, DOI 10.1093/jnci/86.17.1265; Messner DJ, 2006, J CELL BIOCHEM, V99, P241, DOI 10.1002/jcb.20919; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Plechanovova A, 2011, NAT STRUCT MOL BIOL, V18, P1052, DOI 10.1038/nsmb.2108; Robu ME, 2007, PLOS GENET, V3, P787, DOI 10.1371/journal.pgen.0030078; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; van Leeuwen IMM, 2011, CELL CYCLE, V10, P1590, DOI 10.4161/cc.10.10.15519; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108; Wang XJ, 2011, CELL CYCLE, V10, P4225, DOI 10.4161/cc.10.24.18662; Wang XJ, 2011, J BIOL CHEM, V286, P23725, DOI 10.1074/jbc.M110.213868; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Zeng ZQ, 2009, ZEBRAFISH, V6, P405, DOI 10.1089/zeb.2009.0611	39	26	27	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4009	4016		10.1038/onc.2012.409	http://dx.doi.org/10.1038/onc.2012.409			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	23069659				2022-12-28	WOS:000323748100009
J	Chen, M; Bresnick, AR; O'Connor, KL				Chen, M.; Bresnick, A. R.; O'Connor, K. L.			Coupling S100A4 to Rhotekin alters Rho signaling output in breast cancer cells	ONCOGENE			English	Article						Rho; Rhotekin; S100A4/metastasin; lamellipodia; invasive growth	NONMUSCLE MYOSIN-II; ALPHA-6-BETA-4 INTEGRIN; LAMELLAE FORMATION; CARCINOMA CELLS; IN-VIVO; METASTASIS; PROTEIN; ACTIVATION; MIGRATION; EFFECTOR	Rho signaling is increasingly recognized to contribute to invasion and metastasis. In this study, we discovered that metastasis-associated protein S100A4 interacts with the Rho-binding domain (RBD) of Rhotekin, thus connecting S100A4 to the Rho pathway. Glutathione S-transferase pull-down and immunoprecipitation assays demonstrated that S100A4 specifically and directly binds to Rhotekin RBD, but not the other Rho effector RBDs. S100A4 binding to Rhotekin is calcium-dependent and uses residues distinct from those bound by active Rho. Interestingly, we found that S100A4 and Rhotekin can form a complex with active RhoA. Using RNA interference, we determined that suppression of both S100A4 and Rhotekin leads to loss of Rho-dependent membrane ruffling in response to epidermal growth factor, an increase in contractile F-actin 'stress' fibers and blocks invasive growth in three-dimensional culture. Accordingly, our data suggest that interaction of S100A4 and Rhotekin permits S100A4 to complex with RhoA and switch Rho function from stress fiber formation to membrane ruffling to confer an invasive phenotype.	[Chen, M.; O'Connor, K. L.] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40506 USA; [Bresnick, A. R.] Albert Einstein Coll Med, Bronx, NY 10467 USA	University of Kentucky; Yeshiva University; Albert Einstein College of Medicine	O'Connor, KL (corresponding author), Univ Kentucky, Markey Canc Ctr, 741 South Limestone St, Lexington, KY 40506 USA.	mch235@uky.edu; kloconnor@uky.edu	O'Connor, Kathleen L/H-2569-2013	O'Connor, Kathleen L/0000-0002-1088-9734	National Institutes of Health [CA109136, CA129598]; NATIONAL CANCER INSTITUTE [R01CA109136, R01CA129598] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Ren Xu for his kind aid with 3D culture-related experiments; Dr Jianhang Jia for assistance with the confocal microscopy analysis; Drs Tianyan Gao and Jianyu Liu for reagents and technical support for generating shRNA stable cell line; Drs Kohich Nagata, Shuh Narumiya and G Steven Martin for reagents; Dr Juanjuan Yang for validating select data; and Diane Wright for assistance with graphics. This work was supported with National Institutes of Health Grants CA109136 (KLO) and CA129598 (ARB).	Andersen K, 2011, DEV BIOL, V352, P181, DOI 10.1016/j.ydbio.2010.12.033; Berdeaux RL, 2004, J CELL BIOL, V166, P317, DOI 10.1083/jcb.200312168; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boye K, 2010, AM J PATHOL, V176, P528, DOI 10.2353/ajpath.2010.090526; Chen M, 2007, AM J PHYSIOL-CELL PH, V292, pC1927, DOI 10.1152/ajpcell.00400.2006; Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Ito H, 2005, ONCOGENE, V24, P7064, DOI 10.1038/sj.onc.1208862; Ito H, 2006, NEUROSCI RES, V56, P165, DOI 10.1016/j.neures.2006.06.014; Kelloff GJ, 1997, CANCER EPIDEM BIOMAR, V6, P267; Kim EJ, 2003, J BIOL CHEM, V278, P30063, DOI 10.1074/jbc.M304909200; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Li ZH, 2003, BIOCHEMISTRY-US, V42, P14258, DOI 10.1021/bi0354379; Li ZH, 2006, CANCER RES, V66, P5173, DOI 10.1158/0008-5472.CAN-05-3087; Li ZH, 2010, MOL BIOL CELL, V21, P2598, DOI 10.1091/mbc.E09-07-0609; Liu CA, 2004, ONCOGENE, V23, P8731, DOI 10.1038/sj.onc.1208106; Liu CA, 2004, J BIOMED SCI, V11, P661, DOI 10.1159/000079679; Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242; Nagata K, 2009, MED MOL MORPHOL, V42, P9, DOI 10.1007/s00795-008-0433-8; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Nishiyama T, 1994, MOL CELL BIOL, V14, P2247; O'Connor KL, 2012, AM J PHYSIOL-CELL PH, V302, pC605, DOI 10.1152/ajpcell.00095.2011; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Pusapati GV, 2012, J BIOL CHEM, V287, P9473, DOI 10.1074/jbc.M112.339564; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Rudland PS, 2000, CANCER RES, V60, P1595; Sandquist JC, 2006, J BIOL CHEM, V281, P35873, DOI 10.1074/jbc.M605343200; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Sudo K, 2006, NEUROSCI RES, V56, P347, DOI 10.1016/j.neures.2006.08.003; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Vallely KM, 2002, BIOCHEMISTRY-US, V41, P12670, DOI 10.1021/bi020365r; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wu D, 2009, ONCOGENE, V28, P2219, DOI 10.1038/onc.2009.96; Wyckoff JB, 2000, CANCER RES, V60, P2504; Xu R, 2007, J BIOL CHEM, V282, P14992, DOI 10.1074/jbc.M610316200; Ying-Tao Z, 2005, EUR J GASTROEN HEPAT, V17, P725, DOI 10.1097/00042737-200507000-00006; Zhao XS, 2009, CANCER RES, V69, P483, DOI 10.1158/0008-5472.CAN-08-2907	49	36	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2013	32	32					3754	3764		10.1038/onc.2012.383	http://dx.doi.org/10.1038/onc.2012.383			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22964635	Green Published, Green Accepted			2022-12-28	WOS:000322904400010
J	Abhari, BA; Cristofanon, S; Kappler, R; von Schweinitz, D; Humphreys, R; Fulda, S				Abhari, B. A.; Cristofanon, S.; Kappler, R.; von Schweinitz, D.; Humphreys, R.; Fulda, S.			RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex	ONCOGENE			English	Article						apoptosis; IAP inhibitor; TRAIL; RIP1; neuroblastoma	NF-KAPPA-B; DRUG-INDUCED APOPTOSIS; TESTING STAGE 1; CANCER-CELLS; DNA-DAMAGE; RECEPTOR; ANTAGONISTS; NECROSIS; CIAP1; IDENTIFICATION	Inhibitor of apoptosis (IAP) proteins represent promising therapeutic targets due to their high expression in many cancers. Here, we report that small-molecule IAP inhibitors at subtoxic concentrations cooperate with monoclonal antibodies against TRAIL receptor 1 (Mapatumumab) or TRAIL-R2 (Lexatumumab) to induce apoptosis in neuroblastoma cells in a highly synergistic manner (combination index <0.1). Importantly, we identify receptor-activating protein 1 (RIP1) as a critical mediator of this synergism. RIP1 is required for the formation of a RIP1/FADD/caspase-8 complex that drives caspase-8 activation, cleavage of Bid into tBid, mitochondrial outer membrane permeabilization, full activation of caspase-3 and caspase-dependent apoptosis. Indeed, knockdown of RIP1 abolishes formation of the RIP1/FADD/caspase-8 complex, caspase activation and apoptosis upon combination treatment. Similarly, inhibition of RIP1 kinase activity by Necrostatin-1 inhibits IAP inhibitor- and TRAIL receptor-triggered apoptosis. In contrast, overexpression of the dominant-negative superrepressor I kappa B alpha-SR or addition of the tumor necrosis factor (TNF)alpha-blocking antibody Enbrel do not interfere with cotreatment-induced apoptosis, pointing to a nuclear factor-kappa B- and TNF alpha-independent mechanism. Of note, IAP inhibitor also sensitizes primary cultured neuroblastoma cells for TRAIL receptor-mediated loss of viability, underscoring the clinical relevance. By identifying RIP1 as a critical mediator of IAP inhibitor- mediated sensitization for Mapatumumab- or Lexatumumab-induced apoptosis, our findings provide new insights into the synergistic interaction of IAP inhibitors together with TRAIL receptor agonists.	[Abhari, B. A.; Cristofanon, S.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Kappler, R.; von Schweinitz, D.] Univ Munich, Dr von Haunerschen Childrens Hosp, Dept Pediat Surg, Munich, Germany; [Humphreys, R.] Human Genome Sci Inc, Oncol Res Dept, Rockville, MD USA	Goethe University Frankfurt; University of Munich; GlaxoSmithKline; Human Genome Sciences Inc	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417; Kappler, Roland/0000-0002-8581-2803	Deutsche Forschungsgemeinschaft; European Community (ApopTrain, APO-SYS); IAP6/18	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Community (ApopTrain, APO-SYS)(European CommissionEuropean Commission Joint Research Centre); IAP6/18	We thank X Wang for providing RIP3 antibody and C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF).	Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bellail AC, 2010, J CELL MOL MED, V14, P1303, DOI 10.1111/j.1582-4934.2009.00777.x; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Chao B, 2006, inventors; Tetrapeptide analogs. United States patent, Patent No. PCT/US2005/024700; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2006, CANCER RES, V66, P10016, DOI 10.1158/0008-5472.CAN-05-4079; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Geserick P, 2009, J CELL BIOL, V187, P1037, DOI 10.1083/jcb.200904158; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Houghton PJ, 2012, PEDIATR BLOOD CANCER, V58, P636, DOI 10.1002/pbc.23167; Humphreys RC, 2008, ADV EXP MED BIOL, V615, P127, DOI 10.1007/978-1-4020-6554-5_7; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Laukens B, 2011, NEOPLASIA, V13, P971, DOI 10.1593/neo.11610; Loder S, 2012, LEUKEMIA, V26, P1020, DOI 10.1038/leu.2011.353; Mader I, 2010, FASEB J, V24, P1997, DOI 10.1096/fj.09-142943; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Naumann I, 2011, CLIN CANCER RES, V17, P3204, DOI 10.1158/1078-0432.CCR-10-2451; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Palacios C, 2010, CANCER LETT, V287, P207, DOI 10.1016/j.canlet.2009.06.012; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Smith MA, 2010, PEDIATR BLOOD CANCER, V54, P307, DOI 10.1002/pbc.22188; Stadel D, 2010, CLIN CANCER RES, V16, P5734, DOI 10.1158/1078-0432.CCR-10-0985; Straub CS, 2011, CURR TOP MED CHEM, V11, P291; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036	41	51	51	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3263	3273		10.1038/onc.2012.337	http://dx.doi.org/10.1038/onc.2012.337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22890322				2022-12-28	WOS:000321301600006
J	Ly, P; Kim, SB; Kaisani, AA; Marian, G; Wright, WE; Shay, JW				Ly, P.; Kim, S. B.; Kaisani, A. A.; Marian, G.; Wright, W. E.; Shay, J. W.			Aneuploid human colonic epithelial cells are sensitive to AICAR-induced growth inhibition through EGFR degradation	ONCOGENE			English	Article						aneuploidy; EGFR; AICAR; chromosomal instability; trisomy	CHROMOSOMAL INSTABILITY; RECEPTOR; CANCER; UBIQUITINATION; TRISOMY; PROLIFERATION; POPULATIONS; METABOLISM; MUTATIONS; PROTEOME	Trisomy for chromosome 7 is frequently observed as an initiating event in sporadic colorectal cancer. Although unstable chromosome numbers and recurrent aneuploidies drive a large fraction of human cancers, targeted therapies selective to pre-neoplastic trisomic cells are non-existent. We have previously characterized a trisomy 7 cell line (1CT+7) spontaneously derived from normal diploid human colonic epithelial cells that aberrantly expresses the epidermal growth factor receptor (EGFR, chromosome 7p11). Recent studies identified AICAR (5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside) as a pharmacological inhibitor of aneuploid murine fibroblast proliferation. Here, we report that AICAR induces profound cytostatic and metabolic effects on 1CT+7 cells, but not on their isogenic diploid counterpart. Dose-response experiments indicate that 1CT+7 cells are fourfold preferentially sensitive to AICAR compared to diploid cells. Unexpectedly, treatment of 1CT+7 cells with AICAR led to a reversible 3.5-fold reduction (P = 0.0025) in EGFR overexpression. AICAR-induced depletion of EGFR protein can be abrogated through inhibition of the proteasome with MG132. AICAR also heavily promoted EGFR ubiquitination in cell-based immunoprecipitation assays, suggesting enhanced degradation of EGFR protein mediated by the proteasome. Moreover, treatment with AICAR reduced EGFR protein levels in a panel of human colorectal cancer cells in vitro and in xenograft tumors in vivo. Our data collectively support the pharmacological compound AICAR as a novel inhibitor of EGFR protein abundance and as a potential anticancer agent for aneuploidy-driven colorectal cancer.	[Ly, P.; Kim, S. B.; Kaisani, A. A.; Marian, G.; Wright, W. E.; Shay, J. W.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Shay, J. W.] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah 21413, Saudi Arabia	University of Texas System; University of Texas Southwestern Medical Center Dallas; King Abdulaziz University	Shay, JW (corresponding author), Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jerry.shay@utsouthwestern.edu	Ly, Peter/B-3722-2012	Ly, Peter/0000-0001-8946-7069; Kim, Sang Bum/0000-0001-5965-3354	CPRIT [RP101496]; NASA [NNX09AU95G, NNX11AC15G, NNX11AC54G]; NCI [SPORE CA70907]; NATIONAL CANCER INSTITUTE [P30CA142543, P50CA070907] Funding Source: NIH RePORTER	CPRIT; NASA(National Aeronautics & Space Administration (NASA)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank RY Quach for figure artwork and U Eskiocak, G Stadler and AR Mullen (UT Southwestern) for technical assistance. We also express gratitude to YC Tang and A Amon (MIT) for providing xenograft tumors for IHC analysis and for critical reading of the manuscript. HA-tagged ubiquitin plasmids and anti-HA antibodies were a kind gift from LJ Huang (UT Southwestern). EGFR-V5 expression constructs and human bronchial epithelial cell-EGFR cell lines were provided by C Nirodi (UT Southwestern). This work was supported by CPRIT Training Grant RP101496 to PL, NASA Grants NNX09AU95G, NNX11AC15G, and NNX11AC54G and NCI SPORE CA70907 to JWS.	Aschenbach WG, 2002, DIABETES, V51, P567, DOI 10.2337/diabetes.51.3.567; Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; BOMME L, 1994, GENE CHROMOSOME CANC, V10, P190, DOI 10.1002/gcc.2870100307; Briand P, 1996, CANCER RES, V56, P2039; Chen GB, 2012, NATURE, V482, P246, DOI 10.1038/nature10795; Cohen G, 2006, CANCER RES, V66, P5656, DOI 10.1158/0008-5472.CAN-05-0308; Das AK, 2007, CANCER RES, V67, P5267, DOI 10.1158/0008-5472.CAN-07-0242; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; GAREWAL H, 1990, DIGEST DIS SCI, V35, P1115, DOI 10.1007/BF01537584; Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; Habermann JK, 2007, GENE CHROMOSOME CANC, V46, P10, DOI 10.1002/gcc.20382; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; Lamprecht SA, 2002, CARCINOGENESIS, V23, P1777, DOI 10.1093/carcin/23.11.1777; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Ly P, 2011, NEOPLASIA, V13, P348, DOI 10.1593/neo.101580; Manchado E, 2011, CELL, V144, P465, DOI 10.1016/j.cell.2011.01.037; McGranahan N, 2012, EMBO REP, V13, P528, DOI 10.1038/embor.2012.61; MELTZER SJ, 1994, CANCER RES, V54, P3379; Messersmith WA, 2008, NEW ENGL J MED, V359, P1834, DOI 10.1056/NEJMe0806778; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052; Sareen D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007630; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Sheltzer JM, 2011, TRENDS GENET, V27, P446, DOI 10.1016/j.tig.2011.07.003; Tang YC, 2011, CELL, V144, P499, DOI 10.1016/j.cell.2011.01.017; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Torres EM, 2010, CELL, V143, P71, DOI 10.1016/j.cell.2010.08.038; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058	36	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2013	32	26					3139	3146		10.1038/onc.2012.339	http://dx.doi.org/10.1038/onc.2012.339			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22890317	Green Accepted			2022-12-28	WOS:000321004600004
J	Yang, Q; Liao, L; Deng, X; Chen, R; Gray, NS; Yates, JR; Lee, JD				Yang, Q.; Liao, L.; Deng, X.; Chen, R.; Gray, N. S.; Yates, J. R., III; Lee, J. D.			BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction	ONCOGENE			English	Article						BMK1; PML; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; MAMMALIAN MAP KINASE; PREMATURE SENESCENCE; SIGNAL-TRANSDUCTION; CUTANEOUS MELANOMA; CELL-PROLIFERATION; GENE-EXPRESSION; E6 ONCOPROTEIN; ONCOGENIC RAS; GROWTH-FACTOR	Promyelocytic leukemia protein (PML) modulates the p53 tumor suppressor through its interaction with p53 and MDM2. We found that activated big MAP kinase 1 (BMK1) preferentially associates with PML isoform IV and disrupts PML-MDM2 interaction. Doxorubicin, a common chemotherapeutic agent, is known to promote PML-mediated p53 activation in part by promoting PML-dependent MDM2 nucleolar sequestration. We discovered that BMK1 deactivation coupled with doxorubicin synergistically enhanced MDM2 nucleolar sequestration and, consequently, promoted PML-mediated p53 upregulation leading to tumor cell apoptosis in vitro and tumor regression in vivo. Collectively, these results not only suggest that BMK1 activity has a role in suppressing p53 by blocking the interaction between PML and MDM2, but also implicate that pharmacological BMK1 inhibitor should significantly enhance the anticancer capacity of doxorubicin-based chemotherapy.	[Yang, Q.; Chen, R.; Lee, J. D.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Liao, L.; Yates, J. R., III] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Deng, X.; Gray, N. S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Scripps Research Institute; Scripps Research Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.	jdlee@scripps.edu	Yang, Qingkai/AAK-5111-2021	Yang, Qingkai/0000-0001-6628-5393; Deng, Xianming/0000-0002-9354-5864	National Institutes of Health [CA079871, CA114059]; University of California [19XT-0084]; NATIONAL CANCER INSTITUTE [R01CA114059, R01CA079871] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California(University of California System); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Giovanni Blandino, Dr Myung Kim and Dr Pier Paolo Pandolfi for generously providing the PML null and control cell lines. This work was supported by the National Institutes of Health [CA079871 and CA114059 to JDL] and by the funds from the Tobacco-Related Disease, Research Program of the University of California [19XT-0084 to JDL].	Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Beech SJ, 2005, EXP CELL RES, V307, P109, DOI 10.1016/j.yexcr.2005.03.012; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Bisht S, 2009, WIRES NANOMED NANOBI, V1, P415, DOI 10.1002/wnan.43; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Ferbeyre G, 2000, GENE DEV, V14, P2015; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Hayashi M, 2005, CANCER RES, V65, P7699, DOI 10.1158/0008-5472.CAN-04-4540; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kondoh K, 2006, MOL CELL BIOL, V26, P1679, DOI 10.1128/MCB.26.5.1679-1690.2006; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Polsky D, 2001, CANCER RES, V61, P7642; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yang QK, 2010, CANCER CELL, V18, P258, DOI 10.1016/j.ccr.2010.08.008; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200	37	30	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3156	3164		10.1038/onc.2012.332	http://dx.doi.org/10.1038/onc.2012.332			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22869143	Green Accepted			2022-12-28	WOS:000321004600006
J	Bagci-Onder, T; Agarwal, A; Flusberg, D; Wanningen, S; Sorger, P; Shah, K				Bagci-Onder, T.; Agarwal, A.; Flusberg, D.; Wanningen, S.; Sorger, P.; Shah, K.			Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors	ONCOGENE			English	Article						live-cell imaging; DR4/5; TRAIL; GBM; neural stem cell; dual luciferase imaging	PHASE-II TRIAL; CANCER-CELLS; INDUCED APOPTOSIS; UP-REGULATION; DOWN-REGULATION; STEM-CELLS; DR5; EXPRESSION; GLIOMA; INHIBITION	Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis specifically in tumor cells and its efficacy has been tested in pre-clinical models by delivering it systemically as a purified ligand or via engineered stem cells (SC). However, about 50% of tumor lines are resistant to TRAIL and overcoming TRAIL resistance in aggressive tumors, such as glioblastoma-multiforme (GBM), and understanding the molecular dynamics of TRAIL-based combination therapies are critical to broadly use TRAIL as a therapeutic agent. In this study, we developed death receptor (DR)4/5-reporters that offer an imaging-based platform to identify agents that act in concert with a potent, secretable variant of TRAIL (S-TRAIL) by monitoring changes in DR4/5 expression. Utilizing these reporters, we show a differential regulation of DR4/5 when exposed to a panel of clinically relevant agents. A histone deacetylase inhibitor, MS-275, resulted in upregulation of DR4/5 in all GBM cell lines, and these changes could be followed in real time both in vitro and in vivo in mice bearing tumors and they correlated with increased TRAIL sensitivity. To further assess the dynamics of combinatorial strategies that overcome resistance of tumors to SC released S-TRAIL, we also engineered tumor cells to express live-cell caspase-reporters and SCs to express S-TRAIL. Utilizing DR4/5 and caspase reporters in parallel, we show that MS-275 sensitizes TRAIL-resistant GBM cells to stem cell (SC) delivered S-TRAIL by changing the time-to-death in vitro and in vivo. This study demonstrates the effectiveness of a combination of real-time reporters of TRAIL-induced apoptosis pathway in evaluating the efficacy of SC-TRAIL-based therapeutics and may have implications in targeting a broad range of cancers.	[Bagci-Onder, T.; Agarwal, A.; Wanningen, S.; Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA; [Bagci-Onder, T.; Agarwal, A.; Wanningen, S.; Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA; [Flusberg, D.; Sorger, P.] Harvard Univ, Dept Syst Biol, Sch Med, Boston, MA 02114 USA; [Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA; [Shah, K.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University	Shah, K (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA.	kshah@mgh.harvard.edu	Onder, Tugba Bagci/AAN-1392-2021	Bagci Onder, Tugba/0000-0003-3646-2613; Sorger, Peter/0000-0002-3364-1838; Flusberg, Deborah/0000-0001-9506-6990	American Cancer Society; NIH [CA138922, NS071197, CA139980]; James McDonnell Foundation; NATIONAL CANCER INSTITUTE [P01CA139980, R01CA138922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS071197] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James McDonnell Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Shi-Yon Sun for providing pDR4 and pDR5 basic constructs; real-time PCR core facility of Neuroscience Department, Massachusetts General Hospital; flow cytometry core facility of Ragon Institute, Massachusetts General Hospital; and Nikon Imaging Center, Harvard Medical School for technical help and equipments. This work was supported by American Cancer Society (KS), NIH grants CA138922, NS071197 (KS), CA139980 (PKS) and the James McDonnell Foundation (KS). There are no competing financial interests to disclose.	Aguilera DG, 2009, J NEURO-ONCOL, V93, P303, DOI 10.1007/s11060-008-9788-x; Albeck JG, 2008, MOL CELL, V30, P11, DOI 10.1016/j.molcel.2008.02.012; Albeck JG, 2008, PLOS BIOL, V6, P2831, DOI 10.1371/journal.pbio.0060299; Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bagci-Onder T, 2011, CANCER RES, V71, P154, DOI 10.1158/0008-5472.CAN-10-1601; Baritaki S, 2007, MOL CANCER THER, V6, P1387, DOI 10.1158/1535-7163.MCT-06-0521; Booth NL, 2009, CANCER IMMUNOL IMMUN, V58, P1229, DOI 10.1007/s00262-008-0637-8; Crosswell HE, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-411; Dhandapani L, 2011, CANCER RES, V71, P5245, DOI 10.1158/0008-5472.CAN-10-4180; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Finlay D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013375; Hingtgen S, 2008, MOL CANCER THER, V7, P3575, DOI 10.1158/1535-7163.MCT-08-0640; Hingtgen SD, 2010, STEM CELLS, V28, P832, DOI 10.1002/stem.313; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Kim MO, 2010, MOL CANCER THER, V9, P833, DOI 10.1158/1535-7163.MCT-09-0610; Kock N, 2007, NEOPLASIA, V9, P435, DOI 10.1593/neo.07223; Liu XG, 2007, CANCER RES, V67, P4981, DOI 10.1158/0008-5472.CAN-06-4274; McDermott U, 2010, CANCER RES, V70, P1625, DOI 10.1158/0008-5472.CAN-09-3620; Mrugala MM, 2008, NAT CLIN PRACT ONCOL, V5, P476, DOI 10.1038/ncponc1155; Nagane M, 2010, NEURO-ONCOLOGY, V12, P687, DOI 10.1093/neuonc/nop069; Nagar S, 2010, ADV EXP MED BIOL, V678, P124; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Neyns B, 2009, ANN ONCOL, V20, P1596, DOI 10.1093/annonc/mdp032; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Prasad S, 2010, MOL CANCER THER, V9, P856, DOI 10.1158/1535-7163.MCT-09-1113; Prince HM, 2009, CLIN CANCER RES, V15, P3958, DOI 10.1158/1078-0432.CCR-08-2785; Raizer JJ, 2010, NEURO-ONCOLOGY, V12, P95, DOI 10.1093/neuonc/nop015; Sasportas LS, 2009, P NATL ACAD SCI USA, V106, P4822, DOI 10.1073/pnas.0806647106; Shah K, 2005, ANN NEUROL, V57, P34, DOI 10.1002/ana.20306; Shah K, 2008, J NEUROSCI, V28, P4406, DOI 10.1523/JNEUROSCI.0296-08.2008; Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585; Song JH, 2008, J BIOL CHEM, V283, P25003, DOI 10.1074/jbc.M802511200; Spencer SL, 2009, NATURE, V459, P428, DOI 10.1038/nature08012; Sung B, 2010, J BIOL CHEM, V285, P11498, DOI 10.1074/jbc.M109.090209; Wiezorek J, 2010, CLIN CANCER RES, V16, P1701, DOI 10.1158/1078-0432.CCR-09-1692; Wood TE, 2010, MOL CANCER THER, V9, P246, DOI 10.1158/1535-7163.MCT-09-0495; Yang A, 2010, CURR OPIN CELL BIOL, V22, P837, DOI 10.1016/j.ceb.2010.08.001; Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693	39	34	35	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2818	2827		10.1038/onc.2012.304	http://dx.doi.org/10.1038/onc.2012.304			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22824792	Green Accepted			2022-12-28	WOS:000320369100002
J	Hulf, T; Sibbritt, T; Wiklund, ED; Patterson, K; Song, JZ; Stirzaker, C; Qu, W; Nair, S; Horvath, LG; Armstrong, NJ; Kench, JG; Sutherland, RL; Clark, SJ				Hulf, T.; Sibbritt, T.; Wiklund, E. D.; Patterson, K.; Song, J. Z.; Stirzaker, C.; Qu, W.; Nair, S.; Horvath, L. G.; Armstrong, N. J.; Kench, J. G.; Sutherland, R. L.; Clark, S. J.			Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer	ONCOGENE			English	Article						microRNA; miR-205; MED1; epigenetics; prostate cancer	ANDROGEN RECEPTOR; EXPRESSION PROFILES; COREGULATORY ROLE; MEDIATOR COMPLEX; LUNG-CANCER; GENE; MIR-205; OVEREXPRESSION; PROLIFERATION; DEREGULATION	Deregulation of microRNA (miRNA) expression can have a critical role in carcinogenesis. Here we show in prostate cancer that miRNA-205 (miR-205) transcription is commonly repressed and the MIR-205 locus is hypermethylated. LOC642587, the MIR-205 host gene of unknown function, is also concordantly inactivated. We show that miR-205 targets mediator 1 (MED1, also called TRAP220 and PPARBP) for transcriptional silencing in normal prostate cells, leading to reduction in MED1 mRNA levels, and in total and active phospho-MED1 protein. Overexpression of miR-205 in prostate cancer cells negatively affects cell viability, consistent with a tumor suppressor function. We found that hypermethylation of the MIR-205 locus was strongly related with a decrease in miR-205 expression and an increase in MED1 expression in primary tumor samples (n = 14), when compared with matched normal prostate (n = 7). An expanded patient cohort (tumor n = 149, matched normal n = 30) also showed significant MIR-205 DNA methylation in tumors compared with normal, and MIR-205 hypermethylation is significantly associated with biochemical recurrence (hazard ratio = 2.005, 95% confidence interval (1.109, 3.625), P = 0.02), in patients with low preoperative prostate specific antigen. In summary, these results suggest that miR-205 is an epigenetically regulated tumor suppressor that targets MED1 and may provide a potential biomarker in prostate cancer management.	[Hulf, T.; Sibbritt, T.; Wiklund, E. D.; Patterson, K.; Song, J. Z.; Stirzaker, C.; Qu, W.; Nair, S.; Horvath, L. G.; Armstrong, N. J.; Kench, J. G.; Sutherland, R. L.; Clark, S. J.] St Vincents Hosp, Garvan Inst Med Res, Epigenet Grp, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Wiklund, E. D.] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark; [Horvath, L. G.] Royal Prince Alfred Hosp, Dept Med Oncol, Sydney Canc Ctr, Camperdown, NSW 2050, Australia; [Armstrong, N. J.] Univ New S Wales, Sch Math & Stat, Sydney, NSW, Australia; [Kench, J. G.] Royal Prince Alfred Hosp, Dept Tissue Pathol, Camperdown, NSW 2050, Australia; [Clark, S. J.] Univ NSW, St Vincents Clin Sch, St Vincents Hosp, Darlinghurst, NSW, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Aarhus University; University of Sydney; University of New South Wales Sydney; University of Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney	Clark, SJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Epigenet Grp, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	s.clark@garvan.org.au	Armstrong, Nicola J./AAF-3045-2021; Clark, Susan J/U-7365-2019; Clark, Susan J/B-2272-2008	Armstrong, Nicola J./0000-0002-4477-293X; Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030; Stirzaker, Clare/0000-0001-5601-3140; Horvath, Lisa/0000-0001-6842-9223; Kench, James Geoffrey/0000-0001-8687-4988; Patterson, Kate/0000-0003-3919-7261	Cancer Institute NSW (CINSW); Cure Cancer Australia fellowships; National Health and Medical Research Council; CINSW project grants	Cancer Institute NSW (CINSW); Cure Cancer Australia fellowships; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); CINSW project grants	We would like to thank Gillian Lehrbach, Ann-Maree Haynes, Ruth Pe Benito and Clarisse Puno for technical assistance. This work is supported by Cancer Institute NSW (CINSW), Cure Cancer Australia fellowships (TH), and National Health and Medical Research Council and CINSW project grants (SJC).	Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Belakavadi M, 2008, MOL CELL BIOL, V28, P3932, DOI 10.1128/MCB.02191-07; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Childs G, 2009, AM J PATHOL, V174, P736, DOI 10.2353/ajpath.2009.080731; Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-60; Chung TKH, 2009, INT J CANCER, V124, P1358, DOI 10.1002/ijc.24071; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Cooper CS, 2009, BRIT J CANCER, V100, P240, DOI 10.1038/sj.bjc.6604771; Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140-6736(08)60729-1; Devaney J, 2011, CANCER EPIDEM BIOMAR, V20, P148, DOI 10.1158/1055-9965.EPI-10-0719; Dijckmeester WA, 2009, J GASTROINTEST SURG, V13, P846, DOI 10.1007/s11605-009-0799-5; Feber A, 2008, J THORACIC CARDIOVAS, V135, P60; Feber A, 2008, J THORAC CARDIOV SUR, V135, P255, DOI 10.1016/j.jtcvs.2007.08.055; Fletcher AM, 2008, TRANSL ONCOL, V1, P202, DOI 10.1593/tlo.08163; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Horvath LG, 2004, CLIN CANCER RES, V10, P615, DOI 10.1158/1078-0432.CCR-0707-03; Hulf T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-54; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Karginov FV, 2010, MOL CELL, V38, P781, DOI 10.1016/j.molcel.2010.06.001; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; Koschubs T, 2010, NUCLEIC ACIDS RES, V38, P3186, DOI 10.1093/nar/gkq029; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lebanony D, 2009, J CLIN ONCOL, V27, P2030, DOI 10.1200/JCO.2008.19.4134; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Majid S, 2010, CANCER-AM CANCER SOC, V116, P5637, DOI 10.1002/cncr.25488; Markou A, 2008, CLIN CHEM, V54, P1696, DOI 10.1373/clinchem.2007.101741; Mouillet JF, 2010, FASEB J, V24, P2030, DOI 10.1096/fj.09-149724; Neely LA, 2010, UROL ONCOL-SEMIN ORI, V28, P39, DOI 10.1016/j.urolonc.2008.06.006; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Paoletti AC, 2006, P NATL ACAD SCI USA, V103, P18928, DOI 10.1073/pnas.0606379103; Platica Micsunica, 1997, In Vitro Cellular and Developmental Biology Animal, V33, P147; Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392; Ryan D, 2006, MOL VIS, V12, P1175; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Tran N, 2007, BIOCHEM BIOPH RES CO, V358, P12, DOI 10.1016/j.bbrc.2007.03.201; Vijayvargia R, 2007, CANCER RES, V67, P4034, DOI 10.1158/0008-5472.CAN-06-3039; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yu J, 2008, P NATL ACAD SCI USA, V105, P19300, DOI 10.1073/pnas.0803992105; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	55	71	76	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2891	2899		10.1038/onc.2012.300	http://dx.doi.org/10.1038/onc.2012.300			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22869146				2022-12-28	WOS:000320369100009
J	Kern, F; Doma, E; Rupp, C; Niault, T; Baccarini, M				Kern, F.; Doma, E.; Rupp, C.; Niault, T.; Baccarini, M.			Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis	ONCOGENE			English	Article						B-Raf; conditional ablation; epidermis; Raf-1; Ras-driven skin tumorigenesis	C-RAF; KERATINOCYTE DIFFERENTIATION; EPIDERMAL NEOPLASIA; BRAF INHIBITION; TUMOR-FORMATION; K-RAS; CARCINOGENESIS; KINASES; CANCER; CELLS	Ras-driven tumorigenesis is assumed to depend on Raf for ERK activation and proliferation; yet, an in vivo requirement for Raf as MEK/ERK activator in this setting has not been demonstrated to date. Here, we show that epidermis-restricted B-Raf ablation restrains the onset and stops the progression of established Ras-driven tumors by limiting MEK/ERK activation and proliferation. Concomitant elimination of B-Raf and Raf-1 enforces the abrupt regression of established tumors owing to the decrease in ERK activation and proliferation caused by B-Raf ablation combined with the ERK-independent increase in Rho-dependent kinase (Rok) signaling and differentiation triggered by Raf-1 inactivation. Thus, B-Raf and Raf-1 have non-redundant functions in Ras-driven tumorigenesis. Of note, Raf kinase inhibitors achieve impressive results in melanomas harboring oncogenic BRAF, but are ineffective against Ras-driven tumors; moreover, therapy-related skin tumors driven by a paradox ERK activation as well as primary and acquired resistance have been reported. Our results suggest that therapies targeting both Raf kinase-dependent and -independent pathways may be effective against a broader range of malignancies and reduce the risks of adverse effects and/or resistance.	[Kern, F.; Doma, E.; Rupp, C.; Niault, T.; Baccarini, M.] Univ Vienna, Dept Microbiol & Immunobiol, Max F Perutz Labs, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Baccarini, M (corresponding author), Univ Vienna, Dept Microbiol & Immunobiol, Max F Perutz Labs, Doktor Bohr Gasse 9, A-1030 Vienna, Austria.	manuela.baccarini@univie.ac.at	Baccarini, Manuela/B-6481-2014	Baccarini, Manuela/0000-0002-3033-391X	European Commission [LSH-CT-2003-506803]; Austrian Research Fund [P19530-B11]	European Commission(European CommissionEuropean Commission Joint Research Centre); Austrian Research Fund(Austrian Science Fund (FWF))	We thank Karin Ehrenreiter and the animal house team for excellent technical help, M Sibilia for the K5-SOS-F mice and P Chambon for the K5-Cre-er(T) animals. This work was supported by European Commission grant LSH-CT-2003-506803 and by Austrian Research Fund grant P19530-B11 (to MB).	Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bourcier C, 2006, CANCER RES, V66, P2700, DOI 10.1158/0008-5472.CAN-05-3129; Brower V, 2010, J NATL CANCER I, V102, P214, DOI 10.1093/jnci/djq037; Cichowski K, 2010, NATURE, V464, P358, DOI 10.1038/464358a; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Downward J, 2011, NAT MED, V17, P286, DOI 10.1038/nm0311-286; Dumesic PA, 2009, J CELL BIOL, V185, P409, DOI 10.1083/jcb.200804038; Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162; Ehrenreiter K, 2009, CANCER CELL, V16, P149, DOI 10.1016/j.ccr.2009.06.008; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Galabova-Kovacs G, 2006, P NATL ACAD SCI USA, V103, P1325, DOI 10.1073/pnas.0507399103; Gonzalez-Garcia A, 2005, CANCER CELL, V7, P219, DOI 10.1016/j.ccr.2005.01.029; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Honma M, 2006, MOL BIOL CELL, V17, P1888, DOI 10.1091/mbc.E05-12-1173; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Karreth FA, 2011, CANCER DISCOV, V1, P128, DOI 10.1158/2159-8290.CD-10-0044; Kern F, 2011, BRIT J CANCER, V104, P229, DOI 10.1038/sj.bjc.6606009; Khavari TA, 2007, CELL CYCLE, V6, P2928, DOI 10.4161/cc.6.23.4998; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Lock FE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008190; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Maurer G, 2011, ONCOGENE, V30, P3477, DOI 10.1038/onc.2011.160; McMullan R, 2003, CURR BIOL, V13, P2185, DOI 10.1016/S0960-9822(03)00906-0; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Murayama K, 2007, ONCOGENE, V26, P4882, DOI 10.1038/sj.onc.1210274; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; Oki-Idouchi CE, 2007, CANCER RES, V67, P276, DOI 10.1158/0008-5472.CAN-06-3080; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Ridky TW, 2004, CELL CYCLE, V3, P621; Riva C, 1995, ORAL ONCOL, V31B, P384, DOI 10.1016/0964-1955(95)00045-3; Scholl FA, 2009, ONCOGENE, V28, P1485, DOI 10.1038/onc.2008.459; Scholl FA, 2007, DEV CELL, V12, P615, DOI 10.1016/j.devcel.2007.03.009; Scholl FA, 2009, CANCER RES, V69, P3772, DOI 10.1158/0008-5472.CAN-08-1963; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Wang Z.A., 2010, ONCOGENE; Wimmer R, 2010, TRENDS BIOCHEM SCI, V35, P660, DOI 10.1016/j.tibs.2010.06.001	44	24	24	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2483	2492		10.1038/onc.2012.254	http://dx.doi.org/10.1038/onc.2012.254			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22733131				2022-12-28	WOS:000318694900012
J	Qian, X; Hulit, J; Suyama, K; Eugenin, EA; Belbin, TJ; Loudig, O; Smirnova, T; Zhou, ZN; Segall, J; Locker, J; Phillips, GR; Norton, L; Hazan, RB				Qian, X.; Hulit, J.; Suyama, K.; Eugenin, E. A.; Belbin, T. J.; Loudig, O.; Smirnova, T.; Zhou, Z. N.; Segall, J.; Locker, J.; Phillips, G. R.; Norton, L.; Hazan, R. B.			p21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis	ONCOGENE			English	Article						cell cycle; p21CIP1; cyclin E; cytoskeleton; invasion; metastasis; breast cancer	BREAST-CANCER; CELL-MIGRATION; N-CADHERIN; GENOMIC INSTABILITY; RHO GTPASES; EXPRESSION; P21(WAF1/CIP1); P21(CIP1); RAS; INHIBITION	Cell proliferation and invasion are critical for malignant progression, yet how these processes relate to each other and whether they regulate one another during metastasis is unknown. We show that invasiveness of breast cancer cells is associated with growth arrest due to p21CIP1 upregulation. Knockdown of p21CIP1 increases cell proliferation and suppresses invasion. Since p21CIP1 acts to inhibit cyclin E during cell-cycle progression, we demonstrated that a constitutively active form of cyclin E had similar effects to p21CIP1 inhibition resulting in enhanced cell growth and suppressed invasiveness. We tested these findings in vivo in the Polyoma middle T mammary tumor model in which p21CIP1 was deleted. p21CIP1 knockout mice exhibited dramatic suppression of metastasis, independent of tumor growth, which was rescued by p21CIP1. Metastasis suppression by p21CIP1 ablation was associated with striking cytoskeletal reorganization leading to a non-invasive and highly proliferative state. Thus, p21CIP1 regulates metastasis by mediating reciprocal switching between invasion and proliferation.	[Qian, X.; Hulit, J.; Suyama, K.; Eugenin, E. A.; Belbin, T. J.; Loudig, O.; Locker, J.; Hazan, R. B.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10463 USA; [Smirnova, T.; Zhou, Z. N.; Segall, J.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10463 USA; [Phillips, G. R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA; [Norton, L.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center	Hazan, RB (corresponding author), Albert Einstein Coll Med, Dept Pathol, 1300 Morris Pk Ave,F529S, Bronx, NY 10463 USA.	rachel.hazan@einstein.yu.edu	Qian, Xia/D-8255-2014; qian, xia/L-1616-2013	Norton, Larry/0000-0003-3701-9250	National Cancer Institute grant [1R01 CA135061-01A1]; Breast Cancer Research Foundation; Susan G Komen foundation; NATIONAL CANCER INSTITUTE [R01CA135061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH096625, K01MH076679] Funding Source: NIH RePORTER	National Cancer Institute grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; Susan G Komen foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank Dr Larry Herbst for his expert advice on animal studies. We thank the analytical imaging facility at AECOM for assistance with imaging. This work was supported by grants from National Cancer Institute grant (1R01 CA135061-01A1) and the Breast Cancer Research Foundation (RB Hazan). James Hulit was supported by the Susan G Komen foundation.	Bearss DJ, 2002, CANCER RES, V62, P2077; Bedrosian I, 2004, ONCOGENE, V23, P2648, DOI 10.1038/sj.onc.1207408; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Charames GS, 2003, CURR MOL MED, V3, P589, DOI 10.2174/1566524033479456; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheng XY, 2010, BIOCHEM BIOPH RES CO, V403, P103, DOI 10.1016/j.bbrc.2010.10.126; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Donegan WL, 1997, CA-CANCER J CLIN, V47, P28, DOI 10.3322/canjclin.47.1.28; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARPER JW, 1993, CELL, V75, P805; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Norton L, 2006, NAT MED, V12, P875, DOI 10.1038/nm0806-875; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Winters ZE, 2003, BREAST CANCER RES, V5, pR242, DOI 10.1186/bcr654; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2000, CANCER RES, V60, P5401; Yang WC, 2001, CANCER RES, V61, P6297; Yang WT, 2003, CANCER, V98, P1123, DOI 10.1002/cncr.11625	37	32	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2292	2303		10.1038/onc.2012.249	http://dx.doi.org/10.1038/onc.2012.249			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22751124	Green Accepted			2022-12-28	WOS:000318683600006
J	Ishikawa, Y; Hosogane, M; Okuyama, R; Aoyama, S; Onoyama, I; Nakayama, KI; Nakayama, K				Ishikawa, Y.; Hosogane, M.; Okuyama, R.; Aoyama, S.; Onoyama, I.; Nakayama, K. I.; Nakayama, K.			Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch	ONCOGENE			English	Article						ubiquitin ligase; Fbxw7; Notch; c-Myc; keratinocyte	F-BOX PROTEIN; TUMOR-SUPPRESSOR; STEM-CELLS; CYCLIN-E; GENE; DEGRADATION; CANCER; SEL-10; DETERMINANT; PROTEOLYSIS	The tumor suppressor Fbxw7 (also known as Sel-10, hCdc4, hAgo, or Fbw7) is an F-box protein that functions as the substrate-recognition subunit of an SCF ubiquitin ligase complex and targets a group of oncoproteins for degradation. We now show that Fbxw7 regulates the proliferation and differentiation of keratinocytes by mediating the degradation of c-Myc and Notch proteins. Fbxw7-deficient keratinocytes showed an increased proliferative capacity that was dependent on the accumulation of c-Myc but not on that of Notch. Fbxw7 deficiency also resulted in the premature differentiation of keratinocytes in a manner dependent on both c-Myc and Notch. Although Fbxw7-deficient keratinocytes proliferated excessively in vitro, loss of Fbxw7 did not predispose keratinocytes to the formation of squamous cell carcinoma in vivo induced by the expression of oncogenic Ras, possibly because the stem cell population of keratinocytes becomes exhausted as a result of enhanced Notch activity. Indeed, suppression of Notch signaling by additional ablation of RBP-J in Fbxw7-deficient keratinocytes conferred a more aggressive tumorigenic capacity. Collectively, these results indicate that Fbxw7 controls the proliferation and differentiation of keratinocytes, and that it exerts both inhibitory and stimulatory actions in skin carcinogenesis by counteracting the proliferation-promoting effect of c-Myc and the tumor-suppressive effect of Notch, respectively. Oncogene (2013) 32, 1921-1932; doi:10.1038/onc.2012.213; published online 4 June 2012	[Ishikawa, Y.; Hosogane, M.; Aoyama, S.; Nakayama, K.] Tohoku Univ, Grad Sch Med, United Ctr Adv Res & Translat Med, Dept Cell Proliferat, Sendai, Miyagi 9808575, Japan; [Ishikawa, Y.; Hosogane, M.; Aoyama, S.; Onoyama, I.; Nakayama, K. I.; Nakayama, K.] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan; [Okuyama, R.] Shinshu Univ, Grad Sch Med, Dept Dermatol, Matsumoto, Nagano 390, Japan; [Onoyama, I.; Nakayama, K. I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan	Tohoku University; Japan Science & Technology Agency (JST); Shinshu University; Kyushu University	Nakayama, K (corresponding author), Tohoku Univ, Grad Sch Med, United Ctr Adv Res & Translat Med, Dept Cell Proliferat,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	nakayak2@med.tohoku.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan; Global Center of Excellence Program of Japan; Grants-in-Aid for Scientific Research [23591615] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global Center of Excellence Program of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank T Honjo for Rbpj<SUP>F/F</SUP> mice; IM de Alboran for c-Myc<SUP>F/F</SUP> mice; R Tsunematsu for the NICD1 plasmid; T Kitamura for pMX-puro and Plat-E cells; Y Gotoh for pMX-Cre-SV40-GFP; S Ikawa for the cDNA-encoding H-Ras<SUP>G12V</SUP>; E Ogawa and E Nishimura for technical advice; Y Ono, T Senga and N Yanagihara for technical assistance; and other laboratory members for discussion. This study was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by the Global Center of Excellence Program of Japan.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Babaei-Jadidi R, 2011, J EXP MED, V208, P295, DOI 10.1084/jem.20100830; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Dotto GP, 2005, SCIENCE, V309, P890, DOI 10.1126/science.1117192; Fuchs E, 2008, J CELL BIOL, V180, P273, DOI 10.1083/jcb.200708185; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Ishikawa Y, 2008, ONCOGENE; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lefort K, 2007, GENE DEV, V21, P562, DOI 10.1101/gad.1484707; Mandinova A, 2008, EMBO J, V27, P1243, DOI 10.1038/emboj.2008.45; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Masuda K, 2010, ONCOGENE, V29, P1798, DOI 10.1038/onc.2009.469; Matsumoto A, 2011, J BIOL CHEM, V286, P13754, DOI 10.1074/jbc.M110.194936; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MORRIS RJ, 1988, CANCER RES, V48, P6285; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Okuyama R, 2007, ONCOGENE, V26, P4478, DOI 10.1038/sj.onc.1210235; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Perez-Losada J, 2005, CANCER RES, V65, P6488, DOI 10.1158/0008-5472.CAN-05-1294; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rounbehler RJ, 2001, ONCOGENE, V20, P5341, DOI 10.1038/sj.onc.1204691; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tan Y, 2008, CANC LETT; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yu L, 2009, J ONCOL, V2009, DOI 10.1155/2009/780874	49	21	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1921	1932		10.1038/onc.2012.213	http://dx.doi.org/10.1038/onc.2012.213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22665065				2022-12-28	WOS:000317599900006
J	Morikawa, M; Koinuma, D; Miyazono, K; Heldin, CH				Morikawa, M.; Koinuma, D.; Miyazono, K.; Heldin, C-H			Genome-wide mechanisms of Smad binding	ONCOGENE			English	Review						ChIP-chip; ChIP-sequencing; TGF-beta; BMP; Smad	GROWTH-FACTOR-BETA; GENE-EXPRESSION SIGNATURE; TGF-BETA; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; UBIQUITIN LIGASE; INITIATING CELLS; STEM-CELLS; CHIP-SEQ; SYNEXPRESSION GROUP	A dual role of transforming growth factor beta (TGF-beta), to both suppress and promote tumor progression and metastasis, has been well established, but its molecular basis has remained elusive. In this review, we focus on Smad proteins, which are central mediators of the signal transduction of TGF-beta family members. We describe current knowledge of cell-type-specific binding patterns of Smad proteins and mechanisms of transcriptional regulation, obtained from recent studies on genome-wide binding sites of Smad molecules. We also discuss potential application of the genome-wide analyses for cancer research, which will allow clarification of the complex mechanisms occurring during cancer progression, and the identification of potential biomarkers for future cancer diagnosis, prognosis and therapy. Oncogene (2013) 32, 1609-1615; doi:10.1038/onc.2012.191; published online 21 May 2012	[Morikawa, M.; Miyazono, K.; Heldin, C-H] Uppsala Univ, Sci Life Lab, Ludwig Inst Canc Res, Biomed Ctr, Uppsala, Sweden; [Morikawa, M.; Koinuma, D.; Miyazono, K.] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	Ludwig Institute for Cancer Research; Uppsala University; University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Morikawa, Masato/D-1932-2011; Koinuma, Daizo/Y-8716-2018	Morikawa, Masato/0000-0002-6191-7176; Koinuma, Daizo/0000-0001-5611-2122	Swedish Cancer Society [100452]; KAKENHI [22112002, 22790750]; Global Center of Excellence Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Takeda Science Foundation; Ministry of Health, Labour and Welfare of Japan [H22-013]; Grants-in-Aid for Scientific Research [22112002, 24390070] Funding Source: KAKEN	Swedish Cancer Society(Swedish Cancer Society); KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Global Center of Excellence Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Takeda Science Foundation(Takeda Science Foundation (TSF)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a grant from Swedish Cancer Society (Grant number 100452); KAKENHI (grants-in-aid for scientific research on Innovative Area (Integrative Research on Cancer Microenvironment Network; Grant number 22112002)) and for Young Scientists (B) (Grant numbers 22790750 (DK)); the Global Center of Excellence Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; a Research Grant from the Takeda Science Foundation and a Grant-in-Aid for Cancer Research for the Third-Term Comprehensive 10-Year Strategy for Cancer Control (H22-013) from the Ministry of Health, Labour and Welfare of Japan.	Agricola E, 2011, MOL CELL, V43, P85, DOI 10.1016/j.molcel.2011.05.020; Akizu N, 2010, DEVELOPMENT, V137, P2915, DOI 10.1242/dev.049395; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Aragon E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811; Aubin J, 2004, GENE DEV, V18, P1482, DOI 10.1101/gad.1202604; BabuRajendran N, 2010, NUCLEIC ACIDS RES, V38, P3477, DOI 10.1093/nar/gkq046; Cao Y, 2010, DEV CELL, V18, P662, DOI 10.1016/j.devcel.2010.02.014; Chai JJ, 2003, J BIOL CHEM, V278, P20327, DOI 10.1074/jbc.C300134200; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Dahle O, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000841; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636; Fei T, 2010, GENOME RES, V20, P36, DOI 10.1101/gr.092114.109; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Fuentealba LC, 2007, CELL, V131, P980, DOI 10.1016/j.cell.2007.09.027; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Harvey SA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000101; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027123; Ikushima H, 2008, EMBO J, V27, P2955, DOI 10.1038/emboj.2008.218; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Inui M, 2011, NAT CELL BIOL, V13, P1368, DOI 10.1038/ncb2346; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759; Kaneda A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002359; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kennedy BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022606; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kim SW, 2011, DEV BIOL, V357, P492, DOI 10.1016/j.ydbio.2011.06.009; Koinuma D, 2009, CANCER SCI, V100, P2133, DOI 10.1111/j.1349-7006.2009.01299.x; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Landry JR, 2009, BLOOD, V113, P5783, DOI 10.1182/blood-2008-11-187757; Lee KL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002130; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Miyazono K, 2012, UPSALA J MED SCI, V117, P143, DOI 10.3109/03009734.2011.638729; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Mizutani A, 2011, J BIOL CHEM, V286, P29848, DOI 10.1074/jbc.M110.217745; Morikawa M, 2011, NUCLEIC ACIDS RES, V39, P8712, DOI 10.1093/nar/gkr572; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641; Penn BH, 2004, GENE DEV, V18, P2348, DOI 10.1101/gad.1234304; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Pepke S, 2009, NAT METHODS, V6, pS22, DOI [10.1038/NMETH.1371, 10.1038/nmeth.1371]; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pimanda JE, 2007, P NATL ACAD SCI USA, V104, P840, DOI 10.1073/pnas.0607196104; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Silvestri C, 2008, DEV CELL, V14, P411, DOI 10.1016/j.devcel.2008.01.004; Simonis M, 2007, NAT METHODS, V4, P895, DOI 10.1038/NMETH1114; Trompouki E, 2011, CELL, V147, P577, DOI 10.1016/j.cell.2011.09.044; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Xi QR, 2011, CELL, V147, P1511, DOI 10.1016/j.cell.2011.11.032; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yokoyama S, 2009, DEV CELL, V17, P836, DOI 10.1016/j.devcel.2009.10.011; Yoon SJ, 2011, GENE DEV, V25, P1654, DOI 10.1101/gad.16800511; Yoshimura A, 2010, J BIOCHEM, V147, P781, DOI 10.1093/jb/mvq043; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020319; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	80	68	70	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1609	1615		10.1038/onc.2012.191	http://dx.doi.org/10.1038/onc.2012.191			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614010	Green Published, hybrid			2022-12-28	WOS:000316855800001
J	Momi, N; Ponnusamy, MP; Kaur, S; Rachagani, S; Kunigal, SS; Chellappan, S; Ouellette, MM; Batra, SK				Momi, N.; Ponnusamy, M. P.; Kaur, S.; Rachagani, S.; Kunigal, S. S.; Chellappan, S.; Ouellette, M. M.; Batra, S. K.			Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through alpha 7nAChR-mediated MUC4 upregulation	ONCOGENE			English	Article						MUC4; mucin; cigarette smoke; nicotine; metastasis and pancreatic cancer	NICOTINIC ACETYLCHOLINE-RECEPTOR; MEDIATED TOBACCO TOXICITY; ORAL EPITHELIAL-CELLS; CIGARETTE-SMOKING; GENE-EXPRESSION; RETINOIC ACID; TUMOR-GROWTH; ACTIVATION; STAT3; PROLIFERATION	Despite evidence that long-term smoking is the leading risk factor for pancreatic malignancies, the underlying mechanism(s) for cigarette-smoke (CS)-induced pancreatic cancer (PC) pathogenesis has not been well established. Our previous studies revealed an aberrant expression of the MUC4 mucin in PC as compared with the normal pancreas, and its association with cancer progression and metastasis. Interestingly, here we explore a potential link between MUC4 expression and smoking-mediated PC pathogenesis and report that both cigarette smoke extract and nicotine, which is the major component of CS, significantly upregulates MUC4 in PC cells. This nicotine-mediated MUC4 overexpression was via the alpha 7 subunit of nicotinic acetylcholine receptor (nAChR) stimulation and subsequent activation of the JAK2/STAT3 downstream signaling cascade in cooperation with the MEK/ERK1/2 pathway; this effect was blocked by the alpha 7nAChR antagonists, alpha-bungarotoxin and mecamylamine, and by specific siRNA-mediated STAT3 inhibition. In addition, we demonstrated that nicotine-mediated MUC4 upregulation promotes the PC cell migration through the activation of the downstream effectors, such as HER2, c-Src and FAK; this effect was attenuated by shRNA-mediated MUC4 abrogation, further implying that these nicotine-mediated pathological effects on PC cells are MUC4 dependent. Furthermore, the in vivo studies showed a marked increase in the mean pancreatic tumor weight (low dose (100 mg/m(3) total suspended particulate (TSP)), P = 0.014; high dose (247 mg/m(3) TSP), P = 0.02) and significant tumor metastasis to various distant organs in the CS-exposed mice, orthotopically implanted with luciferase-transfected PC cells, as compared with the sham controls. Moreover, the CS-exposed mice had elevated levels of serum cotinine (low dose, 155.88 +/- 35.96 ng/ml; high dose, 216.25 +/- 29.95 ng/ml) and increased MUC4, alpha 7nAChR and pSTAT3 expression in the pancreatic tumor tissues. Altogether, our findings revealed for the first time that CS upregulates the MUC4 mucin in PC via the alpha 7nAChR/JAK2/STAT3 downstream signaling cascade, thereby promoting metastasis of PC. Oncogene (2013) 32, 1384-1395; doi:10.1038/onc.2012.163; published online 21 May 2012	[Momi, N.; Ponnusamy, M. P.; Kaur, S.; Rachagani, S.; Ouellette, M. M.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Kunigal, S. S.; Chellappan, S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Ouellette, M. M.; Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu		Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	National Institutes of Health [RO1 CA133774, RO1 CA131944, RO1 CA78590, UO1 CA111294, P50 CA127297, U54 CA163120]; NATIONAL CANCER INSTITUTE [U54CA163120, R01CA078590, U01CA111294, R01CA133774, P50CA127297, R01CA131944] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ms Kristi L Berger for editing the manuscript. We acknowledge the invaluable technical support from Mr Erik Moore and Mrs Kavita Mallya. We also thank Janice A Tayor and James R Talaska, the members of the confocal laser scanning microscope core facility at UNMC, for their support. This work was, in part, supported by grants from the National Institutes of Health (RO1 CA133774,RO1 CA131944, RO1 CA78590, UO1 CA111294, P50 CA127297 and U54 CA163120).	Andoh A, 2009, J IMMUNOL, V183, P687, DOI 10.4049/jimmunol.0804169; Andrianifahanana M, 2007, ONCOGENE, V26, P7251, DOI 10.1038/sj.onc.1210532; Andrianifahanana M, 2005, ONCOGENE, V24, P6143, DOI 10.1038/sj.onc.1208756; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Arredondo J, 2005, AM J PATHOL, V166, P597, DOI 10.1016/S0002-9440(10)62281-X; Arredondo J, 2006, FASEB J, V20, P2093, DOI 10.1096/fj.06-6191com; Arredondo J, 2006, CANCER BIOL THER, V5, P511, DOI 10.4161/cbt.5.5.2601; Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Boyle P, 1996, INT J CANCER, V67, P63, DOI 10.1002/(SICI)1097-0215(19960703)67:1<63::AID-IJC12>3.0.CO;2-D; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chen RJ, 2008, TOXICOL SCI, V104, P283, DOI 10.1093/toxsci/kfn086; Chen RJ, 2010, TOXICOL SCI, V115, P118, DOI 10.1093/toxsci/kfq028; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Dasgupta P, 2006, J CLIN INVEST, V116, P2208, DOI 10.1172/JCI28164; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; Finnie IA, 1996, CLIN SCI, V91, P359, DOI 10.1042/cs0910359; Fuchs CS, 1996, ARCH INTERN MED, V156, P2255, DOI 10.1001/archinte.156.19.2255; Heeschen C, 2002, J CLIN INVEST, V110, P527, DOI 10.1172/JCI200214676; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; LINDSTROM J, 1987, MOL NEUROBIOL, V1, P281, DOI 10.1007/BF02935740; Lowenfels AB, 2005, J CELL BIOCHEM, V95, P649, DOI 10.1002/jcb.20461; LUK ISC, 1994, DIGESTION, V55, P399, DOI 10.1159/000201172; Macha MA, 2011, CARCINOGENESIS, V32, P368, DOI 10.1093/carcin/bgq278; MAJUMDAR APN, 1985, AM J PHYSIOL, V248, pG158, DOI 10.1152/ajpgi.1985.248.2.G158; Malfertheiner P, 2006, AM J GASTROENTEROL, V101, P160, DOI 10.1111/j.1572-0241.2006.00402.x; Marrero MB, 2009, BRAIN RES, V1256, P1, DOI 10.1016/j.brainres.2008.11.053; Mejias-Luque R, 2010, ONCOGENE, V29, P1753, DOI 10.1038/onc.2009.467; Mejias-Luque R, 2008, BBA-MOL CELL RES, V1783, P1728, DOI 10.1016/j.bbamcr.2008.05.020; Mimeault M, 2010, CANCER LETT, V295, P69, DOI 10.1016/j.canlet.2010.02.015; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Muscat JE, 1997, CANCER EPIDEM BIOMAR, V6, P15; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Plummer HK, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-29; Ponnusamy MP, 2008, BRIT J CANCER, V99, P520, DOI 10.1038/sj.bjc.6604517; Provenzano PP, 2009, CELL ADHES MIGR, V3, P347, DOI 10.4161/cam.3.4.9458; Rachagani S, 2009, BIOFACTORS, V35, P509, DOI 10.1002/biof.64; Rubin H, 2002, ONCOGENE, V21, P7392, DOI 10.1038/sj.onc.1205800; Shen JX, 2009, ACTA PHARMACOL SIN, V30, P673, DOI 10.1038/aps.2009.64; Sheppard BJ, 2000, INT J ONCOL, V16, P513; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wittel UA, 2006, AM J GASTROENTEROL, V101, P148, DOI 10.1111/j.1572-0241.2006.00405.x; Wittel UA, 2006, PANCREAS, V33, P364, DOI 10.1097/01.mpa.0000240601.80570.31; Wong HPS, 2009, DIGESTION, V80, P209, DOI 10.1159/000231898	51	91	94	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1384	1395		10.1038/onc.2012.163	http://dx.doi.org/10.1038/onc.2012.163			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22614008	Green Accepted			2022-12-28	WOS:000316455600005
J	Shi, J; Wang, E; Zuber, J; Rappaport, A; Taylor, M; Johns, C; Lowe, SW; Vakoc, CR				Shi, J.; Wang, E.; Zuber, J.; Rappaport, A.; Taylor, M.; Johns, C.; Lowe, S. W.; Vakoc, C. R.			The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia	ONCOGENE			English	Article						chromatin; leukemia; epigenetics; MLL; PRC2	HISTONE METHYLTRANSFERASE ACTIVITY; H3 LYSINE 27; GROUP PROTEIN; STEM-CELLS; GENE EZH2; DEVELOPMENTAL REGULATORS; MUTATIONS; METHYLATION; TARGET; DIFFERENTIATION	The Trithorax and Polycomb groups of chromatin regulators are critical for cell-lineage specification during normal development; functions that often become deregulated during tumorigenesis. As an example, oncogenic fusions of the Trithorax-related protein mixed lineage leukemia (MLL) can initiate aggressive leukemias by altering the transcriptional circuitry governing hematopoietic cell differentiation, a process that requires multiple epigenetic pathways to implement. Here we used shRNA screening to identify chromatin regulators uniquely required in a mouse model of MLL-fusion acute myeloid leukemia, which revealed a role for the Polycomb repressive complex 2 (PRC2) in maintenance of this disease. shRNA-mediated suppression of PRC2 subunits Eed, Suz12 or Ezh1/Ezh2 led to proliferation arrest and differentiation of leukemia cells, with a minimal impact on growth of several non-transformed hematopoietic cell lines. The requirement for PRC2 in leukemia is partly because of its role in direct transcriptional repression of genes that limit the self-renewal potential of hennatopoietic cells, including Cdkn2a. In addition to implicating a role for PRC2 in the pathogenesis of MLL-fusion leukemia, our results suggest, more generally, that Trithorax and Polycomb group proteins can cooperate with one another to maintain aberrant lineage programs in cancer. Oncogene (2013) 32, 930-938; doi:10.1038/onc.2012.110; published online 2 April 2012	[Shi, J.; Wang, E.; Zuber, J.; Rappaport, A.; Taylor, M.; Johns, C.; Lowe, S. W.; Vakoc, C. R.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Shi, J.] SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA; [Zuber, J.] Res Inst Mol Pathol IMP, Vienna, Austria; [Rappaport, A.] Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; [Lowe, S. W.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; [Lowe, S. W.] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Cold Spring Harbor Laboratory; Memorial Sloan Kettering Cancer Center; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Vakoc, CR (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowes@mskcc.org; vakoc@cshl.edu	Zuber, Johannes/E-7517-2011; Clovis, Jeff/C-1020-2009	Zuber, Johannes/0000-0001-8810-6835; Wang, Eric/0000-0001-7865-6702; Vakoc, Christopher/0000-0002-1158-7180	Don Monti Memorial Research Foundation; Laurie Strauss Leukemia Foundation; Sass Foundation; Edward P Evans Foundation; FM Kirby Foundation; German Research Foundation (DFG); Andrew Seligson Memorial Clinical Fellowship at CSHL; NIH; Barbara McClintock fellowship; Leukemia and Lymphoma Society of America; National Cancer Institute and by the Howard Hughes Medical Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065094] Funding Source: NIH RePORTER	Don Monti Memorial Research Foundation; Laurie Strauss Leukemia Foundation; Sass Foundation; Edward P Evans Foundation; FM Kirby Foundation; German Research Foundation (DFG)(German Research Foundation (DFG)); Andrew Seligson Memorial Clinical Fellowship at CSHL; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Barbara McClintock fellowship; Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); National Cancer Institute and by the Howard Hughes Medical Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J Simon, E Earl and L Bianco for support with mouse work; S Hearn for microscopy support; G Hannon laboratory for support of shRNA screening methodology; and G Blobel for comments on the manuscript. CRV, JS, EW and MT were supported by the Don Monti Memorial Research Foundation, Laurie Strauss Leukemia Foundation, Sass Foundation, Edward P Evans Foundation and FM Kirby Foundation for research support. JZ was supported by a research fellowship from the German Research Foundation (DFG) and by the Andrew Seligson Memorial Clinical Fellowship at CSHL; ARR was supported by an NIH traineeship and the Barbara McClintock fellowship. SWL is supported by a Specialized Center of Research (SCOR) grant from the Leukemia and Lymphoma Society of America, a Cancer Target Discovery and Development (CTD2) grant from the National Cancer Institute and by the Howard Hughes Medical Institute.	Attardi LD, 2000, GENE DEV, V14, P704; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Dickins RA, 2007, NAT GENET, V39, P914, DOI 10.1038/ng2045; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787; Hellborg F, 2001, ONCOGENE, V20, P5466, DOI 10.1038/sj.onc.1204722; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Maillard I, 2009, BLOOD, V113, P1661, DOI [10.1182/blood-2008-01-135012, 10.1182/blood-2009-01-135012]; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Mochizuki-Kashio M, 2011, BLOOD, V118, P6553, DOI 10.1182/blood-2011-03-340554; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nigten J, 2005, LEUKEMIA, V19, P799, DOI 10.1038/sj.leu.2403699; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Schuettengruber B, 2011, NAT REV MOL CELL BIO, V12, P799, DOI 10.1038/nrm3230; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Tan JY, 2011, CANCER CELL, V20, P563, DOI 10.1016/j.ccr.2011.09.008; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wigle TJ, 2011, FEBS LETT, V585, P3011, DOI 10.1016/j.febslet.2011.08.018; Williams RT, 2008, COLD SH Q B, V73, P461, DOI 10.1101/sqb.2008.73.039; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720; Zuber J, 2009, GENE DEV, V23, P877, DOI 10.1101/gad.1771409	49	87	89	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					930	938		10.1038/onc.2012.110	http://dx.doi.org/10.1038/onc.2012.110			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469984	Green Accepted			2022-12-28	WOS:000316581100013
J	Liu, TJ; Sun, BC; Zhao, XL; Zhao, XM; Sun, T; Gu, Q; Yao, Z; Dong, XY; Zhao, N; Liu, N				Liu, T. J.; Sun, B. C.; Zhao, X. L.; Zhao, X. M.; Sun, T.; Gu, Q.; Yao, Z.; Dong, X. Y.; Zhao, N.; Liu, N.			CD133(+) cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer	ONCOGENE			English	Article						cancer stem cells; vasculogenic mimicry; triple-negative breast cancer	FUNCTIONAL-SIGNIFICANCE; HEPATOCELLULAR-CARCINOMA; EXPRESSION; VASCULARIZATION; CD44(+)/CD24(-); IDENTIFICATION; MARKER	Vasculogenic mimicry (VM) refers to the unique capability of aggressive tumor cells to mimic the pattern of embryonic vasculogenic networks. In the study we demonstrated that CD133 expression was the highest in triple-negative (TN) breast cancer specimens. Importantly, VM showed statistical correlation with CD133(+) expression. The presence of the close relationship between VM and CD133(+) expression might be central for TN tumor relapse and progression. The TN breast cancer cell line, MDA-MB-231 cells developed a range of colony morphologies paralleling the holoclone, meroclone and paraclone morphologies produced by normal keratinocytes and other epithelial cancer cell lines when plated at clonal densities. Holoclone cells were capable of forming more colonies on soft agar than meroclone cells and paraclone cells, suggesting that holoclone cells had higher self-renew potential and might harbors cancer stem cells (CSCs) subpopulation. Strikingly, it was holoclone that displayed CD133(+) phenotype and formed VM. In addition, holoclone acquired endothelial cell marker vascular endothelial-cadherin expression and upregulated VM mediators matrix nnetalloproteinase (MMP)-2 and MMP-9 expression. The subpopulation with holoclone morphology, CD133(+) phenotype and CSCs characteristics might have the capacity of transdifferentiation and contributed to VM in TN breast cancer. The related molecular pathways may be used as novel therapeutic targets for the inhibition of angiogenesis and metastasis in TN breast carcinoma. Oncogene (2013) 32, 544-553; doi:10.1038/onc.2012.85; published online 2 April 2012	[Liu, T. J.; Sun, B. C.; Zhao, X. L.; Zhao, X. M.; Sun, T.; Gu, Q.; Yao, Z.; Dong, X. Y.; Zhao, N.; Liu, N.] Tianjin Med Univ, Dept Pathol, Tianjin 300070, Peoples R China; [Sun, B. C.] Tianjin Med Univ, Tianjin Canc Hosp, Dept Pathol, Tianjin 300070, Peoples R China; [Liu, T. J.; Sun, B. C.; Zhao, X. L.; Gu, Q.] Tianjin Med Univ, Tianjin Gen Hosp, Dept Pathol, Tianjin 300070, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Sun, BC (corresponding author), Tianjin Med Univ, Dept Pathol, Tianjin 300070, Peoples R China.	sunbaocun@yahoo.com.cn	liu, tieju/AAU-2050-2020		National Natural Science Foundation of China [30830049, 81172046, 81173091]; International Cooperation project of China-Sweden [09ZCZDSF04400]; Ministry of Science and Technology of China [2009CB918903]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Cooperation project of China-Sweden; Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was partly supported by a Grant from Key project of the National Natural Science Foundation of China (No. 30830049), the International Cooperation project of China-Sweden (No. 09ZCZDSF04400), the National Natural Science Foundation of China (No. 81172046 and No. 81173091) and the 973 Program from the Ministry of Science and Technology of China (No. 2009CB918903).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bruno S, 2006, AM J PATHOL, V169, P2223, DOI 10.2353/ajpath.2006.060498; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Chen LX, 2011, CANCER BIOL THER, V11, P229, DOI 10.4161/cbt.11.2.13842; Dean M, 2006, MOL INTERV, V6, P140, DOI 10.1124/mi.6.3.5; Dong J, 2011, STEM CELL REV REP, V7, P141, DOI 10.1007/s12015-010-9169-7; Eaton CL, 2010, PROSTATE, V70, P875, DOI 10.1002/pros.21121; Florek M, 2005, CELL TISSUE RES, V319, P15, DOI 10.1007/s00441-004-1018-z; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Immervoll H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-48; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Liu WB, 2011, MED ONCOL, V28, pS228, DOI 10.1007/s12032-010-9706-x; Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931; Monzani E, 2008, STEM CELL REV, V4, P51, DOI 10.1007/s12015-008-9009-1; Ping YF, 2011, CURR MOL MED, V11, P69, DOI 10.2174/156652411794474383; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Seftor EA, 2002, CRIT REV ONCOL HEMAT, V44, P17, DOI 10.1016/S1040-8428(01)00199-8; Shen RL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001652; Shevde LA, 2010, J CELL MOL MED, V14, P1693, DOI 10.1111/j.1582-4934.2009.00821.x; Sun T, 2010, HEPATOLOGY, V51, P545, DOI 10.1002/hep.23311; Wang JY, 2008, CANCER BIOL THER, V7, P758, DOI 10.4161/cbt.7.5.5765; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yan XW, 2011, P NATL ACAD SCI USA, V108, P1591, DOI 10.1073/pnas.1018696108; Yeh CT, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-324; Zhang KX, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-319; Zhang SW, 2007, CANCER LETT, V254, P157, DOI 10.1016/j.canlet.2006.12.036; Zhong XF, 2007, INT J CANCER, V121, P2125, DOI 10.1002/ijc.22880	29	190	212	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					544	553		10.1038/onc.2012.85	http://dx.doi.org/10.1038/onc.2012.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22469978				2022-12-28	WOS:000316164700002
J	Yuan, G; Regel, I; Lian, F; Friedrich, T; Hitkova, I; Hofheinz, RD; Strobel, P; Langer, R; Keller, G; Rocken, C; Zimmermann, W; Schmid, RM; Ebert, MPA; Burgermeister, E				Yuan, G.; Regel, I.; Lian, F.; Friedrich, T.; Hitkova, I.; Hofheinz, R. D.; Stroebel, P.; Langer, R.; Keller, G.; Roecken, C.; Zimmermann, W.; Schmid, R. M.; Ebert, M. P. A.; Burgermeister, E.			WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells	ONCOGENE			English	Article						WNT; caveolin; stomach; gastric cancer; epirubicin	ACTIVATED-RECEPTOR-GAMMA; BETA-CATENIN; SIGNALING PATHWAY; UP-REGULATION; P53 ACTIVATION; POOR-PROGNOSIS; NEOADJUVANT CHEMOTHERAPY; DIFFERENTIAL EXPRESSION; DRUG-RESISTANCE; CARCINOMA-CELLS	Resistance to chemotherapy is a major obstacle for curative treatment of human gastric cancer (GC). However, the underlying molecular mechanisms are largely unknown. Wingless-type MMTV integration site family members (WNTs) are secreted glycoproteins involved in embryogenesis and, on inappropriate expression in the adult, in cancer. Here, we show expression of WNT6 in GC patient specimens, human GC cell lines and in a mouse model of GC. In human GC cells, WNT6 expression was enhanced by caveolin-1 (Cav1), a scaffold protein of plasma membrane caveolae. WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox). Epi increased the activity of the human WNT6 promoter through Cav1-dependent binding of beta-catenin to the proximal WNT6 promoter. Epi increased both WNT6/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg). In GC patients, WNT6 expression was positively associated with the tumor stage and the nodal status, and inversely correlated with the response to ECF (Epi, cisplatin, 5-fluorouracil) chemotherapy. These results showed that WNT6 and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to anthracycline drugs. Understanding the molecular mechanisms driving WNT6/Cav1-induced drug resistance will provide benefits in developing new therapies for GC. Oncogene (2013) 32, 375-387; doi:10.1038/onc.2012.40; published online 27 February 2012	[Yuan, G.; Regel, I.; Friedrich, T.; Schmid, R. M.] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 2, D-80290 Munich, Germany; [Yuan, G.; Lian, F.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China; [Hitkova, I.; Ebert, M. P. A.; Burgermeister, E.] Heidelberg Univ, Univ Klinikum Mannheim, Dept Med 2, D-68167 Mannheim, Baden Wurttembe, Germany; [Hofheinz, R. D.] Heidelberg Univ, Univ Klinikum Mannheim, Dept Med 3, D-68167 Mannheim, Baden Wurttembe, Germany; [Stroebel, P.] Heidelberg Univ, Univ Klinikum Mannheim, Inst Pathol, D-68167 Mannheim, Baden Wurttembe, Germany; [Langer, R.; Keller, G.] Tech Univ Munich, Klinikum Rechts Isar, Inst Pathol, D-80290 Munich, Germany; [Roecken, C.] Univ Kiel, Inst Pathol, Kiel, Germany; [Zimmermann, W.] Univ Munich, Tumor Immunol Lab, LIFE Ctr, Munich, Germany	Technical University of Munich; Sun Yat Sen University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Technical University of Munich; University of Kiel; University of Munich	Burgermeister, E (corresponding author), Heidelberg Univ, Univ Klinikum Mannheim, Dept Med 2, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Baden Wurttembe, Germany.	elke.burgermeister@medma.uni-heidelberg.de	Langer, Rupert/AAU-1174-2021; Regel, Ivonne/AFS-1831-2022; Röcken, Christoph/A-9239-2010	Langer, Rupert/0000-0001-9491-3609; Röcken, Christoph/0000-0002-6989-8002	Deutsche Krebshilfe [107885, 108096, 108287]; DFG [SFB 824, TP B1, BU-2285]; Else Kroner Stiftung [P14/07//A104/06]; BMBF (Mobimed) [01EZ0802]; BMBF (KMU-innovativ Initiative of the BMBF) [0315116B]	Deutsche Krebshilfe(Deutsche Krebshilfe); DFG(German Research Foundation (DFG)); Else Kroner Stiftung; BMBF (Mobimed)(Federal Ministry of Education & Research (BMBF)); BMBF (KMU-innovativ Initiative of the BMBF)(Federal Ministry of Education & Research (BMBF))	We are grateful to Minhu Chen, Xiao Chen, Jie Chen for support on collaborations. M Ebert is supported by grants from the Deutsche Krebshilfe (107885, 108096), the DFG (SFB 824, TP B1), the Else Kroner Stiftung (Nr P14/07//A104/06), the BMBF (Mobimed 01EZ0802 and KMU-innovativ Initiative of the BMBF No 0315116B). E Burgermeister receives funds from the Deutsche Krebshilfe (108287) and DFG (BU-2285).	Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Asciutti S, 2011, ONCOGENE, V30, P956, DOI 10.1038/onc.2010.475; Barresi V, 2006, ACTA NEUROPATHOL, V112, P617, DOI 10.1007/s00401-006-0097-1; Becker K, 2003, CANCER-AM CANCER SOC, V98, P1521, DOI 10.1002/cncr.11660; Becker K, 2011, ANN SURG, V253, P934, DOI 10.1097/SLA.0b013e318216f449; Belanger MM, 2004, CANCER BIOL THER, V3, P954, DOI 10.4161/cbt.3.10.1112; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Bourquin C, 2010, J IMMUNOL, V185, P2580, DOI 10.4049/jimmunol.0903231; Burgermeister E, 2006, MOL ENDOCRINOL, V20, P809, DOI 10.1210/me.2005-0171; Burgermeister E, 2007, CANCER RES, V67, P8519, DOI 10.1158/0008-5472.CAN-07-1125; Burgermeister E, 2011, MOL CELL BIOL, V31, P3497, DOI 10.1128/MCB.01421-10; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Chen J, 2005, GUT, V54, P920, DOI 10.1136/gut.2004.047340; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Du ZM, 2009, INT J CANCER, V125, P1832, DOI 10.1002/ijc.24531; Dvory-Sobol H, 2007, CANCER-AM CANCER SOC, V109, P188, DOI 10.1002/cncr.22416; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Flahaut M, 2009, ONCOGENE, V28, P2245, DOI 10.1038/onc.2009.80; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103; Hausmann G, 2007, NAT REV MOL CELL BIO, V8, P331, DOI 10.1038/nrm2141; Ho CC, 2008, LUNG CANCER, V59, P105, DOI 10.1016/j.lungcan.2007.07.024; Huang J, 2011, CANCER RES, V71, P6310, DOI 10.1158/0008-5472.CAN-10-3397; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Joo HJ, 2004, BJU INT, V93, P291, DOI 10.1111/j.1464-410X.2004.04604.x; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Karam JA, 2007, PROSTATE, V67, P614, DOI 10.1002/pros.20557; Kelley JR, 2003, J CLIN EPIDEMIOL, V56, P1, DOI 10.1016/S0895-4356(02)00534-6; Kikuchi A, 2009, TRENDS CELL BIOL, V19, P119, DOI 10.1016/j.tcb.2009.01.003; Kirikoshi H, 2001, BIOCHEM BIOPH RES CO, V283, P798, DOI 10.1006/bbrc.2001.4855; Kobune M, 2007, MOL CANCER THER, V6, P1774, DOI 10.1158/1535-7163.MCT-06-0684; Krawetz R, 2008, CELL SIGNAL, V20, P506, DOI 10.1016/j.cellsig.2007.11.001; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee KH, 2010, P NATL ACAD SCI USA, V107, P69, DOI 10.1073/pnas.0909734107; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Noda T, 2009, BRIT J CANCER, V100, P1647, DOI 10.1038/sj.bjc.6605064; Nyeng P, 2007, DEV BIOL, V303, P295, DOI 10.1016/j.ydbio.2006.11.017; Ordway JM, 2006, CARCINOGENESIS, V27, P2409, DOI 10.1093/carcin/bgl161; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Ravid D, 2005, ONCOGENE, V24, P1338, DOI 10.1038/sj.onc.1208337; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Shatz M, 2004, LEUKEMIA RES, V28, P907, DOI 10.1016/j.leukres.2004.03.013; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Thompson J, 2000, INT J CANCER, V86, P863, DOI 10.1002/(SICI)1097-0215(20000615)86:6<863::AID-IJC16>3.0.CO;2-4; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003; Yamamoto H, 2009, GASTROENTEROLOGY, V137, P242, DOI 10.1053/j.gastro.2009.02.003; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4	58	63	68	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2013	32	3					375	387		10.1038/onc.2012.40	http://dx.doi.org/10.1038/onc.2012.40			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370641	Bronze			2022-12-28	WOS:000314736600011
J	Wang, SD; Rath, P; Lal, B; Richard, JP; Li, Y; Goodwin, CR; Laterra, J; Xia, S				Wang, S. D.; Rath, P.; Lal, B.; Richard, J-P; Li, Y.; Goodwin, C. R.; Laterra, J.; Xia, S.			EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase	ONCOGENE			English	Article						glioblastoma-derived stem-like neurospheres; orthotopic xenograft; EphB2; proliferation/migration dichotomy; invasion; focal adhesion kinase	CELL-MIGRATION; CANCER-CELLS; TUMOR-GROWTH; STEM-CELLS; EPHA2; PATHWAY; EXPRESSION; INVASION; INHIBITION; EPHRINS	Glioblastoma multiforme (GBM) is the most frequent and aggressive primary brain tumors in adults. Uncontrolled proliferation and abnormal cell migration are two prominent spatially and temporally disassociated characteristics of GBMs. In this study, we investigated the role of the receptor tyrosine kinase EphB2 in controlling the proliferation/migration dichotomy of GBM. We studied EphB2 gain of function and loss of function in glioblastoma-derived stem-like neurospheres, whose in vivo growth pattern closely replicates human GBM. EphB2 expression stimulated GBM neurosphere cell migration and invasion, and inhibited neurosphere cell proliferation in vitro. In parallel, EphB2 silencing increased tumor cell proliferation and decreased tumor cell migration. EphB2 was found to increase tumor cell invasion in vivo using an internally controlled dual-fluorescent xenograft model. Xenografts derived from EphB2-overexpressing GBM neurospheres also showed decreased cellular proliferation. The non-receptor tyrosine kinase focal adhesion kinase (FAK) was found to be co-associated with and highly activated by EphB2 expression, and FAK activation facilitated focal adhesion formation, cytoskeleton structure change and cell migration in EphB2-expressing GBM neurosphere cells. Taken together, our findings indicate that EphB2 has pro-invasive and anti-proliferative actions in GBM stem-like neurospheres mediated, in part, by interactions between EphB2 receptors and FAK. These novel findings suggest that tumor cell invasion can be therapeutically targeted by inhibiting EphB2 signaling, and that optimal antitumor responses to EphB2 targeting may require concurrent use of anti-proliferative agents. Oncogene (2012) 31, 5132-5143; doi:10.1038/onc.2012.16; published online 6 February 2012	[Wang, S. D.; Rath, P.; Lal, B.; Richard, J-P; Li, Y.; Laterra, J.; Xia, S.] Johns Hopkins Sch Med, Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA; [Rath, P.; Lal, B.; Richard, J-P; Li, Y.; Laterra, J.; Xia, S.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Goodwin, C. R.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Laterra, J.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Laterra, J.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Xia, S (corresponding author), Johns Hopkins Sch Med, Hugo W Moser Res Inst Kennedy Krieger, 707 N Broadway,Room 400K, Baltimore, MD 21205 USA.	xia@kennedykrieger.org		Richard, Jean-Philippe/0000-0003-2890-2316; Goodwin, C. Rory/0000-0002-6540-2751	Maryland Stem Cell Research Fund (MSCRFE) [2009-0126-00]; NIH [NS43987]; James S McDonnell Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER	Maryland Stem Cell Research Fund (MSCRFE); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James S McDonnell Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Maryland Stem Cell Research Fund (MSCRFE) 2009-0126-00 (SX), NIH NS43987 (JL) and the James S McDonnell Foundation (JL). We thank Dr Hugo Guerrero-Cazares for technical advice and Miss Mir Shanaz Hossain for technical assistance. We also thank Mr Hao Zhang from Johns Hopkins School of Public Health for assistance with flow cytometric analysis.	Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580; Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Candolfi M, 2007, J NEURO-ONCOL, V85, P133, DOI 10.1007/s11060-007-9400-9; Chatzizacharias NA, 2008, HISTOL HISTOPATHOL, V23, P629, DOI 10.14670/HH-23.629; Chiu ST, 2009, CARCINOGENESIS, V30, P1475, DOI 10.1093/carcin/bgp133; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11; Cox BD, 2006, J CELL BIOCHEM, V99, P36, DOI 10.1002/jcb.20956; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Fukai J, 2008, MOL CANCER THER, V7, P2768, DOI 10.1158/1535-7163.MCT-07-2263; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Garber K, 2010, J NATL CANCER I, V102, P1692, DOI 10.1093/jnci/djq479; Genander M, 2009, CELL, V139, P679, DOI 10.1016/j.cell.2009.08.048; Giese A, 1996, INT J CANCER, V67, P275, DOI 10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v; Goodwin CR, 2010, CANCER RES, V70, P2932, DOI 10.1158/0008-5472.CAN-09-3570; Heese O, 2005, NEURO-ONCOLOGY, V7, P476, DOI 10.1215/S1152851704000754; Hoelzinger DB, 2005, NEOPLASIA, V7, P7, DOI 10.1593/neo.04535; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Kuijper S, 2007, TRENDS CARDIOVAS MED, V17, P145, DOI 10.1016/j.tcm.2007.03.003; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Lal BC, 2005, CLIN CANCER RES, V11, P4479, DOI 10.1158/1078-0432.CCR-05-0166; Larsen AB, 2007, MOL CANCER RES, V5, P283, DOI 10.1158/1541-7786.MCR-06-0321; Lee HS, 2008, NAT CELL BIOL, V10, P979, DOI 10.1038/ncb1758; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lugli A, 2005, CLIN CANCER RES, V11, P6450, DOI 10.1158/1078-0432.CCR-04-2458; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Nakada M, 2005, AM J PATHOL, V167, P565, DOI 10.1016/S0002-9440(10)62998-7; Nakada M, 2004, CANCER RES, V64, P3179, DOI 10.1158/0008-5472.CAN-03-3667; Nakada M, 2010, INT J CANCER, V126, P1155, DOI 10.1002/ijc.24849; Noblitt LW, 2004, CANCER GENE THER, V11, P757, DOI 10.1038/sj.cgt.7700761; Noren NK, 2007, CANCER RES, V67, P3994, DOI 10.1158/0008-5472.CAN-07-0525; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Quick A, 2010, REV RECENT CLIN TRIA, V5, P14, DOI 10.2174/157488710790820544; Rahman R, 2010, J ONCOL, V2010, DOI 10.1155/2010/251231; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Sarkaria JN, 2006, CLIN CANCER RES, V12, P2264, DOI 10.1158/1078-0432.CCR-05-2510; Schwock J, 2010, EXPERT OPIN THER TAR, V14, P77, DOI 10.1517/14728220903460340; Shi Y, 2009, J NEUROSCI, V29, P8129, DOI 10.1523/JNEUROSCI.4681-08.2009; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Taddei ML, 2009, AM J PATHOL, V174, P1492, DOI 10.2353/ajpath.2009.080473; van Nimwegen MJ, 2007, BIOCHEM PHARMACOL, V73, P597, DOI 10.1016/j.bcp.2006.08.011; Vaught D, 2009, MOL BIOL CELL, V20, P2572, DOI 10.1091/mbc.E08-04-0378; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Ying MY, 2011, STEM CELLS, V29, P20, DOI 10.1002/stem.561; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	63	68	70	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	50					5132	5143		10.1038/onc.2012.16	http://dx.doi.org/10.1038/onc.2012.16			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22310282	Green Submitted, Green Accepted			2022-12-28	WOS:000312449800002
J	Ursini-Siegel, J; Hardy, WR; Zheng, Y; Ling, C; Zuo, D; Zhang, C; Podmore, L; Pawson, T; Muller, WJ				Ursini-Siegel, J.; Hardy, W. R.; Zheng, Y.; Ling, C.; Zuo, D.; Zhang, C.; Podmore, L.; Pawson, T.; Muller, W. J.			The ShcA SH2 domain engages a 14-3-3/PI3 ' K signaling complex and promotes breast cancer cell survival	ONCOGENE			English	Article						ShcA; SH2 domain; breast cancer; polyoma virus middle T; AKT; signal transduction	DEPENDENT ACTIVATION; ADAPTER PROTEIN; TYROSINE; BINDING; PROGRESSION; TUMORS; GROWTH; GRB2; PHOSPHORYLATION; ASSOCIATION	The ShcA adapter protein transmits activating signals downstream of receptor and cytoplasmic tyrosine kinases through the establishment of phosphotyrosine-dependent complexes. In this regard, ShcA possesses both a phosphotyrosine-binding domain (PTB) and Src homology 2 domain (SH2), which bind phosphotyrosine residues in a sequence-specific manner. Although the majority of receptor tyrosine kinases expressed in breast cancer cells bind the PTB domain, very little is known regarding the biological importance of SH2-driven ShcA signaling during mammary tumorigenesis. To address this, we employed transgenic mice expressing a mutant ShcA allele harboring a non-functional SH2 domain (ShcR397K) under the transcriptional control of the endogenous ShcA promoter. Using transplantation approaches, we demonstrate that SH2-dependent ShcA signaling within the mammary epithelial compartment is essential for breast tumor outgrowth, survival and the development of lung metastases. We further show that the ShcA SH2 domain activates the AKT pathway, potentially through a novel SH2-mediated complex between ShcA, 14-3-3 xi and the p85 regulatory subunit of phosphatidylinositol 3 (PI3') kinase. This study is the first to demonstrate that the SH2 domain of ShcA is critical for tumor survival during mammary tumorigenesis. Oncogene (2012) 31, 5038-5044; doi:10.1038/onc.2012.4; published online 30 January 2012	[Ursini-Siegel, J.; Podmore, L.] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Hardy, W. R.] Univ Massachusetts, Sch Med, Worcester, MA USA; [Zheng, Y.; Zhang, C.; Pawson, T.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Ling, C.; Zuo, D.; Muller, W. J.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada	Lady Davis Institute; McGill University; University of Massachusetts System; University of Massachusetts Worcester; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University	Ursini-Siegel, J (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.	giuseppina.ursini-siegel@mcgill.ca	Pawson, Tony J/E-4578-2013		CBCRA; CIHR [MOP-89751, MOP-111143, MOP6849]; Terry Fox team [020002]; Terry Fox Foundation/CIHR [TFF105268]; CIHR/FRSQ	CBCRA; CIHR(Canadian Institutes of Health Research (CIHR)); Terry Fox team; Terry Fox Foundation/CIHR(Canadian Institutes of Health Research (CIHR)); CIHR/FRSQ(Fonds de la Recherche en Sante du QuebecCanadian Institutes of Health Research (CIHR))	We thank Dr Peter Siegel for critical reading of this manuscript and Vasilios Papavasiliou for assisting with the injection studies. This work was supported by CBCRA, CIHR (MOP-89751) and Terry Fox team (020002) grants to WJM, a CIHR operating grant to JU-S (MOP-111143) and CIHR (MOP6849) and Terry Fox Foundation/CIHR (TFF105268) grants to TP JU-S is the recipient of a CIHR New Investigator Salary Support award. LP is supported by a CIHR/FRSQ training grant in cancer research of the McGill Integrated Cancer Research Training Program (MICRTP). WJM is supported by a CRC chair in molecular oncology. TP is a CIHR distinguished scientist.	ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Barry EF, 2009, J BIOL CHEM, V284, P12080, DOI 10.1074/jbc.M807637200; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Bone H, 2000, CELL SIGNAL, V12, P183, DOI 10.1016/S0898-6568(99)00088-1; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Cook RS, 2011, CANCER RES, V71, P3941, DOI 10.1158/0008-5472.CAN-10-3775; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Davol PA, 2003, CANCER RES, V63, P6772; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; Frackelton AR, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1631; George R, 2008, J MOL BIOL, V377, P740, DOI 10.1016/j.jmb.2007.12.040; Gillgrass A, 2003, ONCOGENE, V22, P9151, DOI 10.1038/sj.onc.1206983; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hardy WR, 2007, SCIENCE, V317, P251, DOI 10.1126/science.1140114; Hodgson JG, 2005, CANCER RES, V65, P9695, DOI 10.1158/0008-5472.CAN-05-0755; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Jones RA, 2009, ONCOGENE, V28, P2152, DOI 10.1038/onc.2009.79; Komiya Y, 2008, J BIOL CHEM, V283, P18753, DOI 10.1074/jbc.M802530200; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Ling C, 2010, GENE DEV, V24, P947, DOI 10.1101/gad.1896810; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; Neal CL, 2011, ONCOGENE; Orlando FA, 2009, ANN SURG ONCOL, V16, P2270, DOI 10.1245/s10434-009-0500-y; Patrussi L, 2005, ONCOGENE, V24, P2218, DOI 10.1038/sj.onc.1208384; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Rauh MJ, 1999, MOL CELL BIOL, V19, P8169; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Su CH, 2011, CANCER RES, V71, P884, DOI 10.1158/0008-5472.CAN-10-2518; Telles E, 2009, EXP CELL RES, V315, P1448, DOI 10.1016/j.yexcr.2009.01.018; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Ursini-Siegel J, 2007, MOL CELL BIOL, V27, P6361, DOI 10.1128/MCB.00686-07; Ursini-Siegel J, 2010, CANCER RES, V70, P7776, DOI 10.1158/0008-5472.CAN-10-2229; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Vijapurkar U, 1998, J BIOL CHEM, V273, P20996, DOI 10.1074/jbc.273.33.20996; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Zhang ZG, 2004, STEROIDS, V69, P523, DOI 10.1016/j.steroids.2004.05.012; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119	45	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					5038	5044		10.1038/onc.2012.4	http://dx.doi.org/10.1038/onc.2012.4			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22286768				2022-12-28	WOS:000311888600008
J	Yamada, T; Takeuchi, S; Fujita, N; Nakamura, A; Wang, W; Li, Q; Oda, M; Mitsudomi, T; Yatabe, Y; Sekido, Y; Yoshida, J; Higashiyama, M; Noguchi, M; Uehara, H; Nishioka, Y; Sone, S; Yano, S				Yamada, T.; Takeuchi, S.; Fujita, N.; Nakamura, A.; Wang, W.; Li, Q.; Oda, M.; Mitsudomi, T.; Yatabe, Y.; Sekido, Y.; Yoshida, J.; Higashiyama, M.; Noguchi, M.; Uehara, H.; Nishioka, Y.; Sone, S.; Yano, S.			Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations	ONCOGENE			English	Article						Akt kinase-interacting protein1; EGFR mutation; novel therapeutic target; lung cancer	GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; INCREASED SENSITIVITY; SCAFFOLD PROTEINS; DRUG-RESISTANCE; MAPK SCAFFOLD; PHASE-II; INHIBITOR; GEFITINIB; PATHWAY	Despite initial dramatic response, epidermal growth factor receptor (EGFR) mutant lung cancer patients always acquire resistance to EGFR-tyrosine kinase inhibitors (TKIs). Gatekeeper T790M mutation in EGFR is the most prevalent genetic alteration underlying acquired resistance to EGFR-TKI, and EGFR mutant lung cancer cells are reported to be addictive to EGFR/Akt signaling even after acquired T790M mutation. Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinositide 3-kinase)/PDK1 (3-phosphoinositide-dependent protein kinase)/Akt that determines receptor signal selectivity for non-mutated EGFR, and assessed its role in EGFR mutant lung cancer with or without gatekeeper T790M mutation. Cell line-based assays showed that Aki1 constitutively associates with mutant EGFR in lung cancer cells with (H1975) or without (PC-9 and HCC827) T790M gatekeeper mutation. Silencing of Aki1 induced apoptosis of EGFR mutant lung cancer cells. Treatment with Aki1 siRNA dramatically inhibited growth of H1975 cells in a xenograft model. Moreover, silencing of Aki1 further potentiated growth inhibitory effect of new generation EGFR-TKIs against H1975 cells in vitro. Aki1 was frequently expressed in tumor cells of EGFR mutant lung cancer patients (53/56 cases), including those with acquired resistance to EGFR-TKI treatment (7/7 cases). Our data suggest that Aki1 may be a critical mediator of survival signaling from mutant EGFR to Akt, and may therefore be an ideal target for EGFR mutant lung cancer patients, especially those with acquired EGFR-TKI resistance due to EGFR T790M gatekeeper mutation.	[Yamada, T.; Takeuchi, S.; Wang, W.; Li, Q.; Yano, S.] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa 9200934, Japan; [Fujita, N.; Nakamura, A.] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan; [Oda, M.] Kanazawa Univ, Dept Gen & Cardiothorac Surg, Kanazawa, Ishikawa 9200934, Japan; [Mitsudomi, T.] Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan; [Yatabe, Y.] Aichi Canc Ctr Hosp, Dept Pathol, Nagoya, Aichi 464, Japan; [Sekido, Y.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan; [Yoshida, J.] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan; [Higashiyama, M.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Surg, Osaka, Japan; [Noguchi, M.] Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Tsukuba, Ibaraki 305, Japan; [Uehara, H.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Mol & Environm Pathol, Tokushima 770, Japan; [Nishioka, Y.; Sone, S.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Resp Med & Rheumatol, Tokushima 770, Japan	Kanazawa University; Japanese Foundation for Cancer Research; Kanazawa University; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; National Cancer Center - Japan; Osaka Medical Center for Cancer & Cardiovascular Diseases; University of Tsukuba; Tokushima University; Tokushima University	Yamada, T (corresponding author), Kanazawa Univ, Canc Res Inst, Div Med Oncol, Takara Machi 13-1, Kanazawa, Ishikawa 9200934, Japan.	tadaakiy@med.kanazawa-u.ac.jp	Yamada, Tadaaki/L-5378-2015; Sekido, Yoshitaka/P-9756-2015; YATABE, Yasushi/J-6461-2014	Yamada, Tadaaki/0000-0002-6945-281X; YATABE, Yasushi/0000-0003-1788-559X; wang, wei/0000-0001-8887-8499; Sekido, Yoshitaka/0000-0002-2428-3848; Mitsudomi, Tetsuya/0000-0001-9860-8505; Yoshida, Junji/0000-0002-1433-9297	Ministry of Health, Labor and Welfare [16-1]; Scientific Research on Innovative Areas 'Integrative Research on Cancer Microenvironment Network' from the Ministry of Education, Culture, Sports, Science, and Technology of Japan [23790902, 21390256, 22112010]	Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Scientific Research on Innovative Areas 'Integrative Research on Cancer Microenvironment Network' from the Ministry of Education, Culture, Sports, Science, and Technology of Japan	We thank Dr John D Minna (University of Texas Southwestern Medical Center) and Dr Isaiah J Fidler (MD Anderson Cancer Center, Houston, TX, USA) for kindly provided by H1975 and PC14PE6, respectively. We thank Mrs Takayuki Nakagawa and Kenji Kita (Cancer Research Institute, Kanazawa University) for technical assistance and fruitful discussion. This work was supported in part by the Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare (M Noguchi, 16-1) and was supported by Grants-in-Aid for Cancer Research (T Yamada, 23790902 and S Yano, 21390256) and Scientific Research on Innovative Areas 'Integrative Research on Cancer Microenvironment Network' (S Yano, 22112010) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Godin-Heymann N, 2007, CANCER RES, V67, P7319, DOI 10.1158/0008-5472.CAN-06-4625; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Jackman D, 2010, J CLIN ONCOL, V28, P357, DOI 10.1200/JCO.2009.24.7049; Janjigian YY, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.7525; Karp DD, 2009, J CLIN ONCOL, V27, P2516, DOI 10.1200/JCO.2008.19.9331; Kobayashi S, 2005, CANCER RES, V65, P7096, DOI 10.1158/0008-5472.CAN-05-1346; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mitsudomi T, 2007, CANCER SCI, V98, P1817, DOI 10.1111/j.1349-7006.2007.00607.x; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Morrison DK, 2001, J CELL SCI, V114, P1609; Mouri A, 2012, J NEUROSCI, V32, P4562, DOI 10.1523/JNEUROSCI.6458-11.2012; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Nakamura A, 2008, MOL CELL BIOL, V28, P5996, DOI 10.1128/MCB.00114-08; Neal JW, 2010, CURR TREAT OPTION ON, V11, P36, DOI 10.1007/s11864-010-0120-6; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Sequist LV, 2010, J CLIN ONCOL, V28, P3076, DOI 10.1200/JCO.2009.27.9414; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Whitmarsh AJ, 2006, BIOCHEM SOC T, V34, P828, DOI 10.1042/BST0340828; Yano S, 2000, AM J PATHOL, V157, P1893, DOI 10.1016/S0002-9440(10)64828-6; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yu Z, 2007, CANCER RES, V67, P10417, DOI 10.1158/0008-5472.CAN-07-1248; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhou WJ, 2009, NATURE, V462, P1070, DOI 10.1038/nature08622	38	22	24	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4427	4435		10.1038/onc.2012.446	http://dx.doi.org/10.1038/onc.2012.446			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23045273	Green Submitted			2022-12-28	WOS:000324404200011
J	Zheng, Y; Gierut, J; Wang, Z; Miao, J; Asara, JM; Tyner, AL				Zheng, Y.; Gierut, J.; Wang, Z.; Miao, J.; Asara, J. M.; Tyner, A. L.			Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT	ONCOGENE			English	Article						BRK; Sik; PTK6; FAK; AKT; anoikis	BREAST-TUMOR KINASE; BRK; SURVIVAL; EXPRESSION; MIGRATION; GROWTH; PROLIFERATION; BRK/SIK; BINDING; FAK	Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase expressed in epithelial cancers. Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice by preventing signal transducer and activator of transcription 3 activation. Relocalization of PTK6 in prostate cancers contributes to increased growth. Although not expressed in normal breast or ovary, PTK6 promotes anchorage-independent survival of breast and ovarian tumor cells. We identified several potential PTK6 substrates in the human SW620 colon cancer cell line using mass spectrometry, including FAK (focal adhesion kinase). We show that FAK is a direct substrate of PTK6 in vitro and in vivo. Expression of membrane-targeted active PTK6 (Palm-PTK6-YF) induces constitutive activation of FAK and cell morphology changes, which are independent of SRC family kinases in Src-/-, Yes-/-, Fyn-/- (SYF) mouse embryonic fibroblasts (MEFs). Palm-PTK6-YF expressing SYF cells are transformed and overcome contact inhibition, form colonies in transformation assays, proliferate in suspension and form tumors in a xenograft model. Expression of FAK and Palm-PTK6-YF in Fak-/- MEFs synergistically activates AKT and protects cells against anoikis. However, expression of Palm-PTK6-YF in Akt1/2-/- MEFs fails to protect cells from anoikis, indicating AKT is critical in PTK6 and FAK-mediated survival signaling. In a conditional Pten knockout murine prostate cancer model, we identify prostate epithelial cells with enhanced activation of endogenous PTK6 and FAK at the plasma membrane. Knockdown of PTK6 in the PC3 human prostate cancer cell line disrupts FAK and AKT activation and promotes anoikis, which can be rescued by exogenous expression of FAK. Our data reveal important roles for a PTK6-FAK-AKT signaling axis in promoting anchorage-independent cell survival.	[Zheng, Y.; Gierut, J.; Wang, Z.; Miao, J.; Tyner, A. L.] Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; [Asara, J. M.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; [Asara, J. M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, M-C 669,900 South Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Tyner, Angela/0000-0001-7448-8625	NIH [5R01DK044525, 5P01CA120964]; NIH DF/HCC Cancer Center Support Grant [5P30CA006516]; NATIONAL CANCER INSTITUTE [P30CA006516, P01CA120964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH DF/HCC Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH Grants 5R01DK044525 (ALT), 5P01CA120964 (JMA) and NIH DF/HCC Cancer Center Support Grant 5P30CA006516 (JMA). We thank Wenjun Bie and Min Yuan for technical assistance, Dr Nissim Hay (University of Illinois at Chicago, Chicago, IL, USA) for his gifts of Akt1/2-/- MEFs and PTEN<SUP>fl/fl</SUP>, Probasin-Cre and control mouse tissues, and Dr David D Schlaepfer (University of California, San Diego, CA, USA) for providing FAK expression constructs.	Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Bouchard V, 2007, J CELL PHYSIOL, V212, P717, DOI 10.1002/jcp.21096; Brauer PM, 2010, CELL CYCLE, V9, P4190, DOI 10.4161/cc.9.20.13518; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Castro NE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2622; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gierut J, 2011, GASTROENTEROLOGY, V141, P1371, DOI 10.1053/j.gastro.2011.06.071; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200; Irie HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011729; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Li X, 2012, ONCOGENE, V31, P4372, DOI 10.1038/onc.2011.608; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Lin HS, 2004, ARCH OTOLARYNGOL, V130, P311, DOI 10.1001/archotol.130.3.311; Liu L, 2006, ONCOGENE, V25, P4904, DOI 10.1038/sj.onc.1209501; Llor X, 1999, CLIN CANCER RES, V5, P1767; Lofgren KA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2946; Lukong KE, 2009, CELL SIGNAL, V21, P1415, DOI 10.1016/j.cellsig.2009.04.008; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Palka-Hamblin HL, 2010, J CELL SCI, V123, P236, DOI 10.1242/jcs.053264; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Rasband W.S., 1997, IMAGE J; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Sakamoto S, 2010, MOL ASPECTS MED, V31, P205, DOI 10.1016/j.mam.2010.02.001; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Schmandt RE, 2006, CANCER BIOL THER, V5, P1136, DOI 10.4161/cbt.5.9.2953; Serfas MS, 2003, ONCOL RES, V13, P409; Shen CH, 2008, CANCER RES, V68, P7779, DOI 10.1158/0008-5472.CAN-08-0997; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Weaver AM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1794; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Xiang B, 2008, P NATL ACAD SCI USA, V105, P12463, DOI 10.1073/pnas.0805009105; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010; Zheng Y, 2012, J BIOL CHEM, V287, P148, DOI 10.1074/jbc.M111.298117; Zheng Y, 2010, MOL CELL BIOL, V30, P4280, DOI 10.1128/MCB.00024-10; Zouq NK, 2009, J CELL SCI, V122, P357, DOI 10.1242/jcs.030478	50	39	41	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4304	4312		10.1038/onc.2012.427	http://dx.doi.org/10.1038/onc.2012.427			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23027128	Green Submitted, Green Accepted			2022-12-28	WOS:000324168000012
J	Ketchart, W; Smith, KM; Krupka, T; Wittmann, BM; Hu, Y; Rayman, PA; Doughman, YQ; Albert, JM; Bai, X; Finke, JH; Xu, Y; Exner, AA; Montano, MM				Ketchart, W.; Smith, K. M.; Krupka, T.; Wittmann, B. M.; Hu, Y.; Rayman, P. A.; Doughman, Y. Q.; Albert, J. M.; Bai, X.; Finke, J. H.; Xu, Y.; Exner, A. A.; Montano, M. M.			Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis	ONCOGENE			English	Article						HEXIM1; breast cancer; metastasis; angiogenesis	67-KDA LAMININ RECEPTOR; ENDOTHELIAL PROGENITOR CELLS; BREAST-CANCER; GROWTH-FACTOR; HEXAMETHYLENE BISACETAMIDE; TUMOR VASCULATURE; TGF-BETA; EXPRESSION; IDENTIFICATION; CHEMOTHERAPY	We report on the role of hexamethylene-bis-acetamide-inducible protein 1 (HEXIM1) as an inhibitor of metastasis. HEXIM1 expression is decreased in human metastatic breast cancers when compared with matched primary breast tumors. Similarly we observed decreased expression of HEXIM1 in lung metastasis when compared with primary mammary tumors in a mouse model of metastatic breast cancer, the polyoma middle T antigen (PyMT) transgenic mouse. Re-expression of HEXIM1 (through transgene expression or localized delivery of a small molecule inducer of HEXIM1 expression, hexamethylene-bis-acetamide) in PyMT mice resulted in inhibition of metastasis to the lung. Our present studies indicate that HEXIM1 downregulation of HIF-1 alpha protein allows not only for inhibition of vascular endothelial growth factor-regulated angiogenesis, but also for inhibition of compensatory proangiogenic pathways and recruitment of bone marrow-derived cells (BMDCs). Another novel finding is that HEXIM1 inhibits cell migration and invasion that can be partly attributed to decreased membrane localization of the 67 kDa laminin receptor, 67LR, and inhibition of the functional interaction of 67LR with laminin. Thus, HEXIM1 re-expression in breast cancer has therapeutic advantages by simultaneously targeting more than one pathway involved in angiogenesis and metastasis. Our results also support the potential for HEXIM1 to indirectly act on multiple cell types to suppress metastatic cancer.	[Ketchart, W.; Wittmann, B. M.; Hu, Y.; Doughman, Y. Q.; Montano, M. M.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Smith, K. M.; Xu, Y.] Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; [Krupka, T.; Exner, A. A.] Case Western Reserve Univ, Dept Radiol, Cleveland, OH 44106 USA; [Rayman, P. A.; Finke, J. H.] Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44106 USA; [Albert, J. M.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; [Bai, X.] Case Western Reserve Univ, Ctr RNA Mol Biol, Cleveland, OH USA	Case Western Reserve University; University System of Ohio; Cleveland State University; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, HG Wood Bldg W305,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@case.edu	Xu, Yan/AAW-4085-2021; Smith, Kerri/P-4609-2019; Smith, Kerri M/D-9878-2011; Albert, Jeffrey/P-7273-2019	Albert, Jeffrey/0000-0003-2245-1745; Exner, Agata/0000-0003-3913-7066; Smith, Kerri/0000-0001-5161-3278	National Institute of Health [CA92440, R01CA118399]; Chulalongkorn University in Thailand; National Science Foundation MRI [CHE-0923308]; US Department of Education GAANN [P200A070595-08]; NATIONAL CANCER INSTITUTE [R01CA092440, R01CA118399] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chulalongkorn University in Thailand; National Science Foundation MRI(National Science Foundation (NSF)); US Department of Education GAANN(US Department of Education); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institute of Health grants CA92440 grant to MMM and R01CA118399 to AAE. WK was supported by a Scholarship for the Development of New Faculty Staff from the Chulalongkorn University in Thailand. The HPLC-MS-MS instrument used for HMBA analysis was funded by National Science Foundation MRI grant (CHE-0923308) to YX. KS is supported by a US Department of Education GAANN grant (P200A070595-08) to YX.	Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Ardini E, 2002, CANCER RES, V62, P1321; Barker HE, 2011, CANCER RES, V71, P1561, DOI 10.1158/0008-5472.CAN-10-2868; Buto S, 1998, J CELL BIOCHEM, V69, P244, DOI 10.1002/(SICI)1097-4644(19980601)69:3<244::AID-JCB2>3.0.CO;2-R; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; CASTRONOVO V, 1993, INVAS METAST, V13, P1; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Dome B, 2009, CRIT REV ONCOL HEMAT, V69, P108, DOI 10.1016/j.critrevonc.2008.06.009; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Gad HA, 2008, AAPS PHARMSCITECH, V9, P878, DOI 10.1208/s12249-008-9126-9; Gao D, 2009, TRENDS MOL MED, V15, P333, DOI 10.1016/j.molmed.2009.06.006; Givant-Horwitz V, 2004, CANCER RES, V64, P3572, DOI 10.1158/0008-5472.CAN-03-3424; Grepin R, 2010, J ONCOL, V2010, DOI 10.1155/2010/835680; Gu YC, 2003, BLOOD, V101, P877, DOI 10.1182/blood-2002-03-0796; GUILBAUD NF, 1990, J CELL PHYSIOL, V145, P162, DOI 10.1002/jcp.1041450122; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; HINEK A, 1994, CELL ADHES COMMUN, V2, P185, DOI 10.3109/15419069409004436; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hoenig MR, 2008, CURR DRUG TARGETS, V9, P422, DOI 10.2174/138945008784221215; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jiang M, 2008, INT J BIOCHEM CELL B, V40, P2284, DOI 10.1016/j.biocel.2008.03.012; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Ketchart W, 2011, ONCOGENE, V30, P3563, DOI 10.1038/onc.2011.76; Lee K, 2009, P NATL ACAD SCI USA, V106, P2353, DOI 10.1073/pnas.0812801106; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Magnifico A, 1996, J BIOL CHEM, V271, P31179, DOI 10.1074/jbc.271.49.31179; Marks P A, 1978, Antibiot Chemother (1971), V23, P33; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Montuori N, 1996, CURR TOP MICROBIOL, V213, P205; Nannuru KC, 2010, CANCER RES, V70, P3494, DOI 10.1158/0008-5472.CAN-09-3251; Ogba N, 2010, ONCOGENE, V29, P3639, DOI 10.1038/onc.2010.110; Ogba N, 2008, CANCER RES, V68, P7015, DOI 10.1158/0008-5472.CAN-08-0814; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Ravivarapu H B, 2000, AAPS PharmSciTech, V1, pE1, DOI 10.1208/pt010101; Relf M, 1997, CANCER RES, V57, P963; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Schietke R, 2010, J BIOL CHEM, V285, P6658, DOI 10.1074/jbc.M109.042424; Seagroves TN, 2009, PHARMACEUTICAL PERSPECTIVES OF CANCER THERAPEUTICS, P521, DOI 10.1007/978-1-4419-0131-6_16; Selleri C, 2006, BLOOD, V108, P2476, DOI 10.1182/blood-2005-11-012625; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Siler U, 2000, BLOOD, V96, P4194; Smith KM, 2011, J CHROMATOGR B, V879, P2206, DOI 10.1016/j.jchromb.2011.06.002; Southard G L, 1998, Expert Opin Investig Drugs, V7, P1483, DOI 10.1517/13543784.7.9.1483; Taylor MA, 2011, GENE EXPRESSION, V15, P117, DOI 10.3727/105221611X13176664479322; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Udagawa T, 2006, FASEB J, V20, P95, DOI 10.1096/fj.04-3669com; Viacava P, 1997, J PATHOL, V182, P36, DOI 10.1002/(SICI)1096-9896(199705)182:1<36::AID-PATH802>3.0.CO;2-W; Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555-006-9019-x; Westwell AD, 2004, DRUG DISCOV TODAY, V9, P625, DOI 10.1016/S1359-6446(04)03162-9; Wittmann BM, 2005, ONCOGENE, V24, P5576, DOI 10.1038/sj.onc.1208728; Wittmann BM, 2003, CANCER RES, V63, P5151; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; YOUNG CW, 1988, CANCER RES, V48, P7304	62	25	25	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3829	3839		10.1038/onc.2012.405	http://dx.doi.org/10.1038/onc.2012.405			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22964639	Green Accepted			2022-12-28	WOS:000323210200005
J	da Silva-Diz, V; Sole-Sanchez, S; Valdes-Gutierrez, A; Urpi, M; Riba-Artes, D; Penin, RM; Pascual, G; Gonzalez-Suarez, E; Casanovas, O; Vinals, F; Paramio, JM; Batlle, E; Munoz, P				da Silva-Diz, V.; Sole-Sanchez, S.; Valdes-Gutierrez, A.; Urpi, M.; Riba-Artes, D.; Penin, R. M.; Pascual, G.; Gonzalez-Suarez, E.; Casanovas, O.; Vinals, F.; Paramio, J. M.; Batlle, E.; Munoz, P.			Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis	ONCOGENE			English	Article						cell lineage tracing; hair follicle stem cells; carcinogenesis mouse models; papillomavirus; squamous cell carcinoma	SQUAMOUS-CELL; BETA-CATENIN; TRANSGENIC MICE; SKIN TUMORS; CARCINOMA; CANCER; DIFFERENTIATION; CARCINOGENESIS; MORPHOGENESIS; EXPRESSION	Epidermal keratinocytes and hair follicle (HF) stem cells (SCs) expressing oncogenes are competent at developing squamous cell carcinomas (SCCs) in epidermis and HFs, respectively. To determine whether bulge and hair germ (HG) SCs from HF contribute to SCC generation at distant epidermis, the most frequent epidermal region where these lesions arise in human skin, we used a skin cancer mouse model expressing E6 and E7 oncoproteins from Human papillomavirus (HPV) 16 in SCs and basal keratinocytes. This previously described mouse model recapitulates the human skin papillomavirus-induced SCC pathology. We show that E6 and E7 expression promote the expansion of keratin 15 (K15)-expressing cells. These K15(+) aberrant cells exhibit some HGSC markers and diminished expression of Tcf3 and Sox9 hair SC specification genes, which are accumulated in HFs and mislocalized to interfollicular epidermis. Leucine-rich G-protein-coupled receptor 5 (Lgr5)-expressing SCs, localized in the bulge and HG, are the origin of the expanded K15(+) cell population. A large subset of the Lgr5(+) SC progeny, expressing K15 and P-cadherin, is aberrantly mobilized to the upper region of HFs and the epidermis, and accumulates at E6/E7-induced pre-neoplastic lesions and epidermal tumors. These findings indicate that aberrant accumulation of altered SCs in HFs and their subsequent migration to the epidermis contribute to HPV-induced tumor development.	[da Silva-Diz, V.; Sole-Sanchez, S.; Valdes-Gutierrez, A.; Urpi, M.; Riba-Artes, D.; Gonzalez-Suarez, E.; Munoz, P.] Bellvitge Biomed Res Inst IDIBELL, PEBC, Barcelona 08907, Spain; [Penin, R. M.] Hosp Univ Bellvitge IDIBELL, Pathol Serv, Barcelona, Spain; [Pascual, G.] CRG, Dept Cell Differentiat & Canc, Barcelona, Spain; [Casanovas, O.; Vinals, F.] Catalan Inst Oncol ICO IDIBELL, Translat Res Lab, Barcelona, Spain; [Vinals, F.] Univ Barcelona IDIBELL, Dept Ciencies Fisiol 2, Unitat Bioquim & Biol Mol, Barcelona, Spain; [Paramio, J. M.] Ctr Invstigac Energet Medioambientales & Tecnol, Mol Oncol Unit, Madrid, Spain; [Batlle, E.] IRB, Oncol Program, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona	Munoz, P (corresponding author), Bellvitge Biomed Res Inst IDIBELL, PEBC, Aging & Canc Grp, Av Gran Via LHospitalet 199-203, Barcelona 08907, Spain.	p.munoz@idibell.cat	Viñals, Francesc/F-5928-2016; Gonzalez-Suarez, Eva/L-6298-2014; Batlle, Eduard/K-8080-2014; Paramio, Jesus M/M-8482-2014; Vinals, Francesc/P-6278-2019; Angulo, Gloria Pascual/AAA-7668-2019; Casanovas, Oriol/L-5210-2014	Viñals, Francesc/0000-0002-9918-6751; Gonzalez-Suarez, Eva/0000-0003-0858-8171; Batlle, Eduard/0000-0003-2422-0326; Paramio, Jesus M/0000-0001-7520-3177; Angulo, Gloria Pascual/0000-0003-3810-6647; Valdes, Antonio/0000-0002-9119-3092; Casanovas, Oriol/0000-0002-4298-3995	Spanish Ministry of Science and Innovation [SAF2008-01173]; Spanish Ministry of Education; IDIBELL fellowship; Catalan Department of Health (Generalitat de Catalunya)	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Ministry of Education(Spanish Government); IDIBELL fellowship; Catalan Department of Health (Generalitat de Catalunya)	We thank D Hanahan and JM Arbeit (NCI MMHCC Repository) for the K14-HPV16 mice, A Villanueva for helpful advice, S Gonzalo for critical reading of the manuscript, R Alvarez, J Comas and E Castano (Universitat de Barcelona-SCT) for their technical support in flow cytometry and the IDIBELL animal facility service for mouse care. VdSD is funded by a Spanish Ministry of Science and Innovation fellowship, SSS is funded by a Spanish Ministry of Education fellowship and DRA and AVG received an IDIBELL fellowship. The research of PM's group is supported by the Spanish Ministry of Science and Innovation (SAF2008-01173) and by the Catalan Department of Health (Generalitat de Catalunya).	Alam M, 2001, NEW ENGL J MED, V344, P975, DOI 10.1056/NEJM200103293441306; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; Arwert EN, 2010, P NATL ACAD SCI USA, V107, P19903, DOI 10.1073/pnas.1007404107; Blanco R, 2007, GENE DEV, V21, P206, DOI 10.1101/gad.406207; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Boccardo E, 2010, CARCINOGENESIS, V31, P1905, DOI 10.1093/carcin/bgq176; Boxman ILA, 1999, J CLIN MICROBIOL, V37, P2270, DOI 10.1128/JCM.37.7.2270-2273.1999; Bulut G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027243; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Coussens LM, 1996, AM J PATHOL, V149, P1899; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; Ghittoni R, 2010, VIRUS GENES, V40, P1, DOI 10.1007/s11262-009-0412-8; Gormley RH, 2011, J AM ACAD DERMATOL, V64, P981, DOI 10.1016/j.jaad.2009.10.044; Greco V, 2009, CELL STEM CELL, V4, P155, DOI 10.1016/j.stem.2008.12.009; Hama N, 2006, J DERMATOL, V33, P331, DOI 10.1111/j.1346-8138.2006.00078.x; Hsu YC, 2011, CELL, V144, P92, DOI 10.1016/j.cell.2010.11.049; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Karagas MR, 2006, J NATL CANCER I, V98, P389, DOI 10.1093/jnci/djj092; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Lapouge G, 2011, P NATL ACAD SCI USA, V108, P7431, DOI 10.1073/pnas.1012720108; Liu Y, 2009, CELL STEM CELL, V4, P37, DOI 10.1016/j.stem.2008.11.006; Lorz C, 2010, STEM CELL REV REP, V6, P162, DOI 10.1007/s12015-010-9139-0; Lowry WE, 2005, GENE DEV, V19, P1596, DOI 10.1101/gad.1324905; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Martinez-Cruz AB, 2008, CANCER RES, V68, P683, DOI 10.1158/0008-5472.CAN-07-3049; McLaughlin-Drubin ME, 2009, VIRUS RES, V143, P195, DOI 10.1016/j.virusres.2009.06.008; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Muller-Rover S, 1999, EXP DERMATOL, V8, P237; Munoz P, 2005, NAT GENET, V37, P1063, DOI 10.1038/ng1633; Nguyen H, 2006, CELL, V127, P171, DOI 10.1016/j.cell.2006.07.036; Nowak JA, 2008, CELL STEM CELL, V3, P33, DOI 10.1016/j.stem.2008.05.009; Petersson M, 2011, EMBO J, V30, P3004, DOI 10.1038/emboj.2011.199; Rhee H, 2006, SCIENCE, V312, P1946, DOI 10.1126/science.1128004; Rodriguez-Sastre MA, 2005, GYNECOL ONCOL, V97, P330, DOI 10.1016/j.ygyno.2004.12.062; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Shinohara A, 2001, GYNECOL ONCOL, V82, P450, DOI 10.1006/gyno.2001.6298; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; Vidal VPI, 2005, CURR BIOL, V15, P1340, DOI 10.1016/j.cub.2005.06.064; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; White AC, 2011, P NATL ACAD SCI USA, V108, P7425, DOI 10.1073/pnas.1012670108; Wong SY, 2011, P NATL ACAD SCI USA, V108, P4093, DOI 10.1073/pnas.1013098108; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	57	40	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3732	3743		10.1038/onc.2012.375	http://dx.doi.org/10.1038/onc.2012.375			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22945646				2022-12-28	WOS:000322904400008
J	Manchanda, PK; Jones, GN; Lee, AA; Pringle, DR; Zhang, M; Yu, L; La Perle, KMD; Kirschner, LS				Manchanda, P. K.; Jones, G. N.; Lee, A. A.; Pringle, D. R.; Zhang, M.; Yu, L.; La Perle, K. M. D.; Kirschner, L. S.			Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors	ONCOGENE			English	Article						PKA; PRKAR1A; Schwann cell tumor; Rac1; Merlin	PROTEIN-KINASE-A; NEUROFIBROMATOSIS TYPE-2 GENE; MEDIATES CONTACT INHIBITION; P21-ACTIVATED KINASE; CYCLIC-AMP; NEURAL CREST; MERLIN; GROWTH; PHOSPHORYLATION; PRODUCT	Schwannomas are peripheral nerve sheath tumors that often occur in the setting of an inherited tumor predisposition syndrome, including neurofibromatosis types 1 (NF1) and 2 (NF2), familial schwannomatosis and Carney complex. Loss of the NF2 tumor suppressor (encoding NF2, or Merlin) is associated with upregulation of the Rac1 small GTPase, which is thought to have a key role in mediating tumor formation. In prior studies, we generated a mouse model of schwannomas by performing tissue-specific knockout (KO) of the Carney complex gene Prkar1a, which encodes the type 1A regulatory subunit of protein kinase A. These tumors exhibited down-regulation of Nf2 protein and an increase in activated Rac1. To assess the requirement for Rac1 in schwannoma formation, we generated a double KO (DKO) of Prkar1a and Rac1 in Schwann cells and monitored tumor formation. Loss of Rac1 reduced tumor formation by reducing proliferation and enhancing apoptosis. Surprisingly, the reduction of tumor formation was accompanied by re-expression of the Nf2 protein. Furthermore, activated Rac1 was able to downregulate Nf2 in vitro in a Pak-dependent manner. These in vivo data indicate that activation of Rac1 is responsible for suppression of Nf2 protein production; deficiency of Nf2 in Schwann cells leads to loss of cellular growth control and tumor formation. Further, PKA activation through mutation in Prkar1a is sufficient to initiate Rac1 signaling, with subsequent reduction of Nf2 and schwannomagenesis. Although in vitro evidence has shown that loss of Nf2 activates Rac1, our data indicate that signaling between Nf2 and Rac1 occurs in a bidirectional fashion, and these interactions are modulated by PKA.	[Manchanda, P. K.; Jones, G. N.; Lee, A. A.; Pringle, D. R.; Zhang, M.; Kirschner, L. S.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Yu, L.] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA; [La Perle, K. M. D.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Kirschner, L. S.] Ohio State Univ, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kirschner, LS (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, 420 West 12th Ave,Tzagournis Res Facil 544, Columbus, OH 43210 USA.	Lawrence.Kirschner@osumc.edu	La Perle, Krista Marie DuBray/B-3099-2015; yu, lianbo/B-3472-2010		Department of Defense (DOD) Neurofibromatosis program; NATIONAL CANCER INSTITUTE [R01CA112268, P01CA124570, P30CA016058] Funding Source: NIH RePORTER	Department of Defense (DOD) Neurofibromatosis program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant from the Department of Defense (DOD) Neurofibromatosis program. We thank Dr Matthew D Ringel and Dr Motoyasu Saji for insightful discussions.	Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Beeser A, 2005, J BIOL CHEM, V280, P36609, DOI 10.1074/jbc.M502306200; Benninger Y, 2007, J CELL BIOL, V177, P1051, DOI 10.1083/jcb.200610108; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Chan JR, 2007, J CELL BIOL, V177, P953, DOI 10.1083/jcb.200705105; Cotteret S, 2002, GENOME BIOL, V3; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Feltri ML, 2008, GLIA, V56, P1508, DOI 10.1002/glia.20752; Flaiz C, 2009, EXP NEUROL, V218, P137, DOI 10.1016/j.expneurol.2009.04.019; Gautreau A, 2002, J BIOL CHEM, V277, P31279, DOI 10.1074/jbc.C200125200; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Herrlich P, 2000, ANN NY ACAD SCI, V910, P106; Howe DG, 2000, J NEUROSCI, V20, P3513, DOI 10.1523/JNEUROSCI.20-10-03513.2000; Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207; Izawa I, 1996, FEBS LETT, V382, P53, DOI 10.1016/0014-5793(96)00137-8; Jones GN, 2008, NEOPLASIA, V10, P1213, DOI 10.1593/neo.08652; Jones GN, 2010, MOL ENDOCRINOL, V24, P1559, DOI 10.1210/me.2009-0439; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kim HA, 1997, J NEUROSCI RES, V49, P236; Kim HA, 2001, J NEUROSCI, V21, P1110; Kirschner LS, 2000, HUM MOL GENET, V9, P3037, DOI 10.1093/hmg/9.20.3037; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kirschner LS, 2005, CANCER RES, V65, P4506, DOI 10.1158/0008-5472.CAN-05-0580; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Kissil Joseph L, 2010, Am J Med Genet A, V152A, P269, DOI 10.1002/ajmg.a.33189; Krause S, 2008, J PERIPHER NERV SYST, V13, P188, DOI 10.1111/j.1529-8027.2008.00177.x; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laulajainen M, 2008, ONCOGENE, V27, P3233, DOI 10.1038/sj.onc.1210988; Meng FY, 2007, J BIOL CHEM, V282, P8256, DOI 10.1074/jbc.M607712200; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Okada T, 2007, TRENDS CELL BIOL, V17, P222, DOI 10.1016/j.tcb.2007.03.006; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stemmer-Rachamimov AO, 2004, CANCER RES, V64, P3718, DOI 10.1158/0008-5472.CAN-03-4079; Thaxton C, 2008, ONCOGENE, V27, P2705, DOI 10.1038/sj.onc.1210923; Thaxton C, 2007, MOL CELL NEUROSCI, V34, P231, DOI 10.1016/j.mcn.2006.11.003; Thurnherr T, 2006, J NEUROSCI, V26, P10110, DOI 10.1523/JNEUROSCI.2158-06.2006; Tonks ID, 2003, GENESIS, V37, P131, DOI 10.1002/gene.10242; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yin Z, 2008, GENESIS, V46, P37, DOI 10.1002/dvg.20362; Zhang M, 2010, PROSTATE, V70, P807, DOI 10.1002/pros.21114	50	17	20	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3491	3499		10.1038/onc.2012.374	http://dx.doi.org/10.1038/onc.2012.374			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	23045281	Green Accepted			2022-12-28	WOS:000322220800002
J	Nicol, SM; Bray, SE; Black, HD; Lorimore, SA; Wright, EG; Lane, DP; Meek, DW; Coates, PJ; Fuller-Pace, FV				Nicol, S. M.; Bray, S. E.; Black, H. Derek; Lorimore, S. A.; Wright, E. G.; Lane, D. P.; Meek, D. W.; Coates, P. J.; Fuller-Pace, F. V.			The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell-cycle arrest after DNA damage	ONCOGENE			English	Article						p68 (DDX5) RNA helicase; p53; DNA damage; cell-cycle arrest; apoptosis	HEMATOPOIETIC STEM-CELLS; ESTROGEN-RECEPTOR-ALPHA; IN-VIVO; TRANSCRIPTIONAL COACTIVATOR; IONIZING-RADIATION; CANCER DEVELOPMENT; TUMOR-SUPPRESSOR; P53; PROTEINS; STRESS	The RNA helicase p68 (DDX5) is an established co-activator of the p53 tumour suppressor that itself has a pivotal role in orchestrating the cellular response to DNA damage. Although several factors influence the biological outcome of p53 activation, the mechanisms governing the choice between cell-cycle arrest and apoptosis remain to be elucidated. In the present study, we show that, while p68 is critical for p53-mediated transactivation of the cell-cycle arrest gene p21(WAF1/CIP1), it is dispensable for induction of several pro-apoptotic genes in response to DNA damage. Moreover, p68 depletion results in a striking inhibition of recruitment of p53 and RNA Pol II to the p21 promoter but not to the Bax or PUMA promoters, providing an explanation for the selective effect on p21 induction. Importantly, these findings are mirrored in a novel inducible p68 knockout mouse model in which p68 depletion results in a selective inhibition of p21 induction in several tissues. Moreover, in the bone marrow, p68 depletion results in an increased sensitivity to g-irradiation, consistent with an increased level of apoptosis. These data highlight a novel function of p68 as a modulator of the decision between p53-mediated growth arrest and apoptosis in vitro and in vivo.	[Nicol, S. M.; Lorimore, S. A.; Wright, E. G.; Meek, D. W.; Fuller-Pace, F. V.] Univ Dundee, Ninewells Hosp & Med Sch, Div Canc Res, Dundee DD1 9SY, Scotland; [Bray, S. E.; Coates, P. J.] Univ Dundee, Ninewells Hosp & Med Sch, Tayside Tissue Bank, Dundee DD1 9SY, Scotland; [Black, H. Derek] Univ Dundee, Ninewells Hosp & Med Sch, Med Sch Resource Unit, Dundee DD1 9SY, Scotland; [Lane, D. P.] ASTAR, Immunos, Lab P53, Singapore, Singapore	University of Dundee; University of Dundee; University of Dundee; Agency for Science Technology & Research (A*STAR)	Fuller-Pace, FV (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Div Canc Res, Dundee DD1 9SY, Scotland.	f.v.fullerpace@dundee.ac.uk	Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306; Lane, David/0000-0003-0551-3545	Cancer Research UK [C8745/A11216]; Association for International Cancer Research [06-613]	Cancer Research UK(Cancer Research UK); Association for International Cancer Research	We thank Colin Henderson for helpful discussions. This work was supported by grants from Cancer Research UK (C8745/A11216) and the Association for International Cancer Research (06-613).	Aylon Y, 2007, CELL, V130, P597, DOI 10.1016/j.cell.2007.08.005; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Budram-Mahadeo V, 2002, ONCOGENE, V21, P6123, DOI 10.1038/sj.onc.1205842; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chene P, 2000, J MOL BIOL, V299, P245, DOI 10.1006/jmbi.2000.3738; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Coates PJ, 2003, J PATHOL, V201, P377, DOI 10.1002/path.1456; Das S, 2007, CELL, V130, P624, DOI 10.1016/j.cell.2007.06.013; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Espinosa JM, 2008, ONCOGENE, V27, P4013, DOI 10.1038/onc.2008.37; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fei PW, 2002, CANCER RES, V62, P7316; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; HOY CA, 1993, MUTAT RES, V290, P217, DOI 10.1016/0027-5107(93)90162-9; Hudson CD, 2005, J BIOL CHEM, V280, P11851, DOI 10.1074/jbc.M408679200; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; LORIMORE SA, 1995, CELL DEATH DIFFER, V2, P233; LORIMORE SA, 1990, LEUKEMIA RES, V14, P481, DOI 10.1016/0145-2126(90)90036-9; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; Lu X, 1996, ONCOGENE, V13, P413; MacCallum DE, 1996, ONCOGENE, V13, P2575; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Morachis JM, 2010, GENE DEV, V24, P135, DOI 10.1101/gad.1856710; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wortham NC, 2009, ONCOGENE, V28, P4053, DOI 10.1038/onc.2009.261; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022	34	59	63	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2013	32	29					3461	3469		10.1038/onc.2012.426	http://dx.doi.org/10.1038/onc.2012.426			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22986526	Green Accepted			2022-12-28	WOS:000322014900007
J	Chen, N; Eritja, N; Lock, R; Debnath, J				Chen, N.; Eritja, N.; Lock, R.; Debnath, J.			Autophagy restricts proliferation driven by oncogenic phosphatidylinositol 3-kinase in three-dimensional culture	ONCOGENE			English	Article						autophagy; oncogenic PI3K; proliferation; 3D culture	SIGNALING PATHWAYS; RAT HEPATOCYTES; CANCER; TUMORIGENESIS; MUTATIONS; BECLIN-1; CELLS; GENE; ACTIVATION; INDUCTION	Autophagy is a tightly regulated lysosomal self-digestion process that can both promote and impede tumorigenesis. Here, we utilize a three-dimensional (3D) culture model to address how interactions between autophagy and the phosphatidylinositol 3-kinase(PI3K)/Akt/mammalian target of rapamycin pathway impact the malignant behavior of cells carrying a tumor-derived, activating mutation in PI3K (PI3K-H1047R). In this model, autophagy simultaneously mediates tumor-suppressive and -promoting functions within individual glandular structures. In 3D culture, constitutive PI3K activation overcomes proliferation arrest and promotes resistance to anoikis in the luminal space, resulting in aberrant structures with filled lumen. Inhibiting autophagy in PI3K-H1047R structures triggers luminal cell apoptosis, resulting in lumen clearance. At the same time, autophagy gene depletion strongly enhances PI3K-H1047R cell proliferation during 3D morphogenesis, revealing an unexpected role for autophagy in restricting proliferation driven by PI3K activation. Intriguingly, overexpression of the autophagy cargo receptor p62/SQSTM1 in PI3K-H1047R cells is sufficient to enhance cell proliferation, activate the extracellular signal-related kinase/mitogen-activated protein kinase pathway and to promote epidermal growth factor-independent proliferation in 3D culture. Overall, these results indicate that autophagy antagonizes specific aspects of oncogenic PI3K transformation, with the loss of autophagy promoting proliferation.	[Chen, N.; Eritja, N.; Lock, R.; Debnath, J.] Univ Calif San Francisco, Dept Pathol, Biomed Sci Grad Program, San Francisco, CA 94143 USA; [Chen, N.; Eritja, N.; Lock, R.; Debnath, J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Eritja, N.] Univ Lleida, IRBLleida, Inst Recerca Biomed Lleida, Oncol Pathol Grp, Lleida, Spain	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida	Debnath, J (corresponding author), Univ Calif San Francisco, Dept Pathol, Biomed Sci Grad Program, 513 Parnassus Ave,HSW 450B Box 0502, San Francisco, CA 94143 USA.	Jayanta.Debnath@ucsf.edu	Eritja, Nuria/M-1347-2015; Eritja, Núria/S-3700-2019	Eritja, Nuria/0000-0003-1018-6649; Eritja, Núria/0000-0003-2131-7915; Debnath, Jayanta/0000-0002-8745-4069	NIH [RO1 CA126792, CA126792-S1]; DOD BCRP [W81XWH-11-1-0130]; Spanish Ministry of Health; NATIONAL CANCER INSTITUTE [R01CA126792] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD BCRP(United States Department of Defense); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs William Weiss, Qiwen Fan and members of the Debnath lab for critically reading the manuscript, and Drs William Weiss and Terge Johansen for generously providing constructs. Grant support to JD includes the NIH (RO1 CA126792 and ARRA supplement CA126792-S1) and the DOD BCRP (W81XWH-11-1-0130). NE received a Short-Term Stay Fellowship from the Spanish Ministry of Health. RL is a DOD BCRP Predoctoral Scholar (W81XWH-08-1-0759).	Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Debnath J, 2009, METHOD ENZYMOL, V452, P423, DOI 10.1016/S0076-6879(08)03625-2; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Luiken JJFP, 1996, EUR J BIOCHEM, V235, P564; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Moscat J, 2011, CELL, V147, P724, DOI 10.1016/j.cell.2011.10.021; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	34	32	32	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2013	32	20					2543	2554		10.1038/onc.2012.277	http://dx.doi.org/10.1038/onc.2012.277			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22777351	Green Submitted, Green Accepted			2022-12-28	WOS:000319274300006
J	Wang, Q; Xia, N; Li, T; Xu, Y; Zou, Y; Zuo, Y; Fan, Q; Bawa-Khalfe, T; Yeh, ETH; Cheng, J				Wang, Q.; Xia, N.; Li, T.; Xu, Y.; Zou, Y.; Zuo, Y.; Fan, Q.; Bawa-Khalfe, T.; Yeh, E. T. H.; Cheng, J.			SUMO-specific protease 1 promotes prostate cancer progression and metastasis	ONCOGENE			English	Article						SENP1; MMP; HIF1 alpha; prostate cancer; metastasis	MATRIX METALLOPROTEINASE-2; ANDROGEN RECEPTOR; EXPRESSION; DESUMOYLATION; TRANSCRIPTION; SUMOYLATION; HYPOXIA; SENP1; CELLS; ANGIOGENESIS	SUMO-specific protease 1 (SENP1) is a member of de-SUMOylation protease family and has an important role in the regulation of androgen receptor-dependent transcription and hypoxia signaling. This activity profile of SENP1 prompted us to investigate whether SENP1 is involved in the pathogenesis of prostate cancer. In previous studies, we have detected the overexpression of SENP1 in both precancerous prostate intraepithelial neoplasia (PIN) lesions and prostate cancer tissue samples from patients. Whereas our whole-animal model has demonstrated that SENP1 induction is critical for prostate cell transformation, the role of SENP1 in prostate cancer progression is still unknown. In this study, we show that SENP1 expression directly correlates with prostate cancer aggressiveness and reccurrence, by analyzing more than 150 prostate cancer specimens. Modulating SENP1 level dictates colony formation of prostate cancer cell lines, tumor growth in nude mice and also prostate cancer cell migration and invasion. Silencing SENP1 level in highly metastatic prostate cancer cells perturbs their ability to metastasize to the bone and initiates secondary tumors. Mechanistically, the expression of two critical bone remodeling proteins, matrix metalloproteinase 2 (MMP2) and MMP9, is regulated by SENP1 through the HIF1 alpha signaling pathway. All these results show the contribution of SENP1 to the progression of prostate cancer, and suggest that SENP1 may be a prognostic marker and a therapeutic target for metastasis in prostate cancer patients.	[Wang, Q.; Xia, N.; Xu, Y.; Zou, Y.; Zuo, Y.; Fan, Q.; Cheng, J.] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai 200025, Peoples R China; [Wang, Q.; Xia, N.; Zou, Y.; Zuo, Y.; Fan, Q.; Cheng, J.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200025, Peoples R China; [Li, T.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Rui Jin Hosp, Shanghai 200025, Peoples R China; [Bawa-Khalfe, T.; Yeh, E. T. H.] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA; [Yeh, E. T. H.; Cheng, J.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Texas System; UTMD Anderson Cancer Center; Saint Lukes Episcopal Hospital; Texas Heart Institute	Cheng, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, 280 Chongqing South Rd, Shanghai 200025, Peoples R China.	jkcheng@shsmu.edu.cn	Xia, Nan/ABG-4600-2021		National Natural Science Foundation of China [81071665, 30900740]; National Basic Research Program of China (973 Program) [2010CB912104]; Shanghai Committee of Science and Technology [10140902000, 10410700900, 11XD1403200, 11DZ2260200]; United States Department of Defense [PC060932]; NIH [CA 239520]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); United States Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr E Benveniste (The University of Alabama at Birmingham) for the MMP2-Luc plasmid. This work was supported in part by National Natural Science Foundation of China (81071665 to JC, 30900740 to YZ), National Basic Research Program of China (973 Program) (2010CB912104 to JC), Shanghai Committee of Science and Technology (10140902000, 10410700900, 11XD1403200 to JC, 11DZ2260200), United States Department of Defense Grants (PC060932 to JC) and NIH (CA 239520 to ETHY). ETHY is the McNair Scholar of the Texas Heart Institute/St Luke's Episcopal Hospital.	Bawa-Khalfe T, 2007, J BIOL CHEM, V282, P37341, DOI 10.1074/jbc.M706978200; Bawa-Khalfe T, 2010, J BIOL CHEM, V285, P25859, DOI 10.1074/jbc.M110.134874; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Cheng JK, 2006, NEOPLASIA, V8, P667, DOI 10.1593/neo.06445; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Gohji K, 1998, INT J CANCER, V79, P96, DOI 10.1002/(SICI)1097-0215(19980220)79:1<96::AID-IJC18>3.0.CO;2-F; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Kaikkonen S, 2009, MOL ENDOCRINOL, V23, P292, DOI 10.1210/me.2008-0219; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JH, 2006, NAT CELL BIOL, V8, P631, DOI 10.1038/ncb1415; Littlepage LE, 2010, CANCER RES, V70, P2224, DOI 10.1158/0008-5472.CAN-09-3515; Nemeth JA, 2002, J NATL CANCER I, V94, P17; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Sehgal G, 1998, AM J PATHOL, V152, P591; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Stearns M, 1996, ONCOL RES, V8, P69; Trudel D, 2003, CANCER RES, V63, P8511; Xu Y, 2010, J BIOL CHEM, V285, P36682, DOI 10.1074/jbc.M110.164236; Yamaguchi T, 2005, MOL CELL BIOL, V25, P5171, DOI 10.1128/MCB.25.12.5171-5182.2005; Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200; Yu LY, 2010, J EXP MED, V207, P1183, DOI 10.1084/jem.20092215; Zhou LX, 2010, ASIAN J ANDROL, V12, P171, DOI 10.1038/aja.2009.81	23	93	105	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2493	2498		10.1038/onc.2012.250	http://dx.doi.org/10.1038/onc.2012.250			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22733136				2022-12-28	WOS:000318694900013
J	DeGregori, J				DeGregori, J.			Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?	ONCOGENE			English	Review						mutation; evolution; aging	HEMATOPOIETIC STEM-CELLS; DETECTABLE CLONAL MOSAICISM; SELF-RENEWAL; DNA-DAMAGE; C-CBL; MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR; MICE; DIFFERENTIATION; QUIESCENCE	A widely accepted paradigm in cancer research holds that the development of cancers is rate limited by the occurrence of oncogenic mutations. In particular, the exponential rise in the incidence of most cancers with age is thought to reflect the time required for cells to accumulate the multiple oncogenic mutations needed to confer the cancer phenotype. Here I will argue against the axiom that the occurrence of oncogenic mutations limits cancer incidence with age, based on several observations, including that the rate of mutation accumulation is maximal during ontogeny, oncogenic mutations are frequently detected in normal tissues, the evolution of complex multicellularity was not accompanied by reductions in mutation rates, and that many oncogenic mutations have been shown to impair stem cell activity. Moreover, although evidence that has been used to support the current paradigm includes increased cancer incidence in individuals with inherited DNA repair deficiencies or exposed to mutagens, the pleotropic effects of these contexts could enhance tumorigenesis at multiple levels. I will further argue that age-dependent alteration of selection for oncogenic mutations provides a more plausible explanation for increased cancer incidence in the elderly. Although oncogenic mutations are clearly required for cancer evolution, together these observations counter the common view that age dependence of cancers is largely explained by the time required to accumulate sufficient oncogenic mutations. Oncogene (2013) 32, 1869-1875; doi:10.1038/onc.2012.281; published online 2 July 2012	Univ Colorado, Dept Biochem & Mol Genet, Dept Immunol, Dept Pediat,Sch Med,Program Mol Biol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	DeGregori, J (corresponding author), Univ Colorado, Dept Biochem & Mol Genet, Dept Immunol, Dept Pediat,Sch Med,Program Mol Biol, Mail Stop 8101,POB 6511, Aurora, CO 80045 USA.	james.degregori@ucdenver.edu		DeGregori, James/0000-0002-1287-1976	National Institutes of Health [R01-CA157850]; Leukemia Lymphoma Society; NATIONAL CANCER INSTITUTE [R01CA157850] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by grants from the National Institutes of Health (R01-CA157850) and the Leukemia Lymphoma Society. I thank Robert Sclafani, Michael Weil, Andriy Marusyk, Ruth Hershberg, Andrew Thorburn and members of my laboratory for their critical comments and suggestions.	ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; ARMITAGE P, 1957, BRIT J CANCER, V11, P161, DOI 10.1038/bjc.1957.22; Bagby Grover C, 2011, Front Biosci (Schol Ed), V3, P487, DOI 10.2741/s167; Bagley J, 2004, BLOOD, V104, P572, DOI 10.1182/blood-2003-12-4226; Bensimon A, 2011, FEBS LETT, V585, P1625, DOI 10.1016/j.febslet.2011.05.013; BIERNAUX C, 1995, BLOOD, V86, P3118; Bilousova G, 2005, PLOS BIOL, V3, P2135, DOI 10.1371/journal.pbio.0030401; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Blagosklonny MV, 2005, CELL DEATH DIFFER, V12, P592, DOI 10.1038/sj.cdd.4401610; Bondar T, 2010, CELL STEM CELL, V6, P309, DOI 10.1016/j.stem.2010.03.002; Bose S, 1998, BLOOD, V92, P3362, DOI 10.1182/blood.V92.9.3362; Campbell TB, 2009, BLOOD, V114, P3392, DOI 10.1182/blood-2008-12-195214; Chen C, 2008, J EXP MED, V205, P2397, DOI 10.1084/jem.20081297; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cortopassi GA, 1996, MECH AGEING DEV, V91, P211, DOI 10.1016/S0047-6374(96)01788-5; Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6; Daria D, 2008, BLOOD, V111, P1894, DOI 10.1182/blood-2007-02-071746; DeGregori J, 2011, CANCER RES, V71, P3739, DOI 10.1158/0008-5472.CAN-11-0342; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; Fleenor CJ, 2010, CELL CYCLE, V9, P3005, DOI 10.4161/cc.9.15.12311; Forsberg LA, 2012, AM J HUM GENET, V90, P217, DOI 10.1016/j.ajhg.2011.12.009; Frank SA, 2010, P NATL ACAD SCI USA, V107, P1725, DOI 10.1073/pnas.0909343106; Freitas AA, 2011, MUTAT RES-REV MUTAT, V728, P12, DOI 10.1016/j.mrrev.2011.05.001; FRITH CH, 1993, TOXICOL PATHOL, V21, P206, DOI 10.1177/019262339302100213; Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595; Gan B, 2008, P NATL ACAD SCI USA, V105, P19384, DOI 10.1073/pnas.0810584105; Gatenby RA, 2008, NAT REV CANCER, V8, P56, DOI 10.1038/nrc2255; Giese H, 2002, MUTAT RES-GEN TOX EN, V514, P153, DOI 10.1016/S1383-5718(01)00329-1; Gomes NMV, 2011, AGING CELL, V10, P761, DOI 10.1111/j.1474-9726.2011.00718.x; Gorbunova V, 2009, MECH AGEING DEV, V130, P3, DOI 10.1016/j.mad.2008.02.008; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Greaves MF, 2003, NAT REV CANCER, V3, P1, DOI DOI 10.1038/NRC1164; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henry CJ, 2011, AGING-US, V3, P643, DOI 10.18632/aging.100351; Henry CJ, 2010, P NATL ACAD SCI USA, V107, P21713, DOI 10.1073/pnas.1005486107; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Holyoake TL, 2002, LEUKEMIA, V16, P549, DOI 10.1038/sj.leu.2402444; Huang J, 2009, J CLIN INVEST, V119, P3519, DOI 10.1172/JCI40572; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Jacobs KB, 2012, NAT GENET, V44, P651, DOI 10.1038/ng.2270; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Kennedy SR, 2012, MECH AGEING DEV, V133, P118, DOI 10.1016/j.mad.2011.10.009; Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381; Laconi E, 2008, SEMIN CANCER BIOL, V18, P322, DOI 10.1016/j.semcancer.2008.03.019; Laurie CC, 2012, NAT GENET, V44, P642, DOI 10.1038/ng.2271; Li WG, 2012, GERONTOLOGY, V58, P129, DOI 10.1159/000334368; Lynch M, 2010, TRENDS GENET, V26, P345, DOI 10.1016/j.tig.2010.05.003; Maillard I, 2009, BLOOD, V113, P1661, DOI [10.1182/blood-2008-01-135012, 10.1182/blood-2009-01-135012]; Marusyk A, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000324; Marusyk A, 2008, BBA-REV CANCER, V1785, P1, DOI 10.1016/j.bbcan.2007.09.001; Matioli GT, 2002, MED HYPOTHESES, V59, P588, DOI 10.1016/S0306-9877(02)00220-7; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Min IM, 2008, CELL STEM CELL, V2, P380, DOI 10.1016/j.stem.2008.01.015; Mullighan CG, 2008, NATURE; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Mutter GL, 2001, CANCER RES, V61, P4311; Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ogawa S, 2010, CLIN CANCER RES, V16, P3825, DOI 10.1158/1078-0432.CCR-09-2341; Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7; Papathanasiou P, 2009, STEM CELLS, V27, P3082, DOI 10.1002/stem.232; Perry JM, 2011, GENE DEV, V25, P1928, DOI 10.1101/gad.17421911; PETO R, 1975, BRIT J CANCER, V32, P411, DOI 10.1038/bjc.1975.242; Preston BD, 2010, SEMIN CANCER BIOL, V20, P281, DOI 10.1016/j.semcancer.2010.10.009; PROMISLOW DEL, 1994, J THEOR BIOL, V170, P291, DOI 10.1006/jtbi.1994.1190; Qian ZJ, 2008, J EXP MED, V205, P2163, DOI 10.1084/jem.20080578; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Rathinam C, 2008, GENE DEV, V22, P992, DOI 10.1101/gad.1651408; Rathinam C, 2010, CANCER CELL, V18, P341, DOI 10.1016/j.ccr.2010.09.008; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reynaud D, 2011, CANCER CELL, V20, P661, DOI 10.1016/j.ccr.2011.10.012; Rodriguez-Santiago B, 2010, AM J HUM GENET, V87, P129, DOI 10.1016/j.ajhg.2010.06.002; Sabnis AJ, 2009, PLOS BIOL, V7, P537, DOI 10.1371/journal.pbio.1000059; Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387; Schemionek M, 2010, BLOOD, V115, P3185, DOI 10.1182/blood-2009-04-215376; Serrano M, 2007, NAT REV MOL CELL BIO, V8, P715, DOI 10.1038/nrm2242; Sieber OM, 2005, NAT REV CANCER, V5, P649, DOI 10.1038/nrc1674; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Venkatesan RN, 2007, MOL CELL BIOL, V27, P7669, DOI 10.1128/MCB.00002-07; Vickers M, 1996, BRIT J HAEMATOL, V94, P1; Vijg J, 2005, ANN NY ACAD SCI, V1055, P35, DOI 10.1196/annals.1323.007; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Walkley CR, 2007, CELL, V129, P1081, DOI 10.1016/j.cell.2007.03.055; Weinberg RA, 2007, BIOL CANC; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Westbrook AM, 2010, CANCER RES, V70, P1875, DOI 10.1158/0008-5472.CAN-09-2584; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Wilson A, 2009, CURR OPIN GENET DEV, V19, P461, DOI 10.1016/j.gde.2009.08.005; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	95	62	63	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1869	1875		10.1038/onc.2012.281	http://dx.doi.org/10.1038/onc.2012.281			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22751134	Green Accepted			2022-12-28	WOS:000317599900001
J	Zhai, H; Song, B; Xu, X; Zhu, W; Ju, J				Zhai, H.; Song, B.; Xu, X.; Zhu, W.; Ju, J.			Inhibition of autophagy and tumor growth in colon cancer by miR-502	ONCOGENE			English	Article						miR-502; autophagy; p53; colon cancer	CELL-CYCLE; GENE-EXPRESSION; SMALL RNAS; TRANSCRIPTIONAL ACTIVATION; P53; MICRORNAS; MIR-34A; PROLIFERATION; CHEMORESISTANCE; 5-FLUOROURACIL	Autophagy is a catabolic process that allows cellular macromolecules to be broken down and recycled as metabolic precursors. The influence of non-coding microRNAs in autophagy has not been explored in colon cancer. In this study, we discover a novel mechanism of autophagy regulated by hsa-miR-502-5p (miR-502) by suppression of Rab1B, a critical mediator of autophagy. A number of other miR-502 suppressed mRNA targets (for example, dihydroorotate dehydrogenase) are also identified by microarray analysis. Ectopic expression of miR-502 inhibited autophagy, colon cancer cell growth and cell-cycle progression of colon cancer cells in vitro. miR-502 also inhibited in-vivo colon cancer growth in a mouse tumor xenografts model. In addition, the expression of miR-502 was regulated by p53 via a negative feedback regulatory mechanism. The expression of miR-502 was downregulated in colon cancer patient specimens compared with the paired normal control samples. These results suggest that miR-502 may function as a potential tumor suppressor and therefore be a novel candidate for developing miR-502-based therapeutic strategies. Oncogene (2013) 32, 1570-1579; doi:10.1038/onc.2012.167; published online 14 May 2012	[Zhai, H.; Ju, J.] SUNY Stony Brook, Dept Pathol, Translat Res Lab, Stony Brook, NY 11794 USA; [Song, B.] Dalian Med Univ, Dept Pathol, Dalian, Peoples R China; [Xu, X.; Zhu, W.] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Dalian Medical University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ju, J (corresponding author), SUNY Stony Brook, Dept Pathol, Translat Res Lab, BST L9,Room 185, Stony Brook, NY 11794 USA.	jingfang.ju@stonybrookmedicine.edu	zhai, haiyan/K-4659-2014	Ju, Jingfang/0000-0002-4821-7458	Stony Brook University Translational Research Laboratory [R01CA155019, R33CA147966]; NATIONAL CANCER INSTITUTE [R01CA155019, R33CA147966] Funding Source: NIH RePORTER	Stony Brook University Translational Research Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate the critical review by Ms Sonya R Lorrain. We thank Dr Stella E Tsirka for technical support in animal experiments. This study was supported in part by Stony Brook University Translational Research Laboratory Start-up Fund (J Ju), R01CA155019 (J Ju) and R33CA147966 (J Ju).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Akao Y, 2010, CANCER GENE THER, V17, P398, DOI 10.1038/cgt.2009.88; Akao Y, 2007, DNA CELL BIOL, V26, P311, DOI 10.1089/dna.2006.0550; Akao Y, 2009, LEUKEMIA RES, V33, P1530, DOI 10.1016/j.leukres.2009.04.019; Alwan A, 2007, DISASTER MED PUBLIC, V1, P7, DOI 10.1097/DMP.0b013e3180676d32; Baumann P, 2009, MOL CANCER THER, V8, P366, DOI 10.1158/1535-7163.MCT-08-0664; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Crawford L V, 1984, Mol Biol Med, V2, P261; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; DRESSLER LG, 1988, CANCER, V61, P420, DOI 10.1002/1097-0142(19880201)61:3<420::AID-CNCR2820610303>3.0.CO;2-0; Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Georges SA, 2008, CANCER RES, V68, P10105, DOI 10.1158/0008-5472.CAN-08-1846; Ghodgaonkar MM, 2009, CELL DEATH DIFFER, V16, P858, DOI 10.1038/cdd.2009.15; Gunaratne PH, 2010, METHODS MOL BIOL, V667, P297, DOI 10.1007/978-1-60761-811-9_20; He H, 2002, GENE EXPRESSION, V10, P231, DOI 10.3727/000000002783992406; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hegde Sanjay R, 2008, Expert Rev Gastroenterol Hepatol, V2, P135, DOI 10.1586/17474124.2.1.135; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Karaayvaz M, 2011, CLIN COLORECTAL CANC, V10, P340, DOI 10.1016/j.clcc.2011.06.002; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Zoppino FCM, 2010, TRAFFIC, V11, P1246, DOI 10.1111/j.1600-0854.2010.01086.x; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Michael MZ, 2003, MOL CANCER RES, V1, P882; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Navarro F, 2010, J IMMUNOL, V184, P5939, DOI 10.4049/jimmunol.0902567; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107; SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Shin S, 2009, INT J ONCOL, V35, P1343, DOI 10.3892/ijo_00000452; Shin S, 2009, INT J ONCOL, V34, P1645, DOI 10.3892/ijo_00000295; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489; Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274; Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-96; Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Tang FC, 2010, DIFFERENTIATION, V79, P141, DOI 10.1016/j.diff.2009.11.002; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang XD, 2010, FEBS LETT, V584, P3392, DOI 10.1016/j.febslet.2010.06.033; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xi YG, 2006, BIOMARK INSIGHTS, V1, P113; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Zhao RB, 2000, GENE DEV, V14, P981; Zhou JF, 2010, ONCOL REP, V23, P121, DOI 10.3892/or_00000613	72	103	113	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1570	1579		10.1038/onc.2012.167	http://dx.doi.org/10.1038/onc.2012.167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22580605	Green Accepted			2022-12-28	WOS:000316456000010
J	Yin, D; Ogawa, S; Kawamata, N; Leiter, A; Ham, M; Li, D; Doans, NB; Said, JW; Black, KL; Koeffler, HP				Yin, D.; Ogawa, S.; Kawamata, N.; Leiter, A.; Ham, M.; Li, D.; Doans, N. B.; Said, J. W.; Black, K. L.; Koeffler, H. Phillip			miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme	ONCOGENE			English	Article						glioblastoma multiforme; genomic profiling; miR-34a; EGFR; YY-1	GROWTH-FACTOR RECEPTOR; PROSTATE-CANCER; DOWN-REGULATION; EXPRESSION PROFILES; GENE-EXPRESSION; C-MET; APOPTOSIS; IDENTIFICATION; NEUROBLASTOMA; PATHWAY	Chromosome 1p36.23 is frequently deleted in glioblastoma multiforme (GBM). miR-34a localizes in this region. Our experiments found that miR-34a was often deleted and epidermal growth factor receptor (EGFR) was frequently amplified in genomic DNA of 55 GBMs using single-nucleotide polymorphism DNA microarray. Notably, we found that the mean survival time was significantly shortened for patients whose GBMs had both EGFR amplification and miR-34a deletion. Expression of miR-34a was significantly lower in GBM samples compared with normal brain tissue. Forced expression of miR-34a in GBM cells decreased their ability to migrate and profoundly decreased their levels of cyclin-A1, -B1, -D1, and -D3, as well as cyclin-dependent kinase and increased expression of cyclin kinase inhibitor proteins (p21, p27). Also, human GBM cells (U251) stable overexpressing mir-34a formed smaller tumors when growing as xenografts in immunodeficient mice compared with wild-type U251 GBM cells. Furthermore, the protein expression of EGFR decreased in the cells with forced overexpression of miR-34a. Additional studies showed that mir-34a targeted Yin Yang-1 (YY1) and YY1 is a transcription factor that can stimulate the expression of EGFR. Thus, our data suggest that miR-34a acts as a tumor suppressor by inhibiting growth of GBM cells in vitro and in vivo associated with moderating the expression of cell-cycle proteins and EGFR. Moreover, we discovered for the first time that both deletion of miR-34a and amplification of EGFR were associated with significantly decreased overall survival of GBM patients. Oncogene (2013) 32, 1155-1163; doi:10.1038/onc.2012.132; published online 14 May 2012	[Yin, D.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Key Lab Malignant Tumor Gene Regulat, Guangzhou 510275, Guangdong, Peoples R China; [Yin, D.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Target Therapy Guangdong Higher Educ Inst, Guangzhou 510275, Guangdong, Peoples R China; [Yin, D.; Kawamata, N.; Leiter, A.; Ham, M.; Koeffler, H. Phillip] Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Los Angeles, CA 90024 USA; [Ogawa, S.] Univ Tokyo, Sch Med, Tokyo 113, Japan; [Li, D.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [Said, J. W.] Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA; [Black, K. L.] Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA USA; [Koeffler, H. Phillip] Natl Univ Hlth Syst, Natl Univ Canc Inst Singapore, Dept Hematol Oncol, Singapore, Singapore; [Koeffler, H. Phillip] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore	Sun Yat Sen University; Sun Yat Sen University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Tokyo; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National University of Singapore; National University of Singapore	Yin, D (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangzhou 510275, Guangdong, Peoples R China.	Dong.Yin@cshs.org	Ogawa, Seishi/AAE-7088-2019	Black, Keith/0000-0002-0546-4934	National Institutes of Health [1U54CA143930-02, 5R01CA026038-32]; Tom Collier Foundation; A *STAR award of Singapore; Maxine Dunitz Neurosurgical Institute; Cedars-Sinai Medical Center; NSFC [81071788]; '985 project' of Sun Yat-sen University; NATIONAL CANCER INSTITUTE [U54CA143930, P50CA092131, R01CA026038] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tom Collier Foundation; A *STAR award of Singapore; Maxine Dunitz Neurosurgical Institute; Cedars-Sinai Medical Center; NSFC(National Natural Science Foundation of China (NSFC)); '985 project' of Sun Yat-sen University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Institutes of Health grant 1U54CA143930-02 and 5R01CA026038-32, Tom Collier Foundation, A *STAR award of Singapore (HPK); a grant from the Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center (KLB); NSFC grant 81071788, '985 project' of Sun Yat-sen University. HPK is a member of the Molecular Biology Institute and Jonsson Comprehensive Cancer Center at UCLA, and holds the endowed Mark Goodson Chair of Oncology Research at Cedars-Sinai Medical Center/UCLA School of Medicine. This study is in loving memory of matt schreck.	Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Bheda A, 2008, ONCOGENE, V27, P4315, DOI 10.1038/onc.2008.65; Chakravarti A, 2001, CLIN CANCER RES, V7, P2387; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen H, 2009, INT J NEUROPSYCHOPH, V12, P1; Chen QR, 2011, J PROTEOME RES, V10, P479, DOI 10.1021/pr1006697; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; Dong Z, 2004, BRIT J CANCER, V91, P1105, DOI 10.1038/sj.bjc.6602093; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Feinberg-Gorenshtein G, 2009, GENE CHROMOSOME CANC, V48, P539, DOI 10.1002/gcc.20662; Ghimenti C, 2003, J NEURO-ONCOL, V61, P95, DOI 10.1023/A:1022127302008; Guessous F, CELL CYCLE, V9, P1031; Hagman Z, 2010, INT J CANCER, V127, P2768, DOI 10.1002/ijc.25269; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Ichimura K, 2008, ONCOGENE, V27, P2097, DOI 10.1038/sj.onc.1210848; Kaller M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.010462; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Lee CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007314; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Ljubimova JY, 2001, INT J ONCOL, V18, P287; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rokhlin OW, 2008, CANCER BIOL THER, V7, P1288, DOI 10.4161/cbt.7.8.6284; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Solomon DA, 2008, CANCER RES, V68, P2564, DOI 10.1158/0008-5472.CAN-07-6388; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun F, 2008, FEBS LETT, V582, P1564, DOI 10.1016/j.febslet.2008.03.057; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Taylor BS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003179; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Ueki K, 1996, CANCER RES, V56, P150; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Yamamoto G, 2007, AM J HUM GENET, V81, P114, DOI 10.1086/518809; Yan DS, 2009, INVEST OPHTH VIS SCI, V50, P1559, DOI 10.1167/iovs.08-2681; Yin D, 2010, INT J CANCER, V127, P2257, DOI 10.1002/ijc.25257; Yin D, 2009, MOL CANCER RES, V7, P665, DOI 10.1158/1541-7786.MCR-08-0270; Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003	45	87	93	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1155	1163		10.1038/onc.2012.132	http://dx.doi.org/10.1038/onc.2012.132			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22580610	Green Accepted			2022-12-28	WOS:000316428800009
J	Kikuchi, K; Soundararajan, A; Zarzabal, LA; Weems, CR; Nelon, LD; Hampton, ST; Michalek, JE; Rubin, BP; Fields, AP; Keller, C				Kikuchi, K.; Soundararajan, A.; Zarzabal, L. A.; Weems, C. R.; Nelon, L. D.; Hampton, S. T.; Michalek, J. E.; Rubin, B. P.; Fields, A. P.; Keller, C.			Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma	ONCOGENE			English	Article						alveolar rhabdomyosarcoma; protein kinase C iota; Rac1; mitosis; aurothiomalate; vincristine	TRANSFORMED GROWTH; CELL; EXPRESSION; VINCRISTINE; ACTIVATION; PAX3-FKHR; ONCOGENE; PHARMACOKINETICS; DIFFERENTIATION; RESISTANCE	Alveolar rhabdomyosarcoma is an aggressive pediatric cancer exhibiting skeletal-muscle differentiation. New therapeutic targets are required to improve the dismal prognosis for invasive or metastatic alveolar rhabdomyosarcoma. Protein kinase C iota (PKC iota) has been shown to have an important role in tumorigenesis of many cancers, but little is known about its role in rhabdomyosarcoma. Our gene-expression studies in human tumor samples revealed overexpression of PRKCl. We confirmed overexpression of PKC iota at the mRNA and protein levels using our conditional mouse model that authentically recapitulates the progression of rhabdomyosarcoma in humans. Inhibition of Prkci by RNA interference resulted in a dramatic decrease in anchorage-independent colony formation. Interestingly, treatment of primary cell cultures using aurothiomalate (ATM), which is a gold-containing classical anti-rheumatic agent and a PKC iota-specific inhibitor, resulted in decreased interaction between PKC iota and Par6, decreased Rac1 activity and reduced cell viability at clinically relevant concentrations. Moreover, co-treatment with ATM and vincristine (VCR), a nnicrotubule inhibitor currently used in rhabdomyosarcoma treatment regimens, resulted in a combination index of 0.470-0.793 through cooperative accumulation of non-proliferative multinuclear cells in the G2/M phase, indicating that these two drugs synergize. For in vivo tumor growth inhibition studies, ATM demonstrated a trend toward enhanced VCR sensitivity. Overall, these results suggest that PKC iota is functionally important in alveolar rhabdomyosarcoma anchorage-independent growth and tumor-cell proliferation and that combination therapy with ATM and microtubule inhibitors holds promise for the treatment of alveolar rhabdomyosarcoma. Oncogene (2013) 32, 286-295; doi:10.1038/onc.2012.46; published online 20 February 2012	[Kikuchi, K.; Keller, C.] Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Pediat Canc Biol Program, Portland, OR 97239 USA; [Soundararajan, A.; Nelon, L. D.; Hampton, S. T.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Zarzabal, L. A.; Michalek, J. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol, San Antonio, TX 78229 USA; [Zarzabal, L. A.; Michalek, J. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA; [Weems, C. R.; Fields, A. P.] Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA; [Rubin, B. P.] Cleveland Clin, Taussig Canc Ctr, Dept Anat Pathol, Cleveland, OH 44106 USA; [Rubin, B. P.] Cleveland Clin, Taussig Canc Ctr, Dept Mol Genet, Cleveland, OH 44106 USA; [Rubin, B. P.] Lerner Res Inst, Cleveland, OH USA	Oregon Health & Science University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Mayo Clinic; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Keller, C (corresponding author), Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Pediat Canc Biol Program, 3181 SW Sam Jackson Pk Rd,Mail Code L321, Portland, OR 97239 USA.	keller@ohsu.edu	Kikuchi, Ken/ABG-8290-2020	Kikuchi, Ken/0000-0003-3097-7480; Keller, Charles/0000-0003-2505-7487	NIH/NCI Grant [1R01CA133229-04, 1R01CA133229-05, 4R01CA081436-13]; V Foundation for Cancer Research; National Cancer Institute; NICHD; NATIONAL CANCER INSTITUTE [R01CA133229, R01CA081436] Funding Source: NIH RePORTER	NIH/NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI Grant 1R01CA133229-04 and -05 awarded to CK, NIH/NCI Grant 4R01CA081436-13 and the V Foundation for Cancer Research awarded to APF. Human tissue samples were provided by the Pediatric Cooperative Human Tissue network, which is funded by the National Cancer Institute. The Developmental Studies Hybridoma Bank is developed under the auspices of the NICHD and maintained by the University of Iowa, Iowa City, IA, USA.	Ali AS, 2009, CANCER TREAT REV, V35, P1, DOI 10.1016/j.ctrv.2008.07.006; Amstutz R, 2008, CANCER RES, V68, P3767, DOI 10.1158/0008-5472.CAN-07-2447; Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; BLOCKA KLN, 1986, CLIN PHARMACOKINET, V11, P133, DOI 10.2165/00003088-198611020-00003; BOUCHE M, 1995, CELL GROWTH DIFFER, V6, P845; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Cen L, 2007, MODERN PATHOL, V20, P936, DOI 10.1038/modpathol.3800834; Chen LG, 1999, GYNECOL ONCOL, V72, P171, DOI 10.1006/gyno.1998.5242; Erdogan E, 2006, J BIOL CHEM, V281, P28450, DOI 10.1074/jbc.M606054200; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Fields AP, 2007, BIOCHEM SOC T, V35, P996, DOI 10.1042/BST0350996; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Fields AP, 2008, ADV ENZYME REGUL, V48, P166, DOI 10.1016/j.advenzreg.2007.11.014; GERMANI A, 1994, BIOCHEM BIOPH RES CO, V202, P17, DOI 10.1006/bbrc.1994.1887; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; HOUGHTON JA, 1982, CANCER RES, V42, P535; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; JORDAN MA, 1991, CANCER RES, V51, P2212; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; Liu LN, 1998, CELL GROWTH DIFFER, V9, P699; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; Maroto B, 2008, ONCOGENE, V27, P4900, DOI 10.1038/onc.2008.131; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; NELSON RL, 1982, MED PEDIATR ONCOL, V10, P115, DOI 10.1002/mpo.2950100202; Nishijo K, 2009, CANCER RES, V69, P2902, DOI 10.1158/0008-5472.CAN-08-3723; Regala RP, 2008, CANCER RES, V68, P5888, DOI 10.1158/0008-5472.CAN-08-0438; Regala RP, 2009, CANCER RES, V69, P7603, DOI 10.1158/0008-5472.CAN-09-2066; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Sundberg C, 2004, J BIOL CHEM, V279, P51601, DOI 10.1074/jbc.M403753200; Svensson K, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-10; TENNYSON GS, 1983, CANCER TREAT REP, V67, P1113; Thimmaiah KN, 2010, CANCER RES, V70, P2000, DOI 10.1158/0008-5472.CAN-09-3693; Thompson J, 1999, CLIN CANCER RES, V5, P3617; Wachtel M, 2010, CANCER TREAT REV, V36, P318, DOI 10.1016/j.ctrv.2010.02.007; Win HY, 2009, CELL PROLIFERAT, V42, P182, DOI 10.1111/j.1365-2184.2009.00582.x; Win HY, 2008, CANCER LETT, V270, P302, DOI 10.1016/j.canlet.2008.05.023; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Woodcock SA, 2010, CURR BIOL, V20, P669, DOI 10.1016/j.cub.2010.02.033; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	50	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					286	295		10.1038/onc.2012.46	http://dx.doi.org/10.1038/onc.2012.46			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22349825	Green Accepted			2022-12-28	WOS:000314736600003
J	Yu, EJ; Kim, SH; Kim, MJ; Seo, WY; Song, KA; Kang, MS; Yang, CK; Stallcup, MR; Kim, JH				Yu, E. J.; Kim, S-H; Kim, M. J.; Seo, W-Y; Song, K-A; Kang, M-S; Yang, C. K.; Stallcup, M. R.; Kim, J. H.			SUMOylation of ZFP282 potentiates its positive effect on estrogen signaling in breast tumorigenesis	ONCOGENE			English	Article						breast cancer; co-activator; CoCoA; SUMOylation; ZFP282	TERMINAL ACTIVATION DOMAIN; ZINC-FINGER PROTEIN; TRANSCRIPTIONAL ACTIVITY; RECEPTOR-ALPHA; COACTIVATOR COCOA; SUMO MODIFICATION; RECRUITMENT; EXPRESSION; REPRESSES; SYNERGY	Estrogen receptor alpha (ER alpha) has critical roles in the development and progression of breast cancer, and the coiled-coil co-activator (CoCoA) is an important ER alpha co-activator for estrogen-induced gene expression. The small ubiquitin-like modifier (SUMO) pathway is hyperactivated in breast cancer, but the mechanism by which SUMOylation regulates ER alpha-mediated transcription remains poorly understood. Here, we identified ZFP282 as a CoCoA-binding protein. ZFP282 associates directly with ER alpha and cooperates synergistically with CoCoA to enhance ER alpha function. ZFP282 is required for estrogen-induced expression of ER alpha target genes and estrogen-dependent breast cancer cell growth and tumorigenesis. In addition, we found that ZFP282 is SUMOylated and that SUMOylation positively regulates the co-activator activity of ZFP282 by increasing its binding affinity to ER alpha and CoCoA, and consequently increasing recruitment of ZFP282-CoCoA complex to the promoter of ER alpha target genes. These findings reveal essential roles for ZFP282 and its SUMOylation in estrogen signaling and breast tumorigenesis.	[Yu, E. J.; Kim, S-H; Kim, M. J.; Seo, W-Y; Song, K-A; Kang, M-S; Kim, J. H.] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea; [Kim, S-H] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea; [Seo, W-Y; Kang, M-S; Kim, J. H.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Samsung Biomed Res Inst, Seoul, South Korea; [Yang, C. K.; Stallcup, M. R.] Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.	stallcup@usc.edu; jeongkim@skku.edu			National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2010-0021428]; Samsung Biomedical Research Institute [GE1-B2-061]; Korea Healthcare Technology RD Project; Ministry for Health Welfare [A092255]; United States National Institutes of Health [DK43093]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Samsung Biomedical Research Institute(Samsung); Korea Healthcare Technology RD Project; Ministry for Health Welfare; United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Geoffrey L Greene (University of Chicago) for pET-23d-hER alpha-LBD, Dr David K Ann (City of Hope Beckman Research Institute) for SENP1 and Ubc9 expression vectors, Dr Hisato Saitoh (Kimamoto University) for pT-E1E2S1, and Dr Ichi Fujisawa (Kansai Medical University) for pLTR-GL3. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0021428) (to JHK), by the Samsung Biomedical Research Institute grant (GE1-B2-061 to JHK), by Korea Healthcare Technology R&D Project funded by the Ministry for Health & Welfare (A092255), and by grant DK43093 from the United States National Institutes of Health (to MRS).	Buache E, 2011, ONCOGENE, V30, P3261, DOI 10.1038/onc.2011.41; Chupreta S, 2007, J BIOL CHEM, V282, P36155, DOI 10.1074/jbc.M708130200; Conroy AT, 2002, J BIOL CHEM, V277, P9326, DOI 10.1074/jbc.M107702200; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Karamouzis MV, 2008, BREAST CANCER RES TR, V107, P195, DOI 10.1007/s10549-007-9552-5; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Kim JH, 2006, NUCLEIC ACIDS RES, V34, P2736, DOI 10.1093/nar/gkl361; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kuo HY, 2005, P NATL ACAD SCI USA, V102, P16973, DOI 10.1073/pnas.0504460102; Li SS, 2007, CELL SIGNAL, V19, P1101, DOI 10.1016/j.cellsig.2007.02.002; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Okumura K, 1997, NUCLEIC ACIDS RES, V25, P5025, DOI 10.1093/nar/25.24.5025; Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Tamura T, 2004, J HEALTH SCI, V50, P417, DOI 10.1248/jhs.50.417; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Uchimura Y, 2004, ANAL BIOCHEM, V331, P204, DOI 10.1016/j.ab.2004.04.034; Wu HJ, 2006, J BIOL CHEM, V281, P21848, DOI 10.1074/jbc.M603772200; Yang CK, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-12; Yu EJ, 2011, NUCLEIC ACIDS RES, V39, P6932, DOI 10.1093/nar/gkr347	23	12	13	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4160	4168		10.1038/onc.2012.420	http://dx.doi.org/10.1038/onc.2012.420			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	22986521	Green Accepted, hybrid			2022-12-28	WOS:000323748500011
J	Scherf, DB; Sarkisyan, N; Jacobsson, H; Claus, R; Bermejo, JL; Peil, B; Gu, L; Muley, T; Meister, M; Dienemann, H; Plass, C; Risch, A				Scherf, D. B.; Sarkisyan, N.; Jacobsson, H.; Claus, R.; Bermejo, J. L.; Peil, B.; Gu, L.; Muley, T.; Meister, M.; Dienemann, H.; Plass, C.; Risch, A.			Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4	ONCOGENE			English	Article						DNA methylation; risk factors; non-small cell lung cancer (NSCLC); CHRNB4; TERT	CANCER SUSCEPTIBILITY LOCUS; LUNG-CANCER; MASS-SPECTROMETRY; NICOTINE; GENES; SEQUENCE; BINDING; RISK; POLYMORPHISMS; TRANSCRIPTION	Genome-wide association studies have highlighted three major lung cancer susceptibility regions at 15q25.1, 5p15.33 and 6p21.33. To gain insight into the possible mechanistic relevance of the genes in these regions, we investigated the regulation of candidate susceptibility gene expression by epigenetic alterations in healthy and lung tumor tissues. For genes up or downregulated in lung tumors, the influence of genetic variants on DNA methylation was investigated and in vitro studies were performed. We analyzed 394 CpG units within 19 CpG islands in the susceptibility regions in a screening set of 34 patients. Significant findings were validated in an independent patient set (n = 50) with available DNA and RNA. The most consistent overall DNA methylation difference between tumor and adjacent normal tissue on 15q25 was tumor hypomethylation in the promoter region of CHRNB4 with a median difference of 8% (P<0.001), which resulted in overexpression of the transcript in tumors (P<0.001). Confirming previous studies, we also found hypermethylation in CHRNA3 and telomerase reverse transcriptase (TERT) with significant expression changes. Decitabine treatment of H1299 cells resulted in reduced methylation levels in gene promoters, elevated transcript levels of CHRNB4 and CHRNA3, and a slight downregulation of TERT demonstrating epigenetic regulation of lung cancer cells. Single-nucleotide polymorphisms rs421629 on 5p15.33 and rs1948, rs660652, rs8040868 and rs2036527 on 15q25.1, previously identified as lung cancer risk or nicotine-addiction modifiers, were associated with tumor DNA methylation levels in the promoters of TERT and CHRNB4 (P < 0.001), respectively, in two independent sample sets (n = 82; n = 150). In addition, CHRNB4 knockdown in two different cell lines (A549 and H1299) resulted in reduced proliferation (P-A549 < 0.05; P-H1299 < 0.001) and propensity to form colonies in H1299 cells. These results suggest epigenetic deregulation of nicotinic acetylcholine receptor subunit (nAChR) genes which in the case of CHRNB4 is strongly associated with genetic lung cancer susceptibility variants and a functional impact on tumorigenic potential.	[Scherf, D. B.; Sarkisyan, N.; Jacobsson, H.; Claus, R.; Gu, L.; Plass, C.; Risch, A.] German Canc Res Ctr, Div Epigen & Canc Risk Factors C010, D-69120 Heidelberg, Germany; [Bermejo, J. L.; Peil, B.] Univ Heidelberg Hosp, German Canc Res Ctr, Div Mol Genet Epidemiol, Inst Med Biometry & Informat, Heidelberg, Germany; [Muley, T.; Meister, M.] Heidelberg Univ, Thoraxklin Heidelberg gGmbH, Translat Res Unit, D-69115 Heidelberg, Germany; [Dienemann, H.] Heidelberg Univ, Thoraxklin Heidelberg gGmbH, Dept Thorac Surg, D-69115 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Risch, A (corresponding author), German Canc Res Ctr, Div Epigen & Canc Risk Factors C010, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	a.risch@dkfz.de	Claus, Rainer/AAZ-5606-2020; Risch, Angela/H-2669-2013; Plass, Christoph/H-7192-2014	Claus, Rainer/0000-0003-2617-8766; Risch, Angela/0000-0002-8026-5505; 	Genetic Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer Post-GWAS Initiative; National Institute of Health (USA) [CA148127]; Deutsche Krebshilfe [70-2387]; Deutsche Forschungsgemeinschaft (DFG) [SFB/TRR77]; NATIONAL CANCER INSTITUTE [U19CA148127] Funding Source: NIH RePORTER	Genetic Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer Post-GWAS Initiative; National Institute of Health (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Frau Heinzmann-Groth, Birgit Jager and all other members of the clinical and laboratory teams for help with sample and/or data collection and archiving for the Heidelberg lung study. We are grateful to all patients at the Thoraxklinik Heidelberg, who participated in the study. We thank Ruprecht Kuner for the cell lines, Oliver Mucke for competent technical assistance, Chris Amos for helpful comments on the manuscript and the members of the Plass Laboratory for thoughtful discussions. The scientific development and funding of this project were in part supported by the Genetic Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer Post-GWAS Initiative. This work was in part supported by the National Institute of Health (USA; grant number CA148127) and earlier sample collection by the Deutsche Krebshilfe (grant number 70-2387). JLB was in part supported by a grant of the Deutsche Forschungsgemeinschaft (DFG, SFB/TRR77, project Z2).	Allemand E, 2008, CURR OPIN GENET DEV, V18, P145, DOI 10.1016/j.gde.2008.01.006; Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109; Amos CI, 2010, J NATL CANCER I, V102, P1199, DOI 10.1093/jnci/djq232; Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Brena RM, 2007, PLOS MED, V4, P572, DOI 10.1371/journal.pmed.0040108; Brena RM, 2007, HUM MOL GENET, V16, pR96, DOI 10.1093/hmg/ddm073; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Erlich PM, 2010, HUM GENET, V128, P491, DOI 10.1007/s00439-010-0876-6; Esteller M, 1997, CARCINOGENESIS, V18, P2307, DOI 10.1093/carcin/18.12.2307; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840; Gebhard C, 2010, CANCER RES, V70, P1398, DOI 10.1158/0008-5472.CAN-09-3406; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Herceg Zdenko, 2009, Eur J Cancer, V45 Suppl 1, P442, DOI 10.1016/S0959-8049(09)70082-6; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hitchins MP, 2011, CANCER CELL, V20, P200, DOI 10.1016/j.ccr.2011.07.003; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Improgo MR, MOL CANC RES, V8, P194; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Joseph J, 2002, CANCER RES, V62, P6467; Kawai H, 2001, J NEUROCHEM, V78, P1367, DOI 10.1046/j.1471-4159.2001.00526.x; Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Liu Y, 2009, CANCER RES, V69, P7844, DOI 10.1158/0008-5472.CAN-09-1833; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; McCabe MT, 2009, CANCER RES, V69, P282, DOI 10.1158/0008-5472.CAN-08-3274; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Oeth P, 2009, METHODS MOL BIOL, V578, P307, DOI 10.1007/978-1-60327-411-1_20; Paliwal A, 2010, CANCER RES, V70, P2779, DOI 10.1158/0008-5472.CAN-09-4550; Park JC, 2008, BIOCHEM BIOPH RES CO, V365, P221, DOI 10.1016/j.bbrc.2007.10.144; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125; Schalkwyk LC, 2010, AM J HUM GENET, V86, P196, DOI 10.1016/j.ajhg.2010.01.014; Schlaelpfer IR, 2008, BIOL PSYCHIAT, V63, P1039, DOI 10.1016/j.biopsych.2007.10.024; Schuller HM, 2009, NAT REV CANCER, V9, P195, DOI 10.1038/nrc2590; Schuller HM, 1999, CANCER RES, V59, P4510; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shiraishi K, 2009, CARCINOGENESIS, V30, P65, DOI 10.1093/carcin/bgn257; Shivapurkar N, 2008, CANCER EPIDEM BIOMAR, V17, P995, DOI 10.1158/1055-9965.EPI-07-2808; Stephens SH, 2012, BEHAV GENET, V42, P402, DOI 10.1007/s10519-011-9514-x; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; Van den Berg RM, 2010, INT J ONCOL, V37, P455, DOI 10.3892/ijo_00000694; Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273; Zhang YY, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-12-r138	49	29	31	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2013	32	28					3329	3338		10.1038/onc.2012.344	http://dx.doi.org/10.1038/onc.2012.344			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22945651	Green Accepted			2022-12-28	WOS:000321620200003
J	Ben-Shmuel, A; Shvab, A; Gavert, N; Brabletz, T; Ben-Ze'ev, A				Ben-Shmuel, A.; Shvab, A.; Gavert, N.; Brabletz, T.; Ben-Ze'ev, A.			Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-kappa B signaling that promotes colon cancer progression	ONCOGENE			English	Article						L1; IGFBP-2; ezrin; NF-kappa B; CRC	FACTOR-BINDING PROTEIN-2; I IGF-I; THERAPEUTIC TARGET; ERM PROTEINS; INSULIN; EXPRESSION; SERUM; L1; BIOMARKER; RECEPTOR	L1, a neuronal cell adhesion receptor of the immunoglobulin-like protein family is expressed in invading colorectal cancer (CRC) cells as a target gene of Wnt/beta-catenin signaling. Overexpression of L1 in CRC cells enhances cell motility and proliferation, and confers liver metastasis. We recently identified ezrin and the I kappa B-NF-kappa B pathway as essential for the biological properties conferred by L1 in CRC cells. Here, we studied the underlying molecular mechanisms and found that L1 enhances ezrin phosphorylation, via Rho-associated protein kinase (ROCK), and is required for L1-ezrin co-localization at the juxtamembrane domain and for enhancing cell motility. Global transcriptomes from L1-expressing CRC cells were compared with transcriptomes from the same cells expressing small hairpin RNA (shRNA) to ezrin. Among the genes whose expression was elevated by L1 and ezrin we identified insulin-like growth factor-binding protein 2 (IGFBP-2) and showed that its increased expression is mediated by an NF-kappa B-mediated transactivation of the IGFBP-2 gene promoter. Expression of a constitutively activated mutant ezrin (Ezrin567D) could also increase IGFBP-2 levels in CRC cells. Overexpression of IGFBP-2 in CRC cells lacking L1-enhanced cell proliferation (in the absence of serum), cell motility, tumorigenesis and induced liver metastasis, similar to L1 overexpression. Suppression of endogenous IGFBP-2 in L1-transfected cells inhibited these properties conferred by L1. We detected IGFBP-2 in a unique organization at the bottom of human colonic crypts in normal mucosa and at increased levels throughout human CRC tissue samples co-localizing with the phosphorylated p65 subunit of NF-kappa B. Finally, we found that IGFBP-2 and L1 can form a molecular complex suggesting that L1-mediated signaling by the L1-ezrin-NF-kappa B pathway, that induces IGFBP-2 expression, has an important role in CRC progression.	[Ben-Shmuel, A.; Shvab, A.; Gavert, N.; Ben-Ze'ev, A.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Brabletz, T.] Univ Freiburg, Dept Visceral Surg, D-79106 Freiburg, Germany	Weizmann Institute of Science; University of Freiburg	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	avri.ben-zeev@weizmann.ac.il		ben-ze'ev, avri/0000-0001-6113-3921; Gavert, Nancy/0000-0003-1639-4684	Israel Science Foundation (ISF); Israel Cancer Research Fund (ICRF)	Israel Science Foundation (ISF)(Israel Science Foundation); Israel Cancer Research Fund (ICRF)	We thank Drs M Arpin, M Pollak, W Zhang and V Lemmon for providing reagents. This study was supported by grants from the Israel Science Foundation (ISF) and from Israel Cancer Research Fund (ICRF). AB-Z is the incumbent of the Lunenfeld-Kunin Professorial chair of genetics.	Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Bulut G, 2012, ONCOGENE, V31, P269, DOI 10.1038/onc.2011.245; Busund LTR, 2004, VIRCHOWS ARCH, V444, P142, DOI 10.1007/s00428-003-0931-y; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; COHEN P, 1993, J CLIN ENDOCR METAB, V76, P1031, DOI 10.1210/jc.76.4.1031; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Degenhardt T, 2006, J BIOL CHEM, V281, P39607, DOI 10.1074/jbc.M605623200; ELATIQ F, 1994, INT J CANCER, V57, P491, DOI 10.1002/ijc.2910570409; Elmlinger MW, 2001, ENDOCRINOLOGY, V142, P1652, DOI 10.1210/en.142.4.1652; Fievet B, 2007, BBA-MOL CELL RES, V1773, P653, DOI 10.1016/j.bbamcr.2006.06.013; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Gautreau A, 2002, J CELL BIOL, V10, P193; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gavert N, 2008, EXPERT OPIN BIOL TH, V8, P1749, DOI 10.1517/14712598.8.11.1749 ; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Gavert N, 2011, MOL CANCER RES, V9, P14, DOI 10.1158/1541-7786.MCR-10-0406; Gavert N, 2010, J CELL SCI, V123, P2134, DOI 10.1242/jcs.069542; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; Hoeflich A, 2001, CANCER RES, V61, P8601; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592; KARASIK A, 1994, J CLIN ENDOCR METAB, V78, P271, DOI 10.1210/jc.78.2.271; Langsrud O, 2007, J APPL STAT, V34, P1275, DOI 10.1080/02664760701594246; Liou JM, 2010, J CLIN ENDOCR METAB, V95, P1717, DOI 10.1210/jc.2009-2668; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Mendes KN, 2010, INT J ONCOL, V37, P143, DOI 10.3892/ijo_00000662; Mishra L, 1998, GROWTH HORM IGF RES, V8, P473, DOI 10.1016/S1096-6374(98)80300-6; Miyako K, 2009, MOL ENDOCRINOL, V23, P169, DOI 10.1210/me.2008-0168; Moore LM, 2009, P NATL ACAD SCI USA, V106, P16675, DOI 10.1073/pnas.0900807106; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2012, CLIN CANCER RES, V18, P40, DOI 10.1158/1078-0432.CCR-11-0998; Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437; Renehan AG, 2000, J CLIN ENDOCR METAB, V85, P3402, DOI 10.1210/jc.85.9.3402; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; So AI, 2008, CLIN CANCER RES, V14, P6944, DOI 10.1158/1078-0432.CCR-08-0408; Tang FQ, 2009, J BIOL CHEM, V284, P27456, DOI 10.1074/jbc.M109.033795; Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200	40	37	40	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3220	3230		10.1038/onc.2012.340	http://dx.doi.org/10.1038/onc.2012.340			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22869145				2022-12-28	WOS:000321301600002
J	Wu, J; Mukherjee, A; Lebman, DA; Fang, X				Wu, J.; Mukherjee, A.; Lebman, D. A.; Fang, X.			Gene expression of the lysophosphatidic acid receptor 1 is a target of transforming growth factor beta	ONCOGENE			English	Article						cancer; LPA; TGF beta; LPA1; migration; invasion	BREAST-CANCER CELLS; PROTEIN-COUPLED RECEPTOR; SMAD-BINDING-ELEMENT; TGF-BETA; OVARIAN-CANCER; EPITHELIAL-CELLS; LPA RECEPTORS; C-MYC; MOTILITY; METASTASIS	The lysophosphatidic acid (LPA) receptor LPA(1)/Edg2 is the first identified LPA receptor. Although its wide tissue distribution and biological functions have been well studied, little is known about how LPA(1) is transcriptionally regulated. In the current study, we showed that LPA(1) is a physiological target of transforming growth factor beta (TGF beta)-mediated repression. In both normal and neoplastic cells, TGF beta inhibits LPA(1) promoter activity, LPA(1) mRNA expression and LPA(1)-dependent chemotaxis and tumor cell invasion. Knockdown of the TGF beta intracellular effector Smad3 or Smad4 with lentivirally transduced short hairpin RNA relieved these inhibitory effects of TGF beta. Interestingly, the LPA(1) promoter contains two potential TGF beta inhibitory elements (TIEs), each consisting of a Smad-binding site and an adjacent E2F4/5 element, structurally similar to the TIE found on the promoter of the well-defined TGF beta target gene c-myc. Deletion and point mutation analyses indicate that the distal TIE located at 401 bp from the transcription initiation site, is required for TGF beta repression of the LPA(1) promoter. A DNA pull-down assay showed that the -401 TIE was capable of binding Samd3 and E2F4 in TGF beta-treated cells. TGF beta-induced binding of the Smad complex to the native -401 TIE sequence of the LPA(1) gene promoter was further verified by chromatin immunoprecipitation assays. We therefore identified a novel role of TGF beta in the control of LPA(1) expression and LPA(1)-coupled biological functions, adding LPA(1) to the list of TGF beta-repressed target genes.	[Wu, J.; Mukherjee, A.; Fang, X.] Virginia Commonwealth Univ, Dept Biochem, Sch Med, Richmond, VA 23298 USA; [Wu, J.; Mukherjee, A.; Fang, X.] Virginia Commonwealth Univ, Dept Mol Biol, Sch Med, Richmond, VA 23298 USA; [Lebman, D. A.] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Sch Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Fang, X (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, POB 980614,Sanger Hall,1101 E Marshall St, Richmond, VA 23298 USA.	xfang@vcu.edu			NIH/NCI [2R01CA102196]; Department of Defense [W81XWH-11-1-0541]; Jeffress Memorial Fund award; NIH [P30 CA16059]; NATIONAL CANCER INSTITUTE [P30CA016059, R01CA102196] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Jeffress Memorial Fund award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work was supported in part by the NIH/NCI grant 2R01CA102196 (XF), the Department of Defense ovarian cancer research program grant W81XWH-11-1-0541 (XF), the Jeffress Memorial Fund award (XF), and the NIH grant P30 CA16059 to Massey Cancer Center of Virginia Commonwealth University School of Medicine.	AUERSPERG N, 1994, LAB INVEST, V71, P510; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blount AL, 2008, J BIOL CHEM, V283, P7016, DOI 10.1074/jbc.M709502200; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen HJ, 2010, CANCER RES, V70, P9979, DOI 10.1158/0008-5472.CAN-10-2394; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Horak CE, 2007, CANCER RES, V67, P11751, DOI 10.1158/0008-5472.CAN-07-3175; Horak CE, 2007, CANCER RES, V67, P7238, DOI 10.1158/0008-5472.CAN-07-0962; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Jazag A, 2005, ONCOGENE, V24, P662, DOI 10.1038/sj.onc.1208102; Jeon ES, 2008, STEM CELLS, V26, P789, DOI 10.1634/stemcells.2007-0742; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Lee Z, 2006, CANCER RES, V66, P2740, DOI 10.1158/0008-5472.CAN-05-2947; Lee Z, 2008, MOL BIOL CELL, V19, P5435, DOI 10.1091/mbc.E08-03-0316; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; Lin SB, 2009, GASTROENTEROLOGY, V136, P1711, DOI 10.1053/j.gastro.2009.01.002; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marshall JC, 2010, EUR J CANCER, V46, P1278, DOI 10.1016/j.ejca.2010.02.042; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Murph MM, 2008, BBA-MOL CELL BIOL L, V1781, P547, DOI 10.1016/j.bbalip.2008.04.007; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Panupinthu N, 2010, BRIT J CANCER, V102, P941, DOI 10.1038/sj.bjc.6605588; Pasternack SM, 2008, NAT GENET, V40, P329, DOI 10.1038/ng.84; Pradere JP, 2007, J AM SOC NEPHROL, V18, P3110, DOI 10.1681/ASN.2007020196; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Sauer B, 2004, J INVEST DERMATOL, V123, P840, DOI 10.1111/j.0022-202X.2004.23458.x; Seoane J, 2006, CARCINOGENESIS, V27, P2148, DOI 10.1093/carcin/bgl068; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146; Shida D, 2003, CANCER RES, V63, P1706; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Stadler CR, 2006, CELL SIGNAL, V18, P783, DOI 10.1016/j.cellsig.2005.07.002; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Sugiyama N, 2010, P NATL ACAD SCI USA, V107, P15786, DOI 10.1073/pnas.0914459107; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Wu JH, 2011, MOL CANCER RES, V9, P1562, DOI 10.1158/1541-7786.MCR-11-0340; Xu MY, 2009, AM J PATHOL, V174, P1264, DOI 10.2353/ajpath.2009.080160; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378	51	8	8	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3198	3206		10.1038/onc.2012.325	http://dx.doi.org/10.1038/onc.2012.325			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22824789	Green Accepted			2022-12-28	WOS:000321004600010
J	Kappelmann, M; Kuphal, S; Meister, G; Vardimon, L; Bosserhoff, AK				Kappelmann, M.; Kuphal, S.; Meister, G.; Vardimon, L.; Bosserhoff, A-K			MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression	ONCOGENE			English	Article						malignant melanoma; miRNA; c-Jun; migration; post-transcriptionally; protein expression	CELL INVASION; TRANSCRIPTION FACTORS; MALIGNANT-MELANOMA; MESSENGER-RNAS; PROLIFERATION; GENE; AP-1; MELANOCYTES; MECHANISMS; REGIONS	A fundamental event in the development and progression of malignant melanoma is the deregulation of cancer-relevant transcription factors. We recently showed that c-Jun is a main regulator of tumor progression in melanoma and thus the most important member of the AP-1 transcription factor family for this disease. Interestingly, we revealed that c-Jun expression was regulated on the post-transcriptional level and therefore speculated that miRNAs could be involved in c-Jun regulation. We determined seed sequences for miR-125b and miR-527 in the coding region of c-Jun mRNA that hints at the direct involvement of miRNA-dependent regulation on the protein level. We found that the expression of miR-125b was significantly reduced in malignant melanoma cell lines and tissue samples compared with melanocytes, whereas miR-527 remained unchanged. In further functional experiments, treatment of melanoma cells with pre-miR-125b resulted in strong suppression of cellular proliferation and migration, supporting the role of miR-125b in melanoma. In addition, transfection of pre-miR-125b led to strong downregulation of c-Jun protein but not mRNA expression in melanoma cells. Luciferase assays using reporter plasmids containing the miR-125b seed sequence in the luciferase coding region confirmed the direct interaction with miR-125b. Furthermore, immunoprecipitation of Ago-2 revealed that c-Jun mRNA accumulated in the RNA-induced silencing complex after pre-miR-125b transfection in melanoma cells. In summary, we identified an important role for miR-125b in malignant melanoma. Moreover, we demonstrated post-transcriptional regulation of c-Jun by this miRNA and showed that c-Jun is a main mediator of the effects of miR-125b on melanoma cells.	[Kappelmann, M.; Kuphal, S.; Bosserhoff, A-K] Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; [Meister, G.] Univ Regensburg, Inst Biochem, D-93053 Regensburg, Germany; [Vardimon, L.] Tel Aviv Univ, Dept Biochem & Mol Biol, IL-69978 Tel Aviv, Israel	University of Regensburg; University of Regensburg; Tel Aviv University	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X; Kappelmann-Fenzl, Melanie/0000-0003-0312-1687	Melanoma Research Network of the Deutsche Krebshilfe e.V. (German Cancer Aid); DFG; Bavarian Ministry for education and science (BayGene); European Union; Bundesministerium fur Bildung und Forschung (BMBF, NGFN+)	Melanoma Research Network of the Deutsche Krebshilfe e.V. (German Cancer Aid)(Deutsche Krebshilfe); DFG(German Research Foundation (DFG)); Bavarian Ministry for education and science (BayGene); European Union(European Commission); Bundesministerium fur Bildung und Forschung (BMBF, NGFN+)(Federal Ministry of Education & Research (BMBF))	We would like to thank Lisa Ellmann for continuous assistance in cultivation. This work was supported by Melanoma Research Network of the Deutsche Krebshilfe e.V. (German Cancer Aid) and the DFG. GM is supported by grants from the Bavarian Ministry for education and science (BayGene), the European Union (ERC starting grant 'sRNAs', FP7 project 'ONCOMIRs') and the Bundesministerium fur Bildung und Forschung (BMBF, NGFN+).	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Braig S, 2013, ONCOGENE, V32, P837, DOI 10.1038/onc.2012.115; Braig S, 2011, BRIT J CANCER, V105, P231, DOI 10.1038/bjc.2011.226; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen JM, 2010, AM J PATHOL, V176, P2520, DOI 10.2353/ajpath.2010.091061; Dalmay T, 2006, ONCOGENE, V25, P6170, DOI 10.1038/sj.onc.1209911; Deng Y, 2011, INT J BIOL SCI, V7, P133, DOI 10.7150/ijbs.7.133; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Ender C, 2010, J CELL SCI, V123, P1819, DOI 10.1242/jcs.055210; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fang YX, 2012, HEPATOLOGY, V55, P1852, DOI 10.1002/hep.25576; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Glud M, 2011, MELANOMA RES, V21, P253, DOI 10.1097/CMR.0b013e328345333b; Glud M, 2010, MELANOMA RES, V20, P479, DOI 10.1097/CMR.0b013e32833e32a1; Howell PM, 2010, OCHSNER J, V10, P83; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Janga SC, 2011, ADV EXP MED BIOL, V722, P59, DOI 10.1007/978-1-4614-0332-6_4; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Katiyar S, 2010, MOL BIOL CELL, V21, P4264, DOI 10.1091/mbc.E10-08-0705; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Le XF, 2010, CANCER MICROENVIRON, V3, P137, DOI 10.1007/s12307-010-0037-4; Libermann TA, 2006, CURR GENE THER, V6, P17, DOI 10.2174/156652306775515501; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Mueller DW, 2009, BRIT J CANCER, V101, P551, DOI 10.1038/sj.bjc.6605204; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Papaconstantinou I, 2012, EUR J GASTROEN HEPAT, V24, P223, DOI 10.1097/MEG.0b013e3283505063; Philippidou D, 2010, CANCER RES, V70, P4163, DOI 10.1158/0008-5472.CAN-09-4512; Polak P, 2006, ONCOGENE, V25, P665, DOI 10.1038/sj.onc.1209114; Poser I, 2004, ONCOGENE, V23, P6115, DOI 10.1038/sj.onc.1207797; Poser I, 2004, HISTOL HISTOPATHOL, V19, P173, DOI 10.14670/HH-19.173; Rigoutsos I, 2009, CANCER RES, V69, P3245, DOI 10.1158/0008-5472.CAN-09-0352; Rothhammer T, 2005, CANCER RES, V65, P448; Russo AE, 2009, INT J ONCOL, V34, P1481, DOI 10.3892/ijo_00000277; Schmid R, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.78; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shoo BA, 2009, SEMIN CUTAN MED SURG, V28, P96, DOI 10.1016/j.sder.2009.04.005; Spangler B, 2011, PIGM CELL MELANOMA R, V24, P148, DOI 10.1111/j.1755-148X.2010.00787.x; Spangler B, 2012, INT J CANCER, V130, P2801, DOI 10.1002/ijc.26277; Vasudevan S, 2012, WIRES RNA, V3, P311, DOI 10.1002/wrna.121; Weiss C, 2004, CELL CYCLE, V3, P111; Xu Y, 2012, BRIT J CANCER, V106, P553, DOI 10.1038/bjc.2011.568; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	45	111	111	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2984	2991		10.1038/onc.2012.307	http://dx.doi.org/10.1038/onc.2012.307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797068				2022-12-28	WOS:000320369700008
J	Benayoun, BA; Anttonen, M; L'Hote, D; Bailly-Bechet, M; Andersson, N; Heikinheimo, M; Veitia, RA				Benayoun, B. A.; Anttonen, M.; L'Hote, D.; Bailly-Bechet, M.; Andersson, N.; Heikinheimo, M.; Veitia, R. A.			Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation	ONCOGENE			English	Article						FOXL2; ovarian granulosa cell tumor; ovary; transcriptome	EXPRESSION; VISUALIZATION; HALLMARKS; STRESS	Ovarian granulosa cell tumors (OGCT) are the most frequent kind of sex cord-stromal tumors, and represent similar to 2-5% of all ovarian malignancies. OGCTs exist as two entities, juvenile and adult types, with specific clinical and pathological characteristics. The molecular pathogenesis of these tumors has just begun to be unraveled. Indeed, recent studies have indicated that mutation and/or misregulation of the key ovarian transcription factor FOXL2 has a role in OGCT formation, although the mechanisms remain unclear. To better understand the molecular characteristics of OGCT, we studied the transcriptomic profiles of ten human adult-type OGCT samples, as well as ethnically matched granulosa cell (GC) controls. We find that the OGCT samples analyzed herein exhibit several hallmarks of cancer, including increased expression of genes linked to cell proliferation, but decreased expression of those conferring sensitivity to cell death. Moreover, genes differentially expressed in OGCTs are significantly enriched for known FOXL2 target genes, consistently with the prevalence of FOXL2 somatic mutation in these tumors. Expression of these targets is altered in a way expected to promote malignant transformation, for instance, through induction of genes associated with faster cell cycling and downregulation of genes associated with cell death. Over time, such defects may be responsible at least partly for the malignant transformation of healthy GCs into OGCT. These insights into the molecular pathogenesis of OGCTs may open the way to new efforts in the development of more targeted therapeutic strategies for OGCT patients.	[Benayoun, B. A.; L'Hote, D.; Veitia, R. A.] Inst Jacques Monod, F-75251 Paris, France; [Benayoun, B. A.; L'Hote, D.; Veitia, R. A.] Univ Paris 07, Paris 13, France; [Anttonen, M.] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland; [Anttonen, M.; Andersson, N.; Heikinheimo, M.] Univ Helsinki, Childrens Hosp, Helsinki, Finland; [Anttonen, M.; Andersson, N.; Heikinheimo, M.] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Bailly-Bechet, M.] Univ Lyon, UMR 5558, CNRS, Laborat Biometrie & Biol Evolut, Villeurbanne, France	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); VetAgro Sup	Veitia, RA (corresponding author), Univ Paris 07, Batiment Buffon,15 Rue Helene Brion, Paris 13, France.	veitia.reiner@ijm.univ-paris-diderot.fr	Bailly-Bechet, Marc/B-6292-2012; Andersson, Noora/AAW-2030-2020; Benayoun, Bérénice A./K-7048-2012; LHOTE, David/AAD-5390-2020; L'Hote, David/L-2653-2017	Andersson, Noora/0000-0003-4708-7273; Benayoun, Bérénice A./0000-0002-7401-4777; L'Hote, David/0000-0001-5658-5018	AMN/Universite Paris Diderot-Paris 7; The Helsinki University Central Hospital Research Funds; Academy of Finland; Sigrid Juselius Foundation; Helsinki University Central Hospital; Universite Paris Diderot-Paris 7; CNRS; Universite Lyon 1; Institut Universitaire de France; Fondation pour la Recherche Medicale; Ligue Nationale Contre le Cancer (Comite de Paris); Groupement d'Entreprises Francaises dans la Lutte contre le Cancer; Universite Paris VII; Fondation pour la Recherche Medicale (FRM)	AMN/Universite Paris Diderot-Paris 7; The Helsinki University Central Hospital Research Funds; Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Helsinki University Central Hospital; Universite Paris Diderot-Paris 7; CNRS(Centre National de la Recherche Scientifique (CNRS)); Universite Lyon 1; Institut Universitaire de France; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Ligue Nationale Contre le Cancer (Comite de Paris); Groupement d'Entreprises Francaises dans la Lutte contre le Cancer; Universite Paris VII; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	We thank Dr Ralf Butzow and Dr Unkila-Kallio for help and collection of the human OGCT samples. We thank Dr Denis Mestivier for his advice on clustering analysis of the OGCT microarray samples. BAB was funded by AMN/Universite Paris Diderot-Paris 7 fellowships. MA was funded by a grant from The Helsinki University Central Hospital Research Funds. NA and MH were funded by Academy of Finland, Sigrid Juselius Foundation and Helsinki University Central Hospital. DL was funded by Universite Paris Diderot-Paris 7. MBB was funded by CNRS and Universite Lyon 1. RAV was funded by Institut Universitaire de France, Fondation pour la Recherche Medicale, Ligue Nationale Contre le Cancer (Comite de Paris), Groupement d'Entreprises Francaises dans la Lutte contre le Cancer, CNRS and Universite Paris VII. This work was supported by grants from Fondation pour la Recherche Medicale (FRM), from The Helsinki University Central Hospital Research Funds and from Academy of Finland, Sigrid Juselius Foundation and Helsinki University Central Hospital.	Batista F, 2007, P NATL ACAD SCI USA, V104, P3330, DOI 10.1073/pnas.0611326104; Benayoun BA, 2011, HUM MOL GENET, V20, P1673, DOI 10.1093/hmg/ddr042; Benayoun BA, 2010, BBA-REV CANCER, V1805, P1, DOI 10.1016/j.bbcan.2009.09.002; Benayoun BA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008789; Benayoun BA, 2009, HUM MOL GENET, V18, P632, DOI 10.1093/hmg/ddn389; Blount AL, 2009, J BIOL CHEM, V284, P7631, DOI 10.1074/jbc.M806676200; Chen C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017238; Cocquet J, 2002, J MED GENET, V39, P916, DOI 10.1136/jmg.39.12.916; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; East N, 2005, J OBSTET GYNAECOL CA, V27, P363, DOI 10.1016/S1701-2163(16)30464-9; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Fleming NI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014389; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jamieson S, 2010, MODERN PATHOL, V23, P1477, DOI 10.1038/modpathol.2010.145; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kalfa N, 2007, FERTIL STERIL, V87, P896, DOI 10.1016/j.fertnstert.2006.11.016; Kalfa N, 2009, GENOME MED, V1, DOI 10.1186/gm81; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kim JH, 2011, ONCOGENE, V30, P1653, DOI 10.1038/onc.2010.541; Kim MS, 2010, J PATHOL, V221, P147, DOI 10.1002/path.2688; Kyronlahti A, 2010, ENDOCR-RELAT CANCER, V17, P709, DOI 10.1677/ERC-10-0041; Lee K, 2005, BIOCHEM BIOPH RES CO, V336, P876, DOI 10.1016/j.bbrc.2005.08.184; Moumne L, 2008, HUM MOL GENET, V17, P1010, DOI 10.1093/hmg/ddm373; Nagaraja AK, 2010, ENDOCRINOLOGY, V151, P4994, DOI 10.1210/en.2010-0428; Pangas SA, 2008, MOL CELL BIOL, V28, P248, DOI 10.1128/MCB.01404-07; Pectasides D, 2008, CANCER TREAT REV, V34, P1, DOI 10.1016/j.ctrv.2007.08.007; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Sambrook J., 2001, MOL CLONING LAB MANU; Schrader KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007988; Schumer ST, 2003, J CLIN ONCOL, V21, P1180, DOI 10.1200/JCO.2003.10.019; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uhlenhaut NH, 2009, CELL, V139, P1130, DOI 10.1016/j.cell.2009.11.021; Zhang H, 2000, MOL HUM REPROD, V6, P146, DOI 10.1093/molehr/6.2.146	40	41	42	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2739	2746		10.1038/onc.2012.298	http://dx.doi.org/10.1038/onc.2012.298			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22797072				2022-12-28	WOS:000319808000005
J	Gil-Henn, H; Patsialou, A; Wang, Y; Warren, MS; Condeelis, JS; Koleske, AJ				Gil-Henn, H.; Patsialou, A.; Wang, Y.; Warren, M. S.; Condeelis, J. S.; Koleske, A. J.			Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo	ONCOGENE			English	Article						breast cancer; metastasis; invasion; proliferation; Arg kinase	ABL-FAMILY KINASES; TYROSINE-KINASE; C-ABL; TUMOR SIZE; METASTASIS; CELLS; ARG; EXPRESSION; GENE; T(1/12)(Q25,P13)	Tumor progression is a complex, multistep process involving accumulation of genetic aberrations and alterations in gene expression patterns leading to uncontrolled cell division, invasion into surrounding tissue and finally dissemination and metastasis. We have previously shown that the Arg/Abl2 non-receptor tyrosine kinase acts downstream of the EGF receptor and Src tyrosine kinases to promote invadopodium function in breast cancer cells, thereby promoting their invasiveness. However, whether and how Arg contributes to tumor development and dissemination in vivo has never been investigated. Using a mouse xenograft model, we show that knocking down Arg in breast cancer cells leads to increased tumor cell proliferation and significantly enlarged tumor size. Despite having larger tumors, the Arg-knockdown (Arg KD) tumor-bearing mice exhibit significant reductions in tumor cell invasion, intravasation into blood vessels and spontaneous metastasis to lungs. Interestingly, we found that proliferationassociated genes in the Ras-MAPK (mitogen-activated protein kinase) pathway are upregulated in Arg KD breast cancer cells, as is Ras-MAPK signaling, while invasion-associated genes are significantly downregulated. These data suggest that Arg promotes tumor cell invasion and dissemination, while simultaneously inhibiting tumor growth. We propose that Arg acts as a switch in metastatic cancer cells that governs the decision to 'grow or go' (divide or invade).	[Gil-Henn, H.; Warren, M. S.; Koleske, A. J.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Patsialou, A.; Wang, Y.; Condeelis, J. S.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; [Condeelis, J. S.] Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY 10461 USA	Yale University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Condeelis, JS (corresponding author), Albert Einstein Coll Med, Dept Anat & Struct Biol, 1301 Morris Pk Ave, Bronx, NY 10461 USA.	john.condeelis@einstein.yu.edu; anthony.koleske@yale.edu			Breast Cancer Alliance [CA133346];  [CA100324]; NATIONAL CANCER INSTITUTE [R01CA133346, R01CA164468, P01CA100324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100411] Funding Source: NIH RePORTER	Breast Cancer Alliance; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank the Einstein Histotechnology and Comparative Pathology Facility for their excellent service, and Dr Rani Sellers for helpful advice and suggestions. This work was supported by PHS grant CA133346 and an Exceptional Project Award from the Breast Cancer Alliance (AJK) and CA100324 (JSC).	Advani AS, 2002, LEUKEMIA RES, V26, P713, DOI 10.1016/S0145-2126(01)00197-7; Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412; Backert S, 2008, TRENDS BIOCHEM SCI, V33, P80, DOI 10.1016/j.tibs.2007.10.006; Bradley WD, 2009, J CELL SCI, V122, P3441, DOI 10.1242/jcs.039859; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Chen WS, 1999, INT J CANCER, V83, P579, DOI 10.1002/(SICI)1097-0215(19991126)83:5<579::AID-IJC1>3.0.CO;2-R; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; Derkinderen P, 2005, J NEUROSCI, V25, P6584, DOI 10.1523/JNEUROSCI.1487-05.2005; Ganguly SS, 2012, ONCOGENE, V31, P1804, DOI 10.1038/onc.2011.361; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Iijima Y, 2000, BLOOD, V95, P2126; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Newsome TP, 2006, CELL MICROBIOL, V8, P233, DOI 10.1111/j.1462-5822.2005.00613.x; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Podtcheko A, 2003, J CLIN ENDOCR METAB, V88, P1889, DOI 10.1210/jc.2002-021230; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Sirvent A, 2008, BIOL CELL, V100, P617, DOI 10.1042/BC20080020; Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Wang WG, 2007, CANCER RES, V67, P3505, DOI 10.1158/0008-5472.CAN-06-3714; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802; Wo JY, 2011, J CLIN ONCOL, V29, P2619, DOI 10.1200/JCO.2010.29.5907; Wyckoff JB, 2000, CANCER RES, V60, P5401; Wyckoff JB, 2000, CANCER RES, V60, P2504	38	89	92	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2622	2630		10.1038/onc.2012.284	http://dx.doi.org/10.1038/onc.2012.284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22777352	Green Accepted			2022-12-28	WOS:000319806700003
J	Snow, JJ; Lee, MH; Verheyden, J; Kroll-Conner, PL; Kimble, J				Snow, J. J.; Lee, M-H; Verheyden, J.; Kroll-Conner, P. L.; Kimble, J.			C. elegans FOG-3/Tob can either promote or inhibit germline proliferation, depending on gene dosage and genetic context	ONCOGENE			English	Article						FOG-3; Tob/BTG; proliferation; tumor formation; germ cells; C. elegans	RNA-BINDING PROTEIN; MITOTIC REGION; EARLY EVENT; STEM-CELLS; TOB; PHOSPHORYLATION; EXPRESSION; FAMILY; FATE; BTG1	Vertebrate Tob/BTG proteins inhibit cell proliferation when overexpressed in tissue-culture cells, and they can function as tumor suppressors in mice. The single Caenorhabditis elegans Tob/BTG ortholog, FOG-3, by contrast, was identified from its loss-of-function phenotype as a regulator of sperm fate specification. Here we report that FOG-3 also regulates proliferation in the germline tissue. We first demonstrate that FOG-3 is a positive regulator of germline proliferation. Thus, fog-3 null mutants possess fewer germ cells than normal, a modest but reproducible decrease observed for each of two distinct fog-3 null alleles. A similar decrease also occurred in fog-3/+ heterozygotes, again for both fog-3 alleles, revealing a haplo-insufficient effect on proliferation. Therefore, FOG-3 normally promotes proliferation, and two copies of the fog-3 gene are required for this function. We next overexpressed FOG-3 by removal of FBF, the collective term for FBF-1 and FBF-2, two nearly identical PUF RNA-binding proteins. We find that overexpressed FOG-3 blocks proliferation in fbf-1 fbf-2 mutants; whereas germ cells stop dividing and instead differentiate in fbf-1 fbf-2 double mutants, they continue to proliferate in fog-3; fbf-1 fbf-2 triple mutants. Therefore, like its vertebrate Tob/BTG cousins, overexpressed FOG-3 is 'antiproliferative'. Indeed, some fog-3; fbf-1 fbf-2 mutants possess small tumors, suggesting that FOG-3 can act as a tumor suppressor. Finally, we show that FOG-3 and FBF work together to promote tumor formation in animals carrying oncogenic Notch mutations. A similar effect was not observed when germline tumors were induced by manipulation of other regulators; therefore, this FOG-3 tumor-promoting effect is context dependent. We conclude that FOG-3 can either promote or inhibit proliferation in a manner that is sensitive to both genetic context and gene dosage. The discovery of these FOG-3 effects on proliferation has implications for our understanding of vertebrate Tob/BTG proteins and their influence on normal development and tumorigenesis.	[Snow, J. J.; Kimble, J.] Univ Wisconsin, Program Cellular & Mol Biol, Madison, WI 53706 USA; [Lee, M-H; Kroll-Conner, P. L.; Kimble, J.] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; [Verheyden, J.; Kimble, J.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kimble, J (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	jekimble@wisc.edu		Lee, Myon Hee/0000-0001-9020-2391	NIH [5T32GM007215, R01GM069454, 5F32GM095036]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM095036, R01GM069454, T32GM007215] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Japanese consortium for generation of fog-3(tm4376) and the CGC for strains. We also thank members of the Kimble lab for helpful discussions, Laura Vanderploeg for help with figures and Anne Helsley for help preparing the manuscript. JJS was supported by NIH Training Grant 5T32GM007215 in Molecular Biosciences. JK is supported by NIH R01GM069454. JV is supported by NIH 5F32GM095036. JK is an investigator of the Howard Hughes Medical Institute.	Albrecht M, 2004, FEBS LETT, V569, P18, DOI 10.1016/j.febslet.2004.03.126; BARTON MK, 1987, GENETICS, V115, P107; Berry LW, 1997, DEVELOPMENT, V124, P925; BRENNER S, 1974, GENETICS, V77, P71; Busson M, 2005, ONCOGENE, V24, P1698, DOI 10.1038/sj.onc.1208373; Byrd DT, 2009, SEMIN CELL DEV BIOL, V20, P1107, DOI 10.1016/j.semcdb.2009.09.005; Chen PJ, 2000, DEV BIOL, V217, P77, DOI 10.1006/dbio.1999.9521; Cinquin O, 2010, P NATL ACAD SCI USA, V107, P2048, DOI 10.1073/pnas.0912704107; Crittenden SL, 2006, MOL BIOL CELL, V17, P3051, DOI 10.1091/mbc.E06-03-0170; Crittenden SL, 2002, NATURE, V417, P660, DOI 10.1038/nature754; el-Ghissassi F, 2002, ONCOGENE, V21, P6772, DOI 10.1038/sj.onc.1205888; ELLIS RE, 1995, GENETICS, V139, P561; Farioli-Vecchioli S, 2007, FASEB J, V21, P2215, DOI 10.1096/fj.06-7548com; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Ito Y, 2005, CANCER LETT, V220, P237, DOI 10.1016/j.canlet.2004.08.017; Iwanaga K, 2003, CANCER LETT, V202, P71, DOI 10.1016/j.canlet.2003.08.019; Jia SJ, 2007, DEV DYNAM, V236, P913, DOI 10.1002/dvdy.21092; Kadyk LC, 1998, DEVELOPMENT, V125, P1803; Kawakubo H, 2006, CANCER RES, V66, P7075, DOI 10.1158/0008-5472.CAN-06-0379; Kawamura-Tsuzuku J, 2004, ONCOGENE, V23, P6630, DOI 10.1038/sj.onc.1207890; Kershner AM, 2010, P NATL ACAD SCI USA, V107, P3936, DOI 10.1073/pnas.1000495107; Kimble J, 2007, ANNU REV CELL DEV BI, V23, P405, DOI 10.1146/annurev.cellbio.23.090506.123326; Lamont LB, 2004, DEV CELL, V7, P697, DOI 10.1016/j.devcel.2004.09.013; Lamont LB, 2007, DEV DYNAM, V236, P871, DOI 10.1002/dvdy.21081; Lee MH, 2011, P NATL ACAD SCI USA, V108, P9125, DOI 10.1073/pnas.1106027108; Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042; Mauxion F, 2009, TRENDS BIOCHEM SCI, V34, P640, DOI 10.1016/j.tibs.2009.07.008; Podbilewicz B., 2006, WORMBOOK; Rodier A, 2001, ONCOGENE, V20, P2691, DOI 10.1038/sj.onc.1204398; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Thompson BE, 2006, P NATL ACAD SCI USA, V103, P620, DOI 10.1073/pnas.0510264103; Thompson BE, 2005, DEVELOPMENT, V132, P3471, DOI 10.1242/dev.01921; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919; Yanagie H, 2009, BIOMED PHARMACOTHER, V63, P275, DOI 10.1016/j.biopha.2008.04.010; Yoneda M, 2009, CANCER SCI, V100, P225, DOI 10.1111/j.1349-7006.2008.01030.x; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003; Zhang BL, 1997, NATURE, V390, P477, DOI 10.1038/37297	41	10	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2614	2621		10.1038/onc.2012.291	http://dx.doi.org/10.1038/onc.2012.291			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22797076	Green Accepted			2022-12-28	WOS:000319806700002
J	Ward, TM; Iorns, E; Liu, X; Hoe, N; Kim, P; Singh, S; Dean, S; Jegg, AM; Gallas, M; Rodriguez, C; Lippman, M; Landgraf, R; Pegram, MD				Ward, T. M.; Iorns, E.; Liu, X.; Hoe, N.; Kim, P.; Singh, S.; Dean, S.; Jegg, A-M; Gallas, M.; Rodriguez, C.; Lippman, M.; Landgraf, R.; Pegram, M. D.			Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5	ONCOGENE			English	Article						ERBB2; truncated; p95; p110; breast cancer; STAT5	HUMAN-BREAST-CANCER; EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODY; TERMINAL FRAGMENTS; SIGNAL TRANSDUCER; TUMOR-CELLS; HER2; RECEPTOR; TRASTUZUMAB; EXPRESSION	Truncated-ERBB2 isoforms (t-ERBB2s), resulting from receptor proteolysis or alternative translation of the ERBB2 mRNA, exist in a subset of human breast tumors. t-ERBB2s lack the receptor extracellular domain targeted by therapeutic anti-ERBB2 antibodies and antibody-drug conjugates, including trastuzumab, trastuzumab-DM1 and pertuzumab. In clinical studies, expression of t-ERBB2 in breast tumors correlates with metastasis as well as trastuzumab resistance. By using a novel immuno-microarray method, we detect a significant t-ERBB2 fraction in 18 of 31 (58%) of immunohistochemistry (IHC)3+ ERBB2+ human tumor specimens, and further show that t-ERBB2 isoforms are phosphorylated in a subset of IHC3+ samples (10 of 31, 32%). We investigated t-ERBB2 biological activity via engineered expression of full-length and truncated ERBB2 isoforms in human mammary epithelial cells (HMECs), including HMEC and MCF10A cells. Expression of p110 t-ERBB2, but not p95m (m = membrane, also 648CTF) or intracellular ERBB2s, significantly enhanced cell migration and invasion in multiple cell types. In addition, only expression of the p110 isoform led to human breast epithelial cell (HMLE) xenograft formation in vivo. Expression of t-ERBB2s did not result in hyperactivation of the phosphoinositide kinase-3/AKT or mitogen-activated protein kinase signaling pathways in these cells; rather, phosphoproteomic array profiling revealed attenuation of phosphorylated signal transducer and activator of transcription 5 (STAT5) in p110-t-ERBB2-expressing cells compared to controls. Short hairpin-mediated silencing of STAT5 phenocopied p110-t-ERBB2-driven cell migration and invasion, while expression of constitutively active STAT5 reversed these effects. Thus, we provide novel evidence that (1) expression of p110 t-ERBB2 is sufficient for full transformation of HMEC, yielding in vivo xenograft formation, and (2) truncated p110 t-ERBB2 expression is associated with decreased phosphorylation of STAT5.	[Ward, T. M.; Jegg, A-M; Gallas, M.; Rodriguez, C.; Pegram, M. D.] Univ Miami, Miller Sch Med, Dept Hematol & Oncol, Miami, FL 33136 USA; [Iorns, E.; Dean, S.; Lippman, M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Liu, X.; Hoe, N.; Kim, P.; Singh, S.] Prometheus Labs, San Diego, CA USA; [Landgraf, R.] Univ Miami, Miller Sch Med, Dept Biochem, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Pegram, MD (corresponding author), Univ Miami, Miller Sch Med, Dept Hematol & Oncol, 1501 North West 10th Ave, Miami, FL 33136 USA.	mpegram@stanford.edu			Young Investigator Award from the Expedition-Inspiration Breast Cancer Research Fund; National Cancer Institute [T32CA119929]; NATIONAL CANCER INSTITUTE [T32CA119929] Funding Source: NIH RePORTER	Young Investigator Award from the Expedition-Inspiration Breast Cancer Research Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Young Investigator Award from the Expedition-Inspiration Breast Cancer Research Fund, and by award T32CA119929 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institute of Health.	Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Arribas J, 2010, CLIN CANCER RES, V16, P4071, DOI 10.1158/1078-0432.CCR-10-1501; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Christianson TA, 1998, CANCER RES, V58, P5123; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Dillon MF, 2008, ENDOCR-RELAT CANCER, V15, P745, DOI 10.1677/ERC-08-0009; Egeblad M, 2001, INT J CANCER, V94, P185, DOI 10.1002/ijc.1459; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Garcia-Castillo J, 2009, J BIOL CHEM, V284, P25302, DOI 10.1074/jbc.M109.001982; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Hatanaka Y, 2001, PATHOL INT, V51, P33, DOI 10.1046/j.1440-1827.2001.01162.x; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Kim P, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-75; KLAPPER MH, 1963, J BIOL CHEM, V238, P3736; Liu PCC, 2006, CANCER BIOL THER, V5, P657, DOI 10.4161/cbt.5.6.2708; Liu PK, 2009, ASCO ANN M ORL FL; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mass R, 2000, SEMIN ONCOL, V27, P46; Molina MA, 2002, CLIN CANCER RES, V8, P347; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P759, DOI 10.1093/jnci/djh133; PUPA SM, 1993, ONCOGENE, V8, P2917; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Saez R, 2006, CLIN CANCER RES, V12, P424, DOI 10.1158/1078-0432.CCR-05-1807; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2010, CLIN CANCER RES, V16, P2688, DOI 10.1158/1078-0432.CCR-09-3407; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sperinde J, 2010, CLIN CANCER RES, V16, P4226, DOI 10.1158/1078-0432.CCR-10-0410; Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Yuan CX, 2003, PROTEIN EXPRES PURIF, V29, P217, DOI 10.1016/S1046-5928(03)00058-5	42	27	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2463	2474		10.1038/onc.2012.256	http://dx.doi.org/10.1038/onc.2012.256			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751112	Green Published, hybrid			2022-12-28	WOS:000318694900010
J	Wendt, MK; Schiemann, BJ; Parvani, JG; Lee, YH; Kang, Y; Schiemann, WP				Wendt, M. K.; Schiemann, B. J.; Parvani, J. G.; Lee, Y-H; Kang, Y.; Schiemann, W. P.			TGF-beta stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer	ONCOGENE			English	Article						EMT; FAK; metastasis; Pyk2; signal transduction; TGF-beta	FOCAL ADHESION KINASE; GROWTH-FACTOR-BETA; PROTEIN-TYROSINE KINASE; CELL-PROLIFERATION; SIGNALING EVENTS; BONE METASTASIS; UP-REGULATION; SRC; FAK; INHIBITION	Epithelial-mesenchymal transition (EMT) programs are essential in promoting breast cancer invasion, systemic dissemination and in arousing proliferative programs in breast cancer micrometastases, a reaction that is partially dependent on focal adhesion kinase (FAK). Many functions of FAK are shared by its homolog, protein tyrosine kinase 2 (Pyk2), raising the question as to whether Pyk2 also participates in driving the metastatic outgrowth of disseminated breast cancer cells. In addressing this question, we observed Pyk2 expression to be (i) significantly upregulated in recurrent human breast cancers; (ii) differentially expressed across clonal isolates of human MDA-MB-231 breast cancer cells in a manner predictive for metastatic outgrowth, but not for invasiveness; and (iii) dramatically elevated in ex vivo cultures of breast cancer cells isolated from metastatic lesions as compared with cells that produced the primary tumor. We further show that metastatic human and murine breast cancer cells robustly upregulate their expression of Pyk2 during EMT programs stimulated by transforming growth factor-beta (TGF-beta). Genetic and pharmacological inhibition of Pyk2 demonstrated that the activity of this protein tyrosine kinase was dispensable for the ability of breast cancer cells to undergo invasion in response to TGF-beta, and to form orthotopic mammary tumors in mice. In stark contrast, Pyk2-deficiency prevented TGF-beta from stimulating the growth of breast cancer cells in 3D-organotypic cultures that recapitulated pulmonary microenvironments, as well as inhibited the metastatic outgrowth of disseminated breast cancer cells in the lungs of mice. Mechanistically, Pyk2 expression was inversely related to that of E-cadherin, such that elevated Pyk2 levels stabilized beta 1 integrin expression necessary to initiate the metastatic outgrowth of breast cancer cells. Thus, we have delineated novel functions for Pyk2 in mediating distinct elements of the EMT program and metastatic cascade regulated by TGF-beta, particularly the initiation of secondary tumor outgrowth by disseminated cells. Oncogene (2013) 32, 2005-2015; doi:10.1038/onc.2012.230; published online 18 June 2012	[Wendt, M. K.; Schiemann, B. J.; Parvani, J. G.; Lee, Y-H; Schiemann, W. P.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Case Western Reserve University; Princeton University	Schiemann, WP (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Wolstein Res Bldg,2103 Cornell Rd, Cleveland, OH 44106 USA.	william.schiemann@case.edu		Kang, Yibin/0000-0002-1626-6730; Wendt, Mike/0000-0002-3665-7413	National Institutes of Health [CA129359]; Susan G Komen for the Cure Foundation [BCTR0706967]; Department of Defense [BC084561]; Case Comprehensive Cancer Center [P30 CA043703]; American Cancer Society [PF-09-120-01]; NATIONAL CANCER INSTITUTE [R01CA129359, P30CA043703] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen for the Cure Foundation(Susan G. Komen Breast Cancer Foundation); Department of Defense(United States Department of Defense); Case Comprehensive Cancer Center; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Pfizer for generously providing the small molecule inhibitors against FAK and Pyk2. Members of the Schiemann Laboratory are thanked for critical reading of the manuscript. WPS was supported in part by grants from the National Institutes of Health (CA129359), the Susan G Komen for the Cure Foundation (BCTR0706967), the Department of Defense (BC084561), and pilot funding from the Case Comprehensive Cancer Center (P30 CA043703), while MKW was supported by a fellowship from the American Cancer Society (PF-09-120-01).	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Avsian-Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003-0227; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Behmoaram E, 2008, AM J PATHOL, V173, P1540, DOI 10.2353/ajpath.2008.080292; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Burdick AD, 2006, CARCINOGENESIS, V27, P2331, DOI 10.1093/carcin/bgl083; Carelli S, 2006, LUNG CANCER, V53, P263, DOI 10.1016/j.lungcan.2006.06.001; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dahl U, 1996, DEVELOPMENT, V122, P2895; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fan HP, 2011, J BIOL CHEM, V286, P18573, DOI 10.1074/jbc.M110.200717; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Galliher Amy J, 2006, Future Oncol, V2, P743, DOI 10.2217/14796694.2.6.743; Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524; Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851; Galliher-Beckley AJ, 2008, CARCINOGENESIS, V29, P244, DOI 10.1093/carcin/bgm245; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; ILLC D, 1995, NATURE, V377, P539; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kim SJ, 2004, J KOREAN MED SCI, V19, P710, DOI 10.3346/jkms.2004.19.5.710; Korpal M, 2009, NAT MED; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lightfoot HM, 2004, BREAST CANCER RES TR, V88, P109, DOI 10.1007/s10549-004-1022-8; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Lim ST, 2010, J BIOL CHEM, V285, P1743, DOI 10.1074/jbc.M109.064212; Lipinski CA, 2010, EXPERT OPIN THER TAR, V14, P95, DOI 10.1517/14728220903473194; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359; Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Parvani JG, 2011, J MAMMARY GLAND BIOL, V16, P127, DOI 10.1007/s10911-011-9207-3; Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008-5472.CAN-07-5155; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Sun CK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018878; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1; Ungefroren H, 2011, CURR CANCER DRUG TAR, V11, P524, DOI 10.2174/156800911795538075; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Weis SM, 2008, J CELL BIOL, V181, P43, DOI 10.1083/jcb.200710038; Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377; Wendt MK, 2011, JOVE-J VIS EXP, DOI 10.3791/3245; Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306; Wendt MK, 2009, J BIOL CHEM, V284, P34145, DOI 10.1074/jbc.M109.023614; Wendt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2360; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	58	51	54	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2005	2015		10.1038/onc.2012.230	http://dx.doi.org/10.1038/onc.2012.230			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22710711	Green Accepted			2022-12-28	WOS:000317919900002
J	Thuault, S; Hayashi, S; Lagirand-Cantaloube, J; Plutoni, C; Comunale, F; Delattre, O; Relaix, F; Gauthier-Rouviere, C				Thuault, S.; Hayashi, S.; Lagirand-Cantaloube, J.; Plutoni, C.; Comunale, F.; Delattre, O.; Relaix, F.; Gauthier-Rouviere, C.			P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness	ONCOGENE			English	Article						P-cadherin; rhabdomyosarcoma; PAX3-FOXO1A; invasion; cadherin switch	TRANSCRIPTIONAL ACTIVATOR; SKELETAL MYOGENESIS; CELL-MIGRATION; GENE FUSIONS; PAX GENES; EXPRESSION; PAX3-FKHR; IDENTIFICATION; FAMILY; TRANSFORMATION	Alveolar rhabdomyosarcoma (ARMS) is an aggressive childhood cancer of striated muscle characterized by the presence of the PAX3-FOXO1A or PAX7-FOXO1A chimeric oncogenic transcription factor. Identification of their targets is essential for understanding ARMS pathogenesis. To this aim, we analyzed transcriptomic data from rhabdomyosarcoma samples and found that P-cadherin expression is correlated with PAX3/7-FOXO1A presence. We then show that expression of a PAX3 dominant negative variant inhibits P-cadherin expression in ARMS cells. Using mouse models carrying modified Pax3 alleles, we demonstrate that P-cadherin is expressed in the dermomyotome and lies genetically downstream from the myogenic factor Pax3. Moreover, in vitro gel shift analysis and chromatin immunoprecipitation indicate that the P-cadherin gene is a direct transcriptional target for PAX3/7-FOXO1A. Finally, P-cadherin expression in normal myoblasts inhibits myogenesis and induces myoblast transformation, migration and invasion. Conversely, P-cadherin downregulation by small hairpin RNA decreases the transformation, migration and invasive potential of ARMS cells. P-cadherin also favors cadherin switching, which is a hallmark of metastatic progression, by controlling N- and M-cadherin expression and/or localization. Our findings demonstrate that P-cadherin is a direct PAX3-FOXO1A transcriptional target involved in ARMS aggressiveness. Therefore, P-cadherin emerges as a new and attractive target for therapeutic intervention in ARMS. Oncogene (2013) 32, 1876-1887; doi:10.1038/onc.2012.217; published online 18 June 2012	[Thuault, S.; Lagirand-Cantaloube, J.; Plutoni, C.; Comunale, F.; Gauthier-Rouviere, C.] Univ Montpellier 2, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France; [Thuault, S.; Lagirand-Cantaloube, J.; Plutoni, C.; Comunale, F.; Gauthier-Rouviere, C.] Univ Montpellier I, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France; [Hayashi, S.; Relaix, F.] INSERM UPMC AIM, UMRS787, Paris, France; [Delattre, O.] Inst Curie, INSERM Unite 830, Unite Genet Somat, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Gauthier-Rouviere, C (corresponding author), Univ Montpellier 2, CRBM, CNRS, UMR 5237, 1919 Route Mende, F-34293 Montpellier, France.	cecile.gauthier@crbm.cnrs.fr		GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; THUAULT, Sylvie/0000-0003-0133-3803; Hayashi, Shinichiro/0000-0001-5553-7698; Comunale, Franck/0000-0001-8838-2151; Relaix, Frederic/0000-0003-1270-1472; delattre, olivier/0000-0002-8730-2276	"Cartes d'Identite des Tumeurs" program of the Ligue Nationale contre le Cancer; Ligue Nationale contre le Cancer (LNCC) ("Equipe labellisee"); Institut National du Cancer (INCa); INSERM; INCa; Association pour la Recherche contre le Cancer (ARC); INSERM Avenir Program; Association Francaise Contre les Myopathies; LNCC; ARC; Fondation pour la Recherche Medicale; European Union, project ENDOSTEM [241440]	"Cartes d'Identite des Tumeurs" program of the Ligue Nationale contre le Cancer; Ligue Nationale contre le Cancer (LNCC) ("Equipe labellisee"); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); INCa(Institut National du Cancer (INCA) France); Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR)); INSERM Avenir Program(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association Francaise Contre les Myopathies(Association Francaise contre les Myopathies); LNCC; ARC(Australian Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); European Union, project ENDOSTEM	We thank Vincent Mouly for the LHCN-M2 myoblasts, Setsuo Hirohashi and Keith Johnson for the P-cadherin cDNA, Mickael Rudnicki for the pBRIT plasmid, Pete Zammit for the pMSCV-Pax3-En-IRES-eGFP plasmids. We thank the Montpellier Imaging Facility (http://www.mri.cnrs.fr/) and Lionel Larue, Sophie Charrasse and Stephane Bodin for discussion. This work was supported by the "Cartes d'Identite des Tumeurs" program (http://cit.ligue-cancer.net/) of the Ligue Nationale contre le Cancer, the Ligue Nationale contre le Cancer (LNCC) ("Equipe labellisee") and the Institut National du Cancer (INCa). CGR was supported by INSERM, ST by INCa and JLC by the Association pour la Recherche contre le Cancer (ARC). FR's team is supported by the INSERM Avenir Program, Association Francaise Contre les Myopathies, LNCC, ARC, Fondation pour la Recherche Medicale, INCa and from the European Union Seventh Framework Programme, project ENDOSTEM (number 241440).	Bach AS, 2010, MOL BIOL CELL, V21, P2412, DOI 10.1091/mbc.E09-12-1063; Bajard L, 2006, GENE DEV, V20, P2450, DOI 10.1101/gad.382806; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Ben-Yair R, 2005, DEVELOPMENT, V132, P689, DOI 10.1242/dev.01617; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Charrasse S, 2004, ONCOGENE, V23, P2420, DOI 10.1038/sj.onc.1207382; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Cheung LWT, 2010, ONCOGENE, V29, P2427, DOI 10.1038/onc.2009.523; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Collins CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004475; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Fortier M, 2008, CELL DEATH DIFFER, V15, P1221, DOI 10.1038/cdd.2008.34; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Grass B, 2009, HISTOPATHOLOGY, V54, P873, DOI 10.1111/j.1365-2559.2009.03303.x; Hayashi S, 2011, MOL BIOL EVOL, V28, P2787, DOI 10.1093/molbev/msr114; Imai K, 2008, CLIN CANCER RES, V14, P6487, DOI 10.1158/1078-0432.CCR-08-1086; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kjaer KW, 2005, J MED GENET, V42, P292, DOI 10.1136/jmg.2004.027821; Kucharczak J, 2008, CANCER RES, V68, P6559, DOI 10.1158/0008-5472.CAN-08-0196; Lae M, 2007, J PATHOL, V212, P143, DOI 10.1002/path.2170; Manceau M, 2008, GENE DEV, V22, P668, DOI 10.1101/gad.454408; McKinnell IW, 2008, NAT CELL BIOL, V10, P77, DOI 10.1038/ncb1671; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059; Park J, 2011, INVEST NEW DRUGS, V11, P9710; Puskulluoglu M, 2010, FOLIA HISTOCHEM CYTO, V48, P671, DOI 10.2478/v10042-010-0046-7; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tarnowski M, 2010, MOL CANCER RES, V8, P1, DOI 10.1158/1541-7786.MCR-09-0259; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Wiercinska E, 2011, BREAST CANCER RES TR, V128, P657, DOI 10.1007/s10549-010-1147-x; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Zhang CC, 2010, CLIN CANCER RES, V16, P5177, DOI 10.1158/1078-0432.CCR-10-1343	46	23	23	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1876	1887		10.1038/onc.2012.217	http://dx.doi.org/10.1038/onc.2012.217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22710718				2022-12-28	WOS:000317599900002
J	Bhandari, A; Gordon, W; Dizon, D; Hopkin, AS; Gordon, E; Yu, Z; Andersen, B				Bhandari, A.; Gordon, W.; Dizon, D.; Hopkin, A. S.; Gordon, E.; Yu, Z.; Andersen, B.			The Grainyhead transcription factor Grhl3/Get1 suppresses miR-21 expression and tumorigenesis in skin: modulation of the miR-21 target MSH2 by RNA-binding protein DND1	ONCOGENE			English	Article						mir-21; Grhl3; Dnd1; skin; tumorigenesis; MSH2	IN-VIVO; MESENCHYMAL TRANSITION; MICRORNA EXPRESSION; REPRESSORS ZEB1; CELL-MIGRATION; CANCER-CELLS; FAMILY; DIFFERENTIATION; MORPHOGENESIS; KERATINOCYTES	Epidermal differentiation and stratification, crucial for barrier formation, are regulated by a complex interplay of transcription factors, including the evolutionarily conserved Grainyhead-like 3 (Grhl3/Get1); Grhl3-deleted mice exhibit impaired epidermal differentiation and decreased expression of multiple differentiation genes. To test whether Grhl3 regulates epidermal genes indirectly by controlling the expression of specific microRNAs (miRs), we performed miR profiling and identified 11 miRs that are differentially regulated in Grhl3(-/-) skin, one of which is miR-21, previously shown to be upregulated in diseased skin, including in psoriasis and squamous cell skin cancer. We found that miR-21 is normally expressed in the post-mitotic suprabasal layers of the epidermis, overlapping with Grhl3. The miR-21 promoter is bound and repressed by Grhl3 indicating that these two factors are involved in a regulatory loop maintaining homeostasis in the epidermis. Although miR-21 overexpression in normal keratinocytes had mild effects on the expression of several known miR-21 targets, an enhanced downregulation of the miR-21 tumor-related targets, including MSH2, was observed in Ras-transformed keratinocytes. The increased sensitivity of transformed keratinocytes to miR-21's effects occurs in part through downregulation of the RNA-binding protein DND1 during the transformation process. Additionally, we observed increased tumorigenesis in mice subcutaneously injected with transformed keratinocytes lacking Grhl3. These findings indicate that decreased Grhl3 expression contributes to tumor progression and upregulation of the oncomir miR-21 in squamous cell carcinoma of the skin. Oncogene (2013) 32, 1497-1507; doi:10.1038/onc.2012.168; published online 21 May 2012	[Bhandari, A.; Gordon, W.; Dizon, D.; Hopkin, A. S.; Yu, Z.; Andersen, B.] Univ Calif Irvine, Dept Biol Chem, Dept Med, Irvine, CA 92697 USA; [Gordon, W.; Andersen, B.] Univ Calif Irvine, Ctr Complex Biol Syst, Irvine, CA 92697 USA; [Gordon, E.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; [Gordon, E.] Univ Calif Irvine, Inst Genom & Bioinformat, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Andersen, B (corresponding author), Univ Calif Irvine, Dept Biol Chem, Dept Med, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu	Dizon, Don Steven/I-3634-2019; Hopkin, Amelia Soto/AAT-2609-2021	Dizon, Don Steven/0000-0001-6541-9580; Yu, Zhengquan/0000-0001-8696-2013	NIH [AR44882, T32-HD60555]; Irving Weinstein Foundation; California Tobacco Related Disease Research Program [17DT-0192]; National Library of Medicine [LM07443]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD060555] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007443] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Irving Weinstein Foundation; California Tobacco Related Disease Research Program(University of California System); National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank Stuart Yuspa and Andrew Ryscavage for the gift of mouse papilloma and carcinoma sample and the Ras virus. We also thank Reuven Agami for HA-DND1 expression plasmid. This work was supported by grants from the NIH (AR44882) and the Irving Weinstein Foundation (to BA); the California Tobacco Related Disease Research Program (17DT-0192 to AB); the NIH training program in Systems Biology of Development (T32-HD60555 to WG); the National Library of Medicine training grant (LM07443 to EG).	Ahmed MI, 2011, J CELL SCI, V124, P3399, DOI 10.1242/jcs.086710; Andl T, 2006, CURR BIOL, V16, P1041, DOI 10.1016/j.cub.2006.04.005; Antonini D, 2010, J INVEST DERMATOL, V130, P1249, DOI 10.1038/jid.2009.438; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; Cottonham CL, 2010, J BIOL CHEM, V285, P35293, DOI 10.1074/jbc.M110.160069; Darido C, 2011, CANCER CELL, V20, P635, DOI 10.1016/j.ccr.2011.10.014; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dziunycz P, 2010, J INVEST DERMATOL, V130, P2686, DOI 10.1038/jid.2010.169; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hildebrand J, 2011, J INVEST DERMATOL, V131, P20, DOI 10.1038/jid.2010.268; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jiang RC, 2009, NEOPLASIA, V11, P964, DOI 10.1593/neo.09706; Joyce CE, 2011, HUM MOL GENET, V20, P4025, DOI 10.1093/hmg/ddr331; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kira M, 2002, J BIOL CHEM, V277, P12931, DOI 10.1074/jbc.M110795200; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Koster MI, 2007, ANNU REV CELL DEV BI, V23, P93, DOI 10.1146/annurev.cellbio.23.090506.123357; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Lin KK, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000573; Ma XD, 2011, P NATL ACAD SCI USA, V108, P10144, DOI 10.1073/pnas.1103735108; Meira LB, 2002, DNA REPAIR, V1, P929, DOI 10.1016/S1568-7864(02)00143-X; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108; Reitmair AH, 1996, CANCER RES, V56, P3842; Ribas J, 2010, CELL CYCLE, V9, P923, DOI 10.4161/cc.9.5.10930; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; SHEIBANI N, 1991, CANCER RES, V51, P5967; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2010, J INVEST DERMATOL, V130, P124, DOI 10.1038/jid.2009.294; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511; Ting Stephen B, 2005, Organogenesis, V2, P33; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Y, 2009, J CELL MOL MED, V13, P12, DOI 10.1111/j.1582-4934.2008.00510.x; Yang X, 2011, INT J BIOL SCI, V7, P685, DOI 10.7150/ijbs.7.685; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Yi R, 2009, P NATL ACAD SCI USA, V106, P498, DOI 10.1073/pnas.0810766105; Yu Y, 2010, MOL CANCER RES, V8, P1633, DOI 10.1158/1541-7786.MCR-10-0362; Yu ZQ, 2006, DEV BIOL, V299, P122, DOI 10.1016/j.ydbio.2006.07.015; Zhu R, 2011, BMC MOL BIOL, V12, DOI 10.1186/1471-2199-12-37; Zibert JR, 2010, J DERMATOL SCI, V58, P177, DOI 10.1016/j.jdermsci.2010.03.004	52	53	57	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1497	1507		10.1038/onc.2012.168	http://dx.doi.org/10.1038/onc.2012.168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22614019	Green Accepted			2022-12-28	WOS:000316456000003
J	Sakakibara, S; Espigol-Frigole, G; Gasperini, P; Uldrick, TS; Yarchoan, R; Tosato, G				Sakakibara, S.; Espigol-Frigole, G.; Gasperini, P.; Uldrick, T. S.; Yarchoan, R.; Tosato, G.			A20/TNFAIP3 inhibits NF-kappa B activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein	ONCOGENE			English	Article						KSHV; NF-kappa B; vFLIP/K13; endothelial cells; Kaposi's sarcoma; AIDS	ZINC-FINGER PROTEIN; DEPENDENT GENE-EXPRESSION; IKK-GAMMA; ENDOTHELIAL-CELLS; UBIQUITIN CHAINS; KINASE COMPLEX; A20 INTERACTS; KSHV VFLIP; ENZYME A20; RECEPTOR	Kaposi's sarcoma-associated herpesvirus (KSHV) K13/vFLIP (viral Flice-inhibitory protein) induces transcription of numerous genes through NF-kappa B activation, including pro-inflammatory cytokines, which contribute to the pathogenesis of Kaposi's sarcoma (KS). In this study, we report that KSHV vFLIP induces the expression of the NF-kappa B regulatory proteins A20, ABIN-1 and ABIN-3 (A20-binding NF-kappa B inhibitors) in primary human endothelial cells, and that KS spindle cells express A20 in KS tissue. In reporter assays, A20 strongly impaired vFLIP-induced NF-kappa B activation in 293T cells, but ABIN-1 and ABIN-3 did not. Mutational analysis established that the C-terminal domain (residues 427-790) is critical for A20 modulation of NF-kappa B, but the ubiquitin-editing OTU (ovarian tumor) domain is not. In functional assays, A20 inhibited vFLIP-induced expression of the chemokine IP-10, reduced vFLIP-induced cell proliferation and increased IKK1 protein levels. Thus, we demonstrate that A20 negatively regulates NF-kappa B activation directly induced by KSHV vFLIP. By attenuating excessive and prolonged vFLIP-induced NF-kappa B activation that could be harmful to KSHV-infected cells, A20 likely has an important role in the pathogenesis of KSHV-associated diseases, in which vFLIP is expressed. Oncogene (2013) 32, 1223-1232; doi:10.1038/onc.2012.145; published online 23 April 2012	[Sakakibara, S.; Espigol-Frigole, G.; Gasperini, P.; Tosato, G.] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Uldrick, T. S.; Yarchoan, R.] NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Espigol-Frigole, G (corresponding author), NCI, Cellular Oncol Lab, CCR, NIH, Bldg 37,Room 4134, Bethesda, MD 20892 USA.	GESPIGOL@clinic.ub.es		Gasperini, Paola/0000-0002-3016-9742; Tosato, Giovanna/0000-0003-1663-3227; Sakakibara, Shuhei/0000-0003-3157-5870	intramural research program in Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA; NATIONAL CANCER INSTITUTE [ZIASC010356, ZIABC010885] Funding Source: NIH RePORTER	intramural research program in Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank G Nolan (Stanford University), BK Weaver (Missouri State University), J-M Peloponese Jr, K-T Jeang (NIAID, NIH), DB Conze, JD Ashwell (NCI, NIH), AV Grishin (University of Southern California), A Leonardi (University of Naples, Italy), R Lin (Jewish General Hospital, Canada) for reagents; the patients who volunteered for this study; Dr MN Polizzotto (NCI, NIH), K Aleman and K Wyvill for patient care; the Confocal Microscopy Core Facility (Laboratory of Experimental Carcinogenesis, CCR, NCI) for providing LSM510 and the DNA Minicore Facility (Laboratory of Experimental Carcinogenesis, CCR, NCI) for DNA sequencing, and K Sakakibara (NCI, NIH) for her help in reporter assay. We also thank Drs D Lowy, O Salvucci, H Ohnuki and all members of Laboratory of Cellular Oncology Branch for their advice and help on this work. This study was supported by the intramural research program in Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD20892, USA.	Ambinder RF, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P885; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bagneris C, 2008, MOL CELL, V30, P620, DOI 10.1016/j.molcel.2008.04.029; Ballon G, 2011, J CLIN INVEST, V121, P1141, DOI 10.1172/JCI44417; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Daniel S, 2004, BLOOD, V104, P2376, DOI 10.1182/blood-2003-02-0635; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Giulino L, 2011, BLOOD, V117, P4852, DOI 10.1182/blood-2010-10-310995; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Guasparri I, 2006, EMBO REP, V7, P114, DOI 10.1038/sj.embor.7400580; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hacker Hans, 2006, Sci STKE, V2006, pre13, DOI 10.1126/stke.3572006re13; Hadian K, 2011, J BIOL CHEM, V286, P26107, DOI 10.1074/jbc.M111.233163; Harhaj EW, 2011, CELL RES, V21, P22, DOI 10.1038/cr.2010.166; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Lin RT, 2006, J BIOL CHEM, V281, P2095, DOI 10.1074/jbc.M510326200; Liu B, 2007, CELL, V129, P903, DOI 10.1016/j.cell.2007.03.056; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Matta H, 2007, J BIOL CHEM, V282, P24858, DOI 10.1074/jbc.M700118200; Matta H, 2011, J BIOL CHEM, V286, P21555, DOI 10.1074/jbc.M111.224048; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; Narazaki M, 2006, BLOOD, V107, P3892, DOI 10.1182/blood-2005-10-4113; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; O'Reilly SM, 2003, BIOCHEM BIOPH RES CO, V303, P586, DOI 10.1016/S0006-291X(03)00389-9; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Punj V, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-50; Rahighi S, 2009, CELL, V136, P1098, DOI 10.1016/j.cell.2009.03.007; Sakakibara S, 2011, J VIROL, V85, P3179, DOI 10.1128/JVI.02333-10; Sakakibara S, 2009, J VIROL, V83, P2140, DOI 10.1128/JVI.01871-08; Salvucci O, 2009, BLOOD, V114, P1707, DOI 10.1182/blood-2008-12-192294; Schulz TF, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P490; Shembade N, 2011, NAT IMMUNOL, V12, P834, DOI 10.1038/ni.2066; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Shembade N, 2009, EMBO J, V28, P513, DOI 10.1038/emboj.2008.285; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Stilo R, 2008, J CELL SCI, V121, P1165, DOI 10.1242/jcs.021105; Thurau M, 2009, J VIROL, V83, P598, DOI 10.1128/JVI.00629-08; Uldrick TS, 2010, CLIN INFECT DIS, V51, P350, DOI 10.1086/654798; Verstrepen L, 2010, BIOCHEM PHARMACOL, V80, P2009, DOI 10.1016/j.bcp.2010.06.044; Wagner S, 2008, ONCOGENE, V27, P3739, DOI 10.1038/sj.onc.1211042; Weaver BK, 2007, MOL CELL BIOL, V27, P4603, DOI 10.1128/MCB.00223-07; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wullaert A, 2007, J BIOL CHEM, V282, P81, DOI 10.1074/jbc.M607481200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yoshikawa A, 2009, FEBS LETT, V583, P3317, DOI 10.1016/j.febslet.2009.09.028; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	65	15	22	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1223	1232		10.1038/onc.2012.145	http://dx.doi.org/10.1038/onc.2012.145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22525270	Green Accepted			2022-12-28	WOS:000316454500003
J	Foskolou, IP; Stellas, D; Rozani, I; Lavigne, MD; Politis, PK				Foskolou, I. P.; Stellas, D.; Rozani, I.; Lavigne, M. D.; Politis, P. K.			Prox1 suppresses the proliferation of neuroblastoma cells via a dual action in p27-Kip1 and Cdc25A	ONCOGENE			English	Article						prospero; cyclinE1; G0/G1-arrest; cell cycle; SH-SY5Y; tet-on	HOMEOBOX TRANSCRIPTION FACTOR; NEURAL STEM-CELLS; SELF-RENEWAL; HUMAN CANCER; CYCLE EXIT; NEURONAL DIFFERENTIATION; SYMPATHETIC-GANGLIA; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; EXPRESSION	Neuroblastoma is a pediatric tumor that originates from precursor cells of the sympathetic nervous system with less than 40% long-term survival in children diagnosed with high-risk disease. These clinical observations underscore the need for novel insights in the mechanisms of malignant transformation and progression. Accordingly, it was recently reported that Prox1, a homeobox transcription regulator, is expressed in higher levels in human neuroblastonna with favorable prognosis. Consistently, we have recently shown that Prox1 exerts a strong antiproliferative effect on neural precursor cells during embryonic development. Thus, Prox1 is a candidate gene with a critical role in suppressing malignant neuroblastoma transformation. Here, we provide evidence that Prox1 strongly suppresses the proliferation of mouse and human neuroblastoma cell lines and blocks the growth of neuroblastoma tumors in SCID mice. Conversely, short hairpin RNA (shRNA) -mediated knockdown of basal Prox1 expression significantly induces proliferation, genomic instability and the ability of neuroblastoma cells to form tumors. Mechanistically, analysis of an inducible Prox1-overexpressing Neuro2A cell line indicates that Prox1 is sufficient to suppress CyclinD1, CyclinA and CyclinB1, consistent with a role in cell cycle arrest. Surprisingly, Prox1 strongly induces CyclinE1 expression in the same system despite its action on blocking cell cycle progression, which could account for the context dependent oncogenic function of Prox1. Most importantly, Prox1 was sufficient to decrease Cdc25A and induce p27-Kip1, but not p21-Cip1 or p53. By alleviating the Prox1 action in Cdc25A and p27-Kip1 expression, we were able to rescue its effect on cell cycle arrest. Together these data suggest that Prox1 negatively regulates neuroblastoma carcinogenesis through suppression of Cdc25A and induction of p27-Kip1 to counteract CyclinE1 overexpression and block cell cycle progression. Furthermore, these observations render Prox1 a candidate target for the treatment of neuroblastoma tumors. Oncogene (2013) 32, 947-960; doi:10.1038/onc.2012.129; published online 16 April 2012	[Foskolou, I. P.; Stellas, D.; Rozani, I.; Lavigne, M. D.; Politis, P. K.] Acad Athens, Biomed Res Fdn, Ctr Basic Res, Athens 11527, Greece	Academy of Athens	Politis, PK (corresponding author), Acad Athens, Biomed Res Fdn, Ctr Basic Res, 4 Soranou Efesiou, Athens 11527, Greece.	ppolitis@bioacademy.gr	Stellas, Dimitris/AAG-2473-2021; Stellas, Dimitris/AAP-8958-2021; Foskolou, Iosifina Petrina/AAY-4662-2021; Politis, Panagiotis/AAO-2423-2020; Foskolou, Iosifina/AAM-5164-2020	Stellas, Dimitris/0000-0002-7787-3921; Lavigne, Matthieu/0000-0003-1543-8745; Foskolou, Iosifina- Petrina/0000-0003-1874-6356; Politis, Panagiotis/0000-0002-2556-2857; Stellas, Dimitris/0000-0002-9587-6288				Airoldi I, 2004, BRIT J CANCER, V90, P2210, DOI 10.1038/sj.bjc.6601842; Akagami M, 2011, ANN SURG ONCOL, V18, P3868, DOI 10.1245/s10434-011-1683-6; Baxter SA, 2011, BBA-MOL CELL RES, V1813, P201, DOI 10.1016/j.bbamcr.2010.10.015; Becker J, 2010, PEDIATR RES, V68, P112, DOI 10.1203/00006450-201011001-00215; Bello B, 2006, DEVELOPMENT, V133, P2639, DOI 10.1242/dev.02429; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Chang HH, 2010, CLIN CANCER RES, V16, P4411, DOI 10.1158/1078-0432.CCR-09-3360; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Choksi SP, 2006, DEV CELL, V11, P775, DOI 10.1016/j.devcel.2006.09.015; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Colonques J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019342; Dudas J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-92; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Elkouris M, 2011, STEM CELLS, V29, P89, DOI 10.1002/stem.554; Georgopoulou N, 2006, J BIOL CHEM, V281, P33606, DOI 10.1074/jbc.M602689200; GRANA X, 1995, ONCOGENE, V11, P211; Griffiths RL, 2004, EMBO J, V23, P2440, DOI 10.1038/sj.emboj.7600258; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hope KJ, 2011, CURR OPIN HEMATOL, V18, P203, DOI 10.1097/MOH.0b013e328347888a; Hope KJ, 2010, CELL STEM CELL, V7, P101, DOI 10.1016/j.stem.2010.06.007; Itoh Y, 2007, J BIOL CHEM, V282, P390, DOI 10.1074/jbc.M609944200; Kaltezioti V, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000565; Kamiya A, 2008, HEPATOLOGY, V48, P252, DOI 10.1002/hep.22303; Kazenwadel J, 2010, BLOOD, V116, P2395, DOI 10.1182/blood-2009-12-256297; Laerm A, 2007, J HEPATOL, V46, P89, DOI 10.1016/j.jhep.2006.07.033; Lee CY, 2006, DEV CELL, V10, P441, DOI 10.1016/j.devcel.2006.01.017; Li L, 2000, GENE DEV, V14, P147; Liu SC, 2009, CANCER LETT, V286, P240, DOI 10.1016/j.canlet.2009.05.038; Liu TH, 2002, MECH DEVELOP, V112, P25, DOI 10.1016/S0925-4773(01)00626-8; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Nagai H, 2003, GENE CHROMOSOME CANC, V38, P13, DOI 10.1002/gcc.10248; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Pearson ADJ, 2008, LANCET ONCOL, V9, P247, DOI 10.1016/S1470-2045(08)70069-X; Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Politis PK, 2008, FEBS LETT, V582, P741, DOI 10.1016/j.febslet.2008.01.052; Politis PK, 2007, P NATL ACAD SCI USA, V104, P17861, DOI 10.1073/pnas.0610973104; Ribatti D, 2006, BRIT J CANCER, V94, P1845, DOI 10.1038/sj.bjc.6603186; Risebro CA, 2009, DEVELOPMENT, V136, P495, DOI 10.1242/dev.030007; Rodriguez-Niedenfuhr M, 2001, ANAT EMBRYOL, V204, P399, DOI 10.1007/s00429-001-0214-9; Rother K, 2007, ONCOGENE, V26, P1949, DOI 10.1038/sj.onc.1209989; Schneider M, 2006, INT J ONCOL, V28, P883; Schulte JH, 2010, NUCLEIC ACIDS RES, V38, P5919, DOI 10.1093/nar/gkq342; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimoda M, 2006, CLIN CANCER RES, V12, P6005, DOI 10.1158/1078-0432.CCR-06-0712; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Southall TD, 2009, EMBO J, V28, P3799, DOI 10.1038/emboj.2009.309; Stellas D, 2007, CLIN CANCER RES, V13, P1831, DOI 10.1158/1078-0432.CCR-06-1585; Takahashi M, 2006, NEOPLASIA, V8, P1003, DOI 10.1593/neo.06595; Timofeev O, 2010, J BIOL CHEM, V285, P16978, DOI 10.1074/jbc.M109.096552; Tsarovina K, 2008, MOL CELL NEUROSCI, V37, P20, DOI 10.1016/j.mcn.2007.08.010; Versmold B, 2007, INT J CANCER, V121, P547, DOI 10.1002/ijc.22705; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505	60	27	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					947	960		10.1038/onc.2012.129	http://dx.doi.org/10.1038/onc.2012.129			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22508481				2022-12-28	WOS:000316523200002
J	Trerotola, M; Cantanelli, P; Guerra, E; Tripaldi, R; Aloisi, AL; Bonasera, V; Lattanzio, R; de Lange, R; Weidle, UH; Piantelli, M; Alberti, S				Trerotola, M.; Cantanelli, P.; Guerra, E.; Tripaldi, R.; Aloisi, A. L.; Bonasera, V.; Lattanzio, R.; de Lange, R.; Weidle, U. H.; Piantelli, M.; Alberti, S.			Upregulation of Trop-2 quantitatively stimulates human cancer growth	ONCOGENE			English	Article						Trop-2; human tumours; cell growth; signalling; oncogene	CELL-SURFACE GLYCOPROTEIN; DNA METHYLATION PREVENTS; GENE-EXPRESSION; MAMMALIAN-CELLS; MONOCLONAL-ANTIBODIES; COLORECTAL-CANCER; HUMAN CARCINOMAS; TRANSGENIC MICE; FLOW-CYTOMETRY; BREAST-CANCER	Trop-2 is a calcium signal transducer that is associated with transformed cell growth in experimental systems. However, its role in human cancer remains essentially unknown. In this study, we profiled Trop-2 expression in normal human tissues at the mRNA and protein levels. We then systematically compared Trop-2 mRNA and protein levels in tumours with their tissues of origin. We find that Trop-2 expression is invariably upregulated in tumours, regardless of baseline expression in normal tissues, which suggests a corresponding selective advantage. Thus, we investigated the outcome of Trop-2 upregulation on tumour growth. Overexpression of wild-type Trop-2 was shown to be necessary and sufficient to drive cancer growth in a widely invariant manner across cell type and species. Upregulation of Trop-2 was shown to quantitatively stimulate tumour growth, as proportional to expression levels in vivo, and tumour cell growth was abrogated by somatic knockdown of Trop-2 expression. On the other hand, we found no evidence of tumour-associated TROP2 mutations, nor of TROP2 induction of oncogenic transformation per se. Our data support a model where above-baseline expression of wild-type Trop-2 is a key driver of human cancer growth. Oncogene (2013) 32, 222-233; doi:10.1038/onc.2012.36; published online 20 February 2012	[Trerotola, M.; Cantanelli, P.; Guerra, E.; Tripaldi, R.; Aloisi, A. L.; Bonasera, V.; Lattanzio, R.; Piantelli, M.; Alberti, S.] Fdn Univ G dAnnunzio, CeSI, Dept Oncol & Expt Med, Unit Canc Pathol, I-66100 Chieti, Italy; [de Lange, R.; Weidle, U. H.] Roche Diagnost GmbH, Pharma Res, Penzberg, Germany; [Alberti, S.] Univ G DAnnunzio, Dept Neurosci & Imaging, Chieti, Italy	G d'Annunzio University of Chieti-Pescara; Roche Holding; G d'Annunzio University of Chieti-Pescara	Alberti, S (corresponding author), Fdn Univ G dAnnunzio, CeSI, Dept Oncol & Expt Med, Unit Canc Pathol, Via Colle dell Ara, I-66100 Chieti, Italy.	s.alberti@unich.it	Trerotola, Marco/J-9015-2016; Lattanzio, Rossano/K-1927-2018; Alberti, Saverio/M-4511-2014	Trerotola, Marco/0000-0003-1855-7002; Lattanzio, Rossano/0000-0001-9803-4476; Alberti, Saverio/0000-0002-4647-6042; Piantelli, Mauro/0000-0003-0154-482X; Guerra, Emanuela/0000-0002-7091-8621	Fondazione of the Cassa di Risparmio della Provincia di Chieti; ABO Foundation [CH01D0081]; Fondazione compagnia di San Paolo; Italian Ministry of Health [RicOncol RF-EMR-2006-361866]; Italian Foundation for Cancer Research (FIRC, Italy); Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Fondazione of the Cassa di Risparmio della Provincia di Chieti; ABO Foundation; Fondazione compagnia di San Paolo(Compagnia di San Paolo); Italian Ministry of Health(Ministry of Health, Italy); Italian Foundation for Cancer Research (FIRC, Italy)(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We are grateful to Professor B Ponder and Dr S Martin for the generous supply of the genomic DNA of MEN-2A, pheochromocytoma and medullary thyroid carcinomas. We thank Dr A Mironov and GV Beznoussenko for help during the course of this work. This research was supported by the Fondazione of the Cassa di Risparmio della Provincia di Chieti, ABO Foundation (CH01D0081), Fondazione compagnia di San Paolo and Italian Ministry of Health (RicOncol RF-EMR-2006-361866). MT was a recipient of a scholarship from the Italian Foundation for Cancer Research (FIRC, Italy).	ALBERTI S, 1994, P NATL ACAD SCI USA, V91, P5833, DOI 10.1073/pnas.91.13.5833; ALBERTI S, 1988, P NATL ACAD SCI USA, V85, P8391, DOI 10.1073/pnas.85.22.8391; ALBERTI S, 1990, NUCLEIC ACIDS RES, V18, P351, DOI 10.1093/nar/18.2.351; ALBERTI S, 1987, CYTOMETRY, V8, P114, DOI 10.1002/cyto.990080203; ALBERTI S, 1991, J HISTOCHEM CYTOCHEM, V39, P701, DOI 10.1177/39.5.1901878; ALBERTI S, 1992, HYBRIDOMA, V11, P539, DOI 10.1089/hyb.1992.11.539; BASU A, 1995, INT J CANCER, V62, P472, DOI 10.1002/ijc.2910620419; Bignotti E, 2010, EUR J CANCER, V46, P944, DOI 10.1016/j.ejca.2009.12.019; Bonasera V, 2007, BIOTECHNIQUES, V43, P173, DOI 10.2144/000112500; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carletti E, 2006, TRENDS BIOTECHNOL, V24, P443, DOI 10.1016/j.tibtech.2006.07.006; Chalk AM, 2004, BIOCHEM BIOPH RES CO, V319, P264, DOI 10.1016/j.bbrc.2004.04.181; CORDONCARDO C, 1984, J HISTOCHEM CYTOCHEM, V32, P1035, DOI 10.1177/32.10.6384360; Cubas R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-253; Cubas R, 2009, BBA-REV CANCER, V1796, P309, DOI 10.1016/j.bbcan.2009.08.001; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; El Sewedy T, 1998, INT J CANCER, V75, P324, DOI 10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.3.CO;2-5; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ERBA E, 1989, BRIT J CANCER, V60, P45, DOI 10.1038/bjc.1989.217; Fang YJ, 2009, INT J COLORECTAL DIS, V24, P875, DOI 10.1007/s00384-009-0725-z; Fong D, 2008, BRIT J CANCER, V99, P1290, DOI 10.1038/sj.bjc.6604677; Fong D, 2008, MODERN PATHOL, V21, P186, DOI 10.1038/modpathol.3801001; FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; Goldstein AS, 2010, MOL ONCOL, V4, P385, DOI 10.1016/j.molonc.2010.06.009; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guerra E, 2008, CANCER RES, V68, P8113, DOI 10.1158/0008-5472.CAN-07-6135; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KLEIN CE, 1990, J INVEST DERMATOL, V95, P74, DOI 10.1111/1523-1747.ep12873988; KLEIN CE, 1987, J INVEST DERMATOL, V89, P500, DOI 10.1111/1523-1747.ep12460996; Lal A, 1999, CANCER RES, V59, P5403; LIPINSKI M, 1981, P NATL ACAD SCI-BIOL, V78, P5147, DOI 10.1073/pnas.78.8.5147; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Muhlmann G, 2009, J CLIN PATHOL, V62, P152, DOI 10.1136/jcp.2008.060590; Nakashima K, 2004, INT J CANCER, V112, P1029, DOI 10.1002/ijc.20517; NAQUET P, 1989, THYMUS, V13, P217; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Ohmachi T, 2006, CLIN CANCER RES, V12, P3057, DOI 10.1158/1078-0432.CCR-05-1961; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Polishchuk RS, 2000, J CELL BIOL, V148, P45, DOI 10.1083/jcb.148.1.45; Querzoli P, 2006, CLIN CANCER RES, V12, P6696, DOI 10.1158/1078-0432.CCR-06-0569; Ripani E, 1998, INT J CANCER, V76, P671; Rossi C, 2008, EUR J CANCER, V44, P2696, DOI 10.1016/j.ejca.2008.08.021; Shi LM, 2010, NAT BIOTECHNOL, V28, P827, DOI 10.1038/nbt.1665; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Sukhthankar M, 2010, ANTICANCER RES, V30, P2497; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Trerotola M, 2010, AM J TRANSL RES, V2, P135; Trerotola M, 2010, BBA-REV CANCER, V1805, P119, DOI 10.1016/j.bbcan.2009.12.002; Varughese J, 2011, CANCER-AM CANCER SOC, V117, P3163, DOI 10.1002/cncr.25891; Wang JB, 2008, MOL CANCER THER, V7, P280, DOI 10.1158/1535-7163.MCT-07-2003; Wang JB, 2011, MOL CANCER RES, V9, P1686, DOI 10.1158/1541-7786.MCR-11-0241; Wolter S, 2002, J BIOL CHEM, V277, P3576, DOI 10.1074/jbc.M105800200; Zanna P, 2007, CANCER-AM CANCER SOC, V110, P452, DOI 10.1002/cncr.22785; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	59	144	158	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					222	233		10.1038/onc.2012.36	http://dx.doi.org/10.1038/onc.2012.36			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349828				2022-12-28	WOS:000314075500010
J	Clendening, JW; Penn, LZ				Clendening, J. W.; Penn, L. Z.			Targeting tumor cell metabolism with statins	ONCOGENE			English	Review						mevalonate; HMGCR; statins; metabolism; transformation; cancer	COA REDUCTASE INHIBITORS; LOVASTATIN-INDUCED APOPTOSIS; POTENTIATES ANTITUMOR-ACTIVITY; BREAST-CANCER RECURRENCE; CORONARY-ARTERY-DISEASE; HUMAN ENDOTHELIAL-CELLS; COENZYME-A REDUCTASE; HIGH-DOSE LOVASTATIN; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; MEVALONATE PATHWAY	The mevalonate pathway is a core biochemical process, crucial for the generation of cholesterol and other key metabolic end products. The rate-limiting enzyme of the mevalonate pathway, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is safely and effectively targeted by the statin family of inhibitors to treat hypercholesterolemia. The anticancer activity of statins has also been widely reported, yet the tumor-selective mechanisms that mediate these antiproliferative effects remain largely unclear. The importance of altered metabolism in the context of tumorigenesis has received renewed attention as metabolic changes entwined with the molecular hallmarks of cancer have been elucidated. Although several metabolic pathways have been linked to cancer progression and etiology, it was only recently that HMGCR and the mevalonate pathway were also shown to have a distinct role in cellular transformation. In this review, we chart the historical progression of statins from cholesterol-lowering blockbusters to anticancer agents with imminent potential, and further discuss an emerging role for HMGCR and the mevalonate pathway in the metabolic reprogramming of cancer. Oncogene (2012) 31, 4967-4978; doi:10.1038/onc.2012.6; published online 6 February 2012	[Penn, L. Z.] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	lpenn@uhnres.utoronto.ca		Penn, Linda/0000-0001-8133-5459	Canada Research Chairs Program; Ontario Institute for Cancer Research through Province of Ontario; Canadian Breast Cancer Foundation, Ontario Region; Canadian Institutes for Health Research; Ontario Ministry of Health and Long Term Care	Canada Research Chairs Program(Canada Research Chairs); Ontario Institute for Cancer Research through Province of Ontario; Canadian Breast Cancer Foundation, Ontario Region; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario)	We gratefully thank members of the Penn lab for helpful discussions and critical review of the manuscript. Financial support: This work was undertaken, in part, thanks to funding from the Canada Research Chairs Program (L.Z.P), the Ontario Institute for Cancer Research through funding provided by the Province of Ontario (L.Z.P.), the Canadian Breast Cancer Foundation, Ontario Region (L.Z.P.), the Excellence In Radiation Research for the 21st Century Strategic Training Initiative In Health Research from the Canadian Institutes for Health Research (J.W.C.), and the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the Ontario Ministry of Health and Long Term Care.	Abud-Mendoza C, 2003, LUPUS, V12, P607, DOI 10.1191/0961203303lu429oa; Ahern TP, 2011, JNCI-J NATL CANCER I, V103, P1461, DOI 10.1093/jnci/djr291; Ahn KS, 2008, BIOCHEM PHARMACOL, V75, P907, DOI 10.1016/j.bcp.2007.10.010; ALBERTS AW, 1989, CARDIOVASC DRUG REV, V7, P89, DOI 10.1111/j.1527-3466.1989.tb00519.x; Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Banker DE, 2004, BLOOD, V104, P1816, DOI 10.1182/blood-2004-01-0395; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Bischoff H, 1997, ATHEROSCLEROSIS, V135, P119, DOI 10.1016/S0021-9150(97)00188-3; BISCHOFF KM, 1992, BIOCHEM MED METAB B, V48, P149, DOI 10.1016/0885-4505(92)90060-C; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; Bonovas S, 2005, J CLIN ONCOL, V23, P8606, DOI 10.1200/JCO.2005.02.7045; Boudreau DM, 2007, CANCER EPIDEM BIOMAR, V16, P416, DOI 10.1158/1055-9965.EPI-06-0737; Boudreau DM, 2010, EXPERT OPIN DRUG SAF, V9, P603, DOI 10.1517/14740331003662620; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 2009, J LIPID RES, V50, pS15; BUCHWALD H, 1992, LANCET, V339, P1154, DOI 10.1016/0140-6736(92)90744-N; Burbelo P, 2004, BREAST CANCER RES TR, V84, P43, DOI 10.1023/B:BREA.0000018422.02237.f9; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Cao ZW, 2011, CANCER RES, V71, P2286, DOI 10.1158/0008-5472.CAN-10-3367; Cauley JA, 2006, J NATL CANCER I, V98, P700, DOI 10.1093/jnci/djj188; Celis JE, 2006, MOL CELL PROTEOMICS, V5, P462, DOI 10.1074/mcp.M500348-MCP200; Cernuda-Morollon E, 2006, CIRC RES, V98, P757, DOI 10.1161/01.RES.0000210579.35304.d3; Chan KKW, 2003, CLIN CANCER RES, V9, P10; CHAO FC, 1975, CANCER, V35, P1223, DOI 10.1002/1097-0142(197504)35:4<1223::AID-CNCR2820350429>3.0.CO;2-T; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clendening JW, 2010, P NATL ACAD SCI USA, V107, P15051, DOI 10.1073/pnas.0910258107; Clendening JW, 2010, BLOOD, V115, P4787, DOI 10.1182/blood-2009-07-230508; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; Cox G, 2001, ANTICANCER RES, V21, P4207; CUTTS JL, 1989, J CELL PHYSIOL, V139, P550, DOI 10.1002/jcp.1041390314; Dale KM, 2006, JAMA-J AM MED ASSOC, V295, P74, DOI 10.1001/jama.295.1.74; Davidson MH, 2001, DRUGS, V61, P197, DOI 10.2165/00003495-200161020-00005; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dimitroulakos J, 1999, BLOOD, V93, P1308, DOI 10.1182/blood.V93.4.1308.404k08_1308_1318; Dimitroulakos J, 2001, CLIN CANCER RES, V7, P158; Dimitroulakos J, 1996, NAT MED, V2, P326, DOI 10.1038/nm0396-326; Dirks AJ, 2006, AM J PHYSIOL-CELL PH, V291, pC1208, DOI 10.1152/ajpcell.00226.2006; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Duncan Robin E., 2004, Journal of Pharmacological and Toxicological Methods, V50, P139, DOI 10.1016/j.vascn.2004.03.001; El-Serag HB, 2009, GASTROENTEROLOGY, V136, P1601, DOI 10.1053/j.gastro.2009.01.053; ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9; ENDO A, 1992, J LIPID RES, V33, P1569; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Feleszko W, 2000, CLIN CANCER RES, V6, P2044; Feleszko W, 2002, INT J CANCER, V100, P111, DOI 10.1002/ijc.10440; Fildes JE, 2009, CANCER IMMUNOL IMMUN, V58, P461, DOI 10.1007/s00262-008-0541-2; Forrester JS, 2007, AM J CARDIOL, V99, P732, DOI 10.1016/j.amjcard.2006.09.125; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fritz G, 2003, INT J RADIAT BIOL, V79, P601, DOI 10.1080/09553000310001609233; Fritz G, 2009, CURR CANCER DRUG TAR, V9, P626, DOI 10.2174/156800909789057033; Fritz G, 2011, BRIT MED BULL, V97, P17, DOI 10.1093/bmb/ldq044; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Garwood ER, 2010, BREAST CANCER RES TR, V119, P137, DOI 10.1007/s10549-009-0507-x; Gauthaman K, 2007, REPROD BIOMED ONLINE, V15, P566, DOI 10.1016/S1472-6483(10)60390-2; Goard CA, 2010, INT J CANCER, V127, P2936, DOI 10.1002/ijc.25295; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027; Graf H, 2008, DIGESTION, V78, P34, DOI 10.1159/000156702; GrayBablin J, 1997, CANCER RES, V57, P604; Gronich N, 2004, J INVEST MED, V52, P335, DOI 10.1136/jim-52-05-34; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; Guan Jing-Zhi, 2004, J Atheroscler Thromb, V11, P56; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haria M, 1997, DRUGS, V53, P299, DOI 10.2165/00003495-199753020-00008; Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022; Holstein SA, 2006, CANCER CHEMOTH PHARM, V57, P155, DOI 10.1007/s00280-005-0013-8; Hu J, 2011, ANN ONCOL; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; Jakobisiak M, 2010, MED RES REV, V30, P102, DOI 10.1002/med.20162; Janardhan S, 2006, CURR MED CHEM, V13, P1169, DOI 10.2174/092986706776360923; JONES KD, 1994, BIOCHEM BIOPH RES CO, V205, P1681, DOI 10.1006/bbrc.1994.2861; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Kajinami K, 2000, EXPERT OPIN INV DRUG, V9, P2653, DOI 10.1517/13543784.9.11.2653; Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; KANEKO I, 1978, EUR J BIOCHEM, V87, P313; KANNEL WB, 1995, CIRCULATION, V92, P3350, DOI 10.1161/01.CIR.92.11.3350; Katz MS, 2005, INT J RADIAT ONCOL, V62, P1363, DOI 10.1016/j.ijrobp.2004.12.033; Katz MS, 2005, NAT CLIN PRACT ONCOL, V2, P82, DOI 10.1038/ncponc0097; Kawata S, 2001, BRIT J CANCER, V84, P886, DOI 10.1054/bjoc.2000.1716; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kikuchi H, 2009, CANCER RES, V69, P8499, DOI 10.1158/0008-5472.CAN-09-2213; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kim WS, 2001, INVEST NEW DRUG, V19, P81, DOI 10.1023/A:1006481423298; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Knox JJ, 2005, EUR J CANCER, V41, P523, DOI 10.1016/j.ejca.2004.12.013; Kok DEG, 2011, PROSTATE CANCER P D, V14, P340, DOI 10.1038/pcan.2011.30; Konings IRHM, 2010, EUR J CANCER, V46, P3200, DOI 10.1016/j.ejca.2010.07.036; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Kornblau SM, 2007, BLOOD, V109, P2999, DOI 10.1182/blood-2006-08-044446; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kuhajda FP, 2008, INT J OBESITY, V32, pS36, DOI 10.1038/ijo.2008.121; Kumar AS, 2008, CANCER EPIDEM BIOMAR, V17, P1028, DOI 10.1158/1055-9965.EPI-07-0726; Kuoppala J, 2008, EUR J CANCER, V44, P2122, DOI 10.1016/j.ejca.2008.06.025; Kwan ML, 2008, BREAST CANCER RES TR, V109, P573, DOI 10.1007/s10549-007-9683-8; Lamperti C, 2005, ARCH NEUROL-CHICAGO, V62, P1709, DOI 10.1001/archneur.62.11.1709; Landsberger M, 2007, ATHEROSCLEROSIS, V190, P43, DOI 10.1016/j.atherosclerosis.2006.02.009; Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010; Larsson O, 1996, CRIT REV ONCOL HEMAT, V22, P197, DOI 10.1016/1040-8428(96)00193-X; Lee J, 2009, CANCER CHEMOTH PHARM, V64, P657, DOI 10.1007/s00280-008-0913-5; Leoni V, 2002, NEUROSCI LETT, V331, P163, DOI 10.1016/S0304-3940(02)00887-X; Lersch C, 2004, HEPATO-GASTROENTEROL, V51, P1099; Li HY, 2003, BLOOD, V101, P3628, DOI 10.1182/blood-2002-07-2283; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Locatelli S, 2002, ARCH NEUROL-CHICAGO, V59, P213, DOI 10.1001/archneur.59.2.213; Lopez-Aguilar E, 1999, ARCH MED RES, V30, P128, DOI 10.1016/S0188-0128(98)00018-9; Lopez-Aguilar E, 2008, ARCH MED RES, V39, P655, DOI 10.1016/j.arcmed.2008.05.008; Lucken-Ardjomande S, 2008, CELL DEATH DIFFER, V15, P484, DOI 10.1038/sj.cdd.4402280; Lupattelli G, 2004, METABOLISM, V53, P744, DOI 10.1016/j.metabol.2004.01.010; Macaulay RJB, 1999, J NEURO-ONCOL, V42, P1, DOI 10.1023/A:1006164406202; Malinowski JM, 1998, AM J HEALTH-SYST PH, V55, P2253, DOI 10.1093/ajhp/55.21.2253; Martirosyan A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-103; Mason RP, 2005, AM J CARDIOL, V96, p11F, DOI 10.1016/j.amjcard.2005.06.008; Mathew B, 2011, AM J RESP CELL MOL, V44, P415, DOI 10.1165/rcmb.2010-0122OC; McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0; McTaggart F, 2001, AM J CARDIOL, V87, p28B; Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Migita T, 2009, JNCI-J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030; Minden MD, 2001, LEUKEMIA LYMPHOMA, V40, P659, DOI 10.3109/10428190109097663; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Mo HB, 2004, EXP BIOL MED, V229, P567, DOI 10.1177/153537020422900701; Moorman PG, 2007, EPIDEMIOLOGY, V18, P194, DOI 10.1097/01.ede.0000254699.31405.e2; Morgan MA, 2005, BRIT J HAEMATOL, V130, P912, DOI 10.1111/j.1365-2141.2005.05696.x; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Muller C, 1998, INT J ONCOL, V12, P717; Nabatov AA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000470; Newman A, 1997, LEUKEMIA LYMPHOMA, V24, P533, DOI 10.3109/10428199709055590; NEWMAN A, 1994, LEUKEMIA, V8, P2022; NIH Consensus Development Conference, 1985, WIS MED J, V84, P18; Nubel T, 2006, CLIN CANCER RES, V12, P933, DOI 10.1158/1078-0432.CCR-05-1903; OLIVER MF, 1994, LANCET, V344, P633; Ostrau C, 2009, RADIOTHER ONCOL, V92, P492, DOI 10.1016/j.radonc.2009.06.020; Otsuki T, 2004, ONCOL REP, V11, P1053; Pallottini V, 2008, J CELL BIOCHEM, V104, P701, DOI 10.1002/jcb.21757; Pan James G, 2007, Sci STKE, V2007, ppe14; Pedersen TR, 1996, ARCH INTERN MED, V156, P2085, DOI 10.1001/archinte.156.18.2085; PEDERSEN TR, 1994, LANCET, V344, P1383; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; PLOSKER GL, 1995, DRUGS, V50, P334, DOI 10.2165/00003495-199550020-00009; Plosker GL, 1996, DRUGS, V51, P433, DOI 10.2165/00003495-199651030-00011; Pocathikorn A, 2010, CLIN EXP PHARMACOL P, V37, P471, DOI 10.1111/j.1440-1681.2009.05337.x; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Ray KK, 2005, J AM COLL CARDIOL, V46, P1425, DOI 10.1016/j.jacc.2005.05.086; Rubins JB, 1998, AM J RESP CRIT CARE, V157, P1616, DOI 10.1164/ajrccm.157.5.9709020; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; Samson KTR, 2005, CELL IMMUNOL, V235, P136, DOI 10.1016/j.cellimm.2005.08.028; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sassano A, 2008, CANCER LETT, V260, P11, DOI 10.1016/j.canlet.2007.11.036; Schmidmaier R, 2007, EUR J HAEMATOL, V79, P240, DOI 10.1111/j.1600-0609.2007.00902.x; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shitara Y, 2006, PHARMACOL THERAPEUT, V112, P71, DOI 10.1016/j.pharmthera.2006.03.003; Siperstein M D, 1970, Trans Am Clin Climatol Assoc, V81, P107; Sondergaard TE, 2009, HEMATOL ONCOL, V27, P17, DOI 10.1002/hon.869; Stanislaus R, 2002, NEUROSCI LETT, V333, P167, DOI 10.1016/S0304-3940(02)00943-6; Steinberg D, 1999, JAMA-J AM MED ASSOC, V282, P2043, DOI 10.1001/jama.282.21.2043; Stirewalt DL, 2003, LEUKEMIA RES, V27, P133, DOI 10.1016/S0145-2126(02)00085-1; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tan N, 2011, J UROLOGY, V186, P86, DOI 10.1016/j.juro.2011.03.004; Tanaka T, 2007, INT IMMUNOL, V19, P163, DOI 10.1093/intimm/dxl133; Taylor ML, 2008, EUR J CANCER PREV, V17, P259, DOI 10.1097/CEJ.0b013e3282b721fe; Thibault A, 1996, CLIN CANCER RES, V2, P483; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; TSUJITA Y, 1979, ATHEROSCLEROSIS, V32, P307, DOI 10.1016/0021-9150(79)90174-6; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; van de Donk NWCJ, 2002, LEUKEMIA, V16, P1362, DOI 10.1038/sj.leu.2402501; van der Spek E, 2007, HAEMATOLOGICA, V92, pE130, DOI 10.3324/haematol.12071; van der Spek E, 2006, HAEMATOLOGICA, V91, P542; Veillard NR, 2006, ATHEROSCLEROSIS, V188, P51, DOI 10.1016/j.atherosclerosis.2005.10.015; Wachtershauser A, 2001, CARCINOGENESIS, V22, P1061, DOI 10.1093/carcin/22.7.1061; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211; Wang WG, 2002, FEBS LETT, V531, P415, DOI 10.1016/S0014-5793(02)03575-5; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; Weng TC, 2010, J CLIN PHARM THER, V35, P139, DOI 10.1111/j.1365-2710.2009.01085.x; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Woditschka S, 2010, CANCER EPIDEM BIOMAR, V19, P2479, DOI 10.1158/1055-9965.EPI-10-0524; Wong WWL, 2007, MOL CANCER THER, V6, P1886, DOI 10.1158/1535-7163.MCT-06-0745; Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476; Wong WWL, 2001, CLIN CANCER RES, V7, P2067; YAMAMOTO A, 1980, ATHEROSCLEROSIS, V35, P259, DOI 10.1016/0021-9150(80)90124-0; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhou Z, 2006, AM HEART J, V151, P273, DOI 10.1016/j.ahj.2005.04.003	207	159	164	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					4967	4978		10.1038/onc.2012.6	http://dx.doi.org/10.1038/onc.2012.6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22310279				2022-12-28	WOS:000311888600001
J	Bhattacharya, S; HuangFu, WC; Dong, G; Qian, J; Baker, DP; Karar, J; Koumenis, C; Diehl, JA; Fuchs, SY				Bhattacharya, S.; HuangFu, W-C; Dong, G.; Qian, J.; Baker, D. P.; Karar, J.; Koumenis, C.; Diehl, J. A.; Fuchs, S. Y.			Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses	ONCOGENE			English	Article						interferon; tumor microenvironment; integrated stress response; PERK; GCN2; IFNAR1	I-INTERFERON; PROTEIN-KINASE; DOWN-REGULATION; IFNAR1 CHAIN; ALPHA; HYPOXIA; PERK; PHOSPHORYLATION; DEGRADATION; CELLS	Viral and pharmacological inducers of protein kinase RNA-activated (PKR)-like ER kinase (PERK) were shown to accelerate the phosphorylation-dependent degradation of the IFNAR1 chain of the Type 1 interferon (IFN) receptor and to limit cell sensitivity to IFN. Here we report that hypoxia can elicit these effects in a PERK-dependent manner. The altered fate of IFNAR1 affected by signaling downstream of PERK depends on phosphorylation of eIF2 alpha (eukaryotic translational initiation factor 2-alpha) and ensuing activation of p38 alpha kinase. Activators of other eIF2 alpha kinases such as PKR or GCN2 (general control nonrepressed-2) are also capable of eliminating IFNAR1 and blunting IFN responses. Modulation of constitutive PKR activity in human breast cancer cells stabilizes IFNAR1 and sensitizes these cells to IFNAR1-dependent anti-tumorigenic effects. Although downregulation of IFNAR1 and impaired IFNAR1 signaling can be elicited in response to amino-acid deficit, the knockdown of GCN2 in melanoma cells reverses these phenotypes. We propose that, in cancer cells and the tumor microenvironment, activation of diverse eIF2 alpha kinases followed by IFNAR1 downregulation enables multiple cellular components of tumor tissue to evade the direct and indirect anti-tumorigenic effects of Type 1 IFN.	[Bhattacharya, S.; HuangFu, W-C; Dong, G.; Qian, J.; Fuchs, S. Y.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Bhattacharya, S.; HuangFu, W-C; Dong, G.; Qian, J.; Fuchs, S. Y.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; [Baker, D. P.] Biogen Idec Inc, Cambridge, MA USA; [Karar, J.; Koumenis, C.] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; [Diehl, J. A.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Biogen; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 380 S Univ Ave,Hill 316, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu	Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726	'Training in Tumor Virology' Grant [2-T32-CA-557726-06]; NIH [CA92900, CA142425, CA94214, CA104838]; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA092900, R01CA142425, R01CA094214, P01CA104838] Funding Source: NIH RePORTER	'Training in Tumor Virology' Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Herlyn, R Kaufman, A Koromilas, A Nebreda, D Ron and Z Ronai for reagents, Dr Yong Zhang for technical help, and the members of Fuchs, Diehl and Koumenis labs for discussion. The support to SB from the 'Training in Tumor Virology' Grant 2-T32-CA-557726-06 is greatly appreciated. This work was supported by the NIH Grants CA92900 and CA142425 (to SYF), CA94214 (to CK), CA104838 (to JAD) and by a grant with the Pennsylvania Department of Health (to JAD, CK, and SYF). The Department specifically disclaims responsibility for any analyses, interpretation or conclusions.	Bhattacharya S, 2011, BLOOD, V118, P4179, DOI 10.1182/blood-2010-12-325373; Bhattacharya S, 2011, J BIOL CHEM, V286, P22069, DOI 10.1074/jbc.M111.238766; Bhattacharya S, 2010, J BIOL CHEM, V285, P2318, DOI 10.1074/jbc.M109.071498; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Blalock WL, 2010, J CELL PHYSIOL, V223, P572, DOI 10.1002/jcp.22092; Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153; Bobrovnikova-Marjon E, 2012, MOL CELL BIOL, V32, P2268, DOI 10.1128/MCB.00063-12; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; Brassard DL, 2002, J LEUKOCYTE BIOL, V71, P565; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; Diehl JA, 2011, GASTROENTEROLOGY, V141, P38, DOI 10.1053/j.gastro.2011.05.018; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Eggermont AMM, 2001, EUR J CANCER, V37, P2147, DOI 10.1016/S0959-8049(01)00272-6; Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967; Fidler IJ, 2002, DIFFERENTIATION, V70, P498, DOI 10.1046/j.1432-0436.2002.700904.x; Folkman J, 1992, Semin Cancer Biol, V3, P89; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Hamanaka RB, 2009, ONCOGENE, V28, P910, DOI 10.1038/onc.2008.428; HuangFu WC, 2012, ONCOGENE, V31, P161, DOI 10.1038/onc.2011.221; Huangfu Wei-Chun, 2010, Genes Cancer, V1, P725, DOI 10.1177/1947601910382901; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar KGS, 2003, EMBO J, V22, P5480; Li YZ, 2004, ARCH IMMUNOL THER EX, V52, P156; Liu J, 2008, BIOCHEM BIOPH RES CO, V367, P388, DOI 10.1016/j.bbrc.2007.12.137; Liu JH, 2009, MOL CELL BIOL, V29, P6401, DOI 10.1128/MCB.00478-09; Liu JH, 2009, CELL HOST MICROBE, V5, P72, DOI 10.1016/j.chom.2008.11.008; Liu Y, 2010, NEOPLASIA, V12, P61, DOI 10.1593/neo.91354; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Noman MZ, 2011, CRIT REV IMMUNOL, V31, P357, DOI 10.1615/CritRevImmunol.v31.i5.10; Nussbaum JM, 2003, CANCER LETT, V196, P207, DOI 10.1016/S0304-3835(03)00276-3; Parmar Simrit, 2003, Current Opinion in Oncology, V15, P431, DOI 10.1097/00001622-200311000-00005; PFEFFER LM, 1980, J CELL BIOL, V85, P9, DOI 10.1083/jcb.85.1.9; Pindel A, 2011, J INTERF CYTOK RES, V31, P59, DOI 10.1089/jir.2010.0099; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Qian J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002065; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Tang WG, 2005, CANCER RES, V65, P1904, DOI 10.1158/0008-5472.CAN-04-2597; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Ye JB, 2009, CURR MOL MED, V9, P411, DOI 10.2174/156652409788167096; Zheng H, 2011, BLOOD, V118, P4003, DOI 10.1182/blood-2011-06-359745; Zheng H, 2011, MOL CELL BIOL, V31, P710, DOI 10.1128/MCB.01154-10	49	51	51	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4214	4221		10.1038/onc.2012.439	http://dx.doi.org/10.1038/onc.2012.439			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045272	Green Accepted			2022-12-28	WOS:000324168000003
J	Kerr, BA; McCabe, NP; Feng, W; Byzova, TV				Kerr, B. A.; McCabe, N. P.; Feng, W.; Byzova, T. V.			Platelets govern pre-metastatic tumor communication to bone	ONCOGENE			English	Article						platelet; bone metastasis; bone remodeling; tumor	ENDOTHELIAL GROWTH-FACTOR; PROSTATE-CANCER GROWTH; CELL-PROLIFERATION; RICH PLASMA; FACTOR-BETA; ANGIOGENESIS; MICROENVIRONMENT; DIFFERENTIATION; ACTIVATION; EXPRESSION	Although the survival rate for early detected cancers is high, once a cancer metastasizes to bone, it is incurable. Interestingly, patients without visible metastases display abnormal bone formation and resorption, suggesting a link between primary cancers and the bone microenvironment prior to metastasis, and this link likely facilitates preparation of the pre-metastatic niche. We hypothesized that communication with the primary tumor would result in bone remodeling alterations, and that platelets could facilitate this communication. By using three tumor models, we demonstrate that primary tumor growth stimulates bone formation measured by microcomputed tomography. Further, platelet depletion prevented tumor-induced bone formation, highlighting the importance of platelets in the communication between tumors and the bone microenvironment. Finally, we determine that platelets sequester a variety of tumor-derived proteins, TGF-beta 1 and MMP-1 in particular, which regulate bone formation. Thus, our data reveal that platelets function as mediators of tumor-bone communication prior to metastasis.	[Kerr, B. A.; McCabe, N. P.; Feng, W.; Byzova, T. V.] Cleveland Clin, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA; [Feng, W.] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Xian 710049, Shaanxi, Peoples R China; [Byzova, T. V.] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Xi'an Jiaotong University; Cleveland Clinic Foundation	Byzova, TV (corresponding author), Cleveland Clin, Taussig Canc Ctr, Dept Mol Cardiol, 9500 Euclid Ave,NB-50, Cleveland, OH 44195 USA.	byzovat@ccf.org	Kerr, Bethany/D-1644-2012	Kerr, Bethany/0000-0002-2995-7549; Byzova, Tatiana/0000-0002-2615-875X	NIAMS Core Cente [1P30 AR050953]; Ruth L Kirschstein NRSA award from the NIH/NCI [F32 CA142133]; Ruth L Kirstein NRSA award [F32 CA117262]; NIH/NCI [CA126847]; NATIONAL CANCER INSTITUTE [F32CA142133, R01CA126847] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL073311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050953] Funding Source: NIH RePORTER	NIAMS Core Cente; Ruth L Kirschstein NRSA award from the NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L Kirstein NRSA award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Miroslava Tischenko, Steven Maximuk and Richard Rozic for their technical assistance. Dr Amit Vasanji developed the software and techniques for the microCT analysis. Cleveland Clinic Biomedical Imaging and Analysis Core Center was funded, in part by NIAMS Core Center, grant no. 1P30 AR050953. BAK was supported by a Ruth L Kirschstein NRSA award (F32 CA142133) from the NIH/NCI. NPM was supported by a Ruth L Kirstein NRSA award (F32 CA117262). This study was supported by research funding from the NIH/NCI (grant no. CA126847) to TVB.	*AM CANC SOC, 2008, MEL SKIN CANC; American Cancer Society, 2008, PROSTATE CANC; Baselga J, 2008, BIOMARKERS, V13, P217, DOI [10.1080/13547500701676019, 10.1080/13547500701676019 ]; Blouin S, 2008, BRIT J CANCER, V98, P809, DOI 10.1038/sj.bjc.6604238; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Borsig L, 2008, EXPERT REV ANTICANC, V8, P1247, DOI 10.1586/14737140.8.8.1247; Coleman RE, 2008, CLIN CANCER RES, V14, P6387, DOI 10.1158/1078-0432.CCR-08-1572; Edlund M, 2004, J CELL BIOCHEM, V91, P686, DOI 10.1002/jcb.10702; Feng WY, 2011, BLOOD, V117, P3893, DOI 10.1182/blood-2010-08-304808; Feng WY, 2008, J CELL BIOL, V183, P1145, DOI 10.1083/jcb.200802179; GASIC GJ, 1968, P NATL ACAD SCI USA, V61, P46, DOI 10.1073/pnas.61.1.46; Gomes RR, 2009, CLIN EXP METASTAS, V26, P641, DOI 10.1007/s10585-009-9263-x; Gruber R, 2002, BONE, V30, P726, DOI 10.1016/S8756-3282(02)00697-X; Haeusler G, 2005, CALCIFIED TISSUE INT, V76, P326, DOI 10.1007/s00223-004-0161-6; Italiano JE, 2008, BLOOD, V111, P1227, DOI 10.1182/blood-2007-09-113837; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KARPATKIN S, 1988, J CLIN INVEST, V81, P1012, DOI 10.1172/JCI113411; Kawasumi M, 2008, J BONE JOINT SURG BR, V90B, P966, DOI 10.1302/0301-620X.90B7.20235; Kerr BA, 2012, COMPUT TOMOGR, P211; Kerr BA, 2010, NEOPLASIA, V12, P388, DOI 10.1593/neo.10166; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Klement GL, 2009, BLOOD, V113, P2835, DOI 10.1182/blood-2008-06-159541; McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429; McCabe NP, 2008, CLIN EXP METASTAS, V25, P581, DOI 10.1007/s10585-008-9175-1; McCabe NP, 2011, NEOPLASIA, V13, P31, DOI 10.1593/neo.10998; Mishra A, 2009, TISSUE ENG PART C-ME, V15, P431, DOI 10.1089/ten.tec.2008.0534; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nair MB, 2009, TISSUE ENG PT A, V15, P1619, DOI 10.1089/ten.tea.2008.0229; Oprea WE, 2003, J CRANIOFAC SURG, V14, P292, DOI 10.1097/00001665-200305000-00006; Reinholz GG, 2000, CANCER RES, V60, P6001; Rhee JS, 2004, THROMB HAEMOSTASIS, V92, P394, DOI 10.1160/TH03-04-0213; Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140; Saadeh PB, 1999, AM J PHYSIOL-CELL PH, V277, pC628, DOI 10.1152/ajpcell.1999.277.4.C628; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Shariat SF, 2001, J CLIN ONCOL, V19, P2856, DOI 10.1200/JCO.2001.19.11.2856; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016; Stellos K, 2007, THROMB HAEMOSTASIS, V98, P922, DOI 10.1160/TH07-02-0147; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; Uggeri J, 2007, J PERIODONTOL, V78, P1985, DOI 10.1902/jop.2007.070116; Zelzer E, 2002, DEVELOPMENT, V129, P1893	42	55	57	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4319	4324		10.1038/onc.2012.447	http://dx.doi.org/10.1038/onc.2012.447			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23069656	Green Accepted			2022-12-28	WOS:000324168000014
J	van Jaarsveld, MTM; Helleman, J; Boersma, AWM; van Kuijk, PF; van IJcken, WF; Despierre, E; Vergote, I; Mathijssen, RHJ; Berns, EMJJ; Verweij, J; Pothof, J; Wiemer, EAC				van Jaarsveld, M. T. M.; Helleman, J.; Boersma, A. W. M.; van Kuijk, P. F.; van IJcken, W. F.; Despierre, E.; Vergote, I.; Mathijssen, R. H. J.; Berns, E. M. J. J.; Verweij, J.; Pothof, J.; Wiemer, E. A. C.			miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells	ONCOGENE			English	Article						cisplatin; drug resistance; KEAP1; miR-141; ovarian cancer	MICRORNA EXPRESSION PROFILES; MIR-200 FAMILY; MESENCHYMAL TRANSITION; PLATINUM RESISTANCE; CONFERS RESISTANCE; CLINICAL-TRIALS; REPRESSORS ZEB1; DOWN-REGULATION; TRANSCRIPTION; ACTIVATION	Epithelial ovarian cancer is the most lethal gynecological malignancy in the Western world. A major impediment for the successful treatment is the development of drug resistance. The molecular processes that contribute to resistance have been extensively studied; however, there is not much known about regulation by microRNAs (miRNAs). We compared miRNA expression profiles of an isogenic cisplatin-sensitive and -resistant ovarian cancer cell line pair (A2780/A2780 DDP) and found 27 miRNAs to be differentially expressed (>= 2-fold). Five of these, including the family members miR-141/200c, showed a correlation with cisplatin sensitivity in the NCI-60 panel. Overexpression of miR-141 resulted in enhanced resistance to cisplatin in ovarian cancer cell lines. We next correlated the expression level of miR-141 in 132 primary ovarian tumors (108 serous and 24 non-serous) with response to platinum-based chemotherapy. Although no differences were observed in the serous tumors, miR-141 levels were higher in non-serous ovarian tumors that did not respond well to therapy (platinum-free interval <6 months). We demonstrate that miR-141 directly targets KEAP1, and that downregulation of KEAP1 induces cisplatin resistance. Conversely, overexpression of KEAP1 significantly enhanced cisplatin sensitivity. Expression of KEAP1 with its 3'-UTR, and a 3'-UTR in which the miR-141 target site has been mutated, revealed that miR-141 regulates KEAP1 upon exposure to cisplatin. Finally, we show that the NF-kappa B pathway, which can be regulated by KEAP1, is activated upon miR-141 overexpression, and that inhibition of this pathway partially reverses miR-141-mediated cisplatin resistance. These findings demonstrate that the miR-141-mediated regulation of KEAP1 has a crucial role in the cellular response to cisplatin.	[van Jaarsveld, M. T. M.; Helleman, J.; Boersma, A. W. M.; van Kuijk, P. F.; Mathijssen, R. H. J.; Berns, E. M. J. J.; Verweij, J.; Wiemer, E. A. C.] Erasmus Univ, Daniel den Hoed Canc Ctr, Med Ctr, Dept Med Oncol, NL-3015 GE Rotterdam, Netherlands; [van IJcken, W. F.] Erasmus MC, Erasmus Ctr Biom, Rotterdam, Netherlands; [Despierre, E.; Vergote, I.] Univ Hosp Leuven, Dept Obstet & Gynecol, European Union, Louvain, Belgium; [Despierre, E.; Vergote, I.] Univ Hosp Leuven, Leuven Canc Inst, Div Gynecol Oncol, European Union, Louvain, Belgium; [Pothof, J.] Erasmus MC, Dept Genet, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Erasmus University Rotterdam; Erasmus MC	Wiemer, EAC (corresponding author), Erasmus Univ, Daniel den Hoed Canc Ctr, Med Ctr, Dept Med Oncol, Room Be422,Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	e.wiemer@erasmusmc.nl	van ijcken, willem/N-9805-2018	van ijcken, willem/0000-0002-0421-8301; Wiemer, Erik/0000-0002-0673-7236	Dutch Cancer Society EMCR [2007-3794]	Dutch Cancer Society EMCR	We thank Dr Kevin Scanlon (Keck Graduate Institute of Applied Life Sciences, Claremont, USA) for the kind gift of the cisplatin-sensitive/resistant A2780 cell line pair. We thank Mariel Brok and Kirsten Ruigrok-Ritstier for technical assistance, Andrea Sacchetti for FACS-sorting KEAP1-transfected cells and Herman Burger for critical comments on the manuscript. This project is supported by a grant from the Dutch Cancer Society EMCR 2007-3794.	Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Blower PE, 2007, MOL CANCER THER, V6, P1483, DOI 10.1158/1535-7163.MCT-07-0009; Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007; Burger H, 2011, DRUG RESIST UPDATE, V14, P22, DOI 10.1016/j.drup.2010.12.002; Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234; CARMICHAEL J, 1987, CANCER RES, V47, P936; Cochrane DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/821717; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Devling TWP, 2005, P NATL ACAD SCI USA, V102, P7280, DOI 10.1073/pnas.0501475102; Eades G, 2011, J BIOL CHEM, V286, P40725, DOI 10.1074/jbc.M111.275495; Eberle KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021496; Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014; Friedlander M, 2011, INT J GYNECOL CANCER, V21, P771, DOI 10.1097/IGC.0b013e31821bb8aa; Gallagher MF, 2009, J OVARIAN RES, V2, DOI 10.1186/1757-2215-2-19; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Giudice A, 2010, METHODS MOL BIOL, V647, P37, DOI 10.1007/978-1-60761-738-9_3; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Imanaka Y, 2011, J HUM GENET, V56, P270, DOI 10.1038/jhg.2011.1; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Kim JE, 2010, CELL SIGNAL, V22, P1645, DOI 10.1016/j.cellsig.2010.06.004; Kong FF, 2011, J HUAZHONG U SCI-MED, V31, P543, DOI 10.1007/s11596-011-0487-z; Konstantinopoulos PA, 2011, CANCER RES, V71, P5081, DOI 10.1158/0008-5472.CAN-10-4668; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Ledermann JA, 2011, INT J GYNECOL CANCER, V21, P763, DOI 10.1097/IGC.0b013e31821b2669; Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025; Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; McLellan LI, 1999, DRUG RESIST UPDATE, V2, P153, DOI 10.1054/drup.1999.0083; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; OZOLS RF, 2005, PRINCIPLES PRACTICE; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pectasides D, 2006, ONCOLOGIST, V11, P1089, DOI 10.1634/theoncologist.11-10-1089; Pothof J, 2009, EMBO J, V28, P2090, DOI 10.1038/emboj.2009.156; Reichard JF, 2007, NUCLEIC ACIDS RES, V35, P7074, DOI 10.1093/nar/gkm638; SCHMIDT W, 1993, CANCER RES, V53, P799; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Stewart DJ, 2007, CRIT REV ONCOL HEMAT, V63, P12, DOI 10.1016/j.critrevonc.2007.02.001; Venkatraman M, 2005, MOL CARCINOGEN, V44, P51, DOI 10.1002/mc.20116; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wang YL, 1999, J BIOL CHEM, V274, P22095, DOI 10.1074/jbc.274.31.22095; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wyman SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005311; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang N, 2008, CANCER RES, V68, P10307, DOI 10.1158/0008-5472.CAN-08-1954; Ye G, 2011, J CELL SCI, V124, P359, DOI 10.1242/jcs.072223	50	179	181	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4284	4293		10.1038/onc.2012.433	http://dx.doi.org/10.1038/onc.2012.433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045278				2022-12-28	WOS:000324168000010
J	de Leeuw, R; Flach, K; Toaldo, CB; Alexi, X; Canisius, S; Neefjes, J; Michalides, R; Zwart, W				de Leeuw, R.; Flach, K.; Toaldo, C. Bentin; Alexi, X.; Canisius, S.; Neefjes, J.; Michalides, R.; Zwart, W.			PKA phosphorylation redirects ER alpha to promoters of a unique gene set to induce tamoxifen resistance	ONCOGENE			English	Article						estrogen receptor; breast cancer; protein kinase A; tamoxifen resistance; myc; ChIP-seq	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; PROTEIN-KINASE; NUCLEAR P21-ACTIVATED-KINASE-1; SERINE 305; CHIP-SEQ; ACTIVATION; EXPRESSION; TRANSCRIPTION; GROWTH	Protein kinase A (PKA)-induced estrogen receptor alpha (ER alpha) phosphorylation at serine residue 305 (ER alpha S305-P) can induce tamoxifen (TAM) resistance in breast cancer. How this phospho-modification affects ER alpha specificity and translates into TAM resistance is unclear. Here, we show that S305-P modification of ER alpha reprograms the receptor, redirecting it to new transcriptional start sites, thus modulating the transcriptome. By altering the chromatin-binding pattern, Ser305 phosphorylation of ER alpha translates into a 26-gene expression classifier that identifies breast cancer patients with a poor disease outcome after TAM treatment. MYC-target genes and networks were significantly enriched in this gene classifier that includes a number of selective targets for ER alpha S305-P. The enhanced expression of MYC increased cell proliferation in the presence of TAM. We demonstrate that activation of the PKA signaling pathway alters the transcriptome by redirecting ERa to new transcriptional start sites, resulting in altered transcription and TAM resistance.	[de Leeuw, R.; Toaldo, C. Bentin; Neefjes, J.; Michalides, R.] Netherlands Canc Inst, Dept Cell Biol, NL-1066 CX Amsterdam, Netherlands; [Flach, K.; Alexi, X.; Canisius, S.; Zwart, W.] Netherlands Canc Inst, Dept Mol Pathol, NL-1066 CX Amsterdam, Netherlands; [Canisius, S.] Netherlands Canc Inst, Dept Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Zwart, W (corresponding author), Netherlands Canc Inst, Dept Mol Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	w.zwart@nki.nl	Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211; Zwart, Wilbert/0000-0002-9823-7289; de Leeuw, Renee/0000-0002-5550-7613	Top Institute Pharma; KWF Dutch Cancer Society Fellowship	Top Institute Pharma; KWF Dutch Cancer Society Fellowship	We thank the Central Microarray Facility of the Netherlands Cancer Institute for processing the microarray samples. RL is in part supported by Top Institute Pharma. WZ is supported by a KWF Dutch Cancer Society Fellowship.	Al-Dhaheri MH, 2007, MOL ENDOCRINOL, V21, P439, DOI 10.1210/me.2006-0059; Bossis I, 2004, ENDOCRINOLOGY, V145, P5452, DOI 10.1210/en.2004-0900; Bostner J, 2010, CLIN CANCER RES, V16, P1624, DOI 10.1158/1078-0432.CCR-09-1733; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Callero MA, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/923250; Carascossa S, 2010, GENE DEV, V24, P708, DOI 10.1101/gad.568410; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chandra V, 2008, NATURE, V456, P350, DOI 10.1038/nature07413; Chen DS, 1999, MOL CELL BIOL, V19, P1002; de Leeuw R, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/232435; Dudek P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001859; Fan P, 2007, CANCER RES, V67, P1352, DOI 10.1158/0008-5472.CAN-06-1020; Ferlay J, 2010, IARC CANCERBASE; Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Holm C, 2009, J PATHOL, V217, P372, DOI 10.1002/path.2455; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Inoue A, 2004, J MOL ENDOCRINOL, V32, P649, DOI 10.1677/jme.0.0320649; Ji XW, 2006, NUCLEIC ACIDS RES, V34, pW551, DOI 10.1093/nar/gkl322; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kok M, 2011, BREAST CANCER RES TR, V125, P1, DOI 10.1007/s10549-010-0798-y; Krum SA, 2008, MOL ENDOCRINOL, V22, P2393, DOI 10.1210/me.2008-0100; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Louie MC, 2010, MOL CANCER RES, V8, P343, DOI 10.1158/1541-7786.MCR-09-0395; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; Lupien M, 2009, MOL CELL BIOL, V29, P3413, DOI 10.1128/MCB.00020-09; Madak-Erdogan Z, 2012, TOXICOL SCI, V125, P401, DOI 10.1093/toxsci/kfr300; Madak-Erdogan Z, 2011, MOL CELL BIOL, V31, P226, DOI 10.1128/MCB.00821-10; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567; Miller WR, 2002, ANN NY ACAD SCI, V968, P37, DOI 10.1111/j.1749-6632.2002.tb04325.x; Musgrove EA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002987; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Rayala SK, 2006, CANCER RES, V66, P5985, DOI 10.1158/0008-5472.CAN-06-0978; REINER GCA, 1986, CANCER RES, V46, P1124; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Robertson JFR, 2004, CANCER TREAT REV, V30, P695, DOI 10.1016/j.ctrv.2004.04.003; Robinson JLL, 2011, EMBO J, V30, P3019, DOI 10.1038/emboj.2011.216; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Skliris GP, 2009, BREAST CANCER RES TR, V118, P443, DOI 10.1007/s10549-008-0267-z; Skliris GP, 2010, ENDOCR-RELAT CANCER, V17, P589, DOI 10.1677/ERC-10-0030; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Suzuki T, 2007, ENDOCR-RELAT CANCER, V14, P279, DOI 10.1677/ERC-06-0005; Wang CY, 2011, MOL ENDOCRINOL, V25, P1527, DOI 10.1210/me.2011-1037; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Yi P, 2008, MOL CELL, V29, P465, DOI 10.1016/j.molcel.2007.12.030; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zwart W, 2007, EMBO J, V26, P3534, DOI 10.1038/sj.emboj.7601791	58	28	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3543	3551		10.1038/onc.2012.361	http://dx.doi.org/10.1038/onc.2012.361			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22907427				2022-12-28	WOS:000322220800007
J	Batlle, R; Alba-Castellon, L; Loubat-Casanovas, J; Armenteros, E; Franci, C; Stanisavljevic, J; Barderas, R; Martin-Caballero, J; Bonilla, F; Baulida, J; Casal, JI; Gridley, T; de Herreros, AG				Batlle, R.; Alba-Castellon, L.; Loubat-Casanovas, J.; Armenteros, E.; Franci, C.; Stanisavljevic, J.; Barderas, R.; Martin-Caballero, J.; Bonilla, F.; Baulida, J.; Casal, J. I.; Gridley, T.; Garcia de Herreros, A.			Snail1 controls TGF-beta responsiveness and differentiation of mesenchymal stem cells	ONCOGENE			English	Article						Snail1; mesenchymal stem cells; TGF-beta; Akt	TRANSCRIPTION FACTOR SNAIL; NF-KAPPA-B; EXPRESSION; REPRESSOR; TRANSITIONS; PROTEIN; STROMA; BINDS; PTEN; AKT1	The Snail1 transcriptional repressor plays a key role in triggering epithelial-to-mesenchymal transition. Although Snail1 is widely expressed in early development, in adult animals it is limited to a subset of mesenchymal cells where it has a largely unknown function. Using a mouse model with inducible depletion of Snail1, here we demonstrate that Snail1 is required to maintain mesenchymal stem cells (MSCs). This effect is associated to the responsiveness to transforming growth factor (TGF)-beta 1 that shows a strong Snail1 dependence. Snail1 depletion in conditional knockout adult animals causes a significant decrease in the number of bone marrow-derived MSCs. In culture, Snail1-deficient MSCs prematurely differentiate to osteoblasts or adipocytes and, in contrast to controls, are resistant to the TGF-beta 1-induced differentiation block. These results demonstrate a new role for Snail1 in TGF-beta response and MSC maintenance.	[Batlle, R.; Alba-Castellon, L.; Loubat-Casanovas, J.; Armenteros, E.; Franci, C.; Stanisavljevic, J.; Baulida, J.; Garcia de Herreros, A.] IMIM, Programa Recerca Cancer, Hosp Mar, Barcelona 08003, Spain; [Barderas, R.; Casal, J. I.] CSIC, Dept Med Mol, Ctr Invest Biol, Madrid, Spain; [Martin-Caballero, J.] Parc Recerca Biomed Barcelona, Anim Facil, Barcelona, Spain; [Bonilla, F.] Hosp Puerta Hierro, Serv Oncol Med, Majadahonda, Spain; [Gridley, T.] Maine Med Ctr Res Inst, Ctr Mol Med, Scarborough, ME USA; [Garcia de Herreros, A.] Univ Pompeu Fabra, Dept Ciencies Expt Salut, Barcelona, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Hospital Puerta de Hierro-Majadahonda; Maine Medical Center; Pompeu Fabra University	de Herreros, AG (corresponding author), IMIM, Programa Recerca Cancer, C Doctor Aiguader 88, Barcelona 08003, Spain.	agarcia@imim.es	Stanisavljević, Jelena/J-7152-2017; Barderas, Rodrigo/K-3560-2014; de Herreros, A Garcia/H-3104-2014; Casal, Ignacio/M-2312-2014; Stanisavljević, Jelena/ABG-8136-2020	Stanisavljević, Jelena/0000-0002-4880-4513; Barderas, Rodrigo/0000-0003-3539-7469; de Herreros, A Garcia/0000-0001-5270-0808; Casal, Ignacio/0000-0003-1085-2840; Stanisavljević, Jelena/0000-0002-4880-4513; Loubat Casanovas, Jordina/0000-0002-0158-3944; Alba-Castellon, Lorena/0000-0003-3449-7820	la Fundacion Cientifica de la Asociacion Espanola contra el Cancer; Ministerio de Ciencia y Tecnologia [SAF2006-00339, SAF2010-16089]; Fundacio La Marato de TV3; NIH [R01HD034883]; ISCIII/FEDER [RD06/0020/0109, RD06/0020/0040, RD06/0020/0020]; Generalitat de Catalunya [2009SGR867]; FPI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034883] Funding Source: NIH RePORTER	la Fundacion Cientifica de la Asociacion Espanola contra el Cancer; Ministerio de Ciencia y Tecnologia(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fundacio La Marato de TV3; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ISCIII/FEDER(Spanish Government); Generalitat de Catalunya(Generalitat de Catalunya); FPI(Spanish Government); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank M Massoumi for help in the preparation of MSCs, Td'Altri for assistance in the FACS analysis, N Garcia-Giralt and L Larue for reagents, L diCroce for comments and E Batlle for support and advice. This study was funded by a grant awarded by la Fundacion Cientifica de la Asociacion Espanola contra el Cancer to AGH, JIC and FB. Support from the Ministerio de Ciencia y Tecnologia (SAF2006-00339 and SAF2010-16089) and Fundacio La Marato de TV3 to AGH, and NIH R01HD034883 to TG is also appreciated. We also acknowledge support from ISCIII/FEDER (RD06/0020/0109, RD06/0020/0040, RD06/0020/0020), Generalitat de Catalunya (2009SGR867). RB and LA-C were recipients from FPI predoctoral fellowships.	Perez-Mancera PA, 2007, HUM MOL GENET, V16, P2972, DOI 10.1093/hmg/ddm278; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Choudhury GG, 2004, CELL SIGNAL, V16, P31, DOI 10.1016/S0898-6568(03)00094-9; de Frutos CA, 2007, DEV CELL, V13, P872, DOI 10.1016/j.devcel.2007.09.016; de Frutos CA, 2009, EMBO J, V28, P686, DOI 10.1038/emboj.2009.23; Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364; Escriva M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Franci C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005595; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Hill R, 2009, J BIOL CHEM, V284, P11755, DOI 10.1074/jbc.R800071200; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361-11; Murray SA, 2006, GENESIS, V44, P7, DOI 10.1002/gene.20178; Murray SA, 2006, P NATL ACAD SCI USA, V103, P10300, DOI 10.1073/pnas.0602234103; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Peiro S, 2006, NUCLEIC ACIDS RES, V34, P2077, DOI 10.1093/nar/gkl141; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rowe RG, 2009, J CELL BIOL, V184, P399, DOI 10.1083/jcb.200810113; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Ryu JM, 2010, J CELL PHYSIOL, V224, P59, DOI [10.1002/jcp.22091, 10.1002/jcp.2209]; Sawyer JS, 2003, J MED CHEM, V46, P3953, DOI 10.1021/jm0205705; Solanas G, 2008, J CELL SCI, V121, P2224, DOI 10.1242/jcs.021667; Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221; Stanisavljevic J, 2011, J CELL SCI, V124, P4159, DOI 10.1242/jcs.078824; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Villagrasa P, 2011, ONCOGENE, V31, P4064; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wu XH, 2011, J BIOL CHEM, V286, P13512, DOI 10.1074/jbc.M110.187351; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200	36	44	44	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2013	32	28					3381	3389		10.1038/onc.2012.342	http://dx.doi.org/10.1038/onc.2012.342			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22869142	Green Submitted, Green Accepted			2022-12-28	WOS:000321620200008
J	Bianchi-Smiraglia, A; Paesante, S; Bakin, AV				Bianchi-Smiraglia, A.; Paesante, S.; Bakin, A. V.			Integrin beta 5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways	ONCOGENE			English	Article						integrin; focal adhesion kinase (FAK); extracellular signal-regulated kinase (ERK); anchorage-independent growth; transforming growth factor beta (TGF-beta)	FOCAL-ADHESION KINASE; GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; REGULATED KINASE; PHOSPHORYLATION; ALPHA-V-BETA-5; EXPRESSION; MATRIX-METALLOPROTEINASE-9; TYROSINE-861; MIGRATION	Cancer progression, response to therapy and metastasis depend on tumor microenvironment. Integrins are cell-adhesion receptors that mediate interactions of cells with extracellular matrix. The alpha v-beta-family of integrins contributes to tumorigenesis, response to therapy and cancer stem cell biology. Thus, understanding the function of specific integrins in cancer is critical for the development of therapeutic approaches targeting integrins. The study investigated the role of integrin beta 5 in breast carcinomas by depleting integrin b5 using RNA interference and reexpression of integrin beta 5. Depletion of integrin b5 in triple-negative breast carcinoma cells markedly reduced tumor take, growth and tumor angiogenesis, whereas reexpression of integrin b5 rescued this phenotype. Reduction in tumor angiogenesis is associated with lower expression of vascular endothelial growth factor-A in integrin beta 5-depleted tumors. Tumor cells deficient in integrin beta 5 have lower migration and proliferative capacities. Biochemical assays revealed that integrin beta 5 mediates the Src-focal adhesion kinase and MEK-extracellular signal-regulated kinase signaling events that operate independently, and inhibition of these pathways phenocopies integrin beta 5 deficiency. Breast carcinoma cells express high levels of integrin beta 5, whereas expression of integrin beta 3 is limited to stromal compartments and integrin beta 6 is lost in metastatic cells. Together, these findings show a critical role for integrin beta 5 in the tumorigenic potential of breast carcinoma cells and therapeutic targeting of integrin beta 5 is especially attractive for triple-negative breast carcinomas, which are refractory to most of the current therapies.	[Bianchi-Smiraglia, A.; Paesante, S.; Bakin, A. V.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Bakin, AV (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm Carlton St, Buffalo, NY 14263 USA.	Andrei.Bakin@RoswellPark.org		Bakin, Andrei/0000-0002-7728-1969; Bianchi-Smiraglia, Anna/0000-0002-5963-103X	NYSDOH-HSRB Peter T Rowley Breast Cancer Project; RPCI Cancer Center Support Grant [CA 16056]; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA095263] Funding Source: NIH RePORTER	NYSDOH-HSRB Peter T Rowley Breast Cancer Project; RPCI Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NYSDOH-HSRB Peter T Rowley Breast Cancer Project and in part by RPCI Cancer Center Support Grant CA 16056. We thank Dr Irwin Gelman for his helpful discussion of the manuscript, Drs Raymond Birge, Jianmin Zhang and Yahao Bu for providing reagents and Drs Kitty De Jong and Janice Hoffmann (RPCI flow cytometry facility) for their technical help.	Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Alvarez RH, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2572; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bianchi A, 2010, CELL CYCLE, V9, P1647, DOI 10.4161/cc.9.8.11517; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Colombo PE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2890; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Frey RS, 1997, CANCER RES, V57, P628; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Ishigaki T, 2011, J CELL PHYSIOL, V226, P2617, DOI 10.1002/jcp.22614; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Maubant S, 2002, INT J CANCER, V97, P186, DOI 10.1002/ijc.1600; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Meyer T, 1998, BRIT J CANCER, V77, P530, DOI 10.1038/bjc.1998.86; Mitra SK, 2006, ONCOGENE, V25, P5969, DOI 10.1038/sj.onc.1209588; Monferran S, 2008, INT J CANCER, V123, P357, DOI 10.1002/ijc.23498; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Ogata H, 2001, CANCER LETT, V172, P159, DOI 10.1016/S0304-3835(01)00648-6; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Ricono JM, 2009, CANCER RES, V69, P1383, DOI 10.1158/0008-5472.CAN-08-3612; Safina A, 2008, ONCOGENE, V27, P1198, DOI 10.1038/sj.onc.1210768; Safina A, 2007, ONCOGENE, V26, P2407, DOI 10.1038/sj.onc.1210046; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneider BP, 2007, NAT CLIN PRACT ONCOL, V4, P181, DOI 10.1038/ncponc0740; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Yom CK, 2011, BREAST CANCER RES TR, V128, P647, DOI 10.1007/s10549-010-1150-2; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008	47	90	96	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3049	3058		10.1038/onc.2012.320	http://dx.doi.org/10.1038/onc.2012.320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22824793	Green Accepted, Green Submitted			2022-12-28	WOS:000320705700005
J	Kilbride, SM; Prehn, JHM				Kilbride, S. M.; Prehn, J. H. M.			Central roles of apoptotic proteins in mitochondrial function	ONCOGENE			English	Review						mitochondria; bioenergetics; apoptosis	CYTOCHROME-C RELEASE; CELL-DEATH; PERMEABILITY TRANSITION; ENDONUCLEASE-G; MEMBRANE PERMEABILIZATION; CASPASE ACTIVATION; OUTER-MEMBRANE; BCL-X; OXIDATIVE STRESS; SERINE-PROTEASE	Mitochondria have been classically characterized as organelles with responsibility for cellular energy production in the form of ATP, but they are also the organelles through which apoptotic signaling occurs. Cell stress stimuli can result in outer membrane permeabilization, after which mitochondria release numerous proteins involved in apoptotic signaling, including cytochrome c, apoptosis-inducing factor, endonuclease G, Smac/DIABLO and Omi/HtrA2. Cell fate is determined by signaling through apoptotic proteins within the Bcl-2 (B-cell lymphoma 2) protein family, which converges on mitochondria. Many cancerous cells display abnormal levels of Bcl-2 protein family member expression that results in defective apoptotic signaling. Alterations in bioenergetic function also contribute to cancer as well as numerous other disorders. Recent evidence indicates that several pro-apoptotic proteins localized within mitochondria, as well as proteins within the Bcl-2 protein family, can influence mitochondrial bioenergetic function. This review focuses on the emerging roles of these proteins in the control of mitochondrial activity.	[Kilbride, S. M.; Prehn, J. H. M.] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Ctr Syst Med, Dublin 2, Ireland	Royal College of Surgeons - Ireland	Prehn, JHM (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Ctr Syst Med, 123 St Stephens Green, Dublin 2, Ireland.	prehn@rcsi.ie	Prehn, Jochen HM/A-3928-2010	Prehn, Jochen HM/0000-0003-3479-7794	Health Research Board [RP/2008/14]; Science Foundation Ireland [08/IN1/1949]	Health Research Board; Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	This work was funded by Health Research Board (RP/2008/14) and Science Foundation Ireland (08/IN1/1949) grants to JHMP.	Abu-Hamad S, 2008, J BIOL CHEM, V283, P13482, DOI 10.1074/jbc.M708216200; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; AKAO Y, 1994, CANCER RES, V54, P2468; Alavian KN, 2011, NAT CELL BIOL, V13, P1224, DOI 10.1038/ncb2330; Andrews ZB, 2005, NAT REV NEUROSCI, V6, P829, DOI 10.1038/nrn1767; Arbour N, 2008, J NEUROSCI, V28, P6068, DOI 10.1523/JNEUROSCI.4940-07.2008; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Basnakian AG, 2006, EXP CELL RES, V312, P4139, DOI 10.1016/j.yexcr.2006.09.012; Belzacq AS, 2003, CANCER RES, V63, P541; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boohaker RJ, 2011, AM J PHYSIOL-CELL PH, V300, pC1466, DOI 10.1152/ajpcell.00325.2010; Brown D, 2006, P NATL ACAD SCI USA, V103, P9918, DOI 10.1073/pnas.0603950103; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Burge D, 2009, ARCH DIS CHILD-FETAL, V94, pF290, DOI 10.1136/adc.2008.145102; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chen YB, 2011, J CELL BIOL, V195, P263, DOI 10.1083/jcb.201108059; Chen ZX, 2007, CELL DEATH DIFFER, V14, P1617, DOI 10.1038/sj.cdd.4402165; Chen ZX, 2010, CELL DEATH DIFFER, V17, P408, DOI 10.1038/cdd.2009.132; Cheng J, 2011, AM J HUM GENET, V89, P56, DOI 10.1016/j.ajhg.2011.05.027; Cheung ECC, 2006, EMBO J, V25, P4061, DOI 10.1038/sj.emboj.7601276; Chinta SJ, 2009, FREE RADICAL BIO MED, V46, P939, DOI 10.1016/j.freeradbiomed.2009.01.010; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Clement MV, 2001, REDOX REP, V6, P211, DOI 10.1179/135100001101536346; Concannon CG, 2010, J CELL BIOL, V189, P83, DOI 10.1083/jcb.200909166; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Flanagan L, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.26; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Gray MW, 2001, GENOME BIOL, V2; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hickman JA, 2008, J NEUROPHYSIOL, V99, P1515, DOI 10.1152/jn.00598.2007; Hosler JP, 2006, ANNU REV BIOCHEM, V75, P165, DOI 10.1146/annurev.biochem.75.062003.101730; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Huber HJ, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.2; Ishihara Y, 2006, J BIOL CHEM, V281, P6726, DOI 10.1074/jbc.M510382200; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Jones RG, 2007, IMMUNITY, V27, P268, DOI 10.1016/j.immuni.2007.05.023; Joza N, 2005, MOL CELL BIOL, V25, P10261, DOI 10.1128/MCB.25.23.10261-10272.2005; Karbowski J, 2006, J THEOR BIOL, V242, P652, DOI 10.1016/j.jtbi.2006.04.012; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kilbride SM, 2010, J BIOL CHEM, V285, P36199, DOI 10.1074/jbc.M110.138107; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Krantic S, 2007, PROG NEUROBIOL, V81, P179, DOI 10.1016/j.pneurobio.2006.12.002; Krishna S, 2011, BIOCHEM J, V435, P545, DOI 10.1042/BJ20101996; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Lemasters JJ, 2006, BBA-MOL BASIS DIS, V1762, P181, DOI 10.1016/j.bbadis.2005.10.006; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Low ICC, 2011, ANTIOXID REDOX SIGN, V15, P2975, DOI 10.1089/ars.2010.3851; Mammucari C, 2010, MECH AGEING DEV, V131, P536, DOI 10.1016/j.mad.2010.07.003; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McDermott-Roe C, 2011, NATURE, V478, P114, DOI 10.1038/nature10490; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; NICHONGHAILE T, 2012, SCIENCE, V334, P1129; Ohsato T, 2002, EUR J BIOCHEM, V269, P5765, DOI 10.1046/j.1432-1033.2002.03238.x; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; Perciavalle RM, 2012, NAT CELL BIOL, V14, P575, DOI 10.1038/ncb2488; Rego AC, 2001, CELL DEATH DIFFER, V8, P995, DOI 10.1038/sj.cdd.4400916; Rinkenberger JL, 2000, GENE DEV, V14, P23; Schafer P, 2004, J MOL BIOL, V338, P217, DOI 10.1016/j.jmb.2004.02.069; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shulga N, 2010, J CELL SCI, V123, P894, DOI 10.1242/jcs.061846; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Tsujimoto Y, 2006, BBA-BIOENERGETICS, V1757, P1297, DOI 10.1016/j.bbabio.2006.03.017; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; van Empel VPM, 2005, CIRC RES, V96, pE92, DOI 10.1161/01.RES.0000172081.30327.28; Vande Walle L, 2007, J PROTEOME RES, V6, P1006, DOI 10.1021/pr060510d; Velours J, 2009, INT J BIOCHEM CELL B, V41, P1783, DOI 10.1016/j.biocel.2009.01.011; Vempati UD, 2009, J BIOL CHEM, V284, P4383, DOI 10.1074/jbc.M805972200; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Waterhouse NJ, 2006, CELL DEATH DIFFER, V13, P607, DOI 10.1038/sj.cdd.4401772; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weisova P, 2011, ANTIOXID REDOX SIGN, V14, P1863, DOI 10.1089/ars.2010.3544; Whelan RS, 2012, P NATL ACAD SCI USA, V109, P6566, DOI 10.1073/pnas.1201608109; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu YF, 2004, NEUROSCI LETT, V364, P203, DOI 10.1016/j.neulet.2004.04.093; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Youdim MBH, 2006, NAT REV NEUROSCI, V7, P295, DOI 10.1038/nrn1883; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; Zanna C, 2005, APOPTOSIS, V10, P997, DOI 10.1007/s10495-005-0742-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	128	110	113	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2703	2711		10.1038/onc.2012.348	http://dx.doi.org/10.1038/onc.2012.348			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22869150				2022-12-28	WOS:000319808000001
J	Grkovic, S; O'Reilly, VC; Han, S; Hong, M; Baxter, RC; Firth, SM				Grkovic, S.; O'Reilly, V. C.; Han, S.; Hong, M.; Baxter, R. C.; Firth, S. M.			IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments	ONCOGENE			English	Article						autophagy; breast cancer; GRP78; IGFBP-3; starvation	UNFOLDED PROTEIN RESPONSE; GROWTH-INHIBITION; TUMOR-DEVELOPMENT; SURFACE BINDING; RECEPTOR; APOPTOSIS; CYCLE; EXPRESSION; INDUCTION; FIBRONECTIN	Despite the established role of insulin-like growth factor binding protein-3 (IGFBP-3) as a growth inhibitor in vitro, a high level of IGFBP-3 in breast tumor tissue is associated with the stimulation of xenograft growth in mice and poor prognosis in patients. To understand the contribution of IGFBP-3 to breast cancer progression, tandem affinity purification was used to identify novel interacting proteins. The endoplasmic reticulum protein, glucose-regulated protein 78 (GRP78), was shown to bind to IGFBP-3, confirmed by colocalization, coimmunoprecipitations, glutathione S-transferase (GST) pulldowns and a nanomolar binding affinity. GST pulldowns also indicated that the GRP78 ATPase domain mediated the interaction with IGFBP-3. The critical roles of GRP78 in the unfolded protein response and macroautophagy led to an investigation of possible links between IGFBP-3, GRP78 and cellular stress responses. IGFBP-3 was found to stimulate the survival of breast cancer cells subjected to glucose starvation and hypoxia. Pharmacological inhibitors and small interfering RNA knockdown established that the increased survival of IGFBP-3-expressing cells was dependent on an intact autophagy response, as well as GRP78. The contribution of autophagy was confirmed by the demonstration that IGFBP-3 expression increases both the formation of autophagic puncta and flux through the system. In conclusion, we have shown that IGFBP-3 stimulates autophagy and thereby promotes the survival of breast cancer cells exposed to conditions that represent the adverse microenvironments encountered by solid tumor cells in vivo.	[Grkovic, S.; O'Reilly, V. C.; Han, S.; Hong, M.; Baxter, R. C.; Firth, S. M.] Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Grkovic, S (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	sgrkovic@yahoo.com.au	Hong, Martin/AAO-5432-2020; Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142; Hong, Martin/0000-0002-2327-4261	Cancer Institute NSW; Sydney Medical School, University of Sydney; Allan and Beryl Stephens Trust; University of Sydney	Cancer Institute NSW; Sydney Medical School, University of Sydney(University of Sydney); Allan and Beryl Stephens Trust; University of Sydney(University of Sydney)	We thank G Lu for his assistance with immunocytochemistry. SG and SMF were recipients of Cancer Institute NSW Early Career and Career Development Fellowships, respectively. SH and MH received Summer Research Scholarships from the Sydney Medical School, University of Sydney. This project was partly supported by the Allan and Beryl Stephens Trust and University of Sydney Bridging Support Grant.	BRUNNER M, 1973, CANCER RES, V33, P29; Butt AJ, 2004, J CLIN ENDOCR METAB, V89, P1950, DOI 10.1210/jc.2003-030914; Butt AJ, 2002, ENDOCRINOLOGY, V143, P2693, DOI 10.1210/en.143.7.2693; Chan SSY, 2009, AM J PHYSIOL-ENDOC M, V296, pE654, DOI 10.1152/ajpendo.90846.2008; Chen WS, 2009, EUR J HUM GENET, V17, P1668, DOI 10.1038/ejhg.2009.86; Criollo A, 2007, CELL DEATH DIFFER, V14, P1029, DOI 10.1038/sj.cdd.4402099; Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625; DiPaola RS, 2008, PROSTATE, V68, P1743, DOI 10.1002/pros.20837; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Espina V, 2011, NAT REV CANCER, V11, P68, DOI 10.1038/nrc2950; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Feldman DE, 2005, MOL CANCER RES, V3, P597, DOI 10.1158/1541-7786.MCR-05-0221; Feldser D, 1999, CANCER RES, V59, P3915; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Firth SM, 1999, J ENDOCRINOL, V160, P379, DOI 10.1677/joe.0.1600379; Firth Sue M., 1995, Progress in Growth Factor Research, V6, P223, DOI 10.1016/0955-2235(95)00009-7; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gonzalez-Gronow M, 2009, ANTIOXID REDOX SIGN, V11, P2299, DOI [10.1089/ars.2009.2568, 10.1089/ARS.2009.2568]; Grimberg A, 2005, J CLIN ENDOCR METAB, V90, P3568, DOI 10.1210/jc.2004-1213; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Itakura E, 2010, AUTOPHAGY, V6, P764, DOI 10.4161/auto.6.6.12709; Jogie-Brahim S, 2009, ENDOCR REV, V30, P417, DOI 10.1210/er.2008-0028; Kaminskyy V, 2011, AUTOPHAGY, V7, P83, DOI 10.4161/auto.7.1.13893; Kim HS, 2010, HORM METAB RES, V42, P165, DOI 10.1055/s-0029-1243190; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kratzner R, 2008, MOL PHARMACOL, V73, P509, DOI 10.1124/mol.107.035568; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660; Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; Liu B, 2003, GROWTH HORM IGF RES, V13, P89, DOI 10.1016/S1096-6374(03)00007-8; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Martin JL, 2009, J BIOL CHEM, V284, P25542, DOI 10.1074/jbc.M109.007120; McIntosh J, 2010, J BIOL CHEM, V285, P38788, DOI 10.1074/jbc.M110.177311; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; O'Han MK, 2009, GROWTH FACTORS, V27, P394, DOI 10.3109/08977190903185032; Oufattole M, 2006, ENDOCRINOLOGY, V147, P2138, DOI 10.1210/en.2005-1269; Perks C, 2008, J MAMMARY GLAND BIOL, V13, P455, DOI 10.1007/s10911-008-9106-4; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Ren ZF, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1634; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Schedlich LJ, 2004, BIOCHEM BIOPH RES CO, V314, P83, DOI 10.1016/j.bbrc.2003.12.049; Schedlich LJ, 2007, MOL ENDOCRINOL, V21, P2378, DOI 10.1210/me.2006-0558; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scriven P, 2009, BRIT J CANCER, V101; Sheen-Chen SM, 2009, ANTICANCER RES, V29, P1131; Vestey SB, 2005, BREAST CANCER RES, V7, pR119, DOI 10.1186/bcr963; Wang M, 2009, ANTIOXID REDOX SIGN, V11, P2307, DOI [10.1089/ars.2009.2485, 10.1089/ARS.2009.2485]; Weinzimer SA, 2001, J CLIN ENDOCR METAB, V86, P1806, DOI 10.1210/jc.86.4.1806; Wisniewska M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008625; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1; Yu H, 1996, BRIT J CANCER, V74, P1242, DOI 10.1038/bjc.1996.523; Yu H, 1998, INT J CANCER, V79, P624, DOI 10.1002/(SICI)1097-0215(19981218)79:6<624::AID-IJC12>3.0.CO;2-9	60	58	60	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2412	2420		10.1038/onc.2012.264	http://dx.doi.org/10.1038/onc.2012.264			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751133				2022-12-28	WOS:000318694900005
J	Gallagher, SJ; Rambow, F; Kumasaka, M; Champeval, D; Bellacosa, A; Delmas, V; Larue, L				Gallagher, S. J.; Rambow, F.; Kumasaka, M.; Champeval, D.; Bellacosa, A.; Delmas, V.; Larue, L.			Beta-catenin inhibits melanocyte migration but induces melanoma metastasis	ONCOGENE			English	Article						Wnt; melanoblast; melanoma; MITF; CSK; mouse	SIGNALING PATHWAY; EXPRESSION; PROLIFERATION; ACTIVATION; CANCER; PROGRESSION; MUTATIONS; CADHERIN; TUMORS; CELLS	The canonical Wnt signalling pathway induces the beta-catenin/lymphoid enhancer factor transcription factors. It is activated in various cancers, most characteristically carcinomas, in which it promotes metastatic spread by increasing migration and/or invasion. The Wnt/beta-catenin signalling pathway is frequently activated in melanoma, but the presence of beta-catenin in the nucleus does not seem to be a sign of aggressiveness in these tumours. We found that, unlike its positive role in stimulating migration and invasion of carcinoma cells, beta-catenin signalling decreased the migration of melanocytes and melanoma cell lines. In vivo, beta-catenin signalling in melanoblasts reduced the migration of these cells, causing a white belly-spot phenotype. The inhibition by beta-catenin of migration was dependent on MITF-M, a key transcription factor of the melanocyte lineage, and CSK, an Src-inhibitor. Despite reducing migration, beta-catenin signalling promoted lung metastasis in the NRAS-driven melanoma murine model. Thus, beta-catenin may have conflicting roles in the metastatic spread of melanoma, repressing migration while promoting metastasis. These results highlight that metastasis formation requires a series of successful cellular processes, any one of which may not be optimally efficient. Oncogene (2013) 32, 2230-2238; doi:10.1038/onc.2012.229; published online 4 June 2012	[Gallagher, S. J.; Rambow, F.; Kumasaka, M.; Champeval, D.; Delmas, V.; Larue, L.] Inst Curie, Ctr Rech, F-91405 Orsay, France; [Gallagher, S. J.; Rambow, F.; Kumasaka, M.; Champeval, D.; Delmas, V.; Larue, L.] CNRS, UMR3347, F-91405 Orsay, France; [Gallagher, S. J.; Rambow, F.; Kumasaka, M.; Champeval, D.; Delmas, V.; Larue, L.] Univ Paris 11, INSERM, U1021, F-91405 Orsay, France; [Bellacosa, A.] Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19111 USA; [Bellacosa, A.] Fox Chase Canc Ctr, Epigenet & Progenitor Cells Keystone Program, Philadelphia, PA 19111 USA	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; Fox Chase Cancer Center; Fox Chase Cancer Center	Larue, L (corresponding author), Inst Curie, Ctr Rech, Bat 110, F-91405 Orsay, France.	lionel.larue@curie.fr	Larue, Lionel/F-7355-2013; Larue, Lionel/I-6532-2016; Gallagher, Stuart J/E-6617-2011; Gallagher, Stuart/S-6718-2019	Gallagher, Stuart J/0000-0003-2651-9671; Gallagher, Stuart/0000-0003-2651-9671; rambow, florian/0000-0002-9727-8986; Delmas, veronique/0000-0001-7368-3664	LNCC; Curie; Ligue Nationale Contre le Cancer (Equipe labellisee); INCa; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA078412] Funding Source: NIH RePORTER	LNCC; Curie; Ligue Nationale Contre le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); INCa(Institut National du Cancer (INCA) France); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank D Bennett, M Herlyn and F Beermann for kindly providing materials. We thank staff from the animal colony and imaging facilities of Curie, including Y Bourgeois, F Cordelieres and H Harmange in particular. SG was supported by LNCC and Curie. This work was supported by the Ligue Nationale Contre le Cancer (Equipe labellisee) and INCa.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Baldus SE, 2004, CLIN CANCER RES, V10, P2790, DOI 10.1158/1078-0432.CCR-03-0163; BENNETT DC, 1989, DEVELOPMENT, V105, P379; Bottomly D, 2010, NUCLEIC ACIDS RES, V38, P5735, DOI 10.1093/nar/gkq363; Brooks SA, 2010, ACTA HISTOCHEM, V112, P3, DOI 10.1016/j.acthis.2008.11.022; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; de Melker AA, 2004, DEV DYNAM, V230, P708, DOI 10.1002/dvdy.20091; Delmas V, 2003, GENESIS, V36, P73, DOI 10.1002/gene.10197; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Eichhoff OM, 2011, PIGM CELL MELANOMA R, V24, P631, DOI 10.1111/j.1755-148X.2011.00871.x; Gallagher SJ, 2011, PIGM CELL MELANOMA R, V24, P987, DOI 10.1111/j.1755-148X.2011.00907.x; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kielhorn E, 2003, INT J CANCER, V103, P652, DOI 10.1002/ijc.10893; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; Larue L, 1996, DEVELOPMENT, V122, P3185; Larue L, 2007, PIGM CELL RES, V20, P485, DOI 10.1111/j.1600-0749.2007.00411.x; Luciani F, 2011, DEVELOPMENT, V138, P3943, DOI 10.1242/dev.067447; Lugli A, 2007, HISTOPATHOLOGY, V50, P453, DOI 10.1111/j.1365-2559.2007.02620.x; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; Murakami T, 2001, BIOCHEM BIOPH RES CO, V288, P8, DOI 10.1006/bbrc.2001.5719; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Schepsky A, 2006, MOL CELL BIOL, V26, P8914, DOI 10.1128/MCB.02299-05; Sinnberg T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023429; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049	32	79	81	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2230	2238		10.1038/onc.2012.229	http://dx.doi.org/10.1038/onc.2012.229			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22665063	Green Accepted			2022-12-28	WOS:000318062800012
J	Gu, Z; Zhang, F; Wang, ZQ; Ma, W; Davis, RE; Wang, Z				Gu, Z.; Zhang, F.; Wang, Z-Q; Ma, W.; Davis, R. E.; Wang, Z.			The p44/wdr77-dependent cellular proliferation process during lung development is reactivated in lung cancer	ONCOGENE			English	Article						lung; lung cancer; p44/wdr77; proliferation; differentiation	RECEPTOR COFACTOR P44; RETINOBLASTOMA PROTEIN; PHENOTYPIC DIFFERENTIATION; MYOGENIC DIFFERENTIATION; POTENTIAL MEDIATOR; ANALYSIS REVEALS; CYCLE ARREST; EXPRESSION; P21; IDENTIFICATION	During lung development, cells proliferate for a defined length of time before they begin to differentiate. Factors that control this proliferative process and how this growth process is related to lung cancer are currently unknown. Here, we found that the WD40-containing protein (p44/wdr77) was expressed in growing epithelial cells at the early stages of lung development. In contrast, p44/wdr77 expression was diminished in fully differentiated epithelial cells in the adult lung. Loss of p44/wdr77 gene expression led to cell growth arrest and differentiation. Re-expression of p44/wdr77 caused terminally differentiated cells to re-enter the cell cycle. Our findings suggest that p44/wdr77 is essential and sufficient for proliferation of lung epithelial cells. P44/Wdr77 was re-expressed in lung cancer, and silencing p44/wdr77 expression strongly inhibited growth of lung adenocarcinoma cells in tissue culture and abolished growth of lung adenocarcinoma tumor xenografts in mice. The growth arrest induced by loss of p44/wdr77 expression was partially through the p21-Rb signaling. Our results suggest that p44/wdr77 controls cellular proliferation during lung development, and this growth process is reactivated during lung tumorigenesis. Oncogene (2013) 32, 1888-1900; doi:10.1038/onc.2012.207; published online 4 June 2012	[Gu, Z.; Zhang, F.; Wang, Z.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Gu, Z.] Fourth Mil Med Univ, Tangdu Hosp, Dept Thorac Surg, Xian, Peoples R China; [Wang, Z-Q; Ma, W.; Davis, R. E.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Air Force Military Medical University; University of Texas System; UTMD Anderson Cancer Center	Wang, Z (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	zhenwang@mdanderson.org		Gu, Zhongping/0000-0002-7395-7888	National Institutes of Health through MD Anderson's Cancer Center [CA16672]; National Natural Science Foundation of China [81171922]; Key Project Research Fund of Shaanxi Provincial Science and Technology Program, China [2008K27G01]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	National Institutes of Health through MD Anderson's Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project Research Fund of Shaanxi Provincial Science and Technology Program, China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Joe Munch in MD Anderson's Department of Scientific Publications for editing the manuscript and Shen Gao for performing the experiment as described in Supplementary Figure S1. This work was supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant CA16672, National Natural Science Foundation of China (81171922) and Key Project Research Fund of Shaanxi Provincial Science and Technology Program, China (2008K27G01). No additional external funding for this study was received. The funding agency had no role in study design, data collection or analysis, decision to publish, or manuscript preparation.	Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chen G, 1999, DNA CELL BIOL, V18, P305, DOI 10.1089/104454999315367; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Conlon I, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-36; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Conlon IJ, 2001, NAT CELL BIOL, V3, P918, DOI 10.1038/ncb1001-918; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gao S, 2010, ENDOCRINOLOGY, V151, P3941, DOI 10.1210/en.2009-1080; Gemma A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-174; Gonzalo S, 2005, CELL CYCLE, V4, P752, DOI 10.4161/cc.4.6.1720; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hosohata K, 2003, MOL CELL BIOL, V23, P7019, DOI 10.1128/MCB.23.19.7019-7029.2003; Jakt LM, 2001, GENOME RES, V11, P112, DOI 10.1101/gr.148301; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; Langley RR, 2003, CANCER RES, V63, P2971; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2004, DEV BIOL, V273, P418, DOI 10.1016/j.ydbio.2004.05.035; Ma WC, 2010, CANCER EPIDEM BIOMAR, V19, P2445, DOI 10.1158/1055-9965.EPI-10-0565; Mal A, 2000, J CELL BIOL, V149, P281, DOI 10.1083/jcb.149.2.281; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; Peng Y, 2008, P NATL ACAD SCI USA, V105, P5236, DOI 10.1073/pnas.0712262105; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Reymann S, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-46; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shi W, 2009, RESPIROLOGY, V14, P656, DOI 10.1111/j.1440-1843.2009.01565.x; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Wachi S, 2005, BIOINFORMATICS, V21, P4205, DOI 10.1093/bioinformatics/bti688; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhou LR, 2006, J MOL ENDOCRINOL, V37, P283, DOI 10.1677/jme.1.02062	48	22	22	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1888	1900		10.1038/onc.2012.207	http://dx.doi.org/10.1038/onc.2012.207			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22665061	Green Accepted			2022-12-28	WOS:000317599900003
J	Kyrkou, A; Soufi, M; Bahtz, R; Ferguson, C; Bai, M; Parton, RG; Hoffmann, I; Zerial, M; Fotsis, T; Murphy, C				Kyrkou, A.; Soufi, M.; Bahtz, R.; Ferguson, C.; Bai, M.; Parton, R. G.; Hoffmann, I.; Zerial, M.; Fotsis, T.; Murphy, C.			RhoD participates in the regulation of cell-cycle progression and centrosome duplication	ONCOGENE			English	Article						RhoD; proliferation; centrosome cycle	CENTRIOLE DUPLICATION; ENDOSOME DYNAMICS; GTPASES; EXPRESSION; BINDING; PROTEIN; RAC1; NUCLEOPHOSMIN/B23; PHOSPHORYLATION; MICROTUBULES	We have previously identified a Rho protein, RhoD, which localizes to the plasma membrane and the early endocytic compartment. Here, we show that a GTPase-deficient mutant of RhoD, RhoDG26V, causes hyperplasia and perturbed differentiation of the epidermis, when targeted to the skin of transgenic mice. In vitro, gain-of-function and loss-of-function approaches revealed that RhoD is involved in the regulation of G1/S-phase progression and causes overduplication of centrosomes. Centriole overduplication assays in aphidicolin-arrested p53-deficient U2OS cells, in which the cell and the centrosome cycles are uncoupled, revealed that the effects of RhoD and its mutants on centrosome duplication and cell cycle are independent. Enhancement of G1/S-phase progression was mediated via Diaph1, a novel effector of RhoD, which we have identified using a two-hybrid screen. These results indicate that RhoD participates in the regulation of cell-cycle progression and centrosome duplication. Oncogene (2013) 32, 1831-1842; doi: 10.1038/onc.2012.195; published online 4 June 2012	[Kyrkou, A.; Soufi, M.; Fotsis, T.] Univ Ioannina, Sch Med, Lab Biol Chem, GR-45110 Ioannina, Greece; [Kyrkou, A.; Fotsis, T.; Murphy, C.] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Dept Biomed Res, Ioannina 45110, Greece; [Bahtz, R.; Hoffmann, I.] German Canc Res Ctr, Heidelberg, Germany; [Ferguson, C.; Parton, R. G.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Ferguson, C.; Parton, R. G.] Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld, Australia; [Bai, M.] Univ Ioannina, Sch Med, Dept Pathol, GR-45110 Ioannina, Greece; [Zerial, M.] Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Helmholtz Association; German Cancer Research Center (DKFZ); University of Queensland; University of Queensland; University of Ioannina; Max Planck Society	Murphy, C (corresponding author), Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Dept Biomed Res, Univ Campus Ioannina, Ioannina 45110, Greece.	cmurphy@cc.uoi.gr	Murphy, Carol/ABE-4282-2021; Parton, Robert/C-5673-2009	Murphy, Carol/0000-0003-1353-8558; Parton, Robert/0000-0002-7494-5248	European Commission [HRPN-CT-2000-00081]; short-term EMBO fellowship; Biotechnology of the University of Ioannina; Ministry of Education and Religious Affairs of Greece; E.U.-European Social Fund; Greek Ministry of Development-GSRT; National Health and Medical Research Council of Australia	European Commission(European CommissionEuropean Commission Joint Research Centre); short-term EMBO fellowship; Biotechnology of the University of Ioannina; Ministry of Education and Religious Affairs of Greece; E.U.-European Social Fund(European Social Fund (ESF)European Commission); Greek Ministry of Development-GSRT(Greek Ministry of Development-GSRT); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank the confocal laser microscope facility of the University of Ioannina for the use of the Leica TCS-SP confocal microscope. We thank George Bartholomatos for FACS analysis; Zoi Lygerou, University of Patras, Greece for critical reading of the manuscript; George Keech for excellent animal husbandry; and Angelika Giner for expert technical assistance. This work was supported by a Research Training Network grant (to MZ and CM) of the European Commission (contract no: HRPN-CT-2000-00081). CM was supported by a short-term EMBO fellowship. MS was supported by the Postgraduate Master's Program of Biotechnology of the University of Ioannina funded by the Ministry of Education and Religious Affairs of Greece. AK was supported by the PENED 03E Delta 688 program, which was co-financed by E.U.-European Social Fund (75%) and the Greek Ministry of Development-GSRT (25%). RGP was supported by grants from the National Health and Medical Research Council of Australia.	BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bellou S, 2009, AM J PHYSIOL-CELL PH, V297, pC1477, DOI 10.1152/ajpcell.00058.2009; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Christoforidis S, 2000, METHODS, V20, P403, DOI 10.1006/meth.2000.0953; Cizmecioglu O, 2008, CELL CYCLE, V7, P3548, DOI 10.4161/cc.7.22.7071; Cizmecioglu O, 2010, J CELL BIOL, V191, P731, DOI 10.1083/jcb.201007107; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eckerdt F, 2011, CURR BIOL, V21, P428, DOI 10.1016/j.cub.2011.01.072; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kato T, 2001, J CELL SCI, V114, P775; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Krause A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009849; Kubo A, 2003, J CELL SCI, V116, P919, DOI 10.1242/jcs.00282; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Ma Z, 2006, MOL CELL BIOL, V26, P9016, DOI 10.1128/MCB.01383-06; Mammoto A, 2004, J BIOL CHEM, V279, P26323, DOI 10.1074/jbc.M402725200; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Murphy C, 2001, EUR J CELL BIOL, V80, P391, DOI 10.1078/0171-9335-00173; Nagasaki T, 1996, J CELL SCI, V109, P2461; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Panopoulou E, 2005, CANCER RES, V65, P1877, DOI 10.1158/0008-5472.CAN-04-2828; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Sflomos G, 2011, J CELL SCI, V124, P3209, DOI 10.1242/jcs.062307; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Tong Y, 2007, J BIOL CHEM, V282, P37215, DOI 10.1074/jbc.M703800200; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; Villalonga P, 2006, GROWTH FACTORS, V24, P159, DOI 10.1080/08977190600560651; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; Wen YD, 2004, KENYON REV, V26, P1; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Zanata SM, 2002, J NEUROSCI, V22, P471, DOI 10.1523/JNEUROSCI.22-02-00471.2002	47	14	15	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1831	1842		10.1038/onc.2012.195	http://dx.doi.org/10.1038/onc.2012.195			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22665057				2022-12-28	WOS:000317043900009
J	Hollern, DP; Yuwanita, I; Andrechek, ER				Hollern, D. P.; Yuwanita, I.; Andrechek, E. R.			A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin- low human breast cancer	ONCOGENE			English	Article						Myc; Ras; breast cancer; mammary gland; mutation	TRANSGENIC MICE; GENE; RAS; AMPLIFICATION; PROTEIN; OVEREXPRESSION; CLASSIFICATION; TUMORIGENESIS; HETEROGENEITY; ACTIVATION	Expression of c-Myc is highly prevalent in human breast cancer and stability of the oncoprotein is regulated through Ras-regulated phosphorylation at serine 62 and threonine 58. Previous studies have illustrated the importance of accumulation of KRas mutations in Myc-mediated tumor formation. To examine Myc dependence upon Ras mutations we have generated MMTV regulated Myc and Myc T58A transgenic mice. Expression of the more stable T58A Myc allele resulted in a reduction in KRas-activating mutations. However, in a low-level expression T58A Myc transgenic, the majority of the tumors were squamous or epithelial-to-mesenchymal in nature and accumulated KRas mutations at a higher frequency. Interestingly, we show that these mice develop similar gene expression patterns and signaling pathway utilization as a subtype of human claudin-low breast cancer. Indeed, our results demonstrate a clear division in human claudin-low tumors based on Myc pathway activation and target genes. Together, our results demonstrate that Myc expression and stability has critical effects on molecular heterogeneity in mouse mammary tumors that parallel subtypes of human breast cancer. Oncogene (2013) 32, 1296-1304; doi:10.1038/onc.2012.142; published online 23 April 2012	[Hollern, D. P.; Yuwanita, I.; Andrechek, E. R.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	Michigan State University	Andrechek, ER (corresponding author), Michigan State Univ, Dept Physiol, 2194 BPS Bldg, E Lansing, MI 48824 USA.	andrech1@msu.edu		Andrechek, Eran/0000-0002-8680-3423	Elsa U Pardee foundation	Elsa U Pardee foundation	A portion of this project was funded by a grant from the Elsa U Pardee foundation to ERA.	AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Andrechek ER, 2008, DEVELOPMENT, V135, P2403, DOI 10.1242/dev.019018; Andrechek ER, 2010, J MOL MED, V88, P1095, DOI 10.1007/s00109-010-0644-z; Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Blancato J, 2004, BRIT J CANCER, V90, P1612, DOI 10.1038/sj.bjc.6601703; Chrzan P, 2001, CLIN BIOCHEM, V34, P557, DOI 10.1016/S0009-9120(01)00260-0; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032	30	17	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1296	1304		10.1038/onc.2012.142	http://dx.doi.org/10.1038/onc.2012.142			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22525269				2022-12-28	WOS:000316454500010
J	Campbell, HG; Mehta, R; Neumann, AA; Rubio, C; Baird, M; Slatter, TL; Braithwaite, AW				Campbell, H. G.; Mehta, R.; Neumann, A. A.; Rubio, C.; Baird, M.; Slatter, T. L.; Braithwaite, A. W.			Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD)	ONCOGENE			English	Article						p53; apoptosis; DNA repair	LI-FRAUMENI-SYNDROME; FUNCTIONAL DOMAIN; TUMOR-SUPPRESSOR; MICE LACKING; APOPTOSIS; E1A; TRANSACTIVATION; PROTEINS; REGION; CELLS	The tumor suppressor protein, p53 is one of the most important cellular defences against malignant transformation. In response to cellular stressors p53 can induce apoptosis, cell cycle arrest or senescence as well as aid in DNA repair. Which p53 function is required for tumor suppression is unclear. The proline-rich domain (PRD) of p53 (residues 58-101) has been reported to be essential for the induction of apoptosis. To determine the importance of the PRD in tumor suppression in vivo we previously generated a mouse containing a 33-amino-acid deletion (residues 55-88) in p53 (m Delta pro). We showed that m Delta pro mice are protected from T-cell tumors but not late-onset B-cell tumors. Here, we characterize the functionality of the PRD and show that it is important for mediating the p53 response to DNA damage induced by gamma-radiation, but not the p53-mediated responses to Ha-Ras expression or oxidative stress. We conclude that the PRD is important for receiving incoming activating signals. Failure of PRD mutants to respond to the activating signaling produced by DNA damage leads to impaired downstream signaling, accumulation of mutations, which potentially leads to late-onset tumors. Oncogene (2013) 32, 827-836; doi:10.1038/onc.2012.102; published online 9 April 2012	[Campbell, H. G.; Mehta, R.; Neumann, A. A.; Rubio, C.; Braithwaite, A. W.] Univ Sydney, Childrens Med Res Inst, Sydney, NSW 2006, Australia; [Baird, M.] Univ Otago, Dept Microbiol & Immunol, Sch Med Sci, Dunedin, New Zealand; [Slatter, T. L.; Braithwaite, A. W.] Univ Otago, Sch Med, Dept Pathol, Dunedin, New Zealand	Children's Medical Research Institute - Australia; University of Sydney; University of Otago; University of Otago	Braithwaite, AW (corresponding author), Childrens Med Res Inst, Cell Transformat Unit, Locked Bag 23, Wentworthville, NSW 2145, Australia.	abraithwaite@cmri.org.au						Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Braithwaite AW, 2005, CARCINOGENESIS, V26, P1161, DOI 10.1093/carcin/bgi091; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Edwards SJ, 2003, ONCOGENE, V22, P4517, DOI 10.1038/sj.onc.1206726; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hansen RS, 1996, ONCOGENE, V13, P995; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORN PL, 1984, J CELL PHYSIOL, V121, P309, DOI 10.1002/jcp.1041210207; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Salvador JM, 2002, IMMUNITY, V16, P499, DOI 10.1016/S1074-7613(02)00302-3; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Slatter TL, 2010, CELL DEATH DIFFER, V17, P540, DOI 10.1038/cdd.2009.136; TEODORO JG, 1995, ONCOGENE, V11, P467; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Toledo F, 2007, MOL CELL BIOL, V27, P1425, DOI 10.1128/MCB.00999-06; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xu J., 2001, PREPARATION CULTURE	37	10	10	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2013	32	7					827	836		10.1038/onc.2012.102	http://dx.doi.org/10.1038/onc.2012.102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22484427				2022-12-28	WOS:000316581100003
J	Peschiaroli, A; Giacobbe, A; Formosa, A; Markert, EK; Bongiorno-Borbone, L; Levine, AJ; Candi, E; D'Alessandro, A; Zolla, L; Agro, AF; Melino, G				Peschiaroli, A.; Giacobbe, A.; Formosa, A.; Markert, E. K.; Bongiorno-Borbone, L.; Levine, A. J.; Candi, E.; D'Alessandro, A.; Zolla, L.; Agro, A. Finazzi; Melino, G.			miR-143 regulates hexokinase 2 expression in cancer cells	ONCOGENE			English	Article						miRNAs; hexokinases; prostate cancer; breast cancer; glucose metabolism	DOWN-REGULATION; II HEXOKINASE; GLUCOSE CATABOLISM; GENE; METABOLISM; WARBURG; MICRORNAS; CARCINOMA; TARGET; MITOCHONDRIA	Tumor cells activate pathways that facilitate and stimulate glycolysis even in the presence of adequate levels of oxygen in order to satisfy their continuous need of molecules, such as nucleotides, ATP and fatty acids, necessary to support their rapid proliferation. Accordingly, a variety of human tumors are characterized by elevated expression levels of the hexokinase 2 isoform (HK2). Although different molecular mechanisms, including genetic and epigenetic mechanisms, have been suggested to account for the altered expression of HK2 in tumors, the potential role of microRNAs (miRNAs) in the regulation of HK2 expression has not been evaluated. Here, we report that miR-143 inhibits HK2 expression via a conserved miR-143 recognition motif located in the 3'-untranslated region (3'UTR) of HK2 mRNA. We demonstrate that miR143 inhibits HK2 expression both in primary keratinocytes and in head and neck squamous cell carcinoma (HNSCC)-derived cell lines. Importantly, we found that miR-143 inversely correlates with HK2 expression in HNSCC-derived cell lines and in primary tumors. We also report that the miRNA-dependent regulation of hexokinase expression is not limited to HK2 as miR-138 targets HK1 via a specific recognition motif located in its 3'UTR. All these data unveil a new miRNA-dependent mechanism of regulation of hexokinase expression potentially important in the regulation of glucose metabolism of cancer cells.	[Peschiaroli, A.] CNR, Inst Cellular Biol & Neurobiol, Rome, Italy; [Peschiaroli, A.; Formosa, A.; Melino, G.] Univ Roma Tor Vergata, IDI IRCCS Biochem Lab, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; [Giacobbe, A.; Bongiorno-Borbone, L.; Candi, E.; Agro, A. Finazzi] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; [Markert, E. K.; Levine, A. J.] Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA; [D'Alessandro, A.; Zolla, L.] Univ Tuscia, Dept Environm Sci, Viterbo, Italy; [Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata; University of Rome Tor Vergata; Institute for Advanced Study - USA; Tuscia University; University of Leicester	Melino, G (corresponding author), Univ Roma Tor Vergata, IDI IRCCS Biochem Lab, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.	peschiaroli@med.uniroma2.it; melino@uniroma2.it	D'Alessandro, Angelo/AAA-4695-2019	D'Alessandro, Angelo/0000-0002-2258-6490; PESCHIAROLI, ANGELO/0000-0001-6311-2382; Giacobbe, Arianna/0000-0002-5874-1851	Medical Research Council, UK; Alleanza contro il Cancro [ACC12]; MIUR/PRIN [20078P7T3K_001)/FIRB, RBIP06LCA9_0023, RBIP06LCA9_0C, 2008MRLSNZ_004]; AIRC [5471, 2011-IG11955]; Telethon Grant [GGPO9133]; AIRC 5xmille [9979, RF06, c.73, RF08 c.15, RF07 c.57]; Ric. Finalizzata [08-GIOV_RIC]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alleanza contro il Cancro; MIUR/PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); Telethon Grant(Fondazione Telethon); AIRC 5xmille(Fondazione AIRC per la ricerca sul cancro); Ric. Finalizzata; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been supported by the Medical Research Council, UK; grants from 'Alleanza contro il Cancro' Grant (ACC12), MIUR/PRIN (20078P7T3K_001)/FIRB (RBIP06LCA9_0023, RBIP06LCA9_0C), AIRC grant no. 5471; 2011-IG11955), Telethon Grant GGPO9133 to GM, MIUR/PRIN 2008MRLSNZ_004, AIRC 5xmille (no. 9979), RF06 c.73, RF08 c.15, RF07 c.57 awarded to GM and EC. Research described in this article was also supported by Ric. Finalizzata 08-GIOV_RIC awarded to AP.	Aberdam D, 2008, TRENDS BIOCHEM SCI, V33, P583, DOI 10.1016/j.tibs.2008.09.002; Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bhatnagar N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.85; Boettger T, 2009, J CLIN INVEST, V119, P2634, DOI 10.1172/JCI38864; Borralho PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023787; Cook CC, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.141; Davis-Dusenbery BN, 2011, J BIOL CHEM, V286, P28097, DOI 10.1074/jbc.M111.236950; Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Israel M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-70; Jiang L, 2011, HUM GENET, V129, P189, DOI 10.1007/s00439-010-0915-3; Kolev V, 2008, NAT CELL BIOL, V10, DOI 10.1038/ncb1750; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Liu XQ, 2009, CANCER LETT, V286, P217, DOI 10.1016/j.canlet.2009.05.030; Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025; Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mitomo S, 2008, CANCER SCI, V99, P280, DOI 10.1111/j.1349-7006.2007.00666.x; Morton SU, 2008, P NATL ACAD SCI USA, V105, P17830, DOI 10.1073/pnas.0804673105; Munoz-Pinedo C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.123; Noguchi S, 2011, CANCER LETT, V307, P211, DOI 10.1016/j.canlet.2011.04.005; Pedersen PL, 2008, J BIOENERG BIOMEMBR, V40, P123, DOI 10.1007/s10863-008-9165-7; Rempel A, 1996, CANCER RES, V56, P2468; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Siegel G, 2009, NAT CELL BIOL, V11, P705, DOI 10.1038/ncb1876; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tsai HJ, 1996, ARCH BIOCHEM BIOPHYS, V329, P17, DOI 10.1006/abbi.1996.0186; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Chunmei, 2007, Journal of Genetics and Genomics, V34, P966, DOI 10.1016/S1673-8527(07)60109-X; WARBURG O, 1956, SCIENCE, V124, P269; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470	40	138	147	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					797	802		10.1038/onc.2012.100	http://dx.doi.org/10.1038/onc.2012.100			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22469988				2022-12-28	WOS:000315746700013
J	Keum, YS; Kim, HG; Bode, AM; Surh, YJ; Dong, Z				Keum, Y-S; Kim, H-G; Bode, A. M.; Surh, Y-J; Dong, Z.			UVB-induced COX-2 expression requires histone H3 phosphorylation at Ser10 and Ser28	ONCOGENE			English	Article						COX-2; UVB; histone H3; phosphorylation; Cdk9; RNA polymerase II	CHROMATIN MODIFICATIONS; RNA; METHYLATION; CYCLOOXYGENASE-2; ACETYLATION; SERINE-10; HUR	Cyclooxygenase-2 (COX-2) is an inducible enzyme that contributes to the generation of chronic inflammation in response to chemical carcinogens and environmental stresses, including ultraviolet B (UVB) irradiation. Although post-translational histone modifications are believed to have an important role in modulating transcriptional regulation of UVB-induced COX-2, the underlying biochemical mechanisms are completely unknown. Here, we show that UVB activates the p38 MAPK/MSK1 kinase cascade to phosphorylate histone H3 at Ser10 and Ser28, contributing to UVB-induced COX-2 expression. UVB has no effect on the global tri-methylation level of histone H3 (H3K4me3, H3K9me3, and H3K27me3). We observed that selected mammalian 14-3-3 proteins bind to UVB-induced phosphorylated histone H3 (Ser10 and Ser28). In particular, 14-3-3 epsilon is critical for recruiting MSK1 and Cdk9 to the chromatin and subsequently phosphorylating the C-terminal domain of RNA polymerase II in the cox-2 promoter. We propose that histone H3 phosphorylation at Ser10 and Ser28 serve as critical switches to promote cox-2 gene expression by facilitating the recruitment of MSK1 and Cdk9 to the cox-2 promoter, thereby promoting RNA polymerase II phosphorylation. Oncogene (2013) 32, 444-452; doi:10.1038/onc.2012.71; published online 5 March 2012	[Keum, Y-S; Kim, H-G; Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Surh, Y-J; Dong, Z.] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Chem, WCU Program, Seoul, South Korea; [Surh, Y-J; Dong, Z.] Seoul Natl Univ, Coll Med, Seoul, South Korea; [Keum, Y-S] Dongguk Univ, Coll Pharm, Dept Biochem, Goyang, South Korea	University of Minnesota System; Seoul National University (SNU); Seoul National University (SNU); Dongguk University	Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu			Hormel Foundation; National Institutes of Health [CA120388, R37 CA081064, ES016548]; Korea WCU project of the MEST [R31-2008-000-10103-0]; NRF; NATIONAL CANCER INSTITUTE [R37CA081064, R01CA120388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016548] Funding Source: NIH RePORTER	Hormel Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Korea WCU project of the MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea); NRF; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by The Hormel Foundation and National Institutes of Health grants CA120388, R37 CA081064, ES016548 and Grant no. R31-2008-000-10103-0 from the Korea WCU project of the MEST and the NRF.	Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Bachelor MA, 2005, MOL CANCER RES, V3, P90, DOI 10.1158/1541-7786.MCR-04-0065; Bernstein E, 2006, MOL CELL BIOL, V26, P2560, DOI 10.1128/MCB.26.7.2560-2569.2006; Bode Ann M, 2005, Sci STKE, V2005, pre4, DOI 10.1126/stke.2812005re4; Buratowski S, 2009, MOL CELL, V36, P541, DOI 10.1016/j.molcel.2009.10.019; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Egloff S, 2008, TRENDS GENET, V24, P280, DOI 10.1016/j.tig.2008.03.008; Fernau NS, 2010, J BIOL CHEM, V285, P3896, DOI 10.1074/jbc.M109.081430; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Johansen KM, 2006, CHROMOSOME RES, V14, P393, DOI 10.1007/s10577-006-1063-4; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Perez-Cadahia B, 2009, BIOCHEM CELL BIOL, V87, P695, DOI 10.1139/O09-053; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Rundhaug JE, 2008, PHOTOCHEM PHOTOBIOL, V84, P322, DOI 10.1111/j.1751-1097.2007.00261.x; Rundhaug JE, 2007, MOL CARCINOGEN, V46, P692, DOI 10.1002/mc.20329; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang GG, 2007, TRENDS MOL MED, V13, P363, DOI 10.1016/j.molmed.2007.07.003; Winter S, 2008, CELL CYCLE, V7, P1336, DOI 10.4161/cc.7.10.5946; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhang J, 2008, MOL CARCINOGEN, V47, P974, DOI 10.1002/mc.20450; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200	32	35	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					444	452		10.1038/onc.2012.71	http://dx.doi.org/10.1038/onc.2012.71			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391560	Green Accepted			2022-12-28	WOS:000315551300005
J	Ivanov, SV; Panaccione, A; Brown, B; Guo, Y; Moskaluk, CA; Wick, MJ; Brown, JL; Ivanova, AV; Issaeva, N; El-Naggar, AK; Yarbrough, WG				Ivanov, S. V.; Panaccione, A.; Brown, B.; Guo, Y.; Moskaluk, C. A.; Wick, M. J.; Brown, J. L.; Ivanova, A. V.; Issaeva, N.; El-Naggar, A. K.; Yarbrough, W. G.			TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior	ONCOGENE			English	Article						TrkC; Bcl2; neurotrophin-3; migration; salivary adenoid cystic carcinoma; invasion	SALIVARY-GLAND TUMORS; TYROSINE KINASE RECEPTOR; ETV6-NTRK3 GENE FUSION; CELL-PROLIFERATION; NEUROTROPHIN RECEPTORS; NEUROBLASTOMA-CELLS; MYOEPITHELIAL CELLS; SOMATIC MUTATIONS; BREAST-CANCER; EXPRESSION	Treatment options for adenoid cystic carcinoma (ACC) of the salivary gland, a slowly growing tumor with propensity for neuroinvasion and late recurrence, are limited to surgery and radiotherapy. Based on expression analysis performed on clinical specimens of salivary cancers, we identified in ACC expression of the neurotrophin-3 receptor TrkC/NTRK3, neural crest marker SOX10, and other neurologic genes. Here, we characterize TrkC as a novel ACC marker, which was highly expressed in 17 out of 18 ACC primary-tumor specimens, but not in mucoepidermoid salivary carcinomas or head and neck squamous cell carcinoma. Expression of the TrkC ligand NT-3 and Tyr-phosphorylation of TrkC detected in our study suggested the existence of an autocrine signaling loop in ACC with potential therapeutic significance. NT-3 stimulation of U2OS cells with ectopic TrkC expression triggered TrkC phosphorylation and resulted in Ras, Erk 1/2 and Akt activation, as well as VEGFR1 phosphorylation. Without NT-3, TrkC remained unphosphorylated, stimulated accumulation of phospho-p53 and had opposite effects on p-Akt and p-Erk 1/2. NT-3 promoted motility, migration, invasion, soft-agar colony growth and cytoskeleton restructuring in TrkC-expressing U2OS cells. Immunohistochemical analysis demonstrated that TrkC-positive ACC specimens also show high expression of Bcl2, a Trk target regulated via Erk 1/2, in agreement with activation of the TrkC pathway in real tumors. In normal salivary gland tissue, both TrkC and Bcl2 were expressed in myoepithelial cells, suggesting a principal role for this cell lineage in the ACC origin and progression. Sub-micromolar concentrations of a novel potent Trk inhibitor AZD7451 completely blocked TrkC activation and associated tumorigenic behaviors. Pre-clinical studies on ACC tumors engrafted in mice showed efficacy and low toxicity of AZD7451, validating our in vitro data and stimulating more research into its clinical application. In summary, we describe in ACC a previously unrecognized pro-survival neurotrophin signaling pathway and link it with cancer progression.	[Ivanov, S. V.; Panaccione, A.; Ivanova, A. V.; Issaeva, N.; Yarbrough, W. G.] Yale Univ, Sch Med, Dept Surg, Otolaryngol Sect, New Haven, CT 06510 USA; [Panaccione, A.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Brown, B.] Vanderbilt Univ, Sch Med, Dept Otolaryngol, Nashville, TN 37212 USA; [Brown, B.] Vanderbilt Univ, Sch Med, Barry Baker Lab Head & Neck Oncol, Nashville, TN 37212 USA; [Guo, Y.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA; [Moskaluk, C. A.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Wick, M. J.] South Texas Accelerated Res Therapeut, Sun Antonio, TX USA; [Brown, J. L.] AstraZeneca R&D Boston, Waltham, MA USA; [El-Naggar, A. K.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Yarbrough, W. G.] Smilow Canc Hosp, H&N Dis Ctr, New Haven, CT USA; [Yarbrough, W. G.] Yale Canc Ctr, Mol Virol Program, New Haven, CT USA	Yale University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Virginia; AstraZeneca; University of Texas System; UTMD Anderson Cancer Center; Yale University	Ivanov, SV (corresponding author), Yale Phys Bldg,800 Howard Ave,4th Floor, New Haven, CT 06519 USA.	sergey.ivanov@yale.edu; wendell.yarbrough@yale.edu	Issaeva, Natalia/K-4577-2019	Issaeva, Natalia/0000-0001-5483-6610; Ivanov, Sergey/0000-0001-9770-7237	Adenoid Cystic Carcinoma Research Foundation; NIH from the National Institute of Dental and Craniofacial Research [5RC1DE020332-02]; Vanderbilt Ingram Cancer Center; Vanderbilt Bill Wilkerson Center for Otolaryngology and Communication Sciences; Robert J Kleberg Jr and Helen C Kleberg Foundation; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [RC1DE020332] Funding Source: NIH RePORTER	Adenoid Cystic Carcinoma Research Foundation; NIH from the National Institute of Dental and Craniofacial Research; Vanderbilt Ingram Cancer Center; Vanderbilt Bill Wilkerson Center for Otolaryngology and Communication Sciences; Robert J Kleberg Jr and Helen C Kleberg Foundation; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was supported by funds from the Adenoid Cystic Carcinoma Research Foundation to SI and WGY and by the NIH Challenge Grant 5RC1DE020332-02 from the National Institute of Dental and Craniofacial Research to WGY. This work was also supported in part by the Vanderbilt Ingram Cancer Center, the Vanderbilt Bill Wilkerson Center for Otolaryngology and Communication Sciences, the Robert J Kleberg Jr and Helen C Kleberg Foundation, and by an endowment to the Barry Baker Laboratory for Head and Neck Oncology.	Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Azevedo RS, 2008, HEAD NECK PATHOL, V2, P257, DOI 10.1007/s12105-008-0074-1; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Barnabe-Heider F, 2003, J NEUROSCI, V23, P5149; Bartkowska K, 2007, DEVELOPMENT, V134, P4369, DOI 10.1242/dev.008227; Bohm J, 2008, AM J PATHOL, V173, P1455, DOI 10.2353/ajpath.2008.071039; Bouzas-Rodriguez J, 2010, J CLIN INVEST, V120, P850, DOI 10.1172/JCI41013; Buzanska L, 2010, TOXICOLOGY, V270, P35, DOI 10.1016/j.tox.2009.06.005; Chummun S, 2001, BRIT J PLAST SURG, V54, P476, DOI 10.1054/bjps.2001.3636; DARDICK I, 1985, HEAD NECK SURG, V7, P395, DOI 10.1002/hed.2890070509; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Edsjo A, 2001, CELL GROWTH DIFFER, V12, P39; Fagiani E, 2007, CANCER RES, V67, P3064, DOI 10.1158/0008-5472.CAN-06-2301; Fernandez RM, 2009, ANN HUM GENET, V73, P19, DOI 10.1111/j.1469-1809.2008.00479.x; FITZPATRICK PJ, 1986, INT J RADIAT ONCOL, V12, P1743, DOI 10.1016/0360-3016(86)90314-7; Frenzel A, 2009, APOPTOSIS, V14, P584, DOI 10.1007/s10495-008-0300-z; Goldberg L, 2006, CANCER RES, V66, P11709, DOI 10.1158/0008-5472.CAN-06-1878; Hardy G, 1998, SADJ, V53, P371; Harel L, 2010, DEV NEUROBIOL, V70, P298, DOI 10.1002/dneu.20769; HUBNER G, 1971, CANCER-AM CANCER SOC, V27, P1255, DOI 10.1002/1097-0142(197105)27:5<1255::AID-CNCR2820270533>3.0.CO;2-1; Jaglin XH, 2009, NAT GENET, V41, P746, DOI 10.1038/ng.380; JAO W, 1976, CANCER, V37, P1322, DOI 10.1002/1097-0142(197603)37:3<1322::AID-CNCR2820370313>3.0.CO;2-7; Jin W, 2008, J BIOL CHEM, V283, P1391, DOI 10.1074/jbc.M705052200; Jin W, 2010, CARCINOGENESIS, V31, P1939, DOI 10.1093/carcin/bgq180; Katayama K, 2009, PLOS ONE, V4, pA151, DOI 10.1371/journal.pone.0007786; Katoh M, 2011, CURR PHARM BIOTECHNO, V12, P160, DOI 10.2174/138920111794295710; Kelsh RN, 2006, BIOESSAYS, V28, P788, DOI 10.1002/bies.20445; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kruttgen A, 2006, BRAIN PATHOL, V16, P304, DOI 10.1111/j.1750-3639.2006.00037.x; Kumar S, 1998, J NEUROSCI RES, V54, P754, DOI 10.1002/(SICI)1097-4547(19981215)54:6<754::AID-JNR3>3.0.CO;2-K; Kummoona R, 2008, J ORAL PATHOL MED, V37, P345, DOI 10.1111/j.1600-0714.2007.00624.x; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Lannon CL, 2005, SEMIN CANCER BIOL, V15, P215, DOI 10.1016/j.semcancer.2005.01.003; Lavoie JF, 2005, J BIOL CHEM, V280, P29199, DOI 10.1074/jbc.M502364200; Marchetti D, 2007, J EXP CLIN CANC RES, V26, P5; Marchetti D, 2003, PATHOL ONCOL RES, V9, P147, DOI 10.1007/BF03033729; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Mehlen P, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3151pe47; Montano X, 1997, ONCOGENE, V15, P245, DOI 10.1038/sj.onc.1201215; Montano X, 2009, ONCOGENE, V28, P3787, DOI 10.1038/onc.2009.143; Moskaluk CA, 2011, LAB INVEST, V91, P1480, DOI 10.1038/labinvest.2011.105; Nikoletopoulou V, 2010, NATURE, V467, P59, DOI 10.1038/nature09336; Phuchareon J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006040; Postigo A, 2002, GENE DEV, V16, P633, DOI 10.1101/gad.217902; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rajan N, 2011, ONCOGENE, V30, P4243, DOI 10.1038/onc.2011.133; REGEZI JA, 1977, OTOLARYNG CLIN N AM, V10, P297; Rottner K, 2010, TRENDS CELL BIOL, V20, P650, DOI 10.1016/j.tcb.2010.08.014; Sakamoto Y, 2001, ONCOL REP, V8, P477; Sanchez-Mejias A, 2009, J MED GENET, V46, P862, DOI 10.1136/jmg.2009.067819; Sinnappah-Kang ND, 2005, INT J ONCOL, V27, P617; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Slebos RJC, 2006, CLIN CANCER RES, V12, P701, DOI 10.1158/1078-0432.CCR-05-2017; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sundram U, 2003, MODERN PATHOL, V16, P802, DOI 10.1097/01.MP.0000081726.49886.CF; Tauszig-Delamasure S, 2011, EXPERT OPIN THER TAR, V15, P847, DOI 10.1517/14728222.2011.575361; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Wang T, 2008, J MED CHEM, V51, P4672, DOI 10.1021/jm800343j; Wang T, 2009, EXPERT OPIN THER PAT, V19, P305, DOI 10.1517/13543770902721261; Wood Laura D, 2006, Hum Mutat, V27, P1060, DOI 10.1002/humu.9452; Wu SM, 2010, STEM CELL RES, V4, P38, DOI 10.1016/j.scr.2009.09.002; Zandi R, 2007, CELL SIGNAL, V19, P2013, DOI 10.1016/j.cellsig.2007.06.023; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475	65	51	53	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3698	3710		10.1038/onc.2012.377	http://dx.doi.org/10.1038/onc.2012.377			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	23027130				2022-12-28	WOS:000322904400005
J	Xuan, C; Wang, Q; Han, X; Duan, Y; Li, L; Shi, L; Wang, Y; Shan, L; Yao, Z; Shang, Y				Xuan, C.; Wang, Q.; Han, X.; Duan, Y.; Li, L.; Shi, L.; Wang, Y.; Shan, L.; Yao, Z.; Shang, Y.			RBB, a novel transcription repressor, represses the transcription of HDM2 oncogene	ONCOGENE			English	Article						MDM2; p53; RBB; transcription repressor; NuRD complex	PROTEIN INTERACTION MOTIF; ACUTE PROMYELOCYTIC LEUKEMIA; POZ-DOMAIN; TUMOR-SUPPRESSOR; DOWN-REGULATION; MDM2 GENE; P53; COREPRESSOR; EXPRESSION; PROMOTES	The p53 tumor suppressor is important in many aspects of cell biology. Tight regulation of p53 is thus imperative for maintaining cell homeostasis and preventing tumorigenesis. The stabilization and activity of p53 is primarily regulated by MDM2, which is encoded for by HDM2. However, how the expression and activity of MDM2 is regulated remains largely unknown. Here, we report a novel BTB and BEN domains-containing protein, RBB. We demonstrated that RBB is a novel transcriptional repressor binding specific DNA motif via a homodimer and interacting with the nucleosome remodeling and deacetylase (NuRD) complex. Genome wide transcription target analysis by ChIP sequencing revealed that RBB represses the transcription of a series of functionally important genes including HDM2. We showed that RBB recruits the NuRD complex to the internal promoter of HDM2 and inhibits the expression of MDM2 protein, leading to subsequent stabilization of tumor suppressor p53. Significantly, we showed that RBB suppresses cell proliferation and sensitizes cells to DNA damage-induced apoptosis. Our data indicate that RBB is a novel transcriptional repressor and an important regulator of p53 pathway.	[Xuan, C.; Wang, Q.; Duan, Y.; Li, L.; Shi, L.; Wang, Y.; Shan, L.; Yao, Z.; Shang, Y.] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Tianjin 300070, Peoples R China; [Wang, Q.; Yao, Z.] Tianjin Med Univ, Dept Immunol, Tianjin 300070, Peoples R China; [Han, X.] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res, Beijing 100871, Peoples R China	Tianjin Medical University; Tianjin Medical University; Peking University	Xuan, C (corresponding author), Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.	chenghaoxuan@bjmu.edu.cn; yshang@hsc.pku.edu.cn	duan, yang/GZA-6440-2022; Han, Xiao/A-1109-2017	Han, Xiao/0000-0002-5395-4022; Han, Xiao/0000-0002-6024-6286	National Natural Science Foundation of China [81000876, 81130048, 30921062]; Ministry of Science and Technology of China [2011CB504204]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by grants (81000876, 81130048 and 30921062 to YS) from the National Natural Science Foundation of China and grants (973 Program: 2011CB504204 to YS) from the Ministry of Science and Technology of China.	Abhiman S, 2008, BIOINFORMATICS, V24, P458, DOI 10.1093/bioinformatics/btn007; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Brooks CL, 2004, CELL CYCLE, V3, P895; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; Grochola LF, 2010, PANCREAS, V39, P76, DOI 10.1097/MPA.0b013e3181b9f105; Grzenda A, 2009, BBA-GENE REGUL MECH, V1789, P443, DOI 10.1016/j.bbagrm.2009.05.007; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Huynh KD, 2000, GENE DEV, V14, P1810; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Jung CR, 2010, J CLIN INVEST, V120, P4493, DOI 10.1172/JCI42674; JUVEN T, 1993, ONCOGENE, V8, P3411; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Xuan C, 2008, CELL MICROBIOL, V10, P31, DOI 10.1111/j.1462-5822.2007.01011.x; Xuan CH, 2007, J BIOL CHEM, V282, P28800, DOI 10.1074/jbc.M702823200; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334	52	13	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3711	3721		10.1038/onc.2012.386	http://dx.doi.org/10.1038/onc.2012.386			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22926524				2022-12-28	WOS:000322904400006
J	Chen, DWC; Saha, V; Liu, JZ; Schwartz, JM; Krstic-Demonacos, M				Chen, D. W-C; Saha, V.; Liu, J-Z; Schwartz, J-M; Krstic-Demonacos, M.			Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia	ONCOGENE			English	Article						glucocorticoid receptor; gene expression; systems biology; dynamic model	TRANSCRIPTION FACTOR ERG; FACTOR-KAPPA-B; GENE-EXPRESSION; C-JUN; INDUCED APOPTOSIS; TMPRSS2-ERG FUSION; BH3-ONLY PROTEINS; JNK PATHWAY; RECEPTOR; CELLS	Glucocorticoids (GCs) are among the most widely prescribed medications in clinical practice. The beneficial effects of GCs in acute lymphoblastic leukemia (ALL) are based on their ability to induce apoptosis, but the underlying transcriptional mechanisms remain poorly defined. Computational modeling has enormous potential in the understanding of biological processes such as apoptosis and the discovery of novel regulatory mechanisms. We here present an integrated analysis of gene expression kinetic profiles using microarrays from GC sensitive and resistant ALL cell lines and patients, including newly generated and previously published data sets available from the Gene Expression Omnibus. By applying time-series clustering analysis in the sensitive ALL CEM-C7-14 cells, we identified 358 differentially regulated genes that we classified into 15 kinetic profiles. We identified GC response element (GRE) sequences in 33 of the upregulated known or potential GC receptor (GR) targets. Comparative study of sensitive and resistant ALL showed distinct gene expression patterns and indicated unexpected similarities between sensitivity-restored and resistant ALL. We found that activator protein 1 (AP-1), Ets related gene (Erg) and GR pathways were differentially regulated in sensitive and resistant ALL. Erg protein levels were substantially higher in CEM-C1-15-resistant cells, c-Jun was significantly induced in sensitive cells, whereas c-Fos was expressed at low levels in both. c-Jun was recruited on the AP-1 site on the Bim promoter, whereas a transient Erg occupancy on the GR promoter was detected. Inhibition of Erg and activation of GR lead to increased apoptosis in both sensitive and resistant ALL. These novel findings significantly advance our understanding of GC sensitivity and can be used to improve therapy of leukemia.	[Chen, D. W-C; Schwartz, J-M; Krstic-Demonacos, M.] Univ Manchester, Fac Life Sci, Manchester M1 7DN, Lancs, England; [Saha, V.; Liu, J-Z] Univ Manchester, Sch Med, Manchester M1 7DN, Lancs, England; [Chen, D. W-C; Schwartz, J-M; Krstic-Demonacos, M.] Univ Manchester, Fac Life Sci, Manchester Inst Biotechnol, Manchester M1 7DN, Lancs, England	University of Manchester; University of Manchester; University of Manchester	Schwartz, JM (corresponding author), Univ Manchester, Fac Life Sci, Manchester Inst Biotechnol, Manchester M1 7DN, Lancs, England.	jean-marc.schwartz@manchester.ac.uk; m.k.demonacos@manchester.ac.uk	Schwartz, Jean-Marc/AAS-8274-2020	Schwartz, Jean-Marc/0000-0002-6472-0184; Saha, Vaskar/0000-0002-2916-9649				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Baldus CD, 2007, J CLIN ONCOL, V25, P3739, DOI 10.1200/JCO.2007.11.5253; Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580; Barrett TJ, 1996, BIOCHEMISTRY-US, V35, P9746, DOI 10.1021/bi960058j; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016; Birdsey GM, 2008, BLOOD, V111, P3498, DOI 10.1182/blood-2007-08-105346; Biswas SC, 2007, J BIOL CHEM, V282, P29368, DOI 10.1074/jbc.M702634200; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Cai JA, 2010, TRANSL ONCOL, V3, P195, DOI 10.1593/tlo.09328; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chen DWC, 2010, PHARMACOGENOMICS, V11, P1545, DOI [10.2217/pgs.10.125, 10.2217/PGS.10.125]; Davies L, 2008, MOL ENDOCRINOL, V22, P1331, DOI 10.1210/me.2007-0360; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Ernst J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-191; Ernst J, 2005, BIOINFORMATICS, V21, pI159, DOI 10.1093/bioinformatics/bti1022; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Geng CD, 2005, J BIOL CHEM, V280, P43264, DOI 10.1074/jbc.M508245200; Grice EA, 2010, P NATL ACAD SCI USA, V107, P14799, DOI 10.1073/pnas.1004204107; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hollenhorst PC, 2011, GENE DEV, V25, P2147, DOI 10.1101/gad.17546311; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jin JY, 2003, J PHARMACOL EXP THER, V307, P93, DOI 10.1124/jpet.103.053256; Kettritz R, 2004, J BIOL CHEM, V279, P2657, DOI 10.1074/jbc.M309778200; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; Leung KT, 2008, CARCINOGENESIS, V29, P544, DOI 10.1093/carcin/bgm294; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li L, 2004, J BIOL CHEM, V279, P4058, DOI 10.1074/jbc.M310415200; Loffler M, 1999, ONCOGENE, V18, P4626, DOI 10.1038/sj.onc.1202820; Lynch JT, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-38; Martens JHA, 2011, INT J BIOCHEM CELL B, V43, P1413, DOI 10.1016/j.biocel.2011.05.014; Medh RD, 1998, CANCER RES, V58, P3684; Medh RD, 2001, ONCOGENE, V20, P4629, DOI 10.1038/sj.onc.1204680; Miller AL, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-18; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Mitchell CD, 2005, BRIT J HAEMATOL, V129, P734, DOI 10.1111/j.1365-2141.2005.05509.x; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; Pearce D, 1998, J BIOL CHEM, V273, P30081, DOI 10.1074/jbc.273.46.30081; Ploner C, 2008, LEUKEMIA, V22, P370, DOI 10.1038/sj.leu.2405039; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; Rahim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019343; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Schmidt S, 2006, BLOOD, V107, P2061, DOI 10.1182/blood-2005-07-2853; Segal E, 2005, NAT GENET, V37, pS38, DOI 10.1038/ng1561; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; So AYL, 2007, PLOS GENET, V3, P927, DOI 10.1371/journal.pgen.0030094; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Thoms JAI, 2011, BLOOD, V117, P7079, DOI 10.1182/blood-2010-12-317990; Tsuzuki S, 2011, BLOOD, V10, P1182; Verger A, 2001, J BIOL CHEM, V276, P17181, DOI 10.1074/jbc.M010208200; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wen LP, 1997, AM J PHYSIOL-LUNG C, V273, pL921, DOI 10.1152/ajplung.1997.273.5.L921; White RJ, 2010, TRENDS GENET, V26, P214, DOI 10.1016/j.tig.2010.02.004; Xenaki G, 2008, ONCOGENE, V27, P5785, DOI 10.1038/onc.2008.192; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Zhao F, 2005, NUCLEIC ACIDS RES, V33, pD103, DOI 10.1093/nar/gki004; Zhou F, 1996, MOL ENDOCRINOL, V10, P306, DOI 10.1210/me.10.3.306; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	73	26	27	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3039	3048		10.1038/onc.2012.321	http://dx.doi.org/10.1038/onc.2012.321			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22869147				2022-12-28	WOS:000320705700004
J	Wolf, S; Rudolph, C; Morgan, M; Busche, G; Salguero, G; Stripecke, R; Schlegelberger, B; Baum, C; Modlich, U				Wolf, S.; Rudolph, C.; Morgan, M.; Buesche, G.; Salguero, G.; Stripecke, R.; Schlegelberger, B.; Baum, C.; Modlich, U.			Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas	ONCOGENE			English	Article						NRas; myelomonocytic leukemia; malignant histiocytosis; murine BMT model; retroviral vector; Evi1	ACUTE MYELOID-LEUKEMIA; N-RAS PROTOONCOGENE; HEMATOPOIETIC-CELLS; DENDRITIC CELLS; RETROVIRAL VECTORS; TRANSGENIC MICE; DOWN-REGULATION; TARGETING RAS; MOUSE MODEL; MUTATIONS	Activation of NRas signaling is frequently found in human myeloid leukemia and can be induced by activating mutations as well as by mutations in receptors or signaling molecules upstream of NRas. To study NRas-induced leukemogenesis, we retrovirally overexpressed wild-type NRas in a murine bone marrow transplantation (BMT) model in C57BL/6J mice. Overexpression of wild-type NRas caused myelomonocytic leukemias similar to 3 months after BMT in the majority of mice. A subset of mice (30%) developed malignant histiocytosis similar to mice that received mutationally activated NRas(G12D)-expressing bone marrow. Aberrant Ras signaling was demonstrated in cells expressing mutationally active or wild-type NRas, as increased activation of Erk and Akt was observed in both models. However, more NRas(G12D) were found to be in the activated, GTP-bound state in comparison with wild-type NRas. Consistent with observations reported for primary human myelomonocytic leukemia cells, Stat5 activation was also detected in murine leukemic cells. Furthermore, clonal evolution was detected in NRas wild-type-induced leukemias, including expansion of clones containing activating vector insertions in known oncogenes, such as Evi1 and Prdm16. In vitro cooperation of NRas and Evi1 improved long-term expansion of primary murine bone marrow cells. Evi1-positive cells upregulated Bcl-2 and may, therefore, provide anti-apoptotic signals that collaborate with the NRas-induced proliferative effects. As activation of Evi1 has been shown to coincide with NRAS mutations in human acute myeloid leukemia, our murine model recapitulates crucial events in human leukemogenesis.	[Wolf, S.; Baum, C.; Modlich, U.] Hannover Med Sch, Inst Expt Hematol, D-30625 Hannover, Germany; [Rudolph, C.; Schlegelberger, B.] Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany; [Morgan, M.; Salguero, G.; Stripecke, R.] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, D-30625 Hannover, Germany; [Buesche, G.] Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School; Hannover Medical School	Modlich, U (corresponding author), Hannover Med Sch, Inst Expt Hematol, OE6960,Carl Neuberg Str 1, D-30625 Hannover, Germany.	modlich.ute@mh-hannover.de	Stripecke, Renata/G-3252-2013	Modlich, Ute/0000-0001-8018-4118; Wolf, Susanne/0000-0003-0922-8418; Salguero, Gustavo/0000-0002-5018-9927	Deutsche Forschungsgemeinschaft [DFG RU- 1476]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Hans Grundtke, Jorg Fruhauf and Martin Werner (Radiotherapy) for irradiation of the mice, Sabine Knoss, Johanna Krause (Institute of Experimental Hematology) and Andrea Schienke (Institute of Cell and Molecular Pathology) for their excellent technical help, Axel Schambach (Institute of Experimental Hematology) for providing the vector backbone and Sandra Liessem (Institute of Pathology) for help with the immunohistochemistry (all Hannover Medical School). This study was supported by grants from the Deutsche Forschungsgemeinschaft (DFG RU- 1476 and Excellence Cluster REBIRTH).	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Arico M, 1997, BLOOD, V90, P479, DOI 10.1182/blood.V90.2.479.479_479_488; Bacher U, 2006, BLOOD, V107, P3847, DOI 10.1182/blood-2005-08-3522; BAUM C, 1995, J VIROL, V69, P7541, DOI 10.1128/JVI.69.12.7541-7547.1995; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Braun BS, 2008, CLIN CANCER RES, V14, P2249, DOI 10.1158/1078-0432.CCR-07-1005; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Calmels B, 2005, BLOOD, V106, P2530, DOI 10.1182/blood-2005-03-1115; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CLINE MJ, 1994, BLOOD, V84, P2840; Cuenco GM, 2004, ONCOGENE, V23, P569, DOI 10.1038/sj.onc.1207143; De Weer A, 2011, BRIT J HAEMATOL, V154, P337, DOI 10.1111/j.1365-2141.2011.08737.x; Diaz R, 2004, CARCINOGENESIS, V25, P535, DOI 10.1093/carcin/bgh026; Diaz R, 2002, CANCER RES, V62, P4514; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Du Y, 2005, BLOOD, V106, P3932, DOI 10.1182/blood-2005-03-1113; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gomez-Benito M, 2002, BRIT J CANCER, V103, P1292; Haferlach C, 2011, LEUKEMIA, V25, P874, DOI 10.1038/leu.2011.5; Hao X, 2010, VET PATHOL, V47, P434, DOI 10.1177/0300985810363705; HAUPT Y, 1992, ONCOGENE, V7, P981; Jin GA, 2007, BLOOD, V109, P3998, DOI 10.1182/blood-2006-08-041202; Kohlmann A, 2010, J CLIN ONCOL, V28, P3858, DOI 10.1200/JCO.2009.27.1361; Koike K, 2008, BRIT J HAEMATOL, V141, P567, DOI 10.1111/j.1365-2141.2008.07104.x; Konrad TA, 2009, J LEUKOCYTE BIOL, V86, P813, DOI 10.1189/jlb.0109042; Kotecha N, 2008, CANCER CELL, V14, P335, DOI 10.1016/j.ccr.2008.08.014; Kustikova O, 2005, SCIENCE, V308, P1171, DOI 10.1126/science.1105063; Kustikova Olga S., 2009, V506, P373, DOI 10.1007/978-1-59745-409-4_25; Laricchia-Robbio L, 2009, CANCER RES, V69, P1633, DOI 10.1158/0008-5472.CAN-08-2562; Leenen PJM, 2010, J LEUKOCYTE BIOL, V87, P949, DOI 10.1189/jlb.0609432; LEENEN PJM, 1990, EUR J IMMUNOL, V20, P27, DOI 10.1002/eji.1830200105; Li Q, 2011, BLOOD, V117, P2022, DOI 10.1182/blood-2010-04-280750; Loh ML, 2009, BLOOD, V114, P1859, DOI 10.1182/blood-2009-01-198416; LOHLER J, 1987, LEUKEMIA, V1, P58; Lugthart S, 2008, BLOOD, V111, P4329, DOI 10.1182/blood-2007-10-119230; Lugthart S, 2010, J CLIN ONCOL, V28, P3890, DOI 10.1200/JCO.2010.29.2771; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; MANGUES R, 1994, CANCER RES, V54, P6395; Mangues R, 1996, ONCOGENE, V13, P1053; MANGUES R, 1992, ONCOGENE, V7, P2073; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; Modlich U, 2008, LEUKEMIA, V22, P1519, DOI 10.1038/leu.2008.118; Modlich U, 2006, BLOOD, V108, P2545, DOI 10.1182/blood-2005-08-024976; Modlich U, 2009, MOL THER, V17, P1919, DOI 10.1038/mt.2009.179; Morgan MA, 2003, LEUKEMIA, V17, P1482, DOI 10.1038/sj.leu.2403024; Niemeyer CM, 2010, NAT GENET, V42, P794, DOI 10.1038/ng.641; Omidvar N, 2007, CANCER RES, V67, P11657, DOI 10.1158/0008-5472.CAN-07-0196; Parikh C, 2006, BLOOD, V108, P2349, DOI 10.1182/blood-2004-08-009498; Pileri SA, 2002, HISTOPATHOLOGY, V41, P1, DOI 10.1046/j.1365-2559.2002.01418.x; Pradhan AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025370; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Reuter CWM, 2000, BLOOD, V96, P1655, DOI 10.1182/blood.V96.5.1655.h8001655_1655_1669; Schambach A, 2006, GENE THER, V13, P1524, DOI 10.1038/sj.gt.3302807; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shing DC, 2007, J CLIN INVEST, V117, P3696, DOI 10.1172/JCI32390; Steinemann D, 2010, HAEMATOL-HEMATOL J, V95, P320, DOI 10.3324/haematol.2009.010355; Takaoka M, 2004, ONCOGENE, V23, P6760, DOI 10.1038/sj.onc.1207923; Vazquez I, 2011, HAEMATOL-HEMATOL J, V96, P1448, DOI 10.3324/haematol.2011.040535; Wahlers A, 2002, MOL THER, V6, P313, DOI 10.1006/mthe.2002.0671; Wahlers A, 2002, J VIROL, V76, P303, DOI 10.1128/JVI.76.1.303-312.2002; Wang JY, 2010, BLOOD, V116, P5991, DOI 10.1182/blood-2010-04-281527; Wiesner SM, 2005, BLOOD, V106, P1054, DOI 10.1182/blood-2004-08-3306	66	6	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2013	32	25					3028	3038		10.1038/onc.2012.329	http://dx.doi.org/10.1038/onc.2012.329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22847614				2022-12-28	WOS:000320705700003
J	Kasper, S; Breitenbuecher, F; Reis, H; Brandau, S; Worm, K; Kohler, J; Paul, A; Trarbach, T; Schmid, KW; Schuler, M				Kasper, S.; Breitenbuecher, F.; Reis, H.; Brandau, S.; Worm, K.; Koehler, J.; Paul, A.; Trarbach, T.; Schmid, K. W.; Schuler, M.			Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade	ONCOGENE			English	Article						cetuximab; colorectal cancer; RAS; ADCC; anti-EGFR antibodies; BCL-XL	GROWTH-FACTOR RECEPTOR; BCL-2 FAMILY PROTEINS; PLUS CETUXIMAB; LUNG-CANCER; APOPTOSIS; EXPRESSION; RESISTANCE; MUTATIONS; INHIBITOR; DEFECTS	Monoclonal antibodies against the epidermal growth factor receptor (EGFR) are effective cancer therapeutics, but tumors harboring RAS mutations are resistant. To functionally dissect RAS-mediated resistance, we have studied clinically approved anti-EGFR antibodies, cetuximab and panitumumab, in cancer models. Both antibodies were equally cytotoxic in vitro. However, cetuximab, which also triggers antibody-dependent cellular cytotoxicity (ADCC), was more effective than panitumumab in vivo. Oncogenic RAS neutralized the activity of both antibodies in vivo. Mechanistically, RAS upregulated BCL-XL in cancer cell lines and in primary colorectal cancers. Suppression of BCL-XL by short hairpin RNA or treatment with a BH3 mimetic overcame RAS-mediated antibody resistance. In conclusion, RAS-mutant tumors escape anti-EGFR antibody-mediated receptor blockade as well as ADCC in vivo. Pharmacological targeting of RAS effectors can restore sensitivity to antibody therapy.	[Kasper, S.; Breitenbuecher, F.; Koehler, J.; Trarbach, T.; Schuler, M.] Univ Duisburg Essen, West German Canc Ctr, Dept Med Oncol, Univ Hosp Essen, D-45147 Essen, Germany; [Reis, H.; Worm, K.; Schmid, K. W.] Univ Duisburg Essen, West German Canc Ctr, Dept Pathol & Neuropathol, Univ Hosp Essen, D-45147 Essen, Germany; [Brandau, S.] Univ Duisburg Essen, West German Canc Ctr, Dept Otorhinolaryngol, Univ Hosp Essen, D-45147 Essen, Germany; [Paul, A.] Univ Duisburg Essen, West German Canc Ctr, Dept Gen Visceral & Transplant Surg, Univ Hosp Essen, D-45147 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen	Schuler, M (corresponding author), Univ Duisburg Essen, West German Canc Ctr, Dept Med Oncol, Univ Hosp Essen, Hufelandstr 55, D-45147 Essen, Germany.	martin.schuler@uk-essen.de	Trarbach, Tanja/F-4944-2019; Kasper, Stefan/I-4521-2015; Reis, Henning/AAX-9545-2020; Köhler, Jens/AAK-1541-2021	Trarbach, Tanja/0000-0002-1275-4040; Kasper, Stefan/0000-0002-5947-8733; Reis, Henning/0000-0003-1373-5295; Brandau, Sven/0000-0002-2702-4163	Merck Serono; Amgen; Wilhelm Sander-Stiftung [2005.136.3]; Deutsche Forschungsgemeinschaft [SCHU 1541/5-1]; Mercator Research Center Ruhr-MERCUR [An-2011-0031]; CESAR Research Fellowship; Wiedenfeld-Stiftung; IFORES program of the Medical Faculty of the University Duisburg-Essen; Pathology and Molecular Pathology Laboratories, University Hospital Essen	Merck Serono(Merck & Company); Amgen(Amgen); Wilhelm Sander-Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Mercator Research Center Ruhr-MERCUR; CESAR Research Fellowship; Wiedenfeld-Stiftung; IFORES program of the Medical Faculty of the University Duisburg-Essen; Pathology and Molecular Pathology Laboratories, University Hospital Essen	Martin Schuler has served as consultant to Amgen; Tanja Trarbach has received research funding, consulting and speaker honoraria from Merck Serono and Amgen. The other authors declare no conflict of interest.; We thank Sandra Hoffarth, Sarah-Luise Stergar, Kirsten Bruderek, Jeannette Markowetz, Anna Even, Miriam Backs, Ali Sak, Sabine Harde and the staff of the Central Animal Facility, and the Pathology and Molecular Pathology Laboratories, University Hospital Essen, for their support. Robert Coffey, Roman Thomas, Hyatt Balke-Want, Scott W Lowe, Gary P Nolan and Abbott are acknowledged for providing reagents. This work was funded by grants from the Wilhelm Sander-Stiftung (2005.136.3, MS), the Deutsche Forschungsgemeinschaft (SCHU 1541/5-1, MS), Mercator Research Center Ruhr-MERCUR (An-2011-0031, SK) a CESAR Research Fellowship (SK), the Wiedenfeld-Stiftung (SK) and the IFORES program of the Medical Faculty of the University Duisburg-Essen (MS).	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Barriere J, 2009, J CLIN ONCOL, V27; Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Haehnel PS, 2008, CANCER RES, V68, P3899, DOI 10.1158/0008-5472.CAN-07-6286; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara M, 2008, CANCER SCI, V99, P1471, DOI 10.1111/j.1349-7006.2008.00821.x; Huber C, 2005, CELL DEATH DIFFER, V12, P317, DOI 10.1038/sj.cdd.4401563; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kasper S, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.5; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kurai J, 2007, CLIN CANCER RES, V13, P1552, DOI 10.1158/1078-0432.CCR-06-1726; Marques CA, 2008, BLOOD, V111, P1413, DOI 10.1182/blood-2007-05-089458; MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Piloto O, 2006, CANCER RES, V66, P4843, DOI 10.1158/0008-5472.CAN-06-0018; Ravi R, 2006, CANCER RES, V66, P1730, DOI 10.1158/0008-5472.CAN-05-3377; REMMELE W, 1987, PATHOLOGE, V8, P138; Schneider-Merck T, 2010, J IMMUNOL, V184, P512, DOI 10.4049/jimmunol.0900847; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; SHULTZ LD, 1995, J IMMUNOL, V154, P180; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Wesarg E, 2007, INT J CANCER, V121, P2387, DOI 10.1002/ijc.22977; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	34	31	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2873	2881		10.1038/onc.2012.302	http://dx.doi.org/10.1038/onc.2012.302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22797062				2022-12-28	WOS:000320369100007
J	Brennan, K; McSherry, EA; Hudson, L; Kay, EW; Hill, ADK; Young, LS; Hopkins, AM				Brennan, K.; McSherry, E. A.; Hudson, L.; Kay, E. W.; Hill, A. D. K.; Young, L. S.; Hopkins, A. M.			Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling	ONCOGENE			English	Article						junctional adhesion molecule-A; breast cancer; tight junction; human epidermal growth factor receptor-2; AKT; estrogen receptor	ADJUVANT CHEMOTHERAPY; POOR-PROGNOSIS; CANCER; EXPRESSION; SURVIVAL; TRASTUZUMAB; RECEPTOR; GROWTH; MIGRATION; MOTILITY	Junctional adhesion molecule-A (JAM-A) is a membranous cell-cell adhesion protein involved in tight-junction formation in epithelial and endothelial cells. Its overexpression in breast tumors has recently been linked with increased risk of metastasis. We sought to identify if JAM-A overexpression was associated with specific subtypes of breast cancer as defined by the expression of human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER) and progesterone receptor. To this end, JAM-A immunohistochemistry was performed in two breast cancer tissue microarrays. In parallel, cross-talk between JAM-A, HER2 and ER was examined in several breast cell lines, using complementary genetic and pharmacological approaches. High JAM-A expression correlated significantly with HER2 protein expression, ER negativity, lower patient age, high-grade breast cancers, and aggressive luminal B, HER2 and basal subtypes of breast cancer. JAM-A and HER2 were co-expressed at high levels in vitro in SKBR3, UACC-812, UACC-893 and MCF7-HER2 cells. Knockdown or functional antagonism of HER2 did not alter JAM-A expression in any cell line tested. Interestingly, however, JAM-A knockdown decreased HER2 and ER-alpha expression, resulting in reduced levels of phospho-(active) AKT without an effect on the extracellular signal-related kinase phosphorylation. The downstream effects of JAM-A knockdown on HER2 and phospho-AKT were partially reversed upon treatment with the proteasomal inhibitor MG132. We conclude that JAM-A is co-expressed with HER2 and associates with aggressive breast cancer phenotypes. Furthermore, we speculate that JAM-A may regulate HER2 proteasomal degradation and activity, potentially offering a promise as a therapeutic target in HER2-positive breast cancers.	[Brennan, K.; McSherry, E. A.; Hudson, L.; Hill, A. D. K.; Young, L. S.; Hopkins, A. M.] Royal Coll Surgeons Ireland, RCSI Educ & Res Ctr, Dept Surg, Dublin 2, Ireland; [Kay, E. W.] Royal Coll Surgeons Ireland, Dept Pathol, RCSI Educ & Res Ctr, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland	Hopkins, AM (corresponding author), Beaumont Hosp, Royal Coll Surg Ireland, RCSI Educ & Res Ctr, Dept Surg, Dublin 9, Ireland.	annhopkins@rcsi.ie	Hopkins, Ann/C-3400-2012; brennan, kieran/HCI-2509-2022	brennan, kieran/0000-0003-3520-6394; Hopkins, Ann/0000-0003-2836-6584; Young, Leonie/0000-0002-4904-0367	Science Foundation Ireland [2008/RFP/NSC1427]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We are grateful for funding from Science Foundation Ireland (2008/RFP/NSC1427 to AMH), to Dr Tony O'Grady and Trudi Roche for their assistance with obtaining tissue microarray clinical data, and to Dr Marie McIlroy for statistical advice. Herceptin was a kind gift from the St James' Hospital Pharmacy, Dublin, Ireland; LCC1 cells were a kind gift from Professor Robert Clarke, Georgetown University, USA; and MCF7-HER2 cells were a kind gift from Professor Dennis Slamon, University College Los Angeles, USA and Dr Norma O'Donovan, Dublin City University, Ireland.	Babinska A, 2002, THROMB HAEMOSTASIS, V87, P712, DOI 10.1055/s-0037-1613070; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bazzoni G, 2005, J CELL SCI, V118, P623, DOI 10.1242/jcs.01661; Braniste V, 2009, J PHYSIOL-LONDON, V587, P3317, DOI 10.1113/jphysiol.2009.169300; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chakraborty AK, 2008, CANCER RES, V68, P1538, DOI 10.1158/0008-5472.CAN-07-5935; Clark AS, 2002, MOL CANCER THER, V1, P707; Cooke VG, 2006, ARTERIOSCL THROM VAS, V26, P2005, DOI 10.1161/01.ATV.0000234923.79173.99; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Ferlay J, 2010, IARC CANCERBASE; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gotte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hewitt KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-186; Hoevel T, 2004, INT J CANCER, V108, P374, DOI 10.1002/ijc.11571; Jang JY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-391; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Lanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159; Liang TW, 2000, AM J PHYSIOL-CELL PH, V279, pC1733, DOI 10.1152/ajpcell.2000.279.6.C1733; Mandell KJ, 2005, J BIOL CHEM, V280, P11665, DOI 10.1074/jbc.M412650200; Martin TA, 2005, CLIN EXP MED, V5, P122, DOI 10.1007/s10238-005-0076-1; McSherry EA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2853; McSherry EA, 2009, INT J CANCER, V125, P1343, DOI 10.1002/ijc.24498; Murakami M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021242; Naik MU, 2008, CANCER RES, V68, P2194, DOI 10.1158/0008-5472.CAN-07-3057; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x; Osanai M, 2007, CANCER SCI, V98, P1027, DOI 10.1111/j.1349-7006.2007.00494.x; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Severson EA, 2009, MOL BIOL CELL, V20, P1916, DOI 10.1091/mbc.E08-10-1014; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	40	30	32	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2799	2804		10.1038/onc.2012.276	http://dx.doi.org/10.1038/onc.2012.276			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22751120	Green Submitted			2022-12-28	WOS:000319808000011
J	Xu, E; Zhang, J; Chen, X				Xu, E.; Zhang, J.; Chen, X.			MDM2 expression is repressed by the RNA-binding protein RNPC1 via mRNA stability	ONCOGENE			English	Article						RNA-binding proteins; RNPC1; MDM2; mRNA stability	ONCOPROTEIN MDM2; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; UBIQUITIN LIGASE; P53 FAMILY; DEGRADATION; TARGET; INHIBITION; DOMAIN; HUR	The RNA-binding protein (RBP) RNPC1 is a target of the p53 family and forms a feedback regulatory loop with the p53 family proteins. The murine double minute-2 (MDM2) oncogene, a key negative regulator of p53, has a critical role in a variety of fundamental cellular processes. MDM2 expression is found to be regulated via gene amplification, transcription, protein translation and protein stability. In the current study, we reported a novel regulation of MDM2 by RNPC1 via mRNA stability. Specifically, we found that overexpression of RNPC1 decreases, whereas knockdown or knockout of RNPC1 increases, the level of MDM2 transcript and protein independent of p53. To uncover the underlying mechanism, we found that RNPC1 is able to destabilize the MDM2 transcript via binding to multiple AU-/U-rich elements in MDM2 3'untranslated region (3'UTR). Consistent with this, we showed that RNPC1 inhibits expression of exogenous MDM2 from an expression vector as long as the vector contains an AU-/U-rich element from MDM2 3'UTR. Finally, we showed that the RNA-binding activity of RNPC1 is required for binding to MDM2 transcript and consequently, for inhibiting MDM2 expression. Together, we uncover a novel regulation of MDM2 by the RBP RNPC1 via mRNA stability. Oncogene (2013) 32, 2169-2178; doi:10.1038/onc.2012.238; published online 18 June 2012	[Xu, E.; Zhang, J.; Chen, X.] Univ Calif Davis, Dept Surg & Radiol Sci, Comparat Oncol Lab, Davis, CA 95616 USA	University of California System; University of California Davis	Zhang, J (corresponding author), Univ Calif Davis, Dept Surg & Radiol Sci, Comparat Oncol Lab, 2128 Tupper Hall, Davis, CA 95616 USA.	jinzhang@ucdavis.edu; xbchen@ucdavis.edu			NIH [R01 CA076069, R01 CA102188]; NATIONAL CANCER INSTITUTE [R01CA076069, R01CA102188] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by NIH grants R01 CA076069 and R01 CA102188.	BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bouska A, 2009, TRENDS BIOCHEM SCI, V34, P279, DOI 10.1016/j.tibs.2009.02.006; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Cho SJ, 2010, NUCLEIC ACIDS RES, V38, P2256, DOI 10.1093/nar/gkp1229; Cho SJ, 2012, J BIOL CHEM, V287, P14535, DOI 10.1074/jbc.M111.326827; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Ghosh M, 2009, J CLIN INVEST, V119, P3530, DOI 10.1172/JCI38263; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Harms KL, 2007, CANCER RES, V67, P3145, DOI 10.1158/0008-5472.CAN-06-4397; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jung YS, 2012, DNA REPAIR, V11, P177, DOI 10.1016/j.dnarep.2011.10.017; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leveille N, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1519; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lukas J, 2001, CANCER RES, V61, P3212; LUNA RMD, 1995, NATURE, V378, P203; Miyamoto S, 2009, GENES CELLS, V14, P1241, DOI 10.1111/j.1365-2443.2009.01347.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moumen A, 2007, DEVELOPMENT, V134, P1443, DOI 10.1242/dev.02820; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Peritz T, 2006, NAT PROTOC, V1, P577, DOI 10.1038/nprot.2006.82; Shu LM, 2006, GENE DEV, V20, P2961, DOI 10.1101/gad.1463306; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Xiao JN, 2011, EMBO J, V30, P5021, DOI 10.1038/emboj.2011.463; Xiong L, 2007, J CELL BIOL, V178, P995, DOI 10.1083/jcb.200703044; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Yan W, MOL CELL BIOL; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang J, 2013, ONCOGENE, V32, P61, DOI 10.1038/onc.2012.28; Zhang J, 2011, GENE DEV, V25, P1528, DOI 10.1101/gad.2069311; Zhang J, 2010, P NATL ACAD SCI USA, V107, P9614, DOI 10.1073/pnas.0912594107; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	46	38	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2169	2178		10.1038/onc.2012.238	http://dx.doi.org/10.1038/onc.2012.238			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22710720	Green Accepted			2022-12-28	WOS:000318062800006
J	Sutendra, G; Dromparis, P; Kinnaird, A; Stenson, TH; Haromy, A; Parker, JMR; McMurtry, MS; Michelakis, ED				Sutendra, G.; Dromparis, P.; Kinnaird, A.; Stenson, T. H.; Haromy, A.; Parker, J. M. R.; McMurtry, M. S.; Michelakis, E. D.			Mitochondrial activation by inhibition of PDKII suppresses HIF1 alpha signaling and angiogenesis in cancer	ONCOGENE			English	Article						mitochondria; angiogenesis; hypoxia-inducible-factor; stem cell; tumor perfusion; vascularity	DICHLOROACETATE INDUCES APOPTOSIS; TUMOR-ASSOCIATED FIBROBLASTS; BONE-MARROW; PYRUVATE-KINASE; STROMAL CELLS; HEXOKINASE-II; DNA-DAMAGE; STEM-CELLS; IN-VITRO; HYPOXIA	Most solid tumors are characterized by a metabolic shift from glucose oxidation to glycolysis, in part due to actively suppressed mitochondrial function, a state that favors resistance to apoptosis. Suppressed mitochondrial function may also contribute to the activation of hypoxia-inducible factor 1 alpha (HIF1 alpha) and angiogenesis. We have previously shown that the inhibitor of pyruvate dehydrogenase kinase (PDK) dichloroacetate (DCA) activates glucose oxidation and induces apoptosis in cancer cells in vitro and in vivo. We hypothesized that DCA will also reverse the 'pseudohypoxic' mitochondrial signals that lead to HIF1 alpha activation in cancer, even in the absence of hypoxia and inhibit cancer angiogenesis. We show that inhibition of PDKII inhibits HIF1 alpha in cancer cells using several techniques, including HIF1 alpha luciferase reporter assays. Using pharmacologic and molecular approaches that suppress the prolyl-hydroxylase (PHD)-mediated inhibition of HIF1 alpha, we show that DCA inhibits HIF1 alpha by both a PHD-dependent mechanism (that involves a DCA-induced increase in the production of mitochondria-derived alpha-ketoglutarate) and a PHD-independent mechanism, involving activation of p53 via mitochondrial-derived H2O2, as well as activation of GSK3 beta. Effective inhibition of HIF1 alpha is shown by a decrease in the expression of several HIF1 alpha regulated gene products as well as inhibition of angiogenesis in vitro in matrigel assays. More importantly, in rat xenotransplant models of non-small cell lung cancer and breast cancer, we show effective inhibition of angiogenesis and tumor perfusion in vivo, assessed by contrast-enhanced ultrasonography, nuclear imaging techniques and histology. This work suggests that mitochondria-targeting metabolic modulators that increase pyruvate dehydrogenase activity, in addition to the recently described pro-apoptotic and anti-proliferative effects, suppress angiogenesis as well, normalizing the pseudo-hypoxic signals that lead to normoxic HIF1 alpha activation in solid tumors. Oncogene (2013) 32, 1638-1650; doi:10.1038/onc.2012.198; published online 21 May 2012	[Sutendra, G.; Dromparis, P.; Kinnaird, A.; Stenson, T. H.; Haromy, A.; Parker, J. M. R.; McMurtry, M. S.; Michelakis, E. D.] Univ Alberta, Dept Med, Edmonton, AB T6G 2B7, Canada	University of Alberta	Michelakis, ED (corresponding author), Univ Alberta, Dept Med, Edmonton, AB T6G 2B7, Canada.	em2@ualberta.ca	; Kinnaird, Adam/O-3969-2017	Stenson, Trevor/0000-0001-7164-1137; Kinnaird, Adam/0000-0002-4115-4327	Canadian Institutes for Health Research (CIHR); Alberta Innovates Health Solutions (AIHS)	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Innovates Health Solutions (AIHS)	This study was funded by grants from the Canadian Institutes for Health Research (CIHR) and Alberta Innovates Health Solutions (AIHS) to EDM. We would like to thank Dr Gregg Semenza for his help, providing materials and advice.	Aghi M, 2006, CANCER RES, V66, P9054, DOI 10.1158/0008-5472.CAN-05-3759; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Babu E, 2011, ONCOGENE, V30, P4026, DOI 10.1038/onc.2011.113; Bhattacharyya A, 2010, AM J PHYSIOL-GASTR L, V299, pG1177, DOI 10.1152/ajpgi.00372.2010; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; Chen YJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007033; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dekker PBD, 2003, J PATHOL, V201, P480, DOI 10.1002/path.1461; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dromparis P, 2010, J MOL MED, V88, P1003, DOI 10.1007/s00109-010-0670-x; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Francia G, 2009, CANCER CELL, V15, P3, DOI 10.1016/j.ccr.2008.12.011; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Honczarenko M, 2006, STEM CELLS, V24, P1030, DOI 10.1634/stemcells.2005-0319; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Karshovska E, 2007, ARTERIOSCL THROM VAS, V27, P2540, DOI 10.1161/ATVBAHA.107.151050; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Knoechel TR, 2006, BIOCHEMISTRY-US, V45, P402, DOI 10.1021/bi051402s; Li J, 2009, J BIOL CHEM, V284, P34458, DOI 10.1074/jbc.M109.065557; Lu CT, 2008, INT J ARTIF INTELL T, V17, P1; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Muangnoi P, 2007, PLANTA MED, V73, P748, DOI 10.1055/s-2007-981542; Okuyama H, 2006, J BIOL CHEM, V281, P15554, DOI 10.1074/jbc.M602003200; Pan James G, 2007, Sci STKE, V2007, ppe14; Papandreou I, 2011, INT J CANCER, V128, P1001, DOI 10.1002/ijc.25728; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Ravi R, 2000, GENE DEV, V14, P34; Rebelatto CK, 2008, EXP BIOL MED, V233, P901, DOI 10.3181/0712-RM-356; Saed GM, 2011, REPROD SCI, V18, P1253, DOI 10.1177/1933719111411731; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sanchez-Arago M, 2010, CARCINOGENESIS, V31, P567, DOI 10.1093/carcin/bgq012; Schmid T, 2004, BIOCHEM J, V380, P289, DOI 10.1042/BJ20031299; Semenza G.L., 2007, SCI STKE, V2007, pcm8; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9; Sutendra G, 2010, SCI TRANSL MED, V2; Sutendra G, 2011, J MOL MED, V89, P771, DOI 10.1007/s00109-011-0762-2; Sutendra G, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002194; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Vella S, 2012, INT J CANCER, V130, P1484, DOI 10.1002/ijc.26173; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; Wang SW, 2000, AM J PHYSIOL-CELL PH, V279, pC868, DOI 10.1152/ajpcell.2000.279.3.C868; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	75	137	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1638	1650		10.1038/onc.2012.198	http://dx.doi.org/10.1038/onc.2012.198			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614004				2022-12-28	WOS:000316855800004
J	Leskov, I; Pallasch, CP; Drake, A; Iliopoulou, BP; Souza, A; Shen, CH; Schweighofer, CD; Abruzzo, L; Frenzel, LP; Wendtner, CM; Hemann, MT; Chen, J				Leskov, I.; Pallasch, C. P.; Drake, A.; Iliopoulou, B. P.; Souza, A.; Shen, C-H; Schweighofer, C. D.; Abruzzo, L.; Frenzel, L. P.; Wendtner, C. M.; Hemann, M. T.; Chen, J.			Rapid generation of human B-cell lymphomas via combined expression of Myc and Bc12 and their use as a preclinical model for biological therapies	ONCOGENE			English	Article						humanized mouse model; MYC; BCL2; double-hit lymphoma; antibody	SCID IL2R-GAMMA(NULL) MICE; HEMATOPOIETIC STEM-CELLS; CD34(+) CELLS; C-MYC; IN-VIVO; ENFORCED EXPRESSION; BURKITTS-LYMPHOMA; TRANSGENIC MICE; SELF-RENEWAL; BCL-2	Although numerous mouse models of B-cell malignancy have been developed via the enforced expression of defined oncogenic lesions, the feasibility of generating lineage-defined human B-cell malignancies using mice reconstituted with modified human hematopoietic stem cells (HSCs) remains unclear. In fact, whether human cells can be transformed as readily as murine cells by simple oncogene combinations is a subject of considerable debate. Here, we describe the development of humanized mouse model of MYC/BCL2-driven 'double-hit' lymphoma. By engrafting human HSCs transduced with the oncogene combination into immunodeficient mice, we generate a fatal B malignancy with complete penetrance. This humanized-MYC/BCL2-model (hMB) accurately recapitulates the histopathological and clinical aspects of steroid-, chemotherapy- and rituximab-resistant human 'double-hit' lymphomas that involve the MYC and BCL2 loci. Notably, this model can serve as a platform for the evaluation of antibody-based therapeutics. As a proof of principle, we used this model to show that the anti-CD52 antibody alemtuzumab effectively eliminates lymphoma cells from the spleen, liver and peripheral blood, but not from the brain. The hMB humanized mouse model underscores the synergy of MYC and BCL2 in 'double-hit' lymphomas in human patients. Additionally, our findings highlight the utility of humanized mouse models in interrogating therapeutic approaches, particularly human-specific monoclonal antibodies. Oncogene (2013) 32, 1066-1072; doi: 10.1038/onc.2012.117; published online 9 April 2012	[Leskov, I.; Pallasch, C. P.; Drake, A.; Iliopoulou, B. P.; Souza, A.; Shen, C-H; Hemann, M. T.; Chen, J.] MIT, Koch Inst Integrat Canc Res, Dept Biol, Cambridge, MA 02139 USA; [Pallasch, C. P.; Schweighofer, C. D.; Frenzel, L. P.; Wendtner, C. M.] Univ Cologne, Dept Internal Med 1, Ctr Integrated Oncol, D-50931 Cologne, Germany; [Pallasch, C. P.; Abruzzo, L.; Frenzel, L. P.; Wendtner, C. M.] Univ Cologne, Cluster Excellence Cellular Stress Response Aging, D-50931 Cologne, Germany; [Schweighofer, C. D.] UT MD Anderson Canc Ctr Houston, Dept Hematopathol, Houston, TX USA	Massachusetts Institute of Technology (MIT); University of Cologne; University of Cologne; University of Texas System; UTMD Anderson Cancer Center	Hemann, MT (corresponding author), MIT, Koch Inst Integrat Canc Res, Dept Biol, 77 Massachusetts Ave,76-310, Cambridge, MA 02139 USA.	hemann@mit.edu; jchen@mit.edu	Pallasch, Christian Philipp/T-3088-2018	Pallasch, Christian P./0000-0001-5675-6905	Marble Family Foundation; Singapore-MIT Alliance for Research and Technology; NIH [R01-CA128803]; German Research foundation; MIT School of Science Cancer Research Fellowship; Ludwig Academic Graduate Fellowship; Medical Scientist Training Program from the National Institute Of General Medical Sciences [T32GM007753]; NATIONAL CANCER INSTITUTE [P30CA014051, R01CA128803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	Marble Family Foundation; Singapore-MIT Alliance for Research and Technology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research foundation(German Research Foundation (DFG)); MIT School of Science Cancer Research Fellowship; Ludwig Academic Graduate Fellowship; Medical Scientist Training Program from the National Institute Of General Medical Sciences; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank P Bak and Herman Eisen for helpful discussions and the Swanson Biotechnology Center for excellent technical support. This work was partly supported by grants from the Marble Family Foundation (to JC and MTH), Singapore-MIT Alliance for Research and Technology (to JC) and the NIH (R01-CA128803 to MTH). CPP is supported by a research fellowship of the German Research foundation. IL was supported in part by the MIT School of Science Cancer Research Fellowship, the Ludwig Academic Graduate Fellowship and the Medical Scientist Training Program (Grant Number T32GM007753 from the National Institute Of General Medical Sciences). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of General Medical Sciences or the National Institutes of Health.	Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Bacher U, 2011, GENE CHROMOSOME CANC, V50, P43, DOI 10.1002/gcc.20831; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Basecke J, 2005, LEUKEMIA LYMPHOMA, V46, P265, DOI 10.1080/10428190400010767; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Buske C, 2001, BLOOD, V97, P2286, DOI 10.1182/blood.V97.8.2286; Chung KY, 2006, CANCER RES, V66, P11781, DOI 10.1158/0008-5472.CAN-06-0706; Chung KY, 2005, BLOOD, V105, P77, DOI 10.1182/blood-2003-12-4445; Gallamini A, 2007, BLOOD, V110, P2316, DOI 10.1182/blood-2007-02-074641; Giassi LJ, 2008, EXP BIOL MED, V233, P997, DOI 10.3181/0802-RM-70; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Harrington AM, 2011, AM J CLIN PATHOL, V135, P649, DOI 10.1309/AJCPL11MAHISIJBQ; Hasserjian Robert P, 2009, J Hematop, V2, P89, DOI 10.1007/s12308-009-0039-7; Hu YP, 2009, IMMUNOLOGY, V128, P260, DOI 10.1111/j.1365-2567.2009.03115.x; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Li S., 2011, MODERN PATHOL, V25, P145; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Montes R, 2011, BLOOD, V117, P4746, DOI 10.1182/blood-2010-12-322230; Moreau T, 2004, MOL THER, V10, P45, DOI 10.1016/j.ymthe.2004.04.005; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; Schuringa JJ, 2004, J EXP MED, V200, P623, DOI 10.1084/jem.20041024; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Snuderl M, 2010, AM J SURG PATHOL, V34, P327, DOI 10.1097/PAS.0b013e3181cd3aeb; Stern P, 2008, P NATL ACAD SCI USA, V105, P13895, DOI 10.1073/pnas.0806907105; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Tomita N, 2011, J CLIN EXP HEMATOP, V51, P7, DOI 10.3960/jslrt.51.7; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wendtner CM, 2004, LEUKEMIA, V18, P1093, DOI 10.1038/sj.leu.2403354; Wu D, 2010, AM J CLIN PATHOL, V134, P258, DOI 10.1309/AJCP7YLDTJPLCE5F; Wunderlich M, 2006, BLOOD, V108, P1690, DOI 10.1182/blood-2005-12-012773; Zhang CC, 2008, BLOOD, V111, P3415, DOI 10.1182/blood-2007-11-122119	35	35	41	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					1066	1072		10.1038/onc.2012.117	http://dx.doi.org/10.1038/onc.2012.117			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22484426	Green Accepted, Green Submitted			2022-12-28	WOS:000316523200014
J	Schulte, JH; Lindner, S; Bohrer, A; Maurer, J; De Preter, K; Lefever, S; Heukamp, L; Schulte, S; Molenaar, J; Versteeg, R; Thor, T; Kunkele, A; Vandesompele, J; Speleman, F; Schorle, H; Eggert, A; Schramm, A				Schulte, J. H.; Lindner, S.; Bohrer, A.; Maurer, J.; De Preter, K.; Lefever, S.; Heukamp, L.; Schulte, S.; Molenaar, J.; Versteeg, R.; Thor, T.; Kuenkele, A.; Vandesompele, J.; Speleman, F.; Schorle, H.; Eggert, A.; Schramm, A.			MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells	ONCOGENE			English	Article						neuroblastoma; MYCN; neural crest progenitor cell	EXPRESSION; MEDULLOBLASTOMA; ORIGIN	Neuroblastonna is an embryonal tumor with a heterogeneous clinical course. The tumor is presumed to be derived from the neural crest, but the cells of origin remain to be determined. To date, few recurrent genetic changes contributing to neuroblastoma formation, such as amplification of the MYCN oncogene and activating mutations of the ALK oncogene, have been identified. The possibility to model neuroblastoma in mice allows investigation of the cell of origin hypothesis in further detail. Here we present the evidence that murine neural crest progenitor cells can give rise to neuroblastonna upon transformation with MYCN or ALK(F1174L). For this purpose we used JoMa1, a multipotent neural crest progenitor cell line, which is kept in a viable and undifferentiated state by a tamoxifen-activated c-Myc transgene (c-MycER(T)). Expression of MYCN or ALK(F1174L), one of the oncogenic ALK variants identified in primary neuroblastomas, enabled these cells to grow independently of c-MycER(T) activity in vitro and caused formation of neuroblastoma-like tumors in vivo in contrast to parental JoMa1 cells and JoMa1 cells-expressing TrkA or GFP. Tumorigenicity was enhanced upon serial transplantation of tumor-derived cells, and tumor cells remained susceptible to the MYC-inhibitor, NBT-272, indicating that cell growth depended on functional MYCN. Our findings support neural crest progenitor cells as the precursor cells of neuroblastoma, and indicate that neuroblastomas arise as their malignant progeny. Oncogene (2013) 32, 1059-1065; doi:10.1038/onc.2012.106; published online 9 April 2012	[Schulte, J. H.; Lindner, S.; Bohrer, A.; Schulte, S.; Thor, T.; Kuenkele, A.; Eggert, A.; Schramm, A.] Univ Childrens Hosp Essen, Dept Pediat Oncol & Haematol, D-45122 Essen, Germany; [Maurer, J.; Schorle, H.] Univ Bonn, Inst Pathol, Dept Dev Pathol, Bonn, Germany; [De Preter, K.; Lefever, S.; Vandesompele, J.; Speleman, F.] Ghent Univ Hosp, CMGG, Ghent, Belgium; [Heukamp, L.] Univ Bonn, Dept Pathol, Bonn, Germany; [Molenaar, J.; Versteeg, R.] Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands	University of Duisburg Essen; University of Bonn; Ghent University; Ghent University Hospital; University of Bonn; University of Amsterdam; Academic Medical Center Amsterdam	Schulte, JH (corresponding author), Univ Childrens Hosp Essen, Dept Pediat Oncol & Haematol, Hufelandstr 55, D-45122 Essen, Germany.	Johannes.schulte@uni-due.de	Schorle, Hubert/M-5001-2016; speleman, frank/AAR-5184-2020; Heukamp, Lukas C/A-8338-2013; Eggert, Angelika/AAE-6907-2022; Vandesompele, Jo/W-3411-2018; Versteeg, Rogier/AAQ-1765-2020; Maurer, Jochen/G-4832-2018; Schorle, Hubert/S-1713-2019; Schulte, Johannes H./V-2474-2018; Schulte, Johannes H/G-3981-2010; Schramm, Alexander/G-5688-2010; De Preter, Katleen/I-7135-2013; Heukamp, Lukas/G-9967-2012	Schorle, Hubert/0000-0001-8272-0076; speleman, frank/0000-0002-6628-8559; Eggert, Angelika/0000-0003-3476-8184; Vandesompele, Jo/0000-0001-6274-0184; Maurer, Jochen/0000-0003-3962-3128; Schramm, Alexander/0000-0001-7670-7529; De Preter, Katleen/0000-0002-7726-5096; Kunkele, Annette/0000-0002-8406-5412; Heukamp, Lukas/0000-0002-3388-3482; Versteeg, Rogier/0000-0001-7172-0388; Schulte, Johannes Hubertus/0000-0003-0671-1201	German National Genome Research Network (NGFN) [PKN-01GS0894-6]; German Cancer Aid [108941]	German National Genome Research Network (NGFN); German Cancer Aid(Deutsche Krebshilfe)	We thank E Mahlow, 5 Dreesmann, A Odersky and M Baumann for their excellent technical assistance and K Astrahantseff for proof reading the manuscript. This work was supported by the German National Genome Research Network (NGFN plus grant no. PKN-01GS0894-6 to JHS, AE and AS) and by the German Cancer Aid (grant no. 108941 to JHS and AE).	Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; De Preter K, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r84; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Hata K, 2007, LIVER TRANSPLANT, V13, P114, DOI 10.1002/lt.20957; Jager R, 2004, GENESIS, V38, P145, DOI 10.1002/gene.20014; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Maurer J, 2007, DIFFERENTIATION, V75, P580, DOI 10.1111/j.1432-0436.2007.00164.x; Pajtler K, 2010, J VIS EXP; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Schulte JH, 2005, ONCOGENE, V24, P165, DOI 10.1038/sj.onc.1208000; Schulte JH, 2010, INT J CANCER, V127, P2374, DOI 10.1002/ijc.25436; Schulte JH, 2009, INT J CANCER, V124, P2488, DOI 10.1002/ijc.24204; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510; von Bueren AO, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-19; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061	22	69	71	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					1059	1065		10.1038/onc.2012.106	http://dx.doi.org/10.1038/onc.2012.106			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22484425				2022-12-28	WOS:000316523200013
J	Wagner, L; Marschall, V; Karl, S; Cristofanon, S; Zobel, K; Deshayes, K; Vucic, D; Debatin, KM; Fulda, S				Wagner, L.; Marschall, V.; Karl, S.; Cristofanon, S.; Zobel, K.; Deshayes, K.; Vucic, D.; Debatin, K-M; Fulda, S.			Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1-and NF-kappa B-dependent manner	ONCOGENE			English	Article						Smac; apoptosis; glioblastoma; temozolomide; RIP1	IRRADIATION-INDUCED APOPTOSIS; MALIGNANT GLIOMA; BETULINIC ACID; ACTIVATION; GAMMA; DEATH; RESISTANCE; CASPASE-8; CIAP1; IAPS	Inhibitor of apoptosis (IAP) proteins are expressed at high levels in many cancers and therefore represent attractive targets for therapeutic intervention. Here, we report for the first time that the second mitochondria-derived activator of caspases (Smac) mimetic BV6 sensitizes glioblastoma cells toward Temozolomide (TMZ), the first-line chemotherapeutic agent in the treatment of glioblastoma. BV6 and TMZ synergistically reduce cell viability and trigger apoptosis in glioblastoma cells (combination index <0.4-0.8), which is accompanied by increased loss of mitochondrial-membrane potential, cytochrome c release, caspase activation and caspase-dependent apoptosis. Analysis of the molecular mechanisms reveals that BV6 causes rapid degradation of clAP1, leading to stabilization of NF-kappa B-inducing kinase and NF-kappa B activation. BV6-stimulated NF-kappa B activation is critically required for sensitization toward TMZ, as inhibition of NF-kappa B by overexpression of the mutant l kappa B alpha super-repressor profoundly reduces loss of mitochondrial membrane potential, cytochrome c release, caspase activation and apoptosis. Of note, BV6-mediated sensitization to TMZ is not associated with increased tumor necrosis factor alpha (TNF alpha) production. Also, TNF alpha, CD95 or TRAIL-blocking antibodies or knockdown of TNFR1 have no or little effect on combination treatment-induced apoptosis. Interestingly, BV6 and TMZ cooperate to trigger the formation of a RIP1 (receptor activating protein 1)/caspase-8/FADD complex. Knockdown of RIP1 by small interfering RNA significantly reduces BV6- and TMZ-induced caspase-8 activation and apoptosis, showing that RIP1 is necessary for apoptosis induction. By demonstrating that BV6 primes glioblastoma cells for TMZ in a NF-kappa B- and RIP1-dependent manner, these findings build the rationale for further (pre)clinical development of Smac mimetics in combination with TMZ. Oncogene (2013) 32, 988-997; doi:10.1038/onc.2012.108; published online 2 April 2012	[Wagner, L.; Karl, S.; Debatin, K-M; Fulda, S.] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Marschall, V.; Cristofanon, S.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Hesse, Germany; [Zobel, K.; Deshayes, K.; Vucic, D.] Genentech Inc, San Francisco, CA USA	Ulm University; Goethe University Frankfurt; Roche Holding; Genentech	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; European Community (ApopTrain, APO-SYS); IAP6/18; International Graduate School in Molecular Medicine Ulm, Ulm University	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Community (ApopTrain, APO-SYS)(European CommissionEuropean Commission Joint Research Centre); IAP6/18; International Graduate School in Molecular Medicine Ulm, Ulm University	We thank C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF) and by a scholarship from the International Graduate School in Molecular Medicine Ulm, Ulm University (to LW). Kerry Zobel, Kurt Deshayes, and Domagoj Vucic are employees of Genentech, Inc.	Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Berger R, 2011, MOL CANCER THER, V10, P1867, DOI 10.1158/1535-7163.MCT-11-0218; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Mohr A, 2004, CELL DEATH DIFFER, V11, P1153, DOI 10.1038/sj.cdd.4401480; Opel D, 2008, CANCER RES, V68, P6271, DOI 10.1158/0008-5472.CAN-07-6769; Probst BL, 2010, CELL DEATH DIFFER, V17, P1645, DOI 10.1038/cdd.2010.44; Shirley S., 2010, CANC LETT; Straub CS, 2011, CURR TOP MED CHEM, V11, P291; Stupp R, 2007, J CLIN ONCOL, V25, P4127, DOI 10.1200/JCO.2007.11.8554; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vellanki S, 2009, NEOPLASIA, V11, P743, DOI 10.1593/neo.09436; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036	29	78	79	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					988	997		10.1038/onc.2012.108	http://dx.doi.org/10.1038/onc.2012.108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22469979				2022-12-28	WOS:000316523200006
J	Xu, J; Li, Y; Wang, F; Wang, X; Cheng, B; Ye, F; Xie, X; Zhou, C; Lu, W				Xu, J.; Li, Y.; Wang, F.; Wang, X.; Cheng, B.; Ye, F.; Xie, X.; Zhou, C.; Lu, W.			Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer	ONCOGENE			English	Article						miR-424; cervical cancer; progression; Chk1; p-Chk1	SQUAMOUS-CELL CARCINOMAS; MICRORNA MIR-21; BREAST-CANCER; CHECKPOINT; IDENTIFICATION; PROFILES; TONGUE; MMP9	MicroRNAs (miRNAs) act as important gene regulators in human genomes and their aberrant expression links to many malignancies. We previously identified a different characteristic miRNA expression profile in cervical cancer from that in cervical normal tissues, including the downregulated miR-424. However, the role and mechanism of miR-424 in cervical cancer still remain unknown. Here, we focused on identifying the tumor-suppressive function and clinical significance of miR-424 and exploring the mechanistic relevance by characterizing its target. We showed a significantly decreased expression of miR-424 in 147 cervical cancer tissues versus 74 cervical normal tissues by performing quantitative RT-PCR. In 147 cervical cancer tissue samples, low-level expression of miR-424 was positively correlated with poor tumor differentiation, advanced clinical stage, lymph node metastasis and other poor prognostic clinicopathological parameters. Further in vitro observations showed that enforced expression of miR-424 inhibited cell growth by both enhancing apoptosis and blocking G1/S transition, and suppressed cell migration and invasion in two human cervical cancer cell lines, SiHa and CaSki, implying that miR-424 functions as a tumor suppressor in the progression of cervical cancer. Interestingly, overexpression of miR-424 inhibited the expression of protein checkpoint kinase 1 (Chk1) and phosphorylated Chk1 (p-Chk1) at residues Ser345 and decreased the activity of luciferase-reporter containing the 3'-untranslated region (UTR) of Chk1 with predicted miR-424-binding site. Moreover, miR-424 expression levels were inversely correlated with Chk1 and p-Chk1 protein levels in both cervical cancer and normal tissues. Furthermore, RNAi-mediated knockdown of Chk1 decreased matrix metalloproteinase 9 expression and phenocopied the tumor suppressive effects of miR-424 in cell models. Taken together, our results identify a crucial tumor suppressive role of miR-424 in the progression of cervical cancer at least partly via upreglating the expression of Chk1 and p-Chk1, and suggest that miR-424 might be a candidate of prognostic predictor or an anticancer therapeutic target for cervical cancer patients. Oncogene (2013) 32, 976-987; doi:10.1038/onc.2012.121; published online 2 April 2012	[Xu, J.; Li, Y.; Wang, F.; Ye, F.] Zhejiang Univ, Sch Med, Womens Hosp, Womens Reprod Hlth Lab Zhejiang Prov, Hangzhou 310006, Zhejiang, Peoples R China; [Wang, X.; Cheng, B.; Xie, X.; Lu, W.] Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China; [Zhou, C.] Zhejiang Univ, Sch Med, Womens Hosp, Dept Pathol, Hangzhou 310006, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Lu, W (corresponding author), Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China.	lwg@hzcnc.com		Xu, Junfen/0000-0002-2377-0775; Lv, Weiguo/0000-0003-2062-7145	National Natural Science Foundation of China [81172475]; Zhejiang Provincial Natural Science Foundation of China [Z2110056]; Zhejiang Provincial Medical and Health Science and Technology Project [2009A132, 2011ZDA015]; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); Zhejiang Provincial Medical and Health Science and Technology Project; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents	We thank pathologist Xiaoduan Chen for histological diagnoses of cervical tissues and Dr Yifan Cheng for sample collections. We also thank continuous financial support by grants from the National Natural Science Foundation of China (Grant No. 81172475), Zhejiang Provincial Natural Science Foundation of China (Grant No. Z2110056), Zhejiang Provincial Medical and Health Science and Technology Project (Grant No. 2009A132 and No. 2011ZDA015) and Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents.	Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Chen ZL, 2011, J BIOL CHEM, V286, P10725, DOI 10.1074/jbc.M110.165654; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Ehlen Asa, 2011, Transl Oncol, V4, P212; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Forrest ARR, 2010, LEUKEMIA, V24, P460, DOI 10.1038/leu.2009.246; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Gao QL, 2006, APOPTOSIS, V11, P1789, DOI 10.1007/s10495-006-9421-4; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Imig J, 2011, NUCLEIC ACIDS RES, V39, P1880, DOI 10.1093/nar/gkq1043; Kawahigashi Yutaka, 2009, Journal of Nippon Medical School, V76, P188; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li JS, 2009, CLIN CANCER RES, V15, P3998, DOI 10.1158/1078-0432.CCR-08-3053; Li YL, 2010, EUR J CANCER, V46, P2104, DOI 10.1016/j.ejca.2010.04.015; Li YL, 2009, ANAL BIOCHEM, V394, P110, DOI 10.1016/j.ab.2009.07.022; Li Y, 2011, J PATHOL, V224, P484, DOI 10.1002/path.2873; Lin LF, 2010, CANCER RES, V70, P192, DOI 10.1158/0008-5472.CAN-09-2641; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Madoz-Gurpide J, 2007, MOL CELL PROTEOMICS, V6, P2150, DOI 10.1074/mcp.M700006-MCP200; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Pallasch CP, 2009, BLOOD, V114, P3255, DOI 10.1182/blood-2009-06-229898; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; Rentoft M, 2011, INT J ONCOL, V38, P61, DOI 10.3892/ijo_00000824; Rosa A, 2007, P NATL ACAD SCI USA, V104, P19849, DOI 10.1073/pnas.0706963104; Sarkar S, 2010, MOL BIOL CELL, V21, P2138, DOI 10.1091/mbc.E10-01-0062; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Shen YM, 2010, ANAL BIOCHEM, V405, P224, DOI 10.1016/j.ab.2010.06.029; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Wang YX, 2010, J DIGEST DIS, V11, P50, DOI 10.1111/j.1751-2980.2009.00413.x; Wang ZQ, 2009, J CELL PHYSIOL, V221, P213, DOI 10.1002/jcp.21844; Witten D, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-58; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Ye F, 2008, HISTOPATHOLOGY, V53, P224, DOI 10.1111/j.1365-2559.2008.03068.x; Yu WW, 2009, PATHOL RES PRACT, V205, P709, DOI 10.1016/j.prp.2009.05.010; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	44	186	201	2	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					976	987		10.1038/onc.2012.121	http://dx.doi.org/10.1038/onc.2012.121			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22469983				2022-12-28	WOS:000316523200005
J	Bensimon, J; Altmeyer-Morel, S; Benjelloun, H; Chevillard, S; Lebeau, J				Bensimon, J.; Altmeyer-Morel, S.; Benjelloun, H.; Chevillard, S.; Lebeau, J.			CD24(-/low) stem-like breast cancer marker defines the radiation-resistant cells involved in memorization and transmission of radiation-induced genomic instability	ONCOGENE			English	Article						radiation effects; breast cancer stem cells; genomic instability	IONIZING-RADIATION; CD24 EXPRESSION; INITIATING CELLS; GROWTH ARREST; DNA-DAMAGE; TUMOR CELL; METASTASIS; DEATH; PROPAGATION; MECHANISMS	A growing body of evidence attributes properties of chemo- and/or radiation-resistance to cancer stem cells (CSCs). Moreover, non-targeted delayed effects such as genomic instability, transmitted through many generations, can be observed in the progeny of surviving irradiated cells. As a consequence, we propose that radiation-resistance properties associated to CSCs could confer a key role to this subpopulation in the transmission of genomic instability. To test this hypothesis, we searched the CSC markers associated to radiation-resistance in breast cancer cell lines and studied the role of the resistant cells in the transmission of genomic instability. First, we show that irradiation induces a 2-4 weeks period of intense cell death leading to the emergence of chromosomal unstable cells during more than 35 population doublings. Then, among seven breast CSC markers, we identify CD24(-/low) labelling as a marker of radiation-resistance. We demonstrate that CD24(+) progeny of irradiated cells exclusively descends from CD24(-/low) cells. Finally, we show that delayed chromosomal instability is only expressed by CD24(+) cells, but is transmitted by stable surviving CD24(-/low) cells. So, for the first time a CSC marker, CD24, is associated with the transmission of genomic instability. This work may assign a new deleterious role to breast CSCs in aggressive recurrence after radiotherapy, as the transmitted genomic instability potentially leads tumour cells to acquire more aggressive characteristics. Oncogene (2013) 32, 251-258; doi:10.1038/onc.2012.31; published online 13 February 2012	[Bensimon, J.; Altmeyer-Morel, S.; Chevillard, S.; Lebeau, J.] CEA, DSV, iRCM, SREIT,LCE, F-92265 Fontenay Aux Roses, France; [Benjelloun, H.] CEA, DSV, iRCM, SCSR, F-92265 Fontenay Aux Roses, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Lebeau, J (corresponding author), CEA, DSV, iRCM, SREIT,LCE, F-92265 Fontenay Aux Roses, France.	jerome.lebeau@cea.fr		Etzol, Julie/0000-0002-5572-6197; Chevillard, Sylvie/0000-0001-5889-4041	Electricite de France (EDF); MELODI Network; DoReMi Network	Electricite de France (EDF)(Electricite de France (EDF)); MELODI Network; DoReMi Network	We thank Dr P-H. Romeo for constructive criticism on this manuscript. We also thank Drs J Baijer, D Lewandowski and P Fouchet for flow cytometry technical assistance and advices. This work was supported by grants from Electricite de France (EDF) and from MELODI and DoReMi Networks.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aypar U, 2011, INT J RADIAT BIOL, V87, P179, DOI 10.3109/09553002.2010.522686; Aypar U, 2011, MUTAT RES-FUND MOL M, V707, P24, DOI 10.1016/j.mrfmmm.2010.12.003; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Bircan S, 2006, PATHOL RES PRACT, V202, P569, DOI 10.1016/j.prp.2006.05.004; Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105; Debeb BG, 2009, J MAMMARY GLAND BIOL, V14, P11, DOI 10.1007/s10911-009-9114-z; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gewirtz DA, 2000, BREAST CANCER RES TR, V62, P223, DOI 10.1023/A:1006414422919; Gewirtz DA, 2000, CELL BIOCHEM BIOPHYS, V33, P19, DOI 10.1385/CBB:33:1:19; Giatromanolaki A, 2011, MED ONCOL, V28, P745, DOI 10.1007/s12032-010-9530-3; Hernandez-Vargas H, 2011, EPIGENETICS-US, V6, P429, DOI 10.4161/epi.6.4.14515; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Kai K, 2010, BREAST CANCER-TOKYO, V17, P80, DOI 10.1007/s12282-009-0176-y; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Lagadec C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2479; Lahtz C, 2011, J MOL CELL BIOL, V3, P51, DOI 10.1093/jmcb/mjq053; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Luce A, 2009, CARCINOGENESIS, V30, P432, DOI 10.1093/carcin/bgp008; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Mothersill C, 1998, MUTAGENESIS, V13, P421, DOI 10.1093/mutage/13.5.421; Nguyen NP, 2010, CANCER TREAT REV, V36, P485, DOI 10.1016/j.ctrv.2010.02.016; Olivier M, 1998, MOL CARCINOGEN, V23, P1; Pajonk F, 2010, STEM CELLS, V28, P639, DOI 10.1002/stem.318; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Ponnaiya B, 1997, RADIAT RES, V147, P288, DOI 10.2307/3579335; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Resetkova E, 2010, BREAST CANCER RES TR, V123, P97, DOI 10.1007/s10549-009-0619-3; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Rossi L, 2011, METHODS MOL BIOL, V750, P47, DOI 10.1007/978-1-61779-145-1_3; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Sudo H, 2008, RADIAT RES, V170, P23, DOI 10.1667/RR1317.1; Suzuki K, 2006, MUTAT RES-FUND MOL M, V597, P73, DOI 10.1016/j.mrfmmm.2005.04.024; Vlashi E, 2009, J CELL BIOCHEM, V108, P339, DOI 10.1002/jcb.22275; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	39	19	19	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2013	32	2					251	258		10.1038/onc.2012.31	http://dx.doi.org/10.1038/onc.2012.31			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22330142				2022-12-28	WOS:000314075500013
J	Allende-Vega, N; Dayal, S; Agarwala, U; Sparks, A; Bourdon, JC; Saville, MK				Allende-Vega, N.; Dayal, S.; Agarwala, U.; Sparks, A.; Bourdon, J-C; Saville, M. K.			p53 is activated in response to disruption of the pre-mRNA splicing machinery	ONCOGENE			English	Article						p53; spliceosome; splicing; MdmX; Mdm2; TG003	EMERGING ROLE; PROTEIN; CANCER; TRANSCRIPTION; DEGRADATION; STRESS; DOMAIN; MDM2; PHOSPHORYLATION; LOCALIZATION	In this study, we show that interfering with the splicing machinery results in activation of the tumour-suppressor p53. The spliceosome was targeted by small interfering RNA-mediated knockdown of proteins associated with different small nuclear ribonucleoprotein complexes and by using the small-molecule splicing modulator TG003. These interventions cause: the accumulation of p53, an increase in p53 transcriptional activity and can result in p53-dependent G(1) cell cycle arrest. Mdm2 and MdmX are two key repressors of p53. We show that a decrease in MdmX protein level contributes to p53 activation in response to targeting the spliceosome. Interfering with the spliceosome also causes an increase in the rate of degradation of Mdm2. Alterations in splicing are linked with tumour development. There are frequently global changes in splicing in cancer. Our study suggests that p53 activation could participate in protection against potential tumour-promoting defects in the spliceosome. A number of known p53-activating agents affect the splicing machinery and this could contribute to their ability to upregulate p53. Preclinical studies indicate that tumours can be more sensitive than normal cells to small-molecule spliceosome inhibitors. Activation of p53 could influence the selective anti-tumour activity of this therapeutic approach. Oncogene (2013) 32, 1-14; doi:10.1038/onc.2012.38; published online 20 February 2012	[Allende-Vega, N.; Dayal, S.; Agarwala, U.; Sparks, A.; Bourdon, J-C; Saville, M. K.] Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Div Canc Res, Dundee DD1 9SY, Angus, Scotland	University of Dundee	Saville, MK (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Div Canc Res, Mail Box 11, Dundee DD1 9SY, Angus, Scotland.	m.k.saville@dundee.ac.uk	JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386; Allende-Vega, Nerea/0000-0001-5569-6461	Cancer Research UK	Cancer Research UK(Cancer Research UK)	This work was funded by Cancer Research UK.	Alexander R, 2010, BIOCHEM SOC T, V38, P1251, DOI 10.1042/BST0381251; Allende-Vega N, 2010, ONCOGENE, V29, P432, DOI 10.1038/onc.2009.330; Andre F, 2009, LANCET ONCOL, V10, P381, DOI 10.1016/S1470-2045(09)70024-5; Bartel F, 2004, MOL CANCER RES, V2, P29; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brody Y, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000573; Brooks CL, 2011, FEBS LETT, V585, P2803, DOI 10.1016/j.febslet.2011.05.022; Busa R, 2010, RNA BIOL, V7, P390, DOI 10.4161/rna.7.4.12466; Cao WH, 1998, J BIOL CHEM, V273, P20629, DOI 10.1074/jbc.273.32.20629; Cass DM, 2006, BIOCHEMISTRY-US, V45, P10092, DOI 10.1021/bi060429o; Chandler DS, 2006, CANCER RES, V66, P9502, DOI 10.1158/0008-5472.CAN-05-4271; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Corrionero A, 2011, GENE DEV, V25, P445, DOI 10.1101/gad.2014311; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; Disher K, 2007, GENOME, V50, P946, DOI 10.1139/G07-074; Egecioglu DE, 2011, RNA, V17, P383, DOI 10.1261/rna.2454711; Fackenthal JD, 2008, DIS MODEL MECH, V1, P37, DOI 10.1242/dmm.000331; Ghosh G, 2011, FEBS J, V278, P587, DOI 10.1111/j.1742-4658.2010.07992.x; Giglio S, 2005, CANCER RES, V65, P9687, DOI 10.1158/0008-5472.CAN-05-0450; Golas MM, 2003, SCIENCE, V300, P980, DOI 10.1126/science.1084155; Grainger RJ, 2005, RNA, V11, P533, DOI 10.1261/rna.2220705; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Hernandez H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007202; Hock A, 2010, INT J BIOCHEM CELL B, V42, P1618, DOI 10.1016/j.biocel.2010.06.011; Kaida D, 2007, NAT CHEM BIOL, V3, P576, DOI 10.1038/nchembio.2007.18; Katzenberger RJ, 2006, MOL CELL BIOL, V26, P9256, DOI 10.1128/MCB.01125-06; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kim E, 2008, TRENDS GENET, V24, P7, DOI 10.1016/j.tig.2007.10.001; Kim MY, 2009, BMB REP, V42, P125, DOI 10.5483/BMBRep.2009.42.3.125; Kotake Y, 2007, NAT CHEM BIOL, V3, P570, DOI 10.1038/nchembio.2007.16; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222; Lenos K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/876173; Ljungman M, 2007, CELL CYCLE, V6, P2252, DOI 10.4161/cc.6.18.4751; Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553; Marcel V, 2010, FEBS LETT, V584, P4463, DOI 10.1016/j.febslet.2010.10.005; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Munoz MJ, 2009, CELL, V137, P708, DOI 10.1016/j.cell.2009.03.010; Muraki M, 2004, J BIOL CHEM, V279, P24246, DOI 10.1074/jbc.M314298200; Newman AJ, 2010, CURR OPIN STRUC BIOL, V20, P82, DOI 10.1016/j.sbi.2009.12.003; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Reyal F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2192; Ritchie DB, 2009, BBA-GENE REGUL MECH, V1789, P624, DOI 10.1016/j.bbagrm.2009.08.010; Ritchie W, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000011; Schaffert N, 2004, EMBO J, V23, P3000, DOI 10.1038/sj.emboj.7600296; Singh J, 2009, NAT STRUCT MOL BIOL, V16, P1128, DOI 10.1038/nsmb.1666; Sleeman J, 2007, J CELL SCI, V120, P1540, DOI 10.1242/jcs.001529; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Svejstrup JQ, 2007, TRENDS BIOCHEM SCI, V32, P165, DOI 10.1016/j.tibs.2007.02.005; UTANS U, 1992, GENE DEV, V6, P631, DOI 10.1101/gad.6.4.631; Valadkhan S, 2010, PROTEOMICS, V10, P4128, DOI 10.1002/pmic.201000354; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649; Wilkinson CRM, 2004, CURR BIOL, V14, P2283, DOI 10.1016/j.cub.2004.11.058; Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Zhao XL, 2007, NUCLEIC ACIDS RES, V35, P550, DOI 10.1093/nar/gkl1084	67	47	47	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					1	14		10.1038/onc.2012.38	http://dx.doi.org/10.1038/onc.2012.38			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22349816				2022-12-28	WOS:000313029500001
J	Serrano, I; McDonald, PC; Lock, FE; Dedhar, S				Serrano, I.; McDonald, P. C.; Lock, F. E.; Dedhar, S.			Role of the integrin-linked kinase (ILK)/Rictor complex in TGF beta-1-induced epithelial-mesenchymal transition (EMT)	ONCOGENE			English	Article						integrin-linked kinase; breast epithelial cells; ILK/Rictor complex; EMT; Rictor; cancer	GLYCOGEN-SYNTHASE KINASE-3; E-CADHERIN REPRESSOR; BREAST-CANCER CELLS; TGF-BETA; MAMMALIAN TARGET; EXPRESSION; RICTOR; SNAIL; PHOSPHORYLATION; ACTIVATION	Epithelial-to-mesenchymal transition (EMT) causes fibrosis, cancer progression and metastasis. Integrin-linked kinase (ILK) is a focal adhesion adaptor and a serine/threonine protein kinase that regulates cell proliferation, survival and EMT. Elucidating the molecular mechanisms necessary for development and progression of human malignancies is critical to predict the most appropriate targets for cancer therapy. Here, we used transforming growth factor beta-1 (TGF beta-1) to promote EMT and migration in mammary epithelial cells. We demonstrate a requirement of ILK activity for TGF beta-1-mediated EMT in mammary epithelial cells. In addition to nuclear translocation of Snail and Slug, TGF beta-1 treatment also induced expression of the mammalian target of rapamycin complex 2 component Rictor and its phosphorylation on Thr1135. Interestingly, TGF beta-1 treatment also induced an interaction between ILK and Rictor. All of these TGF beta-1-induced processes were significantly suppressed by inhibiting ILK activity or by disrupting the ILK/Rictor complex using small-interfering RNA-mediated knockdown. Furthermore, we identified ILK/Rictor complex formation in cancer but not in normal cell types, and this was accompanied by ILK-dependent phosphorylation of Rictor on residue Thr1135. Inhibition of ILK partially reversed the basal mesenchymal phenotype of MDA-MB-231 cells and prevented EMT in MCF10A cells after TGF beta-1 treatment. These data demonstrate a requirement for ILK function in TGF beta-1-induced EMT in mammary epithelial cells and identify the ILK/Rictor complex as a potential molecular target for preventing/reversing EMT. Oncogene (2013) 32, 50-60; doi:10.1038/onc.2012.30; published online 6 February 2012	[Dedhar, S.] Univ British Columbia, BC Canc Res Ctr, Inst Life Sci, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1L3, Canada; [Serrano, I.; McDonald, P. C.; Lock, F. E.; Dedhar, S.] BC Canc Agcy, British Columbia Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; British Columbia Cancer Agency	Dedhar, S (corresponding author), Univ British Columbia, BC Canc Res Ctr, Inst Life Sci, Dept Biochem & Mol Biol, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@bccrc.ca		Dedhar, Shoukat/0000-0003-4355-1657	Canadian Cancer Society Research Institute (CCSRI); Canadian Institutes for Health Research (CIHR)	Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This study was supported by grants to SD from the Canadian Cancer Society Research Institute (CCSRI) and the Canadian Institutes for Health Research (CIHR). We thank Quadra Logic Technology Inc (QLT Inc), Vancouver, BC, for supplying QLT-0267.	Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boulbes D, 2010, MOL CANCER RES, V8, P896, DOI 10.1158/1541-7786.MCR-09-0409; Garcia SAD, 2011, CANCER MICROENVIRON, V4, P33, DOI 10.1007/s12307-010-0059-y; Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09; Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Dzwonek J, 2009, MOL CANCER RES, V7, P1342, DOI 10.1158/1541-7786.MCR-08-0558; Fielding AB, 2008, CELL CYCLE, V7, P1899, DOI 10.4161/cc.7.13.6204; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Futterman MA, 2011, DEV DYNAM, V240, P1502, DOI 10.1002/dvdy.22607; Gao H, 2012, CELL BIOL INT, V36, P155, DOI 10.1042/CBI20100240; Garcia G, 2009, J MED CHEM, V52, P7220, DOI 10.1021/jm9003957; Gil D, 2011, ADV ENZYME REGUL, V51, P195, DOI 10.1016/j.advenzreg.2010.09.005; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hong-Brown LQ, 2011, ALCOHOL CLIN EXP RES, V35, P1445, DOI 10.1111/j.1530-0277.2011.01480.x; Jing YY, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-29; Jo M, 2009, J BIOL CHEM, V284, P22825, DOI 10.1074/jbc.M109.023960; Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kavvadas P, 2010, VIRCHOWS ARCH, V457, P563, DOI 10.1007/s00428-010-0976-7; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lee YI, 2004, BIOCHEM BIOPH RES CO, V316, P997, DOI 10.1016/j.bbrc.2004.02.150; Li YJ, 2009, J AM SOC NEPHROL, V20, P1907, DOI 10.1681/ASN.2008090930; Margadant C, 2010, EMBO REP, V11, P97, DOI 10.1038/embor.2009.276; Matsui Y, 2012, INT J CANCER, V130, P521, DOI 10.1002/ijc.26008; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; McPhee TR, 2008, DEV DYNAM, V237, P2737, DOI 10.1002/dvdy.21685; Mikami S, 2011, LAB INVEST, V91, P1443, DOI 10.1038/labinvest.2011.111; Oh JS, 2002, NEOPLASIA, V4, P204, DOI 10.1038/sj.neo.7900229; Papanikolaou S, 2010, HISTOPATHOLOGY, V56, P799, DOI 10.1111/j.1365-2559.2010.03556.x; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Piek E, 1999, J CELL SCI, V112, P4557; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Somasiri A, 2001, J CELL SCI, V114, P1125; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Treins C, 2010, ONCOGENE, V29, P1003, DOI 10.1038/onc.2009.401; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhao JH, 2011, CANCER INVEST, V29, P377, DOI 10.3109/07357907.2010.512595; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	49	96	110	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					50	60		10.1038/onc.2012.30	http://dx.doi.org/10.1038/onc.2012.30			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22310280				2022-12-28	WOS:000313029500005
J	Leucci, E; Zriwil, A; Gregersen, LH; Jensen, KT; Obad, S; Bellan, C; Leoncini, L; Kauppinen, S; Lund, AH				Leucci, E.; Zriwil, A.; Gregersen, L. H.; Jensen, K. T.; Obad, S.; Bellan, C.; Leoncini, L.; Kauppinen, S.; Lund, A. H.			Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo	ONCOGENE			English	Article						miR-9; cytokines; Hodgkin lymphoma; HuR; DICER1	MICRORNA EXPRESSION; BINDING PROTEINS; POSTTRANSCRIPTIONAL CONTROL; STERNBERG CELLS; CANCER; INFLAMMATION; INVOLVEMENT; TRANSCRIPTION; METASTASIS; CYTOKINES	MicroRNAs are important regulators of gene expression in normal development and disease. miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL). Here we demonstrated a relevance for miR-9 in HL pathogenesis and identified two new targets Dicer1 and HuR. HL is characterized by a massive infiltration of immune cells and fibroblasts in the tumour, whereas malignant cells represent only 1% of the tumour mass. These infiltrates provide important survival and growth signals to the tumour cells, and several lines of evidence indicate that they are essential for the persistence of HL. We show that inhibition of miR-9 leads to derepression of DICER and HuR, which in turn results in a decrease in cytokine production by HL cells followed by an impaired ability to attract normal inflammatory cells. Finally, inhibition of miR-9 by a systemically delivered antimiR-9 in a xenograft model of HL increases the protein levels of HuR and DICER1 and results in decreased tumour outgrowth, confirming that miR-9 actively participates in HL pathogenesis and points to miR-9 as a potential therapeutic target. Oncogene (2012) 31, 5081-5089; doi:10.1038/onc.2012.15; published online 6 February 2012	[Leucci, E.; Zriwil, A.; Gregersen, L. H.; Jensen, K. T.; Lund, A. H.] Univ Copenhagen, Copenhagen Bioctr, Biotech Res & Innovat Ctr, DK-2200 Copenhagen N, Denmark; [Obad, S.; Kauppinen, S.] Santaris Pharma, Horsholm, Denmark; [Bellan, C.; Leoncini, L.] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; [Kauppinen, S.] Aalborg Univ, Copenhagen Inst Technol, Ballerup, Denmark	University of Copenhagen; University of Siena; Aalborg University	Lund, AH (corresponding author), Univ Copenhagen, Copenhagen Bioctr, Biotech Res & Innovat Ctr, DK-2200 Copenhagen N, Denmark.	anders.lund@bric.ku.dk	LEONCINI, Lorenzo/U-4413-2019; Lund, Anders H./F-4786-2014; BELLAN, CRISTIANA/ABG-4750-2021; Gregersen, Lea H/AAI-2386-2021; BELLAN, CRISTIANA/L-3903-2013; leoncini, lorenzo/P-8361-2018; Leucci, Eleonora/G-4938-2011	LEONCINI, Lorenzo/0000-0002-7457-300X; Lund, Anders H./0000-0002-7407-3398; BELLAN, CRISTIANA/0000-0001-6119-9007; Gregersen, Lea H/0000-0002-1205-604X; BELLAN, CRISTIANA/0000-0001-6119-9007; leoncini, lorenzo/0000-0002-7457-300X; Leucci, Eleonora/0000-0002-2898-748X; Zriwil, Alya/0000-0001-6262-7253	Danish National Advanced Technology Foundation; EC FP7 ONCOMIRS consortium [201102]; Novo Nordisk Foundation; Lundbeck Foundation; Danish Cancer Society; Danish National Research Foundation; Monte dei Paschi di Siena Foundation; Danish Medical Research Council	Danish National Advanced Technology Foundation; EC FP7 ONCOMIRS consortium; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); Danish National Research Foundation(Danmarks Grundforskningsfond); Monte dei Paschi di Siena Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by The Danish National Advanced Technology Foundation, The EC FP7 ONCOMIRS consortium (Grant agreement number 201102: this publication reflects only authors' views; the commission is not liable for any use that may be made of the information herein), The Novo Nordisk Foundation, The Lundbeck Foundation, The Danish Cancer Society and the Danish National Research Foundation. Dr Bellan's and Professor Leoncini's work is supported by the Monte dei Paschi di Siena Foundation. Dr Leucci is supported by a grant from the Danish Medical Research Council.	Aldinucci D, 2008, INT J CANCER, V122, P769, DOI 10.1002/ijc.23119; Anderson P, 2008, NAT IMMUNOL, V9, P353, DOI 10.1038/ni1584; Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dewan MZ WM, 2005, CANCER SCI, V96, P7; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gentleman R, 2005, BIOINFORMATICS COMPU, P473; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Katsanou V, 2005, MOL CELL, V19, P777, DOI 10.1016/j.molcel.2005.08.007; Kawai T, 2006, MOL CELL BIOL, V26, P3295, DOI 10.1128/MCB.26.8.3295-3307.2006; Khabar KSA, 2010, CELL MOL LIFE SCI, V67, P2937, DOI 10.1007/s00018-010-0383-x; Khan G, 2006, EXP HEMATOL, V34, P399, DOI 10.1016/j.exphem.2005.11.008; Kota SK, 2010, DRUG DISCOV TODAY, V15, P733, DOI 10.1016/j.drudis.2010.07.003; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kuppers R, 2009, NAT REV CANCER, V9, P15, DOI 10.1038/nrc2542; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lambertz I, 2010, CELL DEATH DIFFER, V17, P633, DOI 10.1038/cdd.2009.202; Lawrie CH, 2008, LEUKEMIA, V22, P1440, DOI 10.1038/sj.leu.2405083; Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008; Limma G.S., 2005, BIOINFORMATICS COMPU, P23; Linker K, 2005, NUCLEIC ACIDS RES, V33, P4813, DOI 10.1093/nar/gki797; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Marstrand TT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001623; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Navarro A, 2008, BLOOD, V111, P2825, DOI 10.1182/blood-2007-06-096784; Nie K, 2008, AM J PATHOL, V173, P242, DOI 10.2353/ajpath.2008.080009; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Schetter AJ, 2009, CLIN CANCER RES, V15, P5878, DOI 10.1158/1078-0432.CCR-09-0627; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; Stein CA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp841; Van Vlierberghe P, 2009, BRIT J HAEMATOL, V147, P686, DOI 10.1111/j.1365-2141.2009.07909.x; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Wynendaele J, 2010, CANCER RES, V70, P9641, DOI 10.1158/0008-5472.CAN-10-0527	44	63	67	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5081	5089		10.1038/onc.2012.15	http://dx.doi.org/10.1038/onc.2012.15			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22310293				2022-12-28	WOS:000312000900004
J	Emmenegger, BA; Hwang, EI; Moore, C; Markant, SL; Brun, SN; Dutton, JW; Read, TA; Fogarty, MP; Singh, AR; Durden, DL; Yang, C; McKeehan, WL; Wechsler-Reya, RJ				Emmenegger, B. A.; Hwang, E. I.; Moore, C.; Markant, S. L.; Brun, S. N.; Dutton, J. W.; Read, T-A; Fogarty, M. P.; Singh, A. R.; Durden, D. L.; Yang, C.; McKeehan, W. L.; Wechsler-Reya, R. J.			Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastoma	ONCOGENE			English	Article						basic FGF; cerebellum; medulloblastoma; granule; sonic hedgehog	HEDGEHOG PATHWAY INHIBITOR; FACTOR RECEPTOR; CELL-PROLIFERATION; STEM-CELLS; SUPPRESSOR; PRECURSORS; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; PROGRESSION	Cerebellar granule neurons are the most abundant neurons in the brain, and a critical element of the circuitry that controls motor coordination and learning. In addition, granule neuron precursors (GNPs) are thought to represent cells of origin for medulloblastoma, the most common malignant brain tumor in children. Thus, understanding the signals that control the growth and differentiation of these cells has important implications for neurobiology and neurooncology. Our previous studies have shown that proliferation of GNPs is regulated by Sonic hedgehog (Shh), and that aberrant activation of the Shh pathway can lead to medulloblastoma. Moreover, we have demonstrated that Shh-dependent proliferation of GNPs and medulloblastoma cells can be blocked by basic fibroblast growth factor (bFGF). But while the mitogenic effects of Shh signaling have been confirmed in vivo, the inhibitory effects of bFGF have primarily been studied in culture. Here, we demonstrate that mice lacking FGF signaling in GNPs exhibit no discernable changes in GNP proliferation or differentiation. In contrast, activation of FGF signaling has a potent effect on tumor growth: treatment of medulloblastoma cells with bFGF prevents them from forming tumors following transplantation, and inoculation of tumor-bearing mice with bFGF markedly inhibits tumor growth in vivo. These results suggest that activators of FGF signaling may be useful for targeting medulloblastoma and other Shh-dependent tumors.	[Emmenegger, B. A.; Markant, S. L.; Brun, S. N.; Wechsler-Reya, R. J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA; [Emmenegger, B. A.; Markant, S. L.; Brun, S. N.; Wechsler-Reya, R. J.] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA; [Hwang, E. I.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Moore, C.; Markant, S. L.; Brun, S. N.; Wechsler-Reya, R. J.] Sanford Burnham Med Res Inst, Tumor Dev Program, La Jolla, CA 92037 USA; [Dutton, J. W.] N Carolina State Univ, Coll Vet Med, Raleigh, NC USA; [Read, T-A] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA; [Fogarty, M. P.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Singh, A. R.; Durden, D. L.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Yang, C.; McKeehan, W. L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, Houston, TX USA	Duke University; Duke University; Children's National Health System; Sanford Burnham Prebys Medical Discovery Institute; University of North Carolina; North Carolina State University; Emory University; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wechsler-Reya, RJ (corresponding author), Sanford Burnham Med Res Inst, Tumor Dev Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rwreya@sanfordburnham.org		Read, Tracy-Ann/0000-0002-5436-1296	National Institute of Mental Health [MH67916]; Pediatric Brain Tumor Foundation of the US; California Institute for Regenerative Medicine [LA1-01747]; NATIONAL CANCER INSTITUTE [P50CA140388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067916] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Pediatric Brain Tumor Foundation of the US; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank Marcie Kritzik for help with the paper, Kerry Dorr for contributions to the early stages of this work, Albert Basson for helpful discussions, Chuxia Deng, David Ornitz and James Olson for providing mice, Matthias Lauth and Rune Toftgard for Sufu<SUP>-/-</SUP> MEFs, Sam Johnson for help with microscopy, Amanda Conway for help with western blotting, and Mike Cook and Beth Harvat for help with flow cytometry. This work was funded by grant number MH67916 from the National Institute of Mental Health, by funds from the Pediatric Brain Tumor Foundation of the US, and by a Leadership Award (LA1-01747) from the California Institute for Regenerative Medicine.	Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Ballinger MD, 1999, NAT BIOTECHNOL, V17, P1199, DOI 10.1038/70746; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Corrales JD, 2006, DEVELOPMENT, V133, P1811, DOI 10.1242/dev.02351; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Debinski W, 2009, EXPERT REV NEUROTHER, V9, P1519, DOI 10.1586/ERN.09.99; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FISHELL G, 1991, DEVELOPMENT, V113, P755; Fogarty MP, 2007, P NATL ACAD SCI USA, V104, P2973, DOI 10.1073/pnas.0605770104; FUJITA S, 1966, J COMP NEUROL, V128, P191, DOI 10.1002/cne.901280206; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hamre KM, 1997, DEVELOPMENT, V124, P4201; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Hsu P, 2001, BRAIN RES, V896, P188, DOI 10.1016/S0006-8993(01)02173-4; Humke EW, 2010, GENE DEV, V24, P670, DOI 10.1101/gad.1902910; Jia J, 2006, CELL MOL LIFE SCI, V63, P1249, DOI 10.1007/s00018-005-5519-z; Kenigsberg RL, 1997, AM J PATHOL, V151, P867; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; Komuro H, 1998, J NEUROSCI, V18, P1478; Lauth M, 2007, ONCOGENE, V26, P5163, DOI 10.1038/sj.onc.1210321; Lauth M, 2010, NAT STRUCT MOL BIOL, V17, P718, DOI 10.1038/nsmb.1833; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Lewis PM, 2004, DEV BIOL, V270, P393, DOI 10.1016/j.ydbio.2004.03.007; Li SZ, 2009, DEV NEUROBIOL, V69, P837, DOI 10.1002/dneu.20740; Lumpkin EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI 10.1016/S1567-133X(03)00089-9; MARES V, 1970, BRAIN RES, V23, P323, DOI 10.1016/0006-8993(70)90060-0; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Mullen RJ, 1997, PERSPECT DEV NEUROBI, V5, P43; NICHOLSO.JL, 1972, BRAIN RES, V44, P13, DOI 10.1016/0006-8993(72)90362-9; Nicot A, 2002, J NEUROSCI, V22, P9244; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Olson DC, 1998, CELL GROWTH DIFFER, V9, P557; PASCUALCASTROVIEJO I, 1994, NEUROPEDIATRICS, V25, P183, DOI 10.1055/s-2008-1073020; Pons S, 2001, DEVELOPMENT, V128, P1481; Read TA, 2009, CANCER CELL, V15, P1; Rios I, 2004, DEVELOPMENT, V131, P3159, DOI 10.1242/dev.01188; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Song BW, 2002, J PHARMACOL EXP THER, V301, P605, DOI 10.1124/jpet.301.2.605; Spassky N, 2008, DEV BIOL, V317, P246, DOI 10.1016/j.ydbio.2008.02.026; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Traiffort E, 1999, EUR J NEUROSCI, V11, P3199, DOI 10.1046/j.1460-9568.1999.00777.x; Vachon P, 2004, J NEURO-ONCOL, V67, P139, DOI 10.1023/B:NEON.0000021824.41701.e5; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wang VY, 2001, NAT REV NEUROSCI, V2, P484, DOI 10.1038/35081558; Ward RJ, 2009, CANCER RES, V69, P4682, DOI 10.1158/0008-5472.CAN-09-0342; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Weinstein M, 1998, DEVELOPMENT, V125, P3615; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Xu XL, 2002, GENESIS, V32, P85, DOI 10.1002/gene.10028; Yaguchi Y, 2009, DEV DYNAM, V238, P2058, DOI 10.1002/dvdy.22013; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yu CD, 2005, J BIOL CHEM, V280, P17707, DOI 10.1074/jbc.M411771200; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408	67	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4181	4188		10.1038/onc.2012.440	http://dx.doi.org/10.1038/onc.2012.440			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23045271	Green Accepted, Green Submitted			2022-12-28	WOS:000323748500013
J	Ha, S; Iqbal, NJ; Mita, P; Ruoff, R; Gerald, WL; Lepor, H; Taneja, SS; Lee, P; Melamed, J; Garabedian, MJ; Logan, SK				Ha, S.; Iqbal, N. J.; Mita, P.; Ruoff, R.; Gerald, W. L.; Lepor, H.; Taneja, S. S.; Lee, P.; Melamed, J.; Garabedian, M. J.; Logan, S. K.			Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer	ONCOGENE			English	Article						PIM1; AR; phosphorylation; prostate cancer; hormone refractory	C-MYC; GROWTH-FACTOR; TUMOR-GROWTH; CYCLIN A1; KINASE; PROGRESSION; PROTEIN; CELLS; ACTIVATION; EXPRESSION	Integration of cellular signaling pathways with androgen receptor (AR) signaling can be achieved through phosphorylation of AR by cellular kinases. However, the kinases responsible for phosphorylating the AR at numerous sites and the functional consequences of AR phosphorylation are only partially understood. Bioinformatic analysis revealed AR serine 213 (S213) as a putative substrate for PIM1, a kinase overexpressed in prostate cancer. Therefore, phosphorylation of AR serine 213 by PIM1 was examined using a phosphorylation site-specific antibody. Wild-type PIM1, but not catalytically inactive PIM1, specifically phosphorylated AR but not an AR serine-to-alanine mutant (S213A). In vitro kinase assays confirmed that PIM1 can phosphorylate AR S213 in a ligand-independent manner and cell type-specific phosphorylation was observed in prostate cancer cell lines. Upon PIM1 overexpression, AR phosphorylation was observed in the absence of hormone and was further increased in the presence of hormone in LNCaP, LNCaP-abl and VCaP cells. Moreover, phosphorylation of AR was reduced in the presence of PIM kinase inhibitors. An examination of AR-mediated transcription showed that reporter gene activity was reduced in the presence of PIM1 and wild-type AR, but not S213A mutant AR. Androgen-mediated transcription of endogenous PSA, Nkx3.1 and IGFBP5 was also decreased in the presence of PIM1, whereas IL6, cyclin A1 and caveolin 2 were increased. Immunohistochemical analysis of prostate cancer tissue microarrays showed significant P-AR S213 expression that was associated with hormone refractory prostate cancers, likely identifying cells with catalytically active PIM1. In addition, prostate cancers expressing a high level of P-AR S213 were twice as likely to be from biochemically recurrent cancers. Thus, AR phosphorylation by PIM1 at S213 impacts gene transcription and is highly prevalent in aggressive prostate cancer.	[Ha, S.; Iqbal, N. J.; Mita, P.; Ruoff, R.; Lepor, H.; Taneja, S. S.; Garabedian, M. J.; Logan, S. K.] NYU, Sch Med, Dept Urol, New York, NY 10016 USA; [Ha, S.; Ruoff, R.; Logan, S. K.] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA; [Gerald, W. L.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Lee, P.; Melamed, J.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Garabedian, M. J.] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University; New York University; Memorial Sloan Kettering Cancer Center; New York University; New York University	Logan, SK (corresponding author), NYU, Sch Med, Dept Urol, 550 1st Ave,MSB 424, New York, NY 10016 USA.	susan.logan@nyumc.org	Melamed, Jonathan/AAV-3769-2020	Melamed, Jonathan/0000-0003-2844-7990; Logan, Susan/0000-0002-7904-5927; Iqbal, Niloy/0000-0003-0367-2569	New York University School of Medicine Department of Urology at New York University School of Medicine; NIH [R01CA112226, UO1 1U01CA149556-01]; NYU Department of Urology; DOD [PC094786, PC080010]; NATIONAL CANCER INSTITUTE [R01CA112226, U01CA149556] Funding Source: NIH RePORTER	New York University School of Medicine Department of Urology at New York University School of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NYU Department of Urology; DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge funding from the New York University School of Medicine Department of Urology at New York University School of Medicine. This work was supported by NIH R01CA112226 (SL), funds from the NYU Department of Urology, DOD grant PC094786 for the Prostate Cancer Biorepository Network (PCBN, JM), DOD grant PC080010 (PL) and NIH UO1 1U01CA149556-01(PL).	Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Beharry Z, 2011, P NATL ACAD SCI USA, V108, P528, DOI 10.1073/pnas.1013214108; Bowen C, 2000, CANCER RES, V60, P6111; Chen SY, 2012, J BIOL CHEM, V287, P8571, DOI 10.1074/jbc.M111.325290; Chen WW, 2008, MOL ENDOCRINOL, V22, P1754, DOI 10.1210/me.2007-0219; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Chun JY, 2009, CLIN CANCER RES, V15, P4815, DOI 10.1158/1078-0432.CCR-09-0640; Cibull TL, 2006, J CLIN PATHOL, V59, P285, DOI 10.1136/jcp.2005.027672; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; CUYPERS HT, 1984, CELL, V37, P141; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Garraway IP, 2010, PROSTATE, V70, P491, DOI 10.1002/pros.21083; Gould ML, 2010, PROSTATE, V70, P1609, DOI 10.1002/pros.21195; Gstaiger M, 2003, SCIENCE, V302, P1208, DOI 10.1126/science.1088401; Ha S, 2011, ENDOCR-RELAT CANCER, P11; Ha S, 2011, ENDOCR-RELAT CANCER, V18, P245, DOI 10.1530/ERC-10-0204; Hendriksen PJM, 2006, CANCER RES, V66, P5012, DOI 10.1158/0008-5472.CAN-05-3082; Kim J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-248; Kim O, 2004, ONCOGENE, V23, P1838, DOI 10.1038/sj.onc.1207304; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Mumenthaler SM, 2009, MOL CANCER THER, V8, P2882, DOI 10.1158/1535-7163.MCT-09-0293; Nwachukwu JC, 2009, CANCER RES, V69, P3140, DOI 10.1158/0008-5472.CAN-08-3738; Payne H, 2011, UROL ONCOL-SEMIN ORI, V29, P593, DOI 10.1016/j.urolonc.2009.11.003; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Song H, 2009, ONCOGENE, V28, P3307, DOI 10.1038/onc.2009.181; Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97; Taneja SS, 2005, J BIOL CHEM, V280, P40916, DOI 10.1074/jbc.M508442200; Thompson J, 2003, LAB INVEST, V83, P1301, DOI 10.1097/01.LAB.0000087585.03162.A3; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang J, 2010, ONCOGENE, V29, P2477, DOI 10.1038/onc.2010.10; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Ward RD, 2009, BIOFACTORS, V35, P528, DOI 10.1002/biof.66; Wegiel B, 2005, ONCOGENE, V24, P6385, DOI 10.1038/sj.onc.1208795; Wegiel B, 2008, JNCI-J NATL CANCER I, V100, P1022, DOI 10.1093/jnci/djn214; Wen Y, 2000, CANCER RES, V60, P6841; Xia ZP, 2009, J MED CHEM, V52, P74, DOI 10.1021/jm800937p; Xie Y, 2006, ONCOGENE, V25, P70, DOI 10.1038/sj.onc.1209058; Xie Y, 2008, J BIOL CHEM, V283, P3349, DOI 10.1074/jbc.M707773200; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	55	38	41	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3992	4000		10.1038/onc.2012.412	http://dx.doi.org/10.1038/onc.2012.412			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22986532	Green Accepted			2022-12-28	WOS:000323748100007
J	Wang, Y; Wang, Z; Joshi, BH; Puri, RK; Stultz, B; Yuan, Q; Bai, Y; Zhou, P; Yuan, Z; Hursh, DA; Bi, X				Wang, Y.; Wang, Z.; Joshi, B. H.; Puri, R. K.; Stultz, B.; Yuan, Q.; Bai, Y.; Zhou, P.; Yuan, Z.; Hursh, D. A.; Bi, X.			The tumor suppressor Caliban regulates DNA damage-induced apoptosis through p53-dependent and -independent activity	ONCOGENE			English	Article						Apoptosis; Caliban; p53; tumor suppressor	CELL-DEATH; GENOMIC INSTABILITY; IONIZING-RADIATION; P53 FUNCTION; DROSOPHILA; ATM; SENESCENCE; PROTEIN; MAINTENANCE; RESTORATION	We previously identified Caliban (Clbn) as the Drosophila homolog of human Serologically defined colon cancer antigen 1 gene and demonstrated that it could function as a tumor suppressor in human non-small-cell lung cancer (NSCLC) cells, although its mode of action was unknown. Herein, we identify roles for Clbn in DNA damage response. We generate clbn knockout flies using homologous recombination and demonstrate that they have a heightened sensitivity to irradiation. We show that normal Clbn function facilitates both p53-dependent and -independent DNA damage-induced apoptosis. Clbn coordinates different apoptosis pathways, showing a two-stage upregulation following DNA damage. Clbn has proapoptotic functions, working with both caspase and the proapoptotic gene Hid. Finally, ecotopic expression of clbn(+) in NSCLC cells suppresses tumor formation in athymic nude mice. We conclude that Caliban is a regulator of DNA damage-induced apoptosis, functioning as a tumor suppressor in both p53-dependent and -independent pathways.	[Wang, Y.; Wang, Z.; Yuan, Q.; Bi, X.] Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China; [Wang, Z.; Bi, X.] Dalian Med Univ, Inst Canc Stem Cell, Ctr Canc, Dalian, Peoples R China; [Joshi, B. H.; Puri, R. K.; Stultz, B.; Hursh, D. A.] US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bethesda, MD USA; [Bai, Y.; Yuan, Z.] Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100049, Peoples R China; [Zhou, P.] Beijing Inst Radiat Med, Dept Radiat Toxicol & Oncol, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Dalian Medical University; US Food & Drug Administration (FDA); Chinese Academy of Sciences; Institute of Biophysics, CAS; Academy of Military Medical Sciences - China	Bi, X (corresponding author), Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.	bixl@ihep.ac.cn	Bi, Xiaolin/E-7469-2010; Yuan, Qing/ABF-3033-2020; Bi, Xiaolin/C-7038-2014	Bi, Xiaolin/0000-0002-7172-7851; Bi, Xiaolin/0000-0003-2837-9457; Hursh, Deborah/0000-0002-5614-7111	National Basic Research Program of China (973 Program) [2010CB934004]; National Natural Science Foundation of China [30871388]; CAS; Food and Drug Administration, Center for Biologics Evaluation and Research	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAS(Chinese Academy of Sciences); Food and Drug Administration, Center for Biologics Evaluation and Research	We thank Drs Hermann Steller, Laura Johnston and Tin Tin Su; the Bloomington Stock Center for fly stocks; Dr Dong Han at National Center for Nanoscience and Technology for help with the scanning electron microscope; and the members of the Bi laboratory for advice and discussions. We also thank Dr Mark Mortin for generating the knockout clbn flies and for critically reading this manuscript. We are grateful for comments on this manuscript from Tehyen Chu and Brent McCright. This work was supported by grants from National Basic Research Program of China (973 Program grant no. 2010CB934004), National Natural Science Foundation of China (grant no. 30871388) and CAS Knowledge Innovation Program to XB and by the Food and Drug Administration, Center for Biologics Evaluation and Research.	Akdemir F, 2007, ONCOGENE, V26, P5184, DOI 10.1038/sj.onc.1210328; Attardi LD, 2005, MUTAT RES-FUND MOL M, V569, P145, DOI 10.1016/j.mrfmmm.2004.04.019; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Baum JS, 2007, CELL DEATH DIFFER, V14, P1508, DOI 10.1038/sj.cdd.4402155; Bennett K, 2010, J PROTEOME RES, V9, P4289, DOI 10.1021/pr1003467; Bi XL, 2005, ONCOGENE, V24, P8229, DOI 10.1038/sj.onc.1208962; Bi XL, 2004, CURR BIOL, V14, P1348, DOI 10.1016/j.cub.2004.06.063; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Carbonnelle D, 2001, INT J CANCER, V92, P388, DOI 10.1002/ijc.1197; Chalastanis A, 2010, J NATL CANCER I, V102, P1731, DOI 10.1093/jnci/djq389; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Fan Y, 2010, CELL DEATH DIFFER, V17, P912, DOI 10.1038/cdd.2009.182; Gong WJ, 2003, P NATL ACAD SCI USA, V100, P2556, DOI 10.1073/pnas.0535280100; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kornbluth S, 2005, J CELL SCI, V118, P1779, DOI 10.1242/jcs.02377; Lannan E, 2007, J VIROL, V81, P9319, DOI 10.1128/JVI.00247-07; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; Long SW, 2011, BIOSCIENCE REP, V31, P333, DOI 10.1042/BSR20100124; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McKinnon PJ, 2004, EMBO REP, V5, P772, DOI 10.1038/sj.embor.7400210; McNamee LM, 2009, GENETICS, V182, P423, DOI 10.1534/genetics.109.102327; Moon NS, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000153; Oikemus SR, 2004, GENE DEV, V18, P1850, DOI 10.1101/gad.1202504; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Papait R, 2009, BIOCHEM BIOPH RES CO, V379, P434, DOI 10.1016/j.bbrc.2008.12.091; Rasti M, 2012, PATHOL ONCOL RES, V18, P169, DOI 10.1007/s12253-011-9423-6; Sabourin M, 2008, TRENDS CELL BIOL, V18, P337, DOI 10.1016/j.tcb.2008.04.004; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Silva E, 2004, CURR BIOL, V14, P1341, DOI 10.1016/j.cub.2004.06.056; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Song YH, 2004, CURR BIOL, V14, P1354, DOI 10.1016/j.cub.2004.06.064; Squillaro T, 2010, FASEB J, V24, P1593, DOI 10.1096/fj.09-143057; Steller H, 2008, CELL DEATH DIFFER, V15, P1132, DOI 10.1038/cdd.2008.50; Stultz BG, 2006, DEV BIOL, V296, P329, DOI 10.1016/j.ydbio.2006.05.034; Titen SWA, 2008, GENETICS, V180, P1821, DOI 10.1534/genetics.108.093625; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wichmann A, 2006, P NATL ACAD SCI USA, V103, P9952, DOI 10.1073/pnas.0510528103; Wichmann A, 2010, DEV BIOL, V346, P80, DOI 10.1016/j.ydbio.2010.07.023; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529	46	4	4	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3857	3866		10.1038/onc.2012.395	http://dx.doi.org/10.1038/onc.2012.395			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22964637				2022-12-28	WOS:000323210200008
J	Linger, RMA; Cohen, RA; Cummings, CT; Sather, S; Migdall-Wilson, J; Middleton, DHG; Lu, X; Baron, AE; Franklin, WA; Merrick, DT; Jedlicka, P; DeRyckere, D; Heasley, LE; Graham, DK				Linger, R. M. A.; Cohen, R. A.; Cummings, C. T.; Sather, S.; Migdall-Wilson, J.; Middleton, D. H. G.; Lu, X.; Baron, A. E.; Franklin, W. A.; Merrick, D. T.; Jedlicka, P.; DeRyckere, D.; Heasley, L. E.; Graham, D. K.			Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer	ONCOGENE			English	Article						targeted therapy; receptor tyrosine kinase; MerTK; signal transduction; xenograft; chemosensitivity	SYSTEMIC-LUPUS-ERYTHEMATOSUS; ELEMENT-BINDING PROTEIN; NF-KAPPA-B; GENE-EXPRESSION; BREAST-CANCER; TUMOR-GROWTH; THERAPEUTIC TARGETS; PROLONGS SURVIVAL; DISEASE-ACTIVITY; DRUG-RESISTANCE	Non-small cell lung cancer (NSCLC) is a prevalent and devastating disease that claims more lives than breast, prostate, colon and pancreatic cancers combined. Current research suggests that standard chemotherapy regimens have been optimized to maximal efficiency. Promising new treatment strategies involve novel agents targeting molecular aberrations present in subsets of NSCLC. We evaluated 88 human NSCLC tumors of diverse histology and identified Mer and Axl as receptor tyrosine kinases (RTKs) overexpressed in 69% and 93%, respectively, of tumors relative to surrounding normal lung tissue. Mer and Axl were also frequently overexpressed and activated in NSCLC cell lines. Ligand-dependent Mer or Axl activation stimulated MAPK, AKT and FAK signaling pathways indicating roles for these RTKs in multiple oncogenic processes. In addition, we identified a novel pro-survival pathway-involving AKT, CREB, Bcl-xL, survivin, and Bcl-2-downstream of Mer, which is differentially modulated by Axl signaling. We demonstrated that short hairpin RNA (shRNA) knockdown of Mer or Axl significantly reduced NSCLC colony formation and growth of subcutaneous xenografts in nude mice. Mer or Axl knockdown also improved in vitro NSCLC sensitivity to chemotherapeutic agents by promoting apoptosis. When comparing the effects of Mer and Axl knockdown, Mer inhibition exhibited more complete blockade of tumor growth while Axl knockdown more robustly improved chemosensitivity. These results indicate that Mer and Axl have complementary and overlapping roles in NSCLC and suggest that treatment strategies targeting both RTKs may be more effective than singly-targeted agents. Our findings validate Mer and Axl as potential therapeutic targets in NSCLC and provide justification for development of novel therapeutic compounds that selectively inhibit Mer and/or Axl.	[Linger, R. M. A.; Cohen, R. A.; Cummings, C. T.; Sather, S.; Migdall-Wilson, J.; DeRyckere, D.; Graham, D. K.] Univ Colorado, Dept Pediat, Sect Hematol Oncol & Bone Marrow Transplantat, Aurora, CO 80045 USA; [Middleton, D. H. G.] Univ Colorado, Program Canc Biol, Aurora, CO 80045 USA; [Lu, X.; Baron, A. E.] Univ Colorado, Dept Biostat & Informat, Aurora, CO 80045 USA; [Franklin, W. A.; Merrick, D. T.; Jedlicka, P.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA; [Merrick, D. T.] Denver VA Med Ctr, Dept Pathol, Denver, CO USA; [Heasley, L. E.] Denver VA Med Ctr, Dept Craniofacial Biol, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Graham, DK (corresponding author), Univ Colorado, Dept Pediat, Sect Hematol Oncol & Bone Marrow Transplantat, Anschutz Med Campus,Mail Stop 8302,12800 East 19t, Aurora, CO 80045 USA.	doug.graham@ucdenver.edu		Maller, Justine/0000-0001-6930-7375; Cummings, Christopher/0000-0002-2978-2494	Uniting Against Lung Cancer: Elliot's Legacy (RMAL); Lung Cancer Research Foundation (RMAL); American Cancer Society [RSG-08-291-01-LIB]; National Institutes of Health [RO1CA137078]; University of Colorado Cancer Center SPORE in Lung Cancer [NIH 5P50CA058187]; Damon Runyon Cancer Research Foundation [CI-39-07]; NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187, R01CA127105, R01CA137078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008497] Funding Source: NIH RePORTER	Uniting Against Lung Cancer: Elliot's Legacy (RMAL); Lung Cancer Research Foundation (RMAL); American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Colorado Cancer Center SPORE in Lung Cancer; Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by grants from Uniting Against Lung Cancer: Elliot's Legacy (RMAL), the Lung Cancer Research Foundation (RMAL), the American Cancer Society (RSG-08-291-01-LIB, DKG) and the National Institutes of Health (RO1CA137078, DKG). RMA Linger received a Career Development Award from the University of Colorado Cancer Center SPORE in Lung Cancer (NIH 5P50CA058187). DK Graham is the Damon Runyon-Novartis Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (CI-39-07). The authors wish to thank Karen Helm, Christine Childs and Lester Acosta in the University of Colorado Cancer Center Flow Cytometry Core for their expert technical assistance, Randall Wong in the University of Colorado Denver Diabetes and Endocrinology Research Center Molecular Biology Core Facility (NIH P30 DK57516) for cell line authentication services, Patricia Lenhart for help optimizing Mer and Axl immunohistochemistry of human tissues, and Storey Wilson and Andrea Abeyta for technical assistance with the Aperio imaging system used to digitize stained tumor microarray slides.	Aggarwal S, 2008, CANCER RES, V68, P981, DOI 10.1158/0008-5472.CAN-06-0249; Alciato F, 2010, J LEUKOCYTE BIOL, V87, P869, DOI 10.1189/jlb.0909610; Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; Allen MP, 2002, J BIOL CHEM, V277, P38133, DOI 10.1074/jbc.M200826200; [Anonymous], 2011, SEER CANC STAT REV 1; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Balogh I, 2005, ARTERIOSCL THROM VAS, V25, P1280, DOI 10.1161/01.ATV.0000163845.07146.48; Brandao Luis, 2011, Critical Reviews in Oncogenesis, V16, P47; Bremnes RM, 2002, J CLIN ONCOL, V20, P2417, DOI 10.1200/JCO.2002.08.159; Brose MS, 2002, CANCER RES, V62, P6997; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Ekman C, 2011, RHEUMATOLOGY, V50, P1064, DOI 10.1093/rheumatology/keq459; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Grosso S, 2009, MOL CANCER THER, V8, P1924, DOI 10.1158/1535-7163.MCT-09-0168; Gustafsson A, 2009, CLIN CANCER RES, V15, P4742, DOI 10.1158/1078-0432.CCR-08-2514; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Han ZY, 1996, CANCER RES, V56, P1621; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Janku F, 2011, J THORAC ONCOL, V6, P1601, DOI 10.1097/JTO.0b013e31822944b3; Jansen FH, 2012, J PROTEOME RES, V11, P728, DOI 10.1021/pr2006473; Keating AK, 2006, ONCOGENE, V25, P6092, DOI 10.1038/sj.onc.1209633; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Macleod K, 2005, CANCER RES, V65, P6789, DOI 10.1158/0008-5472.CAN-04-2684; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mudduluru G, 2011, BIOL CELL, V103, P21, DOI 10.1042/BC20100094; Nielsen-Preiss SM, 2007, ENDOCRINOLOGY, V148, P2806, DOI 10.1210/en.2007-0039; Oliver L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019820; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rogers AEJ, 2012, ONCOGENE, V31, P4171, DOI 10.1038/onc.2011.588; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Shankar SL, 2006, J NEUROSCI, V26, P5638, DOI 10.1523/JNEUROSCI.5063-05.2006; Shaw AT, 2011, LANCET ONCOL, V12, P1004, DOI 10.1016/S1470-2045(11)70232-7; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Shinoura N, 1999, CANCER RES, V59, P4119; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Society AC, 2012, CANC FACTS FIG 2012; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Wallin JJ, 2011, MOL CANCER THER, V10, P2426, DOI 10.1158/1535-7163.MCT-11-0446; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Wu J, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3316; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632; Yamamoto H, 2008, CANCER RES, V68, P6913, DOI 10.1158/0008-5472.CAN-07-5084; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang LQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034100; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	65	135	154	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2013	32	29					3420	3431		10.1038/onc.2012.355	http://dx.doi.org/10.1038/onc.2012.355			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22890323	Green Accepted			2022-12-28	WOS:000322014900003
J	Deeraksa, A; Pan, J; Sha, Y; Liu, XD; Eissa, NT; Lin, SH; Yu-Lee, LY				Deeraksa, A.; Pan, J.; Sha, Y.; Liu, X-D; Eissa, N. T.; Lin, S-H; Yu-Lee, L-y			Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis	ONCOGENE			English	Article						Plk1; BI2536; mitotic catastrophe; necroptosis; autophagy; prostate cancer	POLO-LIKE KINASES; MITOTIC CATASTROPHE; DEATH PATHWAY; LNCAP MODEL; PHOSPHORYLATION; IDENTIFICATION; CYTOKINESIS; KINETOCHORE; PROGRESSION; INDUCTION	Castration-resistant prostate cancer (PCa) is refractory to hormone therapy and new strategies for treatment are urgently needed. We found that androgen-insensitive (AI) PCa cells, LNCaP-AI, are reprogrammed to upregulate the mitotic kinase Plk1 (Polo-like kinase 1) and other M-phase cell-cycle proteins, which may underlie AI PCa growth. In androgen-depleted media, LNCaP-AI cells showed exquisite sensitivity to growth inhibition by subnanomolar concentrations of a small molecule inhibitor of Plk1, BI2536, suggesting that these cells are dependent on Plk1 for growth. In contrast, the androgen-responsive parental LNCaP cells showed negligible responses to BI2536 treatment under the same condition. BI2536 treatment of LNCaP-AI cells resulted in an increase in cell death marker PARP-1 (polymerase-1) but did not activate caspase-3, an apoptosis marker, suggesting that the observed cell death was caspase-independent. BI2536-treated LNCaP-AI cells formed multinucleated giant cells that contain clusters of nuclear vesicles indicative of mitotic catastrophe. Live-cell time-lapse imaging revealed that BI2536-treated giant LNCaP-AI cells underwent necroptosis, as evidenced by 'explosive' cell death and partial reversal of cell death by a necroptosis inhibitor. Our studies suggest that LNCaP-AI cells underwent reprogramming in both their cell growth and cell death pathways, rendering them highly sensitive to Plk1 inhibition that induces necroptosis. Harnessing necroptosis through Plk1 inhibition may be explored for therapeutic intervention of castration-resistant PCa.	[Deeraksa, A.; Pan, J.; Yu-Lee, L-y] Dept Med, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Sha, Y.; Liu, X-D; Eissa, N. T.] Dept Med, Sect Pulm Crit Care & Sleep Med, Houston, TX 77030 USA; [Lin, S-H] UT Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX USA; [Yu-Lee, L-y] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Yu-Lee, LY (corresponding author), Dept Med, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA.	yulee@bcm.edu		Liu, xiande/0000-0002-9639-0458	NIH [T32-AI07495, T32-DK07696, HL080205, CA111479, DK53176, AI071130]; DOD [PC080847, PC093132]; Dan L Duncan Cancer Center; Alkek Award in Experimental Therapeutics; NATIONAL CANCER INSTITUTE [R01CA111479] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI071130, T32AI007495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053176, T32DK007696] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Dan L Duncan Cancer Center; Alkek Award in Experimental Therapeutics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Anna Ferrari of New York University for the LNCaP-AI cells and Ms Shenyan Zeng for FACS analysis. This work was supported by NIH training Grants T32-AI07495 and T32-DK07696 for AD and Grants from the NIH (HL080205 to NTE; CA111479 to S-HL; DK53176, AI071130 to L-yY-L), DOD (PC080847, PC093132 to S-HL), Dan L Duncan Cancer Center (L-yY-L and S-HL) and Alkek Award in Experimental Therapeutics (L-yY-L and S-HL).	Alano CC, 2006, TRENDS BIOCHEM SCI, V31, P309, DOI 10.1016/j.tibs.2006.04.006; Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bastos RN, 2010, J CELL BIOL, V191, P751, DOI 10.1083/jcb.201008108; Brennan IM, 2007, P NATL ACAD SCI USA, V91, P5046; Caserta TM, 2003, VIROLOGY, V191, P589; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Guan R, 2005, CANCER RES, V65, P2698, DOI 10.1158/0008-5472.CAN-04-2131; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kurasawa Y, 2010, MOL BIOL CELL, V21, P1188, DOI 10.1091/mbc.E09-11-0950; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lenart P, 2007, CURR BIOL, V17, P1; Li J, 2010, J GENET GENOMICS, V37, P159, DOI 10.1016/S1673-8527(09)60034-5; Liu XS, 2010, PROTEIN CELL, V1, P999, DOI 10.1007/s13238-010-0131-x; Macy B, 2009, CELL CYCLE, V8, P35, DOI 10.4161/cc.8.1.7327; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nishino M, 2006, CURR BIOL, V16, P1414, DOI 10.1016/j.cub.2006.05.052; Park JE, 2011, P NATL ACAD SCI USA, V108, P8200, DOI 10.1073/pnas.1102020108; Reagan-Shaw S, 2005, FASEB J, V19, P611, DOI 10.1096/fj.04-2910fje; Schmit TL, 2009, J INVEST DERMATOL, V129, P2843, DOI 10.1038/jid.2009.172; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Speirs CK, 2011, AM J CANCER RES, V1, P43; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Takaki T, 2008, CURR OPIN CELL BIOL, V20, P650, DOI 10.1016/j.ceb.2008.10.005; THALMANN GN, 1994, CANCER RES, V54, P2577; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Wang LG, 2004, ONCOGENE, V23, P5175, DOI 10.1038/sj.onc.1207654; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	41	53	59	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2973	2983		10.1038/onc.2012.309	http://dx.doi.org/10.1038/onc.2012.309			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22890325	Green Accepted			2022-12-28	WOS:000320369700007
J	Skalka, N; Caspi, M; Caspi, E; Loh, YP; Rosin-Arbesfeld, R				Skalka, N.; Caspi, M.; Caspi, E.; Loh, Y. P.; Rosin-Arbesfeld, R.			Carboxypeptidase E: a negative regulator of the canonical Wnt signaling pathway	ONCOGENE			English	Article						Wnt signaling; carboxypeptidase E (CPE); beta-catenin; functional screen	NEUROPEPTIDE-PROCESSING ENZYME; BETA-CATENIN; SECRETORY GRANULES; CANCER CELLS; AXIN; POLYMERIZATION; TRANSDUCTION; ENDOCRINE; MUTATIONS; PROTEINS	Aberrant activation of the canonical Wnt signal transduction pathway is involved in many diseases including cancer and is especially implicated in the development and progression of colorectal cancer. The key effector protein of the canonical Wnt pathway is beta-catenin, which functions with T-cell factor/lymphoid enhancer factor to activate expression of Wnt target genes. In this study, we used a new functional screen based on cell survival in the presence of cDNAs encoding proteins that activate the Wnt pathway thus identifying novel Wnt signaling components. Here we identify carboxypeptidase E (vertical bar CPE) and its splice variant, Delta N-CPE, as novel regulators of the Wnt pathway. We show that whereas Delta N-CPE activates the Wnt signal, the full-length CPE (F-CPE) protein is an inhibitor of Wnt/beta-catenin signaling. F-CPE forms a complex with the Wnt3a ligand and the Frizzled receptor. Moreover, F-CPE disrupts disheveled-induced signalosomes that are important for transducing the Wnt signal and reduces beta-catenin protein levels and activity. Taken together, our data indicate that F-CPE and Delta N-CPE regulate the canonical Wnt signaling pathway negatively and positively, respectively, and demonstrate that this screening approach can be a rapid means for isolation of novel Wnt signaling components.	[Skalka, N.; Caspi, M.; Caspi, E.; Rosin-Arbesfeld, R.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Loh, Y. P.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular Neurobiol, Program Dev Neurosci, NIH, Bethesda, MD USA	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Rosin-Arbesfeld, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	arina@post.tau.ac.il			Israel Science Foundation; Public Committee for Allocation of Estate Funds, Ministry of Justice, Israel [20120016]; Recanati Foundation; Israel Cancer Association through the Estate of the late Alexander Smidoda; US-Israel Binational Science Foundation; Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008804, ZIAHD000056] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); Public Committee for Allocation of Estate Funds, Ministry of Justice, Israel; Recanati Foundation; Israel Cancer Association through the Estate of the late Alexander Smidoda; US-Israel Binational Science Foundation(US-Israel Binational Science Foundation); Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by the Israel Science Foundation, by grant no. 20120016 from the Public Committee for Allocation of Estate Funds, Ministry of Justice, Israel, the Recanati Foundation, Israel Cancer Association through the Estate of the late Alexander Smidoda, US-Israel Binational Science Foundation and in part by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development to YPL.	Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Cawley NX, 2012, ENDOCR REV, V33, P216, DOI 10.1210/er.2011-1039; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Dobrowolski R, 2012, NAT REV MOL CELL BIO, V13, P53, DOI 10.1038/nrm3244; Du JL, 2001, CANCER LETT, V165, P211, DOI 10.1016/S0304-3835(01)00409-8; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; Golan T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200; Hausmann G, 2007, NAT REV MOL CELL BIO, V8, P331, DOI 10.1038/nrm2141; He P, 2004, HUM PATHOL, V35, P1196, DOI 10.1016/j.humpath.2004.06.014; Horing E, 2012, ACTA NEUROPATHOL, V124, P83, DOI 10.1007/s00401-011-0940-x; Lee TK, 2011, J CLIN INVEST, V121, P880, DOI 10.1172/JCI40433; Liu YT, 2011, J BIOL CHEM, V286, P8597, DOI 10.1074/jbc.M110.186742; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Metcalfe C, 2011, J CELL SCI, V124, P3537, DOI 10.1242/jcs.091991; Metcalfe C, 2010, J CELL SCI, V123, P1588, DOI 10.1242/jcs.067546; Moeller C, 2003, DEVELOPMENT, V130, P5103, DOI 10.1242/dev.00686; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murthy SRK, 2010, CELL MOL NEUROBIOL, V30, P1377, DOI 10.1007/s10571-010-9592-y; Murthy SR, 2012, AACR ANN M 2012 CHIC; Park J, 2009, J MOL NEUROSCI, V37, P151, DOI 10.1007/s12031-008-9098-y; Polakis P, 2000, GENE DEV, V14, P1837; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Schwarz-Romond T, 2007, J CELL SCI, V120, P2402, DOI 10.1242/jcs.002956; Schwarz-Romond T, 2007, NAT STRUCT MOL BIOL, V14, P484, DOI 10.1038/nsmb1247; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; STROUS GJAM, 1983, J CELL BIOL, V97, P1815, DOI 10.1083/jcb.97.6.1815; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tang SS, 2009, MOL CELL ENDOCRINOL, V303, P43, DOI 10.1016/j.mce.2009.01.020; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang L, 2009, J BONE MINER RES, V24, P265, DOI [10.1359/jbmr.081014, 10.1359/JBMR.081014]; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540	39	33	35	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2013	32	23					2836	2847		10.1038/onc.2012.308	http://dx.doi.org/10.1038/onc.2012.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22824791	Green Accepted			2022-12-28	WOS:000320369100004
J	Ward, Y; Lake, R; Martin, PL; Killian, K; Salerno, P; Wang, T; Meltzer, P; Merino, M; Cheng, SY; Santoro, M; Garcia-Rostan, G; Kelly, K				Ward, Y.; Lake, R.; Martin, P. L.; Killian, K.; Salerno, P.; Wang, T.; Meltzer, P.; Merino, M.; Cheng, S-Y; Santoro, M.; Garcia-Rostan, G.; Kelly, K.			CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model	ONCOGENE			English	Article						CD97; LPAR; thyroid cancer; metastasis; vascular invasion; anaplastic	LYSOPHOSPHATIDIC ACID; MAMMARY TUMORIGENESIS; TUMOR PROGRESSION; HORMONE RECEPTOR; EXPRESSION; AUTOTAXIN; INVASION; 7-TRANSMEMBRANE; METASTASIS; CARCINOMA	CD97, a member of the adhesion family of G-protein-coupled receptors (GPCRs), complexes with and potentiates lysophosphatidic acid (LPA) receptor signaling to the downstream effector RHOA. We show here that CD97 was expressed in a majority of thyroid cancers but not normal thyroid epithelium and that the level of CD97 expression was further elevated with progression to poorly differentiated and undifferentiated carcinoma. Intratumoral progression also showed that CD97 expression correlates with invasiveness and dedifferentiation. To determine the functional role of CD97, we produced a transgenic model of thyroglobulin promoter-driven CD97 expression. Transgenic CD97 in combination with Thrb(PV), an established mouse model of thyroid follicular cell carcinogenesis, significantly increased the occurrence of vascular invasion and lung metastasis. Expression of transgenic CD97 in thyroid epithelium led to elevated ERK phosphorylation and increased numbers of Ki67 + cells in developing tumors. In addition, tumor cell cultures derived from CD97 transgenic as compared with non-transgenic mice demonstrated enhanced, constitutive and LPA-stimulated ERK activation. In human thyroid cancer cell lines, CD97 depletion reduced RHO-GTP and decreased LPA-stimulated invasion but not EGF-stimulated invasion, further suggesting that CD97 influences an LPA-associated mechanism of progression. Consistent with the above, CD97 expression in human thyroid cancers correlated with LPA receptor and markers of aggressiveness including Ki67 and pAKT. This study shows an autonomous effect of CD97 on thyroid cancer progression and supports the investigation of this GPCR as a therapeutic target for these cancers.	[Ward, Y.; Lake, R.; Martin, P. L.; Kelly, K.] NCI, Cell & Canc Biol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Killian, K.; Meltzer, P.] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Salerno, P.] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Wang, T.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Merino, M.] NCI, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Cheng, S-Y] NCI, Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Santoro, M.] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy; [Garcia-Rostan, G.] Univ Valladolid, Spanish Res Council, Inst Biol & Mol Genet, Valladolid, Spain	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); The Wistar Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Naples Federico II; Universidad de Valladolid	Kelly, K (corresponding author), NCI, Cell & Canc Biol Branch, Ctr Canc Res, Bldg 37 Room 1068, Bethesda, MD 20892 USA.	kellyka@mail.nih.gov	Rostan, Ginesa Garcia/E-4093-2018	Rostan, Ginesa Garcia/0000-0002-9238-1263	Intramural Research Program; Center for Cancer Research; National Cancer Institute; Programa Ramon y Cajal-Ministerio de Ciencia e Innovacion; Social EU Funds; Universidad de Valladolid, Spain; NATIONAL CANCER INSTITUTE [ZIABC011191, ZIASC009389, ZIABC011091] Funding Source: NIH RePORTER	Intramural Research Program; Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Programa Ramon y Cajal-Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Social EU Funds; Universidad de Valladolid, Spain; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Intramural Research Program, Center for Cancer Research, National Cancer Institute and the Programa Ramon y Cajal-Ministerio de Ciencia e Innovacion, Social EU Funds, Universidad de Valladolid, Spain. We acknowledge Barbara J Taylor, Subhadra Banerjee, William G Telford, and Veena Kapoor of the CCR FACS Core Facilities and Christopher D Heger of the CCR Antibody and Protein Purification Unit for their excellent technical support. We thank Drs Cameselle-Teijeiro, X Matias-Guiu, A Herrero and M Fresno-Forcelledo for providing human PDC and UC samples.	Adeniran AJ, 2006, AM J SURG PATHOL, V30, P216, DOI 10.1097/01.pas.0000176432.73455.1b; Aust G, 2002, AM J CLIN PATHOL, V118, P699; Cheng SY, 2011, ONCOGENE; DeLellis R, 2004, PATHOLOGY GENETICS T; Gray JX, 1996, J IMMUNOL, V157, P5438; Guo R, 2006, ENDOCRINOLOGY, V147, P4883, DOI 10.1210/en.2005-1635; Gupte R, 2011, CHEMMEDCHEM, V6, P922, DOI 10.1002/cmdc.201000425; Horak CE, 2007, CANCER RES, V67, P11751, DOI 10.1158/0008-5472.CAN-07-3175; Jonkers J, 2009, CANCER CELL, V15, P457, DOI 10.1016/j.ccr.2009.05.003; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kehlen A, 2004, INT J CANCER, V109, P833, DOI 10.1002/ijc.20022; Kjellman P, 2003, THYROID, V13, P371, DOI 10.1089/105072503321669866; Kojic SL, 2011, EXPERT REV ANTICANC, V11, P387, DOI [10.1586/ERA.10.179, 10.1586/era.10.179]; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518; Lin ME, 2010, PROSTAG OTH LIPID M, V91, P130, DOI 10.1016/j.prostaglandins.2009.02.002; Lin SB, 2009, GASTROENTEROLOGY, V136, P1711, DOI 10.1053/j.gastro.2009.01.002; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Loberg RD, 2005, UROLOGY, V66, P1321, DOI 10.1016/j.urology.2005.06.094; MEIER CA, 1993, J CLIN INVEST, V92, P1986, DOI 10.1172/JCI116793; Mustafa T, 2005, CANCER EPIDEM BIOMAR, V14, P108; Nagaiah G, 2011, J ONCOL, V2011, DOI 10.1155/2011/542358; Nikiforov YE, 2011, MODERN PATHOL, V24, pS34, DOI 10.1038/modpathol.2010.167; Saji M, 2011, ONCOGENE, V30, P4307, DOI 10.1038/onc.2011.136; Sipos JA, 2011, CLIN ONCOL-UK, V22, P395; Sobrinho-Simoes M, 2011, DIAGN HISTOPATHOL, V17, P114, DOI DOI 10.1016/J.MPDHP.2010.12.001; Steinert M, 2002, AM J PATHOL, V161, P1657, DOI 10.1016/S0002-9440(10)64443-4; Stortelers C, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-387; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Ward Y, 2011, CANCER RES, V71, P7301, DOI 10.1158/0008-5472.CAN-11-2381; Wiseman SM, 2003, HEAD NECK-J SCI SPEC, V25, P662, DOI 10.1002/hed.10277; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Yona S, 2008, TRENDS BIOCHEM SCI, V33, P491, DOI 10.1016/j.tibs.2008.07.005	33	47	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2726	2738		10.1038/onc.2012.301	http://dx.doi.org/10.1038/onc.2012.301			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22797060	Bronze, Green Accepted			2022-12-28	WOS:000319808000004
J	Xie, C; Jiang, XH; Zhang, JT; Sun, TT; Dong, JD; Sanders, AJ; Diao, RY; Wang, Y; Fok, KL; Tsang, LL; Yu, MK; Zhang, XH; Chung, YW; Ye, L; Zhao, MY; Guo, JH; Xiao, ZJ; Lan, HY; Ng, CF; Lau, KM; Cai, ZM; Jiang, WG; Chan, HC				Xie, C.; Jiang, X. H.; Zhang, J. T.; Sun, T. T.; Dong, J. D.; Sanders, A. J.; Diao, R. Y.; Wang, Y.; Fok, K. L.; Tsang, L. L.; Yu, M. K.; Zhang, X. H.; Chung, Y. W.; Ye, L.; Zhao, M. Y.; Guo, J. H.; Xiao, Z. J.; Lan, H. Y.; Ng, C. F.; Lau, K. M.; Cai, Z. M.; Jiang, W. G.; Chan, H. C.			CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer	ONCOGENE			English	Article						CFTR; miR-193b; uPA	TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; NF-KAPPA-B; MESENCHYMAL TRANSITION; MUC4 EXPRESSION; CELL MIGRATION; MIR-200 FAMILY; BREAST-CANCER; RISK; METHYLATION	Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is expressed in the epithelial cells of a wide range of organs/tissues from which most cancers are derived. Although accumulating reports have indicated the association of cancer incidence with genetic variations in CFTR gene, the exact role of CFTR in cancer development and the possible underlying mechanism have not been elucidated. Here, we report that CFTR expression is significantly decreased in both prostate cancer cell lines and human prostate cancer tissue samples. Overexpression of CFTR in prostate cancer cell lines suppresses tumor progression (cell growth, adhesion and migration), whereas knockdown of CFTR leads to enhanced malignancies both in vitro and in vivo. In addition, we demonstrate that CFTR knockdown-enhanced cell proliferation, cell invasion and migration are significantly reversed by antibodies against either urokinase plasminogen activator (uPA) or uPA receptor (uPAR), which are known to be involved in various malignant traits of cancer development. More interestingly, overexpression of CFTR suppresses uPA by upregulating the recently described tumor suppressor microRNA-193b (miR-193b), and overexpression of pre-miR-193b significantly reverses CFTR knockdown-enhanced malignant phenotype and abrogates elevated uPA activity in prostate cancer cell line. Finally, we show that CFTR gene transfer results in significant tumor repression in prostate cancer xenografts in vivo. Taken together, the present study has demonstrated a previously undefined tumor-suppressing role of CFTR and its involvement in regulation of miR-193b in prostate cancer development.	[Xie, C.; Jiang, X. H.; Zhang, J. T.; Sun, T. T.; Dong, J. D.; Diao, R. Y.; Wang, Y.; Fok, K. L.; Tsang, L. L.; Yu, M. K.; Zhang, X. H.; Chung, Y. W.; Zhao, M. Y.; Guo, J. H.; Xiao, Z. J.; Chan, H. C.] Chinese Univ Hong Kong, Sch Biomed Sci, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China; [Jiang, X. H.; Chan, H. C.] Chinese Univ Hong Kong, Minist Educ Peoples Republ China, Key Lab Regenerat Med, Jinan Univ, Guangzhou, Guangdong, Peoples R China; [Sanders, A. J.; Ye, L.; Jiang, W. G.] Cardiff Univ, Sch Med, Metastasis & Angiogenesis Res Grp, Dept Surg, Cardiff CF10 3AX, S Glam, Wales; [Diao, R. Y.; Cai, Z. M.] Peking Univ, Shenzhen Hosp, Shenzhen Key Lab Male Reprod Med & Genet, Shenzhen, Peoples R China; [Lan, H. Y.] Chinese Univ Hong Kong, Fac Med, Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Ng, C. F.] Chinese Univ Hong Kong, Div Urol, Dept Surg, Shatin, Hong Kong, Peoples R China; [Lau, K. M.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; [Chan, H. C.] Sichuan Univ, Chinese Univ Hong Kong, West China Second Univ Hosp, Joint Lab Reprod Med, Chengdu 610064, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Jinan University; Ministry of Education, China; Cardiff University; Peking University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Sichuan University	Jiang, WG (corresponding author), Cardiff Univ, Sch Med, Metastasis & Angiogenesis Res Grp, Dept Surg, Cardiff CF10 3AX, S Glam, Wales.	jiangw@cf.ac.uk; hsiaocchan@cuhk.edu.hk	Fok, Kin Lam/G-2757-2017; Dong, Jianda/C-3338-2018; Chi-fai, NG/AAV-8270-2021; Jiang, Wen G/B-1293-2010; Lan, Hui Yao/C-9734-2015; jiang, wen/GYI-9662-2022; Jiang, Wen G./AAF-1876-2020; Ng, Chi-Fai/E-5134-2011; jiang, cynthia xiaohua/F-7580-2017; Sun, Tung-Tien/J-4425-2015; Chan, Hsiao Chang/E-1507-2016; Ye, Lin/G-9819-2016; Fok, Ellis/M-2784-2019	Fok, Kin Lam/0000-0003-3038-1337; Dong, Jianda/0000-0001-5583-0210; Jiang, Wen G/0000-0002-3283-1111; Lan, Hui Yao/0000-0003-4283-9755; Jiang, Wen G./0000-0002-3283-1111; Ng, Chi-Fai/0000-0002-1723-9646; jiang, cynthia xiaohua/0000-0002-7372-4961; Sun, Tung-Tien/0000-0002-6841-1063; Ye, Lin/0000-0002-0303-2409; Fok, Ellis/0000-0003-3038-1337; Zhang, Xiaohu/0000-0002-5329-1599; Sanders, Andrew/0000-0002-7997-5286; Lau, Kin-Mang/0000-0001-5888-1937	Focused Investment Scheme of the Chinese University of Hong Kong and National 973 project [2012CB944900]; Fundamental Research Funds for the Central Universities (JiNan University);  [GRF-CUHK466111]	Focused Investment Scheme of the Chinese University of Hong Kong and National 973 project; Fundamental Research Funds for the Central Universities (JiNan University); 	The work was supported by the Focused Investment Scheme of the Chinese University of Hong Kong and National 973 project (2012CB944900), GRF-CUHK466111, and the Fundamental Research Funds for the Central Universities (JiNan University). We are grateful to Professor Tzyh-Chang Hwang at Department of Biological Engineering, University of Missouri-Columbia, USA for providing CFTR-peGFP-C3 and control plasmids. The authors thank Mrs Huang Xiao ru and Mr Qin Wei from Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, for their helpful technical assistance.	Abraham EH, 1996, NAT MED, V2, P593, DOI 10.1038/nm0596-593; Boncoeur E, 2008, AM J PATHOL, V172, P1184, DOI 10.2353/ajpath.2008.070310; Chen JM, 2011, AM J PATHOL, V179, P2162, DOI 10.1016/j.ajpath.2011.07.010; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Cozzi PJ, 2006, HUM PATHOL, V37, P1442, DOI 10.1016/j.humpath.2006.05.002; Cuthbert AW, 2011, BRIT J PHARMACOL, V163, P173, DOI 10.1111/j.1476-5381.2010.01137.x; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Ding S, 2004, WORLD J GASTROENTERO, V10, P3433; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hou CC, 2005, AM J PATHOL, V166, P761, DOI 10.1016/S0002-9440(10)62297-3; Hsing AW, 2006, FRONT BIOSCI-LANDMRK, V11, P1388, DOI 10.2741/1891; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kumano M, 2009, UROL ONCOL-SEMIN ORI, V27, P180, DOI 10.1016/j.urolonc.2008.01.012; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245; Li Y, 2010, LUNG CANCER, V70, P14, DOI 10.1016/j.lungcan.2010.01.005; Malinowsky K, 2010, CURR MED CHEM, V17, P4370, DOI 10.2174/092986710793361216; McMahon B, 2007, PATHOPHYSIOL HAEMO T, V36, P184, DOI 10.1159/000175156; McWilliams RR, 2010, CANCER, V116, P203, DOI [10.1002/cncr.24697, 10.1002/cncr.25465]; McWilliams RR, 2005, CANCER, V104, P388, DOI 10.1002/cncr.21166; Mishra DK, 2010, MOL CANCER THER, V9, P33, DOI 10.1158/1535-7163.MCT-09-0486; Moribe T, 2009, INT J CANCER, V125, P388, DOI 10.1002/ijc.24394; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Padua RA, 1997, HUM MUTAT, V10, P45, DOI 10.1002/(SICI)1098-1004(1997)10:1<45::AID-HUMU6>3.0.CO;2-L; Qiao D, 2008, J CYST FIBROS, V7, P210, DOI 10.1016/j.jcf.2007.07.011; Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sen R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000257; Singh AP, 2007, ONCOGENE, V26, P30, DOI 10.1038/sj.onc.1209764; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Smith HW, 2010, NAT REV MOL CELL BIO, V11, P23, DOI 10.1038/nrm2821; Son JW, 2011, RESPIROLOGY, V16, P1203, DOI 10.1111/j.1440-1843.2011.01994.x; Southey MC, 1998, INT J CANCER, V79, P487, DOI 10.1002/(SICI)1097-0215(19981023)79:5<487::AID-IJC7>3.3.CO;2-X; Vij N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004664; WARREN N, 1991, BRIT MED J, V302, P760, DOI 10.1136/bmj.302.6779.760; Wiehe Melissa, 2010, AANA J, V78, P246; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	41	94	100	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2282	2291		10.1038/onc.2012.251	http://dx.doi.org/10.1038/onc.2012.251			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22797075				2022-12-28	WOS:000318683600005
J	Chimge, NO; Frenkel, B				Chimge, N-O; Frenkel, B.			The RUNX family in breast cancer: relationships with estrogen signaling	ONCOGENE			English	Review						RUNX1; RUNX2; RUNX3; tumor suppressor; oncogene; ER alpha	TRANSCRIPTION FACTOR RUNX2; ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE MORPHOGENETIC PROTEIN-7; TO-MESENCHYMAL TRANSITION; MAMMARY EPITHELIAL-CELLS; TUMOR-SUPPRESSOR RUNX3; PROSTATE-CANCER; AML1 GENE	The three RUNX family members are lineage specific master regulators, which also have important, context-dependent roles in carcinogenesis as either tumor suppressors or oncogenes. Here we review evidence for such roles in breast cancer (BCa). RUNX1, the predominant RUNX family member in breast epithelial cells, has a tumor suppressor role reflected by many somatic mutations found in primary tumor biopsies. The classical tumor suppressor gene RUNX3 does not consist of such a mutation hot spot, but it too seems to inhibit BCa; it is often inactivated in human BCa tumors and its haploinsufficiency in mice leads to spontaneous BCa development. The tumor suppressor activities of RUNX1 and RUNX3 are mediated in part by antagonism of estrogen signaling, a feature recently attributed to RUNX2 as well. Paradoxically, however RUNX2, a master osteoblast regulator, has been implicated in various aspects of metastasis in general and bone metastasis in particular. Reciprocating the anti-estrogenic tumor suppressor activity of RUNX proteins, inhibition of RUNX2 by estrogens may help explain their context-dependent anti-metastatic roles. Such roles are reserved to non-osseous metastasis, because ER alpha is associated with increased, not decreased skeletal dissemination of BCa cells. Finally, based on diverse expression patterns in BCa subtypes, the successful use of future RUNX-based therapies will most likely require careful patient selection. Oncogene (2013) 32, 2121-2130; doi:10.1038/onc.2012.328; published online 8 October 2012	[Chimge, N-O; Frenkel, B.] Univ So Calif, Dept Biochem & Mol Biol, Inst Med Genet, Keck Sch Med, Los Angeles, CA 90033 USA; [Frenkel, B.] Univ So Calif, Dept Orthopaed Surg, Inst Med Genet, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Chimge, NO (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Inst Med Genet, 2250 Alcazar St,CSC 240, Los Angeles, CA 90033 USA.	chimgee@usc.edu; frenkel@usc.edu			NIH grant from the National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK071122]	NIH grant from the National Institute of Diabetes and Digestive and Kidney Diseases	We thank Gerhard A Coetzee, Debu Tripathy, Gillian H Little (University of Southern California) and Andre van Wijnen (University of Massachusetts Medical School) for carefully reading the manuscript and providing critical comments. We are particularly thankful to Charles Perou (University of North Carolina), Dan Koboldt and Matthew Ellis (Washington University), who also shared, analyzed and edited data for this review. This work was supported by NIH grant R01 DK071122 from the National Institute of Diabetes and Digestive and Kidney Diseases to BF, who holds the J Harold and Edna L LaBriola Chair in Genetic Orthopaedic Research at USC.	Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94; Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389; Alarmo EL, 2009, CANCER LETT, V275, P35, DOI 10.1016/j.canlet.2008.09.028; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Bae SC, 1999, HISTOL HISTOPATHOL, V14, P1213, DOI 10.14670/HH-14.1213; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Baniwal SK, 2012, OSTEOPOROSIS INT, V23, P1399, DOI 10.1007/s00198-011-1728-5; Baniwal SK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-258; Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008-0470; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; BELLAHCENE A, 1994, CANCER RES, V54, P2823; Blyth K, 2006, CANCER RES, V66, P2195, DOI 10.1158/0008-5472.CAN-05-3558; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Blyth K, 2010, BLOOD CELL MOL DIS, V45, P117, DOI 10.1016/j.bcmd.2010.05.007; Blyth K, 2009, BLOOD CELL MOL DIS, V43, P12, DOI 10.1016/j.bcmd.2009.01.013; Boonstra JJ, 2012, GENE CHROMOSOME CANC, V51, P272, DOI 10.1002/gcc.20952; Brady G, 2009, J VIROL, V83, P6909, DOI 10.1128/JVI.00216-09; Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Carlinfante G, 2003, CLIN EXP METASTAS, V20, P437, DOI 10.1023/A:1025419708343; Chen G, 2006, CANCER-AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978; Chen LF, 2012, J CELL BIOCHEM, V113, P1470, DOI 10.1002/jcb.24074; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073; Chimge NO, 2012, CLIN CANCER RES, V18, P901, DOI 10.1158/1078-0432.CCR-11-1530; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Cross SS, 2006, J CLIN PATHOL, V59, P716, DOI 10.1136/jcp.2005.030031; Das K, 2009, EUR J CANCER, V45, P2239, DOI 10.1016/j.ejca.2009.06.021; De Braekeleer E, 2008, CANCER GENET CYTOGEN, V185, P47, DOI 10.1016/j.cancergencyto.2008.04.011; De Braekeleer E, 2009, ANTICANCER RES, V29, P1031; Dicker F, 2010, LEUKEMIA, V24, P1528, DOI 10.1038/leu.2010.124; Doll A, 2009, INT J CANCER, V125, P257, DOI 10.1002/ijc.24330; Douet-Guilbert N, 2003, CANCER GENET CYTOGEN, V144, P143, DOI 10.1016/S0165-4608(02)00932-9; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Ellis MJ, 2009, JAMA-J AM MED ASSOC, V302, P774, DOI 10.1001/jama.2009.1204; Endo T, 2008, J CLIN ENDOCR METAB, V93, P2409, DOI 10.1210/jc.2007-2805; Fijneman RJA, 2012, CANCER SCI, V103, P593, DOI 10.1111/j.1349-7006.2011.02189.x; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Frenkel B, 2010, J CELL PHYSIOL, V224, P305, DOI 10.1002/jcp.22159; Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121; Gaidzik VI, 2011, J CLIN ONCOL, V29, P1364, DOI 10.1200/JCO.2010.30.7926; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Gao F, 2009, J CANCER RES CLIN, V135, P739, DOI 10.1007/s00432-008-0508-x; Gelsi-Boyer V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-299; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Han YX, 2012, INT J ONCOL, V40, P673, DOI 10.3892/ijo.2011.1249; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Harada H, 2003, BLOOD, V101, P673, DOI 10.1182/blood-2002-04-1010; Harewood L, 2003, LEUKEMIA, V17, P547, DOI 10.1038/sj.leu.2402849; He L, 2012, PLOS ONE, V7, P3; He N, 2011, J CELL BIOCHEM, V112, P653, DOI 10.1002/jcb.22968; Hess KR, 2003, BREAST CANCER RES TR, V78, P105, DOI 10.1023/A:1022166517963; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hoi CSL, 2010, MOL CELL BIOL, V30, P2518, DOI 10.1128/MCB.01308-09; Hromas R, 2000, BLOOD, V95, P4011; Hsu YL, 2011, J BIOL CHEM, V286, P37335, DOI 10.1074/jbc.M111.256156; Huang B, 2012, ONCOGENE, V31, P527, DOI 10.1038/onc.2011.252; Huang SP, 2011, BJU INT, V107, P486, DOI 10.1111/j.1464-410X.2010.09512.x; Hwang KT, 2007, J KOREAN MED SCI, V22, pS24, DOI 10.3346/jkms.2007.22.S.S24; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Janes KA, 2011, CELL CYCLE, V10, P3461, DOI 10.4161/cc.10.20.18029; Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102; Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385; Kadota M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009201; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kayed H, 2007, BRIT J CANCER, V97, P1106, DOI 10.1038/sj.bjc.6603984; Khalid O, 2008, ENDOCRINOLOGY, V149, P5984, DOI 10.1210/en.2008-0680; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Koeneman KS, 1999, PROSTATE, V39, P246; Kohlmann A, 2010, J CLIN ONCOL, V28, P3858, DOI 10.1200/JCO.2009.27.1361; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441-009-0832-8; Kouros-Mehr H, 2006, DEV DYNAM, V235, P3404, DOI 10.1002/dvdy.20978; Kuo MC, 2009, LEUKEMIA, V23, P1426, DOI 10.1038/leu.2009.48; Kuo YH, 2009, BLOOD, V113, P3323, DOI 10.1182/blood-2008-06-162248; Lam K, 2012, FRONT BIOSCI-LANDMRK, V17, P1120, DOI 10.2741/3977; Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377; Leong DT, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2762; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li DL, 2007, J BIOL CHEM, V282, P13542, DOI 10.1074/jbc.M700074200; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lim M, 2010, LAB INVEST, V90, P222, DOI 10.1038/labinvest.2009.128; Little GH, 2012, NUCLEIC ACIDS RES, V40, P3538, DOI 10.1093/nar/gkr1219; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Mangan James K., 2011, Critical Reviews in Oncogenesis, V16, P77; Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745; Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187; Maynadier M, 2008, FASEB J, V22, P671, DOI 10.1096/fj.07-9322com; Mendoza-Villanueva D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3048; Mendoza-Villanueva D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-171; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Miething C, 2007, P NATL ACAD SCI USA, V104, P4594, DOI 10.1073/pnas.0604716104; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Morrissey C, 2010, NEOPLASIA, V12, P192, DOI 10.1593/neo.91836; Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805; Mundlos S, 1999, J MED GENET, V36, P177; Network TCGA, NATURE IN PRESS; Nevadunsky NS, 2009, GYNECOL ONCOL, V112, P325, DOI 10.1016/j.ygyno.2008.09.006; Niini T, 2000, HAEMATOLOGICA, V85, P362; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Onodera Y, 2010, CANCER SCI, V101, P2670, DOI 10.1111/j.1349-7006.2010.01742.x; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Patani N, 2008, ANTICANCER RES, V28, P4105; Pencovich N, 2011, BLOOD, V117, pE1, DOI 10.1182/blood-2010-07-295113; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Planaguma J, 2004, CANCER RES, V64, P8846, DOI 10.1158/0008-5472.CAN-04-2066; Planaguma J, 2011, HUM PATHOL, V42, P57, DOI 10.1016/j.humpath.2010.01.025; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Pratap J, 2003, CANCER RES, V63, P5357; Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008-5472.CAN-08-1078; Pratap J, 2011, BONE, V48, P30, DOI 10.1016/j.bone.2010.05.035; Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008-5472.CAN-09-1471; Radtke I, 2009, P NATL ACAD SCI USA, V106, P12944, DOI 10.1073/pnas.0903142106; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richiardi L, 2009, J CLIN ONCOL, V27, P3161, DOI 10.1200/JCO.2008.18.2485; Robinson HM, 2003, LEUKEMIA, V17, P2249, DOI 10.1038/sj.leu.2403140; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; Sakakura C, 2005, INT J CANCER, V113, P221, DOI 10.1002/ijc.20551; Salto-Tellez M, 2006, ONCOGENE, V25, P7646, DOI 10.1038/sj.onc.1209739; Sase T, 2012, INT J CANCER, V131, P2284, DOI 10.1002/ijc.27525; Sato K, 2006, ONCOL REP, V15, P129; Shiraha H, 2011, J CELL BIOCHEM, V112, P745, DOI 10.1002/jcb.22973; Shore P, 2005, J CELL BIOCHEM, V96, P484, DOI 10.1002/jcb.20557; Silva FPG, 2003, ONCOGENE, V22, P538, DOI 10.1038/sj.onc.1206141; Slattery ML, 2011, CARCINOGENESIS, V32, P318, DOI 10.1093/carcin/bgq245; Smith N, 2005, J CELL PHYSIOL, V203, P133, DOI 10.1002/jcp.20210; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Soong R, 2009, BRIT J CANCER, V100, P676, DOI 10.1038/sj.bjc.6604899; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Spender LC, 2005, ONCOGENE, V24, P1873, DOI 10.1038/sj.onc.1208404; Steensma DP, 2005, EUR J HAEMATOL, V74, P47, DOI 10.1111/j.1600-0609.2004.00363.x; Stender JD, 2010, MOL CELL BIOL, V30, P3943, DOI 10.1128/MCB.00118-10; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Subramaniam MM, 2009, AM J GASTROENTEROL, V104, P426, DOI 10.1038/ajg.2008.141; Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4; Suzuki M, 2005, BRIT J CANCER, V93, P1029, DOI 10.1038/sj.bjc.6602837; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tan SH, 2007, ONCOL REP, V18, P1225; Tang JL, 2009, BLOOD, V114, P5352, DOI 10.1182/blood-2009-05-223784; Thalmann GN, 1999, CLIN CANCER RES, V5, P2271; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Tsoli E, 2007, J CLIN PATHOL, V60, P261, DOI 10.1136/jcp.2006.037887; Tsunematsu T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005892; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; van der Deen M, 2012, J BIOL CHEM, V287, P4503, DOI 10.1074/jbc.M111.287771; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang LX, 2011, P NATL ACAD SCI USA, V108, pE803, DOI 10.1073/pnas.1103423108; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Wolff EM, 2008, CANCER RES, V68, P6208, DOI 10.1158/0008-5472.CAN-07-6616; Wotton S, 2008, ONCOGENE, V27, P5856, DOI 10.1038/onc.2008.195; Wu C, 2011, NAT GENET, V43, P679, DOI 10.1038/ng.849; Yan C, 2012, J SURG ONCOL, V105, P425, DOI 10.1002/jso.22087; Yang SX, 2006, CANCER RES, V66, P4285, DOI 10.1158/0008-5472.CAN-05-4456; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yeon S, 2012, MODERN PATHOL, V25, P185, DOI 10.1038/modpathol.2011.160; Young DW, 2007, NATURE, V445, P442, DOI 10.1038/nature05473; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	192	94	98	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2121	2130		10.1038/onc.2012.328	http://dx.doi.org/10.1038/onc.2012.328			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	23045283	Green Accepted			2022-12-28	WOS:000318062800001
J	Skrypek, N; Duchene, B; Hebbar, M; Leteurtre, E; van Seuningen, I; Jonckheere, N				Skrypek, N.; Duchene, B.; Hebbar, M.; Leteurtre, E.; van Seuningen, I.; Jonckheere, N.			The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family	ONCOGENE			English	Article						MUC4; mucin; pancreatic cancer; gemcitabine; hCNT1; NF-kappa B	KAPPA-B; ADJUVANT GEMCITABINE; TRANSCRIPTION FACTOR; ANTITUMOR-ACTIVITY; ORTHOTOPIC MODEL; BILE-ACIDS; GENE; EXPRESSION; SURVIVAL; PROTEIN	The fluorinated analog of deoxycytidine, Gemcitabine (Gemzar), is the main chemotherapeutic drug in pancreatic cancer, but survival remains weak mainly because of the high resistance of tumors to the drug. Recent works have shown that the mucin MUC4 may confer an advantage to pancreatic tumor cells by modifying their susceptibility to drugs. However, the cellular mechanism(s) responsible for this MUC4-mediated resistance is unknown. The aim of this work was to identify the cellular mechanisms responsible for gemcitabine resistance linked to MUC4 expression. CAPAN-2 and CAPAN-1 adenocarcinomatous pancreatic cancer (PC) cell lines were used to establish stable MUC4-deficient clones (MUC4-KD) by shRNA interference. Measurement of the IC50 index using tetrazolium salt test indicated that MUC4-deficient cells were more sensitive to gemcitabine. This was correlated with increased Bax/Bcl(XL) ratio and apoptotic cell number. Expression of Equilibrative/Concentrative Nucleoside Transporter (hENT1, hCNT1/3), deoxycytidine kinase (dCK), ribonucleotide reductase (RRM1/2) and Multidrug-Resistance Protein (MRP3/4/5) was evaluated by quantitative RT-PCR (qRT-PCR) and western blotting. Alteration of MRP3, MRP4, hCNT1 and hCNT3 expression was observed in MUC4-KD cells, but only hCNT1 alteration was correlated to MUC4 expression and sensitivity to gemcitabine. Decreased activation of MAPK, JNK and NF-kappa B pathways was observed in MUC4-deficient cells, in which the NF-kappa B pathway was found to have an important role in both sensitivity to gemcitabine and hCNT1 regulation. Finally, and in accordance with our in vitro data, we found that MUC4 expression was conversely correlated to that of hCNT1 in tissues from patients with pancreatic adenocarcinoma. This work describes a new mechanism of PC cell resistance to gemcitabine, in which the MUC4 mucin negatively regulates the hCNT1 transporter expression via the NF-kappa B pathway. Altogether, these data point out to MUC4 and hCNT1 as potential targets to ameliorate the response of pancreatic tumors to gemcitabine treatment. Oncogene (2013) 32, 1714-1723; doi:10.1038/onc.2012.179; published online 14 May 2012	[Skrypek, N.; Duchene, B.; Hebbar, M.; Leteurtre, E.; van Seuningen, I.; Jonckheere, N.] INSERM, JPARC, UMR837, F-59045 Lille, France; [Skrypek, N.; Duchene, B.; Hebbar, M.; Leteurtre, E.; van Seuningen, I.; Jonckheere, N.] Univ Lille Nord France, Lille, France; [Skrypek, N.; Duchene, B.; van Seuningen, I.; Jonckheere, N.] Ctr Hosp Reg & Univ Lille, Lille, France; [Hebbar, M.] Ctr Hosp Reg & Univ Lille, Dept Med Oncol, Lille, France; [Leteurtre, E.] Ctr Hosp Reg & Univ Lille, Ctr Biol Pathol, Dept Pathol, Lille, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille	Jonckheere, N (corresponding author), INSERM, JPARC, UMR837, Rue Polonovski, F-59045 Lille, France.	nicolas.jonckheere@inserm.fr	Jonckheere, Nicolas/J-6028-2013; VAN SEUNINGEN, Isabelle/N-6176-2016	Jonckheere, Nicolas/0000-0002-0496-0661; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Duchene, Belinda/0000-0002-4810-4680	PhD fellowship of Centre Hospitalier Regional et Universitaire (CHRU) de Lille; Region Nord-Pas de Calais; Institut National du Cancer (INCa); Ligue Nationale contre le Cancer (LNCC); la Ligue Nationale contre le Cancer (Equipe Labellisee Ligue, IVS); 'Contrat Hospitalier de Recherche Translationnelle'/CHRT, AVIESAN	PhD fellowship of Centre Hospitalier Regional et Universitaire (CHRU) de Lille; Region Nord-Pas de Calais(Region Hauts-de-FranceEuropean Commission); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer (LNCC)(Ligue nationale contre le cancer); la Ligue Nationale contre le Cancer (Equipe Labellisee Ligue, IVS); 'Contrat Hospitalier de Recherche Translationnelle'/CHRT, AVIESAN	We thank MH Gevaert and R Siminsky (Department of Histology, Faculty of Medicine, University of Lille 2) and the technical platform IFR114/IMPRT for flow cytometry (Dr N Jouy) and luciferase (AS Drucbert) analyses. Gemcitabine and oxaliplatin are a kind gift from Dr A Lansiaux (Centre Oscar Lambret, Universite Lille Nord de France, Inserm UMR837, team 4, Lille, France). Cytarabine/aracytin ARA-C is a kind gift from Pr B Quesnel (Oncohaematology department, Centre Hospitalier Regional et Universitaire de Lille, Inserm UMR837, team 3, Lille, France). We thank Dr JL Desseyn (Inserm U995) for his help in designing MUC4 shRNA. Nicolas Skrypek is a recipient of a PhD fellowship of Centre Hospitalier Regional et Universitaire (CHRU) de Lille and Region Nord-Pas de Calais. Dr Nicolas Jonckheere is a recipient of postdoctoral fellowship from the Institut National du Cancer (INCa) and Ligue Nationale contre le Cancer (LNCC). This work is supported by a grant from la Ligue Nationale contre le Cancer (Equipe Labellisee Ligue 2010, IVS). Isabelle Van Seuningen is the recipient of a 'Contrat Hospitalier de Recherche Translationnelle'/CHRT 2010, AVIESAN. The funders had no role in study design, data collection and analysis, decision to publish or in preparation of the paper.	Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Banerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158/0008-5472.CAN-05-1330; Bhutia YD, 2011, CANCER RES, V71, P1825, DOI 10.1158/0008-5472.CAN-10-2736; Blackstock AW, 2001, CLIN CANCER RES, V7, P3263; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952; Farrell JJ, 2009, GASTROENTEROLOGY, V136, P187, DOI 10.1053/j.gastro.2008.09.067; Garcia-Manteiga J, 2003, CLIN CANCER RES, V9, P5000; Giovannetti E, 2006, CANCER RES, V66, P3928, DOI 10.1158/0008-5472.CAN-05-4203; Hagmann W, 2010, NEOPLASIA, V12, P740, DOI 10.1593/neo.10576; Hu YP, 2003, BIOCHEM PHARMACOL, V65, P1419, DOI 10.1016/S0006-2952(03)00086-8; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jonckheere N, 2004, ONCOGENE, V23, P5729, DOI 10.1038/sj.onc.1207769; Jonckheere N, 2009, BRIT J CANCER, V101, P637, DOI 10.1038/sj.bjc.6605190; Jonckheere N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032232; Jonckheere Nicolas, 2010, Cancers (Basel), V2, P1794, DOI 10.3390/cancers2041794; Jordheim LP, 2011, LANCET ONCOL, V12, P693, DOI 10.1016/S1470-2045(10)70244-8; Kalra AV, 2007, BRIT J CANCER, V97, P910, DOI 10.1038/sj.bjc.6603972; Kalra AV, 2009, EUR J CANCER, V45, P164, DOI 10.1016/j.ejca.2008.10.008; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Kong R, 2010, CANCER LETT, V291, P90, DOI 10.1016/j.canlet.2009.10.001; Konig J, 2005, INT J CANCER, V115, P359, DOI 10.1002/ijc.20831; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; Kunnumakkara AB, 2007, CANCER RES, V67, P3853, DOI 10.1158/0008-5472.CAN-06-4257; Lee K, 2000, JNCI-J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934; Mackey TJ, 1998, UROLOGY, V52, P1085, DOI 10.1016/S0090-4295(98)00360-4; Marechal R, 2010, CANCER-AM CANCER SOC, V116, P5200, DOI 10.1002/cncr.25303; Marechal R, 2009, CLIN CANCER RES, V15, P2913, DOI 10.1158/1078-0432.CCR-08-2080; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; O'Reilly Eileen M, 2009, Gastrointest Cancer Res, V3, pS11; Oguri T, 2001, INT J CANCER, V93, P584, DOI 10.1002/ijc.1369; Ohishi Y, 2002, CLIN CANCER RES, V8, P3767; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Theile D, 2009, BIOCHEM PHARMACOL, V78, P1366, DOI 10.1016/j.bcp.2009.07.006; Tian Q, 2005, PHARM RES-DORDR, V22, P1837, DOI 10.1007/s11095-005-7595-z; van der Sluis M, 2004, BIOCHEM BIOPH RES CO, V325, P952, DOI 10.1016/j.bbrc.2004.10.108; Van Seuningen I, 2000, BIOCHEM J, V348, P675; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wang SJ, 2010, CANCER LETT, V293, P99, DOI 10.1016/j.canlet.2010.01.001; Wang WX, 1999, CLIN CANCER RES, V5, P119; Workman HC, 2009, CANCER RES, V69, P2845, DOI 10.1158/0008-5472.CAN-08-2089	49	111	112	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1714	1723		10.1038/onc.2012.179	http://dx.doi.org/10.1038/onc.2012.179			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22580602	Green Submitted, Green Accepted			2022-12-28	WOS:000316855800011
J	Pullamsetti, SS; Banat, GA; Schmall, A; Szibor, M; Pomagruk, D; Hanze, J; Kolosionek, E; Wilhelm, J; Braun, T; Grimminger, F; Seeger, W; Schermuly, RT; Savai, R				Pullamsetti, S. S.; Banat, G. A.; Schmall, A.; Szibor, M.; Pomagruk, D.; Haenze, J.; Kolosionek, E.; Wilhelm, J.; Braun, T.; Grimminger, F.; Seeger, W.; Schermuly, R. T.; Savai, R.			Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF	ONCOGENE			English	Article						lung cancer; hypoxia; phosphodiesterases; proliferation; angiogenesis	TUMOR-GROWTH; CELLS; HYPOXIA; INHIBITION; EXPRESSION; APOPTOSIS; COMPONENTS; MIGRATION; LEUKEMIA; TARGETS	Lung cancer is the leading cause of cancer death worldwide. Recent data suggest that cyclic nucleotide phosphodiesterases (PDEs) are relevant in various cancer pathologies. Pathophysiological role of phosphodiesterase 4 (PDE4) with possible therapeutic prospects in lung cancer was investigated. We exposed 10 different lung cancer cell lines (adenocarcinoma, squamous and large cell carcinoma) to hypoxia and assessed expression and activity of PDE4 by real-time PCR, immunocytochemistry, western blotting and PDE activity assays. Expression and activity of distinct PDE4 isoforms (PDE4A and PDE4D) increased in response to hypoxia in eight of the studied cell lines. Furthermore, we analyzed various in silico predicted hypoxia-responsive elements (p-HREs) found in PDE4A and PDE4D genes. Performing mutation analysis of the p-HRE in luciferase reporter constructs, we identified four functional HRE sites in the PDE4A gene and two functional HRE sites in the PDE4D gene that mediated hypoxic induction of the reporter. Silencing of hypoxia-inducible factor subunits (HIF1 alpha and HIF2 alpha by small interfering RNA reduced hypoxic induction of PDE4A and PDE4D. Vice versa, using a PDE4 inhibitor (PDE4i) as a cyclic adenosine monophosphate (cAMP) -elevating agent, cAMP analogs or protein kinase A (PKA)-modulating drugs and an exchange protein directly activated by cAMP (EPAC) activator, we demonstrated that PDE4-cAMP-PKA/EPAC axis enhanced HIF signaling as measured by HRE reporter gene assay, HIF and HIF target genes expression ((lactate dehydrogenase A), LDHA, (pyruvate dehydrogenase kinase 1) PDK1 and (vascular endothelial growth factor A) VEGFA). Notably, inhibition of PDE4 by PDE4i or silencing of PDE4A and PDE4D reduced human lung tumor cell proliferation and colony formation. On the other hand, overexpression of PDE4A or PDE4D increased human lung cancer proliferation. Moreover, PDE4i treatment reduced hypoxia-induced VEGF secretion in human cells. In vivo, PDE4i inhibited tumor xenograft growth in nude mice by attenuating proliferation and angiogenesis. Our findings suggest that PDE4 is expressed in lung cancer, crosstalks with HIF signaling and promotes lung cancer progression. Thus, PDE4 may represent a therapeutic target for lung cancer therapy. Oncogene (2013) 32, 1121-1134; doi:10.1038/onc.2012.136; published online 23 April 2012	[Pullamsetti, S. S.; Schmall, A.; Seeger, W.; Schermuly, R. T.; Savai, R.] Max Planck Inst Heart & Lung Res, Dept Lung Dev & Remodelling, D-61231 Bad Nauheim, Germany; [Pullamsetti, S. S.; Banat, G. A.; Pomagruk, D.; Kolosionek, E.; Wilhelm, J.; Grimminger, F.; Seeger, W.; Schermuly, R. T.] Univ Giessen, Univ Giessen Lung Ctr, D-35390 Giessen, Germany; [Szibor, M.; Braun, T.] Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodelling, D-61231 Bad Nauheim, Germany; [Haenze, J.] Philipps Univ, Dept Urol & Pediat Urol, Marburg, Germany	Max Planck Society; Justus Liebig University Giessen; Max Planck Society; Philipps University Marburg	Savai, R (corresponding author), Max Planck Inst Heart & Lung Res, Pk Str 1, D-61231 Bad Nauheim, Germany.	rajkumar.savai@mpi-bn.mpg.de	Braun, Thomas/B-2310-2008; Wilhelm, Jochen/AAX-4302-2021	Wilhelm, Jochen/0000-0001-5544-9647; Pullamsetti, Soni Savai/0000-0003-0440-8831; Grimminger, Friedrich/0000-0001-8725-6276; Seeger, Werner/0000-0003-1946-0894; Hanze, Jorg/0000-0001-5424-7808; Braun, Thomas/0000-0002-6165-4804; Savai, Rajkumar/0000-0003-1538-2091; Schermuly, Ralph/0000-0002-5167-6970	STARTUP AWARD from Justus-Liebig University Giessen, Germany; LOEWE-Center UGMLC (University of Giessen); LOEWE-Center UGMLC (University of Marburg Lung Center)	STARTUP AWARD from Justus-Liebig University Giessen, Germany; LOEWE-Center UGMLC (University of Giessen); LOEWE-Center UGMLC (University of Marburg Lung Center)	The authors thank Marianne Hoeck and Katharina Weidl for her excellent technical assistance. Dr Rajkumar Saves research was supported by the STARTUP AWARD from Justus-Liebig University Giessen, Germany and LOEWE-Center UGMLC (Universities of Giessen and Marburg Lung Center).	Chen TC, 2002, CANCER BIOL THER, V1, P268, DOI 10.4161/cbt.80; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; Cox G, 2000, LUNG CANCER, V29, P169, DOI 10.1016/S0169-5002(00)00124-0; Dastidar SG, 2007, CURR OPIN INVEST DR, V8, P364; Deguchi A, 2004, CANCER RES, V64, P3966, DOI 10.1158/0008-5472.CAN-03-3740; Goldhoff P, 2008, CLIN CANCER RES, V14, P7717, DOI 10.1158/1078-0432.CCR-08-0827; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hung JJ, 2009, THORAX, V64, P1082, DOI 10.1136/thx.2009.115691; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kolosionek E, 2009, MOL BIOL CELL, V20, P4751, DOI 10.1091/mbc.E09-01-0019; Lerner A, 2006, BIOCHEM J, V393, P21, DOI 10.1042/BJ20051368; Lipworth BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3; Malec V, 2010, FREE RADICAL BIO MED, V48, P1626, DOI 10.1016/j.freeradbiomed.2010.03.008; Marko D, 2000, CHEM RES TOXICOL, V13, P944, DOI 10.1021/tx000090l; Marko Doris, 1998, Cell Biochemistry and Biophysics, V28, P75, DOI 10.1007/BF02737806; McEwan DG, 2007, CANCER RES, V67, P5248, DOI 10.1158/0008-5472.CAN-07-0097; Millen J, 2006, EUR J CELL BIOL, V85, P679, DOI 10.1016/j.ejcb.2006.01.006; Mouratidis PXE, 2009, PANCREAS, V38, P78, DOI 10.1097/MPA.0b013e318183d72f; Murata K, 2001, CLIN EXP METASTAS, V18, P599, DOI 10.1023/A:1011926116777; Narita M, 2007, ONCOL REP, V17, P1133; Nunes AR, 2009, ADV EXP MED BIOL, V648, P113, DOI 10.1007/978-90-481-2259-2_13; Ogawa R, 2002, BLOOD, V99, P3390, DOI 10.1182/blood.V99.9.3390; Omori K, 2007, CIRC RES, V100, P309, DOI 10.1161/01.RES.0000256354.95791.f1; Pallis AG, 2009, EUR J CANCER, V45, P2473, DOI 10.1016/j.ejca.2009.06.005; Rossi Antonio, 2009, Curr Drug Discov Technol, V6, P91; Savai R, 2005, INT J ONCOL, V27, P393; Semenza GL, 2006, EXP PHYSIOL, V91, P803, DOI 10.1113/expphysiol.2006.033498; Sowter HM, 2003, CANCER RES, V63, P6130; Swinson DEB, 2006, CLIN LUNG CANCER, V7, P250, DOI 10.3816/CLC.2006.n.002; Timoshenko AV, 2003, EXP CELL RES, V289, P265, DOI 10.1016/S0014-4827(03)00269-6; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Yamanaka Y, 2002, CANCER LETT, V176, P143, DOI 10.1016/S0304-3835(01)00764-9; Zhang LZ, 2008, P NATL ACAD SCI USA, V105, P19532, DOI 10.1073/pnas.0806152105	34	98	102	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1121	1134		10.1038/onc.2012.136	http://dx.doi.org/10.1038/onc.2012.136			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22525277				2022-12-28	WOS:000316428800006
J	Luo, B; Lee, AS				Luo, B.; Lee, A. S.			The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies	ONCOGENE			English	Review						chaperone proteins; unfolded protein response; tumorigenesis	BREAST-CANCER CELLS; HEMATOPOIETIC STEM-CELLS; STRESS-INDUCED AUTOPHAGY; DISULFIDE-ISOMERASE; ER-STRESS; CALRETICULIN EXPOSURE; TRANSLATIONAL REGULATION; REGULATOR GRP78/BIP; PROSTATE-CANCER; TUMOR-GROWTH	Cancer progression is characterized by rapidly proliferating cancer cells that are in need of increased protein synthesis. Therefore, enhanced endoplasmic reticulum (ER) activity is required to facilitate the folding, assembly and transportation of membrane and secretory proteins. These functions are carried out by ER chaperones. It is now becoming clear that the ER chaperones have critical functions outside of simply facilitating protein folding. For example, cancer progression requires glucose regulated protein (GRP) 78 for cancer cell survival and proliferation, as well as angiogenesis in the microenvironment GRP78 can translocate to the cell surface acting as a receptor regulating oncogenic signaling and cell viability. Calreticulin, another ER chaperone, can translocate to the cell surface of apoptotic cancer cells and induce immunogenic cancer cell death and antitumor responses in vivo. Tumor-secreted GRP94 has been shown to elicit antitumor immune responses when used as antitumor vaccines. Protein disulfide isomerase is another ER chaperone that demonstrates pro-oncogenic and pro-survival functions. Because of intrinsic alterations of cellular metabolism and extrinsic factors in the tumor microenvironment, cancer cells are under ER stress, and they respond to this stress by activating the unfolded protein response (UPR). Depending on the severity and duration of ER stress, the signaling branches of the UPR can activate adaptive and pro-survival signals, or induce apoptotic cell death. The protein kinase RNA-like ER kinase signaling branch of the UPR has a dual role in cancer proliferation and survival, and is also required for ER stress-induced autophagy. The activation of the inositol-requiring kinase 1 alpha branch promotes tunnorigenesis, cancer cell survival and regulates tumor invasion. In summary, perturbance of ER homeostasis has critical roles in tumorigenesis, and therapeutic modulation of ER chaperones and/or UPR components presents potential antitumor treatments. Oncogene (2013) 32, 805-818; doi:10.1038/onc.2012.130; published online 16 April 2012	[Luo, B.; Lee, A. S.] Univ So Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90089 USA	University of Southern California	Lee, AS (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Keck Sch Med, 1441 Eastlake Ave,Room 5308, Los Angeles, CA 90089 USA.	amylee@ccnt.usc.edu		Lee, Amy/0000-0002-0378-5443	University of Southern California Norris Comprehensive Cancer Center Wang Scholarship in Cancer Research; National Institutes of Health [CA027607, 1 P01 AG034906]; NATIONAL CANCER INSTITUTE [R37CA027607, R01CA027607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG034906] Funding Source: NIH RePORTER	University of Southern California Norris Comprehensive Cancer Center Wang Scholarship in Cancer Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	BL is a recipient of the University of Southern California Norris Comprehensive Cancer Center Wang Scholarship in Cancer Research. We thank Costas Koumenis, Albert Koong, Kyle Pfaffenbach and Kate Ott for helpful discussions. This work was supported in part by National Institutes of Health Grants CA027607 and 1 P01 AG034906 to ASL.	Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Auf G, 2010, P NATL ACAD SCI USA, V107, P15553, DOI 10.1073/pnas.0914072107; Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11; Backer JM, 2009, NEOPLASIA, V11, P1165, DOI 10.1593/neo.09878; Baker-LePain JC, 2002, J EXP MED, V196, P1447, DOI 10.1084/jem.20020436; Bartkowiak K, 2010, J PROTEOME RES, V9, P3158, DOI 10.1021/pr100039d; Baumeister P, 2009, MOL CANCER THER, V8, P1086, DOI 10.1158/1535-7163.MCT-08-1166; Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Caramelo JJ, 2008, J BIOL CHEM, V283, P10221, DOI 10.1074/jbc.R700048200; Carrasco DR, 2007, CANCER CELL, V11, P349, DOI 10.1016/j.ccr.2007.02.015; Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014; Davies MPA, 2008, INT J CANCER, V123, P85, DOI 10.1002/ijc.23479; De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014; di Pietro A, 2011, EXPERT OPIN BIOL TH, V11, P1395, DOI 10.1517/14712598.2011.605353; Diehl JA, 2011, GASTROENTEROLOGY, V141, P38, DOI 10.1053/j.gastro.2011.05.018; Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Dong DZ, 2011, CANCER RES, V71, P2848, DOI 10.1158/0008-5472.CAN-10-3151; Dong DZ, 2005, CANCER RES, V65, P5785, DOI 10.1158/0008-5472.CAN-05-0754; Dong DZ, 2004, HUM GENE THER, V15, P553, DOI 10.1089/104303404323142006; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Drogat B, 2007, CANCER RES, V67, P6700, DOI 10.1158/0008-5472.CAN-06-3235; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Ermakova SP, 2006, CANCER RES, V66, P9260, DOI 10.1158/0008-5472.CAN-06-1586; Eton O, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-9; Fels DR, 2008, CANCER RES, V68, P9323, DOI 10.1158/0008-5472.CAN-08-2873; Fonseca C, 2009, BLOOD, V113, P1681, DOI 10.1182/blood-2007-09-114157; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Fujimoto T, 2007, ANTICANCER RES, V27, P127; Gelebart P, 2005, INT J BIOCHEM CELL B, V37, P260, DOI 10.1016/j.biocel.2004.02.030; Ghosh R, 2010, PLOS ONE, V5, pA104, DOI 10.1371/journal.pone.0009575; Glimcher LH, 2010, ANN RHEUM DIS, V69, P67, DOI 10.1136/ard.2009.119388; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Gold LI, 2010, FASEB J, V24, P665, DOI 10.1096/fj.09-145482; Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com; Gong JL, 2010, J IMMUNOL, V184, P488, DOI 10.4049/jimmunol.0902255; Gonzalez-Gronow M, 2009, ANTIOXID REDOX SIGN, V11, P2299, DOI [10.1089/ars.2009.2568, 10.1089/ARS.2009.2568]; Goplen D, 2006, CANCER RES, V66, P9895, DOI 10.1158/0008-5472.CAN-05-4589; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Gruber CW, 2006, TRENDS BIOCHEM SCI, V31, P455, DOI 10.1016/j.tibs.2006.06.001; Guo QY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-24; Gupta S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008008; Haefliger S, 2011, BLOOD, V117, P5931, DOI 10.1182/blood-2010-08-304485; Hamanaka RB, 2005, MOL BIOL CELL, V16, P5493, DOI 10.1091/mbc.E05-03-0268; Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631; Hollien J, 2009, J CELL BIOL, V186, P323, DOI 10.1083/jcb.200903014; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Hsiao JR, 2009, CANCER RES, V69, P4461, DOI 10.1158/0008-5472.CAN-09-0277; Jakobsen CG, 2007, CANCER RES, V67, P9507, DOI 10.1158/0008-5472.CAN-06-4686; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Katanasaka Y, 2010, INT J CANCER, V127, P2685, DOI 10.1002/ijc.25276; Kern J, 2009, BLOOD, V114, P3960, DOI 10.1182/blood-2009-03-209668; Khan MM, 2004, J BIOL CHEM, V279, P11814, DOI 10.1074/jbc.M312121200; Kim JY, 2010, J CELL PHYSIOL, V224, P33, DOI 10.1002/jcp.22085; Kim KW, 2010, ONCOGENE, V29, P3241, DOI 10.1038/onc.2010.74; Kim Y, 2006, BIOCHEMISTRY-US, V45, P9434, DOI 10.1021/bi060264j; Ko HS, 2002, J BIOL CHEM, V277, P35386, DOI 10.1074/jbc.M203412200; Konopleva M, 2002, BRIT J HAEMATOL, V118, P521, DOI 10.1046/j.1365-2141.2002.03637.x; Koong AC, 2006, CANCER BIOL THER, V5, P756, DOI 10.4161/cbt.5.7.2973; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Kruse KB, 2006, MOL BIOL CELL, V17, P203, DOI 10.1091/mbc.e04-09-0779; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Li MJ, 2009, J CELL MOL MED, V13, P4540, DOI 10.1111/j.1582-4934.2008.00575.x; Liu SL, 2005, CANCER RES, V65, P9126, DOI 10.1158/0008-5472.CAN-05-0945; Liu Y, 2010, NEOPLASIA, V12, P61, DOI 10.1593/neo.91354; Liu Y, 2007, MOL PHARMACEUT, V4, P435, DOI 10.1021/mp060122j; Lovat PE, 2008, CANCER RES, V68, P5363, DOI 10.1158/0008-5472.CAN-08-0035; Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Maestre L, 2009, HAEMATOL-HEMATOL J, V94, P419, DOI 10.3324/haematol.2008.001156; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Mahoney DJ, 2011, CANCER CELL, V20, P443, DOI 10.1016/j.ccr.2011.09.005; Martin S, 2010, PIGM CELL MELANOMA R, V23, P675, DOI 10.1111/j.1755-148X.2010.00731.x; Martins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500; Martins I, 2010, ANN NY ACAD SCI, V1209, P77, DOI 10.1111/j.1749-6632.2010.05740.x; Michalak M, 2009, BIOCHEM J, V417, P651, DOI 10.1042/BJ20081847; Miharada K, 2011, CELL STEM CELL, V9, P330, DOI 10.1016/j.stem.2011.07.016; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Misra UK, 2011, J BIOL CHEM, V286, P1248, DOI 10.1074/jbc.M110.129767; Misra UK, 2010, CANCER BIOL THER, V9, P142, DOI 10.4161/cbt.9.2.10422; Momoi T, 2006, CURR MOL MED, V6, P111, DOI 10.2174/156652406775574596; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Ni M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006868; Nikrad M, 2005, MOL CANCER THER, V4, P443; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2008, J IMMUNOL, V181, P2533, DOI 10.4049/jimmunol.181.4.2533; Obeid M, 2007, IMMUNOL REV, V220, P22, DOI 10.1111/j.1600-065X.2007.00567.x; Obeid M, 2007, CANCER RES, V67, P7941, DOI 10.1158/0008-5472.CAN-07-1622; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Oki Y, 2007, CANCER-AM CANCER SOC, V109, P77, DOI 10.1002/cncr.22389; Oppermann M, 2005, ONCOGENE, V24, P7369, DOI 10.1038/sj.onc.1208890; Ota J, 2003, ONCOGENE, V22, P5720, DOI 10.1038/sj.onc.1206855; Ouyang YB, 2011, MITOCHONDRION, V11, P279, DOI 10.1016/j.mito.2011.09.001; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pakravan N, 2011, CELL STRESS CHAPERON, V16, P449, DOI 10.1007/s12192-011-0258-6; Pakravan N, 2011, CELL STRESS CHAPERON, V16, P41, DOI 10.1007/s12192-010-0219-5; Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood-2010-08-303099; Penas C, 2011, CELL DEATH DIFFER, V18, P1617, DOI 10.1038/cdd.2011.24; Pereira ER, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012521; Perkins DJ, 2004, MOL CELL BIOL, V24, P2025, DOI 10.1128/MCB.24.5.2025-2040.2004; Pfaffenbach KT, 2011, CURR OPIN CELL BIOL, V23, P150, DOI 10.1016/j.ceb.2010.09.007; Podack ER, 2007, EXPERT OPIN BIOL TH, V7, P1679, DOI 10.1517/14712598.7.11.1679; Pootrakul L, 2006, CLIN CANCER RES, V12, P5987, DOI 10.1158/1078-0432.CCR-06-0133; Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625; Qian JF, 2009, BLOOD, V114, P3880, DOI 10.1182/blood-2009-06-227355; Qian J, 2011, J IMMUNOL, V187, P2905, DOI 10.4049/jimmunol.1100703; Ranganathan AC, 2008, CANCER RES, V68, P3260, DOI 10.1158/0008-5472.CAN-07-6215; Ranganathan AC, 2006, CANCER BIOL THER, V5, P729, DOI 10.4161/cbt.5.7.2968; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rauschert N, 2008, LAB INVEST, V88, P375, DOI 10.1038/labinvest.2008.2; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Ren FL, 2010, CANCER BIOL THER, V9, P134, DOI 10.4161/cbt.9.2.10391; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Romero-Ramirez L, 2009, TRANSL ONCOL, V2, P31, DOI 10.1593/tlo.08211; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosati E, 2010, BLOOD, V116, P2713, DOI 10.1182/blood-2010-03-275628; Roue G, 2011, BLOOD, V117, P1270, DOI 10.1182/blood-2010-04-278853; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191; Sato M, 2010, ADV GENET, V69, P97, DOI 10.1016/S0065-2660(10)69006-2; Schewe DM, 2009, CANCER RES, V69, P1545, DOI 10.1158/0008-5472.CAN-08-3858; Schreiber TH, 2009, CANCER RES, V69, P2026, DOI 10.1158/0008-5472.CAN-08-3706; Schroder M, 2006, CURR MOL MED, V6, P5, DOI 10.2174/156652406775574569; Sequeira SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000615; Shani G, 2008, MOL CELL BIOL, V28, P666, DOI 10.1128/MCB.01716-07; Sinkovics JG, 2008, ARCH IMMUNOL THER EX, V56, p3S, DOI 10.1007/s00005-008-0047-9; Strbo N, 2008, AM J REPROD IMMUNOL, V59, P407, DOI 10.1111/j.1600-0897.2008.00594.x; Tamura Y, 2011, J IMMUNOL, V186, P4325, DOI 10.4049/jimmunol.1004048; Tan SS, 2011, J PATHOL, V223, P81, DOI 10.1002/path.2795; Tanimura A, 2009, LEUKEMIA RES, V33, P924, DOI 10.1016/j.leukres.2009.01.027; Teske BF, 2011, MOL BIOL CELL, V22, P4390, DOI 10.1091/mbc.E11-06-0510; Testori A, 2008, J CLIN ONCOL, V26, P955, DOI 10.1200/JCO.2007.11.9941; Thorpe JA, 2010, CELL STRESS CHAPERON, V15, P497, DOI 10.1007/s12192-009-0163-4; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Uckun FM, 2011, BRIT J HAEMATOL, V153, P741, DOI 10.1111/j.1365-2141.2011.08671.x; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; Verras M, 2008, MOL CELL BIOL, V28, P7212, DOI 10.1128/MCB.00947-08; Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060; Wang M, 2009, ANTIOXID REDOX SIGN, V11, P2307, DOI [10.1089/ars.2009.2485, 10.1089/ARS.2009.2485]; Wang XY, 2010, J IMMUNOL, V184, P6309, DOI 10.4049/jimmunol.0903891; Wei JW, 2008, J CELL PHYSIOL, V217, P693, DOI 10.1002/jcp.21543; Wemeau M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.82; Wey S, 2012, BLOOD, V119, P817, DOI 10.1182/blood-2011-06-357384; Wood C, 2008, LANCET, V372, P145, DOI 10.1016/S0140-6736(08)60697-2; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; Wu MJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-283; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Yoshida H, 2007, ANTIOXID REDOX SIGN, V9, P2323, DOI 10.1089/ars.2007.1800; Yu DH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003951; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang KZ, 2005, J CLIN INVEST, V115, P268, DOI 10.1172/JCI200521848; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang W, 2006, CELL METAB, V4, P491, DOI 10.1016/j.cmet.2006.11.002; Zhang Y, 2010, J BIOL CHEM, V285, P15065, DOI 10.1074/jbc.M109.087445; Zhang YC, 2006, MOL PHARMACOL, V70, P1424, DOI 10.1124/mol.106.024323; Zhou H, 2011, J BIOL CHEM, V286, P25687, DOI 10.1074/jbc.M110.212944; Zhuang LQ, 2009, HISTOPATHOLOGY, V54, P462, DOI 10.1111/j.1365-2559.2009.03242.x	185	391	408	3	130	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					805	818		10.1038/onc.2012.130	http://dx.doi.org/10.1038/onc.2012.130			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22508478	Green Accepted			2022-12-28	WOS:000316581100001
J	Saito, R; Shirakawa, R; Nishiyama, H; Kobayashi, T; Kawato, M; Kanno, T; Nishizawa, K; Matsui, Y; Ohbayashi, T; Horiguchi, M; Nakamura, T; Ikeda, T; Yamane, K; Nakayama, E; Nakamura, E; Toda, Y; Kimura, T; Kita, T; Ogawa, O; Horiuchi, H				Saito, R.; Shirakawa, R.; Nishiyama, H.; Kobayashi, T.; Kawato, M.; Kanno, T.; Nishizawa, K.; Matsui, Y.; Ohbayashi, T.; Horiguchi, M.; Nakamura, T.; Ikeda, T.; Yamane, K.; Nakayama, E.; Nakamura, E.; Toda, Y.; Kimura, T.; Kita, T.; Ogawa, O.; Horiuchi, H.			Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer	ONCOGENE			English	Article						RaIGAP alpha 2; Ral small GTPase; bladder cancer; invasion; metastasis	TRANSITIONAL-CELL-CARCINOMA; IN-VITRO; PROSTATE-CANCER; EXPRESSION; GROWTH; PROLIFERATION; TUMORIGENESIS; CHEMOTHERAPY; TISSUE; GENES	The small GTPase Ral is known to be highly activated in several human cancers, such as bladder, colon and pancreas cancers. It is reported that activated Ral is involved in cell proliferation, migration and metastasis of bladder cancer. This protein is activated by Ral guanine nucleotide exchange factors (RaIGEFs) and inactivated by Rat GTPase-activating proteins (RaIGAPs), the latter of which consist of heterodimers containing a catalytic alpha 1 or alpha 2 subunit and a common beta subunit. In Ras-driven cancers, such as pancreas and colon cancers, constitutively active Ras mutant activates Ral through interaction with RaIGEFs, which contain the Ras association domain. However, little is known with regard to the mechanism that governs aberrant activation of Ral in bladder cancer, in which Ras mutations are relatively infrequent. Here, we show that Ral was highly activated in invasive bladder cancer cells due to reduced expression of RaIGAP alpha 2, the dominant catalytic subunit in bladder, rather than increased expression of RaIGEFs. Exogenous expression of wild-type RaIGAP alpha 2 in KU7 bladder cancer cells with invasive phenotype, but not mutant RaIGAID alpha 2-N1742K lacking RaIGAP activity, resulted in attenuated cell migration in vitro and lung metastasis in vivo. Furthermore, genetic ablation of Ralgapa2 promoted tumor invasion in a chemically-induced murine bladder cancer model. Importantly, immunohistochennical analysis of human bladder cancer specimens revealed that lower expression of RaIGAP alpha 2 was associated with advanced clinical stage and poor survival of patients. Collectively, these results are highly indicative that attenuated expression of RaIGAP alpha 2 leads to disease progression of bladder cancer through enhancement of Ral activity. Oncogene (2013) 32, 894-902; doi:10.1038/onc.2012.101; published online 26 March 2012	[Saito, R.; Kobayashi, T.; Kanno, T.; Nishizawa, K.; Matsui, Y.; Nakamura, E.; Ogawa, O.] Kyoto Univ, Dept Urol, Grad Sch Med, Kyoto, Japan; [Shirakawa, R.; Horiuchi, H.] Tohoku Univ, Dept Mol & Cellular Biol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan; [Nishiyama, H.] Univ Tsukuba, Dept Urol, Fac Med, Tsukuba, Ibaraki 3058575, Japan; [Kawato, M.; Horiguchi, M.; Ikeda, T.; Yamane, K.; Nakayama, E.; Kimura, T.; Kita, T.] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan; [Ohbayashi, T.] Tottori Univ, Div Lab Anim Sci, Res Ctr Biosci & Technol, Yonago, Tottori, Japan; [Nakamura, T.] Kansai Med Univ, Dept Pharmacol, Moriguchi, Osaka 570, Japan; [Toda, Y.] Kyoto Univ, Grad Sch Med, Ctr Anat Studies, Kyoto, Japan	Kyoto University; Tohoku University; University of Tsukuba; Kyoto University; Tottori University; Kansai Medical University; Kyoto University	Nishiyama, H (corresponding author), Univ Tsukuba, Dept Urol, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	nishiuro@md.tsukuba.ac.jp; horiuchi@idac.tohoku.ac.jp	MATSUI, Yoshiyuki/I-2323-2019		Ministry of Education, Culture, Sports, Science and Technology, Japan [22591766, 22890015, 22501009, 20013201, 23113702]; Uehara Memorial Foundation; Takeda Science Foundation; Suzuken Memorial Foundation; Daiichi-Sankyo Foundation of Life-Science; Kurokawa Cancer Research Foundation; Novartis Foundation for the Promotion of Science; Grants-in-Aid for Scientific Research [22501009] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Suzuken Memorial Foundation; Daiichi-Sankyo Foundation of Life-Science; Kurokawa Cancer Research Foundation(Kurokawa Cancer Research Foundation); Novartis Foundation for the Promotion of Science; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We would like to thank Aaron Mathew Coutts for proofreading of the manuscript. We appreciate all members of the Cancer Research Course for Integrated Research Training in Kyoto University Graduate School of Medicine for their helpful advice and discussion. This study was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (No. 22591766 to HN and OO, 22890015, 22501009, 20013201 and 23113702 to R Shirakawa and HH) as well as grants from Uehara Memorial Foundation (to T Kobayashi and 00), Takeda Science Foundation, the Suzuken Memorial Foundation, Daiichi-Sankyo Foundation of Life-Science, Kurokawa Cancer Research Foundation (to R Shirakawa), and Novartis Foundation for the Promotion of Science (to HH).	Adhim Z, 2011, BRIT J CANCER, V105, P393, DOI 10.1038/bjc.2011.262; Badea L, 2008, HEPATO-GASTROENTEROL, V55, P2016; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Copeland NG, 2001, NAT REV GENET, V2, P769, DOI 10.1038/35093556; Cordon-Cardo C, 2008, SCAND J UROL NEPHROL, V42, P154, DOI 10.1080/03008880802291915; Ding ST, 2010, J UROLOGY, V184, P1175, DOI 10.1016/j.juro.2010.04.073; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gaspar C, 2008, AM J PATHOL, V172, P1363, DOI 10.2353/ajpath.2008.070851; Hadaschik BA, 2008, CLIN CANCER RES, V14, P1510, DOI 10.1158/1078-0432.CCR-07-4475; Hsieh JL, 2003, BRIT J CANCER, V88, P1492, DOI 10.1038/sj.bjc.6600908; Hurst RE, 2003, ANTICANCER RES, V23, P3119; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Kawato M, 2008, J BIOL CHEM, V283, P166, DOI 10.1074/jbc.M705340200; Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310; Kobayashi T, 2010, MOL ENDOCRINOL, V24, P722, DOI 10.1210/me.2009-0326; Konety BR, 2001, J UROLOGY, V165, P253, DOI 10.1097/00005392-200101000-00074; Korkola JE, 2006, CANCER RES, V66, P820, DOI 10.1158/0008-5472.CAN-05-2445; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Martin TD, 2011, CANCER RES, V71, P206, DOI 10.1158/0008-5472.CAN-10-1517; MASTERS JRW, 1986, CANCER RES, V46, P3630; Matsui Y, 2010, BJU INT, V105, P558, DOI 10.1111/j.1464-410X.2009.08732.x; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Shao HP, 2000, J BIOL CHEM, V275, P26914; SHIBAYAMA T, 1991, J UROLOGY, V146, P1136, DOI 10.1016/S0022-5347(17)38025-4; Shirakawa R, 2009, J BIOL CHEM, V284, P21580, DOI 10.1074/jbc.M109.012112; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Vigil D, 2010, J BIOL CHEM, V285, P34729, DOI 10.1074/jbc.M110.116756; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; Wang H, 2010, CANCER RES, V70, P8760, DOI 10.1158/0008-5472.CAN-10-0952; Williams SV, 2002, GENE CHROMOSOME CANC, V34, P86, DOI 10.1002/gcc.10050; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	44	45	45	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					894	902		10.1038/onc.2012.101	http://dx.doi.org/10.1038/onc.2012.101			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22450745	Green Submitted			2022-12-28	WOS:000316581100009
J	Galavotti, S; Bartesaghi, S; Faccenda, D; Shaked-Rabi, M; Sanzone, S; McEvoy, A; Dinsdale, D; Condorelli, F; Brandner, S; Campanella, M; Grose, R; Jones, C; Salomoni, P				Galavotti, S.; Bartesaghi, S.; Faccenda, D.; Shaked-Rabi, M.; Sanzone, S.; McEvoy, A.; Dinsdale, D.; Condorelli, F.; Brandner, S.; Campanella, M.; Grose, R.; Jones, C.; Salomoni, P.			The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells	ONCOGENE			English	Article						autophagy; cancer stem cell; invasion	MALIGNANT GLIOMA-CELLS; HUMAN BRAIN-TUMORS; INDUCED CYTOTOXICITY; GENE-EXPRESSION; GLUCOSE TRANSPORTERS; IONIZING-RADIATION; MYELOID-LEUKEMIA; CANCER; DEATH; CHLOROQUINE	The aggressiveness of glioblastoma multiforme (GBM) is defined by local invasion and resistance to therapy. Within established GBM, a subpopulation of tumor-initiating cells with stem-like properties (GBM stem cells, GSCs) is believed to underlie resistance to therapy. The metabolic pathway autophagy has been implicated in the regulation of survival in GBM. However, the status of autophagy in GBM and its role in the cancer stem cell fraction is currently unclear. We found that a number of autophagy regulators are highly expressed in GBM tumors carrying a mesenchymal signature, which defines aggressiveness and invasion, and are associated with components of the MAPK pathway. This autophagy signature included the autophagy-associated genes DRAM1 and SQSTM1, which encode a key regulator of selective autophagy, p62. High levels of DRAM1 were associated with shorter overall survival in GBM patients. In GSCs, DRAM? and SQSTM1 expression correlated with activation of MAPK and expression of the mesenchymal marker c-MET. DRAM1 knockdown decreased p62 localization to autophagosomes and its autophagy-mediated degradation, thus suggesting a role for DRAM1 in p62-mediated autophagy. In contrast, autophagy induced by starvation or inhibition of mTOR/PI-3K was not affected by either DRAM1 or p62 downregulation. Functionally, DRAM1 and p62 regulate cell motility and invasion in GSCs. This was associated with alterations of energy metabolism, in particular reduced ATP and lactate levels. Taken together, these findings shed new light on the role of autophagy in GBM and reveal a novel function of the autophagy regulators DRAM1 and p62 in control of migration/invasion in cancer stem cells. Oncogene (2013) 32, 699-712; doi:10.1038/onc.2012.111; published online 23 April 2012	[Galavotti, S.; Bartesaghi, S.; Salomoni, P.] UCL Canc Inst, Samantha Dickson Brain Canc Unit, London WC1E 6BT, England; [Faccenda, D.; Campanella, M.] Univ London Royal Vet Coll, London, England; [Shaked-Rabi, M.; Brandner, S.] UCL, Neurol Inst, London, England; [Sanzone, S.; Condorelli, F.] Univ Piemonte Orientale, Novara, Italy; [McEvoy, A.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; [Dinsdale, D.] MRC Toxicol Unit, Leicester, Leics, England; [Campanella, M.] UCL Consortium Mitochondrial Res, London, England; [Grose, R.] Barts Canc Inst, London, England; [Jones, C.] Inst Canc Res, London SW3 6JB, England	University of London; University College London; University of London; University of London Royal Veterinary College; University of London; University College London; University of Eastern Piedmont Amedeo Avogadro; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; Queen Mary University London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Salomoni, P (corresponding author), UCL Canc Inst, Samantha Dickson Brain Canc Unit, London WC1E 6BT, England.	p.salomoni@ucl.ac.uk	Brandner, Sebastian/J-4562-2014; Condorelli, Fabrizio/AAT-1953-2020; Jones, Chris/ABE-6059-2021; Bartesaghi, Stefano/G-1916-2015	Brandner, Sebastian/0000-0002-9821-0342; Condorelli, Fabrizio/0000-0002-9943-0857; Jones, Chris/0000-0001-8118-2296; Bartesaghi, Stefano/0000-0002-2083-7807; Grose, Richard/0000-0002-4738-0173	Samantha Dickson Brain Tumour Trust [SDK-I-0805]; University of Modena and Reggio Emilia, Modena, Italy; NHS; Cancer Research UK [C8851/A10844]; National Hospital Development foundation; UCLH CBRC [31]; BBSRC [BB/I013695/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/I013695/1] Funding Source: researchfish; The Brain Tumour Charity [8/47] Funding Source: researchfish	Samantha Dickson Brain Tumour Trust; University of Modena and Reggio Emilia, Modena, Italy; NHS; Cancer Research UK(Cancer Research UK); National Hospital Development foundation; UCLH CBRC; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); The Brain Tumour Charity	We thank Susan Short, Sergio Quezada, Steven Pollard and Daniel Hochhauser (UCL Cancer Institute, London, UK), Sharon Tooze (CRUK London Research Institute, London, UK), Bruno Calabretta (Kimmel Cancer Center, Philadelphia, USA), Andrea Cossarizza and Paola Loria (University of Modena and Reggio Emilia, Italy) for reagents and critical discussion. We also thank other members of PS lab (UCL Cancer Institute) and Melania Capasso (Bans and the London, UK). We thank Carol Mercer and Pat Dennis (University of Cincinnati, USA) for the BHMT plasmid, and Scott Lowe (CSHL, USA) for the hRAS-V12 IRES GFP plasmid (Addgene). Finally, we thank the UCL Scientific Services and in particular Tomas Adejumo for support with flow cytometry. PS is supported by the Samantha Dickson Brain Tumour Trust and a generous donation by David Hunter and Wendy Tansey in memory of Peter Clark. SG is recipient of a PhD studentship from the University of Modena and Reggio Emilia, Modena, Italy. CJ acknowledges NHS funding to the NIHR Biomedical Research Centre. ET acknowledges Cancer Research UK funding to his laboratory (C8851/A10844). MSR is funded by the National Hospital Development foundation and SB (Institute of Neurology, loN) received support from UCLH CBRC (Ref 31) and the Samantha Dickson Brain tumor trust (Ref SDK-I-0805). SB (IoN) acknowledges the Neurosurgical team at the National Hospital for their continued support of the brain tumor bank.	Beckner ME, 2010, INT J CANCER, V126, P2282, DOI 10.1002/ijc.24918; Beckner ME, 2005, LAB INVEST, V85, P316, DOI 10.1038/labinvest.3700239; Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Bilir A, 2008, INT J ONCOL, V32, P829; BOADO RJ, 1994, MOL BRAIN RES, V27, P51, DOI 10.1016/0169-328X(94)90183-X; Briceno Eduardo, 2003, Neurosurg Focus, V14, pe3; BROOKS DJ, 1986, J CEREBR BLOOD F MET, V6, P230, DOI 10.1038/jcbfm.1986.36; Campanella M, 2008, CELL METAB, V8, P13, DOI 10.1016/j.cmet.2008.06.001; Campello S, 2006, J EXP MED, V203, P2879, DOI 10.1084/jem.20061877; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026; Cheng Y, 2011, CANCER RES, V71, P2654, DOI 10.1158/0008-5472.CAN-10-2889; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Crighton D, 2007, AUTOPHAGY, V3, P72, DOI 10.4161/auto.3438; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Dang LN, 2010, TRENDS MOL MED, V16, P387, DOI 10.1016/j.molmed.2010.07.002; Day SE, 2011, MAGN RESON MED, V65, P557, DOI 10.1002/mrm.22698; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027; Fan QW, 2011, AUTOPHAGY, V7, P536, DOI 10.4161/auto.7.5.14779; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030; Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958; KIRSCH WM, 1967, J NEUROSURG, V27, P45, DOI 10.3171/jns.1967.27.1.0045; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kroemer G, 2010, CURR OPIN CELL BIOL, V22, P121, DOI 10.1016/j.ceb.2010.02.003; Lee Y, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-52; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Lock R, 2011, CELL CYCLE, V10, P1516, DOI 10.4161/cc.10.10.15434; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Lusa L, 2007, JNCI-J NATL CANCER I, V99, P1715, DOI 10.1093/jnci/djm216; Martinou M, 2011, CANCER GENOM PROTEOM, V8, P33; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Munshi A, 2009, CANCER, V115, P2380, DOI 10.1002/cncr.24288; NAGAMATSU S, 1993, J NEUROCHEM, V61, P2048, DOI 10.1111/j.1471-4159.1993.tb07441.x; Natsumeda M, 2011, NEUROPATHOLOGY, V31, P486, DOI 10.1111/j.1440-1789.2010.01197.x; NISHIOKA T, 1992, CANCER RES, V52, P3972; Paugh BS, 2010, J CLIN ONCOL, V28, P3061, DOI 10.1200/JCO.2009.26.7252; Perou CM, 2010, LANCET ONCOL, V11, P718, DOI 10.1016/S1470-2045(10)70176-5; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Reitman ZJ, 2010, JNCI-J NATL CANCER I, V102, P932, DOI 10.1093/jnci/djq187; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Salomoni P, 2009, AUTOPHAGY, V5, P1050, DOI 10.4161/auto.5.7.9509; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Shima Y, 2007, BIOCHEM BIOPH RES CO, V353, P60, DOI 10.1016/j.bbrc.2006.11.137; Shingu T, 2009, AUTOPHAGY, V5, P537, DOI 10.4161/auto.5.4.8164; Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030; Siegelin MD, 2011, J CLIN INVEST, V121, P1349, DOI 10.1172/JCI44855; Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004; Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008; Tatsuta T, 2008, EMBO J, V27, P306, DOI 10.1038/sj.emboj.7601972; Terpstra M, 1998, CANCER RES, V58, P5083; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wild-Bode C, 2001, CANCER RES, V61, P2744; Wolf A, 2011, NEUROBIOL DIS, V44, P84, DOI 10.1016/j.nbd.2011.06.007; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	77	178	190	4	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					699	712		10.1038/onc.2012.111	http://dx.doi.org/10.1038/onc.2012.111			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22525272	Green Published			2022-12-28	WOS:000315746700004
J	Palorini, R; De Rasmo, D; Gaviraghi, M; Danna, LS; Signorile, A; Cirulli, C; Chiaradonna, F; Alberghina, L; Papa, S				Palorini, R.; De Rasmo, D.; Gaviraghi, M.; Danna, L. Sala; Signorile, A.; Cirulli, C.; Chiaradonna, F.; Alberghina, L.; Papa, S.			Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration	ONCOGENE			English	Article						cancer cell metabolism; oncogenic K-ras; PKA; mitochondrial morphology; mitochondrial activity; glucose deprivation	DEPENDENT PROTEIN-KINASE; ADENYLATE-CYCLASE ACTIVITY; CYCLIC-AMP; COMPLEX-I; REGULATORY SUBUNITS; GENE-EXPRESSION; THYROID-CELLS; HUMAN CANCER; METABOLISM; PHOSPHORYLATION	The Warburg effect in cancer cells has been proposed to involve several mechanisms, including adaptation to hypoxia, oncogenes activation or loss of oncosuppressors and impaired mitochondria! function. In previous papers, it has been shown that K-ras transformed mouse cells are much more sensitive as compared with normal cells to glucose withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of mitochondrial complex I. Recent observations suggest that transformed cells have a derangement in the cyclic adenosine nnonophosphate/cAMP-dependent protein kinase (cAMP/PKA) pathway, which is known to regulate several mitochondrial functions. Herein, the derangement of the cAMP/PKA pathway and its impact on transformation-linked changes of mitochondrial functions is investigated. Exogenous stimulation of PKA activity, achieved by forskolin treatment protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels. Several of these effects were almost completely prevented by inhibiting the PKA activity. Short-time treatment with compounds favoring mitochondrial fusion strongly decreased the cellular ROS levels especially in transformed cells. These findings support the notion that glucose shortage-induced apoptosis, specific of K-ras-transformed cells, is associated to a derangement of PKA signaling that leads to mitochondrial complex I decrease, reduction of ATP formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs. Oncogene (2013) 32, 352-362; doi:10.1038/onc.2012.50; published online 12 March 2012	[Palorini, R.; Gaviraghi, M.; Danna, L. Sala; Cirulli, C.; Chiaradonna, F.; Alberghina, L.] Univ Milano Bicocca, Dept Biosci & Biotechnol, I-20126 Milan, MI, Italy; [De Rasmo, D.; Signorile, A.; Papa, S.] Univ Bari, Dept Med Biochem Biol & Phys DIBIFIM, Bari, Italy; [De Rasmo, D.; Papa, S.] CNR, Inst Biomembranes & Bioenerget IBBE, I-70126 Bari, Italy	University of Milano-Bicocca; Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR)	Chiaradonna, F (corresponding author), Univ Milano Bicocca, Dept Biosci & Biotechnol, Piazza Sci 2, I-20126 Milan, MI, Italy.	ferdinando.chiaradonna@unimib.it	Gaviraghi, Marco/AAB-1582-2020; De Rasmo, Domenico/AAC-4672-2020; CHIARADONNA, Ferdinando/K-4959-2016	Gaviraghi, Marco/0000-0003-2791-3638; De Rasmo, Domenico/0000-0002-3917-2411; CHIARADONNA, Ferdinando/0000-0001-8529-2732; Papa, Sergio/0000-0002-4417-1763; Signorile, Anna/0000-0001-9045-891X; Alberghina, Lilia/0000-0003-1694-931X	MIUR (FIRB-ITALBIONET); Italian Government (FAR); MIUR (Progetto FIRB Rete Nazionale per lo Studio della Proteomica Umana-Italian Human ProteomeNet); Progetto Strategico [Ric.002]; Cip [PS 101]; FOR [2000/06]	MIUR (FIRB-ITALBIONET)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Italian Government (FAR); MIUR (Progetto FIRB Rete Nazionale per lo Studio della Proteomica Umana-Italian Human ProteomeNet)(Ministry of Education, Universities and Research (MIUR)); Progetto Strategico; Cip; FOR	This work has been supported by a grant to LA from MIUR (FIRB-ITALBIONET), grants to FC from the Italian Government (FAR) and MIUR (Prin 2008), grant to DDR and CC from MIUR (Progetto FIRB futuro in ricerca, 2008), grants to SP from MIUR (Progetto FIRB Rete Nazionale per lo Studio della Proteomica Umana-Italian Human ProteomeNet, 2009) and Progetto Strategico Ric.002, Cip PS 101, FOR 2000/06.	Acin-Perez R, 2009, CELL METAB, V9, P265, DOI 10.1016/j.cmet.2009.01.012; Alchanati I, 2006, ONCOGENE, V25, P7138, DOI 10.1038/sj.onc.1209708; Balestrieri C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S12-S1; Baracca A, 2010, BBA-BIOENERGETICS, V1797, P314, DOI 10.1016/j.bbabio.2009.11.006; Baratta MG, 2009, MOL ENDOCRINOL, V23, P838, DOI 10.1210/me.2008-0353; Bellis A, 2009, ARTERIOSCL THROM VAS, V29, P1207, DOI 10.1161/ATVBAHA.109.184135; Benard G, 2007, J CELL SCI, V120, P838, DOI 10.1242/jcs.03381; Borlikova G, 2009, MOL NEUROBIOL, V40, P73, DOI 10.1007/s12035-009-8072-1; BOS JL, 1989, CANCER RES, V49, P4682; Bossu P, 2000, ONCOGENE, V19, P2147, DOI 10.1038/sj.onc.1203539; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Capaldi RA, 2002, BBA-BIOENERGETICS, V1555, P192, DOI 10.1016/S0005-2728(02)00277-3; Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Chiaradonna F, 2006, ONCOGENE, V25, P5391, DOI 10.1038/sj.onc.1209528; Chiaradonna F, 2012, BIOTECHNOL ADV, V30, P30, DOI 10.1016/j.biotechadv.2011.07.006; Chiaradonna F, 2008, FRONT BIOSCI-LANDMRK, V13, P5257, DOI 10.2741/3079; Chiaradonna F, 2006, BBA-BIOENERGETICS, V1757, P1338, DOI 10.1016/j.bbabio.2006.08.001; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; De Rasmo D, 2011, EUR J PHARMACOL, V652, P15, DOI 10.1016/j.ejphar.2010.11.016; De Rasmo D, 2009, FEBS J, V276, P4325, DOI 10.1111/j.1742-4658.2009.07133.x; Depre C, 1998, J CLIN INVEST, V101, P390, DOI 10.1172/JCI1168; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; FRANKS DJ, 1987, J CELL BIOCHEM, V33, P87, DOI 10.1002/jcb.240330203; Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56; Gaglio D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004715; GALLO A, 1995, CELL GROWTH DIFFER, V6, P91; Gerits N, 2008, CELL SIGNAL, V20, P1592, DOI 10.1016/j.cellsig.2008.02.022; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Grandemange S, 2009, SEMIN CANCER BIOL, V19, P50, DOI 10.1016/j.semcancer.2008.12.001; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HIRAKI Y, 1989, MOL ENDOCRINOL, V3, P1470, DOI 10.1210/mend-3-9-1470; HOSAKA Y, 1992, ENDOCRINOLOGY, V131, P159, DOI 10.1210/en.131.1.159; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; KONISHIIMAMURA L, 1988, BIOCHEM BIOPH RES CO, V153, P1214, DOI 10.1016/S0006-291X(88)81357-3; KONISHIIMAMURA L, 1987, BIOCHEM BIOPH RES CO, V146, P47, DOI 10.1016/0006-291X(87)90688-7; Koopman WJH, 2005, AM J PHYSIOL-CELL PH, V289, pC881, DOI 10.1152/ajpcell.00104.2005; Lee HC, 2009, INT J MOL SCI, V10, P674, DOI 10.3390/ijms10020674; Lenaz G, 2010, BBA-BIOENERGETICS, V1797, P633, DOI 10.1016/j.bbabio.2010.01.025; Lu JX, 2009, CELL RES, V19, P802, DOI 10.1038/cr.2009.69; Ma WZ, 2007, J BIOENERG BIOMEMBR, V39, P243, DOI 10.1007/s10863-007-9083-0; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Mazurek S, 2003, ANTICANCER RES, V23, P1149; McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200; Merrill RA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000612; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; Palmer CS, 2011, CELL SIGNAL, V23, P1534, DOI 10.1016/j.cellsig.2011.05.021; Papa S, 1996, EUR J BIOCHEM, V240, P461, DOI 10.1111/j.1432-1033.1996.0461h.x; Papa S, 2008, BBA-BIOENERGETICS, V1777, P719, DOI 10.1016/j.bbabio.2008.04.005; Papa S, 2006, IUBMB LIFE, V58, P173, DOI 10.1080/15216540500494516; Piccoli C, 2006, FEBS LETT, V580, P4539, DOI 10.1016/j.febslet.2006.06.085; Plecita-Hlavata L, 2008, BBA-BIOENERGETICS, V1777, P834, DOI 10.1016/j.bbabio.2008.04.002; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sardanelli AM, 2006, FEBS LETT, V580, P5690, DOI 10.1016/j.febslet.2006.09.020; SCHWOCH G, 1990, BIOCHEM J, V270, P181, DOI 10.1042/bj2700181; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Signorile A, 2002, FEBS LETT, V512, P91, DOI 10.1016/S0014-5793(02)02226-3; Simonnet H, 2003, CARCINOGENESIS, V24, P1461, DOI 10.1093/carcin/bgg109; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Vizan P, 2005, CANCER RES, V65, P5512, DOI 10.1158/0008-5472.CAN-05-0074; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; YAMAMOTO F, 1984, NUCLEIC ACIDS RES, V12, P8873, DOI 10.1093/nar/12.23.8873; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zippin JH, 2002, FASEB J, V16, P82, DOI 10.1096/fj.02-0598fje; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136	72	43	44	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					352	362		10.1038/onc.2012.50	http://dx.doi.org/10.1038/onc.2012.50			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22410778				2022-12-28	WOS:000314736600009
J	Sambandam, Y; Sundaram, K; Liu, A; Kirkwood, KL; Ries, WL; Reddy, SV				Sambandam, Y.; Sundaram, K.; Liu, A.; Kirkwood, K. L.; Ries, W. L.; Reddy, S. V.			CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment	ONCOGENE			English	Article						oral squamous cell carcinoma; CXCL13; RANK ligand; c-Myc; osteoblast	KAPPA-B LIGAND; SOLUBLE RECEPTOR ACTIVATOR; INDUCED OSTEOLYSIS; PROSTATE-CANCER; NECK-CANCER; OSTEOCLAST DIFFERENTIATION; CHEMOKINE RECEPTORS; OSTEOBLASTS; METASTASIS; INVASION	CXC chemokine ligand-13 (CXCL13) has been implicated in oral squamous cell carcinoma (OSCC) tumor progression and osteolysis. The tumor necrosis factor family member RANKL (receptor activator of NF-kappa B ligand), a critical bone resorbing osteoclastogenic factor, has an important role in cancer invasion of bone/osteolysis. Here, we show high-level expression of CXCL13 in primary human OSCC tumor specimens; however, human bone marrow-derived stromal (SAKA-T) and murine preosteoblast (MC3T3-E1) cells produce at very low level. Recombinant CXCL13 (0-15 ng/ml) dose dependently induced CXCR5 expression in SAKA-T and MC3T3-E1 cells. Conditioned media obtained from OSCC cell lines increased the RANKL expression and an antibody against the CXCL13 specific receptor, CXCR5 markedly decreased RANKL expression in these cells. Furthermore, CXCL13 increased hRANKL-Luc promoter activity. Superarray screening identified c-Myc and NFATc3 transcription factors upregulated in CXCL13-stimulated SAKA-T cells. Immunohistochemical analysis of OSCC tumors that developed in athymic mice demonstrated RANKL and NFATc3 expression in tumor and osteoblast cells, however, showed p-c-Myc expression specific to osteoblastic cells at the tumor-bone interface. We further identified NFATc3 expression, but not c-Myc activation in primary human OSCC tumor specimens compared with adjacent normal tissue. Also, CXCL13 significantly increased p-ERK1/2 in SAKA-T and MC3T3-E1 cells. siRNA suppression of c-Myc expression markedly decreased CXCL13-induced RANKL and NFATc3 expression in preosteoblast cells. Chromatin-immuno precipitation assay confirmed p-c-Myc binding to the hRANKL promoter region. In summary, c-Myc activation through CXCL13-CXCR5 signaling axis stimulates RANKL expression in stromal/preosteoblast cells. Thus, our results implicate CXCL13 as a potential therapeutic target to prevent OSCC invasion of bone/osteolysis. Oncogene (2013) 32, 97-105; doi:10.1038/onc.2012.24; published online 13 February 2012	[Sambandam, Y.; Sundaram, K.; Reddy, S. V.] Med Univ S Carolina, Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA; [Liu, A.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Kirkwood, K. L.; Ries, W. L.] Med Univ S Carolina, Sch Dent Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Reddy, SV (corresponding author), Med Univ S Carolina, Charles P Darby Childrens Res Inst, 173 Ashley Ave, Charleston, SC 29425 USA.	reddysv@musc.edu	Reddy, Sakamuri/H-6419-2019; Kirkwood, Keith L/L-4728-2018	Kirkwood, Keith/0000-0003-4519-8973	National Institutes of Health from National Center for Research Resources [C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015455] Funding Source: NIH RePORTER	National Institutes of Health from National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Thomas E Carey, University of Michigan, Ann Arbor, MI for generously providing OSCC cells and Alfredo A Molinolo MD, PhD, NIDCR, NIH for providing the OSCC tumor tissue microarray slides. This work was conducted in a facility constructed with the support from the National Institutes of Health, Grant Number C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources.	Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P417, DOI 10.1002/hed.21198; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Chen G, 2006, CANCER-AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978; Choi S, 2008, J DENT RES, V87, P14, DOI 10.1177/154405910808700104; Darimont C, 2002, CELL GROWTH DIFFER, V13, P59; Deyama Y, 2008, ONCOL REP, V20, P663, DOI 10.3892/or_00000057; El-Haibi CP, 2011, CELL PROLIFERAT, V44, P311, DOI 10.1111/j.1365-2184.2011.00757.x; Funk GF, 2002, HEAD NECK-J SCI SPEC, V24, P165, DOI 10.1002/hed.10004; Habib T, 2007, J CELL BIOL, V179, P717, DOI 10.1083/jcb.200704173; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Ishikuro M, 2008, BONE, V43, P621, DOI 10.1016/j.bone.2008.05.014; Jimi E, 2011, ORAL DIS, V17, P462, DOI 10.1111/j.1601-0825.2010.01781.x; Kayamori K, 2010, AM J PATHOL, V176, P968, DOI 10.2353/ajpath.2010.090299; Kikuchi T, 2003, J DENT RES, V82, P546, DOI 10.1177/154405910308200712; Lee SK, 2002, J IMMUNOL, V169, P2374, DOI 10.4049/jimmunol.169.5.2374; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Lisignoli G, 2004, EXP GERONTOL, V39, P659, DOI 10.1016/j.exger.2003.09.030; Lisignoli G, 2003, J CELL PHYSIOL, V194, P71, DOI 10.1002/jcp.10188; Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Marampon F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-31; Mikami S, 2009, J PATHOL, V218, P530, DOI 10.1002/path.2567; Mishra A, 2006, INT J CANCER, V119, P2840, DOI 10.1002/ijc.22262; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Muller A, 2006, INT J CANCER, V118, P2147, DOI 10.1002/ijc.21514; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Nomura T, 2007, ORAL ONCOL, V43, P257, DOI 10.1016/j.oraloncology.2006.03.015; Pandruvada SNM, 2010, INT J CANCER, V126, P2319, DOI 10.1002/ijc.24920; Perez-Sayans M, 2011, ORAL ONCOL, V47, P688, DOI 10.1016/j.oraloncology.2011.05.016; Roccisana JL, 2004, J BIOL CHEM, V279, P10500, DOI 10.1074/jbc.M303727200; Roux S, 2004, LEUKEMIA LYMPHOMA, V45, P1111, DOI 10.1080/10428194310001593193; Singh G, 2010, J BIOL CHEM, V285, P27241, DOI 10.1074/jbc.M110.100438; Singh S, 2009, CANCER LETT, V283, P29, DOI 10.1016/j.canlet.2009.03.022; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Thiolloy S, 2009, CANCER RES, V69, P6747, DOI 10.1158/0008-5472.CAN-08-3949; Uchida D, 2001, INT J CANCER, V93, P489, DOI 10.1002/ijc.1368; Vachani A, 2007, CLIN CANCER RES, V13, P2905, DOI 10.1158/1078-0432.CCR-06-1670; Wilson TJ, 2008, CANCER RES, V68, P5803, DOI 10.1158/0008-5472.CAN-07-5889; Yuvaraj S, 2009, MOL CANCER RES, V7, P1399, DOI 10.1158/1541-7786.MCR-08-0589; Ziober AF, 2006, CLIN CANCER RES, V12, P5960, DOI 10.1158/1078-0432.CCR-06-0535; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	44	47	50	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					97	105		10.1038/onc.2012.24	http://dx.doi.org/10.1038/onc.2012.24			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22330139	Green Accepted			2022-12-28	WOS:000313029500010
J	Long, JS; Ryan, KM				Long, J. S.; Ryan, K. M.			New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy	ONCOGENE			English	Review						cancer; apoptosis; necroptosis; autophagy; therapy	RECEPTOR-INTERACTING PROTEIN; NF-KAPPA-B; CASPASE-MEDIATED CLEAVAGE; BCL-2 FAMILY PROTEINS; C-MYC; PROGRAMMED NECROSIS; CD95 APO-1/FAS; SUPPRESSES TUMORIGENESIS; FRAMESHIFT MUTATIONS; REGULATES AUTOPHAGY	Cancer is a multifaceted disease comprising a combination of genetic, metabolic and signalling aberrations, which severely disrupt the normal homeostasis of cell growth and death. Many oncogenic events while promoting tumour development also increase the sensitivity of cells to cell death stimuli including chemotherapeutic drugs. As a result, tumour cells often acquire the ability to evade death by inactivating cell death pathways that normally function to eliminate damaged and harmful cells. The impairment of cell death function is also often the reason for the development of chemotherapeutic resistance encountered during treatment. It is therefore necessary to achieve a comprehensive understanding of existing cell death pathways and the relevant regulatory components involved, with the intention of identifying new strategies to kill cancer cells. This review provides an insightful overview of the common forms of cell death signalling pathways, the interactions between these pathways and the ways in which these pathways are deregulated in cancer. We also discuss the emerging therapies targeted at activating or restoring cell death pathways to induce tumour cell death, which are currently being tested in clinical trials. Oncogene (2012) 31, 5045-5060; doi: 10.1038/onc.2012.7; published online 6 February 2012	[Long, J. S.; Ryan, K. M.] Beatson Inst Canc Res, Tumour Cell Death Lab, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Ryan, KM (corresponding author), Beatson Inst Canc Res, Tumour Cell Death Lab, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.ryan@beatson.gla.ac.uk		Ryan, Kevin M./0000-0002-1059-9681	Cancer Research UK; Association for International Cancer Research; Cancer Research UK [15816] Funding Source: researchfish; Worldwide Cancer Research [09-0170] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Association for International Cancer Research; Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	We apologise to researchers whose studies we were unable to cite due to the length of this review. We thank the members of the Tumour Cell Death Laboratory for critical reading of the manuscript. Work in the Tumour Cell Death Laboratory is supported by Cancer Research UK and the Association for International Cancer Research.	Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Artal-Sanz M, 2006, J CELL BIOL, V173, P231, DOI 10.1083/jcb.200511103; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bianchi K, 2009, MOL CELL, V36, P736, DOI 10.1016/j.molcel.2009.11.029; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Briceno E, 2007, SURG NEUROL, V67, P388, DOI 10.1016/j.surneu.2006.08.080; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Ch'en IL, 2011, J EXP MED, V208, P633, DOI 10.1084/jem.20110251; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Chen DJ, 2009, ANTI-CANCER DRUG, V20, P646, DOI 10.1097/CAD.0b013e32832ced78; Cheung WC, 2004, J CLIN INVEST, V113, P1763, DOI 10.1172/JCI200420369; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Cho DH, 2009, CANCER LETT, V274, P95, DOI 10.1016/j.canlet.2008.09.004; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Delavallee L, 2011, IUBMB LIFE, V63, P221, DOI 10.1002/iub.432; DETER RL, 1967, J CELL BIOL, V35, pC11, DOI 10.1083/jcb.35.2.C11; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eguchi Y, 1997, CANCER RES, V57, P1835; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fecker LF, 2006, J INVEST DERMATOL, V126, P1366, DOI 10.1038/sj.jid.5700192; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Gdynia G, 2007, MOL CANCER RES, V5, P1232, DOI 10.1158/1541-7786.MCR-07-0343; Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greenhalgh DG, 1998, INT J BIOCHEM CELL B, V30, P1019, DOI 10.1016/S1357-2725(98)00058-2; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Healy E, 1998, KIDNEY INT, V54, P1955, DOI 10.1046/j.1523-1755.1998.00202.x; Helgason GV, 2011, BLOOD, V118, P2035, DOI 10.1182/blood-2011-01-330621; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hetschko H, 2008, FEBS J, V275, P1925, DOI 10.1111/j.1742-4658.2008.06351.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020; Koneri K, 2007, ANTICANCER RES, V27, P1453; Koschny R, 2007, CLIN CANCER RES, V13, P3403, DOI 10.1158/1078-0432.CCR-07-0251; Kosta A, 2004, J BIOL CHEM, V279, P48404, DOI 10.1074/jbc.M408924200; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; LEE JT, 1989, J CLIN INVEST, V84, P1454, DOI 10.1172/JCI114320; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leontieva OV, 2010, CELL CYCLE, V9, P4323, DOI 10.4161/cc.9.21.13584; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li G, 1998, BRIT J DERMATOL, V139, P3; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V270, pF700, DOI 10.1152/ajprenal.1996.270.4.F700; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; McKenzie S, 2006, J CELL BIOCHEM, V97, P18, DOI 10.1002/jcb.20634; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miracco C, 2007, INT J ONCOL, V30, P429; Miura M, 2011, DEV GROWTH DIFFER, V53, P125, DOI 10.1111/j.1440-169X.2010.01228.x; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NOVIKOFF AB, 1964, FED PROC, V23, P1010; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Odonkor Charles Amoatey, 2008, Open Biochem J, V2, P121, DOI 10.2174/1874091X00802010121; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pavet V, 2011, ONCOGENE, V30, P1, DOI 10.1038/onc.2010.460; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031; Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Salvesen GS, 2002, DEV CELL, V2, P256, DOI 10.1016/S1534-5807(02)00137-5; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 1999, J PATHOL, V187, P127; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; SCHWARZE PE, 1985, EXP CELL RES, V157, P15, DOI 10.1016/0014-4827(85)90148-X; Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shiraishi H, 2010, BBA-GEN SUBJECTS, V1800, P405, DOI 10.1016/j.bbagen.2009.11.008; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Solary E, 1996, EUR RESPIR J, V9, P1293, DOI 10.1183/09031936.96.09061293; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Temkin V, 2006, MOL CELL BIOL, V26, P2215, DOI 10.1128/MCB.26.6.2215-2225.2006; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wiman KG, 2010, ONCOGENE, V29, P4245, DOI 10.1038/onc.2010.188; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007; Wu YT, 2011, CELL DEATH DIFFER, V18, P26, DOI 10.1038/cdd.2010.72; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang YH, 2005, BIOCHEM BIOPH RES CO, V332, P181, DOI 10.1016/j.bbrc.2005.04.114; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zeng H, 2010, CANCER BIOTHER RADIO, V25, P705, DOI 10.1089/cbr.2010.0786; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhang HB, 2011, NATURE, V471, P373, DOI 10.1038/nature09878; Zhang J, 2006, J CLIN INVEST, V116, P3042, DOI 10.1172/JCI28746; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	176	147	151	1	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5045	5060		10.1038/onc.2012.7	http://dx.doi.org/10.1038/onc.2012.7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22310284				2022-12-28	WOS:000312000900001
J	Ono, H; Imoto, I; Kozaki, K; Tsuda, H; Matsui, T; Kurasawa, Y; Muramatsu, T; Sugihara, K; Inazawa, J				Ono, H.; Imoto, I.; Kozaki, K.; Tsuda, H.; Matsui, T.; Kurasawa, Y.; Muramatsu, T.; Sugihara, K.; Inazawa, J.			SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation	ONCOGENE			English	Article						SIX1; epithelial-mesenchymal transition; colorectal cancer; ZEB1; miR-200 family; CDH1	TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; HOMEOPROTEIN SIX1; GENE-EXPRESSION; FEEDBACK LOOP; TUMOR PROGRESSION; METASTASIS; OVEREXPRESSION; REPRESSOR; FAMILY	Epithelial-mesenchymal transition (EMT) has a major role in cancer progression, as well as normal organ development and human pathology such as organ fibrosis and wound healing. Here, we performed a gene expression array specialized in EMT of colorectal cancer (CRC). From a comprehensive gene expression analysis using epithelial- and mesenchymal-like CRC cell lines, and following the ontology (GO) analysis, SIX1 gene was identified to be an EMT-related gene in CRC. Using SW480 cells stably transfected with a SIX1 expression construct and their control counterparts, we demonstrated that SIX1 overexpression represses CDH1 expression and promotes EMT in CRC. SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression. In primary tumors of CRC, in accord with the functional findings, aberrant expression of SIX1 in cancer cells was observed at the disruption of the basement membrane and at the tumor invasive front, where tumor cells underwent EMT in vivo. Taken together, SIX1 overexpression is suggested to occur in carcinogenesis, and contribute to repression of CDH1 expression and promotion of EMT partly through repression of miR-200-family expression and activation of ZEB1 in CRC. Oncogene (2012) 31, 4923-4934; doi:10.1038/onc.2011.646; published online 30 January 2012	[Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; [Ono, H.; Sugihara, K.] Tokyo Med & Dent Univ, Grad Sch, Dept Surg, Tokyo 1138510, Japan; [Imoto, I.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Human Genet, Tokushima 770, Japan; [Tsuda, H.] Natl Canc Ctr, Dept Pathol, Tokyo, Japan; [Tsuda, H.] Natl Canc Ctr, Clin Labs, Tokyo, Japan; [Matsui, T.] Tokyo Med & Dent Univ, Med Res Inst, Med Top Track Program, Tokyo 1138510, Japan; [Matsui, T.] Tokyo Med & Dent Univ, Sch Biomed Sci, Tokyo 1138510, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Global Ctr Excellence Program Frontier Res Mol De, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokushima University; National Cancer Center - Japan; National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Kozaki, Ken-ichi/M-6281-2014; Imoto, Issei/AAD-5799-2020; Matsui, Takeshi/C-4730-2017	Kozaki, Ken-ichi/0000-0003-3286-819X; 	Ministry of Education, Culture, Sports, Science, and Technology, Japan; Ministry of Health, Labour and Welfare, Japan; New Energy and Industrial Technology Development Organization (NEDO); Grants-in-Aid for Scientific Research [22134002, 23390077, 21790267] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); New Energy and Industrial Technology Development Organization (NEDO)(New Energy and Industrial Technology Development Organization (NEDO)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by grants-in-aid for Scientific Research (A), (B) (C) and on Priority Areas, and the Global Center of Excellence (GCOE) Program; International Research Center for Molecular Science in Tooth and Bone Diseases from the Ministry of Education, Culture, Sports, Science, and Technology, Japan; a Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan; and a grant from the New Energy and Industrial Technology Development Organization (NEDO). We thank Yoko Takagi, Ayako Takahashi, Rumi Mori and Kathy Masker for technical assistance.	Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Buck E, 2007, MOL CANCER THER, V6, P532, DOI 10.1158/1535-7163.MCT-06-0462; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Hajra KM, 2002, CANCER RES, V62, P1613; Haruki S, 2010, CARCINOGENESIS, V31, P1027, DOI 10.1093/carcin/bgq053; Hoshino H, 2009, BIOCHEM BIOPH RES CO, V390, P1061, DOI 10.1016/j.bbrc.2009.10.117; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Khanna C, 2001, CANCER RES, V61, P3750; Kumar JP, 2009, CELL MOL LIFE SCI, V66, P565, DOI 10.1007/s00018-008-8335-4; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Micalizzi DS, 2010, CANCER RES, V70, P10371, DOI 10.1158/0008-5472.CAN-10-1354; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Rodriguez S, 2008, DEV BIOL, V314, P40, DOI 10.1016/j.ydbio.2007.10.056; Roy HK, 2005, DIGEST DIS SCI, V50, P42, DOI 10.1007/s10620-005-1275-z; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Tanami H, 2005, LAB INVEST, V85, P1118, DOI 10.1038/labinvest.3700312; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wan F, 2008, INT J CANCER, V123, P32, DOI 10.1002/ijc.23463; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zheng WM, 2003, DEVELOPMENT, V130, P3989, DOI 10.1242/dev.00628	42	88	92	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	47					4923	4934		10.1038/onc.2011.646	http://dx.doi.org/10.1038/onc.2011.646			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22286765				2022-12-28	WOS:000311430200004
J	Sampson, ER; McMurray, HR; Hassane, DC; Newman, L; Salzman, P; Jordan, CT; Land, H				Sampson, E. R.; McMurray, H. R.; Hassane, D. C.; Newman, L.; Salzman, P.; Jordan, C. T.; Land, H.			Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery	ONCOGENE			English	Article						oncogene cooperation; gene expression; driver genes	HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID; CELL-CYCLE ARREST; MYC-INDUCED PROLIFERATION; PHASE-I; VALPROIC ACID; SODIUM PHENYLBUTYRATE; EXPRESSION; APOPTOSIS; P53	Malignant cell transformation commonly results in the deregulation of thousands of cellular genes, an observation that suggests a complex biological process and an inherently challenging scenario for the development of effective cancer interventions. To better define the genes/pathways essential to regulating the malignant phenotype, we recently described a novel strategy based on the cooperative nature of carcinogenesis that focuses on genes synergistically deregulated in response to cooperating oncogenic mutations. These so-called 'cooperation response genes' (CRGs) are highly enriched for genes critical for the cancer phenotype, thereby suggesting their causal role in the malignant state. Here, we show that CRGs have an essential role in drug-mediated anticancer activity and that anticancer agents can be identified through their ability to antagonize the CRG expression profile. These findings provide proof-of-concept for the use of the CRG signature as a novel means of drug discovery with relevance to underlying anticancer drug mechanisms.	[Sampson, E. R.; McMurray, H. R.; Newman, L.; Land, H.] Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA; [Hassane, D. C.; Jordan, C. T.] Univ Rochester, Med Ctr, Dept Hematol & Oncol, Rochester, NY 14642 USA; [Hassane, D. C.] Weill Cornell Med Coll, Dept Pathol & Lab Med, Inst Computat Biomed, New York, NY USA; [Salzman, P.] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA; [Land, H.] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; Cornell University; University of Rochester; University of Rochester	Land, H (corresponding author), Univ Rochester, Med Ctr, Dept Biomed Genet, 601 Elmwood Ave, Rochester, NY 14642 USA.	Land@urmc.rochester.edu	Hassane, Duane/AAA-3456-2021; jordan, craig/D-7666-2014	salzman, peter/0000-0001-8114-4863; McMurray, Helene/0000-0003-1738-8622; Hassane, Duane/0000-0002-0719-9572; jordan, craig/0000-0003-0869-3465	NIH [CA90663, CA120317, CA138249, GM075299, T32 CA09363, K99 LM009477]; James P Wilmot Cancer Center; NATIONAL CANCER INSTITUTE [R01CA120317, R01CA090663, R01CA138249, T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075299] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [K99LM009477] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James P Wilmot Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank Drs D Bohmann and M Noble for discussion, Drs A Burgess and R Whitehead for materials. This work was supported in part by NIH grants CA90663, CA120317, CA138249, GM075299, and a James P Wilmot Cancer Center pilot grant. HRM was supported in part by NIH T32 CA09363, PS by NIH K99 LM009477.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Angelucci A, 2006, ANTI-CANCER DRUG, V17, P1141, DOI 10.1097/01.cad.0000236302.89843.fc; Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851; Batty N, 2009, CANCER LETT, V280, P192, DOI 10.1016/j.canlet.2009.03.013; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Braiteh F, 2008, CLIN CANCER RES, V14, P6296, DOI 10.1158/1078-0432.CCR-08-1247; Butler LM, 2000, CANCER RES, V60, P5165; Carducci MA, 2001, CLIN CANCER RES, V7, P3047; Corsello SM, 2009, BLOOD, V113, P6193, DOI 10.1182/blood-2008-07-166090; Fantin VR, 2007, CLIN CANCER RES, V13, P7237, DOI 10.1158/1078-0432.CCR-07-2114; Friedman DR, 2009, CLIN CANCER RES, V15, P6947, DOI 10.1158/1078-0432.CCR-09-1132; Fritsche P, 2009, GUT; Gilbert J, 2001, CLIN CANCER RES, V7, P2292; Gore SD, 2002, CLIN CANCER RES, V8, P963; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hassane DC, 2008, BLOOD; HEERDT BG, 1994, CANCER RES, V54, P3288; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Kuendgen A, 2006, CANCER-AM CANCER SOC, V106, P112, DOI 10.1002/cncr.21552; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Li XN, 2005, MOL CANCER THER, V4, P1912, DOI 10.1158/1535-7163.MCT-05-0184; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; McMurray HR, 2008, NATURE, V453, P1112, DOI 10.1038/nature06973; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Mori S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006772; Munster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165; Patnaik A, 2002, CLIN CANCER RES, V8, P2142; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rochette PJ, 2005, J MOL BIOL, V352, P44, DOI 10.1016/j.jmb.2005.06.033; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takai N, 2004, CANCER-AM CANCER SOC, V101, P2760, DOI 10.1002/cncr.20709; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia MX, 2007, NAT STRUCT MOL BIOL, V14, P215, DOI 10.1038/nsmb1208; Zhang HT, 2007, ACTA PHARMACOL SIN, V28, P1783, DOI 10.1111/j.1745-7254.2007.00660.x; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	59	4	4	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3809	3818		10.1038/onc.2012.389	http://dx.doi.org/10.1038/onc.2012.389			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22964631	Green Accepted			2022-12-28	WOS:000323210200003
J	Yang, Y; Wu, J; Demir, A; Castillo-Martin, M; Melamed, RD; Zhang, G; Fukunaga-Kanabis, M; Perez-Lorenzo, R; Zheng, B; Silvers, DN; Brunner, G; Wang, S; Rabadan, R; Cordon-Cardo, C; Celebi, JT				Yang, Y.; Wu, J.; Demir, A.; Castillo-Martin, M.; Melamed, R. D.; Zhang, G.; Fukunaga-Kanabis, M.; Perez-Lorenzo, R.; Zheng, B.; Silvers, D. N.; Brunner, G.; Wang, S.; Rabadan, R.; Cordon-Cardo, C.; Celebi, J. T.			GAB2 induces tumor angiogenesis in NRAS-driven melanoma	ONCOGENE			English	Article						melanoma; angiogenesis; scaffold; adaptor	ADAPTER PROTEINS; CELLS; RAS; AMPLIFICATION; SUSCEPTIBILITY; STIMULATION; BRAF(V600E); ACTIVATION; MIGRATION; ONCOGENE	GAB2 is a scaffold protein with diverse upstream and downstream effectors. MAPK and PI3K signaling pathways are known effectors of GAB2. It is amplified and overexpressed in a variety of human tumors including melanoma. Here we show a previously undescribed role for GAB2 in NRAS-driven melanoma. Specifically, we found that GAB2 is co-expressed with mutant NRAS in melanoma cell lines and tumor samples and its expression correlated with metastatic potential. Co-expression of GAB2(WT) and NRAS(G12D) in melanocytes and in melanoma cells increased anchorage-independent growth by providing GAB2-expressing cells a survival advantage through upregulation of BCL-2 family of anti-apoptotic factors. Of note, collaboration of GAB2 with mutant NRAS enhanced tumorigenesis in vivo and led to an increased vessel density with strong CD34 and VEGFR2 activity. We found that GAB2 facilitiated an angiogenic switch by upregulating HIF-1 alpha and VEGF levels. This angiogenic response was significantly suppressed with the MEK inhibitor PD325901. These data suggest that GAB2-mediated signaling cascades collaborate with NRAS-driven downstream activation for conferring an aggressive phenotype in melanoma. Second, we show that GAB2/NRAS signaling axis is non-linear and non-redundant in melanocytes and melanoma, and thus are acting independent of each other. Finally, we establish a link between GAB2 and angiogenesis in melanoma for the first time. In conclusion, our findings provide evidence that GAB2 is a novel regulator of tumor angiogenesis in NRAS-driven melanoma through regulation of HIF-1 alpha and VEGF expressions mediated by RAS-RAF-MEK-ERK signaling.	[Yang, Y.; Wu, J.; Demir, A.; Perez-Lorenzo, R.; Zheng, B.; Silvers, D. N.; Celebi, J. T.] Columbia Univ, Dept Dermatol, New York, NY 10032 USA; [Castillo-Martin, M.; Cordon-Cardo, C.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA; [Melamed, R. D.; Rabadan, R.] Columbia Univ, Dept Bioinformat, New York, NY 10032 USA; [Zhang, G.; Fukunaga-Kanabis, M.] Wistar Inst Anat & Biol, Melanoma Res Ctr, Philadelphia, PA 19104 USA; [Perez-Lorenzo, R.; Zheng, B.; Silvers, D. N.] Columbia Univ, Dept Pathol, New York, NY 10032 USA; [Brunner, G.] Fachklin Hornheide, Dept Canc Res, Munster, Germany; [Wang, S.] Columbia Univ, Dept Biostat, New York, NY 10032 USA	Columbia University; Icahn School of Medicine at Mount Sinai; Columbia University; The Wistar Institute; Columbia University; Columbia University	Celebi, JT (corresponding author), Columbia Univ, Dept Dermatol, 1150 St,St Nicholas Ave,Room 318, New York, NY 10032 USA.	jt165@columbia.edu	Zhang, Gao/D-3471-2017; DEMIR, AHU/A-5650-2015; Castillo-Martin, Mireia/H-6152-2013; Rabadan, Raul/AAZ-7367-2020	DEMIR, AHU/0000-0001-9276-6318; Zheng, Bin/0000-0002-0998-7177; Perez-Lorenzo, Rolando/0000-0002-9355-9617; Melamed, Rachel/0000-0003-3089-9806; Rabadan, Raul/0000-0001-7946-9255	NIH/NCI [RO1 CA138678]; Dow Foundation; Neuberger Dorothy Rodbell Cohen Foundation; NATIONAL CANCER INSTITUTE [R01CA138678, U54CA121852] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Dow Foundation; Neuberger Dorothy Rodbell Cohen Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work has been supported by grants from the NIH/NCI RO1 CA138678 to JTC, the Dow Foundation to JTC and the Neuberger Dorothy Rodbell Cohen Foundation to JTC. We appreciate the technical assistance of Ruzhen Chen, Tasneem Fatima, Yan Lu, Rong Du and Tingting Wu. We are grateful to the following Shared Resources of the Herbert Irving Comprehensive Cancer Center, Pathology Shared Resource, Flow Cytometry Shared Resource, and Confocal & Microscopy Shared Resource, as well as to the Department of Dermatology's Skin Diseases Research Center Cell Culture Core and Division of Dermatopathology.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bennett HL, 2008, ONCOGENE, V27, P2693, DOI 10.1038/sj.onc.1210928; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Bocanegra M, 2010, ONCOGENE, V29, P774, DOI 10.1038/onc.2009.364; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Caron C, 2009, CELL SIGNAL, V21, P943, DOI 10.1016/j.cellsig.2009.02.004; Chernoff KA, 2009, CLIN CANCER RES, V15, P4288, DOI 10.1158/1078-0432.CCR-09-0280; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; D'Alessio A, 2007, CELL SIGNAL, V19, P1193, DOI 10.1016/j.cellsig.2006.12.011; Dance M, 2006, J BIOL CHEM, V281, P23285, DOI 10.1074/jbc.M600987200; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dickson PV, 2011, SURG ONCOL CLIN N AM, V20, P1, DOI 10.1016/j.soc.2010.09.007; Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227; Gerhardt Holger, 2008, P68, DOI 10.1007/978-0-387-78632-2_6; Gershenwald JE, 2010, ANN SURG ONCOL, V17, P1475, DOI 10.1245/s10434-010-0986-3; Ghosh Papia, 2009, Expert Rev Dermatol, V4, P131, DOI 10.1586/edm.09.2; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kameda H, 2006, CLIN EXP IMMUNOL, V144, P335, DOI 10.1111/j.1365-2249.2006.03067.x; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; Laramee M, 2007, J BIOL CHEM, V282, P7758, DOI 10.1074/jbc.M611327200; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; Lu Y, 2011, P NATL ACAD SCI USA, V108, P2957, DOI 10.1073/pnas.1009395108; Mao YW, 2005, J CELL BIOL, V170, P305, DOI 10.1083/jcb.200505061; Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229; Milagre C, 2010, CANCER RES, V70, P5549, DOI 10.1158/0008-5472.CAN-09-4254; Mishra PJ, 2010, ONCOGENE, V29, P2449, DOI 10.1038/onc.2009.521; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; Nishida K, 2003, CANCER SCI, V94, P1029, DOI 10.1111/j.1349-7006.2003.tb01396.x; Petti C, 2006, CANCER RES, V66, P6503, DOI 10.1158/0008-5472.CAN-05-4671; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Sun JM, 2008, J BIOL CHEM, V283, P27444, DOI 10.1074/jbc.M709703200; Tsatsanis C, 2004, ANN NY ACAD SCI, V1028, P168, DOI 10.1196/annals.1322.019; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wozniak A, 2012, CRIT REV ONCOL HEMAT, V82, P200, DOI 10.1016/j.critrevonc.2011.05.003; Zatkova A, 2006, GENE CHROMOSOME CANC, V45, P798, DOI 10.1002/gcc.20344	53	17	18	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3627	3637		10.1038/onc.2012.367	http://dx.doi.org/10.1038/onc.2012.367			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22926523	hybrid, Green Accepted			2022-12-28	WOS:000322638400007
J	Li, Z; Hann, SR				Li, Z.; Hann, S. R.			Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription	ONCOGENE			English	Article						c-Myc; NPM/B23; nucleolus; rRNA	RIBOSOMAL DNA; PROTEIN; DEGRADATION; CELLS; STABILIZATION; ACCUMULATION; PROTEOLYSIS; ISOFORM; NETWORK; PATHWAY	The transcription factor c-Myc has a critical role in cell proliferation and growth. The control of ribosome biogenesis by c-Myc through the regulation of transcription mediated by all three RNA polymerases is essential for c-Myc-driven proliferation. Specifically, in the nucleolus, c-Myc has been shown to be recruited to ribosomal DNA and activate RNA polymerase (pol) I-mediated transcription of ribosomal RNA (rRNA) genes. In addition, c-Myc accumulates in nucleoli upon inhibition of the proteasome, suggesting nucleolar localization also has a role in c-Myc proteolysis. Nucleophosmin (NPM), a predominantly nucleolar protein, is also critical in ribosome biogenesis and, like c-Myc, is found overexpressed in many types of tumors. Previously, we demonstrated that NPM directly interacts with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Here, we show that NPM is necessary for the localization of c-Myc protein to nucleoli, whereas c-Myc nucleolar localization is independent of p53, Mdm2 and ARF. Conversely, high transient NPM expression enhances c-Myc nucleolar localization, leading to increased c-Myc proteolysis. In addition, NPM is necessary for the ability of c-Myc to induce rRNA synthesis in the nucleolus, and constitutive NPM overexpression stimulates c-Myc-mediated rRNA synthesis. Taken together, these results demonstrate an essential role for NPM in c-Myc nucleolar localization and c-Myc-mediated rDNA transcription. Oncogene (2013) 32, 1988-1994; doi:10.1038/onc.2012.227; published online 4 June 2012	[Li, Z.; Hann, S. R.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University	Hann, SR (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, MCN B-2317, Nashville, TN 37232 USA.	steve.hann@vanderbilt.edu			NCI [RO1 CA109586, CA125760]; NATIONAL CANCER INSTITUTE [R01CA109586, R01CA125760, R56CA109586] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank C Pfarr for pCMV14-NPM-Flag vector, S McMahon for pSUPER retro vector, E Lee for the anti-HA (12CA5), W Tansey for pCGN-HA-Myc1-220 and pCGN-HA-Myc221-439 vectors, E Colombo and PG Pelicci for NPM<SUP>-/-</SUP> p53<SUP>-/-</SUP> MEFs, G Zambetti for ARF<SUP>-/-</SUP> p53<SUP>-/-</SUP> MEFs, E Ruley for p53<SUP>-/-</SUP> MEFs and J Sedivy for c-myc<SUP>-/-</SUP> cells. This work was supported by grants RO1 CA109586 and CA125760 from NCI to SRH.	Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Boisvert FM, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.011429; Bonetti P, 2008, J CELL BIOL, V182, P19, DOI 10.1083/jcb.200711040; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grim JE, 2008, J CELL BIOL, V181, P913, DOI 10.1083/jcb.200802076; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Li J, 2007, CARCINOGENESIS, V28, P1163, DOI 10.1093/carcin/bgm025; Li ZL, 2009, CELL CYCLE, V8, P2703, DOI 10.4161/cc.8.17.9418; Li ZL, 2008, P NATL ACAD SCI USA, V105, P18794, DOI 10.1073/pnas.0806879105; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Murano K, 2008, MOL CELL BIOL, V28, P3114, DOI 10.1128/MCB.02078-07; Okuwaki M, 2008, J BIOCHEM, V143, P441, DOI 10.1093/jb/mvm222; Poortinga G, 2011, NUCLEIC ACIDS RES, V39, P3267, DOI 10.1093/nar/gkq1205; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sanders JA, 2005, BBA-MOL CELL RES, V1743, P141, DOI 10.1016/j.bbamcr.2004.09.009; Shiue CN, 2009, ONCOGENE, V28, P1833, DOI 10.1038/onc.2009.21; Sirri V, 2008, HISTOCHEM CELL BIOL, V129, P13, DOI 10.1007/s00418-007-0359-6; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Stoldt S, 2007, BIOL CELL, V99, P541, DOI 10.1042/BC20060117; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	34	39	39	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1988	1994		10.1038/onc.2012.227	http://dx.doi.org/10.1038/onc.2012.227			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22665062	Green Accepted			2022-12-28	WOS:000317599900013
J	Li, Q; Yang, XH; Xu, F; Sharma, C; Wang, HX; Knoblich, K; Rabinovitz, I; Granter, SR; Hemler, ME				Li, Q.; Yang, X. H.; Xu, F.; Sharma, C.; Wang, H-X; Knoblich, K.; Rabinovitz, I.; Granter, S. R.; Hemler, M. E.			Tetraspanin CD151 plays a key role in skin squamous cell carcinoma	ONCOGENE			English	Article						tetraspanin CD151; skin squamous cell carcinoma; chemical carcinogenesis; integrin alpha 6 beta 4; STAT3; PKC alpha	TRANSMEMBRANE 4 SUPERFAMILY; KERATINOCYTE STEM-CELLS; ALPHA-6-BETA-4 INTEGRIN; BETA-4 INTEGRIN; MICE LACKING; MALIGNANT PROGRESSION; PROSTATE-CANCER; IN-VIVO; KINASE; STAT3	Here we provide the first evidence that tetraspanin CD151 can support de novo carcinogenesis. During two-stage mouse skin chemical carcinogenesis, CD151 reduces tumor lag time and increases incidence, multiplicity, size and progression to malignant squamous cell carcinoma (SCC), while supporting both cell survival during tumor initiation and cell proliferation during the promotion phase. In human skin SCC, CD151 expression is selectively elevated compared with other skin cancer types. CD151 support of keratinocyte survival and proliferation may depend on activation of transcription factor STAT3 (signal transducers and activators of transcription), a regulator of cell proliferation and apoptosis. CD151 also supports protein kinase C (PKC)alpha-alpha 6 beta 4 integrin association and PKC-dependent beta 4 S1424 phosphorylation, while regulating alpha 6 beta 4 distribution. CD151-PKC alpha effects on integrin beta 4 phosphorylation and subcellular localization are consistent with epithelial disruption to a less polarized, more invasive state. CD151 ablation, while minimally affecting normal cell and normal mouse functions, markedly sensitized mouse skin and epidermoid cells to chemicals/drugs including 7,12-dimethylbenz[alpha]anthracene (mutagen) and camptothecin (topoisomerase inhibitor), as well as to agents targeting epidermal growth factor receptor, PKC, Jak2/Tyk2 and STAT3. Hence, CD151 'co-targeting' may be therapeutically beneficial. These findings not only support CD151 as a potential tumor target, but also should apply to other cancers utilizing CD151/laminin-binding integrin complexes. Oncogene (2013) 32, 1772-1783; doi: 10.1038/onc.2012.205; published online 23 July 2012	[Li, Q.; Xu, F.; Sharma, C.; Wang, H-X; Knoblich, K.; Hemler, M. E.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; [Li, Q.; Xu, F.; Sharma, C.; Wang, H-X; Knoblich, K.; Rabinovitz, I.; Hemler, M. E.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Yang, X. H.] Univ Kentucky, Dept Mol & Biomed Pharmacol, Lexington, KY USA; [Rabinovitz, I.] Beth Israel Deaconess Med Ctr, Div Canc Biol & Angiogenesis, Dept Pathol, Boston, MA 02215 USA; [Granter, S. R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Kentucky; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Hemler, ME (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Room D1430,44 Binney St, Boston, MA 02115 USA.	martin_hemler@dfci.harvard.edu	Knoblich, Konstantin/B-5980-2009; Li, Qinglin/K-2570-2015	Knoblich, Konstantin/0000-0002-5646-837X; Li, Qinglin/0000-0002-4125-1944	NIH [CA42368]; SG Komen Career Catalyst Award; NATIONAL CANCER INSTITUTE [R01CA042368] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SG Komen Career Catalyst Award(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr R Bronson for assistance with mouse histopathology, Dr Julie Aldridge for assistance with statistical analyses, and Drs David Frank, Sarah Walker and coworkers for nifuroxazide, ST3-01, assistance with STAT3 functional assay and helpful discussions. This work was supported by NIH grant CA42368 (to MEH), and a SG Komen Career Catalyst Award (to XHY).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Alam M, 2001, NEW ENGL J MED, V344, P975, DOI 10.1056/NEJM200103293441306; Ang J, 2004, CANCER EPIDEM BIOMAR, V13, P1717; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Baldwin G, 2008, J BIOL CHEM, V283, P35445, DOI 10.1074/jbc.M806394200; Baleato RM, 2008, AM J PATHOL, V173, P927, DOI 10.2353/ajpath.2008.071149; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Chan KS, 2008, ONCOGENE, V27, P1087, DOI 10.1038/sj.onc.1210726; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Charrin S, 2003, BIOCHEM BIOPH RES CO, V304, P107, DOI 10.1016/S0006-291X(03)00545-X; Cowin AJ, 2006, J INVEST DERMATOL, V126, P680, DOI 10.1038/sj.jid.5700142; Crew VK, 2004, BLOOD, V104, P2217, DOI 10.1182/blood-2004-04-1512; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; de Wit J, 2011, BLOOD, V118, P6107, DOI 10.1182/blood-2011-05-352682; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dudley Andrew C, 2004, Cell Commun Signal, V2, P8, DOI 10.1186/1478-811X-2-8; Fitter S, 1999, BIOCHEM J, V338, P61, DOI 10.1042/0264-6021:3380061; Franco M, 2010, J BIOL CHEM, V285, P38756, DOI 10.1074/jbc.M110.145417; Frank DA, 2007, CANCER LETT, V251, P199, DOI 10.1016/j.canlet.2006.10.017; Frijns E, 2010, J BIOL CHEM, V285, P37650, DOI 10.1074/jbc.M110.138818; Germain EC, 2009, MOL BIOL CELL, V20, P56, DOI 10.1091/mbc.E08-06-0646; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Hara T, 2005, CANCER RES, V65, P7356, DOI 10.1158/0008-5472.CAN-04-4241; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Kangsamaksin T, 2007, MOL CARCINOGEN, V46, P579, DOI 10.1002/mc.20355; Kashyap T, 2011, LAB INVEST, V91, P1414, DOI 10.1038/labinvest.2011.104; Kazarov AR, 2002, J CELL BIOL, V158, P1299, DOI 10.1083/jcb.200204056; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; Kim DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010290; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; Madoux F., 2010, MODULATORS STAT TRAN; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Nelson EA, 2008, BLOOD, V112, P5095, DOI 10.1182/blood-2007-12-129718; Owens DM, 2001, CANCER RES, V61, P5248; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rajasekhar VK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1159; Raymond K, 2007, MOL BIOL CELL, V18, P4210, DOI 10.1091/mbc.E06-08-0720; Romanska HM, 2011, J PATHOL, V223, P4, DOI 10.1002/path.2779; Sachs N, 2006, J CELL BIOL, V175, P33, DOI 10.1083/jcb.200603073; Sadej R, 2009, MOL CANCER RES, V7, P787, DOI 10.1158/1541-7786.MCR-08-0574; Sattler M, 2003, CANCER RES, V63, P5462; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Sheng KC, 2009, EUR J IMMUNOL, V39, P50, DOI 10.1002/eji.200838798; Sincock PM, 1999, J CELL SCI, V112, P833; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404; Sterk LMT, 2002, J CELL SCI, V115, P1161; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; Stipp CS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001355; Syed ZA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-180; Takeda Y, 2007, BLOOD, V109, P1524, DOI 10.1182/blood-2006-08-041970; Takeda Y, 2011, BLOOD, V118, P464, DOI 10.1182/blood-2010-08-302240; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; TENNENBAUM T, 1993, CANCER RES, V53, P4803; Tokura Yoshiki, 2010, Journal of UOEH, V32, P317; Torrero MN, 2006, CLIN CANCER RES, V12, P257, DOI 10.1158/1078-0432.CCR-05-1514; Tran M, 2008, CANCER RES, V68, P2885, DOI 10.1158/0008-5472.CAN-07-6160; Voss MA, 2011, BRIT J CANCER, V104, P1611, DOI 10.1038/bjc.2011.80; Weinberg AS, 2007, DERMATOL SURG, V33, P885, DOI 10.1111/j.1524-4725.2007.33190.x; Wilhelmsen K, 2007, MOL BIOL CELL, V18, P3512, DOI 10.1091/mbc.E07-04-0306; Winterwood NE, 2006, MOL BIOL CELL, V17, P2707, DOI 10.1091/mbc.E05-11-1042; Wright MD, 2004, MOL CELL BIOL, V24, P5978, DOI 10.1128/MCB.24.13.5978-5988.2004; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yang XWH, 2008, CANCER RES, V68, P3204, DOI 10.1158/0008-5472.CAN-07-2949; Yang XWH, 2012, J CELL SCI, V125, P1478, DOI 10.1242/jcs.093963; Yang XWH, 2010, CANCER RES, V70, P2256, DOI 10.1158/0008-5472.CAN-09-4032; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	77	58	62	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1772	1783		10.1038/onc.2012.205	http://dx.doi.org/10.1038/onc.2012.205			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22824799	Green Accepted, Green Submitted			2022-12-28	WOS:000317043900004
J	Rybanska, I; Ishaq, O; Chou, J; Prakash, M; Bakhsheshian, J; Huso, DL; Franco, S				Rybanska, I.; Ishaq, O.; Chou, J.; Prakash, M.; Bakhsheshian, J.; Huso, D. L.; Franco, S.			PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis	ONCOGENE			English	Article						telomere; DNA-PKcs; PARP1; p53; lymphoma; mutation	DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; POLY(ADP-RIBOSE) POLYMERASE; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; ONCOGENIC TRANSLOCATIONS; GENOMIC INSTABILITY; CHROMOSOME BREAKS; DAMAGE CHECKPOINT; REPAIR PROTEINS	Poly(ADP-ribose) polymerase 1 (PARP1) interacts genetically with the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to suppress early-onset T-lineage lymphomas in the mouse, but the underlying mechanisms have remained unknown. To address this question, we analyzed a series of lymphomas arising in PARP1(-/-)/DNA-PKcs(-/-) (P1(-/-)/D-/-) mice. We found that, despite defective V(D)J recombination, P1(-/-)/D-/- lymphomas lacked clonal reciprocal translocations involving antigen-receptor loci. Instead, tumor cells were characterized by aneuploidy driven by two main mechanisms: p53 inactivation and abnormal chromosome disjunction due to telomere fusions (TFs). Aberrant accumulation of p53 was observed in 13/19 (68.4%) lymphomas. Sequence analysis revealed five p53 mutations: three missense point mutations (one transition in exon 8 and two transversions in exons 5 and 8, respectively), one in-frame 5-11 microindel in exon 7 and a 410-bp deletion encompassing exons 5-8, resulting in a truncated protein. Analysis of tumor metaphases using sequential telomere fluorescent in-situ hybridization and spectral karyotyping revealed that nine out of nine lymphomas contained TFs. Mutant but not wild-type p53 status was associated with frequent clonal and nonclonal TFs, suggesting that p53 normally limits the extent of telomere dysfunction during transformation. Chromosomes involved in TFs were more likely to be aneuploid than chromosomes not involved in TFs in the same metaphases, regardless of the p53 status, indicating that TFs promote aneuploidy via a mechanism that is distinct from p53 loss. Finally, analysis of radiation responses in P1(-/-)/D-/-, and control primary cells and tissues indicates that loss of PARP1 increases in vivo radiosensitivity and genomic instability in DNA-PKcs-deficient mice without impairing p53 stabilization and effector functions, suggesting a more severe defect in double-strand break (DSB) repair in double mutants. Together, our findings uncover defective DSB repair leading to tumor suppressor inactivation and abnormal segregation of fused chromosomes as two novel mechanisms promoting tumorigenesis in thymocytes lacking PARP1 and DNA-PKcs. Oncogene (2013) 32, 1761-1771; doi: 10.1038/onc.2012.199; published online 21 May 2012	[Rybanska, I.; Ishaq, O.; Chou, J.; Prakash, M.; Bakhsheshian, J.; Franco, S.] Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Canc Ctr, Baltimore, MD 21287 USA; [Rybanska, I.; Ishaq, O.; Chou, J.; Prakash, M.; Bakhsheshian, J.; Franco, S.] Johns Hopkins Univ, Dept Oncol, Sidney Kimmel Canc Ctr, Baltimore, MD 21287 USA; [Huso, D. L.] Johns Hopkins Univ, Dept Mol & Comparat Pathobiol, Baltimore, MD 21287 USA; [Huso, D. L.] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Franco, S (corresponding author), Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Canc Ctr, 1550 Orleans St,CRB 2 Room 405, Baltimore, MD 21287 USA.	sfranco2@jhmi.edu		Bakhsheshian, Joshua/0000-0003-2983-6082	NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA006973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahel D, 2009, SCIENCE, V325, P1240, DOI 10.1126/science.1177321; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2004, DNA REPAIR, V3, P349, DOI 10.1016/j.dnarep.2003.11.007; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Cesare AJ, 2010, NAT REV GENET, V11, P319, DOI 10.1038/nrg2763; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Davoli T, 2010, CELL, V141, P81, DOI 10.1016/j.cell.2010.01.031; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; di Fagagna FD, 1999, NAT GENET, V23, P76; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Espejel S, 2004, EMBO REP, V5, P503, DOI 10.1038/sj.embor.7400127; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Franco S, 2008, J EXP MED, V205, P557, DOI 10.1084/jem.20080044; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gomez M, 2006, MOL BIOL CELL, V17, P1686, DOI 10.1091/mbc.E05-07-0672; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Gurley KE, 1998, CANCER RES, V58, P3111; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Jordan JJ, 2010, MOL CANCER RES, V8, P701, DOI 10.1158/1541-7786.MCR-09-0442; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Maser RS, 2007, MOL CELL BIOL, V27, P2253, DOI 10.1128/MCB.01354-06; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; McIlrath J, 2001, CANCER RES, V61, P912; Meek K, 2008, ADV IMMUNOL, V99, P33, DOI 10.1016/S0065-2776(08)00602-0; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Mitchell J, 2009, INT J RADIAT ONCOL, V75, P1520, DOI 10.1016/j.ijrobp.2009.07.1722; Miyazaki M, 2008, IMMUNITY, V28, P231, DOI 10.1016/j.immuni.2007.12.013; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Orsburn B, 2010, MOL CELL BIOL, V30, P2341, DOI 10.1128/MCB.00091-10; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Piskunova Tatiana S, 2008, Curr Gerontol Geriatr Res, P754190, DOI 10.1155/2008/754190; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Qi L, 2005, NAT CELL BIOL, V7, P706, DOI 10.1038/ncb1276; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Scaringe WA, 2008, HUM MOL GENET, V17, P2910, DOI 10.1093/hmg/ddn190; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shibata A, 2005, ONCOGENE, V24, P1328, DOI 10.1038/sj.onc.1208289; Shibata A, 2009, MUTAT RES-FUND MOL M, V664, P20, DOI 10.1016/j.mrfmmm.2009.02.001; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stimpson KM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001061; Stracker TH, 2008, MOL CELL, V31, P21, DOI 10.1016/j.molcel.2008.04.028; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Veuger SJ, 2003, CANCER RES, V63, P6008; Veuger SJ, 2004, ONCOGENE, V23, P7322, DOI 10.1038/sj.onc.1207984; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	69	10	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1761	1771		10.1038/onc.2012.199	http://dx.doi.org/10.1038/onc.2012.199			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22614020	Green Accepted			2022-12-28	WOS:000317043900003
J	Ahlqvist, K; Saamarthy, K; Khaja, ASS; Bjartell, A; Massoumi, R				Ahlqvist, K.; Saamarthy, K.; Khaja, A. S. Syed; Bjartell, A.; Massoumi, R.			Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer	ONCOGENE			English	Article						Bcl-3; prostate cancer; interleukin-6; inhibitor of DNA binding (Id)	NF-KAPPA-B; PROLIFERATIVE INFLAMMATORY ATROPHY; PROMOTES CELL-SURVIVAL; BREAST-CANCER; ACTIVATION; APOPTOSIS; PATHWAY; NF-KAPPA-B2/P52; INTERLEUKIN-6; INHIBITOR	B-cell leukemia 3 (Bcl-3) is a member of the inhibitor of kappa B family, which regulates a wide range of biological processes by functioning as a transcriptional activator or as a repressor of target genes. As high levels of Bcl-3 expression and activation have been detected in different types of human cancer, Bcl-3 has been labeled a proto-oncogene. Our study uncovered a markedly upregulated Bcl-3 expression in human prostate cancer (PCa), where inflammatory cell infiltration was observed. Elevated Bcl-3 expression in PCa was dependent on the proinflammatory cytokine interleukin-6-mediated STAT3 activation. Microarray analyses, using Bcl-3 knockdown in PCa cells, identified the inhibitor of DNA-binding (Id) family of helix-loop-helix proteins as potential Bcl-3-regulated genes. Bcl-3 knockdown reduced the abundance of Id-1 and Id-2 proteins and boosted PCa cells to be more receptive to undergoing apoptosis following treatment with anticancer drug. Our data imply that inactivation of Bcl-3 may lead to sensitization of cancer cells to chemotherapeutic drug-induced apoptosis, thus suggesting a potential therapeutic strategy in PCa treatment. Oncogene (2013) 32, 1601-1608; doi:10.1038/onc.2012.175; published online 14 May 2012	[Ahlqvist, K.; Saamarthy, K.; Massoumi, R.] Lund Univ, Skane Univ Hosp, Dept Lab Med, Ctr Mol Tumor Pathol, SE-20502 Malmo, Sweden; [Khaja, A. S. Syed; Bjartell, A.] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Div Urol Canc, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Massoumi, R (corresponding author), Lund Univ, Skane Univ Hosp, Dept Lab Med, SUS, Entrance 78,2nd Floor, SE-20502 Malmo, Sweden.	Ramin.Massoumi@med.lu.se	Massoumi, Ramin/AAG-4786-2019; Syed Khaja, Azharuddin Sajid/AAF-2693-2021	Syed Khaja, Azharuddin Sajid/0000-0003-1594-1826	Swedish Society for Medical Research; Swedish Cancer Foundation; Swedish Medical Research Council; Royal Physiographic Society in Lund; U-MAS Research Foundations; European Research Council under the European Union [260460]	Swedish Society for Medical Research; Swedish Cancer Foundation; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Royal Physiographic Society in Lund; U-MAS Research Foundations; European Research Council under the European Union(European Research Council (ERC))	We thank Elise Nilsson for excellent technical assistance, Dr Zoran Culig (Innsbruck Medical University, Austria) for providing us the LNCaP-IL-6<SUP>+</SUP> cells, Dr Takashi Tokino (Cancer Research Institute, Sapporo, Japan) for human Id-2 promoter luciferase reporter construct, Dr Roland M Schmid (Technical University Munich, Munich, Germany) for FLAG-Bcl-3 expression construct, Dr David Ulmert (Lund University, Lund, Sweden) for characterization of the human PCa tissue microarray and Dr Srinivas Veerla (SCIBLU, Lund University, Lund, Sweden) for microarray analysis and gene expression profiling. This work was supported by the Swedish Society for Medical Research, Swedish Cancer Foundation, Swedish Medical Research Council, Royal Physiographic Society in Lund, U-MAS Research Foundations, and funding from the European Research Council under the European Union's seventh framework program ERC grant agreement (260460 to RM).	Brocke-Heidrich K, 2006, ONCOGENE, V25, P7297, DOI 10.1038/sj.onc.1209711; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Cai C, 2011, PATHOL ONCOL RES, V17, P873, DOI 10.1007/s12253-011-9396-5; Cheung HW, 2004, CARCINOGENESIS, V25, P881, DOI 10.1093/carcin/bgh087; Choi HJ, 2010, BIOCHEM BIOPH RES CO, V400, P396, DOI 10.1016/j.bbrc.2010.08.084; Chung TDK, 2000, PROSTATE, V42, P1; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; CORREA P, 1992, CANCER RES, V52, P6735; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140-6736(08)60729-1; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Forootan SS, 2007, HUM PATHOL, V38, P1321, DOI 10.1016/j.humpath.2007.02.011; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hobisch A, 2000, J PATHOL, V191, P239, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X; Hobisch A, 2001, CLIN CANCER RES, V7, P2941; Hua H, 2007, ENDOCRINE, V32, P329, DOI 10.1007/s12020-008-9039-0; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kashatus D, 2006, GENE DEV, V20, P225, DOI 10.1101/gad.1352206; Keutgens A, 2010, MOL CELL BIOL, V30, P4006, DOI 10.1128/MCB.01600-09; Kim H, 2008, BREAST CANCER RES TR, V112, P287, DOI 10.1007/s10549-007-9871-6; Kuphal S, 2011, ONCOGENE, V30, P4523, DOI 10.1038/onc.2011.163; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; Monticelli LA, 2009, P NATL ACAD SCI USA, V106, P19461, DOI 10.1073/pnas.0908249106; Nadiminty N, 2010, CANCER RES, V70, P3309, DOI 10.1158/0008-5472.CAN-09-3703; Nadiminty N, 2008, PROSTATE, V68, P1725, DOI 10.1002/pros.20839; Paule B, 2007, WORLD J UROL, V25, P477, DOI 10.1007/s00345-007-0175-6; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Smith PC, 2001, PROSTATE, V48, P47; Sottnik JL, 2011, CANCER MICROENVIRON, V4, P283, DOI 10.1007/s12307-011-0073-8; Thornburg NJ, 2003, CANCER RES, V63, P8293; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Wong YC, 2008, ADV EXP MED BIOL, V617, P565, DOI 10.1007/978-0-387-69080-3_58; Zha S, 2001, CANCER RES, V61, P8617; Zhang HM, 2007, AM J PATHOL, V171, P1113, DOI 10.2353/ajpath.2007.070226; Zhang XM, 2007, J BIOL CHEM, V282, P33284, DOI 10.1074/jbc.M705089200; Zhang XM, 2007, CANCER SCI, V98, P308, DOI 10.1111/j.1349-7006.2007.00400.x; Zhang XM, 2006, INT J CANCER, V118, P2072, DOI 10.1002/ijc.21592; Zielinski AJ, 2010, INT J CANCER, V126, P2490, DOI 10.1002/ijc.24811	45	30	35	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1601	1608		10.1038/onc.2012.175	http://dx.doi.org/10.1038/onc.2012.175			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22580608				2022-12-28	WOS:000316456000013
J	Galeano, F; Rossetti, C; Tomaselli, S; Cifaldi, L; Lezzerini, M; Pezzullo, M; Boldrini, R; Massimi, L; Di Rocco, CM; Locatelli, F; Gallo, A				Galeano, F.; Rossetti, C.; Tomaselli, S.; Cifaldi, L.; Lezzerini, M.; Pezzullo, M.; Boldrini, R.; Massimi, L.; Di Rocco, C. M.; Locatelli, F.; Gallo, A.			ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis	ONCOGENE			English	Article						RNA editing; ADAR2; GBM; cell cycle; CDC14B	TO-INOSINE RNA; MESSENGER-RNA; DOWN-REGULATION; EDITING SITES; CELL-CYCLE; SKP2; ENZYME; P21; IDENTIFICATION; HYBRIDIZATION	Grade IV astrocytoma or glioblastoma multiforme (GBM) is one of the most aggressive and lethal tumors affecting humans. ADAR2-mediated A-to-I RNA editing, an essential post-transcriptional modification event in brain, is impaired in GBMs and astrocytoma cell lines. However, the role of ADAR2 editing in astrocytomas remains to be defined. Here, we show that ADAR2 editing rescue in astrocytomas prevents tumor growth in vivo and modulates an important cell cycle pathway involving the Skp2/p21/p27 proteins, often altered in glioblastoma. We demonstrate that ADAR2 deaminase activity is essential to inhibit tumor growth. Indeed, we identify the phosphatase CDC14B, which acts upstream of the Skp2/p21/p27 pathway, as a novel and critical ADAR2 target gene involved in glioblastonna growth. Specifically, ADAR2-mediated editing on CDC14B pre-mRNA increases its expression with a consequent reduction of the Skp2 target protein, as shown both in vitro and in vivo. We found that, compared to normal brain, both CDC14B editing and expression are progressively impaired in astrocytomas from grade I to IV, being very low in GBMs. These findings (1) demonstrate that post-transcriptional A-to-I RNA editing might be crucial for glioblastoma pathogenesis, (2) identify ADAR2-editing enzyme as a novel candidate tumor suppressor gene and (3) provide proof of principle that ADAR2 or its substrates may represent a suitable target(s) for possible novel, more effective and less toxic approaches to the treatment of GBMs. Oncogene (2013) 32, 998-1009; doi:10.1038/onc.2012.125; published online 23 April 2012	[Galeano, F.; Rossetti, C.; Tomaselli, S.; Cifaldi, L.; Lezzerini, M.; Pezzullo, M.; Boldrini, R.; Locatelli, F.; Gallo, A.] IRCCS, Osped Pediat Bambino Gesu, Oncohaematol Dept, Lab RNA Editing, I-00165 Rome, Italy; [Massimi, L.; Di Rocco, C. M.] Policlin Gemelli, Pediat Neurosurg Dept, Rome, Italy; [Locatelli, F.] Univ Pavia, Oncohaematol Dept, I-27100 Pavia, Italy	IRCCS Bambino Gesu; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Pavia	Gallo, A (corresponding author), IRCCS, Osped Pediat Bambino Gesu, Oncohaematol Dept, Lab RNA Editing, Piazza S Onofrio 4, I-00165 Rome, Italy.	angela.gallo@opbg.net	Gallo, Angela/E-7837-2011; Gallo, Angela/AAA-5003-2020; Pezzullo, Marco/AAI-2404-2019; Cifaldi, Loredana/AAI-1972-2019	Gallo, Angela/0000-0003-0297-1807; Gallo, Angela/0000-0003-0297-1807; Cifaldi, Loredana/0000-0001-5014-430X	Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan, Italy); AIRC	Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan, Italy)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro)	This study was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan, Italy) grant to A Gallo and a special project 5 x 1000 AIRC grant to F Locatelli. The authors are grateful to Genevieve Rodier for the CDC14B clones, to Alekos Athanasiadis and to Ernesto Picardi for bioinformatics support and to Mattia Locatelli for statistical analysis.	Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Athanasiadis A, 2004, PLOS BIOL, V2, P2144, DOI 10.1371/journal.pbio.0020391; BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Cenci C, 2008, J BIOL CHEM, V283, P7251, DOI 10.1074/jbc.M708316200; Chen LL, 2008, CELL CYCLE, V7, P3294, DOI 10.4161/cc.7.21.6927; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; Chiesa M, 2011, CELL CYCLE, V10, P1607, DOI 10.4161/cc.10.10.15566; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dominissini D, 2011, CARCINOGENESIS, V32, P1569, DOI 10.1093/carcin/bgr124; Farajollahi S, 2010, TRENDS GENET, V26, P221, DOI 10.1016/j.tig.2010.02.001; Galeano F, 2010, INT J CANCER, V127, P127, DOI 10.1002/ijc.25022; Gallo A, 2003, EMBO J, V22, P3421, DOI 10.1093/emboj/cdg327; Gallo A, 2011, BIOL REV CAMB PHILOS, V87, P95, DOI DOI 10.1111/J.1469-185X.2011.00186.X; Greenberger S, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-608; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Halfter H, 2006, CANCER RES, V66, P6530, DOI 10.1158/0008-5472.CAN-04-3734; Heale BSE, 2009, EMBO J, V28, P3145, DOI 10.1038/emboj.2009.244; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Jackson RJ, 2003, CANCER RES, V63, P3021; Keegan LP, 2001, NAT REV GENET, V2, P869, DOI 10.1038/35098584; Kiran A, 2010, BIOINFORMATICS, V26, P1772, DOI 10.1093/bioinformatics/btq285; Kitagawa K, 2009, CANCER SCI, V100, P1374, DOI 10.1111/j.1349-7006.2009.01196.x; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kwon CH, 2008, CANCER RES, V68, P3286, DOI 10.1158/0008-5472.CAN-07-6867; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Lee SH, 2005, J MOL MED, V83, P296, DOI 10.1007/s00109-004-0611-7; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; Macbeth MR, 2005, SCIENCE, V309, P1534, DOI 10.1126/science.1113150; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Nishikura K, 2004, NAT BIOTECHNOL, V22, P962, DOI 10.1038/nbt0804-962; Nishikura K, 2006, NAT REV MOL CELL BIO, V7, P919, DOI 10.1038/nrm2061; Nishikura K, 2010, ANNU REV BIOCHEM, V79, P321, DOI 10.1146/annurev-biochem-060208-105251; Ohlson J, 2007, RNA, V13, P698, DOI 10.1261/rna.349107; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; Paz N, 2007, GENOME RES, V17, P1586, DOI 10.1101/gr.6493107; Picardi E, 2011, BIOINFORMATICS, V27, P1311, DOI 10.1093/bioinformatics/btr117; Rodier G, 2008, EMBO J, V27, P679, DOI 10.1038/emboj.2008.6; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Saigusa K, 2005, CANCER SCI, V96, P676, DOI 10.1111/j.1349-7006.2005.00099.x; Schiffer D, 2002, NEUROSCI LETT, V328, P125, DOI 10.1016/S0304-3940(02)00483-4; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Seeburg PH, 2002, NEURON, V35, P17, DOI 10.1016/S0896-6273(02)00760-2; Stupp Roger, 2005, Curr Neurol Neurosci Rep, V5, P198, DOI 10.1007/s11910-005-0047-7; Tumurbaatar I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014711; Wahlstedt H, 2009, GENOME RES, V19, P978, DOI 10.1101/gr.089409.108; Yang L, 2010, FASEB J, V24, P3720, DOI 10.1096/fj.09-152363; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	59	95	100	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					998	1009		10.1038/onc.2012.125	http://dx.doi.org/10.1038/onc.2012.125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22525274	Green Published, hybrid			2022-12-28	WOS:000316523200007
J	Xie, Z; Jiang, Y; Liao, EY; Chen, Y; Pennypacker, SD; Peng, J; Chang, SM				Xie, Z.; Jiang, Y.; Liao, E-Y; Chen, Y.; Pennypacker, S. D.; Peng, J.; Chang, S. M.			PIKE mediates EGFR proliferative signaling in squamous cell carcinoma cells	ONCOGENE			English	Article						SCC; EGFR; PLC-gamma 1; PIKE; proliferation	PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; HUMAN KERATINOCYTE DIFFERENTIATION; GENE COPY NUMBER; PHOSPHOLIPASE C-GAMMA-1; PHOSPHATIDYLINOSITOL 3-KINASE; NUCLEAR TRANSLOCATION; COLORECTAL-CANCER; ACTIVATES RAF-1; POOR-PROGNOSIS	One of the key drivers for squamous cell carcinoma (SCC) proliferation is activation of the epidermal growth factor receptor (EGFR), a known proto-oncogene. However, the mechanism of EGFR-dependent SCC proliferation remains unclear. Our previous studies indicate that epidermal growth factor (EGF)-induced SCC cell proliferation requires the SH3 domain of phospholipase C-gamma 1 (PLC-gamma 1), but not its catalytic activity. The SH3 domain of PLC-gamma 1 is known to activate the short form of nuclear phosphatidylinositol 3-kinase enhancer (PIKE) that enhances the activity of nuclear class Ia phosphatidylinositol 3-kinase (PI3K) required for proliferation. However, PIKE has been described for more than a decade to be present exclusively in neuronal cells. In the present study, we found that PIKE was highly expressed in malignant human keratinocytes (SCC4 and SCC12B2) but had low expression in normal human keratinocytes. Immunohistochemical analysis showed strong nuclear staining of PIKE in human epidermal and tongue SCC specimens but little staining in the adjacent non-cancerous epithelium. Treatment of SCC4 cells with EGF-induced translocation of PLC-gamma 1 to the nucleus and binding of PLC-gamma 1 to the nuclear PIKE. Knockdown of PLC-gamma 1 or PIKE blocked EGF-induced activation of class Ia PI3K and protein kinase C-zeta and phosphorylation of nucleolin in the nucleus as well as EGF-induced SCC cell proliferation. However, inhibition of the catalytic activity of PLC-gamma 1 had little effect. These data suggest that PIKE has a critical role in EGF-induced SCC cell proliferation and may function as a proto-oncogene in SCC. Oncogene (2012) 31, 5090-5098; doi:10.1038/onc.2012.10; published online 20 February 2012	[Xie, Z.; Liao, E-Y; Peng, J.] Cent S Univ, Xiangya Hosp 2, Inst Metab & Endocrinol, Changsha 410011, Hunan, Peoples R China; [Xie, Z.; Pennypacker, S. D.; Chang, S. M.] Vet Affairs Med Ctr, No Calif Inst Res & Educ, Endocrine Unit, San Francisco, CA 94121 USA; [Xie, Z.; Pennypacker, S. D.; Chang, S. M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Jiang, Y.] Cent S Univ, Xiang Ya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China; [Chen, Y.] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China	Central South University; Northern California Institute for Research & Education; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Central South University; China Academy of Chinese Medical Sciences; Institute of Chinese Materia Medica, CACMS	Xie, Z (corresponding author), Cent S Univ, Xiangya Hosp 2, Inst Metab & Endocrinol, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.	Zhongjian.Xie@gmail.com		Yi, Jiang/0000-0002-7877-0561	National Natural Science Foundation of China [81072219]; US National Institutes of Health [1R03DE01800, 1R21DE019529]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE018001, R21DE019529] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the grant 81072219 from the National Natural Science Foundation of China and grants 1R03DE018001 and 1R21DE019529 from the US National Institutes of Health. We thank Drs Daniel D Bikle, Chia-Ling Tu and Yongmei Wang for helpful discussions. We also thank Dr Larry L Wang (Department of Pathology, Children Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles) for reviewing pathological slides.	Ahn JY, 2004, P NATL ACAD SCI USA, V101, P6993, DOI 10.1073/pnas.0400921101; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Calcerrada MC, 2002, FEBS LETT, V514, P361, DOI 10.1016/S0014-5793(02)02401-8; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Destro A, 2006, LUNG CANCER, V51, P207, DOI 10.1016/j.lungcan.2005.10.016; Ettl T, 2008, HISTOPATHOLOGY, V53, P567, DOI 10.1111/j.1365-2559.2008.03159.x; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Galizia G, 2007, WORLD J SURG, V31, P1458, DOI 10.1007/s00268-007-9016-4; Ginisty H, 1999, J CELL SCI, V112, P761; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hiraishi Y, 2006, PATHOL ONCOL RES, V12, P87, DOI 10.1007/BF02893450; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Kim MA, 2008, HISTOPATHOLOGY, V52, P738, DOI 10.1111/j.1365-2559.2008.03021.x; Kim MJ, 2000, EXP MOL MED, V32, P101, DOI 10.1038/emm.2000.18; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Liu X, 2007, ONCOGENE, V26, P4918, DOI 10.1038/sj.onc.1210290; Livasy CA, 2006, GYNECOL ONCOL, V100, P101, DOI 10.1016/j.ygyno.2005.07.124; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; Rakosy Z, 2007, INT J CANCER, V121, P1729, DOI 10.1002/ijc.22928; ROTIN D, 1992, J BIOL CHEM, V267, P9678; Schiff BA, 2004, CLIN CANCER RES, V10, P8594, DOI 10.1158/1078-0432.CCR-04-0690; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; Spano JP, 2005, ANN ONCOL, V16, P102, DOI 10.1093/annonc/mdi006; Speake G, 2005, CURR OPIN PHARMACOL, V5, P343, DOI 10.1016/j.coph.2005.02.007; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Storck S, 2009, BIOL CELL, V101, P153, DOI 10.1042/BC20080054; Tajrishi Marjan M, 2011, Commun Integr Biol, V4, P267, DOI 10.4161/cib.4.3.14884; Thomas SM, 2003, CANCER RES, V63, P5629; TOKER A, 1994, J BIOL CHEM, V269, P32358; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Xie ZJ, 2007, J BIOL CHEM, V282, P8695, DOI 10.1074/jbc.M609135200; Xie ZJ, 2010, BIOCHEM BIOPH RES CO, V398, P719, DOI 10.1016/j.bbrc.2010.07.007; Xie ZJ, 2010, BIOCHEM BIOPH RES CO, V397, P296, DOI 10.1016/j.bbrc.2010.05.103; Xie ZJ, 2009, MOL BIOL CELL, V20, P1695, DOI 10.1091/mbc.E08-07-0756; Xie ZJ, 2005, MOL BIOL CELL, V16, P3236, DOI 10.1091/mbc.E05-02-0109; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130; Zlobec I, 2007, BRIT J CANCER, V96, P793, DOI 10.1038/sj.bjc.6603619; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	51	8	9	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5090	5098		10.1038/onc.2012.10	http://dx.doi.org/10.1038/onc.2012.10			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22349826				2022-12-28	WOS:000312000900005
J	Hu, Q; Lu, YY; Noh, H; Hong, S; Dong, Z; Ding, HF; Su, SB; Huang, S				Hu, Q.; Lu, Y-Y; Noh, H.; Hong, S.; Dong, Z.; Ding, H-F; Su, S-B; Huang, S.			Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression	ONCOGENE			English	Article						uPA; ILF3; transcription; miRNA	MESSENGER-RNA STABILITY; GENE-EXPRESSION; SIGNALING PATHWAYS; NUCLEAR FACTOR; KAPPA-B; CANCER; RECEPTOR; NF90; TRANSCRIPTION; METASTASIS	Sustained urokinase-type plasminogen activator (uPA) expression is detected in aggressive breast tumors. Although uPA can be transiently upregulated by diverse extracellular stimuli, sustained, but not transiently upregulated uPA expression contributes to breast cancer invasion/metastasis. Unfortunately, how sustained uPA expression is achieved in invasive/metastatic breast cancer cells is unknown. Here, we show that sustained and transiently upregulated uPA expression are regulated by distinct mechanisms. Using a collection of transcription factor-targeted small-interfering RNAs, we discovered that interleukin enhancer-binding factor 3 (ILF3) is required for sustained uPA expression. Two discrete mechanisms mediate ILF3 action. The first is that ILF3 activates uPA transcription by binding to the CTGTT sequence in the nucleotides - 1004B similar to - 1000 of the uPA promoter; the second is that ILF3 inhibits the processing of uPA mRNA-targeting primary microRNAs (pri-miRNAs). Knockdown of ILF3 led to significant reduction in in vitro cell growth/migration/invasion and in vivo breast tumor development. Importantly, immunohistochemistry (IHC) showed that nuclear ILF3, but not cytoplasmic ILF3 staining correlates with elevated uPA level and higher grades of human breast tumor specimens. Nuclear localization of ILF3 highlights the role of ILF3 in sustained uPA expression as a transcription activator and pri-miRNA processing blocker. In conclusion, this study shows that ILF3 promotes breast tumorigenicity by regulating sustained uPA expression.	[Hu, Q.; Noh, H.; Hong, S.; Huang, S.] Georgia Hlth Sci Univ, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Lu, Y-Y; Su, S-B; Huang, S.] Shanghai Univ Tradit Chinese Med, Res Ctr Tradit Chinese Med Complex Syst, Shanghai, Peoples R China; [Dong, Z.] Georgia Hlth Sci Univ, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; [Ding, H-F] Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA; [Ding, H-F; Huang, S.] Georgia Hlth Sci Univ, Ctr Canc, Augusta, GA 30912 USA	University System of Georgia; Augusta University; Shanghai University of Traditional Chinese Medicine; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Huang, S (corresponding author), Georgia Hlth Sci Univ, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	shuang@georgiahealth.edu		Ding, Han-Fei/0000-0001-5702-3439	NIH [CA093926]; NSF of China [81 073 134]; Shanghai Eastern Scholar Fund; NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF of China(National Natural Science Foundation of China (NSFC)); Shanghai Eastern Scholar Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by funding from NIH CA093926 (SH), NSF of China Fund 81 073 134 (SBS) and Shanghai Eastern Scholar Fund (SH). We would like to thank Dr Michael Mathews for providing ILF3 splicing isoform constructs.	Almholt K, 2005, INT J CANCER, V113, P525, DOI 10.1002/ijc.20631; Amorino GP, 2002, MOL BIOL CELL, V13, P2233, DOI 10.1091/mbc.01-12-0572; Annecke K, 2008, ADV CLIN CHEM, V45, P31, DOI 10.1016/S0065-2423(07)00002-9; Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; Crippa MP, 2007, INT J BIOCHEM CELL B, V39, P690, DOI 10.1016/j.biocel.2006.10.008; Das R, 2004, J BIOL CHEM, V279, P11051, DOI 10.1074/jbc.M310256200; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; Dunn SE, 2001, CANCER RES, V61, P1367; Foekens JA, 2000, CANCER RES, V60, P636; Fung LF, 2000, LIFE SCI, V67, P923, DOI 10.1016/S0024-3205(00)00684-6; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Guan DY, 2008, MOL CELL BIOL, V28, P4629, DOI 10.1128/MCB.00120-08; Guo NL, 2008, CLIN CANCER RES, V14, P8213, DOI 10.1158/1078-0432.CCR-08-0095; Guo Y, 2012, ONCOL REP, V27, P286, DOI 10.3892/or.2011.1483; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Harbeck Nadia, 2004, Clin Breast Cancer, V5, P348, DOI 10.3816/CBC.2004.n.040; HUANG SA, 1994, J BIOL CHEM, V269, P28764; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; KAO PN, 1994, J BIOL CHEM, V269, P20691; Kiesler P, 2010, J BIOL CHEM, V285, P8256, DOI 10.1074/jbc.M109.041004; Kuwano Y, 2008, MOL CELL BIOL, V28, P4562, DOI 10.1128/MCB.00165-08; Kuwano Y, 2010, NUCLEIC ACIDS RES, V38, P225, DOI 10.1093/nar/gkp861; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Li Y, 2008, MOL CELL BIOL, V28, P4275, DOI 10.1128/MCB.00369-08; Mahanivong C, 2008, ONCOGENE, V27, P1273, DOI 10.1038/sj.onc.1210746; Mahanivong C, 2007, MOL CARCINOGEN, V46, P165, DOI 10.1002/mc.20249; Mazumdar A, 2001, CANCER RES, V61, P400; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Noh Hyangsoon, 2011, Genes Cancer, V2, P140, DOI 10.1177/1947601911408888; Pei Y, 2008, J IMMUNOL, V180, P222, DOI 10.4049/jimmunol.180.1.222; PRICE JE, 1990, CANCER RES, V50, P717; Reichman TW, 2003, J MOL BIOL, V332, P85, DOI 10.1016/S0022-2836(03)00885-4; Sakamoto S, 2009, MOL CELL BIOL, V29, P3754, DOI 10.1128/MCB.01836-08; Shi LF, 2007, J EXP MED, V204, P971, DOI 10.1084/jem.20052078; Sliva D, 2002, BIOCHEM BIOPH RES CO, V290, P552, DOI 10.1006/bbrc.2001.6225; Su S, 2009, ONCOGENE, V28, P3047, DOI 10.1038/onc.2009.163; Vanden Berghe W, 2006, CANCER RES, V66, P4852, DOI 10.1158/0008-5472.CAN-05-2957; Vumbaca F, 2008, MOL CELL BIOL, V28, P772, DOI 10.1128/MCB.02078-06; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9	46	50	50	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3933	3943		10.1038/onc.2012.414	http://dx.doi.org/10.1038/onc.2012.414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22986534	Green Accepted			2022-12-28	WOS:000323748100002
J	Chatain, N; Ziegler, P; Fahrenkamp, D; Jost, E; Moriggl, R; Schmitz-Van de Leur, H; Muller-Newen, G				Chatain, N.; Ziegler, P.; Fahrenkamp, D.; Jost, E.; Moriggl, R.; Schmitz-Van de Leur, H.; Mueller-Newen, G.			Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells	ONCOGENE			English	Article						CML; BCR-ABL; STAT5; Src; inhibitors	CHRONIC MYELOID-LEUKEMIA; DNA-BINDING ACTIVITY; SIGNAL TRANSDUCERS; CONSTITUTIVE ACTIVATION; LYMPHOBLASTIC-LEUKEMIA; PHOSPHORYLATED STAT5; TRANSCRIPTION STAT; INHIBITS APOPTOSIS; TYROSINE KINASE; SURVIVAL	Persistent activation of the Abl tyrosine kinase in the BCR-ABL fusion protein is the major cause of chronic myeloid leukemia (CML). Among many other substrates BCR-ABL phosphorylates STAT5 and Src family kinases (SFK). Activated pSTAT5 is essential for initial transformation and maintenance of the disease. Cytokine-induced phosphorylation on tyrosine 694 typically leads to nuclear accumulation of pSTAT5 and target gene expression. We verified that in BCR-ABL-positive progenitor cells from a CML patient and in K562 cells pSTAT5 is cytoplasmic. However, upon ectopic expression of BCR-ABL p210 in non-myeloid cells, co-transfected STAT5A is phosphorylated on Y694 and localized in the nucleus arguing for an additional factor mediating cytoplasmic retention in CML cells. Expression of the SFK v-Src, Hck or Lyn together with STAT5A results in phosphorylation on Y694 and cytoplasmic retention. Upon coexpression of BCR-ABL and individual SFK the cytoplasmic retention of activated STAT5A mediated by v-Src and Hck but not Lyn is dominant over nuclear translocation induced by BCR-ABL. Cytoplasmic retention depends on the kinase activity of SFK and is mediated through the interaction of the SH2 domain of STAT5A with the SFK. Interestingly, nuclear accumulation of STAT5A as a result of activation by FLT3-ITD, an oncogene found in acute myeloid leukemia, cannot be prevented by coexpression of SFK. Importantly, inhibition of SFK in K562 cells restored nuclear accumulation of pSTAT5A, enhanced STAT5 target gene expression and increased colony formation. Thus, SFK mediate cytoplasmic retention of pSTAT5A in BCR-ABL-positive cells. Cytoplasmic pSTAT5A in CML cells might balance the controversial functions of STAT5 in cellular senescence and differentiation versus G(1)/S progression and survival.	[Chatain, N.; Fahrenkamp, D.; Schmitz-Van de Leur, H.; Mueller-Newen, G.] Rhein Westfal TH Aachen, Inst Biochem & Mol Biol, D-52074 Aachen, NRW, Germany; [Ziegler, P.; Jost, E.] Rhein Westfal TH Aachen, Klin Onkol Hamatol & Stammzelltransplantat, D-52074 Aachen, NRW, Germany; [Moriggl, R.] Ludwig Boltzmann Inst Canc Res LBI CR, Vienna, Austria	RWTH Aachen University; RWTH Aachen University; Ludwig Boltzmann Institute	Muller-Newen, G (corresponding author), Rhein Westfal TH Aachen, Inst Biochem & Mol Biol, Pauwelsstr 30, D-52074 Aachen, NRW, Germany.	mueller-newen@rwth-aachen.de	Moriggl, Richard/H-8118-2019	Moriggl, Richard/0000-0003-0918-9463	Deutsche Forschungsgemeinschaft (DFG) [SFB 542]; Austrian Science Funds (FWF) [SFB F28]; IZKF Aachen (Interdisciplinary Center for Clinical Research within the Faculty of Medicine at RWTH Aachen University); Austrian Science Fund (FWF) [F 2807] Funding Source: researchfish	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Austrian Science Funds (FWF)(Austrian Science Fund (FWF)); IZKF Aachen (Interdisciplinary Center for Clinical Research within the Faculty of Medicine at RWTH Aachen University); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	The research project was supported by grants from the Deutsche Forschungsgemeinschaft (DFG, SFB 542, projects B12 and Z1 to GMN), the Austrian Science Funds (FWF, SFB F28 to RM) and the core facility confocal microscopy of the IZKF Aachen (Interdisciplinary Center for Clinical Research within the Faculty of Medicine at RWTH Aachen University). We would like to thank Frank-D Bohmer, Tim Brummendorf, Michael Huber, Isabelle Maridonneau-Parini, Fred Schaper and Veronika Sexl for their critical discussion and helping us with plasmid constructs.	Baumgartner C, 2009, AM J PATHOL, V175, P2416, DOI 10.2353/ajpath.2009.080953; Bunting KD, 2007, BLOOD, V110, P2775, DOI 10.1182/blood-2007-05-090969; Bunting KD, 2007, FRONT BIOSCI-LANDMRK, V12, P2807, DOI 10.2741/2274; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Cortes JE, 2011, BLOOD, V118, P4567, DOI 10.1182/blood-2011-05-355594; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Ferbeyre G, 2011, BBA-REV CANCER, V1815, P104, DOI 10.1016/j.bbcan.2010.10.004; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harir N, 2007, BLOOD, V109, P1678, DOI 10.1182/blood-2006-01-029918; Heltemes-Harris LM, 2011, ANN NY ACAD SCI, V1217, P18, DOI 10.1111/j.1749-6632.2010.05907.x; Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908; Herrmann A, 2007, J CELL SCI, V120, P3249, DOI 10.1242/jcs.03482; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Hoelbl A, 2010, EMBO MOL MED, V2, P98, DOI 10.1002/emmm.201000062; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kotecha N, 2008, CANCER CELL, V14, P335, DOI 10.1016/j.ccr.2008.08.014; Li G, 2010, LEUKEMIA, V24, P1397, DOI 10.1038/leu.2010.131; Li GQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009152; Li SG, 2005, EXPERT OPIN THER TAR, V9, P329, DOI 10.1517/14728222.9.2.329; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; Lim CP, 2006, MOL BIOSYST, V2, P536, DOI 10.1039/b606246f; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Mallette FA, 2010, ANN NY ACAD SCI, V1197, P142, DOI 10.1111/j.1749-6632.2010.05192.x; Meyn MA, 2006, J BIOL CHEM, V281, P30907, DOI 10.1074/jbc.M605902200; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Nyga R, 2005, BIOCHEM J, V390, P359, DOI 10.1042/BJ20041523; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Ozawa Y, 2008, LEUKEMIA RES, V32, P893, DOI 10.1016/j.leukres.2007.11.032; Poincloux R, 2007, J CELL PHYSIOL, V213, P212, DOI 10.1002/jcp.21112; Schenone S, 2010, EXPERT OPIN INV DRUG, V19, P931, DOI 10.1517/13543784.2010.499898; Schmidt-Arras D, 2009, BLOOD, V113, P3568, DOI 10.1182/blood-2007-10-121426; Shiotsu Y, 2009, BLOOD, V114, P1607, DOI 10.1182/blood-2009-01-199307; Shuai K, 1996, ONCOGENE, V13, P247; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Stanglmaier M, 2003, LEUKEMIA, V17, P283, DOI 10.1038/sj.leu.2402778; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Vogt M, 2011, J CELL SCI, V124, P900, DOI 10.1242/jcs.072520; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182/blood-2011-12-397554; Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Ziegler P, 2007, CURR PROTOC TOXICOL	48	24	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2013	32	31					3587	3597		10.1038/onc.2012.369	http://dx.doi.org/10.1038/onc.2012.369			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22926520				2022-12-28	WOS:000322638400003
J	Siu, MKY; Wong, ESY; Kong, DSH; Chan, HY; Jiang, L; Wong, OGW; Lam, EWF; Chan, KKL; Ngan, HYS; Le, XF; Cheung, AN				Siu, M. K. Y.; Wong, E. S. Y.; Kong, D. S. H.; Chan, H. Y.; Jiang, L.; Wong, O. G. W.; Lam, E. W-F; Chan, K. K. L.; Ngan, H. Y. S.; Le, X-F; Cheung, A. N.			Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers	ONCOGENE			English	Article						NANOG; cell migration and invasion; prognostic marker; therapeutic molecular target; ovarian cancer	CARCINOMA CELLS; DIFFERENTIAL EXPRESSION; TUMOR-CELLS; IDENTIFICATION; OVEREXPRESSION; PLURIPOTENCY; MODULATION; ACTIVATION; PROGNOSIS	Ovarian cancer is the most lethal of all gynecological malignancies, and the identification of novel prognostic and therapeutic targets for ovarian cancer is crucial. It is believed that only a small subset of cancer cells are endowed with stem cell properties, which are responsible for tumor growth, metastatic progression and recurrence. NANOG is one of the key transcription factors essential for maintaining self-renewal and pluripotency in stem cells. This study investigated the role of NANOG in ovarian carcinogenesis and showed overexpression of NANOG mRNA and protein in the nucleus of ovarian cancers compared with benign ovarian lesions. Increased nuclear NANOG expression was significantly associated with high-grade cancers, serous histological subtypes, reduced chemosensitivity, and poor overall and disease-free survival. Further analysis showed NANOG is an independent prognostic factor for overall and disease-free survival. Moreover, NANOG was highly expressed in ovarian cancer cell lines with metastasis-associated property and in clinical samples of metastatic foci. Stable knockdown of NANOG impeded ovarian cancer cell proliferation, migration and invasion, which was accompanied by an increase in mRNA expression of E-cadherin, caveolin-1, FOXO1, FOXO3a, FOXJ1 and FOXB1. Conversely, ectopic NANOG overexpression enhanced ovarian cancer cell migration and invasion along with decreased E-cadherin, caveolin-1, FOXO1, FOXO3a, FOXJ1 and FOXB1 mRNA expression. Importantly, we found Nanog-mediated cell migration and invasion involved its regulation of E-cadherin and FOXJ1. This is the first report revealing the association between NANOG expression and clinical outcome of patients with ovarian cancers, suggesting NANOG to be a potential prognostic marker and therapeutic molecular target in ovarian cancer.	[Siu, M. K. Y.; Wong, E. S. Y.; Kong, D. S. H.; Chan, H. Y.; Jiang, L.; Wong, O. G. W.; Cheung, A. N.] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London, England; [Chan, K. K. L.; Ngan, H. Y. S.] Univ Hong Kong, Queen Mary Hosp, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Le, X-F] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA	University of Hong Kong; Imperial College London; University of Hong Kong; University of Texas System; UTMD Anderson Cancer Center	Cheung, AN (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	mkysiu@hkucc.hku.hk; anycheun@hkucc.hku.hk	Lam, Eric W-F/AAW-8566-2020; Wong, Gee Wan/C-4661-2009; Chan, Karen/E-4041-2015; Cheung, Annie Nga Yin/C-4231-2009	Lam, Eric W-F/0000-0003-1274-3576; Ngan, Hextan Y S/0000-0003-3945-159X; Chan, Karen/0000-0001-9947-4713; Cheung, Annie Nga Yin/0000-0002-1584-7568	Hong Kong Anti-Cancer Society Grant; Strategic Research Theme of Cancer Award; Conference and Research grant from the University of Hong Kong; Cancer Research UK [12011] Funding Source: researchfish	Hong Kong Anti-Cancer Society Grant; Strategic Research Theme of Cancer Award; Conference and Research grant from the University of Hong Kong; Cancer Research UK(Cancer Research UK)	We thank Dr Judy Yam for providing the anti-caveolin-1 antibody. The work was supported by funding from the Hong Kong Anti-Cancer Society Grant, Strategic Research Theme of Cancer Award and the Conference and Research grant from the University of Hong Kong.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Cavaleri F, 2003, CELL, V113, P551, DOI 10.1016/S0092-8674(03)00394-5; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Demircan B, 2009, GENE CHROMOSOME CANC, V48, P83, DOI 10.1002/gcc.20620; Di Fiore R, 2009, J CELL PHYSIOL, V219, P301, DOI 10.1002/jcp.21667; Fei M, 2009, CANCER INVEST, V27, P52, DOI 10.1080/07357900802146204; de Mattos SF, 2008, MOL CANCER THER, V7, P3237, DOI 10.1158/1535-7163.MCT-08-0398; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Huff CA, 2006, BLOOD, V107, P431, DOI 10.1182/blood-2005-06-2517; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Jiang LL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-318; Klonisch T, 2008, TRENDS MOL MED, V14, P450, DOI 10.1016/j.molmed.2008.08.003; Kurman RJ, 2008, AM J OBSTET GYNECOL, V198, P351, DOI 10.1016/j.ajog.2008.01.005; Lin L, 2004, SCIENCE, V303, P1017, DOI 10.1126/science.1093889; MANN SC, 1991, INT J CANCER, V48, P866, DOI 10.1002/ijc.2910480613; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Miotti S, 2005, AM J PATHOL, V167, P1411, DOI 10.1016/S0002-9440(10)61228-X; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Pan YY, 2008, INT J CLIN EXP MED, V1, P260; PEREZ RP, 1991, SEMIN ONCOL, V18, P186; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Seidman JD, 2003, HEMATOL ONCOL CLIN N, V17, P909, DOI 10.1016/S0889-8588(03)00061-3; Singh SK, 2003, CANCER RES, V63, P5821; Siu MKY, 2008, AM J PATHOL, V173, P1165, DOI 10.2353/ajpath.2008.080288; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Siu MKY, 2010, INT J CANCER, V127, P21, DOI 10.1002/ijc.25005; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Wilson AP, 1999, HUM CELL, P25; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	37	116	120	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3500	3509		10.1038/onc.2012.363	http://dx.doi.org/10.1038/onc.2012.363			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22945654	Green Submitted			2022-12-28	WOS:000322220800003
J	Wolyniec, K; Levav-Cohen, Y; Jiang, YH; Haupt, S; Haupt, Y				Wolyniec, K.; Levav-Cohen, Y.; Jiang, Y-H; Haupt, S.; Haupt, Y.			The E6AP E3 ubiquitin ligase regulates the cellular response to oxidative stress	ONCOGENE			English	Article						reactive oxygen species; cellular senescence; anti-oxidants; oxidative stress; cell death; peroxiredoxin 1	INDUCED DNA-DAMAGE; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; TUMOR SUPPRESSION; GROWTH ARREST; INDUCE SENESCENCE; FIBROBLAST CELLS; CERVICAL-CANCER; C-MYC; P53	The E6AP E3 ubiquitin ligase has been linked to the regulation of cell growth and to the cellular stress response. However, the specific stress conditions that are controlled by E6AP have not been defined. An important stress condition that controls cell growth is oxidative stress, where the levels of intracellular reactive oxygen species (ROS) regulate the appropriate cellular response. Here, we describe a novel role for E6AP in the control of oxidative stress response. Cells lacking E6AP expression have reduced capacity to accumulate ROS, and oxidative DNA damage, in response to 20% cell culture oxygen levels, treatment with hydrogen peroxide and expression of oncogenic RAS. This effect of E6AP is associated with the regulation of the anti-oxidant enzyme, Prx1, a previously identified target of E6AP, and can be corrected by downregulation of Prx1 or by reconstitution of E6AP expression. Consequently, cells with compromised E6AP have impaired senescent and apoptotic response to sub-lethal and lethal doses of oxidative stress, respectively. In a xenograft model, downregulation of E6AP renders transplanted tumours refractory to growth-suppressive effects of hydrogen peroxide. Our results provide the first demonstration that E6AP is an important regulator of ROS-mediated cellular senescence and cell death.	[Wolyniec, K.; Haupt, S.; Haupt, Y.] Peter MacCallum Canc Ctr, Tumour Suppress Lab, East Melbourne, Vic, Australia; [Wolyniec, K.; Haupt, S.; Haupt, Y.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Levav-Cohen, Y.] Hebrew Univ Jerusalem Hadassah Hosp & Med Sch, Sch Med, Jerusalem, Israel; [Jiang, Y-H] Duke Univ, Sch Med, Dept Pediat & Neurobiol, Div Med Genet, Durham, NC USA; [Haupt, Y.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Haupt, Y.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Hebrew University of Jerusalem; Hadassah University Medical Center; Duke University; University of Melbourne; Monash University	Haupt, Y (corresponding author), Peter MacCallum Canc Ctr, Tumour Suppress Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.	ygal.haupt@petermac.org		Haupt, Ygal/0000-0001-5925-0096	National Health and Medical Research Council (NHMRC) of Australia [509196, 509197, 1026990, 1026988]; Cancer Council Victoria; VESKI award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043494] Funding Source: NIH RePORTER	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); VESKI award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank Scott Lowe, Martin Scheffner and Ikuo Shoji who generously provided plasmids. This work was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia to YH (NHMRC #509196, #509197, #1026990, #1026988), by a grant from the Cancer Council Victoria, and by the VESKI award. YH is NHMRC Senior Research Fellow.	Bacsi A, 2007, MECH AGEING DEV, V128, P637, DOI 10.1016/j.mad.2007.09.005; Beaudenon S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S4; BENYOSEPH O, 1994, BRIT J CANCER, V70, P1131, DOI 10.1038/bjc.1994.460; Bertram C, 2008, BIOL CHEM, V389, P211, DOI 10.1515/BC.2008.031; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Busuttil RA, 2003, AGING CELL, V2, P287, DOI 10.1046/j.1474-9728.2003.00066.x; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Cha MK, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-93; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Egler RA, 2005, ONCOGENE, V24, P8038, DOI 10.1038/sj.onc.1208821; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Howley Peter M, 2006, Trans Am Clin Climatol Assoc, V117, P113; Jones FS, 2001, CIRC RES, V89, P131, DOI 10.1161/hh1401.093582; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Levav-Cohen Y, 2012, ONCOGENE, V31, P2199, DOI 10.1038/onc.2011.402; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lu T, 2008, EXP CELL RES, V314, P1918, DOI 10.1016/j.yexcr.2008.01.011; Matentzoglu K, 2008, BIOCHEM SOC T, V36, P797, DOI 10.1042/BST0360797; Nasu J, 2010, J CELL BIOCHEM, V111, P676, DOI 10.1002/jcb.22752; NATHAN CF, 1981, J EXP MED, V154, P1539, DOI 10.1084/jem.154.5.1539; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Ramamoorthy S, 2012, BREAST CANCER RES TR, V132, P97, DOI 10.1007/s10549-011-1567-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SUGIURA K, 1958, NATURE, V182, P1310, DOI 10.1038/1821310a0; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; van Loon B, 2010, DNA REPAIR, V9, P604, DOI 10.1016/j.dnarep.2010.03.004; Vurusaner B, 2012, FREE RADICAL BIO MED, V52, P7, DOI 10.1016/j.freeradbiomed.2011.09.035; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wolyniec K, 2009, ONCOGENE, V28, P2502, DOI 10.1038/onc.2009.101; Yoshizaki K, 2009, BIOSCI BIOTECH BIOCH, V73, P311, DOI 10.1271/bbb.80517; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584	43	18	18	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3510	3519		10.1038/onc.2012.365	http://dx.doi.org/10.1038/onc.2012.365			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22986523				2022-12-28	WOS:000322220800004
J	Fimia, GM; Corazzari, M; Antonioli, M; Piacentini, M				Fimia, G. M.; Corazzari, M.; Antonioli, M.; Piacentini, M.			Ambra1 at the crossroad between autophagy and cell death	ONCOGENE			English	Review						Ambra1; Bcl-2; Beclin 1; caspases; calpains; apoptosis	III PHOSPHATIDYLINOSITOL 3-KINASE; BECLIN 1-DEPENDENT AUTOPHAGY; CALPAIN-MEDIATED CLEAVAGE; BCL-2 FAMILY-MEMBERS; REGULATES AUTOPHAGY; JNK1-MEDIATED PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; JNK PHOSPHORYLATION; MAMMALIAN AUTOPHAGY; TUMOR SUPPRESSION	Autophagy is a self-digesting mechanism responsible for the degradation and recycling of most intracellular macromolecules and the removal of damaged organelles by the lysosome. An impressive number of recent studies have provided key information about the regulation of autophagy and its role in cell survival during nutrient depletion and many other stressful situations. In particular, many evidences have highlighted a crucial role of dysregulated autophagy in oncogenesis. Perturbations of the autophagic pathway have been shown to contribute to tumor development. Moreover, cancer cells have developed several mechanisms that allow them to evade chemotherapy-induced cell death, as well as to use autophagy-associated pathways, to potentiate their survival. In this regard, a complex crosstalk between autophagy and apoptosis has recently emerged; the understanding of the molecular mechanisms regulating this interplay may provide new hints on how to properly modulate these processes to halt cancer. Indeed, key proteins originally thought to be apoptosis-specific inhibitors also block autophagy, while apoptosis proteolytic enzymes hamper autophagy by cleaving autophagy-specific proteins and, in some cases, converting them into proapoptotic factors. This review is focused on the role that Ambra1, a central component of the autophagosome formation machinery, has in the switch between autophagy and apoptosis and its implication in cancer development and chemotherapy resistance.	[Fimia, G. M.; Corazzari, M.; Antonioli, M.; Piacentini, M.] Natl Inst Infect Dis IRCCS Lazzaro Spallanzani, Dept Epidemiol & Preclin Res, Rome, Italy; [Corazzari, M.; Piacentini, M.] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy	IRCCS Lazzaro Spallanzani; University of Rome Tor Vergata	Piacentini, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00173 Rome, Italy.	mauro.piacentini@uniroma2.it	Corazzari, Marco/B-4631-2019; Corazzari, Marco/K-6422-2016; antonioli, manuela/L-6681-2019; antonioli, manuela/F-5898-2015; Piacentini, Mauro/I-2411-2016; Corazzari, Marco/J-5825-2019; Fimia, Gian Maria/K-3232-2016	Corazzari, Marco/0000-0002-6246-5968; Corazzari, Marco/0000-0002-6246-5968; antonioli, manuela/0000-0002-7568-4713; antonioli, manuela/0000-0002-7568-4713; Piacentini, Mauro/0000-0003-2919-1296; Corazzari, Marco/0000-0002-6246-5968; Fimia, Gian Maria/0000-0003-4438-3325	Italian Ministry of University FIRB; Ministry of Health of Italy; AIRC; Telethon; EU	Italian Ministry of University FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Ministry of Health of Italy(Ministry of Health, Italy); AIRC(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon); EU(European Commission)	This work was supported by grants from the Italian Ministry of University FIRB, Compagnia di San Paolo to MP, the Ministry of Health of Italy 'Ricerca Corrente' and 'Ricerca Finalizzata' to MP and GMF, AIRC to MP and MC, and Telethon to GMF. The support of the EU grant 'Transpath ' Marie Curie project to MP is also acknowledged.	Abrahamsen H, 2012, FEBS LETT, V586, P1584, DOI 10.1016/j.febslet.2012.04.046; Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595; Apweiler R, 2012, NUCLEIC ACIDS RES, V40, pD71, DOI 10.1093/nar/gkr981; Arias E, 2011, CURR OPIN CELL BIOL, V23, P184, DOI 10.1016/j.ceb.2010.10.009; Armstrong JL, 2011, CLIN CANCER RES, V17, P2216, DOI 10.1158/1078-0432.CCR-10-3003; Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250; Burman C, 2010, FEBS LETT, V584, P1302, DOI 10.1016/j.febslet.2010.01.011; Cecconi F, 2008, CELL DEATH DIFFER, V15, P1170, DOI 10.1038/cdd.2008.64; Chang NC, 2010, EMBO J, V29, P606, DOI 10.1038/emboj.2009.369; Cho DH, 2009, CANCER LETT, V274, P95, DOI 10.1016/j.canlet.2008.09.004; Corazzari M, 2012, AUTOPHAGY, V8, P1255, DOI 10.4161/auto.20671; Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Deretic V, 2009, CELL HOST MICROBE, V5, P527, DOI 10.1016/j.chom.2009.05.016; Di Bartolomeo S, 2010, J CELL BIOL, V191, P155, DOI 10.1083/jcb.201002100; Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Fimia GM, 2010, CELL MOL LIFE SCI, V67, P1581, DOI 10.1007/s00018-010-0284-z; Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009; He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001; Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080; Jahreiss L, 2008, TRAFFIC, V9, P574, DOI 10.1111/j.1600-0854.2008.00701.x; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475; Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121; Luo SQ, 2012, MOL CELL, V47, P359, DOI 10.1016/j.molcel.2012.05.040; Maglott D, 2011, NUCLEIC ACIDS RES, V39, pD52, DOI 10.1093/nar/gkq1237; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Mizushima N, 2009, CURR TOP MICROBIOL, V335, P71, DOI 10.1007/978-3-642-00302-8_3; Orenstein SJ, 2010, SEMIN CELL DEV BIOL, V21, P719, DOI 10.1016/j.semcdb.2010.02.005; Pagliarini V, 2012, CELL DEATH DIFFER, V19, P1495, DOI 10.1038/cdd.2012.27; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Placzek WJ, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.18; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Radoshevich L, 2010, CELL, V142, P590, DOI 10.1016/j.cell.2010.07.018; Rubinstein AD, 2011, MOL CELL, V44, P698, DOI 10.1016/j.molcel.2011.10.014; Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340; Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49; Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Van Humbeeck C, 2011, J NEUROSCI, V31, P10249, DOI 10.1523/JNEUROSCI.1917-11.2011; Velasco G, 2012, NAT REV CANCER, V12, P436, DOI 10.1038/nrc3247; Wagner SA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.013284; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16; Wirawan E, 2012, AUTOPHAGY, V8, P6, DOI 10.4161/auto.8.1.16645; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yi C, 2012, SCIENCE, V336, P474, DOI 10.1126/science.1216990; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854	90	67	70	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2013	32	28					3311	3318		10.1038/onc.2012.455	http://dx.doi.org/10.1038/onc.2012.455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	23069654				2022-12-28	WOS:000321620200001
J	Chau, WK; Ip, CK; Mak, ASC; Lai, HC; Wong, AST				Chau, W. K.; Ip, C. K.; Mak, A. S. C.; Lai, H-C; Wong, A. S. T.			c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling	ONCOGENE			English	Article						c-Kit; ovarian cancer; chemoresistance; beta-catenin; ABCG2	BETA-CATENIN; EPITHELIAL OVARIAN; IMATINIB MESYLATE; CLINICOPATHOLOGICAL FEATURES; GENE-EXPRESSION; STEM-CELLS; CARCINOMA; RESISTANCE; RECURRENT; BIOLOGY	Cisplatin and paclitaxel are standard chemotherapy for metastatic ovarian cancer, but with limited efficacy. Cancer stem/progenitor cells (or tumor-initiating cells, TICs) are hypothesized to be chemoresistant, and the existence of TICs in ovarian cancer has been previously demonstrated. However, the key signals and molecular events regulating the formation and expansion of ovarian tumor-initiating cells (OTICs) remain elusive. Here, we show that c-Kit is not just a marker of OTICs, but also a critical mediator of the phenotype that can be a viable target for the treatment of ovarian cancer. In contrast to non-OICs, c-Kit was overexpressed in OTICs. Moreover, the use of small interfering RNA to inhibit c-Kit expression markedly attenuated the number and size of OTIC subpopulations, inhibited the expression of stem cell markers and decreased the tumorigenic capabilities of OTICs. Imatinib (Gleevec), a clinical drug that blocks c-Kit kinase activity, also demonstrated its inhibition potency on OTICs. In addition, cisplatin/paclitaxel, which killed non-OTICs, with c-Kit knockdown or imatinib revealed that this was critically required for intervening ovarian cancer progression and recurrence in vitro and in xenograft tumors in vivo. Similar results were obtained with OTICs derived from ovarian carcinoma patients. Studies into the mechanisms suggest an important role for the activation of Wnt/beta-catenin and ATP-binding cassette G2 downstream of c-Kit. The tumor-promoting microenvironment, such as hypoxia, could promote OTICs via upregulation of c-Kit expression. These results unravel an integral role for c-Kit in ovarian neoplastic processes and shed light on its mechanisms of action.	[Chau, W. K.; Ip, C. K.; Mak, A. S. C.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China; [Lai, H-C] Natl Def Med Ctr, Triserv Gen Hosp, Dept Obstet & Gynecol, Taipei, Taiwan	University of Hong Kong; National Defense Medical Center; Tri-Service General Hospital	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475; Ip, Carman K.M./0000-0002-6672-5982	National Health Research Institute of Taiwan [NHRI-EX100-9717NC]; HKU Strategic Research Theme Fund on Cancer, CRCG [201109176078, CUHK8/CRF/11R]; Croucher Senior Research Fellowship	National Health Research Institute of Taiwan(National Health Research Institutes - Taiwan); HKU Strategic Research Theme Fund on Cancer, CRCG; Croucher Senior Research Fellowship	This study was supported by the National Health Research Institute of Taiwan (NHRI-EX100-9717NC) to H-C Lai, and by HKU Strategic Research Theme Fund on Cancer, CRCG (201109176078), CUHK8/CRF/11R, and Croucher Senior Research Fellowship to AST Wong.	Alberts DS, 2007, INT J GYNECOL CANCER, V17, P784, DOI 10.1111/j.1525-1438.2007.00882.x; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Birner P, 2001, CLIN CANCER RES, V7, P1661; BROUDY VC, 1994, BLOOD, V83, P2145; Brustmann H, 2005, GYNECOL ONCOL, V98, P396, DOI 10.1016/j.ygyno.2005.04.035; Cheon S, 2005, LAB INVEST, V85, P416, DOI 10.1038/labinvest.3700237; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; Coleman RL, 2006, GYNECOL ONCOL, V101, P126, DOI 10.1016/j.ygyno.2005.09.041; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; HEINRICH MC, 1993, BLOOD, V82, P771, DOI 10.1182/blood.V82.3.771.bloodjournal823771; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Johnson SW, 1997, CANCER RES, V57, P850; Karlsson MO, 1999, DRUG METAB DISPOS, V27, P1220; Kildal W, 2005, EUR J CANCER, V41, P1127, DOI 10.1016/j.ejca.2005.01.022; Lee CM, 2003, GYNECOL ONCOL, V88, P363, DOI 10.1016/S0090-8258(02)00015-X; Luo LJ, 2011, EXP MOL PATHOL, V91, P596, DOI 10.1016/j.yexmp.2011.06.005; Matei D, 2008, CANCER-AM CANCER SOC, V113, P723, DOI 10.1002/cncr.23605; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Mundhenke C, 2008, J CANCER RES CLIN, V134, P1397, DOI 10.1007/s00432-008-0408-0; MUTCH DG, 1994, CLIN OBSTET GYNECOL, V37, P406, DOI 10.1097/00003081-199406000-00017; Nakayama K, 2002, CANCER LETT, V176, P215, DOI 10.1016/S0304-3835(01)00762-5; Norton L, 2006, NAT MED, V12, P875, DOI 10.1038/nm0806-875; Pon YL, 2006, MOL ENDOCRINOL, V20, P3336, DOI 10.1210/me.2006-0125; Posadas EM, 2007, CANCER-AM CANCER SOC, V110, P309, DOI 10.1002/cncr.22757; Raspollini AR, 2004, ANN ONCOL, V15, P594, DOI 10.1093/annonc/mdh139; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roberts KG, 2007, MOL CANCER THER, V6, P1159, DOI 10.1158/1535-7163.MCT-06-0641; Sattler M, 2004, LEUKEMIA RES, V28, pS11, DOI 10.1016/j.leukres.2003.10.004; Schilder RJ, 2008, J CLIN ONCOL, V26, P3418, DOI 10.1200/JCO.2007.14.3420; Schmandt RE, 2003, CANCER-AM CANCER SOC, V98, P758, DOI 10.1002/cncr.11561; Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950; Shaw TJ, 2007, GYNECOL ONCOL, V105, P122, DOI 10.1016/j.ygyno.2006.10.052; Shield K, 2009, GYNECOL ONCOL, V113, P143, DOI 10.1016/j.ygyno.2008.11.032; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Stewart JM, 2011, P NATL ACAD SCI USA, V108, P6468, DOI 10.1073/pnas.1005529108; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG GL, 1993, BLOOD, V82, P3610; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Zajchowski DA, 2012, MOL CANCER THER, V11, P492, DOI 10.1158/1535-7163.MCT-11-0746; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	50	147	150	1	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2767	2781		10.1038/onc.2012.290	http://dx.doi.org/10.1038/onc.2012.290			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22797058				2022-12-28	WOS:000319808000008
J	Vitolo, MI; Boggs, AE; Whipple, RA; Yoon, JR; Thompson, K; Matrone, MA; Cho, EH; Balzer, EM; Martin, SS				Vitolo, M. I.; Boggs, A. E.; Whipple, R. A.; Yoon, J. R.; Thompson, K.; Matrone, M. A.; Cho, E. H.; Balzer, E. M.; Martin, S. S.			Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin	ONCOGENE			English	Article						PTEN; microtentacle; actin; contractility; cofilin; metastasis	CIRCULATING TUMOR-CELLS; NONMUSCLE MYOSIN-II; LIGHT-CHAIN KINASE; BREAST-CANCER; LIM-KINASE; F-ACTIN; PHOSPHOINOSITIDE-BINDING; PHOSPHATASE SLINGSHOT; INHIBITION; EXPRESSION	Loss of PTEN tumor suppressor enhances metastatic risk in breast cancer, although the underlying mechanisms are poorly defined. We report that homozygous deletion of PTEN in mammary epithelial cells induces tubulin-based microtentacles (McTNs) that facilitate cell reattachment and homotypic aggregation. Treatment with contractility-modulating drugs showed that McTNs in PTEN-/- cells are suppressible by controlling the actin cytoskeleton. Because outward microtubule extension is counteracted by actin cortical contraction, increased activity of actin-severing proteins could release constraints on McTN formation in PTEN-/- cells. One such actin-severing protein, cofilin, is activated in detached PTEN-/- cells that could weaken the actin cortex to promote McTNs. Expression of wild-type cofilin, an activated mutant (S3A), and an inactive mutant (S3E) demonstrated that altering cofilin phosphorylation directly affects McTNs formation. Chemical inhibition of PI3K did not reduce McTNs or inactivate cofilin in PTEN-/- cells. Additionally, knock-in expression of the two most common PI3K-activating mutations observed in human cancer patients did not increase McTNs or activate cofilin. PTEN loss and PI3K activation also caused differential activation of the cofilin regulators, LIM-kinase1 (LIMK) and Slingshot-1L (SSH). Furthermore, McTNs were suppressed and cofilin was inactivated by restoration of PTEN in the PTEN-/- cells, indicating that both the elevation of McTNs and the activation of cofilin are specific results arising from PTEN loss. These data identify a novel mechanism by which PTEN loss could remodel the cortical actin network to facilitate McTNs that promote tumor cell reattachment and aggregation. Using isogenic MCF-10A PTEN-/- and PIK3CA mutants, we have further demonstrated that there are clear differences in activation of cofilin, LIMK and SSH between PTEN loss and PI3K activation, providing a new evidence that these mutations yield distinct cytoskeletal phenotypes, which could have an impact on tumor biology. Oncogene (2013) 32, 2200-2210; doi:10.1038/onc.2012.234; published online 11 June 2012	[Vitolo, M. I.; Boggs, A. E.; Whipple, R. A.; Yoon, J. R.; Thompson, K.; Martin, S. S.] Univ Maryland, Marlene & Stewart Greenebaum NCI Canc Ctr, Baltimore, MD 21201 USA; [Boggs, A. E.; Yoon, J. R.; Martin, S. S.] Univ Maryland, Grad Program Life Sci, Program Mol Med, Baltimore, MD 21201 USA; [Matrone, M. A.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; [Cho, E. H.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Balzer, E. M.] Johns Hopkins Univ, Johns Hopkins Inst NanoBioTechnol, Baltimore, MD USA; [Martin, S. S.] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Scripps Research Institute; Scripps Research Institute; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Martin, SS (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Room 10-29,Bressler Bldg,655 West Baltimore St, Baltimore, MD 21201 USA.	ssmartin@som.umaryland.edu	Cho, Edward/B-3727-2012	Cho, Edward/0000-0002-0278-334X; Vitolo, Michele/0000-0001-8055-9645	Ruth L Kirschstein-National Service Research Award [T32-HL07698]; National Cancer Institute [R01-CA124704]; Susan G Komen Foundation [KG100240]; Era of Hope Scholar award from the Department of Defense [BC100675]; NATIONAL CANCER INSTITUTE [P30CA134274, R01CA154624, R01CA124704] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007698] Funding Source: NIH RePORTER	Ruth L Kirschstein-National Service Research Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); Era of Hope Scholar award from the Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants from the Ruth L Kirschstein-National Service Research Award, T32-HL07698 (MIV), National Cancer Institute, R01-CA124704 (SSM), Susan G Komen Foundation, KG100240 (SSM) and an Era of Hope Scholar award from the Department of Defense, BC100675 (SSM).	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Asch HL, 1996, CANCER RES, V56, P4841; Balzer EM, 2010, BREAST CANCER RES TR, V121, P65, DOI 10.1007/s10549-009-0457-3; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Clark J, 2011, NAT METHODS, V8, P267, DOI 10.1038/NMETH.1564; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Doreian BW, 2009, MOL BIOL CELL, V20, P3142, DOI 10.1091/mbc.E09-03-0197; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Eiseler T, 2009, NAT CELL BIOL, V11, P545, DOI 10.1038/ncb1861; Even-Ram S, 2007, NAT CELL BIOL, V9, P299, DOI 10.1038/ncb1540; Fraley TS, 2005, J BIOL CHEM, V280, P15479, DOI 10.1074/jbc.M500631200; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Glinsky VV, 2003, CANCER RES, V63, P3805; Guck J, 2005, BIOPHYS J, V88, P3689, DOI 10.1529/biophysj.104.045476; Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106; Hale CM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007054; Hsieh SHK, 2006, J NEUROSCI, V26, P1006, DOI 10.1523/JNEUROSCI.2806-05.2006; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; Janmey PA, 2004, NAT REV MOL CELL BIO, V5, P658, DOI 10.1038/nrm1434; Janssen EAM, 2007, CELL ONCOL, V29, P25; Kobayashi M, 2006, EMBO J, V25, P713, DOI 10.1038/sj.emboj.7600973; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; Kusano K, 1999, MOL CELL BIOCHEM, V190, P133, DOI 10.1023/A:1006962210692; Liu CR, 2004, CHINESE MED J-PEKING, V117, P213; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Matrone MA, 2010, ONCOGENE, V29, P3217, DOI 10.1038/onc.2010.68; Matrone MA, 2010, CANCER RES, V70, P7737, DOI 10.1158/0008-5472.CAN-10-1569; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nagata-Ohashi K, 2004, J CELL BIOL, V165, P465, DOI 10.1083/jcb.200401136; Naumov GN, 2002, CANCER RES, V62, P2162; Nishita M, 2004, J BIOL CHEM, V279, P7193, DOI 10.1074/jbc.M312591200; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okagaki T, 1999, J BIOCHEM-TOKYO, V125, P619, DOI 10.1093/oxfordjournals.jbchem.a022328; Perez-Tenorio G, 2007, CLIN CANCER RES, V13, P3577, DOI 10.1158/1078-0432.CCR-06-1609; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Shin DH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007451; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tohtong R, 2003, PROSTATE CANCER P D, V6, P212, DOI 10.1038/sj.pcan.4500663; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Vitolo MI, 2009, CANCER RES, V69, P8275, DOI 10.1158/0008-5472.CAN-09-1067; WEISS L, 1992, CANCER METAST REV, V11, P227, DOI 10.1007/BF01307179; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Whipple RA, 2007, EXP CELL RES, V313, P1326, DOI 10.1016/j.yexcr.2007.02.001; Wiggan O, 2012, DEV CELL, V22, P530, DOI 10.1016/j.devcel.2011.12.026; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; Zschiesche W, 1997, ANTICANCER RES, V17, P561	58	32	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 25	2013	32	17					2200	2210		10.1038/onc.2012.234	http://dx.doi.org/10.1038/onc.2012.234			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689060	Green Accepted			2022-12-28	WOS:000318062800009
J	Whale, AD; Dart, A; Holt, M; Jones, GE; Wells, CM				Whale, A. D.; Dart, A.; Holt, M.; Jones, G. E.; Wells, C. M.			PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity	ONCOGENE			English	Article						prostate; cancer; motility	CHRONIC MYELOID-LEUKEMIA; SIGNALING PATHWAY; LIM KINASE; CANCER; MIGRATION; INVASION; LOOP; RESISTANCE; IMATINIB; COFILIN	Hepatocyte growth factor (HGF) and its receptor (c-Met) are associated with cancer cell motility and invasiveness. p21-activated kinase 4 (PAK4), a potential therapeutic target, is recruited to and activated by c-Met. In response, PAK4 phosphorylates LIM kinase 1 (LIMK1) in an HGF-dependent manner in metastatic prostate carcinoma cells. PAK4 overexpression is known to induce increased cell migration speed but the requirement for kinase activity has not been established. We have used a panel of PAK4 truncations and mutations in a combination of overexpression and RNAi rescue experiments to determine the requirement for PAK4 kinase activity during carcinoma cell motility downstream of HGF. We find that neither the kinase domain alone nor a PAK4 mutant unable to bind Cdc42 is able to fully rescue cell motility in a PAK4-deficient background. Nevertheless, we find that PAK4 kinase activity and associated LIMK1 activity are essential for carcinoma cell motility, highlighting PAK4 as a potential anti-metastatic therapeutic target. We also show here that overexpression of PAK4 harbouring a somatic mutation, E329K, increased the HGF-driven motility of metastatic prostate carcinoma cells. E329 lies within the glycine-rich loop region of the kinase. Our data suggest that E329K mutation leads to a modest increase in kinase activity, conferring resistance to competitive ATP inhibitors in addition to promoting cell migration. The existence of such a mutation may have implications for the development of PAK4-specific competitive ATP inhibitors should PAK4 be further explored for clinical inhibition. Oncogene (2013) 32, 2114-2120; doi:10.1038/onc.2012.233; published online 11 June 2012	[Whale, A. D.; Holt, M.; Jones, G. E.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Whale, A. D.; Dart, A.; Wells, C. M.] Kings Coll London, Div Canc Studies, London SE1 1UL, England	University of London; King's College London; University of London; King's College London	Wells, CM (corresponding author), Kings Coll London, Div Canc Studies, New Hunts House,Guys Campus, London SE1 1UL, England.	claire.wells@kcl.ac.uk	Jones, Gareth E/H-2282-2012	Jones, Gareth E/0000-0001-5879-3048; Dart, Anna/0000-0002-2412-3502; Holt, Mark/0000-0001-7775-8539	Cancer Research UK; Breast Cancer Campaign	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign	ADW and work in the laboratories of GEJ and CMW is supported by a grant from the Cancer Research UK. AD is supported by a grant from Breast Cancer Campaign. We would like to thank Matthias Krause for gateway destination and pGIPZ-control shRNA vectors. We also thank Mary Holdom for helpful discussion and advice with protein structure analysis and Mike Olsen for practical advice with using LIMKi.	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Ahmed T, 2008, CELL SIGNAL, V20, P1320, DOI 10.1016/j.cellsig.2008.02.021; Baldassa S, 2010, J CELL PHYSIOL, V224, P722, DOI 10.1002/jcp.22172; Barouch-Bentov R, 2009, MOL CELL, V33, P43, DOI 10.1016/j.molcel.2008.12.024; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Cecchi F, 2010, EUR J CANCER, V46, P1260, DOI 10.1016/j.ejca.2010.02.028; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Eswaran J, 2007, STRUCTURE, V15, P201, DOI 10.1016/j.str.2007.01.001; Eswaran J, 2009, CANCER METAST REV, V28, P209, DOI 10.1007/s10555-008-9181-4; Finkelstein E, 2004, J CELL SCI, V117, P1533, DOI 10.1242/jcs.00986; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Girdler F, 2008, CHEM BIOL, V15, P552, DOI 10.1016/j.chembiol.2008.04.013; Grant BD, 1998, BIOCHEMISTRY-US, V37, P7708, DOI 10.1021/bi972987w; Griswold IJ, 2006, MOL CELL BIOL, V26, P6082, DOI 10.1128/MCB.02202-05; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Knudsen BS, 2008, CURR OPIN GENET DEV, V18, P87, DOI 10.1016/j.gde.2008.02.001; Lai AZ, 2009, TRENDS CELL BIOL, V19, P542, DOI 10.1016/j.tcb.2009.07.002; Lai FP, 2008, EMBO J, V27, P982, DOI 10.1038/emboj.2008.34; Li ZL, 2010, MOL BIOL CELL, V21, P3317, DOI 10.1091/mbc.E10-03-0245; Li ZL, 2010, J BIOL CHEM, V285, P23699, DOI 10.1074/jbc.M110.123497; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Murray BW, 2010, P NATL ACAD SCI USA, V107, P9446, DOI 10.1073/pnas.0911863107; Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286-08; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Pavlovsky C, 2009, AM J HEMATOL, V84, P287, DOI 10.1002/ajh.21380; Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Skaggs BJ, 2006, P NATL ACAD SCI USA, V103, P19466, DOI 10.1073/pnas.0609239103; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Wells CM, 2010, J CELL SCI, V123, P1663, DOI 10.1242/jcs.055707; Whale A, 2011, FRONT BIOSCI-LANDMRK, V16, P849, DOI 10.2741/3724; Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V319, P1272, DOI 10.1016/j.bbrc.2004.05.113; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Zhao Zhuo-Shen, 2010, F1000 Biol Rep, V2, P70, DOI 10.3410/B2-70; Zicha D, 1997, Methods Mol Biol, V75, P449	37	40	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2114	2120		10.1038/onc.2012.233	http://dx.doi.org/10.1038/onc.2012.233			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22689056	Green Accepted			2022-12-28	WOS:000317919900013
J	Baker, AM; Bird, D; Lang, G; Cox, TR; Erler, JT				Baker, A-M; Bird, D.; Lang, G.; Cox, T. R.; Erler, J. T.			Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK	ONCOGENE			English	Article						colorectal cancer; metastasis; lysyl oxidase; focal adhesion kinase	FOCAL ADHESION KINASE; TUMOR-GROWTH; METASTASIS; TENSION; CELLS; SRC	The extracellular, matrix-modifying enzyme lysyl oxidase (LOX) has recently been linked to colorectal cancer (CRC) progression, in particular to the stages of invasion and metastasis. In this report, we use cell lines expressing a catalytically inactive mutant form of LOX to show that catalytic activity is required for LOX-mediated effects on proliferation and invasion in both in vitro and in vivo models of CRC. Furthermore, we use rheology to measure the relative stiffness of modified collagen matrices and subcutaneous tumors, and show that LOX-induced collagen cross-linking results in stiffening of the matrix both in vitro and in vivo. We observe a strong association between matrix stiffness and activation of the FAK (focal adhesion kinase)/SRC-signaling pathway, with a stiffer environment resulting in increased FAK/SRC phosphorylation and a more proliferative and invasive phenotype. We are the first to show a direct relationship between LOX enzymatic activity and tissue stiffness, and to demonstrate a role for stiffness in driving CRC progression. Our findings provide significant evidence to suggest that therapeutic inhibition of LOX activity may provide a novel effective treatment option for patients with metastatic CRC. Oncogene (2013) 32, 1863-1868; doi: 10.1038/onc.2012.202; published online 28 May 2012	[Baker, A-M; Bird, D.; Lang, G.; Cox, T. R.; Erler, J. T.] Inst Canc Res, Div Canc Biol, Hypoxia & Metastasis Team, London SW3 6JB, England; [Bird, D.; Lang, G.; Cox, T. R.; Erler, J. T.] Inst Canc Res, Div Canc Biol, CRUK Tumour Cell Signalling Unit, London SW3 6JB, England; [Cox, T. R.; Erler, J. T.] Univ Copenhagen, BRIC, DK-2200 Copenhagen N, Denmark	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Copenhagen	Erler, JT (corresponding author), Univ Copenhagen, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen N, Denmark.	janine.erler@bric.ku.dk		Baker, Ann-Marie/0000-0001-8905-9137; Cox, Thomas/0000-0001-9294-1745; Erler, Janine/0000-0001-8675-6527	Medical Research Council [G0800102]; Institute of Cancer Research, Cancer Research UK [C107/A10433]; BRIC; Worldwide Cancer Research [09-0796] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Institute of Cancer Research, Cancer Research UK(Cancer Research UK); BRIC; Worldwide Cancer Research	We would like to thank the staff of the BSU and histopathology departments at the Institute of Cancer Research for assistance with in vivo work and processing of tissue samples. Funding was provided by the Medical Research Council (G0800102 to AMB), the Institute of Cancer Research (JTE), Cancer Research UK (C107/A10433 to TRC, DB, GL and JTE) and BRIC (TRC and JTE).	Baker AM, 2011, JNCI-J NATL CANCER I, V103, P407, DOI 10.1093/jnci/djq569; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Colpaert C, 2001, AM J SURG PATHOL, V25, P1557, DOI 10.1097/00000478-200112000-00016; Csiszar K, 2002, INT J CANCER, V97, P636, DOI 10.1002/ijc.10035; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Girton TS, 1999, J BIOMED MATER RES, V46, P87, DOI 10.1002/(SICI)1097-4636(199907)46:1<87::AID-JBM10>3.0.CO;2-K; Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kim Y, 2009, ONCOL REP, V22, P799, DOI 10.3892/or_00000502; Le QT, 2009, J CLIN ONCOL, V27, P4281, DOI 10.1200/JCO.2008.20.6003; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Pez F, 2011, CANCER RES, V71, P1647, DOI 10.1158/0008-5472.CAN-10-1516; Samuel MS, 2011, CANCER CELL, V19, P776, DOI 10.1016/j.ccr.2011.05.008; Sinkus R, 2000, PHYS MED BIOL, V45, P1649, DOI 10.1088/0031-9155/45/6/317; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Tilghman RW, 2008, SEMIN CANCER BIOL, V18, P45, DOI 10.1016/j.semcancer.2007.08.002	18	198	202	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2013	32	14					1863	1868		10.1038/onc.2012.202	http://dx.doi.org/10.1038/onc.2012.202			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22641216				2022-12-28	WOS:000317043900012
J	Guerra, E; Trerotola, M; Aloisi, AL; Tripaldi, R; Vacca, G; La Sorda, R; Lattanzio, R; Piantelli, M; Alberti, S				Guerra, E.; Trerotola, M.; Aloisi, A. L.; Tripaldi, R.; Vacca, G.; La Sorda, R.; Lattanzio, R.; Piantelli, M.; Alberti, S.			The Trop-2 signalling network in cancer growth	ONCOGENE			English	Article						Trop-2; human tumours; cell growth; cell signalling	CELL-ADHESION MOLECULES; HUMAN CARCINOMAS; BREAST-CANCER; MESSENGER-RNA; FREE SURVIVAL; PH DOMAINS; CYCLIN D1; EP-CAM; GENE; TRANSCRIPTION	Our findings show that upregulation of a wild-type Trop-2 has a key controlling role in human cancer growth, and that tumour development is quantitatively driven by Trop-2 expression levels. However, little is known about the regulation of expression of the TROP2 gene. Hence, we investigated the TROP2 transcription control network. TROP2 expression was shown to depend on a highly interconnected web of transcription factors: TP63/TP53L, ERG, GRHL1/Get-1 (grainyhead-like epithelial transactivator), HNF1A/TCF-1 (T-cell factor), SPI1/PU.1, WT (Wilms' tumour) 1, GLIS2, AIRE (autoimmune regulator), FOXM1 (forkhead box M1) and FOXP3, with HNF4A as the major network hub. TROP2 upregulation was shown to subsequently drive the expression and activation of CREB1 (cyclic AMP-responsive-element binding protein), Jun, NF-kappa B, Rb, STAT1 and STAT3 through induction of the cyclin D1 and ERK (extracellular signal regulated kinase)/MEK (MAPK/ERK kinase) pathways. Growth-stimulatory signalling through NF-kappa B, cyclin D1 and ERK was shown to require an intact Trop-2 cytoplasmic tail. Network hubs and interacting partners are co-expressed with Trop-2 in primary human tumours, supporting a role of this signalling network in cancer growth. Oncogene (2013) 32, 1594-1600; doi:10.1038/onc.2012.151; published online 7 May 2012	[Guerra, E.; Trerotola, M.; Aloisi, A. L.; Tripaldi, R.; Vacca, G.; La Sorda, R.; Lattanzio, R.; Piantelli, M.; Alberti, S.] Fdn Univ G DAnnunzio, Dept Oncol & Expt Med, Unit Canc Pathol, Chieti, Italy; [Guerra, E.; Trerotola, M.; Aloisi, A. L.; Tripaldi, R.; Vacca, G.; La Sorda, R.; Lattanzio, R.; Piantelli, M.; Alberti, S.] Fdn Univ G DAnnunzio, CeSI, Chieti, Italy; [Alberti, S.] Univ G DAnnunzio, Dept Neurosci & Imaging, Chieti, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Alberti, S (corresponding author), Fdn Univ G DAnnunzio, CeSI, Dept Oncol & Expt Med, Unit Canc Pathol, Via Colle Ara, I-66100 Chieti, Italy.	s.alberti@unich.it	Trerotola, Marco/J-9015-2016; Lattanzio, Rossano/K-1927-2018; Alberti, Saverio/M-4511-2014	Trerotola, Marco/0000-0003-1855-7002; Lattanzio, Rossano/0000-0001-9803-4476; Alberti, Saverio/0000-0002-4647-6042; Guerra, Emanuela/0000-0002-7091-8621; Piantelli, Mauro/0000-0003-0154-482X	Fondazione of the Cassa di Risparmio della Provincia di Chieti; ABO Foundation [CH01D0081]; Fondazione compagnia di San Paolo; Italian Ministry of Health [RicOncol RF-EMR-2006-361866]; Italian Foundation for Cancer Research (FIRC, Italy); Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Fondazione of the Cassa di Risparmio della Provincia di Chieti; ABO Foundation; Fondazione compagnia di San Paolo(Compagnia di San Paolo); Italian Ministry of Health(Ministry of Health, Italy); Italian Foundation for Cancer Research (FIRC, Italy)(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This study was supported by the Fondazione of the Cassa di Risparmio della Provincia di Chieti, ABO Foundation (Grant CH01D0081), Fondazione compagnia di San Paolo, and the Italian Ministry of Health (RicOncol RF-EMR-2006-361866). MT was a recipient of a scholarship from the Italian Foundation for Cancer Research (FIRC, Italy).	Alberti S, 1999, PROTEINS, V35, P360; Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; ALBERTI S, 1988, P NATL ACAD SCI USA, V85, P8391, DOI 10.1073/pnas.85.22.8391; ALBERTI S, 1990, NUCLEIC ACIDS RES, V18, P351, DOI 10.1093/nar/18.2.351; ALBERTI S, 1992, HYBRIDOMA, V11, P539, DOI 10.1089/hyb.1992.11.539; Ambrogi F, 2006, CLIN CANCER RES, V12, P781, DOI 10.1158/1078-0432.CCR-05-0763; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Aplin AE, 1998, PHARMACOL REV, V50, P197; Attanasio M, 2007, NAT GENET, V39, P1018, DOI 10.1038/ng2072; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bienvenu F, 2005, MOL BIOL CELL, V16, P1850, DOI 10.1091/mbc.e04-08-0654; Biganzoli E, 2011, JPN J CLIN ONCOL, V41, P172, DOI 10.1093/jjco/hyq227; Blazar M, 2001, MOL CELL BIOL, V21, P2570, DOI 10.1128/MCB.21.7.2570-2580.2001; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Calabrese G, 2001, CYTOGENET CELL GENET, V92, P164, DOI 10.1159/000056891; Castellone MD, 2009, CANCER RES, V69, P1867, DOI 10.1158/0008-5472.CAN-08-1982; Cheng C, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-225; Chong JM, 2001, J BIOL CHEM, V276, P5804, DOI 10.1074/jbc.M008839200; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Cubas R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-253; Cubas R, 2009, BBA-REV CANCER, V1796, P309, DOI 10.1016/j.bbcan.2009.08.001; El Sewedy T, 1998, INT J CANCER, V75, P324, DOI 10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.3.CO;2-5; FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520; Guerra E, 2008, CANCER RES, V68, P8113, DOI 10.1158/0008-5472.CAN-07-6135; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Horiuchi K, 2006, P NATL ACAD SCI USA, V103, P17278, DOI 10.1073/pnas.0608357103; Humphries MJ, 1998, TRENDS CELL BIOL, V8, P78, DOI 10.1016/S0962-8924(98)80016-0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LINNENBACH AJ, 1993, MOL CELL BIOL, V13, P1507, DOI 10.1128/MCB.13.3.1507; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; Loeb DM, 2002, INT J HEMATOL, V76, P117, DOI 10.1007/BF02982573; Mangino G, 2002, INT J CANCER, V101, P353, DOI 10.1002/ijc.10616; Mazumdar J, 2010, NAT CELL BIOL, V12, P1007, DOI 10.1038/ncb2102; Merlo A, 2009, J CLIN ONCOL, V27, P1746, DOI 10.1200/JCO.2008.17.9036; NAQUET P, 1989, THYMUS, V13, P217; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Peiro G, 2007, AM J CLIN PATHOL, V127, P780, DOI 10.1309/FWHEQX6HB9190LVY; Querzoli P, 2006, CLIN CANCER RES, V12, P6696, DOI 10.1158/1078-0432.CCR-06-0569; Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; Siu YT, 2007, FEBS J, V274, P3224, DOI 10.1111/j.1742-4658.2007.05884.x; Su AI, 2001, CANCER RES, V61, P7388; Terrinoni A, 2001, GENE CHROMOSOME CANC, V31, P209, DOI 10.1002/gcc.1137; Tinari N, 2006, CLIN CANCER RES, V12, P1501, DOI 10.1158/1078-0432.CCR-05-0978; Trerotola M, 2013, ONCOGENE, V32, P222, DOI 10.1038/onc.2012.36; Trerotola M, 2010, BBA-REV CANCER, V1805, P119, DOI 10.1016/j.bbcan.2009.12.002; Varughese J, 2011, CANCER-AM CANCER SOC, V117, P3163, DOI 10.1002/cncr.25891; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Yu ZQ, 2006, DEV BIOL, V299, P122, DOI 10.1016/j.ydbio.2006.07.015; Yuan L, 2009, CIRC RES, V104, P1049, DOI 10.1161/CIRCRESAHA.108.190751; Zanna P, 2007, CANCER-AM CANCER SOC, V110, P452, DOI 10.1002/cncr.22785; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	55	71	80	5	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1594	1600		10.1038/onc.2012.151	http://dx.doi.org/10.1038/onc.2012.151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22562244				2022-12-28	WOS:000316456000012
J	Cortes-Sempere, M; de Miguel, MP; Pernia, O; Rodriguez, C; Carpeno, JD; Nistal, M; Conde, E; Lopez-Rios, F; Belda-Iniesta, C; Perona, R; Ibanez de Caceres, I				Cortes-Sempere, M.; de Miguel, M. P.; Pernia, O.; Rodriguez, C.; de Castro Carpeno, J.; Nistal, M.; Conde, E.; Lopez-Rios, F.; Belda-Iniesta, C.; Perona, R.; Ibanez de Caceres, I.			IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer	ONCOGENE			English	Article						NSCLC; cisplatin resistance; IGFIR; IGFBP-3; hypermethylation	GROWTH-FACTOR RECEPTOR; INDUCED DNA HYPERMETHYLATION; OXIDATIVE STRESS; DRUG-RESISTANCE; TUMOR-GROWTH; GENE; CHEMOTHERAPY; EXPRESSION; GEFITINIB; MUTATION	Although many cancers initially respond to cisplatin (CDDP)-based chemotherapy, resistance frequently develops. Insulin-like growth factor-binding protein-3 (IGFBP-3) silencing by promoter methylation is involved in the CDDP-acquired resistance process in non-small cell lung cancer (NSCLC) patients. Our purpose is to design a translational-based profile to predict resistance in NSCLC by studying the role of IGFBP-3 in the phosphatidyl inositol 3-kinase (PI3K) signaling pathway. We have first examined the relationship between IGFBP-3 expression regulated by promoter methylation and activation of the epidermal growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGFIR) and PI3K/AKT pathways in 10 human cancer cell lines and 25 NSCLC patients with known IGFBP-3 methylation status and response to CDDP. Then, to provide a helpful tool that enables clinicians to identify patients with a potential response to CDDP, we have calculated the association between our diagnostic test and the true outcome of analyzed samples in terms of cisplatin IC50; the inhibitory concentration that kills 50% of the cell population. Our results suggest that loss of IGFBP-3 expression by promoter methylation in tumor cells treated with CDDP may activate the PI3K/AKT pathway through the specific derepression of IGFIR signaling, inducing resistance to CDDP. This study also provides a predictive test for clinical practice with an accuracy and precision of 0.84 and 0.9, respectively, (P = 0.0062). We present a biomarker test that could provide clinicians with a robust tool with which to decide on the use of CDDP, improving patient clinical outcomes.	[Cortes-Sempere, M.; Perona, R.] CSIC UAM, CIBER Enfermedades Raras CIBERER, Inst Invest Biomed, Madrid 28029, Spain; [Cortes-Sempere, M.; Pernia, O.; Rodriguez, C.; de Castro Carpeno, J.; Belda-Iniesta, C.; Perona, R.; Ibanez de Caceres, I.] Biomarkers & Expt Therapeut Canc IdiPAZ, Madrid, Spain; [de Miguel, M. P.] La Paz Univ Hosp, IdiPAZ, Lab Cellular Engn, Madrid, Spain; [Pernia, O.; Rodriguez, C.; Ibanez de Caceres, I.] La Paz Univ Hosp, INGEMM, Canc Epigenet Lab, Madrid, Spain; [Nistal, M.] La Paz Univ Hosp, Dept Pathol, Madrid, Spain; [Conde, E.] Madrid Norte Sanchinarro Univ Hosp, Dept Pathol, Madrid, Spain; [Belda-Iniesta, C.] Madrid Norte Sanchinarro Univ Hosp, Dept Med Oncol, Madrid, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital Universitario La Paz	Perona, R (corresponding author), CSIC UAM, CIBER Enfermedades Raras CIBERER, Biomarkers & Expt Therapeut Canc IdiPAZ, Inst Invest Biomed, C Arturo Duperier 4, Madrid 28029, Spain.	rperona@iib.uam.es; inma.ibanezca@salud.madrid.org	Rodriguez-Antolin, Carlos/ABD-9119-2020	Rodriguez-Antolin, Carlos/0000-0001-6682-0771; Belda Iniesta, Cristobal/0000-0003-3254-7492	'Miguel Servet' program [CP08/000689, PI-717]; MINECO [SAF2010-19230]; FIS [PS09/00472, PI08-1485, FIS 11-00949]; Miguel Servet [PI-717, CP 08/000689];  [PI08/1485];  [PI11/00949]	'Miguel Servet' program; MINECO(Spanish Government); FIS(Instituto de Salud Carlos III); Miguel Servet; ; 	We thank J Siegfried for the English correction, F Dominguez for her technical help, the Health Investigation Funding to IIC through the 'Miguel Servet' program (CP08/000689; PI-717) and acknowledge the support of PI08/1485 and PS09/00472 and PI11/00949 projects. We thank MINECO for its support through SAF2010-19230 Grant. This work was supported by FIS PI08-1485, FIS 11-00949, PS09/00472 and Miguel Servet financial support to Ibanez de Caceres, I (CP 08/000689; PI-717).	Aleksic T, 2010, CANCER RES, V70, P6412, DOI 10.1158/0008-5472.CAN-10-0052; Attia SM, 2012, MUTAT RES-GEN TOX EN, V741, P22, DOI 10.1016/j.mrgentox.2011.10.008; Bai T, 2006, INT J ONCOL, V28, P497; Campos ACE, 2007, NEOPLASIA, V9, P1111, DOI 10.1593/neo.07712; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chakravarti A, 2002, CANCER RES, V62, P200; Chang XF, 2010, CANCER RES, V70, P2870, DOI 10.1158/0008-5472.CAN-09-3427; Chang YS, 2002, CLIN CANCER RES, V8, P3796; Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Chen HB, 2006, CANCER RES, V66, P9009, DOI 10.1158/0008-5472.CAN-06-0101; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Ferroni P, 2011, REJUV RES, V14, P293, DOI 10.1089/rej.2010.1141; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Hamano R, 2011, CLIN CANCER RES, V17, P3029, DOI 10.1158/1078-0432.CCR-10-2532; Ibanez de Caceres I, 2010, ONCOGENE, V29, P1681, DOI 10.1038/onc.2009.454; Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; James SR, 2006, ONCOGENE, V25, P6975, DOI 10.1038/sj.onc.1209678; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Judde JG, 2007, INT J CANCER, V120, P1579, DOI 10.1002/ijc.22364; Khan R, 2012, TOXICOL APPL PHARM, V258, P315, DOI 10.1016/j.taap.2011.11.013; Koul S, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-16; Lawless MW, 2009, J CELL MOL MED, V13, P826, DOI 10.1111/j.1582-4934.2008.00571.x; Lawless MW, 2010, EXPERT OPIN THER TAR, V14, P1225, DOI 10.1517/14728222.2010.526933; Malinen M, 2011, NUCLEIC ACIDS RES, V39, P502, DOI 10.1093/nar/gkq820; Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Niu X, 2012, ONCOGENE, V31, P776, DOI 10.1038/onc.2011.266; NYCE J, 1989, CANCER RES, V49, P5829; Nyce JW, 1997, MUTAT RES-REV MUTAT, V386, P153, DOI 10.1016/S1383-5742(96)00051-8; Oliveras-Ferraros C, 2008, INT J ONCOL, V33, P1165, DOI 10.3892/ijo_00000106; Qiu YY, 2005, CANCER DETECT PREV, V29, P456, DOI 10.1016/j.cdp.2005.05.004; Romanelli RJ, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M704309200; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Sonnweber B, 2006, J CLIN PATHOL, V59, P255, DOI 10.1136/jcp.2005.027615; Takeda K, 2010, J CLIN ONCOL, V28, P753, DOI 10.1200/JCO.2009.23.3445; Tsai CM, 2011, J THORAC ONCOL, V6, P559, DOI 10.1097/JTO.0b013e3182021ff5; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Wiley A, 2006, INT J GYNECOL CANCER, V16, P210, DOI 10.1111/j.1525-1438.2006.00299.x; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; Zeller C, 2012, ONCOGENE; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	47	52	55	0	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1274	1283		10.1038/onc.2012.146	http://dx.doi.org/10.1038/onc.2012.146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543588				2022-12-28	WOS:000316454500008
J	Jarde, T; Evans, RJ; McQuillan, KL; Parry, L; Feng, GJ; Alvares, B; Clarke, AR; Dale, TC				Jarde, T.; Evans, R. J.; McQuillan, K. L.; Parry, L.; Feng, G. J.; Alvares, B.; Clarke, A. R.; Dale, T. C.			In vivo and in vitro models for the therapeutic targeting of Wnt signaling using a Tet-O Delta N89 beta-catenin system	ONCOGENE			English	Article						Wnt pathway; reversal; colorectal cancer; crypt culture; organoids	SMALL-MOLECULE INHIBITORS; BETA-CATENIN; STEM-CELLS; WNT/BETA-CATENIN; TRANSGENIC MICE; SMALL-INTESTINE; CANCER; DIFFERENTIATION; EXPRESSION; APOPTOSIS	Although significant progress has been made in understanding the importance of Wnt signaling in the initiation of colorectal cancer, less is known about responses that accompany the reversal of oncogenic Wnt signaling. The aim of this study was to analyze in vivo and in vitro responses to an 'ideal' Wnt pathway inhibitor as a model for the therapeutic targeting of the pathway. A tetracycline-inducible transgenic mouse model expressing truncated beta-catenin (Delta N89 beta-catenin) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic beta-catenin expression both in 3D 'crypt culture' and in vivo. Oncogenic Wnt signaling was rapidly and completely reversed. The strongest inhibition of Wnt target gene expression occurred within 24 h of doxycycline removal at which time the target genes Ascl2, Axin2 and C-myc were downregulated to levels below that in the control intestine. In vitro, the small molecule Wnt inhibitor CCT036477 induced a response within 4 h of treatment. By 7 days following doxycycline withdrawal, gene expression, cell proliferation and tissue morphology were undistinguishable from control animals.In conclusion, these results demonstrate that the reversal of Wnt signaling by inhibitors should ideally be studied within hours of treatment. The reversible system described, involving medium throughput in vitro approaches and rapid in vivo responses, should allow the rapid advance of early stage compounds into efficacy models that are more usually considered later in the drug discovery pipeline. Oncogene (2013) 32, 883-893; doi:10.1038/onc.2012.103; published online 2 April 2012	[Jarde, T.; Evans, R. J.; McQuillan, K. L.; Parry, L.; Feng, G. J.; Alvares, B.; Clarke, A. R.; Dale, T. C.] Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Cardiff University	Dale, TC (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Biomed Sci Bldg,Museum Ave, Cardiff CF10 3US, S Glam, Wales.	daletc@cardiff.ac.uk	Jarde, Thierry/H-6781-2019; Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014; Dale, Trevor/D-3749-2009; Parry, Lee/A-9623-2011	Jarde, Thierry/0000-0001-7483-8672; Dale, Trevor/0000-0002-4880-9963; Clarke, Alan/0000-0002-4281-426X; Parry, Lee/0000-0002-4467-9196	Cancer Research UK; Breast Cancer Campaign; BBSRC [BB/D00117X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D00117X/1] Funding Source: researchfish; Cancer Research UK [15937] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK)	This work was supported by Cancer Research UK and the Breast Cancer Campaign. We thank C Beard and R Jaenisch (The Whitehead Institute for Biomedical Research, Massachusetts) for the embryonic stem cell lines and for technical advice; K Ewan, A Offergeld and S Braun (Cardiff School of Biosciences) for their assistance in tissue staining and cell counting; P Watson (Cardiff School of Biosciences) for his assistance in fluorescence microscopy; O Sansom and K Myant for their assistance in organoid culture; B Allen and O Asby for technical assistance in blastocyst injections and chimera crosses; and D Scarborough for help with histology.	Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180; Binnerts ME, 2007, P NATL ACAD SCI USA, V104, P14700, DOI 10.1073/pnas.0702305104; BOCKER R, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2116; Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816; Coste I, 2007, GASTROENTEROLOGY, V132, P1299, DOI 10.1053/j.gastro.2007.01.029; Ewan K, 2010, CANCER RES, V70, P5963, DOI 10.1158/0008-5472.CAN-10-1028; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Minke KS, 2009, EUR J HAEMATOL, V82, P165, DOI 10.1111/j.1600-0609.2008.01188.x; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Polakis P, 2000, GENE DEV, V14, P1837; Romagnolo B, 1999, CANCER RES, V59, P3875; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Scholer-Dahirel A, 2011, P NATL ACAD SCI USA, V108, P17135, DOI 10.1073/pnas.1104182108; Shorning BY, 2012, GUT, V61, P202, DOI 10.1136/gutjnl-2011-300046; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Wang YQ, 2009, MOL CANCER THER, V8, P2103, DOI 10.1158/1535-7163.MCT-09-0282; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8	38	34	35	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					883	893		10.1038/onc.2012.103	http://dx.doi.org/10.1038/onc.2012.103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469981	Green Accepted			2022-12-28	WOS:000316581100008
J	Ross, RL; Askham, JM; Knowles, MA				Ross, R. L.; Askham, J. M.; Knowles, M. A.			PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs	ONCOGENE			English	Article						PIK3CA; PI3K signaling; bladder cancer; urothelium	BLADDER-CANCER; HIGH-FREQUENCY; N-CADHERIN; GENE; KINASE; P110-ALPHA; EXPRESSION; GROWTH; DOMAIN; FGFR3	Although activating mutations of PIK3CA are frequent in urothelial carcinoma (UC), no information is available on their specific effects in urothelial cells or the basis for the observed mutation spectrum, which has a large excess of helical domain mutations. We investigated the phenotypic and signaling consequences of hotspot and UC-specific rare PIK3CA mutations in immortalized normal human urothelial cells (NHUC) and mouse fibroblasts (NIH3T3). Our results indicate that in NHUC, rare mutant forms and all three hotspot mutant forms of PIK3CA can activate the PI3K/AKT pathway. The relative frequency at which helical domain and kinase domain mutations are found in UC is related to their potency in inducing signaling downstream of AKT and to the phenotypic effects induced in this cell type (E545K>E542K>H1047R). Helical domain mutations E542K and E545K conferred a significant proliferative advantage at confluence and under conditions of nutrient depletion, and increased cellular resistance to anoikis. Both helical and kinase domain mutants induced increased NHUC cell motility and migration towards a chemoattractant, though no significant differences were found between the mutant forms. In NIH3T3 cells, the kinase domain mutant H1047R induced high levels of AKT activation, but helical domain mutants were significantly less potent and this was reflected in their relative abilities to confer anchorage-independent growth. Our findings indicate that the effects of mutant PIK3CA are both cell type- and mutation-specific. Helical domain mutations in PIK3CA may confer a selective advantage in the urotheliunn in vivo by overcoming normal contact-mediated inhibitory signals and allowing proliferation in nutrient-limiting conditions. Mutant forms of PIK3CA may also stimulate intraepithelial cell movement, which could contribute to spread of cells within the urothelium. Oncogene (2013) 32, 768-776; doi:10.1038/onc.2012.87; published online 19 March 2012	[Ross, R. L.; Askham, J. M.; Knowles, M. A.] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds Inst Mol Med, Sect Expt Oncol, Leeds LS9 7TF, W Yorkshire, England; [Askham, J. M.] Univ Leeds, Mol Epidemiol Unit, Leeds Inst Genet Hlth & Therapeut, LIGHT Labs, Leeds, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; University of Leeds	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Leeds Inst Mol Med, Sect Expt Oncol, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	m.a.knowles@leeds.ac.uk		Knowles, Margaret/0000-0002-9363-8657	Medical Research Council; University of Leeds	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Leeds	This work was funded by a PhD studentship from the Medical Research Council, awarded via the University of Leeds.	Askham JM, 2010, ONCOGENE, V29, P150, DOI 10.1038/onc.2009.315; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Cain RJ, 2009, BIOL CELL, V101, P13, DOI 10.1042/BC20080079; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Carson JD, 2008, BIOCHEM J, V409, P519, DOI 10.1042/BJ20070681; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Chaussade C, 2009, BIOCHEM BIOPH RES CO, V381, P577, DOI 10.1016/j.bbrc.2009.02.081; di Martino E, 2009, ONCOGENE, V28, P4306, DOI 10.1038/onc.2009.280; Fu Z, 2003, P NATL ACAD SCI USA, V100, P3275, DOI 10.1073/pnas.0535975100; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo XN, 2007, CANCER RES, V67, P5851, DOI 10.1158/0008-5472.CAN-07-0049; Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310; Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821; Lopez-Knowles E, 2006, CANCER RES, V66, P7401, DOI 10.1158/0008-5472.CAN-06-1182; Mandelker D, 2009, P NATL ACAD SCI USA, V106, P16996, DOI 10.1073/pnas.0908444106; Murugan AK, 2008, INT J ONCOL, V32, P101; Pang H, 2009, CANCER RES, V69, P8868, DOI 10.1158/0008-5472.CAN-09-1968; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Rieger-Christ KM, 2007, J CELL BIOCHEM, V102, P377, DOI 10.1002/jcb.21299; Rieger-Christ KM, 2004, ONCOGENE, V23, P4745, DOI 10.1038/sj.onc.1207629; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Samuels Y, 2006, CURR OPIN ONCOL, V18, P77, DOI 10.1097/01.cco.0000198021.99347.b9; Shekar SC, 2005, J BIOL CHEM, V280, P27850, DOI 10.1074/jbc.M506005200; Shin JJ, 2004, ARCH OTOLARYNGOL, V130, P68, DOI 10.1001/archotol.130.1.68; Sjodahl G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018583; SOULE HD, 1990, CANCER RES, V50, P6075; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Theodorescu D, 1998, CELL GROWTH DIFFER, V9, P919; Tomlinson D, 2007, ONCOGENE, V26, P5889, DOI 10.1038/sj.onc.1210399; Tomlinson DC, 2007, J PATHOL, V213, P91, DOI 10.1002/path.2207; Wu X, 2004, BJU INT, V93, P143, DOI 10.1111/j.1464-410X.2004.04574.x; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zhang HJ, 2008, BREAST CANCER RES TR, V112, P217, DOI 10.1007/s10549-007-9847-6; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	43	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2013	32	6					768	776		10.1038/onc.2012.87	http://dx.doi.org/10.1038/onc.2012.87			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430209				2022-12-28	WOS:000315746700010
J	Boll, K; Reiche, K; Kasack, K; Morbt, N; Kretzschmar, AK; Tomm, JM; Verhaegh, G; Schalken, J; von Bergen, M; Horn, F; Hackermuller, J				Boll, K.; Reiche, K.; Kasack, K.; Moerbt, N.; Kretzschmar, A. K.; Tomm, J. M.; Verhaegh, G.; Schalken, J.; von Bergen, M.; Horn, F.; Hackermueller, J.			MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma	ONCOGENE			English	Article						microRNAs; prostate carcinoma; androgen receptor signaling; MAPK pathway; microRNA targets	ANDROGEN RECEPTOR; MICRORNA EXPRESSION; TRANSCRIPTIONAL ACTIVITY; CANCER CELLS; GROWTH; IDENTIFICATION; PROLIFERATION; PROGRESSION; COACTIVATOR; INVASION	With similar to 30 000 deaths annually in the United States, prostate cancer (PCa) is a major oncologic disease. Here we show that the microRNAs miR-130a, miR-203 and miR-205 jointly interfere with the two major oncogenic pathways in prostate carcinoma and are downregulated in cancer tissue. Using transcriptomics we show that the microRNAs repress several gene products known to be overexpressed in this cancer. Argonaute 2 (AGO2) co-immunoprecipitation, reporter assays and western blot analysis demonstrate that the microRNAs directly target several components of the mitogen-activated protein kinase (MAPK) and androgen receptor (AR) signaling pathways, among those several AR coregulators and HRAS (Harvey rat sarcoma viral oncogene homolog), and repress signaling activity. Both pathways are central for the development of the primary tumor and in particular the progression to its incurable castration-resistant form. Reconstitution of the microRNAs in LNCaP PCa cells induce morphological changes, which resemble the effect of androgen deprivation, and jointly impair tumor cell growth by induction of apoptosis and cell cycle arrest. We therefore propose that these microRNAs jointly act as tumor suppressors in prostate carcinoma and might interfere with progression to castration resistance. Oncogene (2013) 32, 277-285; doi:10.1038/onc.2012.55; published online 5 March 2012	[Boll, K.; Reiche, K.; Kasack, K.; Kretzschmar, A. K.; Horn, F.; Hackermueller, J.] Fraunhofer IZI, RNom Grp, Leipzig, Germany; [Boll, K.; Kasack, K.; Horn, F.] Univ Leipzig, Inst Clin Immunol, D-04109 Leipzig, Germany; [Reiche, K.; Kasack, K.; Hackermueller, J.] UFZ Helmholtz Ctr Environm Res, Young Investigators Grp Bioinformat & Transcript, D-04318 Leipzig, Saxony, Germany; [Kasack, K.] Univ Leipzig, LIFE Leipzig Res Ctr Civilizat Dis, D-04109 Leipzig, Germany; [Moerbt, N.; Tomm, J. M.; von Bergen, M.; Hackermueller, J.] UFZ Helmholtz Ctr Environm Res, Dept Prote, D-04318 Leipzig, Saxony, Germany; [Verhaegh, G.; Schalken, J.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, NL-6525 ED Nijmegen, Netherlands; [von Bergen, M.] UFZ Helmholtz Ctr Environm Res, Dept Metabol, D-04318 Leipzig, Saxony, Germany; [Reiche, K.; Hackermueller, J.] Univ Leipzig, Dept Comp Sci, Bioinformat Grp, D-04109 Leipzig, Germany	Fraunhofer Gesellschaft; Leipzig University; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Leipzig University; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Radboud University Nijmegen; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Leipzig University	Hackermuller, J (corresponding author), UFZ Helmholtz Ctr Environm Res, Young Investigators Grp Bioinformat & Transcript, Permoserstr 15, D-04318 Leipzig, Saxony, Germany.	joerg.hackermueller@ufz.de	Schalken, Jack A/B-1277-2014; Verhaegh, Gerald/L-4708-2015; Hackermüller, Jörg/F-2494-2016; Tomm, Janina M/F-8888-2014; von Bergen, Martin/D-7960-2011	Schalken, Jack A/0000-0001-8274-7797; Verhaegh, Gerald/0000-0003-0227-2280; Hackermüller, Jörg/0000-0003-4920-7072; Tomm, Janina M/0000-0001-8161-1812; von Bergen, Martin/0000-0003-2732-2977; Reiche, Kristin/0000-0002-4452-4872	Medical Faculty of the University of Leipzig through funding of the Interdisciplinary Center for Clinical Research; grant 'Sequence and functional analysis of non-coding RNA in prostate carcinoma' [formel.1]; European Framework Programme 6 Project SYNLET [043312]; Initiative and Networking Fund one of the Helmholtz Association [VH-NG-738]; LIFE-Leipzig Research Center for Civilization Diseases, University of Leipzig; European Social Fund; Free State of Saxony	Medical Faculty of the University of Leipzig through funding of the Interdisciplinary Center for Clinical Research; grant 'Sequence and functional analysis of non-coding RNA in prostate carcinoma'; European Framework Programme 6 Project SYNLET; Initiative and Networking Fund one of the Helmholtz Association; LIFE-Leipzig Research Center for Civilization Diseases, University of Leipzig; European Social Fund(European Social Fund (ESF)); Free State of Saxony	We thank Stephan Schreiber, Anne-Sophie Krakovic, Yvonne Kullnick, Sabina Christ, Kathrin Jager, Rudolf Ascherl and Christine Schumann for technical assistance and Catherine Davis for proof-reading. We thank Gunter Meister and colleagues for providing AGO2 antibodies. This work was supported in part by the Medical Faculty of the University of Leipzig through funding of the Interdisciplinary Center for Clinical Research and a formel.1 grant 'Sequence and functional analysis of non-coding RNA in prostate carcinoma', the European Framework Programme 6 Project SYNLET (EC contract number 043312), by the Initiative and Networking Fund one of the Helmholtz Association (VH-NG-738) and by LIFE-Leipzig Research Center for Civilization Diseases, University of Leipzig, which was funded by means of the European Social Fund and the Free State of Saxony.	Acevedo VD, 2009, CELL CYCLE, V8, P580, DOI 10.4161/cc.8.4.7657; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beitzinger M, 2007, RNA BIOL, V4, P76, DOI 10.4161/rna.4.2.4640; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Edwards J, 2003, CLIN CANCER RES, V9, P5271; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Epis MR, 2009, J BIOL CHEM, V284, P24696, DOI 10.1074/jbc.M109.030098; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gandellini P, 2009, TRENDS MOL MED, V15, P381, DOI 10.1016/j.molmed.2009.07.004; Gavrielides MV, 2006, CANCER RES, V66, P11792, DOI 10.1158/0008-5472.CAN-06-1139; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Harada N, 2008, BIOCHEM BIOPH RES CO, V373, P373, DOI 10.1016/j.bbrc.2008.06.024; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hendriksen PJM, 2006, CANCER RES, V66, P5012, DOI 10.1158/0008-5472.CAN-05-3082; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Koochekpour S, 2005, ASIAN J ANDROL, V7, P147, DOI 10.1111/j.1745-7262.2005.00037.x; Koochekpour S, 2007, PROSTATE, V67, P178, DOI 10.1002/pros.20513; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lee TJ, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-31; Majid S, 2010, CANCER-AM CANCER SOC, V116, P5637, DOI 10.1002/cncr.25488; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Mize GJ, 2008, MOL CANCER RES, V6, P1043, DOI 10.1158/1541-7786.MCR-08-0096; Negrini M, 2009, CURR OPIN CELL BIOL, V21, P470, DOI 10.1016/j.ceb.2009.03.002; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Papatsoris AG, 2007, MOL CANCER THER, V6, P811, DOI 10.1158/1535-7163.MCT-06-0610; Park JJ, 2000, CANCER RES, V60, P5946; Pitkanen-Arsiola T, 2006, PROSTATE, V66, P1177, DOI 10.1002/pros.20450; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Prueitt RL, 2008, PROSTATE, V68, P1152, DOI 10.1002/pros.20786; Rajan P, 2008, J PATHOL, V215, P67, DOI 10.1002/path.2324; Saeed B, 1997, PROSTATE, V31, P145; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Satoh T, 2009, ENDOCRINOLOGY, V150, P3283, DOI 10.1210/en.2008-1122; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Sikand K, 2011, INT J CANCER, V129, P810, DOI 10.1002/ijc.25753; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Tillman JE, 2007, CANCER RES, V67, P4630, DOI 10.1158/0008-5472.CAN-06-4556; Truica CI, 2000, CANCER RES, V60, P4709; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Wang JG, 2006, FASEB J, V20, P2142, DOI 10.1096/fj.06-5900fje; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Watahiki A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024950; Weber MJ, 2004, J CELL BIOCHEM, V91, P13, DOI 10.1002/jcb.10683; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	54	182	187	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					277	285		10.1038/onc.2012.55	http://dx.doi.org/10.1038/onc.2012.55			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22391564				2022-12-28	WOS:000314736600002
J	Gupta, SK; Oommen, S; Aubry, MC; Williams, BP; Vlahakis, NE				Gupta, S. K.; Oommen, S.; Aubry, M-C; Williams, B. P.; Vlahakis, N. E.			Integrin alpha 9 beta 1 promotes malignant tumor growth and metastasis by potentiating epithelial-mesenchymal transition	ONCOGENE			English	Article						EMT; alpha 9 beta 1 integrin; lung cancer; metastasis; cell migration	UP-REGULATION; CANCER-CELLS; BETA-CATENIN; VEGF-C; SRC; EXPRESSION; MIGRATION; INVASION; GENE	The integrin alpha 9 beta 1 binds a number of extracellular matrix components to mediate cell adhesion, migration and tissue invasion. Although expressed in a variety of normal human cells including endothelium, it is also expressed in cancer cells. We have previously shown that alpha 9 beta 1 binds VEGF-A to facilitate angiogenesis, an important component of the tumor microenvironment. As alpha 9 beta 1 induces accelerated cancer cell migration, we wished to determine what role it played in cancer growth and metastasis. In this study, we show that alpha 9 beta 1 expression induces molecular changes consistent with epithelial-mesenchymal transition. In addition, we found that alpha 9 beta 1 forms a tri-partite protein complex with beta-catenin and E-cadherin, which dissociates following integrin activation and subsequent src and beta-catenin phosphorylation. These findings were consistent in cells in which: alpha 9 beta 1 was exogenously over-expressed, or when its expression was suppressed in cancer cells endogenously expressing alpha 9 beta 1. These in vitro results are biologically significant as alpha 9 beta 1-expressing cancer cells induce greater tumor growth and metastases in mice as compared to the cells without alpha 9 beta 1 expression or when integrin expression is suppressed. Furthermore, integrin alpha 9 beta 1 is expressed in primary human small cell lung cancer and patients having a high expression of alpha 9 beta 1 demonstrated significantly worse long-term survival compared with patients with low alpha 9 beta 1 expression. These findings highlight a novel mechanism of integrin alpha 9 beta 1 function in human cancer. Oncogene (2013) 32, 141 -150; doi:10.1038/onc.2012.41; published online 27 February 2012	[Gupta, S. K.; Oommen, S.; Williams, B. P.; Vlahakis, N. E.] Mayo Clin, Div Pulm & Crit Care Med, Thorac Dis Res Unit, Rochester, MN 55905 USA; [Aubry, M-C] Mayo Clin, Dept Lab Med & Anat Pathol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Vlahakis, NE (corresponding author), Mayo Clin, Div Pulm & Crit Care Med, Thorac Dis Res Unit, 200 1st St SW, Rochester, MN 55905 USA.	vlahakis.nicholas@gene.com			NHLBI [K08HL076455-05]; Mayo Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL076455] Funding Source: NIH RePORTER	NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Mayo Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Drs Dean Sheppard (UCSF, CA), Debabrata Mukhopadhyay and Edward Leof (Mayo Clinic, Rochester, MN, USA) for helpful discussions; Mark A. Schroeder for help with animal studies; Aaron Bungam for the lung tissue registry. This work was supported by NHLBI Research Grant K08HL076455-05 and Mayo Foundation Research Grants to NEV.	Aleshin A, 2010, NEOPLASIA, V12, P599, DOI 10.1593/neo.10328; Allen MD, 2011, J PATHOL, V223, P646, DOI 10.1002/path.2833; Alphonso A, 2009, NEOPLASIA, V11, P1264, DOI 10.1593/neo.91302; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bazigou E, 2009, DEV CELL, V17, P175, DOI 10.1016/j.devcel.2009.06.017; Borok Z, 2009, J CLIN INVEST, V119, P7, DOI 10.1172/JCI38084; Brown MC, 2008, NEURO-ONCOLOGY, V10, P968, DOI 10.1215/15228517-2008-047; Chattopadhyay N, 2003, J CELL BIOL, V163, P1351, DOI 10.1083/jcb.200306067; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Gupta SK, 2009, J CELL SCI, V122, P2043, DOI 10.1242/jcs.041632; HIBI K, 1994, ONCOGENE, V9, P611; Huang XZ, 2000, MOL CELL BIOL, V20, P5208, DOI 10.1128/MCB.20.14.5208-5215.2000; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jung H, 2008, ONCOGENE, V27, P2635, DOI 10.1038/sj.onc.1210914; Kajiya K, 2005, EMBO J, V24, P2885, DOI 10.1038/sj.emboj.7600763; Kim KK, 2009, J CLIN INVEST, V119, P213, DOI 10.1172/JCI36940; Kim S, 2010, CARCINOGENESIS, V31, P597, DOI 10.1093/carcin/bgq024; Kim Y, 2009, J CELL BIOL, V184, P309, DOI 10.1083/jcb.200806067; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lydolph MC, 2009, EXP CELL RES, V315, P3312, DOI 10.1016/j.yexcr.2009.09.022; Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nam JS, 2002, CLIN CANCER RES, V8, P2430; Oommen S, 2011, J BIOL CHEM, V286, P1083, DOI 10.1074/jbc.M110.175158; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x; Singh P, 2009, J INVEST DERMATOL, V129, P217, DOI 10.1038/jid.2008.201; Song LX, 2006, CANCER RES, V66, P5542, DOI 10.1158/0008-5472.CAN-05-4620; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; Timoshenko AV, 2007, BRIT J CANCER, V97, P1090, DOI 10.1038/sj.bjc.6603993; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Vlahakis NE, 2005, J BIOL CHEM, V280, P4544, DOI 10.1074/jbc.M412816200; Vlahakis NE, 2007, J BIOL CHEM, V282, P15187, DOI 10.1074/jbc.M609323200; Voulgari A, 2006, BIOCHIM BIOPHYS ACTA, V1796, P75; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009	38	38	40	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					141	150		10.1038/onc.2012.41	http://dx.doi.org/10.1038/onc.2012.41			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22370635	Green Accepted			2022-12-28	WOS:000314075500002
J	Traves, PG; Lopez-Fontal, R; Cuadrado, I; Luque, A; Bosca, L; de las Heras, B; Hortelano, S				Traves, P. G.; Lopez-Fontal, R.; Cuadrado, I.; Luque, A.; Bosca, L.; de las Heras, B.; Hortelano, S.			Critical role of the death receptor pathway in the antitumoral effects induced by hispanolone derivatives	ONCOGENE			English	Article						hispanolone derivatives; apoptosis; death receptors; TRAIL; caspase-8	NF-KAPPA-B; INDUCED APOPTOSIS; NITRIC-OXIDE; ACTIVATION; CANCER; INHIBITION; DITERPENES; MECHANISM; THERAPY; KINASE	Labdane diterpenoids have a broad spectrum of biological activities including antibacterial, antiviral and anti-inflammatory properties. However, little is known about their possible role in the apoptotic cell death machinery. Here, we report that hispanolone derivatives, a group of labdane diterpenoids, induce apoptosis in different tumor cell lines by activating caspase-8 with subsequent participation of mitochondrial signaling. Activation of caspase-8 by hispanolone derivatives was followed by a decrease in mitochondrial membrane potential, the release of apoptotic factors from mitochondria to the cytosol, and activation of caspases-9 and 3. Hispanolone derivatives also led to a time-dependent cleavage of Bid. Inhibition of caspase-8 abrogated these processes, suggesting that the death receptor pathway has a critical role in the apoptotic events induced by hispanolone derivatives. In addition, silencing death receptors with small interfering RNA s or pretreating cells with neutralizing antibodies to Fas ligand, tumor necrosis factor receptor 1 (TNF-R1), and TNF-alpha receptor 2 (TRAIL) inhibited diterpenoid-induced apoptosis, revealing it to be dependent on these death receptors. Interestingly, hispanolone derivatives had no effect on non-tumor cells. Consistently, in vivo bioluminescence imaging corroborates this antineoplasic effect, as hispanolone derivatives significantly decrease cancer growth in tumor xenograft assays. These data demostrate the antitumoral effects of hispanolone derivatives and provide relevant preclinical validation for the use of these compounds as potent therapeutic agents in cancer treatment. Oncogene (2013) 32, 259-268; doi:10.1038/onc.2012.23; published online 6 February 2012	[Traves, P. G.; Bosca, L.] UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Lopez-Fontal, R.] Ctr Nacl Invest Cardiovasc, Madrid, Spain; [Cuadrado, I.; de las Heras, B.] Univ Complutense Madrid, Fac Farm, Dept Farmacol, E-28040 Madrid, Spain; [Luque, A.] FIB Hosp Univ Nino Jesus, Madrid, Spain; [Luque, A.] IIS Hosp La Princesa, Madrid, Spain; [Hortelano, S.] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Inflamac & Canc, Area Biol Celular & Desarrollo, Madrid 28220, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Complutense University of Madrid; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Hortelano, S (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Inflamac & Canc, Area Biol Celular & Desarrollo, Ctra Majadahonda Pozuelo,Km 2,200, Madrid 28220, Spain.	lasheras@farm.ucm.es; shortelano@isciii.es	de las Heras, Beatriz/K-1811-2014; de las Heras, Beatriz/ABB-9645-2021; Cuadrado-Berrocal, Irene/K-7761-2014; Bosca, Lisardo/A-2059-2008; Cuadrado-Berrocal, Irene/P-1360-2014; Luque, Alfonso/C-5846-2018; G. Traves, Paqui/L-5693-2014; Cuadrado-Berrocal, Irene/AAZ-1917-2021; Hortelano, Sonsoles/A-7954-2010	de las Heras, Beatriz/0000-0001-5089-8988; de las Heras, Beatriz/0000-0001-5089-8988; Cuadrado-Berrocal, Irene/0000-0003-0727-9633; Bosca, Lisardo/0000-0002-0253-5469; Cuadrado-Berrocal, Irene/0000-0003-0727-9633; G. Traves, Paqui/0000-0001-5749-8426; Cuadrado-Berrocal, Irene/0000-0003-0727-9633; Hortelano, Sonsoles/0000-0003-2528-0072	FIS [PI08.0070]; ISCIII [MPY 1410/09]; Santander-Complutense grant	FIS(Instituto de Salud Carlos III); ISCIII(Instituto de Salud Carlos III); Santander-Complutense grant	This study was supported by grant PI08.0070 from the FIS and MPY 1410/09 from ISCIII to SH, and by a Santander-Complutense grant to SH and B de las H. We thank Gemma Benito for excellent technical assistance and Simon Bartlett for critical reading of the manuscript. We thank Dr S Alemany and Dr K Roby for kindly provide luc-B16F10 and ID8 cells, respectively.	Castrillo A, 2001, J BIOL CHEM, V276, P15854, DOI 10.1074/jbc.M100010200; Chinou I, 2005, CURR MED CHEM, V12, P1295, DOI 10.2174/0929867054020990; de las Heras B, 2001, LIFE SCI, V70, P269, DOI 10.1016/S0024-3205(01)01402-3; Dirsch VM, 2002, LEUKEMIA, V16, P74, DOI 10.1038/sj.leu.2402337; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Giron N, 2008, TOXICOL APPL PHARM, V228, P179, DOI 10.1016/j.taap.2007.12.006; Hueso-Falcon I, 2011, EUR J MED CHEM, V46, P1291, DOI 10.1016/j.ejmech.2011.01.052; Hwang BY, 2001, PLANTA MED, V67, P406, DOI 10.1055/s-2001-15808; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kuo PL, 2004, J PHARM PHARMACOL, V56, P1399, DOI 10.1211/0022357044625; Lee JH, 2006, BIOCHEM PHARMACOL, V72, P1311, DOI 10.1016/j.bcp.2006.08.014; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liby KT, 2007, NAT REV CANCER, V7, P357, DOI 10.1038/nrc2129; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723; Nagashima F, 2003, CHEM PHARM BULL, V51, P1189, DOI 10.1248/cpb.51.1189; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; RODRIGUEZ B, 1980, PHYTOCHEMISTRY, V19, P1805, DOI 10.1016/S0031-9422(00)83817-0; SAVONA G, 1978, HETEROCYCLES, V9, P257; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Song ZW, 1999, TRENDS CELL BIOL, V9, pM49, DOI 10.1016/S0968-0004(99)01485-1; Wajant H, 2006, CANC TREAT, V130, P141; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207; Zeini M, 2006, J IMMUNOL, V177, P3327, DOI 10.4049/jimmunol.177.5.3327; Zhou J, 2008, MOL CANCER THER, V7, P2170, DOI 10.1158/1535-7163.MCT-08-0071; Zhou J, 2006, BIOCHEM PHARMACOL, V72, P132, DOI 10.1016/j.bcp.2006.04.019	30	14	14	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					259	268		10.1038/onc.2012.23	http://dx.doi.org/10.1038/onc.2012.23			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22310289				2022-12-28	WOS:000314075500014
J	Franzetti, GA; Laud-Duval, K; Bellanger, D; Stern, MH; Sastre-Garau, X; Delattre, O				Franzetti, G-A; Laud-Duval, K.; Bellanger, D.; Stern, M-H; Sastre-Garau, X.; Delattre, O.			MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor	ONCOGENE			English	Article						Ewing sarcoma; EWS-FLI1; CD99; microRNAs; miR-30a-5p	MESENCHYMAL PROGENITOR CELLS; SARCOMA CELLS; TRANSCRIPTION FACTOR; FUSION PROTEINS; STEM-CELLS; EXPRESSION; MICRORNAS; IDENTIFICATION; CANCER; GENE	Ewing sarcoma is a pediatric bone tumor characterized in 85% of cases by the fusion between EWS and FLI1 genes that results in the expression of the EWS-FLI1 aberrant transcription factor. Histologically, the Ewing tumor expresses high levels of the CD99 membrane glycoprotein. It has been recently described that CD99 expression contributes to the Ewing tumor oncogenesis by modulating growth and differentiation of tumor cells. Different studies have also shown that overexpression of EWS-FLI1 induces CD99 expression in non-Ewing cells. At the opposite, the knockdown of EWS-FLI1 expression by siRNA approaches has no significant effect on CD99 mRNA level in Ewing cells. Here, by in vivo and in vitro studies, we show that while EWS-FLI1 inhibition has only slight effects on the amount of CD99 transcript, it induces a dramatic decrease of the CD99 protein expression level, hence suggesting post-transcriptional regulations, possibly mediated by microRNAs. To further investigate this issue, we identified a set of 91 miRNAs that demonstrate EWS-FLI1 modulation, three of them being predicted to bind CD99 3' untranslated region (3'UTR). Among these, we show that miR-30a-5p has the ability to interact with the 3'UTR region of CD99 and to regulate its expression. Moreover, the re-expression of miRNA-30a-5p in Ewing cell line induces decreased cell proliferation and invasion. In this study, we therefore show that miR-30a-5p constitutes a major functional link between EWS-FLI1 and CD99, two critical biomarkers and therapeutic targets in Ewing sarcoma.	[Franzetti, G-A; Laud-Duval, K.; Bellanger, D.; Stern, M-H; Delattre, O.] Inst Curie, Ctr Rech, INSERM U830, F-75248 Paris 05, France; [Franzetti, G-A; Laud-Duval, K.; Bellanger, D.; Stern, M-H; Delattre, O.] Inst Curie, Ctr Rech, F-75248 Paris 05, France; [Sastre-Garau, X.] Grp Hosp Pitie Salpetriere, Inst Curie, Serv Pathol, F-75634 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Delattre, O (corresponding author), Inst Curie, Ctr Rech, INSERM U830, 26 Rue Ulm, F-75248 Paris 05, France.	Olivier.delattre@curie.fr	Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272; delattre, olivier/0000-0002-8730-2276; Sastre-Garau, Xavier/0000-0001-5992-2083	Ligue Nationale Contre le Cancer (Equipe labelise); INCa [2009-1-PLBIO-04-IC-1]; Courir pour Mathieu; Dans les pas du Geant; Olivier Chape; Les Bagouzamanon; les Amis de Claire; Ministere de l'Enseignement Superieur et de la Recherche (France)	Ligue Nationale Contre le Cancer (Equipe labelise); INCa(Institut National du Cancer (INCA) France); Courir pour Mathieu; Dans les pas du Geant; Olivier Chape; Les Bagouzamanon; les Amis de Claire; Ministere de l'Enseignement Superieur et de la Recherche (France)	We thank the members of the cytometry plateform of tumor biology department of the Institut Curie for the cell selection by FACS. This work was supported by grants from the Ligue Nationale Contre le Cancer (Equipe labelise), the INCa (no 2009-1-PLBIO-04-IC-1), and the following associations: Courir pour Mathieu, Dans les pas du Geant, Olivier Chape, Les Bagouzamanon and les Amis de Claire. Georges-Alain Franzetti is a recipient of a fellowship from the Ministere de l'Enseignement Superieur et de la Recherche (France).	Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Ban J, 2011, ONCOGENE, V30, P2173, DOI 10.1038/onc.2010.581; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; Boeva V, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq217; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; Bremond A, 2009, BLOOD, V113, P347, DOI 10.1182/blood-2008-02-137745; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Chansky HA, 2001, CANCER RES, V61, P3586; Cironi L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002634; De Vito C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023592; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Erkizan HV, 2010, CLIN CANCER RES, V16, P4077, DOI 10.1158/1078-0432.CCR-09-2261; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Fujita S, 2008, BIOINFORMATICS, V24, P303, DOI 10.1093/bioinformatics/btm589; Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d; Guillon N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004932; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Kreppel M, 2006, ONCOGENE, V25, P2795, DOI 10.1038/sj.onc.1209300; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Li Jun-cai, 2010, Xibei Zhiwu Xuebao, V30, P30; Martineza I, 2011, P NATL ACAD SCI USA, V108, P522, DOI 10.1073/pnas.1017346108; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; McKinsey EL, 2011, ONCOGENE, V30, P4910, DOI 10.1038/onc.2011.197; Melot T, 2001, EUR J BIOCHEM, V268, P3483, DOI 10.1046/j.1432-1327.2001.02251.x; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; Miyagawa Y, 2008, MOL CELL BIOL, V28, P2125, DOI 10.1128/MCB.00740-07; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Sanchez G, 2008, CELL CYCLE, V7, P2299, DOI 10.4161/cc.6445; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Scotlandi K, 2000, CANCER RES, V60, P5134; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Sohn HW, 2001, J IMMUNOL, V166, P787, DOI 10.4049/jimmunol.166.2.787; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Toomey EC, 2010, ONCOGENE, V29, P4504, DOI 10.1038/onc.2010.205; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008-5472.CAN-05-1704; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Zaragosi LE, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-7-r64; Zhong XM, 2010, J BIOL CHEM, V285, P41961, DOI 10.1074/jbc.M110.169607	54	51	53	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3915	3921		10.1038/onc.2012.403	http://dx.doi.org/10.1038/onc.2012.403			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22986530				2022-12-28	WOS:000323210200014
J	Kim, SJ; Lee, Y; Kim, NY; Hwang, Y; Hwang, B; Min, JK; Koh, SS				Kim, S. J.; Lee, Y.; Kim, N. Y.; Hwang, Y.; Hwang, B.; Min, J-K; Koh, S. S.			Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability	ONCOGENE			English	Article						PAUF; angiogenesis; vascular permeability; CXCR4	GROWTH-FACTOR; HIGH EXPRESSION; POOR-PROGNOSIS; CANCER CELLS; VE-CADHERIN; IN-VITRO; METASTASIS; PAUF; CONSEQUENCES; JUNCTIONS	Pancreatic adenocarcinoma upregulated factor (PAUF) was recently reported to be a metastasis factor for pancreatic cancer cells. Here, we demonstrate a novel role for PAUF as a potent endothelial activator, promoting both angiogenesis and vascular permeability. Overexpression of PAUF in a mouse pancreatic cancer model resulted in increased tumor vascularity. Recombinant PAUF (rPAUF) enhanced proliferation, migration and capillary-like tube formation of human endothelial cells (ECs), consistently with increased neovascularization in vivo. rPAUF also increased endothelial permeability through the disruption of vascular endothelial-cadherin-facilitated cell-cell junctions in vitro and induced vascular leakage in mouse skin. These effects were attenuated upon treatment with an antibody against PAUF. Moreover, PAUF evoked a time-and dose-dependent activation of extracellular signal-regulated kinase (ERK) 1/2, AKT and endothelial NO synthase (eNOS) in ECs, which are closely linked to rPAUF-induced angiogenesis. Finally, rPAUF upregulated the expression of C-X-C chemokine receptor 4 (CXCR4) in ECs and potentiated the in vitro and in vivo EC angiogenic responses to stromal cell-derived factor-1 (SDF-1), a ligand for CXCR4. Taken together, these data demonstrate that PAUF has a novel function in promoting angiogenesis and vascular permeability. Our findings suggest new possibilities for PAUF's role in the pathogenesis of angiogenesis-dependent diseases.	[Kim, S. J.; Lee, Y.; Kim, N. Y.; Hwang, Y.; Hwang, B.; Min, J-K; Koh, S. S.] Korea Res Inst Biosci & Biotechnol, Immunotherapy Res Ctr, Taejon 305806, South Korea; [Kim, S. J.; Kim, N. Y.; Hwang, Y.; Koh, S. S.] Univ Sci & Technol, Dept Funct Genom, Taejon, South Korea; [Hwang, Y.; Hwang, B.] Univ Sci & Technol, Dept Biomol Sci, Taejon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Min, JK (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunotherapy Res Ctr, 125 Gwahak Ro, Taejon 305806, South Korea.	jekmin@kribb.re.kr; sskoh@kribb.re.kr		Min, Jeong-Ki/0000-0003-4924-8739	National Research Foundation of Korea [2011-0015073, 2011-0016309]; Ministry of Education, Science and Technology; Inno-Project of the Korea Research Institute of Bioscience and Biotechnology; Korea Research Council of Fundamental Science and Technology (National Agenda Project)	National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Inno-Project of the Korea Research Institute of Bioscience and Biotechnology; Korea Research Council of Fundamental Science and Technology (National Agenda Project)	This work was supported by grants from the National Research Foundation of Korea (2011-0015073 and 2011-0016309), funded by the Ministry of Education, Science and Technology and a grant from the Inno-Project of the Korea Research Institute of Bioscience and Biotechnology and a grant from the Korea Research Council of Fundamental Science and Technology (National Agenda Project).	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alagappan VKT, 2005, CELL BIOCHEM BIOPHYS, V43, P119, DOI 10.1385/CBB:43:1:119; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cui K, 2011, J SURG RES, V171, P143, DOI 10.1016/j.jss.2010.03.001; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Esser S, 1998, J CELL SCI, V111, P1853; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fukumura D, 1997, AM J PATHOL, V150, P713; Grote K, 2010, BLOOD, V115, P2543, DOI 10.1182/blood-2009-05-224402; Hordijk PL, 1999, J CELL SCI, V112, P1915; Ikeda N, 1999, BRIT J CANCER, V79, P1553, DOI 10.1038/sj.bjc.6690248; Itakura J, 1997, CLIN CANCER RES, V3, P1309; Jia ZL, 2007, CANCER RES, V67, P4878, DOI 10.1158/0008-5472.CAN-06-3494; Kanagawa M, 2011, BIOCHEM BIOPH RES CO, V404, P201, DOI 10.1016/j.bbrc.2010.11.093; Kim SA, 2009, CANCER SCI, V100, P828, DOI 10.1111/j.1349-7006.2009.01106.x; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; Korc M, 2003, MOL CANCER, V2, P1; Kryczek I, 2005, AM J REPROD IMMUNOL, V54, P270, DOI 10.1111/j.1600-0897.2005.00307.x; Lee Y, 2010, ONCOGENE, V29, P56, DOI 10.1038/onc.2009.298; Lee Y, 2011, EXP MOL MED, V43, P291, DOI 10.3858/emm.2011.43.5.030; Marin V, 2001, J IMMUNOL METHODS, V254, P183, DOI 10.1016/S0022-1759(01)00408-2; Mirshahi F, 2000, THROMB RES, V99, P587, DOI 10.1016/S0049-3848(00)00292-9; Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925; Niedergethmann M, 2002, PANCREAS, V25, P122, DOI 10.1097/00006676-200208000-00002; Park HD, 2011, ONCOGENE, V30, P201, DOI 10.1038/onc.2010.401; Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007; Pyun BJ, 2008, CANCER RES, V68, P227, DOI 10.1158/0008-5472.CAN-07-2799; Seo Y, 2000, CANCER, V88, P2239, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wang Z, 2008, BRIT J CANCER, V99, P1695, DOI 10.1038/sj.bjc.6604745; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421; Whipple C, 2008, LANGENBECK ARCH SURG, V393, P901, DOI 10.1007/s00423-008-0280-z; Wong HH, 2009, NAT REV GASTRO HEPAT, V6, P412, DOI 10.1038/nrgastro.2009.89; Wright TJ, 2002, EXP CELL RES, V280, P159, DOI 10.1006/excr.2002.5636; Xie KP, 2006, CYTOKINE GROWTH F R, V17, P147, DOI 10.1016/j.cytogfr.2006.01.002; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	42	31	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3638	3647		10.1038/onc.2012.366	http://dx.doi.org/10.1038/onc.2012.366			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22907431				2022-12-28	WOS:000322638400008
J	Zhang, X; Cruz, FD; Terry, M; Remotti, F; Matushansky, I				Zhang, X.; Cruz, F. D.; Terry, M.; Remotti, F.; Matushansky, I.			Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming	ONCOGENE			English	Article						sarcoma; stem cells; induced pluripotent stem cells	MESENCHYMAL STEM-CELLS; RED-BLOOD-CELLS; HEMATOPOIETIC STEM; DIRECTED DIFFERENTIATION; HUMAN FIBROBLASTS; COPY NUMBER; IN-VITRO; GENES; GENOME; CLASSIFICATION	Pluripotent cells can be derived from various types of somatic cells by nuclear reprogramming using defined transcription factors. It is, however, unclear whether human cancer cells can be similarly reprogrammed and subsequently terminally differentiated with abrogation of tumorigenicity. Here, using sarcomas we show that human-derived complex karyotype solid tumors: (1) can be reprogrammed into a pluripotent-like state as defined by all in vitro criteria used to define pluripotent stem cells generated from somatic cells; (2) can be terminally differentiated into mature connective tissue and red blood cells; and (3) terminal differentiation is accompanied with loss of both proliferation and tumorigenicity. We go on to perform the first global DNA promoter methylation and gene expression analyses comparing human cancers to their reprogrammed counterparts and report that reprogramming/differentiation results in significant epigenetic remodeling of oncogenes and tumor suppressors, while not significantly altering the differentiation status of the reprogrammed cancer cells, in essence dedifferentiating them to a state slightly before the mesenchymal stem cell differentiation stage. Our data demonstrate that direct nuclear reprogramming can restore terminal differentiation potential to human-derived cancer cells, with simultaneous loss of tumorigenicity, without the need to revert to an embryonic state. We anticipate that our models would serve as a starting point to more fully assess how nuclear reprogramming overcomes the multitude of genetic and epigenetic aberrancies inherent in human cancers to restore normal terminal differentiation pathways. Finally, these findings suggest that nuclear reprogramming may be a broadly applicable therapeutic strategy for the treatment of cancer.	[Zhang, X.; Cruz, F. D.; Terry, M.; Remotti, F.; Matushansky, I.] Columbia Univ, Med Ctr, Dept Med, Div Med Oncol, New York, NY 10032 USA	Columbia University	Matushansky, I (corresponding author), Columbia Univ, Med Ctr, Dept Med, Div Med Oncol, 1130 St Nicholas Ave Rm 208C, New York, NY 10032 USA.	im17@columbia.edu			NCI; Gerstner CDA; Damon Runyon Cancer Research Fund; NATIONAL CANCER INSTITUTE [K08CA132986] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gerstner CDA; Damon Runyon Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank: Timothy C Wang MD for critical discussions and manuscript review; Sara Siddiqi and Gannie Tzonove for general technical assistance; Carlos Cordo-Cardo MD PhD for assistance with solid tumor pathological review and discussion; Benjamin Tycko MD PhD for assistance with DNA methylation analysis; Bachir Alobeid MD for assistance with hematological pathological review; Pavel Sumazin PhD for bioniformatic analysis. IM receives funding from NCI, Gerstner CDA and the Damon Runyon Cancer Research Fund.; XZ performed all experiments and assisted with experimental design. MT assisted with experiments and data interpretation. FDC assisted with experiments and data interpretation. FR reviewed and interpreted all histopathology outlined. IM designed the concept and experiments, interpreted the data and wrote the manuscript. IM receives funding from NCI, Gerstner CDA and the Damon Runyon Cancer Research Fund.	BARRIOS C, 1994, AM J CLIN ONCOL-CANC, V17, P273, DOI 10.1097/00000421-199406000-00019; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bock C, 2010, NAT BIOTECHNOL, V28, P1106, DOI 10.1038/nbt.1681; Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845; Chang G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010320; Charytonowicz E, 2012, J CLIN INVEST, V122, P886, DOI 10.1172/JCI60015; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502; Eminli S, 2009, NAT GENET, V41, P968, DOI 10.1038/ng.428; Esteban MA, 2010, CELL STEM CELL, V6, P71, DOI 10.1016/j.stem.2009.12.001; Feng JF, 2011, P NATL ACAD SCI USA, V108, P6503, DOI 10.1073/pnas.1015449108; Giebel B, 2008, BIOL CHEM, V389, P813, DOI 10.1515/BC.2008.092; Glauche I, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000447; Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805; Han JN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012297; Higgins ME, 2007, NUCLEIC ACIDS RES, V35, pD721, DOI 10.1093/nar/gkl811; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Hussein SM, 2011, NATURE, V471, P58, DOI 10.1038/nature09871; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Koche RP, 2011, CELL STEM CELL, V8, P96, DOI 10.1016/j.stem.2010.12.001; Krause U, 2011, METHODS MOL BIOL, V698, P215, DOI 10.1007/978-1-60761-999-4_17; Lai RC, 2011, METHODS MOL BIOL, V698, P141, DOI 10.1007/978-1-60761-999-4_11; Laurent LC, 2011, CELL STEM CELL, V8, P106, DOI 10.1016/j.stem.2010.12.003; Lengner CJ, 2010, ANN NY ACAD SCI, V1192, P38, DOI 10.1111/j.1749-6632.2009.05213.x; Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798; Lu SJ, 2010, METHODS MOL BIOL, V636, P105, DOI 10.1007/978-1-60761-691-7_7; Lu SJ, 2008, BLOOD, V112, P4475, DOI 10.1182/blood-2008-05-157198; Ma F, 2008, P NATL ACAD SCI USA, V105, P13087, DOI 10.1073/pnas.0802220105; Matushansky I, 2008, AM J PATHOL, V172, P1069, DOI 10.2353/ajpath.2008.070284; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Mayshar Y, 2010, CELL STEM CELL, V7, P521, DOI 10.1016/j.stem.2010.07.017; Merryweather-Clarke AT, 2011, BLOOD, V117, pE96, DOI 10.1182/blood-2010-07-290825; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Mills J, 2011, MOL CANCER THER, V10, P313, DOI 10.1158/1535-7163.MCT-10-0724; Mills J, 2009, HUM CELL, V22, P85, DOI 10.1111/j.1749-0774.2009.00073.x; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; OGAWA M, 1983, BLOOD, V61, P823; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Okita K, 2010, NAT PROTOC, V5, P418, DOI 10.1038/nprot.2009.231; Pitha-Rowe I, 2003, LEUKEMIA, V17, P1723, DOI 10.1038/sj.leu.2403065; Pomerantz JH, 2009, J CELL SCI, V122, P1045, DOI 10.1242/jcs.041376; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Siddiqi S, 2010, CURR STEM CELL RES T, V5, P63, DOI 10.2174/157488810790442859; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046; Stadtfeld M, 2010, GENE DEV, V24, P2239, DOI 10.1101/gad.1963910; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tang Y, 2005, CANCER RES, V65, P8324, DOI 10.1158/0008-5472.CAN-05-0027; Theunissen TW, 2011, CURR BIOL, V21, P65, DOI 10.1016/j.cub.2010.11.074; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; West FD, 2008, STEM CELLS, V26, P2768, DOI 10.1634/stemcells.2008-0124; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015336	58	83	88	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2249	2260		10.1038/onc.2012.237	http://dx.doi.org/10.1038/onc.2012.237			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22777357	Green Accepted			2022-12-28	WOS:000318683600002
J	Guo, ST; Jiang, CC; Wang, GP; Li, YP; Wang, CY; Guo, XY; Yang, RH; Feng, Y; Wang, FH; Tseng, HY; Thorne, RF; Jin, L; Zhang, XD				Guo, S. T.; Jiang, C. C.; Wang, G. P.; Li, Y. P.; Wang, C. Y.; Guo, X. Y.; Yang, R. H.; Feng, Y.; Wang, F. H.; Tseng, H-Y; Thorne, R. F.; Jin, L.; Zhang, X. D.			MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer	ONCOGENE			English	Article						colorectal cancer; miR-497; IGF1-R; Akt; copy number variations	FACTOR-I-RECEPTOR; EXPRESSION PROFILES; IGF-1; INHIBITION; MUTATIONS; APOPTOSIS; GENES; CELLS; IGF1R	Past studies have shown that amplified insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1-R) signalling has an important role in colorectal cancer (CRC) development, progression and resistance to treatment. In this report, we demonstrate that downregulation of microRNA-497 (miR-497) as a result of DNA copy number reduction is involved in upregulation of IGF1-R in CRC cells. MiR-497 and miR-195 of the miR-15/16/195/424/497 family that share the same 3' untranslated region (3'UTR) binding seed sequence and are predicted to target IGF1-R were concurrently downregulated in the majority of CRC tissues relative to paired adjacent normal mucosa. However, only overexpression of miR-497 led to suppression of the IGF1-R 3'UTR activity and downregulation of the endogenous IGF1-R protein in CRC cells. This was associated with inhibition of cell survival, proliferation and invasion, and increased sensitivity to apoptosis induced by various stimuli including the chemotherapeutic drugs cisplatin and 5-fluorouracil, and the death ligand tumour necrosis factor-related apoptosis-inducing ligand. The biological effect of miR-497 on CRC cells was largely mediated by inhibition of phosphatidylinositol 3-kinase/Akt signalling, as overexpression of an active form of Akt reversed its impact on cell survival and proliferation, recapitulating the effect of overexpression of IGF1-R. Downregulation of miR-497 and miR-195 appeared to associate with copy number loss of a segment of chromosome 17p13.1, where these miRs are located at proximity. Similarly to miR-195, the members of the same miR family, miR-424 that was upregulated, and miR-15a, miR-15b and miR-16 that were unaltered in expression in CRC tissues compared with paired adjacent normal mucosa, did not appear to have a role in regulating the expression of IGF1-R. Taken together, these results identify downregulation of miR-497 as an important mechanism of upregulation of IGF1-R in CRC cells that contributes to malignancy of CRC. Oncogene (2013) 32, 1910-1920; doi:10.1038/onc.2012.214; published online 18 June 2012	[Guo, S. T.; Wang, G. P.; Wang, C. Y.; Guo, X. Y.; Yang, R. H.; Feng, Y.; Wang, F. H.; Zhang, X. D.] Shanxi Canc Hosp & Inst, Dept Mol Biol, Taiyuan, Peoples R China; [Jiang, C. C.; Tseng, H-Y; Thorne, R. F.; Zhang, X. D.] Univ Newcastle, Prior Res Ctr Canc Res, Newcastle, NSW 2300, Australia; [Jiang, C. C.; Tseng, H-Y; Thorne, R. F.; Zhang, X. D.] Hunter Med Res Inst, Canc Res Program, Newcastle, NSW, Australia; [Li, Y. P.] Shanxi Canc Hosp & Inst, Dept Colorectal Surg, Taiyuan, Peoples R China; [Thorne, R. F.] Univ Newcastle, Sch Biomed Sci, Canc Res Unit, Newcastle, NSW 2300, Australia; [Jin, L.] Univ Sydney, Kolling Inst Med Res, Immunol & Oncol Lab, Sydney, NSW 2006, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; University of Sydney; Kolling Institute of Medical Research	Zhang, XD (corresponding author), Univ Newcastle, Prior Res Ctr Canc Res, David Maddison Bldg,Cnr King & Watt St, Newcastle, NSW 2300, Australia.	Xu.Zhang@newcastle.edu.au	Tseng, Cindy Hsin-Yi/AAB-8958-2022; Jin, Lei/J-1896-2019; zhang, xu/GRX-9733-2022; zhang, xu/GYE-3558-2022; Jiang, Chenchen/C-2902-2014; Zhang, xiaoyu/GXA-3206-2022; zhang, xian/GYA-0290-2022	Tseng, Cindy Hsin-Yi/0000-0002-7499-7515; Jin, Lei/0000-0001-7187-9671; Zhang, Xu Dong/0000-0001-9457-8003	NSW State Cancer Council; Cancer Institute NSW; National Health and Medical Research Council (NHMRC), Australia; Shanxi Scholarship Council; National '863' High Technology Program, China; NHMRC	NSW State Cancer Council(Cancer Council New South Wales); Cancer Institute NSW; National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); Shanxi Scholarship Council; National '863' High Technology Program, China(National High Technology Research and Development Program of China); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the NSW State Cancer Council, Cancer Institute NSW, and National Health and Medical Research Council (NHMRC), Australia, and the Shanxi Scholarship Council and National '863' High Technology Program, China. CCJ is a recipient of postdoctoral training Fellowship of NHMRC. XDZ is supported by a senior research fellowship of NHMRC.	Alberobello AT, 2010, J BIOL CHEM, V285, P6563, DOI 10.1074/jbc.M109.097410; Board RE, 2008, CLIN CHEM, V54, P757, DOI 10.1373/clinchem.2007.098376; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138; Dong L, 2011, ONCOGENE, V30, P3716, DOI 10.1038/onc.2011.87; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Ferte C, 2010, NAT REV CLIN ONCOL, V7, P367, DOI 10.1038/nrclinonc.2010.84; Flavin RJ, 2009, MODERN PATHOL, V22, P197, DOI 10.1038/modpathol.2008.135; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hart LS, 2011, CELL CYCLE, V10, P2331, DOI 10.4161/cc.10.14.16418; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645; Jiang CC, 2011, CLIN CANCER RES, V17, P721, DOI 10.1158/1078-0432.CCR-10-2225; Jiang L, 2010, BIOCHEM J, V432, P199, DOI 10.1042/BJ20100859; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; La Rocca G, 2009, J CELL PHYSIOL, V220, P485, DOI 10.1002/jcp.21796; Lerman G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020916; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Liang RQ, 2011, AGING CELL, V10, P1080, DOI 10.1111/j.1474-9726.2011.00751.x; Liang Y, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-166; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Liu L, 2010, BIOCHEM BIOPH RES CO, V400, P236, DOI 10.1016/j.bbrc.2010.08.046; McKinley ET, 2011, CLIN CANCER RES, V17, P3332, DOI 10.1158/1078-0432.CCR-10-2274; Nakajima Go, 2006, Cancer Genomics & Proteomics, V3, P317; Patel B, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e14131; Pereira PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011780; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Quek R, 2011, CLIN CANCER RES, V17, P871, DOI 10.1158/1078-0432.CCR-10-2621; Schee K, 2010, AM J PATHOL, V177, P1592, DOI 10.2353/ajpath.2010.100024; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Schetter AJ, 2011, SEMIN ONCOL, V38, P734, DOI 10.1053/j.seminoncol.2011.08.009; Sekharam M, 2003, CANCER RES, V63, P7708; Sekharam M, 2011, CANCER RES, V63, P7708; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Tsafrir D, 2006, CANCER RES, V66, P2129, DOI 10.1158/0008-5472.CAN-05-2569; Wang XQ, 2012, MED ONCOL, V29, P919, DOI 10.1007/s12032-011-9880-5; Weber MM, 2002, CANCER-AM CANCER SOC, V95, P2086, DOI 10.1002/cncr.10945; Wilmott JS, 2011, PATHOLOGY, V43, P657, DOI 10.1097/PAT.0b013e32834a7358; Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243; Yadav S, 2011, J BIOL CHEM, V286, P37347, DOI 10.1074/jbc.M111.235531; Yang F, 2010, CELL DEATH DIFFER, V17, P1354, DOI 10.1038/cdd.2010.29; Yin KJ, 2010, NEUROBIOL DIS, V38, P17, DOI 10.1016/j.nbd.2009.12.021; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhu W, 2012, MED ONCOL, V29, P384, DOI 10.1007/s12032-010-9797-4	53	185	195	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1910	1920		10.1038/onc.2012.214	http://dx.doi.org/10.1038/onc.2012.214			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22710713	Green Published			2022-12-28	WOS:000317599900005
J	Borovski, T; Beke, P; van Tellingen, O; Rodermond, HM; Verhoeff, JJ; Lascano, V; Daalhuisen, JB; Medema, JP; Sprick, MR				Borovski, T.; Beke, P.; van Tellingen, O.; Rodermond, H. M.; Verhoeff, J. J.; Lascano, V.; Daalhuisen, J. B.; Medema, J. P.; Sprick, M. R.			Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme	ONCOGENE			English	Article						glioblastoma multiforme; cancer stem cells; tumor microvasculature; tumor microenvironment; therapy resistance; senescence	STEM-LIKE CELLS; SENESCENCE; CANCER; ANGIOGENESIS; RADIOTHERAPY; TEMOZOLOMIDE; PHENOTYPE; GROWTH	Glioblastoma multiforme (GBM) is a devastating disease with high mortality and poor prognosis. Cancer stem cells (CSCs) have recently been defined as a fraction of tumor cells highly resistant to therapy and subsequently considered to be responsible for tumor recurrence. These cells have been characterized in GBM and suggested to reside in and be supported by the tumor microvascular niche. Here we evaluated the response of tumor microvascular endothelial cells (tMVECs) to radio-and chemotherapy, and analyzed how this affects their interaction with CSCs. Our data demonstrate that tMVECs exhibit extreme resistance to both therapies, with the main response to irradiation being senescence. Importantly, senescent tMVECs can be detected in human GBM samples as well as in mice upon irradiation. Even though permanently arrested, they are still viable and able to support CSC growth with the same efficacy as non-senescent tMVECs. Intriguingly, GBM CSCs themselves are capable of differentiating into cells with similar features as tMVECs that subsequently undergo senescence when exposed to radiation. This indicates that endothelial-like cells are therapy resistant and, more importantly, support expansion of GBM cells. Oncogene (2013) 32, 1539-1548; doi:10.1038/onc.2012.172; published online 21 May 2012	[Borovski, T.; Beke, P.; Rodermond, H. M.; Lascano, V.; Daalhuisen, J. B.; Medema, J. P.] Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol LEXOR, Amsterdam, Netherlands; [van Tellingen, O.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Clin Chem Preclin Pharmacol, Amsterdam, Netherlands; [Verhoeff, J. J.] Univ Amsterdam, Acad Med Ctr, Dept Radiat Oncol, NL-1105 AZ Amsterdam, Netherlands; [Sprick, M. R.] Deutsch Krebsforschungszentrum DKFZ, Heidelberg, Germany; [Sprick, M. R.] HISTEM gGmbH, Heidelberg, Germany	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Helmholtz Association; German Cancer Research Center (DKFZ)	Medema, JP (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol LEXOR, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	J.P.Medema@amc.uva.nl	Sprick, Martin R./A-8611-2008; Sprick, Martin R./I-7995-2019	Sprick, Martin R./0000-0001-9691-7574; Sprick, Martin R./0000-0001-9691-7574; Medema, Jan Paul/0000-0003-3045-2924; Verhoeff, Joost J.C./0000-0001-9673-0793	VICI grant (NWO); KWF grant [2009-4416]; EMBO Long-Term Fellowship [ALTF 1063-2005]	VICI grant (NWO); KWF grant; EMBO Long-Term Fellowship(European Molecular Biology Organization (EMBO))	We thank Jan-Jacob Sonke and Alessia Gasparini for setting up the irradiation machine for irradiating mice, Dr E Aronica for helping with preparation of GBM samples and Dr Louis Vermeulen for helpful discussions and critical reading of the manuscript. Jan Paul Medema is supported by a VICI grant (NWO) and a KWF grant (2009-4416); Martin R Sprick was partially funded by an EMBO Long-Term Fellowship (ALTF 1063-2005).	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Borovski T, 2009, INT J CANCER, V125, P1222, DOI 10.1002/ijc.24408; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Charalambous C, 2007, EXP CELL RES, V313, P1192, DOI 10.1016/j.yexcr.2006.12.027; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Dickson PV, 2007, CLIN CANCER RES, V13, P3942, DOI 10.1158/1078-0432.CCR-07-0278; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Igrashi K, 2007, EXP CELL RES, V313, P3326, DOI 10.1016/j.yexcr.2007.06.001; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verhoeff JJC, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-444; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624	27	36	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 21	2013	32	12					1539	1548		10.1038/onc.2012.172	http://dx.doi.org/10.1038/onc.2012.172			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22614016				2022-12-28	WOS:000316456000007
J	Yigit, MV; Ghosh, SK; Kumar, M; Petkova, V; Kavishwar, A; Moore, A; Medarova, Z				Yigit, M. V.; Ghosh, S. K.; Kumar, M.; Petkova, V.; Kavishwar, A.; Moore, A.; Medarova, Z.			Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis	ONCOGENE			English	Article						imaging; miRNA; metastasis; miR-10b; nanoparticle; therapy	SUPERPARAMAGNETIC IRON-OXIDE; CANCER; MICRORNA; THERAPEUTICS; LNA	Metastases, and not the primary tumor from which they originate, are the main reason for mortality from carcinoma. Although the molecular mechanisms behind metastasis are poorly understood, it is clear that epigenetic dysregulation at the level of microRNA expression is a key characteristic of the metastatic process that can be exploited for therapy. Here, we describe an miRNA-targeted therapeutic approach for the prevention and arrest of lymph node metastasis. Therapy relies on the inhibition of the pro-metastatic microRNA-10b. It is delivered to primary and lymph node metastatic tumor cells using an imaging-capable nanodrug that is designed to specifically home to these tissues. Treatment of invasive human breast tumor cells (MDA-MB-231) with the nanodrug in vitro downregulates miR-10b and abolishes the invasion and migration of the tumor cells. After intravenous delivery to mice bearing orthotopic MDA-MB-231-luc-D3H2LN tumors, the nanodrug accumulates in the primary tumor and lymph nodes. When treatment is initiated before metastasis to lymph nodes, metastasis is prevented. Treatment after the formation of lymph node metastases arrests the metastatic process without a concomitant effect on primary tumor growth raising the possibility of a context-dependent variation in miR-10b breast oncogenesis. Oncogene (2013) 32, 1530-1538; doi:10.1038/onc.2012.173; published online 14 May 2012	[Yigit, M. V.; Ghosh, S. K.; Kumar, M.; Kavishwar, A.; Moore, A.; Medarova, Z.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Mol Imaging Lab, Dept Radiol, Charlestown, MA USA; [Yigit, M. V.; Ghosh, S. K.; Kumar, M.; Kavishwar, A.; Moore, A.; Medarova, Z.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA; [Petkova, V.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Moore, A (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Mol Imaging Lab,MGH MIT HMS Athinoula, Bldg 75,13th St, Charlestown, MA 02129 USA.	amoore@helix.mgh.harvard.edu; zmedarova@partners.org		Kavishwar, Amol/0000-0001-8214-6625	National Cancer Institute [R00CA129070]; Breast Cancer Alliance; NATIONAL CANCER INSTITUTE [R00CA129070, R01CA163461] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR025504] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Alliance; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Pamela Pantazopoulos and Alana Ross for help with the in-vitro, in-vivo and ex-vivo studies and Marytheresa Ifediba for proofreading the manuscript. Confocal microscopy was performed at the Confocal Microscopy Core at MGH with technical assistance from Igor A Bagayev, MS Work at the Martinos Center for Biomedical Imaging was supported in part under Grant R00CA129070 from the National Cancer Institute and a Research Grant from the Breast Cancer Alliance.	Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Beer AJ, 2008, J NUCL MED, V49, P255, DOI 10.2967/jnumed.107.045526; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Gabriely G, 2011, AUTOPHAGY, V7, P1384, DOI 10.4161/auto.7.11.17371; Gabriely G, 2011, CANCER RES, V71, P3563, DOI 10.1158/0008-5472.CAN-10-3568; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; Jepsen JS, 2004, OLIGONUCLEOTIDES, V14, P130, DOI 10.1089/1545457041526317; Kenny LM, 2008, J NUCL MED, V49, P879, DOI 10.2967/jnumed.107.049452; Kumar M, 2010, CANCER RES, V70, P7553, DOI 10.1158/0008-5472.CAN-10-2070; Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004; Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Medarova Z, 2006, NAT PROTOC, V1, P429, DOI 10.1038/nprot.2006.63; Medarova Z, 2007, NAT MED, V13, P372, DOI 10.1038/nm1486; Medarova Z, 2009, CANCER RES, V69, P1182, DOI 10.1158/0008-5472.CAN-08-2001; Michel SCA, 2002, RADIOLOGY, V225, P527, DOI 10.1148/radiol.2252011605; Nathanson SD, 2009, ANN SURG ONCOL, V16, P3396, DOI 10.1245/s10434-009-0659-2; Petersen M, 2003, TRENDS BIOTECHNOL, V21, P74, DOI 10.1016/S0167-7799(02)00038-0; WEISSLEDER R, 1990, RADIOLOGY, V175, P494, DOI 10.1148/radiology.175.2.2326475; Xiang X, 2011, ONCOGENE, V30, P3440, DOI 10.1038/onc.2011.54; Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008-5472.CAN-06-4499	26	70	71	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1530	1538		10.1038/onc.2012.173	http://dx.doi.org/10.1038/onc.2012.173			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22580603	Green Accepted			2022-12-28	WOS:000316456000006
J	Dimberg, LY; Anderson, CK; Camidge, R; Behbakht, K; Thorburn, A; Ford, HL				Dimberg, L. Y.; Anderson, C. K.; Camidge, R.; Behbakht, K.; Thorburn, A.; Ford, H. L.			On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics	ONCOGENE			English	Review						TRAIL; pro-apoptotic receptor agonists; apoptosis; TRAIL resistance; clinical trials	APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR; AGONISTIC MONOCLONAL-ANTIBODY; RECOMBINANT HUMAN APO2L/TRAIL; DEATH RECEPTOR 5; MEDIATED APOPTOSIS; CARCINOMA-CELLS; PHASE-I; PROTEASOME INHIBITION; SIX1 OVEREXPRESSION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic antibodies against TRAIL death receptors (DR) kill tumor cells while causing virtually no damage to normal cells. Several novel drugs targeting TRAIL receptors are currently in clinical trials. However, TRAIL resistance is a common obstacle in TRAIL-based therapy and limits the efficiency of these drugs. In this review article we discuss different mechanisms of TRAIL resistance, and how they can be predicted and therapeutically circumvented. In addition, we provide a brief overview of all TRAIL-based clinical trials conducted so far. It is apparent that although the effects of TRAIL therapy are disappointingly modest overall, a small subset of patients responds very well to TRAIL. We argue that the true potential of targeting TRAIL DRs in cancer can only be reached when we find efficient ways to select for those patients that are most likely to benefit from the treatment. To achieve this, it is crucial to identify biomarkers that can help us predict TRAIL sensitivity. Oncogene (2013) 32, 1341-1350; doi:10.1038/onc.2012.164; published online 14 May 2012	[Dimberg, L. Y.; Anderson, C. K.; Behbakht, K.; Ford, H. L.] Univ Colorado, Sch Med, Dept Obstet & Gynecol, Aurora, CO 80045 USA; [Camidge, R.] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA; [Thorburn, A.; Ford, H. L.] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Ford, HL (corresponding author), Univ Colorado, Sch Med, Dept Obstet & Gynecol, RC2,Room 3100C,MS8613, Aurora, CO 80045 USA.	heide.ford@ucdenver.edu	Camidge, David Ross/AAG-9144-2019	Behbakht, Kian/0000-0003-4793-9958	NIH [CA124545]; Department of Defense (DOD) [BC093627]; Swedish Research Council [2009-618]; DOD Ovarian Cancer Idea Award [OC06143]; Department of Obstetrics and Gynecology Academic Enrichment Fund (AEF), University of Colorado-Denver Hospitals; NATIONAL CANCER INSTITUTE [R01CA124545] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense (DOD)(United States Department of Defense); Swedish Research Council(Swedish Research CouncilEuropean Commission); DOD Ovarian Cancer Idea Award; Department of Obstetrics and Gynecology Academic Enrichment Fund (AEF), University of Colorado-Denver Hospitals; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize to the many investigators whose important works were not cited here owing to space limitations. This work was supported by NIH Grant CA124545 (A Thorburn, K Behbakht and H Ford), Department of Defense (DOD) postdoctoral fellowship BC093627 and Swedish Research Council postdoctoral fellowship 2009-618 (L Dimberg), DOD Ovarian Cancer Idea Award OC06143 (K Behbakht), and Department of Obstetrics and Gynecology Academic Enrichment Fund (AEF), University of Colorado-Denver Hospitals (C Anderson).	Abdulghani J, 2010, EXPERT OPIN THER TAR, V14, P1091, DOI 10.1517/14728222.2010.519701; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Bevis KS, 2010, GYNECOL ONCOL, V119, P157, DOI 10.1016/j.ygyno.2010.05.034; Bin L, 2007, J BIOL CHEM, V282, P28189, DOI 10.1074/jbc.M704210200; Blay JY, 2008, PHASE 1B OPEN LABEL; Budd RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787; Burns TF, 2001, J BIOL CHEM, V276, P37879; Camidge DR, 2008, EXPERT OPIN BIOL TH, V8, P1167, DOI 10.1517/14712598.8.8.1167 ; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Earel JK, 2006, CANCER RES, V66, P499, DOI 10.1158/0008-5472.CAN-05-3017; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Ehrlich S, 2003, CYTOKINE, V24, P244, DOI 10.1016/S1043-4666(03)00094-2; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Fricker N, 2010, J CELL BIOL, V190, P377, DOI 10.1083/jcb.201002060; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Ghiotto F, 2010, CYTOM PART A, V77A, P11, DOI 10.1002/cyto.a.20819; Gillissen B, 2010, J CELL BIOL, V188, P851, DOI 10.1083/jcb.200912070; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Golks A, 2006, J EXP MED, V203, P1295, DOI 10.1084/jem.20051556; Greco FA, 2008, LUNG CANCER, V61, P82, DOI 10.1016/j.lungcan.2007.12.011; Halaas O, 2000, SCAND J IMMUNOL, V51, P244; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Herbst RS, 2010, CLIN CANCER RES, V16, P5883, DOI 10.1158/1078-0432.CCR-10-0631; Herbst RS, 2010, J CLIN ONCOL, V28, P2839, DOI 10.1200/JCO.2009.25.1991; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Horak P, 2005, MOL CANCER RES, V3, P335, DOI 10.1158/1541-7786.MCR-04-0136; Horita H, 2009, J NEURO-ONCOL, V95, P175, DOI 10.1007/s11060-009-9914-4; Hotte SJ, 2008, CLIN CANCER RES, V14, P3450, DOI 10.1158/1078-0432.CCR-07-1416; Imam JS, 2010, ONCOGENE, V29, P4971, DOI 10.1038/onc.2010.233; Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kandasamy K, 2003, CANCER RES, V63, P1712; Kanzler S, 2005, ECCO 13 EUR CANC C, P360; Karapetis CS, 2010, ASCO M, V28, P7535; Karikari CA, 2007, MOL CANCER THER, V6, P957, DOI 10.1158/1535-7163.MCT-06-0634; Kim JY, 2008, J CELL BIOCHEM, V105, P1386, DOI 10.1002/jcb.21958; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kindler, 2009, J CLIN ONCOL, V27, P4501; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee TJ, 2009, FREE RADICAL BIO MED, V46, P1639, DOI 10.1016/j.freeradbiomed.2009.03.022; Leong S, 2009, J CLIN ONCOL, V27, P4413, DOI 10.1200/JCO.2008.21.7422; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; Logan AE, 2010, APOPTOSIS, V15, P1435, DOI 10.1007/s10495-010-0533-5; LoRusso P, 2007, J CLIN ONCOL, V25; Lu JF, 2011, MOL CANCER THER, V10, P902, DOI 10.1158/1535-7163.MCT-10-0864; MacFarlane M, 2005, CELL DEATH DIFFER, V12, P773, DOI 10.1038/sj.cdd.4401649; Makhov P, 2008, CELL DEATH DIFFER, V15, P1745, DOI 10.1038/cdd.2008.106; Martin S, 2005, CANCER RES, V65, P11447, DOI 10.1158/0008-5472.CAN-05-1494; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Mellier G, 2010, MOL ASPECTS MED, V31, P93, DOI 10.1016/j.mam.2009.12.002; Menke C, 2011, CANCER RES, V71, P1883, DOI 10.1158/0008-5472.CAN-10-2252; Menke C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014527; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Mom CH, 2009, CLIN CANCER RES, V15, P5584, DOI 10.1158/1078-0432.CCR-09-0996; Natoni A, 2007, BRIT J HAEMATOL, V139, P568, DOI 10.1111/j.1365-2141.2007.06852.x; Ng CP, 2002, MOL CANCER THER, V1, P1051; Nimmanapalli R, 2001, CANCER RES, V61, P759; Oberst A, 2010, J BIOL CHEM, V285, P16632, DOI 10.1074/jbc.M109.095083; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pacey S, 2005, J CLIN ONCOL, V23, p205S; Paz-Ares L, 2009, J CLIN ONCOL, V27; PEETERS M, 2010, GASTR CANC S ORL FL; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Petak I, 2000, CLIN CANCER RES, V6, P4119; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pop C, 2011, BIOCHEM J, V433, P447, DOI 10.1042/BJ20101738; Psahoulia FH, 2007, MOL CANCER THER, V6, P2591, DOI 10.1158/1535-7163.MCT-07-0001; Ray S, 2005, APOPTOSIS, V10, P1411, DOI 10.1007/s10495-005-2490-y; Reis CR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.61; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Rougier, 2009, J CLIN ONCOL, P4130; Saleh MN, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3537; Saltz, 2009, J CLIN ONCOL, V27, P4079; Sayers TJ, 2006, CANCER IMMUNOL IMMUN, V55, P76, DOI 10.1007/s00262-005-0676-3; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Shenoy K, 2009, CANCER RES, V69, P1941, DOI 10.1158/0008-5472.CAN-08-1996; Sikic BI, 2007, J CLIN ONCOL, V25; Sinicrope FA, 2004, CLIN CANCER RES, V10, P8284, DOI 10.1158/1078-0432.CCR-04-1289; Song JH, 2008, J BIOL CHEM, V283, P25003, DOI 10.1074/jbc.M802511200; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Soria JC, 2010, J CLIN ONCOL, V28, P1527, DOI 10.1200/JCO.2009.25.4847; Stern HM, 2010, CLIN CANCER RES, V16, P1587, DOI 10.1158/1078-0432.CCR-09-3108; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Tolcher AW, 2007, J CLIN ONCOL, V25, P1390, DOI 10.1200/JCO.2006.08.8898; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Von Pawel J, 2010, J CLIN ONCOL, V28; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wakelee HA, 2010, ANN ONCOL, V21, P376, DOI 10.1093/annonc/mdp292; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiezorek J, 2010, CLIN CANCER RES, V16, P1701, DOI 10.1158/1078-0432.CCR-09-1692; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xu LP, 2011, MOL CANCER THER, V10, P550, DOI 10.1158/1535-7163.MCT-10-0571; Yang JK, 2008, YONSEI MED J, V49, P19, DOI 10.3349/ymj.2008.49.1.19; Yee L, 2007, J CLIN ONCOL, V25; Yee L, 2009, J CLIN ONCOL, V27; Younes A VJ, 2005, ASH ANN M, P489; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586; Zhang LA, 2010, CLIN CANCER RES, V16, P4478, DOI 10.1158/1078-0432.CCR-10-0859; Zheng SJ, 2004, J IMMUNOL, V173, P5652, DOI 10.4049/jimmunol.173.9.5652	110	206	215	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1341	1350		10.1038/onc.2012.164	http://dx.doi.org/10.1038/onc.2012.164			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22580613	Green Accepted			2022-12-28	WOS:000316455600001
J	Dong, C; Wu, Y; Wang, Y; Wang, C; Kang, T; Rychahou, PG; Chi, YI; Evers, BM; Zhou, BP				Dong, C.; Wu, Y.; Wang, Y.; Wang, C.; Kang, T.; Rychahou, P. G.; Chi, Y-I; Evers, B. M.; Zhou, B. P.			Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer	ONCOGENE			English	Article						metastasis; EMT; chromatin modifications; transcription; Snail	EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; HISTONE H3; DNA METHYLATION; GENE-EXPRESSION; G9A; METHYLTRANSFERASES; DOMAIN; INFLAMMATION; SUPERFAMILY	Expression of E-cadherin, a hallmark of epithelial-mesenchymal transition (EMT), is often lost due to promoter DNA methylation in basal-like breast cancer (BLBC), which contributes to the metastatic advantage of this disease; however, the underlying mechanism remains unclear. Here, we identified that Snail interacted with Suv39H1 (suppressor of variegation 3-9 homolog 1), a major methyltransferase responsible for H3K9me3 that intimately links to DNA methylation. We demonstrated that the SNAG domain of Snail and the SET domain of Suv39H1 were required for their mutual interactions. We found that H3K9me3 and DNA methylation on the E-cadherin promoter were higher in BLBC cell lines. We showed that Snail interacted with Suv39H1 and recruited it to the E-cadherin promoter for transcriptional repression. Knockdown of Suv39H1 restored E-cadherin expression by blocking H3K9me3 and DNA methylation and resulted in the inhibition of cell migration, invasion and metastasis of BLBC. Our study not only reveals a critical mechanism underlying the epigenetic regulation of EMT, but also paves a way for the development of new treatment strategies against this disease. Oncogene (2013) 32, 1351-1362; doi:10.1038/onc.2012.169; published online 7 May 2012	[Dong, C.; Wang, Y.; Chi, Y-I; Evers, B. M.; Zhou, B. P.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA; [Dong, C.; Wu, Y.; Wang, Y.; Wang, C.; Rychahou, P. G.; Evers, B. M.; Zhou, B. P.] Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40506 USA; [Wu, Y.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40506 USA; [Wang, C.] Univ Kentucky, Coll Med, Dept Biostat, Lexington, KY 40506 USA; [Kang, T.] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Rychahou, P. G.; Evers, B. M.] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40506 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; State Key Lab Oncology South China; University of Kentucky	Zhou, BP (corresponding author), Univ Kentucky, Coll Med, Markey Canc Ctr, Dept Mol & Cellular Biochem, BBSRB Room B336,741 South Limestone, Lexington, KY 40506 USA.	peter.zhou@uky.edu		Rychahou, Piotr/0000-0001-7352-9122	NIH [RO1CA125454]; Susan G Komen Foundation [KG081310]; Mary Kay Ash Foundation; NATIONAL CANCER INSTITUTE [R01CA125454] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); Mary Kay Ash Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Nathan L Vanderford for critical reading and editing of this manuscript. This work was supported by grants from NIH (RO1CA125454), Susan G Komen Foundation (KG081310), and Mary Kay Ash Foundation (to BP Zhou).	Barrallo-Gimeno A, 2009, TRENDS GENET, V25, P248, DOI 10.1016/j.tig.2009.04.001; Bergamaschi A, 2009, MOL ONCOL, V3, P469, DOI 10.1016/j.molonc.2009.07.003; Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; Eissenberg JC, 2010, DEV BIOL, V339, P240, DOI 10.1016/j.ydbio.2009.08.017; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003; Fritsch L, 2010, MOL CELL, V37, P46, DOI 10.1016/j.molcel.2009.12.017; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Mullins M, 2007, CLIN CHEM, V53, P1273, DOI 10.1373/clinchem.2006.083725; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rudolph T, 2007, MOL CELL, V26, P103, DOI 10.1016/j.molcel.2007.02.025; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411; Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wang Yifan, 2011, Chin J Cancer, V30, P603, DOI 10.5732/cjc.011.10226; Eswar Narayanan, 2007, Curr Protoc Protein Sci, VChapter 2, DOI [10.1002/cpbi.3, 10.1002/cpps.20, 10.1002/0471250953.bi0506s15, 10.1002/0471140864.ps0209s50]; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wu H, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0008570, 10.1371/journal.pone.0013316]; Wu Y, 2008, ACTA BIOCH BIOPH SIN, V40, P643, DOI 10.1111/j.1745-7270.2008.00443.x; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Wu YD, 2009, J BIOL CHEM, V284, P640, DOI 10.1074/jbc.M806916200; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	65	145	153	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1351	1362		10.1038/onc.2012.169	http://dx.doi.org/10.1038/onc.2012.169			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22562246	Green Accepted, Green Submitted			2022-12-28	WOS:000316455600002
J	Zhao, X; Dou, W; He, L; Liang, S; Tie, J; Liu, C; Li, T; Lu, Y; Mo, P; Shi, Y; Wu, K; Nie, Y; Fan, D				Zhao, X.; Dou, W.; He, L.; Liang, S.; Tie, J.; Liu, C.; Li, T.; Lu, Y.; Mo, P.; Shi, Y.; Wu, K.; Nie, Y.; Fan, D.			MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor	ONCOGENE			English	Article						miR-7; IGF1R; gastric cancer; invasion and metastasis; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITIONS; HUMAN BREAST-CANCER; CELL LUNG-CANCER; TUMOR PROGRESSION; BETA-CATENIN; METASTASIS; EXPRESSION; INVASION; FAMILY; GENES	Metastasis is a major clinical obstacle in the treatment of gastric cancer (GC) and it accounts for the majority of cancer-related mortality. MicroRNAs have recently emerged as regulators of metastasis by acting on multiple signaling pathways. In this study, we found that miR-7 is significantly downregulated in highly metastatic GC cell lines and metastatic tissues. Both gain-of-function and loss-of-function experiments showed that increased miR-7 expression significantly reduced GC cell migration and invasion, whereas decreased miR-7 expression dramatically enhanced cell migration and invasion. In vivo metastasis assays also demonstrated that overexpression of miR-7 markedly inhibited GC metastasis. Moreover, the insulin-like growth factor-1 receptor (IGF1R) oncogene, which is often mutated or amplified in human cancers and functions as an important regulator of cell growth and tumor invasion, was identified as a direct target of miR-7. Silencing of IGF1R using small interefering RNA (siRNA) recapitulated the anti-metastatic function of miR-7, whereas restoring the IGF1R expression attenuated the function of miR-7 in GC cells. Furthermore, we found that suppression of Snail by miR-7, through targeting IGF1R, increased E-cadherin expression and partially reversed the epithelial-mesenchymal transition (EMT). Finally, analyses of miR-7 and IGF1R levels in human primary GC with matched lymph node metastasis tissue arrays revealed that miR-7 is inversely correlated with IGF1R expression. The present study provides insight into the specific biological behavior of miR-7 in EMT and tumor metastasis. Targeting this novel miR-7/IGF1R/Snail axis would be helpful as a therapeutic approach to block GC metastasis. Oncogene (2013) 32, 1363-1372; doi:10.1038/onc.2012.156; published online 21 May 2012	[Zhao, X.; Dou, W.; Liang, S.; Tie, J.; Liu, C.; Li, T.; Lu, Y.; Mo, P.; Shi, Y.; Wu, K.; Nie, Y.; Fan, D.] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Zhao, X.; Dou, W.; Liang, S.; Tie, J.; Liu, C.; Li, T.; Lu, Y.; Mo, P.; Shi, Y.; Wu, K.; Nie, Y.; Fan, D.] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Peoples R China; [He, L.] Fourth Mil Med Univ, Xijing Hosp, Dept Nephrol, Xian 710032, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Fan, D (corresponding author), Xijing Hosp Digest Dis, State Key Lab Canc Biol, West Changle Rd, Xian 710032, Peoples R China.	yongznie@fmmu.edu.cn; daimingfan@fmmu.edu.cn	Shi, Yongquan/AAE-3954-2020; juan, xie/F-6556-2014; Cui, Tie Jun/Y-3224-2019	Zhao, Xiaodi/0000-0002-1817-803X	National 973 Project of China [2010CB529300, 2010CB529302, 2010CB529305, 2010CB529306]; National Natural Science Foundation of China [81030044, 30970149, 30900675]	National 973 Project of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We acknowledge Dr Tiziana Deangelis from Tomas Jefferson University for providing the pcDNA3-IGF1R plasmid. We thank Professor Zengshan Li and Professor Zhe Wang from Xijing Hospital for their help with pathological analyses. We thank Qing Ye from the Fourth Military Medical University for excellent statistical assistance. This work was supported by the National 973 Project of China (No. 2010CB529300, 02, 05, 06) and the National Natural Science Foundation of China (No. 81030044, 30970149, 30900675).	Aisagbonhi O, 2011, DIS MODEL MECH, V4, P469, DOI 10.1242/dmm.006510; Annunziata M, 2011, ACTA DIABETOL, V48, P1, DOI 10.1007/s00592-010-0227-z; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bai FH, 2007, DIGEST DIS SCI, V52, P1571, DOI 10.1007/s10620-006-9570-x; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bauer TW, 2005, CANCER RES, V65, P7775, DOI 10.1158/0008-5472.CAN-05-0946; Chaudhuri K, 2007, DNA CELL BIOL, V26, P321, DOI 10.1089/dna.2006.0549; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Duncavage E, 2010, J THORAC ONCOL, V5, P1755, DOI 10.1097/JTO.0b013e3181f3909d; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 2000, MOL CARCINOGEN, V27, P10, DOI 10.1002/(SICI)1098-2744(200001)27:1<10::AID-MC3>3.0.CO;2-Z; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669; He LJ, 2009, CANCER LETT, V276, P88, DOI 10.1016/j.canlet.2008.10.044; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Junn E, 2009, P NATL ACAD SCI USA, V106, P13052, DOI 10.1073/pnas.0906277106; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kim HJ, 2007, MOL CELL BIOL, V27, P3165, DOI 10.1128/MCB.01315-06; Li RS, 2009, J MED CHEM, V52, P4981, DOI 10.1021/jm9002395; Liang SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018409; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Packeisen J, 2002, J CLIN PATHOL, V55, P613, DOI 10.1136/jcp.55.8.613; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Saydam O, 2011, CANCER RES, V71, P852, DOI 10.1158/0008-5472.CAN-10-1219; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Shah MA, 2010, JAMA-J AM MED ASSOC, V303, P1753, DOI 10.1001/jama.2010.553; Sutherland BW, 2008, CANCER RES, V68, P3495, DOI 10.1158/0008-5472.CAN-07-6531; Tang YC, 2003, CANCER RES, V63, P1166; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Veerla S, 2009, INT J CANCER, V124, P2236, DOI 10.1002/ijc.24183; Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; White NMA, 2011, NAT REV CLIN ONCOL, V8, P75, DOI 10.1038/nrclinonc.2010.173; Wu H, 2010, MOL CELL, V38, P67, DOI 10.1016/j.molcel.2010.02.021; Wu XM, 2011, ACTA PHARMACOL SIN, V32, P259, DOI 10.1038/aps.2010.204; Xiong SD, 2011, INT J BIOL SCI, V7, P805, DOI 10.7150/ijbs.7.805; Yang SY, 2011, FRONT BIOSCI-LANDMRK, V16, P531, DOI 10.2741/3703; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	53	185	204	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1363	1372		10.1038/onc.2012.156	http://dx.doi.org/10.1038/onc.2012.156			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22614005				2022-12-28	WOS:000316455600003
J	Mueller, AC; Sun, D; Dutta, A				Mueller, A. C.; Sun, D.; Dutta, A.			The miR-99 family regulates the DNA damage response through its target SNF2H	ONCOGENE			English	Article						microRNA; DNA repair; cancer; SNF2H; miR-99	STRAND BREAK REPAIR; GENE-EXPRESSION; DOWN-REGULATION; MICRORNA; IDENTIFICATION; INO80; PHOSPHORYLATION; GAMMA-H2AX; COMPLEX; GLIOMA	Chromatin remodeling factors are becoming known as crucial facilitators of recruitment of repair proteins to sites of DNA damage. Multiple chromatin remodeling protein complexes are now known to be required for efficient double strand break repair. In a screen for microRNAs (miRNAs) that modulate the DNA damage response, we discovered that expression of the miR-99 family of miRNAs correlates with radiation sensitivity. These miRNAs were also transiently induced following radiation. The nniRNAs target the SWI/SNF chromatin remodeling factor SNF2H/SMARCA5, a component of the ACF1 complex. We found that by reducing levels of SNF2H, miR-99a and miR-100 reduced BRCA1 localization to sites of DNA damage. Introduction of the miR-99 family of miRNAs into cells reduced the rate and overall efficiency of repair by both homologous recombination and non-homologous end joining. Finally, induction of the miR-99 family following radiation prevents an increase in SNF2H expression and reduces the recruitment of BRCA1 to the sites of DNA damage following a second dose of radiation, reducing the efficiency of repair after multiple rounds of radiation, as used in fractionated radiotherapy. Oncogene (2013) 32, 1164-1172; doi:10.1038/onc.2012.131; published online 23 April 2012	[Mueller, A. C.; Sun, D.; Dutta, A.] Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016	Mueller, Adam/0000-0003-2678-0159; Dutta, Anindya/0000-0002-4319-0073	DOD BCRP predoctoral traineeship [BC073568]; DOD PCRP predoctoral traineeship [PC094499];  [P01CA104106]; NATIONAL CANCER INSTITUTE [R01CA134697, P01CA104106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	DOD BCRP predoctoral traineeship; DOD PCRP predoctoral traineeship; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	AM was supported by DOD BCRP predoctoral traineeship BC073568. DS was supported by DOD PCRP predoctoral traineeship PC094499. This work was supported by P01CA104106 to AD. We thank members of the Dutta Laboratory for their help and discussion.	Bruno IG, 2011, MOL CELL, V42, P500, DOI 10.1016/j.molcel.2011.04.018; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Dey BK, 2011, MOL CELL BIOL, V31, P203, DOI 10.1128/MCB.01009-10; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Gagan J, 2011, J BIOL CHEM, V286, P19431, DOI 10.1074/jbc.M111.219006; Golding SE, 2009, MOL CANCER THER, V8, P2894, DOI 10.1158/1535-7163.MCT-09-0519; Golding SE, 2009, CANCER BIOL THER, V8, P730, DOI 10.4161/cbt.8.8.7927; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Hu HL, 2011, J MOL CELL BIOL, V3, P151, DOI 10.1093/jmcb/mjq042; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Jha S, 2008, MOL CELL BIOL, V28, P2690, DOI 10.1128/MCB.01983-07; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Lal A, 2009, NAT STRUCT MOL BIOL, V16, P492, DOI 10.1038/nsmb.1589; Lan L, 2010, MOL CELL, V40, P976, DOI 10.1016/j.molcel.2010.12.003; Larsen DH, 2010, J CELL BIOL, V190, P731, DOI 10.1083/jcb.200912135; Lee HS, 2010, EMBO J, V29, P1434, DOI 10.1038/emboj.2010.27; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Marcu LG, 2010, CANCER TREAT REV, V36, P606, DOI 10.1016/j.ctrv.2010.04.004; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Mladenov E, 2011, MUTAT RES-FUND MOL M, V711, P61, DOI 10.1016/j.mrfmmm.2011.02.005; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005; Nakamura K, 2011, MOL CELL, V41, P515, DOI 10.1016/j.molcel.2011.02.002; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Ransburgh DJR, 2010, CANCER RES, V70, P988, DOI 10.1158/0008-5472.CAN-09-2850; Roberts SA, 2007, J BIOL CHEM, V282, P10605, DOI 10.1074/jbc.M611125200; Sirotkin AV, 2010, J CELL PHYSIOL, V223, P49, DOI 10.1002/jcp.21999; Skvortsova I, 2008, PROTEOMICS, V8, P4521, DOI 10.1002/pmic.200800113; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Sun DD, 2011, CANCER RES, V71, P1313, DOI 10.1158/0008-5472.CAN-10-1031; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; van Attikum H, 2007, EMBO J, V26, P4113, DOI 10.1038/sj.emboj.7601835; van Attikum H, 2009, TRENDS CELL BIOL, V19, P207, DOI 10.1016/j.tcb.2009.03.001; Wang P, 2009, CANCER RES, V69, P8157, DOI 10.1158/0008-5472.CAN-09-1996	47	100	107	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1164	1172		10.1038/onc.2012.131	http://dx.doi.org/10.1038/onc.2012.131			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22525276	Green Accepted			2022-12-28	WOS:000316428800010
J	Wei, S; Chen, X; McGraw, K; Zhang, L; Komrokji, R; Clark, J; Caceres, G; Billingsley, D; Sokol, L; Lancet, J; Fortenbery, N; Zhou, J; Eksioglu, EA; Sallman, D; Wang, H; Epling-Burnettel, PK; Djeu, J; Sekeres, M; Maciejewski, JP; List, A				Wei, S.; Chen, X.; McGraw, K.; Zhang, L.; Komrokji, R.; Clark, J.; Caceres, G.; Billingsley, D.; Sokol, L.; Lancet, J.; Fortenbery, N.; Zhou, J.; Eksioglu, E. A.; Sallman, D.; Wang, H.; Epling-Burnettel, P. K.; Djeu, J.; Sekeres, M.; Maciejewski, J. P.; List, A.			Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion	ONCOGENE			English	Article						myelodysplastic syndrome; drug resistance; MDM2	RIBOSOMAL-PROTEIN L11; CANCER; PP2A; PHOSPHORYLATION; UBIQUITINATION; IDENTIFICATION; 5Q-SYNDROME; MUTATIONS; MECHANISM; PATHWAY	Allelic deletion of the RPS14 gene is a key effector of the hypoplastic anemia in patients with myelodysplastic syndrome (MDS) and chromosome 5q deletion (del(5q)). Disruption of ribosome integrity liberates free ribosomal proteins to bind to and trigger degradation of mouse double minute 2 protein (MDM2), with consequent p53 transactivation. Herein we show that p53 is overexpressed in erythroid precursors of primary bone marrow del(5q) MDS specimens accompanied by reduced cellular MDM2. More importantly, we show that lenalidonnide (Len) acts to stabilize MDM2, thereby accelerating p53 degradation. Biochemical and molecular analyses showed that Len inhibits the haplodeficient protein phosphatase 2A catalytic domain alpha (PP2Ac alpha) phosphatase resulting in hyperphosphorylation of inhibitory serine-166 and serine-186 residues on MDM2, and displaces binding of RPS14 to suppress MDM2 autoubiquitination whereas PP2Ac alpha overexpression promotes drug resistance. Bone marrow specimens from del(5q) MDS patients resistant to Len overexpressed PP2Ac alpha accompanied by restored accumulation of p53 in erythroid precursors. Our findings indicate that Len restores MDM2 functionality in the 5q-syndrome to overcome p53 activation in response to nucleolar stress, and therefore may warrant investigation in other disorders of ribosomal biogenesis. Oncogene (2013) 32, 1110-1120; doi:10.1038/onc.2012.139; published online 23 April 2012	[Wei, S.; Chen, X.; McGraw, K.; Zhang, L.; Komrokji, R.; Clark, J.; Caceres, G.; Billingsley, D.; Sokol, L.; Lancet, J.; Fortenbery, N.; Zhou, J.; Eksioglu, E. A.; Sallman, D.; Wang, H.; Epling-Burnettel, P. K.; Djeu, J.; List, A.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33647 USA; [Sekeres, M.; Maciejewski, J. P.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA	H Lee Moffitt Cancer Center & Research Institute; Cleveland Clinic Foundation	Wei, S (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, MRC 4072,12902 Magnolia Dr, Tampa, FL 33647 USA.	sheng.wei@moffitt.org	Eksioglu, Erika/E-6315-2015	Eksioglu, Erika/0000-0003-4458-7192; LIST, ALAN/0000-0002-1647-2972; Sekeres, Mikkael/0000-0003-2009-6524	NIH [1R01CA131076, AI056213]; NATIONAL CANCER INSTITUTE [R01CA131076, P30CA076292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056213] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH Grants 1R01CA131076 and AI056213.	Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; Dutt S, 2011, BLOOD, V117, P2567, DOI 10.1182/blood-2010-07-295238; Ebert BL, 2009, LEUKEMIA, V23, P1252, DOI 10.1038/leu.2009.53; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Ebert BL, 2011, SEMIN ONCOL, V38, P621, DOI 10.1053/j.seminoncol.2011.04.010; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gandhi AK, 2006, LEUKEMIA RES, V30, P849, DOI 10.1016/j.leukres.2006.01.010; Ginzinger DG, 2000, CANCER RES, V60, P5405; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Jadersten M, 2011, J CLIN ONCOL, V29, P1971, DOI 10.1200/JCO.2010.31.8576; Jones NC, 2008, NAT MED, V14, P125, DOI 10.1038/nm1725; Joslin JM, 2007, BLOOD, V110, P719, DOI 10.1182/blood-2007-01-068809; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lehmann S, 2007, LEUKEMIA, V21, P1931, DOI 10.1038/sj.leu.2404852; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; List A, 2005, NEW ENGL J MED, V352, P549, DOI 10.1056/NEJMoa041668; List A, 2006, NEW ENGL J MED, V355, P1456, DOI 10.1056/NEJMoa061292; List A, 2009, CLIN LYMPHOMA MYELOM, V9, pS302, DOI 10.3816/CLM.2009.s.028; Liu G, 2007, J PATHOL, V213, P360, DOI 10.1002/path.2238; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Look A Thomas, 2005, Hematology Am Soc Hematol Educ Program, P156; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Meek DW, 2010, SEMIN CANCER BIOL, V20, P19, DOI 10.1016/j.semcancer.2009.10.005; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mi J, 2009, MOL CANCER THER, V8, P135, DOI 10.1158/1535-7163.MCT-08-0457; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; OCONNOR PM, 1993, CANCER RES, V53, P4776; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Quarello P, 2010, HAEMATOL-HEMATOL J, V95, P206, DOI 10.3324/haematol.2009.011783; Starczynowski DT, 2010, NAT MED, V16, P49, DOI 10.1038/nm.2054; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Volonte D, 2009, AGING-US, V1, P831, DOI 10.18632/aging.100079; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wei S, 2009, P NATL ACAD SCI USA, V106, P12974, DOI 10.1073/pnas.0811267106; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Whelan JA, 2003, J IMMUNOL METHODS, V278, P261, DOI 10.1016/S0022-1759(03)00223-0; Yokobori T, 2009, CANCER RES, V69, P3788, DOI 10.1158/0008-5472.CAN-08-2846; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	48	65	71	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1110	1120		10.1038/onc.2012.139	http://dx.doi.org/10.1038/onc.2012.139			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22525275	Green Accepted			2022-12-28	WOS:000316428800005
J	Weiler, M; Pfenning, PN; Thiepold, AL; Blaes, J; Jestaedt, L; Gronych, J; Dittmann, LM; Berger, B; Jugold, M; Kosch, M; Combs, SE; von Deimling, A; Weller, M; Bendszus, M; Platten, M; Wick, W				Weiler, M.; Pfenning, P-N; Thiepold, A-L; Blaes, J.; Jestaedt, L.; Gronych, J.; Dittmann, L. M.; Berger, B.; Jugold, M.; Kosch, M.; Combs, S. E.; von Deimling, A.; Weller, M.; Bendszus, M.; Platten, M.; Wick, W.			Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment	ONCOGENE			English	Article						angiogenesis; glioblastoma; invasion; mammalian target of rapamycin; regulator of G protein signaling	MAMMALIAN TARGET; PHASE-III; CELLS; GLIOBLASTOMA; REGULATOR; PHOSPHORYLATION; RADIOTHERAPY; EXPRESSION; PROTEINS; CCI-779	An essential mode of acquired resistance to radiotherapy (RT) appears to be promotion of tumor cell motility and invasiveness in various cancer types, including glioblastoma, a process resembling 'evasive resistance'. Hence, a logical advancement of RI would be to identify suitable complementary treatment strategies, ideally targeting cell motility. Here we report that the combination of focal RT and mammalian target of rapamycin (mTOR) inhibition using clinically relevant concentrations of temsirolimus (CCI-779) prolongs survival in a syngeneic mouse glioma model through additive cytostatic effects. In vitro, the mTOR inhibitor CCI-779 exerted marked anti-invasive effects, irrespective of the phosphatase and tensin homolog deleted on chromosome 10 status and counteracted the proinvasive effect of sublethal irradiation. Mechanistically, we identified regulator of G-protein signaling 4 (RGS4) as a novel target of mTOR inhibition and a key driver of glioblastoma invasiveness, sensitive to the anti-invasive properties of CCI-779. Notably, suppression of RGS4-dependent glioma cell invasion was signaled through both mTOR complexes, mTORC1 and mTORC2, in a concentration-dependent manner, indicating that high doses of CCI-779 may overcome tumor-cell resistance associated with the sole inhibition of mTORC1. We conclude that combined RT and mTOR inhibition is a promising therapeutic option that warrants further clinical investigation in upfront glioblastoma therapy. Oncogene (2013) 32, 1099-1109; doi:10.103g/onc.2012.137; published online 7 May 2012	[Weiler, M.; Pfenning, P-N; Thiepold, A-L; Blaes, J.; Berger, B.; Wick, W.] German Canc Res Ctr, Clin Cooperat Unit Neurooncol, Heidelberg, Germany; [Weiler, M.; Platten, M.; Wick, W.] Univ Heidelberg Hosp, Dept Neurooncol, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany; [Jestaedt, L.; Bendszus, M.] Univ Heidelberg Hosp, Dept Neuroradiol, D-69120 Heidelberg, Germany; [Gronych, J.; Dittmann, L. M.] German Canc Res Ctr, Project Grp, Small Anim Imaging Ctr, Div Mol Genet, Heidelberg, Germany; [Berger, B.] Univ Heidelberg Hosp, Dept Neurol, D-69120 Heidelberg, Germany; [Jugold, M.] German Canc Res Ctr, Project Grp, Small Anim Imaging Ctr, Div Med Phys Radiol, Heidelberg, Germany; [Kosch, M.] Pfizer, Berlin, Germany; [Combs, S. E.] Univ Heidelberg Hosp, Dept Radiat Oncol, D-69120 Heidelberg, Germany; [von Deimling, A.] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [von Deimling, A.] Univ Heidelberg Hosp, Dept Neuropathol, D-69120 Heidelberg, Germany; [Weller, M.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Platten, M.] German Canc Res Ctr, Helmholtz Grp Expt Neuroimmunol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Pfizer; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Zurich; University Zurich Hospital; Helmholtz Association; German Cancer Research Center (DKFZ)	Wick, W (corresponding author), Univ Heidelberg Hosp, Dept Neurooncol, Natl Ctr Tumor Dis, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	wolfgang.wick@med.uni-heidelberg.de	Thiepold, Anna-Luisa/AAW-8310-2021; Wick, Wolfgang/AAA-2545-2020; von Deimling, Andreas/F-7774-2013; Platten, Michael/F-2902-2013; Gronych, Jan/G-9954-2013	Wick, Wolfgang/0000-0002-6171-634X; von Deimling, Andreas/0000-0002-5863-540X; Platten, Michael/0000-0002-4746-887X; Combs, Stephanie/0000-0002-6934-2864; Weller, Michael/0000-0002-1748-174X	Brain Tumor Network (BTNplus) [10 01GS0883\]; National Genome Research Network (NGFNplus) by the Federal Ministry of Education and Research (BMBF); Charitable Hertie Foundation	Brain Tumor Network (BTNplus); National Genome Research Network (NGFNplus) by the Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Charitable Hertie Foundation	We thank P Rubmann, A-C Klein and N Sims for excellent technical assistance. We also thank the Microscopy Core Facility of the DKFZ and the Nikon Imaging Center at the University of Heidelberg, Heidelberg, Germany. We are grateful to T Wieland, University of Heidelberg, Mannheim, Germany, for providing the pCR3.0-RGS4 expression vector. This work was supported by the Brain Tumor Network (BTNplus), Subproject 10 01GS0883 (WW) and Subproject 4 (JG, LMD) of the National Genome Research Network (NGFNplus) by the Federal Ministry of Education and Research (BMBF), and the Charitable Hertie Foundation. BB is a fellow in the Postdoc Program of the Medical Faculty of the University of Heidelberg.	Bansal G, 2007, PHARMACOL THERAPEUT, V116, P473, DOI 10.1016/j.pharmthera.2007.09.005; Blazer LL, 2010, MOL PHARMACOL, V78, P524, DOI 10.1124/mol.110.065128; Chakravarti A, 2004, J CLIN ONCOL, V22, P1926, DOI 10.1200/JCO.2004.07.193; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Cotton M, 2009, CELL SIGNAL, V21, P1045, DOI 10.1016/j.cellsig.2009.02.008; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Ding J, 2006, NAT NEUROSCI, V9, P832, DOI 10.1038/nn1700; Doherty L, 2006, NEUROLOGY, V67, P156, DOI 10.1212/01.wnl.0000223844.77636.29; Dudkin L, 2001, CLIN CANCER RES, V7, P1758; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Erdely HA, 2004, EUR J NEUROSCI, V19, P3125, DOI 10.1111/j.0953-816X.2004.03364.x; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Geoerger B, 2001, CANCER RES, V61, P1527; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Hess G, 2009, J CLIN ONCOL, V27, P3822, DOI 10.1200/JCO.2008.20.7977; Hooks SB, 2008, BIOCHEM PHARMACOL, V75, P76, DOI 10.1016/j.bcp.2007.07.045; Hu WH, 2009, AM J PHYSIOL-CELL PH, V296, pC1310, DOI 10.1152/ajpcell.00573.2008; Hurst JH, 2009, BIOCHEM PHARMACOL, V78, P1289, DOI 10.1016/j.bcp.2009.06.028; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Levitt P, 2006, BIOL PSYCHIAT, V60, P534, DOI 10.1016/j.biopsych.2006.04.028; Minniti G, 2010, RADIOTHER ONCOL, V97, P377, DOI 10.1016/j.radonc.2010.08.020; Motzer RJ, 2007, J CLIN ONCOL, V25, P3958, DOI 10.1200/JCO.2006.10.5916; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Opitz CA, 2009, STEM CELLS, V27, P909, DOI 10.1002/stem.7; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park IH, 2002, J BIOL CHEM, V277, P31423, DOI 10.1074/jbc.M204080200; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pitter KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014545; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Reardon DA, 2010, J NEURO-ONCOL, V96, P219, DOI 10.1007/s11060-009-9950-0; Rieger J, 2008, J NEUROCHEM, V106, P2436, DOI 10.1111/j.1471-4159.2008.05586.x; Ronellenfitsch MW, 2009, BRAIN, V132, P1509, DOI 10.1093/brain/awp093; Sampson JH, 1997, NEUROSURGERY, V41, P1365, DOI 10.1097/00006123-199712000-00024; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Tabatabai G, 2006, BRAIN, V129, P2426, DOI 10.1093/brain/awl173; Tatenhorst L, 2004, J NEUROPATH EXP NEUR, V63, P210, DOI 10.1093/jnen/63.3.210; Weiler M, 2006, CELL DEATH DIFFER, V13, P1156, DOI 10.1038/sj.cdd.4401786; Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541; Wild-Bode C, 2001, CANCER RES, V61, P2744; Xie Y, 2009, CANCER RES, V69, P5743, DOI 10.1158/0008-5472.CAN-08-3564; Yang L, 2008, CLIN CANCER RES, V14, P3993, DOI 10.1158/1078-0432.CCR-07-4152	49	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1099	1109		10.1038/onc.2012.137	http://dx.doi.org/10.1038/onc.2012.137			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22562250	Green Accepted			2022-12-28	WOS:000316428800004
J	Catuogno, S; Cerchia, L; Romano, G; Pognonec, P; Condorelli, G; de Franciscis, V				Catuogno, S.; Cerchia, L.; Romano, G.; Pognonec, P.; Condorelli, G.; de Franciscis, V.			miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis	ONCOGENE			English	Article						A549; p53; AP20187	TUMOR-SUPPRESSOR NETWORK; REGULATES APOPTOSIS; SPINDLE CHECKPOINT; DEATH RECEPTORS; DOWN-REGULATION; FEEDBACK LOOP; P53; MYC; MICRORNAS; EXPRESSION	MicroRNAs (miRNAs) constitute a class of small non-coding RNAs that negatively regulate the expression of their target genes. They are involved in many biological processes, including cell proliferation, apoptosis and differentiation, and are considered as promising new therapeutic targets for cancer. However, the identity of miRNAs involved in apoptosis and their respective targets remain largely unknown. Given the elevated complexity of miRNA regulation of gene expression, we performed a functional screening as an alternative strategy to identify those miRNAs that in lung cancer cells may interfere with the apoptotic process. To this aim, we generated a derivative of the non-small cell lung carcinoma A549 cell line in which caspase-8, a critical upstream initiator of apoptosis, can be activated by administration of the small dimerizer drug AP20187. We found a number of miRNAs that may rescue cell viability from caspase-8 activation. They included miRNAs already described as oncogenic such as miR-17, miR-135 and miR-520, but also some miRNAs such as miR-124-1 and miR-34c for which a tumor-suppressive role has instead been described or expected. Among them, nniR-34c-5p markedly increased resistance to paclitaxel-induced apoptosis. We demonstrate that Bmf (Bcl-2-modifying factor) is a target of miR-34c-5p, and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation. Oncogene (2013) 32, 341-351; doi:10.1038/onc.2012.51; published online 27 February 2012	[Catuogno, S.; Cerchia, L.; Condorelli, G.; de Franciscis, V.] CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; [Catuogno, S.; Condorelli, G.] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy; [Romano, G.] IRCCS Fdn SDN, Naples, Italy; [Pognonec, P.] Univ Nice Sophia Antipolis, Fac Med, CNRS, Nice 2, France	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	de Franciscis, V (corresponding author), CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	defranci@unina.it	Condorelli, Gerolama/AAC-3472-2022; Catuogno, Silvia/AAB-9969-2019	Condorelli, Gerolama/0000-0003-0177-8829; Catuogno, Silvia/0000-0002-1653-4205; Cerchia, Laura/0000-0002-7633-7932	CNR [11-0075]; MIUR grant [MERIT RBNE08YFN3_001, 4971, 10620]; Italian Ministry of Economy and Finance; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	CNR(Consiglio Nazionale delle Ricerche (CNR)); MIUR grant(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Economy and Finance; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work was supported by funds from CNR, AICR No. 11-0075 (LC), an MIUR grant, MERIT RBNE08YFN3_001 (VdF), AIRC No. 4971 (LC) and No. 10620 (GC), and from the Italian Ministry of Economy and Finance to the CNR for the Project FaReBio di Qualita. We thank ARIAD Pharmaceuticals Inc. for providing the AP20187 dimerizer drug and Soddu for the pLuc-MDM2 expression vector. We also thank Dr Patrick Martin for help with the development of the inducible death vectors; Dr L Baraldi for technical assistance; CL Esposito, S Camorani, I laccarino and P Verde for suggestions and comments; and A Pollice for critically reading the manuscript.	Allan LA, 2007, MOL CELL, V26, P301, DOI 10.1016/j.molcel.2007.03.019; Allen TD, 2011, CANCER RES, V71, P2212, DOI 10.1158/0008-5472.CAN-10-3590; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Cannell IG, 2010, CELL CYCLE, V9, P2726, DOI 10.4161/cc.9.14.12182; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Carlotti F, 2005, CANCER GENE THER, V12, P627, DOI 10.1038/sj.cgt.7700825; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chang DW, 2003, SCI STKE, V167, pPL1; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642; Dacic S, 2010, MODERN PATHOL, V23, P1577, DOI 10.1038/modpathol.2010.152; DelSal G, 1996, ONCOGENE, V12, P177; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Garofalo M, 2011, ANNU REV PHARMACOL, V51, P25, DOI 10.1146/annurev-pharmtox-010510-100517; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Kress TR, 2011, MOL CELL, V41, P445, DOI 10.1016/j.molcel.2011.01.023; Lee JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021300; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Lu WG, 2002, CANCER RES, V62, P1305; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Mellert HS, 2011, J BIOL CHEM, V286, P4264, DOI 10.1074/jbc.M110.184663; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Sotillo E, 2011, ONCOGENE, V30, P2587, DOI 10.1038/onc.2010.634; Soucek L, 2010, CURR OPIN GENET DEV, V20, P91, DOI 10.1016/j.gde.2009.11.001; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; van Leeuwen I, 2009, ADV CANCER RES, V102, P171, DOI 10.1016/S0065-230X(09)02005-3; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yamakuchi M, 2009, CELL CYCLE, V8, P712, DOI 10.4161/cc.8.5.7753; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003	45	83	87	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2013	32	3					341	351		10.1038/onc.2012.51	http://dx.doi.org/10.1038/onc.2012.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370637				2022-12-28	WOS:000314736600008
J	Norris, AM; Gore, A; Balboni, A; Young, A; Longnecker, DS; Korc, M				Norris, A. M.; Gore, A.; Balboni, A.; Young, A.; Longnecker, D. S.; Korc, M.			AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia	ONCOGENE			English	Article						TGF-beta; AGR2; pancreatic cancer; MUC1; SMAD4	GROWTH-FACTOR RECEPTOR; TGF-BETA; ANTERIOR GRADIENT-2; EXPRESSION PATTERNS; HUMAN HOMOLOG; TUMOR-GROWTH; CANCER; PROTEIN; ADENOCARCINOMA; ANTIGEN	The mechanisms controlling expression of the putative oncogene Anterior gradient 2 (AGR2) in pancreatic ductal adenocarcinoma (PDAC) are not well understood. We now show that AGR2 is a transforming growth factor-beta (TGF-beta)-responsive gene in human pancreatic cancer cells, whose downregulation is SMAD4 dependent. We also provide evidence supporting a role for AGR2 as an ER-chaperone for the cancer-associated mucin, MUC1. AGR2 is both sufficient and required for MUC1 expression in pancreatic cancer cells. Furthermore, AGR2 is coexpressed with MUC1 in mouse pancreatic intraepithelial neoplasia (mPanIN)-like lesions and in the cancer cells of four distinct genetically engineered mouse models of PDAC. We also show that Pdx1-Cre/LSL-Kras(G12D)/Smad4(lox/lox) mice heterozygous for Agr2 exhibit a delay in mPanIN initiation and progression to PDAC. It is proposed that loss of Smad4 may convert TGF-beta from a tumor suppressor to a tumor promoter by causing the upregulation of AGR2, which then leads to increased MUC1 expression, at which point both AGR2 and MUC1 facilitate mPanIN initiation and progression to PDAC.	[Norris, A. M.; Young, A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; [Gore, A.; Korc, M.] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Dept Med, Indianapolis, IN 46202 USA; [Gore, A.; Korc, M.] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Gore, A.; Korc, M.] Pancreat Canc Signature Ctr, Indianapolis, IN USA; [Balboni, A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03756 USA; [Longnecker, D. S.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pathol, Hanover, NH 03756 USA	Dartmouth College; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Dartmouth College; Dartmouth College	Korc, M (corresponding author), Indiana Univ Sch Med, Dept Med, 980 West Walnut St, Indianapolis, IN 46202 USA.	mkorc@iupui.edu			US Public Health Service [CA-R37-075059]; National Cancer Institute; NRSA Molecular and Toxicology Program fellowship [5T32CA009658-18]; Program in Experimental and Molecular Medicine; NATIONAL CANCER INSTITUTE [R37CA075059, R01CA075059, T32CA009658] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NRSA Molecular and Toxicology Program fellowship; Program in Experimental and Molecular Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Ted R Hupp (U of Edinburgh) for the AGR2-RFP and pcDNA-AGR2 plasmids; Dr Park (UCSF) for providing the Agr2<SUP>-/-</SUP> mice; Dr J Gore for helpful discussions; and Ms Catherine Chen for excellent laboratory work. This research was supported by the US Public Health Service Grant CA-R37-075059, awarded by the National Cancer Institute to MK. AMN was supported by the NRSA Molecular and Toxicology Program fellowship 5T32CA009658-18. AB was supported by the Program in Experimental and Molecular Medicine.	Ambolet-Camoit A, 2010, TOXICOL SCI, V115, P501, DOI 10.1093/toxsci/kfq082; AMERICAN CANCER SOCIETY, 2007, CANC FACTS FIG; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Arnold NB, 2005, J BIOL CHEM, V280, P21858, DOI 10.1074/jbc.M500583200; Arnold NB, 2004, CANCER RES, V64, P3599, DOI 10.1158/0008-5472.CAN-03-2999; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Brychtova V, 2011, CANCER LETT, V304, P1, DOI 10.1016/j.canlet.2010.12.023; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; Carriere C, 2007, P NATL ACAD SCI USA, V104, P4437, DOI 10.1073/pnas.0701117104; Carriere C, 2011, GASTROENTEROLOGY, V141, P1091, DOI 10.1053/j.gastro.2011.05.041; Chang Ken Chien-Neng, 2007, V383, P31; Chen R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-149; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dumartin L, 2011, CANCER RES, V71, P7091, DOI 10.1158/0008-5472.CAN-11-1367; FORSTNER G, 1995, ANNU REV PHYSIOL, V57, P585, DOI 10.1146/annurev.ph.57.030195.003101; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Fritzsche FR, 2006, CLIN CANCER RES, V12, P1728, DOI 10.1158/1078-0432.CCR-05-2057; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; Hansel DE, 2003, ANNU REV GENOM HUM G, V4, P237, DOI 10.1146/annurev.genom.4.070802.110341; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hrstka R, 2010, ONCOGENE, V29, P4838, DOI 10.1038/onc.2010.228; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Innes HE, 2006, BRIT J CANCER, V94, P1057, DOI 10.1038/sj.bjc.6603065; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kristiansen G, 2005, J PATHOL, V205, P359, DOI 10.1002/path.1676; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Levi E, 2004, J CLIN PATHOL, V57, P456, DOI 10.1136/jcp.2003.013292; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Liu D, 2005, CANCER RES, V65, P3796, DOI 10.1158/0008-5472.CAN-04-3823; Lowe AW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000323; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Nagata K, 2007, J HEPATO-BILIARY-PAN, V14, P243, DOI 10.1007/s00534-006-1169-2; Norris AM, 2009, PANCREATIC CANC; Park SW, 2009, P NATL ACAD SCI USA, V106, P6950, DOI 10.1073/pnas.0808722106; Persson S, 2005, MOL PHYLOGENET EVOL, V36, P734, DOI 10.1016/j.ympev.2005.04.002; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; Riener MO, 2009, HISTOL HISTOPATHOL, V24, P1121, DOI 10.14670/HH-24.1121; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Sempere LF, 2011, CANCER BIOL THER, V12, P198, DOI 10.4161/cbt.12.3.15979; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; Thompson DA, 1998, BIOCHEM BIOPH RES CO, V251, P111, DOI 10.1006/bbrc.1998.9440; van Heek T, 2002, AM J CLIN PATHOL, V117, P755; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Wilentz R E, 1998, Surg Oncol Clin N Am, V7, P43; Wilentz RE, 2000, CANCER RES, V60, P2002; Wilson CL, 2006, ENDOCR-RELAT CANCER, V13, P617, DOI 10.1677/erc.1.01165; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang JS, 2005, GENE CHROMOSOME CANC, V43, P249, DOI 10.1002/gcc.20188; Zhang YX, 2010, CANCER RES, V70, P240, DOI 10.1158/0008-5472.CAN-09-2904; Zheng W, 2006, GENES IMMUN, V7, P11, DOI 10.1038/sj.gene.6364263	69	43	44	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3867	3876		10.1038/onc.2012.394	http://dx.doi.org/10.1038/onc.2012.394			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22945649	Green Accepted			2022-12-28	WOS:000323210200009
J	Muller, P; Ruckova, E; Halada, P; Coates, PJ; Hrstka, R; Lane, DP; Vojtesek, B				Muller, P.; Ruckova, E.; Halada, P.; Coates, P. J.; Hrstka, R.; Lane, D. P.; Vojtesek, B.			C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances	ONCOGENE			English	Article						Hsp70; Hsp90; CHIP; HOP; chaperone; folding	HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONES; UBIQUITIN LIGASE; DEGRADATION; COMPLEXES; PATHWAYS; RESIDUES; PEPTIDE; DOMAIN; SITES	Heat shock proteins Hsp90 and Hsp70 facilitate protein folding but can also direct proteins for ubiquitin-mediated degradation. The mechanisms regulating these opposite activities involve Hsp binding to co-chaperones including CHIP and HOP at their C-termini. We demonstrated that the extreme C-termini of Hsp70 and Hsp90 contain phosphorylation sites targeted by kinases including CK1, CK2 and GSK3-beta in vitro. The phosphorylation of Hsp90 and Hsp70 prevents binding to CHIP and thus enhances binding to HOP. Highly proliferative cells contain phosphorylated chaperones in complex with HOP and phospho-mimetic and non-phosphorylable Hsp mutant proteins show that phosphorylation is directly associated with increased proliferation rate. We also demonstrate that primary human cancers contain high levels of phosphorylated chaperones and show increased levels of HOP protein and mRNA. These data identify C-terminal phosphorylation of Hsp70 and Hsp90 as a switch for regulating co-chaperone binding and indicate that cancer cells possess an elevated protein folding environment by the concerted action of co-chaperone expression and chaperone modifications. In addition to identifying the pathway responsible for regulating chaperone-mediated protein folding/degradation balances in normal cells, the data provide novel mechanisms to account for the aberrant chaperone activities observed in human cancer cells and have implications for the application of anti-chaperone therapies in cancer treatment.	[Muller, P.; Ruckova, E.; Hrstka, R.; Vojtesek, B.] Masaryk Mem Canc Inst, Brno 65653, Czech Republic; [Halada, P.] Acad Sci Czech Republic, Inst Microbiol, Prague, Czech Republic; [Coates, P. J.] Univ Dundee, Ctr Oncol & Mol Med, Dundee DD1 4HN, Scotland; [Lane, D. P.] p53 Lab A STAR, Immunos, Singapore	Masaryk Memorial Cancer Institute; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Dundee	Vojtesek, B (corresponding author), Masaryk Mem Canc Inst, Zluty Kopec 7, Brno 65653, Czech Republic.	vojtesek@mou.cz	Muller, Petr/F-7762-2015; Muller, Petr/AAK-5014-2021; Halada, Petr/H-3330-2014; Coates, Philip J/H-6854-2019; Hrstka, Roman/AAM-4430-2020	Muller, Petr/0000-0002-8404-4494; Muller, Petr/0000-0002-8404-4494; Halada, Petr/0000-0002-7229-3450; Coates, Philip J/0000-0003-1518-6306; Hrstka, Roman/0000-0002-6139-2664; Lane, David/0000-0003-0551-3545	European Regional Development Fund [GACR P301/11/1678, GACR P206/12/G151, IGA NT/13794-4/2012]; State Budget of the Czech Republic [RECAMO CZ.1.05/2.1.00/03.0101]; Ministry of Health of the Czech Republic [FUNDIN MZ0MOU2005]	European Regional Development Fund(European Commission); State Budget of the Czech Republic; Ministry of Health of the Czech Republic(Ministry of Health, Czech Republic)	This work was supported by grants from GACR P301/11/1678, GACR P206/12/G151, IGA NT/13794-4/2012, by the European Regional Development Fund and the State Budget of the Czech Republic RECAMO CZ.1.05/2.1.00/03.0101 and research program of the Ministry of Health of the Czech Republic FUNDIN MZ0MOU2005.	Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hutt D, 2010, SCIENCE, V329, P766, DOI 10.1126/science.1194160; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Keefe AD, 2001, PROTEIN EXPRES PURIF, V23, P440, DOI 10.1006/prep.2001.1515; Krukenberg KA, 2011, Q REV BIOPHYS, V44, P229, DOI 10.1017/S0033583510000314; Kundrat L, 2010, BIOCHEMISTRY-US, V49, P7428, DOI 10.1021/bi100386w; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; Li J, 2011, BIOCHIM BIOPHYS ACTA, V1823, P624; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; Mayer MP, 2010, MOL CELL, V39, P321, DOI 10.1016/j.molcel.2010.07.012; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Miyata Y, 2009, CELL MOL LIFE SCI, V66, P1840, DOI 10.1007/s00018-009-9152-0; Mollapour M, 2010, MOL CELL, V37, P333, DOI 10.1016/j.molcel.2010.01.005; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Pacey S, 2011, CLIN CANCER RES, V17, P1561, DOI 10.1158/1078-0432.CCR-10-1927; Peterson LB, 2009, FUTURE MED CHEM, V1, P267, DOI [10.4155/fmc.09.17, 10.4155/FMC.09.17]; Powers MV, 2010, CELL CYCLE, V9, P1542, DOI 10.4161/cc.9.8.11204; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Workman P, 2004, TRENDS MOL MED, V10, P47, DOI 10.1016/j.molmed.2003.12.005; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023; Zhang RM, 2004, ANAL BIOCHEM, V331, P138, DOI 10.1016/j.ab.2004.03.009	31	137	139	2	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2013	32	25					3101	3110		10.1038/onc.2012.314	http://dx.doi.org/10.1038/onc.2012.314			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22824801				2022-12-28	WOS:000320705700010
J	Tobin, LA; Robert, C; Rapoport, AP; Gojo, I; Baer, MR; Tomkinson, AE; Rassool, FV				Tobin, L. A.; Robert, C.; Rapoport, A. P.; Gojo, I.; Baer, M. R.; Tomkinson, A. E.; Rassool, F. V.			Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias	ONCOGENE			English	Article						chronic myeloid leukemia; DNA ligase III alpha; PARP1; NHEJ; PARP inhibitors; DNA ligase I and III inhibitors	LIGASE-III; CLINICAL RESISTANCE; DRUG-RESISTANCE; ABL MUTATIONS; BCR/ABL; KU; IMATINIB; PROMOTES; BINDING; STI571	Resistance to imatinib (IM) and other tyrosine kinase inhibitors (TKI)s is an increasing problem in leukemias caused by expression of BCR-ABL1. As chronic myeloid leukemia (CML) cell lines expressing BCR-ABL1 utilize an alternative non-homologous end-joining pathway (ALT NHEJ) to repair DNA double-strand breaks (DSB)s, we asked whether this repair pathway is a novel therapeutic target in TKI-resistant disease. Notably, the steady state levels of two ALT NHEJ proteins, poly-(ADP-ribose) polymerase 1 (PARP1) and DNA ligase III alpha, were increased in the BCR-ABL1-positive CML cell line K562 and, to a greater extent, in its imatinib-resistant (IMR) derivative. Incubation of these cell lines with a combination of DNA ligase and PARP inhibitors inhibited ALT NHEJ and selectively decreased survival with the effect being greater in the IMR derivative. Similar results were obtained with TKI-resistant derivatives of two hematopoietic cell lines that had been engineered to stably express BCR-ABL1. Together our results show that the sensitivity of cell lines expressing BCR-ABL1 to the combination of DNA ligase and PARP inhibitors correlates with the steady state levels of PARP1 and DNA ligase III alpha, and ALT NHEJ activity. Importantly, analysis of clinical samples from CML patients confirmed that the expression levels of PARP1 and DNA ligase III alpha correlated with the sensitivity to the DNA repair inhibitor combination. Thus, the expression levels of PARP1 and DNA ligase III alpha serve as biomarkers to identify a subgroup of CML patients who may be candidates for therapies that target the ALT NHEJ pathway when treatment with TKIs has failed. Oncogene (2013) 32, 1784-1793; doi: 10.1038/onc.2012.203; published online 28 May 2012	[Tobin, L. A.; Robert, C.; Rassool, F. V.] Univ Maryland, Sch Med, Dept Radiat Oncol, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Rapoport, A. P.; Gojo, I.; Baer, M. R.] Univ Maryland, Sch Med, Dept Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Tomkinson, A. E.] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA; [Tomkinson, A. E.] Univ New Mexico, Univ New Mexico Canc Ctr, Albuquerque, NM 87131 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of New Mexico; University of New Mexico	Rassool, FV (corresponding author), Univ Maryland, Sch Med, Dept Radiat Oncol, Marlene & Stewart Greenebaum Canc Ctr,BRB, 655 West Baltimore St,Room 7-023, Baltimore, MD 21201 USA.	frassool@som.umaryland.edu	Classen, Scott/AAY-8176-2020		Cigarette Restitution Funds of Maryland; Leukemia Lymphoma Society; V Foundation; NIH [ES 012512, CA92584]; NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012512] Funding Source: NIH RePORTER	Cigarette Restitution Funds of Maryland; Leukemia Lymphoma Society(Leukemia and Lymphoma Society); V Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We would like to thank Professor Stephen Baylin (JHU) for insightful comments and careful reading of our manuscript. CML patient samples were collected under IMRB no. H25314. These studies were supported by the Cigarette Restitution Funds of Maryland (FR and LT), the Leukemia Lymphoma Society (FR, CR and LT), the V Foundation (FR, LT and AET) and NIH Grants ES 012512 and CA92584 (AET).	Audebert M, 2006, J MOL BIOL, V356, P257, DOI 10.1016/j.jmb.2005.11.028; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Audebert M, 2008, BIOCHEM BIOPH RES CO, V369, P982, DOI 10.1016/j.bbrc.2007.11.132; Ayene IS, 2002, J BIOL CHEM, V277, P9929, DOI 10.1074/jbc.M111366200; Brady N, 2003, CANCER RES, V63, P1798; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Branford S, 2003, BLOOD, V102, P276, DOI 10.1182/blood-2002-09-2896; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chen X, 2008, CANCER RES, V68, P3169, DOI 10.1158/0008-5472.CAN-07-6636; de Smith AJ, 2007, HUM MOL GENET, V16, P2783, DOI 10.1093/hmg/ddm208; FALZON M, 1993, J BIOL CHEM, V268, P10546; Fan JS, 2010, BLOOD, V116, P5298, DOI 10.1182/blood-2010-03-272591; Fattah F, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000855; Foster SS, 2011, MOL CELL BIOL, V31, P4379, DOI 10.1128/MCB.05854-11; Gao YK, 2011, NATURE, V471, P240, DOI 10.1038/nature09773; Gaymes TJ, 2002, CANCER RES, V62, P2791; Gorre M, 2001, SCIENCE, V293, P15; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hehlmann R, 2011, EXPERT OPIN PHARMACO, V12, P269, DOI 10.1517/14656566.2011.533169; Jabbour E, 2011, CANCER-AM CANCER SOC, V117, P1800, DOI 10.1002/cncr.25717; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Lee-Theilen M, 2011, NAT STRUCT MOL BIOL, V18, P75, DOI 10.1038/nsmb.1942; LOBRICH M, 1994, INT J RADIAT BIOL, V65, P623, DOI 10.1080/09553009414550731; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Majsterek I, 2002, CELL BIOL INT, V26, P363, DOI 10.1006/cbir.2002.0865; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nowell P, 1960, SCIENCE, V132, P3; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; Nussenzweig A, 2007, CELL, V131, P223, DOI 10.1016/j.cell.2007.10.005; Ohmine K, 2003, STEM CELLS, V21, P315, DOI 10.1634/stemcells.21-3-315; Rowley JA, 1973, NATURE, V243, P4; Sallmyr A, 2008, BLOOD, V112, P1413, DOI 10.1182/blood-2007-07-104257; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Savage D, 1997, BRIT J HAEMATOL, V96, P7; Shah N, 2002, CANCER CELL, V2, P8; Simsek D, 2011, NATURE, V471, P245, DOI 10.1038/nature09794; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Soverini S, 2005, J CLIN ONCOL, V23, P4100, DOI 10.1200/JCO.2005.05.531; SPIERS ASD, 1995, SEMIN ONCOL, V22, P380; Tobin LA, 2012, MOL CANCER RES, V10, P96, DOI 10.1158/1541-7786.MCR-11-0255; Tsai CJ, 2007, P NATL ACAD SCI USA, V104, P7851, DOI 10.1073/pnas.0702620104; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Zhang Y, 2011, NAT STRUCT MOL BIOL, V18, P80, DOI 10.1038/nsmb.1940; Zhong S, 2008, J MED CHEM, V51, P4553, DOI 10.1021/jm8001668	53	67	69	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1784	1793		10.1038/onc.2012.203	http://dx.doi.org/10.1038/onc.2012.203			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22641215	Green Accepted			2022-12-28	WOS:000317043900005
J	Xue, X; Gao, W; Sun, B; Xu, Y; Han, B; Wang, F; Zhang, Y; Sun, J; Wei, J; Lu, Z; Zhu, Y; Sato, Y; Sekido, Y; Miao, Y; Kondo, Y				Xue, X.; Gao, W.; Sun, B.; Xu, Y.; Han, B.; Wang, F.; Zhang, Y.; Sun, J.; Wei, J.; Lu, Z.; Zhu, Y.; Sato, Y.; Sekido, Y.; Miao, Y.; Kondo, Y.			Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma	ONCOGENE			English	Article						angiogenesis; vasohibin 2; hepatocellular carcinoma; histone modification	NEGATIVE FEEDBACK REGULATOR; ANTI-VEGF THERAPY; BREAST-CARCINOMA; COLON-CANCER; HISTONE H3; EXPRESSION; CELLS	Hepatocellular carcinoma (HCC) typically relies on angiogenesis for its malignant behavior, including growth and metastasis. Vasohibin 2 (VASH2) was previously identified as an angiogenic factor, but its role in tumorigenesis is unknown. Using quantitative PCR and western blot analyses, we found that VASH2 is overexpressed in HCC cells and tissues. Using chromatin immunoprecipitation, we detected histone modifications at the putative VASH2 promoter, with increased H3K4 trimethylation and H3 acetylation and decreased H3K27 trimethylation, suggesting that epigenetic mechanisms are responsible for the deregulated VASH2 transcription in HCC. Knockdown of VASH2 via siRNA inhibited the proliferation of the hepatoma cell lines by delaying cell cycle progression and increasing apoptosis. Importantly, we found VASH2 secreted in the culture supernatant, and co-expression of its secretory chaperone small vasohibin-binding protein (SVBP) further enhanced VASH2 secretion. The supernatant from HepG2 cells expressing VASH2 enhanced the proliferation, migration and tube formation of human umbilical vein endothelial cells, and knockdown of VASH2 significantly inhibited these effects. In an in vivo study using a nude mouse model, we found that exogenous VASH2 significantly contributed to tumor growth, microvessel density and hemoglobin concentration in the tumors. Further analyses showed that the VASH2-mediated increase in the transcription of fibroblast growth factor-2, vascular endothelial growth factor and vasohibin 1 may be the mechanism underlying these effects. Taken together, these data indicate that VASH2 is abnormally expressed in HCC cells as a result of histone modifications and that VASH2 contributes to the angiogenesis in HCC via an SVBP-mediated paracrine mechanism. These results indicate a novel and important role for VASH2 in HCC angiogenesis and malignant transformation. Oncogene (2013) 32, 1724-1734; doi:10.1038/onc.2012.177; published online 21 May 2012	[Xue, X.; Gao, W.; Sun, B.; Xu, Y.; Wang, F.; Zhang, Y.; Sun, J.; Wei, J.; Lu, Z.; Zhu, Y.; Miao, Y.] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China; [Han, B.] Nanjing Med Univ, Nanjing Childrens Hosp, Dept Endocrinol, Nanjing 210029, Jiangsu, Peoples R China; [Sato, Y.] Tohoku Univ, Dept Vasc Biol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 980, Japan; [Sekido, Y.; Kondo, Y.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Nanjing Medical University; Nanjing Medical University; Tohoku University; Aichi Cancer Center	Miao, Y (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, 300 GuangZhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	gao11@hotmail.com; miaoyi@njmu.edu.cn; ykondo@aichi-cc.jp	Lu, Zipeng/AAY-4893-2021; Sato, Yasufumi/AAF-3367-2019; Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848	National Nature Science Foundation of China [81172267, 30901627]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	We are very grateful to Professor Yujie Sun from Nanjing Medical University for continuous technical support. This work was supported by grants from the National Nature Science Foundation of China (no. 81172267 and 30901627).	Cha HJ, 2011, HEPATO-GASTROENTEROL, V58, P790; Doger FK, 2006, EUR SURG RES, V38, P540, DOI 10.1159/000096774; Eccles Suzanne A., 2009, V467, P159, DOI 10.1007/978-1-59745-241-0_9; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Gorisch SM, 2005, J CELL SCI, V118, P5825, DOI 10.1242/jcs.02689; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kimura H, 2009, BLOOD, V113, P4810, DOI 10.1182/blood-2008-07-170316; Liu LZ, 2005, MOL PHARMACOL, V68, P635, DOI 10.1124/mol.105.011254; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Mi J, 2007, BIOCHEM BIOPH RES CO, V359, P475, DOI 10.1016/j.bbrc.2007.05.125; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Semela D, 2004, J HEPATOL, V41, P864, DOI 10.1016/j.jhep.2004.09.006; Shibuya T, 2006, ARTERIOSCL THROM VAS, V26, P1051, DOI 10.1161/01.ATV.0000216747.66660.26; Sitohy B, 2011, CANCER RES, V71, P7021, DOI 10.1158/0008-5472.CAN-11-1693; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suzuki Y, 2010, J CELL SCI, V123, P3094, DOI 10.1242/jcs.067538; Tamaki K, 2009, CANCER SCI, V100, P88, DOI 10.1111/j.1349-7006.2008.01015.x; Tammali R, 2011, ANGIOGENESIS, V14, P209, DOI 10.1007/s10456-011-9206-4; Wang F, 2010, BRIT J CANCER, V103, P567, DOI 10.1038/sj.bjc.6605724; Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152; WEIDNER N, 1995, BREAST CANCER RES TR, V36, P169, DOI 10.1007/BF00666038; Wu XZ, 2007, J GASTROEN HEPATOL, V22, P1178, DOI 10.1111/j.1440-1746.2007.04997.x; Yang ZF, 2008, ANAT REC, V291, P721, DOI 10.1002/ar.20668; Yoshinaga K, 2011, CANCER SCI, V102, P446, DOI 10.1111/j.1349-7006.2010.01812.x; Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30	29	59	63	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 28	2013	32	13					1724	1734		10.1038/onc.2012.177	http://dx.doi.org/10.1038/onc.2012.177			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614011				2022-12-28	WOS:000316855800012
J	Hong, SW; Lee, SH; Moon, JH; Hwang, JJ; Kim, DE; Ko, E; Kim, HS; Cho, IJ; Kang, JS; Kim, DJ; Kim, JE; Shin, JS; Jung, DJ; Jeong, YJ; Cho, BJ; Kim, TW; Lee, JS; Kang, JS; Hwang, YI; Noh, DY; Jin, DH; Lee, WJ				Hong, S-W; Lee, S-H; Moon, J-H; Hwang, J. J.; Kim, D. E.; Ko, E.; Kim, H-S; Cho, I. J.; Kang, J. S.; Kim, D. J.; Kim, J-E; Shin, J-S; Jung, D-J; Jeong, Y-J; Cho, B-J; Kim, T-W; Lee, J. S.; Kang, J-S; Hwang, Y-I; Noh, D-Y; Jin, D-H; Lee, W. J.			SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment	ONCOGENE			English	Article						L-ascorbate; autophagy; SVCT-2; ROS; Beclin-1; LC3	VITAMIN-C TRANSPORTER; TERMINAL HUMAN CANCER; SUPPLEMENTAL ASCORBATE; SUPPORTIVE TREATMENT; HYDROGEN-PEROXIDE; SURVIVAL TIMES; ACID; CELLS; AUTOPHAGY; GROWTH	L-ascorbate (L-ascorbic acid, vitamin C) clearly has an inhibitory effect on cancer cells. However, the mechanism underlying differential sensitivity of cancer cells from same tissue to L-ascorbate is yet to be clarified. Here, we demonstrate that L-ascorbate has a selective killing effect, which is influenced by sodium-dependent vitamin C transporter 2 (SVCT-2) in human breast cancer cells. Treatment of human breast cancer cells with L-ascorbate differentially induced cell death, dependent on the SVCT-2 protein level. Moreover, knockdown of endogenous SVCT-2 via RNA interference in breast cancer cells expressing high levels of the protein induced resistance to L-ascorbate treatment, whereas transfection with SVCT-2 expression plasmids led to enhanced L-ascorbate chemosensitivity. Surprisingly, tumor regression by L-ascorbate administration in mice bearing tumor cell xenograft also corresponded to the SVCT-2 protein level. Interestingly, SVCT-2 expression was absent or weak in normal tissues, but strongly detected in tumor samples obtained from breast cancer patients. In addition, enhanced chemosensitivity to L-ascorbate occurred as a result of caspase-independent autophagy, which was mediated by beclin-1 and LC3 II. In addition, treatment with N-acetyl-L-cysteine, a reactive oxygen species (ROS) scavenger, suppressed the induction of beclin-1 and LC3 II, implying that the differential SVCT-2 protein-dependent L-ascorbate uptake was attributable to intracellular ROS induced by L-ascorbate, subsequently leading to autophagy. These results suggest that functional SVCT-2 sensitizes breast cancer cells to autophagic damage by increasing the L-ascorbate concentration and intracellular ROS production and furthermore, SVCT-2 in breast cancer may act as an indicator for commencing L-ascorbate treatment. Oncogene (2013) 32, 1508-1517; doi:10.1038/onc.2012.176; published online 4 June 2012	[Hong, S-W; Lee, S-H; Kim, J-E; Shin, J-S; Jung, D-J; Jeong, Y-J; Kang, J-S; Hwang, Y-I; Jin, D-H; Lee, W. J.] Seoul Natl Univ, Coll Med, Dept Anat, Seoul, South Korea; [Hong, S-W; Lee, S-H; Kim, J-E; Shin, J-S; Jung, D-J; Jeong, Y-J; Kang, J-S; Hwang, Y-I; Jin, D-H; Lee, W. J.] Seoul Natl Univ, Coll Med, Tumor Immun Res Ctr, Seoul, South Korea; [Hong, S-W; Moon, J-H; Hwang, J. J.; Kim, D. E.; Shin, J-S; Kim, T-W; Lee, J. S.; Jin, D-H] Univ Ulsan, Coll Med, Asan Med Ctr, Inst Innovat Canc Res, Seoul 138736, South Korea; [Lee, S-H] Inje Univ, Paik Hosp, Dept Plast & Reconstruct Surg, Gyeonggi Do, South Korea; [Ko, E.; Kim, H-S; Noh, D-Y] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea; [Ko, E.; Kim, H-S; Noh, D-Y] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Cho, I. J.; Kang, J. S.] Korea Res Insit Biosci & Biotechnol, Bioevaluat Ctr, Chungbuk, South Korea; [Kim, D. J.] Chung Ang Univ, Coll Med, Dept Anat, Seoul 156756, South Korea; [Cho, B-J] Konkuk Univ, Konkuk Univ Hosp, Sch Med, Dept Ophthalmol, Seoul, South Korea; [Cho, B-J; Kim, T-W; Lee, J. S.] Asan Med Ctr, Dept Oncol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); University of Ulsan; Asan Medical Center; Inje University; Seoul National University (SNU); Seoul National University (SNU); Chung Ang University; Chung Ang University Hospital; Konkuk University; Konkuk University Medical Center; University of Ulsan; Asan Medical Center	Jin, DH (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Inst Innovat Canc Res, Seoul 138736, South Korea.	inno183@amc.seoul.kr; kinglee@snu.ac.kr	Kang, Jae Seung/J-5363-2012; Hwang, Jung Jin/F-3424-2014; Noh, Dong-Young/G-5531-2011	Kang, Jong Soon/0000-0001-7698-0162	Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University College of Medicine [R13-2002-025-02001-0]; Ministry of Health and Welfare and Family Affairs, Republic of Korea [A062254]	Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University College of Medicine(Korea Science and Engineering Foundation); Ministry of Health and Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This work was supported by Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University College of Medicine (R13-2002-025-02001-0) and by grants from the Korea Health 21 R&D Project, Ministry of Health and Welfare and Family Affairs, Republic of Korea (A062254). We would like to thank Dr Norio Itoh, Osaka University, for providing SVCT-2 antibody; and Dr Tobias P Dick, German Cancer Research Center, for providing redox-probe cDNAs.	Baader SL, 1996, FEBS LETT, V381, P131, DOI 10.1016/0014-5793(96)00098-1; CAMERON E, 1976, P NATL ACAD SCI USA, V73, P3685, DOI 10.1073/pnas.73.10.3685; CAMERON E, 1978, P NATL ACAD SCI USA, V75, P4538, DOI 10.1073/pnas.75.9.4538; CAMERON E, 1974, CHEM-BIOL INTERACT, V9, P285, DOI 10.1016/0009-2797(74)90019-2; Chen AA, 2009, CARCINOGENESIS, V30, P977, DOI 10.1093/carcin/bgp076; Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102; Chen Q, 2008, P NATL ACAD SCI USA, V105, P11105, DOI 10.1073/pnas.0804226105; CREAGAN ET, 1979, NEW ENGL J MED, V301, P687, DOI 10.1056/NEJM197909273011303; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; Halliwell B, 1996, FREE RADICAL RES, V25, P439, DOI 10.3109/10715769609149066; Head K A, 1998, Altern Med Rev, V3, P174; Jung MS, 2004, J BIOL CHEM, V279, P17765, DOI 10.1074/jbc.M305015200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kang JS, 2005, J CELL PHYSIOL, V204, P192, DOI 10.1002/jcp.20286; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kuo SM, 2004, J NUTR, V134, P2216; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maramag C, 1997, PROSTATE, V32, P188, DOI 10.1002/(SICI)1097-0045(19970801)32:3<188::AID-PROS5>3.0.CO;2-H; Martin A, 2002, J NEUROCHEM, V82, P538, DOI 10.1046/j.1471-4159.2002.00978.x; MENNITI FS, 1986, J BIOL CHEM, V261, P6901; MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301; MURAD S, 1981, P NATL ACAD SCI-BIOL, V78, P2879, DOI 10.1073/pnas.78.5.2879; Ohtani S, 2007, CANCER RES, V67, P6293, DOI 10.1158/0008-5472.CAN-06-3884; Ouyang YB, 2002, FREE RADICAL BIO MED, V33, P544, DOI 10.1016/S0891-5849(02)00912-7; Padayatty SJ, 2000, J AM COLL NUTR, V19, P423, DOI 10.1080/07315724.2000.10718941; Patak P, 2004, ENDOCR RES, V30, P871, DOI 10.1081/ERC-200044126; PETERKOFSKY B, 1977, J CELL PHYSIOL, V90, P61, DOI 10.1002/jcp.1040900109; Reidling JC, 2008, AM J PHYSIOL-GASTR L, V295, pG1217, DOI 10.1152/ajpgi.90399.2008; SCHAUS EE, 1986, BIOCHEM MED METAB B, V36, P369, DOI 10.1016/0885-4505(86)90149-0; Takanaga H, 2004, PFLUG ARCH EUR J PHY, V447, P677, DOI 10.1007/s00424-003-1104-1; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Wang HP, 1999, BBA-BIOMEMBRANES, V1461, P1, DOI 10.1016/S0005-2736(99)00182-0	32	54	56	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 21	2013	32	12					1508	1517		10.1038/onc.2012.176	http://dx.doi.org/10.1038/onc.2012.176			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22665050				2022-12-28	WOS:000316456000004
J	Cheng, JC; Chang, HM; Leung, PCK				Cheng, J-C; Chang, H-M; Leung, P. C. K.			Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells	ONCOGENE			English	Article						EGF; Egr-1; E-cadherin; ovarian cancer	FINGER TRANSCRIPTION FACTOR; MESENCHYMAL TRANSITION; FACTOR RECEPTOR; RESPONSE-1 PROTEIN; TUMOR; SNAIL; ACTIVATION; BINDING; MOUSE; SP1	Loss of the cell adhesion protein E-cadherin increases the invasive capability of ovarian cancer cells. We have previously shown that epidermal growth factor (EGF) downregulates E-cadherin and induces ovarian cancer cell invasion through the H2O2/p38 MAPK-mediated upregulation of the E-cadherin transcriptional repressor Snail. However, the molecular mechanisms underlying the EGF-induced downregulation of E-cadherin are not fully understood. In the current study, we demonstrated that treatment of two ovarian cancer cell lines, SKOV3 and OVCAR5, with EGF induced the expression of the transcription factor Egr-1, and this induction was abolished by small interfering RNA (siRNA)-mediated depletion of the EGF receptor. EGF-induced Egr-1 expression required the activation of the ERK1/2 and PI3K/Akt signaling pathways and was unrelated to EGF-induced H2O2 production and activation of the p38 MAPK pathway. Moreover, depletion of Egr-1 with siRNA abolished the EGF-induced downregulation of E-cadherin and increased cell invasion. Interestingly, siRNA depletion of Egr-1 attenuated the EGF-induced expression of Slug, but not that of Snail. Moreover, chromatin immunoprecipitation (ChIP) analysis showed that Slug is a target gene of Egr-1. These results provide evidence that Egr-1 is a mediator that is involved in the EGF-induced downregulation of E-cadherin and increased cell invasion. Our results also demonstrate that EGF activates two independent signaling pathways, which are the H2O2/p38 MAPK-mediated upregulation of Snail expression and the Egr-1-mediated upregulation of Slug expression. These two signaling pathways contribute to the EGF-induced downregulation of E-cadherin, which subsequently increases the invasive capability of ovarian cancer cells. Oncogene (2013) 32, 1041-1049; doi:10.1038/onc.2012.127; published online 16 April 2012	[Cheng, J-C; Chang, H-M; Leung, P. C. K.] Univ British Columbia, Child & Family Res Inst, Dept Obstet & Gynaecol, Vancouver, BC V6H 3V5, Canada	Child & Family Research Institute; University of British Columbia	Leung, PCK (corresponding author), Univ British Columbia, Child & Family Res Inst, Dept Obstet & Gynaecol, Room 2H-30,4490 Oak St, Vancouver, BC V6H 3V5, Canada.	peter.leung@ubc.ca	Cheng, Jung-Chien/T-4258-2019; Chang, Hsun-Ming/M-8584-2018	Cheng, Jung-Chien/0000-0002-5399-9327; Leung, Peter/0000-0003-3152-3800	Canadian Institutes of Health Research; Child & Family Research Institute Senior Investigator Award; BC Foundation for Non-Animal Research-Evelyn Martin Memorial Fellowship	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Child & Family Research Institute Senior Investigator Award; BC Foundation for Non-Animal Research-Evelyn Martin Memorial Fellowship	This work was supported by grants from Canadian Institutes of Health Research to PCKL. PCKL is the recipient of a Child & Family Research Institute Senior Investigator Award. JCC is the recipient of BC Foundation for Non-Animal Research-Evelyn Martin Memorial Fellowship.	Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Baron V, 2003, ANN NY ACAD SCI, V1002, P197, DOI 10.1196/annals.1281.024; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Bartlett JMS, 1996, BRIT J CANCER, V73, P301, DOI 10.1038/bjc.1996.53; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bouchard F, 2010, BLOOD, V116, P759, DOI 10.1182/blood-2009-12-257030; Cabodi S, 2009, J CELL PHYSIOL, V218, P294, DOI 10.1002/jcp.21603; CAO XM, 1993, J BIOL CHEM, V268, P16949; Cheng JC, 2010, MOL ENDOCRINOL, V24, P1569, DOI 10.1210/me.2010-0034; Dahl KDC, 2008, CANCER RES, V68, P4606, DOI 10.1158/0008-5472.CAN-07-5046; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; Jones N, 2003, J CELL PHYSIOL, V196, P326, DOI 10.1002/jcp.10308; Kaufmann K, 2001, J NEUROL SCI, V189, P83, DOI 10.1016/S0022-510X(01)00562-7; Kim CG, 2007, CELL SIGNAL, V19, P1290, DOI 10.1016/j.cellsig.2007.01.008; Kuo PL, 2011, J CELL PHYSIOL, V226, P1224, DOI 10.1002/jcp.22445; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mayer SI, 2009, J CELL SCI, V122, P3340, DOI 10.1242/jcs.048272; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Niikura H, 1997, INT J GYNECOL PATHOL, V16, P60, DOI 10.1097/00004347-199701000-00010; Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Salah Z, 2007, CANCER RES, V67, P9835, DOI 10.1158/0008-5472.CAN-07-1886; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tsai JC, 2001, AM J PHYSIOL-GASTR L, V281, pG1271, DOI 10.1152/ajpgi.2001.281.5.G1271; Tsunoda T, 1999, BIOINFORMATICS, V15, P622, DOI 10.1093/bioinformatics/15.7.622; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Woo MMM, 2007, IN VITRO CELL DEV-AN, V43, P7, DOI 10.1007/s11626-006-9002-4; Xu ZH, 2010, BIOCHEM BIOPH RES CO, V401, P376, DOI 10.1016/j.bbrc.2010.09.059	44	48	49	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					1041	1049		10.1038/onc.2012.127	http://dx.doi.org/10.1038/onc.2012.127			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22508482				2022-12-28	WOS:000316523200011
J	Qi, Q; He, K; Liu, X; Pham, C; Meyerkord, C; Fu, H; Ye, K				Qi, Q.; He, K.; Liu, X.; Pham, C.; Meyerkord, C.; Fu, H.; Ye, K.			Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion and colony formation	ONCOGENE			English	Article						glioblastoma; protein/protein interaction; PIKE-A; Akt	HUMAN-MALIGNANT GLIOMAS; DEPENDENT KINASES; NUCLEAR GTPASE; HUMAN CANCERS; PROTEIN 4.1N; AKT; CDK4; AMPLIFICATION; MDM2; PHOSPHORYLATION	The cyclin-dependent kinase 4 (CDK4) amplicon is frequently amplified in numerous human cancers including gliomas. PIKE-A, a proto-oncogene that is one of the important components of the CDK4 amplicon, binds to and enhances the kinase activity of Akt, thereby promoting cancer progression. To define the roles of the PIKE-A/Akt interaction in glioblastoma multiform (GBM) progression, we used biochemical protein/protein interaction (PPI) assays and live cell fluorescence-based protein complementation assays to search for small peptide antagonist from these proteins that were able to block their interaction. Here, we show that disruption of the interaction between PIKE-A and Akt by the small peptides significantly reduces glioblastoma cell proliferation, colony formation, migration and invasion. Disruption of PIKE-A/Akt association potently suppressed GBM cell proliferation and sensitized the cells to two clinical drugs that are currently used to treat GBM. Interestingly, GBM cells containing the CDK4 amplicon were more responsive to the inhibition of the PIKE-A/Akt interaction than GBM cells lacking this amplicon. Taken together, our findings provide proof-of-principle that blocking a PPI that is essential for cancer progression provides a valuable strategy for therapeutic discovery. Oncogene (2013) 32, 1030-1040; doi:10.1038/onc.2012.109; published online 26 March 2012	[Qi, Q.; He, K.; Liu, X.; Ye, K.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30300 USA; [Pham, C.; Meyerkord, C.; Fu, H.] Emory Univ, Dept Pharmacol, Atlanta, GA 30300 USA; [Meyerkord, C.; Fu, H.] Emory Univ, Emory Chem Biol Discovery Ctr, Atlanta, GA 30300 USA	Emory University; Emory University; Emory University	Ye, K (corresponding author), Emory Univ, Dept Pathol & Lab Med, 615 Michael St, Atlanta, GA 30300 USA.	kye@emory.edu	Qi, Qi/J-3508-2013	Qi, Qi/0000-0003-4460-0713	National Cancer Institute, National Institutes of Health [HHSN261200800001E, RO1 CA127119]; NATIONAL CANCER INSTITUTE [R01CA127119] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E (H Fu) and RO1 CA127119 (K Ye). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.	Ahn JY, 2004, P NATL ACAD SCI USA, V101, P6993, DOI 10.1073/pnas.0400921101; Ahn JY, 2004, J BIOL CHEM, V279, P16441, DOI 10.1074/jbc.M312175200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Chan CB, 2011, EMBO REP, V12, P847, DOI 10.1038/embor.2011.108; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Marval PLM, 2004, ONCOGENE, V23, P1863, DOI 10.1038/sj.onc.1207309; delPeso L, 1997, SCIENCE, V278, P687; Elkahloun AG, 1997, GENOMICS, V42, P295, DOI 10.1006/geno.1997.4727; Grzmil M, 2010, BBA-PROTEINS PROTEOM, V1804, P476, DOI 10.1016/j.bbapap.2009.10.018; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim H, 2010, P NATL ACAD SCI USA, V107, P2183, DOI 10.1073/pnas.0909896107; Kumar CC, 2005, ONCOGENE, V24, P7493, DOI 10.1038/sj.onc.1209087; Liu X, 2007, ONCOGENE, V26, P4918, DOI 10.1038/sj.onc.1210290; Min W, 2008, CIRC RES, V102, P840, DOI 10.1161/CIRCRESAHA.107.168153; Muthusamy V, 2006, GENE CHROMOSOME CANC, V45, P447, DOI 10.1002/gcc.20310; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Scott JD, 2009, SCIENCE, V326, P1220, DOI 10.1126/science.1175668; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Soundararajan M, 2007, BIOCHEM J, V401, P679, DOI 10.1042/BJ20060555; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Wikman H, 2005, GENE CHROMOSOME CANC, V42, P193, DOI 10.1002/gcc.20122; Xia CZ, 2003, MOL CELL BIOL, V23, P2476, DOI 10.1128/MCB.23.7.2476-2488.2003; Yan J, 2008, J MOL BIOL, V378, P425, DOI 10.1016/j.jmb.2008.02.052; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Ye KQ, 1999, J NEUROSCI, V19, P10747, DOI 10.1523/JNEUROSCI.19-24-10747.1999	32	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					1030	1040		10.1038/onc.2012.109	http://dx.doi.org/10.1038/onc.2012.109			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22450747	Green Accepted			2022-12-28	WOS:000316523200010
J	Braig, S; Bosserhoff, AK				Braig, S.; Bosserhoff, A-K			Death inducer-obliterator 1 (Didol) is a BMP target gene and promotes BMP-induced melanoma progression	ONCOGENE			English	Article						malignant melanoma; bone morphogenic protein; Dido1; integrin alpha V; migration; invasion	BONE MORPHOGENETIC PROTEINS; TRANSCRIPTION FACTOR; CELL INVASION; IN-VITRO; EXPRESSION; INTEGRINS; APOPTOSIS; ANGIOGENESIS; INVOLVEMENT; MECHANISMS	Bone morphogenetic proteins (BMPs) are known to play an important role in melanoma development and progression. However, the downstream targets of BMPs have not been investigated thus far. Therefore, we treated melanoma cell lines with the Smad-specific BMP inhibitor Dorsomorphin and performed a cDNA microarray. We identified death inducer-obliterator 1 (Dido1) as a BMP-specific Smad-regulated target gene, which was confirmed by qRT-PCR, immunofluorescence staining and electrophoretic mobility shift assay experiments. An analysis of Dido1 expression revealed an upregulation of Dido1 levels in melanoma cell lines and tissues compared with normal melanocytes. Colony-formation assays showed that siDido1-transfected cells formed significantly smaller colonies when grown in soft agar compared with control cells. In addition, fluorescence-activated cell sorting and western blot experiments revealed that transfection of melanoma cells with Dido1 small interfering RNAs led to an upregulation of apoptosis. Furthermore, cell migratory and invasive potentials were strongly reduced in siDido1-transfected cells compared with control cells. Finally, we demonstrated that Didol induces the expression of lntegrin alpha V, thereby promoting the attachment, migration, invasion and apoptosis resistance of melanoma cells. Oncogene (2013) 32, 837-848; doi:10.1038/onc.2012.115; published online 2 April 2012	[Braig, S.; Bosserhoff, A-K] Univ Regensburg, Sch Med, Inst Pathol, D-93053 Regensburg, Germany	University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				Anderson GJ, 2008, NAT CHEM BIOL, V4, P15, DOI 10.1038/nchembio0108-15; Arndt S, 2007, MOL CELL NEUROSCI, V34, P603, DOI 10.1016/j.mcn.2007.01.002; Boergermann JH, 2010, INT J BIOCHEM CELL B, V42, P1802, DOI 10.1016/j.biocel.2010.07.018; Braig S, 2010, CELL MOL LIFE SCI, V67, P3535, DOI 10.1007/s00018-010-0394-7; Busch C, 2008, INT J CANCER, V122, P526, DOI 10.1002/ijc.23139; Cavallaro U, 2000, J NEURO-ONCOL, V50, P63, DOI 10.1023/A:1006414621286; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Garcia-Domingo D, 2003, MOL CELL BIOL, V23, P3216, DOI 10.1128/MCB.23.9.3216-3225.2003; Garcia-Domingo D, 1999, P NATL ACAD SCI USA, V96, P7992, DOI 10.1073/pnas.96.14.7992; Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154-006-9000-6; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Hsu MY, 2005, CANCER METAST REV, V24, P251, DOI 10.1007/s10555-005-1575-y; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Koistinen P, 2004, INT J CANCER, V112, P61, DOI 10.1002/ijc.20377; Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555-005-1572-1; Marshall JF, 1996, SEMIN CANCER BIOL, V7, P129, DOI 10.1006/scbi.1996.0018; Moschos Stergios J, 2007, Oncology (Williston Park), V21, P13; Na YR, 2009, CANCER SCI, V100, P2218, DOI 10.1111/j.1349-7006.2009.01301.x; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Rockmann H, 2003, ONKOLOGIE, V26, P581, DOI 10.1159/000074156; Rojas AM, 2005, FEBS J, V272, P3505, DOI 10.1111/j.1742-4658.2005.04759.x; Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182; Rothhammer T, 2005, CANCER RES, V65, P448; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; Rothhammer T, 2008, EUR J CANCER, V44, P2526, DOI 10.1016/j.ejca.2008.07.029; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Trachana V, 2007, P NATL ACAD SCI USA, V104, P2691, DOI 10.1073/pnas.0611132104; Vachon Pierre H, 2011, J Signal Transduct, V2011, P738137, DOI 10.1155/2011/738137; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Wenke AK, 2007, CELL ONCOL, V29, P373; Wenke AK, 2009, FEBS J, V276, P2494, DOI 10.1111/j.1742-4658.2009.06973.x; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Zhang YC, 2011, INVEST NEW DRUG, V29, P666, DOI 10.1007/s10637-010-9616-y	38	43	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					837	848		10.1038/onc.2012.115	http://dx.doi.org/10.1038/onc.2012.115			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469980				2022-12-28	WOS:000316581100004
J	Cavallari, C; Fonsato, V; Herrera, MB; Bruno, S; Tetta, C; Camussi, G				Cavallari, C.; Fonsato, V.; Herrera, M. B.; Bruno, S.; Tetta, C.; Camussi, G.			Role of Lefty in the anti tumor activity of human adult liver stem cells	ONCOGENE			English	Article						lefty; tumor growth; adult stem cells; liver; hepatoma	MELANOMA-CELLS; PHENOTYPE; PATHWAYS; ABSENCE	Recent studies demonstrated that factors derived from embryonic stem cells inhibit the tumorigenicity of a variety of cancer cell lines. Embryonic stem cell-secreted Lefty, an inhibitor of Nodal-signalling pathway, was implicated in reprogramming cancer cells. Whether adult stem cells exhibited similar properties has not been explored. The aim of the present study was to investigate whether the conditioned medium (CM) derived from adult stem cells influence in vitro and in vivo tumor growth by a Nodal-dependent pathway. In particular we compared the anti-tumor effect of CM from human liver stem cells (HLSC) with that of bone marrow-derived mesenchymal stem cells (MSC). We found that HLSC-CM inhibited the in vitro growth and promoted apoptosis in HepG2 cells that expressed a deregulated Nodal pathway. The effect of HLSC-CM was related to the presence of Lefty A in the CM of HLSC. Silencing Lefty A in HLSC or Lefty A blockade with a blocking peptide abrogated the anti-proliferative and pro-apoptotic effect of HLSC-CM. Moreover, the administration of human recombinant Lefty A protein mimicked the effect of HLSC-CM indicating that Nodal pathway is critical for the growth of HepG2. At variance of HLSC, bone marrow-derived MSC did not express and release Lefty A and the MSC-CM did not exhibited an anti-tumor activity in vitro, but rather stimulated proliferation of HepG2. In addition, the intra-tumor administration of HLSC-CM was able to inhibit the in vivo growth of HepG2 hepatoma cells implanted subcutaneously in SCID mice. At variance, HLSC-CM derived from Lefty A silenced HLSC was unable to inhibit tumor growth. In conclusion, the results of present study suggest that Lefty A may account for the tumor suppressive activity of HLSC as a result of an inhibition of the Nodal-signalling pathway by a mechanism similar to that described for embryonic stem cells. Oncogene (2013) 32, 819-826; doi:10.1038/onc.2012.114; published online 2 April 2012	[Cavallari, C.; Fonsato, V.; Herrera, M. B.; Camussi, G.] Univ Turin, Dept Internal Med, Res Ctr Expt Med CeRMS, Turin, Italy; [Cavallari, C.; Fonsato, V.; Herrera, M. B.; Camussi, G.] Univ Turin, Ctr Mol Biotechnol, Turin, Italy; [Bruno, S.; Tetta, C.] SisTER, Palazzo Pignano, Italy; [Bruno, S.; Tetta, C.] Fresenius Med Care, Bad Homburg, Germany	University of Turin; University of Turin	Camussi, G (corresponding author), Osped Maggiore S Giovanni Battista Molinette, Cattedra Nefrol, Dipartimento Med Interna, Corso Dogliotti 14, I-10126 Turin, Italy.	giovanni.camussi@unito.it	Camussi, Giovanni/J-7624-2016	Camussi, Giovanni/0000-0003-2795-232X; BRUNO, Stefania/0000-0002-8879-9536	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG8912]; Fresenius Medical Care; Italian Ministry of University and Research (MIUR); Regione Piemonte, Project Oncoprot and Piattaforme Biotecnologiche, Pi-Stem project	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fresenius Medical Care; Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); Regione Piemonte, Project Oncoprot and Piattaforme Biotecnologiche, Pi-Stem project	We thank Federica Antico for technical help. This study was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), project IG8912, by Fresenius Medical Care, by Italian Ministry of University and Research (MIUR) Prin08 and by Regione Piemonte, Project Oncoprot and Piattaforme Biotecnologiche, Pi-Stem project.	Abbott DE, 2008, CANCER MICROENVIRON, V1, P13, DOI 10.1007/s12307-008-0004-5; Barroso-delJesus A, 2011, FASEB J, V25, P1497, DOI 10.1096/fj.10-172221; Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798; Costa FF, 2009, EPIGENOMICS-UK, V1, P387, DOI 10.2217/EPI.09.25; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Diez-Torre A, 2009, INT J DEV BIOL, V53, P1563, DOI 10.1387/ijdb.093021ad; Dvash T, 2007, STEM CELLS, V25, P465, DOI 10.1634/stemcells.2006-0179; Giuffrida D, 2009, CELL PROLIFERAT, V42, P788, DOI 10.1111/j.1365-2184.2009.00640.x; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Herrera MB, 2010, J CELL MOL MED, V14, P1605, DOI 10.1111/j.1582-4934.2009.00860.x; Herrera MB, 2006, STEM CELLS, V24, P2840, DOI 10.1634/stemcells.2006-0114; Kulesa PM, 2006, P NATL ACAD SCI USA, V103, P3752, DOI 10.1073/pnas.0506977103; Lawrence MG, 2011, PROSTATE, V71, P1198, DOI 10.1002/pros.21335; Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471; Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7; Meno C, 2001, DEV CELL, V1, P127, DOI 10.1016/S1534-5807(01)00006-5; PIERCE GB, 1982, CANCER RES, V42, P1082; PODESTA AH, 1984, P NATL ACAD SCI-BIOL, V81, P7608, DOI 10.1073/pnas.81.23.7608; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Postovit LM, 2006, STEM CELLS, V24, P501, DOI 10.1634/stemcells.2005-0459; Sakuma R, 2002, GENES CELLS, V7, P401, DOI 10.1046/j.1365-2443.2002.00528.x; Tabibzadeh S, 2006, STEM CELLS, V24, P1998, DOI 10.1634/stemcells.2006-0075; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448	23	29	30	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					819	826		10.1038/onc.2012.114	http://dx.doi.org/10.1038/onc.2012.114			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469982	Green Published, hybrid			2022-12-28	WOS:000316581100002
J	Liu, J; Cheng, X; Zhang, Y; Li, S; Cui, H; Zhang, L; Shi, R; Zhao, Z; He, C; Wang, C; Zhao, H; Zhang, C; Fisk, HA; Guadagno, TM; Cui, Y				Liu, J.; Cheng, X.; Zhang, Y.; Li, S.; Cui, H.; Zhang, L.; Shi, R.; Zhao, Z.; He, C.; Wang, C.; Zhao, H.; Zhang, C.; Fisk, H. A.; Guadagno, T. M.; Cui, Y.			Phosphorylation of Mps1 by BRAF(V600E) prevents Mps1 degradation and contributes to chromosome instability in melanoma	ONCOGENE			English	Article						BRAF(V600E); Mps1; centrosome amplification; chromosome instability; melanoma	SPINDLE-CHECKPOINT; CENTROSOME DUPLICATION; KINASE-ACTIVITY; CELL-CYCLE; ACTIVATION; BRAF; AMPLIFICATION; ACCUMULATION; KINETOCHORES; MUTATIONS	Activating BRAF mutations that deregulate the mitogen-activated protein kinase (MAPK) pathway commonly occur in cancer. BRAF(V600E) induces centrosome amplification and spindle abnormalities that result in aneuploidy. We find modification of Mps1 is critical for contributing to centrosome amplification and chromosome instability induced by BRAF(V600E). Phosphorylation of Mps1 at residue S281 induced by BRAF(V600E) stabilizes Mps1 protein by preventing its ubiquitination by APC/C and subsequent degradation, allowing the non-degraded protein to accumulate at centrosomes. Cells in which endogenous Mps1 was replaced with a phospho-mimetic Mps1 mutant are viable but amplify centrosomes and missegregate chromosomes frequently. Importantly, analysis of tumor micro arrays revealed that phospho-MAPK and 5281-phosphorylated Mps1 were highly correlated in human melanoma tissues, implying that MAPK contributes to defects in the degradation of Mps1 in situ. We propose that continuously activated BRAF(V600E) signaling may be a possible mechanism for the deregulation of Mps1 stability and kinase activity in human tumors, and that persistent phosphorylation of Mps1 through BRAFV600E signaling is a key event in disrupting the control of centrosonne duplication and chromosome stability that may contribute to tumorigenesis. Our findings raise the possibility that targeting the oncogenic BRAF and 5281-phosphorylated Mps1, especially when used in combination could potentially provide great therapeutic opportunities for cancer treatment. Oncogene (2013) 32, 713-723; doi:10.1038/onc.2012.94; published online 19 March 2012	[Liu, J.; Zhao, H.] Shanxi Med Univ, Dept Gen Surg, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China; [Liu, J.; Cheng, X.; Zhang, Y.; Li, S.; Cui, H.; Zhang, L.; Zhao, Z.; He, C.; Zhang, C.; Cui, Y.] Shanxi Med Univ, Minist Educ, Key Lab Cellular Physiol, Taiyuan 030001, Shanxi, Peoples R China; [Cheng, X.; Zhang, Y.; Li, S.; Cui, H.; Zhang, L.; Shi, R.; Zhao, Z.; He, C.; Cui, Y.] Shanxi Med Univ, Dept Cell Biol & Genet, Taiyuan 030001, Shanxi, Peoples R China; [Wang, C.] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China; [Fisk, H. A.] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; [Guadagno, T. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	Shanxi Medical University; Shanxi Medical University; Shanxi Medical University; East China Normal University; University System of Ohio; Ohio State University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Cui, Y (corresponding author), Shanxi Med Univ, Dept Cell Biol & Genet, Key Lab Cellular Physiol, Minist Educ, Taiyuan 030001, Shanxi, Peoples R China.	cuiy0922@yahoo.com			Program for New Century Excellent Talents University of China [NCET-10-0872]; National Nature Science Foundation of China [30872932, 30971518, 81071625]; Scientific Research Foundation for the Returned Overseas Chinese Scholars; State Education Ministry [2009-8]; Shanxi Province Foundation for Returness [2008-49]; Trainee Development Award from Bankhead Coley Program [30-15066-02-07]; Program for the Top Young Academic Leaders of Higher Learning Institutions of Shanxi	Program for New Century Excellent Talents University of China(Program for New Century Excellent Talents in University (NCET)); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation for the Returned Overseas Chinese Scholars(Scientific Research Foundation for the Returned Overseas Chinese Scholars); State Education Ministry; Shanxi Province Foundation for Returness(Scientific Research Foundation for the Returned Overseas Chinese Scholars); Trainee Development Award from Bankhead Coley Program; Program for the Top Young Academic Leaders of Higher Learning Institutions of Shanxi	We thank Kenji Fukasawa (H Lee Moffitt Cancer Center) for critical reading of this article. This work was supported by the Program for New Century Excellent Talents University of China (Grant NCET-10-0872), National Nature Science Foundation of China (Grant 30872932 & 30971518), Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (Grant 2009-8), Shanxi Province Foundation for Returness (2008-49), Trainee Development Award from Bankhead Coley Program (Grant 30-15066-02-07) to YC and National Nature Science Foundation of China (Grant 81071625), Program for the Top Young Academic Leaders of Higher Learning Institutions of Shanxi to XC.	Acilan C, 2008, CELL, V134, P572, DOI 10.1016/j.cell.2008.08.007; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Compton DA, 2011, CURR OPIN CELL BIOL, V23, P109, DOI 10.1016/j.ceb.2010.08.007; Cui Y, 2008, ONCOGENE, V27, P3122, DOI 10.1038/sj.onc.1210972; Cui YP, 2010, J BIOL CHEM, V285, P32988, DOI 10.1074/jbc.M110.140905; Cui YP, 2010, CANCER RES, V70, P675, DOI 10.1158/0008-5472.CAN-09-1491; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Haering CH, 2008, NATURE, V454, P297, DOI 10.1038/nature07098; Hewitt L, 2010, J CELL BIOL, V190, P25, DOI 10.1083/jcb.201002133; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jelluma N, 2008, CELL, V132, P233, DOI 10.1016/j.cell.2007.11.046; Kanai M, 2007, GENES CELLS, V12, P797, DOI 10.1111/j.1365-2443.2007.01091.x; Kang JS, 2007, P NATL ACAD SCI USA, V104, P20232, DOI 10.1073/pnas.0710519105; Karreth FA, 2009, CURR OPIN GENET DEV, V19, P4, DOI 10.1016/j.gde.2008.12.006; Kasbek C, 2007, MOL BIOL CELL, V18, P4457, DOI 10.1091/mbc.E07-03-0283; Kasbek C, 2010, MOL BIOL CELL, V21, P3878, DOI 10.1091/mbc.E10-04-0281; Kasbek C, 2009, ENVIRON MOL MUTAGEN, V50, P654, DOI 10.1002/em.20476; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Mangold U, 2008, ONCOGENE, V27, P604, DOI 10.1038/sj.onc.1210685; Mattison CP, 2007, J BIOL CHEM, V282, P30553, DOI 10.1074/jbc.M707063200; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Pike AN, 2011, CELL DIV, V6, DOI 10.1186/1747-1028-6-9; Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Tighe A, 2008, J CELL BIOL, V181, P893, DOI 10.1083/jcb.200712028; Tsou MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985; Tyler RK, 2009, BIOCHEM J, V417, P173, DOI 10.1042/BJ20081310; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X; Yang CH, 2010, MOL BIOL CELL, V21, P4361, DOI 10.1091/mbc.E10-04-0298; Zhao Y, 2006, CURR BIOL, V16, P1764, DOI 10.1016/j.cub.2006.07.058	39	23	25	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					713	723		10.1038/onc.2012.94	http://dx.doi.org/10.1038/onc.2012.94			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430208				2022-12-28	WOS:000315746700005
J	Muramatsu, F; Kidoya, H; Naito, H; Sakimoto, S; Takakura, N				Muramatsu, F.; Kidoya, H.; Naito, H.; Sakimoto, S.; Takakura, N.			microRNA-125b inhibits tube formation of blood vessels through translational suppression of VE-cadherin	ONCOGENE			English	Article						microRNA; mir125b; angiogenesis; VE-cadherin	VASCULAR MORPHOGENESIS; ENDOTHELIAL-CELLS; IN-VIVO; ANGIOGENESIS; EXPRESSION; RECEPTOR; GROWTH; MICE; STEM; SYSTEM	Angiogenesis is controlled positively or negatively by extrinsic and intrinsic molecular cues in endothelial cells (ECs); in the tumor microenvironment, the action of positive regulators exceeds that of negative regulators. Thus, overinduction of negative regulators may inhibit tumor angiogenesis. MicroRNAs (miRNAs or miRs) are endogenous short noncoding RNAs regulating gene expression either through translational inhibition or destabilization of target mRNA. Here, we show that miR-125b expression is transiently induced in ECs on stimulation with vascular endothelial growth factor or by ischemia. miR-125b inhibits translation of vascular endothelial (VE)-cadherin mRNA and in vitro tube formation by ECs. Injection of miR-125b into the tumor inhibited VE-cadherin expression by ECs and induced nonfunctional blood vessel formation, resulting in inhibition of tumor growth. It has been suggested that pro-angiogenic signals in ECs also upregulate anti-angiogenic molecules simultaneously via negative feedback. Because miR-125b induction in ECs is transient after pro-angiogenic stimulation, prolonged overexpression of miR-125b could result in blood vessel regression. Thus, miR-125b may be useful in cancer therapy by causing the collapse of the lumen of ECs. Oncogene (2013) 32, 414-421; doi:10.1038/onc.2012.68; published online 5 March 2012	[Muramatsu, F.; Kidoya, H.; Naito, H.; Sakimoto, S.; Takakura, N.] Osaka Univ, Microbial Dis Res Inst, Dept Signal Transduct, Suita, Osaka 5650871, Japan; [Takakura, N.] CREST, JST, Tokyo, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takakura, N (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Signal Transduct, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	ntakaku@biken.osaka-u.ac.jp		Naito, Hisamichi/0000-0002-0750-1743	Ministry of Education, Science, Sports, and Culture of Japan	Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank S Fukuhara and N Mochizuki for supplying VE-cadherin expression plasmid, and K Fukuhara and N Fujimoto for technical assistance. This work was partly supported by a grant from the Ministry of Education, Science, Sports, and Culture of Japan.	Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Baumer S, 2006, BLOOD, V107, P4754, DOI 10.1182/blood-2006-01-0141; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chen YH, 2003, BIOCHEM BIOPH RES CO, V310, P804, DOI 10.1016/j.bbrc.2003.09.081; Crosby CV, 2005, BLOOD, V105, P2771, DOI 10.1182/blood-2004-06-2244; Dejana E, 1996, J CLIN INVEST, V98, P1949, DOI 10.1172/JCI118997; Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Gotsch U, 1997, J CELL SCI, V110, P583; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Kidoya H, 2012, ONCOGENE, V31, P3254, DOI 10.1038/onc.2011.489; Kidoya H, 2008, EMBO J, V27, P522, DOI 10.1038/sj.emboj.7601982; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Nagahama Y, 2010, CANCER RES, V70, P1215, DOI 10.1158/0008-5472.CAN-09-3662; Niola F, 2006, CANCER BIOL THER, V5, P174, DOI 10.4161/cbt.5.2.2317; Okamoto R, 2005, BLOOD, V105, P2757, DOI 10.1182/blood-2004-08-3317; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Suarez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Takakura N, 2006, CANCER SCI, V97, P568, DOI 10.1111/j.1349-7006.2006.00223.x; Vestweber D, 2009, TRENDS CELL BIOL, V19, P8, DOI 10.1016/j.tcb.2008.10.001; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Yamada Y, 2006, J EXP MED, V203, P1055, DOI 10.1084/jem.20050373; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107	36	77	86	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					414	421		10.1038/onc.2012.68	http://dx.doi.org/10.1038/onc.2012.68			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391569				2022-12-28	WOS:000315551300002
J	van Beijnum, JR; Nowak-Sliwinska, P; van den Boezem, E; Hautvast, P; Buurman, WA; Griffioen, AW				van Beijnum, J. R.; Nowak-Sliwinska, P.; van den Boezem, E.; Hautvast, P.; Buurman, W. A.; Griffioen, A. W.			Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1	ONCOGENE			English	Article						high-mobility group box 1; tumor angiogenesis; chicken embryo chorioallantoic membrane; VEGF; autocrine	END-PRODUCTS RAGE; ENDOTHELIAL-CELLS; NEURITE OUTGROWTH; GENE-EXPRESSION; IN-VIVO; CARDIOVASCULAR-DISEASES; DEPENDENT MECHANISM; SIGNALING PATHWAYS; HMGB1; PROTEIN	The endothelium plays a pivotal role in the progression of solid tumors and is considered a highly relevant target for therapy. However, it emerges that current clinical angiogenesis inhibitors that act through inhibition of tumor-derived growth factors are prone to inducing drug resistance. Therefore, markers of tumor endothelial cells (ECs) themselves provide attractive novel therapeutic targets. In a screen for markers of tumor angiogenesis, we recently identified high-mobility group box 1 (HMGB1), known to act as proinflamnnatory cytokine and chromatin-binding molecule. Here we report on the role of HMGB1 in angiogenesis by showing that its overexpression is associated with an increased angiogenic potential of ECs. HMGB1 stimulates the expression of players in vascular endothelial growth factor and platelet-derived growth factor signaling, both in vitro and in vivo. Importantly, we show that HMGB1 triggers and helps to sustain this proangiogenic gene expression program in ECs, additionally characterized by increased activity of matrix metalloproteinases, integrins and nuclear factor-kappa B. Moreover, we found that HMGB1 is involved in several autocrine and/or paracrine feedback mechanisms resulting in positive enforcement of HMGB1 expression, and that of its receptors, RAGE (receptor for advanced glycation end products) and Toll-like receptor 4 (TLR4). Interference in HMGB1 expression and/or function using knockdown approaches and antibody-mediated targeting to break this vicious circle resulted in inhibited migration and sprouting of ECs. Using different in vivo models, therapeutic efficacy of HMGB1 targeting was confirmed. First, we demonstrated induction of HMGB1 expression in the chicken embryo chorioallantoic membrane (CAM) neovasculature following both photodynannic therapy and tumor challenge. We subsequently showed that anti-HMGB1 antibodies inhibited vessel density in both models, accompanied by a reduced vascular expression of angiogenic growth factor receptors. Collectively, these data identify HMGB1 as an important modulator of tumor angiogenesis and suggest the feasibility of targeting HMGB1 for multi-level cancer treatment. Oncogene (2013) 32, 363-374; doi:10.1038/onc.2012.49; published online 5 March 2012	[van Beijnum, J. R.; Nowak-Sliwinska, P.; Griffioen, A. W.] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Angiogenesis Lab, NL-1081 HV Amsterdam, Netherlands; [van den Boezem, E.; Hautvast, P.] Maastricht Univ, Dept Pathol, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands; [Buurman, W. A.] Maastricht Univ, Med Ctr, Dept Surg, NUTRIM Sch Nutr Toxicol & Metab, Maastricht, Netherlands	Vrije Universiteit Amsterdam; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC)	Griffioen, AW (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Angiogenesis Lab, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	aw.griffioen@vumc.nl	Nowak-Sliwinska, Patrycja/T-7663-2018	Nowak-Sliwinska, Patrycja/0000-0002-8299-0444	transnational University Limburg (tUL); GROW-School for Oncology and Developmental Biology; sixth EU Framework Programme (Integrated Project 'Angiotargeting') [504743]; Center for Translational Molecular Medicine (CTMM) [03O-201 MAMMOTH]; EU Framework Programme Integrated Project 'Angiotargeting' [50474]	transnational University Limburg (tUL); GROW-School for Oncology and Developmental Biology; sixth EU Framework Programme (Integrated Project 'Angiotargeting'); Center for Translational Molecular Medicine (CTMM); EU Framework Programme Integrated Project 'Angiotargeting'	This work was supported by grants of the transnational University Limburg (tUL), GROW-School for Oncology and Developmental Biology, the sixth EU Framework Programme (Integrated Project 'Angiotargeting'; contract no. 504743) in the area of 'Life sciences, genomics and biotechnology for health' and Center for Translational Molecular Medicine (CTMM) '03O-201 MAMMOTH'. We are grateful for financial support from J Jacobi Trust, and technical assistance from Dr Roeland Hanemaaijer, Saskia van der Velden, Iris Schulkens, Rajshri Lalai and Maaike van Berkel.; Transnational University Limburg (tUL); EU Framework Programme Integrated Project 'Angiotargeting'; contract no. 50474; Center for Translational Molecular Medicine (CTMM) '03O-201 MAMMOTH'.	Agresti A, 2003, BIOCHEM BIOPH RES CO, V302, P421, DOI 10.1016/S0006-291X(03)00184-0; Andersson U, 2002, J LEUKOCYTE BIOL, V72, P1084; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Biscetti F, 2010, DIABETES, V59, P1496, DOI 10.2337/db09-1507; Chung HW, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-38; Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONTIJN R, 1995, EXP CELL RES, V216, P199, DOI 10.1006/excr.1995.1025; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Griffioen AW, 1996, BLOOD, V88, P667, DOI 10.1182/blood.V88.2.667.bloodjournal882667; Hagedorn M, 2005, P NATL ACAD SCI USA, V102, P1643, DOI 10.1073/pnas.0408622102; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Kawahara KI, 2008, CARDIOVASC PATHOL, V17, P129, DOI 10.1016/j.carpath.2007.08.006; Laib AM, 2009, NAT PROTOC, V4, P1202, DOI 10.1038/nprot.2009.96; Li W, 2006, CURR OPIN PHARMACOL, V6, P130, DOI 10.1016/j.coph.2005.10.010; Lim SH, 2010, J MED CHEM, V53, P2865, DOI 10.1021/jm901823u; Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225; Liu Y, 2010, EUR J CANCER, V46, P3007, DOI 10.1016/j.ejca.2010.07.016; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Mitola S, 2006, J IMMUNOL, V176, P12, DOI 10.4049/jimmunol.176.1.12; Mullins GE, 2004, SCAND J IMMUNOL, V60, P566, DOI 10.1111/j.0300-9475.2004.01518.x; Nowak-Sliwinska P, 2012, J CELL MOL MED, V16, P1553, DOI 10.1111/j.1582-4934.2011.01440.x; Nowak-Sliwinska P, 2011, J MED CHEM, V54, P3895, DOI 10.1021/jm2002074; Nowak-Sliwinska P, 2010, ANGIOGENESIS, V13, P281, DOI 10.1007/s10456-010-9185-x; Nowak-Sliwinska P, 2010, MICROVASC RES, V79, P21, DOI 10.1016/j.mvr.2009.10.004; Oh YJ, 2009, J IMMUNOL, V182, P5800, DOI 10.4049/jimmunol.0801873; Ohmori H, 2011, EXPERT OPIN THER TAR, V15, P183, DOI 10.1517/14728222.2011.546785; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schlueter C, 2005, AM J PATHOL, V166, P1259, DOI 10.1016/S0002-9440(10)62344-9; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Thijssen VLJL, 2007, CURR PHARM DESIGN, V13, P3576, DOI 10.2174/138161207782794121; Thijssen VLJL, 2004, EXP CELL RES, V299, P286, DOI 10.1016/j.yexcr.2004.06.014; Treutiger CJ, 2003, J INTERN MED, V254, P375, DOI 10.1046/j.1365-2796.2003.01204.x; van Beijnum JR, 2005, BBA-REV CANCER, V1755, P121, DOI 10.1016/j.bbcan.2005.06.001; van Beijnum JR, 2008, NAT PROTOC, V3, P1085, DOI 10.1038/nprot.2008.71; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; van Beijnum JR, 2008, EXP CELL RES, V314, P264, DOI 10.1016/j.yexcr.2007.08.013; van Beijnum JR, 2006, BLOOD, V108, P2339, DOI 10.1182/blood-2006-02-004291; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Youn JH, 2006, J IMMUNOL, V177, P7889, DOI 10.4049/jimmunol.177.11.7889; Zhang CL, 2008, MED HYPOTHESES, V70, P343, DOI 10.1016/j.mehy.2007.05.024	47	115	116	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					363	374		10.1038/onc.2012.49	http://dx.doi.org/10.1038/onc.2012.49			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22391561				2022-12-28	WOS:000314736600010
J	Yin, G; Alvero, AB; Craveiro, V; Holmberg, JC; Fu, HH; Montagna, MK; Yang, Y; Chefetz-Menaker, I; Nuti, S; Rossi, M; Silasi, DA; Rutherford, T; Mor, G				Yin, G.; Alvero, A. B.; Craveiro, V.; Holmberg, J. C.; Fu, H-H; Montagna, M. K.; Yang, Y.; Chefetz-Menaker, I.; Nuti, S.; Rossi, M.; Silasi, D-A; Rutherford, T.; Mor, G.			Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential	ONCOGENE			English	Article						TWIST-1; ovarian cancer stem cells; ovarian cancer; metastasis; recurrence	TO-MESENCHYMAL TRANSITION; SIDE POPULATION; ACTIVATION; EXPRESSION; BREAST; IDENTIFICATION; PATHOGENESIS; MECHANISMS; APOPTOSIS; HYPOXIA	Epithelial-mesenchymal transition (EMT) is a critical process for embryogenesis but is abnormally activated during cancer metastasis and recurrence. This process enables epithelial cancer cells to acquire mobility and traits associated with stemness. It is unknown whether epithelial stem cells or epithelial cancer stem cells are able to undergo EMT, and what molecular mechanism regulates this process in these specific cell types. We found that epithelial-ovarian cancer stem cells (EOC stem cells) are the source of metastatic progenitor cells through a differentiation process involving EMT and mesenchymal-epithelial transition (MET). We demonstrate both in vivo and in vitro the differentiation of EOC stem cells into mesenchymal spheroid-forming cells (MSFCs) and their capacity to initiate an active carcinomatosis. Furthermore, we demonstrate that human EOC stem cells injected intraperitoneally in mice are able to form ovarian tumors, suggesting that the EOC stem cells have the ability to 'home' to the ovaries and establish tumors. Most interestingly, we found that TWIST-1 is constitutively degraded in EOC stem cells, and that the acquisition of TWIST-1 requires additional signals that will trigger the differentiation process. These findings are relevant for understanding the differentiation and metastasis process in EOC stem cells. Oncogene (2013) 32, 39-49; doi:10.1038/onc.2012.33; published online 20 February 2012	[Yin, G.; Alvero, A. B.; Craveiro, V.; Holmberg, J. C.; Fu, H-H; Montagna, M. K.; Yang, Y.; Chefetz-Menaker, I.; Nuti, S.; Rossi, M.; Silasi, D-A; Rutherford, T.; Mor, G.] Yale Univ, Sch Med, Reprod Immunol Unit, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA	Yale University	Mor, G (corresponding author), Yale Univ, Sch Med, Reprod Immunol Unit, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St,LSOG 305A, New Haven, CT 06520 USA.	gil.mor@yale.edu	Yang-Hartwich, Yang/B-3489-2015; Chefetz, Ilana/K-7589-2019	Alvero, Ayesha/0000-0002-6593-3595; Holmberg, Jennie/0000-0002-1106-4718	NCI/NIH [RO1CA127913, RO1CA118678]; Janet Burros Memorial Foundation; Sands Family Foundation; Discovery To Cure Research Program; Brozman Foundation; NATIONAL CANCER INSTITUTE [R01CA111782, R01CA127913, F32CA130472, R01CA112016, R01CA118678] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Janet Burros Memorial Foundation; Sands Family Foundation; Discovery To Cure Research Program; Brozman Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by grants from NCI/NIH RO1CA127913, RO1CA118678, The Janet Burros Memorial Foundation, The Sands Family Foundation and the Discovery To Cure Research Program. GY was supported by the Brozman Foundation. Special thanks to Dr Ernst-Martin Fuchtbauer for the plasmids, pEMSV, pEMSV-TWIST1 and pEMSV-E12; and to Dr Wange Lu for the plasmid pFUIGW.	Abrahams VM, 2003, CANCER RES, V63, P5573; Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Alison MR, 2008, CELL TISSUE RES, V331, P109, DOI 10.1007/s00441-007-0510-7; Alix-Panabieres C, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2326; Alvero AB, 2011, MOL CANCER THER, V10, P1385, DOI 10.1158/1535-7163.MCT-11-0023; Alvero AB, 2009, STEM CELLS, V27, P2405, DOI 10.1002/stem.191; Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bechtel W, 2009, KIDNEY INT, V75, P1255, DOI 10.1038/ki.2009.102; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Carambula SF, 2002, ENDOCRINOLOGY, V143, P1495, DOI 10.1210/en.143.4.1495; Chaffer CL, 2007, DIFFERENTIATION, V75, P831, DOI 10.1111/j.1432-0436.2007.00210.x; CHAMBERS JT, 1986, GYNECOL ONCOL, V23, P346, DOI 10.1016/0090-8258(86)90136-8; Chefetz I, 2011, CELL CYCLE, V10, P2206, DOI 10.4161/cc.10.13.16348; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clarke-Pearson DL, 2009, NEW ENGL J MED, V361, P170, DOI 10.1056/NEJMcp0901926; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Curley MD, 2011, FRONT BIOSCI-LANDMRK, V16, P368, DOI 10.2741/3693; Curley MD, 2009, STEM CELLS, V27, P2875, DOI 10.1002/stem.236; El Ghouzzi V, 2000, HUM MOL GENET, V9, P813, DOI 10.1093/hmg/9.5.813; Entz-Werle N, 2005, INT J CANCER, V117, P349, DOI 10.1002/ijc.21068; Espey DK, 2007, CANCER-AM CANCER SOC, V110, P2119, DOI 10.1002/cncr.23044; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Gao QL, 2009, ULTRASTRUCT PATHOL, V33, P175, DOI 10.1080/01913120903086072; Gort EH, 2008, ONCOGENE, V27, P1501, DOI 10.1038/sj.onc.1210795; Green JM, 2009, CANCER BIOL THER, V8, P1747, DOI 10.4161/cbt.8.18.9285; Hader C, 2010, ONCOGENE, V29, P1031, DOI 10.1038/onc.2009.397; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hay ED, 2005, DEV DYNAM, V233, P706, DOI 10.1002/dvdy.20345; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Horbinski C, 2010, AM J PATHOL, V177, P1044, DOI 10.2353/ajpath.2010.091270; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Koga K, 2009, AM J REPROD IMMUNOL, V61, P196, DOI 10.1111/j.1600-0897.2008.00682.x; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Laursen KB, 2007, J BIOL CHEM, V282, P34623, DOI 10.1074/jbc.M707085200; Lee YB, 2009, NUCLEIC ACIDS RES, V37, P123, DOI 10.1093/nar/gkn920; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mor G, 2011, CANCER BIOL THER, V11, P708, DOI 10.4161/cbt.11.8.14967; Moserle L, 2008, CANCER RES, V68, P5658, DOI 10.1158/0008-5472.CAN-07-6341; Mutch DG, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31589; Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007; Radisky Derek C, 2008, Proc Am Thorac Soc, V5, P316, DOI 10.1513/pats.200711-166DR; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schumer ST, 2003, J CLIN ONCOL, V21, P1180, DOI 10.1200/JCO.2003.10.019; Schwartz Peter E, 2002, Cancer Treat Res, V107, P99; Sharabi AB, 2008, PLOS BIOL, V6, P2786, DOI 10.1371/journal.pbio.0060316; Shih IM, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.08.003; Shintani Y, 2008, AM J RESP CELL MOL, V38, P95, DOI 10.1165/rcmb.2007-0071OC; Steffensen KD, 2011, J ONCOL, V2011, DOI 10.1155/2011/620523; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Visintin I, 2008, CLIN CANCER RES, V14, P1065, DOI 10.1158/1078-0432.CCR-07-1569; Watanabe O, 2004, ANTICANCER RES, V24, P3851; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2006, J BIOL CHEM, V281, P23598, DOI 10.1074/jbc.M602191200; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	64	60	64	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					39	49		10.1038/onc.2012.33	http://dx.doi.org/10.1038/onc.2012.33			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22349827	Green Accepted			2022-12-28	WOS:000313029500004
J	Salm, F; Cwiek, P; Ghosal, A; Buccarello, AL; Largey, F; Wotzkow, C; Holand, K; Styp-Rekowska, B; Djonov, V; Zlobec, I; Bodmer, N; Gross, N; Westermann, F; Schafer, SC; Arcaro, A				Salm, F.; Cwiek, P.; Ghosal, A.; Buccarello, A. Lucia; Largey, F.; Wotzkow, C.; Hoeland, K.; Styp-Rekowska, B.; Djonov, V.; Zlobec, I.; Bodmer, N.; Gross, N.; Westermann, F.; Schaefer, S. C.; Arcaro, A.			RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance	ONCOGENE			English	Article						neuroblastoma; RNAi screen; FGFR2; BCL2; chemoresistance; cisplatin	NF-KAPPA-B; DEPENDENT PATHWAY; EXPRESSION; APOPTOSIS; BCL-2; RESISTANCE; AMPLIFICATION; ENZASTAURIN; INHIBITOR; CISPLATIN	Chemotherapeutic drug resistance is one of the major causes for treatment failure in high-risk neuroblastoma (NB), the most common extra cranial solid tumor in children. Poor prognosis is typically associated with MYCN amplification. Here, we utilized a loss-of-function kinome-wide RNA interference screen to identify genes that cause cisplatin sensitization. We identified fibroblast growth factor receptor 2 (FGFR2) as an important determinant of cisplatin resistance. Pharmacological inhibition of FGFR2 confirmed the importance of this kinase in NB chemoresistance. Silencing of FGFR2 sensitized NB cells to cisplatin-induced apoptosis, which was regulated by the downregulation of the anti-apoptotic proteins BCL2 and BCLXL. Mechanistically, FGFR2 was shown to activate protein kinase C-delta to induce BCL2 expression. FGFR2, as well as the ligand fibroblast growth factor-2, were consistently expressed in primary NB and NB cell lines, indicating the presence of an autocrine loop. Expression analysis revealed that FGFR2 correlates with MYCN amplification and with advanced stage disease, demonstrating the clinical relevance of FGFR2 in NB. These findings suggest a novel role for FGFR2 in chemoresistance and provide a rational to combine pharmacological inhibitors against FGFR2 with chemotherapeutic agents for the treatment of NB.	[Salm, F.; Cwiek, P.; Wotzkow, C.; Hoeland, K.; Arcaro, A.] Univ Bern, Dept Clin Res, CH-3004 Bern, Switzerland; [Ghosal, A.; Buccarello, A. Lucia; Largey, F.; Bodmer, N.] Univ Childrens Hosp Zurich, Dept Oncol, Zurich, Switzerland; [Styp-Rekowska, B.; Djonov, V.] Univ Bern, Inst Anat, CH-3004 Bern, Switzerland; [Zlobec, I.; Schaefer, S. C.] Univ Bern, Inst Pathol, CH-3004 Bern, Switzerland; [Gross, N.] CHU Vaudois, Univ Lausanne Hosp, Dept Paediat, CH-1011 Lausanne, Switzerland; [Westermann, F.] German Canc Res Ctr, Dept Tumor Genet, Heidelberg, Dkfz, Germany	University of Bern; University Children's Hospital Zurich; University of Bern; University of Bern; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Helmholtz Association; German Cancer Research Center (DKFZ)	Arcaro, A (corresponding author), Univ Bern, Dept Clin Res, Div Pediat Hematol Oncol, Tiefenaustr 120C, CH-3004 Bern, Switzerland.	alexandre.arcaro@dkf.unibe.ch	buccarello, lucia/AAO-1407-2020; Arcaro, Alexandre/G-1711-2010; Westermann, Frank/F-7509-2013	buccarello, lucia/0000-0002-3393-653X; Arcaro, Alexandre/0000-0001-9107-2947; Djonov, Valentin/0000-0002-5062-1169; Zlobec, Inti/0000-0001-6741-3000; Cwiek, Paulina/0000-0002-0964-6364	Gottfried und Julia Bangerter-Rhyner-Stiftung; Jubilaumsstiftung Swiss Life; European Union [259348]	Gottfried und Julia Bangerter-Rhyner-Stiftung; Jubilaumsstiftung Swiss Life; European Union(European Commission)	This work was supported by grants from the Gottfried und Julia Bangerter-Rhyner-Stiftung and Jubilaumsstiftung Swiss Life. The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 259348.	Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; Boller D, 2008, CLIN CANCER RES, V14, P1172, DOI 10.1158/1078-0432.CCR-07-0737; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Byron SA, 2009, FUTURE ONCOL, V5, P27, DOI 10.2217/14796694.5.1.27; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cole C, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12585; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Diep CH, 2011, CLIN CANCER RES, V17, P2744, DOI 10.1158/1078-0432.CCR-10-2214; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Erovic BM, 2005, CLIN CANCER RES, V11, P8632, DOI 10.1158/1078-0432.CCR-05-1170; Fanale D, 2012, ONCOGENE, V31, P2121, DOI 10.1038/onc.2011.408; Fang H, 2011, CLIN CANCER RES, V17, P7093, DOI 10.1158/1078-0432.CCR-11-0578; Flahaut M, 2006, GENE CHROMOSOME CANC, V45, P495, DOI 10.1002/gcc.20312; Galanski M, 2006, RECENT PAT ANTI-CANC, V1, P285, DOI 10.2174/157489206777442287; Ghobrial IM, 2011, AM J HEMATOL, V86, P573, DOI 10.1002/ajh.22048; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Goldsmith KC, 2010, CELL DEATH DIFFER, V17, P872, DOI 10.1038/cdd.2009.171; Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048; Guo BC, 2004, CURR OPIN IMMUNOL, V16, P367, DOI 10.1016/j.coi.2004.03.012; Herbst RS, 2007, CLIN CANCER RES, V13, p4641S, DOI 10.1158/1078-0432.CCR-07-0538; Holzel M, 2010, CELL, V142, P218, DOI 10.1016/j.cell.2010.06.004; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Katoh M, 2008, INT J ONCOL, V33, P233, DOI 10.3892/ijo_00000001; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Lee CH, 2008, MOL IMMUNOL, V45, P3693, DOI 10.1016/j.molimm.2008.06.007; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; Ma S, 2007, CURR OPIN ONCOL, V19, P590, DOI 10.1097/CCO.0b013e3282f10a00; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Michaud WA, 2009, CLIN CANCER RES, V15, P1645, DOI 10.1158/1078-0432.CCR-08-2581; Muth D, CANC RES, V70, P3791; Nikolova Z, 1998, J CELL SCI, V111, P2741; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2006, EMBO J, V25, P3078, DOI 10.1038/sj.emboj.7601198; Sagulenko V, 2008, CARCINOGENESIS, V29, P1869, DOI 10.1093/carcin/bgn147; Sheridan C, 2010, ONCOGENE, V29, P6428, DOI 10.1038/onc.2010.380; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; Terrile M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028356; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wilson TR, 2006, ANN ONCOL, V17, pX315, DOI 10.1093/annonc/mdl280; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	47	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3944	3953		10.1038/onc.2012.416	http://dx.doi.org/10.1038/onc.2012.416			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	23027129				2022-12-28	WOS:000323748100003
J	Nakanome, A; Brydun, A; Matsumoto, M; Ota, K; Funayama, R; Nakayama, K; Ono, M; Shiga, K; Kobayashi, T; Igarashi, K				Nakanome, A.; Brydun, A.; Matsumoto, M.; Ota, K.; Funayama, R.; Nakayama, K.; Ono, M.; Shiga, K.; Kobayashi, T.; Igarashi, K.			Bach1 is critical for the transformation of mouse embryonic fibroblasts by Ras(V12) and maintains ERK signaling	ONCOGENE			English	Article						Bach1; ROS; cancer; Ras; ERK	CELL-PROLIFERATION; OXIDATIVE STRESS; FEEDBACK PHOSPHORYLATION; GENETIC ABLATION; DNA-DAMAGE; TNF-ALPHA; SMALL MAF; RAS; PATHWAY; PROTEIN	Reactive oxygen species (ROS), by-products of aerobic respiration, promote genetic instability and contribute to the malignant transformation of cells. Among the genes related to ROS metabolism, Bach1 is a repressor of the oxidative stress response, and a negative regulator of ROS-induced cellular senescence directed by p53 in higher eukaryotes. While ROS are intimately involved in carcinogenesis, it is not clear whether Bach1 is involved in this process. We found that senescent Bach1-deficient mouse embryonic fibroblasts (MEFs) underwent spontaneous immortalization the same as did the wild-type cells. When transduced with constitutively active Ras (H-Ras(V12)), the proliferation and colony formation of these cells in vitro were markedly reduced. When transplanted into athymic nude mice, the growth and vascularization of tumors derived from Bach1-deficient cells were also decreased. Gene expression profiling of the MEFs revealed a new H-Ras(V12) signature, which was distinct from the previously reported signatures in epithelial tumors, and was partly dependent on Bach1. The Bach1-deficient cells showed diminished phosphorylation of MEK and ERK1/2 in response to H-Ras(V12), which was consistent with the alterations in the gene expression profile, including phosphatase genes. Finally, Bach1-deficient mice were less susceptible to 4-nitroquinoline-1-oxidide (4-NQO)-induced tongue carcinoma than wild-type mice. Our data provide evidence for a critical role of Bach1 in cell transformation and tumor growth induced by activated H-Ras(V12).	[Nakanome, A.; Brydun, A.; Matsumoto, M.; Ota, K.; Igarashi, K.] Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 980, Japan; [Nakanome, A.; Shiga, K.; Kobayashi, T.] Tohoku Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sendai, Miyagi 980, Japan; [Brydun, A.; Igarashi, K.] Tohoku Univ, Grad Sch Med, Ctr Regulatory Epigenome & Dis, Sendai, Miyagi 980, Japan; [Matsumoto, M.] Tohoku Univ, Grad Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi 980, Japan; [Funayama, R.; Nakayama, K.] Tohoku Univ, Grad Sch Med, Div Cell Proliferat, Sendai, Miyagi 980, Japan; [Funayama, R.; Igarashi, K.] Japan Sci & Technol Agcy, CREST, Sendai, Miyagi, Japan; [Ono, M.] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 980, Japan	Tohoku University; Tohoku University; Tohoku University; Tohoku University; Tohoku University; Japan Science & Technology Agency (JST); Tohoku University	Igarashi, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Biochem, Seiryo Machi 2-1, Sendai, Miyagi 980, Japan.	igarashi@med.tohoku.ac.jp	Matsumoto, Mitsuyo/AAC-3065-2019	Igarashi, Kazuhiko/0000-0002-2470-2475	Network Medicine Global-COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan	Network Medicine Global-COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan	We are grateful to Nobuyuki Tanaka from Nippon Medical University and Fuyuki Ishikawa from Kyoto University for kindly providing plasmids. This work was supported by Grants-in-aid and the Network Medicine Global-COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Additional initial support was provided by the Uehara Foundation, the Takeda Foundation and the Astelas Foundation for Research on Metabolic Disorders. Restoration of laboratory damage from the 2011 Tohoku earthquake was provided in part by the Astelas Foundation for Research on Metabolic Disorders, the Banyu Foundation, the Naito Foundation, A Miyazaki and A Iida.	Alexandrova AY, 2006, EXP CELL RES, V312, P2066, DOI 10.1016/j.yexcr.2006.03.004; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chiarugi P, 2001, IUBMB LIFE, V52, P55, DOI 10.1080/15216540252774775; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dohi Y, 2008, NAT STRUCT MOL BIOL, V15, P1246, DOI 10.1038/nsmb.1516; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Filleur S, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-28; Friedberg I, 2007, FEBS LETT, V581, P2527, DOI 10.1016/j.febslet.2007.04.059; Gregory SG, 2006, NATURE, V441, P315, DOI 10.1038/nature04727; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; Igarashi K, 2006, ANTIOXID REDOX SIGN, V8, P107, DOI 10.1089/ars.2006.8.107; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Karin M, 2001, BIOFACTORS, V15, P87, DOI 10.1002/biof.5520150207; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kim EY, 2010, ONCOGENE, V29, P1167, DOI 10.1038/onc.2009.412; Kuroishi T, 2008, J LEUKOCYTE BIOL, V83, P912, DOI 10.1189/jlb.0607428; Liu CJ, 2005, EXP CELL RES, V309, P410, DOI 10.1016/j.yexcr.2005.06.022; Liu RG, 2001, ONCOGENE, V20, P1486, DOI 10.1038/sj.onc.1204214; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; MacLeod AK, 2009, CARCINOGENESIS, V30, P1571, DOI 10.1093/carcin/bgp176; Masuda K, 2010, BIOCHEM BIOPH RES CO, V393, P201, DOI 10.1016/j.bbrc.2010.01.097; Matheu A, 2007, NATURE, V448, P375, DOI 10.1038/nature05949; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Omura S, 2005, GENES CELLS, V10, P277, DOI 10.1111/j.1365-2443.2005.00832.x; Oshima Y, 2003, INVEST OPHTH VIS SCI, V44, P1814, DOI 10.1167/iovs.02-0664; Ota K, 2011, ANTIOXID REDOX SIGN, V14, P2441, DOI 10.1089/ars.2010.3574; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Suzui M, 1995, MOL CARCINOGEN, V14, P294, DOI 10.1002/mc.2940140410; Swift S, 2001, CURR PROTOC IMMUNOL; Tang XH, 2004, CLIN CANCER RES, V10, P301, DOI 10.1158/1078-0432.CCR-0999-3; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tumurbaatar I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014711; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Weinberg F, 2009, CELL MOL LIFE SCI, V66, P3663, DOI 10.1007/s00018-009-0099-y; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Xia C, 2007, CANCER RES, V67, P10823, DOI 10.1158/0008-5472.CAN-07-0783; Yamasaki C, 2005, J BIOCHEM, V137, P287, DOI 10.1093/jb/mvi031; Yano Y, 2006, GENES CELLS, V11, P791, DOI 10.1111/j.1365-2443.2006.00979.x; Yu W, 2007, ONCOGENE, V26, P1178, DOI 10.1038/sj.onc.1209899	58	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2013	32	27					3231	3245		10.1038/onc.2012.336	http://dx.doi.org/10.1038/onc.2012.336			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22847612				2022-12-28	WOS:000321301600003
J	Zinkel, SS; Yin, XM; Gross, A				Zinkel, S. S.; Yin, X. M.; Gross, A.			Rejuvenating Bi(d)ology	ONCOGENE			English	Review						Bid; apoptosis; mitochondria; DNA damage; ATM/ATR	HEMATOPOIETIC STEM-CELLS; CYTOCHROME-C RELEASE; NECROSIS-FACTOR-ALPHA; ENDOPLASMIC-RETICULUM CA2+; INDUCED LIVER-INJURY; DNA-DAMAGE RESPONSE; INDUCED APOPTOSIS; REPLICATIVE STRESS; ATAXIA-TELANGIECTASIA; MITOCHONDRIAL RELEASE	The BH3-only Bid protein is a critical sentinel of cellular stress in the liver and the hematopoietic system. Bid's initial 'claim to fame' came from its ability-as a caspase-truncated product-to trigger the mitochondrial apoptotic program following death receptor activation. Today we know that Bid can response to multiple types of proteases, which are activated under different conditions such as T-cell activation, ischemical reperfusion injury and lysosomal injury. Activation of the mitochondrial apoptotic program by Bid-via its recently identified receptor mitochondrial carrier homolog 2-involves multiple mechanisms, including release of cytochrome c and second mitochondria-derived activator of caspase (Smac), alteration of mitochondrial cristae organization, generation of reactive oxygen species and engagement of the permeability transition pore. Bid is also emerging-in its full-length form-as a pivotal sentinel of DNA damage in the bone marrow regulated by the ataxia telangiectasia mutated (ATM)/ataxia telangiectasia and Rad3-related (ATR) kinases. The ATM/ATR-Bid pathway is critically involved in preserving the quiescence and survival of hematopoietic stem cells both in the absence and presence of external stress, and a large part of this review will be dedicated to recent advances in this area of research.	[Zinkel, S. S.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Zinkel, S. S.] Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37212 USA; [Zinkel, S. S.] Vanderbilt Univ, Sch Med, Dept Dev Biol, Nashville, TN 37212 USA; [Yin, X. M.] Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA; [Gross, A.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Vanderbilt University; Vanderbilt University; Vanderbilt University; Indiana University System; Indiana University-Purdue University Indianapolis; Weizmann Institute of Science	Gross, A (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Herzel St, IL-76100 Rehovot, Israel.	atan.gross@weizmann.ac.il	Gross, Atan/ABC-2640-2020	zinkel, sandra/0000-0002-2818-9795	Israel Science Foundation; USA-Israel Binational Science Foundation; German-Israel Foundation; NATIONAL CANCER INSTITUTE [K08CA098394] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088347] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); USA-Israel Binational Science Foundation(US-Israel Binational Science Foundation); German-Israel Foundation(German-Israeli Foundation for Scientific Research and Development); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	AG is supported by the Israel Science Foundation, USA-Israel Binational Science Foundation and the German-Israel Foundation, and is the incumbent of the Armour Family Career Development Chair of Cancer Research.	Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Bai L, 2005, AM J PATHOL, V166, P1523, DOI 10.1016/S0002-9440(10)62368-1; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen XY, 2007, MOL CELL BIOL, V27, P541, DOI 10.1128/MCB.01166-06; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Ding WX, 2004, HEPATOLOGY, V40, P403, DOI 10.1002/hep.20310; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Edlich F, 2011, CELL, V145, P104, DOI 10.1016/j.cell.2011.02.034; Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hikita H, 2009, HEPATOLOGY, V50, P1972, DOI 10.1002/hep.23207; Hikita H, 2009, HEPATOLOGY, V50, P1217, DOI 10.1002/hep.23126; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Ito K, 2007, J IMMUNOL, V178, P103, DOI 10.4049/jimmunol.178.1.103; Jang YY, 2007, BLOOD, V110, P3056, DOI 10.1182/blood-2007-05-087759; Jones RG, 2007, IMMUNITY, V27, P268, DOI 10.1016/j.immuni.2007.05.023; Jost PJ, 2009, NATURE, V460, P1035, DOI 10.1038/nature08229; Juntilla MM, 2010, BLOOD, V115, P4030, DOI 10.1182/blood-2009-09-241000; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kaufmann T, 2007, CELL, V129, P423, DOI 10.1016/j.cell.2007.03.017; Kaufmann T, 2009, IMMUNITY, V30, P56, DOI 10.1016/j.immuni.2008.10.017; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Liu J, 2004, APOPTOSIS, V9, P533, DOI 10.1023/B:APPT.0000038034.16230.ea; Liu Y, 2012, CELL DEATH DIFFER, V19, P1602, DOI 10.1038/cdd.2012.38; Liu Y, 2011, CELL DEATH DIFFER, V18, P841, DOI 10.1038/cdd.2010.151; Liu Y, 2011, MOL CELL BIOL, V31, P4298, DOI 10.1128/MCB.05737-11; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Mandal M, 2008, P NATL ACAD SCI USA, V105, P20840, DOI 10.1073/pnas.0807557106; Maryanovich M, 2012, NAT CELL BIOL, V14, P535, DOI 10.1038/ncb2468; McKenzie MD, 2008, DIABETES, V57, P1284, DOI 10.2337/db07-1692; Mohrin M, 2010, CELL STEM CELL, V7, P174, DOI 10.1016/j.stem.2010.06.014; Ni HM, 2008, AM J PATHOL, V173, P962, DOI 10.2353/ajpath.2008.080358; Ni HM, 2010, HEPATOLOGY, V52, P338, DOI 10.1002/hep.23672; Ni HM, 2009, J BIOL CHEM, V284, P4373, DOI 10.1074/jbc.M807259200; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269; Ott M, 2007, CELL DEATH DIFFER, V14, P1243, DOI 10.1038/sj.cdd.4402135; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmich K, 2011, HEPATOLOGY, V53, P282, DOI 10.1002/hep.23987; Schneider JG, 2006, CELL METAB, V4, P377, DOI 10.1016/j.cmet.2006.10.002; Schungel S, 2009, HEPATOLOGY, V50, P1558, DOI 10.1002/hep.23176; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shen HM, 2011, EXP HEMATOL, V39, P947, DOI 10.1016/j.exphem.2011.06.004; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Tesio M, 2011, BLOOD, V117, P419, DOI 10.1182/blood-2009-06-230359; Vail ME, 2002, ONCOGENE, V21, P1548, DOI 10.1038/sj.onc.1205212; Valentin-Vega YA, 2012, BLOOD, V119, P1490, DOI 10.1182/blood-2011-08-373639; Walter D, 2008, HEPATOLOGY, V48, P1942, DOI 10.1002/hep.22541; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Wei MC, 2000, GENE DEV, V14, P2060; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287; Yamaguchi R, 2008, MOL CELL, V31, P557, DOI 10.1016/j.molcel.2008.07.010; Yin XM, 2006, GENE, V369, P7, DOI 10.1016/j.gene.2005.10.038; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zaltsman Y, 2010, NAT CELL BIOL, V12, P553, DOI 10.1038/ncb2057; Zhao YG, 2003, GASTROENTEROLOGY, V125, P854, DOI 10.1016/S0016-5085(03)01066-7; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200; Zhao Y, 2007, J CELL PHYSIOL, V213, P556, DOI 10.1002/jcp.21136; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	81	10	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2013	32	27					3213	3219		10.1038/onc.2012.454	http://dx.doi.org/10.1038/onc.2012.454			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	23069655	Green Accepted			2022-12-28	WOS:000321301600001
J	Adesso, L; Calabretta, S; Barbagallo, F; Capurso, G; Pilozzi, E; Geremia, R; Delle Fave, G; Sette, C				Adesso, L.; Calabretta, S.; Barbagallo, F.; Capurso, G.; Pilozzi, E.; Geremia, R.; Delle Fave, G.; Sette, C.			Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway	ONCOGENE			English	Article						eIF4E phosphorylation; MNK2 alternative splicing; drug resistance	INITIATION-FACTOR 4E; MAMMALIAN TARGET; EIF4E; PHOSPHORYLATION; TRANSLATION; MNK2; OVEREXPRESSION; PROLIFERATION; VARIANTS; KINASES	Pancreatic ductal adenocarcinoma (PDAC) is an aggressive neoplastic disease. Gemcitabine, the currently used chemotherapeutic drug for PDAC, elicits only minor benefits, because of the development of escape pathways leading to chemoresistance. Herein, we aimed at investigating the involvement of the mitogen activating protein kinase interacting kinase (MNK)/eIF4E pathway in the acquired drug resistance of PDAC cells. Screening of a cohort of PDAC patients by immunohistochemistry showed that eIF4E phosphorylation correlated with disease grade, early onset of disease and worse prognosis. In PDAC cell lines, chemotherapeutic drugs induced MNK-dependent phosphorylation of eIF4E. Importantly, pharmacological inhibition of MNK activity synergistically enhanced the cytostatic effect of gemcitabine, by promoting apoptosis. RNA interference (RNAi) experiments indicated that MNK2 is mainly responsible for eIF4E phosphorylation and gemcitabine resistance in PDAC cells. Furthermore, we found that gemcitabine induced the expression of the oncogenic splicing factor SRSF1 and splicing of MNK2b, a splice variant that overrides upstream regulatory pathways and confers increased resistance to the drug. Silencing of SRSF1 by RNAi abolished this splicing event and recapitulated the effects of MNK pharmacological or genetic inhibition on eIF4E phosphorylation and apoptosis in gemcitabine-treated cells. Our results highlight a novel pro-survival pathway triggered by gemcitabine in PDAC cells, which leads to MNK2-dependent phosphorylation of eIF4E, suggesting that the MNK/eIF4E pathway represents an escape route utilized by PDAC cells to withstand chemotherapeutic treatments.	[Adesso, L.; Calabretta, S.; Barbagallo, F.; Geremia, R.; Delle Fave, G.; Sette, C.] Univ Roma Tor Vergata, Dept Biomed & Prevent, I-00133 Rome, Italy; [Adesso, L.; Calabretta, S.; Capurso, G.; Pilozzi, E.; Delle Fave, G.] Univ Roma La Sapienza, Digest & Liver Dis Unit, Sch Med 2, I-00133 Rome, Italy; [Barbagallo, F.; Sette, C.] Fdn Santa Lucia, Lab Neuroembryol, Rome, Italy	University of Rome Tor Vergata; Sapienza University Rome; IRCCS Santa Lucia	Delle Fave, G (corresponding author), Univ Roma La Sapienza, Digest & Liver Dis Unit, Sch Med 2, I-00133 Rome, Italy.	gianfranco.dellefave@uniroma1.it; claudio.sette@uniroma2.it	PILOZZI, Emanuela/AAC-1854-2022; Sette, Claudio/S-4307-2019; Barbagallo, Federica/K-1185-2018; Capurso, Gabriele/AAB-1389-2019; Adesso, Laura/AAA-7708-2020; Barbagallo, Federica/AAD-4903-2022	PILOZZI, Emanuela/0000-0002-7110-9172; Sette, Claudio/0000-0003-2864-8266; Barbagallo, Federica/0000-0002-2972-370X; Capurso, Gabriele/0000-0002-0019-8753; Adesso, Laura/0000-0003-2121-4924; Barbagallo, Federica/0000-0002-2972-370X; GEREMIA, Raffaele/0000-0001-9056-6603	Associazione Italiana Ricerca sul Cancro [AIRC IG10348]; Association for International Cancer Research (AICR); Worldwide Cancer Research [12-0150] Funding Source: researchfish	Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Association for International Cancer Research (AICR); Worldwide Cancer Research	We wish to thank Professor CG Proud for the generous gift of MNK2a and MNK2b plasmids, Professor A Scarpa for the gift of HPAF2 cells, Dr Enrica Bianchi for help with FACS analysis, Dr Maria Antonietta Talerico for technical support with immunohistochemistry and Dr Alessia Di Florio for helpful suggestions throughout the study. This work was supported by funds from the Associazione Italiana Ricerca sul Cancro (AIRC IG10348) and Association for International Cancer Research (AICR).	Altman JK, 2010, MOL PHARMACOL, V78, P778, DOI 10.1124/mol.110.064642; Assouline S, 2009, BLOOD, V114, P257, DOI 10.1182/blood-2009-02-205153; Bianchini A, 2008, CARCINOGENESIS, V29, P2279, DOI 10.1093/carcin/bgn221; Bielli P, 2011, ENDOCR-RELAT CANCER, V18, pR91, DOI 10.1530/ERC-11-0041; Busa R, 2007, ONCOGENE, V26, P4372, DOI 10.1038/sj.onc.1210224; Buxade M, 2008, FRONT BIOSCI-LANDMRK, V13, P5359, DOI 10.2741/3086; Chrestensen CA, 2007, GENES CELLS, V12, P1133, DOI 10.1111/j.1365-2443.2007.01122.x; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Falasca M, 2011, ANTI-CANCER AGENT ME, V11, P455, DOI 10.2174/187152011795677382; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Goncalves V, 2009, MUTAT RES-FUND MOL M, V662, P33, DOI 10.1016/j.mrfmmm.2008.12.001; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Hayes GM, 2006, CANCER RES, V66, P3819, DOI 10.1158/0008-5472.CAN-05-4065; Hayes GM, 2007, CANCER RES, V67, P2072, DOI 10.1158/0008-5472.CAN-06-2969; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kern SE, 2011, J PATHOL, V223, P295, DOI 10.1002/path.2813; Konicek BW, 2011, CANCER RES, V71, P1849, DOI 10.1158/0008-5472.CAN-10-3298; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; O'Loghlen A, 2004, EXP CELL RES, V299, P343, DOI 10.1016/j.yexcr.2004.06.006; Pedrotti S, 2010, EMBO J, V29, P1235, DOI 10.1038/emboj.2010.19; Sanz DJ, 2010, CLIN CANCER RES, V16, P1957, DOI 10.1158/1078-0432.CCR-09-2564; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Wang XR, 2007, MOL CELL BIOL, V27, P7405, DOI 10.1128/MCB.00760-07; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wolpin BM, 2009, J CLIN ONCOL, V27, P193, DOI 10.1200/JCO.2008.18.9514; Yoshizawa A, 2010, CLIN CANCER RES, V16, P240, DOI 10.1158/1078-0432.CCR-09-0986; Zhang Y, 2008, BIOCHEM BIOPH RES CO, V367, P54, DOI 10.1016/j.bbrc.2007.12.118; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	32	87	93	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2848	2857		10.1038/onc.2012.306	http://dx.doi.org/10.1038/onc.2012.306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22797067				2022-12-28	WOS:000320369100005
J	Cittelly, DM; Finlay-Schultz, J; Howe, EN; Spoelstra, NS; Axlund, SD; Hendricks, P; Jacobsen, BM; Sartorius, CA; Richer, JK				Cittelly, D. M.; Finlay-Schultz, J.; Howe, E. N.; Spoelstra, N. S.; Axlund, S. D.; Hendricks, P.; Jacobsen, B. M.; Sartorius, C. A.; Richer, J. K.			Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4	ONCOGENE			English	Article						breast cancer; microRNA; progesterone; KLF4; cancer stem cells	STEM-CELLS; TRANSCRIPTION FACTOR; REPLACEMENT THERAPY; STEROID-RECEPTOR; DOWN-REGULATION; LUNG-CANCER; C-MYC; EXPRESSION; ESTROGEN; MAINTENANCE	The female hormone progesterone (P4) promotes the expansion of stem-like cancer cells in estrogen receptor (ER)- and progesterone receptor (PR)-positive breast tumors. The expanded tumor cells lose expression of ER and PR, express the tumor-initiating marker CD44, the progenitor marker cytokeratin 5 (CK5) and are more resistant to standard endocrine and chemotherapies. The mechanisms underlying this hormone-stimulated reprogramming have remained largely unknown. In the present study, we investigated the role of microRNAs in progestin-mediated expansion of this dedifferentiated tumor cell population. We demonstrate that P4 rapidly downregulates miR-29 family members, particularly in the CD44(+) cell population. Downregulation of miR-29 members potentiates the expansion of CK5(+) and CD44(+) cells in response to progestins, and results in increased stem-like properties in vitro and in vivo. We demonstrate that miR-29 directly targets Kruppel-like factor 4 (KLF4), a transcription factor required for the reprogramming of differentiated cells to pluripotent stem cells, and for the maintenance of breast cancer stem cells. These results reveal a novel mechanism, whereby progestins increase the stem cell-like population in hormone-responsive breast cancers, by decreasing miR-29 to augment PR-mediated upregulation of KLF4. Elucidating the mechanisms whereby hormones mediate the expansion of stem-like cells furthers our understanding of the progression of hormone-responsive breast cancers.	[Cittelly, D. M.; Finlay-Schultz, J.; Howe, E. N.; Spoelstra, N. S.; Axlund, S. D.; Hendricks, P.; Sartorius, C. A.; Richer, J. K.] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA; [Jacobsen, B. M.] Univ Colorado Denver, Dept Med, Div Endocrinol, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Richer, JK (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA.	Jennifer.Richer@ucdenver.edu		Howe, Erin/0000-0003-0314-6999; Jacobsen, Britta/0000-0001-8234-1690; Cittelly, Diana/0000-0002-8392-0800; Finlay-Schultz, Jessica/0000-0002-7855-9870	University of Colorado Cancer Center Cytometry and Cell Sorting Shared Resource Facility [P30CA046934]; NIH [F31CA165668-01, RO1CA140985]; DOD BCRP Postdoctoral Fellowship [W81XWH-11-1-0101]; DOD Idea Award [BCRP W81XWH-11-1-0210]; NATIONAL CANCER INSTITUTE [F31CA165668, R01CA140985, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER	University of Colorado Cancer Center Cytometry and Cell Sorting Shared Resource Facility; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD BCRP Postdoctoral Fellowship; DOD Idea Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank the University of Colorado Cancer Center Cytometry and Cell Sorting Shared Resource Facility supported by P30CA046934. The human CK5 promoter (KRT5) was a gift from Elaine Fuchs (The Rockefeller University). NIH F31CA165668-01 supported ENH. NIH RO1CA140985 supported CAS. DOD BCRP Postdoctoral Fellowship W81XWH-11-1-0101 (DMC) and DOD Idea Award BCRP W81XWH-11-1-0210 (CAS, JKR) supported this work.	Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147; Cittelly DM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-317; Cittelly DM, 2010, CARCINOGENESIS, V31, P2049, DOI 10.1093/carcin/bgq192; Cochrane DR, 2012, MOL CELL ENDOCRINOL, V355, P15, DOI 10.1016/j.mce.2011.12.020; Cochrane DR, 2011, STEROIDS, V76, P1, DOI 10.1016/j.steroids.2010.11.003; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Graham JD, 2009, ENDOCRINOLOGY, V150, P3318, DOI 10.1210/en.2008-1630; Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hwang HW, 2007, SCIENCE, V315, P97, DOI 10.1126/science.1136235; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Lange CA, 2008, STEROIDS, V73, P914, DOI 10.1016/j.steroids.2007.12.023; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708; Lin SL, 2011, NUCLEIC ACIDS RES, V39, P1054, DOI 10.1093/nar/gkq850; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Liu R, 2011, MOL ENDOCRINOL, V25, P1137, DOI 10.1210/me.2010-0497; Lydon JP, 1999, CANCER RES, V59, P4276; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; Moore MR, 1997, J STEROID BIOCHEM, V62, P243, DOI 10.1016/S0960-0760(97)00036-8; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Nguyen T, 2011, EPIGENETICS-US, V6, P388, DOI 10.4161/epi.6.3.14056; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Pekarsky Y, 2006, CANCER RES, V66, P11590, DOI 10.1158/0008-5472.CAN-06-3613; Radisky DC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2885; Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Sartorius CA, 2005, CANCER RES, V65, P9779, DOI 10.1158/0008-5472.CAN-05-0505; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105; Shcherbata HR, 2006, CELL CYCLE, V5, P172, DOI 10.4161/cc.5.2.2343; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tessel MA, 2010, CURR OPIN ONCOL, V22, P592, DOI 10.1097/CCO.0b013e32833ea80c; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wong CW, 2010, STEM CELLS, V28, P1510, DOI 10.1002/stem.477; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang CS, 2011, RNA, V17, P1451, DOI 10.1261/rna.2664111; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Zhang J, 2012, INT J ONCOL, V40, P747, DOI 10.3892/ijo.2011.1242; Zhang PL, 2010, J BIOL CHEM, V285, P9180, DOI 10.1074/jbc.M109.077958; Zhang Z, 2011, NUCLEIC ACIDS RES, V39, P4387, DOI 10.1093/nar/gkr020; Zhu M, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r77	55	101	103	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2555	2564		10.1038/onc.2012.275	http://dx.doi.org/10.1038/onc.2012.275			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22751119	Green Accepted			2022-12-28	WOS:000319274300007
J	Jones, KB; Su, L; Jin, H; Lenz, C; Randall, RL; Underhill, TM; Nielsen, TO; Sharma, S; Capecchi, MR				Jones, K. B.; Su, L.; Jin, H.; Lenz, C.; Randall, R. L.; Underhill, T. M.; Nielsen, T. O.; Sharma, S.; Capecchi, M. R.			SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; apoptosis; chemotherapy; targeted therapy; mouse model	CELL LINE; BCL-2; EXPRESSION; PROTEIN; INHIBITOR; INSIGHTS; MODEL	Synovial sarcoma is a deadly malignancy with limited sensitivity to traditional cytotoxic chemotherapy. SS18-SSX fusion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse model. Elevated expression of BCL2 is considered a consistent feature of the synovial sarcoma expression profile. Our objective was to evaluate the expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulating SS18-SSX expression on this pathway. We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expression, but represses other anti-apoptotic genes, including MCL1 and BCL2A1. This repression is achieved by directly suppressing expression via binding through activating transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) response element (CRE) in the promoters of these genes and recruiting TLE1/Groucho. The suppression of these two anti-apoptotic pathways silences the typical routes by which other tumors evade BH3-domain peptidomimetic pharmacotherapy. We show that mouse and human synovial sarcoma cells are sensitive in vitro to ABT-263, a BH3-peptidomimetic, much more than the other tested cancer cell lines. ABT-263 also enhances the sensitivity of these cells to doxorubicin, a traditional cytotoxic chemotherapy used for synovial sarcoma. We also demonstrate the capacity of ABT-263 to stunt synovial sarcomagenesis in vivo in a genetic mouse model. These data recommend pursuit of BH3-peptidomimetic pharmacotherapy in human synovial sarcomas.	[Jones, K. B.; Jin, H.; Randall, R. L.] Univ Utah, Dept Orthopaed, Salt Lake City, UT 84112 USA; [Jones, K. B.; Jin, H.; Lenz, C.; Randall, R. L.; Sharma, S.; Capecchi, M. R.] Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Jones, K. B.; Jin, H.; Lenz, C.; Capecchi, M. R.] Univ Utah, Howard Hughes Med Inst, Dept Human Genet, Salt Lake City, UT 84112 USA; [Su, L.; Underhill, T. M.; Nielsen, T. O.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Su, L.; Underhill, T. M.; Nielsen, T. O.] Univ British Columbia, Biomed Res Ctr, Vancouver, BC, Canada; [Sharma, S.] Univ Utah, Dept Med, Div Hematol Oncol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of British Columbia; University of British Columbia; Utah System of Higher Education; University of Utah	Capecchi, MR (corresponding author), Univ Utah, Howard Hughes Med Inst, 15 North 2030 East Room 5440, Salt Lake City, UT 84112 USA.	mario.capecchi@genetics.utah.edu			Huntsman Cancer Foundation; National Cancer Institute (NIH) [K08CA138764]; Canadian Cancer Society Research Institute [018355]; Terry Fox Foundation; CIHR Institute of Cancer [TFF 105265]; NATIONAL CANCER INSTITUTE [K08CA138764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021168] Funding Source: NIH RePORTER	Huntsman Cancer Foundation; National Cancer Institute (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Terry Fox Foundation; CIHR Institute of Cancer(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We gratefully acknowledge the support of the Paul Nabil Bustany Fund for Synovial Sarcoma Research, the Huntsman Cancer Foundation, and career development support from National Cancer Institute (NIH) K08CA138764. This work was also supported by grants from the Canadian Cancer Society Research Institute (Grant no. 018355) and the Terry Fox Foundation and CIHR Institute of Cancer (TFF 105265). We thank Matt Hockin, PhD, at the University of Utah for producing the TATCre protein.	Gandhi L, 2011, J CLIN ONCOL, V29, P909, DOI 10.1200/JCO.2010.31.6208; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Haldar M, 2009, CANCER RES, V69, P3657, DOI 10.1158/0008-5472.CAN-08-4127; Hirakawa N, 1996, HUM PATHOL, V27, P1060, DOI 10.1016/S0046-8177(96)90284-1; Joshi SK, 2002, GENESIS, V33, P48, DOI 10.1002/gene.10089; Joyner DE, 2006, J ORTHOP RES, V24, P474, DOI 10.1002/jor.20087; Kawai A, 2004, CANCER LETT, V204, P105, DOI 10.1016/j.canlet.2003.09.031; Knosel T, 2010, EUR J CANCER, V46, P1170, DOI 10.1016/j.ejca.2010.01.032; Ladanyi M, 2002, CANCER RES, V62, P135; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu TM, 2011, ARTHRITIS RHEUM-US, V63, P2711, DOI 10.1002/art.30430; Mancuso T, 2000, LAB INVEST, V80, P805, DOI 10.1038/labinvest.3780085; Nakayama R, 2007, MODERN PATHOL, V20, P749, DOI 10.1038/modpathol.3800794; Nakayama R, 2010, AM J SURG PATHOL, V34, P1599, DOI 10.1097/PAS.0b013e3181f7ce2c; Su L, 2010, ONCOGENE, V29, P4352, DOI 10.1038/onc.2010.204; Su L, 2012, CANCER CELL, V21, P333, DOI 10.1016/j.ccr.2012.01.010; Sun BC, 2006, EUR J CANCER PREV, V15, P258, DOI 10.1097/01.cej.0000198896.02185.68; Tahir SK, 2010, MOL CANCER THER, V9, P545, DOI 10.1158/1535-7163.MCT-09-0651; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304	21	26	26	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2365	2371		10.1038/onc.2012.247	http://dx.doi.org/10.1038/onc.2012.247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22797074	Green Accepted			2022-12-28	WOS:000318683600013
J	Wimmer, P; Blanchette, P; Schreiner, S; Ching, W; Groitl, P; Berscheminski, J; Branton, PE; Will, H; Dobner, T				Wimmer, P.; Blanchette, P.; Schreiner, S.; Ching, W.; Groitl, P.; Berscheminski, J.; Branton, P. E.; Will, H.; Dobner, T.			Cross-talk between phosphorylation and SUMOylation regulates transforming activities of an adenoviral oncoprotein	ONCOGENE			English	Article						transformation; oncoprotein; SUMO; phosphorylation	E1B 55-KILODALTON PROTEIN; E1B-58KD TUMOR-ANTIGEN; NUCLEAR EXPORT; CELL-TRANSFORMATION; TRANSCRIPTIONAL REPRESSION; DEPENDENT DEGRADATION; SUMO-1 MODIFICATION; VIRAL INCLUSIONS; GENE-EXPRESSION; INFECTED-CELLS	Since the discovery of post-translational modification (PTM) by the small ubiquitin-related modifiers (SUMOs), a multitude of proteins have been described to be reversibly modified, resulting in the alteration of several cellular pathways. Interestingly, various pathogens gain access to this modification system, although the molecular mechanisms and functional consequences are barely understood. We show here that the adenoviral oncoprotein E1B-55K is a substrate of the SUMO conjugation system, which is directly linked to its C-terminal phosphorylation. This regulative connection is indispensable for modulation of the tumor suppressor p53/chromatin-remodeling factor Daxx by E1B-55K and, consequently, its oncogenic potential in primary mammalian cells. In virus infection, E1B-55K PTMs are necessary for localization to viral transcription/replication sites. Furthermore, we identify the E2 enzyme Ubc9 as an interaction partner of E1B-55K, providing a possible molecular explanation for SUMO-dependent modulation of cellular target proteins. In conclusion, these results for the first time provide evidence how E1B-55K PTMs are regulated and subsequently facilitate exploitation of the host cell SUMOylation machinery. Oncogene (2013) 32, 1626-1637; doi:10.1038/onc.2012.187; published online 21 May 2012	[Wimmer, P.; Schreiner, S.; Ching, W.; Groitl, P.; Berscheminski, J.; Will, H.; Dobner, T.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Mol Virol, D-20251 Hamburg, Germany; [Blanchette, P.; Branton, P. E.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Branton, P. E.] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Branton, P. E.] McGill Univ, Goodman Canc Ctr, Montreal, PQ, Canada	Heinrich Pette Institute; McGill University; McGill University; McGill University	Dobner, T (corresponding author), Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Mol Virol, Martinistr 52, D-20251 Hamburg, Germany.	thomas.dobner@hpi.uni-hamburg.de	Ching, Wai-Yim/B-4686-2009	Ching, Wai-Yim/0000-0001-7738-8822; Schreiner, Sabrina/0000-0002-5744-7159	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit; Wilhelm Sander-Stiftung, Munich, Germany; Canadian Institutes of Health Research	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit; Wilhelm Sander-Stiftung, Munich, Germany; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We apologize for all the important publications and excellent reviews we could not cite/refer to due to space limitations. The Heinrich-Pette-Institute is supported by the 'Freie und Hansestadt Hamburg' and the 'Bundesministerium fur Gesundheit'. TD was supported by a grant from the Wilhelm Sander-Stiftung, Munich, Germany. PEB and PB were supported through grants from the Canadian Institutes of Health Research.	Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Berk AJ, 2007, ADENOVIRIDAE VIRUSES; Blackford AN, 2009, J VIROL, V83, P4000, DOI 10.1128/JVI.02417-08; Blanchette P, 2008, J VIROL, V82, P2642, DOI 10.1128/JVI.02309-07; Boggio R, 2006, CURR OPIN MICROBIOL, V9, P430, DOI 10.1016/j.mib.2006.06.008; Boivin D, 1999, J VIROL, V73, P1245, DOI 10.1128/JVI.73.2.1245-1253.1999; Bossis G, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-13; Ching W, 2011, J VIROL; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Escobar-Cabrera E, 2011, J BIOL CHEM, V286, P19816, DOI 10.1074/jbc.M111.231647; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gonzalez RA, 2002, J VIROL, V76, P4507, DOI 10.1128/JVI.76.9.4507-4519.2002; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Groitl P, 2005, ADENOVIRUS METHODS P; Groitl Peter, 2007, Methods Mol Med, V130, P29; Haas AL, 2007, MOL CELL, V27, P174, DOI 10.1016/j.molcel.2007.07.003; Hartl B, 2008, ONCOGENE, V27, P3673, DOI 10.1038/sj.onc.1211039; Hannoun Z, 2010, TOXICOLOGY, V278, P288, DOI 10.1016/j.tox.2010.07.013; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kindsmuller K, 2007, P NATL ACAD SCI USA, V104, P6684, DOI 10.1073/pnas.0702158104; Kindsmuller K, 2009, J VIROL, V83, P9045, DOI 10.1128/JVI.00728-09; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Latonen L, 2011, BIOESSAYS, V33, P386, DOI 10.1002/bies.201100008; Leppard KN, 1998, SEMIN VIROL, V8, P301, DOI 10.1006/smvy.1997.0132; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LEPPARD KN, 1993, J GEN VIROL, V74, P575, DOI 10.1099/0022-1317-74-4-575; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; Li X, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000781; Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005; Logan J, 1984, CANCER CELL, V2, P527; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Mohideen F, 2009, NAT STRUCT MOL BIOL, V16, P945, DOI 10.1038/nsmb.1648; Mukhopadhyay D, 2007, TRENDS BIOCHEM SCI, V32, P286, DOI 10.1016/j.tibs.2007.05.002; Muller S, 2008, CELL CYCLE, V7, P754, DOI 10.4161/cc.7.6.5495; Nevels M, 2006, ADENOVIRUS METHODS P, P187; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Pennella MA, 2010, J VIROL, V84, P12210, DOI 10.1128/JVI.01442-10; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rangasamy D, 2000, J BIOL CHEM, V275, P30487, DOI 10.1074/jbc.M003898200; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; Santiago A, 2009, CELL CYCLE, V8, P76, DOI 10.4161/cc.8.1.7493; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schreiner S, 2011, J VIROL, V85, P8752, DOI 10.1128/JVI.00440-11; Schreiner S, 2010, J VIROL, V84, P7029, DOI 10.1128/JVI.00074-10; Schwartz RA, 2008, J VIROL, V82, P9043, DOI 10.1128/JVI.00925-08; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Soria C, 2010, NATURE, V466, P1076, DOI 10.1038/nature09307; Souquere-Besse S, 2002, MICROSC RES TECHNIQ, V56, P465, DOI 10.1002/jemt.10060; Stehmeier P, 2009, MOL CELL, V33, P400, DOI 10.1016/j.molcel.2009.01.013; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Tan JAT, 2010, MOL CELL BIOL, V30, P2823, DOI 10.1128/MCB.01603-09; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; Ulrich Helle D., 2009, V497, P3, DOI 10.1007/978-1-59745-566-4_1; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Wilson VG, 2001, VIRUS RES, V81, P17, DOI 10.1016/S0168-1702(01)00365-3; Wimmer P, 2010, ONCOGENE, V29, P5511, DOI 10.1038/onc.2010.284; Wimmer P, 2012, J VIROL, V86, P642, DOI 10.1128/JVI.06227-11; Wojcik C, 2003, INT J BIOCHEM CELL B, V35, P579, DOI 10.1016/S1357-2725(02)00380-1; Woo JL, 2007, J VIROL, V81, P575, DOI 10.1128/JVI.01725-06; Yang SH, 2006, EMBO J, V25, P5083, DOI 10.1038/sj.emboj.7601383; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yousef AF, 2010, ONCOGENE, V29, P4693, DOI 10.1038/onc.2010.226; Zhang XD, 2008, MOL CELL, V29, P729, DOI 10.1016/j.molcel.2008.01.013; Zhu JM, 2008, J BIOL CHEM, V283, P29405, DOI 10.1074/jbc.M803632200	88	30	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1626	1637		10.1038/onc.2012.187	http://dx.doi.org/10.1038/onc.2012.187			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614022				2022-12-28	WOS:000316855800003
J	Morancho, B; Parra-Palau, JL; Ibrahim, YH; Morales, CB; Peg, V; Bech-Serra, JJ; Pandiella, A; Canals, F; Baselga, J; Rubio, I; Arribas, J				Morancho, B.; Parra-Palau, J. L.; Ibrahim, Y. H.; Bernado Morales, C.; Peg, V.; Bech-Serra, J. J.; Pandiella, A.; Canals, F.; Baselga, J.; Rubio, I.; Arribas, J.			A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers	ONCOGENE			English	Article						HER2; ErbB2; breast cancer	RECEPTOR; CLEAVAGE; ERBB-2; GELDANAMYCIN; IDENTIFICATION; TRASTUZUMAB; DEGRADATION; EFFECTOR; P95HER2; GROWTH	The transmembrane tyrosine kinase HER2 (ErbB2, neu) is a prototypical biomarker for breast cancers and a therapeutic target. Although anti-HER2 therapies are remarkably effective, HER2-positive tumors are heterogeneous and some subtypes do not respond or develop resistance to these therapies. Here we show that H2NTF, a novel N-terminal fragment of HER2, is expressed at variable levels in 60% of the breast cancer samples analyzed. Characterization of H2NTF shows that it is devoid of the tyrosine kinase domain but it readily interacts with full-length HER2 and other HER receptors. As a consequence, H2NTF acts as a dominant-negative, attenuating the signaling triggered by full-length HER receptors. Expression of H2NTF results in resistance to the treatment with low concentrations of trastuzumab in vitro. However, cells expressing H2NTF and non-expressing cells have similar sensitivity to trastuzumab in vivo, indicating that H2NTF/trastuzumab complexes trigger antibody-dependent cell-mediated cytotoxicity. Oncogene (2013) 32, 1452-1459; doi:10.1038/onc.2012.152; published online 28 May 2012	[Morancho, B.; Parra-Palau, J. L.; Ibrahim, Y. H.; Bernado Morales, C.; Bech-Serra, J. J.; Canals, F.; Baselga, J.; Arribas, J.] Vall dHebron Inst Oncol VHIO, Preclin Res Program, Barcelona 08035, Spain; [Peg, V.] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Pathol, Bellaterra, Spain; [Peg, V.] Univ Autonoma Barcelona, Dept Morphol Sci, Bellaterra, Spain; [Pandiella, A.] Univ Salamanca, CSIC, Inst Biol Mol Celular & Celular Canc, E-37008 Salamanca, Spain; [Baselga, J.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA; [Rubio, I.] Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain; [Arribas, J.] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain; [Arribas, J.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; Harvard University; Harvard Medical School; Massachusetts General Hospital; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; ICREA	Arribas, J (corresponding author), Vall dHebron Inst Oncol VHIO, Preclin Res Program, Psg Vall dHebron 119-129, Barcelona 08035, Spain.	jarribas@vhio.net	rubio, isabel/U-4259-2018; Arribas, Joaquin/M-4482-2014; Morancho, Beatriz/AAD-3540-2021; Pandiella, Atanasio/O-5180-2014; Bech-Serra, Joan Josep/AAA-2330-2020; Peg., Vicente/AAC-9447-2020; Peg, Vicente/E-9160-2018	rubio, isabel/0000-0003-0035-0679; Arribas, Joaquin/0000-0002-0504-0664; Morancho, Beatriz/0000-0003-3369-8647; Pandiella, Atanasio/0000-0002-4704-8971; Bech-Serra, Joan Josep/0000-0003-3486-781X; Peg., Vicente/0000-0002-5203-6166; Peg, Vicente/0000-0002-5203-6166; Bernado Morales, Cristina/0000-0003-1376-0407	Instituto de Salud Carlos III (Intrasalud) [PI081154, PI11/02496]; Instituto de Salud Carlos III (network of cooperative cancer research) [RTICC-RD06/0020/0022, RTICC-RD06/0020/0041]; GlaxoSmithKline; Breast Cancer Research Foundation (BCRF); ICREA Funding Source: Custom	Instituto de Salud Carlos III (Intrasalud); Instituto de Salud Carlos III (network of cooperative cancer research); GlaxoSmithKline(GlaxoSmithKline); Breast Cancer Research Foundation (BCRF); ICREA(ICREA)	This work was supported by Instituto de Salud Carlos III (Intrasalud PI081154, PI11/02496 and the network of cooperative cancer research (RTICC-RD06/0020/0022 and RTICC-RD06/0020/0041)), GlaxoSmithKline and the Breast Cancer Research Foundation (BCRF).	Abramson V, 2011, CLIN CANCER RES, V17, P952, DOI 10.1158/1078-0432.CCR-09-1947; Anelli T, 2008, EMBO J, V27, P315, DOI 10.1038/sj.emboj.7601974; Arribas J, 2011, CANCER RES, V71, P1515, DOI 10.1158/0008-5472.CAN-10-3795; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Benoit V, 2004, CANCER RES, V64, P2684, DOI 10.1158/0008-5472.CAN-03-2914; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; HASUI M, 1989, CELL IMMUNOL, V120, P230, DOI 10.1016/0008-8749(89)90190-1; Kulkarni S, 2010, ONCOGENE, V29, P1339, DOI 10.1038/onc.2009.422; Parra-Palau JL, 2010, CANCER RES, V70, P8537, DOI 10.1158/0008-5472.CAN-10-1701; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Ryan Q, 2008, ONCOLOGIST, V13, P1114, DOI 10.1634/theoncologist.2008-0816; Sanchez-Martin M, 2012, INT J CANCER, V131, P244, DOI 10.1002/ijc.26358; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Sperinde J, 2010, CLIN CANCER RES, V16, P4226, DOI 10.1158/1078-0432.CCR-10-0410; Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200; Tikhomirov O, 2005, ONCOGENE, V24, P3906, DOI 10.1038/sj.onc.1208534; Tikhomirov O, 2003, CANCER RES, V63, P39; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200	23	6	6	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1452	1459		10.1038/onc.2012.152	http://dx.doi.org/10.1038/onc.2012.152			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22641219				2022-12-28	WOS:000316455600011
J	Klokov, D; Leskov, K; Araki, S; Zou, Y; Goetz, EM; Luo, X; Willson, D; Boothman, DA				Klokov, D.; Leskov, K.; Araki, S.; Zou, Y.; Goetz, E. M.; Luo, X.; Willson, D.; Boothman, D. A.			Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGF beta 1 signaling to confer a pro-survival bystander effect	ONCOGENE			English	Article						bystander effects; TGF beta 1; secretory clusterin; insulin-like growth factor-1; low-dose ionizing radiation; p53 suppression	GROWTH-FACTOR-I; CLUSTERIN GENE-EXPRESSION; IONIZING-RADIATION; DNA-DAMAGE; INDUCED SENESCENCE; FACTOR-BETA; CANCER; PROTEIN; APOPTOSIS; ACTIVATION	Inadvertent mammalian tissue exposures to low doses of ionizing radiation (IR) after radiation accidents, remediation of radioactive-contaminated areas, space travel or a dirty bomb represent an interesting trauma to an organism. Possible low-dose IR-induced bystander effects could impact our evaluation of human health effects, as cells within tissue are not equally damaged after doses of IR <= 10 cGy. To understand tissue responses after low IR doses, we generated a reporter system using the human clusterin promoter fused to firefly luciferase (hCLUp-Luc). Secretory clusterin (sCLU), an extracellular molecular chaperone, induced by low doses of cytotoxic agents, clears cell debris. Low-dose IR (>= 2 cGy) exposure induced hCLUp-Luc activity with peak levels at 96 h, consistent with endogenous sCLU levels. As doses increased (>= 1 Gy), sCLU induction amplitudes increased and time-to-peak response decreased. sCLU expression was stimulated by insulin-like growth factor-1, but suppressed by p53. Responses in transgenic hCLUp-Luc reporter mice after low IR doses showed that specific tissues (that is, colon, spleen, mammary, thymus and bone marrow) of female mice induced hCLUp-Luc activity more than male mice after whole body (>= 10 cGy) irradiation. Tissue-specific, non-linear dose- and time-responses of hCLUp-Luc and endogenous sCLU levels were noted. Colon maintained homeostatic balance after 10 cGy. Bone marrow responded with delayed, but prolonged and elevated expression. Intraperitoneal administration of alpha-transforming growth factor (TGF)beta 1 (1D11), but not control (13C4) antibodies, immediately following IR exposure abrogated CLU induction responses. Induction in vivo also correlated with Smad signaling by activated TGF beta 1 after IR. Mechanistically, media with elevated sCLU levels suppressed signaling, blocked apoptosis and increased survival of TGF beta 1-exposed tumor or normal cells. Thus, sCLU is a pro-survival bystander factor that abrogates TGF beta 1 signaling and most likely promotes wound healing. Oncogene (2013) 32, 479-490; doi:10.1038/onc.2012.64; published online 5 March 2012	[Leskov, K.] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Araki, S.; Zou, Y.; Goetz, E. M.; Luo, X.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Program Cell Stress & Canc Nanomed, Dept Pharmacol,Lab Mol Stress Responses, Dallas, TX 75390 USA; [Araki, S.; Zou, Y.; Goetz, E. M.; Luo, X.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Program Cell Stress & Canc Nanomed, Dept Radiat Oncol,Lab Mol Stress Response, Dallas, TX 75390 USA; [Willson, D.] Case Western Reserve Univ, Sch Med, Dept Biomed Engn, Lab Biomed Image Proc, Cleveland, OH USA	Case Western Reserve University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University	Boothman, DA (corresponding author), Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Program Cell Stress & Canc Nanomed, Dept Pharmacol,Lab Mol Stress Responses, Dallas, TX 75390 USA.	David.Boothman@UTSouthwestern.edu	Boothman, David/Q-7776-2019; Klokov, Dmitry/AAM-7316-2020; Leskov, Konstantin S/J-2339-2017	Klokov, Dmitry/0000-0003-1629-1431; Leskov, Konstantin S/0000-0001-6201-5660	DOE [DE-FG02-06ER64186]; NASA; DAB; DOD BCRP [W81XWH-06-0748]; DOD PCRP [X8IXWH-09-1-0168]; NATIONAL CANCER INSTITUTE [U24CA126608, R01CA139217, R01CA078530, P30CA142543] Funding Source: NIH RePORTER	DOE(United States Department of Energy (DOE)); NASA(National Aeronautics & Space Administration (NASA)); DAB; DOD BCRP(United States Department of Defense); DOD PCRP; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by DOE Grant #DE-FG02-06ER64186 to DAB, a pilot grant from NASA to develop BLI imaging of hCLUp-Luc to DW and DAB, a DOD BCRP pre-doctoral fellowship (W81XWH-06-0748) to E.M.G and a DOD PCRP post-doctoral fellowship (X8IXWH-09-1-0168) to XL We thank Ms Lakshmi Sampath and Mr Andrew Bruening for their help with this work. We are also grateful to Dr Mary Helen Barcellos-Hoff for her advice with the animal experiments. We are also grateful to the Robert B. and Virginia Payne Endowment to DAB. This is CSCN 065 and used the Flow Cytometry and Biostatistics Cores, Simmons Cancer Center.	Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Araki S, 2005, BJR S, V27, P106, DOI [10.1259/bjr/18105113, DOI 10.1259/BJR/18105113]]; Araki S, 2010, J CLIN INVEST, V120, P290, DOI 10.1172/JCI39194; Arufe MC, 2011, STEM CELLS DEV, V20, P1199, DOI 10.1089/scd.2010.0315; Bhogal N, 2010, RADIAT RES, V173, P1, DOI 10.1667/RR1851.1; Cardona-Gomez GP, 2001, BRAIN RES REV, V37, P320, DOI 10.1016/S0165-0173(01)00137-0; Chi KN, 2010, J CLIN ONCOL, V28, P4247, DOI 10.1200/JCO.2009.26.8771; Cipriano R, 2011, P NATL ACAD SCI USA, V108, P8668, DOI 10.1073/pnas.1015022108; Cornelissen B, 2011, CANCER RES, V71, P4539, DOI 10.1158/0008-5472.CAN-10-4587; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Criswell T, 2003, CANCER BIOL THER, V2, P372, DOI 10.4161/cbt.2.4.430; DASCH JR, 1989, J IMMUNOL, V142, P1536; Davis TW, 1998, CANCER RES, V58, P767; Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037; Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69; Garkavtsev I, 2011, P NATL ACAD SCI USA, V108, P11596, DOI 10.1073/pnas.1104225108; Goetz EM, 2011, ONCOGENE, V30, P3745, DOI 10.1038/onc.2011.92; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x; Kirshner J, 2006, CANCER RES, V66, P10861, DOI 10.1158/0008-5472.CAN-06-2565; Klokov D, 2004, MUTAT RES-FUND MOL M, V568, P97, DOI 10.1016/j.mrfmmm.2004.06.049; Lee TK, 2002, RADIAT RES, V157, P678, DOI 10.1667/0033-7587(2002)157[0678:POMILO]2.0.CO;2; Li LS, 2008, J BIOL CHEM, V283, P21394, DOI 10.1074/jbc.M709954200; Lindholm C, 2010, RADIAT RES, V173, P71, DOI 10.1667/RR1843.1; Nachtrab U, 1998, INT J RADIAT BIOL, V73, P279, DOI 10.1080/095530098142374; Nguyen DH, 2011, CANCER CELL, V19, P640, DOI 10.1016/j.ccr.2011.03.011; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Redon CE, 2009, ADV SPACE RES, V43, P1171, DOI 10.1016/j.asr.2008.10.011; Rodier F, 2011, J CELL SCI, V124, P68, DOI 10.1242/jcs.071340; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sfeir A, 2010, SCIENCE, V327, P1657, DOI 10.1126/science.1185100; Shahrabani-Gargir L, 2004, ENDOCRINOLOGY, V145, P5679, DOI 10.1210/en.2004-0613; Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779; Snyder AR, 2004, HUM EXP TOXICOL, V23, P87, DOI 10.1191/0960327104ht423oa; Sutton D, 2006, INT J NANOMED, V1, P155, DOI 10.2147/nano.2006.1.2.155; Trougakos IP, 2009, CLIN CANCER RES, V15, P48, DOI 10.1158/1078-0432.CCR-08-1805; Trougakos IP, 2009, CANCER RES, V69, P403, DOI 10.1158/0008-5472.CAN-08-2912; Wagner MW, 2008, J BIOL CHEM, V283, P21382, DOI 10.1074/jbc.M709953200; Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291; Zoubeidi A, 2010, CLIN CANCER RES, V16, P1088, DOI 10.1158/1078-0432.CCR-09-2917	45	22	23	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					479	490		10.1038/onc.2012.64	http://dx.doi.org/10.1038/onc.2012.64			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391565	Green Accepted			2022-12-28	WOS:000315551300009
J	Yuan, W; Stawiski, E; Janakiraman, V; Chan, E; Durinck, S; Edgar, KA; Kljavin, NM; Rivers, CS; Gnad, F; Roose-Girma, M; Haverty, PM; Fedorowicz, G; Heldens, S; Soriano, RH; Zhang, Z; Wallin, JJ; Johnson, L; Merchant, M; Modrusan, Z; Stern, HM; Seshagiri, S				Yuan, W.; Stawiski, E.; Janakiraman, V.; Chan, E.; Durinck, S.; Edgar, K. A.; Kljavin, N. M.; Rivers, C. S.; Gnad, F.; Roose-Girma, M.; Haverty, P. M.; Fedorowicz, G.; Heldens, S.; Soriano, R. H.; Zhang, Z.; Wallin, J. J.; Johnson, L.; Merchant, M.; Modrusan, Z.; Stern, H. M.; Seshagiri, S.			Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations	ONCOGENE			English	Article						Pik3ca; H1047R; knock-in; mammary gland; Trp53; exome sequencing	TO-MESENCHYMAL TRANSITION; BREAST-CANCER; HIGH-FREQUENCY; PIK3CA GENE; PI3K; EXPRESSION; MICE; P110-ALPHA; INHIBITION; CARCINOMA	Oncogenic mutations in PIK3CA, which encodes the phosphoinositide-3-kinase (PI3K) catalytic subunit p110 alpha, occur in similar to 25% of human breast cancers. In this study, we report the development of a knock-in mouse model for breast cancer where the endogenous Pik3ca allele was modified to allow tissue-specific conditional expression of a frequently found Pik3ca(H1047R) (pik3ca(e20H1047R)) mutant allele. We found that activation of the latent Pik3ca(H1047R) allele resulted in breast tumors with multiple histological types. Whole-exome analysis of the Pik3ca(H1047R)-driven mammary tumors identified multiple mutations, including Trp53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors. Further, we used this model to test the efficacy of GDC-0941, a PI3K inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition. Oncogene (2013) 32, 318-326; doi:10.1038/onc.2012.53; published online 27 February 2012	[Yuan, W.; Stawiski, E.; Janakiraman, V.; Durinck, S.; Kljavin, N. M.; Rivers, C. S.; Roose-Girma, M.; Fedorowicz, G.; Heldens, S.; Soriano, R. H.; Johnson, L.; Modrusan, Z.; Seshagiri, S.] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; [Chan, E.; Merchant, M.] Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA; [Edgar, K. A.; Wallin, J. J.] Genentech Inc, Dept Canc Signaling, San Francisco, CA 94080 USA; [Gnad, F.; Haverty, P. M.; Zhang, Z.] Genentech Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA; [Stern, H. M.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Seshagiri, S (corresponding author), Genentech Inc, Dept Mol Biol, 1 DNA Way, San Francisco, CA 94080 USA.	sekar@gene.com		Wallin, Jeffrey/0000-0002-5952-3813; Seshagiri, Somasekar/0000-0003-4272-6443; Merchant, Mark/0000-0003-0690-8581; Gnad, Florian/0000-0002-2287-2251				Adams JR, 2011, CANCER RES, V71, P2706, DOI 10.1158/0008-5472.CAN-10-0738; Amikura T, 2006, GYNECOL ONCOL, V100, P365, DOI 10.1016/j.ygyno.2005.09.010; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Boyault S, 2012, BREAST CANCER RES TR, V132, P29, DOI 10.1007/s10549-011-1518-y; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carter MR, 2006, AM J SURG PATHOL, V30, P300; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Fishler T, 2010, ONCOGENE, V29, P4007, DOI 10.1038/onc.2010.163; Folkes A, 2007, PCT Int Appl, P206, Patent No. [WO 2007127175 A2 20071108, 2007127175]; Grochova D, 2008, ONCOGENE, V27, P1243, DOI 10.1038/sj.onc.1210748; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Horn S, 2008, ONCOGENE, V27, P4096, DOI 10.1038/onc.2008.40; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Hynes NE, 2009, CANCER CELL, V15, P353, DOI 10.1016/j.ccr.2009.04.004; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Khan HN, 2003, EUR J SURG ONCOL, V29, P600, DOI 10.1016/S0748-7983(03)00107-0; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Li G, 2002, DEVELOPMENT, V129, P4159; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Pinheiro J, 2008, R PACKAGE VERSION, V57, P1; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Salphati L, 2010, DRUG METAB DISPOS, V38, P1436, DOI 10.1124/dmd.110.032912; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tiede B, 2011, CELL RES, V21, P245, DOI 10.1038/cr.2011.11; Tuveson D, 2011, NATURE, V471, P316, DOI 10.1038/471316a; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Walrath JC, 2010, ADV CANCER RES, V106, P113, DOI 10.1016/S0065-230X(10)06004-5; Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	53	53	53	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					318	326		10.1038/onc.2012.53	http://dx.doi.org/10.1038/onc.2012.53			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370636	hybrid, Green Published			2022-12-28	WOS:000314736600006
J	Hartman, Z; Zhao, H; Agazie, YM				Hartman, Z.; Zhao, H.; Agazie, Y. M.			HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling	ONCOGENE			English	Article						HER2; EGFR; autophosphorylation; signaling; tumorigenesis	EPIDERMAL-GROWTH-FACTOR; CLATHRIN-COATED PITS; ERBB-RELATED GENE; FACTOR RECEPTOR; DOWN-REGULATION; CRYSTAL-STRUCTURE; BREAST-CANCER; MOLECULAR-MECHANISM; KINASE DOMAIN; ACTIVATION	One of the causes of breast cancer is overexpression of the human epidermal growth factor receptor 2 (HER2). Enhanced receptor autophosphorylation and resistance to activation-induced downregulation have been suggested as mechanisms for HER2-induced sustained signaling and cell transformation. However, the molecular mechanisms underlying these possibilities remain incompletely understood. In the current report, we present evidence that show that HER2 overexpression does not lead to receptor hyper-autophosphorylation, but alters patterns in a manner that favors receptor stability and sustained signaling. Specifically, HER2 overexpression blocks epidermal growth factor receptor (EGFR) tyrosine phosphorylation on Y1045 and Y1068, the known docking sites of c-Cbl and Grb2, respectively, whereas promoting phosphorylation on Y1173, the known docking site of the Gab adaptor proteins and phospholipase C gamma. Under these conditions, HER2 itself is phosphorylated on Y1221/1222, with no known role, and on Y1248 that corresponds to Y1173 of EGFR. Interestingly, suppressed EGFR autophosphorylation on the Grb2 and c-Cbl-binding sites correlated with receptor stability and sustained signaling, suggesting that HER2 accomplishes these tasks by altering autophosphorylation patterns. In conformity with these findings, mutation of the Grb2-binding site on EGFR (Y1068F-EGFR) conferred resistance to ligand-induced degradation, which in turn induced sustained signaling, and increased cell proliferation and transformation. These findings suggest that the Grb2-binding site on EGFR is redundant for signaling, but critical for receptor regulation. On the other hand, mutation of the putative Grb2-binding site in HER2 (Y1139) did not affect stability, signaling or transformation, suggesting that Y1139 in HER2 may not serve as a Grb2-binding site. In agreement with the role of EGFR in HER2 signaling, inhibition of EGFR expression reduced HER2-induced anchorage-independent growth and tumorigenesis. These results imply that complementing HER2-targeted therapies with anti-EGFR drugs may be beneficial in HER2-positive breast cancer.	[Hartman, Z.; Zhao, H.; Agazie, Y. M.] W Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA; [Agazie, Y. M.] W Virginia Univ, Sch Med, Marry Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Agazie, YM (corresponding author), W Virginia Univ, Sch Med, Dept Biochem, 1 Med Ctr Dr, Morgantown, WV 26506 USA.	yagazie@hsc.wvu.edu			National Cancer Institute (NCI), a component of the National Institute of Health (NIH) [CA124940]; NATIONAL CANCER INSTITUTE [R01CA124940] Funding Source: NIH RePORTER	National Cancer Institute (NCI), a component of the National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant number CA124940 from the National Cancer Institute (NCI), a component of the National Institute of Health (NIH) to YMA.	Aertgeerts K, 2011, J BIOL CHEM, V286, P18756, DOI 10.1074/jbc.M110.206193; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Badache A, 2006, J MAMMARY GLAND BIOL, V11, P13, DOI 10.1007/s10911-006-9009-1; Baldys A, 2009, BIOCHEMISTRY-US, V48, P1462, DOI 10.1021/bi801771g; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Carlsson J, 2004, BRIT J CANCER, V90, P2344, DOI 10.1038/sj.bjc.6601881; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DIONNE CA, 1991, ANN NY ACAD SCI, V638, P161, DOI 10.1111/j.1749-6632.1991.tb49026.x; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Fan YX, 2008, J BIOL CHEM, V283, P1588, DOI 10.1074/jbc.M708116200; FENG GS, 1994, ONCOGENE, V9, P1545; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HELIN K, 1991, J BIOL CHEM, V266, P8363; Hendriks BS, 2003, BIOPHYS J, V85, P2732, DOI 10.1016/S0006-3495(03)74696-7; Huang GC, 1999, J CELL BIOCHEM, V74, P23; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229; Monsey J, 2010, J BIOL CHEM, V285, P7035, DOI 10.1074/jbc.M109.096032; Morandell S, 2008, PROTEOMICS, V8, P4383, DOI 10.1002/pmic.200800204; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Ono M, 2006, CLIN CANCER RES, V12, P7242, DOI 10.1158/1078-0432.CCR-06-0646; Pamonsinlapatham P, 2009, BIOCHIMIE, V91, P320, DOI 10.1016/j.biochi.2008.10.010; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Rana P, BREAST CANC AUCKL, V6, P67; Ravichandran KS, 1995, ANN NY ACAD SCI, V766, P202, DOI 10.1111/j.1749-6632.1995.tb26663.x; Russo C, 2002, ANN NY ACAD SCI, V973, P323, DOI 10.1111/j.1749-6632.2002.tb04660.x; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; SORKIN A, 1993, ONCOGENE, V8, P3021; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Sperka T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027511; Sun J, 2007, EXP CELL RES, V313, P3935, DOI 10.1016/j.yexcr.2007.08.021; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yamanashi Y, J BIOCH, V151, P353; Yuan YL, 2008, J LARYNGOL OTOL, V122, P952, DOI 10.1017/S0022215107000606; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhou XD, 2012, CELL SIGNAL, V24, P140, DOI 10.1016/j.cellsig.2011.08.015; Zhou XD, 2009, J BIOL CHEM, V284, P12226, DOI 10.1074/jbc.M900020200	55	41	42	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4169	4180		10.1038/onc.2012.418	http://dx.doi.org/10.1038/onc.2012.418			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23027125	Green Accepted			2022-12-28	WOS:000323748500012
J	Herranz, D; Maraver, A; Canamero, M; Gomez-Lopez, G; Inglada-Perez, L; Robledo, M; Castelblanco, E; Matias-Guiu, X; Serrano, M				Herranz, D.; Maraver, A.; Canamero, M.; Gomez-Lopez, G.; Inglada-Perez, L.; Robledo, M.; Castelblanco, E.; Matias-Guiu, X.; Serrano, M.			SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency	ONCOGENE			English	Article						SIRT1; c-MYC; PTEN; thyroid cancer; prostate cancer	C-MYC; ONCOPROTEIN; BIOGENESIS; MUTATION; MOUSE; P53	Current genetic evidence in mice indicates that SIRT1 has potent tumor suppressor activity in a variety of cancer models, with no evidence yet for SIRT1 oncogenic activity in vivo. We report here that transgenic Sirt1 expression is oncogenic in murine thyroid and prostate carcinogenesis initiated by Pten-deficiency. Based on mRNA expression analyses of pre-tumoral murine thyroids, we find that SIRT1 increases c-MYC transcriptional programs. Moreover, we show higher c-MYC protein levels in murine thyroid cancers from Sirt1 transgenic mice. Similarly, SIRT1 is overexpressed in human thyroid cancers and it is positively correlated with c-MYC protein levels. Finally, we show in cultured thyroid cancer cells that SIRT1 stabilizes c-MYC protein. These results implicate SIRT1 as a new candidate target for the treatment of thyroid carcinomas.	[Herranz, D.; Maraver, A.; Serrano, M.] Spanish Natl Canc Res Ctr CNIO, Tumor Suppress Grp, E-28029 Madrid, Spain; [Canamero, M.] Spanish Natl Canc Res Ctr CNIO, Comparat Pathol Unit, E-28029 Madrid, Spain; [Gomez-Lopez, G.] Spanish Natl Canc Res Ctr CNIO, Bioinformat Unit, E-28029 Madrid, Spain; [Inglada-Perez, L.; Robledo, M.] Spanish Natl Canc Res Ctr CNIO, CIBERER, E-28029 Madrid, Spain; [Inglada-Perez, L.; Robledo, M.] Spanish Natl Canc Res Ctr CNIO, Hereditary Endocrine Canc Grp, E-28029 Madrid, Spain; [Castelblanco, E.; Matias-Guiu, X.] Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Pathol & Mol Genet, Irblleida, Lleida, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Centro Nacional de Investigaciones Oncologicas (CNIO); Universitat de Lleida; University Hospital Arnau de Vilanova	Serrano, M (corresponding author), Spanish Natl Canc Res Ctr CNIO, 3 Melchor Fernandez Almagro St, E-28029 Madrid, Spain.	mserrano@cnio.es	Maraver, Antonio/G-2666-2015; Herranz, Daniel/L-6986-2017; matias-guiu, xavier/C-3039-2009; Inglada-Perez, Lucia/Z-3020-2019; inglada-perez, lucia/H-5378-2015; Gomez-Lopez, Gonzalo/D-9123-2016; Robledo, Mercedes/O-2230-2013; /AAI-3238-2021; E, Esmeralda Castelblanco/A-7588-2011; Serrano, Manuel/H-2634-2015	Herranz, Daniel/0000-0003-1768-5969; matias-guiu, xavier/0000-0002-7201-6605; Gomez-Lopez, Gonzalo/0000-0002-4146-0551; Robledo, Mercedes/0000-0001-6256-5902; E, Esmeralda Castelblanco/0000-0002-2061-6270; Serrano, Manuel/0000-0001-7177-9312; Inglada-Perez, Lucia/0000-0001-9814-4368; Maraver, Antonio/0000-0002-5527-5680; INGLADA, LUCIA/0000-0001-9523-2717	CNIO; Spanish Ministry of Science (SAF); Spanish Ministry of Science (CONSOLIDER); European Research Council (ERC); 'Marcelino Botin' Foundation; AXA Foundation; 'Ramon Areces' Foundation; Spanish Ministry of Health; CIBERER;  [RD09/0076/00059]	CNIO; Spanish Ministry of Science (SAF)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Ministry of Science (CONSOLIDER)(Ministry of Science and Innovation, Spain (MICINN)); European Research Council (ERC)(European Research Council (ERC)European Commission); 'Marcelino Botin' Foundation; AXA Foundation; 'Ramon Areces' Foundation; Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); CIBERER; 	We thank Maribel Munoz and Gema Iglesias for excellent mouse handling. Work in the laboratory of MS is funded by the CNIO and by grants from the Spanish Ministry of Science (SAF and CONSOLIDER), the European Research Council (ERC Advanced Grant), the 'Marcelino Botin' Foundation, the AXA Foundation and the 'Ramon Areces' Foundation. AM is funded by a 'Miguel Servet' grant from the Spanish Ministry of Health. LI-P is supported by CIBERER. Human tumor samples were obtained with the support of Xarxa Catalana de Bancs de Tumors, the Tumor Bank Platform of RTICC, and project RD09/0076/00059.	Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chen X, 2008, COLD SH Q B, V73, P203, DOI 10.1101/sqb.2008.73.026; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Herranz D, 2010, NAT REV CANCER, V10, P819, DOI 10.1038/nrc2962; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Lin CJ, 2009, CANCER RES, V69, P7491, DOI 10.1158/0008-5472.CAN-09-0813; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mao BB, 2011, INT J BIOCHEM CELL B, V43, P1573, DOI 10.1016/j.biocel.2011.07.006; Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135; Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; ROMANO MI, 1993, HORM RES, V39, P161, DOI 10.1159/000182718; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Smith KN, 2010, CELL STEM CELL, V7, P343, DOI 10.1016/j.stem.2010.06.023; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Thomas LR, 2011, ADV CANCER RES, V110, P77, DOI 10.1016/B978-0-12-386469-7.00004-9; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yuan J, 2009, J CELL BIOL, V185, P203, DOI 10.1083/jcb.200809167	25	51	53	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4052	4056		10.1038/onc.2012.407	http://dx.doi.org/10.1038/onc.2012.407			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22986535				2022-12-28	WOS:000323748100014
J	Dikshit, B; Irshad, K; Madan, E; Aggarwal, N; Sarkar, C; Chandra, PS; Gupta, DK; Chattopadhyay, P; Sinha, S; Chosdol, K				Dikshit, B.; Irshad, K.; Madan, E.; Aggarwal, N.; Sarkar, C.; Chandra, P. S.; Gupta, D. K.; Chattopadhyay, P.; Sinha, S.; Chosdol, K.			FAT1 acts as an upstream regulator of oncogenic and inflammatory pathways, via PDCD4, in glioma cells	ONCOGENE			English	Article						FAT1; inflammation; PDCD4; AP-1; COX-2; glioma	TUMOR-SUPPRESSOR GENE; INDEPENDENT PROGNOSTIC-FACTOR; HUMAN LUNG-CANCER; BREAST-CANCER; TRANSCRIPTION FACTOR; DEATH 4; C-JUN; DOWN-REGULATION; TRANSFORMATION SUPPRESSOR; FREQUENT LOSS	Glioblastoma multiforme (GBM) is the most aggressive and the commonest primary brain tumor with a tendency for local invasiveness. The pathways of neoplasia, invasion and inflammation are inextricably linked in cancer and aberrations in several regulatory pathways for these processes have been identified. Here we have studied the FAT1 (Homo sapiens FAT tumor-suppressor homolog 1 (Drosophila)) gene to identify its role in the tumorigenecity of the gliomas. The expression of FAT1 was found to be high in grade IV glioma cell lines (U87MG, A172, U373MG and T98G) but low in grade III glioma cell lines (GOS3 and SW1088). Two cell lines (U87MG and A172) with high FAT1 expression were chosen for in vitro FAT1-knockdown studies. FAT1 knockdown by small interfering RNA resulted in decreased migration and invasion of both the cell lines along with increased expression of the tumor-suppressor gene programmed cell death 4 (PDCD4). Increased PDCD4 expression led to the attenuation of activator protein-1 (AP-1) transcription by inhibiting c-Jun phosphorylation and resulted in concomitant decrease in the expression of AP-1-target genes like MMP3, VEGF-C and PLAU, the pro-inflammatory regulator COX-2 and cytokines IL1 beta and IL-6. Conversely, simultaneous silencing of PDCD4 and FAT1 in these cells significantly enhanced AP-1 activity and expression of its target genes, resulting in increase in mediators of inflammation and in enhanced migratory and invasive properties of the cells. We also observed a negative correlation between the expression of FAT1 and PDCD4 (P = 0.0145), a positive correlation between the expression of FAT1 and COX-2 (P = 0.048) and a similar positive trend between FAT1 and IL-6 expression in 35 primary human GBM samples studied. Taken together, this study identifies a novel signaling mechanism mediated by FAT1 in regulating the activity of PDCD4 and thereby the key transcription factor AP-1, which then affects known mediators of neoplasia and inflammation.	[Dikshit, B.; Irshad, K.; Madan, E.; Aggarwal, N.; Chattopadhyay, P.; Sinha, S.; Chosdol, K.] All India Inst Med Sci, Dept Biochem, New Delhi 110029, India; [Sarkar, C.] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; [Chandra, P. S.] All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, India; [Sinha, S.] Natl Brain Res Ctr, Gurgaon, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC)	Sinha, S (corresponding author), Natl Brain Res Ctr, Near NSG Campus, Manesar 122050, Gurgaon, India.	sub_sinha@hotmail.com; kunzangchosdol@yahoo.com	Irshad, Khushboo/AAT-6842-2020; Aggarwal, Nupur/K-1296-2019	Irshad, Khushboo/0000-0002-1552-3686; Aggarwal, Nupur/0000-0002-7992-0023; chosdol, kunzang/0000-0002-7065-3395	Defense Research and Development Organization (DRDO), India [LSRB167-2008]; National Brain Research Center, India; Council of Scientific and Industrial Research (CSIR, India); Indian Council of Medical Research (ICMR, India)	Defense Research and Development Organization (DRDO), India(Defence Research & Development Organisation (DRDO)); National Brain Research Center, India; Council of Scientific and Industrial Research (CSIR, India)(Council of Scientific & Industrial Research (CSIR) - India); Indian Council of Medical Research (ICMR, India)(Indian Council of Medical Research (ICMR))	The work has been supported by grant from Defense Research and Development Organization (DRDO), India (no. LSRB167-2008) to KC and National Brain Research Center, India, core intramural grant to SS. RF (Research fellowship) to BD and EM from Council of Scientific and Industrial Research (CSIR, India) and RF to KI from Indian Council of Medical Research (ICMR, India). We would like to acknowledge Dr Miguel Iniguez for providing COX-2 promoter luciferase plasmid and Dr Shayamal Goswami, Dr Balaji and Dr Sandeep Saxena for their help during the progress of the work. We thank our Lab technician Ms Jyoti and Lab attendants Late Mathura Prasad, Mr Pappu, Mr Gopal and Mr Ajay for their assistance in routine lab work and cell-culture work.	Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Aggarwal BB, 2009, CURR OPIN PHARMACOL, V9, P351, DOI 10.1016/j.coph.2009.06.020; Alves TR, 2011, LIFE SCI, V89, P532, DOI 10.1016/j.lfs.2011.04.022; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Balkwill F, 2010, CLIN PHARMACOL THER, V87, P401, DOI 10.1038/clpt.2009.312; Bendavid C, 2007, EUR J MED GENET, V50, P66, DOI 10.1016/j.ejmg.2006.09.003; Bennett FC, 2006, CURR BIOL, V16, P2101, DOI 10.1016/j.cub.2006.09.045; Bhattacharya A, 2001, CLIN CANCER RES, V7, P267; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Borrello MG, 2008, CANCER LETT, V267, P262, DOI 10.1016/j.canlet.2008.03.060; Braun GS, 2007, J BIOL CHEM, V282, P22823, DOI 10.1074/jbc.M701758200; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Chiu WT, 2010, NEUROBIOL DIS, V37, P118, DOI 10.1016/j.nbd.2009.09.015; Cho E, 2006, NAT GENET, V38, P1142, DOI 10.1038/ng1887; Chosdol K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-5; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; de Bock CE, 2012, LEUKEMIA, V26, P918, DOI 10.1038/leu.2011.319; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; de Visser KE, 2009, CURR PHARM DESIGN, V15, P1844, DOI 10.2174/138161209788453239; Demaria S, 2010, J IMMUNOTHER, V33, P335, DOI 10.1097/CJI.0b013e3181d32e74; Deorukhkar A, 2010, BIOCHEM PHARMACOL, V80, P1904, DOI 10.1016/j.bcp.2010.06.039; Ding LL, 2012, MED ONCOL, V29, P1758, DOI 10.1007/s12032-011-0042-6; DUNNE J, 1995, GENOMICS, V30, P207, DOI 10.1006/geno.1995.9884; Eberstal S, 2012, CANCER IMMUNOL IMMUN, V61, P1191, DOI 10.1007/s00262-011-1196-y; Fleenor DL, 2003, INVEST OPHTH VIS SCI, V44, P3494, DOI 10.1167/iovs.02-0757; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gao F, 2007, ONCOL REP, V17, P123; Gao F, 2009, J CELL MOL MED, V13, P4257, DOI 10.1111/j.1582-4934.2008.00497.x; Garodia Prachi, 2007, J Soc Integr Oncol, V5, P25, DOI 10.2310/7200.2006.029; Gaur AB, 2011, NEURO-ONCOLOGY, V13, P580, DOI 10.1093/neuonc/nor033; Goldbrunner RH, 1998, MICROSC RES TECHNIQ, V43, P250, DOI 10.1002/(SICI)1097-0029(19981101)43:3<250::AID-JEMT7>3.0.CO;2-C; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Grivennikov SI, 2010, CURR OPIN GENET DEV, V20, P65, DOI 10.1016/j.gde.2009.11.004; Hara A, 2004, ACTA NEUROPATHOL, V108, P43, DOI 10.1007/s00401-004-0860-0; Harris Randall E, 2007, Subcell Biochem, V42, P193; Harris Randall E, 2007, Subcell Biochem, V42, P93; Harris RE, 2007, INT J BIOL SCI, V3, P328; Herseth JI, 2009, TOXICOL IN VITRO, V23, P1342, DOI 10.1016/j.tiv.2009.06.031; Hou R, 2006, J CELL BIOL, V173, P417, DOI 10.1083/jcb.200508121; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Joki T, 2000, CANCER RES, V60, P4926; Karamouzis MV, 2007, MOL CANCER RES, V5, P109, DOI 10.1158/1541-7786.MCR-06-0311; Katoh Y, 2006, INT J MOL MED, V18, P523; Krakauer Teresa, 2004, Current Drug Targets - Inflammation and Allergy, V3, P317; Kwaepila N, 2006, PATHOLOGY, V38, P125, DOI 10.1080/00313020600559975; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; Lankat-Buttgereit B, 2009, BIOL CELL, V101, P309, DOI 10.1042/BC20080191; Leaner VD, 2003, ONCOGENE, V22, P5619, DOI 10.1038/sj.onc.1206644; Leaner VD, 2009, AM J PATHOL, V174, P265, DOI 10.2353/ajpath.2009.071006; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Lim SK, 2011, BMB REP, V44, P158, DOI 10.5483/BMBRep.2011.44.3.158; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Mandal RK, 2011, ARCH MED RES, V42, P620, DOI 10.1016/j.arcmed.2011.10.005; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mao YP, 2006, DEVELOPMENT, V133, P2539, DOI 10.1242/dev.02427; Moeller MJ, 2004, EMBO J, V23, P3769, DOI 10.1038/sj.emboj.7600380; Moore MM, 2010, CLIN PHARMACOL THER, V87, P504, DOI 10.1038/clpt.2009.254; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Munshi A., 2009, Indian Journal of Cancer, V46, P127, DOI 10.4103/0019-509X.49150; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Nakaya K, 2007, ONCOGENE, V26, P5300, DOI 10.1038/sj.onc.1210330; New Pamela, 2004, Cancer Control, V11, P152; Nieves-Alicea R, 2009, BREAST CANCER RES TR, V114, P203, DOI 10.1007/s10549-008-9993-5; Nishikawa Y, 2011, ONCOL REP, V26, P587, DOI 10.3892/or.2011.1324; Noble M, 1997, J NEURO-ONCOL, V35, P193, DOI 10.1023/A:1005898228116; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974; Santhanam AN, 2010, ONCOGENE, V29, P3921, DOI 10.1038/onc.2010.158; Sareddy GR, 2012, J NEURO-ONCOL, V106, P99, DOI 10.1007/s11060-011-0662-x; Schmid T, 2011, CARCINOGENESIS, V32, P1427, DOI 10.1093/carcin/bgr131; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; Sen E, 2011, DRUG DISCOV TODAY, V16, P1044, DOI 10.1016/j.drudis.2011.09.003; Sharma V, 2011, NEUROCHEM INT, V59, P567, DOI 10.1016/j.neuint.2011.06.018; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shono T, 2001, CANCER RES, V61, P4375; Silva E, 2006, CURR BIOL, V16, P2081, DOI 10.1016/j.cub.2006.09.004; Sinha S, 2011, CELL SIGNAL, V23, P1869, DOI 10.1016/j.cellsig.2011.06.024; Subbaramaiah K, 2002, CANCER RES, V62, P2522; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Tafani M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-32; Tanoue T, 2005, J CELL SCI, V118, P2347, DOI 10.1242/jcs.02398; Tanoue T, 2004, J CELL BIOL, V165, P517, DOI 10.1083/jcb.200403006; Teodorczyk M, 2010, J CELL PHYSIOL, V222, P1, DOI 10.1002/jcp.21901; Tewari R, 2012, J MOL MED, V90, P67, DOI 10.1007/s00109-011-0807-6; Tsuji F, 2007, INT IMMUNOPHARMACOL, V7, P1569, DOI 10.1016/j.intimp.2007.07.020; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Wang WQ, 2010, MOL DIAGN THER, V14, P155, DOI 10.2165/11536340-000000000-00000; Wang XY, 2008, ANTICANCER RES, V28, P2991; Waters LC, 2011, J BIOL CHEM, V286, P17270, DOI 10.1074/jbc.M110.166157; Wei ZT, 2009, CANCER SCI, V100, P1408, DOI 10.1111/j.1349-7006.2009.01210.x; Wen YH, 2007, ONCOL REP, V18, P1387; Willecke M, 2006, CURR BIOL, V16, P2090, DOI 10.1016/j.cub.2006.09.005; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yasuda M, 2010, MOL CARCINOGEN, V49, P837, DOI 10.1002/mc.20660; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588	104	44	48	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3798	3808		10.1038/onc.2012.393	http://dx.doi.org/10.1038/onc.2012.393			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22986533				2022-12-28	WOS:000323210200002
J	Gujral, TS; Karp, RL; Finski, A; Chan, M; Schwartz, PE; MacBeath, G; Sorger, P				Gujral, T. S.; Karp, R. L.; Finski, A.; Chan, M.; Schwartz, P. E.; MacBeath, G.; Sorger, P.			Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays	ONCOGENE			English	Article						reverse-phase protein arrays; breast cancer; tumor lysate; cell signaling; MET; AXL	C-MET; HGF TRANSCRIPTION; AXL; RECEPTOR; PATHWAYS; METASTASIS; RESISTANCE; DISCOVERY; SURVIVAL; KINASE	Measuring the states of cell signaling pathways in tumor samples promises to advance the understanding of oncogenesis and identify response biomarkers. Here, we describe the use of Reverse Phase Protein Arrays (RPPAs or RPLAs) to profile signaling proteins in 56 breast cancers and matched normal tissue. In RPPAs, hundreds to thousands of lysates are arrayed in dense regular grids and each grid is probed with a different antibody (100 in the current work, of which 71 yielded strong signals with breast tissue). Although RPPA technology is quite widely used, measuring changes in phosphorylation reflective of protein activation remains challenging. Using repeat deposition and well-validated antibodies, we show that diverse patterns of phosphorylation can be monitored in tumor samples and changes mapped onto signaling networks in a coherent fashion. The patterns are consistent with biomarker-based classification of breast cancers and known mechanisms of oncogenesis. We explore in detail one tumor-associated pattern that involves changes in the abundance of the Axl receptor tyrosine kinase (RTK) and phosphorylation of the cMet RTK. Both cMet and Axl have been implicated in breast cancer, or in resistance to anticancer drugs, but the two RTKs are not known to be linked functionally. Protein depletion and overexpression studies in a 'triple-negative' breast cell line reveal cross talk between Axl and cMet involving Axl-mediated modification of cMet, a requirement for cMet in efficient and timely signal transduction by the Axl ligand Gas6 and the potential for the two receptors to interact physically. These findings have potential therapeutic implications, as they imply that bi-specific receptor inhibitors (for example, ATP-competitive small-kinase inhibitors such as GSK1363089, BMS-777607 or MP470) may be more efficacious than the mono-specific therapeutic antibodies currently in development (for example, Onartuzumab).	[Gujral, T. S.; Karp, R. L.; Finski, A.; Chan, M.; MacBeath, G.; Sorger, P.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; [Gujral, T. S.; MacBeath, G.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; [Finski, A.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Schwartz, P. E.] Prot Biotechnol Inc, Ramona, CA USA	Harvard University; Harvard Medical School; Harvard University; Harvard University	MacBeath, G (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, WAB 438,200 Longwood Ave, Boston, MA 02115 USA.	gavin_macbeath@hms.harvard.edu; peter_sorger@hms.harvard.edu		Sorger, Peter/0000-0002-3364-1838; Gujral, Taran/0000-0002-4453-3031	National Institutes of Health [R33 CA128726, R21 CA126720, 5RC1-HG005354]; Stand Up to Cancer Project [AACR-SU2C-DT0409]; NSF [0856285]; NATIONAL CANCER INSTITUTE [R21CA126720, R33CA128726] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [RC1HG005354] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stand Up to Cancer Project; NSF(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was supported by grants from the National Institutes of Health (R33 CA128726, R21 CA126720, and 5RC1-HG005354) and from the Stand Up to Cancer Project (AACR-SU2C-DT0409). TSG is a Human Frontier Science Program Fellow. RLK is partially supported by NSF 0856285. Supplementary Information accompanies the paper on the Oncogene website.	Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bowers PM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r35; Burstein HJ, 2003, J CLIN ONCOL, V21, P2889, DOI 10.1200/JCO.2003.02.018; Carey MS, 2010, CLIN CANCER RES, V16, P2852, DOI 10.1158/1078-0432.CCR-09-2502; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goentoro L, 2009, MOL CELL, V36, P872, DOI 10.1016/j.molcel.2009.11.017; Gonzalez-Angulo Ana M, 2011, Clin Proteomics, V8, P11, DOI 10.1186/1559-0275-8-11; Grubb RL, 2003, PROTEOMICS, V3, P2142, DOI 10.1002/pmic.200300598; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; ISOLA JJ, 1993, J PATHOL, V170, P31, DOI 10.1002/path.1711700106; Janes KA, 2008, CELL, V135, P343, DOI 10.1016/j.cell.2008.08.034; Jiang RC, 2006, PROTEOMICS, V6, P2964, DOI 10.1002/pmic.200500555; Kataoka Y, 2012, INVEST NEW DRUG, V30, P1352, DOI 10.1007/s10637-011-9699-0; Kolch W, 2010, NAT REV CANCER, V10, P618, DOI 10.1038/nrc2900; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Lim CT, 2007, BIOSENS BIOELECTRON, V22, P1197, DOI 10.1016/j.bios.2006.06.005; Lin Y, 2003, CLIN CHEM LAB MED, V41, P139, DOI 10.1515/CCLM.2003.023; Liu GG, 2010, ADV EXP MED BIOL, V680, P253, DOI 10.1007/978-1-4419-5913-3_29; Luckert K, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002372; Mackiewicz M, 2011, BREAST CANCER RES TR, V130, P663, DOI 10.1007/s10549-011-1690-0; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Makretsov NA, 2004, CLIN CANCER RES, V10, P6143, DOI 10.1158/1078-0432.CCR-04-0429; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Menashe I, 2010, CANCER RES, V70, P4453, DOI 10.1158/0008-5472.CAN-09-4502; Mood K, 2006, MOL BIOL CELL, V17, P3717, DOI 10.1091/mbc.E06-03-0244; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Nanjundan M, 2010, J THORAC ONCOL, V5, P1894, DOI 10.1097/JTO.0b013e3181f2a266; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Pe'er D, 2011, CELL, V144, P864, DOI 10.1016/j.cell.2011.03.001; Previdi S, 2012, MOL CANCER THER, V11, P214, DOI 10.1158/1535-7163.MCT-11-0277; Sam MR, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-69; Sevecka M, 2006, NAT METHODS, V3, P825, DOI 10.1038/nmeth931; Sevecka M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005363; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spruessel A, 2004, BIOTECHNIQUES, V36, P1030, DOI 10.2144/04366RR04; Storey John D, 2003, Methods Mol Biol, V224, P149; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Underiner TL, 2010, ANTI-CANCER AGENT ME, V10, P7, DOI 10.2174/1871520611009010007; VanMeter A, 2007, EXPERT REV MOL DIAGN, V7, P625, DOI 10.1586/14737159.7.5.625; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wojcik EJ, 2006, ONCOGENE, V25, P2773, DOI 10.1038/sj.onc.1209306; Yeh CY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-139; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	54	54	56	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2013	32	29					3470	3476		10.1038/onc.2012.378	http://dx.doi.org/10.1038/onc.2012.378			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22945653	Green Accepted			2022-12-28	WOS:000322014900008
J	Umezu, T; Ohyashiki, K; Kuroda, M; Ohyashiki, JH				Umezu, T.; Ohyashiki, K.; Kuroda, M.; Ohyashiki, J. H.			Leukemia cell to endothelial cell communication via exosomal miRNAs	ONCOGENE			English	Article						exosomal miRNAs; cell-to-cell communication; endothelial migration; tube formation	BONE MORPHOGENETIC PROTEINS; MICRORNAS; EXPRESSION; ANGIOGENESIS; MECHANISM; NOTCH; DICER; FATE	Recent findings indicate that specific microRNAs (miRNAs), such as those of the miR-17-92 cluster, may be responsible for regulating endothelial gene expression during tumor angiogenesis. Secreted miRNAs enclosed in exosomes also have an important role in cell-cell communication. To elucidate whether miRNAs secreted from neoplastic cells transfer into endothelial cells and are functionally active in the recipient cells, we investigated the effect of exosomal miRNAs derived from leukemia cells (K562) on human umbilical vein endothelial cells (HUVECs). As K562 cells released the miR-17-92 cluster, especially miR-92a, into the extracellular environment, K562 cells, transfected with Cy3-labeled pre-miR-92a, were co-cultured with HUVECs. Cy3-miR-92a derived from K562 cells was detected in the cytoplasm of HUVECs, and the Cy3-miR-92a co-localized with the signals of an exosomal marker, CD63. The expression of integrin alpha 5, a target gene for miR-92a, was significantly reduced in HUVECs by exosomal miR-92a, indicating that exogenous miRNA via exosomal transport can function like endogenous miRNA in HUVECs. The most salient feature of this study is the exosome, derived from K562 cells with enforced miR-92a expression, did not affect the growth of HUVECs but did enhance endothelial cell migration and tube formation. Our results support the idea that exosomal miRNAs have an important role in neoplasia-to-endothelial cell communication.	[Umezu, T.; Ohyashiki, K.] Tokyo Med Univ, Dept Mol Sci, Tokyo 1600023, Japan; [Ohyashiki, K.] Tokyo Med Univ, Dept Internal Med 1, Tokyo 1600023, Japan; [Kuroda, M.] Tokyo Med Univ, Dept Mol Pathol, Tokyo 1600023, Japan; [Ohyashiki, J. H.] Tokyo Med Univ, Inst Med Sci, Tokyo 1600023, Japan	Tokyo Medical University; Tokyo Medical University; Tokyo Medical University; Tokyo Medical University	Umezu, T (corresponding author), Tokyo Med Univ, Dept Mol Sci, Shinjuku Ku, 6-7-1 Nishi Shinjuku, Tokyo 1600023, Japan.	t_umezu@tokyo-med.ac.jp	Umezu, Tomohiro/AAK-9711-2020	Umezu, Tomohiro/0000-0002-0123-8921	Private University Strategic Research-Based Support Project: Epigenetics Research Project Aimed at General Cancer Cure Using Epigenetic Targets from MEXT (Ministry of Education, Culture, Sports, Science and Technology), Tokyo, Japan; Grants-in-Aid for Scientific Research [23659626] Funding Source: KAKEN	Private University Strategic Research-Based Support Project: Epigenetics Research Project Aimed at General Cancer Cure Using Epigenetic Targets from MEXT (Ministry of Education, Culture, Sports, Science and Technology), Tokyo, Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Private University Strategic Research-Based Support Project: Epigenetics Research Project Aimed at General Cancer Cure Using Epigenetic Targets from MEXT (Ministry of Education, Culture, Sports, Science and Technology), Tokyo, Japan.	Anand S, 2011, CURR OPIN HEMATOL, V18, P171, DOI 10.1097/MOH.0b013e328345a180; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; CABRERA CV, 1990, DEVELOPMENT, V110, P733; Chen AL, 2004, J ORTHOP RES, V22, P1188, DOI 10.1016/j.orthres.2004.02.013; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Ebara S, 2002, SPINE, V27, pS10, DOI 10.1097/00007632-200208151-00004; Heusschen R, 2010, BBA-REV CANCER, V1805, P87, DOI 10.1016/j.bbcan.2009.09.005; Iguchi Haruhisa, 2010, Commun Integr Biol, V3, P478, DOI 10.4161/cib.3.5.12693; Kishimoto Y, 1997, DEVELOPMENT, V124, P4457; Kosaka N, 2012, J BIOL CHEM, V287, P1397, DOI 10.1074/jbc.M111.288662; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916; Lewis J, 1998, SEMIN CELL DEV BIOL, V9, P583, DOI 10.1006/scdb.1998.0266; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Ohyashiki Junko H, 2010, BMC Res Notes, V3, P347, DOI 10.1186/1756-0500-3-347; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Otsuka M, 2008, J CLIN INVEST, V118, P1944, DOI 10.1172/JCI33680; Scott WJ, 2005, REPROD TOXICOL, V19, P479, DOI 10.1016/j.reprotox.2004.11.013; Suarez Y, 2008, P NATL ACAD SCI USA, V105, P14082, DOI 10.1073/pnas.0804597105; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010	25	341	366	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2747	2755		10.1038/onc.2012.295	http://dx.doi.org/10.1038/onc.2012.295			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22797057				2022-12-28	WOS:000319808000006
J	Choi, JD; Ryu, M; Park, MA; Jeong, G; Lee, JS				Choi, J. D.; Ryu, M.; Park, M. Ae; Jeong, G.; Lee, J-S			FIP200 inhibits beta-catenin-mediated transcription by promoting APC-independent beta-catenin ubiquitination	ONCOGENE			English	Article						FIP200; beta-catenin; ubiquitination	BINDING MOTIF; PROTEIN; COMPLEX; RB1CC1; PHOSPHORYLATION; IDENTIFICATION; DEGRADATION; SUPPRESSION; MODULATION; MUTATIONS	Focal adhesion kinase-family-interacting protein of 200 kDa (FIP200) has been shown to regulate multiple cellular functions, including cell adhesion, autophagy, development and proliferation. Furthermore, FIP200 is considered to have tumor-suppressive activity, which may be correlated with its inactivation in human breast cancers, in addition to its role as an important signal transduction node. Herein, we report that FIP200 interacts with the oncoprotein beta-catenin. Moreover, FIP200 promotes destabilization of wild-type beta-catenin, but not a cancer-causing form of beta-catenin, and as a result represses the beta-catenin-mediated transcription. FIP200-induced degradation of beta-catenin is independent of adenomatous polyposis coli (APC) of the well-established beta-catenin destruction complex (glycogen synthase kinase-3b/axin/APC), in a component of beta-catenin E3 ubiquitin ligase, beta-TrCP-dependent manner. Thus, the APC-independent beta-catenin degradation by FIP200 suggests a role for FIP200 in tumor suppression in the presence of APC dysfunction. These findings reveal a new and important function of FIP200 in regulation of the Wnt/beta-catenin pathway.	[Choi, J. D.; Ryu, M.; Park, M. Ae; Lee, J-S] Ajou Univ, Coll Nat Sci, Dept Mol Sci & Technol, Suwon 443749, South Korea; [Choi, J. D.] Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea	Ajou University; Seoul National University (SNU)	Lee, JS (corresponding author), Ajou Univ, Coll Nat Sci, Dept Mol Sci & Technol, Wonchun Dong 5, Suwon 443749, South Korea.	jsjlee@ajou.ac.kr			National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea [1020210]; National Research Foundation of Korea [313-2008-2-C00626, 2009-0074556, 2010-0018546, 20110030830]	National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1020210) and the National Research Foundation of Korea (313-2008-2-C00626, 2009-0074556, 2010-0018546 and 20110030830).	Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; Bae H, 2011, MOL CANCER RES, V9, P1232, DOI 10.1158/1541-7786.MCR-11-0098; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bonvini P, 2000, BBA-MOL CELL RES, V1495, P308, DOI 10.1016/S0167-4889(99)00162-7; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chano T, 2002, GENE, V291, P29, DOI 10.1016/S0378-1119(02)00585-1; Chano T, 2002, NAT GENET, V31, P285, DOI 10.1038/ng911; Chano T, 2002, ONCOGENE, V21, P1295, DOI 10.1038/sj.onc.1205178; Chano T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011404; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; Gan B, 2008, CELL SIGNAL, V20, P787, DOI 10.1016/j.cellsig.2007.10.021; Gan BY, 2006, J CELL BIOL, V175, P121, DOI 10.1083/jcb.200604129; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200; Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hofmann K, 2009, DNA REPAIR, V8, P544, DOI 10.1016/j.dnarep.2009.01.003; Jang ER, 2011, FEBS LETT, V585, P47, DOI 10.1016/j.febslet.2010.11.034; Koinuma D, 2011, J BIOL CHEM, V286, P32502, DOI 10.1074/jbc.M111.227561; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liang CC, 2010, J BIOL CHEM, V285, P3499, DOI 10.1074/jbc.M109.072389; Liu F, 2010, BLOOD, V116, P4806, DOI 10.1182/blood-2010-06-288589; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Martin N, 2008, MOL CELL BIOL, V28, P2771, DOI 10.1128/MCB.01210-07; Melkoumian ZK, 2005, CANCER RES, V65, P6676, DOI 10.1158/0008-5472.CAN-04-4142; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Park MA, 2008, NUCLEIC ACIDS RES, V36, P263, DOI 10.1093/nar/gkm969; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 2000, GENE DEV, V14, P1837; Sabbioneda S, 2009, P NATL ACAD SCI USA, V106, pE20, DOI 10.1073/pnas.0812744106; Sukhdeo K, 2012, LEUKEMIA, V26, P1116, DOI 10.1038/leu.2011.303; Ueda H, 2000, J CELL BIOL, V149, P423, DOI 10.1083/jcb.149.2.423; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Wei HJ, 2009, J BIOL CHEM, V284, P6004, DOI 10.1074/jbc.M806375200; Wood A, 2007, J BIOL CHEM, V282, P20256, DOI 10.1074/jbc.M702366200; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200	43	7	7	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2421	2432		10.1038/onc.2012.262	http://dx.doi.org/10.1038/onc.2012.262			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751121				2022-12-28	WOS:000318694900006
J	Gomez-Casares, MT; Garcia-Alegria, E; Lopez-Jorge, CE; Ferrandiz, N; Blanco, R; Alvarez, S; Vaque, JP; Bretones, G; Caraballo, JM; Sanchez-Bailon, P; Delgado, MD; Martin-Perez, J; Cigudosa, JC; Leon, J				Gomez-Casares, M. T.; Garcia-Alegria, E.; Lopez-Jorge, C. E.; Ferrandiz, N.; Blanco, R.; Alvarez, S.; Vaque, J. P.; Bretones, G.; Caraballo, J. M.; Sanchez-Bailon, P.; Delgado, M. D.; Martin-Perez, J.; Cigudosa, J. C.; Leon, J.			MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1)	ONCOGENE			English	Article						Myc; imatinib; dasatinib; p27; chronic myeloid leukemia; differentiation	DEPENDENT KINASE INHIBITOR; BCR-ABL; C-MYC; ERYTHROID-DIFFERENTIATION; DEGRADATION; P27; EXPRESSION; MECHANISMS; SKP2; ASSOCIATION	Chronic myeloid leukemia (CML) progresses from a chronic to a blastic phase where the leukemic cells are proliferative and undifferentiated. The CML is nowadays successfully treated with BCR-ABL kinase inhibitors as imatinib and dasatinib. In the CML-derived K562 cell line, low concentrations of imatinib induce proliferative arrest and erythroid differentiation. We found that imatinib upregulated the cell cycle inhibitor p27(KIP1) (p27) in a time- and -concentration dependent manner, and that the extent of imatinib-mediated differentiation was severely decreased in cells with depleted p27. MYC (c-Myc) is a transcription factor frequently deregulated in human cancer. MYC is overexpressed in untreated CML and is associated to poor response to imatinib. Using K562 sublines with conditional MYC expression (induced by Zn2+ or activated by 4-hydroxy-tamoxifen) we show that MYC prevented the erythroid differentiation induced by imatinib and dasatinib. The differentiation inhibition is not due to increased proliferation of MYC-expressing clones or enhanced apoptosis of differentiated cells. As p27 overexpression is reported to induce erythroid differentiation in K562, we explored the effect of MYC on imatinib-dependent induction of p27. We show that MYC abrogated the imatinib-induced upregulation of p27 concomitantly with the differentiation inhibition, suggesting that MYC inhibits differentiation by antagonizing the imatinib-mediated upregulation of p27. This effect occurs mainly by p27 protein destabilization. This was in part due to MYC-dependent induction of SKP2, a component of the ubiquitin ligase complex that targets p27 for degradation. The results suggest that, although MYC deregulation does not directly confer resistance to imatinib, it might be a factor that contributes to progression of CML through the inhibition of differentiation. Oncogene (2013) 32, 2239-2246; doi:10.1038/onc.2012.246; published online 18 June 2012	[Gomez-Casares, M. T.; Lopez-Jorge, C. E.] Hosp Univ Dr Negrin, Serv Hematol, Las Palmas Gran Canaria, Spain; [Gomez-Casares, M. T.; Lopez-Jorge, C. E.] Hosp Univ Dr Negrin, Unidad Invest, Las Palmas Gran Canaria, Spain; [Garcia-Alegria, E.; Ferrandiz, N.; Blanco, R.; Vaque, J. P.; Bretones, G.; Caraballo, J. M.; Delgado, M. D.; Leon, J.] Univ Cantabria CSIC SODERCAN, Inst Biomed & Biotecnol Cantabria IBBTEC, Grp Transcript Control & Canc, Dept Biol Mol,Fac Med, Santander 39011, Cantabria, Spain; [Alvarez, S.; Cigudosa, J. C.] CNIO, Human Canc Genet Program, Madrid, Spain; [Sanchez-Bailon, P.; Martin-Perez, J.] CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Leon, J (corresponding author), Univ Cantabria CSIC SODERCAN, Inst Biomed & Biotecnol Cantabria IBBTEC, Grp Transcript Control & Canc, Dept Biol Mol,Fac Med, Avda Cardenal Herrera Oria S-N, Santander 39011, Cantabria, Spain.	leonj@unican.es	Cigudosa, Juan C/E-4105-2016; CASARES, MARIA TERESA GOMEZ/R-6060-2018; Ferrandiz-Diaz, Nuria/V-4071-2017; Vaqué, José P/H-8413-2015; Bretones, Gabriel/AAB-4637-2021; ALEGRIA, EVA GARCIA/O-3498-2018; Leon, Javier/K-4615-2014; Martin-Perez, Jorge/A-3522-2008; Delgado, M. Dolores/K-9056-2014	CASARES, MARIA TERESA GOMEZ/0000-0003-0505-5126; Ferrandiz-Diaz, Nuria/0000-0002-7410-3470; Vaqué, José P/0000-0002-3913-2495; Bretones, Gabriel/0000-0002-1521-5544; ALEGRIA, EVA GARCIA/0000-0003-4159-0206; Martin-Perez, Jorge/0000-0002-2292-0057; Leon, Javier/0000-0001-5803-0112; Delgado, M. Dolores/0000-0003-4682-4040	Fundacion Mutua Madrilena;  [SAF11-23796];  [ISCIII-RETIC RD06/0020/0017];  [FIS 11/00397];  [SAF09-09254];  [FIS08-0878];  [FIS08-0440]	Fundacion Mutua Madrilena(Instituto de Salud Carlos III); ; ; ; ; ; 	We thank Pilar Frade, Maria Aramburu and Guillermo Santana for technical assistance, Robert Eisenman, Theodore Lee and Robert Sclafani for constructs, and M Teresa Molero and Carlos Richard for useful comments on the manuscript. Funding for this work was provided by grants SAF11-23796 and ISCIII-RETIC RD06/0020/0017 to JL, FIS 11/00397 to MDD, SAF09-09254 and Fundacion Mutua Madrilena to JMP, FIS08-0878 to SA and FIS08-0440 to JCC.	Acosta JC, 2008, MOL CELL BIOL, V28, P7286, DOI 10.1128/MCB.00752-08; Agarwal A, 2008, BLOOD, V112, P1960, DOI 10.1182/blood-2007-09-113860; Albajar M, 2008, CANCER LETT, V270, P328, DOI 10.1016/j.canlet.2008.05.024; Albajar M, 2011, MOL CANCER RES, V9, P564, DOI 10.1158/1541-7786.MCR-10-0356; Andreu EJ, 2005, CANCER RES, V65, P3264, DOI 10.1158/0008-5472.CAN-04-1357; Bretones G, 2011, J BIOL CHEM, V286, P9815, DOI 10.1074/jbc.M110.165977; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen JY, 2009, LEUKEMIA RES, V33, P1520, DOI 10.1016/j.leukres.2009.03.007; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; DELGADO MD, 1995, ONCOGENE, V10, P1659; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Gomez-Casares MT, 2004, HAEMATOLOGICA, V89, P241; GOMEZCASARES MT, 1993, LEUKEMIA, V7, P1824; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kantarjian HM, 2011, CLIN CANCER RES, V17, P1674, DOI 10.1158/1078-0432.CCR-10-2922; Kavalerchik E, 2008, J CLIN ONCOL, V26, P2911, DOI 10.1200/JCO.2008.17.5745; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Leon J, 2009, CELL CYCLE, V8, P1148, DOI 10.4161/cc.8.8.8126; Lerga A, 1999, CELL GROWTH DIFFER, V10, P639; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Munoz-Alonso MJ, 2005, J BIOL CHEM, V280, P18120, DOI 10.1074/jbc.M500758200; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Dwyer ME, 2002, ANNU REV MED, V53, P369, DOI 10.1146/annurev.med.53.082901.103853; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; Roy S, 2008, CELL CYCLE, V7, P1828, DOI 10.4161/cc.7.12.6024; Rubbi L, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001314; Savona M, 2008, NAT REV CANCER, V8, P341, DOI 10.1038/nrc2368; Schenone S, 2010, EXPERT OPIN INV DRUG, V19, P931, DOI 10.1517/13543784.2010.499898; Shah NP, 2008, CANCER CELL, V14, P485, DOI 10.1016/j.ccr.2008.11.001; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wu J, 2008, J NATL CANCER I, V100, P926, DOI 10.1093/jnci/djn188	47	47	48	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2239	2246		10.1038/onc.2012.246	http://dx.doi.org/10.1038/onc.2012.246			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22710719				2022-12-28	WOS:000318062800013
J	Cai, Q; Lin, T; Kamarajugadda, S; Lu, J				Cai, Q.; Lin, T.; Kamarajugadda, S.; Lu, J.			Regulation of glycolysis and the Warburg effect by estrogen-related receptors	ONCOGENE			English	Article						aerobic glycolysis; Warburg effect; nuclear receptor; Randle cycle	PYRUVATE-DEHYDROGENASE KINASE; CANCER-CELL METABOLISM; PDK4 GENE-EXPRESSION; TRANSCRIPTIONAL CONTROL; ERR-ALPHA; HYPOXIA; MYC; SWITCH; PGC-1-ALPHA; ADAPTATION	Cancer cells typically display altered glucose metabolism characterized by a preference of aerobic glycolysis, known as the Warburg effect, which facilitates cell proliferation. Hypoxia-inducible factor (HIF) and oncoprotein Myc are two prominent transcription factors that drive glycolysis. Previously, we reported that the estrogen-related receptors (ERRs) act as cofactors of HIF and enhance HIF-dependent transcription of glycolytic genes under hypoxia. ERRs are orphan nuclear receptors and key regulators of energy metabolism by orchestrating mitochondrial biogenesis, fatty acid oxidation (FAO) and oxidative phosphorylation. Here, we show that ERRs also stimulate glycolysis under normoxia. ERRs directly bind to and activate promoters of many genes encoding glycolytic enzymes, and the ERR-binding sites in such promoters are essential for ERR-mediated transcriptional activation. ERRs interact with Myc, and the two factors synergistically activate transcription of glycolytic genes. Furthermore, overexpression of ERRs increases glycolytic gene expression and lactate production. Conversely, depletion of ERRs in cancer cells reduces expression of glycolytic genes and glucose uptake, resulting in decreased aerobic glycolysis and cell growth. Taken together, these results suggest that ERRs are important transcriptional activators of the glycolytic pathway and contribute to the Warburg effect in cancer cells. Oncogene (2013) 32, 2079-2086; doi:10.1038/onc.2012.221; published online 4 June 2012	[Cai, Q.; Lin, T.; Kamarajugadda, S.; Lu, J.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Lu, J (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, POB 103633, Gainesville, FL 32610 USA.	jrlu@ufl.edu	Cai, Qingsong/J-6428-2012; Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040	National Cancer Institute [R01CA137021]; Florida Bankhead-Coley Cancer Research Program [09BN-12-23092, 2BT01]; NATIONAL CANCER INSTITUTE [R01CA137021] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Florida Bankhead-Coley Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Cancer Institute (R01CA137021) and Florida Bankhead-Coley Cancer Research Program (09BN-12-23092 and 2BT01).	Ao A, 2008, P NATL ACAD SCI USA, V105, P7821, DOI 10.1073/pnas.0711677105; Araki M, 2006, FEBS J, V273, P1669, DOI 10.1111/j.1742-4658.2006.05183.x; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203, DOI 10.2174/1568026610606030203; Chang CY, 2011, CANCER CELL, V20, P500, DOI 10.1016/j.ccr.2011.08.023; Charest-Marcotte A, 2010, GENE DEV, V24, P537, DOI 10.1101/gad.1871610; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Deblois G, 2009, CANCER RES, V69, P6149, DOI 10.1158/0008-5472.CAN-09-1251; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hue L, 2009, AM J PHYSIOL-ENDOC M, V297, pE578, DOI 10.1152/ajpendo.00093.2009; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Semenza GL, 2011, BBA-MOL CELL RES, V1813, P1263, DOI 10.1016/j.bbamcr.2010.08.006; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Stein RA, 2008, CANCER RES, V68, P8805, DOI 10.1158/0008-5472.CAN-08-1594; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tennessen JM, 2011, CELL METAB, V13, P139, DOI 10.1016/j.cmet.2011.01.005; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Zhang Y, 2006, J BIOL CHEM, V281, P39897, DOI 10.1074/jbc.M608657200	34	65	66	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2079	2086		10.1038/onc.2012.221	http://dx.doi.org/10.1038/onc.2012.221			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22665055	Green Accepted			2022-12-28	WOS:000317919900009
J	Sakamoto, K; Hikiba, Y; Nakagawa, H; Hirata, Y; Hayakawa, Y; Kinoshita, H; Nakata, W; Sakitani, K; Takahashi, R; Akanuma, M; Kamata, H; Maeda, S				Sakamoto, K.; Hikiba, Y.; Nakagawa, H.; Hirata, Y.; Hayakawa, Y.; Kinoshita, H.; Nakata, W.; Sakitani, K.; Takahashi, R.; Akanuma, M.; Kamata, H.; Maeda, S.			Promotion of DNA repair by nuclear IKK beta phosphorylation of ATM in response to genotoxic stimuli	ONCOGENE			English	Article						IKK beta; ATM; NF-kappa B; DNA damage	NF-KAPPA-B; ACTIVATION IN-VIVO; DAMAGE RESPONSE; KINASE IKK; AUTOPHOSPHORYLATION SITES; ATAXIA-TELANGIECTASIA; MASS-SPECTROMETRY; STRAND BREAKS; STRESS; CANCER	Ataxia-telangiectasia mutated (ATM) is one of the key molecules involved in the cellular response to DNA damage. A portion of activated ATM is exported from the nucleus into the cytoplasm, where it activates the I kappa B kinase/nuclear factor kappa B (IKK/NF-kappa B) signaling pathway. It has been thought that activated IKK beta, which is a critical kinase for NF-kappa B activation, generally resides in the cytoplasm and phosphorylates cytoplasmic downstream molecules, such as IkB alpha. Here, we identified a new role for IKK beta during the response to DNA damage. ATM phosphorylation in response to alkylating agents consisted of two phases: the early phase (up to 3 h) and late phase (after 6 h). A portion of the activated IKK beta generated during the DNA damage response was found to translocate into the nucleus and directly phosphorylate ATM in the late phase. Furthermore, the phosphorylation of ATM by nuclear IKK beta was suggested to promote DNA repair. In parallel, activated IKK beta induced classical NF-kappa B activation and was involved in anti-apoptosis. Our findings define the function of IKK beta during the response to DNA damage, which promotes cell survival and DNA repair, and maintains cellular homeostasis. Oncogene (2013) 32, 1854-1862; doi: 10.1038/onc.2012.192; published online 21 May 2012	[Sakamoto, K.; Hikiba, Y.; Akanuma, M.] Asahi Life Fdn, Inst Adult Dis, Div Gastroenterol, Tokyo, Japan; [Nakagawa, H.; Hirata, Y.; Hayakawa, Y.; Kinoshita, H.; Nakata, W.; Sakitani, K.; Takahashi, R.] Univ Tokyo, Dept Gastroenterol, Tokyo, Japan; [Kamata, H.] Hiroshima Univ, Grad Sch Biomed Sci, Lab Biomed Chem, Dept Mol Med Sci, Hiroshima, Japan; [Maeda, S.] Yokohama City Univ, Dept Gastroenterol, Yokohama, Kanagawa 2360004, Japan	Asahi Life Foundation; University of Tokyo; Hiroshima University; Yokohama City University	Maeda, S (corresponding author), Yokohama City Univ, Dept Gastroenterol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	shinmaeda2-gi@umin.ac.jp	Kamata, Hideaki/N-3907-2017; Nakagawa, Hayato/I-2837-2012; Hayakawa, Yoku/AAI-8581-2020	Nakagawa, Hayato/0000-0002-6973-5094; Hayakawa, Yoku/0000-0002-3988-2499; Sakitani, Kosuke/0000-0002-4537-6023	Ministry of Education, Culture, Sports, Science and Technology of Japan [22300317]; Naito Foundation; Grants-in-Aid for Scientific Research [22300317] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Naito Foundation(Naito Memorial Foundation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Dr Yosef Shiloh for providing us with the ATM-encoding plasmid. SM was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (22300317) and Naito Foundation.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; CHAN JYH, 1983, CARCINOGENESIS, V4, P1097, DOI 10.1093/carcin/4.9.1097; Chou WC, 2008, EMBO J, V27, P3140, DOI 10.1038/emboj.2008.229; Daniel JA, 2008, J CELL BIOL, V183, P777, DOI 10.1083/jcb.200805154; Debiak M, 2004, DNA REPAIR, V3, P359, DOI 10.1016/j.dnarep.2003.11.013; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Golding SE, 2009, MOL CANCER THER, V8, P2894, DOI 10.1158/1535-7163.MCT-09-0519; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; Hayakawa Y, 2009, J GASTROENTEROL, V44, P935, DOI 10.1007/s00535-009-0098-7; Hegde ML, 2008, CELL RES, V18, P27, DOI 10.1038/cr.2008.8; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Hirata Y, 2006, INFECT IMMUN, V74, P1452, DOI 10.1128/IAI.74.3.1452-1461.2006; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kenneth NS, 2010, EMBO J, V29, P2966, DOI 10.1038/emboj.2010.171; Kim YC, 2009, NAT CELL BIOL, V11, P92, DOI 10.1038/ncb1817; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Landvik NE, 2010, MUTAT RES-FUND MOL M, V684, P11, DOI 10.1016/j.mrfmmm.2009.11.004; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2008, CANCER SCI, V99, P836, DOI 10.1111/j.1349-7006.2008.00763.x; Maeda S, 2009, HEPATOLOGY, V50, P1851, DOI 10.1002/hep.23199; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; MEYN MS, 1995, CANCER RES, V55, P5991; Miyamoto S, 2011, CELL RES, V21, P116, DOI 10.1038/cr.2010.179; Palmieri D, 2011, ONCOGENE, V30, P3024, DOI 10.1038/onc.2011.21; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Roberts KP, 2006, CHEM RES TOXICOL, V19, P300, DOI 10.1021/tx0502589; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sakamoto K, 2010, GASTROENTEROLOGY, V139, P226, DOI 10.1053/j.gastro.2010.03.047; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Stern N, 2002, J BIOL CHEM, V277, P602, DOI 10.1074/jbc.M106798200; Stilmann M, 2009, MOL CELL, V36, P365, DOI 10.1016/j.molcel.2009.09.032; Taricani L, 2009, CELL CYCLE, V8, P482, DOI 10.4161/cc.8.3.7661; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Tsuchiya Y, 2010, MOL CELL, V39, P570, DOI 10.1016/j.molcel.2010.07.030; Wong YH, 2007, NUCLEIC ACIDS RES, V35, pW588, DOI 10.1093/nar/gkm322; Wu LX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018447; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou XF, 2005, ANAL BIOCHEM, V343, P84, DOI 10.1016/j.ab.2005.05.007	51	21	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2013	32	14					1854	1862		10.1038/onc.2012.192	http://dx.doi.org/10.1038/onc.2012.192			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22614018				2022-12-28	WOS:000317043900011
J	Kashyap, A; Zimmerman, T; Ergul, N; Bosserhoff, A; Hartman, U; Alla, V; Bataille, F; Galle, PR; Strand, S; Strand, D				Kashyap, A.; Zimmerman, T.; Erguel, N.; Bosserhoff, A.; Hartman, U.; Alla, V.; Bataille, F.; Galle, P. R.; Strand, S.; Strand, D.			The human Lgl polarity gene, Hugl-2, induces MET and suppresses Snail tumorigenesis	ONCOGENE			English	Article						Lgl; Hugl-2; Snail; EMT; MET; tumour suppression	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; SQUAMOUS-CELL CARCINOMAS; E-CADHERIN EXPRESSION; TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; DROSOPHILA-MELANOGASTER; PANCREATIC-CANCER; BREAST-CANCER; PRIMARY HEAD	Lethal giant larvae proteins have key roles in regulating polarity in a variety of cell types and function as tumour suppressors. A transcriptional programme initiated by aberrant Snail expression transforms epithelial cells to potentially aggressive cancer cells. Although progress in defining the molecular determinants of this programme has been made, we have little knowledge as to how the Snail-induced phenotype can be suppressed. In our studies we identified the human lethal giant larvae homologue 2, Hugl-2, (Llgl2/Lgl2) polarity gene as downregulated by Snail. Snail binds E-boxes in the Hugl-2 promoter and represses Hugl-2 expression, whereas removal of the E-boxes releases Hugl-2 from Snail repression. We demonstrate that inducing Hugl-2 in cells with constitutive Snail expression reverses the phenotype including changes in morphology, motility, tumour growth and dissemination in vivo, and expression of epithelial markers. Hugl-2 expression reduced the nuclear localization of Snail and thus binding of Snail to its target promoters. Our results placing Hugl-2 within the Snail network as well as its ability to suppress Snail carcinogenesis identifies Hugl-2 as a target molecule driving cascades, which may have preventative and therapeutic promise to minimize cancer progression. Oncogene (2013) 32, 1396-1407; doi:10.1038/onc.2012.162; published online 14 May 2012	[Kashyap, A.; Zimmerman, T.; Erguel, N.; Hartman, U.; Alla, V.; Galle, P. R.; Strand, S.; Strand, D.] Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany; [Bosserhoff, A.; Bataille, F.] Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany	Johannes Gutenberg University of Mainz; University of Regensburg	Strand, D (corresponding author), Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Obere Zahlbacherstr 63, D-55101 Mainz, Germany.	dstrand@uni-mainz.de	Galle, Peter/ABE-2872-2021; Bosserhoff, Anja/GNH-4801-2022; Galle, Peter R/T-5292-2018	Galle, Peter/0000-0001-8294-0992; Galle, Peter R/0000-0001-8294-0992; Bosserhoff, Anja/0000-0001-8147-394X	MAIFOR program	MAIFOR program	We thank A Garcia de Herreros for allowing us to use the Snail-HA expression plasmid and PH Krammer for providing anti-Apo-1 antibody. MDA-MB-231 cells were a gift of Thomas Efferth. We kindly thank Anil K Rustgi and Eric R Fearon for providing CyclinD1- and E-cadherin-luciferase constructs, respectively. The expert technical assistance of Mirjam Weisser, Daniela Gottfried, Henry Alizor, Shenchu Jin and Henning Janssen is gratefully acknowledged. Special thanks to the laser-scanning microscopy Core Facility of the Forschungszentrum Immunolgie Mainz. This work was supported by grants from the MAIFOR program to DS and SS. DS and SS should be considered as equal senior authors.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Aichberger KJ, 2009, BLOOD, V114, P5342, DOI 10.1182/blood-2008-08-175190; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Dahiya N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002436; Froldi F, 2008, CURR GENOMICS, V9, P147, DOI 10.2174/138920208784340786; Gaspar C, 2008, AM J PATHOL, V172, P1363, DOI 10.2353/ajpath.2008.070851; GATEFF E, 1967, AM ZOOL, V7, P760; Gavert N, 2008, TRENDS MOL MED, V14, P199, DOI 10.1016/j.molmed.2008.03.004; Grifoni D, 2007, ONCOGENE, V26, P5960, DOI 10.1038/sj.onc.1210389; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Harada T, 2009, PANCREATOLOGY, V9, P13, DOI 10.1159/000178871; Hensen EF, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-168; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lisovsky M, 2010, HUM PATHOL, V41, P902, DOI 10.1016/j.humpath.2009.12.004; Lisovsky M, 2009, MODERN PATHOL, V22, P977, DOI 10.1038/modpathol.2009.68; Lu XF, 2009, CLIN CANCER RES, V15, P3287, DOI 10.1158/1078-0432.CCR-08-2078; Maas K, 2002, J IMMUNOL, V169, P5, DOI 10.4049/jimmunol.169.1.5; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Miyoshi A, 2005, BRIT J CANCER, V92, P252, DOI 10.1038/sj.bjc.6602266; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohali A, 2004, ONCOGENE, V23, P8997, DOI 10.1038/sj.onc.1208060; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pena C, 2009, ONCOGENE, V28, P4375, DOI 10.1038/onc.2009.285; Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Skotheim RI, 2002, CANCER RES, V62, P2359; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Taxman DJ, 2003, CANCER RES, V63, P5095; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tomioka H, 2006, J ORAL PATHOL MED, V35, P206, DOI 10.1111/j.1600-0714.2006.00410.x; Tsuruga T, 2007, ONCOL RES, V16, P431, DOI 10.3727/000000007783980855; Veekony H, 2007, CLIN CANCER RES, V13, P3133, DOI 10.1158/1078-0432.CCR-06-2555; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	51	23	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1396	1407		10.1038/onc.2012.162	http://dx.doi.org/10.1038/onc.2012.162			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22580609				2022-12-28	WOS:000316455600006
J	Arabzadeh, A; Chan, C; Nouvion, AL; Breton, V; Benlolo, S; DeMarte, L; Turbide, C; Brodt, P; Ferri, L; Beauchemin, N				Arabzadeh, A.; Chan, C.; Nouvion, A-L; Breton, V.; Benlolo, S.; DeMarte, L.; Turbide, C.; Brodt, P.; Ferri, L.; Beauchemin, N.			Host-related carcinoembryonic antigen cell adhesion molecule 1 promotes metastasis of colorectal cancer	ONCOGENE			English	Article						CEACAM 1; metastasis; microenvironment; intravital microscopy; MDSC; colorectal cancer	BILIARY GLYCOPROTEIN; TUMOR PROGRESSION; PROSTATE-CANCER; POSSIBLE ROLES; CEACAM1; EXPRESSION; CD66A; ANGIOGENESIS; APOPTOSIS; INVASION	Liver metastasis is the predominant cause of colorectal cancer (CRC)-related mortality in developed countries. Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a cell adhesion molecule with reduced expression in early phases of CRC development and thus functions as a tumor growth inhibitor. However, CEACAM1 is upregulated in metastatic colon cancer, suggesting a bimodal role in CRC progression. To investigate the role of this protein in the host metastatic environment, Ceacam1(-/-) mice were injected intrasplenically with metastatic MC38 mouse CRC cells. A significant reduction in metastatic burden was observed in Ceacam1(-/-) compared with wild-type (WT) livers. Intravital microscopy showed decreased early survival of MC38 cells in Ceacam1(-/-) endothelial environment. Metastatic cell proliferation within the Ceacaml-i- livers was also diminished. Bone marrow-derived cell recruitment, attenuation of immune infiltrates and diminished CCL2, CCL3 and CCL5 chemokine production participated in the reduced Ceacam1(-/-) metastatic phenotype. Transplantations of WT bone marrow (BM) into Ceacam1(-/-) mice fully rescued metastatic development, whereas Ceacam1(-/-) BM transfer into WT mice showed reduced metastatic burden. Chimeric immune cell profiling revealed diminished recruitment of CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) to Ceacam1(-/-)metastatic livers and adoptive transfer of MDSCs confirmed the involvement of these immune cells in reduction of liver metastasis. CEACAM1 may represent a novel metastatic CRC target for treatment. Oncogene (2013) 32, 849-860; doi:10.1038/onc.2012.112; published online 2 April 2012	[Arabzadeh, A.; Chan, C.; Nouvion, A-L; Breton, V.; Benlolo, S.; DeMarte, L.; Turbide, C.; Beauchemin, N.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3G 1Y6, Canada; [Chan, C.; Brodt, P.; Ferri, L.] McGill Univ, Dept Surg, Montreal, PQ H3G 1Y6, Canada; [Brodt, P.; Ferri, L.; Beauchemin, N.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; [Beauchemin, N.] McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; [Beauchemin, N.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, Goodman Canc Res Ctr, Lab 708, McIntyre Bldg,3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	nicole.beauchemin@mcgill.ca		Chan, Carlos HF/0000-0003-3656-2470	Canadian Institutes for Health Research; Canadian Cancer Society Research Institute; Fonds de la Recherche en Sante du Quebec (FRSQ); McGill Integrated Cancer Research Training Program	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Fonds de la Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); McGill Integrated Cancer Research Training Program	We wish to thank Drs Janusz Rak, Peter Siegel and Julie St-Pierre (McGill University) for their helpful corrections and comments on the manuscript. We are also indebted to Dr Russell Jones (McGill University) for help with bone marrow transplantations and Dr Kathryn V Holmes (University of Colorado) for the monoclonal CC1 antibody. This work was supported by grants from the Canadian Institutes for Health Research (NB, LF and PB) and the Canadian Cancer Society Research Institute (LF). AA and ALN were recipients of post-doctoral fellowships from the Fonds de la Recherche en Sante du Quebec (FRSQ). AA and CC received post-doctoral awards from the McGill Integrated Cancer Research Training Program funded by the Canadian Institutes for Health Research and the Fonds de la Recherche en Sante du Quebec (FRSQ).	Bamberger AM, 1998, AM J PATHOL, V152, P1401; Beauchemin N, 1999, EXP CELL RES, V252, P243; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Chen T, 2001, J LEUKOCYTE BIOL, V70, P335; Chen ZG, 2011, J EXP MED, V208, P2633, DOI 10.1084/jem.20102575; Dango S, 2008, LUNG CANCER, V60, P426, DOI 10.1016/j.lungcan.2007.11.015; Ebrahimnejad A, 2004, AM J PATHOL, V165, P1781, DOI 10.1016/S0002-9440(10)63433-5; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; GIAVAZZI R, 1986, CANCER RES, V46, P1928; Gout S, 2008, CANCER MICROENVIRON, V1, P69, DOI 10.1007/s12307-008-0007-2; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hemmila E, 2004, J VIROL, V78, P10156, DOI 10.1128/JVI.78.18.10156-10165.2004; Horst AK, 2009, BLOOD, V113, P6726, DOI 10.1182/blood-2008-10-184556; Horst AK, 2006, J CLIN INVEST, V116, P1596, DOI 10.1172/JCI24340; Ieda J, 2011, INT J CANCER, V129, P1351, DOI 10.1002/ijc.26072; Kang WY, 2007, INT J COLORECTAL DIS, V22, P869, DOI 10.1007/s00384-006-0247-x; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Laurie NA, 2005, CANCER RES, V65, P11010, DOI 10.1158/0008-5472.CAN-04-2841; Leung N, 2008, ONCOGENE, V27, P4943, DOI 10.1038/onc.2008.136; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Liu W, 2007, ONCOGENE, V26, P2747, DOI 10.1038/sj.onc.1210077; Loberg RD, 2007, CANCER RES, V67, P9417, DOI 10.1158/0008-5472.CAN-07-1286; Ma G, 2011, IMMUNITY, V34, P385, DOI 10.1016/j.immuni.2011.02.004; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Nagaishi T, 2006, IMMUNITY, V25, P769, DOI 10.1016/j.immuni.2006.08.026; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Niwa Y, 2001, CLIN CANCER RES, V7, P285; Nollau P, 1997, AM J PATHOL, V151, P521; Nouvion AL, 2010, J CELL SCI, V123, P4221, DOI 10.1242/jcs.073635; Obrink B, 2008, LUNG CANCER, V60, P309, DOI 10.1016/j.lungcan.2008.03.020; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; Pan H, 2010, IMMUNITY, V33, P620, DOI 10.1016/j.immuni.2010.10.009; Popivanova BK, 2009, CANCER RES, V69, P7884, DOI 10.1158/0008-5472.CAN-09-1451; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; ROSENBERG M, 1993, CANCER RES, V53, P4938; Serra S, 2009, APPL IMMUNOHISTO M M, V17, P286, DOI 10.1097/PAI.0b013e318196e13c; SKALLI O, 1989, J HISTOCHEM CYTOCHEM, V37, P315, DOI 10.1177/37.3.2918221; Song JH, 2011, PATHOL ONCOL RES, V17, P67, DOI 10.1007/s12253-010-9282-6; Starke RD, 2011, BLOOD, V117, P1071, DOI 10.1182/blood-2010-01-264507; Wu YJ, 2010, CANCER RES, V70, P57, DOI 10.1158/0008-5472.CAN-09-2472; Xu E, 2009, ENDOCRINOLOGY, V150, P3503, DOI 10.1210/en.2008-1439; Yeatman T J, 1997, J Gastrointest Surg, V1, P292, DOI 10.1016/S1091-255X(97)80123-0; Yoshidome H, 2009, INT J ONCOL, V34, P923, DOI 10.3892/ijo_00000218; Zhou CJ, 2009, PATHOL RES PRACT, V205, P483, DOI 10.1016/j.prp.2009.01.006	48	34	35	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					849	860		10.1038/onc.2012.112	http://dx.doi.org/10.1038/onc.2012.112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469976				2022-12-28	WOS:000316581100005
J	Stresing, V; Baltziskueta, E; Rubio, N; Blanco, J; Arriba, MC; Valls, J; Janier, M; Clezardin, P; Sanz-Pamplona, R; Nieva, C; Marro, M; Dmitri, P; Sierra, A				Stresing, V.; Baltziskueta, E.; Rubio, N.; Blanco, J.; Arriba, Ma C.; Valls, J.; Janier, M.; Clezardin, P.; Sanz-Pamplona, R.; Nieva, C.; Marro, M.; Dmitri, P.; Sierra, A.			Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs	ONCOGENE			English	Article						angiogenesis; lung metastasis; metabolic stress; oxidative stress; peroxiredoxins	TRANSFORMED-CELLS; HYDROGEN-PEROXIDE; BONE METASTASES; LOW-LEVEL; KAPPA-B; PROTEIN; GENES; LINES; ACID; CARCINOMA	Little is known about metastatic pathways that are specific to the lung rather than other organs. We previously showed that antioxidant proteins such as peroxiredoxins were specifically upregulated in lung metastatic breast cancer cells. We hypothesize that cancer cells that live under aerobic conditions, as might be the case in lungs, protect themselves against the damage caused by reactive oxygen species (ROS). To examine this hypothesis, we studied the role of peroxiredoxin-2 (PRDX2) in lung vs bone metastasis formation. A metastatic variant of MDA-MB-435 breast cancer cells that specifically metastasize to lungs (435-L3) was transduced with short hairpin RNAs to specifically silence PRDX2. Conversely, a bone metastatic variant of MDA-MB-231 cells (BO2) was stably transfected to overexpress PRDX2. The 435-L3 cells silenced for PRDX2 were significantly more sensitive to H2O2-induced oxidative stress than the parental and scrambled transfected cells. BO2/PRDX2 cells produced less ROS than BO2/green fluorescent protein control cells under oxidative stress. Moreover, PRDX2 knockdown inhibited the growth of 435-L3 cells in the lungs, whereas lymph node metastasis remained unaffected. In contrast, PRDX2 overexpression in bone metastatic BO2 breast cancer cells led to drastic inhibition of the skeletal tumor burden and reduction of bone destruction. Furthermore, PRDX2 expression in breast cancer cells was associated with a glucose-dependent phenotype, different from bone metastatic cells. Overall, our results strongly suggest that PRDX2 is a targetable 'metabolic adaptor' driver protein implicated in the selective growth of metastatic cells in the lungs by protecting them against oxidative stress. Oncogene (2013) 32, 724-735; doi:10.1038/onc.2012.93; published online 19 March 2012	[Stresing, V.; Baltziskueta, E.; Arriba, Ma C.; Nieva, C.; Sierra, A.] Bellvitge Biomed Res Inst IDIBELL, Biol Clues Invas & Metastat Phenotype Grp, E-08908 Barcelona, Spain; [Stresing, V.; Clezardin, P.] Laennec Sch Med, INSERM, UMR 664, IFR62, Lyon, France; [Rubio, N.; Blanco, J.] Hosp Santa Creu & Sant Pau, CIBER Bioingn Biomat & Nanomed CIBER BBN, Cardiovasc Res Ctr CSIC ICCC, Barcelona, Spain; [Valls, J.] Inst Recerca Biomed Lleida IRBLLEIDA, Lleida, Spain; [Valls, J.] IDIBELL Inst Catala Oncol, Serv Epidemiol, Barcelona, Spain; [Janier, M.] Hop Edouard Herriot, Lyon, France; [Sanz-Pamplona, R.] IDIBELL Inst Catala Oncol, Unit Biomarkers & Susceptibil, Barcelona, Spain; [Sanz-Pamplona, R.] IDIBELL Inst Catala Oncol, CIBERESP, Barcelona, Spain; [Marro, M.; Dmitri, P.] ICFO Inst Ciencies Foton, Castelldefels, E Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut National de la Sante et de la Recherche Medicale (Inserm); CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC); Hospital of Santa Creu i Sant Pau; Institut de Recerca Biomedica - IRB Lleida; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); CHU Lyon; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Barcelona Institute of Science & Technology; Universitat Politecnica de Catalunya; Institut de Ciencies Fotoniques (ICFO)	Sierra, A (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Biol Clues Invas & Metastat Phenotype Grp, Avda Gran Via Hosp Llobregat,199, E-08908 Barcelona, Spain.	asierra@idibell.cat	Marro, Monica/AAV-1362-2021; del Carmen Arriba Pérez, María/I-2112-2015; Rubio, Nuria/H-3156-2015; Valls, Joan/GXM-6532-2022; Clezardin, Philippe/M-8071-2014; Blanco, Jeronimo/H-2764-2015; Marro, Monica/E-4159-2016	Marro, Monica/0000-0003-4031-4605; del Carmen Arriba Pérez, María/0000-0001-8033-7444; Rubio, Nuria/0000-0003-2471-4684; Clezardin, Philippe/0000-0003-0149-4463; Blanco, Jeronimo/0000-0003-3765-0640; Marro, Monica/0000-0003-4031-4605; Valls, Joan/0000-0002-4806-7568; Papkovsky, Dmitri/0000-0003-1556-1145; Janier, Marc/0000-0001-5937-9180; Sierra, Angels/0000-0003-1023-3492; Sanz-Pamplona, Rebeca/0000-0002-2187-3527	Spanish Ministry of Health and Consumer Affairs [FIS/PI071245, FIS/PI10/00057]; EC MetaBre [LSHC-CT-2004-506049]; INCA (ONCOIMAGE) [07/3D1316/PF-108-01/NG-LC]; Ministry of Education and Science [SAF2004-0188-E]; AECC Scientific Foundation; Private Foundation Cellex Barcelona	Spanish Ministry of Health and Consumer Affairs(Spanish Government); EC MetaBre; INCA (ONCOIMAGE); Ministry of Education and Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); AECC Scientific Foundation; Private Foundation Cellex Barcelona	We would like to thank Oriol Casanovas (Angiogenesis Laboratory, IDIBELL) for scientific discussions and his expert advice on angiogenesis. We would also like to thank Berta Martin, Vanessa Hernandez and Mac Dominguez for his expert technical assistance. We are grateful to Mr R Rycroft for expert language advice and Victor Moreno for expert statistical advice (Barcelona University). We thanks Jose Carlos Perales and Andy Mendez for the advice and support the metabolic analysis (Barcelona University). We acknowledge all the partners of the MetaBre consortium for their collaboration and stimulating criticism. This study was supported by grants from the Spanish Ministry of Health and Consumer Affairs (FIS/PI071245 and FIS/PI10/00057), EC MetaBre (contract no. LSHC-CT-2004-506049), INCA (ONCOIMAGE, no 07/3D1316/PF-108-01/NG-LC), the Ministry of Education and Science (SAF2004-0188-E), AECC Scientific Foundation and Private Foundation Cellex Barcelona.	[Anonymous], 2009, LANG ENV STAT COMP; Archer SL, 2008, AM J PHYSIOL-HEART C, V294, pH570, DOI 10.1152/ajpheart.01324.2007; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Budihardjo II, 1998, CLIN CANCER RES, V4, P117; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; Dong F, 2009, CLIN CANCER RES, V15, P2588, DOI 10.1158/1078-0432.CCR-08-2356; El Hilali N, 2005, CLIN CANCER RES, V11, P1253; Espana L, 2005, AM J PATHOL, V167, P1125, DOI 10.1016/S0002-9440(10)61201-1; Fidler IJ, 2002, DIFFERENTIATION, V70, P498, DOI 10.1046/j.1432-0436.2002.700904.x; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Ganong WF, 2005, LANGE BASIC SCI, P631; Graves JA, 2009, J BIOL CHEM, V284, P6520, DOI 10.1074/jbc.M807564200; Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104; Han YH, 2006, FREE RADICAL RES, V40, P1182, DOI 10.1080/10715760600868552; Haraldsen JD, 2009, ORG BIOMOL CHEM, V7, P3040, DOI 10.1039/b901735f; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Iles KE, 2002, IMMUNOL RES, V26, P95, DOI 10.1385/IR:26:1-3:095; Jang YY, 2007, BLOOD, V110, P3056, DOI 10.1182/blood-2007-05-087759; Karihtala P, 2003, CLIN CANCER RES, V9, P3418; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; Lee KW, 2011, J BIOL CHEM, V286, P8394, DOI 10.1074/jbc.M110.179416; Lehtonen ST, 2004, INT J CANCER, V111, P514, DOI 10.1002/ijc.20294; Low FM, 2007, BLOOD, V109, P2611, DOI 10.1182/blood-2006-09-048728; Martin B, 2008, J PROTEOME RES, V7, P3242, DOI 10.1021/pr800137w; Mendez O, 2005, CLIN EXP METASTAS, V22, P297, DOI 10.1007/s10585-005-8751-x; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Neumann CA, 2007, CURR OPIN PHARMACOL, V7, P375, DOI 10.1016/j.coph.2007.04.007; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Olahova M, 2008, P NATL ACAD SCI USA, V105, P19839, DOI 10.1073/pnas.0805507105; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; Peyruchaud O, 2003, J BIOL CHEM, V278, P45826, DOI 10.1074/jbc.M309024200; Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027; Pinheiro J, 2001, MIXED EFFECTS MODELS; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Ralser M, 2009, NAT BIOTECHNOL, V27, P604, DOI 10.1038/nbt0709-604; Roman I, 2007, BIOMATERIALS, V28, P2718, DOI 10.1016/j.biomaterials.2007.02.011; Semenza GL, 2008, J CLIN INVEST, V118, P3835, DOI 10.1172/JCI37373; Seo JH, 2009, J BIOL CHEM, V284, P13455, DOI 10.1074/jbc.M900641200; Tao MF, 2007, MOL BIOSYST, V3, P60, DOI 10.1039/b615284h; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Wang W, 2010, J PROTEOME RES, V9, P3812, DOI 10.1021/pr901180w; Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; ZHANG RD, 1991, INVAS METAST, V11, P204	54	69	70	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					724	735		10.1038/onc.2012.93	http://dx.doi.org/10.1038/onc.2012.93			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430214				2022-12-28	WOS:000315746700006
J	Chaves-Perez, A; Mack, B; Maetzel, D; Kremling, H; Eggert, C; Harreus, U; Gires, O				Chaves-Perez, A.; Mack, B.; Maetzel, D.; Kremling, H.; Eggert, C.; Harreus, U.; Gires, O.			EpCAM regulates cell cycle progression via control of cyclin D1 expression	ONCOGENE			English	Article						EpCAM; EpICD; cyclin D1	BREAST-CANCER; EP-CAM; POTENTIAL TARGET; GENE-EXPRESSION; BETA-CATENIN; STEM-CELLS; FHL2; CARCINOMA; PROTEIN; DIFFERENTIATION	The epithelial cell adhesion molecule (EpCAM) is an integral transmembrane protein that is frequently overexpressed in embryonic stem cells, tissue progenitors, carcinomas and cancer-initiating cells. In cancer cells, expression of EpCAM is associated with enhanced proliferation and upregulation of target genes including c-myc. However, the exact molecular mechanisms underlying the observed EpCAM-dependent cell proliferation remained unexplored. Here, we show that EpCAM directly affects cell cycle progression via its capacity to regulate the expression of cyclin D1 at the transcriptional level and depending on the direct interaction partner FHL2 (four-and-a-half LIM domains protein 2). As a result, downstream events such as phosphorylation of the retinoblastoma protein (Rb) and expression of cyclins E and A are similarly affected. In vivo, EpCAM expression strength and pattern are both positively correlated with the proliferation marker Ki67, high expression and nuclear localisation of cyclin D1, and Rb phosphorylation. Thus, EpCAM enhances cell cycle progression via the classical cyclin-regulated pathway. Oncogene (2013) 32, 641-650; doi:10.1038/onc.2012.75; published online 5 March 2012	[Chaves-Perez, A.; Kremling, H.; Eggert, C.; Gires, O.] Univ Munich, Clin Cooperat Grp Mol Oncol, Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, D-81377 Munich, Germany; [Chaves-Perez, A.; Kremling, H.; Eggert, C.; Gires, O.] Univ Munich, Head & Neck Res Dept, D-81377 Munich, Germany; [Mack, B.; Harreus, U.; Gires, O.] Univ Munich, Dept Otorhinolaryngol Head & Neck Surg, Grosshadern Med Ctr, D-81377 Munich, Germany; [Maetzel, D.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; University of Munich; Massachusetts Institute of Technology (MIT); Whitehead Institute	Gires, O (corresponding author), Univ Munich, Dept Otorhinolaryngol, Grosshadern Med Ctr, Marchioninistr 15, D-81377 Munich, Germany.	Olivier.gires@med.uni-muenchen.de	Gires, Olivier/V-2689-2017	Gires, Olivier/0000-0002-2292-7064				Balzar M, 1999, J MOL MED, V77, P699, DOI 10.1007/s001099900038; Chen HF, 2011, STEM CELL REV REP, V7, P722, DOI 10.1007/s12015-011-9233-y; Denzel S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-402; Gabriel B, 2006, J SOC GYNECOL INVEST, V13, P69, DOI 10.1016/j.jsgi.2005.10.001; Gabriel B, 2004, ANTICANCER RES, V24, P921; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Gires O, 2009, NAT REV CANCER, V9, P143, DOI 10.1038/nrc2499-c1; Gonzalez B, 2009, STEM CELLS, V27, P1782, DOI 10.1002/stem.97; Guo Z, 2010, MOL CARCINOGEN, V49, P826, DOI 10.1002/mc.20659; Huang HP, 2011, J BIOL CHEM, V286, P33520, DOI 10.1074/jbc.M111.256164; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Labalette C, 2008, J BIOL CHEM, V283, P15201, DOI 10.1074/jbc.M800708200; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Litvinov SV, 1996, AM J PATHOL, V148, P865; Lu TY, 2010, J BIOL CHEM, V285, P8719, DOI 10.1074/jbc.M109.077081; Maaser K, 2008, BRIT J CANCER, V99, P1635, DOI 10.1038/sj.bjc.6604725; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; MICHALIDES R, 1995, CANCER RES, V55, P975; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Munz Markus, 2004, Cancer Genomics Proteomics, V1, P241; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Nasr AF, 2003, ONCOGENE, V22, P1668, DOI 10.1038/sj.onc.1206248; Ng CF, 2011, GENE, V481, P41, DOI 10.1016/j.gene.2011.04.005; Ng VY, 2010, STEM CELLS, V28, P29, DOI 10.1002/stem.221; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708; SCHON MP, 1994, J INVEST DERMATOL, V102, P987, DOI 10.1111/1523-1747.ep12384258; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Spizzo G, 2006, GYNECOL ONCOL, V103, P483, DOI 10.1016/j.ygyno.2006.03.035; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Yamashita T, 2007, CANCER RES, V67, P10831, DOI 10.1158/0008-5472.CAN-07-0908; Yanamoto S, 2007, ORAL ONCOL, V43, P869, DOI 10.1016/j.oraloncology.2006.10.010	40	80	81	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					641	650		10.1038/onc.2012.75	http://dx.doi.org/10.1038/onc.2012.75			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22391566	Bronze			2022-12-28	WOS:000316164700011
J	Yan, W; Liu, S; Xu, E; Zhang, J; Zhang, Y; Chen, X; Chen, X				Yan, W.; Liu, S.; Xu, E.; Zhang, J.; Zhang, Y.; Chen, X.; Chen, X.			Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8	ONCOGENE			English	Article						p53; mutant p53; HDAC8; HDAC inhibitor; HoxA5; transcription	CLINICAL-IMPLICATIONS; HDAC INHIBITORS; CANCER; EXPRESSION; APOPTOSIS; ACTIVATION; CELLS; GENE; IDENTIFICATION; ACETYLATION	Mutation of the p53 gene is the most common genetic alteration in human cancer and contributes to malignant process by enhancing transformed properties of cells and resistance to anticancer therapy. Mutant p53 is often highly expressed in tumor cells at least, in part, due to its increased half-life. However, whether mutant p53 expression is regulated by other mechanisms in tumors is unclear. Here we found that histone deacetylase (HDAC) inhibitors suppress both wild-type and mutant p53 transcription in time- and dose-dependent manners. Consistent with this, the levels of wild-type and mutant p53 proteins are decreased upon treatment with HDAC inhibitors. Importantly, we found that upon knockdown of each class I HDAC, only HDAC8 knockdown leads to decreased expression of wild-type and mutant p53 proteins and transcripts. Conversely, we found that ectopic expression of wild-type, but not mutant HDAC8, leads to increased transcription of p53. Furthermore, we found that knockdown of HDAC8 results in reduced expression of HoxA5 and consequently, attenuated ability of HoxA5 to activate p53 transcription, which can be rescued by ectopic expression of HoxA5. Because of the fact that HDAC8 is required for expression of both wild-type and mutant p53, we found that targeted disruption of HDAC8 expression remarkably triggers proliferative defect in cells with a mutant but not wild-type, p53. Together, our data uncover a regulatory mechanism of mutant p53 transcription via HDAC8 and suggest that HDAC inhibitors and especially HDAC8-targeting agents might be explored as an adjuvant for tumors carrying a mutant p53. Oncogene (2013) 32, 599-609; doi:10.1038/onc.2012.81; published online 5 March 2012	[Yan, W.; Liu, S.; Xu, E.; Zhang, J.; Zhang, Y.; Chen, X.; Chen, X.] Univ Calif Davis, Comparat Oncol Lab, Davis, CA 95616 USA	University of California System; University of California Davis	Chen, X (corresponding author), Univ Calif Davis, Comparat Oncol Lab, Davis, CA 95616 USA.	xbchen@ucdavis.edu	qiao, zhixin/I-3408-2012; liu, shou/C-5406-2015	Zhang, Yi/0000-0002-2789-0811	National Institutes of Health [R01 CA121137]; NATIONAL CANCER INSTITUTE [R01CA076069, R01CA121137] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by National Institutes of Health Grant R01 CA121137. We thank S Townson (Merck Pharmaceuticals) for SAHA.	Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Balasubramanian S, 2008, LEUKEMIA, V22, P1026, DOI 10.1038/leu.2008.9; Bertrand P, 2010, EUR J MED CHEM, V45, P2095, DOI 10.1016/j.ejmech.2010.02.030; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Chen HX, 2005, J BIOL CHEM, V280, P19373, DOI 10.1074/jbc.M413528200; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; Dong GE, 2010, AM J PHYSIOL-RENAL, V298, pF293, DOI 10.1152/ajprenal.00410.2009; Dowling DP, 2008, BIOCHEMISTRY-US, V47, P13554, DOI 10.1021/bi801610c; Duvic M, 2007, EXPERT OPIN INV DRUG, V16, P1111, DOI 10.1517/13543784.16.7.1111; Glaser KB, 2003, MOL CANCER THER, V2, P151; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Harms KL, 2007, CANCER RES, V67, P3145, DOI 10.1158/0008-5472.CAN-06-4397; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Kim HJ, 2011, AM J TRANSL RES, V3, P166; Kirschbaum M, 2011, J CLIN ONCOL, V29, P1198, DOI 10.1200/JCO.2010.32.1398; KrennHrubec K, 2007, BIOORG MED CHEM LETT, V17, P2874, DOI 10.1016/j.bmcl.2007.02.064; Lee H, 2004, MOL CELL BIOL, V24, P765, DOI 10.1128/MCB.24.2.765-773.2004; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185; McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156; Noureen N, 2010, CANCER CHEMOTH PHARM, V66, P625, DOI 10.1007/s00280-010-1324-y; Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Peart MJ, 2003, CANCER RES, V63, P4460; Ramalingam SS, 2007, CLIN CANCER RES, V13, P3605, DOI 10.1158/1078-0432.CCR-07-0162; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sasakawa Y, 2005, BIOCHEM PHARMACOL, V69, P603, DOI 10.1016/j.bcp.2004.11.008; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Song J, 2005, APMIS, V113, P264, DOI 10.1111/j.1600-0463.2005.apm_04.x; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang SL, 2006, CANCER RES, V66, P6982, DOI 10.1158/0008-5472.CAN-06-0511; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Yan WS, 2010, J BIOL CHEM, V285, P14229, DOI 10.1074/jbc.M109.097253; Yan WS, 2009, J BIOL CHEM, V284, P12178, DOI 10.1074/jbc.M900994200; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001	54	113	119	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					599	609		10.1038/onc.2012.81	http://dx.doi.org/10.1038/onc.2012.81			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22391568	Green Accepted			2022-12-28	WOS:000316164700007
J	Yu, J; Liang, QY; Wang, J; Cheng, Y; Wang, S; Poon, TCW; Go, MYY; Tao, Q; Chang, Z; Sung, JJY				Yu, J.; Liang, Q. Y.; Wang, J.; Cheng, Y.; Wang, S.; Poon, T. C. W.; Go, M. Y. Y.; Tao, Q.; Chang, Z.; Sung, J. J. Y.			Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer	ONCOGENE			English	Article						Zinc-finger protein 331 (ZNF331); gastric cancer; tumor suppressor; methylation; invasion; 2-D gel electrophoresis	HUMAN POLYNUCLEOTIDE PHOSPHORYLASE; CPG ISLAND METHYLATION; ZINC-FINGER PROTEINS; DEAD-BOX PROTEINS; POTENTIAL TARGET; CELL-GROWTH; GENE; REPRESSION; HPNPASE(OLD-35); INVOLVEMENT	Zinc-finger protein 331 (ZNF331), a Kruppel-associated box zinc-finger protein gene, was identified as a putative tumor suppressor in our previous study. However, the role of ZNF331 in tumorigenesis remains elusive. We aimed to clarify its epigenetic regulation and biological functions in gastric cancer. ZNF331 was silenced or downregulated in 71% (12/17) gastric cancer cell lines. A significant downregulation was also detected in paired gastric tumors compared with adjacent non-cancer tissues. In contrast, ZNF331 was readily expressed in various normal adult tissues. The downregulation of ZNF331 was closely linked to the promoter hypermethylation as evidenced by methylation-specific PCR, bisulfite genomic sequencing and reexpression by demethylation agent treatment. DNA sequencing showed no genetic mutation/deletion of ZNF331 in gastric cancer cell lines. Ectopic expression of ZNF331 in the silenced cancer cell lines MKN28 and HCT116 significantly reduced colony formation and cell viability, induced cell cycle arrests and repressed cell migration and invasive ability. Concordantly, knockdown of ZNF331 increased cell viability and colony formation ability of gastric cancer cell line MKN45. Two-dimensional gel electrophoresis and mass spectrometry-based comparative proteomic approach were applied to analyze the molecular basis of the biological functions of ZNF331. In all, 10 downstream targets of ZNF331 were identified to be associated with regulation of cell growth and metastasis. The tumor-suppressive effect of ZNF331 is mediated at least by downregulation of genes involved in cell growth promotion (DSTN, EIF5A, GARS, DDX5, STAM, UQCRFS1 and SET) and migration/invasion (DSTN and ACTR3), and upregulation of genome-stability gene (SSBP1) and cellular senescence gene (PNPT1). A novel target of ZNF331 (DSTN) was functionally validated. Overexpression of DSTN in BGC-823 cells increased colony formation and migration ability. In conclusion, our results suggest that ZNF331 possesses important functions for the suppression of gastric carcinogenesis as a novel functional tumor-suppressor gene. Oncogene (2013) 32, 307-317; doi:10.1038/onc.2012.54; published online 27 February 2012	[Yu, J.; Liang, Q. Y.; Wang, J.; Wang, S.; Poon, T. C. W.; Go, M. Y. Y.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci,Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Cheng, Y.; Tao, Q.] Chinese Univ Hong Kong, Dept Clin Oncol, Canc Epigenet Lab, Shatin, Hong Kong, Peoples R China; [Chang, Z.] Tsinghua Univ, State Key Lab Biomembrane & Membrane Biotechnol, Natl Engn Lab Antitumor Therapeut, Sch Med, Beijing 100084, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Tsinghua University	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci,Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk; jjysung@cuhk.edu.hk	Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Cheng, Yingduan/J-5507-2015; Liang, Qiaoyi Jessie/G-9612-2019; WANG, JIA/A-2799-2019; Chang, Zhijie/AAH-8109-2019; Tao, Qian/T-4743-2018	Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Liang, Qiaoyi Jessie/0000-0001-8496-3442; Tao, Qian/0000-0001-5383-4808; WANG, JIA/0000-0001-5339-8954	National Basic Research Program of China (973 Program) [2010CB529305]; Research Grants Council RGC CERG CUHK [473008]; CUHK Focused Investment Grant [1903026]; RFCID [10090942, 11100022]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); Research Grants Council RGC CERG CUHK; CUHK Focused Investment Grant; RFCID	This project was supported by the National Basic Research Program of China (973 Program, 2010CB529305), Research Grants Council RGC CERG CUHK (473008), CUHK Focused Investment Grant (1903026) and RFCID (10090942, 11100022).	Anazawa Y, 2005, CANCER RES, V65, P4578, DOI 10.1158/0008-5472.CAN-04-4564; Choi YJ, 2012, J CELL BIOCHEM, V113, P985, DOI 10.1002/jcb.23428; Estornes Y, 2007, INT J CANCER, V121, P2162, DOI 10.1002/ijc.22911; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fredericks WJ, 2000, MOL CELL BIOL, V20, P5019, DOI 10.1128/MCB.20.14.5019-5031.2000; Freist W, 1996, BIOL CHEM H-S, V377, P343; Huang J, 2009, MOL CELL, V35, P384, DOI 10.1016/j.molcel.2009.06.011; Jalal C, 2007, NUCLEIC ACIDS RES, V35, P3590, DOI 10.1093/nar/gkm058; Janknecht R, 2010, AM J TRANSL RES, V2, P223; Jasiulionis MG, 2007, CELL BIOCHEM FUNCT, V25, P109, DOI 10.1002/cbf.1351; Kaneko SJ, 2003, GYNECOL ONCOL, V90, P29, DOI 10.1016/S0090-8258(03)00144-6; Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lee JH, 2004, ONCOGENE, V23, P4646, DOI 10.1038/sj.onc.1207588; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; Leung SY, 2006, MODERN PATHOL, V19, P854, DOI 10.1038/modpathol.3800593; Li G, 2009, PROTEOMICS, V9, P20, DOI 10.1002/pmic.200701195; Li LL, 2010, CLIN CANCER RES, V16, P2949, DOI 10.1158/1078-0432.CCR-09-3178; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Meiboom M, 2003, CYTOGENET GENOME RES, V101, P113, DOI 10.1159/000074165; Ohashi Y, 2004, GYNECOL ONCOL, V93, P54, DOI 10.1016/j.ygyno.2004.01.019; Otsubo T, 2004, MODERN PATHOL, V17, P461, DOI 10.1038/modpathol.3800062; PENNACCHIO LA, 1995, GENE, V155, P207, DOI 10.1016/0378-1119(94)00683-J; Pollard KS, 2008, HUM GENET, V122, P625, DOI 10.1007/s00439-007-0440-1; Rippe V, 1999, GENE CHROMOSOME CANC, V26, P229, DOI 10.1002/(SICI)1098-2264(199911)26:3<229::AID-GCC7>3.0.CO;2-J; Sarkar D, 2005, MOL CELL BIOL, V25, P7333, DOI 10.1128/MCB.25.16.7333-7343.2005; Sarkar D, 2003, J BIOL CHEM, V278, P24542, DOI 10.1074/jbc.M302421200; Sohn JH, 2010, MOL CANCER RES, V8, P246, DOI 10.1158/1541-7786.MCR-09-0141; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; TIRANTI V, 1995, GENOMICS, V25, P559, DOI 10.1016/0888-7543(95)80058-T; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Wu H, 2001, BBA-GENE STRUCT EXPR, V1518, P190, DOI 10.1016/S0167-4781(01)00172-5; Yu J, 2002, BRIT J CANCER, V87, P91, DOI 10.1038/sj.bjc.6600421	35	56	61	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					307	317		10.1038/onc.2012.54	http://dx.doi.org/10.1038/onc.2012.54			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370639				2022-12-28	WOS:000314736600005
J	Zhang, J; Sun, Q; Zhang, Z; Ge, S; Han, ZG; Chen, WT				Zhang, J.; Sun, Q.; Zhang, Z.; Ge, S.; Han, Z-G; Chen, W-T			Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop	ONCOGENE			English	Article						microRNA; miRNA-143/145; MDM2; p53; epithelial maligancies	MIR-143/145 CLUSTER; ANTI-ONCOMIRS; C-MYC; P53; EXPRESSION; ONCOPROTEIN; ACTIVATION; INDUCTION; MICRORNAS; ONCOGENE	Dysregulated microRNAs (miRNAs) have an important role in many malignant tumors. However, elucidating the roles of miRNAs in cancer biology, especially in epithelial cancers, remains an ongoing process. In this study, we show that both miR-143 and miR-145, which belong to the same miRNA cluster, can negatively modulate expression of their target gene, MDM2. The miR-143 and miR-145 is posttranscriptionally activated by upregulated p53, thereby generating a short miRNAs-MDM2-p53 feedback loop. Re-expression of these miRNAs suppresses cellular growth and triggers the apoptosis of epithelial cancer, in vitro and in vivo, by enhancing p53 activity via MDM2 turnover. Moreover, the miRNA-dependent MDM2 turnover contributes to the equilibrium of repeated p53 pulses in response to DNA damage stress. These findings suggest that MDM2 dysregulation caused by downregulation of miR-143 and miR-145 contributes to epithelial cancer development and has a key role in regulating cellular proliferation and apoptosis. Re-expression of miR-143 and miR-145 may be a reasonable strategy for treatment of epithelial cancers. Oncogene (2013) 32, 61-69; doi:10.1038/onc.2012.28; published online 13 February 2012	[Zhang, J.; Zhang, Z.; Chen, W-T] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Stomatol, Dept Oral & Maxillofacial Surg,Peoples Hosp 9, Shanghai 200011, Peoples R China; [Han, Z-G] Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Dis & Hlth Genom, Shanghai, Peoples R China	Shanghai Jiao Tong University	Chen, WT (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Stomatol, Dept Oral & Maxillofacial Surg,Peoples Hosp 9, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.	chenwantao2002@hotmail.com	建军, 张/R-3679-2019		National Natural Science Foundation of China [30973343, 81101515]; Shanghai Science and Technology Committee [08JC1414400, 11DZ2291800, 10DZ1951300, 10XD1402500]; Shanghai Leading Academic Discipline Project [S30206]; Shanghai Municipal Education Commission [12YZ052, shjdy027]; National Basic Research Program of China [2010CB529204]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee); Shanghai Leading Academic Discipline Project(Shanghai Leading Academic Discipline Project); Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC)); National Basic Research Program of China(National Basic Research Program of China)	This study was supported by the National Natural Science Foundation of China (Grant No. 30973343 and 81101515), Projects of the Shanghai Science and Technology Committee (Grant No. 08JC1414400, 11DZ2291800, 10DZ1951300 and 10XD1402500), the Shanghai Leading Academic Discipline Project (S30206), the Program of Shanghai Municipal Education Commission (12YZ052 and shjdy027) and National Basic Research Program of China (2010CB529204).	Akao Y, 2010, CANCER GENE THER, V17, P398, DOI 10.1038/cgt.2009.88; Araki S, 2010, J CLIN INVEST, V120, P290, DOI 10.1172/JCI39194; Arva NC, 2008, ETHN DIS S2, V18, pS2; Asslaber D, 2010, BLOOD, V115, P4191, DOI 10.1182/blood-2009-07-234823; Boucher JM, 2011, J BIOL CHEM, V286, P28312, DOI 10.1074/jbc.M111.221945; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Brown BD, 2009, NAT REV GENET, V10, P578, DOI 10.1038/nrg2628; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Chen LH, 2010, J ONCOL, V2010, DOI 10.1155/2010/135632; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Dai YM, 2011, HEAD NECK-J SCI SPEC, V33, P786, DOI 10.1002/hed.21540; Fan Chun-Yang, 2004, Curr Oncol Rep, V6, P152, DOI 10.1007/s11912-004-0027-0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Ishimura A, 2009, BIOCHEM BIOPH RES CO, V389, P366, DOI 10.1016/j.bbrc.2009.08.155; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kitade Y, 2010, J PHARMACOL SCI, V114, P276, DOI 10.1254/jphs.10R12FM; Langevin SM, 2011, CANCER-AM CANCER SOC, V117, P1454, DOI 10.1002/cncr.25689; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Liu G, 2005, CANCER CELL, V7, P113, DOI 10.1016/j.ccr.2005.01.019; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Phelps M, 2003, CANCER RES, V63, P2616; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Saha MN, 2010, CANCER BIOL THER, V9, P936, DOI 10.4161/cbt.9.11.11882; Soriano ME, 2011, CELL, V145, P15, DOI 10.1016/j.cell.2011.03.025; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Vassilev LT, 2004, CELL CYCLE, V3, P419; Zhang JJ, 2011, CANCER-AM CANCER SOC, V117, P86, DOI 10.1002/cncr.25522; Zhang JJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-211	37	114	120	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					61	69		10.1038/onc.2012.28	http://dx.doi.org/10.1038/onc.2012.28			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22330136	Bronze			2022-12-28	WOS:000313029500006
J	Chaisaingmongkol, J; Popanda, O; Warta, R; Dyckhoff, G; Herpel, E; Geiselhart, L; Claus, R; Lasitschka, F; Campos, B; Oakes, CC; Bermejo, JL; Herold-Mende, C; Plass, C; Schmezer, P				Chaisaingmongkol, J.; Popanda, O.; Warta, R.; Dyckhoff, G.; Herpel, E.; Geiselhart, L.; Claus, R.; Lasitschka, F.; Campos, B.; Oakes, C. C.; Bermejo, J. L.; Herold-Mende, C.; Plass, C.; Schmezer, P.			Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma	ONCOGENE			English	Article						HNSCC; DNA methylation; NEIL1 expression; DNA glycosylase	HYPERMETHYLATION; TUMOR; GLYCOSYLASE; EXPRESSION; HYPOMETHYLATION; INACTIVATION; EXCISION; REVEALS; DAMAGE; METHYLTRANSFERASE	Aberrant promoter methylation of different DNA repair genes has a critical role in the development and progression of various cancer types, including head and neck squamous cell carcinomas (HNSCCs). A systematic analysis of known human repair genes for promoter methylation is however missing. We generated quantitative promoter methylation profiles in single CpG units of 160 human DNA repair genes in a set of DNAs isolated from fresh frozen HNSCC and normal tissues using MassARRAY technology. Ninety-eight percent of these genes contained CpG islands (CGIs) in their promoter region; thus, DNA methylation is a potential regulatory mechanism. Methylation data were obtained for 145 genes, from which 15 genes exhibited more than a 20% difference in methylation levels between tumor and normal tissues, manifested either as hypermethylation or as hypomethylation. Analyses of promoter methylation with mRNA expression identified the DNA glycosylase NEIL1 (nei endonuclease VIII-like 1) as the most prominent candidate gene. NEIL1 promoter hypermethylation was confirmed in additional fresh frozen HNSCC samples, normal mucosa, HNSCC cell lines and primary human skin keratinocytes. The investigation of laser-microdissected tissues further substantiated increased methylation levels in tumor versus matched non-tumor cells. Immunohistological analysis revealed significantly less NEIL1 protein expression in tumor tissues. 5-Aza-2'-deoxycytidine treatment and DNMT1 knockdown resulted in the re-expression of NEIL1 in HNSCC cell lines, which initially carried hypermethylated promoter regions. In conclusion, our results suggest that DNA methylation contributes to the downregulation of NEIL1 expression and might thus have a role in modulating the response to therapies of HNSCC. Oncogene (2012) 31, 5108-5116; doi:10.1038/onc.2011.660; published online 30 January 2012	[Chaisaingmongkol, J.; Popanda, O.; Geiselhart, L.; Claus, R.; Oakes, C. C.; Plass, C.; Schmezer, P.] German Canc Res Ctr, Div Epigen & Canc Risk Factors, D-69120 Heidelberg, Germany; [Warta, R.; Dyckhoff, G.; Herold-Mende, C.] Heidelberg Univ, Dept Otorhinolaryngol Head & Neck Surg, Heidelberg, Germany; [Warta, R.; Campos, B.; Herold-Mende, C.] Heidelberg Univ, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Herpel, E.] Univ Heidelberg Hosp, Inst Pathol, NCT Tissue Bank, Heidelberg, Germany; [Lasitschka, F.] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany; [Bermejo, J. L.] Univ Heidelberg Hosp, Inst Med Biometry & Informat, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Schmezer, P (corresponding author), German Canc Res Ctr, Div Epigen & Canc Risk Factors C010, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.schmezer@dkfz.de	Popanda, Odilia/P-6917-2019; Oakes, Christopher C/H-7288-2014; Plass, Christoph/H-7192-2014; Claus, Rainer/AAZ-5606-2020	Oakes, Christopher C/0000-0001-8000-9694; Claus, Rainer/0000-0003-2617-8766; Chaisaingmongkol, Jittiporn/0000-0001-8019-5562	Royal Thai Government; NIDCR [DE13123]; Deutsche Forschungsgemeinschaft [SFB938 Z2]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER	Royal Thai Government; NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank R Gliniorz, O Muecke, P Waas and O Zelezny ( Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center) and J Scheuerer (Institute of Pathology) for their excellent technical assistance, all other members of the Plass laboratory for their help and thoughtful discussion, M Zucknick (Division of Biostatistics, German Cancer Research Center) for statistical support and P Boukamp (Division of Genetics of Skin Carcinogenesis, German Cancer Research Center) for providing primary human skin keratinocytes. This project was in part supported by a scholarship of The Royal Thai Government to JC. This work was supported in part by NIDCR, grant DE13123 (CP). FL is funded by the Deutsche Forschungsgemeinschaft, grant SFB938 Z2.	Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793; Chan MK, 2009, DNA REPAIR, V8, P786, DOI 10.1016/j.dnarep.2009.03.001; Couve-Privat S, 2007, NUCLEIC ACIDS RES, V35, P5672, DOI 10.1093/nar/gkm592; Das A, 2005, J BIOL CHEM, V280, P35272, DOI 10.1074/jbc.M505526200; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; Dikshit RP, 2007, CANCER-AM CANCER SOC, V110, P1745, DOI 10.1002/cncr.22975; Dokun OY, 2008, INT J CANCER, V123, P2798, DOI 10.1002/ijc.23893; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Doublie S, 2004, P NATL ACAD SCI USA, V101, P10284, DOI 10.1073/pnas.0402051101; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Estecio MRH, 2006, ONCOGENE, V25, P5018, DOI 10.1038/sj.onc.1209509; Esteller M, 2001, CANCER RES, V61, P4689; Freier K, 2010, J ORAL PATHOL MED, V39, P382, DOI 10.1111/j.1600-0714.2009.00864.x; Funke B, 2009, GUT, V58, P483, DOI 10.1136/gut.2008.148908; Guan X, 2007, NUCLEIC ACIDS RES, V35, P2463, DOI 10.1093/nar/gkm075; Ha PK, 2009, ORAL ONCOL, V45, P335, DOI 10.1016/j.oraloncology.2008.05.015; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327; Kraunz KS, 2006, INT J CANCER, V119, P1553, DOI 10.1002/ijc.22013; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Mace-Aime G, 2010, ENVIRON MOL MUTAGEN, V51, P508, DOI 10.1002/em.20548; Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051; Marsit CJ, 2009, CARCINOGENESIS, V30, P416, DOI 10.1093/carcin/bgp006; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Martone T, 2007, CLIN CANCER RES, V13, P5089, DOI 10.1158/1078-0432.CCR-07-0119; Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423; Ninck S, 2003, INT J CANCER, V106, P34, DOI 10.1002/ijc.11188; Pal S, 2010, J GASTROEN HEPATOL, V25, P627, DOI 10.1111/j.1440-1746.2009.06128.x; Poage GM, 2011, CLIN CANCER RES, V17, P3579, DOI 10.1158/1078-0432.CCR-11-0044; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269; Schmezer P, 2008, HNO, V56, P594, DOI 10.1007/s00106-008-1720-3; Seitz HK, 2007, NAT REV CANCER, V7, P599, DOI 10.1038/nrc2191; Seiwert TY, 2007, NAT CLIN PRACT ONCOL, V4, P156, DOI 10.1038/ncponc0750; Sengupta S, 2007, CANCER-AM CANCER SOC, V109, P703, DOI 10.1002/cncr.22430; Shinmura K, 2004, CARCINOGENESIS, V25, P2311, DOI 10.1093/carcin/bgh267; Smith IM, 2010, ORL-J OTO-RHIN-LARYN, V72, P44, DOI 10.1159/000292104; Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102; Vartanian V, 2006, P NATL ACAD SCI USA, V103, P1864, DOI 10.1073/pnas.0507444103; Wiebalk K, 2007, INT J CANCER, V121, P2340, DOI 10.1002/ijc.22981; Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007; Wood RD, 2005, MUTAT RES-FUND MOL M, V577, P275, DOI 10.1016/j.mrfmmm.2005.03.007; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861	48	27	28	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5108	5116		10.1038/onc.2011.660	http://dx.doi.org/10.1038/onc.2011.660			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22286769				2022-12-28	WOS:000312000900007
J	Barroilhet, L; Yang, J; Hasselblatt, K; Paranal, RM; Ng, SK; Rauh-Hain, JA; Welch, WR; Bradner, JE; Berkowitz, RS; Ng, SW				Barroilhet, L.; Yang, J.; Hasselblatt, K.; Paranal, R. M.; Ng, S-K; Rauh-Hain, J. A.; Welch, W. R.; Bradner, J. E.; Berkowitz, R. S.; Ng, S-W			C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors	ONCOGENE			English	Article						ovarian cancer; tumor antigens; HDAC inhibitors	TRANSCRIPTIONAL COREPRESSOR; BETA-CATENIN; CTBP; REPRESSOR; BINDING-PROTEIN-1; ASSOCIATION	Ovarian cancer survival rates have stagnated in the last 20 years despite the development of novel chemotherapeutic agents. Modulators of gene expression, such as histone deacetylase (HDAC) inhibitors, are among the new agents being used in clinical trials. Predictors of sensitivity to chemotherapy have remained elusive. In this study, we show that the expression of the transcriptional corepressor C-terminal binding protein-2 (CtBP2) is elevated in human ovarian tumors. Downregulation of CtBP2 expression in ovarian cancer cell lines using short-hairpin RNA strategy suppressed the growth rate and migration of the resultant cancer cells. The knockdown cell lines also showed upregulation of HDAC activity and increased sensitivity to selected HDAC inhibitors. Conversely, forced expression of wild-type CtBP2 in the knockdown cell lines reversed HDAC activity and partially rescued cellular sensitivity to the HDAC inhibitors. We propose that CtBP2 is an ovarian cancer oncogene that regulates gene expression program by modulating HDAC activity. CtBP2 expression may be a surrogate indicator of cellular sensitivity to HDAC inhibitors.	[Barroilhet, L.; Yang, J.; Hasselblatt, K.; Rauh-Hain, J. A.; Berkowitz, R. S.; Ng, S-W] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; [Paranal, R. M.; Bradner, J. E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Ng, S-K] Griffith Univ, Griffith Hlth Inst, Sch Med, Meadowbrook, Qld 4131, Australia; [Welch, W. R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Griffith University; Menzies Health Institute Queensland; Harvard University; Brigham & Women's Hospital	Ng, SW (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 221 Longwood Ave BLI-449A, Boston, MA 02115 USA.	sng@partners.org		Ng, Shu Kay/0000-0002-6865-9384	Ruth N White Gynecologic Oncology Research Fellowship; Robert and Deborah First Fund; Sperling Family Fund Foundation; Women's Cancer Program; Gillette Center for Women's Cancer from Dana-Farber Cancer Institute; Ovarian Cancer Research Foundation; Adler Foundation, Inc.; Friends of Dana-Farber Cancer Institute	Ruth N White Gynecologic Oncology Research Fellowship; Robert and Deborah First Fund; Sperling Family Fund Foundation; Women's Cancer Program; Gillette Center for Women's Cancer from Dana-Farber Cancer Institute; Ovarian Cancer Research Foundation; Adler Foundation, Inc.; Friends of Dana-Farber Cancer Institute	We thank critical reading of the manuscript by Professor YF Wong. We acknowledge the provision of belinostat, vorinostat, MGCD0103 from Selleck Inc. LB was supported by Ruth N White Gynecologic Oncology Research Fellowship. The Laboratory of Gynecologic Oncology was partly supported by Robert and Deborah First Fund, the Sperling Family Fund Foundation, Women's Cancer Program and Gillette Center for Women's Cancer from Dana-Farber Cancer Institute, Ovarian Cancer Research Foundation, Adler Foundation, Inc., and Friends of Dana-Farber Cancer Institute.	Altekruse SF, 2010, SEER CANC STAT REV 1; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Cuilliere-Dartigues P, 2006, ONCOGENE, V25, P4441, DOI 10.1038/sj.onc.1209471; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Engers R, 2000, J CANCER RES CLIN, V126, P682, DOI 10.1007/s004320000148; Fang M, 2006, EMBO J, V25, P2735, DOI 10.1038/sj.emboj.7601153; Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026; Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Huang KC, 2006, INT J CANCER, V118, P2433, DOI 10.1002/ijc.21671; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Tang LD, 2010, EUR J CANCER, V46, P170, DOI 10.1016/j.ejca.2009.10.003; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200	29	25	26	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3896	3903		10.1038/onc.2012.380	http://dx.doi.org/10.1038/onc.2012.380			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22945647				2022-12-28	WOS:000323210200012
J	Ansari, KI; Kasiri, S; Mandal, SS				Ansari, K. I.; Kasiri, S.; Mandal, S. S.			Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo	ONCOGENE			English	Article						MLL1; histone methylase; xenograft; antisense; hypoxia; tumor supression	CPG-BINDING-PROTEIN; METHYLTRANSFERASE ACTIVITY; CANCER XENOGRAFTS; GENE-EXPRESSION; CHROMATIN; LEUKEMIA; INHIBITION; ANTISENSE; TRITHORAX; HYPOXIA	Mixed lineage leukemias (MLLs) are human histone H3 lysine-4-specific methyl transferases that have critical roles in gene expression, epigenetics and cancer. Herein, we demonstrated that antisense-mediated knockdown of MLL1 induced cell-cycle arrest and apoptosis in cultured cells. Intriguingly, application of MLL1 antisense specifically knocked down MLL1 in vivo and suppressed the growth of xenografted cervical tumor implanted in nude mouse. MLL1 knockdown downregulated various growth and angiogenic factors, such as HIF1 alpha, VEGF and CD31, in tumor tissue affecting tumor growth. MLL1 is overexpressed along the line of vascular network and localized adjacent to endothelial cell layer expressing CD31, indicating potential roles of MLL1 in vasculogenesis. MLL1 is also overexpressed in the hypoxic regions along with HIF1 alpha. Overall, our studies demonstrated that MLL1 is a key factor in hypoxia signaling, vasculogenesis and tumor growth, and its depletion suppresses tumor growth in vivo, indicating its potential in novel cancer therapy.	[Ansari, K. I.; Kasiri, S.; Mandal, S. S.] Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA	University of Texas System; University of Texas Arlington	Mandal, SS (corresponding author), Univ Texas Arlington, Dept Chem & Biochem, 700 Planetarium Pl, Arlington, TX 76019 USA.	smandal@uta.edu		Mandal, Subhrangsu/0000-0001-8495-9881	NIH [1R15 ES019129-01, 2R15 CA113747-02]; NSF [0821969]; NATIONAL CANCER INSTITUTE [R15CA113747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R15ES019129] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Linda Perrotti and Samara Morris-Bobzean for their technical assistance with tissue sectioning and Mandal lab members for discussion. Mandal research is supported by grants from NIH (1R15 ES019129-01, 2R15 CA113747-02) and NSF (0821969).	Ansari KI, 2008, BBA-GENE REGUL MECH, V1779, P66, DOI 10.1016/j.bbagrm.2007.11.006; Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050; Ansari KI, 2011, BIOCHEMISTRY-US, V50, P3517, DOI 10.1021/bi102037t; Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x; Ansari KI, 2009, FEBS J, V276, P3299, DOI 10.1111/j.1742-4658.2009.07055.x; Ansari KI, 2009, J INORG BIOCHEM, V103, P818, DOI 10.1016/j.jinorgbio.2009.02.004; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Canaani E, 2004, BRIT J CANCER, V90, P756, DOI 10.1038/sj.bjc.6601639; Corey DR, 2002, ONCOGENE, V21, P631, DOI 10.1038/sj.onc.1205063; Crawford BD, 2006, ACS CHEM BIOL, V1, P495, DOI 10.1021/cb600367v; Cuthbert G, 2000, LEUKEMIA, V14, P1885, DOI 10.1038/sj.leu.2401919; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Deng LW, 2004, P NATL ACAD SCI USA, V101, P757, DOI 10.1073/pnas.2036345100; Diehl F, 2007, BLOOD, V109, P1472, DOI 10.1182/blood-2006-08-039651; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Glaser S, 2006, DEVELOPMENT, V133, P1423, DOI 10.1242/dev.02302; Gleave ME, 2005, NAT REV CANCER, V5, P468, DOI 10.1038/nrc1631; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Halatsch ME, 2006, CANCER TREAT REV, V32, P74, DOI 10.1016/j.ctrv.2006.01.003; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hendriksen EM, 2009, MICROVASC RES, V77, P96, DOI 10.1016/j.mvr.2008.11.002; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Joaquin M, 2012, EMBO J, V31, P2952, DOI 10.1038/emboj.2012.122; Kang CS, 2006, CANCER GENE THER, V13, P530, DOI 10.1038/sj.cgt.7700932; Kurdistani SK, 2011, PROG DRUG RES, V67, P91, DOI 10.1007/978-3-7643-8989-5_5; Lee JS, 2008, CANCER LETT, V267, P189, DOI 10.1016/j.canlet.2008.03.013; Lee J, 2008, P NATL ACAD SCI USA, V105, P19229, DOI 10.1073/pnas.0810100105; Lee JH, 2002, J BIOL CHEM, V277, P42259, DOI 10.1074/jbc.M205054200; Lee K, 2007, PHARMACOL THERAPEUT, V113, P229, DOI 10.1016/j.pharmthera.2006.08.001; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liu H, 2010, NATURE, V467, P343, DOI 10.1038/nature09350; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; Mishra BP, 2009, FEBS J, V276, P1629, DOI 10.1111/j.1742-4658.2009.06895.x; Monti Elena, 2011, Curr Mol Pharmacol, V4, P62; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Paulussen ADC, 2011, HUM MUTAT, V32, pE2018, DOI 10.1002/humu.21416; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Ruthenburg AJ, 2006, NAT STRUCT MOL BIOL, V13, P704, DOI 10.1038/nsmb1119; Ryan BM, 2009, CANCER TREAT REV, V35, P553, DOI 10.1016/j.ctrv.2009.05.003; Saigo K, 2008, HUM MUTAT, V29, P703, DOI 10.1002/humu.20701; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Sims RJ, 2004, NAT CELL BIOL, V6, P685, DOI 10.1038/ncb0804-685; Singhal SS, 2007, CANCER RES, V67, P4382, DOI 10.1158/0008-5472.CAN-06-4124; Travers J, 2011, NAT CHEM BIOL, V7, P663, DOI 10.1038/nchembio.661; Wang D, 2008, BIOTECH HISTOCHEM, V83, P179, DOI 10.1080/10520290802451085; Wang H, 2002, INT J ONCOL, V21, P73; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wang XX, 2011, PATHOL ONCOL RES, V17, P429, DOI 10.1007/s12253-010-9316-0; Watanabe Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023320; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004	59	46	47	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2013	32	28					3359	3370		10.1038/onc.2012.352	http://dx.doi.org/10.1038/onc.2012.352			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22926525	Green Accepted, Bronze			2022-12-28	WOS:000321620200006
J	Castelli, M; Pieroni, S; Brunacci, C; Piobbico, D; Bartoli, D; Bellet, MM; Colombo, E; Pelicci, PG; Della Fazia, MA; Servillo, G				Castelli, M.; Pieroni, S.; Brunacci, C.; Piobbico, D.; Bartoli, D.; Bellet, M. M.; Colombo, E.; Pelicci, P. G.; Della Fazia, M. A.; Servillo, G.			Hepatocyte odd protein shuttling (HOPS) is a bridging protein in the nucleophosmin-p19(Arf) network	ONCOGENE			English	Article						nucleophosmin (NPM); p19(Arf); hepatocyte odd protein shuttling (HOPS); Tmub1; tumor suppressor gene	ACUTE MYELOID-LEUKEMIA; ARF TUMOR-SUPPRESSOR; ACUTE MYELOGENOUS LEUKEMIA; CYTOPLASMIC NUCLEOPHOSMIN; NORMAL KARYOTYPE; NPMC(+) AML; STABILITY; B23; TUMORIGENESIS; MUTATIONS	Nucleophosmin (NPM), a ubiquitously and abundantly expressed protein, occurs in the nucleolus, shuttling between the nucleoplasm and cytoplasm. The NPM gene is mutated in almost 30% of human acute myeloid leukemia cells. NPM interacts with p53 and p19(Arf), directs localization of p19(Arf) in the nucleolus and protects the latter from degradation. Hepatocyte odd protein shuttling (HOPS) is also a ubiquitously expressed protein that moves between the nucleus and cytoplasm. Within the nucleus of resting cells, HOPS overexpression causes cell cycle arrest in G0/G1. HOPS knockdown causes centrosome hyperamplification leading to multinucleated cells and the formation of micronuclei. We demonstrate a direct interaction of HOPS with NPM and p19(Arf), resulting in a functionally active trimeric complex. NPM appeared to regulate HOPS half-life, which, in turn, stabilized p19(Arf) and controlled its localization in the nucleolus. These findings suggest that HOPS acts as a functional bridge in the interaction between NPM and p19(Arf), providing new mechanistic insight into how NPM and p19(Arf) will oppose tumor cell proliferation.	[Castelli, M.; Pieroni, S.; Brunacci, C.; Piobbico, D.; Bartoli, D.; Bellet, M. M.; Della Fazia, M. A.; Servillo, G.] Univ Perugia, Dept Clin & Expt Med, I-06124 Perugia, Italy; [Colombo, E.; Pelicci, P. G.] Inst Europeo Oncol, Dept Expt Oncol, Milan, Italy	University of Perugia; IRCCS European Institute of Oncology (IEO)	Servillo, G (corresponding author), Univ Perugia, Dept Clin & Expt Med, Via E dal Pozzo,Pad AW, I-06124 Perugia, Italy.	giuseppe.servillo@unipg.it	Colombo, Emanuela/AAO-8113-2020; Colombo, Emanuela/AAO-7810-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Bellet, Marina Maria/K-7794-2016	Colombo, Emanuela/0000-0003-2079-7398; Bellet, Marina Maria/0000-0001-7604-0189; Della Fazia, Maria Agnese/0000-0002-5373-8477; Servillo, Giuseppe/0000-0001-7960-7689; Piobbico, Danilo/0000-0003-4240-1526	Associazione Umbra Contro il Cancro (AUCC); Fondazione Guido Berlucchi; Associazione Italiana Ricerca sul Cancro (AIRC); Only the Brave Foundation; Fondazione Cassa di Risparmio di Perugia; PRIN Project [2008BH7KA2_003]; AUCC fellowship program	Associazione Umbra Contro il Cancro (AUCC); Fondazione Guido Berlucchi; Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Only the Brave Foundation; Fondazione Cassa di Risparmio di Perugia; PRIN Project(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AUCC fellowship program	We thank Paolo Puccetti and Stefano Brancorsini for the critical reading of the manuscript, Silvano Pagnotta for technical assistance. This study was supported by grants from the Associazione Umbra Contro il Cancro (AUCC), Fondazione Guido Berlucchi, the Associazione Italiana Ricerca sul Cancro (AIRC), Only the Brave Foundation and Fondazione Cassa di Risparmio di Perugia. GS is recipient of a PRIN Project n. 2008BH7KA2_003. DB, CB and DP are recipient of the AUCC fellowship program.	Alcalay M, 2005, BLOOD, V106, P899, DOI 10.1182/blood-2005-02-0560; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Braoudaki M, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-41; Brunacci C, 2010, LIVER INT, V30, P388, DOI 10.1111/j.1478-3231.2009.02174.x; Campisi J, 2007, AGING CELL, V6, P261, DOI 10.1111/j.1474-9726.2007.00292.x; Cazzaniga G, 2005, BLOOD, V106, P1419, DOI 10.1182/blood-2005-03-0899; Chou WC, 2006, CANCER RES, V66, P3310, DOI 10.1158/0008-5472.CAN-05-4316; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cordell JL, 1999, BLOOD, V93, P632, DOI 10.1182/blood.V93.2.632; Coutts AS, 2007, CELL CYCLE, V6, P827, DOI 10.4161/cc.6.7.4086; Della Fazia MA, 2005, J CELL SCI, V118, P3185, DOI 10.1242/jcs.02452; den Besten W, 2005, CELL CYCLE, V4, P1593; Enomoto T, 2006, J BIOL CHEM, V281, P18463, DOI 10.1074/jbc.M602788200; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Gjerset RA, 2006, CELL CYCLE, V5, P686, DOI 10.4161/cc.5.7.2623; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Moulin S, 2008, ONCOGENE, V27, P2382, DOI 10.1038/sj.onc.1210887; Pasqualucci L, 2006, BLOOD, V108, P4146, DOI 10.1182/blood-2006-06-026716; Pieroni S, 2008, CELL CYCLE, V7, P1462, DOI 10.4161/cc.7.10.5882; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shinmura K, 2005, FEBS LETT, V579, P6621, DOI 10.1016/j.febslet.2005.10.057; Szebeni A, 1999, PROTEIN SCI, V8, P905; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Yang HJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002809; Zhang WD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011261	38	19	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2013	32	28					3350	3358		10.1038/onc.2012.353	http://dx.doi.org/10.1038/onc.2012.353			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22890319				2022-12-28	WOS:000321620200005
J	Kim, W; Kim, SY; Kim, T; Kim, M; Bae, DJ; Choi, HI; Kim, IS; Jho, E				Kim, W.; Kim, S. Y.; Kim, T.; Kim, M.; Bae, D-J; Choi, H-I; Kim, I-S; Jho, E.			ADP-ribosylation factors 1 and 6 regulate Wnt/beta-catenin signaling via control of LRP6 phosphorylation	ONCOGENE			English	Article						ADP-ribosylation factor (Arf); Wnt; signal transduction; phosphatidylinositol 4,5 bisphosphate (PtdIns (4,5)P-2); LRP6	NUCLEOTIDE-EXCHANGE FACTORS; BETA-CATENIN; ARF FAMILY; ACTIVATION; MEMBRANE; PROTEINS; PATHWAY; COMPLEX; ENDOCYTOSIS; MECHANISM	It has been shown that inhibition of GTPase-activating protein of ADP-ribosylation factor (Arf), ArfGAP, with a small molecule (QS11) results in synergistic activation of Wnt/beta-catenin signaling. However, the role of Arf in Wnt/b-catenin signaling has not yet been elucidated. Here, we show that activation of Arf is essential for Wnt/beta-catenin signaling. The level of the active form of Arf (Arf-GTP) transiently increased in the presence of Wnt, and this induction event was abrogated by blocking the interaction between Wnt and Frizzled (Fzd). In addition, knockdown of Fzds, Dvls or LRP6 blocked the Wnt-mediated activation of Arf. Consistently, depletion of Arf led to inhibition of Wnt-mediated membrane PtdIns (4,5)P-2 (phosphatidylinositol 4,5-bisphosphate) synthesis and LRP6 phosphorylation. Overall, our data suggest that transient activation of Arf modulates LRP6 phosphorylation for the transduction of Wnt/beta-catenin signaling.	[Kim, W.; Kim, T.; Kim, M.; Jho, E.] Univ Seoul, Dept Life Sci, Seoul, South Korea; [Kim, S. Y.; Bae, D-J; Choi, H-I; Kim, I-S] Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Cell & Matrix Res Inst, Taegu 700422, South Korea; [Kim, I-S] Korea Inst Sci & Technol, Biomed Res Inst, Seoul, South Korea	University of Seoul; Kyungpook National University; Korea Institute of Science & Technology (KIST)	Kim, IS (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Cell & Matrix Res Inst, 101 Dongin 2Ga, Taegu 700422, South Korea.	iskim@knu.ac.kr; ej70@uos.ac.kr	김, 인산/I-8988-2014	Jho, Eek-hoon/0000-0003-2414-6234; Choi, Hee-Jung/0000-0002-1167-1526	National Research Foundation of Korea; Ministry of Education, Science and Technology [2006-2004046, 2012R1A2A2A01012472, 2010-0029206, 2011-0003980]; Brain Korea 21 program	National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Brain Korea 21 program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea)	This work was supported by grants from the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2006-2004046 and 2012R1A2A2A01012472 to E-HJ; 2010-0029206 to I-SK; 2011-0003980 to S-YK). WK, TK, and MK were supported by the Brain Korea 21 program.	Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Gagliardi M, 2008, TRAFFIC, V9, P1, DOI 10.1111/j.1600-0854.2007.00662.x; Giguere P, 2006, CELL SIGNAL, V18, P1988, DOI 10.1016/j.cellsig.2006.03.003; Gillingham AK, 2007, ANNU REV CELL DEV BI, V23, P579, DOI 10.1146/annurev.cellbio.23.090506.123209; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Hall B, 2008, ANAL BIOCHEM, V374, P243, DOI 10.1016/j.ab.2007.11.032; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Kahn RA, 2006, J CELL BIOL, V172, P645, DOI 10.1083/jcb.200512057; Kumari S, 2008, NAT CELL BIOL, V10, P30, DOI 10.1038/ncb1666; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; MacDonald BT, 2008, J BIOL CHEM, V283, P16115, DOI 10.1074/jbc.M800327200; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Nishida K, 2011, J IMMUNOL, V187, P932, DOI 10.4049/jimmunol.1100360; Nishioka T, 2008, MOL BIOL CELL, V19, P4213, DOI 10.1091/mbc.E08-03-0315; Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741; Perez-Mansilla B, 2006, BBA-MOL CELL BIOL L, V1761, P1429, DOI 10.1016/j.bbalip.2006.09.006; Sakane H, 2010, J CELL SCI, V123, P360, DOI 10.1242/jcs.058008; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Sawano A, 2000, Nucleic Acids Res, V28, pE78, DOI 10.1093/nar/28.16.e78; Shin HW, 2004, J BIOCHEM, V136, P761, DOI 10.1093/jb/mvh185; Suzuki T, 2006, MOL CELL BIOL, V26, P6149, DOI 10.1128/MCB.00298-06; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhang QS, 2007, P NATL ACAD SCI USA, V104, P7444, DOI 10.1073/pnas.0702136104	40	20	20	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2013	32	28					3390	3396		10.1038/onc.2012.373	http://dx.doi.org/10.1038/onc.2012.373			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22907437				2022-12-28	WOS:000321620200009
J	Gong, J; Zhang, JP; Li, B; Zeng, C; You, K; Chen, MX; Yuan, Y; Zhuang, SM				Gong, J.; Zhang, J-P; Li, B.; Zeng, C.; You, K.; Chen, M-X; Yuan, Y.; Zhuang, S-M			MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R	ONCOGENE			English	Article						miR-125b; apoptosis; Mcl-1; Bcl-w; IL-6R; hepatocellular carcinoma	HEPATOCELLULAR-CARCINOMA; MIR-125B; CANCER; SUPPRESSES; PROLIFERATION; DEREGULATION; TARGET; GROWTH; CELLS; GENE	The microRNA miR-125b is multi-faceted, with the ability to function as a tumor suppressor or an oncogene, depending on the cellular context. To date, the pro-apoptotic role of miR-125b and its underlying mechanisms are unexplored. In this study, both gain-and loss-of-function experiments revealed that miR-125b expression not only induced spontaneous apoptosis in various cell lines derived from the liver, lung and colorectal cancers, but also sensitized cancer cells to diverse apoptotic stimuli, including nutrient starvation and chemotherapeutic treatment. Furthermore, downregulation of miR-125b was a frequent event in hepatocellular carcinoma (HCC) tissues, and the miR-125b level was positively associated with the rate of apoptosis in HCC tissues. Subsequent investigations identified Mcl-1, Bcl-w and interleukin (IL)-6R as direct targets of miR-125b. Restoration of miR-125b expression not only diminished the expression of Mcl-1 and Bcl-w directly but also indirectly reduced the Mcl-1 and Bcl-xL levels by attenuating IL-6/signal transducer and activator of transcription 3 signaling. Consistent with these findings, introduction of miR-125b reduced the mitochondrial membrane potential and promoted the cleavage of pro-caspase-3. These data indicate that miR-125b may promote apoptosis by suppressing the anti-apoptotic molecules of the Bcl-2 family and miR-125b downregulation may facilitate tumor development by conferring upon cells the capability to survive under conditions of nutrient deprivation and chemotherapeutic treatment. Our findings highlight the importance of miR-125b in the regulation of apoptosis and suggest miR-125b as an attractive target for anti-cancer therapy.	[Gong, J.; Zhang, J-P; Zeng, C.; You, K.; Zhuang, S-M] Sch Life Sci, Dept Biochem, State Key Lab Biocontrol, Key Lab Gene Engn,Minist Educ, Guangzhou, Guangdong, Peoples R China; [Li, B.; Chen, M-X; Yuan, Y.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Dept Hepatobiliary Oncol, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Yuan, Y (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Hepatobiliary Oncol, Dongfengdong Rd 651, Guangzhou 510060, Guangdong, Peoples R China.	yuanyf@mail.sysu.edu.cn; zhuangshimei@163.com	ZHANG, JINGPING/AAT-8229-2021; zhang, jingping/AAM-2751-2021	zhang, jingping/0000-0003-0090-6710; , Gong/0000-0003-3767-1636; Yuan, Yunfei/0000-0003-2467-3683; Li, Binkui/0000-0003-3201-2914; Zhuang, Shi-Mei/0000-0002-2512-3942	Ministry of Science and Technology of China [2010CB912803, 2011CB811305]; Ministry of Health of China [2012ZX10002-011]; National Natural Science Foundation of China [30925036]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Ministry of Health of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the Ministry of Science and Technology of China (2010CB912803 and 2011CB811305), the Ministry of Health of China (2012ZX10002-011) and the National Natural Science Foundation of China (30925036).	Alpini G, 2011, J HEPATOL, V55, P1339, DOI 10.1016/j.jhep.2011.04.015; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Bousquet M, 2008, J EXP MED, V205, P2499, DOI 10.1084/jem.20080285; Bousquet M, 2010, P NATL ACAD SCI USA, V107, P21558, DOI 10.1073/pnas.1016611107; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; Glud M, 2011, MELANOMA RES, V21, P253, DOI 10.1097/CMR.0b013e328345333b; Guan Y, 2011, INT J CANCER, V128, P2274, DOI 10.1002/ijc.25575; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hofmann MH, 2009, MOL CANCER RES, V7, P1635, DOI 10.1158/1541-7786.MCR-09-0043; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lee HW, 2003, CANCER RES, V63, P1093; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Li WX, 2008, INT J CANCER, V123, P1616, DOI 10.1002/ijc.23693; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Pogue AI, 2010, NEUROSCI LETT, V476, P18, DOI 10.1016/j.neulet.2010.03.054; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270; Sieghart W, 2006, J HEPATOL, V44, P151, DOI 10.1016/j.jhep.2005.09.010; Soresi M, 2006, WORLD J GASTROENTERO, V12, P2563, DOI 10.3748/wjg.v12.i16.2563; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Surdziel E, 2011, BLOOD, V117, P4338, DOI 10.1182/blood-2010-06-289058; Takehara T, 2001, HEPATOLOGY, V34, P55, DOI 10.1053/jhep.2001.25387; Xia HF, 2009, CELL PHYSIOL BIOCHEM, V23, P347, DOI 10.1159/000218181; Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435	35	151	158	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3071	3079		10.1038/onc.2012.318	http://dx.doi.org/10.1038/onc.2012.318			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22824797				2022-12-28	WOS:000320705700007
J	Jacque, E; Billot, K; Authier, H; Bordereaux, D; Baud, V				Jacque, E.; Billot, K.; Authier, H.; Bordereaux, D.; Baud, V.			RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation	ONCOGENE			English	Article						RelB; NF-kappa B; cell proliferation; p53	NF-KAPPA-B; NUCLEAR-FACTOR; KINASE-ALPHA; MULTIPLE-MYELOMA; GENE-EXPRESSION; PROMOTES; PATHWAYS; DEATH; CARCINOMAS; SUPPRESSOR	The alternative nuclear factor-kappaB (NF-kappa B) - activation pathway proceeds via inducible p100 processing, leading to the activation of RelB-containing dimers. This pathway is aberrantly activated in several types of tumors; however, a direct role for RelB in the control of cell proliferation is still largely unexplored. Here, we demonstrate that RelB provides cell proliferation-inhibitory signals in murine fibroblasts. In agreement with these results, RelB ectopic expression inhibits xenograft tumor growth in vivo, whereas RelB knockdown enhances it. Significantly, we show that RelB inhibits cell proliferation and tumor growth in a p53-dependent manner. Mechanistic studies indicate that RelB regulates the transcription of the p53 tumor-suppressor gene through direct recruitment to the p53 promoter, thus increasing both p53 protein levels and expression of p53 target genes such as p21. Our findings define a novel link between NF-kappa B and growth-inhibitory pathways involving the RelB-dependent transcriptional upregulation of p53. Furthermore, they suggest that inhibition of RelB in some tumor types that retain wild-type p53 may diminish rather than improve therapeutic responses.	[Jacque, E.; Billot, K.; Authier, H.; Bordereaux, D.; Baud, V.] INSERM, Dept Immunol Hematol, Inst Cochin, U1016, F-75014 Paris, France; [Jacque, E.; Billot, K.; Authier, H.; Bordereaux, D.; Baud, V.] CNRS, UMR 8104, Paris, France; [Jacque, E.; Billot, K.; Authier, H.; Bordereaux, D.; Baud, V.] Univ Paris 05, Sorbonne Paris Cite, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Baud, V (corresponding author), INSERM, Dept Immunol Hematol, Inst Cochin, U1016, 123 Blvd Port Royal, F-75014 Paris, France.	veronique.baud@inserm.fr	Baud, Veronique/F-7699-2013; Baud, Veronique/AAL-3950-2020	Baud, Veronique/0000-0002-4090-718X; Baud, Veronique/0000-0002-4090-718X; authier, helene/0000-0002-5556-4570	Agence Nationale pour la Recherche (ANR); Association pour la Recherche sur le Cancer; Belgian InterUniversity Attraction Pole; Canceropole Ile-deFrance and Universite Paris Descartes,; Ministere de la Recherche et des Technologies; Ligue Nationale contre le Cancer; Societe Francaise du Cancer; Bettencourt-Schueller Fundation	Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Belgian InterUniversity Attraction Pole(Belgian Federal Science Policy Office); Canceropole Ile-deFrance and Universite Paris Descartes,; Ministere de la Recherche et des Technologies; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Societe Francaise du Cancer; Bettencourt-Schueller Fundation	D Reisman, G Kroemer, JL Perfettini, M Korner, LA Martinez, T Tchenio, J Browning and I Verma for valuable material; G Piton for technical assistance; N Boggetto for cell sorting (ImagoSeine, Institut Monod, France, Region Ile-de-France grant no. E539); and LL Pritchard for critically reading the manuscript. This work was supported by grants to VB from Agence Nationale pour la Recherche (ANR), Association pour la Recherche sur le Cancer, Belgian InterUniversity Attraction Pole, Canceropole Ile-deFrance and Universite Paris Descartes, post-doctoral funding from ANR (HA and KB), doctoral fellowships from Ministere de la Recherche et des Technologies, Ligue Nationale contre le Cancer, and Societe Francaise du Cancer (EJ), and an award from the Bettencourt-Schueller Fundation (EJ).	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Barre B, 2010, MOL CELL, V38, P524, DOI 10.1016/j.molcel.2010.03.018; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008-5472.CAN-07-1576; Chen F, 2006, J BIOL CHEM, V281, P37142, DOI 10.1074/jbc.M603631200; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fan YJ, 2008, ADV EXP MED BIOL, V615, P223, DOI 10.1007/978-1-4020-6554-5_11; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Jacque E, 2005, P NATL ACAD SCI USA, V102, P14635, DOI 10.1073/pnas.0507342102; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kieusseian A, 2006, BLOOD, V107, P492, DOI 10.1182/blood-2005-02-0529; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Liu BG, 2006, P NATL ACAD SCI USA, V103, P17202, DOI 10.1073/pnas.0604481103; Maeda G, 2007, CLIN CANCER RES, V13, P5041, DOI 10.1158/1078-0432.CCR-07-0463; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324; Mise N, 2006, ONCOGENE, V25, P6637, DOI 10.1038/sj.onc.1209669; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Park E, 2007, CANCER RES, V67, P9158, DOI 10.1158/0008-5472.CAN-07-0590; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Roy B, 1996, ONCOGENE, V13, P2359; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4; Xia YF, 2009, P NATL ACAD SCI USA, V106, P2629, DOI 10.1073/pnas.0812256106; Xu Y, 2009, CANCER RES, V69, P3267, DOI 10.1158/0008-5472.CAN-08-4635; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904	45	20	21	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 23	2013	32	21					2661	2669		10.1038/onc.2012.282	http://dx.doi.org/10.1038/onc.2012.282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22777360				2022-12-28	WOS:000319806700007
J	Agarwal, NK; Chen, CH; Cho, H; Boulbes, DR; Spooner, E; Sarbassov, DD				Agarwal, N. K.; Chen, C-H; Cho, H.; Boulbes, D. R.; Spooner, E.; Sarbassov, D. D.			Rictor regulates cell migration by suppressing RhoGDI2	ONCOGENE			English	Article						rictor (rapamycin-insensitive companion of mTOR); cell migration; Rho proteins; RhoGDI2	GDP-DISSOCIATION INHIBITOR; ENDOPLASMIC-RETICULUM; AKT PHOSPHORYLATION; MTOR COMPLEX; CANCER; METASTASIS; ACTIVATION; GROWTH; SITE; DICTYOSTELIUM	Rictor and its binding partner Sin1 are indispensable components of mTORC2 (mammalian target of rapamycin complex 2). The mTORC2 signaling complex functions as the regulatory kinase of the distinct members of AGC kinase family known to regulate cell proliferation and survival. In the early chemotaxis studies in Dictyostelium, the rictor's ortholog has been identified as a regulator of cell migration. How rictor regulates cell migration is poorly characterized. Here we show that rictor regulates cell migration by controlling a potent inhibitor of Rho proteins known as the Rho-GDP dissociation inhibitor 2 (RhoGDI2). On the basis of on our proteomics study we identified that the rictor-dependent deficiency in cell migration is caused by upregulation of RhoGDI2 leading to a low activity of Rac and Cdc42. We found that a suppression of RhoGDI2 by rictor is not related to the Sin1 or raptor function that excludes a role of mTORC2 or mTORC1 in regulation of RhoGDI2. Our study reveals that rictor by suppressing RhoGDI2 promotes activity of the Rho proteins and cell migration.	[Agarwal, N. K.; Chen, C-H; Cho, H.; Boulbes, D. R.; Sarbassov, D. D.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Chen, C-H; Cho, H.; Sarbassov, D. D.] Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX USA; [Spooner, E.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Massachusetts Institute of Technology (MIT); Whitehead Institute	Sarbassov, DD (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dsarbass@mdanderson.org	Sarbassov, Dos/AAS-4950-2020	Sarbassov, Dos/0000-0002-6848-1133	MD Anderson Metastasis Research Program; NIH [CA133522]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA133522] Funding Source: NIH RePORTER	MD Anderson Metastasis Research Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank MA Magnuson for providing the immortalized rictor null MEFs, David A Guertin and David M Sabatini for providing the rictor null primary MEFs, and Bin Su for providing Sin1 null MEFs. This study was supported by the MD Anderson Metastasis Research Program and the NIH grant CA133522 (DDS).	Aimbetov R, 2012, ONCOGENE, V31, P2115, DOI 10.1038/onc.2011.404; Boulbes D, 2010, MOL CANCER RES, V8, P896, DOI 10.1158/1541-7786.MCR-09-0409; Boulbes DR, 2011, BIOCHEM BIOPH RES CO, V413, P46, DOI 10.1016/j.bbrc.2011.08.034; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chen CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001731; Chen MY, 1997, GENE DEV, V11, P3218, DOI 10.1101/gad.11.23.3218; Dihazi H, 2005, MOL CELL PROTEOMICS, V4, P1445, DOI 10.1074/mcp.M400184-MCP200; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Gao DM, 2010, MOL CELL, V39, P797, DOI 10.1016/j.molcel.2010.08.016; Gildea JJ, 2002, CANCER RES, V62, P6418; Hagan GN, 2008, MOL CELL BIOL, V28, P4215, DOI 10.1128/MCB.00867-07; Imai K, 2002, BIOCHEM BIOPH RES CO, V296, P305, DOI 10.1016/S0006-291X(02)00861-6; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200; Kim SV, 2008, CELL MOL LIFE SCI, V65, P2128, DOI 10.1007/s00018-008-7435-5; Klemm EJ, 2011, J BIOL CHEM, V286, P37602, DOI 10.1074/jbc.M111.284794; Liu LH, 2010, DEV CELL, V19, P845, DOI 10.1016/j.devcel.2010.11.004; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Moissoglu K, 2009, CANCER RES, V69, P2838, DOI 10.1158/0008-5472.CAN-08-1397; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Said N, 2009, CANCER METAST REV, V28, P327, DOI 10.1007/s10555-009-9197-4; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; Zhang YQ, 2009, J BIOL CHEM, V284, P12956, DOI 10.1074/jbc.M807845200; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	33	46	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2013	32	20					2521	2526		10.1038/onc.2012.287	http://dx.doi.org/10.1038/onc.2012.287			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22777355	Green Accepted			2022-12-28	WOS:000319274300003
J	Garcia, AG; Nedev, H; Bijian, K; Su, J; Alaoui-Jamali, MA; Saragovi, HU				Garcia, A. Galan; Nedev, H.; Bijian, K.; Su, J.; Alaoui-Jamali, M. A.; Saragovi, H. U.			Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs	ONCOGENE			English	Article						therapeutic window; chemotherapy; herceptin; conjugate; metastasis	MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; DOXORUBICIN; RESISTANCE; HER2; TRASTUZUMAB; EFFICACY; RECEPTOR; THERAPY; MECHANISMS	Anthracyclines and taxanes have remarkable anticancer efficacy, but have poor selectivity and high toxicity. Targeted delivery of chemotherapeutics has emerged as a strategy to achieve higher drug levels at the tumor site, to spare noncancerous tissue and potentially to use lower systemic drug doses, thus preventing side effects. In this study, we targeted the HER2 receptor using the monoclonal antibody (mAb) Herceptin (Trastuzumab) chemically conjugated to Doxorubicin or Taxol. In vitro, drug-Herceptin conjugates exhibited cytotoxicity comparable to equimolar concentrations of free drugs, with the benefit that the cytotoxicity of the conjugates was selective for cells expressing the HER2 target. In vivo, treatment of tumor-bearing mice with Taxol-Herceptin conjugates had a reduction of primary tumors comparable to equivalent doses of free drugs. However, Taxol-Herceptin conjugates significantly reduced metastasis compared with equivalent doses of free drugs. Thus, the data support the concept that conjugates might target metastasis better than primary tumors. This would offer a potential therapeutic approach for management of metastatic breast cancer.	[Garcia, A. Galan; Nedev, H.; Bijian, K.; Su, J.; Alaoui-Jamali, M. A.; Saragovi, H. U.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; [Alaoui-Jamali, M. A.; Saragovi, H. U.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3T 1E2, Canada; [Alaoui-Jamali, M. A.; Saragovi, H. U.] McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; [Alaoui-Jamali, M. A.; Saragovi, H. U.] McGill Univ, Ctr Canc, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Saragovi, HU (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst, 3755 Cote St Catherine E 535, Montreal, PQ H3T 1E2, Canada.	uri.saragovi@mcgill.ca			McGill Center for Experimental Therapeutics in Cancer Fund; Canadian Institutes of Health Research (CIHR); Quebec Breast Cancer Foundation	McGill Center for Experimental Therapeutics in Cancer Fund; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Quebec Breast Cancer Foundation	We are thankful to Amrit Kirpalani for help with in vivo assays. This work was funded by the McGill Center for Experimental Therapeutics in Cancer Fund to Cure Breast Cancer, and by the Canadian Institutes of Health Research (CIHR), and in part by the Quebec Breast Cancer Foundation.	Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Alley SC, 2010, CURR OPIN CHEM BIOL, V14, P529, DOI 10.1016/j.cbpa.2010.06.170; Anhorn MG, 2008, BIOCONJUGATE CHEM, V19, P2321, DOI 10.1021/bc8002452; Barros FFT, 2010, HISTOPATHOLOGY, V56, P560, DOI 10.1111/j.1365-2559.2010.03494.x; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Cooley S, 1999, EXP HEMATOL, V27, P1533, DOI 10.1016/S0301-472X(99)00089-2; da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364; Danesi R, 2002, CLIN PHARMACOKINET, V41, P431, DOI 10.2165/00003088-200241060-00004; de Azambuja E, 2009, TARGET ONCOL, V4, P77, DOI 10.1007/s11523-009-0112-2; Dean-Colomb W, 2008, EUR J CANCER, V44, P2806, DOI 10.1016/j.ejca.2008.09.013; El Bayoumil T, 2009, CLIN CANCER RES, V15, P1973, DOI 10.1158/1078-0432.CCR-08-2392; Freudenberg JA, 2009, EXP MOL PATHOL, V87, P1, DOI 10.1016/j.yexmp.2009.05.001; Guillemard V, 2005, DNA CELL BIOL, V24, P350, DOI 10.1089/dna.2005.24.351; Guillemard V, 2004, CURR CANCER DRUG TAR, V4, P313, DOI 10.2174/1568009043332989; Guillemard V, 2004, ONCOGENE, V23, P3613, DOI 10.1038/sj.onc.1207463; Guillemard V, 2001, CANCER RES, V61, P694; Harris M, 2004, LANCET ONCOL, V5, P292, DOI 10.1016/S1470-2045(04)01467-6; KATO H, 1993, J BIOL CHEM, V268, P2655; Kojic LD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003597; Krop IE, 2010, J CLIN ONCOL, V28, P2698, DOI 10.1200/JCO.2009.26.2071; Lyass O, 2000, CANCER, V89, P1037, DOI 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z; MENZIN AW, 1994, GYNECOL ONCOL, V54, P103; Monneret C, 2001, EUR J MED CHEM, V36, P483, DOI 10.1016/S0223-5234(01)01244-2; Nabholtz JM, 2005, EXPERT OPIN PHARMACO, V6, P1073, DOI 10.1517/14656566.6.7.1073; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Omelyanenko V, 1996, J DRUG TARGET, V3, P357, DOI 10.3109/10611869608996827; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Pritchard KI, 2006, NEW ENGL J MED, V354, P2103, DOI 10.1056/NEJMoa054504; Rayson D, 2008, ANN ONCOL, V19, P1530, DOI 10.1093/annonc/mdn292; Reichert JM, 2008, CURR PHARM BIOTECHNO, V9, P423, DOI 10.2174/138920108786786358; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stan AC, 1999, CANCER RES, V59, P115; Stockmeyer B, 2003, J IMMUNOL, V171, P5124, DOI 10.4049/jimmunol.171.10.5124; Tai WY, 2010, J CONTROL RELEASE, V146, P264, DOI 10.1016/j.jconrel.2010.04.009; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; Tubiana-Hulin M, 2005, CANCER TREAT REV, V31, pS3, DOI 10.1016/S0305-7372(05)80002-7; Windebank AJ, 1999, CURR OPIN NEUROL, V12, P565, DOI 10.1097/00019052-199910000-00010; Xu Y, 2009, BRIT J CANCER, V100, P633, DOI 10.1038/sj.bjc.6604901; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Yu DH, 2001, SEMIN ONCOL, V28, P12	46	7	9	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2527	2533		10.1038/onc.2012.283	http://dx.doi.org/10.1038/onc.2012.283			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22797066				2022-12-28	WOS:000319274300004
J	Jin, C; Rajabi, H; Rodrigo, CM; Porco, JA; Kufe, D				Jin, C.; Rajabi, H.; Rodrigo, C. M.; Porco, J. A., Jr.; Kufe, D.			Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein	ONCOGENE			English	Article						MUC1-C; translation; AKT; mTOR; PDCD4; silvestrol	GROWTH-FACTOR RECEPTOR; MOLECULAR-MECHANISMS; CARCINOMA ANTIGEN; ACTIVATION; SURVIVAL; DEGRADATION; SILVESTROL; EXPRESSION; INHIBITORS; INITIATION	The oncogenic MUC1 C-terminal subunit (MUC1-C) subunit is aberrantly overexpressed in most human breast cancers by mechanisms that are not well understood. The present studies demonstrate that stimulation of non-malignant MCF-10A cells with epidermal growth factor (EGF) or heregulin (HRG) results in marked upregulation of MUC1-C translation. Growth factor-induced MUC1-C translation was found to be mediated by PI3K -> AKT, and not by MEK -> ERK1/2, signaling. We also show that activation of the mammalian target of rapamycin complex 1 (mTORC1)-> ribosomal protein S6 kinase 1 (S6K1) pathway decreases tumor suppressor programmed cell death protein 4 (PDCD4), an inhibitor of the eIF4A RNA helicase, and contributes to the induction of MUC1-C translation. In concert with these results, treatment of growth factor-stimulated MCF-10A cells with the eIF4A RNA helicase inhibitors, silvestrol and CR-1-31-B, blocked increases in MUC1-C abundance. The functional significance of the increase in MUC1-C translation is supported by the demonstration that MUC1-C, in turn, forms complexes with EGF receptor (EGFR) and promotes EGFR-mediated activation of the PI3K -> AKT pathway and the induction of growth. Compared with MCF-10A cells, constitutive overexpression of MUC1-C in breast cancer cells was unaffected by EGF stimulation, but was blocked by inhibiting PI3K -> AKT signaling. The overexpression of MUC1-C in breast cancer cells was also inhibited by blocking eIF4A RNA helicase activity with silvestrol and CR-1-31-B. These findings indicate that EGF-induced MUC1-C expression is mediated by the PI3K -> AKT pathway and the eIF4A RNA helicase, and that this response promotes EGFR signaling in an autoinductive loop. The findings also indicate that targeting the eIF4A RNA helicase is a novel approach for blocking MUC1-C overexpression in breast cancer cells. Oncogene (2013) 32, 2179-2188; doi:10.1038/onc.2012.236; published online 11 June 2012	[Jin, C.; Rajabi, H.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; [Rodrigo, C. M.; Porco, J. A., Jr.] Boston Univ, Dept Chem, Ctr Chem Methodol & Lib Dev, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Boston University	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute [CA97098, CA42802, CA100707]; National Institutes of Health Grant [GM-073855]; American Cancer Society [PF-11-077-01-CDD]; NATIONAL CANCER INSTITUTE [R01CA166480, R01CA097098, P50CA100707, R01CA042802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073855] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Cancer Institute Grants CA97098, CA42802 and CA100707; the National Institutes of Health Grant GM-073855 (JAP), and a postdoctoral fellowship from the American Cancer Society PF-11-077-01-CDD (CMR).	Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Bordeleau ME, 2008, J CLIN INVEST, V118, P2651, DOI 10.1172/JCI34753; Cencic R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005223; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Gerard B, 2007, ANGEW CHEM INT EDIT, V46, P7831, DOI 10.1002/anie.200702707; Hsieh AC, 2011, BRIT J CANCER, V105, P329, DOI 10.1038/bjc.2011.241; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Hwang BY, 2004, J ORG CHEM, V69, P3350, DOI 10.1021/jo040120f; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Joshi MD, 2009, MOL CANCER THER, V8, P3056, DOI 10.1158/1535-7163.MCT-09-0646; Kong D, 2009, CURR MED CHEM, V16, P2839, DOI 10.2174/092986709788803222; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Lucas DM, 2009, BLOOD, V113, P4656, DOI 10.1182/blood-2008-09-175430; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Newton R, 2000, BRIT J PHARMACOL, V130, P1353, DOI 10.1038/sj.bjp.0703431; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Parsyan A, 2011, NAT REV MOL CELL BIO, V12, P235, DOI 10.1038/nrm3083; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Rodrigo CM, 2012, J MED CHEM, V55, P558, DOI 10.1021/jm201263k; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Schatz JH, 2011, J EXP MED, V208, P1799, DOI 10.1084/jem.20110846; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wedeken L, 2011, J BIOL CHEM, V286, P42855, DOI 10.1074/jbc.M111.269456; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Workman P, 2010, CANCER RES, V70, P2146, DOI 10.1158/0008-5472.CAN-09-4355; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Yin L, 2007, J BIOL CHEM, V282, P257, DOI 10.1074/jbc.M610156200; Zhou YC, 2011, MOL PHARMACOL, V79, P886, DOI 10.1124/mol.110.070797	44	29	32	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2179	2188		10.1038/onc.2012.236	http://dx.doi.org/10.1038/onc.2012.236			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689062	Green Accepted			2022-12-28	WOS:000318062800007
J	Bastid, J; Cottalorda-Regairaz, A; Alberici, G; Bonnefoy, N; Eliaou, JF; Bensussan, A				Bastid, J.; Cottalorda-Regairaz, A.; Alberici, G.; Bonnefoy, N.; Eliaou, J-F; Bensussan, A.			ENTPD1/CD39 is a promising therapeutic target in oncology	ONCOGENE			English	Review						regulatory T cells; immunotherapy; antibody	REGULATORY T-CELLS; ADENOSINE-MEDIATED INHIBITION; LOW-DOSE CYCLOPHOSPHAMIDE; SYNERGISTIC UP-REGULATION; A(2A) RECEPTOR AGONISTS; IN-VIVO EXPANSION; EXTRACELLULAR ATP; CAUSES REGRESSION; IMMUNE-RESPONSES; CD39 EXPRESSION	Regulatory T cells (Tregs) are a subpopulation of CD4(+) T cells that are essential for maintaining the homeostasis of the immune system, limiting self-reactivity and excessive immune responses against foreign antigens. In cancer, infiltrated Tregs inhibit the effector lymphocytes and create a favorable environment for the growth of the tumor. Although Tregs mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities. Here, we review the recent literature supporting CD39 as a promising therapeutic target in oncology. In vitro and in vivo experiments involving knockout models and surrogate inhibitors of CD39 provide evidence in support of the anticancer activity of CD39 inhibition and predict a favorable safety profile for CD39 inhibitory compounds. In addition, we report the ongoing development of CD39-blocking monoclonal antibodies as potential anticancer drugs. Indeed, CD39 antagonistic antibodies could represent novel therapeutic tools for selectively inhibiting Treg function without depletion, a major limitation of current Treg-targeting strategies. Oncogene (2013) 32, 1743-1751; doi: 10.1038/onc.2012.269; published online 2 July 2012	[Bastid, J.; Cottalorda-Regairaz, A.; Alberici, G.] Espace Europeen, OREGA Biotech, F-69130 Ecully, France; [Bonnefoy, N.] Univ Lyon, Lyon, France; [Bonnefoy, N.; Eliaou, J-F] INSERM, U851, F-69008 Lyon, France; [Bonnefoy, N.; Eliaou, J-F] Univ Lyon 1, US8, UMS3444, F-69365 Lyon, France; [Eliaou, J-F] Univ Montpellier I, Ctr Hosp Reg Univ Montpellier, Dept Immunol, Montpellier, France; [Eliaou, J-F] Univ Montpellier I, Fac Med, Montpellier, France; [Bensussan, A.] INSERM, UMR S 976, Paris, France; [Bensussan, A.] Univ Paris Diderot, Sorbonne Paris Cite, Lab Immunol Dermatol & Oncol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Bastid, J (corresponding author), Espace Europeen, OREGA Biotech, Dept Oncol, Batiment G,15 Chemin Saquin, F-69130 Ecully, France.	jeremy.bastid@orega-biotech.com; armand.bensussan@inserm.fr	Bonnefoy, Nathalie/J-2536-2012; Bensussan, Armand/E-5434-2017	Bonnefoy, Nathalie/0000-0003-4814-6722; Bensussan, Armand/0000-0002-0409-2497	INSERM; ANR; OSEO	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ANR(French National Research Agency (ANR)); OSEO	We would like to acknowledge our collaborators, Dr Patrice Hemon, INSERM UMR-S 976 and Ms Caroline Laheurte, INSERM U851. This work was supported by an INSERM and ANR grant (Emergence-BIO 2008 awarded to AB) and OSEO (OSEO aide au transfert awarded to NB).	Beyer M, 2006, BLOOD, V107, P3940, DOI 10.1182/blood-2005-09-3671; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; CHAHWALA SB, 1984, J BIOL CHEM, V259, P3717; Clayton A, 2011, J IMMUNOL, V187, P676, DOI 10.4049/jimmunol.1003884; Colombo MP, 2007, NAT REV CANCER, V7, P880, DOI 10.1038/nrc2250; Couper KN, 2009, J IMMUNOL, V182, P3985, DOI 10.4049/jimmunol.0803053; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Dwyer KM, 2007, PURINERG SIGNAL, V3, P171, DOI 10.1007/s11302-006-9050-y; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; EPPELL BA, 1989, J IMMUNOL, V143, P4141; Feng LL, 2011, NEOPLASIA, V13, P206, DOI 10.1593/neo.101332; Friedman DJ, 2009, P NATL ACAD SCI USA, V106, P16788, DOI 10.1073/pnas.0902869106; Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; GOUTTEFANGEAS C, 1992, EUR J IMMUNOL, V22, P2681, DOI 10.1002/eji.1830221031; Gouttefangeas C, 1995, LEUCOCYTE TYPING 5; Greten TF, 2010, J IMMUNOTHER, V33, P211, DOI 10.1097/CJI.0b013e3181bb499f; Griffiths RW, 2007, CANCER IMMUNOL IMMUN, V56, P1743, DOI 10.1007/s00262-007-0318-z; Hausler SFM, 2011, CANCER IMMUNOL IMMUN, V60, P1405, DOI 10.1007/s00262-011-1040-4; Hasko G, 2012, ARTERIOSCL THROM VAS, V32, P865, DOI 10.1161/ATVBAHA.111.226852; Hilchey SP, 2009, J IMMUNOL, V183, P6157, DOI 10.4049/jimmunol.0900475; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; Jackson SW, 2007, AM J PATHOL, V171, P1395, DOI 10.2353/ajpath.2007.070190; Jones Emma, 2002, Cancer Immun, V2, P1; Koziak K, 1999, THROMB HAEMOSTASIS, V82, P1538; Kunzli BM, 2007, AM J PHYSIOL-GASTR L, V292, pG223, DOI 10.1152/ajpgi.00259.2006; Kunzli BM, 2011, PURINERG SIGNAL, V7, P231, DOI 10.1007/s11302-011-9228-9; Le Buanec H, 2011, P NATL ACAD SCI USA, V108, P18995, DOI 10.1073/pnas.1113301108; Leach DR, 1996, AIDS RES HUM RETRO S, V27, P1734, DOI DOI 10.1126/SCIENCE.271.5256.1734; Leibovich SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002-9440(10)61170-4; Lokshin A, 2006, CANCER RES, V66, P7758, DOI 10.1158/0008-5472.CAN-06-0478; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Mandapathil M, 2010, J BIOL CHEM, V285, P7176, DOI 10.1074/jbc.M109.047423; Mandapathil M, 2009, CLIN CANCER RES, V15, P6348, DOI 10.1158/1078-0432.CCR-09-1143; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Morse MA, 2008, BLOOD, V112, P610, DOI 10.1182/blood-2008-01-135319; Muller CE, 2006, BIOORG MED CHEM LETT, V16, P5943, DOI 10.1016/j.bmcl.2006.09.003; Nikolova M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002110; Nishikawa H, 2010, INT J CANCER, V127, P759, DOI 10.1002/ijc.25429; Novitskiy SV, 2008, BLOOD, V112, P1822, DOI 10.1182/blood-2008-02-136325; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Oh U, 2009, ARCH NEUROL-CHICAGO, V66, P471, DOI 10.1001/archneurol.2009.16; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Ohta A, 2009, J IMMUNOL, V183, P5487, DOI 10.4049/jimmunol.0901247; Peggs KS, 2009, J EXP MED, V206, P1717, DOI 10.1084/jem.20082492; Peng YF, 2004, P NATL ACAD SCI USA, V101, P4572, DOI 10.1073/pnas.0400810101; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; PRIEBE T, 1990, CANCER RES, V50, P4328; Pulte D, 2011, CL LYMPH MYELOM LEUK, V11, P367, DOI 10.1016/j.clml.2011.06.005; Pulte ED, 2007, THROMB RES, V121, P309, DOI 10.1016/j.thromres.2007.04.008; Ramanathan M, 2007, MOL BIOL CELL, V18, P14, DOI 10.1091/mbc.E06-07-0596; RAPAPORT E, 1983, CANCER RES, V43, P4402; Rasku MA, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-12; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; Ribas A, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.lba9011; Ring S, 2011, J INVEST DERMATOL, V131, P1494, DOI 10.1038/jid.2011.50; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; Schuler PJ, 2011, J IMMUNOL METHODS, V369, P59, DOI 10.1016/j.jim.2011.04.004; Stagg J, 2010, ONCOGENE, V29, P5346, DOI 10.1038/onc.2010.292; Sun XF, 2010, GASTROENTEROLOGY, V139, P1030, DOI 10.1053/j.gastro.2010.05.007; Tarhini AA, 2010, ONCOTARGETS THER, V3, P15; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tsukimoto M, 2006, J IMMUNOL, V177, P2842, DOI 10.4049/jimmunol.177.5.2842; Valzasina B, 2006, CANCER RES, V66, P4488, DOI 10.1158/0008-5472.CAN-05-4217; Valzasina B, 2005, BLOOD, V105, P2845, DOI 10.1182/blood-2004-07-2959; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; Wall MJ, 2008, NEUROPHARMACOLOGY, V55, P1251, DOI 10.1016/j.neuropharm.2008.08.005; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; White N, 2009, PURINERG SIGNAL, V5, P327, DOI 10.1007/s11302-009-9156-0; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Williams BA, 1997, BIOCHEM BIOPH RES CO, V231, P264, DOI 10.1006/bbrc.1997.6077; Wolf AM, 2003, CLIN CANCER RES, V9, P606; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244; Yang JC, 2007, J IMMUNOTHER, V30, P825, DOI 10.1097/CJI.0b013e318156e47e; Yang ZZ, 2006, BLOOD, V107, P3639, DOI 10.1182/blood-2005-08-3376; Yegutkin GG, 2011, EUR J IMMUNOL, V41, P1231, DOI 10.1002/eji.201041292; Yu P, 2005, J EXP MED, V201, P779, DOI 10.1084/jem.20041684; Zhao J, 2010, CANCER RES, V70, P4850, DOI 10.1158/0008-5472.CAN-10-0283; Zhoua Q, 2009, AM J TRANSPLANT, V9, P2303, DOI 10.1111/j.1600-6143.2009.02777.x	87	132	139	4	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1743	1751		10.1038/onc.2012.269	http://dx.doi.org/10.1038/onc.2012.269			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22751118				2022-12-28	WOS:000317043900001
J	Freudlsperger, C; Bian, Y; Wise, SC; Burnett, J; Coupar, J; Yang, X; Chen, Z; Van Waes, C				Freudlsperger, C.; Bian, Y.; Wise, S. Contag; Burnett, J.; Coupar, J.; Yang, X.; Chen, Z.; Van Waes, C.			TGF-beta and NF-kappa B signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers	ONCOGENE			English	Article						TGF-beta TAK1; NF-kappa B; SMAD7; celastrol; head and neck cancer	SQUAMOUS-CELL CARCINOMA; INDUCED APOPTOSIS; GENE-EXPRESSION; KINASE TAK1; GROWTH; ACTIVATION; RECEPTOR; PROTEIN; PROLIFERATION; INHIBITOR	Transforming growth factor-beta (TGF-beta) has a dual role in epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC). Attenuation of canonical TGF-beta signaling enhances de novo tumor development, whereas TGF-beta overexpression and signaling paradoxically promotes malignant progression. We recently observed that TGF-beta-induced growth arrest response is attenuated, in association with aberrant activation of nuclear factor-kappa B (NF-kappa B), a transcription factor, which promotes malignant progression in HNSCC. However, what role cross-talk between components of the TGF-beta and NF-kappa B pathways plays in altered activation of these pathways has not been established. Here, we show TGF-beta receptor II and TGF-beta-activated kinase 1 (TAK1) are predominantly expressed in a subset of HNSCC tumors with nuclear activation of NF-kappa B family member RELA (p65). Further, TGF-beta 1 treatment induced sequential phosphorylation of TAK1, IKK, I kappa B alpha and RELA in human HNSCC lines. TAK1 enhances TGF-beta-induced NF-kappa B activation, as TAK1 siRNA knockdown decreased TGF-beta 1-induced phosphorylation of IKK, I kappa B and RELA, degradation of I kappa B alpha, RELA nuclear translocation and DNA binding, and NF-kappa B-induced reporter and target gene transcription. Functionally, TAK1 siRNA inhibited cell proliferation, migration and invasion. Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-beta 1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-beta 1- and tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappa B reporter gene activity. Celastrol also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and Annexin V markers of apoptosis. Furthermore, TGF-beta and RELA activation promoted SMAD7 expression. In turn, SMAD7 preferentially suppressed TGF-beta-induced SMAD and NF-kappa B reporters when compared with constitutive or TNF-alpha-induced NF-kappa B reporter gene activation. Thus, cross-talk by TGF-beta via TAK1 and NF-kappa B promotes the malignant phenotype of HNSCC. Moreover, NF-kappa B may contribute to the downstream attenuation of canonical TGF-beta signaling through increased SMAD7 expression. Celastrol highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-beta-NF-kappa B signal pathway. Oncogene (2013) 32, 1549-1559; doi:10.1038/onc.2012.171; published online 28 May 2012	[Freudlsperger, C.; Bian, Y.; Wise, S. Contag; Burnett, J.; Coupar, J.; Yang, X.; Chen, Z.; Van Waes, C.] Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA; [Freudlsperger, C.] Univ Hosp Tuebingen, Dept Oral & Maxillofacial Surg, Tubingen, Germany	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Chen, Z (corresponding author), Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, 10 Ctr Dr,MSC 1462,Bldg 10,Rm 4-2732, Bethesda, MD 20892 USA.	chenz@nidcd.nih.gov; vanwaesc@nidcd.nih.gov	Freudlsperger, Christian/ABE-2926-2020	Freudlsperger, Christian/0000-0002-4289-0457	National Institute on Deafness and Other Communication Disorders, NIH [ZIA-DC-000016, ZIA-DC-000073]; Clinical Research Training Program; NIH; Pfizer Inc.; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000073, ZIADC000016] Funding Source: NIH RePORTER	National Institute on Deafness and Other Communication Disorders, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Clinical Research Training Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer Inc.(Pfizer); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported by intramural projects ZIA-DC-000016 and ZIA-DC-000073 from the National Institute on Deafness and Other Communication Disorders, NIH. Dr Contag Wise was supported by the Clinical Research Training Program, a public-private partnership supported jointly by the NIH and Pfizer Inc. The authors wish to thank Dr Ning T Yeh (NIDCD/NIH) and Chris Silvin (NHGRI/NIH) for their technical assistance. We would like to thank Drs Adam Glick and Ashok Kulkarni for review of the manuscript and helpful comments.	Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Arsura M, 2003, HEPATOLOGY, V38, P1540; Attisano L, 2001, GENOME BIOL, V2; Azuma M, 1999, EXP CELL RES, V250, P213, DOI 10.1006/excr.1999.4503; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bian YS, 2009, CANCER RES, V69, P5918, DOI 10.1158/0008-5472.CAN-08-4623; Bitzer M, 2000, GENE DEV, V14, P187; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P1195; Calixto Joao B., 2004, Planta Medica, V70, P93, DOI 10.1055/s-2004-815483; Chatterjee A, 2010, CANCER RES, V70, P1419, DOI 10.1158/0008-5472.CAN-09-2613; Cohen J, 2009, CANCER RES, V69, P3415, DOI 10.1158/0008-5472.CAN-08-3704; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dowdy SC, 2003, J BIOL CHEM, V278, P44377, DOI 10.1074/jbc.M307202200; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Friedman J, 2007, CLIN CANCER RES, V13, P6568, DOI 10.1158/1078-0432.CCR-07-1591; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hong S, 2007, CANCER RES, V67, P9577, DOI 10.1158/0008-5472.CAN-07-1179; Hong S, 2007, NAT IMMUNOL, V8, P504, DOI 10.1038/ni1451; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Jackson-Bernitsas DG, 2007, ONCOGENE, V26, P1385, DOI 10.1038/sj.onc.1209945; Jadrich JL, 2003, GENE EXPR PATTERNS, V3, P131, DOI 10.1016/S1567-133X(03)00012-7; Lam LT, 2005, CLIN CANCER RES, V11, P28; Lee TL, 2008, INT J CANCER, V122, P1987, DOI 10.1002/ijc.23324; Li H, 2005, EUR J PHARMACOL, V512, P231, DOI 10.1016/j.ejphar.2005.02.030; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441-011-1201-y; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; REISS M, 1990, CANCER COMMUN, V2, P363, DOI 10.3727/095535490820874029; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sethi G, 2007, BLOOD, V109, P2727, DOI 10.1182/blood-2006-10-050807; Setty AR, 2005, SEMIN ARTHRITIS RHEU, V34, P773, DOI 10.1016/j.semarthrit.2005.01.011; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tao XL, 2002, ARTHRITIS RHEUM, V46, P1735, DOI 10.1002/art.10411; Van Waes C, 2007, CLIN CANCER RES, V13, P1076, DOI 10.1158/1078-0432.CCR-06-2221; Wang WS, 2005, J AM SOC NEPHROL, V16, P1371, DOI 10.1681/ASN.2004121070; White RA, 2010, ONCOGENE, V29, P5437, DOI 10.1038/onc.2010.306; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xie W, 2003, ONCOL RES, V14, P61, DOI 10.3727/000000003108748612; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yan B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r78; Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529; Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357; Zhang PL, 2005, MODERN PATHOL, V18, P924, DOI 10.1038/modpathol.3800372; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	61	178	185	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1549	1559		10.1038/onc.2012.171	http://dx.doi.org/10.1038/onc.2012.171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22641218	Green Accepted			2022-12-28	WOS:000316456000008
J	Law, ME; Corsino, PE; Jahn, SC; Davis, BJ; Chen, S; Patel, B; Pham, K; Lu, J; Sheppard, B; Norgaard, P; Hong, J; Higgins, P; Kim, JS; Luesch, H; Law, BK				Law, M. E.; Corsino, P. E.; Jahn, S. C.; Davis, B. J.; Chen, S.; Patel, B.; Pham, K.; Lu, J.; Sheppard, B.; Norgaard, P.; Hong, J.; Higgins, P.; Kim, J-S; Luesch, H.; Law, B. K.			Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms	ONCOGENE			English	Article						E-cadherin; breast cancer; invasion; glucocorticoid; HDAC inhibitor; PAI-1	DOMAIN-CONTAINING PROTEIN-1; EPITHELIAL TUMOR-CELLS; E-CADHERIN; TYROSINE PHOSPHORYLATION; BETA-CATENIN; BIOLOGICAL SIGNIFICANCE; ADHERENS JUNCTIONS; LOBULAR CARCINOMA; STATISTICAL-MODEL; DOWN-REGULATION	Aggressive cancers often express E-cadherin in cytoplasmic vesicles rather than on the plasma membrane and this may contribute to the invasive phenotype of these tumors. Therapeutic strategies are not currently available that restore the anti-invasive function of E-cadherin in cancers. MDA-MB-231 cells are a frequently used model of invasive triple-negative breast cancer, and these cells express low levels of E-cadherin that is mislocalized to cytoplasmic vesicles. MDA-MB-231 cell lines stably expressing wild-type E-cadherin or E-cadherin fused to glutathione S-transferase or green fluorescent protein were used as experimental systems to probe the mechanisms responsible for cytoplasmic E-cadherin localization in invasive cancers. Although E-cadherin expression partly reduced cell invasion in vitro, E-cadherin was largely localized to the cytoplasm and did not block the invasiveness of the corresponding orthotopic xenograft tumors. Further studies indicated that the glucocorticoid dexamethasone and the highly potent class I histone deacetylase (HDAC) inhibitor largazole cooperated to induce E-cadherin localization to the plasma membrane in triple-negative breast cancers, and to suppress cellular invasion in vitro. Dexamethasone blocked the production of the cleaved form of the CDCP1 (that is, CUB domain-containing protein 1) protein (cCDCP1) previously implicated in the pro-invasive activities of CDCP1 by upregulating the serine protease inhibitor plasminogen activator inhibitor-1. E-cadherin preferentially associated with cCDCP1 compared with the full-length form. In contrast, largazole did not influence CDCP1 cleavage, but increased the association of E-cadherin with gamma-catenin. This effect on E-cadherin/gamma-catenin complexes was shared with the nonisoform selective HDAC inhibitors trichostatin A (TSA) and vorinostat (suberoylanilide hydroxamic acid, SAHA), although largazole upregulated endogenous E-cadherin levels more strongly than TSA. These results demonstrate that glucocorticoids and HDAC inhibitors, both of which are currently in clinical use, cooperate to suppress the invasiveness of breast cancer cells through novel, complementary mechanisms that converge on E-cadherin. Oncogene (2013) 32, 1316-1329; doi:10.1038/onc.2012.138; published online 30 April 2012	[Law, M. E.; Corsino, P. E.; Jahn, S. C.; Davis, B. J.; Pham, K.; Kim, J-S; Law, B. K.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; [Law, M. E.; Corsino, P. E.; Jahn, S. C.; Davis, B. J.; Patel, B.; Pham, K.; Lu, J.; Kim, J-S; Luesch, H.; Law, B. K.] Univ Florida, UF & Shands Canc Ctr, Gainesville, FL 32610 USA; [Chen, S.] Univ Florida, Dept Biol, Gainesville, FL 32610 USA; [Patel, B.; Lu, J.] Univ Florida, Dept Biochem, Gainesville, FL 32610 USA; [Sheppard, B.] Univ Florida, Dept Infect Dis & Pathol, Gainesville, FL 32610 USA; [Norgaard, P.] Univ Copenhagen, Herlev Hosp, Dept Pathol, DK-2730 Herlev, Denmark; [Hong, J.] Duke Univ, Dept Chem, Durham, NC 27706 USA; [Higgins, P.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Kim, J-S] Univ Florida, Dept Surg, Gainesville, FL 32610 USA; [Luesch, H.] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Copenhagen; Herlev & Gentofte Hospital; Duke University; Albany Medical College; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Law, BK (corresponding author), Univ Florida, Dept Pharmacol & Therapeut, 1600 SW Archer Rd,Acad Res Bldg,Room R5-210,POB 1, Gainesville, FL 32610 USA.	bklaw@pharmacology.ufl.edu	Law, Brian/L-6043-2019; Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040	Komen for the Cure grant [KG080510]; Florida Department of Health [07BB-8, 09BB-10]; NIH [R01CA138544, DK079879, GM057242]; NATIONAL CANCER INSTITUTE [R01CA138544, R01CA093651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090115, R01DK079879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057242] Funding Source: NIH RePORTER	Komen for the Cure grant; Florida Department of Health; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Al Reynolds, Vanderbilt University, Nashville, TN for generously providing the E-cadherin/LZRS and pMS vectors and for instruction regarding their use. The Proteomics Division at the Interdisciplinary Center for Biotechnology Research (ICBR) (http://www.biotech.ufl.edu/proteomics/) is acknowledged for the mass spectrometry analysis. This work was supported in part by Komen for the Cure grant KG080510 and Florida Department of Health grants 07BB-8 and 09BB-10 to B Law, and NIH grants R01CA138544 (H Luesch and J Hong), DK079879 (J-S Kim), and GM057242 (PJ Higgins).	Baum B, 2011, J CELL BIOL, V192, P907, DOI 10.1083/jcb.201009141; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Boulos F, 2011, AM J SURG PATHOL, V35, P154, DOI 10.1097/PAS.0b013e3182028f79; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; BUSE P, 1995, J BIOL CHEM, V270, P28223; BUSSO N, 1987, CANCER RES, V47, P364; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Chytil A, 2004, J BIOL CHEM, V279, P47688, DOI 10.1074/jbc.M405938200; Cole KE, 2011, J AM CHEM SOC, V133, P12474, DOI 10.1021/ja205972n; Corsino PE, 2008, NEOPLASIA, V10, P1240, DOI 10.1593/neo.08710; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Daniel JM, 2007, BBA-MOL CELL RES, V1773, P59, DOI 10.1016/j.bbamcr.2006.08.052; Dawson S J, 2009, Eur J Cancer, V45 Suppl 1, P27, DOI 10.1016/S0959-8049(09)70013-9; Facina G, 2010, DIAGN CYTOPATHOL, V38, P235, DOI 10.1002/dc.21181; Feltes CM, 2002, CANCER RES, V62, P6688; Gomez-Hernandez J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-692; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Law M, 2006, CANCER RES, V66, P1070, DOI 10.1158/0008-5472.CAN-05-1672; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Liu YX, 2010, J PHARMACOL EXP THER, V335, P351, DOI 10.1124/jpet.110.172387; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Meyers MO, 2011, ANN SURG ONCOL, V18, P2851, DOI 10.1245/s10434-011-1665-8; Miyagawa R, 2010, CORONARY ARTERY DIS, V21, P144, DOI 10.1097/MCA.0b013e328335790e; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; NORDT TK, 1995, CIRCULATION, V91, P764, DOI 10.1161/01.CIR.91.3.764; Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032; Pan D, 2011, CANCER RES, V71, P6360, DOI 10.1158/0008-5472.CAN-11-0362; Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872; Pazaiti A, 2011, WOMENS HEALTH, V7, P181, DOI [10.2217/whe.11.5, 10.2217/WHE.11.5]; Pishvaian MJ, 1999, CANCER RES, V59, P947; Querzoli P, 2010, BRIT J CANCER, V103, P1835, DOI 10.1038/sj.bjc.6605991; Rakha EA, 2010, AM J SURG PATHOL, V34, P1472, DOI 10.1097/PAS.0b013e3181f01916; Rubenstein NM, 2003, J BIOL CHEM, V278, P10353, DOI 10.1074/jbc.M213121200; Sheffield J, 2006, PROTEOMICS, V6, P1588, DOI 10.1002/pmic.200500503; Singh R, 2009, EXP CELL RES, V315, P2899, DOI 10.1016/j.yexcr.2009.07.002; Smith AL, 2012, MOL BIOL CELL, V23, P99, DOI 10.1091/mbc.E11-06-0497; Swift S, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1017cs31; Taori K, 2008, J AM CHEM SOC, V130, P1806, DOI 10.1021/ja7110064; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Ying YC, 2008, ORG LETT, V10, P4021, DOI 10.1021/ol801532s; Ying YC, 2008, J AM CHEM SOC, V130, P8455, DOI 10.1021/ja8013727; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; Zhang XC, 2009, PATHOL RES PRACT, V205, P375, DOI 10.1016/j.prp.2008.08.009; Zhu MM, 2010, J PROTEOMICS, V73, P790, DOI 10.1016/j.jprot.2009.11.002	64	58	58	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1316	1329		10.1038/onc.2012.138	http://dx.doi.org/10.1038/onc.2012.138			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543582	Green Accepted			2022-12-28	WOS:000316454500012
J	Liu, ZY; Wang, JY; Liu, HH; Ma, XM; Wang, CL; Zhang, XP; Tao, YQ; Lu, YC; Liao, JC; Hu, GH				Liu, Z. Y.; Wang, J. Y.; Liu, H. H.; Ma, X. M.; Wang, C. L.; Zhang, X. P.; Tao, Y. Q.; Lu, Y. C.; Liao, J. C.; Hu, G. H.			Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1) dysregulation in human malignant meningiomas	ONCOGENE			English	Article						retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1); malignant; meningiomas; apoptosis; tumor suppressor gene	ANAPLASTIC MENINGIOMAS; BREAST-CANCER; PR DOMAIN; EXPRESSION; METHYLTRANSFERASE; PRODUCT	Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1) expression is often silenced in many types of human tumors. However, the relationship between RIZ1 expression and malignant meningiomas remains unclear. Here we have found for the first time that the expression of RIZ1 genes are associated with meningiomas progression through extensive analyses of Affymetrix GeneChip microarray data. Further validation methods for gene expression included quantitative PCR (qPCR), western blot and immunohistochemistry analysis, and these methods confirmed that RIZ1 is significantly downregulated in malignant meningioma tissues, as compared with benign meningiomas. In addition, malignant meningioma cells were stably transfected with ectogenic RIZ1 using Lentivirus-mediated transfection, and the transfections were followed by an in vitro 5-bromo-2-deoxyuridin incorporation assay, colony formation assay, cell cycle analysis, invasive analysis, apoptotic assay and western blot analysis. Our results demonstrate that the forced expression of RIZ1 in a malignant meningioma cell line inhibited cellular proliferation and arrested the cells in the G2/M phase of the cell cycle. We also confirmed that overexpression of RIZ1 may induce apoptosis of malignant meningioma cells. Furthermore, RIZ1 overexpression in malignant meningioma cells was associated with the downregulation of c-myc expression. These results from our study indicate that RIZ1 expression is significantly downregulated as the formation of meningiomas progressed, and suggest that RIZ1 may represent a promising candidate tumor suppressor gene that contributes to malignant meningiomas. Oncogene (2013) 32, 1216-1222; doi:10.1038/onc.2012.155; published online 21 May 2012	[Liu, Z. Y.; Wang, J. Y.; Wang, C. L.; Tao, Y. Q.; Lu, Y. C.; Hu, G. H.] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Liu, H. H.; Liao, J. C.] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Otorhinolaryngol Head & Neck, Shanghai, Peoples R China; [Ma, X. M.] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Pathol, Shanghai, Peoples R China; [Wang, C. L.] Dept Neurosurg, Hefei, Anhui, Peoples R China; [Zhang, X. P.] Shanghai Jiao Tong Univ, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai Inst Biol Sci,Chinese Acad Sci,Sch Med, Shanghai 200030, Peoples R China	Naval Medical University; Naval Medical University; Naval Medical University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Hu, GH (corresponding author), Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China.	liaojc@public2.sta.net.cn; huguohan6504@sina.com			Shanghai Science and Technology Foundation of China [08431900400, 09411950900]; Shanghai Science and Technology Youth Fund of China [09ZR410000]; Natural Sciences Fund Project of Anhui Province, China [11040606M212]	Shanghai Science and Technology Foundation of China; Shanghai Science and Technology Youth Fund of China; Natural Sciences Fund Project of Anhui Province, China	The meningioma cell line IOMM-Lee and CH157-MN were kindly provided by Professor Randy Jensen and Dr David Gillespie (Utah State University, USA). The research was supported by Shanghai Science and Technology Foundation of China: 08431900400 (Guohan Hu), Shanghai Science and Technology Foundation of China: 09411950900 (Jianchun Liao), Shanghai Science and Technology Youth Fund of China: 09ZR410000 (Huanhai Liu) and Natural Sciences Fund Project of Anhui Province, China: No. 11040606M212 (Chunlin Wang).	BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Carling T, 2004, MOL CELL BIOL, V24, P7032, DOI 10.1128/MCB.24.16.7032-7042.2004; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Gazzerro P, 2006, EXP CELL RES, V312, P340, DOI 10.1016/j.yexcr.2005.11.002; GLAHOLM J, 1990, INT J RADIAT ONCOL, V18, P755, DOI 10.1016/0360-3016(90)90394-Y; GOLDSMITH BJ, 1994, J NEUROSURG, V80, P195, DOI 10.3171/jns.1994.80.2.0195; He LS, 1998, CANCER RES, V58, P4238; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Jiang GL, 2001, CANCER RES, V61, P1796; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Modha A, 2005, NEUROSURGERY, V57, P538, DOI 10.1227/01.NEU.0000170980.47582.A5; Perry A, 1999, CANCER, V85, P2046, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M; Piao Z, 2000, CANCER RES, V60, P4701; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rossi V, 2009, J CELL PHYSIOL, V221, P771, DOI 10.1002/jcp.21920; Shadat NM, 2001, CANC INVEST, V28, P806; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Tao YQ, 2006, BIOFACTORS, V28, P203, DOI 10.1002/biof.5520280307; Wang JY, 2012, J NEURO-ONCOL, V106, P473, DOI 10.1007/s11060-011-0692-4; Ware ML, 2004, NEUROSURGERY, V54, P55, DOI 10.1227/01.NEU.0000097199.26412.2A; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262; Zhang X, 2010, CANCER RES, V70, P2350, DOI 10.1158/0008-5472.CAN-09-3885	27	26	29	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1216	1222		10.1038/onc.2012.155	http://dx.doi.org/10.1038/onc.2012.155			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22614009				2022-12-28	WOS:000316454500002
J	Muller, PAJ; Trinidad, AG; Timpson, P; Morton, JP; Zanivan, S; van den Berghe, PVE; Nixon, C; Karim, SA; Caswell, PT; Noll, JE; Coffill, CR; Lane, DP; Sansom, OJ; Neilsen, PM; Norman, JC; Vousden, KH				Muller, P. A. J.; Trinidad, A. G.; Timpson, P.; Morton, J. P.; Zanivan, S.; van den Berghe, P. V. E.; Nixon, C.; Karim, S. A.; Caswell, P. T.; Noll, J. E.; Coffill, C. R.; Lane, D. P.; Sansom, O. J.; Neilsen, P. M.; Norman, J. C.; Vousden, K. H.			Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion	ONCOGENE			English	Article						mutant p53; MET; recycling	HEPATOCYTE GROWTH-FACTOR; WILD-TYPE P53; RECEPTOR TYROSINE KINASES; LI-FRAUMENI-SYNDROME; C-MET; BREAST-CANCER; MALIGNANT MESOTHELIOMA; TUMOR-SUPPRESSOR; GENE CONTRIBUTES; CARCINOMA CELLS	Tumour-derived mutant p53 proteins promote invasion, in part, by enhancing Rab coupling protein (RCP)-dependent receptor recycling. Here we identified MET as an RCP-binding protein and showed that mutant p53 promoted MET recycling. Mutant p53-expressing cells were more sensitive to hepatocyte growth factor, the ligand for MET, leading to enhanced MET signalling, invasion and cell scattering that was dependent on both MET and RCP. In cells expressing the p53 family member TAp63, inhibition of TAp63 also lead to cell scattering and MET-dependent invasion. However, in cells that express very low levels of TAp63, the ability of mutant p53 to promote MET-dependent cell scattering was independent of TAp63. Taken together, our data show that mutant p53 can enhance MET signalling to promote cell scattering and invasion through both TAp63-dependent and -independent mechanisms. MET has a predominant role in metastatic progression and the identification of mechanisms through which mutations in p53 can drive MET signalling may help to identify and direct therapy. Oncogene (2013) 32, 1252-1265; doi:10.1038/onc.2012.148; published online 14 May 2012	[Muller, P. A. J.; Trinidad, A. G.; Timpson, P.; Morton, J. P.; Zanivan, S.; van den Berghe, P. V. E.; Nixon, C.; Karim, S. A.; Sansom, O. J.; Norman, J. C.; Vousden, K. H.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Caswell, P. T.] Univ Manchester, Welcome Trust Ctr Cell Matrix Res, Manchester, Lancs, England; [Noll, J. E.; Neilsen, P. M.] Univ Adelaide, Canc Therapeut Labs, Adelaide, SA, Australia; [Coffill, C. R.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; [Lane, D. P.] ASTAR, Lab P53, Singapore, Singapore	Beatson Institute; University of Manchester; University of Adelaide; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Agency for Science Technology & Research (A*STAR)	Vousden, KH (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	j.norman@beatson.gla.ac.uk; k.vousden@beatson.gla.ac.uk	Timpson, Paul/A-9429-2016; Muller, Patricia AJ/AAH-1888-2019; Morton, Jennifer P/E-1633-2011; Morton, Jennifer/AAJ-5113-2021; Zanivan, Sara/GOV-5505-2022; Caswell, Patrick/N-3063-2015	Muller, Patricia AJ/0000-0002-0926-1499; Morton, Jennifer P/0000-0001-5766-9141; Morton, Jennifer/0000-0001-5766-9141; Caswell, Patrick/0000-0002-2633-2324; NORMAN, Jim/0000-0002-0098-3014; Zanivan, Sara/0000-0002-9880-9099; Neilsen, Paul/0000-0001-7937-3675; Sansom, Owen J./0000-0001-9540-3010; Coffill, Cynthia/0000-0003-2914-4481; Noll, Jacqueline/0000-0001-7375-635X; Timpson, Paul/0000-0002-5514-7080; Lane, David/0000-0003-0551-3545	Cancer Research UK; AICR; Rubicon Fellowship from the Netherlands Organisation for Scientific Research; Cancer Research UK [12935, 12481] Funding Source: researchfish; Worldwide Cancer Research [11-0626] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); AICR; Rubicon Fellowship from the Netherlands Organisation for Scientific Research; Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	We thank Cancer Research UK and the AICR for funding of work in KHV and JCN's laboratories. PAJM is a recipient of a Rubicon Fellowship from the Netherlands Organisation for Scientific Research. We thank Julin Wong from DPL's lab for the MET construct, Bert Vogelstein for the HCT116 p53 null and HCT116 248W cells, Karen Oien for help with quantifying the staining in the pancreatic tumours and Christine Gundry for help with optimizing the recycling assays.	Accornero P, 2010, J MOL ENDOCRINOL, V44, P115, DOI 10.1677/JME-09-0035; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brevet M, 2011, J THORAC ONCOL, V6, P864, DOI 10.1097/JTO.0b013e318215a07d; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Cirit M, 2010, J BIOL CHEM, V285, P36736, DOI 10.1074/jbc.M110.148759; Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; DOGAN A, 1995, J CLIN PATHOL, V48, P143, DOI 10.1136/jcp.48.2.143; Edward M, 2005, CARCINOGENESIS, V26, P1215, DOI 10.1093/carcin/bgi064; FUKUYAMA R, 1991, JPN J CANCER RES, V82, P8, DOI 10.1111/j.1349-7006.1991.tb01737.x; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Herrera R, 1998, J CELL SCI, V111, P1039; Hwang CI, 2011, P NATL ACAD SCI USA, V108, P14240, DOI 10.1073/pnas.1017536108; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Kawaguchi K, 2009, CARCINOGENESIS, V30, P1097, DOI 10.1093/carcin/bgp097; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Leonard MK, 2011, CELL DEATH DIFFER, V18, P1924, DOI 10.1038/cdd.2011.73; Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335; Liu J, 2012, DNA REPAIR, V11, P167, DOI 10.1016/j.dnarep.2011.10.016; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; NALDINI L, 1991, ONCOGENE, V6, P501; Noll JE, 2011, ONCOGENE; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Sayan BS, 2007, P NATL ACAD SCI USA, V104, P10871, DOI 10.1073/pnas.0700761104; Seol DW, 1999, J BIOL CHEM, V274, P3565, DOI 10.1074/jbc.274.6.3565; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Sigal A, 2000, CANCER RES, V60, P6788; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; STOKER M, 1985, J CELL SCI, V77, P209; Stolarov J, 2001, P NATL ACAD SCI USA, V98, P13043, DOI 10.1073/pnas.221450598; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; Tepper CG, 2005, PROSTATE, V65, P375, DOI 10.1002/pros.20308; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Wong MYW, 2011, INT J ONCOL, V38, P1189, DOI 10.3892/ijo.2011.970; Xu H, 2011, CLIN CANCER RES, V17, P4425, DOI 10.1158/1078-0432.CCR-10-3339; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061; Zhang JQ, 2009, J CLIN INVEST, V119, P2171, DOI 10.1172/JCI37622; Zhang YH, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.214585	65	145	147	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1252	1265		10.1038/onc.2012.148	http://dx.doi.org/10.1038/onc.2012.148			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22580601	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000316454500006
J	Brooks, K; Oakes, V; Edwards, B; Ranall, M; Leo, P; Pavey, S; Pinder, A; Beamish, H; Mukhopadhyay, P; Lambie, D; Gabrielli, B				Brooks, K.; Oakes, V.; Edwards, B.; Ranall, M.; Leo, P.; Pavey, S.; Pinder, A.; Beamish, H.; Mukhopadhyay, P.; Lambie, D.; Gabrielli, B.			A potent Chkl inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress	ONCOGENE			English	Article						Chk1; replicative stress; melanoma	DNA-DAMAGE CHECKPOINT; MITOTIC CATASTROPHE; ANTICANCER THERAPY; G(2) CHECKPOINT; CELL-DEATH; KINASE 1; ATR; CANCER; ACCUMULATION; PHOSPHATASE	There are few effective treatments for metastatic melanoma. Checkpoint kinase 1 (Chk1) inhibitors are being trialled for their efficacy in enhancing conventional chemotherapeutic agents, but their effectiveness as single agents is not known. We have examined the effectiveness of two novel Chk1 selective inhibitors, AR323 and AR678, in a panel of melanoma cell lines and normal cell types. We demonstrate that these drugs display single-agent activity, with IC50s in the low nanomolar range. The drugs produce cytotoxic effects in cell lines that are most sensitive to these drugs, whereas normal cells are only sensitive to these drugs at the higher concentrations where they have cytostatic activity. The cytotoxic effect is the consequence of inhibition of S-phase Chk1, which drives cells prematurely from late S phase into an aberrant mitosis and results in either failure of cytokinesis or cell death through an apoptotic mechanism. The sensitivity to the Chk1 inhibitors was correlated with the level of endogenous DNA damage indicating replicative stress. Chk1 inhibitors are viable single-agent therapies that target melanoma cells with high levels of endogenous DNA damage. This sensitivity suggests that Chk1 is a critical component of an adaptation to replicative stress in these cells. It also suggests that markers of DNA damage may be useful in identifying the melanomas and potentially other tumour types that are more likely to be sensitive to Chk1 inhibitors as single agents. Oncogene (2013) 32, 788-796; doi:10.1038/onc.2012.72; published online 5 March 2012	[Brooks, K.; Oakes, V.; Edwards, B.; Ranall, M.; Leo, P.; Pavey, S.; Pinder, A.; Beamish, H.; Mukhopadhyay, P.; Gabrielli, B.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Brisbane, Qld 4102, Australia; [Lambie, D.] Princess Alexandra Hosp, Dept Pathol, Brisbane, Qld 4102, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Brisbane, Qld 4102, Australia.	brianG@uq.edu.au	Leo, Paul/R-4464-2019; Gabrielli, Brian G/B-3655-2011; Mukhopadhyay, Pamela/I-6373-2015; Brooks, Kelly M/F-8248-2017; Leo, Paul J/B-3470-2011; Lambie, Duncan/C-1863-2018; Pavey, Sandra/B-3662-2011	Gabrielli, Brian G/0000-0003-3933-1651; Mukhopadhyay, Pamela/0000-0002-5905-1350; Brooks, Kelly M/0000-0002-9751-5961; Leo, Paul J/0000-0001-8325-4134; Lambie, Duncan/0000-0002-0102-6638; Pavey, Sandra/0000-0003-4519-5932	Cancer Council Queensland; National Health and Medical Research Council (NHMRC Australia); Australia Research Council	Cancer Council Queensland(Cancer Council Queensland); National Health and Medical Research Council (NHMRC Australia)(National Health and Medical Research Council (NHMRC) of Australia); Australia Research Council(Australian Research Council)	We wish to acknowledge Drs Kurt Davies and Cheryl Napier (Array Biopharma), and KeeMing Chia for their technical assistance, A/Professor Grant McArthur and Dr Petranel Ferrao for their helpful comments, Prof. Penny Jeggo (University of Sussex) for her gift of the FO2 cells, and the Australasian Biospecimen Network (Oncology) for the melanoma cell lines. This work was supported by funding from Cancer Council Queensland, the National Health and Medical Research Council (NHMRC Australia) and the Australia Research Council. Brian Gabrielli is an NHMRC senior research fellow.	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Brown EJ, 2000, GENE DEV, V14, P397; Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029; Davies KD, 2011, ONCOL RES, V19, P349, DOI 10.3727/096504011X13079697132961; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli B, 2007, J BIOL CHEM, V282, P6954, DOI 10.1074/jbc.M610104200; Ge XQ, 2010, J CELL BIOL, V191, P1285, DOI 10.1083/jcb.201007074; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kuntz K, 2009, CANCER BIOL THER, V8, P1433, DOI 10.4161/cbt.8.15.9081; Lainchbury M, 2011, EXPERT OPIN THER PAT, V21, P1191, DOI 10.1517/13543776.2011.586632; Lazzaro F, 2009, DNA REPAIR, V8, P1055, DOI 10.1016/j.dnarep.2009.04.022; Liu QH, 2000, GENE DEV, V14, P1448; Loffler H, 2006, CELL CYCLE, V5, P2543, DOI 10.4161/cc.5.21.3435; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; McDonald ER, 2001, ANN MED, V33, P113, DOI 10.3109/07853890109002066; McNeely S, 2010, CELL CYCLE, V9, P995, DOI 10.4161/cc.9.5.10935; Morgan MA, 2010, CANCER RES, V70, P4972, DOI 10.1158/0008-5472.CAN-09-3573; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Niida H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Peddibhotla S, 2009, P NATL ACAD SCI USA, V106, P5159, DOI 10.1073/pnas.0806671106; Petermann E, 2010, P NATL ACAD SCI USA, V107, P16090, DOI 10.1073/pnas.1005031107; Ranall MV, 2010, BIOTECHNIQUES, V48, P379, DOI 10.2144/000113410; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Stevens FE, 2008, ONCOGENE, V27, P1345, DOI 10.1038/sj.onc.1210779; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takai H, 2000, GENE DEV, V14, P1439; Tang JB, 2006, P NATL ACAD SCI USA, V103, P11964, DOI 10.1073/pnas.0604987103; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vogel C, 2007, CANCER RES, V67, P339, DOI 10.1158/0008-5472.CAN-06-2548; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wang XQ, 1996, CANCER RES, V56, P2510; Wasco MJ, 2008, HUM PATHOL, V39, P1614, DOI 10.1016/j.humpath.2008.03.007	41	66	69	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					788	796		10.1038/onc.2012.72	http://dx.doi.org/10.1038/onc.2012.72			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22391562				2022-12-28	WOS:000315746700012
J	Su, PH; Lin, YW; Huang, RL; Liao, YP; Lee, HY; Wang, HC; Chao, TK; Chen, CK; Chan, MWY; Chu, TY; Yu, MH; Lai, HC				Su, P-H; Lin, Y-W; Huang, R-L; Liao, Y-P; Lee, H-Y; Wang, H-C; Chao, T-K; Chen, C-K; Chan, M. W. Y.; Chu, T-Y; Yu, M-H; Lai, H-C			Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer	ONCOGENE			English	Article						protein tyrosine phosphatase receptor type R; DNA methyltransferase; mitogen-activated protein kinase; metastasis; methylation; cervical cancer	PROTEIN-TYROSINE PHOSPHATASES; TO-MESENCHYMAL TRANSITION; RISK HUMAN-PAPILLOMAVIRUS; DNA METHYLATION MARKERS; EPITHELIAL-CELLS; E-CADHERIN; INTRAEPITHELIAL NEOPLASIA; INDUCED CARCINOGENESIS; ONCOGENE EXPRESSION; MOTOR COORDINATION	Epigenetic modifications are a driving force in carcinogenesis. However, their role in cancer metastasis remains poorly understood. The present study investigated the role of DNA methylation in the cervical cancer metastasis. Here, we report evidence of the overexpression of DNA methyltransferases 3B (DNMT3B) in invasive cervical cancer and of the inhibition of metastasis by DNMT3B interference. Using methyl-DNA immunoprecipitation coupled with microarray analysis, we found that the protein tyrosine phosphatase receptor type R (PTPRR) was silenced through DNMT3B-mediated methylation in the cervical cancer. PTPRR inhibited p44/42 MAPK signaling, the expression of the transcription factor AP1, human papillomavirus (HPV) oncogenes E6/E7 and DNMTs. The methylation status of PTPRR increased in cervical scrapings (n = 358) in accordance with disease severity, especially in invasive cancer. Methylation of the PTPRR promoter has an important role in the metastasis and may be a biomarker of invasive cervical cancer. Oncogene (2013) 32, 15-26; doi:10.1038/onc.2012.29; published online 13 February 2012	[Huang, R-L; Lee, H-Y; Wang, H-C; Yu, M-H; Lai, H-C] Natl Def Med Ctr, Triserv Gen Hosp, Dept Obstet & Gynecol, Taipei City 114, Taiwan; [Su, P-H; Lai, H-C] Natl Def Med Ctr, Lab Epigenet & Canc Stem Cells, Taipei City 114, Taiwan; [Lin, Y-W] Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei City 114, Taiwan; [Liao, Y-P; Chen, C-K; Lai, H-C] Natl Def Med Ctr, Grad Inst Life Sci, Taipei City 114, Taiwan; [Chao, T-K] Triserv Gen Hosp, Dept Pathol, Taipei, Taiwan; [Chan, M. W. Y.] Natl Chung Cheng Univ, Dept Life Sci, Min Hsiung, Chia Yi, Taiwan; [Chu, T-Y] Tzu Chi Univ, Dept Obstet & Gynecol, Hualien, Taiwan; [Su, P-H; Lai, H-C] Natl Def Med Ctr, Grad Inst Med Sci, Taipei City 114, Taiwan	National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; National Chung Cheng University; Tzu Chi University; National Defense Medical Center	Lai, HC (corresponding author), Natl Def Med Ctr, Triserv Gen Hosp, Dept Obstet & Gynecol, 5F,325,Sec 2,Cheng Gong Rd, Taipei City 114, Taiwan.	hclai@ndmctsgh.edu.tw	Chan, Michael/F-9615-2018	Chan, Michael/0000-0003-1431-322X; Chu, Tang-Yuan/0000-0003-2717-2681; Chan, Michael/0000-0003-0314-2437; Huang, Rui Lan/0000-0001-6458-4672	National Science Council, Taiwan, ROC [NSC98-2314-B-016-030-MY3]; Tri-Service General Hospital [TSGH-C100-010-014-S01, TSGH-C100-010-014-S02]; Teh-Tzer Study Group for Human Medical Research Foundation	National Science Council, Taiwan, ROC(Ministry of Science and Technology, Taiwan); Tri-Service General Hospital; Teh-Tzer Study Group for Human Medical Research Foundation	This work was supported by Grant NSC98-2314-B-016-030-MY3 from the National Science Council, Taiwan, ROC (to H-CL); Grant TSGH-C100-010-014-S01 (to M-HY) and TSGH-C100-010-014-S02 (H-CL) from the Tri-Service General Hospital and Teh-Tzer Study Group for Human Medical Research Foundation (to H-CL).	Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Amara K, 2010, CANCER SCI, V101, P1722, DOI 10.1111/j.1349-7006.2010.01569.x; Berger JC, 2005, CANCER BIOL THER, V4, P805, DOI 10.4161/cbt.4.8.1865; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Branca M, 2004, AM J CLIN PATHOL, V122, P902, DOI 10.1309/VQXFT880JXC7QD2W; Burgers WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950; Buschbeck M, 2002, J BIOL CHEM, V277, P29503, DOI 10.1074/jbc.M202149200; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; Caberg JHD, 2008, CARCINOGENESIS, V29, P1441, DOI 10.1093/carcin/bgn145; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Chirivi RGS, 2007, J NEUROCHEM, V101, P829, DOI 10.1111/j.1471-4159.2006.04398.x; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026; Chung MT, 2009, GYNECOL ONCOL, V112, P301, DOI 10.1016/j.ygyno.2008.10.004; de Wilde J, 2008, CELL ONCOL, V30, P77; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fujisawa T, 2011, INT J CANC; Girault I, 2003, CLIN CANCER RES, V9, P4415; Gu W, 2011, CANCER GENE THER, V18, P897, DOI 10.1038/cgt.2011.58; Hellner K, 2009, VIROLOGY, V391, P57, DOI 10.1016/j.virol.2009.05.036; Hickson JA, 2006, CANCER RES, V66, P2264, DOI 10.1158/0008-5472.CAN-05-3676; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Kikuchi K, 1996, VIRUS GENES, V13, P45, DOI 10.1007/BF00576977; Kwon O, 2010, CARCINOGENESIS; Kyo S, 1997, J GEN VIROL, V78, P401, DOI 10.1099/0022-1317-78-2-401; Lai HC, 2010, CANCER; Lai HC, 2008, INT J CANCER, V123, P161, DOI 10.1002/ijc.23519; Laurson J, 2010, CARCINOGENESIS, V31, P918, DOI 10.1093/carcin/bgq027; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Lemieux E, 2009, INT J CANCER, V125, P1575, DOI 10.1002/ijc.24485; Lichtig H, 2010, VIROLOGY, V396, P47, DOI 10.1016/j.virol.2009.10.011; Lin YW, 2009, J CANCER RES CLIN, V135, P1665, DOI 10.1007/s00432-009-0613-5; Liu CY, 2009, J PATHOL, V219, P222, DOI 10.1002/path.2589; Menigatti M, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-124; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101; Narisawa-Saito M, 2007, CANCER SCI, V98, P1505, DOI 10.1111/j.1349-7006.2007.00546.x; Nephew KP, 2009, GYNECOL ONCOL, V112, P291, DOI 10.1016/j.ygyno.2008.12.016; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Noordman Yvet E, 2006, J Mol Signal, V1, P4, DOI 10.1186/1750-2187-1-4; Nussenzweig MC, 2004, NAT MED, V10, P1304, DOI 10.1038/nm1204-1304; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Paschos K, 2010, TRENDS MICROBIOL, V18, P439, DOI 10.1016/j.tim.2010.07.003; Prusty BK, 2005, INT J CANCER, V113, P951, DOI 10.1002/ijc.20668; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rodenhiser DI, 2009, CLIN EXP METASTAS, V26, P5, DOI 10.1007/s10585-008-9166-2; Rodriguez-Sastre MA, 2005, GYNECOL ONCOL, V97, P330, DOI 10.1016/j.ygyno.2004.12.062; Sankpal NV, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3070; Schmitt I, 2009, CEREBELLUM, V8, P71, DOI 10.1007/s12311-009-0118-4; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shi HD, 2003, CANCER RES, V63, P2164; Sova P, 2006, CANCER EPIDEM BIOMAR, V15, P114, DOI 10.1158/1055-9965.EPI-05-0323; Strippoli R, 2008, DIS MODEL MECH, V1, P264, DOI 10.1242/dmm.001321; Szalmas A, 2009, SEMIN CANCER BIOL, V19, P144, DOI 10.1016/j.semcancer.2009.02.011; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Wang SS, 2008, CANCER RES, V68, P2489, DOI 10.1158/0008-5472.CAN-07-3194; Weng YI, 2009, METHODS MOL BIOL, V590, P165, DOI 10.1007/978-1-60327-378-7_10; Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012; WHO/ICO, 2010, HUM PAP REL CANC WOR; Wilting S, 2006, J PATHOL, V209, P220, DOI 10.1002/path.1966; Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050; Yaqinuddin A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-13; zur Hausen H, 2001, JNCI-J NATL CANCER I, V93, P252	74	49	50	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					15	26		10.1038/onc.2012.29	http://dx.doi.org/10.1038/onc.2012.29			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22330137				2022-12-28	WOS:000313029500002
J	Cork, SM; Kaur, B; Devi, NS; Cooper, L; Saltz, JH; Sandberg, EM; Kaluz, S; Van Meir, EG				Cork, S. M.; Kaur, B.; Devi, N. S.; Cooper, L.; Saltz, J. H.; Sandberg, E. M.; Kaluz, S.; Van Meir, E. G.			A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1	ONCOGENE			English	Article						angiogenesis; cancer; brain; glioma	BRAIN-SPECIFIC ANGIOGENESIS; IN-VIVO ANGIOGENESIS; COLORECTAL-CANCER; TYPE-1 REPEATS; P53 EXPRESSION; CELL-ADHESION; INHIBITOR-1; PROTEIN; FURIN; GENE	Brain-specific angiogenesis inhibitor 1 (BAI1), an orphan G protein-coupled receptor-type seven transmembrane protein, was recently found mutated or silenced in multiple human cancers and can interfere with tumor growth when overexpressed. Yet, little is known about its regulation and the molecular mechanisms through which this novel tumor suppressor exerts its anticancer effects. Here, we demonstrate that the N terminus of BAI1 is cleaved extracellularly to generate a truncated receptor and a 40-kDa fragment (Vasculostatin-40) that inhibits angiogenesis. We demonstrate that this novel proteolytic processing event depends on a two-step cascade of protease activation: proprotein convertases, primarily furin, activate latent matrix metalloproteinase-14, which then directly cleaves BAI1 to release the bioactive fragment. These findings significantly augment our knowledge of BAI1 by showing a novel post-translational mechanism regulating BAI1 activity through cancer-associated proteases, have important implications for BAI1 function and regulation, and present novel opportunities for therapy of cancer and other vascular diseases. Oncogene (2012) 31, 5144-5152; doi:10.1038/onc.2012.1; published online 13 February 2012	[Saltz, J. H.; Kaluz, S.; Van Meir, E. G.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Cork, S. M.; Kaur, B.; Devi, N. S.; Sandberg, E. M.; Kaluz, S.; Van Meir, E. G.] Emory Univ, Sch Med, Dept Neurosurg, Lab Mol Neurooncol, Atlanta, GA 30322 USA; [Cooper, L.; Saltz, J. H.] Emory Univ, Ctr Comprehens Informat, Atlanta, GA 30322 USA; [Van Meir, E. G.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Inst, 1365C Clifton Rd NE,Room C5078, Atlanta, GA 30322 USA.	evanmei@emory.edu	kaur, Balveen/E-3355-2011	Van Meir, Erwin G./0000-0003-2444-7707; Kaluz, Stefan/0000-0002-6273-3766	US National Institutes of Health [R01 CA86335, 29XS193]; Winship Cancer Institute [P30 CA138292]; Emory Neurosciences Initiative; NATIONAL CANCER INSTITUTE [P30CA138292, R01CA086335, R01CA150153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064607, P30NS045758] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Winship Cancer Institute; Emory Neurosciences Initiative; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Paper contributions. SMC performed Vstat40 characterization, angiogenesis, cleavage site detection and furin/MMP-14 protease identification experiments, and SMC and EGVM wrote the manuscript. NSD, BK, EMS and SK performed Vstat40 and protease identification experiments. LC and JHS performed the survival analysis. Experiments were conceived of and planned by the respective authors under the direction of EGVM. We appreciate the helpful advice and assistance of all members of the Laboratory of Molecular Neuro-Oncology. SMC was in the Emory graduate program in Neuroscience and acknowledges project guidance by her thesis committee (Drs Randy Hall, Robert McKeon, Paula Vertino and Wei Zhou). We thank Dr C Dubois (Universitede Sherbrooke) for the kind gift of LoVo cells. The US National Institutes of Health (R01 CA86335 to EGVM and contract 29XS193 to JHS), P30 CA138292 (to the Winship Cancer Institute) and the Emory Neurosciences Initiative (to EGVM) contributed to the funding of this research.	Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; BECKSICKINGER AG, 1992, EUR J BIOCHEM, V206, P957, DOI 10.1111/j.1432-1033.1992.tb17006.x; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bjarnadottir TK, 2004, GENOMICS, V84, P23, DOI 10.1016/j.ygeno.2003.12.004; Cao J, 2005, J BIOL CHEM, V280, P10974, DOI 10.1074/jbc.M412370200; Cork SM, 2011, J MOL MED, V89, P743, DOI 10.1007/s00109-011-0759-x; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013; Duda DG, 2002, BRIT J CANCER, V86, P490, DOI 10.1038/sj.bjc.6600067; Fillmore HL, 2001, J NEURO-ONCOL, V53, P187, DOI 10.1023/A:1012213604731; Fukushima Y, 1998, INT J ONCOL, V13, P967; Guedez L, 2003, AM J PATHOL, V162, P1431, DOI 10.1016/S0002-9440(10)64276-9; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Hardcastle J, 2010, MOL THER, V18, P285, DOI 10.1038/mt.2009.232; Hatanaka H, 2000, INT J MOL MED, V5, P181; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Hsiao CC, 2009, FEBS LETT, V583, P3285, DOI 10.1016/j.febslet.2009.09.001; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jin ZH, 2007, HUM MOL GENET, V16, P1972, DOI 10.1093/hmg/ddm144; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kaur B, 2005, ONCOGENE, V24, P3632, DOI 10.1038/sj.onc.1208317; Kaur B, 2003, AM J PATHOL, V162, P19, DOI 10.1016/S0002-9440(10)63794-7; Kaur B, 2009, CANCER RES, V69, P1212, DOI 10.1158/0008-5472.CAN-08-1166; Klenotic PA, 2010, AM J PATHOL, V176, P2039, DOI 10.2353/ajpath.2010.090782; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; Kudo S, 2007, ONCOL REP, V18, P785; Lin HH, 2004, J BIOL CHEM, V279, P31823, DOI 10.1074/jbc.M402974200; Mercapide J, 2002, CLIN CANCER RES, V8, P1740; Nam DH, 2004, ONCOL REP, V11, P863; Nicholson AC, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-11; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6; Yoon KC, 2005, GENE THER, V12, P617, DOI 10.1038/sj.gt.3302442; Yoshida Y, 1999, INT J ONCOL, V15, P1221; Zhang XF, 2007, MICROVASC RES, V74, P90, DOI 10.1016/j.mvr.2007.04.007; Zhu D, 2011, CANCER RES, V71, P5859, DOI 10.1158/0008-5472.CAN-11-1157	46	56	57	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5144	5152		10.1038/onc.2012.1	http://dx.doi.org/10.1038/onc.2012.1			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22330140	Green Accepted			2022-12-28	WOS:000312449800003
J	Mizuno, T; Murakami, H; Fujii, M; Ishiguro, F; Tanaka, I; Kondo, Y; Akatsuka, S; Toyokuni, S; Yokoi, K; Osada, H; Sekido, Y				Mizuno, T.; Murakami, H.; Fujii, M.; Ishiguro, F.; Tanaka, I.; Kondo, Y.; Akatsuka, S.; Toyokuni, S.; Yokoi, K.; Osada, H.; Sekido, Y.			YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes	ONCOGENE			English	Article						malignant mesothelioma; Hippo pathway; YAP; CCND1; cell cycle	YES-ASSOCIATED PROTEIN; PATHWAY; DROSOPHILA; MUTATIONS; MERLIN; NF2; PROGRESSION; COMPONENTS; APOPTOSIS; MARKER	Malignant mesothelioma (MM) shows frequent inactivation of the neurofibromatosis type 2 (NF2) -tumor-suppressor gene. Recent studies have documented that the Hippo signaling pathway, a downstream cascade of Merlin (a product of NF2), has a key role in organ size control and carcinogenesis by regulating cell proliferation and apoptosis. We previously reported that MMs show overexpression of Yes-associated protein (YAP) transcriptional coactivator, the main downstream effector of the Hippo signaling pathway, which results from the inactivation of NF2, LATS2 and/or SAV1 genes (the latter two encoding core components of the mammalian Hippo pathway) or amplification of YAP itself. However, the detailed roles of YAP remain unclear, especially the target genes of YAP that enhance MM cell growth and survival. Here, we demonstrated that YAP-knockdown inhibited cell motility, invasion and anchorage-independent growth as well as cell proliferation of MM cells in vitro. We analyzed genes commonly regulated by YAP in three MM cell lines with constitutive YAP-activation, and found that the major subsets of YAP-upregulating genes encode cell cycle regulators. Among them, YAP directly induced the transcription of CCND1 and FOXM1, in cooperation with TEAD transcription factor. We also found that knockdown of CCND1 and FOXM1 suppressed MM cell proliferation, although the inhibitory effects were less evident than those of YAP knockdown. These results indicate that constitutive YAP activation in MM cells promotes cell cycle progression giving more aggressive phenotypes to MM cells. Oncogene (2012) 31, 5117-5122; doi:10.1038/onc.2012.5; published online 30 January 2012	[Sekido, Y.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; [Mizuno, T.; Ishiguro, F.; Yokoi, K.] Nagoya Univ, Grad Sch Med, Dept Thorac Surg, Nagoya, Aichi 4648601, Japan; [Akatsuka, S.; Toyokuni, S.] Nagoya Univ, Grad Sch Med, Dept Pathol & Biol Responses, Nagoya, Aichi 4648601, Japan; [Osada, H.; Sekido, Y.] Nagoya Univ, Grad Sch Med, Program Funct Construct Med, Dept Canc Genet, Nagoya, Aichi 4648601, Japan	Aichi Cancer Center; Nagoya University; Nagoya University; Nagoya University	Sekido, Y (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Kanokoden 1-1, Nagoya, Aichi 4648681, Japan.	ysekido@aichi-cc.jp	Yokoi, Kohei/I-7261-2014; Toyokuni, Shinya/C-1358-2010; Sekido, Yoshitaka/P-9756-2015; Toyokuni, Shinya/ABE-7714-2021	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109; Sekido, Yoshitaka/0000-0002-2428-3848	Special Coordination Fund for Promoting Science and Technology from Ministry of Education, Culture, Sports, Science and Technology of Japan [H18-1-3-3-1]; KAKENHI [18390245, 22300338]; Ministry of Health, Labor and Welfare of Japan; Takeda Science Foundation; Kobayashi Foundation for Cancer Research; Grants-in-Aid for Scientific Research [23501281] Funding Source: KAKEN	Special Coordination Fund for Promoting Science and Technology from Ministry of Education, Culture, Sports, Science and Technology of Japan; KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Takeda Science Foundation(Takeda Science Foundation (TSF)); Kobayashi Foundation for Cancer Research(Kobayashi Foundation for Cancer Research); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ms Mika Yamamoto for her excellent technical assistance. This work was supported in part by a Special Coordination Fund for Promoting Science and Technology from the Ministry of Education, Culture, Sports, Science and Technology of Japan (H18-1-3-3-1), KAKENHI (18390245, 22300338), Grant-in-Aid for Third-Term Comprehensive Control Research for Cancer from the Ministry of Health, Labor and Welfare of Japan, the Takeda Science Foundation and the Kobayashi Foundation for Cancer Research.	Anbanandam A, 2006, P NATL ACAD SCI USA, V103, P17225, DOI 10.1073/pnas.0607171103; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Cao XW, 2008, GENE DEV, V22, P3320, DOI 10.1101/gad.1726608; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Illei PB, 2003, CANCER CYTOPATHOL, V99, P51, DOI 10.1002/cncr.10923; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Nishioka N, 2009, DEV CELL, V16, P398, DOI 10.1016/j.devcel.2009.02.003; Pass HI, 2004, CURR PROB CANCER, V28, P85; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 2011, PATHOL INT, V61, P331, DOI 10.1111/j.1440-1827.2011.02666.x; Sekido Y, 2010, CANCER SCI, V101, P1, DOI 10.1111/j.1349-7006.2009.01336.x; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yang HN, 2008, CURR TREAT OPTION ON, V9, P147, DOI 10.1007/s11864-008-0067-z; Yokoyama T, 2008, CARCINOGENESIS, V29, P2139, DOI 10.1093/carcin/bgn200; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	35	183	188	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5117	5122		10.1038/onc.2012.5	http://dx.doi.org/10.1038/onc.2012.5			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22286761				2022-12-28	WOS:000312000900008
J	Peyre, M; Stemmer-Rachamimov, A; Clermont-Taranchon, E; Quentin, S; El-Taraya, N; Walczak, C; Volk, A; Niwa-Kawakita, M; Karboul, N; Giovannini, M; Kalamarides, M				Peyre, M.; Stemmer-Rachamimov, A.; Clermont-Taranchon, E.; Quentin, S.; El-Taraya, N.; Walczak, C.; Volk, A.; Niwa-Kawakita, M.; Karboul, N.; Giovannini, M.; Kalamarides, M.			Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation	ONCOGENE			English	Article						meningioma; adenovirus; NF2; CDKN2AB; mouse model	TUMOR-SUPPRESSOR; MALIGNANT PROGRESSION; DCE-MRI; P16(INK4A); GENE; SENESCENCE; BENIGN; RECURRENCE; P15(INK4B); REGRESSION	Aggressive variants of meningiomas (WHO grade II and III) represent up to 30% of those tumors that are among the most common primary central nervous system tumors in adults. Currently, there is no effective treatment for grade-II and -III meningiomas, the main treatment remaining surgical excision. Genetic studies have highlighted two main events associated with meningioma progression: an increase of chromosomal instability in tumors with NF2 inactivation and homozygous deletions or point mutations of the CDKN2AB locus. In this study we demonstrated that in mice, in addition to bi-allelic Nf2 inactivation, homozygous and heterozygous Adenovirus Cre-mediated Cdkn2ab deletions lead to increased meningioma frequency (72% and 50%, respectively) with a shorter latency (3.5 and 7.8 months, respectively) compared with control cohorts and induce grade II/III meningioma progression with an incidence of 34% and 28%, respectively. Moreover, Cdkn2ab inactivation in arachnoidal cells was associated with decreased senescence compared with Nf2(-/-) and wild-type arachnoidal cells in vitro. We have established three mouse meningioma cell lines and generated a syngenic orthotopic meningioma mouse model with 50-100% grade-II/III meningiomas after reimplantation. Comparative genomic hybridization of four meningiomas from Cdkn2ab homozygous mice and three cell cultures revealed the absence of unbalanced chromosomal segments in tumors and several chromosome imbalances in cell cultures. In addition, we were able to detect meningiomas by using bioluminescence and to evaluate tumor vascular permeability by dynamic magnetic resonance imaging. These results show that Nf2 and Cdkn2ab cooperate to promote meningioma progression in mice. The short latency of tumor development and the ability to derive grade II/III meningioma cell cultures are key aspects of this model to promote its use in pre-clinical drug testing.	[Peyre, M.; Kalamarides, M.] Hop Beaujon, AP HP, Dept Neurosurg, F-92110 Clichy, France; [Peyre, M.; Clermont-Taranchon, E.; Niwa-Kawakita, M.; Karboul, N.; Kalamarides, M.] Univ Paris 07, Paris, France; [Peyre, M.; Clermont-Taranchon, E.; Niwa-Kawakita, M.; Karboul, N.; Kalamarides, M.] Fdn Jean Dausset, Unite Inserm U674, Paris, France; [Stemmer-Rachamimov, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neuropathol, Boston, MA USA; [Quentin, S.] Inst Univ Hematol, INSERM, U944, Paris, France; [El-Taraya, N.; Walczak, C.; Volk, A.] Univ Paris 11, INSERM, U759, F-91405 Orsay, France; [El-Taraya, N.; Walczak, C.; Volk, A.] Inst Curie, Ctr Rech, F-91405 Orsay, France; [Giovannini, M.] House Res Inst, Los Angeles, CA USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Harvard University; Harvard Medical School; Massachusetts General Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Kalamarides, M (corresponding author), Hop Beaujon, AP HP, Dept Neurosurg, 100 Blvd Gen Leclerc, F-92110 Clichy, France.	michel.kalamarides@bjn.aphp.fr	Volk, Andreas/A-8474-2019	Volk, Andreas/0000-0003-0915-5458; Kawakita, Michiko/0000-0002-9450-583X; Peyre, Matthieu/0000-0001-8470-9516	Association pour la Recherche sur le Cancer; Ligue Nationale contre le Cancer-comite Paris; Fondation Anber; Association Neurofibromatoses et Recklinghausen; Inserm	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale contre le Cancer-comite Paris; Fondation Anber; Association Neurofibromatoses et Recklinghausen; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank A Berns for Ink4ab<SUP>-/+</SUP> mutant mice, M Pla and staff of the Institut Universitaire d'Hematologie (IUH), Universite Paris 7, for mouse housing. We also thank J Calderaro and G Morcrette for their help in additional pathological analyses. This work was supported by Grants from the Association pour la Recherche sur le Cancer (subvention fixe and funding to MP), Ligue Nationale contre le Cancer-comite Paris, Fondation Anber, Association Neurofibromatoses et Recklinghausen (to ECT and NK) and Inserm.	Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63; Al-Mefty O, 2004, J NEUROSURG, V101, P210, DOI 10.3171/jns.2004.101.2.0210; Bostrom J, 2001, AM J PATHOL, V159, P661, DOI 10.1016/S0002-9440(10)61737-3; Buschges R, 2002, BRAIN PATHOL, V12, P145; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Evans DGR, 2006, J MED GENET, V43, P289, DOI 10.1136/jmg.2005.036319; Gaya A, 2008, BRIT J CANCER, V99, P321, DOI 10.1038/sj.bjc.6604426; Goutagny S, 2011, ANN ONCOL, V22, P990, DOI 10.1093/annonc/mdr012; Goutagny S, 2010, CLIN CANCER RES, V16, P4155, DOI 10.1158/1078-0432.CCR-10-0891; Hanft S, 2010, J NEURO-ONCOL, V99, P433, DOI 10.1007/s11060-010-0348-9; James MF, 2008, NEUROBIOL DIS, V29, P278, DOI 10.1016/j.nbd.2007.09.002; Jongsma J, 2008, CANCER CELL, V13, P261, DOI 10.1016/j.ccr.2008.01.030; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kalamarides M, 2008, BRAIN PATHOL, V18, P62, DOI 10.1111/j.1750-3639.2007.00105.x; Kamijo T, 1999, CANCER RES, V59, P2217; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Korshunov A, 2003, INT J CANCER, V104, P728, DOI 10.1002/ijc.11013; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Lamszus K, 2000, J NEUROPATH EXP NEUR, V59, P504, DOI 10.1093/jnen/59.6.504; Leone PE, 1999, ONCOGENE, V18, P2231, DOI 10.1038/sj.onc.1202531; Lopez-Gines C, 2004, CANCER GENET CYTOGEN, V148, P123, DOI 10.1016/S0165-4608(03)00279-6; Lou E, 2012, J NEURO-ONCOL, V109, P63, DOI 10.1007/s11060-012-0861-0; Loveless ME, 2012, NEOPLASIA, V14, P54, DOI 10.1593/neo.111478; Lyons SK, 2003, CANCER RES, V63, P7042; Menon AG, 1997, ONCOGENE, V14, P611, DOI 10.1038/sj.onc.1200853; Mihaila D, 2003, CLIN CANCER RES, V9, P4443; Morrison JP, 2007, TOXICOL PATHOL, V35, P838, DOI 10.1080/01926230701584130; Perry A, 2002, BRAIN PATHOL, V12, P183; Pistolesi S, 2004, NEUROPATH APPL NEURO, V30, P118, DOI 10.1046/j.0305-1846.2003.00516.x; Puchner MJA, 2010, ANN ONCOL, V21, P2445, DOI 10.1093/annonc/mdq634; Ragel BT, 2008, SURG NEUROL, V70, P295, DOI 10.1016/j.surneu.2007.06.031; Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Simon M, 2001, J NEURO-ONCOL, V55, P149, DOI 10.1023/A:1013863630293; Sotillo R, 2009, CANCER CELL, V16, P451, DOI 10.1016/j.ccr.2009.11.014; The WHO, 2020, CLASSIFICATION TUMOU; Vautier J, 2010, MAGN RESON MED, V64, P313, DOI 10.1002/mrm.22396; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719	41	26	26	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4264	4272		10.1038/onc.2012.436	http://dx.doi.org/10.1038/onc.2012.436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045274				2022-12-28	WOS:000324168000008
J	Yang, Y; Zhou, L; Lu, L; Wang, L; Li, X; Jiang, P; Chan, LKY; Zhang, T; Yu, J; Kwong, J; Cheung, T; Chung, T; Mak, K; Sun, H; Wang, H				Yang, Y.; Zhou, L.; Lu, L.; Wang, L.; Li, X.; Jiang, P.; Chan, L. K. Y.; Zhang, T.; Yu, J.; Kwong, J.; Cheung, T. H.; Chung, T.; Mak, K.; Sun, H.; Wang, H.			A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma	ONCOGENE			English	Article						YY1; EEC; APC; EZH2; H3K27me3; microRNA	YIN YANG 1; SKELETAL MYOGENESIS; TUMOR-SUPPRESSOR; CATENIN PATHWAY; DNA METHYLATION; CANCER; MICRORNAS; PATHOGENESIS; DISEASE; BIOLOGY	Aberrant expression and altered function of transcription factors (TFs) have vital roles in many aspects of tumor development and progression. In this study, we investigated the functional significance of a TF, Yin Yang1 (YY1) in tumorigenesis of endometrioid endometrial carcinoma (EEC). We demonstrated that YY1 is upregulated in EEC cell lines and primary tumors; and its expression is associated with tumor stages. Depletion of YY1 inhibits EEC cell proliferation and migration both in vitro and in vivo, whereas overexpression of YY1 promotes EEC cell growth. These results suggest that YY1 functions as an oncogenic factor in EEC. Transcriptome analysis revealed a significant effect of YY1 on critical aspects of EEC tumorigenesis through inhibition of APC expression. Further mechanistic investigation uncovered a new epigenetic silencing mode of APC by YY1 through recruitment of EZH2 and trimethylation of histone 3 lysine 27 on its promoter region. Moreover, YY1 overexpression was found to be a consequence of miR-193a-5p downregulation through direct miR-193a-5p-YY1 interplay. Our results therefore establish a novel miR-193a-5p-YY1-APC axis, which contributes to EEC development, and may serve as future intervention target.	[Yang, Y.; Zhou, L.; Wang, L.; Chan, L. K. Y.; Zhang, T.; Kwong, J.; Cheung, T. H.; Chung, T.; Wang, H.] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Yang, Y.; Zhou, L.; Lu, L.; Wang, L.; Li, X.; Jiang, P.; Chan, L. K. Y.; Zhang, T.; Yu, J.; Kwong, J.; Sun, H.; Wang, H.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Lu, L.; Jiang, P.; Sun, H.] Chinese Univ Hong Kong, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China; [Li, X.; Yu, J.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Li, X.; Yu, J.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Mak, K.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Wang, H (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci 507A, Hong Kong, Hong Kong, Peoples R China.	huating.wang@cuhk.edu.hk	Sun, Hao/J-9964-2013; sun, hao/GRS-7732-2022; JIANG, Peiyong/AAZ-9898-2020; Li, Xiao-xing/B-9114-2008; Sun, Hao/T-5576-2019; Zhou, Liang/P-4174-2015; Zhang, Tao/ADM-1606-2022; Wang, Huating/C-6719-2014; Kwong, Joseph/H-2368-2013; Yu, Jun/D-8569-2015	Sun, Hao/0000-0002-5547-9501; Li, Xiao-xing/0000-0001-8791-7505; Sun, Hao/0000-0002-5547-9501; Zhou, Liang/0000-0001-5973-7873; Zhang, Tao/0000-0002-8644-8468; Wang, Huating/0000-0001-5474-2905; Kwong, Joseph/0000-0002-3380-6882; Yu, Jun/0000-0001-5008-2153; Jiang, Peiyong/0000-0003-4523-3476; CHUNG, Tony/0000-0002-6362-8546; Mak, Kingston King-Lun/0000-0002-4733-9146	Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China [CUHK476309, CUHK476310, CUHK473211]; CUHK direct grants [2041474, 2041492, 2041662]	Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); CUHK direct grants	The work described in this paper was substantially supported by three General Research Funds (GRFs) from Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China (CUHK476309 and CUHK476310 to HW, and CUHK473211 to HS), and three CUHK direct grants (2041474 to HS and 2041492 and 2041662 to HW).	Aguilera Oscar, 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P13; Andl CD, 2010, J ONCOL, V2010, DOI 10.1155/2010/174715; Bansal N, 2009, CANCER CONTROL, V16, P8, DOI 10.1177/107327480901600102; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boren T, 2008, GYNECOL ONCOL, V110, P206, DOI 10.1016/j.ygyno.2008.03.023; Castellano G, 2009, CELL CYCLE, V8, P1367, DOI 10.4161/cc.8.9.8314; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Chung TKH, 2009, INT J CANCER, V124, P1358, DOI 10.1002/ijc.24071; DAWE CJ, 1964, JNCI-J NATL CANCER I, V33, P441; Fullgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Hatziapostolou M, 2011, CELL MOL LIFE SCI, V68, P1681, DOI 10.1007/s00018-010-0624-z; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Knuutila S, 1998, AM J PATHOL, V152, P1107; Ko CY, 2008, J BIOL CHEM, V283, P30919, DOI 10.1074/jbc.M804029200; Lu LN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027596; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Nebert DW, 2002, TOXICOLOGY, V181, P131, DOI 10.1016/S0300-483X(02)00269-X; Pan Q, 2008, SEMIN REPROD MED, V26, P479, DOI 10.1055/s-0028-1096128; RICHARDSON GS, 1984, GYNECOL ONCOL, V17, P213, DOI 10.1016/0090-8258(84)90080-5; SUI G, 2009, MOL CELL PHARM, V1, P157, DOI DOI 10.4255/MCPHARMACOL.09.20; Takeshita F, 2010, MOL THER, V18, P181, DOI 10.1038/mt.2009.207; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020-06; Wang H, 2009, CELL CYCLE, V8, P1833, DOI 10.4161/cc.8.12.8851; Wang LJ, 2012, MOL THER, V20, P1222, DOI 10.1038/mt.2012.35; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Yang HJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-212; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zaravinos A, 2010, CELL CYCLE, V9, P512, DOI 10.4161/cc.9.3.10588; Zysman M, 2002, CANCER RES, V62, P3663	32	60	66	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2013	32	29					3432	3442		10.1038/onc.2012.360	http://dx.doi.org/10.1038/onc.2012.360			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22907428				2022-12-28	WOS:000322014900004
J	Kim, KJ; Moon, SM; Kim, SA; Kang, KW; Yoon, JH; Ahn, SG				Kim, K-J; Moon, S-M; Kim, S-A; Kang, K-W; Yoon, J-H; Ahn, S-G			Transcriptional regulation of MDR-1 by HOXC6 in multidrug-resistant cells	ONCOGENE			English	Article						HOXC6; MDR-1; multidrug resistance (MDR); apoptosis	CANCER-CELLS; GENE-EXPRESSION; PROSTATE-CANCER; HOMEOBOX B3; MORPHOGENESIS; GROWTH; PHENOTYPE; BINDING; TISSUE; GLAND	Resistance to chemotherapeutic drugs is a significant clinical problem in the treatment of cancer and this resistance has been linked to the cellular expression of multidrug-efflux transporters. The aim of this study was to explore the role of HOXC6 in the regulation of multidrug resistance (MDR) to chemotherapeutic drugs. The HOXC6 gene was identified as being overexpressed in drug-resistant cells compared with parental cell lines. Transfection assays demonstrated that HOXC6 activated MDR-1 promoter activity. A series of MDR-1 promoter deletion mutants was examined and the minimal HOXC6-responsive region was identified to be in the TAAT motif (-2243 bp) of the MDR-1 promoter. Interestingly, overexpression of HOXC6 in the parental cell lines resulted in the upregulation of MDR-1 expression. The inhibition of HOXC6 using small interfering RNA led to the repression of MDR-1. We determined that knockdown of HOXC6 expression in MDR cells increased their sensitivity to paclitaxel. Flow cytometry analysis suggested that siHOXC6 could induce paclitaxel-induced apoptosis and that this was accompanied by an increased accumulation and a decreased release of paclitaxel. Taken together, our findings suggest that HOXC6 expression is an important mechanism of chemotherapeutic drug resistance via its regulation of MDR-1.	[Kim, K-J; Moon, S-M; Ahn, S-G] Chosun Univ, Dept Pathol, Sch Dent, Kwangju 501759, South Korea; [Kim, S-A] Dongguk Univ, Dept Biochem, Gyeongju, South Korea; [Kang, K-W] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Yoon, J-H] Wonkwang Univ, Daejeon Dent Hosp, Dept Oral Pathol, Taejon, South Korea	Chosun University; Dongguk University; Seoul National University (SNU); Wonkwang University	Ahn, SG (corresponding author), Chosun Univ, Dept Pathol, Sch Dent, 375 Seosuk Dong, Kwangju 501759, South Korea.	ahnsg@chosun.ac.kr		Kim, Soo-A/0000-0001-6777-739X	National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [R13-2008-010-00000-0, 2011-0029091]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This research was supported by National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (No. R13-2008-010-00000-0; No. 2011-0029091).	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Bodey B, 2000, ANTICANCER RES, V20, P3281; Bodey B, 2000, ANTICANCER RES, V20, P2717; CASTRONOVO V, 1994, BIOCHEM PHARMACOL, V47, P137, DOI 10.1016/0006-2952(94)90447-2; Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525; Cho S, 2011, P NATL ACAD SCI USA, V108, P20778, DOI 10.1073/pnas.1019452108; Deeley RG, 2006, FEBS LETT, V580, P1103, DOI 10.1016/j.febslet.2005.12.036; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; FRIEDMANN Y, 1994, CANCER RES, V54, P5981; Fujiki K, 2008, GASTROENTEROLOGY, V135, P907, DOI 10.1053/j.gastro.2008.06.034; Garcia-Gasca A, 2000, DEV DYNAM, V219, P261, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1048>3.0.CO;2-3; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grishina IB, 2005, DEV BIOL, V288, P334, DOI 10.1016/j.ydbio.2005.08.018; Guo CC, 2005, INT J CANCER, V116, P155, DOI 10.1002/ijc.20919; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; Kim SA, 2012, J CELL PHYSIOL, V227, P1, DOI 10.1002/jcp.22948; Lin YS, 2007, DEVELOPMENT, V134, P723, DOI 10.1242/dev.02765; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; McCabe CD, 2008, CANCER RES, V68, P1988, DOI 10.1158/0008-5472.CAN-07-5843; Miller GJ, 2003, CANCER RES, V63, P5879; Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906; Ricort JM, 2002, J BIOL CHEM, V277, P19448, DOI 10.1074/jbc.M200439200; Svingen T, 2006, HEREDITY, V97, P88, DOI 10.1038/sj.hdy.6800847; Szakacs G, 2004, CANCER CELL, V6, P129, DOI 10.1016/j.ccr.2004.06.026; TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Veraksa A, 2000, MOL GENET METAB, V69, P85, DOI 10.1006/mgme.2000.2963	29	20	20	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2013	32	28					3339	3349		10.1038/onc.2012.354	http://dx.doi.org/10.1038/onc.2012.354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22907429				2022-12-28	WOS:000321620200004
J	Chell, V; Balmanno, K; Little, AS; Wilson, M; Andrews, S; Blockley, L; Hampson, M; Gavine, PR; Cook, SJ				Chell, V.; Balmanno, K.; Little, A. S.; Wilson, M.; Andrews, S.; Blockley, L.; Hampson, M.; Gavine, P. R.; Cook, S. J.			Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance	ONCOGENE			English	Article						acquired resistance; ERK1/2; FGFR; PKB; tyrosine kinase inhibitors	MULTIPLE-MYELOMA; BLADDER-CANCER; STOMACH-CANCER; GASTRIC-CANCER; PROTEIN-KINASE; C/EBP-ALPHA; LINES; GENE; PHOSPHORYLATION; AMPLIFICATION	Fibroblast growth factor receptors (FGFRs) can act as driving oncoproteins in certain cancers, making them attractive drug targets. Here we have characterized tumour cell responses to two new inhibitors of FGFR1-3, AZ12908010 and the clinical candidate AZD4547, making comparisons with the well-characterized FGFR inhibitor PD173074. In a panel of 16 human tumour cell lines, the anti-proliferative activity of AZ12908010 or AZD4547 was strongly linked to the presence of deregulated FGFR signalling, indicating that addiction to deregulated FGFRs provides a therapeutic opportunity for selective intervention. Acquired resistance to targeted tyrosine kinase inhibitors is a growing problem in the clinic but has not yet been explored for FGFR inhibitors. To assess how FGFR-dependent tumour cells adapt to long-term FGFR inhibition, we generated a derivative of the KMS-11 myeloma cell line (FGFR(Y373C)) with acquired resistance to AZ12908010 (KMS-11R cells). Basal phosphorylated FGFR and FGFR-dependent downstream signalling were constitutively elevated and refractory to drug in KMS-11R cells. Sequencing of FGFR3 in KMS-11R cells revealed the presence of a heterozygous mutation at the gatekeeper residue, encoding FGFR3(V555M); consistent with this, KMS-11R cells were cross-resistant to AZD4547 and PD173074. These results define the selectivity and efficacy of two new FGFR inhibitors and identify a secondary gatekeeper mutation as a mechanism of acquired resistance to FGFR inhibitors that should be anticipated as clinical evaluation proceeds.	[Chell, V.; Balmanno, K.; Little, A. S.; Wilson, M.; Cook, S. J.] Babraham Inst, Signalling Lab, Cambridge CB22 3AT, England; [Andrews, S.] Babraham Inst, Bioinformat Grp, Cambridge CB22 3AT, England; [Blockley, L.; Hampson, M.] AstraZeneca, R&D Genet, Macclesfield, Cheshire, England; [Gavine, P. R.] AstraZeneca R&D, Innovat Ctr China, Shanghai, Peoples R China	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; AstraZeneca; AstraZeneca	Cook, SJ (corresponding author), Babraham Inst, Signalling Lab, Babraham Res Campus, Cambridge CB22 3AT, England.	simon.cook@babraham.ac.uk		Cook, Simon/0000-0001-9087-1616; Balmanno, Kathryn/0000-0002-6417-3889	CASE PhD studentship (nee Victoria Knights); Biotechnology and Biological Sciences Research Council (BBSRC); AstraZeneca; Babraham Institute; BBSRC [BBS/E/B/0000C235, BBS/E/B/000C0417, BBS/E/B/000C0419] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0419, BBS/E/B/000C0417, BBS/E/B/0000C235, BBS/E/B/0000C199] Funding Source: researchfish; Worldwide Cancer Research [12-1259] Funding Source: researchfish	CASE PhD studentship (nee Victoria Knights); Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); AstraZeneca(AstraZeneca); Babraham Institute(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Worldwide Cancer Research	We would like to thank Anne Segonds-Pichon (Babraham Bioinformatics Group) for statistical analysis of qRT-PCR data and Jonathan Keats, Janet Nutt, Margaret Knowles, Matthias Ebert and Andrew Garner for provision of some of the cell lines used in this study. We would especially like to thank Andrew Garner for initiating this project, and for discussions and encouragement in its early stages. We are grateful to Teresa Klinowska, Nigel Brooks, Elaine Kilgour and Paul Smith for many useful discussions and suggestions throughout. This work was supported by a CASE PhD studentship (VC, nee Victoria Knights) funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and AstraZeneca, and a sponsored research agreement between AstraZeneca and the Babraham Institute.	Al-Ahmadie HA, 2011, J PATHOL, V224, P270, DOI 10.1002/path.2892; Azam M, 2008, NAT STRUCT MOL BIOL, V15, P1109, DOI 10.1038/nsmb.1486; Azam M, 2006, MOL DIAGN THER, V10, P67, DOI 10.1007/BF03256446; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Binato R, 2009, MOL MED REP, V2, P657, DOI 10.3892/mmr_00000153; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Hammerman PS, 2009, CLIN CANCER RES, V15, P7502, DOI 10.1158/1078-0432.CCR-09-0189; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307; Huynh H, 2008, CLIN CANCER RES, V14, P6146, DOI 10.1158/1078-0432.CCR-08-0509; Jang JH, 2001, CANCER RES, V61, P3541; Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705; Jeffers Michael, 2002, Expert Opin Ther Targets, V6, P469, DOI 10.1517/14728222.6.4.469; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Keats JJ, 2006, LEUKEMIA LYMPHOMA, V47, P2289, DOI 10.1080/10428190600822128; Kimura T, 2001, CANCER-AM CANCER SOC, V92, P2555, DOI 10.1002/1097-0142(20011115)92:10<2555::AID-CNCR1607>3.0.CO;2-M; Klinowska T, 2008, GORD RES C 2 7 MARCH; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Knights V, 2010, PHARMACOL THERAPEUT, V125, P105, DOI 10.1016/j.pharmthera.2009.10.001; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; Lamont FR, 2011, BRIT J CANCER, V104, P75, DOI 10.1038/sj.bjc.6606016; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lombardi L, 2007, GENE CHROMOSOME CANC, V46, P226, DOI 10.1002/gcc.20404; Milojkovic D, 2009, CLIN CANCER RES, V15, P7519, DOI 10.1158/1078-0432.CCR-09-1068; Moffa AB, 2004, MOL CANCER RES, V2, P643; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; MOR O, 1993, CANCER GENET CYTOGEN, V65, P111, DOI 10.1016/0165-4608(93)90217-A; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Qing J, 2009, J CLIN INVEST, V119, P1216, DOI 10.1172/JCI38017; Radomska HS, 2006, J EXP MED, V203, P371, DOI 10.1084/jem.20052242; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Squires M, 2011, MOL CANCER THER, V10, P1542, DOI 10.1158/1535-7163.MCT-11-0426; Sun SS, 2012, J SURG ONCOL, V105, P773, DOI 10.1002/jso.22120; Tannheimer SL, 2000, BREAST CANCER RES, V2, P311, DOI 10.1186/bcr73; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; Tomlinson D, 2007, ONCOGENE, V26, P5889, DOI 10.1038/sj.onc.1210399; Tomlinson DC, 2007, J PATHOL, V213, P91, DOI 10.1002/path.2207; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; Tsujimoto H, 1997, VIRCHOWS ARCH, V431, P383, DOI 10.1007/s004280050115; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Zhou WJ, 2010, CHEM BIOL, V17, P285, DOI 10.1016/j.chembiol.2010.02.007	60	103	109	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2013	32	25					3059	3070		10.1038/onc.2012.319	http://dx.doi.org/10.1038/onc.2012.319			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22869148				2022-12-28	WOS:000320705700006
J	Bai, F; Smith, MD; Chan, HL; Pei, XH				Bai, F.; Smith, M. D.; Chan, H. L.; Pei, X-H			Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation	ONCOGENE			English	Article						Brca1; luminal progenitor; basal-like tumor	SUPPRESSOR GENE BRCA1; BREAST-CANCER; ESTROGEN-RECEPTOR; CDK INHIBITORS; EPITHELIAL PROGENITORS; MOLECULAR ANALYSIS; P18(INK4C); EXPRESSION; CYCLE; DIFFERENTIATION	Breast cancer developed in familial BRCA1 mutation carriers bears striking similarities to sporadic basal-like breast tumors. The mechanism underlying the function of BRCA1 in suppressing basal-like breast cancer remains unclear. We previously reported that the deletion of p18(Ink4c) (p18), an inhibitor of G1 cyclin Ds-dependent CDK4 and CDK6, stimulates mammary luminal progenitor cell proliferation and leads to spontaneous luminal tumor development. We report here that germline mutation of Brca1 in p18-deficient mice blocks the increase of luminal progenitor cells, impairs luminal gene expression and promotes malignant transformation of mammary tumors. Instead of the luminal mammary tumors developed in p18 single-mutant mice, mammary tumors developed in the p18; Brca1 mice, similar to breast cancer developed in familial BRCA1 carriers, exhibited extensive basal-like features and lost the remaining wild-type allele of Brca1. These results reveal distinct functions of the RB and BRCA1 pathways in suppressing luminal and basal-like mammary tumors, respectively. These results also suggest a novel mechanism-causing luminal-to-basal transformation-for the development of basal-like breast cancer in familial BRCA1 carriers and establish a unique mouse model for developing therapeutic strategies to target both luminal and basal-like breast cancers.	[Bai, F.; Chan, H. L.; Pei, X-H] Univ Miami, Miller Sch Med, Dept Surg, Mol Oncol Program, Miami, FL 33136 USA; [Smith, M. D.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Pei, X-H] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami; University of North Carolina; University of North Carolina Chapel Hill; University of Miami	Pei, XH (corresponding author), Univ Miami, Miller Sch Med, Dept Surg, Mol Oncol Program, 1550 NW 10th Ave, Miami, FL 33136 USA.	xhpei@med.miami.edu	Pei, Xin-Hai/P-1812-2014	Chan, Ho Lam/0000-0001-9799-0618; pei, xin-hai/0000-0001-6441-1691	DOD Idea Award [W81XWH-101-0302]; University of Miami Miller School of Medicine	DOD Idea Award; University of Miami Miller School of Medicine	This project was initiated at the Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill. We thank Dr Yue Xiong for his invaluable support, discussion and critical reading of the manuscript, Dr Beverly Koller for providing Brca1 germline mutant mice and Drs Anthony Capobianco and Xiangxi Xu for discussions. This study was supported in part by a DOD Idea Award (W81XWH-101-0302) and startup funds from the University of Miami Miller School of Medicine to XHP.	Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558; Arnes JB, 2005, CLIN CANCER RES, V11, P4003, DOI 10.1158/1078-0432.CCR-04-2064; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Bai F, 2007, MOL CELL BIOL, V27, P1495, DOI 10.1128/MCB.01764-06; Bai F, 2006, MOL CELL BIOL, V26, P4564, DOI 10.1128/MCB.00266-06; Bennett LM, 2000, CANCER RES, V60, P3461; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Buckley NE, 2012, STEM CELL REV REP, V8, P982, DOI 10.1007/s12015-012-9354-y; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Drost RM, 2009, BRIT J CANCER, V101, P1651, DOI 10.1038/sj.bjc.6605350; Foulkes WD, 2004, CANCER RES, V64, P830, DOI 10.1158/0008-5472.CAN-03-2970; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Honrado E, 2005, MODERN PATHOL, V18, P1305, DOI 10.1038/modpathol.3800453; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kubista M, 2002, ONCOGENE, V21, P4747, DOI 10.1038/sj.onc.1205580; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lapointe J, 1996, CANCER RES, V56, P4586; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Lee YH, 2011, GENE DEV, V25, P176, DOI 10.1101/gad.1975811; Leone PE, 2008, CLIN CANCER RES, V14, P6033, DOI 10.1158/1078-0432.CCR-08-0347; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Pei XH, 2007, CANCER RES, V67, P3162, DOI 10.1158/0008-5472.CAN-06-4517; Pei XH, 2009, CANCER CELL, V15, P389, DOI 10.1016/j.ccr.2009.03.004; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Ramsey MR, 2007, CANCER RES, V67, P4732, DOI 10.1158/0008-5472.CAN-06-3437; Ribeiro-Silva A, 2005, HISTOPATHOLOGY, V47, P458, DOI 10.1111/j.1365-2559.2005.02249.x; Rosen EM, 2006, CANCER LETT, V236, P175, DOI 10.1016/j.canlet.2005.04.037; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shakya R, 2011, SCIENCE, V334, P525, DOI 10.1126/science.1209909; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Smart CE, 2011, ONCOGENE, V30, P1597, DOI 10.1038/onc.2010.538; Smart CE, 2008, BREAST CANCER RES TR, V112, P237, DOI 10.1007/s10549-007-9859-2; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spirin KS, 1997, INT J ONCOL, V11, P737; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; Suspitsin EN, 2011, BREAST CANCER-TOKYO, V18, P137, DOI 10.1007/s12282-009-0105-0; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Wiedemeyer R, 2008, CANCER CELL, V13, P355, DOI 10.1016/j.ccr.2008.02.010; Williamson EA, 2006, ONCOGENE, V25, P1391, DOI 10.1038/sj.onc.1209170; Wright MH, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-29; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zindy F, 2003, CANCER RES, V63, P5420	70	31	31	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2715	2725		10.1038/onc.2012.293	http://dx.doi.org/10.1038/onc.2012.293			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22777348				2022-12-28	WOS:000319808000003
J	Kobayashi, K; Jakt, LM; Nishikawa, SI				Kobayashi, K.; Jakt, L. M.; Nishikawa, S-I			Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn	ONCOGENE			English	Article						Arid3b; Mycn; neuroblastoma; embryonic stems cell; molecular network for pluripotency; epigenetics	CELL-DIFFERENTIATION CULTURE; PLURIPOTENT STEM-CELLS; EMBRYONIC STEM; GROUND-STATE; SELF-RENEWAL; NETWORK; CANCER; TRANSCRIPTION; TRANSGENE; ENDODERM	AT-rich interaction domain molecule 3B (ARID3B) and MYCN are expressed in a portion of neuroblastoma, and form a combination that has strong oncogenic activity in mouse embryonic fibroblasts (MEFs). Here, we show that this combination can also convert neural stem cells to neuroblastoma-like tumor. To address whether there are common mechanisms regulating the expression of this combination of genes, we examined public repositories of gene expression data and found that although these genes are rarely expressed together, co-expression was observed in a proportion of germ cell tumors (GCTs), in embryonic stem (ES) cells and in testis. These cell types and tissues are related to pluripotency and we show here that in mouse ES cells, Arid3b and Mycn are indeed involved in cell proliferation; the former in avoiding cell death and the latter in driving cell cycle progression. Accordingly, the two genes are induced during somatic cell reprogramming to iPS, and this induction is accompanied by the switching of promoter histone marks from H3K27me3 to H3K4me3. Conversely, the switch from H3K4me3 to H3K27me3 in these genes occurs during the differentiation of neural crest to mature sympathetic ganglia cells. In many, if not most, neuroblastomas these genes carry H3K4me3 marks within their promoters. Thus, a failure of the epigenetic silencing of these genes during development may be an underlying factor responsible for neuroblastoma.	[Kobayashi, K.; Jakt, L. M.; Nishikawa, S-I] RIKEN, Ctr Dev Biol, Lab Stem Cell Biol, Kobe, Hyogo 6500047, Japan	RIKEN	Kobayashi, K (corresponding author), RIKEN, Ctr Dev Biol, Lab Stem Cell Biol, Kobe, Hyogo 6500047, Japan.	kkobayashi@cdb.riken.jp		Jakt, Lars Martin/0000-0002-3787-8138	Grants-in-Aid for Scientific Research [20229005] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Aiden AP, 2010, CELL STEM CELL, V6, P591, DOI 10.1016/j.stem.2010.03.016; Ban H, 2011, P NATL ACAD SCI USA, V108, P14234, DOI 10.1073/pnas.1103509108; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Guo G, 2009, DEVELOPMENT, V136, P1063, DOI 10.1242/dev.030957; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kobayashi K, 2006, CANCER RES, V66, P8331, DOI 10.1158/0008-5472.CAN-06-0756; Larsson LG, 2010, EXP CELL RES, V316, P1429, DOI 10.1016/j.yexcr.2010.03.025; Li ZL, 2009, CELL CYCLE, V8, P2703, DOI 10.4161/cc.8.17.9418; Maris JM, 2002, CANCER CELL, V2, P447, DOI 10.1016/S1535-6108(02)00206-4; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Miyoshi Hiroyuki, 2004, Methods Mol Biol, V246, P429; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Nakagawara A, 2004, PROG BRAIN RES, V146, P233, DOI 10.1016/S0079-6123(03)46015-9; Nishishita N, 2011, BIOMATERIALS, V32, P3555, DOI 10.1016/j.biomaterials.2010.12.063; Numata S, 1999, CANCER RES, V59, P3741; Pardo M, 2010, CELL STEM CELL, V6, P382, DOI 10.1016/j.stem.2010.03.004; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; SAWAI S, 1993, DEVELOPMENT, V117, P1445; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Smith KN, 2010, CELL STEM CELL, V7, P343, DOI 10.1016/j.stem.2010.06.023; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Tachibana M, 2008, EMBO J, V27, P2681, DOI 10.1038/emboj.2008.192; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takebe A, 2006, DEV BIOL, V293, P25, DOI 10.1016/j.ydbio.2005.12.016; Varlakhanova NV, 2010, DIFFERENTIATION, V80, P9, DOI 10.1016/j.diff.2010.05.001; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Yoshimizu T, 1999, DEV GROWTH DIFFER, V41, P675	34	19	19	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 23	2013	32	21					2640	2648		10.1038/onc.2012.285	http://dx.doi.org/10.1038/onc.2012.285			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22751132	hybrid, Green Published			2022-12-28	WOS:000319806700005
J	Furcht, CM; Rojas, ARM; Nihalani, D; Lazzara, MJ				Furcht, C. M.; Rojas, A. R. Munoz; Nihalani, D.; Lazzara, M. J.			Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations	ONCOGENE			English	Article						extracellular signal-regulated kinase (ERK); gefitinib; endocytosis; GRB2-associated binder 1 (GAB1)	SIGNAL-REGULATED KINASE; MOLECULAR-MECHANISM; TYROSINE KINASE; GEFITINIB; PHOSPHATASE; SENSITIVITY; MET; PHOSPHORYLATION; RESISTANCE; INHIBITORS	Non-small cell lung cancer (NSCLC) cells harboring activating mutations of the epidermal growth factor receptor (EGFR) tend to display elevated activity of several survival signaling pathways. Surprisingly, these mutations also correlate with reduced phosphorylation of ERK and SHP2, a protein tyrosine phosphatase required for complete ERK activation downstream of most receptor tyrosine kinases. As ERK activity influences cellular response to EGFR inhibition, altered SHP2 function could have a role in the striking response to gefitinib witnessed with EGFR mutation. Here, we demonstrate that impaired SHP2 phosphorylation correlates with diminished SHP2 function in NSCLC cells expressing mutant, versus wild-type, EGFR. In NSCLC cells expressing wild-type EGFR, SHP2 knockdown decreased ERK phosphorylation, basally and in response to gefitinib, and increased cellular sensitivity to gefitinib. In cells expressing EGFR mutants, these effects of SHP2 knockdown were less substantial, but the expression of constitutively active SHP2 reduced cellular sensitivity to gefitinib. In cells expressing EGFR mutants, which do not undergo efficient ligand-mediated endocytosis, SHP2 was basally associated with GRB2-associated binder 1 (GAB1) and EGFR, and SHP2's presence in membrane fractions was dependent on EGFR activity. Whereas EGF promoted a more uniform intracellular distribution of initially centrally localized SHP2 in cells expressing wild-type EGFR, SHP2 was basally evenly distributed and did not redistribute in response to EGF in cells with EGFR mutation. Thus, EGFR mutation may promote association of a fraction of SHP2 at the plasma membrane with adapters that promote SHP2 activity. Consistent with this, SHP2 immunoprecipitated from cells with EGFR mutation was active, and EGF treatment did not change this activity. Overall, our data suggest that a fraction of SHP2 is sequestered at the plasma membrane in cells with EGFR mutation in a way that impedes SHP2's ability to promote ERK activity and identify SHP2 as a potential target for co-inhibition with EGFR in NSCLC.	[Furcht, C. M.; Lazzara, M. J.] Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA; [Rojas, A. R. Munoz; Lazzara, M. J.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Nihalani, D.] Univ Penn, Dept Med, Renal Electrolyde & Hypertens Div, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazzara, MJ (corresponding author), Univ Penn, Dept Chem & Biomol Engn, 311A Towne Bldg,220 South 33rd St, Philadelphia, PA 19104 USA.	mlazzara@seas.upenn.edu	nihalani, deepak/AAK-9453-2020	Munoz-Rojas, Andres R./0000-0002-1251-723X; Furcht, Christopher/0000-0002-5403-4914	University of Pennsylvania Cell and Molecular Biology Training Grant [T32 GM-07229]; National Cancer Institute [R25 CA101871-07]; Ashton Foundation; University of Pennsylvania Institute for Regenerative Medicine; Pennsylvania Department of Health; National Institutes of Health through the NIDDK [1R01DK087956]; University of Pennsylvania; NATIONAL CANCER INSTITUTE [R25CA101871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER	University of Pennsylvania Cell and Molecular Biology Training Grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ashton Foundation; University of Pennsylvania Institute for Regenerative Medicine; Pennsylvania Department of Health; National Institutes of Health through the NIDDK; University of Pennsylvania; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	CMF was supported in part by the University of Pennsylvania Cell and Molecular Biology Training Grant (T32 GM-07229), grant R25 CA101871-07 from the National Cancer Institute and a fellowship from the Ashton Foundation. AMR received support from the University of Pennsylvania Institute for Regenerative Medicine. This project was funded, in part, under a grant with the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. Support for DN was provided by the National Institutes of Health Grant 1R01DK087956 through the NIDDK. This work was also supported in part by laboratory startup funds from the University of Pennsylvania. We thank Dr Ben Neel, Dr Eric Haura, Dr Pasi Janne, Dr Tyler Jacks, Dr Marilyn Farquhar, Dr Gary Nolan, Dr Anil Rustgi and Dr Susan Margulies for generously providing reagents and access to instrumentation. We also thank Ms Gladys Gray Lawrence, Dr Ranganath Parthasarathy, Mr Calixte Monast and Ms Alice Macdonald Walsh for technical assistance.	Akca H, 2006, LUNG CANCER, V54, P25, DOI 10.1016/j.lungcan.2006.06.007; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Coldren CD, 2006, MOL CANCER RES, V4, P521, DOI 10.1158/1541-7786.MCR-06-0095; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Hendriks BS, 2006, IEE P SYST BIOL, V153, P457, DOI 10.1049/ip-syb:20050108; Hendriks BS, 2003, CANCER RES, V63, P1130; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kontaridis MI, 2006, J BIOL CHEM, V281, P6785, DOI 10.1074/jbc.M513068200; Lazzara MJ, 2010, CANCER RES, V70, P3843, DOI 10.1158/0008-5472.CAN-09-3421; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Offterdinger M, 2008, TRAFFIC, V9, P147, DOI 10.1111/j.1600-0854.2007.00665.x; Paulsen CE, 2012, NAT CHEM BIOL, V8, P57, DOI 10.1038/nchembio.736; Ren Yuan, 2010, Genes Cancer, V1, P994, DOI 10.1177/1947601910395582; Salvi M, 2004, CELL MOL LIFE SCI, V61, P2393, DOI 10.1007/s00018-004-4211-z; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Zhou XD, 2009, J BIOL CHEM, V284, P12226, DOI 10.1074/jbc.M900020200	31	32	35	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2346	2355		10.1038/onc.2012.240	http://dx.doi.org/10.1038/onc.2012.240			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22777356	Green Accepted			2022-12-28	WOS:000318683600011
J	Shanmugasundaram, K; Block, K; Nayak, BK; Livi, CB; Venkatachalam, MA; Sudarshan, S				Shanmugasundaram, K.; Block, K.; Nayak, B. K.; Livi, C. B.; Venkatachalam, M. A.; Sudarshan, S.			PI3K regulation of the SKP-2/p27 axis through mTORC2	ONCOGENE			English	Article						p27; SKP-2; mTOR; RICTOR	RENAL-CELL CARCINOMA; RAPAMYCIN COMPLEX 2; PROTEIN-KINASE B; TISSUE MICROARRAY; SUBCELLULAR-LOCALIZATION; CYTOPLASMIC LOCALIZATION; AKT PHOSPHORYLATION; MAMMALIAN TARGET; UBIQUITIN LIGASE; SKP2	The cyclin-dependent kinase inhibitor p27 is a key regulator of cell-cycle progression. Its expression and localization are altered in several types of malignancies, which has prognostic significance in cancers such as renal cell carcinoma (RCC). S-phase kinase-associated protein 2 (SKP-2) is an F-box protein that is part of the SKP-1/Cul1/F-box ubiquitin ligase complex that targets nuclear p27 among many other cell-cycle proteins for proteosomal degradation. Its overexpression has been observed in several tumor types. Signaling by phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) has previously been shown to regulate the SKP-2/p27 axis. Recent evidence suggests that PI3K signaling may activate mammalian target of rapamycin complex 2 (mTORC2) activity. As PI3K signaling is known to regulate SKP-2 and p27, we sought to determine whether these effects were mediated by mTORC2. Here we provide additional genetic evidence that PI3K signaling activates mTORC2 kinase activity. We also demonstrate a novel role for mTORC2 in the modulation of nuclear p27 levels. In particular, mTORC2 signaling promotes the reduction of nuclear p27 protein levels through the increased protein expression of SKP-2. These are the first data to demonstrate a role for mTOR in the regulation of SKP-2. In concordance with these findings, mTORC2 activity promotes cell proliferation of RCC cells at the G1-S interphase of the cell cycle. Collectively, these data implicate mTORC2 signaling in the regulation of the SKP-2/p27 axis, a signaling node commonly altered in cancer. Oncogene (2013) 32, 2027-2036; doi:10.1038/onc.2012.226; published online 25 June 2012	[Shanmugasundaram, K.; Sudarshan, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA; [Block, K.; Nayak, B. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Livi, C. B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA; [Venkatachalam, M. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Block, K.] Audie L Murphy Mem Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Sudarshan, S (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, 7703 Floyd Curl Dr,MC 7845, San Antonio, TX 78229 USA.	sudarshan@uthscsa.edu		Livi, Carolina/0000-0001-8389-2830	Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center [NIH P30 CA054174-17]; NIH [K08 CA138774, R01 NCI CA131272]; Voelcker Fund Young Investigator Award; AUA Foundation/Astellas Rising Star Award; Veterans Administration Career Development Award [CDA-2]; NATIONAL CANCER INSTITUTE [P30CA054174, K08CA138774, R01CA131272] Funding Source: NIH RePORTER	Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Voelcker Fund Young Investigator Award; AUA Foundation/Astellas Rising Star Award; Veterans Administration Career Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center (NIH P30 CA054174-17). SS is supported by NIH K08 CA138774, Voelcker Fund Young Investigator Award, AUA Foundation/Astellas Rising Star Award and a special gift from Mr Charles Butt and the employees of HEB. KB is supported by Veterans Administration Career Development Award (CDA-2) and NIH R01 NCI CA131272. We thank Z David Sharp for critical review of the manuscript. We thank William Friedrichs and Korri Weldon for technical assistance.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anastasiadis AG, 2003, ANTICANCER RES, V23, P217; Bashir T, 2010, CELL CYCLE, V9, P971, DOI 10.4161/cc.9.5.10914; Boutonnet C, 2010, CELL CYCLE, V9, P975, DOI 10.4161/cc.9.5.10915; Cho DC, 2010, CLIN CANCER RES, V16, P3628, DOI 10.1158/1078-0432.CCR-09-3022; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Gan XQ, 2011, J BIOL CHEM, V286, P10998, DOI 10.1074/jbc.M110.195016; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Haitel A, 2001, UROLOGY, V58, P477, DOI 10.1016/S0090-4295(01)01188-8; Hedberg Y, 2003, BRIT J CANCER, V88, P1417, DOI 10.1038/sj.bjc.6600922; Hedberg Y, 2002, INT J CANCER, V102, P601, DOI 10.1002/ijc.10763; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975; Kim EK, 2011, ONCOGENE, V30, P2954, DOI 10.1038/onc.2011.22; Kim J, 2009, CLIN CANCER RES, V15, P81, DOI 10.1158/1078-0432.CCR-08-0170; Langner C, 2004, VIRCHOWS ARCH, V445, P631, DOI 10.1007/s00428-004-1121-2; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu Z, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-51; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Migita T, 2002, CANCER-AM CANCER SOC, V94, P973, DOI 10.1002/cncr.10338.abs; Nogueira V, 2012, EMBO J, V31, P1134, DOI 10.1038/emboj.2011.478; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sgambato A, 2010, CANCER SCI, V101, P2080, DOI 10.1111/j.1349-7006.2010.01644.x; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sudarshan S, 2009, MOL CELL BIOL, V29, P4080, DOI 10.1128/MCB.00483-09; Tato I, 2011, J BIOL CHEM, V286, P6128, DOI 10.1074/jbc.M110.166991; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Wang HB, 2010, CELL CYCLE, V9, P1021, DOI 10.4161/cc.9.5.10916; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206	43	24	26	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2013	32	16					2027	2036		10.1038/onc.2012.226	http://dx.doi.org/10.1038/onc.2012.226			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22733130	Green Accepted			2022-12-28	WOS:000317919900004
J	Chaudhry, SI; Hooper, S; Nye, E; Williamson, P; Harrington, K; Sahai, E				Chaudhry, S. I.; Hooper, S.; Nye, E.; Williamson, P.; Harrington, K.; Sahai, E.			Autocrine IL-1 beta-TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine INF alpha, signalling to carcinoma-associated fibroblasts	ONCOGENE			English	Article						Traf6; Interleukin-1; TNR alpha; invasion; carcinoma-associated fibroblast	NECROSIS-FACTOR-ALPHA; KAPPA-B; CYTOSKELETAL CHANGES; ACTIN CYTOSKELETON; CANCER CELLS; TNF-ALPHA; TGF-BETA; ACTIVATION; TRAF6; TUMORS	The invasion of squamous cell carcinoma (SCC) is a significant cause of morbidity and mortality. Here, we identify an E3 ligase, Traf6 and a de-ubiquitinating enzyme, Cezanne/ZA20D1, as important regulators of this process in organotypic models. Traf6 can promote the formation of Cdc42-dependent F-actin microspikes. Furthermore, Traf6 has a key role in autocrine interleukin-1 beta signalling in SCC cells, which in turn is required to drive the expression of tumour necrosis factor alpha (TNF alpha). TNF alpha acts in a paracrine manner to increase the invasion-promoting potential of carcinoma-associated fibroblasts (CAFs). Exogenous TNF alpha signalling can restore invasion in cells depleted of Traf6. In conclusion, Traf6 has two important roles in SCC invasion: it promotes cell intrinsic Cdc42-dependent regulation of the actin cytoskeleton and enables production of the paracrine signal, TNF alpha, that enhances the activity of CAFs. Oncogene (2013) 32, 747-758; doi:10.1038/onc.2012.91; published online 26 March 2012	[Chaudhry, S. I.; Hooper, S.; Sahai, E.] Canc Res UK London Res Inst, Tumour Cell Biol Lab, London WC2A 3LY, England; [Chaudhry, S. I.] UCL Eastman Dent Inst, London, England; [Chaudhry, S. I.] UCLHT Eastman Dent Hosp, London, England; [Nye, E.] Canc Res UK London Res Inst, Expt Histopathol Lab, London WC2A 3LY, England; [Williamson, P.] St George Hosp, Thomas Tatum Head & Neck Unit, London, England; [Harrington, K.] Inst Canc Res, London SW3 6JB, England	Cancer Research UK; University of London; University College London; University of London; University College London; Cancer Research UK; St Georges University London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Sahai, E (corresponding author), Canc Res UK London Res Inst, Tumour Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.	erik.sahai@cancer.org.uk		Harrington, Kevin/0000-0002-6014-348X; Sahai, Erik/0000-0002-3932-5086	Cancer Research UK; Cancer Research UK [15154] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank the Cancer Research UK for funding. We thank St George's Thomas Tatum Head and the Neck Unit staff involved in tissue collection, Martin Gore for providing reagents, and lab members for their advice and discussions.	Ahn KS, 2007, CURR MOL MED, V7, P619, DOI 10.2174/156652407782564363; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bremm A, 2010, NAT STRUCT MOL BIOL, V17, P939, DOI 10.1038/nsmb.1873; Castillo-Lluva S, 2010, NAT CELL BIOL, V12, P1078, DOI 10.1038/ncb2112; Chen YZ, 2009, MOL CELL, V35, P841, DOI 10.1016/j.molcel.2009.09.004; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Elmets CA, 2010, JNCI-J NATL CANCER I, V102, P1835, DOI 10.1093/jnci/djq442; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Evans PC, 2001, BIOCHEM J, V357, P617, DOI 10.1042/0264-6021:3570617; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gil Z, 2009, ISR MED ASSOC J, V11, P296; GRONOWICZ G, 1992, J PERIODONTAL RES, V27, P562, DOI 10.1111/j.1600-0765.1992.tb01737.x; Hanna AN, 2001, MOL BIOL CELL, V12, P3618, DOI 10.1091/mbc.12.11.3618; Heyninck K, 1999, FEBS LETT, V442, P147, DOI 10.1016/S0014-5793(98)01645-7; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; HOOPER S, BR J CANC, V102, P392; Jeong JG, 2004, BIOCHEM BIOPH RES CO, V324, P3, DOI 10.1016/j.bbrc.2004.09.011; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Krelin Y, 2007, CANCER RES, V67, P1062, DOI 10.1158/0008-5472.CAN-06-2956; Kurihara Y, 2009, CLIN EXP METASTAS, V26, P425, DOI 10.1007/s10585-009-9241-3; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pritchard S, 2006, ARTHRITIS RHEUM-US, V54, P2164, DOI 10.1002/art.21941; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Rosenblum H, 2011, AUTOIMMUN REV, V10, P563, DOI 10.1016/j.autrev.2011.04.010; Sanz-Moreno V, 2011, CANCER CELL, V20, P229, DOI 10.1016/j.ccr.2011.06.018; Scott KA, 2003, MOL CANCER THER, V2, P445; Shah JP, 2009, ORAL ONCOL, V45, P394, DOI 10.1016/j.oraloncology.2008.05.017; Smith PC, 2009, J PERIODONTAL RES, V44, P73, DOI 10.1111/j.1600-0765.2007.01081.x; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Tse WKF, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-637; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang KZQ, 2006, J CELL SCI, V119, P1579, DOI 10.1242/jcs.02889; Windheim M, 2008, MOL CELL BIOL, V28, P1783, DOI 10.1128/MCB.02380-06; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yao M, 2007, ORAL ONCOL, V43, P213, DOI 10.1016/j.oraloncology.2006.04.013; Yin Q, 2009, NAT STRUCT MOL BIOL, V16, P658, DOI 10.1038/nsmb.1605	44	29	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					747	758		10.1038/onc.2012.91	http://dx.doi.org/10.1038/onc.2012.91			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22450746	Green Accepted			2022-12-28	WOS:000315746700008
J	Bernardo, GM; Bebek, G; Ginther, CL; Sizemore, ST; Lozada, KL; Miedler, JD; Anderson, LA; Godwin, AK; Abdul-Karim, FW; Slamon, DJ; Keri, RA				Bernardo, G. M.; Bebek, G.; Ginther, C. L.; Sizemore, S. T.; Lozada, K. L.; Miedler, J. D.; Anderson, L. A.; Godwin, A. K.; Abdul-Karim, F. W.; Slamon, D. J.; Keri, R. A.			FOXA1 represses the molecular phenotype of basal breast cancer cells	ONCOGENE			English	Article						FOXA1; luminal; basal; breast cancer	ESTROGEN-RECEPTOR-ALPHA; ANDROGEN RECEPTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LUMINAL SUBTYPE; GATA-3; MORPHOGENESIS; BINDING; BRCA1; DIFFERENTIATION	Breast cancer is a heterogeneous disease that comprises multiple subtypes. Luminal subtype tumors confer a more favorable patient prognosis, which is, in part, attributed to estrogen receptor (ER)-alpha positivity and antihormone responsiveness. Expression of the forkhead box transcription factor, FOXA1, similarly correlates with the luminal subtype and patient survival, but is also present in a subset of ER-negative tumors. FOXA1 is also consistently expressed in luminal breast cancer cell lines even in the absence of ER. In contrast, breast cancer cell lines representing the basal subtype do not express FOXA1. To delineate an ER-independent role for FOXA1 in maintaining the luminal phenotype, and hence a more favorable prognosis, we performed expression microarray analyses on FOXA1-positive and ER-positive (MCF7, T47D), or FOXA1-positive and ER-negative (MDA-MB-453, SKBR3) luminal cell lines in the presence or absence of transient FOXA1 silencing. This resulted in three FOXA1 transcriptomes: (1) a lumina! signature (consistent across cell lines), (2) an ER-positive signature (restricted to MCF7 and T47D) and (3) an ER-negative signature (restricted to MDA-MB-453 and SKBR3). Gene set enrichment analyses revealed FOXA1 silencing causes a partial transcriptome shift from luminal to basal gene expression signatures. FOXA1 binds to a subset of both luminal and basal genes within luminal breast cancer cells, and loss of FOXA1 increases enhancer RNA transcription for a representative basal gene (CD58). These data suggest FOXA1 directly represses a subset of basal signature genes. Functionally, FOXA1 silencing increases migration and invasion of luminal cancer cells, both of which are characteristics of basal subtype cells. We conclude FOXA1 controls plasticity between basal and luminal breast cancer cells, not only by inducing luminal genes but also by repressing the basal phenotype, and thus aggressiveness. Although it has been proposed that FOXA1-targeting agents may be useful for treating luminal tumors, these data suggest that this approach may promote transitions toward more aggressive cancers. Oncogene (2013) 32, 554-563; doi:10.1038/onc.2012.62; published online 5 March 2012	[Bernardo, G. M.; Sizemore, S. T.; Lozada, K. L.; Keri, R. A.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Bebek, G.] Case Western Reserve Univ, Sch Med, Case Ctr Prote & Bioinformat, Cleveland, OH 44106 USA; [Bebek, G.] Cleveland Clin, Genom Med Inst, Cleveland, OH 44106 USA; [Ginther, C. L.; Anderson, L. A.; Slamon, D. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; [Miedler, J. D.; Abdul-Karim, F. W.] Univ Hosp Case Med Ctr, Dept Pathol, Cleveland, OH USA; [Godwin, A. K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [Abdul-Karim, F. W.] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Keri, R. A.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; [Keri, R. A.] Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Case Western Reserve University; Case Western Reserve University Hospital; University of Kansas; University of Kansas Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Keri, RA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	keri@case.edu	Sizemore, Gina/ABI-7542-2020; Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	Department of Defense [W81XWH-06-1-0712, W81XWH-09-1-0696, W81XWH-08-1-0347]; National Institutes of Health [T32-HD-07104-33, UL1-RR024989, R01 CA090398]; Case Western Reserve University Comprehensive Cancer Center [P30 CA043703]; University Hospitals of Cleveland Pathology Research Associates Grant; Fox Chase Cancer Center [P30 CA006927]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007104] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA090398, P30CA043703] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Case Western Reserve University Comprehensive Cancer Center; University Hospitals of Cleveland Pathology Research Associates Grant; Fox Chase Cancer Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work is supported by the Department of Defense (W81XWH-06-1-0712, GMB; W81XWH-09-1-0696, STS; W81XWH-08-1-0347, RAK), the National Institutes of Health (T32-HD-07104-33, GMB; UL1-RR024989, GB; R01 CA090398, RAK), the Case Western Reserve University Comprehensive Cancer Center (P30 CA043703, GB and RAK), a University Hospitals of Cleveland Pathology Research Associates Grant (FWA and RAK) and a Fox Chase Cancer Center Support Grant (P30 CA006927, AKG).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122; Bernardo GM, 2012, BIOSCIENCE REP, V32, P113, DOI 10.1042/BSR20110046; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Feng Y, 2007, P NATL ACAD SCI USA, V104, P14718, DOI 10.1073/pnas.0706933104; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fu XY, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2849; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Habashy HO, 2008, EUR J CANCER, V44, P1541, DOI 10.1016/j.ejca.2008.04.020; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Krum SA, 2008, MOL ENDOCRINOL, V22, P2393, DOI 10.1210/me.2008-0100; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Malik S, 2010, MOL CELL BIOL, V30, P399, DOI 10.1128/MCB.00907-09; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Mehta RJ, 2012, BREAST CANCER RES TR, V131, P881, DOI 10.1007/s10549-011-1482-6; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Naderi A, 2008, NEOPLASIA, V10, P542, DOI 10.1593/neo.08274; Nakanishi T, 2010, BRIT J CANCER, V102, P815, DOI 10.1038/sj.bjc.6605553; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Robinson JLL, 2011, EMBO J, V30, P3019, DOI 10.1038/emboj.2011.216; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Schug J, 2008, CURR PROTOC BIOINFOR, V21, P261, DOI DOI 10.1002/; Serandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110; Smyth GK, 2005, P 55 SESS INT STAT I; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thorat MA, 2008, J CLIN PATHOL, V61, P327, DOI 10.1136/jcp.2007.052431; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Williamson EA, 2006, ONCOGENE, V25, P1391, DOI 10.1038/sj.onc.1209170; Wolf I, 2007, INT J CANCER, V120, P1013, DOI 10.1002/ijc.22389; Yamaguchi N, 2008, BIOCHEM BIOPH RES CO, V365, P711, DOI 10.1016/j.bbrc.2007.11.064	53	102	104	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					554	563		10.1038/onc.2012.62	http://dx.doi.org/10.1038/onc.2012.62			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22391567	Green Accepted			2022-12-28	WOS:000316164700003
J	Gulzar, ZG; McKenney, JK; Brooks, JD				Gulzar, Z. G.; McKenney, J. K.; Brooks, J. D.			Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1	ONCOGENE			English	Article						prostate cancer; gene-expression profiling; NuSAP; E2F1; recurrence	GENE-EXPRESSION; PROGNOSTIC BIOMARKERS; BINDING PROTEIN-3; BREAST-CANCER; PROLIFERATION; SURVIVAL; REVEALS; OVEREXPRESSION; IDENTIFICATION; PROGRESSION	Increasing evidence suggests that prostate cancer is overdiagnosed and overtreated, and prognostic biomarkers would aid in treatment selection. To define prognostic biomarkers for aggressive prostate cancer, we carried out gene-expression profiling of 98 prostate tumors and 52 benign adjacent prostate tissue samples with detailed clinical annotation. We identified 28 transcripts significantly associated with recurrence after radical prostatectomy including NuSAP, a protein that binds DNA to the mitotic spindle. Elevated NuSAP transcript levels were associated with poor outcome in two independent prostate cancer gene-expression datasets. To characterize the role and regulation of NuSAP in prostate cancer, we studied the expression of NuSAP in the LNCaP and PC3 human prostate cancer cell lines. Posttranscriptional silencing of the NuSAP gene severely hampered the ability of PC3 to invade and proliferate in vitro. The promoter region of the NuSAP gene contains two CCAAT boxes and binding sites for E2F. Transient transfection of an E2F1 cDNA and 431 bp of the NuSAP promoter demonstrated E2F1 as an important regulator of expression. Deletion of the E2F-binding site at nucleotide -246 negated the effects of E2F1 on NuSAP expression. Electrophoretic mobility shift assays demonstrated that nuclear extracts of cells overexpressing E2F1 bound directly to the E2F-binding site in the NuSAP promoter region. Finally, immunohistochemistry showed a strong correlation between E2F1 and NuSAP expression in human prostate cancer samples. NuSAP is a novel biomarker for prostate cancer recurrence after surgery and its overexpression appears to be driven in part by E2F1 activation. Oncogene (2013) 32, 70-77; doi:10.1038/onc.2012.27; published online 20 February 2012	[Gulzar, Z. G.; Brooks, J. D.] Stanford Univ, Dept Urol, Sch Med, Stanford, CA 94305 USA; [McKenney, J. K.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Brooks, JD (corresponding author), Stanford Univ, Dept Urol, Sch Med, Room S287,300 Pasteur Dr, Stanford, CA 94305 USA.	jdbrooks@stanford.edu			NIH [CA112016, CA111782, CA130472]; Department of Defense [W81XWH-11-1-0447]; NATIONAL CANCER INSTITUTE [R01CA112016, R01CA111782, F32CA130472] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was funded by the NIH (CA112016, CA111782 and CA130472 to JDB) and the Department of Defense (W81XWH-11-1-0447 to JDB).	Abraham JE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2629; Adamo B, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2852; Amemiya H, 2010, INVEST CLIN, V51, P369; Aune G, 2011, GYNECOL ONCOL, V121, P402, DOI 10.1016/j.ygyno.2010.12.355; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550; Chan JM, 2002, J NATL CANCER I, V94, P1099; Chotteau-Lelievre A, 2004, CLIN CANCER RES, V10, P7297, DOI 10.1158/1078-0432.CCR-04-0593; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Engers R, 2007, ENDOCR-RELAT CANCER, V14, P245, DOI 10.1677/ERC-06-0036; Freedland SJ, 2005, JAMA-J AM MED ASSOC, V294, P433, DOI 10.1001/jama.294.4.433; Fujiwara T, 2006, BRIT J HAEMATOL, V135, P583, DOI 10.1111/j.1365-2141.2006.06340.x; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Gorter A, 2010, MODERN PATHOL, V23, P1605, DOI 10.1038/modpathol.2010.154; Helfenstein A, 2004, AM J CLIN PATHOL, V122, P912, DOI 10.1309/G638TKNNG2CJUXWL; Hussain S, 2009, J CELL BIOL, V186, P27, DOI 10.1083/jcb.200810180; Iyer J, 2011, CELL SIGNAL, V23, P991, DOI 10.1016/j.cellsig.2010.11.006; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim YH, 2009, METHODS MOL BIOL, V556, P21, DOI 10.1007/978-1-60327-192-9_3; Kosari F, 2008, CLIN CANCER RES, V14, P1734, DOI 10.1158/1078-0432.CCR-07-1494; Lammers L A, 2010, Br J Cancer, V103, P765, DOI 10.1038/sj.bjc.6605800; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; LaTulippe E, 2002, CANCER RES, V62, P4499; Luo J, 2001, CANCER RES, V61, P4683; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; Malhotra S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020293; Miyata Y, 2004, UROLOGY, V63, P1184, DOI 10.1016/j.urology.2004.02.015; Monge M, 2009, CARCINOGENESIS, V30, P1288, DOI 10.1093/carcin/bgp119; Murphy AJ, 2007, CANCER RES, V67, P2893, DOI 10.1158/0008-5472.CAN-06-2962; Mustjoki S, 2009, HAEMATOL-HEMATOL J, V94, P1469, DOI 10.3324/haematol.2009.008094; Pflueger D, 2011, GENOME RES, V21, P56, DOI 10.1101/gr.110684.110; Rodriguez-Enriquez S, 2011, J CELL BIOCHEM, V112, P2703, DOI 10.1002/jcb.23224; Roobol MJ, 2009, EUR UROL, V56, P584, DOI 10.1016/j.eururo.2009.07.018; Schrader C, 2005, BRIT J CANCER, V93, P939, DOI 10.1038/sj.bjc.6602795; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; Setoguchi T, 2011, CANCER SCI, V102, P883, DOI 10.1111/j.1349-7006.2011.01872.x; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Sherlock G, 2001, NUCLEIC ACIDS RES, V29, P152, DOI 10.1093/nar/29.1.152; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Vanden Bosch A, 2010, J CELL SCI, V123, P3244, DOI 10.1242/jcs.063875; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; von Euler H, 2011, VET COMP ONCOL, V9, P1, DOI 10.1111/j.1476-5829.2010.00238.x; Wadia PP, 2010, BLOOD, V115, P2077, DOI 10.1182/blood-2009-03-211375; Welsh JB, 2001, CANCER RES, V61, P5974; Wong N, 2009, INT J CANCER, V124, P644, DOI 10.1002/ijc.23968; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yuan RH, 2007, CLIN CANCER RES, V13, P5368, DOI 10.1158/1078-0432.CCR-07-1113	51	76	81	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					70	77		10.1038/onc.2012.27	http://dx.doi.org/10.1038/onc.2012.27			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22349817	Green Accepted			2022-12-28	WOS:000313029500007
J	Sanchez, M; Picard, N; Sauve, K; Tremblay, A				Sanchez, M.; Picard, N.; Sauve, K.; Tremblay, A.			Coordinate regulation of estrogen receptor beta degradation by Mdm2 and CREB-binding protein in response to growth signals	ONCOGENE			English	Article						ErbB2/Her-2/Neu; ErbB3; PI3-K/Akt pathway; 26S proteasome-ubiquitin system; CBP/p300; breast cancer	BREAST-CANCER CELLS; PHOSPHORYLATION; ACTIVATION; ALPHA; PATHWAY; KINASE; PROTEASOME; COACTIVATOR; GAMMA; CBP	The biological actions of estrogen are mediated via estrogen receptors ER alpha and ER beta. Yet, other cellular signaling events that also impact ER functions have an important role in breast carcinogenesis. Here, we show that activation of ErbB2/ErbB3 tyrosine kinase receptors with growth factor heregulin-beta prompts ER beta degradation by the 26S proteasome, a mechanism that requires the coactivator cAMP response element-binding (CREB)-binding protein (CBP). We found that CBP promotes ER beta ubiquitination and degradation through enhancement of the PI3-K/Akt pathway by heregulin-beta, an effect potentiated by a negatively charged hinge region of ER beta. Activated Akt triggered the recruitment of E3 ubiquitin ligase Mdm2 to ER beta, which was further stabilized by CBP, resulting in ER beta poly-ubiquitination. Mutation of CBP Thr-1872 or Mdm2 Ser-186/188 Akt sites resulted in a dissociation of the ER beta-CBP-Mdm2 complex and reduced ER beta turnover. We found that the decrease in ER beta induced by heregulin-beta was associated with reduced target gene promoter occupancy and enhanced proliferation of breast cancer cells. However, knockdown of Mdm2 restored endogenous ER beta levels resulting in reduction of breast cancer cell growth. These studies identify a tripartite Akt-regulated phosphorylation mechanism that functions to hamper normal ER beta activity and turnover through the concerted actions of CBP and Mdm2 in response to growth factor signaling pathways in breast cancer cells. Oncogene (2013) 32, 117-126; doi:10.1038/onc.2012.19; published online 20 February 2012	[Sanchez, M.; Picard, N.; Sauve, K.; Tremblay, A.] Univ Montreal, Ste Justine Hosp Res Ctr, Dept Biochem, Montreal, PQ H3T 1C5, Canada; [Tremblay, A.] Univ Montreal, Dept Obstet & Gynecol, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal	Tremblay, A (corresponding author), Univ Montreal, Ste Justine Hosp Res Ctr, Dept Biochem, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	andre.tremblay.1@umontreal.ca			FHSJ (Fondation de l'Hopital Ste-Justine); FRSQ (Fonds de la Recherche en Sante du Quebec); GRUM (Groupe de Recherche sur le Medicament de l'Universite de Montreal); CIHR (Canadian Institutes of Health Research); NSERC (Natural Sciences and Engineering Research Council of Canada); Cancer Research Society Inc.; Canadian Foundation for Innovation; FHSJ	FHSJ (Fondation de l'Hopital Ste-Justine); FRSQ (Fonds de la Recherche en Sante du Quebec)(Fonds de la Recherche en Sante du Quebec); GRUM (Groupe de Recherche sur le Medicament de l'Universite de Montreal); CIHR (Canadian Institutes of Health Research)(Canadian Institutes of Health Research (CIHR)); NSERC (Natural Sciences and Engineering Research Council of Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Cancer Research Society Inc.; Canadian Foundation for Innovation(Canada Foundation for Innovation); FHSJ	We thank members of the laboratory for critical reading and useful comments. MS is supported by a doctoral award from the FHSJ (Fondation de l'Hopital Ste-Justine), NP by the FRSQ (Fonds de la Recherche en Sante du Quebec) and the FHSJ, and KS by the GRUM (Groupe de Recherche sur le Medicament de l'Universite de Montreal), the FHSJ and the CIHR (Canadian Institutes of Health Research). AT is a New Investigator of the CIHR. This work was supported by grants from the CIHR, the NSERC (Natural Sciences and Engineering Research Council of Canada), the Cancer Research Society Inc. and the Canadian Foundation for Innovation.	Ariazi EA, 2002, CANCER RES, V62, P6510; Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; Avallone R, 2006, MOL ENDOCRINOL, V20, P3165, DOI 10.1210/me.2006-0146; Berry NB, 2008, MOL ENDOCRINOL, V22, P1535, DOI 10.1210/me.2007-0449; Brekman A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2804; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Demers A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007728; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kim K, 2011, J MOL ENDOCRINOL, V46, P67, DOI 10.1677/JME-10-0110; Lazennec G, 2006, CANCER LETT, V231, P151, DOI 10.1016/j.canlet.2005.01.021; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Leygue E, 1998, CANCER RES, V58, P3197; Lindberg K, 2010, J CELL PHYSIOL, V222, P156, DOI 10.1002/jcp.21932; Loda M, 2010, CANCER CELL, V17, P311, DOI 10.1016/j.ccr.2010.03.013; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2010, SEMIN CANCER BIOL, V20, P19, DOI 10.1016/j.semcancer.2009.10.005; Nair HB, 2011, STEROIDS, V76, P792, DOI 10.1016/j.steroids.2011.02.038; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Picard N, 2008, MOL ENDOCRINOL, V22, P317, DOI 10.1210/me.2007-0281; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Roger P, 2008, ADV EXP MED BIOL, V617, P139, DOI 10.1007/978-0-387-69080-3_13; Sakamoto G, 2009, BREAST CANCER-TOKYO, V16, P281, DOI 10.1007/s12282-009-0110-3; SANCHEZ M, 2005, MOL GENET CANC, V5, P149; Sanchez M, 2007, J BIOL CHEM, V282, P4830, DOI 10.1074/jbc.M607908200; Sanchez M, 2010, TRENDS ENDOCRIN MET, V21, P104, DOI 10.1016/j.tem.2009.09.007; Sauve K, 2009, CANCER RES, V69, P5793, DOI 10.1158/0008-5472.CAN-08-4924; Shao WL, 2004, P NATL ACAD SCI USA, V101, P11599, DOI 10.1073/pnas.0402997101; Shi DD, 2009, P NATL ACAD SCI USA, V106, P16275, DOI 10.1073/pnas.0904305106; St-Laurent V, 2005, J STEROID BIOCHEM, V94, P23, DOI 10.1016/j.jsbmb.2005.02.001; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Treeck O, 2010, BREAST CANCER RES TR, V120, P557, DOI 10.1007/s10549-009-0413-2; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay A, 2001, J STEROID BIOCHEM, V77, P19, DOI 10.1016/S0960-0760(01)00031-0; Weigel NL, 2007, MOL ENDOCRINOL, V21, P2311, DOI 10.1210/me.2007-0101	44	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2013	32	1					117	126		10.1038/onc.2012.19	http://dx.doi.org/10.1038/onc.2012.19			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22349818				2022-12-28	WOS:000313029500012
J	De Menna, M; D'Amato, V; Ferraro, A; Fusco, A; Di Lauro, R; Garbi, C; De Vita, G				De Menna, M.; D'Amato, V.; Ferraro, A.; Fusco, A.; Di Lauro, R.; Garbi, C.; De Vita, G.			Wnt4 inhibits cell motility induced by oncogenic Ras	ONCOGENE			English	Article						cancer; cell motility; miR-24; Ras; Wnt4	UP-REGULATION; EXPRESSION; MIGRATION; DIFFERENTIATION; ACTIVATION; PATHWAY; BETA	Aberrant motility and invasive ability are relevant hallmarks of malignant tumor cells. Pathways regulating the movement of cancer cells from the site of primary tumor toward adjacent and/or distant tissues are not entirely defined. By using a model of malignant transformation induced by Ras, we identified Wnt4 as an early target of Ras oncogenic signaling. Here we show that Wnt4 is repressed by Ras and that forced Wnt4 expression inhibits Ras-induced cell motility. Accordingly, we found that Wnt4 is downregulated in human anaplastic thyroid carcinomas, the most malignant and metastatic thyroid cancer histotype. Wnt4 interferes with Ras-induced actin cytoskeleton reorganization through non-canonical pathways, by altering the balance between the activation of different Rho-family small guanosine triphosphatases (GTPases). Finally, we demonstrate that Wnt4 is post-transcriptionally repressed by miR-24, a Ras-induced micro RNA (miRNA) targeting the 3'-untranslated region (UTR) of Wnt4. Taken together our data highlight a novel Ras-regulated miRNA-dependent circuitry regulating the motile phenotype of cancer cells.	[De Menna, M.; D'Amato, V.; Ferraro, A.; Fusco, A.; Di Lauro, R.; Garbi, C.; De Vita, G.] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-580131 Naples, Italy; [Fusco, A.] CNR, Ist Endocrinol Oncol Sperimentale, I-80125 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	De Vita, G (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-580131 Naples, Italy.	gdevita@unina.it	Ferraro, Angelo/H-3193-2019; De Vita, Gabriella/H-4422-2011; Di Lauro, Roberto/A-2746-2012; Ferraro, Angelo/A-4172-2014	Ferraro, Angelo/0000-0002-2044-7569; De Vita, Gabriella/0000-0002-7302-1174; Di Lauro, Roberto/0000-0001-9493-3036; Ferraro, Angelo/0000-0002-2044-7569; Fusco, Alfredo/0000-0003-3332-5197; De Menna, Marta/0000-0002-6306-3485	Associazione Italiana per la Ricerca sul Cancro (AIRC)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC).	Abreu MTH, 2011, MOL BIOL CELL, V22, P105, DOI 10.1091/mbc.E10-03-0185; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Baratta MG, 2009, MOL ENDOCRINOL, V23, P838, DOI 10.1210/me.2008-0353; Benhaj K, 2006, ONCOL REP, V15, P701; Bhushan L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022484; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; De Vita G, 2005, MOL ENDOCRINOL, V19, P76, DOI 10.1210/me.2004-0172; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Frezzetti D, 2011, ONCOGENE, V30, P275, DOI 10.1038/onc.2010.416; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; HUGUET EL, 1994, CANCER RES, V54, P2615; Jeays-Ward K, 2003, DEVELOPMENT, V130, P3663, DOI 10.1242/dev.00591; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miyakoshi T, 2008, ENDOCR PATHOL, V19, P261, DOI 10.1007/s12022-008-9048-9; Papadimitriou E, 2012, ONCOGENE, V31, P2862, DOI 10.1038/onc.2011.457; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429; Quinlan MP, 1999, ONCOGENE, V18, P6434, DOI 10.1038/sj.onc.1203026; Roger PP, 2010, MOL CELL ENDOCRINOL, V321, P3, DOI 10.1016/j.mce.2009.11.015; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Tanigawa S, 2011, DEV BIOL, V352, P58, DOI 10.1016/j.ydbio.2011.01.012; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Vainio SJ, 2003, J NEPHROL, V16, P279; Vincent JP, 2011, EMBO J, V30, P3665, DOI 10.1038/emboj.2011.311; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Xie L, 2011, CLIN BIOCHEM, V44, P216, DOI 10.1016/j.clinbiochem.2010.11.002	38	16	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4110	4119		10.1038/onc.2012.419	http://dx.doi.org/10.1038/onc.2012.419			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23027131				2022-12-28	WOS:000323748500006
J	Granit, RZ; Gabai, Y; Hadar, T; Karamansha, Y; Liberman, L; Waldhorn, I; Gat-Viks, I; Regev, A; Maly, B; Darash-Yahana, M; Peretz, T; Ben-Porath, I				Granit, R. Z.; Gabai, Y.; Hadar, T.; Karamansha, Y.; Liberman, L.; Waldhorn, I.; Gat-Viks, I.; Regev, A.; Maly, B.; Darash-Yahana, M.; Peretz, T.; Ben-Porath, I.			EZH2 promotes a bi-lineage identity in basal-like breast cancer cells	ONCOGENE			English	Article						basal-like; breast cancer; differentiation; EZH2; Polycomb; GATA3	STEM-CELLS; POLYCOMB; GATA-3; MUTATION; FATE; DIFFERENTIATION; IDENTIFICATION; MORPHOGENESIS; PROGENITORS; POPULATION	The mechanisms regulating breast cancer differentiation state are poorly understood. Of particular interest are molecular regulators controlling the highly aggressive and poorly differentiated traits of basal-like breast carcinomas. Here we show that the Polycomb factor EZH2 maintains the differentiation state of basal-like breast cancer cells, and promotes the expression of progenitor-associated and basal-lineage genes. Specifically, EZH2 regulates the composition of basal-like breast cancer cell populations by promoting a 'bi-lineage' differentiation state, in which cells co-express basal- and luminal-lineage markers. We show that human basal-like breast cancers contain a subpopulation of bi-lineage cells, and that EZH2-deficient cells give rise to tumors with a decreased proportion of such cells. Bi-lineage cells express genes that are active in normal luminal progenitors, and possess increased colony-formation capacity, consistent with a primitive differentiation state. We found that GATA3, a driver of luminal differentiation, performs a function opposite to EZH2, acting to suppress bi-lineage identity and luminal-progenitor gene expression. GATA3 levels increase upon EZH2 silencing, mediating a decrease in bi-lineage cell numbers. Our findings reveal a novel role for EZH2 in controlling basal-like breast cancer differentiation state and intra-tumoral cell composition.	[Granit, R. Z.; Gabai, Y.; Hadar, T.; Karamansha, Y.; Liberman, L.; Waldhorn, I.; Ben-Porath, I.] Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel; [Hadar, T.] Hadassah Med Ctr, Dept Surg, IL-91120 Jerusalem, Israel; [Gat-Viks, I.; Regev, A.] Broad Inst Harvard & MIT, Cambridge, MA USA; [Gat-Viks, I.; Regev, A.] MIT, Dept Biol, Cambridge, MA USA; [Maly, B.] Hadassah Med Ctr, Dept Pathol, IL-91120 Jerusalem, Israel; [Darash-Yahana, M.; Peretz, T.] Hadassah Med Ctr, Sharett Inst Oncol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Ben-Porath, I (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel.	ittaibp@mail.huji.ac.il		Granit, Roy Zvi/0000-0002-6487-2559	Israel Science Foundation [1560/07]; Israel Cancer Association; Israel Cancer Research Foundation; Joint Research Fund IMRIC-Hadassah	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Israel Cancer Research Foundation; Joint Research Fund IMRIC-Hadassah	We thank Eli Pikarsky, Yuval Dor and Yehudit Bergman for critical reviewing of the manuscript, Marius Wernig for the Fip-EZH2 construct, Alex Roesch and Meenhard Herlyn for the pLU-JARID1Bp-GFP-Blast<SUP>R</SUP> construct and Sabine Werner for the CK14 promoter plasmid. We thank Norma E. Kidess-Bassir for histological support. This study was supported by the Israel Science Foundation (Grant 1560/07), the Israel Cancer Association, the Israel Cancer Research Foundation, and the Joint Research Fund IMRIC-Hadassah.	Alford SH, 2012, BREAST CANCER RES TR, V132, P429, DOI 10.1007/s10549-011-1591-2; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Asselin-Labat ML, 2011, MOL CELL BIOL, V31, P4609, DOI 10.1128/MCB.05766-11; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; Gusterson B, 2009, NAT REV CANCER, V9, P128, DOI 10.1038/nrc2571; Hock H, 2012, GENE DEV, V26, P751, DOI 10.1101/gad.191163.112; Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rakha EA, 2009, BREAST CANCER RES TR, V113, P411, DOI 10.1007/s10549-008-9952-1; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Spike BT, 2012, CELL STEM CELL, V10, P183, DOI 10.1016/j.stem.2011.12.018; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	44	27	29	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3886	3895		10.1038/onc.2012.390	http://dx.doi.org/10.1038/onc.2012.390			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22986524	Green Submitted			2022-12-28	WOS:000323210200011
J	Saandi, T; Baraille, F; Derbal-Wolfrom, L; Cattin, AL; Benahmed, F; Martin, E; Cardot, P; Duclos, B; Ribeiro, A; Freund, JN; Duluc, I				Saandi, T.; Baraille, F.; Derbal-Wolfrom, L.; Cattin, A-L; Benahmed, F.; Martin, E.; Cardot, P.; Duclos, B.; Ribeiro, A.; Freund, J-N; Duluc, I.			Regulation of the tumor suppressor homeogene Cdx2 by HNF4 alpha in intestinal cancer	ONCOGENE			English	Article						intestine; hepatocyte nuclear factor; tumor suppressor; homeobox gene	HEPATOCYTE NUCLEAR FACTOR-4-ALPHA; IV GENE-TRANSCRIPTION; HOMEOBOX GENE; COLORECTAL-CANCER; CHROMOSOMAL INSTABILITY; EPITHELIAL-CELLS; GUT DEVELOPMENT; DOWN-REGULATION; MUTANT MICE; EXPRESSION	The gut-specific homeotic transcription factor Cdx2 is a crucial regulator of intestinal development and homeostasis, which is downregulated in colorectal cancers (CRC) and exhibits a tumor suppressor function in the colon. We have previously established that several endodermal transcription factors, including HNF4 alpha and GATA6, are involved in Cdx2 regulation in the normal gut. Here we have studied the role of HNF4 alpha in the mechanism of deregulation of Cdx2 in colon cancers. Crossing Apc(Delta 14/+) mice prone to spontaneous intestinal tumor development with pCdx2-9LacZ transgenic mice containing the LacZ reporter under the control of the 9.3-kb Cdx2 promoter showed that this promoter segment contains sequences recapitulating the decrease of Cdx2 expression in intestinal cancers. Immunohistochemistry revealed that HNF4 alpha, unlike GATA6, exhibited a similar decrease to Cdx2 in genetic (Apc(min/+) and Apc(Delta 14/+)) and chemically induced (Azoxymethane (AOM) treatment) models of intestinal tumors in mice. HNF4 alpha and Cdx2 also exhibited a comparable deregulated pattern in human CRC. Correlated patterns were observed between HNF4 alpha and Cdx2 in several experimental models of human colon cancer cell lines: xenografts in nude mice, wound healing and glucose starvation. Furthermore, Cdx2 decreased by knocking down HNF4 alpha in human colon cancer cells using siRNA and in the colon of mice conditionally knocked out for the Hnf4 alpha gene in the adult intestine (Hnf4 alpha(f/f); VilCre(ERT2) mice). Finally, the conditionally knocked out mice Hnf4 alpha(f/f); VilCre(ERT2) treated with the carcinogen AOM developed colorectal tumors earlier than wild-type mice, as previously reported for mice with a reduced Cdx2 expression. In conclusion, this study provides evidence that the downregulation of HNF4 alpha is an important determinant of the reduced expression of the Cdx2 tumor suppressor gene in intestinal cancers. Consistently, similar to Cdx2, HNF4 alpha exerts a tumor suppressor function in the colon in that its loss of function facilitates tumor progression.	[Saandi, T.; Derbal-Wolfrom, L.; Benahmed, F.; Martin, E.; Duclos, B.; Freund, J-N; Duluc, I.] INSERM, U682, F-67200 Strasbourg, France; [Saandi, T.; Derbal-Wolfrom, L.; Martin, E.; Duclos, B.; Freund, J-N; Duluc, I.] Univ Strasbourg, Fac Med, Strasbourg, France; [Baraille, F.; Cattin, A-L; Cardot, P.; Ribeiro, A.] Ctr Rech Cordeliers, INSERM, UMRS 872, Paris, France; [Baraille, F.; Cattin, A-L; Cardot, P.; Ribeiro, A.] Univ Paris 06, UMRS 872, Paris, France; [Baraille, F.; Cattin, A-L; Cardot, P.; Ribeiro, A.] Univ Paris 05, UMRS 872, Paris, France; [Benahmed, F.] Hosp Special Surg, Autoimmun & Inflammat Program, New York, NY 10021 USA; [Duclos, B.] CHU Strasbourg, Serv Gastroenterol, F-67000 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Duluc, I (corresponding author), INSERM, U682, 3 Ave Moliere, F-67200 Strasbourg, France.	isabelle.duluc@inserm.fr	Ribeiro, Agnès/Q-9702-2017; Duluc, Isabelle/O-1972-2017; DULUC, Isabelle/AAA-7062-2022; Freund, Jean-Noel/R-4383-2016	Ribeiro, Agnès/0000-0003-2063-6084; Duluc, Isabelle/0000-0001-8396-6385; DULUC, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774	Inserm; Ligue contre le Cancer du Haut-Rhin; Canceropole Grand-Est (France); Association for International Cancer Research (AICR, UK); Departement de Mayotte (France); Canceropole Ile-de-France	Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue contre le Cancer du Haut-Rhin; Canceropole Grand-Est (France); Association for International Cancer Research (AICR, UK); Departement de Mayotte (France); Canceropole Ile-de-France(Region Ile-de-France)	This work was supported by Inserm, Ligue contre le Cancer du Haut-Rhin and the Canceropole Grand-Est (France). TS was funded by the Association for International Cancer Research (AICR, UK) and by the Departement de Mayotte (France), and Fl B by the Canceropole Ile-de-France.	Ahn SH, 2008, INFLAMM BOWEL DIS, V14, P908, DOI 10.1002/ibd.20413; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Archer A, 2005, MOL ENDOCRINOL, V19, P2320, DOI 10.1210/me.2004-0462; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Benahmed F, 2008, GASTROENTEROLOGY, V135, P1238, DOI 10.1053/j.gastro.2008.06.045; Benahmed F, 2007, AM J PATHOL, V170, P733, DOI 10.2353/ajpath.2007.060696; Bonhomme C, 2008, ONCOGENE, V27, P4497, DOI 10.1038/onc.2008.78; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Boyd M, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-68; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; Calon A, 2007, GUT, V56, P1688, DOI 10.1136/gut.2007.125542; Carriere V, 2005, J BIOL CHEM, V280, P5406, DOI 10.1074/jbc.M408002200; Cattin AL, 2009, MOL CELL BIOL, V29, P6294, DOI 10.1128/MCB.00939-09; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Darsigny M, 2010, CANCER RES, V70, P9423, DOI 10.1158/0008-5472.CAN-10-1697; Drewes T, 1996, MOL CELL BIOL, V16, P925; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Garrison WD, 2006, GASTROENTEROLOGY, V130, P1207, DOI 10.1053/j.gastro.2006.01.003; Gross I, 2008, ONCOGENE, V27, P107, DOI 10.1038/sj.onc.1210601; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; Lazarevich N. L., 2010, Experimental Oncology, V32, P167; Li TG, 2010, J LIPID RES, V51, P832, DOI 10.1194/jlr.M002782; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Neuville A, 2011, HUM PATHOL, V42, P244, DOI 10.1016/j.humpath.2010.07.003; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stringer EJ, 2012, DEVELOPMENT, V139, P465, DOI 10.1242/dev.070722; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Subtil C, 2007, CANCER LETT, V247, P197, DOI 10.1016/j.canlet.2006.04.004; Tanaka T, 2006, INT J CANCER, V118, P25, DOI 10.1002/ijc.21282; Tanaka T, 2006, J PATHOL, V208, P662, DOI 10.1002/path.1928; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Verzi MP, 2010, DEV CELL, V19, P713, DOI 10.1016/j.devcel.2010.10.006	36	32	38	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3782	3788		10.1038/onc.2012.401	http://dx.doi.org/10.1038/onc.2012.401			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22986531	Bronze			2022-12-28	WOS:000322904400012
J	Zhen, C; Chen, L; Zhao, Q; Liang, B; Gu, YX; Bai, ZF; Wang, K; Xu, X; Han, QY; Fang, DF; Wang, SX; Zhou, T; Xia, Q; Gong, WL; Wang, N; Li, HY; Jin, BF; Man, JH				Zhen, C.; Chen, L.; Zhao, Q.; Liang, B.; Gu, Y-X; Bai, Z-f; Wang, K.; Xu, X.; Han, Q-y; Fang, D-f; Wang, S-x; Zhou, T.; Xia, Q.; Gong, W-l; Wang, N.; Li, H-Y; Jin, B-F; Man, J-h			Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity	ONCOGENE			English	Article						Gankyrin; Rac; RhoA; adhesion; metastasis	GROWTH-FACTOR RECEPTOR; RHO-GTPASES; MIGRATION; ADHESION; OVEREXPRESSION; DEGRADATION; ONCOPROTEIN; INVASION; INACTIVATION; ACTIVATION	Tumor metastasis is responsible for most cancer patients' deaths. Understanding the mechanism of metastasis is crucial for improving the cure rate for cancer. Here, we report that Gankyrin, a chaperone of ubiquitin-proteasome, has an essential role in breast cancer metastasis. We find that Gankyrin is highly overexpressed in human breast cancers and the expression correlates strongly with lymph node metastasis. Knocking down Gankyrin expression in highly metastatic human breast cancer cells significantly decreases cancer cell migration and invasion. Furthermore, we demonstrate that depletion of Gankyrin inhibits intrinsic Rac1 activity and induces large focal adhesions. Overexpression of Gankyrin accelerates focal adhesion turnover and increases cell migration. Notably, reduction of Gankyrin expression in mouse mammary tumor cell significantly decreases tumor metastasis to lung in animal models. Therefore, our findings suggest that Gankyrin is crucial for breast cancer metastasis and highlight the potential of Gankyrin as a therapeutic target for tumor metastasis.	[Zhen, C.; Chen, L.; Zhao, Q.; Liang, B.; Gu, Y-X; Bai, Z-f; Wang, K.; Xu, X.; Han, Q-y; Fang, D-f; Wang, S-x; Zhou, T.; Xia, Q.; Gong, W-l; Wang, N.; Li, H-Y; Jin, B-F; Man, J-h] Natl Ctr Biomed Anal, Beijing 100850, Peoples R China		Jin, BF (corresponding author), Natl Ctr Biomed Anal, 27 Tai Ping Rd, Beijing 100850, Peoples R China.	jinbaofeng73@hotmail.com; jianghong_man@hotmail.com	FANG, DIFENG/G-7796-2018	FANG, DIFENG/0000-0003-2105-6743	Major Research Plan of the National Natural Science Foundation of China [91029733]; National Basic Research Program of China [2012CB910700]; China National Natural Science Foundation [81001174, 81171918]; Beijing Municipal Science and Technology Commission [2010B040]	Major Research Plan of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Beijing Municipal Science and Technology Commission(Beijing Municipal Science & Technology Commission)	This work was supported by grants from the Major Research Plan of the National Natural Science Foundation of China (No. 91029733), National Basic Research Program of China (2012CB910700), China National Natural Science Foundation (No. 81001174 and No. 81171918), Beijing Municipal Science and Technology Commission (2010B040).	Boulter E, 2010, NAT CELL BIOL, V12, P477, DOI 10.1038/ncb2049; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Dawson S, 2006, TRENDS CELL BIOL, V16, P229, DOI 10.1016/j.tcb.2006.03.001; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Frank SR, 2006, EMBO J, V25, P1848, DOI 10.1038/sj.emboj.7601092; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hirsch DS, 2006, CANCER RES, V66, P3523, DOI 10.1158/0008-5472.CAN-05-1547; Jin BF, 2006, J PROTEOME RES, V5, P2815, DOI 10.1021/pr060283f; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Lee KW, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-158; Li Z, 2008, J BIOL CHEM, V283, P7007, DOI 10.1074/jbc.M706992200; Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242; Man JH, 2010, J CLIN INVEST, V120, P2829, DOI 10.1172/JCI42542; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Ortiz CM, 2008, INT J CANCER, V122, P325, DOI 10.1002/ijc.23106; Pan X, 2011, NAT MED, V17, P708, DOI 10.1038/nm.2369; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Ridley AJ, 2001, J CELL SCI, V114, P2713; Roelofs J, 2009, NATURE, V459, P861, DOI 10.1038/nature08063; Saeki Y, 2009, CELL, V137, P900, DOI 10.1016/j.cell.2009.05.005; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sun W, 2011, HEPATOLOGY, V54, P1259, DOI 10.1002/hep.24530; Tang SH, 2010, CANCER BIOL THER, V9, P88, DOI 10.4161/cbt.9.2.10283; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wu KM, 2008, P NATL ACAD SCI USA, V105, P6924, DOI 10.1073/pnas.0802085105; Yang CF, 2006, MOL CELL BIOL, V26, P831, DOI 10.1128/MCB.26.3.831-842.2006; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019	38	48	50	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2013	32	29					3452	3460		10.1038/onc.2012.356	http://dx.doi.org/10.1038/onc.2012.356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22890318				2022-12-28	WOS:000322014900006
J	Zhang, X; Wang, W; Wang, H; Wang, MH; Xu, W; Zhang, R				Zhang, X.; Wang, W.; Wang, H.; Wang, M-H; Xu, W.; Zhang, R.			Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop	ONCOGENE			English	Article						RPS25; p53; MDM2; ribosomal stress	EMBRYONIC LETHALITY; P53 UBIQUITINATION; ONCOPROTEIN MDM2; STABILIZES P53; C-MYC; ACTIVATION; TRANSLATION; DEGRADATION; L11; INHIBITION	There is an increasing interest in determining the role of ribosomal proteins (RPs) in the regulation of MDM2-p53 pathway in coordinating cellular response to stress. Herein, we report a novel regulatory role of ribosomal protein S25 (RPS25) in MDM2-mediated p53 degradation and a feedback regulation of S25 by p53. We demonstrated that S25 interacted with MDM2 and inhibited its E3 ligase activity, resulting in the reduction of MDM2-mediated p53 ubiquitination and the stabilization and activation of p53. S25, MDM2 and p53 formed a ternary complex following ribosomal stress. The nucleolar localization and MDM2-binding domains of S25 were critical for its role in MDM2-mediated p53 regulation. Knockdown of S25 by siRNA attenuated the induction and activation of p53 following ribosomal stress. S25 stabilized and cooperated with MDMX to regulate MDM2 E3 ligase activity. Furthermore, S25 was identified to be a transcriptional target of p53; p53 directly bound to S25 promoter and suppressed S25 expression. Our results suggest that there is a S25-MDM2-p53 regulatory feedback loop, which may have an important role in cancer development and progression.	[Zhang, X.; Wang, W.; Zhang, R.] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA; [Zhang, X.; Xu, W.] Jiangsu Univ, Affiliated Hosp, Ctr Clin Lab, Sch Med Sci & Lab Med, Zhenjiang, Peoples R China; [Wang, W.; Wang, M-H; Zhang, R.] Texas Tech Univ, Hlth Sci Ctr, Canc Biol Ctr, Sch Pharm, Amarillo, TX 79106 USA; [Wang, H.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai, Peoples R China; [Wang, M-H] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Biomed Sci, Amarillo, TX 79106 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Jiangsu University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo	Zhang, R (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, 1300 Coulter Dr, Amarillo, TX 79106 USA.	ruiwen.zhang@ttuhsc.edu			NIH/NCI [R01 CA112029, R01 CA121211]; Susan G Komen Foundation [BCTR0707731]; NIH grant [R01 CA91980]; One Hundred Talents Program, Chinese Academy of Sciences; National Nature Science Foundation [30870513, 31070680, 91029715, 81025017]; Ministry of Science and Technology of China [2007CB947100]; Science and Technology Commission of Shanghai Municipality [08391910800, 10391902100]; National Science and Technology Major Project 'Key New Drug Creation and Manufacturing Program' [2009ZX09102-114, 2009ZX09301-011]; NATIONAL CANCER INSTITUTE [R01CA112029, R01CA121211, R01CA091980] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); One Hundred Talents Program, Chinese Academy of Sciences; National Nature Science Foundation(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); National Science and Technology Major Project 'Key New Drug Creation and Manufacturing Program'; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr J Chen for the kind gift of the MDMX plasmid; Dr G Lozano for the mdmx<SUP>-/-</SUP>p53<SUP>-/-</SUP> and mdm2<SUP>-/-</SUP>p53<SUP>-/-</SUP> MEF cell lines; and Drs G Jin, D Chen, Z Zhang, L Ao, X Yang, J Qin and S Voruganti for helpful discussions and excellent technical support. This work was supported in part by NIH/NCI grants R01 CA112029, R01 CA121211 and a Susan G Komen Foundation grant BCTR0707731 (to RZ). MW was supported by NIH grant R01 CA91980. HW was supported by the One Hundred Talents Program, Chinese Academy of Sciences, grants from National Nature Science Foundation (30870513, 31070680, 91029715 and 81025017) and Ministry of Science and Technology of China (2007CB947100), the Science and Technology Commission of Shanghai Municipality (08391910800, 10391902100), National Science and Technology Major Project 'Key New Drug Creation and Manufacturing Program' (2009ZX09102-114, 2009ZX09301-011).	Adilakshmi T, 2002, J BIOL CHEM, V277, P4147, DOI 10.1074/jbc.M109785200; Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; Artero-Castro A, 2011, HUM PATHOL, V42, P194, DOI 10.1016/j.humpath.2010.04.020; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Castro ME, 2008, CARCINOGENESIS, V29, P1343, DOI 10.1093/carcin/bgm302; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Chen D, 2009, EMBO REP, V10, P166, DOI 10.1038/embor.2008.231; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Golomb L, 2012, MOL CELL, V45, P222, DOI 10.1016/j.molcel.2011.11.022; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAINE RO, 1994, J BIOL CHEM, V269, P9693; Landry DM, 2009, GENE DEV, V23, P2753, DOI 10.1101/gad.1832209; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; LI ML, 1992, FEBS LETT, V298, P142, DOI 10.1016/0014-5793(92)80041-E; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Loging WT, 1999, CANCER EPIDEM BIOMAR, V8, P1011; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Mancini F, 2010, INT J BIOCHEM CELL B, V42, P1080, DOI 10.1016/j.biocel.2010.04.010; Mancini F, 2009, EMBO J, V28, P1926, DOI 10.1038/emboj.2009.154; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Nishiyama T, 2007, NUCLEIC ACIDS RES, V35, P1514, DOI 10.1093/nar/gkl1121; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200; Sun XX, 2011, J BIOL CHEM, V286, P22730, DOI 10.1074/jbc.M111.223651; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhang Z, 2008, EMBO J, V27, P852, DOI 10.1038/emboj.2008.25; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	55	63	63	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2782	2791		10.1038/onc.2012.289	http://dx.doi.org/10.1038/onc.2012.289			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22777350	Green Accepted			2022-12-28	WOS:000319808000009
J	Wu, CL; Qiang, L; Han, W; Ming, M; Viollet, B; He, YY				Wu, C. L.; Qiang, L.; Han, W.; Ming, M.; Viollet, B.; He, Y. Y.			Role of AMPK in UVB-induced DNA damage repair and growth control	ONCOGENE			English	Article							NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; ACTIVATED PROTEIN-KINASE; NONMELANOMA SKIN-CANCER; XERODERMA-PIGMENTOSUM; HUMAN KERATINOCYTES; ULTRAVIOLET-B; CELL-GROWTH; PATHWAY; IRRADIATION	Skin cancer is the most common cancer in the United States, while DNA-damaging ultraviolet B (UVB) radiation from the sun remains the major environmental risk factor. Reducing skin cancer incidence is becoming an urgent issue. The energy-sensing enzyme 50-AMP-activated protein kinase (AMPK) has a key role in the regulation of cellular lipid and protein metabolism in response to stimuli such as exercise and changes in fuel availability. However, the role of AMPK in the response of skin cells to UVB damage and in skin cancer prevention remains unknown. Here we show that AMPK activation is reduced in human and mouse squamous cell carcinoma as compared with normal skin, and by UVB irradiation, suggesting that AMPK is a tumor suppressor. At the molecular level, AMPK deletion reduced the expression of the DNA repair protein xeroderma pigmentosum C (XPC) and UVB-induced DNA repair. AMPK activation by its activators AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) and metformin (N', N'-dimethylbiguanide), the most widely used antidiabetic drug, increased the expression of XPC and UVB-induced DNA repair in mouse skin, normal human epidermal keratinocytes, and AMPK wild-type (WT) cells but not in AMPK-deficient cells, indicating an AMPK-dependent mechanism. Topical treatment with AICAR and metformin not only delayed onset of UVB-induced skin tumorigenesis but also reduced tumor multiplicity. Furthermore, AMPK deletion increased extracellular signal-regulated kinase (ERK) activation and cell proliferation, whereas AICAR and metformin inhibited ERK activation and cell proliferation in keratinocytes, mouse skin, AMPK WT and AMPK-deficient cells, suggesting an AMPK-independent mechanism. Finally, in UVB-damaged tumorbearing mice, both topical and systemic metformin prevented the formation of new tumors and suppressed growth of established tumors. Our findings not only suggest that AMPK is a tumor suppressor in the skin by promoting DNA repair and controlling cell proliferation, but also demonstrate previously unknown mechanisms by which the AMPK activators prevent UVB-induced skin tumorigenesis.	[Wu, C. L.] China Med Univ, Dept Radiat Oncol, Affiliated Hosp 4, Shenyang, Peoples R China; [Wu, C. L.; Qiang, L.; Han, W.; Ming, M.; He, Y. Y.] Univ Chicago, Dept Med, Dermatol Sect, Chicago, IL 60637 USA; [Viollet, B.] Inst Cochin, INSERM, U1016, Paris, France; [Viollet, B.] CNRS, UMR8104, Paris, France; [Viollet, B.] Univ Paris 05, Sorbonne Paris Cite, Paris, France	China Medical University; University of Chicago; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	He, YY (corresponding author), Univ Chicago, Dept Med, Dermatol Sect, 5841 S Maryland Ave,MC5067, Chicago, IL 60637 USA.	yyhe@medicine.bsd.uchicago.edu	Viollet, Benoit/N-2397-2019; Viollet, Benoit/O-6927-2017; Qiang, Lei/B-2763-2012	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Qiang, Lei/0000-0002-7164-3164	NIH [ES016936]; University of Chicago Comprehensive Cancer Center Pilot program [P30 CA014599]; CTSA [NIH UL1RR024999]; UC Friends of Dermatology Research Funds; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016936] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Chicago Comprehensive Cancer Center Pilot program; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); UC Friends of Dermatology Research Funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by NIH grant ES016936 (YYH), the University of Chicago Comprehensive Cancer Center Pilot program (P30 CA014599), the CTSA (NIH UL1RR024999) and UC Friends of Dermatology Research Funds. We thank Terri Li for the Ki67 immunohistochemistry, Dr Pradip Raychaudhuri (University of Illinois at Chicago, Chicago, IL, USA) for kindly providing the XPC promoter luciferase construct, and Dr Ann Motten for critical reading of the manuscript.	Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Ben Sahra I, 2010, MOL CANCER THER, V9, P1092, DOI 10.1158/1535-7163.MCT-09-1186; Bode Ann M, 2003, Sci STKE, V2003, pRE2, DOI 10.1126/stke.2003.167.re2; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; Cleaver JE, 2009, NAT REV GENET, V10, P756, DOI 10.1038/nrg2663; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Drakos E, 2009, LEUKEMIA, V23, P784, DOI 10.1038/leu.2008.348; Du JH, 2008, BIOCHEM BIOPH RES CO, V368, P402, DOI 10.1016/j.bbrc.2008.01.099; Foretz M, 2010, J CLIN INVEST, V120, P2355, DOI 10.1172/JCI40671; Fu XA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002009; Garinis GA, 2005, EMBO J, V24, P3952, DOI 10.1038/sj.emboj.7600849; Green AS, 2010, BLOOD, V116, P4262, DOI 10.1182/blood-2010-02-269837; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; Han WN, 2011, J BIOL CHEM, V286, P22825, DOI 10.1074/jbc.M111.222349; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; Jans J, 2005, CURR BIOL, V15, P105, DOI 10.1016/j.cub.2005.01.001; Johnson TM, 1998, J AM ACAD DERMATOL, V38, P681, DOI 10.1016/S0190-9622(98)70196-3; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI 10.2217/FON.09.174; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Maeda T, 2001, J INVEST DERMATOL, V117, P1490, DOI 10.1046/j.0022-202x.2001.01562.x; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Miller RA, 2010, J CLIN INVEST, V120, P2267, DOI 10.1172/JCI43661; Ming M, 2010, ONCOGENE, V29, P492, DOI 10.1038/onc.2009.357; Ming M, 2011, CANCER RES, V71, P5287, DOI 10.1158/0008-5472.CAN-10-4614; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; NIGGLI HJ, 1988, J INVEST DERMATOL, V91, P579, DOI 10.1111/1523-1747.ep12477095; Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175; Ries G, 2000, NATURE, V406, P98, DOI 10.1038/35017595; Saha AK, 2006, BIOCHEM BIOPH RES CO, V349, P519, DOI 10.1016/j.bbrc.2006.08.107; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 2006, J MOL HISTOL, V37, P189, DOI 10.1007/s10735-006-9044-7; VINK AA, 1991, CARCINOGENESIS, V12, P861, DOI 10.1093/carcin/12.5.861; Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013; Wischermann K, 2008, ONCOGENE, V27, P4269, DOI 10.1038/onc.2008.70; Woodard J, 2010, BIOCHEM BIOPH RES CO, V398, P135, DOI 10.1016/j.bbrc.2010.06.052; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200; Zhang J, 2008, MOL CARCINOGEN, V47, P974, DOI 10.1002/mc.20450	45	65	68	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 23	2013	32	21					2682	2689		10.1038/onc.2012.279	http://dx.doi.org/10.1038/onc.2012.279			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22751115	Green Accepted			2022-12-28	WOS:000319806700009
J	Eissmann, M; Melzer, IM; Fernandez, SBM; Michel, G; de Angelis, MH; Hoefler, G; Finkenwirth, P; Jauch, A; Schoell, B; Grez, M; Schmidt, M; Bartholomae, CC; Newrzela, S; Haetscher, N; Rieger, MA; Zachskorn, C; Mittelbronn, M; Zornig, M				Eissmann, M.; Melzer, I. M.; Fernandez, S. B. M.; Michel, G.; de Angelis, M. Hrabe; Hoefler, G.; Finkenwirth, P.; Jauch, A.; Schoell, B.; Grez, M.; Schmidt, M.; Bartholomae, C. C.; Newrzela, S.; Haetscher, N.; Rieger, M. A.; Zachskorn, C.; Mittelbronn, M.; Zoernig, M.			Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms	ONCOGENE			English	Article						AVEN; apoptosis; T-ALL; acute lymphoblastic leukemia; p53; transgenic mice	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACTIVATION; APOPTOSOME; MOUSE	AVEN has been identified as an inhibitor of apoptosis, which binds to the adaptor protein, APAF-1, and thereby prevents apoptosome formation and mitochondrial apoptosis. Recent data have demonstrated high expression levels of AVEN messenger RNA in acute leukemias as well as a positive correlation between AVEN mRNA overexpression and poor prognosis in childhood acute lymphoblastic leukemia. On the basis of these data, we investigated the potential involvement of AVEN in tumorigenesis. First, we confirmed the overexpression of AVEN in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) patient samples. We then established a transgenic mouse model with T-cell-specific overexpression of AVEN, with which we demonstrated the oncogenic cooperation of AVEN with heterozygous loss of p53. Finally, we used a subcutaneous xenograft mouse model to show that AVEN knockdown in the T-ALL cell lines, MOLT-4 and CCRF-CEM, and in the acute myeloblastic leukemia cell line, Kasumi-1, leads to a halt in tumor growth owing to the increased apoptosis and decreased proliferation of tumor cells. Collectively, our data demonstrate that the anti-apoptotic molecule, AVEN, functions as an oncoprotein in hematopoietic neoplasms.	[Eissmann, M.; Melzer, I. M.; Fernandez, S. B. M.; Finkenwirth, P.; Grez, M.; Haetscher, N.; Rieger, M. A.; Zoernig, M.] Chemotherapeut Forschungsinst Georg Speyer Haus, D-60596 Frankfurt, Germany; [Michel, G.; de Angelis, M. Hrabe] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Expt Genet, German Mouse Clin, Neuherberg, Germany; [de Angelis, M. Hrabe] Tech Univ Munich, Chair Expt Genet, Freising Weihenstephan, Germany; [Hoefler, G.] Med Univ Graz, Inst Pathol, Graz, Austria; [Jauch, A.; Schoell, B.] Univ Heidelberg Hosp, Inst Human Genet, Heidelberg, Germany; [Schmidt, M.; Bartholomae, C. C.] German Canc Res Ctr, Natl Ctr Tumor Dis Heidelberg NCT, Heidelberg, Germany; [Newrzela, S.] Goethe Univ Hosp, Senckenberg Inst Pathol, Frankfurt, Germany; [Zachskorn, C.; Mittelbronn, M.] Edinger Inst, Inst Neurol, Frankfurt, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Medical University of Graz; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Zornig, M (corresponding author), Chemotherapeut Forschungsinst Georg Speyer Haus, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	zoernig@em.uni-frankfurt.de	de Angelis, Martin Hrabe/F-5531-2012; Rieger, Michael A/L-8324-2017; Hoefler, Gerald/H-1796-2016	de Angelis, Martin Hrabe/0000-0002-7898-2353; Rieger, Michael A/0000-0002-4158-5872; Hoefler, Gerald/0000-0002-9056-3063; Mittelbronn, Michel/0000-0002-2998-052X	German Cancer Aid Foundation [108659]; German National Genome Research Network (NGFN project) [N1KR-S12T23]; SFB 'Lipotox' of the Austrian Science foundation FWF [W30]; LOEWE Center for Cell and Gene Therapy Frankfurt [HMWK III L 4-518/17.004 (2010)]; German Federal Ministry of Health (BMG); Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK)	German Cancer Aid Foundation; German National Genome Research Network (NGFN project); SFB 'Lipotox' of the Austrian Science foundation FWF; LOEWE Center for Cell and Gene Therapy Frankfurt; German Federal Ministry of Health (BMG); Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK)	The authors would like to thank Susanne Bosser for excellent technical support. This work was supported by grants from the German Cancer Aid Foundation (no. 108659; MZ), the German National Genome Research Network (NGFN project N1KR-S12T23, MZ) and the SFB 'Lipotox' of the Austrian Science foundation FWF (no. W30; GH). MZ, IMM and MAR are thankful for the support by the LOEWE Center for Cell and Gene Therapy Frankfurt (HMWK III L 4-518/17.004 (2010)). The Georg-Speyer-Haus is funded jointly by the German Federal Ministry of Health (BMG) and the Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK).	ASOU H, 1991, BLOOD, V77, P2031; Bao Q, 2007, CELL DEATH DIFFER, V14, P56, DOI 10.1038/sj.cdd.4402028; Bratton SB, 2010, J CELL SCI, V123, P3209, DOI 10.1242/jcs.073643; Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004; Burkhardt B, 2010, BRIT J HAEMATOL, V149, P653, DOI 10.1111/j.1365-2141.2009.08006.x; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Choi J, 2006, LEUKEMIA RES, V30, P1019, DOI 10.1016/j.leukres.2005.11.001; Cleaver AL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-105; de Leval L, 2009, CRIT REV ONCOL HEMAT, V72, P125, DOI 10.1016/j.critrevonc.2009.01.002; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Esmaili AM, 2010, CELL CYCLE, V9, P3913, DOI 10.4161/cc.9.19.13138; Guo JY, 2008, CURR BIOL, V18, P933, DOI 10.1016/j.cub.2008.05.045; Hajra KM, 2004, APOPTOSIS, V9, P691, DOI 10.1023/B:APPT.0000045786.98031.1d; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Imada K, 2003, INT J HEMATOL, V77, P336, DOI 10.1007/BF02982640; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Ledgerwood EC, 2009, CLIN CANCER RES, V15, P420, DOI 10.1158/1078-0432.CCR-08-1172; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Paolini S, 2011, SEMIN DIAGN PATHOL, V28, P124, DOI 10.1053/j.semdp.2011.02.008; Paydas S, 2003, ANN ONCOL, V14, P1045, DOI 10.1093/annonc/mdg277; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Riz I, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-181; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Swerdlow SH, 2008, WHO CLASSIFICATION T; Vangestel C, 2009, CANCER BIOTHER RADIO, V24, P395, DOI 10.1089/cbr.2008.0598; Xu GW, 2007, CELL RES, V17, P759, DOI 10.1038/cr.2007.52	28	12	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2586	2591		10.1038/onc.2012.263	http://dx.doi.org/10.1038/onc.2012.263			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22751129				2022-12-28	WOS:000319274300010
J	Park, MH; Lee, HS; Lee, CS; You, ST; Kim, DJ; Park, BH; Kang, MJ; Heo, WD; Shin, EY; Schwartz, MA; Kim, EG				Park, M-H; Lee, H-S; Lee, C-S; You, S. T.; Kim, D-J; Park, B-H; Kang, M. J.; Heo, W. D.; Shin, E-Y; Schwartz, M. A.; Kim, E-G			p21-Activated kinase 4 promotes prostate cancer progression through CREB	ONCOGENE			English	Article						prostate cancer; p21-activated kinase 4; protein kinase A; CREB; neuroendocrine differentiation; chemoresistance	PROTEIN-KINASE; CELL-MIGRATION; IN-VITRO; PAK4; ACTIVATION; DOMAIN; BCL-2; TRANSDIFFERENTIATION; DIFFERENTIATION; EXPRESSION	Prostate cancer is initially androgen-dependent but, over time, usually develops hormone-and chemo-resistance. The present study investigated a role for p21-activated kinase 4 (PAK4) in prostate cancer progression. PAK4 activation was markedly inhibited by H89, a specific protein kinase A (PKA) inhibitor, and PAK4 was activated by the elevation of cAMP. The catalytic subunit of PKA interacted with the regulatory domain of PAK4, and directly phosphorylated PAK4 at serine 474 (S474). Catalytically active PAK4 enhanced the transcriptional activity of CREB independent of S133 phosphorylation. Stable knockdown of PAK4 in PC-3 and DU145 prostate cancer cells inhibited tumor formation in nude mice. Decreased tumorigenicity correlated with decreased expression of CREB and its targets, including Bcl-2 and cyclin A1. Additionally, in androgen-dependent LNCap-FGC cells, PAK4 regulated cAMP-induced neuroendocrine differentiation, which is known to promote tumor progression. Finally, PAK4 enhanced survival and decreased apoptosis following chemotherapy. These results suggested that PAK4 regulates progression toward hormone-and chemo-resistance in prostate cancer, and this study identified both a novel activation mechanism and potential downstream effector pathways. Therefore, PAK4 may be a promising therapeutic target in prostate cancer.	[Park, M-H; Lee, C-S; You, S. T.; Kim, D-J; Shin, E-Y; Kim, E-G] Chungbuk Natl Univ, Coll Med, Dept Biochem, Chonju 361763, Chungbuk, South Korea; [Park, M-H; Lee, C-S; You, S. T.; Kim, D-J; Shin, E-Y; Kim, E-G] Chungbuk Natl Univ, Coll Med, Med Res Ctr, Chonju 361763, Chungbuk, South Korea; [Lee, H-S; Park, B-H] Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju, Jeonbuk, South Korea; [Kang, M. J.] Chonbuk Natl Univ, Sch Med, Dept Pathol, Jeonju, Jeonbuk, South Korea; [Heo, W. D.] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Schwartz, M. A.] Yale Univ, Sch Med, Yale Cardiovasc Res Ctr, Dept Med, New Haven, CT USA; [Schwartz, M. A.] Yale Univ, Sch Med, Yale Cardiovasc Res Ctr, Dept Cell Biol, New Haven, CT USA	Chungbuk National University; Chungbuk National University; Jeonbuk National University; Jeonbuk National University; Korea Advanced Institute of Science & Technology (KAIST); Yale University; Yale University	Kim, EG (corresponding author), Chungbuk Natl Univ, Coll Med, Med Res Ctr, Chonju 361763, Chungbuk, South Korea.	eyshin@chungbuk.ac.kr; egkim@chungbuk.ac.kr	Heo, Won-Do/C-1696-2011	schwartz, martin/0000-0002-2071-1243	National Research Foundation of Korea [2012-0005747]; USPHS [RO1 CA14397]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075092] Funding Source: NIH RePORTER	National Research Foundation of Korea(National Research Foundation of Korea); USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	CRE-luciferase reporter gene containing 6x CRE binding sites was gift from Dr Jung EB at Chungbuk National University (Cheongju, Korea). This work was supported by a grant of the National Research Foundation of Korea (2012-0005747). MAS was supported by USPHS grant RO1 CA14397.	Ahmed T, 2008, CELL SIGNAL, V20, P1320, DOI 10.1016/j.cellsig.2008.02.021; Bagchi G, 2008, CANCER RES, V68, P3225, DOI 10.1158/0008-5472.CAN-07-5026; Baldassa S, 2010, J CELL PHYSIOL, V224, P722, DOI 10.1002/jcp.22172; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Donkena KV, 2010, CURR CANCER DRUG TAR, V10, P402, DOI 10.2174/156800910791208544; Eswaran J, 2007, STRUCTURE, V15, P201, DOI 10.1016/j.str.2007.01.001; Eswaran J, 2009, CANCER METAST REV, V28, P209, DOI 10.1007/s10555-008-9181-4; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Lee KH, 2010, P NATL ACAD SCI USA, V107, P3412, DOI 10.1073/pnas.0911262107; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Murray BW, 2010, P NATL ACAD SCI USA, V107, P9446, DOI 10.1073/pnas.0911863107; Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286-08; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; RAFFO AJ, 1995, CANCER RES, V55, P4438; Shaywitz AJ, 1995, ANNU REV BIOCHEM, V68, P821; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Wells CM, 2010, J CELL SCI, V123, P1663, DOI 10.1242/jcs.055707; Wells CM, 2010, BIOCHEM J, V425, P465, DOI 10.1042/BJ20091173; Wells CM, 2002, J CELL SCI, V115, P3947, DOI 10.1242/jcs.00080; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Xiao X, 2010, CURR CANCER DRUG TAR, V10, P384, DOI 10.2174/156800910791208535; Yuan TC, 2007, ENDOCR-RELAT CANCER, V14, P531, DOI 10.1677/ERC-07-0061	33	76	79	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2475	2482		10.1038/onc.2012.255	http://dx.doi.org/10.1038/onc.2012.255			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22710715				2022-12-28	WOS:000318694900011
J	Serrano, MA; Li, Z; Dangeti, M; Musich, PR; Patrick, S; Roginskaya, M; Cartwright, B; Zou, Y				Serrano, M. A.; Li, Z.; Dangeti, M.; Musich, P. R.; Patrick, S.; Roginskaya, M.; Cartwright, B.; Zou, Y.			DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair	ONCOGENE			English	Article						p53-RPA interaction; DNA-PK; ATM; ATR; homologous recombination repair; nonhomologous recombination end joining	REPLICATION-PROTEIN-A; DOUBLE-STRAND BREAKS; DAMAGE-INDUCED PHOSPHORYLATION; RPA PHOSPHORYLATION; INDUCED HYPERPHOSPHORYLATION; COMPLEX-FORMATION; P53; BINDING; RAD52; TRANSACTIVATION	Homologous recombination (HR) and nonhomologous end joining (NHEJ) are two distinct DNA double-stranded break (DSB) repair pathways. Here, we report that DNA-dependent protein kinase (DNA-PK), the core component of NHEJ, partnering with DNA-damage checkpoint kinases ataxia telangiectasia mutated (ATM) and ATM-and Rad3-related (ATR), regulates HR repair of DSBs. The regulation was accomplished through modulation of the p53 and replication protein A (RPA) interaction. We show that upon DNA damage, p53 and RPA were freed from a p53-RPA complex by simultaneous phosphorylations of RPA at the N-terminus of RPA32 subunit by DNA-PK and of p53 at Ser37 and Ser46 in a Chk1/Chk2-independent manner by ATR and ATM, respectively. Neither the phosphorylation of RPA nor of p53 alone could dissociate p53 and RPA. Furthermore, disruption of the release significantly compromised HR repair of DSBs. Our results reveal a mechanism for the crosstalk between HR repair and NHEJ through the co-regulation of p53-RPA interaction by DNA-PK, ATM and ATR.	[Serrano, M. A.; Li, Z.; Musich, P. R.; Roginskaya, M.; Cartwright, B.; Zou, Y.] E Tennessee State Univ, Dept Biochem & Mol Biol, James H Quillen Coll Med, Johnson City, TN 37614 USA; [Dangeti, M.; Patrick, S.] Univ Toledo, Med Ctr, Biochem & Canc Biol Dept, Toledo, OH 43606 USA	East Tennessee State University; University System of Ohio; University of Toledo	Zou, Y (corresponding author), E Tennessee State Univ, Dept Biochem & Mol Biol, James H Quillen Coll Med, Johnson City, TN 37614 USA.	zouy@etsu.edu	Roginskaya, Marina/ABD-3144-2021; Zou, Yue/ABA-8429-2020; Li, Zhengke/J-8527-2016	Li, Zhengke/0000-0001-5560-343X; Serrano, Moises/0000-0002-1037-9304; Musich, Phillip/0000-0001-8816-4242	National Institutes of Health [CA86927, GM083307, ES017214]; NATIONAL CANCER INSTITUTE [R56CA086927, R01CA086927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F31ES017214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088249, R15GM083307] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We gratefully acknowledge Dr Xiaohua Wu for providing U2OS cells expressing RPA32-WT and PD-RPA proteins. We also gratefully acknowledge Dr Carl W Anderson for providing the p53-expression constructs (pCAG3.1-WT, -S15A, -S20A, -S37A and -S46A) and Dr Karen Vousden for the pCB6 expression vectors p53-WT and p53-S15A. This work is supported by National Institutes of Health grants CA86927 and GM083307 (to YZ) as well as ES017214 (to MAS).	Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Anantha RW, 2008, P NATL ACAD SCI USA, V105, P12903, DOI 10.1073/pnas.0803001105; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Bochkareva E, 2005, P NATL ACAD SCI USA, V102, P15412, DOI 10.1073/pnas.0504614102; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Derheimer FA, 2007, P NATL ACAD SCI USA, V104, P12778, DOI 10.1073/pnas.0705317104; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Guo SL, 2006, J BIOL CHEM, V281, P21607, DOI 10.1074/jbc.M603504200; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hass CS, 2010, MOL CANCER RES, V8, P1017, DOI 10.1158/1541-7786.MCR-10-0161; Hill R, 2010, CELL CYCLE, V9, P3460, DOI 10.4161/cc.9.17.13043; Huen MSY, 2010, TRENDS BIOCHEM SCI, V35, P101, DOI 10.1016/j.tibs.2009.09.001; Jackson D, 2002, J MOL BIOL, V321, P133, DOI 10.1016/S0022-2836(02)00541-7; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Kantake N, 2003, J BIOL CHEM, V278, P23410, DOI 10.1074/jbc.M302995200; Kaustov L, 2006, CELL CYCLE, V5, P489, DOI 10.4161/cc.5.5.2489; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; Leiter LM, 1996, ONCOGENE, V12, P2661; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu YY, 2005, J BIOL CHEM, V280, P32775, DOI 10.1074/jbc.M505705200; Meek K, 2008, ADV IMMUNOL, V99, P33, DOI 10.1016/S0065-2776(08)00602-0; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Miller SD, 1997, MOL CELL BIOL, V17, P2194, DOI 10.1128/MCB.17.4.2194; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Nuss JE, 2005, BIOCHEMISTRY-US, V44, P8428, DOI 10.1021/bi0480584; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; Olson E, 2006, J BIOL CHEM, V281, P39517, DOI 10.1074/jbc.M605121200; Patrick SM, 2005, BIOCHEMISTRY-US, V44, P8438, DOI 10.1021/bi048057b; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Plate I, 2008, J BIOL CHEM, V283, P29077, DOI 10.1074/jbc.M804881200; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Robison JG, 2007, CELL CYCLE, V6, P2408, DOI 10.4161/cc.6.19.4773; Romanova LY, 2004, ONCOGENE, V23, P9025, DOI 10.1038/sj.onc.1207982; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sakasai R, 2010, DNA REPAIR, V9, P76, DOI 10.1016/j.dnarep.2009.10.008; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shell SM, 2009, MOL MECH ATAXIA TELA, P42; Shi W, 2010, CARCINOGENESIS, V31, P994, DOI 10.1093/carcin/bgq035; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sommers JA, 2005, CANCER RES, V65, P1223, DOI 10.1158/0008-5472.CAN-03-0231; Stauffer ME, 2004, J BIOL CHEM, V279, P25638, DOI 10.1074/jbc.M400029200; Sugiyama T, 2006, EMBO J, V25, P5539, DOI 10.1038/sj.emboj.7601412; Sugiyama T, 2009, J MOL BIOL, V390, P45, DOI 10.1016/j.jmb.2009.05.009; Sun JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013554; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; VIRSHUP DM, 1990, UCLA SYM BI, V127, P303; Vise PD, 2005, NUCLEIC ACIDS RES, V33, P2061, DOI 10.1093/nar/gki336; Wang YX, 2005, NAT GENET, V37, P750, DOI 10.1038/ng1587; Wood JL, 2008, TRENDS CELL BIOL, V18, P451, DOI 10.1016/j.tcb.2008.07.006; Wu X, 2005, BIOCHEM J, V391, P473, DOI 10.1042/BJ20050379; Wu XM, 2005, ONCOGENE, V24, P4728, DOI 10.1038/sj.onc.1208674; Yang ZG, 2002, BIOCHEMISTRY-US, V41, P13012, DOI 10.1021/bi026064z; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	63	67	72	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2452	2462		10.1038/onc.2012.257	http://dx.doi.org/10.1038/onc.2012.257			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22797063	Green Accepted			2022-12-28	WOS:000318694900009
J	Sullivan, RJ; Flaherty, K				Sullivan, R. J.; Flaherty, K.			MAP kinase signaling and inhibition in melanoma	ONCOGENE			English	Review						melanoma; targeted therapy; BRAF	RANDOMIZED DISCONTINUATION TRIAL; CHRONIC MYELOID-LEUKEMIA; B-RAF INHIBITOR; NF-KAPPA-B; BRAF INHIBITION; WILD-TYPE; MULTIKINASE INHIBITOR; ACQUIRED-RESISTANCE; AZD6244 ARRY-142886; IMPROVED SURVIVAL	The mitogen-activated protein kinase (MAPK) pathway is critical to oncogenic signaling in the majority of patients with malignant melanoma. Driver mutations in both NRAS and BRAF have important implications for prognosis and treatment. The development of inhibitors to mediators of the MAPK pathway, including those to CRAF, BRAF, and MEK, has led to major advances in the treatment of patients with melanoma. In particular, the selective BRAF inhibitor vemurafenib has been shown to improve overall survival in patients with tumors harboring BRAF mutations. However, the duration of benefit is limited in many patients and highlights the need for understanding the limitations of therapy in order to devise more effective strategies. MEK inhibitors have proven to particularly active in BRAF mutant melanomas also. Emerging knowledge about mechanisms of resistance as well as a more complete understanding of the biology of MAPK pathway signaling provides insight into rational combination regimens and sequences of molecularly targeted therapies.	[Sullivan, R. J.; Flaherty, K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Flaherty, K (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.	kflaherty@partners.org	Sullivan, Ryan J/O-2965-2013					Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Amaravadi RK, 2009, CLIN CANCER RES, V15, P7711, DOI 10.1158/1078-0432.CCR-09-2074; Banerji U, 2010, CLIN CANCER RES, V16, P1613, DOI 10.1158/1078-0432.CCR-09-2483; Bardeesy N, 2005, MOL CELL BIOL, V25, P4176, DOI 10.1128/MCB.25.10.4176-4188.2005; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Beeram M, 2005, J CLIN ONCOL, V23, P6771, DOI 10.1200/JCO.2005.08.036; Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; Cartlidge RA, 2008, PIGM CELL MELANOMA R, V21, P534, DOI 10.1111/j.1755-148X.2008.00491.x; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Chiarion-Sileni V, 2013, J CLIN ONCOL, V31; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; Comin-Anduix B, 2010, CLIN CANCER RES, V16, P6040, DOI 10.1158/1078-0432.CCR-10-1911; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delord J, 2010, J CLIN ONCOL, V28, P2504; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Dong JL, 2003, CANCER RES, V63, P3883; DR Trefzer UM, P SOC MEL RES C 2011; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Fischer A, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M607458200; Flaherty KT, 2008, CLIN CANCER RES, V14, P4836, DOI 10.1158/1078-0432.CCR-07-4123; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2009, J CLIN ONCOL, V27, P2823, DOI 10.1200/JCO.2007.15.7636; Hauschild Axel JJG, 2012, J CLIN ONCOL S, V30; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Infante JR, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.2503; Jakob JA, 2011, CANCER, DOI [10.1002/cncr.26724, DOI 10.1002/CNCR.26724)]; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kaplan FM, 2011, ONCOGENE, V30, P366, DOI 10.1038/onc.2010.408; KIRKWOOD JM, 2012, J CLIN ONCOL S, V30; Levey R, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e15053; Lin J, 2011, BRIT J CANCER, V104, P464, DOI 10.1038/sj.bjc.6606072; Liu J, 2007, ONCOGENE, V26, P1954, DOI 10.1038/sj.onc.1209994; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883; Mahoney S, 2010, J CLIN ONCOL S, V28, p15s; Margolin KA, 2012, CLIN CANCER RES, V18, P1129, DOI 10.1158/1078-0432.CCR-11-2488; Marquette A, 2011, NAT STRUCT MOL BIOL, V18, P584, DOI 10.1038/nsmb.2022; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Moreno C, 2012, J CLIN ONCOL, V30; Nathanson KL, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8501; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Ratain MJ, 2006, J CLIN ONCOL, V24, P2505, DOI 10.1200/JCO.2005.03.6723; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Smalley KSM, 2008, MOL CANCER THER, V7, P2876, DOI 10.1158/1535-7163.MCT-08-0431; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Sosman JA, 2012, J CLIN ONCOL, V30; Strausman RT, NATURE, DOI [10.1038/nature11183, DOI 10.1038/NATURE11183)]; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Tap WD, 2010, NEOPLASIA, V12, P637, DOI 10.1593/neo.10414; Terai K, 2006, EMBO J, V25, P3556, DOI 10.1038/sj.emboj.7601241; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tran NH, 2005, J BIOL CHEM, V280, P16244, DOI 10.1074/jbc.M501185200; Vakiani E, 2011, J PATHOL, V223, P219, DOI 10.1002/path.2796; VanBrocklin MW, 2009, CANCER RES, V69, P1985, DOI 10.1158/0008-5472.CAN-08-3934; Vergani E, 2011, NEOPLASIA, V13, P1132, DOI 10.1593/neo.111102; Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wardelmann E, 2006, CLIN CANCER RES, V12, P1743, DOI 10.1158/1078-0432.CCR-05-1211; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; Zhao YH, 2008, BIOCHEM BIOPH RES CO, V370, P509, DOI 10.1016/j.bbrc.2008.03.148; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026	96	102	106	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2373	2379		10.1038/onc.2012.345	http://dx.doi.org/10.1038/onc.2012.345			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22945644	Bronze			2022-12-28	WOS:000318694900001
J	Longoni, N; Kunderfranco, P; Pellini, S; Albino, D; Mello-Grand, M; Pinton, S; D'Ambrosio, G; Sarti, M; Sessa, F; Chiorino, G; Catapano, CV; Carbone, GM				Longoni, N.; Kunderfranco, P.; Pellini, S.; Albino, D.; Mello-Grand, M.; Pinton, S.; D'Ambrosio, G.; Sarti, M.; Sessa, F.; Chiorino, G.; Catapano, C. V.; Carbone, G. M.			Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression	ONCOGENE			English	Article						prostate cancer; DCDC2; doublecortin domain containing 2 protein; ESE3/EHF; ETS; cell migration; taxol resistance	MICROTUBULE-ASSOCIATED PROTEIN; PACLITAXEL SENSITIVITY; TRANSCRIPTION FACTORS; DOUBLECORTIN GENE; DCX SUPERFAMILY; MARKER; DISEASE; FAMILY; AGENTS; ROLES	By integrating gene profiling and immunohistochemical data with functional experiments in cell lines in this study we show for the first time that doublecortin (DCX) domain containing 2 (DCDC2), a protein belonging to the DCX family and involved in neuronal cell migration, is aberrantly expressed in prostate tumors whereas absent in normal prostate. Furthermore, in patients treated with radical prostatectomy, high levels of DCDC2 RNA were significantly associated with increased biochemical relapse (LogRank Mantel-Cox 0.012). Mechanistically, we found that the ETS transcription factor ESE3/EHF, which is expressed in normal prostate and frequently lost in prostate tumors, maintained DCDC2 repressed by binding to a novel identified ETS binding site in the gene promoter. Consistently, in prostate tumors and in cellular models of gain and loss of ESE3/EHF, the expression of DCDC2 and ESE3/EHF were inversely correlated. In prostate cancer cells, DCDC2 colocalized with microtubules and promoted cell migration and resistance to the microtubule-targeting drug taxol. Collectively, this study establishes DCDC2 as a novel ESE3/EHF oncogenic target in prostate cancer. These findings may be relevant for the clinical management of prostate cancer as DCDC2 may signal tumors more prone to relapse and resistant to taxol treatment.	[Longoni, N.; Kunderfranco, P.; Pellini, S.; Albino, D.; Pinton, S.; Sarti, M.; Catapano, C. V.; Carbone, G. M.] IOR, Bellinzona, Switzerland; [Longoni, N.; Kunderfranco, P.; Pellini, S.; Albino, D.; Pinton, S.; Sarti, M.; Catapano, C. V.; Carbone, G. M.] Oncol Inst Sourthern Switzerland IOSI, CH-6500 Bellinzona, Switzerland; [Mello-Grand, M.; Chiorino, G.] Fdn Edo & Elvo Tempia Valenta, Lab Canc Genom, Biella, Italy; [Sessa, F.] IRCCS Multimed, Milan, Italy; [Sessa, F.] Univ Insubria, Dept Pathol, Varese, Italy	Institute of Oncology Research (IOR); Universita della Svizzera Italiana; Institute of Oncology Research (IOR); IRCCS Multimedica; University of Insubria	Carbone, GM (corresponding author), Oncol Inst Sourthern Switzerland IOSI, IOR, Via Vela 6, CH-6500 Bellinzona, Switzerland.	pina.carbone@ior.iosi.ch	Kunderfranco, Paolo/J-7636-2016; Kunderfranco, Paolo/GUQ-8968-2022; Chiorino, Giovanna/K-5037-2016; Kunderfranco, Paolo/ABH-9294-2020	Kunderfranco, Paolo/0000-0003-3636-3391; Kunderfranco, Paolo/0000-0001-7477-8710; Chiorino, Giovanna/0000-0002-9502-6400; Kunderfranco, Paolo/0000-0001-7477-8710; Catapano, Carlo V./0000-0002-7079-557X	Oncosuisse [KFS-01913-08, KFS-02573-02-2010]; Swiss National Science Foundation [FNS-31003A-118113]; Ticino Foundation for Cancer Research; Compagnia di San Paolo, Torino, Italy	Oncosuisse; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Ticino Foundation for Cancer Research; Compagnia di San Paolo, Torino, Italy(Compagnia di San Paolo)	This work was supported by grants from Oncosuisse (KFS-01913-08 and KFS-02573-02-2010), Swiss National Science Foundation (FNS-31003A-118113) and Ticino Foundation for Cancer Research to GMC. MMG and GC were supported by Compagnia di San Paolo, Torino, Italy.	Albertini V, 2006, NUCLEIC ACIDS RES, V34, P1721, DOI 10.1093/nar/gkl063; Bowen C, 2000, CANCER RES, V60, P6111; Burbridge TJ, 2008, NEUROSCIENCE, V152, P723, DOI 10.1016/j.neuroscience.2008.01.020; Cangemi R, 2008, ONCOGENE, V27, P2877, DOI 10.1038/sj.onc.1210953; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Coquelle FM, 2006, CELL CYCLE, V5, P976, DOI 10.4161/cc.5.9.2715; Daou MC, 2005, ACTA NEUROPATHOL, V110, P472, DOI 10.1007/s00401-005-1070-0; DeMarzo AM, 2003, LANCET, V361, P955, DOI 10.1016/S0140-6736(03)12779-1; Dijkmans Thomas Frederik, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P32; Dobyns WB, 1999, NEUROLOGY, V53, P270, DOI 10.1212/WNL.53.2.270; Dumontet C, 2010, NAT REV DRUG DISCOV, V9, P790, DOI 10.1038/nrd3253; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Kim MH, 2003, NAT STRUCT BIOL, V10, P324, DOI 10.1038/nsb918; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Koizumi H, 2006, NAT NEUROSCI, V9, P779, DOI 10.1038/nn1704; Kumar-Sinha C, 2008, NAT REV CANCER, V8, P497, DOI 10.1038/nrc2402; Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547; Massinen S, PLOS ONE, V6; Meng HY, 2011, BEHAV GENET, V41, P58, DOI 10.1007/s10519-010-9408-3; Meng HY, 2005, P NATL ACAD SCI USA, V102, P17053, DOI 10.1073/pnas.0508591102; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Oltra S, 2005, DIAGN MOL PATHOL, V14, P53, DOI 10.1097/01.pas.0000149876.32376.c0; Reiner O, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-188; Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102; Sapir T, 2000, HUM MOL GENET, V9, P703, DOI 10.1093/hmg/9.5.703; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Soltani MH, 2005, AM J PATHOL, V166, P1841, DOI 10.1016/S0002-9440(10)62493-5; Tint I, 2009, J NEUROSCI, V29, P10995, DOI 10.1523/JNEUROSCI.3399-09.2009; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Viprey VF, 2008, J PATHOL, V216, P245, DOI 10.1002/path.2406; Wagner P, 2005, CELL CYCLE, V4, P1149, DOI 10.4161/cc.4.9.2038; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	35	16	17	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2315	2324		10.1038/onc.2012.245	http://dx.doi.org/10.1038/onc.2012.245			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22733135				2022-12-28	WOS:000318683600008
J	Asada, K; Ando, T; Niwa, T; Nanjo, S; Watanabe, N; Okochi-Takada, E; Yoshida, T; Miyamoto, K; Enomoto, S; Ichinose, M; Tsukamoto, T; Ito, S; Tatematsu, M; Sugiyama, T; Ushijima, T				Asada, K.; Ando, T.; Niwa, T.; Nanjo, S.; Watanabe, N.; Okochi-Takada, E.; Yoshida, T.; Miyamoto, K.; Enomoto, S.; Ichinose, M.; Tsukamoto, T.; Ito, S.; Tatematsu, M.; Sugiyama, T.; Ushijima, T.			FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect	ONCOGENE			English	Article						field for cancerization; chromosome X; DNA methylation; gastrointestinal cancer; Helicobacter pylori	ABERRANT DNA METHYLATION; SQUAMOUS-CELL CARCINOMA; GASTRIC MUCOSAE; HELICOBACTER-PYLORI; SILENCED GENES; CANCER; HYPERMETHYLATION; EXPRESSION; BREAST; RISK	Tumor-suppressor genes on chromosome X can be inactivated by a single hit, any of the point mutations, chromosomal loss and aberrant DNA methylation. As aberrant DNA methylation can be induced frequently, we here aimed to identify a tumor-suppressor gene on chromosome X inactivated by promoter DNA methylation. Of 69 genes on chromosome X upregulated by treatment of a gastric cancer cell line with a DNA-demethylating agent, 5-aza-2'-deoxycytidine, 11 genes had low or no expression in the cell line and abundant expression in normal gastric mucosae. Among them, FHL1 was frequently methylation-silenced in gastric and colon cancer cell lines, and methylated in primary gastric (21/80) and colon (5/50) cancers. Knockdown of the endogenous FHL1 in two cell lines by two kinds of shRNAs significantly increased cell growth in vitro and sizes of xenografts in nude mice. Expression of exogenous FHL1 in a non-expressing cell line significantly reduced its migration, invasion and growth. Notably, a somatic mutation (G642T; Lys214Asn) was identified in one of 144 colon cancer specimens, and the mutant FHL1 was shown to lack its inhibitory effects on migration, invasion and growth. FHL1 methylation was associated with Helicobacter pylori infection and accumulated in normal-appearing gastric mucosae of gastric cancer patients. These data showed that FHL1 is a methylation-silenced tumor-suppressor gene on chromosome X in gastrointestinal cancers, and that its silencing contributes to the formation of an epigenetic field for cancerization. Oncogene (2013) 32, 2140-2149; doi:10.1038/onc.2012.228; published online 11 June 2012	[Asada, K.; Ando, T.; Niwa, T.; Nanjo, S.; Watanabe, N.; Okochi-Takada, E.; Yoshida, T.; Ushijima, T.] Natl Canc Ctr, Div Epigen, Tokyo 1040045, Japan; [Ando, T.; Sugiyama, T.] Toyama Univ, Dept Internal Med 3, Toyama 930, Japan; [Miyamoto, K.] Chugoku Canc Ctr, Natl Hosp Org Kure Med Ctr, Inst Clin Res, Hiroshima, Japan; [Miyamoto, K.] Chugoku Canc Ctr, Natl Hosp Org Kure Med Ctr, Dept Surg, Hiroshima, Japan; [Enomoto, S.; Ichinose, M.] Wakayama Med Univ, Dept Internal Med 2, Wakayama, Japan; [Tsukamoto, T.; Tatematsu, M.] Aichi Canc Ctr Res Inst, Div Oncol Pathol, Nagoya, Aichi, Japan; [Ito, S.] Aichi Canc Ctr Hosp, Dept Gastroenterol Surg, Nagoya, Aichi 464, Japan	National Cancer Center - Japan; University of Toyama; Wakayama Medical University; Aichi Cancer Center; Aichi Cancer Center	Ushijima, T (corresponding author), Natl Canc Ctr, Div Epigen, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Ichinose, Masao/HAB-1645-2022; Tsukamoto, Tetsuya/ABD-4397-2020; Asada, Kiyoshi/GPW-7758-2022; Asada, Kiyoshi/AFL-8696-2022; Ushijima, Toshikazu/AAP-5742-2021	Tsukamoto, Tetsuya/0000-0002-7502-8724; Asada, Kiyoshi/0000-0002-4515-6047; Ushijima, Toshikazu/0000-0003-3405-7817	Ministry of Health, Labour and Welfare, Japan; National Cancer Center Research and Development Fund; Foundation for Promotion of Cancer Research	Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Foundation for Promotion of Cancer Research	We thank Dr Yanagihara and Dr Yasui for their kind gift of cell lines. This study was supported by a Grant-in-Aid for the Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan, and by the National Cancer Center Research and Development Fund. TA is a recipient of the Research Resident Fellowship from the Foundation for Promotion of Cancer Research.	Achyut BR, 2011, GASTROENTEROLOGY, V141, P1167, DOI 10.1053/j.gastro.2011.07.048; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Arai E, 2006, INT J CANCER, V119, P288, DOI 10.1002/ijc.21807; CHENG H, 1984, GASTROENTEROLOGY, V86, P78; Ding LH, 2011, J CELL MOL MED, V15, P72, DOI 10.1111/j.1582-4934.2009.00938.x; Ding LH, 2009, J CLIN INVEST, V119, P349, DOI 10.1172/JCI35930; Enomoto S, 2007, CANCER SCI, V98, P1853, DOI 10.1111/j.1349-7006.2007.00625.x; FUKAYAMA M, 1994, LAB INVEST, V71, P73; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hosoya K, 2009, CANCER LETT, V285, P182, DOI 10.1016/j.canlet.2009.05.016; Ishii T, 2007, GUT, V56, P13, DOI 10.1136/gut.2005.089813; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kaneda A, 2004, CANCER LETT, V212, P203, DOI 10.1016/j.canlet.2004.03.020; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee YC, 2011, CANCER PREV RES, V4, P1982, DOI 10.1158/1940-6207.CAPR-11-0096; Li X, 2008, CANCER SCI, V99, P1326, DOI 10.1111/j.1349-7006.2008.00816.x; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Luo B, 2005, WORLD J GASTROENTERO, V11, P629, DOI 10.3748/wjg.v11.i5.629; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; Matsumoto M, 2010, INT J MOL MED, V26, P241, DOI 10.3892/ijmm_00000458; Matsusaka K, 2011, CANCER RES, V71, P7187, DOI 10.1158/0008-5472.CAN-11-1349; Moriguchi K, 2007, CANCER LETT, V249, P178, DOI 10.1016/j.canlet.2006.08.014; Nakajima T, 2006, CANCER EPIDEM BIOMAR, V15, P2317, DOI 10.1158/1055-9965.EPI-06-0436; Niu C, 2012, INT J CANCER, V130, P2549, DOI 10.1002/ijc.26259; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Oka D, 2009, CANCER-AM CANCER SOC, V115, P3412, DOI 10.1002/cncr.24394; Ota N, 2006, ANTICANCER RES, V26, P3729; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Sakashita K, 2008, ANN SURG ONCOL, V15, P2293, DOI 10.1245/s10434-008-9904-3; Shathasivam T, 2010, J CELL MOL MED, V14, P2702, DOI 10.1111/j.1582-4934.2010.01176.x; Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275; Shen YQ, 2006, CANCER RES, V66, P1543, DOI 10.1158/0008-5472.CAN-05-3152; Ushijima T, 2005, CANCER RES, V65, P11; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142; Van Vlierberghe P, 2010, NAT GENET, V42, P338, DOI 10.1038/ng.542; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x; Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	43	34	35	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2140	2149		10.1038/onc.2012.228	http://dx.doi.org/10.1038/onc.2012.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689052				2022-12-28	WOS:000318062800003
J	Tsang, YHN; Wu, XW; Lim, JS; Ong, CW; Salto-Tellez, M; Ito, K; Ito, Y; Chen, LF				Tsang, Y-H Nicole; Wu, X-W; Lim, J-S; Ong, C. Wee; Salto-Tellez, M.; Ito, K.; Ito, Y.; Chen, L-F			Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer	ONCOGENE			English	Article						breast cancer; degradation; Pin1; RUNX3; tumor suppressor; ubiquitination	PROMOTER HYPERMETHYLATION; PHOSPHORYLATION; GENE; ISOMERIZATION; ACETYLATION; BETA; UBIQUITINATION; DEGRADATION; RECEPTOR; ALPHA	Emerging evidence demonstrates that RUNX3 is a tumor suppressor in breast cancer. Inactivation of RUNX3 in mice results in spontaneous mammary gland tumors, and decreased or silenced expression of RUNX3 is frequently found in breast cancer cell lines and human breast cancer samples. However, the underlying mechanism for initiating RUNX3 inactivation in breast cancer remains elusive. Here, we identify prolyl isomerase Pin1, which is often overexpressed in breast cancer, as a key regulator of RUNX3 inactivation. In human breast cancer cell lines and breast cancer samples, expression of Pin1 inversely correlates with the expression of RUNX3. In addition, Pin1 recognizes four phosphorylated Ser/Thr-Pro motifs in RUNX3 via its WW domain. Binding of Pin1 to RUNX3 suppresses the transcriptional activity of RUNX3. Furthermore, Pin1 reduces the cellular levels of RUNX3 in an isomerase activity-dependent manner by inducing the ubiquitination and proteasomal degradation of RUNX3. Knocking down Pin1 enhances the cellular levels and transcriptional activity of RUNX3 by inhibiting the ubiquitination and degradation of RUNX3. Our results identify Pin1 as a new regulator of RUNX3 inactivation in breast cancer. Oncogene (2013) 32, 1488-1496; doi:10.1038/onc.2012.178; published online 14 May 2012	[Tsang, Y-H Nicole; Wu, X-W; Lim, J-S; Chen, L-F] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; [Tsang, Y-H Nicole; Ito, Y.] Natl Univ Singapore, Inst Mol & Cell Biol, Dept Canc Genet, Singapore 117548, Singapore; [Ong, C. Wee; Salto-Tellez, M.] Natl Univ Singapore, Dept Pathol, Singapore 117548, Singapore; [Ong, C. Wee; Salto-Tellez, M.; Ito, Y.] Natl Univ Singapore, Canc Sci Inst Singapore, Dept Canc Biol, Singapore 117548, Singapore; [Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, Nagasaki 852, Japan; [Chen, L-F] Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National University of Singapore; Nagasaki University; University of Illinois System; University of Illinois Urbana-Champaign	Chen, LF (corresponding author), Univ Illinois, Coll Med, Dept Biochem, 600 S Matthews Ave,MC-714, Urbana, IL 61801 USA.	lfchen@life.illinois.edu		Salto-Tellez, Manuel/0000-0001-8586-282X	UIUC; NIH [DK-085158]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK085158] Funding Source: NIH RePORTER	UIUC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs Lu KP and Kao HY for the gift of reagents and members in the Chen lab for discussion. This work is supported in part by fund provided by UIUC (to LFC) and NIH grants DK-085158 (to LFC). YHT is an A*STAR-Illinois Partnership fellow.	Bae JS, 2003, BIOCHEM BIOPH RES CO, V305, P1094, DOI 10.1016/S0006-291X(03)00869-6; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Butt AJ, 2008, ADV EXP MED BIOL, V630, P189; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2012, J CELL BIOCHEM, V113, P1470, DOI 10.1002/jcb.24074; Cheskis BJ, 2007, J CELL PHYSIOL, V213, P610, DOI 10.1002/jcp.21253; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Huang B, 2012, ONCOGENE, V31, P527, DOI 10.1038/onc.2011.252; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Hwang KT, 2007, J KOREAN MED SCI, V22, pS24, DOI 10.3346/jkms.2007.22.S.S24; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236; Lim JH, 2011, J BIOL CHEM, V286, P44403, DOI 10.1074/jbc.M111.289512; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Liou YC, 2011, TRENDS BIOCHEM SCI, V36, P501, DOI 10.1016/j.tibs.2011.07.001; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Nakano A, 2009, J BIOL CHEM, V284, P6109, DOI 10.1074/jbc.M804659200; Rajbhandari P, 2012, MOL CELL BIOL, V32, P445, DOI 10.1128/MCB.06073-11; Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07; Rustighi A, 2009, NAT CELL BIOL, V11, P133, DOI 10.1038/ncb1822; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Subramaniam MM, 2009, BBA-REV CANCER, V1796, P315, DOI 10.1016/j.bbcan.2009.07.004; Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4; Tsang YH, 2010, ONCOGENE, V29, P5643, DOI 10.1038/onc.2010.304; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yi P, 2005, MOL CELL BIOL, V25, P9687, DOI 10.1128/MCB.25.21.9687-9699.2005; Zhang DH, 2003, LIFE SCI, V73, P3189, DOI 10.1016/j.lfs.2003.05.006; Zhang M, 2009, J CELL SCI, V122, P1382, DOI 10.1242/jcs.040709; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	40	24	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1488	1496		10.1038/onc.2012.178	http://dx.doi.org/10.1038/onc.2012.178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22580604	Green Accepted			2022-12-28	WOS:000316456000002
J	Chen, J; Abi-Daoud, M; Wang, A; Yang, X; Zhang, X; Feilotter, HE; Tron, VA				Chen, J.; Abi-Daoud, M.; Wang, A.; Yang, X.; Zhang, X.; Feilotter, H. E.; Tron, V. A.			Stathmin 1 is a potential novel oncogene in melanoma	ONCOGENE			English	Article						STMN1; miR-193b; melanoma; oncogene	HUMAN BREAST-CANCER; PROSTATE-CANCER; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; MALIGNANT-MELANOMA; MICRORNA TARGETS; LUNG-CANCER; EXPRESSION; OVEREXPRESSION; PROGRESSION	In previous studies, we demonstrated that miR-193b expression is reduced in melanoma relative to benign nevi, and also that miR193b represses cyclin D1 and Mcl-1 expression. We suggested that stathmin 1 (STMN1) might be a target of miR-193b. STMN1 normally regulates microtubule dynamics either by sequestering free tubulin heterodimers or by promoting microtubule catastrophe. Increased expression of STMN1 has been observed in a variety of human malignancies, but its association with melanoma is unknown. We now report that STMN1 is upregulated during the progression of melanoma relative to benign nevi, and that STMN1 is directly regulated by miR-193b. Using an experimental cell culture approach, overexpression of miR-193b using synthetic microRNAs repressed STMN1 expression, whereas inhibition of miR-193b with anti-miR oligos increased STMN1 expression in melanoma cells. The use of a luciferase reporter assay confirmed that miR-193b directly regulates STMN1 by targeting the 3'-untranslated region of STMN1 mRNA. We further demonstrated that STMN1 is overexpressed in malignant melanoma compared with nevi in two independent melanoma cohorts, and that its level is inversely correlated with miR-193b expression. However, STMN1 expression was not significantly associated with patient survival, Breslow depth, mitotic count or patient age. STMN1 knockdown by small-interfering RNA in melanoma cells drastically repressed cell proliferation and migration potential, whereas ectopic expression of STMN1 using lentivirus increased cell proliferation and migration rates. Subsequent gene expression analysis indicated that interconnected cytoskeletal networks are directly affected following STMN1 knockdown. In addition, we identified deregulated genes associated with proliferation and migration, and revealed that p21(Cip1/Waf1) and p27(Kip) could be downstream effectors of STMN1 signaling. Taken together, our study suggests that downregulation of miR-193b may contribute to increased STMN1 expression in melanoma, which consequently promotes migration and proliferation of tumor cells. Oncogene (2013) 32, 1330-1337; doi:10.1038/onc.2012.141; published online 4 June 2012	[Chen, J.; Abi-Daoud, M.; Wang, A.; Yang, X.; Zhang, X.; Feilotter, H. E.; Tron, V. A.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada	Tron, VA (corresponding author), Queens Univ, Dept Pathol & Mol Med, Richardson Lab, 88 Stuart St,Room 202, Kingston, ON K7L 3N6, Canada.	tronv@queensu.ca			Canadian Institutes of Health Research (CIHR) Grant; Queen's University Terry Fox Foundation Training Program in Transdisciplinary Cancer Research; CIHR	Canadian Institutes of Health Research (CIHR) Grant(Canadian Institutes of Health Research (CIHR)); Queen's University Terry Fox Foundation Training Program in Transdisciplinary Cancer Research; CIHR(Canadian Institutes of Health Research (CIHR))	This work is supported by the Canadian Institutes of Health Research (CIHR) Grant (VAT; HEF). JC is funded in part by the Queen's University Terry Fox Foundation Training Program in Transdisciplinary Cancer Research in partnership with CIHR.	Akslen LA, 2005, J INVEST DERMATOL, V125, P312, DOI 10.1111/j.0022-202X.2005.23788.x; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Boyle GM, 2011, PIGM CELL MELANOMA R, V24, P525, DOI 10.1111/j.1755-148X.2011.00849.x; Buhusi M, 2003, J BIOL CHEM, V278, P25024, DOI 10.1074/jbc.M303084200; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Chen G, 2003, MOL CELL PROTEOMICS, V2, P107, DOI 10.1074/mcp.M200055-MCP200; Chen JM, 2011, AM J PATHOL, V179, P2162, DOI 10.1016/j.ajpath.2011.07.010; Chen JM, 2010, AM J PATHOL, V176, P2520, DOI 10.2353/ajpath.2010.091061; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Curmi PA, 1999, CELL STRUCT FUNCT, V24, P345; Edlundh-Rose E, 2006, MELANOMA RES, V16, P471, DOI 10.1097/01.cmr.0000232300.22032.86; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Ghosh R, 2007, PROSTATE, V67, P1038, DOI 10.1002/pros.20601; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Hsieh SY, 2010, MOL CARCINOGEN, V49, P476, DOI 10.1002/mc.20627; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kumar PS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-42; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Leivonen SK, 2009, ONCOGENE, V28, P3926, DOI 10.1038/onc.2009.241; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245; Li Z, 2011, J BIOL CHEM, V286, P21164, DOI 10.1074/jbc.M110.207571; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Niethammer P, 2004, SCIENCE, V303, P1862, DOI 10.1126/science.1094108; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162; Rothhammer T, 2007, PIGM CELL RES, V20, P92, DOI 10.1111/j.1600-0749.2007.00367.x; Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Singer S, 2009, CANCER RES, V69, P2234, DOI 10.1158/0008-5472.CAN-08-3338; Slipicevic A, 2005, AM J CLIN PATHOL, V124, P528, DOI 10.1309/YT58WWMTA6YR1PRV; Sun ZJ, 2008, BRIT J CANCER, V99, P1656, DOI 10.1038/sj.bjc.6604712; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wellen J, 2009, NEUROPHARMACOLOGY, V56, P386, DOI 10.1016/j.neuropharm.2008.09.011; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Zheng P, 2010, J PROTEOME RES, V9, P4897, DOI 10.1021/pr100712t	51	35	36	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1330	1337		10.1038/onc.2012.141	http://dx.doi.org/10.1038/onc.2012.141			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22665054				2022-12-28	WOS:000316454500013
J	Paul, I; Ahmed, SF; Bhowmik, A; Deb, S; Ghosh, MK				Paul, I.; Ahmed, S. F.; Bhowmik, A.; Deb, S.; Ghosh, M. K.			The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity	ONCOGENE			English	Article						Hsp70; Hsp90; c-Myc; CHIP (STUB1); proteasome	PROTEASOMAL DEGRADATION; CELL PROLIFERATION; PROTEIN STABILITY; PHOSPHORYLATION; MUTATIONS; PATHWAYS; COMPLEX; GLIOMA; TUMOR; SKP2	c-Myc is a proto-oncogenic transcription factor and its rapid turnover mediated by the ubiquitin-proteasome system is critical for maintaining normal cellular homeostasis. Multiple ubiquitin ligases have been assigned for c-Myc regulation till date. However, the available data suggest for the possible existence of additional E3 ligase(s). Here, we report a new E3 ligase for c-Myc, the carboxyl terminus of Hsc70-interacting protein or CHIP, which is a chaperone-associated Ubox-containing E3 ligase. In this report, we show that CHIP interacts and ubiquitinates c-Myc, thus targeting it for proteasome-mediated degradation. Overexpression of CHIP could accelerate the turnover rate of c-Myc protein. Conversely, knockdown of CHIP by RNAi stabilizes endogenous c-Myc. The interaction between CHIP and c-Myc depends on the N-terminally located tetratricopeptide repeats of CHIP, which has been implicated as a chaperone-binding motif. Inhibition of Hsp90 chaperone activity by 17-N-allylamino-17-demethoxygeldanamycin reduces c-Myc protein level. We found that the association between CHIP and c-Myc is dependent on the chaperones; particularly Hsp70. CHIP antagonizes the transcriptional activity of c-Myc and decreases the abundance of the transcripts of its target genes. Overall, CHIP-knockdown increases malignant behavior of C6 glioma cells. To the best of our knowledge, this is the first report of c-Myc being regulated by a bona-fide chaperone-associated E3 ligase in HEK293 as well as glioma cells. Because CHIP has been reported earlier to be negatively regulating Akt1, BCR-ABL and hTERT, and now c-Myc, the present study may strengthen the view that CHIP acts as a tumor suppressor. Oncogene (2013) 32, 1284-1295; doi:10.1038/onc.2012.144; published online 30 April 2012	[Paul, I.; Ahmed, S. F.; Bhowmik, A.; Deb, S.; Ghosh, M. K.] CSIR, IICB, Lab Signal Transduct Canc & Stem Cells, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Ghosh, MK (corresponding author), CSIR, IICB, Lab Signal Transduct Canc & Stem Cells, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	mrinal.res@gmail.com	Paul, Indranil/AAX-7638-2021; Ahmed, Syed Feroj/D-7860-2014	Paul, Indranil/0000-0003-0327-5002; Ahmed, Syed Feroj/0000-0003-1033-2538; Deb, Satamita/0000-0003-0315-7030	Council of Scientific and Industrial Research, CSIR (EMPOWER); DST	Council of Scientific and Industrial Research, CSIR (EMPOWER); DST(Department of Science & Technology (India))	This work was supported by grants provided by Council of Scientific and Industrial Research, CSIR (EMPOWER) and DST to MKG.	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Belova L, 2006, BIOCHEM J, V400, P235, DOI 10.1042/BJ20060905; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Carystinos GD, 2003, MOL PHARMACOL, V63, P821, DOI 10.1124/mol.63.4.821; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; CLARK HM, 1994, CANCER RES, V54, P3383; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Deribe YL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000576; Dickey CA, 2008, P NATL ACAD SCI USA, V105, P3622, DOI 10.1073/pnas.0709180105; Ding XD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005949; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Ghosh MK, 2005, ONCOGENE, V24, P7290, DOI 10.1038/sj.onc.1208894; Grobben B, 2002, CELL TISSUE RES, V310, P257, DOI 10.1007/s00441-002-0651-7; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HENRIKSSON M, 1992, EXP CELL RES, V203, P383, DOI 10.1016/0014-4827(92)90012-W; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Ko HS, 2009, P NATL ACAD SCI USA, V106, P2897, DOI 10.1073/pnas.0810123106; Kundrat L, 2010, BIOCHEMISTRY-US, V49, P7428, DOI 10.1021/bi100386w; Levens David, 2010, Genes Cancer, V1, P547; Li F, 2009, J BIOL CHEM, V284, P20090, DOI 10.1074/jbc.M109.017046; Li XN, 2008, J CELL BIOL, V181, P959, DOI 10.1083/jcb.200711044; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; NAGANO N, 1993, ACTA NEUROPATHOL, V86, P117, DOI 10.1007/BF00334878; Nie L, 2008, J BIOL CHEM, V283, P684, DOI 10.1074/jbc.M704981200; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; PULVERER BJ, 1994, ONCOGENE, V9, P59; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sha JF, 2010, J VIROL, V84, P4050, DOI 10.1128/JVI.02131-09; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Whittle IR, 1998, J NEURO-ONCOL, V36, P231, DOI 10.1023/A:1005831111337; Xia T, 2007, AM J PHYSIOL-HEART C, V293, pH3080, DOI 10.1152/ajpheart.00579.2007; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	44	98	102	3	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1284	1295		10.1038/onc.2012.144	http://dx.doi.org/10.1038/onc.2012.144			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543587				2022-12-28	WOS:000316454500009
J	Ward, A; Balwierz, A; Zhang, JD; Kublbeck, M; Pawitan, Y; Hielscher, T; Wiemann, S; Sahin, O				Ward, A.; Balwierz, A.; Zhang, J. D.; Kueblbeck, M.; Pawitan, Y.; Hielscher, T.; Wiemann, S.; Sahin, Oe			Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer	ONCOGENE			English	Article						microRNAs; tamoxifen resistance; epithelial-mesenchymal transition; breast cancer; metadherin	EPITHELIAL-MESENCHYMAL TRANSITION; DOWN-REGULATION; MIR-200 FAMILY; CELL-SURVIVAL; E-CADHERIN; RECEPTOR; TARGETS; PROLIFERATION; 14-3-3-ZETA; METASTASIS	Epithelial-mesenchynnal transition (EMT) is an initiating event in tumor cell invasion and metastasis. It has been shown to occur in resistance to a range of cancer therapies, including tamoxifen. MicroRNAs (miRNAs) have been associated with EMT as well as resistance to standard therapies. To investigate the role of nniRNAs in the development of resistance to tamoxifen as well as accompanying EMT-like properties, we established a tamoxifen-resistant (TamR) model by continually exposing MCF-7 breast cancer cells to tamoxifen. In addition to the molecular changes known to be involved in acquired tamoxifen resistance, TamR cells displayed nnesenchymal features and had increased invasiveness. Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in resistant cells. Re-expression of miR-375 was sufficient to sensitize TamR cells to tamoxifen and partly reversed EMT. A combination of mRNA profiling, bioinformatics analysis and experimental validation identified metadherin (MTDH) as a direct target of miR-375. Knockdown of MTDH partially phenocopied the effects of miR-375 on the sensitivity to tamoxifen and the reversal of EMT. We observed an inverse correlation between the expression of miR-375 and its target MTDH in primary breast cancer samples, implying the pathological relevance of targeting. Finally, tamoxifen-treated patients with higher expression of MTDH had a shorter disease-free survival and higher risk of relapse. As most cancer-related deaths occur because of resistance to standard therapies and metastasis, re-expression of miR-375 or targeting MTDH might serve as potential therapeutic approaches for the treatment of TamR breast cancer. Oncogene (2013) 32, 1173-1182; doi:10.1038/onc.2012.128; published online 16 April 2012	[Ward, A.; Balwierz, A.; Zhang, J. D.; Kueblbeck, M.; Wiemann, S.; Sahin, Oe] German Canc Res Ctr, Div Mol Genome Anal, D-69120 Heidelberg, Baden Wurttembe, Germany; [Pawitan, Y.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Hielscher, T.] German Canc Res Ctr, Div Biostat, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet; Helmholtz Association; German Cancer Research Center (DKFZ)	Sahin, O (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, Neuenheimer Feld 580, D-69120 Heidelberg, Baden Wurttembe, Germany.	sahinozgur@gmail.com	Sahin, Özgür/F-4403-2014; Wiemann, Stefan/E-4424-2013	Sahin, Özgür/0000-0002-8033-7089; Wiemann, Stefan/0000-0003-4683-3174; Balwierz, Aleksandra/0000-0002-5640-9839; Ward Gahlawat, Aoife/0000-0001-7854-7207	National Genome Research Network [01GS0864]; German Federal Ministry of Education and Research (BMBF); Wilhelm Sanderstiftung [2009.051.1]; DKFZ International PhD Program	National Genome Research Network; German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Wilhelm Sanderstiftung; DKFZ International PhD Program	We thank Sara Burmester for excellent technical help as well as Stefan Uhlmann and Sarah Jurmeister for valuable discussions. We also thank Brian Pickering for critical reading of the manuscript. We would also like to thank Doris Mayer for providing the ERE-reporter construct. This work was supported within the National Genome Research Network (grant 01GS0864) of the German Federal Ministry of Education and Research (BMBF) and Wilhelm Sanderstiftung (grant 2009.051.1). JDZ was supported by the DKFZ International PhD Program.	Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Berstein LM, 2004, CLIN CANCER RES, V10, P1530, DOI 10.1158/1078-0432.CCR-0433-03; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Dweep H, 2011, J BIOMED INFORM, P14; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hiscox S, 2006, BREAST CANCER RES TR, V97, P263, DOI 10.1007/s10549-005-9120-9; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KATZENELLENBOGEN BS, 1985, BREAST CANCER RES TR, V5, P231, DOI 10.1007/BF01806018; Kim MR, 2009, CANCER SCI, V100, P1834, DOI 10.1111/j.1349-7006.2009.01260.x; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Li XA, 2011, CANCER SCI, V102, P1151, DOI 10.1111/j.1349-7006.2011.01919.x; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Mazar J, 2011, FEBS LETT, V585, P2467, DOI 10.1016/j.febslet.2011.06.025; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Sahin O, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-1; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193	36	202	215	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2013	32	9					1173	1182		10.1038/onc.2012.128	http://dx.doi.org/10.1038/onc.2012.128			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22508479	hybrid			2022-12-28	WOS:000316428800011
J	Amin, ARMR; Thakur, VS; Gupta, K; Agarwal, MK; Wald, DN; Shin, DM; Agarwal, ML				Amin, A. R. M. Ruhul; Thakur, V. S.; Gupta, K.; Agarwal, M. K.; Wald, D. N.; Shin, D. M.; Agarwal, M. L.			N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy	ONCOGENE			English	Article						DNA damage; apoptosis; signal transduction; aspartate transcarbamylase inhibitor; p53 family; replicative stress	PHASE-II TRIAL; KINASE C-ABL; DNA-DAMAGE; BH3-ONLY PROTEINS; P73 GENE; CHROMOSOME 1P36.3; UP-REGULATION; P53 HOMOLOG; MUTANT P53; CELL-DEATH	p53 is essential for the cellular responses to DNA damage that help to maintain genomic stability. However, the great majority of human cancers undergo disruption of the p53-network. Identification and characterization of molecular components important in both p53-dependent and -independent apoptosis might be useful in developing novel therapies for cancers. In the complete absence of p53, cells treated with N-(phosphonacetyl)-L-aspartate (PALA) continue to synthesize DNA slowly and eventually progress through S-phase, suffering severe DNA damage that in turn triggers apoptosis, whereas cells with functional p53 undergo growth arrest. In this study, we investigated apoptotic signaling in response to PALA and the role of p53 expression in this pathway. We found that treatment of cells lacking p53 with PALA induced TAp73, Noxa and Bim and inactivation of these proteins with dominant-negative plasmids or small interfering RNAs significantly inhibited apoptosis, suggesting that PALA-induced apoptosis was mediated via TAp73-dependent expression of Noxa and Binn. However, PALA treatment inhibited the expression of Delta Np73 only in cells lacking p53 but not in cells expressing p53. In addition, PALA treatment inhibited Bcl-2, and overexpression of Bcl-2 significantly inhibited PALA-induced apoptosis. Moreover, expression of p53 in these cells protected them from PALA-induced apoptosis by activating p21, sustaining the expression of Delta Np73 and inhibiting the induction of Noxa and Bim. Taken together, our study identifies novel but opposing roles for the p53 and TAp73 in the induction of Noxa and Bim and regulation of apoptosis. Our data will help to develop strategies to eliminate cancer cells lacking p53 while protecting normal cells with wild-type p53. Oncogene (2013) 32, 920-929; doi:10.1038/onc.2012.96; published online 19 March 2012	[Amin, A. R. M. Ruhul; Thakur, V. S.; Agarwal, M. L.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; [Amin, A. R. M. Ruhul; Shin, D. M.] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA; [Gupta, K.; Wald, D. N.] Case Western Reserve Univ, Dept Pathol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Agarwal, M. K.] Invenio Therapeut, Cleveland, OH USA	Case Western Reserve University; Emory University; Case Western Reserve University	Amin, ARMR (corresponding author), Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Bldg C,Room 3074, Atlanta, GA 30322 USA.	aamin9@emory.edu; munnaagarwal@hotmail.com	Shin, Dong Moon/G-9649-2013; Ray, Dana M/C-3470-2013	Shin, Dong Moon/0000-0002-8245-4174; AMIN, ARM/0000-0001-9144-2960	National Institutes of Health [R01 CA98916, P50 CA128613]; Career Development Award; NATIONAL CANCER INSTITUTE [P50CA128613, R01CA098916] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Career Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are thankful to Dr George R Stark (Cleveland Clinic Foundation) for his continuous encouragement and criticism throughout the course of the work and critically reading and editing the manuscript, and to Dr Anthea Hammond (Emory University) for editorial assistance. We also thank Dr Rajib K Paul for screening SKp53 cells. This work was supported by National Institutes of Health Grants R01 CA98916 to MLA and P50 CA128613 to DMS and ARA. ARA is a recipient of Career Development Award.	Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Agarwal MK, 2006, P NATL ACAD SCI USA, V103, P16278, DOI 10.1073/pnas.0607210103; Amin ARMR, 2007, CANCER RES, V67, P5617, DOI 10.1158/0008-5472.CAN-07-0655; Amin ARMR, 2007, P NATL ACAD SCI USA, V104, P5419, DOI 10.1073/pnas.0700642104; Amin ARMR, 2010, J BIOL CHEM, V285, P34557, DOI 10.1074/jbc.M110.141135; Amin ARMR, 2010, MOL CANCER THER, V9, P471, DOI 10.1158/1535-7163.MCT-09-0732; Amin ARMR, 2009, J CLIN ONCOL, V27, P2712, DOI 10.1200/JCO.2008.20.6235; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004; Busuttil V, 2010, P NATL ACAD SCI USA, V107, P18061, DOI 10.1073/pnas.1006163107; Chakraborty J, 2010, J BIOL CHEM, V285, P33104, DOI 10.1074/jbc.M110.122705; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Chung J, 2010, CURR DRUG TARGETS, V11, P667, DOI 10.2174/138945010791170833; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dotsch V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004887; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Faridoni-Laurens L, 2008, CELL CYCLE, V7, P1587, DOI 10.4161/cc.7.11.5894; Farnebo M, 2010, BIOCHEM BIOPH RES CO, V396, P85, DOI 10.1016/j.bbrc.2010.02.152; Ghiotto F, 2010, CYTOM PART A, V77A, P11, DOI 10.1002/cyto.a.20819; Gong JG, 1999, NATURE, V399, P806; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Gottlieb E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001040; GREM JL, 1993, CANCER RES, V53, P4828; Hastak K, 2005, FASEB J, V19, P789, DOI 10.1096/fj.04-2226fje; Hastak K, 2008, P NATL ACAD SCI USA, V105, P6314, DOI 10.1073/pnas.0802080105; HEO DS, 1989, CANCER RES, V49, P5167; Ibrahim N, 2010, CANCER RES, V70, P7155, DOI 10.1158/0008-5472.CAN-10-0668; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Joerger AC, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000919; John K, 2011, CELL DEATH DIFFER, V18, P874, DOI 10.1038/cdd.2010.153; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kirschnek S, 2011, CELL DEATH DIFFER, V18, P1805, DOI 10.1038/cdd.2011.69; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Leibowitz Brian, 2010, Cancer Biol Ther, V9, P417, DOI 10.4161/cbt.9.6.11392; Leupin N, 2004, LEUKEMIA LYMPHOMA, V45, P1205, DOI 10.1080/10298190310001623829; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lomonosova E, 2008, ONCOGENE, V27, pS2, DOI 10.1038/onc.2009.39; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Lunghi P, 2009, CLIN CANCER RES, V15, P6495, DOI 10.1158/1078-0432.CCR-09-1229; Maisse C, 2004, CELL DEATH DIFFER, V11, P685, DOI 10.1038/sj.cdd.4401376; Malaguarnera R, 2007, ENDOCR-RELAT CANCER, V14, P43, DOI 10.1677/erc.1.01223; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Miyaguchi Y, 2009, CELL BIOL INT, V33, P853, DOI 10.1016/j.cellbi.2009.04.017; Moffitt KL, 2010, J PHARM PHARMACOL, V62, P547, DOI 10.1211/jpp.62.05.0001; Morales AA, 2008, BLOOD, V111, P5152, DOI 10.1182/blood-2007-10-116889; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ozaki T, 2005, CANCER SCI, V96, P729, DOI 10.1111/j.1349-7006.2005.00116.x; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; REDEI I, 1994, INVEST NEW DRUG, V12, P319, DOI 10.1007/BF00873047; Rufini Alessandro, 2011, Genes Cancer, V2, P491, DOI 10.1177/1947601911408890; Santidrian AF, 2010, BLOOD, V116, P3023, DOI 10.1182/blood-2010-05-283960; Sedletska Yuliya, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P251, DOI 10.2174/1568011053765967; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Sunahara M, 1998, INT J ONCOL, V13, P319; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Toh WH, 2010, CELL DEATH DIFFER, V17, P787, DOI 10.1038/cdd.2009.181; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Vilgelm A, 2008, DRUG RESIST UPDATE, V11, P152, DOI 10.1016/j.drup.2008.08.001; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wadler S, 1996, EUR J CANCER, V32A, P1254, DOI 10.1016/0959-8049(96)00035-4; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Wiman KG, 2010, ONCOGENE, V29, P4245, DOI 10.1038/onc.2010.188; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yokomizo A, 1999, PROSTATE, V39, P94; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	79	9	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					920	929		10.1038/onc.2012.96	http://dx.doi.org/10.1038/onc.2012.96			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22430213	Green Accepted			2022-12-28	WOS:000316581100012
J	Katz, SG; Fisher, JK; Correll, M; Bronson, RT; Ligon, KL; Walensky, LD				Katz, S. G.; Fisher, J. K.; Correll, M.; Bronson, R. T.; Ligon, K. L.; Walensky, L. D.			Brain and testicular tumors in mice with progenitor cells lacking BAX and BAK	ONCOGENE			English	Article						BAX; BAK; neural progenitor cell; apoptosis; tumorigenesis	NEURAL STEM-CELLS; ABUNDANT NEUROPIL; MALIGNANT GLIOMA; TRANSGENIC MICE; NERVOUS-SYSTEM; EMBRYONIC STEM; TRUE ROSETTES; LEYDIG-CELLS; MOUSE MODEL; IN-VIVO	The proapoptotic BCL-2 family proteins BAX and BAK serve as essential gatekeepers of the intrinsic apoptotic pathway and, when activated, transform into pore-forming homo-oligomers that permeabilize the mitochondrial outer membrane. Deletion of Bax and Bak causes marked resistance to death stimuli in a variety of cell types. Bax(-/-) Bak(-/-) mice are predominantly non-viable and survivors exhibit multiple developmental abnormalities characterized by cellular excess, including accumulation of neural progenitor cells in the periventricular, hippocampal, cerebellar and olfactory bulb regions of the brain. To explore the long-term pathophysiological consequences of BAX/BAK deficiency in a stem cell niche, we generated Bak(-/-) mice with conditional deletion of Bax in Nestin-positive cells. Aged Nestin(Cre)Bax(fl/fl)Bak(-/-) mice manifest progressive brain enlargement with a profound accumulation of NeuN- and Sox2-positive neural progenitor cells within the subventricular zone (SVZ). One-third of the mice develop frank masses comprised of neural progenitors, and in 20% of these cases, more aggressive, hypercellular tumors emerged. Unexpectedly, 60% of Nestin(Cre)Bax(fl/fl)Bak(-/-) mice harbored high-grade tumors within the testis, a peripheral site of Nestin expression. This in vivo model of severe apoptotic blockade highlights the constitutive role of BAX/BAK in long-term regulation of Nestin-positive progenitor cell pools, with loss of function predisposing to adult-onset tumorigenesis.	[Katz, S. G.; Fisher, J. K.; Walensky, L. D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA; [Katz, S. G.; Fisher, J. K.; Walensky, L. D.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02215 USA; [Katz, S. G.; Ligon, K. L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Correll, M.] Dana Farber Canc Inst, Boston, MA 02215 USA; [Bronson, R. T.; Ligon, K. L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Ligon, K. L.] Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA USA; [Ligon, K. L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Walensky, LD (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 664, Boston, MA 02215 USA.	Loren_Walensky@dfci.harvard.edu			NIH [5R01CA050239, 1P01CA142536, 5K08HL103847]; Todd J Schwartz Memorial Fund; NATIONAL CANCER INSTITUTE [R01CA050239, P01CA142536] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL103847] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Todd J Schwartz Memorial Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank E Smith for editorial and graphics assistance, R Segal, R Folkerth and C Stiles for helpful discussions, and S Rodig and the Harvard Medical School Rodent Histopathology and Brigham and Women's Hospital, Specialized Histopathology cores for technical support. This work was supported by NIH Grants 5R01CA050239 and 1P01CA142536 to LDW, NIH Grant 5K08HL103847 to SGK and the Todd J Schwartz Memorial Fund.	ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; Amoh Y, 2005, CANCER RES, V65, P5352, DOI 10.1158/0008-5472.CAN-05-0821; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Burness ML, 2010, SEMIN CANCER BIOL, V20, P107, DOI 10.1016/j.semcancer.2010.05.006; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Carvalho BS, BIOINFORMATICS, V26, P2363; Culhane AC, 2012, NUCLEIC ACIDS RES, V40, pD1060, DOI 10.1093/nar/gkr901; Dansen TB, 2006, J BIOL CHEM, V281, P10890, DOI 10.1074/jbc.M513655200; Davidoff MS, 2004, J CELL BIOL, V167, P935, DOI 10.1083/jcb.200409107; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Dubois NC, 2006, GENESIS, V44, P355, DOI 10.1002/dvg.20226; Eberhart CG, 2000, PEDIATR DEVEL PATHOL, V3, P346, DOI 10.1007/s100249910049; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gessi M, 2009, AM J SURG PATHOL, V33, P211, DOI 10.1097/PAS.0b013e318186235b; Gil-Perotin S, 2006, J NEUROSCI, V26, P1107, DOI 10.1523/JNEUROSCI.3970-05.2006; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Lindsten T, 2003, J NEUROSCI, V23, P11112; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lobo MVT, 2004, CELL TISSUE RES, V316, P369, DOI 10.1007/s00441-003-0848-4; McCall MN, 2011, NUCLEIC ACIDS RES, V39, pD1011, DOI 10.1093/nar/gkq1259; Mehta S, 2011, CANCER CELL, V19, P359, DOI 10.1016/j.ccr.2011.01.035; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Preusser M, 2003, ACTA NEUROPATHOL, V106, P506, DOI 10.1007/s00401-003-0758-2; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reyes NA, 2010, J CLIN INVEST, V120, P3673, DOI 10.1172/JCI42986; Sauvageot CM, 2007, NEUROL CLIN, V25, P891, DOI 10.1016/j.ncl.2007.07.014; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Takeuchi O, 2005, P NATL ACAD SCI USA, V102, P11272, DOI 10.1073/pnas.0504783102; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	42	6	6	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4078	4085		10.1038/onc.2012.421	http://dx.doi.org/10.1038/onc.2012.421			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	22986529	Green Accepted			2022-12-28	WOS:000323748500003
J	Nguyen, HB; Babcock, JT; Wells, CD; Quilliam, LA				Nguyen, H. B.; Babcock, J. T.; Wells, C. D.; Quilliam, L. A.			LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap	ONCOGENE			English	Article						LKB1; Yap; Hippo; polarity; growth	HIPPO SIGNALING PATHWAY; LUNG-CANCER; ORGAN SIZE; ACTIVATION; PROTEIN; TRANSCRIPTION; APOPTOSIS; POLARITY; ACTS; GENE	The liver kinase B1 (LKB1) tumor suppressor inhibits cell growth through its regulation of cellular metabolism and apical-basal polarity. The best understood mechanism whereby LKB1 limits cell growth is through activation of the AMP-activated-protein-kinase/mammalian-target-of-rapamycin (AMPK/mTOR) pathway to control metabolism. As LKB1 is also required for polarized epithelial cells to resist hyperplasia, it is anticipated to function through additional mechanisms. Recently, Yes-associated protein (Yap) has emerged as a transcriptional co-activator that modulates tissue homeostasis in response to cell-cell contact. Thus this study examined a possible connection between Yap and LKB1. Restoration of LKB1 expression in HeLa cells, which lack this tumor suppressor, or short-hairpin RNA knockdown of LKB1 in NTERT immortalized keratinocytes, demonstrated that LKB1 promotes Yap phosphorylation, nuclear exclusion and proteasomal degradation. The ability of phosphorylation-defective Yap mutants to rescue LKB1 phenotypes, such as reduced cell proliferation and cell size, suggest that Yap inhibition contributes to LKB1 tumor suppressor function(s). However, failure of Lats1/2 knockdown to suppress LKB1-mediated Yap regulation suggested that LKB1 signals to Yap via a non-canonical pathway. Additionally, LKB1 inhibited Yap independently of either AMPK or mTOR activation. These findings reveal a novel mechanism whereby LKB1 may restrict cancer cell growth via the inhibition of Yap.	[Nguyen, H. B.; Babcock, J. T.; Wells, C. D.; Quilliam, L. A.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Quilliam, LA (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, MS 4075,635 Barnhill Dr, Indianapolis, IN 46202 USA.	lquillia@iupui.edu			US Department of Defense [W81XWH1110355]; LAM Foundation; IUPUI; NATIONAL CANCER INSTITUTE [R01CA151765] Funding Source: NIH RePORTER	US Department of Defense(United States Department of Defense); LAM Foundation; IUPUI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dan Spandau for NTERT cells, Jacob Adler and Bill Ranahan for experimental advice. This work was supported by US Department of Defense award W81XWH1110355, the LAM Foundation and a research support funds grant from IUPUI to LAQ.	Asuri S, 2008, J CELL BIOCHEM, V105, P1027, DOI 10.1002/jcb.21902; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bao YJ, 2011, J BIOCHEM, V150, P199, DOI 10.1093/jb/mvr063; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bertini E, 2009, CELL CYCLE, V8, P49, DOI 10.4161/cc.8.1.7259; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Granot Z, 2009, CELL METAB, V10, P296, DOI 10.1016/j.cmet.2009.08.010; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Heller B, 2010, J BIOL CHEM, V285, P12308, DOI 10.1074/jbc.M109.096230; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Huang H, 1999, DEVELOPMENT, V126, P5365; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Humbert N, 2010, EMBO J, V29, P376, DOI 10.1038/emboj.2009.342; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Mauviel A, 2012, ONCOGENE, V31, P1743, DOI 10.1038/onc.2011.363; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Ranahan WP, 2011, CANCER RES, V71, P2203, DOI 10.1158/0008-5472.CAN-10-1995; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saucedo LJ, 2002, CURR OPIN GENET DEV, V12, P565, DOI 10.1016/S0959-437X(02)00341-6; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Willecke M, 2006, CURR BIOL, V16, P2090, DOI 10.1016/j.cub.2006.09.005; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zong H, 2001, MOL CELL BIOL, V21, P5287, DOI 10.1128/MCB.21.16.5287-5298.2001	45	60	67	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4100	4109		10.1038/onc.2012.431	http://dx.doi.org/10.1038/onc.2012.431			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23027127	Green Accepted			2022-12-28	WOS:000323748500005
J	Leisner, TM; Moran, C; Holly, SP; Parise, LV				Leisner, T. M.; Moran, C.; Holly, S. P.; Parise, L. V.			CIB1 prevents nuclear GAPDH accumulation and non-apoptotic tumor cell death via AKT and ERK signaling	ONCOGENE			English	Article						cell death; CIB1; GAPDH; AKT; ERK	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; BAD PHOSPHORYLATION; BINDING PROTEIN; DNA-REPAIR; PATHWAYS; TRANSLOCATION; ACTIVATION; IDENTIFICATION; TRANSFORMATION; LOCALIZATION	CIB1 is a 22-kDa regulatory protein previously implicated in cell survival and proliferation. However, the mechanism by which CIB1 regulates these processes is poorly defined. Here, we report that CIB1 depletion in SK-N-SH neuroblastoma and MDA-MB-468 breast cancer cells promotes non-apoptotic, caspase-independent cell death that is not initiated by increased outer mitochondrial membrane permeability or translocation of apoptosis-inducing factor to the nucleus. Instead, cell death requires nuclear GAPDH accumulation. Furthermore, CIB1 depletion disrupts two commonly dysregulated, oncogenic pathways-PI3K/AKT and Ras/MEK/ERK, resulting in a synergistic mechanism of cell death, which was mimicked by simultaneous pharmacological inhibition of both pathways, but not either pathway alone. In defining each pathway's contributions, we found that AKT inhibition alone maximally induced GAPDH nuclear accumulation, whereas MEK/ERK inhibition alone had no effect on GAPDH localization. Concurrent GAPDH nuclear accumulation and ERK inhibition were required, however, to induce a significant DNA damage response, which was critical to subsequent cell death. Collectively, our results indicate that CIB1 is uniquely positioned to regulate PI3K/AKT and MEK/ERK signaling and that simultaneous disruption of these pathways synergistically induces a nuclear GAPDH-dependent cell death. The mechanistic insights into cell death induced by CIB1 interference suggest novel molecular targets for cancer therapy.	[Leisner, T. M.; Moran, C.; Holly, S. P.; Parise, L. V.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [Moran, C.] PRA Int, Raleigh, NC USA; [Parise, L. V.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Leisner, TM (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 120 Mason Farm Rd Suite 3010, Chapel Hill, NC 27599 USA.	tml13@med.unc.edu			NIH [HL07149T32, 5R01HL092544]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092544, T32HL007149] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank members of the Parise, Cook and A Sancar laboratories, Drs Yue Xiong, Matthew Torres, and Howard Fried for critical review and suggestions. We also thank Dr Akira Sawa for generously providing GAPDH plasmids. Special thanks to Dr H Fried and Andrew McFadden for lentiviral plasmid construction. This work was funded by the postdoctoral fellowship grant HL07149T32 (CM) and 5R01HL092544 (LVP) from the NIH.	Arias-Romero LE, 2010, ONCOGENE, V29, P5839, DOI 10.1038/onc.2010.318; Azam S, 2008, J BIOL CHEM, V283, P30632, DOI 10.1074/jbc.M801401200; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Broniowska KA, 2010, AM J PHYSIOL-HEART C, V299, pH1212, DOI 10.1152/ajpheart.00472.2010; Carujo S, 2006, ONCOGENE, V25, P4033, DOI 10.1038/sj.onc.1209433; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Colell A, 2009, CELL DEATH DIFFER, V16, P1573, DOI 10.1038/cdd.2009.137; Dai Y, 2008, BLOOD, V112, P2439, DOI 10.1182/blood-2008-05-159392; Dastoor Z, 2001, J CELL SCI, V114, P1643; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dent P, 2009, DRUG RESIST UPDATE, V12, P65, DOI 10.1016/j.drup.2009.03.001; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gentry HR, 2005, J BIOL CHEM, V280, P8407, DOI 10.1074/jbc.M411515200; Golding SE, 2007, CANCER RES, V67, P1046, DOI 10.1158/0008-5472.CAN-06-2371; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Hara MR, 2006, CELL MOL NEUROBIOL, V26, P527, DOI 10.1007/s10571-006-9011-6; Hara MR, 2006, P NATL ACAD SCI USA, V103, P3887, DOI 10.1073/pnas.0511321103; Huynh N, 2010, BBA-MOL CELL RES, V1803, P1106, DOI 10.1016/j.bbamcr.2010.05.007; Kodama R, 2005, GENES CELLS, V10, P1211, DOI 10.1111/j.1365-2443.2005.00911.x; Kornberg MD, 2010, NAT CELL BIOL, V12, P1094, DOI 10.1038/ncb2114; Kragten E, 1998, J BIOL CHEM, V273, P5821, DOI 10.1074/jbc.273.10.5821; Kwon HJ, 2010, EXP MOL MED, V42, P254, DOI 10.3858/emm.2010.42.4.025; Lartigue L, 2009, MOL BIOL CELL, V20, P4871, DOI 10.1091/mbc.E09-07-0649; Leisner TM, 2005, J CELL BIOL, V170, P465, DOI 10.1083/jcb.200502090; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Mikami I, 2010, ONCOL REP, V24, P1677, DOI 10.3892/or_00001033; Mills JR, 2012, CELL CYCLE, V11, P88, DOI 10.4161/cc.11.1.18408; Milosevic J, 2009, PROTEOMICS, V9, P1230, DOI 10.1002/pmic.200700604; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nakajima H, 2009, J BIOL CHEM, V284, P34331, DOI 10.1074/jbc.M109.027698; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Phadke MS, 2009, J PHARMACOL EXP THER, V331, P77, DOI 10.1124/jpet.109.155671; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sastry KSR, 2006, J BIOL CHEM, V281, P27367, DOI 10.1074/jbc.M511485200; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Schmitz HD, 2001, EUR J CELL BIOL, V80, P419, DOI 10.1078/0171-9335-00174; Sen N, 2008, NAT CELL BIOL, V10, P866, DOI 10.1038/ncb1747; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Tristan C, 2011, CELL SIGNAL, V23, P317, DOI 10.1016/j.cellsig.2010.08.003; Xing CG, 2004, P NATL ACAD SCI USA, V101, P5862, DOI 10.1073/pnas.0307476101; Xu Y, 2008, ONCOGENE, V27, P3501, DOI 10.1038/sj.onc.1211023; Yoon KB, 2009, TOP CATAL, V52, P1, DOI 10.1007/s11244-008-9132-x; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan W, 2006, MOL CELL BIOL, V26, P8507, DOI 10.1128/MCB.01488-06; Zayed MA, 2007, CIRC RES, V101, P1185, DOI 10.1161/CIRCRESAHA.107.157586; Zayed MA, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-17	53	29	33	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4017	4027		10.1038/onc.2012.408	http://dx.doi.org/10.1038/onc.2012.408			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22964641	Green Accepted			2022-12-28	WOS:000323748100010
J	To, MD; Rosario, RD; Westcott, PMK; Banta, KL; Balmain, A				To, M. D.; Rosario, R. D.; Westcott, P. M. K.; Banta, K. L.; Balmain, A.			Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis	ONCOGENE			English	Article						Ras; Hras; Kras; Nras; skin carcinogenesis; lung carcinogenesis	MOUSE SKIN; SPINDLE CARCINOMAS; HUMAN CANCER; PAS1 LOCUS; K-RAS; PROGRESSION; MUTATIONS; EXPRESSION; TUMORS; SUSCEPTIBILITY	Ras oncogenes (Hras, Kras and Nras) are important drivers of carcinogenesis. However, tumors with Ras mutations often show loss of the corresponding wild-type (WT) allele, suggesting that proto-oncogenic forms of Ras can function as a suppressor of carcinogenesis. In vitro studies also suggest that WT Ras proteins can suppress the tumorigenic properties of alternate mutant Ras family members, but in vivo evidence for these heterologous interactions is lacking. We have investigated the genetic interactions between different combinations of mutant and WT Ras alleles in vivo using carcinogen-induced lung and skin carcinogenesis in mice with targeted deletion of different Ras family members. The major suppressor effect of WT Kras is observed only in mutant Kras-driven lung carcinogenesis, where loss of one Kras allele led to increased tumor number and size. Deletion of one Hras allele dramatically reduced the number of skin papillomas with Hras mutations, consistent with Hras as the major target of mutation in these tumors. However, skin carcinoma numbers were very similar, suggesting that WT Hras functions as a suppressor of progression from papillomas to invasive squamous carcinomas. In the skin, the Kras proto-oncogene functions cooperatively with mutant Hras to promote papilloma development, although the effect is relatively small. In contrast, the Hras proto-oncogene attenuated the activity of mutant Kras in lung carcinogenesis. Interestingly, loss of Nras increased the number of mutant Kras-induced lung tumors, but decreased the number of mutant Hras-induced skin papillomas. These results show that the strongest suppressor effects of WT Ras are only seen in the context of mutation of the cognate Ras protein, and only relatively weak effects are detected on tumor development induced by mutations in alternative family members. The data also underscore the complex and context-dependent nature of interactions between proto-oncogenic and oncogenic forms of different Ras family members during tumor development.	[To, M. D.] Univ Calif San Francisco, Dept Surg, Thorac Oncol Program, San Francisco, CA 94115 USA; [To, M. D.; Rosario, R. D.; Westcott, P. M. K.; Banta, K. L.; Balmain, A.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94115 USA; [Westcott, P. M. K.; Balmain, A.] Univ Calif San Francisco, Pharmaceut Sci & Pharmacogen Program, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	To, MD (corresponding author), Univ Calif San Francisco, Dept Surg, Thorac Oncol Program, 2340 Sutter St,Room N219, San Francisco, CA 94115 USA.	mto@cc.ucsf.edu; abalmain@cc.ucsf.edu			NCI [CA111834-01, CA84244]; NIH [T32 GM007175]; National Science Foundation Graduate Research Fellowship; Nan Tucker McEvoy Research Fund in Thoracic Oncology; Barbara Bass Bakar Chair in Cancer Genetics; NATIONAL CANCER INSTITUTE [U01CA084244, R01CA111834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007175] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); Nan Tucker McEvoy Research Fund in Thoracic Oncology; Barbara Bass Bakar Chair in Cancer Genetics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Dr Motoya Katsuki and Dr Hiroki Nagase for the Hras<SUP>KO</SUP> mice, and Dr Tyler Jacks for the LSL-Kras<SUP>G12D</SUP> mice. This work was supported by NCI Grants CA111834-01 and CA84244 to AB. PMKW is supported by NIH Training Grant T32 GM007175 and a National Science Foundation Graduate Research Fellowship. MDT acknowledges the support from the Nan Tucker McEvoy Research Fund in Thoracic Oncology. AB acknowledges support from the Barbara Bass Bakar Chair in Cancer Genetics.	BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BOS JL, 1989, CANCER RES, V49, P4682; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Diaz R, 2005, INT J CANCER, V113, P241, DOI 10.1002/ijc.20563; Diaz R, 2002, CANCER RES, V62, P4514; Dworkin AM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001136; Hager JH, 2004, CANCER RES, V64, P2406, DOI 10.1158/0008-5472.CAN-03-3522; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Lee KE, 2010, CANCER CELL, V18, P448, DOI 10.1016/j.ccr.2010.10.020; Manenti G, 2008, ONCOGENE, V27, P5753, DOI 10.1038/onc.2008.194; Mao JH, 2004, GENE DEV, V18, P1800, DOI 10.1101/gad.1213804; Modrek B, 2009, MOL CANCER RES, V7, P1244, DOI 10.1158/1541-7786.MCR-08-0532; Nagase H, 2003, CANCER RES, V63, P4849; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Quinlan MP, 2008, CELL CYCLE, V7, P1332, DOI 10.4161/cc.7.10.5927; Sweet-Cordero A, 2006, GENE CHROMOSOME CANC, V45, P338, DOI 10.1002/gcc.20296; To MD, 2008, NAT GENET, V40, P1240, DOI 10.1038/ng.211; To MD, 2006, NAT GENET, V38, P926, DOI 10.1038/ng1836; To MD, 2011, MOL CANCER RES, V9, P1339, DOI 10.1158/1541-7786.MCR-11-0219; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	29	51	51	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4028	4033		10.1038/onc.2012.404	http://dx.doi.org/10.1038/onc.2012.404			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22945650	Green Submitted, Green Accepted			2022-12-28	WOS:000323748100011
J	Sully, K; Akinduro, O; Philpott, MP; Naeem, AS; Harwood, CA; Reeve, VE; O'Shaughnessy, RF; Byrne, C				Sully, K.; Akinduro, O.; Philpott, M. P.; Naeem, A. S.; Harwood, C. A.; Reeve, V. E.; O'Shaughnessy, R. F.; Byrne, C.			The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKB alpha isoform signaling	ONCOGENE			English	Article						mTOR; rapamycin; epidermis; Akt/PKB; squamous cell carcinoma; ultraviolet radiation	INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE B; SKIN-CANCER; KERATINOCYTE DIFFERENTIATION; TRANSPLANT RECIPIENTS; 3-KINASE/AKT PATHWAY; MAMMALIAN TARGET; GROWTH-FACTOR; MOUSE SKIN; AKT	Epidermal squamous cell carcinoma (SCC) is the most aggressive non-melanoma skin cancer and is dramatically increased in patients undergoing immunosuppression following solid organ transplantation, contributing substantially to morbidity and mortality. Recent clinical studies show that use of the mammalian target of rapamycin (mTOR) inhibitor rapamycin as a post-transplantation immunosuppressive significantly reduces SCC occurrence compared with other immunosuppressives, though the mechanism is not fully understood. We show that rapamycin selectively upregulates epidermal Akt1, while failing to upregulate epidermal Akt2. Rapamycin increases epidermal Akt1 phosphorylation via inhibition of the mTOR complex 1-dependent regulation of insulin receptor substrate-1. Epidermal Akt1 is commonly downregulated in SCC while Akt2 is upregulated. We now demonstrate similar Akt1 downregulation and Akt2 upregulation by ultraviolet (UV) radiation, the most important skin carcinogen. Hence, rapamycin's upregulation of Akt1 signaling could potentially oppose the effects of UV radiation and/or tumor-associated changes on Akt1 signaling. We show in skin culture that rapamycin does enhance restoration of Akt1 phosphorylation in skin recovering from UV radiation, suggesting a mechanism for rapamycin's antitumor activity in epidermis in spite of its efficient immunosuppressive properties.	[Sully, K.; Akinduro, O.; Philpott, M. P.; Harwood, C. A.; Byrne, C.] Queen Mary Univ London, Blizard Inst, Ctr Cutaneous Res, Barts & London Sch Med & Dent, London E1 2AT, England; [Naeem, A. S.; O'Shaughnessy, R. F.] UCL, Inst Child Hlth, London, England; [Reeve, V. E.] Univ Sydney, Fac Vet Sci, Sydney, NSW 2006, Australia	University of London; Queen Mary University London; University of London; University College London; University of Sydney	Byrne, C (corresponding author), Queen Mary Univ London, Blizard Inst, Ctr Cutaneous Res, Barts & London Sch Med & Dent, London E1 2AT, England.	c.r.byrne@qmul.ac.uk		Harwood, Catherine/0000-0002-1375-0965; Nevin, Katherine/0000-0003-4710-2592; O'Shaughnessy, Ryan/0000-0002-3701-0267; Philpott, Michael/0000-0002-1255-4612	British Skin Foundation [941S]; Medical Research Council DTA studentship; Royal Society International Outgoing Short Visit [VO0872438]; Cancer Research UK [13044] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [W1039, W0907] Funding Source: researchfish	British Skin Foundation; Medical Research Council DTA studentship; Royal Society International Outgoing Short Visit; Cancer Research UK(Cancer Research UK); Great Ormond Street Hospital Childrens Charity	This work was supported by the British Skin Foundation 941S, a Medical Research Council DTA studentship for OA and a Royal Society International Outgoing Short Visit VO0872438.	Alberu J, 2011, TRANSPLANTATION, V92, P303, DOI 10.1097/TP.0b013e3182247ae2; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BADEN HP, 1983, J INVEST DERMATOL, V80, P124, DOI 10.1111/1523-1747.ep12532899; Berg CE, 2002, BIOCHEM BIOPH RES CO, V293, P1021, DOI 10.1016/S0006-291X(02)00333-9; Boura-Halfon S, 2009, AM J PHYSIOL-ENDOC M, V296, P26; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Cao C, 2009, J CELL PHYSIOL, V220, P277, DOI 10.1002/jcp.21780; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; de Gruijl FR, 2010, INT J CANCER, V8, P8; Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016; Esposito DL, 2001, ENDOCRINOLOGY, V142, P2833, DOI 10.1210/en.142.7.2833; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gan XQ, 2011, J BIOL CHEM, V286, P10998, DOI 10.1074/jbc.M110.195016; Geissler EK, 2010, NAT REV NEPHROL, V6, P639, DOI 10.1038/nrneph.2010.130; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Haratake A, 1997, J INVEST DERMATOL, V108, P769, DOI 10.1111/1523-1747.ep12292163; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Kim MA, 2009, ONCOGENE, V19, P19; Koehl GE, 2010, ONCOGENE, V29, P1553, DOI 10.1038/onc.2009.435; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Lu ZH, 2010, CANCER RES, V70, P3287, DOI 10.1158/0008-5472.CAN-09-3467; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mao JH, 2004, GENE DEV, V18, P1800, DOI 10.1101/gad.1213804; Meeran SM, 2009, NEOPLASIA, V11, P846, DOI 10.1593/neo.09528; Mitchell C, 2010, AM J TRANSPLANT, V10, P1343, DOI 10.1111/j.1600-6143.2010.03133.x; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; O'Shaughnessy RFL, 2007, CANCER RES, V67, P8207, DOI 10.1158/0008-5472.CAN-07-0755; O'Shaughnessy RFL, 2007, J BIOL CHEM, V282, P17297, DOI 10.1074/jbc.M610386200; O'Shaughnessy RFL, 2009, DEVELOPMENT, V136, P3423, DOI 10.1242/dev.037010; Pfeifer GP, 2012, PHOTOCH PHOTOBIO SCI, V11, P90, DOI 10.1039/c1pp05144j; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Rao RR, 2010, IMMUNITY, V32, P67, DOI 10.1016/j.immuni.2009.10.010; Reeve VE, 2006, PHOTOCHEM PHOTOBIOL, V82, P406, DOI 10.1562/2005-09-29-RA-703; Sadagurski M, 2006, MOL CELL BIOL, V26, P2675, DOI 10.1128/MCB.26.7.2675-2687.2006; Sadagurski M, 2007, J CELL PHYSIOL, V213, P519, DOI 10.1002/jcp.21131; Salgo R, 2010, AM J TRANSPLANT, V10, P1385, DOI 10.1111/j.1600-6143.2009.02997.x; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482; Tato I, 2011, J BIOL CHEM, V286, P6128, DOI 10.1074/jbc.M110.166991; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wang HQ, 2003, J BIOL CHEM, V278, P45737, DOI 10.1074/jbc.M300574200; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wertheimer E, 2001, ENDOCRINOLOGY, V142, P1234, DOI 10.1210/en.142.3.1234; Wulff BC, 2008, J INVEST DERMATOL, V128, P2467, DOI 10.1038/jid.2008.121; YAMAMOTO A, 1991, ARCH DERMATOL RES, V283, P219, DOI 10.1007/BF01106105; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	63	20	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2013	32	27					3254	3262		10.1038/onc.2012.338	http://dx.doi.org/10.1038/onc.2012.338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22890326				2022-12-28	WOS:000321301600005
J	Zhang, P; Guo, A; Possemato, A; Wang, C; Beard, L; Carlin, C; Markowitz, SD; Polakiewicz, RD; Wang, Z				Zhang, P.; Guo, A.; Possemato, A.; Wang, C.; Beard, L.; Carlin, C.; Markowitz, S. D.; Polakiewicz, R. D.; Wang, Z.			Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14	ONCOGENE			English	Article						PTPN14; p130Cas; tumorigenesis; colorectal cancer	HUMAN BREAST; TGF-BETA; SRC; RECEPTOR; ASSOCIATION; KINASE; PEZ; CAS; PHOSPHORYLATION; RESISTANCE	Protein tyrosine phosphatase nonreceptor type 14 (PTPN14) is frequently mutated in a variety of human cancers. However, the cell signaling pathways regulated by PTPN14 largely remain to be elucidated. Here, we identify a list of potential substrates of PTPN14 using a phospho-proteomic approach. We show that p130 Crk-associated substrate (p130Cas) is a direct substrate of PTPN14 and that PTPN14 specifically regulates p130Cas phosphorylation at tyrosine residue 128 (Y128) in colorectal cancer (CRC) cells. We engineered CRC cells homozygous for a p130Cas Y128F knock-in mutant and found that these cells exhibit significantly reduced migration and colony formation, impaired anchorage-independent growth, slower xenograft tumor growth in nude mice and have decreased phosphorylation of AKT. Furthermore, we demonstrate that SRC phosphorylates p130Cas Y128 and that CRC cell lines harboring high levels of pY128Cas are more sensitive to SRC family kinase inhibitor Dasatinib. These findings suggest that p130Cas Y128 phosphorylation may be exploited as a predictive marker for Dasatinib response in cancer patients. In aggregate, our studies reveal a novel signaling pathway that has an important role in colorectal tumorigenesis. Oncogene (2013) 32, 2087-2095; doi:10.1038/onc.2012.220; published online 18 June 2012	[Zhang, P.; Wang, C.; Wang, Z.] Case Western Reserve Univ, Dept Genet, Sch Med, Cleveland, OH 44106 USA; [Zhang, P.; Wang, C.; Beard, L.; Markowitz, S. D.; Wang, Z.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, Cleveland, OH 44106 USA; [Guo, A.; Possemato, A.; Polakiewicz, R. D.] Cell Signaling Technol Inc, Danvers, MA USA; [Beard, L.; Markowitz, S. D.] Case Western Reserve Univ, Dept Genet, Sch Med, Case Med Ctr, Cleveland, OH 44106 USA; [Wang, Z.] Cleveland Clin Fdn, Genom Med Inst, Cleveland, OH 44195 USA; [Carlin, C.] Case Western Reserve Univ, Dept Microbiol & Mol Biol, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University	Wang, Z (corresponding author), Case Western Reserve Univ, Dept Genet, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	zhenghe.wang@case.edu			National Institutes of Health [R01-CA127590, R01-HG004722]; Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [P50CA150964, R01CA127590, P30CA043703] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004722] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Yueting Chen for excellent technical assistance, Drs Susann Brady-Kalnay, Hua Luo and CK Qu for helpful discussions, and Anthony Scott for critical reading of the manuscript. This research was supported by grants from the National Institutes of Health Grant R01-CA127590, R01-HG004722 and a pilot grant from the Case Comprehensive Cancer Center.	Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Blanchetot C, 2005, METHODS, V35, P44, DOI 10.1016/j.ymeth.2004.07.007; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bohnacker T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000259; Brognard J, 2011, CURR OPIN GENET DEV, V21, P4, DOI 10.1016/j.gde.2010.10.012; Burnham MR, 1996, ONCOGENE, V12, P2467; Cabodi S, 2006, CANCER RES, V66, P4672, DOI 10.1158/0008-5472.CAN-05-2909; Montero JC, 2011, CLIN CANCER RES, V17, P5546, DOI 10.1158/1078-0432.CCR-10-2616; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; DORSSERS LCJ, 1993, MOL ENDOCRINOL, V7, P870, DOI 10.1210/me.7.7.870; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Hirata R, 2002, NAT BIOTECHNOL, V20, P735, DOI 10.1038/nbt0702-735; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Liang FB, 2007, MOL BIOSYST, V3, P308, DOI 10.1039/b700704n; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905; Patwardhan P, 2006, J BIOL CHEM, V281, P20689, DOI 10.1074/jbc.M602311200; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Riggins RB, 2003, MOL CANCER RES, V1, P428; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wadham C, 2000, J CELL SCI, V113, P3117; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wei XM, 2011, NAT GENET, V43, P442, DOI 10.1038/ng.810; Wyatt L, 2008, CELL CYCLE, V7, P2290, DOI 10.4161/cc.6443; Wyatt L, 2007, J CELL BIOL, V178, P1223, DOI 10.1083/jcb.200705035; Yarom N, 2011, DISCOV MED, V11, P95; Zhang P, 2011, MOL CANCER RES, V9, P1418, DOI 10.1158/1541-7786.MCR-11-0147; Zhang XD, 2008, NAT METHODS, V5, P163, DOI [10.1038/nmeth1170, 10.1038/NMETH1170]; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; Zhao YQ, 2010, P NATL ACAD SCI USA, V107, P2592, DOI 10.1073/pnas.0914884107	43	28	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2087	2095		10.1038/onc.2012.220	http://dx.doi.org/10.1038/onc.2012.220			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22710723	Green Accepted			2022-12-28	WOS:000317919900010
J	Kim, K; Jutooru, I; Chadalapaka, G; Johnson, G; Frank, J; Burghardt, R; Kim, S; Safe, S				Kim, K.; Jutooru, I.; Chadalapaka, G.; Johnson, G.; Frank, J.; Burghardt, R.; Kim, S.; Safe, S.			HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer	ONCOGENE			English	Article						HOTAIR; invasion; cell cycle progression; pro-oncogenic; prognostic	LONG NONCODING RNA; GENE-EXPRESSION; DUCTAL ADENOCARCINOMA; CHROMATIN; PROTEIN; MECHANISMS; MIRNAS; INTERFERON; ACTIVATION; REPRESSION	HOTAIR is a long intervening non-coding RNA (lincRNA) that associates with the Polycomb Repressive Complex 2 (PRC2) and overexpression is correlated with poor survival for breast, colon and liver cancer patients. In this study, we show that HOTAIR expression is increased in pancreatic tumors compared with non-tumor tissue and is associated with more aggressive tumors. Knockdown of HOTAIR (siHOTAIR) by RNA interference shows that HOTAIR has an important role in pancreatic cancer cell invasion, as reported in other cancer cell lines. In contrast, HOTAIR knockdown in Panc1 and L3.6pL pancreatic cancer cells that overexpress this lincRNA decreased cell proliferation, altered cell cycle progression and induced apoptosis, demonstrating an expanded function of HOTAIR in pancreatic cancer cells compared with other cancer cell lines. Results of gene array studies showed that there was minimal overlap between HOTAIR-regulated genes in pancreatic cells and breast cancer cells, and HOTAIR uniquely suppressed several interferon-related genes and gene sets related to cell cycle progression in pancreatic cancer cells and tumors. Analysis of selected genes suppressed by HOTAIR in Panc1 and L3.6pL cells showed by knockdown of EZH2 and chromatin immunoprecipitation assays that HOTAIR- mediated gene repression was both PRC2-dependent and -independent. HOTAIR knockdown in L3.6pL cells inhibited tumor growth in mouse xenograft model, further demonstrating the pro-oncogenic function of HOTAIR in pancreatic cancer. Oncogene (2013) 32, 1616-1625; doi: 10.1038/onc.2012.193; published online 21 May 2012	[Kim, K.; Safe, S.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [Jutooru, I.; Chadalapaka, G.; Safe, S.] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; [Johnson, G.; Frank, J.; Burghardt, R.] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA; [Kim, S.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Texas System; UTMD Anderson Cancer Center	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, 4466 TAMU,Vet Res Bldg 410, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	Burghardt, Robert C./AAF-4847-2021	Burghardt, Robert C./0000-0003-1021-8444; Kim, Kyounghyun/0000-0002-7240-2768	National Institutes of Health [CA136571]; Texas AgriLife; NATIONAL CANCER INSTITUTE [R01CA136571] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Texas AgriLife; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by National Institutes of Health (CA136571) and Texas AgriLife.	Badea L, 2008, HEPATO-GASTROENTEROL, V55, P2016; Baek SJ, 2005, MOL PHARMACOL, V67, P356, DOI 10.1124/mol.104.005108; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Berezikov E, 2005, HUM MOL GENET, V14, pR183, DOI 10.1093/hmg/ddi271; Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Chintharlapalli S, 2005, MOL PHARMACOL, V68, P1782, DOI 10.1124/mol.105.017046; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Costa FF, 2010, BIOESSAYS, V32, P599, DOI 10.1002/bies.200900112; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Haller O, 2007, CYTOKINE GROWTH F R, V18, P425, DOI 10.1016/j.cytogfr.2007.06.001; Hatano H, 2008, CLIN CANCER RES, V14, P6097, DOI 10.1158/1078-0432.CCR-07-4761; Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Jutooru I, 2010, J BIOL CHEM, V285, P25332, DOI 10.1074/jbc.M109.095240; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kim K, 2012, ONCOGENE, V31, P1034, DOI 10.1038/onc.2011.296; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Lei P, 2008, MOL CANCER THER, V7, P3363, DOI 10.1158/1535-7163.MCT-08-0439; Li MC, 2009, J LEUKOCYTE BIOL, V86, P23, DOI [10.1189/JLB.1208761, 10.1189/jlb.1208761]; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maia CJB, 2008, MOL CELL BIOCHEM, V314, P113, DOI 10.1007/s11010-008-9771-z; Mattick JS, 2004, NAT REV GENET, V5, P316, DOI 10.1038/nrg1321; Mattick JS, 2003, BIOESSAYS, V25, P930, DOI 10.1002/bies.10332; Nelson KM, 2008, MOL CANCER THER, V7, P3655, DOI 10.1158/1535-7163.MCT-08-0586; Numasaki M, 2007, J IMMUNOL, V178, P5086, DOI 10.4049/jimmunol.178.8.5086; Perez DS, 2008, HUM MOL GENET, V17, P642, DOI 10.1093/hmg/ddm336; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; Prasanth KV, 2007, GENE DEV, V21, P11, DOI 10.1101/gad.1484207; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Simon R, 2007, CANCER INFORM, V3, P11; Spitale RC, 2011, EPIGENETICS-US, V6, P539, DOI 10.4161/epi.6.5.15221; Steen HC, 2010, J INTERF CYTOK RES, V30, P597, DOI 10.1089/jir.2010.0058; Stratford JK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000307; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wongthida P, 2010, CANCER RES, V70, P4539, DOI 10.1158/0008-5472.CAN-09-4658; Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y; Yu F, 2011, J NEURO-ONCOL, V103, P187, DOI 10.1007/s11060-010-0377-4; Zhang XQ, 2009, BLOOD, V113, P2526, DOI 10.1182/blood-2008-06-162164	45	655	699	4	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 28	2013	32	13					1616	1625		10.1038/onc.2012.193	http://dx.doi.org/10.1038/onc.2012.193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614017	Green Accepted			2022-12-28	WOS:000316855800002
J	Deshiere, A; Duchemin-Pelletier, E; Spreux, E; Ciais, D; Combes, F; Vandenbrouck, Y; Coute, Y; Mikaelian, I; Giusiano, S; Charpin, C; Cochet, C; Filhol, O				Deshiere, A.; Duchemin-Pelletier, E.; Spreux, E.; Ciais, D.; Combes, F.; Vandenbrouck, Y.; Coute, Y.; Mikaelian, I.; Giusiano, S.; Charpin, C.; Cochet, C.; Filhol, O.			Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction	ONCOGENE			English	Article						EMT; protein kinase CK2; Snail1; epithelial plasticity; breast cancer	BREAST-CANCER CELLS; FACTOR-KAPPA-B; BETA-CATENIN; STEM-CELLS; TUMOR PROGRESSION; CASEIN KINASE-2; ALPHA-CATENIN; MAMMARY-GLAND; PHENOTYPE; PHOSPHORYLATION	Epithelial-to-mesenchymal transition (EMT) is closely linked to conversion of early-stage tumours into invasive malignancies. Many signalling pathways are involved in EMT, but the key regulatory kinases in this important process have not been clearly identified. Protein kinase CK2 is a multi-subunit protein kinase, which, when overexpressed, has been linked to disease progression and poor prognosis in various cancers. Specifically, overexpression of CK2 alpha in human breast cancers is correlated with metastatic risk. In this article, we show that an imbalance of CK2 subunits reflected by a decrease in the CK2 beta regulatory subunit in a subset of breast tumour samples is correlated with induction of EMT-related markers. CK2 beta-depleted epithelial cells displayed EMT-like morphological changes, enhanced migration, and anchorage-independent growth, all of which require Snail1 induction. In epithelial cells, Snail1 stability is negatively regulated by CK2 and GSK3 beta through synergistic hierarchal phosphorylation. This process depends strongly on CK2 beta, thus confirming that CK2 functions upstream of Snail1. In primary breast tumours, CK2 beta underexpression also correlates strongly with expression of EMT markers, emphasizing the link between asymmetric expression of CK2 subunits and EMT in vivo. Our results therefore highlight the importance of CK2 beta in controlling epithelial cell plasticity. They show that CK2 holoenzyme activity is essential to suppress EMT, and that it contributes to maintaining a normal epithelial morphology. This study also suggests that unbalanced expression of CK2 subunits may drive EMT, thereby contributing to tumour progression. Oncogene (2013) 32, 1373-1383; doi:10.1038/onc.2012.165; published online 7 May 2012	[Deshiere, A.; Duchemin-Pelletier, E.; Spreux, E.; Ciais, D.; Cochet, C.; Filhol, O.] INSERM, U1036, Grenoble, France; [Deshiere, A.; Duchemin-Pelletier, E.; Spreux, E.; Ciais, D.; Cochet, C.; Filhol, O.] Univ Grenoble 1, U1036, Grenoble, France; [Deshiere, A.; Duchemin-Pelletier, E.; Spreux, E.; Ciais, D.; Cochet, C.; Filhol, O.] CEA, Dept Sci Vivant, Inst Rech Technol & Sci Vivant, F-38054 Grenoble, France; [Combes, F.; Vandenbrouck, Y.; Coute, Y.] CEA, DSV, iRTSV, Lab Etud Dynam Proteomes, F-38054 Grenoble, France; [Mikaelian, I.] Univ Lyon 1, Ctr Rech Cancerol Lyon, INSERM, CNRS,UMR5286,U1052, F-69365 Lyon, France; [Giusiano, S.; Charpin, C.] Univ Aix Marseille 2, Marseille, France; [Giusiano, S.; Charpin, C.] Univ Aix Marseille 2, INSERM, UMR 624, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Filhol, O (corresponding author), CEA, INSERM, DSV, iRTSV,U1036, 17 Rue Martyrs, F-38054 Grenoble, France.	odile.filhol-cochet@cea.fr	VANDENBROUCK, Yves/Q-2675-2017; Couté, Yohann/G-2695-2015; Ciais, Delphine/O-9435-2016; Filhol-Cochet, Odile/I-3962-2016	VANDENBROUCK, Yves/0000-0002-1292-373X; Couté, Yohann/0000-0003-3896-6196; Ciais, Delphine/0000-0002-1649-897X; Filhol, Odile/0000-0003-1964-7958; Cochet, Claude/0000-0002-1772-4270; GIUSIANO, sophie/0000-0003-3490-5556; Combes, Florence/0000-0001-7384-4587	INSERM; CEA; Ligue Nationale contre le Cancer; UJF; French National Research Agency [PCV-08 CoCCINet]; ARC	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CEA(French Atomic Energy Commission); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); UJF; French National Research Agency(French National Research Agency (ANR)); ARC(Australian Research Council)	This research was supported by recurrent institutional funding from INSERM, CEA, Ligue Nationale contre le Cancer (accredited team 2010-2012), UJF, and grants from the French National Research Agency (PCV-08 CoCCINet), ARC. We thank L Larue and BP Zhou for promoter reporter constructs, AG de Herreros for Snail1 antibody, M Thery and S Ansieau for critical reading of the manuscript.	Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Bek S, 2002, J CELL SCI, V115, P4743, DOI 10.1242/jcs.00154; Bibby AC, 2005, INT J BIOL SCI, V1, P67; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Buchou T, 2003, MOL CELL BIOL, V23, P908, DOI 10.1128/MCB.23.3.908-915.2003; Bussard KM, 2010, CANCER RES, V70, P6336, DOI 10.1158/0008-5472.CAN-10-0591; Canton DA, 2006, CELL SIGNAL, V18, P267, DOI 10.1016/j.cellsig.2005.07.008; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Charpin C, 2009, INT J CANCER, V124, P2124, DOI 10.1002/ijc.24177; COCHET C, 1983, J BIOL CHEM, V258, P1403; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Deshiere A, 2011, MOL CELL BIOCHEM, V316, P107; Deshiere A, 2008, MOL CELL BIOCHEM, V316, P107, DOI 10.1007/s11010-008-9845-y; Filhol O, 2003, MOL CELL BIOL, V23, P975, DOI 10.1128/MCB.23.3.975-987.2003; Filhol O, 2009, CELL MOL LIFE SCI, V66, P1830, DOI 10.1007/s00018-009-9151-1; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Giusiano S, 2011, EUR J CANCER, V47, P792, DOI 10.1016/j.ejca.2010.11.028; Gort EH, 2008, CURR MOL MED, V8, P60; Gyenis L, 2008, MOL CELL BIOCHEM, V316, P5, DOI 10.1007/s11010-008-9830-5; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hill RP, 2009, SEMIN RADIAT ONCOL, V19, P106, DOI 10.1016/j.semradonc.2008.12.002; Huillard E, 2010, MOL CELL BIOL, V30, P2737, DOI 10.1128/MCB.01566-09; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Laramas M, 2007, EUR J CANCER, V43, P928, DOI 10.1016/j.ejca.2006.11.021; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mottet D, 2005, INT J CANCER, V117, P764, DOI 10.1002/ijc.21268; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pluemsampant S, 2008, INT J CANCER, V122, P333, DOI 10.1002/ijc.23094; Poletto G, 2008, BIOCHEMISTRY-US, V47, P8317, DOI 10.1021/bi800216d; MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Rozanov DV, 2008, CANCER RES, V68, P4086, DOI 10.1158/0008-5472.CAN-07-6458; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2003, CURR OPIN GENET DEV, V13, P365, DOI 10.1016/S0959-437X(03)00088-1; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Wu H, 2009, J CELL BIOCHEM, V108, P52, DOI 10.1002/jcb.22260; Xu Y, 2010, ONCOGENE, V29, P3124, DOI 10.1038/onc.2010.77; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	54	58	61	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1373	1383		10.1038/onc.2012.165	http://dx.doi.org/10.1038/onc.2012.165			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22562247				2022-12-28	WOS:000316455600004
J	Barger, JF; Gallo, CA; Tandon, P; Liu, H; Sullivan, A; Grimes, HL; Plas, DR				Barger, J. F.; Gallo, C. A.; Tandon, P.; Liu, H.; Sullivan, A.; Grimes, H. L.; Plas, D. R.			S6K1 determines the metabolic requirements for BCR-ABL survival	ONCOGENE			English	Article						S6K1; glycolysis; fatty-acid oxidation; rapamycin; leukemia; Cpt1c	CHRONIC MYELOID-LEUKEMIA; FACTOR-INDEPENDENT SURVIVAL; GLUCOSE-METABOLISM; CELL-GROWTH; IMATINIB RESISTANCE; POSITIVE CELLS; RAG GTPASES; ACTIVATION; AKT; INHIBITION	In chronic myelogenous leukemia, the constitutive activation of the BCR-ABL kinase transforms cells to an addicted state that requires glucose metabolism for survival. We investigated S6K1, a protein kinase that drives glycolysis in leukemia cells, as a target for counteracting glucose-dependent survival induced by BCR-ABL. BCR-ABL potently activated S6K1-dependent signaling and glycolysis. Although S6K1 knockdown or rapamycin treatment suppressed glycolysis in BCR-ABL-transformed cells, these treatments did not induce cell death. Instead, loss of S6K1 triggered compensatory activation of fatty-acid oxidation, a metabolic program that can support glucose-independent cell survival. Fatty-acid oxidation in response to S6K1 inactivation required the expression of the fatty-acid transporter carnitine palmitoyl transferase 1c, which was recently linked to rapamycin resistance in cancer. Finally, addition of an inhibitor of fatty-acid oxidation significantly enhanced cytotoxicity in response to S6K1 inactivation. These data indicate that S6K1 dictates the metabolic requirements mediating BCR-ABL survival and provide a rationale for combining targeted inhibitors of signal transduction, with strategies to interrupt oncogene-induced metabolism. Oncogene (2013) 32, 453-461; doi:10.1038/onc.2012.70; published online 5 March 2012	[Barger, J. F.; Gallo, C. A.; Tandon, P.; Liu, H.; Sullivan, A.; Plas, D. R.] Univ Cincinnati, Dept Canc & Cell Biol, Cincinnati, OH 45208 USA; [Grimes, H. L.] Cincinnati Childrens Hosp, Div Immunobiol, Cincinnati, OH USA; [Grimes, H. L.] Cincinnati Childrens Hosp, Div Expt Hematol, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Plas, DR (corresponding author), Univ Cincinnati, Dept Canc & Cell Biol, 3125 Eden Ave, Cincinnati, OH 45208 USA.	plasd@uc.edu	Barger, Jennifer/N-1263-2015	Grimes, H. Leighton/0000-0001-8162-6758	IGERT [0333377]; NIH [CA133164]; American Cancer Society [RSG-08-293-01-CCG]; University of Cincinnati; NATIONAL CANCER INSTITUTE [T32CA117846, R01CA133164] Funding Source: NIH RePORTER	IGERT(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); University of Cincinnati; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs George Thomas and Sara Kozma for their advice and access to S6K1 knockout mice. We thank Dr Shane Horman, Jim Phelan and Meghan Brundage for their help with CML models in mice, and Drs Czyzyk-Krzeska and Godar for critique of the manuscript. JFB was supported by an IGERT fellowship #0333377. This work was supported by NIH Grant CA133164, the American Cancer Society RSG-08-293-01-CCG and the University of Cincinnati's Millennium Scholars program.	Barnes K, 2005, ONCOGENE, V24, P3257, DOI 10.1038/sj.onc.1208461; Bonnefont Jean-Paul, 2004, Molecular Aspects of Medicine, V25, P495, DOI 10.1016/j.mam.2004.06.004; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Burchert A, 2005, LEUKEMIA, V19, P1774, DOI 10.1038/sj.leu.2403898; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Chalhoub N, 2006, BRAIN RES, V1100, P32, DOI 10.1016/j.brainres.2006.05.013; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Djouadi F, 2003, MOL GENET METAB, V78, P112, DOI 10.1016/S1096-7192(03)00017-9; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Eaton S, 1996, BIOCH J 2, V320, P345; Gottschalk S, 2004, CLIN CANCER RES, V10, P6661, DOI 10.1158/1078-0432.CCR-04-0039; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Kharas MG, 2008, J CLIN INVEST, V118, P3038, DOI 10.1172/JCI33337; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Klawitter J, 2009, BRIT J PHARMACOL, V158, P588, DOI 10.1111/j.1476-5381.2009.00345.x; Kominsky DJ, 2009, CLIN CANCER RES, V15, P3442, DOI 10.1158/1078-0432.CCR-08-3291; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Markova B, 2010, ONCOGENE, V29, P739, DOI 10.1038/onc.2009.374; Mason EF, 2010, CANCER RES, V70, P8066, DOI 10.1158/0008-5472.CAN-10-0608; McCubrey JA, 2008, LEUKEMIA, V22, P708, DOI 10.1038/leu.2008.27; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Nardella C, 2011, CANCER RES, V71, P3669, DOI 10.1158/0008-5472.CAN-10-3962; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Plas DR, 2009, CURR OPIN CELL BIOL, V21, P230, DOI 10.1016/j.ceb.2008.12.013; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Sengupta S, 2010, NATURE, V468, P1100, DOI 10.1038/nature09584; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Tandon P, 2011, P NATL ACAD SCI USA, V108, P2361, DOI 10.1073/pnas.1013629108; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; Vander Heiden MG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001210; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Zaugg K, 2011, GENE DEV, V25, P1041, DOI 10.1101/gad.1987211	50	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					453	461		10.1038/onc.2012.70	http://dx.doi.org/10.1038/onc.2012.70			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391570	Green Accepted			2022-12-28	WOS:000315551300006
J	Kesanakurti, D; Chetty, C; Dinh, DH; Gujrati, M; Rao, JS				Kesanakurti, D.; Chetty, C.; Dinh, D. H.; Gujrati, M.; Rao, J. S.			Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with alpha 5 beta 1 integrin in glioma	ONCOGENE			English	Article						MMP-2; alpha 5 beta 1; glioma; IL-6; STAT3; CyclinD1	BREAST-CARCINOMA CELLS; MATRIX METALLOPROTEINASE-2; CANCER CELLS; ALPHA(5)BETA(1) INTEGRIN; STAT3 ACTIVATION; TUMOR INVASION; KAPPA-B; EXPRESSION; GROWTH; APOPTOSIS	Matrix metalloproteinase-2 (MMP-2) has pivotal role in the degradation of extracellular matrix, and thereby enhances the invasive, proliferative and metastatic potential in cancer. Knockdown of MMP-2 using MMP-2 small interfering RNA (pM) in human glioma xenograft cell lines 4910 and 5310 decreased cell proliferation compared with mock and pSV (scrambled vector) treatments, as determined by 5-bromo-2'-deoxyuridine incorporation, Ki-67 staining and clonogenic survival assay. Cytokine array and western blotting using tumor-conditioned media displayed modulated secretory levels of various cytokines including granulocyte-macrophage colony-stimulating factor, interleukin-6 (IL-6), IL-8, IL-10, tumor necrosis factor-alpha, angiogenin, vascular endothelial growth factor and PDGF-BB in MMP-2 knockdown cells. Further, cDNA PCR array indicated potential negative regulation of Janus kinase/Stat3 pathway in pM-treated cells. Mechanistically, MMP-2 is involved in complex formation with alpha 5 and beta 1 integrins and MMP-2 downregulation inhibited alpha 5 beta 1 integrin-mediated Stat3 phosphorylation and nuclear translocation. Electrophoretic mobility shift assay and chromatin immunoprecipitation assays showed inhibited Stat3 DNA-binding activity and recruitment at CyclinD1 and c-Myc promoters in pM-treated cells. In individual experiments, IL-6 or siRNA-insensitive MMP-2 overexpression by pM-FL-A141G counteracted and restored the pM-inhibited Stat3 DNA-binding activity, suggesting IL-6/Stat3 signaling suppression in pM-treated 4910 and 5310 cells. MMP-2/alpha 5 beta 1 binding is enhanced in human recombinant MMP-2 treatments, resulting in elevated Stat3 DNA-binding activity and recruitment on CyclinD1 and c-Myc promoters. Activation of alpha 5 beta 1 signaling by Fibronectin adhesion elevated pM-inhibited Stat3 phosphorylation whereas blocking alpha 5 beta 1 abrogated constitutive Stat3 activation. In vivo experiments with orthotropic tumor model revealed the decreased tumor size in pM treatment compared with mock or pSV treatments. Innmunofluorescence studies in tumor sections corroborated our in vitro findings evidencing high expression and co-localization of MMP-2/alpha 5 beta 1, which is decreased upon pM treatment along with significantly reduced IL-6, phospho-Stat3, CyclinD1, c-Myc, Ki-67 and PCNA expression levels. Our data indicate the possible role of MMP-2/alpha 5 beta 1 interaction in the regulation of alpha 5 beta 1-mediated IL-6/Stat3 signaling activation and signifies the therapeutic potential of blocking MMP-2/alpha 5 beta 1 interaction in glioma treatment. Oncogene (2013) 32, 327-340; doi:10.1038/onc.2012.52; published online 20 February 2012	[Kesanakurti, D.; Chetty, C.; Rao, J. S.] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Dinh, D. H.; Rao, J. S.] Univ Illinois, Coll Med Peoria, Dept Neurosurg, Peoria, IL 61605 USA; [Gujrati, M.] Univ Illinois, Coll Med Peoria, Dept Pathol, Peoria, IL 61605 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, 1 Illini Dr, Peoria, IL 61605 USA.	jsrao@uic.edu			National Institute of Neurological Disorders and Stroke [NS64535-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064535] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Shellee Abraham for manuscript preparation and Diana Meister and Sushma Jasti for manuscript review. This research was supported by award NS64535-01A2 (to JSR) from the National Institute of Neurological Disorders and Stroke.	Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026; Badiga AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020614; Bhaskar V, 2008, INVEST NEW DRUG, V26, P7, DOI 10.1007/s10637-007-9078-z; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chetty C, 2006, MOL CANCER THER, V5, P2289, DOI 10.1158/1535-7163.MCT-06-0169; Chetty C, 2010, INT J CANCER, V127, P1081, DOI 10.1002/ijc.25134; Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Farber K, 2008, MOL CELL NEUROSCI, V39, P579, DOI 10.1016/j.mcn.2008.08.005; Galatioto J, 2010, J CELL SCI, V123, P3789, DOI 10.1242/jcs.073387; Ganji PCN, 2011, MOL CANCER RES, V9, P51, DOI 10.1158/1541-7786.MCR-10-0399; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Han X., 2010, EUR J CLIN MED ONCOL, V2, P59; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Hsu CP, 2011, EUR J CLIN INVEST, V41, P277, DOI 10.1111/j.1365-2362.2010.02405.x; Huang C, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-51; Isaji T, 2009, J BIOL CHEM, V284, P12207, DOI 10.1074/jbc.M807920200; Kesanakurti D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019341; Kesanakurti D, 2009, BIOCHEM BIOPH RES CO, V390, P427, DOI 10.1016/j.bbrc.2009.09.046; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535-7163.MCT-06-0100; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008-5472.CAN-03-3853; Lee BH, 2005, J CELL BIOCHEM, V95, P1214, DOI 10.1002/jcb.20488; Levkau B, 2002, CELL DEATH DIFFER, V9, P1360, DOI 10.1038/sj.cdd.4401106; Levy DE, 2006, P NATL ACAD SCI USA, V103, P10151, DOI 10.1073/pnas.0604042103; Li RH, 2010, ONCOL REP, V23, P1553, DOI 10.3892/or_00000795; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Maglott A, 2006, CANCER RES, V66, P6002, DOI 10.1158/0008-5472.CAN-05-4105; Martinkova E, 2010, INT J CANCER, V127, P1240, DOI 10.1002/ijc.25187; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Melet A, 2008, ADV EXP MED BIOL, V615, P47, DOI 10.1007/978-1-4020-6554-5_4; Mino K, 2011, CANCER SCI, V102, P1052, DOI 10.1111/j.1349-7006.2011.01901.x; Mitra Aparna, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P167, DOI 10.1615/JEnvPathToxOncol.v22.i3.20; Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200; Morozevich GE, 2008, BIOCHEMISTRY-MOSCOW+, V73, P791, DOI 10.1134/S0006297908070079; Morozevich G, 2009, CELL CYCLE, V8, P2219, DOI 10.4161/cc.8.14.8980; Ogier C, 2006, GLIA, V54, P272, DOI 10.1002/glia.20349; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Rojas A, 2011, ONCOGENE, V30, P2345, DOI 10.1038/onc.2010.605; Salgado R, 2003, INT J CANCER, V103, P642, DOI 10.1002/ijc.10833; Senft C, 2011, J NEURO-ONCOL, V101, P393, DOI 10.1007/s11060-010-0273-y; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; Song LX, 2011, MOL CANCER THER, V10, P481, DOI 10.1158/1535-7163.MCT-10-0502; Wang H, 2009, STEM CELLS, V27, P2393, DOI 10.1002/stem.188; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971; Zhang XY, 2009, ANTICANCER RES, V29, P4497	59	83	88	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					327	340		10.1038/onc.2012.52	http://dx.doi.org/10.1038/onc.2012.52			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22349830	Green Accepted			2022-12-28	WOS:000314736600007
J	Guo, J; Kim, D; Gao, J; Kurtyka, C; Chen, H; Yu, C; Wu, D; Mittal, A; Beg, AA; Chellappan, SP; Haura, EB; Cheng, JQ				Guo, J.; Kim, D.; Gao, J.; Kurtyka, C.; Chen, H.; Yu, C.; Wu, D.; Mittal, A.; Beg, A. A.; Chellappan, S. P.; Haura, E. B.; Cheng, J. Q.			IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer	ONCOGENE			English	Article						IKBKE; STAT3; tobacco carcinogen; chemosensitivity; lung cancer	B KINASE-EPSILON; PULMONARY NEUROENDOCRINE CELLS; TUMOR-SUPPRESSOR CYLD; IKK-EPSILON; BREAST-CANCER; NICOTINIC RECEPTOR; EPITHELIAL-CELLS; GENE-EXPRESSION; SRC ONCOPROTEIN; IN-VIVO	Serine/threonine kinase IKBKE is a newly identified oncogene; however, its regulation remains elusive. Here, we provide evidence that IKBKE is a downstream target of signal transducer and activator of transcription 3 (STAT3) and that tobacco components induce IKBKE expression through STAT3. Ectopic expression of constitutively active STAT3 increased IKBKE mRNA and protein levels, whereas inhibition of STAT3 reduced IKBKE expression. Furthermore, expression levels of IKBKE are significantly associated with STAT3 activation and tobacco use history in non-small cell lung cancer (NSCLC) patients examined. In addition, we show induction of IKBKE by two components of cigarette smoke, nicotine and nicotine-derived nitrosamine ketone (NNK). Upon exposure to nicotine or NNK, cells express high levels of IKBKE protein and mRNA, which are largely abrogated by inhibition of STAT3. Characterization of the IKBKE promoter revealed two STAT3-response elements. The IKBKE promoter directly bound to STAT3 and responded to nicotine and NNK stimulation. Notably, enforcing expression of IKBKE induces chemoresistance, whereas knockdown of IKBKE not only sensitizes NSCLC cells to chemotherapy but also abrogates STAT3- and nicotine-induced cell survival. These data indicate for the first time that IKBKE is a direct target of STAT3 and is induced by tobacco carcinogens through STAT3 pathway. In addition, our study also suggests that IKBKE is an important therapeutic target and could have a pivotal role in tobacco-associated lung carcinogenesis. Oncogene (2013) 32, 151-159; doi:10.1038/onc.2012.39; published online 13 February 2012	[Guo, J.; Kim, D.; Gao, J.; Kurtyka, C.; Chen, H.; Yu, C.; Wu, D.; Mittal, A.; Cheng, J. Q.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Mol Oncol, Tampa, FL 33682 USA; [Beg, A. A.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Immunol, Tampa, FL 33682 USA; [Chellappan, S. P.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Tumor Biol, Tampa, FL 33682 USA; [Haura, E. B.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Thorac Oncol, Tampa, FL 33682 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Cheng, JQ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr,SRB3, Tampa, FL 33612 USA.	jin.cheng@moffitt.org	Chen, Huihua/D-9162-2019	Chen, Huihua/0000-0002-5045-6845; Wu, Danwei/0000-0003-3411-0382	NCI [CA137041, P50 CA119997]; James and Esther King Biomedical Research Program [1KG02, 1KD04, 1KN08]; NATIONAL CANCER INSTITUTE [R01CA137041, R01CA160455, P50CA119997, P30CA076292] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); James and Esther King Biomedical Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Tissue Procurement, DNA Sequence and Image Core Facilities at H Lee Moffitt Cancer Center for providing cancer specimens, sequencing and cell apoptosis analysis as well as Fumi Kinose for helping provide lung cancer cell lines from the Moffitt lung cancer cell line core. This work was supported by NCI Grants CA137041 (JQC) and P50 CA119997 (EBH) and James and Esther King Biomedical Research Program 1KG02 (JQC), 1KD04 (JG) and 1KN08 (DK).	Adli M, 2006, J BIOL CHEM, V281, P26976, DOI 10.1074/jbc.M603133200; Arredondo J, 2006, FASEB J, V20, P2093, DOI 10.1096/fj.06-6191com; Barre B, 2005, J BIOL CHEM, V280, P15673, DOI 10.1074/jbc.M413203200; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Chang KT, 2005, AM J PHYSIOL-LUNG C, V289, pL446, DOI 10.1152/ajplung.00089.2005; Chen RJ, 2008, TOXICOL SCI, V104, P283, DOI 10.1093/toxsci/kfn086; Chen RJ, 2010, TOXICOL SCI, V115, P118, DOI 10.1093/toxsci/kfq028; Cheng AN, 2011, AM J CLIN PATHOL, V136, P60, DOI 10.1309/AJCP2JJGYNIUAS2V; Dasgupta P, 2006, CELL CYCLE, V5, P2324, DOI 10.4161/cc.5.20.3366; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fan J, 2007, EJSO-EUR J SURG ONC, V33, P639, DOI 10.1016/j.ejso.2007.02.001; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Guo JP, 2011, J BIOL CHEM, V286, P37389, DOI 10.1074/jbc.M111.287433; Guo JP, 2010, J BIOL CHEM, V285, P3676, DOI 10.1074/jbc.M109.078212; Guo JP, 2009, AM J PATHOL, V175, P324, DOI 10.2353/ajpath.2009.080767; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Hosur V, 2011, MOL PHARMACOL, V79, P167, DOI 10.1124/mol.110.066381; Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Keen JC, 2006, IMMUNOLOGY, V117, P29, DOI 10.1111/j.1365-2567.2005.02260.x; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Liu XD, 2007, BIOCHEM BIOPH RES CO, V353, P121, DOI 10.1016/j.bbrc.2006.11.147; Liu Y, 2010, ANTI-CANCER AGENT ME, V10, P512, DOI 10.2174/187152010793498636; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; Memmott RM, 2010, CLIN CANCER RES, V16, P4, DOI 10.1158/1078-0432.CCR-09-0234; Nadiminty N, 2006, P NATL ACAD SCI USA, V103, P7264, DOI 10.1073/pnas.0509808103; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Tenoever BR, 2007, SCIENCE, V315, P1274, DOI 10.1126/science.1136567; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Wang NZ, 2005, GENE, V353, P118, DOI 10.1016/j.gene.2005.04.013; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Xie XD, 2011, P NATL ACAD SCI USA, V108, P6474, DOI 10.1073/pnas.1016132108; Yoshida H, 2005, J BIOL CHEM, V280, P41111, DOI 10.1074/jbc.M509526200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	50	57	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2013	32	2					151	159		10.1038/onc.2012.39	http://dx.doi.org/10.1038/onc.2012.39			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22330135	Green Accepted			2022-12-28	WOS:000314075500003
J	Zhang, S; Chen, H; Zhao, X; Cao, J; Tong, J; Lu, J; Wu, W; Shen, H; Wei, Q; Lu, D				Zhang, S.; Chen, H.; Zhao, X.; Cao, J.; Tong, J.; Lu, J.; Wu, W.; Shen, H.; Wei, Q.; Lu, D.			REV3L 3 ' UTR 460 T > C polymorphism in microRNA target sites contributes to lung cancer susceptibility	ONCOGENE			English	Article						genetic polymorphism; REV3L; lung cancer; microRNA	DNA-POLYMERASE-ZETA; CATALYTIC SUBUNIT; GENETIC-VARIANTS; BINDING-SITE; RISK; DISRUPTION; CHINESE; LEADS	REV3Lp, the catalytic subunit of DNA polymerase zeta, is the major participant in translesion DNA synthesis. Recent evidence suggests that REV3L has an important role in the maintenance of genome stability despite its mutagenic characteristics. Such a function makes it a cancer susceptibility candidate gene. To investigate association between REV3L polymorphisms and lung cancer risk in a Chinese population, we first genotyped 15 common polymorphisms of the REV3L gene and found that three single nucleotide polymorphisms (rs465646, rs459809 and rs1002481) were significantly associated with lung cancer risk. One of the strongest associations observed was for the 3'-terminal untranslated region (3'UTR) 460 T>C polymorphism (rs465646) (adjusted odds ratio (OR) = 0.69 for TC/CC; P = 0.007, compared with TT). Similar results were obtained in a subsequent replication study (adjusted OR = 0.72; P = 0.016). Combined data from the two studies of 1072 lung cancer patients and 1064 cancer-free controls generated an even stronger association (adjusted OR = 0.71; P = 3.04 x 10(-4)). This 3'UTR 460 T>C variant was predicted to modulate the binding of several micro RNAs. Surface plasmon resonance analysis and luciferase assays showed that the T allele demonstrated a stronger binding affinity for miR-25 and miR-32, resulting in significantly weaker reporter expression levels. Additional experiments revealed that miR-25/32 could downregulate endogenous REV3L. Furthermore, the tumor-suppressing role of REV3L was confirmed by the foci formation assay. These results support our hypothesis that the REV3L rs465646 variant modifies lung cancer susceptibility in Chinese Han population by affecting miRNA-mediated gene regulation. Oncogene (2013) 32, 242-250; doi:10.1038/onc.2012.32; published online 20 February 2012	[Zhang, S.; Chen, H.; Zhao, X.; Lu, J.; Wu, W.; Lu, D.] Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Zhang, S.; Chen, H.; Zhao, X.; Lu, J.; Wu, W.; Lu, D.] Fudan Univ, Sch Life Sci, Inst Genet, MOE Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China; [Zhang, S.; Cao, J.; Tong, J.] Soochow Univ, Coll Med, Sch Radiat Med & Protect, Suzhou, Peoples R China; [Shen, H.] Nanjing Med Univ, Ctr Canc, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China; [Wei, Q.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Fudan University; Fudan University; Soochow University - China; Nanjing Medical University; University of Texas System; UTMD Anderson Cancer Center	Lu, D (corresponding author), Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, 220 Handan Rd, Shanghai 200433, Peoples R China.	drlu@fudan.edu.cn	wu, wenting/Q-4979-2016	wu, wenting/0000-0003-0982-771X	Shanghai Science and Technology Research Program [09JC1402200, 10410709100]; Natural Science Foundation of China [30800622, 81001114, 81020108028]; Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry); Ministry of Education of China; Shanghai Key Subject Project for Public Health [08GWZX0301]	Shanghai Science and Technology Research Program; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry)(Scientific Research Foundation for the Returned Overseas Chinese Scholars); Ministry of Education of China(Ministry of Education, China); Shanghai Key Subject Project for Public Health	This work was partially supported by the Shanghai Science and Technology Research Program (Grants 09JC1402200 and 10410709100), the Natural Science Foundation of China (Grants 30800622, 81001114 and 81020108028), the Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry), the Doctoral Fund of the Ministry of Education of China and the Shanghai Key Subject Project for Public Health (Grant 08GWZX0301).	Bemark M, 2000, CURR BIOL, V10, P1213, DOI 10.1016/S0960-9822(00)00724-7; Brondello JM, 2008, ONCOGENE, V27, P6093, DOI 10.1038/onc.2008.212; Chen D, 2008, CARCINOGENESIS, V29, P342, DOI 10.1093/carcin/bgm285; Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Esposito G, 2000, CURR BIOL, V10, P1221, DOI 10.1016/S0960-9822(00)00726-0; Friedberg EC, 2005, MOL CELL, V18, P499, DOI 10.1016/j.molcel.2005.03.032; Gan GN, 2008, CELL RES, V18, P174, DOI 10.1038/cr.2007.117; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Hoeijmakers JHJ, 2007, MECH AGEING DEV, V128, P460, DOI 10.1016/j.mad.2007.05.002; Hu ZB, 2007, HUM MUTAT, V28, P431, DOI 10.1002/humu.20462; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kajiwara K, 1996, BIOCHEM BIOPH RES CO, V219, P795, DOI 10.1006/bbrc.1996.0313; Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003; Krieg AJ, 2006, MOL CELL BIOL, V26, P7030, DOI 10.1128/MCB.00322-06; Lawrence CW, 2001, PHILOS T R SOC B, V356, P41, DOI 10.1098/rstb.2000.0001; Lehmann AR, 2005, FEBS LETT, V579, P873, DOI 10.1016/j.febslet.2004.11.029; LEMONTT JF, 1972, MOL GEN GENET, V119, P27, DOI 10.1007/BF00270441; Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2; Lu J, 2009, FASEB J, V23, P3459, DOI 10.1096/fj.09-136549; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104; Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541; Nojima K, 2005, CANCER RES, V65, P11704, DOI 10.1158/0008-5472.CAN-05-1214; Pan QR, 2005, CANCER LETT, V217, P139, DOI 10.1016/j.canlet.2004.07.021; Rockwell S, 2001, Novartis Found Symp, V240, P133; Rockwell S, 2001, NOVART FDN SYMP, V240, P142; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Sonoda E, 2003, EMBO J, V22, P3188, DOI 10.1093/emboj/cdg308; Vatolin S, 2006, J MOL BIOL, V358, P983, DOI 10.1016/j.jmb.2006.02.063; Venkatesan RN, 2006, DNA REPAIR, V5, P294, DOI 10.1016/j.dnarep.2005.10.012; Wang G, 2008, AM J HUM GENET, V82, P283, DOI 10.1016/j.ajhg.2007.09.021; Wang HB, 2009, NEURO-ONCOLOGY, V11, P790, DOI 10.1215/15228517-2009-015; Wang QZ, 2009, CURR CANCER DRUG TAR, V9, P572, DOI 10.2174/156800909788486731; Wittschieben JP, 2006, CANCER RES, V66, P134, DOI 10.1158/0008-5472.CAN-05-2982; Yu ZB, 2007, NUCLEIC ACIDS RES, V35, P4535, DOI 10.1093/nar/gkm480; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhu F, 2003, WORLD J GASTROENTERO, V9, P888	40	44	48	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					242	250		10.1038/onc.2012.32	http://dx.doi.org/10.1038/onc.2012.32			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349819				2022-12-28	WOS:000314075500012
J	Maruani, DM; Spiegel, TN; Harris, EN; Shachter, AS; Unger, HA; Herrero-Gonzalez, S; Holz, MK				Maruani, D. M.; Spiegel, T. N.; Harris, E. N.; Shachter, A. S.; Unger, H. A.; Herrero-Gonzalez, S.; Holz, M. K.			Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation	ONCOGENE			English	Article						S6K1; mTOR; estrogen; rapamycin; breast cancer	RECEPTOR-ALPHA BINDING; 17Q23 AMPLICON; COPY NUMBER; KINASE; PROTEIN; ACTIVATION; REVEALS; TARGET; GENES; SITES	The 40S ribosomal S6 kinase 1 (S6K1) is an important regulator of cell growth. Expression of S6K1 is often elevated in breast cancer cells. However, the transcriptional mechanism of S6K1 overexpression is not understood. In this report, we demonstrate that estrogen activates expression of S6K1 via estrogen receptor (ER) a in ER-positive breast cancer cells. We also show that estrogen acts on the proximal promoter of the S6K1 gene in a mechanism involving the transcriptional factor GATA-3. Finally, we provide data that support the importance of estrogenic regulation of S6K1 expression in breast cancer cell proliferation. S6K1 directly phosphorylates and regulates ligand-independent activity of ER alpha, while ERa upregulates S6K1 expression. This S6K1-ER alpha relationship creates a positive feed-forward loop in control of breast cancer cell proliferation. Furthermore, the co-dependent association between S6K1 and ER alpha may be exploited in the development of targeted breast cancer therapies. Oncogene (2012) 31, 5073-5080; doi:10.1038/onc.2011.657; published online 30 January 2012	[Maruani, D. M.; Spiegel, T. N.; Harris, E. N.; Shachter, A. S.; Unger, H. A.; Holz, M. K.] Yeshiva Univ, Stern Coll Women, Dept Biol, New York, NY 10016 USA; [Herrero-Gonzalez, S.] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10467 USA; [Holz, M. K.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA	Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Holz, MK (corresponding author), Yeshiva Univ, Stern Coll Women, Dept Biol, 245 Lexington Ave, New York, NY 10016 USA.	mholz@yu.edu		Spiegel Strauss, Tirtza/0000-0002-3485-0850	NIH [CA151112]; Atol Charitable Trust; Wendy Will Case Cancer Fund; Yeshiva University; S Daniel Abraham Honors Program of Yeshiva University; NATIONAL CANCER INSTITUTE [R15CA151112] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Atol Charitable Trust; Wendy Will Case Cancer Fund; Yeshiva University; S Daniel Abraham Honors Program of Yeshiva University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank W Lee Kraus for expression constructs and Jonathan Backer for help with kinase assays. We are especially grateful to Matthew Gamble and members of his laboratory for assistance and guidance with ChIP assays. We also like to acknowledge Antonio Di Cristofano for scientific generosity and help with animal experiments. We also thank Fannie F Seligman, Faygel Beren and Miriam Ciner for technical assistance. This work was founded by grants to MKH from NIH (CA151112), Atol Charitable Trust, Wendy Will Case Cancer Fund and Yeshiva University. TNS, ENH, ASS and HAU received support from the S Daniel Abraham Honors Program of Yeshiva University.	[Anonymous], 1992, Lancet, V339, P1; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373; Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Couch FJ, 1999, CANCER RES, V59, P1408; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ellis M, 2004, ONCOLOGIST, V9, P20, DOI 10.1634/theoncologist.9-suppl_3-20; Fenton TR, 2011, INT J BIOCHEM CELL B, V43, P47, DOI 10.1016/j.biocel.2010.09.018; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Frizzell KM, 2009, J BIOL CHEM, V284, P33926, DOI 10.1074/jbc.M109.023879; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008; Han W, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-92; Hu XL, 2009, MOL CANCER RES, V7, P511, DOI 10.1158/1541-7786.MCR-08-0107; Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25; Ikeda K, 2004, ARCH HISTOL CYTOL, V67, P435, DOI 10.1679/aohc.67.435; Jiang Shoulei, 2010, Hormones & Cancer, V1, P11, DOI 10.1007/s12672-010-0006-x; Johnston SRD, 2011, BREAST CANCER RES TR, V128, P607, DOI 10.1007/s10549-010-1207-2; Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; van der Hage JA, 2004, BRIT J CANCER, V90, P1543, DOI 10.1038/sj.bjc.6601741; Yamnik RL, 2010, FEBS LETT, V584, P124, DOI 10.1016/j.febslet.2009.11.041; Yamnik RL, 2009, J BIOL CHEM, V284, P6361, DOI 10.1074/jbc.M807532200; Zhang Y, 2009, CANCER RES, V69, P3795, DOI 10.1158/0008-5472.CAN-08-4596	35	48	49	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5073	5080		10.1038/onc.2011.657	http://dx.doi.org/10.1038/onc.2011.657			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22286763	Green Accepted			2022-12-28	WOS:000312000900003
J	Robinson, GL; Dinsdale, D; MacFarlane, M; Cain, K				Robinson, G. L.; Dinsdale, D.; MacFarlane, M.; Cain, K.			Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL	ONCOGENE			English	Article						TRAIL; apoptosis; oxidative phosphorylation; aerobic glycolysis; mitochondria; 2DG	INDUCED APOPTOSIS; RECEPTOR; DEATH; GLUCOSE; INHIBITION; CANCER; RESISTANCE; LIGAND; MCL-1; ATP	TRAIL (TNF (tumour necrosis factor)-related apoptosis-inducing ligand) a putative anti-cancer cytokine induces apoptosis through DISC (death-inducing signalling complex)-mediated activation of caspase-8 and/or cleavage of Bid. TRAIL is relatively specific for tumour cells but primary chronic lymphocytic leukaemia and mantle cell lymphoma (MCL) cells are resistant. Herein, we show that cellular metabolism influences cell death and that MCL cells (Z138 cell line) can survive/proliferate in glucose-free media by switching from aerobic glycolysis to 'coupled' oxidative phosphorylation. Extracellular flux analysis and mitochondrial inhibitors reveal that in the absence of glycolysis, Z138 cells have enhanced respiratory capacity coupled to ATP synthesis, similar to 'classical' state 3 mitochondria. Conversely, 2-deoxyglucose (2DG) blocked glycolysis and partially inhibited glycolytic-dependent oxidative phosphorylation, resulting in a 50% reduction in cellular ATP levels. Also, 2DG sensitised Z138 cells to TRAIL and induced a marked decrease in caspase-8, -3, cFLIP(S), Bid and Mcl-1 expression but Bak remained unchanged, altering the Mcl-1/Bak ratio, facilitating cytochrome c release and cell death. Conversely, under glucose-free conditions, Z138 cells were less sensitive to TRAIL with reduced TRAIL-R1/R2 surface receptor expression and impaired DISC formation. Anti-apoptotic proteins Bcl-2 and XIAP were up-regulated while pro-apoptotic BAX was down-regulated. Additionally, mitochondria had higher levels of cytochrome c and ultrastucturally exhibited a condensed configuration with enhanced intracristal spaces. Thus, metabolic switching was accompanied by mitochondrial proteome and ultrastructural remodelling enabling enhanced respiration activity. Cytochrome c release was decreased in glucose-free cells, suggesting that either pore formation was inhibited or that cytochrome c was more tightly bound. Glucose-free Z138 cells were also resistant to intrinsic cell death stimuli (ABT-737 and ionising radiation). In summary, in MCL cells, the anti-glycolytic effects of 2DG and glucose restriction produced opposite effects on TRAIL-induced cell death, demonstrating that mitochondrial metabolism directly modulates sensitivity of tumour cells to apoptosis. Oncogene (2012) 31, 4996-5006; doi:10.1038/onc.2012.13; published online 6 February 2012	[Robinson, G. L.; Dinsdale, D.; MacFarlane, M.; Cain, K.] Univ Leicester, MRC Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	MacFarlane, M (corresponding author), Univ Leicester, MRC Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mm21@le.ac.uk; kc5@le.ac.uk			UK Medical Research Council; MRC [MC_U132685863] Funding Source: UKRI; Medical Research Council [MC_U132685863] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the UK Medical Research Council.	Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Benard G, 2008, ANTIOXID REDOX SIGN, V10, P1313, DOI 10.1089/ars.2007.2000; Boyd RS, 2009, MOL CELL PROTEOMICS, V8, P1501, DOI 10.1074/mcp.M800515-MCP200; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Capasso M, 2010, NAT IMMUNOL, V11, P265, DOI 10.1038/ni.1843; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; Coloff JL, 2011, CANCER RES, V71, P5204, DOI 10.1158/0008-5472.CAN-10-4531; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dyer MJS, 2007, J CLIN ONCOL, V25, P4505, DOI 10.1200/JCO.2007.13.1011; El Mjiyad N, 2011, ONCOGENE, V30, P253, DOI 10.1038/onc.2010.466; Falschlehner C, 2009, IMMUNOLOGY, V127, P145, DOI 10.1111/j.1365-2567.2009.03058.x; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882; Gillissen B, 2010, J CELL BIOL, V188, P851, DOI 10.1083/jcb.200912070; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; HALICKA HD, 1995, CANCER RES, V55, P444; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Harper N, 2008, METHOD ENZYMOL, V446, P293, DOI 10.1016/S0076-6879(08)01618-2; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hughes MA, 2009, MOL CELL, V35, P265, DOI 10.1016/j.molcel.2009.06.012; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Liu H, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-122; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; Marino K, 2010, NAT CHEM BIOL, V6, P713, DOI [10.1038/nchembio.437, 10.1038/NCHEMBIO.437]; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; PARNIAK M, 1985, CAN J BIOCHEM CELL B, V63, P333, DOI 10.1139/o85-049; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Poukkula M, 2005, J BIOL CHEM, V280, P27345, DOI 10.1074/jbc.M504019200; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Samraj AK, 2006, J BIOL CHEM, V281, P29652, DOI 10.1074/jbc.M603487200; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; THAKKAR NS, 1993, CANCER RES, V53, P2057; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WARBURG O, 1956, SCIENCE, V124, P269; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wood TE, 2008, MOL CANCER THER, V7, P3546, DOI 10.1158/1535-7163.MCT-08-0569; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Yamaguchi R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024102; Zagorodna O, 2012, ONCOGENE, V31, P2738, DOI 10.1038/onc.2011.454; Zamaraeva MV, 2005, CELL DEATH DIFFER, V12, P1390, DOI 10.1038/sj.cdd.4401661	51	66	67	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					4996	5006		10.1038/onc.2012.13	http://dx.doi.org/10.1038/onc.2012.13			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22310286				2022-12-28	WOS:000311888600004
J	Santag, S; Jager, W; Karsten, CB; Kati, S; Pietrek, M; Steinemann, D; Sarek, G; Ojala, PM; Schulz, TF				Santag, S.; Jaeger, W.; Karsten, C. B.; Kati, S.; Pietrek, M.; Steinemann, D.; Sarek, G.; Ojala, P. M.; Schulz, T. F.			Recruitment of the tumour suppressor protein p73 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells	ONCOGENE			English	Article						KSHV; primary effusion lymphoma; LANA; p73; Nutlin-3; RETRA	DNA-SEQUENCES; TRANSCRIPTIONAL ACTIVATION; ENDOTHELIAL-CELLS; ONCOPROTEIN MDM2; GENE-EXPRESSION; P53 PATHWAY; APOPTOSIS; BINDING; VIRUS; INSTABILITY	Kaposi's Sarcoma Herpesvirus (KSHV) is the causative agent of Kaposi's Sarcoma (KS) and two rare lymphoproliferative disorders, primary effusion lymphoma (PEL) and the plasmablastic variant of multicentric Castleman's disease (MCD). The KSHV latency-associated nuclear antigen-1 (LANA), required for the replication and maintenance of latent viral episomal DNA, is involved in the transcriptional regulation of viral and cellular genes and interacts with different cellular proteins, including the tumour suppressor p53. Here, we report that LANA also recruits the p53-related nuclear transcription factor p73, which influences cellular processes like DNA damage response, cell cycle progression and apoptosis. Both the full-length isoform TAp73 alpha, as well as its dominant negative regulator Delta Np73 alpha, interact with LANA. LANA affects TAp73 alpha stability and sub-nuclear localisation, as well as TAp73 alpha-mediated transcriptional activation of target genes. We observed that the small-molecule inhibitor Nutlin-3, which disrupts the interaction of p53 and p73 with MDM2, induces apoptotic cell death in p53 wild-type, as well as p53-mutant PEL cell lines, suggesting a possible involvement of p73. The small-molecule RETRA, which activates p73 in the context of mutant p53, leads to the induction of apoptosis in p53-mutant PEL cell lines. RNAi-mediated knockdown of p73 confirmed that these effects depend on the presence of the p73 protein. Furthermore, both Nutlin-3 and RETRA disrupt the LANA-p73 interaction in different PEL cell lines. These results suggest that LANA modulates p73 function and that the LANA-p73 interaction may represent a therapeutic target to interfere with the survival of latently KSHV-infected cells.	[Santag, S.; Jaeger, W.; Karsten, C. B.; Kati, S.; Pietrek, M.; Schulz, T. F.] Hannover Med Sch, Inst Virol, D-30625 Hannover, Germany; [Steinemann, D.] Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany; [Sarek, G.; Ojala, P. M.] Univ Helsinki, Inst Biotechnol, Helsinki, Finland; [Sarek, G.; Ojala, P. M.] Univ Helsinki, Res Programs Unit, Genome Scale Biol Biomedicum Helsinki, Helsinki, Finland	Hannover Medical School; Hannover Medical School; University of Helsinki; University of Helsinki	Schulz, TF (corresponding author), Hannover Med Sch, Inst Virol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	schulz.thomas@mh-hannover.de	Karsten, Christina B./J-8689-2019; Schulz, Thomas/AAA-1634-2019; Karsten, Christina B./GNH-2673-2022; Ojala, Paivi M/J-3266-2014	Karsten, Christina B./0000-0003-1934-6442; Ojala, Paivi/0000-0001-9065-1832; Schulz, Thomas/0000-0001-8792-5345	DFG IRTG [1273]; EU Integrated Project INCA [LSHC-CT-18730]; collaborative research centre (CRC) 900 of the Deutsche Forschungsgemeinschaft	DFG IRTG(German Research Foundation (DFG)); EU Integrated Project INCA; collaborative research centre (CRC) 900 of the Deutsche Forschungsgemeinschaft	We thank Magdalena Weidner-Glunde for cloning of the GST fusion construct LANA N, as well as Eva Gellermann for cloning the GST fusion constructs C8a and C8b. This work was supported by the DFG IRTG 1273, the EU Integrated Project INCA (LSHC-CT-18730) and the collaborative research centre (CRC) 900 of the Deutsche Forschungsgemeinschaft.	Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Amin ARMR, 2007, CANCER RES, V67, P5617, DOI 10.1158/0008-5472.CAN-07-0655; An FQ, 2005, J BIOL CHEM, V280, P3862, DOI 10.1074/jbc.M407435200; Ben-Yehoyada M, 2003, J BIOL CHEM, V278, P34475, DOI 10.1074/jbc.M301051200; Busuttil V, 2010, P NATL ACAD SCI USA, V107, P18061, DOI 10.1073/pnas.1006163107; Cai QL, 2006, PLOS PATHOG, V2, P1002, DOI 10.1371/journal.ppat.0020116; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen WG, 2010, J VIROL, V84, P3898, DOI 10.1128/JVI.01321-09; D'Amours D, 2001, J CELL SCI, V114, P3771; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Godfrey A, 2005, BLOOD, V105, P2510, DOI 10.1182/blood-2004-08-3052; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Gwack Y, 2001, J VIROL, V75, P6245, DOI 10.1128/JVI.75.13.6245-6248.2001; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; Katano H, 2001, CANCER, V92, P3076, DOI 10.1002/1097-0142(20011215)92:12<3076::AID-CNCR10117>3.0.CO;2-D; Kliche S, 1998, J VIROL, V72, P8143, DOI 10.1128/JVI.72.10.8143-8149.1998; Kravchenko JE, 2008, P NATL ACAD SCI USA, V105, P6302, DOI 10.1073/pnas.0802091105; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Moll UM, 2004, MOL CANCER RES, V2, P371; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Ohsaki E, 2009, VIRUS RES, V139, P74, DOI 10.1016/j.virusres.2008.10.011; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pan HY, 2004, CANCER RES, V64, P4064, DOI 10.1158/0008-5472.CAN-04-0657; Park J, 2000, J VIROL, V74, P11977, DOI 10.1128/JVI.74.24.11977-11982.2000; Park JS, 2001, INT J CANCER, V91, P822, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1130>3.0.CO;2-0; Petre CE, 2007, J VIROL, V81, P1912, DOI 10.1128/JVI.01757-06; Platt GM, 1999, J VIROL, V73, P9789, DOI 10.1128/JVI.73.12.9789-9795.1999; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128/JVI.75.1.458-468.2001; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Rosenbluth JM, 2008, GENE DEV, V22, P2591, DOI 10.1101/gad.1727408; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Santarelli R, 2008, J VIROL, V82, P4562, DOI 10.1128/JVI.02400-07; Sarek G, 2013, ONCOGENE, V32, P1091, DOI 10.1038/onc.2012.118; Sarek G, 2007, J CLIN INVEST, V117, P1019, DOI 10.1172/JCI30945; Seo T, 2001, J VIROL, V75, P6193, DOI 10.1128/JVI.75.13.6193-6198.2001; Si HX, 2006, J VIROL, V80, P697, DOI 10.1128/JVI.80.2.697-709.2006; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Toh WH, 2010, CELL DEATH DIFFER, V17, P787, DOI 10.1038/cdd.2009.181; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Viejo-Borbolla A, 2005, J VIROL, V79, P13618, DOI 10.1128/JVI.79.21.13618-13629.2005; Viejo-Borbolla A, 2003, J VIROL, V77, P7093, DOI 10.1128/JVI.77.12.7093-7100.2003; Wang L, 2008, CANCER RES, V68, P4640, DOI 10.1158/0008-5472.CAN-07-5988; Wies E, 2008, BLOOD, V111, P320, DOI 10.1182/blood-2007-05-092288; Wong LY, 2004, J VIROL, V78, P10074, DOI 10.1128/JVI.78.18.10074-10085.2004; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	55	28	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3676	3685		10.1038/onc.2012.385	http://dx.doi.org/10.1038/onc.2012.385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22964633				2022-12-28	WOS:000322904400003
J	Pelosi, A; Careccia, S; Lulli, V; Romania, P; Marziali, G; Testa, U; Lavorgna, S; Lo-Coco, F; Petti, MC; Calabretta, B; Levrero, M; Piaggio, G; Rizzo, MG				Pelosi, A.; Careccia, S.; Lulli, V.; Romania, P.; Marziali, G.; Testa, U.; Lavorgna, S.; Lo-Coco, F.; Petti, M. C.; Calabretta, B.; Levrero, M.; Piaggio, G.; Rizzo, M. G.			miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia	ONCOGENE			English	Article						acute myeloid leukemia; microRNA; PBX2	ACUTE PROMYELOCYTIC LEUKEMIA; MICRORNA; EXPRESSION; CELLS; ALPHA; RAS; TRANSFORMATION; HEMATOPOIESIS; DELTA-N-P73; PREDICTION	MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression post-transcriptionally, are involved in many complex cellular processes. Several miRNAs are differentially expressed in hematopoietic tissues and play important roles in normal differentiation, but, when aberrantly regulated, contribute to the abnormal proliferation and differentiation of leukemic cells. Recently, we reported that a small subset of miRNAs is differentially expressed in acute promyelocytic leukemia (APL) blasts and is modulated by treatment with all-trans-retinoic acid (ATRA). In particular, PML/RARa-positive blasts from APL patients display lower levels of miRNA let-7c, a member of the let-7 family, than normal promyelocytes and its expression increases after ATRA treatment. In this study, we investigated the effects of let-7c in acute myeloid leukemia (AML) cells. We found that ectopic expression of let-7c promotes granulocytic differentiation of AML cell lines and primary blasts. Moreover, we identified PBX2, a well-known homeodomain protein whose aberrant expression enhances HoxA9-dependent leukemogenesis, as a novel let-7c target that may contribute to the AML phenotype. Together, these studies raise the possibility that perturbation of the let-7c-PBX2 pathway may have a therapeutic value in AML.	[Pelosi, A.; Careccia, S.; Piaggio, G.; Rizzo, M. G.] Regina Elena Inst Canc Res, Dept Expt Oncol, Lab Mol Oncogenesis, I-00158 Rome, Italy; [Lulli, V.; Romania, P.; Marziali, G.; Testa, U.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Lavorgna, S.; Lo-Coco, F.] Univ Roma Tor Vergata, Dept Biopathol, Rome, Italy; [Lavorgna, S.; Lo-Coco, F.] Santa Lucia Fdn, Lab Neurooncohematol, Rome, Italy; [Petti, M. C.] Regina Elena Inst Canc Res, Dept Med Oncol, Div Hematol, Rome, Italy; [Calabretta, B.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Levrero, M.] Univ Roma La Sapienza, Dept Internal Med, I-00185 Rome, Italy; [Levrero, M.] Fdn Andrea Cesalpino, Gene Express Lab, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; IRCCS Santa Lucia; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University; Sapienza University Rome	Rizzo, MG (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via delle Messi dOro 156, I-00158 Rome, Italy.	rizzo@ifo.it	Lulli, Valentina/J-9189-2016; Rizzo, Maria Giulia/B-2107-2018; lavorgna, serena/O-8490-2016; Pelosi, Andrea/J-9690-2018; Piaggio, Giulia/J-7214-2018; Romania, Paolo/K-3839-2018; Careccia, Silvia/K-6475-2016; Piaggio, Giulia/AAD-7336-2022; Marziali, Giovanna/J-9808-2016; Testa, Ugo/J-6472-2016; Levrero, Massimo/G-5680-2016	Lulli, Valentina/0000-0002-2143-4436; Rizzo, Maria Giulia/0000-0002-5009-2412; lavorgna, serena/0000-0001-8812-2325; Pelosi, Andrea/0000-0003-2308-9215; Piaggio, Giulia/0000-0003-2114-1892; Romania, Paolo/0000-0001-6855-1464; Careccia, Silvia/0000-0001-7221-8170; Marziali, Giovanna/0000-0001-7450-1017; Testa, Ugo/0000-0001-7900-8942; Levrero, Massimo/0000-0002-4978-0875	NCI [CA95111]; AIL 'Alberto Landi'; Associazione Italiana Ricerca sul Cancro (AIRC); NATIONAL CANCER INSTITUTE [R01CA095111] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AIL 'Alberto Landi'; Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Alessandro Fatica from 'Sapienza' University in Rome for a kind gift of lentiviral vector pRRLSIN-cPPT-PGK-GFP-WPRE and Dr Gianluca Bossi for kindly providing information on lentiviral utilization; Alessandra Boe for technical assistance for cell sorting and FACS analysis. We also acknowledge Dr Silvia Bacchetti for helpful comments on the manuscript. Associazione Italiana Leucemie (AIL) and Ministry of Health, Ricerca oncologica-Project of integrated program to MGR. G Piaggio was supported, in part, by Associazione Italiana Ricerca sul Cancro (AIRC). B Calabretta was supported, in part, by NCI grant CA95111. A Pelosi and S Careccia are PhD students University of Rome 'Sapienza'. A Pelosi is a recipient of a fellowship from AIRC. S Careccia is a recipient of the fellowship AIL 'Alberto Landi'.	Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Brown G, 2002, EXP CELL RES, V281, P28, DOI 10.1006/excr.2002.5654; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Careccia S, 2009, ONCOGENE, V28, P4034, DOI 10.1038/onc.2009.255; Chan IT, 2006, BLOOD, V108, P1708, DOI 10.1182/blood-2006-04-015040; Chaudhuri AA, 2012, P NATL ACAD SCI USA, V109, P4233, DOI 10.1073/pnas.1200677109; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186; Havelange V, 2010, AM J HEMATOL, V85, P935, DOI 10.1002/ajh.21863; Isken F, 2008, BRIT J HAEMATOL, V140, P153, DOI 10.1111/j.1365-2141.2007.06915.x; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Laurent A, 2008, INT J DEV BIOL, V52, P9, DOI 10.1387/ijdb.072304al; Leucci E, 2008, J PATHOL, V216, P440, DOI 10.1002/path.2410; Li X, 2012, NAT PROD COMMUN, V7, P181; Mainardi S, 2007, CELL DEATH DIFFER, V14, P1968, DOI 10.1038/sj.cdd.4402210; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Mi SL, 2007, P NATL ACAD SCI USA, V104, P19971, DOI 10.1073/pnas.0709313104; Rizzo MG, 2004, LEUKEMIA, V18, P1804, DOI 10.1038/sj.leu.2403483; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang XW, 2008, BIOINFORMATICS, V24, P325, DOI 10.1093/bioinformatics/btm595; Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107	34	49	51	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2013	32	31					3648	3654		10.1038/onc.2012.398	http://dx.doi.org/10.1038/onc.2012.398			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22964640	Green Accepted			2022-12-28	WOS:000322638400009
J	Lok, BH; Carley, AC; Tchang, B; Powell, SN				Lok, B. H.; Carley, A. C.; Tchang, B.; Powell, S. N.			RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination	ONCOGENE			English	Article						BRCA1; PALB2; BRCA2; RAD52; synthetic lethality; RAD51	CANCER SUSCEPTIBILITY GENE; REPLICATION PROTEIN-A; STRAND BREAK REPAIR; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; CELLS; PHOSPHORYLATION; COMPLEX; TUMORS; DAMAGE	Synthetic lethality is an approach to study selective cell killing based on genotype. Previous work in our laboratory has shown that loss of RAD52 is synthetically lethal with BRCA2 deficiency, while exhibiting no impact on cell growth and viability in BRCA2-proficient cells. We now show that this same synthetically lethal relationship is evident in cells with deficiencies in BRCA1 or PALB2, which implicates BRCA1, PALB2 and BRCA2 in an epistatic relationship with one another. When RAD52 was depleted in BRCA1- or PALB2-deficient cells, a severe reduction in plating efficiency was observed, with many abortive attempts at cell division apparent in the double-depleted background. In contrast, when RAD52 was depleted in a BRCA1- or PALB2-wildtype background, a negligible decrease in colony survival was observed. The frequency of ionizing radiation-induced RAD51 foci formation and double-strand break-induced homologous recombination (HR) was decreased by 3- and 10-fold, respectively, when RAD52 was knocked down in BRCA1- or PALB2-depleted cells, with minimal effect in BRCA1- or PALB2-proficient cells. RAD52 function was independent of BRCA1 status, as evidenced by the lack of any defect in RAD52 foci formation in BRCA1-depleted cells. Collectively, these findings suggest that RAD52 is an alternative repair pathway of RAD51-mediated HR, and a target for therapy in cells deficient in the BRCA1-PALB2-BRCA2 repair pathway.	[Lok, B. H.; Carley, A. C.; Tchang, B.; Powell, S. N.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Lok, B. H.] NYU, Langone Med Ctr, Sch Med, Dept Med, New York, NY USA; [Lok, B. H.] NYU, Langone Med Ctr, Sch Med, Dept Radiat Oncol, New York, NY USA; [Tchang, B.] Cornell Univ, Weill Cornell Grad Sch Med Sci, New York, NY USA; [Powell, S. N.] Suny Downstate Med Ctr, Coll Med, New York, NY USA	Memorial Sloan Kettering Cancer Center; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Powell, SN (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1250 1st Ave,Box 33, New York, NY 10065 USA.	Powells@mskcc.org		Lok, Benjamin/0000-0002-3675-8847	Howard Hughes Medical Institute Medical Research Training Fellowship; Radiological Society of North America Research Medical Student Grant; National Cancer Institute; Susan G. Komen for the Cure; NATIONAL CANCER INSTITUTE [R01CA107640, P30CA008748] Funding Source: NIH RePORTER	Howard Hughes Medical Institute Medical Research Training Fellowship(Howard Hughes Medical Institute); Radiological Society of North America Research Medical Student Grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G. Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the Howard Hughes Medical Institute Medical Research Training Fellowship, the Radiological Society of North America Research Medical Student Grant (BHL) and by grants from the National Cancer Institute and the Susan G. Komen for the Cure (SNP).	Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng ZH, 2011, P NATL ACAD SCI USA, V108, P686, DOI 10.1073/pnas.1010959107; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Holloman WK, 2011, NAT STRUCT MOL BIOL, V18, P748, DOI 10.1038/nsmb.2096; Iglehart JD, 2009, NEW ENGL J MED, V361, P189, DOI 10.1056/NEJMe0903044; Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202; Kojic M, 2011, MOL MICROBIOL, V79, P180, DOI 10.1111/j.1365-2958.2010.07440.x; Konstantinopoulos PA, 2010, J CLIN ONCOL, V28, P3555, DOI 10.1200/JCO.2009.27.5719; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Qing Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002148; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shi W, 2008, J BIOL CHEM, V283, P31608, DOI 10.1074/jbc.M801082200; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Singleton MR, 2002, P NATL ACAD SCI USA, V99, P13492, DOI 10.1073/pnas.212449899; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Wang WY, 2010, CLIN CANCER RES, V16, P1016, DOI 10.1158/1078-0432.CCR-09-2796; Willers H, 2009, MOL CANCER RES, V7, P1304, DOI 10.1158/1541-7786.MCR-09-0149; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004	35	134	137	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2013	32	30					3552	3558		10.1038/onc.2012.391	http://dx.doi.org/10.1038/onc.2012.391			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22964643	Green Accepted			2022-12-28	WOS:000322220800008
J	Ling, H; Jolicoeur, P				Ling, H.; Jolicoeur, P.			Notch-1 signaling promotes the cyclinD1-dependent generation of mammary tumor-initiating cells that can revert to bi-potential progenitors from which they arise	ONCOGENE			English	Article						mammary tumors; Notch1; Cyclin D1 addiction; tumor-initiating cells	CANCER STEM-CELLS; BREAST-CANCER; STEM/PROGENITOR CELLS; GLAND DEVELOPMENT; HETEROGENEITY; FATE; IDENTIFICATION; TUMORIGENESIS; POPULATION; PHENOTYPE	In a previous work, we reported that young transgenic (Tg) mice expressing the intracellular domain of Notch1 (N1(IC)) showed expansion of lin(-) CD24(+) CD29(high) mammary cells enriched for stem cells and later developed mammary tumors. Mammary tumor formation was abolished or greatly reduced in cyclin D1(-/-) or cyclin D1(+/-) N1(IC) Tg mice, respectively. Here, we studied the epithelial cell subsets present in N1(IC)-induced tumors. CD24(-) CD29(int) and CD24(+) CD29(high) cells were found to be present at low numbers in tumors. The latter had the same properties as those expanded in young Tg females, and neither cell population showed tumor-initiating potential nor were they required for maintenance of tumors after transplantation. CD24(int) CD29(int) cells were identified as tumor-initiating and mammosphere-forming cells and represent a large percentage tumor cells in this model. Their number was significantly lower in tumors from cyclin D1(+/-) N1(IC) Tg mice. Using cyclin D1 shRNA knockdown, we also show that N1(IC)-induced tumor cells remain addicted to cyclin D1 for growth and survival. Interestingly, at lower levels of cyclin D1 or after transplantation in the presence of normal mammary cells, these N1(IC)-expressing tumor cells reverted to a state of low malignancy and differentiate into duct-like structures. They seem to adopt the fate of bi-potential stem/progenitor cells similar to that of the expanded CD24(+) CD29(high) stem/progenitor cells from which they are likely to be derived. Our data indicate that decreasing cyclin D1 levels would be an efficient treatment for tumors induced by N1 signaling.	[Ling, H.; Jolicoeur, P.] Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; [Jolicoeur, P.] McGill Univ, Div Expt Med, Montreal, PQ, Canada; [Jolicoeur, P.] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	Paul.Jolicoeur@ircm.qc.ca			Canadian Institute of Health Research (CIHR); Canada Research Chair	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	This work was supported by grant to PJ from the Canadian Institute of Health Research (CIHR). PJ is a recipient of a Canada Research Chair. We thank Jean-Rene Sylvestre for excellent animal care. We are grateful to Annie Lavallee as well as to Eric Massicotte and Julie Lord for their excellent assistance with tissue sections and flow cytometry, respectively.	Baker M, 2008, NATURE, V454, P556, DOI [10.1038/454556a, 10.1038/456553a]; Booth BW, 2011, ONCOGENE, V30, P679, DOI 10.1038/onc.2010.439; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Bussard KM, 2010, CANCER RES, V70, P6336, DOI 10.1158/0008-5472.CAN-10-0591; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; DEOME KB, 1959, CANCER RES, V19, P515; Dirks PB, 2006, NATURE, V444, P687, DOI 10.1038/444687a; Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911-005-2542-5; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; HEPPNER GH, 1984, CANCER RES, V44, P2259; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549, DOI 10.1073/pnas.73.2.549; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Li Z, 2007, CANCER CELL, V12, P542, DOI 10.1016/j.ccr.2007.11.012; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Ling H, 2010, ONCOGENE, V29, P4543, DOI 10.1038/onc.2010.186; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Smith GH, 2001, MICROSC RES TECHNIQ, V52, P190, DOI 10.1002/1097-0029(20010115)52:2<190::AID-JEMT1005>3.0.CO;2-O; Smith GH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1856; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353; Zheng XS, 2007, CANCER RES, V67, P3691, DOI 10.1158/0008-5472.CAN-06-3912	49	18	19	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2013	32	29					3410	3419		10.1038/onc.2012.341	http://dx.doi.org/10.1038/onc.2012.341			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22907433	Green Accepted			2022-12-28	WOS:000322014900002
J	Razandi, M; Pedram, A; Jordan, VC; Fuqua, S; Levin, ER				Razandi, M.; Pedram, A.; Jordan, V. C.; Fuqua, S.; Levin, E. R.			Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer	ONCOGENE			English	Article						estrogen receptor; mitochondria; apoptosis; tamoxifen resistance	MANGANESE-SUPEROXIDE-DISMUTASE; KINASE-C-DELTA; REACTIVE OXYGEN; INDUCED APOPTOSIS; EPITHELIAL-CELLS; RESPIRATORY-CHAIN; PLASMA-MEMBRANE; CYTOCHROME-C; STRESS; ALPHA	Tamoxifen (TAM) has both cytostatic and cytotoxic properties for breast cancer. TAM engaged mitochondrial estrogen receptor beta (ER beta) as an antagonist in MCF7-BK cells, increasing reactive oxygen species (ROS) concentrations from the mitochondria that were required for cytotoxicity. In part, this derived from TAM downregulating manganese superoxide dismutase (MnSOD) activity by causing the nitrosylation of tyrosine 34, thereby increasing ROS. ROS-activated protein kinase C delta and c-jun N-terminal kinases, resulting in the mitochondrial translocation of Bax and cytochrome C release. Interestingly, TAM failed to cause high ROS levels or induce cell death in MCF7-BK-TR cells due to stimulation of MnSOD activity through agonistic effects at mitochondrial ER beta. In several mouse xenograft models, lentiviral shRNA-induced knockdown of MnSOD caused tumors that grew in the presence of TAM to undergo substantial apoptosis. Tumor MnSOD and mitochondrial ER beta are therefore targets for therapeutic intervention to reverse TAM resistance and enhance a cell death response.	[Razandi, M.; Pedram, A.; Levin, E. R.] Vet Affairs Med Ctr, Div Endocrinol, Med Serv 111 1, Long Beach, CA 90822 USA; [Razandi, M.; Pedram, A.; Levin, E. R.] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; [Razandi, M.; Pedram, A.; Levin, E. R.] Univ Calif Irvine, Dept Biochem, Irvine, CA 92717 USA; [Jordan, V. C.] Georgetown Univ, Lombardi Canc Ctr, Washington, DC USA; [Fuqua, S.] Baylor Coll Med, Houston, TX 77030 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; Georgetown University; Baylor College of Medicine	Levin, ER (corresponding author), Vet Affairs Med Ctr, Div Endocrinol, Med Serv 111 1, 5901 E,7th St, Long Beach, CA 90822 USA.	ellis.levin@va.gov	JORDAN, V.Craig/AAX-3562-2020; Jordan, V. Craig/H-4491-2011; Levin, Ellis/J-5402-2013		Research Service of the Department of Veteran's Affairs; NIH [CA-10036]; SPORE in Breast Cancer [P50CA89018]; Department of Defense Center of Excellence Grant [W81XWH-06-1-0590]; Georgetown Lombardi Comprehensive Cancer Spore Grant [P30CA051008]; NATIONAL CANCER INSTITUTE [R01CA100366, P30CA062203, P30CA051008, R01CA072038] Funding Source: NIH RePORTER	Research Service of the Department of Veteran's Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SPORE in Breast Cancer(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense Center of Excellence Grant; Georgetown Lombardi Comprehensive Cancer Spore Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work was supported by grants from the Research Service of the Department of Veteran's Affairs, and NIH CA-10036 to ERL and SPORE in Breast Cancer (#P50CA89018), Department of Defense Center of Excellence Grant (#W81XWH-06-1-0590) (VCJ) and Georgetown Lombardi Comprehensive Cancer Spore Grant (#P30CA051008).	Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; Aslan M, 2003, ANTIOXID REDOX SIGN, V5, P781, DOI 10.1089/152308603770380089; Barone I, 2011, JNCI-J NATL CANCER I, V103, P538, DOI 10.1093/jnci/djr058; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chalut KJ, 2009, CANCER RES, V69, P1199, DOI 10.1158/0008-5472.CAN-08-3079; Chapman KE, 2005, AM J PHYSIOL-LUNG C, V289, pL834, DOI 10.1152/ajplung.00069.2005; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Chua PJ, 2009, EXP BIOL MED, V234, P1086, DOI 10.3181/0903-RM-98; Clarke M, 1998, LANCET, V351, P1451; Dejean LM, 2005, MOL BIOL CELL, V16, P2424, DOI 10.1091/mbc.E04-12-1111; Di X, 2009, BIOCHEM PHARMACOL, V77, P1139, DOI 10.1016/j.bcp.2008.12.016; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Fan P, 2007, CANCER RES, V67, P1352, DOI 10.1158/0008-5472.CAN-06-1020; Felty Q, 2005, ONCOGENE, V24, P4883, DOI 10.1038/sj.onc.1208667; Flynn JM, 2008, AM J PHYSIOL-ENDOC M, V295, pE637, DOI 10.1152/ajpendo.90407.2008; Fuqua SAW, 2004, BREAST CANCER RES TR, V87, pS3; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; Han P, 2009, BIOCHEM BIOPH RES CO, V385, P251, DOI 10.1016/j.bbrc.2009.05.059; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Hsieh YC, 2006, J MOL CELL CARDIOL, V41, P511, DOI 10.1016/j.yjmcc.2006.06.001; Huang CC, 2009, TOXICOLOGY, V255, P58, DOI 10.1016/j.tox.2008.10.001; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Luce A, 2009, CARCINOGENESIS, V30, P432, DOI 10.1093/carcin/bgp008; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Milanesi L, 2009, STEROIDS, V74, P489, DOI 10.1016/j.steroids.2009.01.005; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Moriai R, 2009, BREAST CANCER RES TR, V117, P261, DOI 10.1007/s10549-008-0164-5; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Park WC, 2005, INT J ONCOL, V27, P1459; Pedram A, 2006, MOL BIOL CELL, V17, P2125, DOI 10.1091/mbc.E05-11-1013; Pedram A, 2006, MOL ENDOCRINOL, V20, P1996, DOI 10.1210/me.2005-0525; Pedram A, 2010, MOL ENDOCRINOL, V24, P2152, DOI 10.1210/me.2010-0154; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Poyton RO, 2009, TRENDS ENDOCRIN MET, V20, P332, DOI 10.1016/j.tem.2009.04.001; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Speirs V, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2140; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Xiao D, 2008, J BIOL CHEM, V283, P30151, DOI 10.1074/jbc.M802529200; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101	53	55	57	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2013	32	27					3274	3285		10.1038/onc.2012.335	http://dx.doi.org/10.1038/onc.2012.335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22907432	Green Accepted, Green Submitted			2022-12-28	WOS:000321301600007
J	Ke, G; Liang, L; Yang, JM; Huang, X; Han, D; Huang, S; Zhao, Y; Zha, R; He, X; Wu, X				Ke, G.; Liang, L.; Yang, J. M.; Huang, X.; Han, D.; Huang, S.; Zhao, Y.; Zha, R.; He, X.; Wu, X.			MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene	ONCOGENE			English	Article						miR-181a; PRKCD; apoptosis; cervical cancer; radiation therapy	KINASE-C-DELTA; CASPASE ACTIVATION; MICRORNAS; CELLS	The purpose of this study was to define the roles of miR-181a in determining sensitivity of cervical cancer to radiation therapy, to explore the underlying mechanism and to evaluate the potential of miR-181a as a biomarker for predicting radio-sensitivity. Tumor specimens from 18 patients with a histological diagnosis of squamous cervical carcinoma (stage IIIB) were used in the micro-RNA profiling and comparison. These patients never received any chemotherapy before radiation therapy. Human cervical cancer cell lines, SiHa and Me180, were used in vitro (cell culture) and in vivo (animal) studies. Transfection of tumor cells with the mimic or inhibitor of miR-181a, and reporter gene assay, were performed to investigate the role of miR-181a in determining radio-sensitivity and the target gene. Higher expression of miR-181a was observed in human cervical cancer specimens and cell lines that were insensitive to radiation therapy, as compared with sensitive cancer specimens and the cell lines. We also found that miR-181a negatively regulated the expression of PRKCD, a pro-apoptotic protein kinase, via targeting its 3'-untranslated region (UTR), thereby inhibiting irradiation-induced apoptosis and decreasing G(2)/M block. The role of miR-181a in conferring cellular resistance to radiation treatment was validated both in cell culture models and in mouse tumor xenograft models. The effect of miR-181a on radio-resistance was mediated through targeting the 3'-UTR of PRKCD gene. Thus, the expression level of miR-181a in cervical cancer may serve as a biomarker for sensitivity to radiation therapy, and targeting miR-181a may represent a new approach to sensitizing cervical cancer to radiation treatment.	[Ke, G.; Huang, X.; Han, D.; Wu, X.] Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai 200433, Peoples R China; [Ke, G.; Huang, X.; Han, D.; Wu, X.] Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Liang, L.; Huang, S.; Zhao, Y.; Zha, R.; He, X.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200032, Peoples R China; [Yang, J. M.] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA USA; [Yang, J. M.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Hershey, PA USA; [Yang, J. M.] Milton S Hershey Med Ctr, Hershey, PA USA	Fudan University; Shanghai Jiao Tong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	He, X (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200032, Peoples R China.	xhhe@shsci.org; docwuxh@hotmail.com	liang, linhui/AAW-4176-2021; He, Xianghuo/I-1497-2014; Huang, Shenglin/N-9472-2018	He, Xianghuo/0000-0001-8872-668X; Huang, Shenglin/0000-0003-1279-0794	National Natural Science Foundation of China [81072128]; Science and Technology Commission of Shanghai Municipality (Academic leader foundation of Shanghai) [09XD1401100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality (Academic leader foundation of Shanghai)	We are most grateful for the pWPXL, psPAX2 and pMD2.Glentivirus plasmids that were provided by Professor Didier Trono from the School of Life Sciences, EcolePoly technique Federale de Lausanne, 1015 Lausanne, Switzerland. This work was supported by National Natural Science Foundation of China (No. 81072128), and Science and Technology Commission of Shanghai Municipality (Academic leader foundation of Shanghai, 09XD1401100).	Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Chen G, 2010, ONCOL REP, V23, P997, DOI 10.3892/or_00000725; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hamano R, 2011, CLIN CANCER RES, V17, P3029, DOI 10.1158/1078-0432.CCR-10-2532; Hu X, 2001, CANCER RES, V70, P1441; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Waggoner SE, 2003, LANCET, V361, P2217, DOI 10.1016/S0140-6736(03)13778-6; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zhang BH, 2007, J CELL PHYSIOL, V210, P279, DOI 10.1002/jcp.20869	21	128	141	2	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3019	3027		10.1038/onc.2012.323	http://dx.doi.org/10.1038/onc.2012.323			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22847611	Bronze			2022-12-28	WOS:000320705700002
J	Wang, P; Dong, Q; Zhang, C; Kuan, PF; Liu, Y; Jeck, WR; Andersen, JB; Jiang, W; Savich, GL; Tan, TX; Auman, JT; Hoskins, JM; Misher, AD; Moser, CD; Yourstone, SM; Kim, JW; Cibulskis, K; Getz, G; Hunt, HV; Thorgeirsson, SS; Roberts, LR; Ye, D; Guan, KL; Xiong, Y; Qin, LX; Chiang, DY				Wang, P.; Dong, Q.; Zhang, C.; Kuan, P-F; Liu, Y.; Jeck, W. R.; Andersen, J. B.; Jiang, W.; Savich, G. L.; Tan, T-X; Auman, J. T.; Hoskins, J. M.; Misher, A. D.; Moser, C. D.; Yourstone, S. M.; Kim, J. W.; Cibulskis, K.; Getz, G.; Hunt, H. V.; Thorgeirsson, S. S.; Roberts, L. R.; Ye, D.; Guan, K-L; Xiong, Y.; Qin, L-X; Chiang, D. Y.			Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas	ONCOGENE			English	Article						DNA methylation; epigenetics; tumor metabolism	CELL SELF-RENEWAL; IDH2 MUTATIONS; OLLIER DISEASE; TET PROTEINS; PHENOTYPE; DNA; 5-METHYLCYTOSINE; EXPRESSION; CONVERSION; EVENTS	Mutations in the genes encoding isocitrate dehydrogenase, IDH1 and IDH2, have been reported in gliomas, myeloid leukemias, chondrosarcomas and thyroid cancer. We discovered IDH1 and IDH2 mutations in 34 of 326 (10%) intrahepatic cholangiocarcinomas. Tumor with mutations in IDH1 or IDH2 had lower 5-hydroxymethylcytosine and higher 5-methylcytosine levels, as well as increased dimethylation of histone H3 lysine 79 (H3K79). Mutations in IDH1 or IDH2 were associated with longer overall survival (P = 0.028) and were independently associated with a longer time to tumor recurrence after intrahepatic cholangiocarcinoma resection in multivariate analysis (P = 0.021). IDH1 and IDH2 mutations were significantly associated with increased levels of p53 in intrahepatic cholangiocarcinomas, but no mutations in the p53 gene were found, suggesting that mutations in IDH1 and IDH2 may cause a stress that leads to p53 activation. We identified 2309 genes that were significantly hypermethylated in 19 cholangiocarcinomas with mutations in IDH1 or IDH2, compared with cholangiocarcinomas without these mutations. Hypermethylated CpG sites were significantly enriched in CpG shores and upstream of transcription start sites, suggesting a global regulation of transcriptional potential. Half of the hypermethylated genes overlapped with DNA hypermethylation in IDH1-mutant gliobastomas, suggesting the existence of a common set of genes whose expression may be affected by mutations in IDH1 or IDH2 in different types of tumors.	[Wang, P.; Jiang, W.; Guan, K-L; Xiong, Y.] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200032, Peoples R China; [Wang, P.; Jiang, W.; Ye, D.; Guan, K-L; Xiong, Y.] Fudan Univ, Inst Biomed Sci, Mol & Cell Biol Lab, Shanghai 200032, Peoples R China; [Dong, Q.; Qin, L-X] Fudan Univ, Liver Canc Inst, Shanghai 200032, Peoples R China; [Dong, Q.; Qin, L-X] Fudan Univ, Zhongshan Hosp, Inst Biomed Sci, Shanghai 200032, Peoples R China; [Zhang, C.; Liu, Y.] Univ N Carolina, Carolina Ctr Genome Sci, Dept Stat & Operat Res, Chapel Hill, NC 27599 USA; [Kuan, P-F] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA; [Kuan, P-F; Jeck, W. R.; Savich, G. L.; Tan, T-X; Auman, J. T.; Hoskins, J. M.; Misher, A. D.; Yourstone, S. M.; Xiong, Y.; Chiang, D. Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Jeck, W. R.; Savich, G. L.; Tan, T-X; Yourstone, S. M.; Chiang, D. Y.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Andersen, J. B.; Thorgeirsson, S. S.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Auman, J. T.; Hoskins, J. M.; Misher, A. D.] Univ N Carolina, Inst Pharmacogen & Individualized Med, Chapel Hill, NC 27599 USA; [Moser, C. D.; Roberts, L. R.] Mayo Clin, Ctr Canc, Ctr Cell Signaling Gastroenterol, Div Gastroenterol & Hepatol, Rochester, MN USA; [Kim, J. W.] Wake Forest Univ, Baptist Med Ctr, Ctr Canc Genom, Winston Salem, NC 27109 USA; [Cibulskis, K.; Getz, G.] 7 Cambridge Ctr, Broad Inst, Genome Sequencing Anal Program & Platform, Cambridge, MA USA; [Hunt, H. V.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Guan, K-L] Fudan Univ, Shanghai Med Coll, Dept Biochem, Shanghai 200032, Peoples R China; [Guan, K-L] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Guan, K-L] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Xiong, Y.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Fudan University; Fudan University; Fudan University; Fudan University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; Mayo Clinic; Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of North Carolina; University of North Carolina Chapel Hill; Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295,450 West Dr, Chapel Hill, NC 27599 USA.	yxiong@email.unc.edu; qin.lunxiu@zs-hospital.sh.cn; chiang@med.unc.edu	Core, Mammalian Genotyping/AFU-1631-2022; Cibulskis, Kristian/AAC-7380-2019; , Pathology Services Core/CEZ-2246-2022; Chiang, Derek/L-6452-2019; Kuan, Pei Fen/GRX-4622-2022; Facility, Biospecimen Processing/AAC-7837-2022; Guan, Kun-Liang/ADK-7088-2022	Chiang, Derek/0000-0002-1131-6065; Tan, Ting Xu/0000-0002-7067-898X; Andersen, Jesper B/0000-0003-1760-5244; Roberts, Lewis/0000-0001-7885-8574; Kim, Johnny/0000-0002-5226-5460; Cibulskis, Kristian/0000-0003-1343-1582; Auman, James/0000-0002-9328-8829	985 Program from the Chinese Ministry of Education; MOST 973 [2009CB918401, 2011CB910600, 2012CB910300, 2012CB910101]; NSFC Program of International Cooperation and Exchanges [81120108016]; China National Key Projects for Infectious Disease [2008ZX10002-021, 2012ZX10002-012]; National Institutes of Health; James S McDonnell Foundation; Samuel Waxman Cancer Research Foundation; American Gastroenterological Association Foundation for Digestive Health and Nutrition; Alfred P Sloan Foundation; Nancy Stegman Cancer Research Fund; University Cancer Research Fund	985 Program from the Chinese Ministry of Education(Ministry of Education, China); MOST 973(National Basic Research Program of China); NSFC Program of International Cooperation and Exchanges; China National Key Projects for Infectious Disease; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James S McDonnell Foundation; Samuel Waxman Cancer Research Foundation; American Gastroenterological Association Foundation for Digestive Health and Nutrition; Alfred P Sloan Foundation(Alfred P. Sloan Foundation); Nancy Stegman Cancer Research Fund; University Cancer Research Fund	The UNC Biospecimen Core Facility, Mammalian Genotyping Core Facility and Translational Pathology Laboratory provided technical assistance for this study. Funding for this research was provided by: the 985 Program from the Chinese Ministry of Education (KLG, YX), MOST 973 (No. 2009CB918401, No. 2011CB910600, No. 2012CB910300, No. 2012CB910101; DY, YX and KLG); the NSFC Program of International Cooperation and Exchanges (No. 81120108016; LXQ, YX) and the China National Key Projects for Infectious Disease (2008ZX10002-021, 2012ZX10002-012; LZQ), the National Institutes of Health (KLG, YX, SST, LRR), the James S McDonnell Foundation (YX), the Samuel Waxman Cancer Research Foundation (YX), the American Gastroenterological Association Foundation for Digestive Health and Nutrition (LRR), the Alfred P Sloan Foundation fellowship (DYC), the Nancy Stegman Cancer Research Fund (DYC) and the University Cancer Research Fund (DYC, YX).	Abdel-Wahab O, 2010, CANCER RES, V70, P447, DOI 10.1158/0008-5472.CAN-09-3783; Aishima S, 2006, HISTOPATHOLOGY, V49, P35, DOI 10.1111/j.1365-2559.2006.02414.x; Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Andersen JB, 2012, GASTROENTEROLOGY, V142, P1021, DOI 10.1053/j.gastro.2011.12.005; Andersen JB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001338; Blechacz B, 2008, HEPATOLOGY, V48, P308, DOI 10.1002/hep.22310; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524; Cardinale V, 2012, NAT REV GASTRO HEPAT, V9, P231, DOI 10.1038/nrgastro.2012.23; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hezel AF, 2010, J CLIN ONCOL, V28, P3531, DOI 10.1200/JCO.2009.27.4787; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kipp BR, 2012, HUM PATHOL; Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Shibata T, 2011, AM J PATHOL, V178, P1395, DOI 10.1016/j.ajpath.2010.12.011; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Turner R, 2011, HEPATOLOGY, V53, P1035, DOI 10.1002/hep.24157; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang B, 2010, CELL RES, V20, P1188, DOI 10.1038/cr.2010.145; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	46	262	291	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3091	3100		10.1038/onc.2012.315	http://dx.doi.org/10.1038/onc.2012.315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22824796	Green Accepted, Green Submitted			2022-12-28	WOS:000320705700009
J	Neilsen, PM; Noll, JE; Mattiske, S; Bracken, CP; Gregory, PA; Schulz, RB; Lim, SP; Kumar, R; Suetani, RJ; Goodall, GJ; Callen, DF				Neilsen, P. M.; Noll, J. E.; Mattiske, S.; Bracken, C. P.; Gregory, P. A.; Schulz, R. B.; Lim, S. P.; Kumar, R.; Suetani, R. J.; Goodall, G. J.; Callen, D. F.			Mutant p53 drives invasion in breast tumors through up-regulation of miR-155	ONCOGENE			English	Article						breast cancer; invasion; miR-155; mutant p53; ZNF652	CANCER PATIENTS; GENE; EXPRESSION; MICRORNA-155; METASTASIS; GROWTH; TRANSITION; CARCINOMA; CELLS; PDCD4	Loss of p53 function is a critical event during tumorigenesis, with half of all cancers harboring mutations within the TP53 gene. Such events frequently result in the expression of a mutated p53 protein with gain-of-function properties that drive invasion and metastasis. Here, we show that the expression of miR-155 was up-regulated by mutant p53 to drive invasion. The miR-155 host gene was directly repressed by p63, providing the molecular basis for mutant p53 to drive miR-155 expression. Significant overlap was observed between miR-155 targets and the molecular profile of mutant p53-expressing breast tumors in vivo. A search for cancer-related target genes of miR-155 revealed ZNF652, a novel zinc-finger transcriptional repressor. ZNF652 directly repressed key drivers of invasion and metastasis, such as TGFB1, TGFB2, TGFBR2, EGFR, SMAD2 and VIM. Furthermore, silencing of ZNF652 in epithelial cancer cell lines promoted invasion into matrigel. Importantly, loss of ZNF652 expression in primary breast tumors was significantly correlated with increased local invasion and defined a population of breast cancer patients with metastatic tumors. Collectively, these findings suggest that miR-155 targeted therapies may provide an attractive approach to treat mutant p53-expressing tumors.	[Neilsen, P. M.; Noll, J. E.; Mattiske, S.; Schulz, R. B.; Lim, S. P.; Kumar, R.; Suetani, R. J.; Callen, D. F.] Univ Adelaide, Ctr Personalised Canc Med, Adelaide, SA 5005, Australia; [Neilsen, P. M.; Noll, J. E.; Mattiske, S.; Bracken, C. P.; Gregory, P. A.; Schulz, R. B.; Lim, S. P.; Kumar, R.; Suetani, R. J.; Goodall, G. J.; Callen, D. F.] Univ Adelaide, Discipline Med, Adelaide, SA 5005, Australia; [Bracken, C. P.; Gregory, P. A.; Goodall, G. J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia; [Goodall, G. J.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide; Centre for Cancer Biology; SA Pathology; University of Adelaide	Neilsen, PM (corresponding author), Univ Adelaide, Ctr Personalised Canc Med, Sarcoma Res Grp, Adelaide, SA 5005, Australia.	Paul.Neilsen@health.sa.gov.au	Callen, David F/G-1975-2012; Gregory, Philip/F-4089-2013; Kumar, Raman/AHE-0538-2022	Gregory, Philip/0000-0002-0999-0632; Kumar, Raman/0000-0001-7976-8386; Neilsen, Paul/0000-0001-7937-3675; Noll, Jacqueline/0000-0001-7375-635X; Goodall, Gregory/0000-0003-1294-0692; Callen, David/0000-0002-6189-9991; Bracken, Cameron/0000-0001-7722-625X	National Health and Medical Research Council (NHMRC) of Australia [1009447]; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation	We thank Dr Erik Flemington for his kind gift of the pMSCV-Puro-GFP-miR-155 plasmid. We also thank Dr Emily Paterson and Bee Suan Tay for technical assistance. This study was supported by the National Health and Medical Research Council (NHMRC) of Australia (project # 1009447).	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brosh R, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.65; DAVIDOFF AM, 1991, J SURG ONCOL, V48, P260, DOI 10.1002/jso.2930480409; Do TV, 2008, MOL CANCER RES, V6, P695, DOI 10.1158/1541-7786.MCR-07-0294; Huang Y, 2011, CELL DEATH DIFFER, V18, P1220, DOI 10.1038/cdd.2010.188; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Kouwenhoven EN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001065; Kumar R, 2008, J BIOL CHEM, V283, P19026, DOI 10.1074/jbc.M709136200; Kumar R, 2006, MOL CANCER RES, V4, P655, DOI 10.1158/1541-7786.MCR-05-0249; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nieves-Alicea R, 2009, BREAST CANCER RES TR, V114, P203, DOI 10.1007/s10549-008-9993-5; Noll JE, 2012, ONCOGENE, V31, P2836, DOI 10.1038/onc.2011.456; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pishas KI, 2011, CLIN CANCER RES, V17, P494, DOI 10.1158/1078-0432.CCR-10-1587; Santhanam AN, 2010, ONCOGENE, V29, P3921, DOI 10.1038/onc.2010.158; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Utku Y, 2006, MOL BIOSYST, V2, P312, DOI 10.1039/b603229j; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wen YH, 2007, ONCOL REP, V18, P1387; Xiang X, 2011, ONCOGENE, V30, P3440, DOI 10.1038/onc.2011.54; Xu GR, 2010, RNA, V16, P1610, DOI 10.1261/rna.2194910; Yin QY, 2008, J VIROL, V82, P5295, DOI 10.1128/JVI.02380-07; Yu Q, 2004, CLIN EXP METASTAS, V21, P235, DOI 10.1023/B:CLIN.0000037705.25256.d3	38	121	125	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2992	3000		10.1038/onc.2012.305	http://dx.doi.org/10.1038/onc.2012.305			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797073	Green Published			2022-12-28	WOS:000320369700009
J	Perez-Gomez, E; Andradas, C; Flores, JM; Quintanilla, M; Paramio, JM; Guzman, M; Sanchez, C				Perez-Gomez, E.; Andradas, C.; Flores, J. M.; Quintanilla, M.; Paramio, J. M.; Guzman, M.; Sanchez, C.			The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas	ONCOGENE			English	Article						GPR55; G protein-coupled receptors; skin carcinogenesis; squamous cell carcinoma; cannabinoids	LYSOPHOSPHATIDIC ACID RECEPTOR-2; L-ALPHA-LYSOPHOSPHATIDYLINOSITOL; PROTEIN-COUPLED RECEPTORS; CANNABINOID RECEPTOR; OVARIAN-CANCER; LPA RECEPTORS; COLORECTAL-CANCER; OVER-EXPRESSION; GROWTH-FACTOR; IDENTIFICATION	G protein-coupled receptors (GPCRs) control crucial physiological processes and their dysfunction contributes to various human diseases, including cancer. The orphan GPCR GPR55 was identified and cloned more than a decade ago, but very little is known about its physio-pathological relevance. It has been recently shown that GPR55 controls the behavior of human cancer cell lines in culture and xenografts. However, the assessment of the actual role of this receptor in malignant transformation in vivo is hampered by the lack of studies on its functional impact in clinically-relevant models of cancer. Here we demonstrate that GPR55 drives mouse skin tumor development. Thus, GPR55-deficient mice were more resistant to DMBA/TPA-induced papilloma and carcinoma formation than their wild-type littermates. GPR55 exerted this pro-tumor effect primarily by conferring a proliferative advantage on cancer cells. In addition, GPR55 enhanced skin cancer cell anchorage-independent growth, invasiveness and tumorigenicity in vivo, suggesting that it promotes not only tumor development but also tumor aggressiveness. Finally, we observed that GPR55 is upregulated in human skin tumors and other human squamous cell carcinomas compared with the corresponding healthy tissues. Altogether, these findings reveal the pivotal importance of GPR55 in skin tumor development, and suggest that this receptor may be used as a new biomarker and therapeutic target in squamous cell carcinomas.	[Perez-Gomez, E.; Andradas, C.; Guzman, M.; Sanchez, C.] Univ Complutense Madrid, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; [Flores, J. M.] Univ Complutense Madrid, Sch Vet, Dept Anim Surg & Med, E-28040 Madrid, Spain; [Quintanilla, M.] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Paramio, J. M.] CIEMAT, Div Biomed, Mol Oncol Unit, E-28040 Madrid, Spain; [Guzman, M.] Ctr Invest Biomed Red Enfermedade Neurodegenerat, Madrid, Spain; [Guzman, M.] Inst Ramon y Cajal Invest Sanitaria, Madrid, Spain	Complutense University of Madrid; Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; CIBERNED	Sanchez, C (corresponding author), Univ Complutense Madrid, Sch Biol, Dept Biochem & Mol Biol 1, C Jose Antonio Novais 2, E-28040 Madrid, Spain.	cristina.sanchez@quim.ucm.es	Perez-gomez, Eduardo/F-5906-2015; Sanchez, Cristina/H-4980-2017; Quintanilla, Miguel/K-9293-2017; Paramio, Jesus M/M-8482-2014; Pérez-Gómez, Eduardo/GYA-5856-2022; Sanchez, Cristina/AFQ-4745-2022	Perez-gomez, Eduardo/0000-0003-0160-5565; Sanchez, Cristina/0000-0002-1428-3078; Paramio, Jesus M/0000-0001-7520-3177; Pérez-Gómez, Eduardo/0000-0003-0160-5565; Guzman, Manuel/0000-0001-7475-118X	Fondo de Investigaciones Sanitarias [PI080253]; Fundacion Mutua Madrilena; GW Pharmaceuticals/Otsuka Pharmaceuticals; Comunidad de Madrid [S2010/BMD-2038]; Spanish Ministry of Science and Innovation [SAF2010-19152, SAF2008-00121, SAF2011-26122-C02-01]; Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC); Spanish Ministry of Science and Innovation	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); GW Pharmaceuticals/Otsuka Pharmaceuticals(Otsuka Pharmaceutical); Comunidad de Madrid(Comunidad de Madrid); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	We are indebted to the members of our laboratories and to Dr MM Caffarel for critical discussion on this work. We thank Dr Manuel M Morente, Head of the CNIO Tumor Bank Core Unit, for kindly provided us with human tumor samples. This work was supported by grants from Fondo de Investigaciones Sanitarias (PI080253 to CS), Fundacion Mutua Madrilena (to CS), GW Pharmaceuticals/Otsuka Pharmaceuticals (to CS), Comunidad de Madrid (S2010/BMD-2038 to MG) and Spanish Ministry of Science and Innovation (SAF2010-19152 to MQ and SAF2008-00121 and SAF2011-26122-C02-01 to JMP). EPG and CA were the recipients of a Postdoctoral Research Contract from Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC) and a PFIS PhD studentship from the Spanish Ministry of Science and Innovation, respectively.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Andradas C, 2011, ONCOGENE, V30, P245, DOI 10.1038/onc.2010.402; Cantarella G, 2011, BIOCHEM PHARMACOL, V82, P380, DOI 10.1016/j.bcp.2011.05.004; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476-5381.2010.00743.x; Henstridge CM, 2011, MOL ENDOCRINOL, V25, P1835, DOI 10.1210/me.2011-1197; Henstridge CM, 2009, FASEB J, V23, P183, DOI 10.1096/fj.08-108670; Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555-011-9319-7; Huang L, 2011, LAB INVEST, V91, P1007, DOI 10.1038/labinvest.2011.62; Kapur A, 2009, J BIOL CHEM, V284, P29817, DOI 10.1074/jbc.M109.050187; Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; Ligresti A, 2003, GASTROENTEROLOGY, V125, P677, DOI 10.1016/S0016-5085(03)00881-3; Lin ME, 2010, PROSTAG OTH LIPID M, V91, P130, DOI 10.1016/j.prostaglandins.2009.02.002; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Oka S, 2010, J BIOCHEM, V147, P671, DOI 10.1093/jb/mvp208; Oka S, 2009, J BIOCHEM, V145, P13, DOI 10.1093/jb/mvn136; Pagotto U, 2001, J CLIN ENDOCR METAB, V86, P2687, DOI 10.1210/jc.86.6.2687; Patterson AD, 2011, CANCER RES, V71, P6590, DOI 10.1158/0008-5472.CAN-11-0885; Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348; Petersen G, 2005, J NEUROCHEM, V93, P299, DOI 10.1111/j.1471-4159.2005.03013.x; Pineiro R, 2011, ONCOGENE, V30, P142, DOI 10.1038/onc.2010.417; Ross RA, 2009, TRENDS PHARMACOL SCI, V30, P156, DOI 10.1016/j.tips.2008.12.004; Sawzdargo M, 1999, MOL BRAIN RES, V64, P193, DOI 10.1016/S0169-328X(98)00277-0; Schicho R, 2011, INFLAMM BOWEL DIS, V17, P1651, DOI 10.1002/ibd.21538; Schmid PC, 2002, LIPIDS, V37, P907, DOI 10.1007/s11745-002-0978-z; Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1166>3.0.CO;2-D; Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146; Staton PC, 2008, PAIN, V139, P225, DOI 10.1016/j.pain.2008.04.006; Sticht C, 2008, NEOPLASIA, V10, P462, DOI 10.1593/neo.08164; Sutphen R, 2004, CANCER EPIDEM BIOMAR, V13, P1185; Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yamashita H, 2006, J SURG ONCOL, V93, P30, DOI 10.1002/jso.20397; Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200; Yun CC, 2005, AM J PHYSIOL-CELL PH, V289, pC2, DOI 10.1152/ajpcell.00610.2004; Zeng Y, 2009, PROSTATE, V69, P283, DOI 10.1002/pros.20879	44	62	65	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2013	32	20					2534	2542		10.1038/onc.2012.278	http://dx.doi.org/10.1038/onc.2012.278			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22751111				2022-12-28	WOS:000319274300005
J	Moleirinho, S; Chang, N; Sims, AH; Tilston-Lunel, AM; Angus, L; Steele, A; Boswell, V; Barnett, SC; Ormandy, C; Faratian, D; Gunn-Moore, FJ; Reynolds, PA				Moleirinho, S.; Chang, N.; Sims, A. H.; Tilston-Luenel, A. M.; Angus, L.; Steele, A.; Boswell, V.; Barnett, S. C.; Ormandy, C.; Faratian, D.; Gunn-Moore, F. J.; Reynolds, P. A.			KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals	ONCOGENE			English	Article						KIBRA; Hippo pathway; Merlin; Willin; breast cancer; claudin-low	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; ORGAN SIZE CONTROL; CYCLE EXIT; DROSOPHILA; YAP; APOPTOSIS; PROLIFERATION; ONCOGENE; PROTEIN	The Salvador/Warts/Hippo (Hippo) signaling pathway defines a novel signaling cascade regulating cell contact inhibition, organ size control, cell growth, proliferation, apoptosis and cancer development in mammals. The upstream regulation of this pathway has been less well defined than the core kinase cassette. KIBRA has been shown to function as an upstream member of the Hippo pathway by influencing the phosphorylation of LATS and YAP, but functional consequences of these biochemical changes have not been previously addressed. We show that in MCF10A cells, loss of KIBRA expression displays epithelial-to-mesenchymal transition (EMT) features, which are concomitant with decreased LATS and YAP phosphorylation, but not MST1/2. In addition, ectopic KIBRA expression antagonizes YAP via the serine 127 phosphorylation site and we show that KIBRA, Willin and Merlin differentially regulate genes controlled by YAP. Finally, reduced KIBRA expression in primary breast cancer specimens correlates with the recently described claudin-low subtype, an aggressive sub-group with EMT features and a poor prognosis. Oncogene (2013) 32, 1821-1830; doi: 10.1038/onc.2012.196; published online 21 May 2012	[Moleirinho, S.; Chang, N.; Steele, A.; Boswell, V.; Reynolds, P. A.] Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland; [Moleirinho, S.; Tilston-Luenel, A. M.; Angus, L.; Gunn-Moore, F. J.] Univ St Andrews, Sch Biol, St Andrews KY16 9TF, Fife, Scotland; [Sims, A. H.; Faratian, D.] Univ Edinburgh, Western Gen Hosp, Breakthrough Res Unit, Edinburgh, Midlothian, Scotland; [Sims, A. H.; Faratian, D.] Univ Edinburgh, Western Gen Hosp, Div Pathol, Edinburgh, Midlothian, Scotland; [Barnett, S. C.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland; [Ormandy, C.] St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	University of St Andrews; University of St Andrews; University of Edinburgh; University of Edinburgh; University of Glasgow; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Gunn-Moore, FJ (corresponding author), Univ St Andrews, Sch Biol, Med & Biol Sci Bldg, St Andrews KY16 9TF, Fife, Scotland.	fjg1@st-andrews.ac.uk; par10@st-andrews.ac.uk	Ormandy, Chris/G-4165-2014; Sims, Andrew/E-4819-2012	Reynolds, Paul/0000-0001-8738-1245; Sims, Andrew/0000-0001-9082-3665; Tilston-Lunel, Andrew/0000-0002-5582-6884; Ormandy, Christopher/0000-0002-2504-7919; Gunn-Moore, Francis James/0000-0003-3422-3387	Scottish University Life Science Alliance; Breakthrough Breast Cancer; National Health and Medical Research Council of Australia; New South Wales Cancer Council; Cancer Institute New South Wales; Banque Nationale de Paris-Paribas Australia; Banque Nationale de Paris-Paribas New Zealand; RT Hall Trust; Australian Cancer Research Foundation; National Breast Cancer Foundation	Scottish University Life Science Alliance; Breakthrough Breast Cancer; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); New South Wales Cancer Council(Cancer Council New South Wales); Cancer Institute New South Wales; Banque Nationale de Paris-Paribas Australia; Banque Nationale de Paris-Paribas New Zealand; RT Hall Trust; Australian Cancer Research Foundation; National Breast Cancer Foundation	We are very grateful to Dr Avruch for providing the MOBKL1A/B antibody and to Dr Takeichi for providing the Willin antibody. We thank V Fedele and E Campbell for technical assistance. We also thank the Scottish University Life Science Alliance for funding for SM and Breakthrough Breast Cancer for funding for AHS and DF. CJO was funded by The National Health and Medical Research Council of Australia, New South Wales Cancer Council, Cancer Institute New South Wales, Banque Nationale de Paris-Paribas Australia and New Zealand, RT Hall Trust, Australian Cancer Research Foundation and the National Breast Cancer Foundation.	Angus L, 2012, ONCOGENE, V31, P238, DOI 10.1038/onc.2011.224; Bates TC, 2009, NEUROSCI LETT, V458, P140, DOI 10.1016/j.neulet.2009.04.050; Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Board R, 2005, DRUG RESIST UPDATE, V8, P75, DOI 10.1016/j.drup.2005.03.004; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Corneveaux JJ, 2010, NEUROBIOL AGING, V31, P901, DOI 10.1016/j.neurobiolaging.2008.07.014; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Grusche FA, 2010, CURR BIOL, V20, pR574, DOI 10.1016/j.cub.2010.05.023; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Hilton HN, 2008, BBA-MOL CELL RES, V1783, P383, DOI 10.1016/j.bbamcr.2007.12.007; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Johnson KC, 2002, ONCOGENE, V21, P5990, DOI 10.1038/sj.onc.1205693; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kremerskothen J, 2003, BIOCHEM BIOPH RES CO, V300, P862, DOI 10.1016/S0006-291X(02)02945-5; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mao YP, 2011, DEVELOPMENT, V138, P947, DOI 10.1242/dev.057166; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Papassotiropoulos A, 2006, SCIENCE, V314, P475, DOI 10.1126/science.1129837; Pellock BJ, 2007, DEV BIOL, V304, P102, DOI 10.1016/j.ydbio.2006.12.021; Praskova M, 2008, CURR BIOL, V18, P311, DOI 10.1016/j.cub.2008.02.006; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Saburi S, 2008, NAT GENET, V40, P1010, DOI 10.1038/ng.179; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Schaper K, 2008, NEUROBIOL AGING, V29, P1123, DOI 10.1016/j.neurobiolaging.2007.02.001; Sims AH, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-42; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	50	92	94	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1821	1830		10.1038/onc.2012.196	http://dx.doi.org/10.1038/onc.2012.196			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22614006				2022-12-28	WOS:000317043900008
J	Sun, Y; Cao, S; Yang, M; Wu, S; Wang, Z; Lin, X; Song, X; Liao, DJ				Sun, Y.; Cao, S.; Yang, M.; Wu, S.; Wang, Z.; Lin, X.; Song, X.; Liao, D. J.			Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase-4	ONCOGENE			English	Article						PRS6KA6; RSK4; alternative splicing; breast cancer; pancreatic cancer	X-LINKED GENES; TRANSLATIONAL REGULATION; C-MYC; MESSENGER-RNA; BREAST-CANCER; CYCLIN D1; INDUCED SENESCENCE; PANCREATIC-CANCER; TRANSGENIC MOUSE; OVARIAN-CANCER	The RPS6KA6 gene encodes the p90 ribosomal S6 kinase-4 (RSK4) that is still largely uncharacterized. In this study we identified a new RSK4 transcription initiation site and several alternative splice sites with a 5'-RACE approach. The resulting mRNA variants encompass four possible first start codons. The first 15 nucleotides (nt) of exon 22 in mouse and the penultimate exon in both human (exon 21) and mouse (exon 24) RSK4 underwent alternative splicing, although the penultimate exon deleted variant appeared mainly in cell clines, but not in most normal tissues. Demethylation agent 5-azacytidine inhibited the deletion of the penultimate exon, whereas two indolocarbazole-derived inhibitors of cyclin-dependent kinase 4 or 6 induced deletion of the first 39 nt from exon 21 of human RSK4. In all human cancer cell lines studied, the 90-kDa wild-type RSK4 was sparse but, surprisingly, several isoforms at or smaller than 72 kDa were expressed as detected by seven different antibodies. On immunoblots, each of these smaller isoforms often appeared as a duplet or triplet and the levels of these isoforms varied greatly among different cell lines and culture conditions. Cyclin D1 inhibited RSK4 expression and serum starvation enhanced the inhibition, whereas c-Myc and RSK4 inhibited cyclin D1. The effects of RSK4 on cell growth, cell death and chemoresponse depended on the mRNA variant or the protein isoform expressed, on the specificity of the cell lines, as well as on the anchorage-dependent or -independent growth conditions and the in vivo situation. Moreover, we also observed that even a given cDNA might be expressed to multiple proteins; therefore, when using a cDNA, one needs to exclude this possibility before attribution of the biological results from the cDNA to the anticipated protein. Collectively, our results suggest that whether RSK4 is oncogenic or tumor suppressive depends on many factors. Oncogene (2013) 32, 1794-1810; doi: 10.1038/onc.2012.200; published online 21 May 2012	[Sun, Y.; Yang, M.; Wu, S.; Wang, Z.; Liao, D. J.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Cao, S.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; [Lin, X.] Chinese Acad Sci, Inst Oceanol, Qingdao, Peoples R China; [Song, X.] Shandong Canc Hosp & Inst, Shandong Prov Key Lab Radiat Oncol, Jinan, Peoples R China	University of Minnesota System; Roswell Park Cancer Institute; Chinese Academy of Sciences; Institute of Oceanology, CAS; Shandong First Medical University & Shandong Academy of Medical Sciences	Cao, S (corresponding author), Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA.	shousong.cao@roswellpark.org; djliao@hi.umn.edu		Lin, Xiukun/0000-0002-0306-4953	NIH [RO1 CA100864]; Pardee Foundation grant on pancreatic cancer; NATIONAL CANCER INSTITUTE [R01CA100864] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pardee Foundation grant on pancreatic cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a NIH grant RO1 CA100864 and a Pardee Foundation grant on pancreatic cancer to DJ Liao. We would like to thank Dr Fred Bogott from Austin Medical Center at Austin of Minnesota for his excellent English editing of the manuscript.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Arava Y, 2005, NUCLEIC ACIDS RES, V33, P2421, DOI 10.1093/nar/gki331; Bender C, 2012, INT J CANCER, V131, pE45, DOI 10.1002/ijc.26486; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bignone PA, 2007, ONCOGENE, V26, P683, DOI 10.1038/sj.onc.1209827; Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419; Biliran H, 2007, CLIN CANCER RES, V13, P2811, DOI 10.1158/1078-0432.CCR-06-1844; Calvo SE, 2009, P NATL ACAD SCI USA, V106, P7507, DOI 10.1073/pnas.0810916106; Campbell MJ, 2002, IN VITRO CELL DEV-AN, V38, P326; Cao SS, 1999, CLIN CANCER RES, V5, P1925; Chatterjee S, 2009, BIOL CELL, V101, P251, DOI 10.1042/BC20080104; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Dewdney SB, 2011, CLIN CANCER RES, V17, P2120, DOI 10.1158/1078-0432.CCR-10-2668; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; El-Kady Ayman, 2011, J Carcinog, V10, P24, DOI 10.4103/1477-3163.90437; Fitzgerald KD, 2009, BBA-GENE REGUL MECH, V1789, P518, DOI 10.1016/j.bbagrm.2009.07.004; Foster BA, 1997, CANCER RES, V57, P3325; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gresner P, 2009, ACTA BIOCHIM POL, V56, P307; Hauge C, 2006, J CELL SCI, V119, P3021, DOI 10.1242/jcs.02950; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; Iacono M, 2005, GENE, V349, P97, DOI 10.1016/j.gene.2004.11.041; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Ivanov IP, 2010, NUCLEIC ACIDS RES, V38, P353, DOI 10.1093/nar/gkp1037; Kohn M, 2003, GENE EXPR PATTERNS, V3, P173, DOI 10.1016/S1567-133X(03)00004-8; Kozak M, 2005, NUCLEIC ACIDS RES, V33, P6593, DOI 10.1093/nar/gki958; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Kozak M, 2008, GENE, V423, P108, DOI 10.1016/j.gene.2008.07.013; Kozak M, 2007, GENE, V403, P194, DOI 10.1016/j.gene.2007.08.017; Kozak M, 2007, J CELL BIOCHEM, V102, P280, DOI 10.1002/jcb.21464; Kozak M, 2006, GENE, V382, P1, DOI 10.1016/j.gene.2006.06.004; Le Quesne JPC, 2010, J PATHOL, V220, P140, DOI 10.1002/path.2627; Liao D. Joshua, 2007, Critical Reviews in Oncogenesis, V13, P93; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; Liao DZJ, 1998, CARCINOGENESIS, V19, P2173, DOI 10.1093/carcin/19.12.2173; Liao DZJ, 2000, CARCINOGENESIS, V21, P2167, DOI 10.1093/carcin/21.12.2167; Liao JD, 2007, HISTOL HISTOPATHOL, V22, P661, DOI 10.14670/HH-22.661; Lin HC, 2001, CANCER LETT, V173, P63, DOI 10.1016/S0304-3835(01)00677-2; Lleonart ME, 2006, ONCOL REP, V16, P603; Lopez-Vicente L, 2011, CARCINOGENESIS, V32, P470, DOI 10.1093/carcin/bgr003; Lopez-Vicente L, 2009, CLIN CANCER RES, V15, P4546, DOI 10.1158/1078-0432.CCR-08-3159; Mercer TR, 2011, NUCLEIC ACIDS RES, V39, P2393, DOI 10.1093/nar/gkq1158; Myers AP, 2004, MOL CELL BIOL, V24, P4255, DOI 10.1128/MCB.24.10.4255-4266.2004; Niehof M, 2005, MOL PHARMACOL, V67, P604, DOI 10.1124/mol.104.008672; Nyiko T, 2009, PLANT MOL BIOL, V71, P367, DOI 10.1007/s11103-009-9528-4; Palazzo AF, 2012, BBA-GENE REGUL MECH, V1819, P566, DOI 10.1016/j.bbagrm.2011.12.012; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shatsky IN, 2010, MOL CELLS, V30, P285, DOI 10.1007/s10059-010-0149-1; Sumanasekera C, 2008, BIOCHEM SOC T, V36, P483, DOI 10.1042/BST0360483; Sun Y, 2012, J CANCER, V3, P93, DOI 10.7150/jca.4163; Sun Y, 2011, J CANCER, V2, P36, DOI 10.7150/jca.2.36; Szamecz B, 2008, GENE DEV, V22, P2414, DOI 10.1101/gad.480508; Tanner DR, 2009, J BIOL CHEM, V284, P34809, DOI 10.1074/jbc.M109.039040; Thakur A, 2005, BREAST CANCER RES TR, V93, P135, DOI 10.1007/s10549-005-4516-0; Thakur A, 2008, MOL CANCER, V7, DOI [10.1086/1476-4598-7-11, DOI 10.1086/1476-4598-7-11]; Thakur A, 2008, CLIN CANCER RES, V14, P4427, DOI 10.1158/1078-0432.CCR-08-0458; Thakur A, 2007, MOL CANCER RES, V5, P171, DOI 10.1158/1541-7786.MCR-06-0071; Vila-Perello M, 2010, CELL, V143, P191, DOI 10.1016/j.cell.2010.09.031; Wang CG, 2011, CELL CYCLE, V10, P57, DOI 10.4161/cc.10.1.14449; Wang Y, 2007, CANCER RES, V67, P3698, DOI 10.1158/0008-5472.CAN-06-4000; Wethmar K, 2010, BIOESSAYS, V32, P885, DOI 10.1002/bies.201000037; Yang M, 2011, J CANCER, V2, P386, DOI 10.7150/jca.2.386; Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004	64	26	26	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2013	32	14					1794	1810		10.1038/onc.2012.200	http://dx.doi.org/10.1038/onc.2012.200			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22614021	Green Accepted			2022-12-28	WOS:000317043900006
J	Lee, CG; Park, GY; Han, YK; Lee, JH; Chun, SH; Park, HY; Lim, KH; Kim, EG; Choi, YJ; Yang, K; Lee, CW				Lee, C. G.; Park, G-Y; Han, Y. K.; Lee, J. H.; Chun, S. H.; Park, H-Y; Lim, K-H; Kim, E-G; Choi, Y-J; Yang, K.; Lee, C-W			Roles of 14-3-3 eta in mitotic progression and its potential use as a therapeutic target for cancers	ONCOGENE			English	Article						14-3-3; mitosis; cell death; aneuploid; caspase	CELL-DEATH; SPINDLE DAMAGE; CHECKPOINT; APOPTOSIS; PROTEINS; 14-3-3-PROTEINS; CATASTROPHE; CHROMOSOME; 14-3-3-SIGMA; CYTOKINESIS	14-3-3 proteins are involved in several cellular processes, including the G1/S and G2/M cell cycle transitions. However, their roles during mitosis are not well understood. Here, we showed that depletion of 14-3-3 eta, a 14-3-3 protein isoform, enhanced mitotic cell death, resulting in sensitization to microtubule inhibitors and inhibition of aneuploidy formation. The enhanced mitotic cell death by depletion of 14-3-3 eta appeared to be both caspase-dependent and independent. Furthermore, enhanced mitotic cell death and a reduction in aneuploidy following 14-3-3 eta depletion were independent of the mitotic checkpoint, which is thought to be the primary signaling event in the regulation of the cell death induced by microtubule inhibitors. When 14-3-3 eta depletion was combined with microtubule inhibitors in HCT116 and U87MG cells, it sensitized both cancer cell lines to microtubule inhibitors. These results collectively suggest that 14-3-3 eta may be required for mitotic progression and may be considered as a novel anti-cancer strategy in combination with microtubule inhibitors. Oncogene (2013) 32, 1560-1569; doi:10.1038/onc.2012.170; published online 7 May 2012	[Lee, C. G.; Park, G-Y; Han, Y. K.; Lee, J. H.; Chun, S. H.; Choi, Y-J; Yang, K.] Dongnam Inst Radiol & Med Sci, Res Ctr, Pusan 619953, South Korea; [Lee, C. G.; Park, H-Y; Lim, K-H; Kim, E-G; Lee, C-W] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, Suwon 440746, South Korea; [Lee, C. G.; Lee, C-W] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Ctr Mol Med, Suwon 440746, South Korea; [Lee, C-W] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Suwon 440746, South Korea	Korea Institute of Radiological & Medical Sciences; Sungkyunkwan University (SKKU); Samsung; Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU)	Lee, CW (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, Suwon 440746, South Korea.	cglee@dirams.re.kr; cwlee1234@skku.edu		Lee, Chang-Woo/0000-0002-0943-1646	National Research Foundation; Korea government (MEST) [2011-0030833, 2010-0007555]; National R and D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea [0920290]; National R and D Program through the Dong-nam Institute of Radiological and Medical Sciences (DIRAMS); Ministry of Education, Science and Technology [50593-2011, 50594-2011, 50597-2012]	National Research Foundation; Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); National R and D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea; National R and D Program through the Dong-nam Institute of Radiological and Medical Sciences (DIRAMS); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	We thank Ye Won Lee, Dr Jung Ki Kim, Min Young Kim and Min Su Ju for administrative support. This study was supported by National Research Foundation grant funded by the Korea government (MEST) (2011-0030833 and 2010-0007555), a grant from National R and D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (0920290) and National R and D Program through the Dong-nam Institute of Radiological and Medical Sciences (DIRAMS) funded by the Ministry of Education, Science and Technology (50593-2011, 50594-2011 and 50597-2012).	Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Di Leonardo A, 1997, CANCER RES, V57, P1013; Didier C, 2008, ONCOGENE, V27, P3811, DOI 10.1038/sj.onc.1211041; Ha GH, 2009, CELL DEATH DIFFER, V16, P483, DOI 10.1038/cdd.2008.182; Hermeking H, 2006, SEMIN CANCER BIOL, V16, P183, DOI 10.1016/j.semcancer.2006.03.002; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Liu Y, 2007, MOL ENDOCRINOL, V21, P3050, DOI 10.1210/me.2007-0323; Meek SEM, 2004, J BIOL CHEM, V279, P32046, DOI 10.1074/jbc.M403044200; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Niikura Y, 2007, J CELL BIOL, V178, P283, DOI 10.1083/jcb.200702134; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Saurin AT, 2008, NAT CELL BIOL, V10, P891, DOI 10.1038/ncb1749; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Stevens JB, 2007, CANCER RES, V67, P7686, DOI 10.1158/0008-5472.CAN-07-0472; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Wilker EW, 2007, NATURE, V446, P329, DOI 10.1038/nature05584; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yang XL, 2009, J NEUROL SCI, V276, P54, DOI 10.1016/j.jns.2008.08.040	35	10	11	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 21	2013	32	12					1560	1569		10.1038/onc.2012.170	http://dx.doi.org/10.1038/onc.2012.170			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22562251				2022-12-28	WOS:000316456000009
J	Little, AS; Smith, PD; Cook, SJ				Little, A. S.; Smith, P. D.; Cook, S. J.			Mechanisms of acquired resistance to ERK1/2 pathway inhibitors	ONCOGENE			English	Review						acquired resistance; BRAF; ERK1/2; MEK1/2; RAS	TYROSINE KINASE INHIBITORS; SIGNAL-REGULATED KINASE; POTENTIAL MECHANISM; AZD6244 ARRY-142886; MEK1/2 INHIBITORS; TUMOR PROGRESSION; DOWN-REGULATION; BRAF GENE; RAF; MUTATIONS	The ERK1/2 (extracellular signal-regulated kinase 1 and 2) pathway, comprising the protein kinases RAF (v-raf-1 murine leukemia viral oncogene homolog 1), MEK1/2 (mitogen-activated protein kinase or ERK kinase 1 and 2) and ERK1/2 is frequently de-regulated in human cancers, due to mutations in RAS or BRAF (v-raf-1 murine leukemia viral oncogene homolog B1). New, highly selective inhibitors of BRAF and MEK1/2 have shown promise in clinical trials, including in previously intractable diseases such as melanoma. However, drug-resistant tumour cells invariably emerge leading to disease progression. It is important to understand the mechanisms underlying such acquired resistance since this may lead to the development of rational strategies either to delay its onset or to overcome it once established. It also offers unique insights into the plasticity of signalling pathways, which may in turn inform our understanding of the basic biology of these pathways and lead to the validation of new drug targets. Several recent reports have identified diverse mechanisms of acquired resistance to MEK1/2 or BRAF inhibitors. In this article, we review these studies, discuss the different mechanisms, identify common themes and consider their therapeutic implications. Oncogene (2013) 32, 1207-1215; doi:10.1038/onc.2012.160; published online 7 May 2012	[Little, A. S.; Cook, S. J.] Babraham Inst, Signalling Lab, Cambridge CB22 3AT, Cambs, England; [Smith, P. D.] AstraZeneca, Oncol iMed, Macclesfield, Cheshire, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; AstraZeneca	Cook, SJ (corresponding author), Babraham Inst, Signalling Lab, Babraham Res Campus, Cambridge CB22 3AT, Cambs, England.	simon.cook@babraham.ac.uk		Cook, Simon/0000-0001-9087-1616	AstraZeneca; Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0419, BBS/E/B/000C0417, BBS/E/B/0000C199] Funding Source: researchfish; Cancer Research UK [14867] Funding Source: researchfish; Worldwide Cancer Research [12-1259] Funding Source: researchfish; BBSRC [BBS/E/B/000C0417, BBS/E/B/000C0419] Funding Source: UKRI	AstraZeneca(AstraZeneca); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Worldwide Cancer Research; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We apologise to colleagues whose work we have not been able to cite due to space limitations. Dr Simon Cook's laboratory was supported by the Babraham Institute, which receives strategic support from the Biotechnology and Biological Sciences Research Council. Work in Dr Cook's laboratory on mechanisms of resistance to ERK1/2 pathway inhibitors was funded by a collaborative research grant from AstraZeneca, which provided Dr Annette Little's salary and research consumables. Neither Dr Cook or Dr Little received any personal renumeration from AstraZeneca. This article is dedicated to the memory of Maureen Cook, a devoted, loving and much-loved mother whose life was blighted by dementia; she is sorely missed.	Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; Balmanno K, 2009, INT J CANCER, V125, P2332, DOI 10.1002/ijc.24604; Birtwistle MR, 2011, CELL CYCLE, V10, P2069, DOI 10.4161/cc.10.13.16245; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; BUDAY L, 1995, ONCOGENE, V11, P1327; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delaney AM, 2002, MOL CELL BIOL, V22, P7593, DOI 10.1128/MCB.22.21.7593-7602.2002; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Engelman JA, 2008, CURR OPIN GENET DEV, V18, P73, DOI 10.1016/j.gde.2008.01.004; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Fedorenko IV, 2011, BIOCHEM PHARMACOL, V82, P201, DOI 10.1016/j.bcp.2011.05.015; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gillings AS, 2009, FEBS J, V276, P6050, DOI 10.1111/j.1742-4658.2009.07329.x; Halilovic E, 2010, CANCER RES, V70, P6804, DOI 10.1158/0008-5472.CAN-10-0409; Hammerman PS, 2009, CLIN CANCER RES, V15, P7502, DOI 10.1158/1078-0432.CCR-09-0189; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatzivassiliou G, 2012, MOL CANCER THER, DOI [10.1158/1535-7163, DOI 10.1158/1535-7163]; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; Ji ZY, 2012, TRENDS MOL MED, V18, P27, DOI 10.1016/j.molmed.2011.08.001; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Li X, 2008, CELL SIGNAL, V20, P2145, DOI 10.1016/j.cellsig.2008.08.006; Little AS, 2012, BIOCHEM SOC T, V40, P73, DOI 10.1042/BST20110647; Little AS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001752; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Meng JR, 2009, CANCER BIOL THER, V8, P2073, DOI 10.4161/cbt.8.21.9844; Milojkovic D, 2009, CLIN CANCER RES, V15, P7519, DOI 10.1158/1078-0432.CCR-09-1068; Modrek B, 2009, MOL CANCER RES, V7, P1244, DOI 10.1158/1541-7786.MCR-08-0532; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nava C, 2007, J MED GENET, V44, P763, DOI 10.1136/jmg.2007.050450; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Paraiso KH, 2012, CLIN CANCER RES, DOI [10.1158/1078-0432, DOI 10.1158/1078-0432]; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Rodriguez-Viciana P, 2008, METHOD ENZYMOL, V438, P277, DOI 10.1016/S0076-6879(07)38019-1; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Smalley KSM, 2008, MOL CANCER THER, V7, P2876, DOI 10.1158/1535-7163.MCT-08-0431; Soh J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007464; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sturm OE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001212; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Tolcher AW, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.2502; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wang HS, 2011, CANCER RES, V71, P5535, DOI 10.1158/0008-5472.CAN-10-4351; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Whittaker S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000758; Witzel II, 2010, BIOCHEM SOC T, V38, P217, DOI 10.1042/BST0380217; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xi LQ, 2012, BLOOD, V119, P3330, DOI 10.1182/blood-2011-09-379339; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	75	78	82	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1207	1215		10.1038/onc.2012.160	http://dx.doi.org/10.1038/onc.2012.160			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22562245				2022-12-28	WOS:000316454500001
J	Chen, PL; Chen, CF; Chen, Y; Guo, XE; Huang, CK; Shew, JY; Reddick, RL; Wallace, DC; Lee, WH				Chen, P-L; Chen, C-F; Chen, Y.; Guo, X. E.; Huang, C-K; Shew, J-Y; Reddick, R. L.; Wallace, D. C.; Lee, W-H			Mitochondrial genome instability resulting from SUV3 haploinsufficiency leads to tumorigenesis and shortened lifespan	ONCOGENE			English	Article						mitochondrial dysfunction; Suv3; animal model; tumorigenesis	TUMOR-SUPPRESSOR; DNA MUTATIONS; OXIDATIVE STRESS; RNA HELICASE; INACTIVATION; METABOLISM; TRANSCRIPTS; MAINTENANCE; STABILITY; INTEGRITY	Mitochondrial dysfunction has been a hallmark of cancer. However, whether it has a causative role awaits to be elucidated. Here, using an animal model derived from inactivation of SUV3, a mitochondrial helicase, we demonstrated that mSuv3+/- mice harbored increased mitochondrial DNA (mtDNA) mutations and decreased mtDNA copy numbers, leading to tumor development in various sites and shortened lifespan. These phenotypes were transmitted maternally, indicating the etiological role of the mitochondria. Importantly, reduced SUV3 expression was observed in human breast tumor specimens compared with corresponding normal tissues in two independent cohorts. These results demonstrated for the first time that maintaining mtDNA integrity by SUV3 helicase is critical for cancer suppression. Oncogene (2013) 32, 1193-1201; doi:10.1038/onc.2012.120; published online 7 May 2012	[Chen, P-L; Chen, C-F; Guo, X. E.; Wallace, D. C.; Lee, W-H] Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA; [Chen, Y.] Univ Calif Irvine, Sch Med, Dept Med, Irvine, CA 92697 USA; [Huang, C-K; Shew, J-Y; Lee, W-H] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Reddick, R. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Wallace, D. C.] Univ Calif Irvine, Sch Med, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Academia Sinica - Taiwan; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Irvine	Lee, WH (corresponding author), Univ Calif Irvine, Sch Med, Dept Biol Chem, 124 Sprague Hall, Irvine, CA 92697 USA.	plchen@uci.edu; whlee@uci.edu	Chen, Phang-Lang/J-5031-2013	Chen, Chi-Fen/0000-0002-6391-821X	NIH [AG027877, NS21328, AG13154]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328, R01NS041850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027877, R01AG024373, R01AG013154] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dennis Wang for his critical reading, Dr Tom Doetschman for providing 129/Sv mouse genomic library, Andrea Nikitin, Suna Cai and Weiwei Fan for their excellent assistance. This study was supported by grant NIH AG027877 to WHL and PLC, and NS21328 and AG13154 to DCW. Based on the UCI's policy, it is declared that WHL serves as a member of Board of Directors of GeneTex, Inc. This arrangement has been reviewed and approved by the UCI COI committee.	Alberici P, 2006, ONCOGENE, V25, P1841, DOI 10.1038/sj.onc.1209226; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Chen PL, 2005, MOL CELL BIOL, V25, P3535, DOI 10.1128/MCB.25.9.3535-3542.2005; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101; de Grey ADNJ, 2002, EUR J BIOCHEM, V269, P2003, DOI 10.1046/j.1432-1033.2002.02868.x; Dziembowski A, 2003, J BIOL CHEM, V278, P1603, DOI 10.1074/jbc.M208287200; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Golden TR, 2001, MECH AGEING DEV, V122, P1577, DOI 10.1016/S0047-6374(01)00288-3; GOLIK P, 1995, CURR GENET, V28, P217, DOI 10.1007/BF00309780; Guo XE, 2011, J BIOL CHEM, V286, P38783, DOI 10.1074/jbc.M111.257956; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Khidr L, 2008, J BIOL CHEM, V283, P27064, DOI 10.1074/jbc.M802991200; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lin XQ, 2007, MOL CELL BIOL, V27, P4905, DOI 10.1128/MCB.02396-06; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pereira M, 2007, MECH AGEING DEV, V128, P609, DOI 10.1016/j.mad.2007.09.001; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Rodriguez-Santiago B, 2001, EUR J HUM GENET, V9, P279, DOI 10.1038/sj.ejhg.5200629; Rowley PT, 2005, ANNU REV MED, V56, P539, DOI 10.1146/annurev.med.56.061704.135235; Shu ZY, 2004, BIOCHEMISTRY-US, V43, P4781, DOI 10.1021/bi0356449; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; STEPIEN PP, 1995, CURR GENET, V27, P234, DOI 10.1007/BF00326154; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988; Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314; Wallace DC, 2009, GENE DEV, V23, P1714, DOI 10.1101/gad.1784909; Wang DDH, 2009, J BIOL CHEM, V284, P20812, DOI 10.1074/jbc.M109.009605; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yui R, 2003, GENES GENET SYST, V78, P245; Zanssen S, 2005, PLOS MED, V2, P1082, DOI 10.1371/journal.pmed.0020401; Zheng L, 2002, ADV CANCER RES, V85, P13, DOI 10.1016/S0065-230X(02)85002-3	51	28	29	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1193	1201		10.1038/onc.2012.120	http://dx.doi.org/10.1038/onc.2012.120			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22562243	Green Accepted, Green Submitted			2022-12-28	WOS:000316428800013
J	Zheng, HX; Cai, YD; Wang, YD; Cui, XB; Xie, TT; Li, WJ; Peng, L; Zhang, Y; Wang, ZQ; Wang, J; Jiang, B				Zheng, H. X.; Cai, Y. D.; Wang, Y. D.; Cui, X. B.; Xie, T. T.; Li, W. J.; Peng, L.; Zhang, Y.; Wang, Z. Q.; Wang, J.; Jiang, B.			Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer	ONCOGENE			English	Article						Fas signaling; metastasis; motility; epithelial-mesenchymal transition	COLORECTAL CANCER.; TUMOR PROGRESSION; GLIOMA-CELLS; CD95; EXPRESSION; COLON; MECHANISMS; CARCINOMA; RESECTION; SURVIVAL	Fas signaling was reported to participate in cell apoptosis. However, this pathway has also been shown to promote tumor cell motility, leading to the hypothesis that Fas signaling may induce epithelial mesenchymal transition (EMT) to promote metastasis. The effects of Fas-ligand (FasL) treatment and inhibition of Fas signaling on colorectal and gastric cancer cells were tested using motility assay, immunofluorescence, RT-PCR and immunoblot analyses. Fas signaling downregulated epithelial markers, upregulated mesenchymal markers and promoted motility in gastrointestinal (GI) cancer cells. FasL treatment also increased the expression of EMT transcriptional factors in the nucleus and induced a spindle shape cell morphology in these cells. Knockdown of Snail or Twist expression significantly decreased FasL-induced motility. The ERK1/2 pathway was activated by Fas signaling and is required for FasL-induced EMT and motility. Moreover, oxaliplatin, a chemotherapeutic agent, induced EMT partly through Fas signaling. Evaluation of human GI clinical specimens showed that FasL expression increased whereas E-cadherin expression decreased during GI cancer progression. Both markers were significantly inversely correlated. Tissue samples with a non-EMT phenotype were mainly distributed in patients with early cancer stages, whereas samples with an EMT phenotype were mostly distributed in patients with advanced cancer stages. A non-EMT phenotype significantly correlated with better prognosis. Altogether, these data indicate that Fas signaling may induce EMT to promote tumor motility and metastasis in GI cancer in vivo and in vitro. Oncogene (2013) 32, 1183-1192; doi:0.1038/onc.2012.126; published online 16 April 2012	[Zheng, H. X.; Cai, Y. D.; Wang, Y. D.; Cui, X. B.; Xie, T. T.; Li, W. J.; Peng, L.; Zhang, Y.; Wang, Z. Q.; Wang, J.; Jiang, B.] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China; [Cai, Y. D.] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Gastroenterol, Beijing, Peoples R China; [Peng, L.] Mt Sinai Sch Med, Dept Med, Inst Immunol, New York, NY USA; [Zhang, Y.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Wang, Z. Q.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA	Southern Medical University - China; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; Icahn School of Medicine at Mount Sinai; Harvard University; Dana-Farber Cancer Institute; Icahn School of Medicine at Mount Sinai	Jiang, B (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guanzhoudabaobei 1838, Guangzhou 510515, Guangdong, Peoples R China.	prof.jiang@yahoo.com.cn	Cui, XiaoBing/K-8159-2012	Cui, XiaoBing/0000-0002-5460-0357	Science and Technology Project of Guangzhou [2009Z1-E051]; Nanfang Hospital President Foundation [2011C015]	Science and Technology Project of Guangzhou; Nanfang Hospital President Foundation	This study was supported by Science and Technology Project of Guangzhou (2009Z1-E051) and Nanfang Hospital President Foundation(2011C015).	Adam R, 2004, ANN SURG, V240, P1052, DOI 10.1097/01.sla.0000145964.08365.01; Ametller E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-161; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Chen L, 2010, NATURE, V465, P492, DOI 10.1038/nature09075; Choi C, 2001, CANCER RES, V61, P3084; Curtin JF, 2003, CELL SIGNAL, V15, P983, DOI 10.1016/S0898-6568(03)00093-7; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; GRIFFIN MR, 1987, CANCER-AM CANCER SOC, V60, P2318, DOI 10.1002/1097-0142(19871101)60:9<2318::AID-CNCR2820600934>3.0.CO;2-B; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kleber S, 2008, CANCER CELL, V13, P235, DOI 10.1016/j.ccr.2008.02.003; Lavrik IN, 2007, J BIOL CHEM, V282, P13664, DOI 10.1074/jbc.M700434200; Li HC, 2008, AM J PHYSIOL-GASTR L, V294, pG263, DOI 10.1152/ajpgi.00267.2007; Li HC, 2011, GASTROENTEROLOGY, V140, pS162; Li HC, 2009, GASTROENTEROLOGY, V137, P934, DOI 10.1053/j.gastro.2009.06.004; Medici D, 2006, MOL BIOL CELL, V17, P1871, DOI 10.1091/mbc.E05-08-0767; Mitsiades N, 2001, CANCER RES, V61, P577; O'Brien DI, 2005, EXPERT OPIN THER TAR, V9, P1031, DOI 10.1517/14728222.9.5.1031; Park DR, 2003, J IMMUNOL, V170, P6209, DOI 10.4049/jimmunol.170.12.6209; Pryczynicz A, 2010, FOLIA HISTOCHEM CYTO, V48, P425, DOI 10.2478/v10042-010-0058-3; Przybylo JA, 2007, INT J BIOCHEM CELL B, V39, P1082, DOI 10.1016/j.biocel.2007.03.002; Shinohara H, 2000, CANCER RES, V60, P1766; Soumaoro LT, 2004, CLIN CANCER RES, V10, P8465, DOI 10.1158/1078-0432.CCR-04-0653; Tsanou E, 2008, ANTICANCER RES, V28, P3815; Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089; Wang J, 2009, J HISTOCHEM CYTOCHEM, V57, P363, DOI 10.1369/jhc.2008.953091; Yan W, 2009, BIOCHEM BIOPH RES CO, V382, P631, DOI 10.1016/j.bbrc.2009.03.088; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Zhu Q, 2006, EUR J GASTROEN HEPAT, V18, P1071, DOI 10.1097/01.meg.0000231750.68513.6c	33	53	53	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1183	1192		10.1038/onc.2012.126	http://dx.doi.org/10.1038/onc.2012.126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22508480	Bronze			2022-12-28	WOS:000316428800012
J	Cho, KW; Park, JH; Park, CW; Lee, D; Lee, E; Kim, DJ; Kim, KJ; Yoon, SH; Park, Y; Kim, E; Cho, S; Jang, S; Park, BC; Chi, SW; Yoo, SH; Jang, MH; Kim, HN; Kim, E; Jo, K; Park, YW				Cho, K-W; Park, J. H.; Park, C-W; Lee, D.; Lee, E.; Kim, D. J.; Kim, K. J.; Yoon, S. H.; Park, Y.; Kim, E.; Cho, S.; Jang, S.; Park, B-C; Chi, S-W; Yoo, S. H.; Jang, M. H.; Kim, H. N.; Kim, E.; Jo, K.; Park, Y. W.			Identification of a pivotal endocytosis motif in c-Met and selective modulation of HGF-dependent aggressiveness of cancer using the 16-mer endocytic peptide	ONCOGENE			English	Article						c-Met; endocytosis; dileucine motif; peptide delivery; cancer	GLUCOSE-TRANSPORTER GLUT4; DILEUCINE MOTIF; RECEPTOR; CLATHRIN; PHOSPHORYLATION; TRAFFICKING; PENETRATIN; BINDING; DOMAIN; INTERNALIZATION	Since c-Met has an important role in the development of cancer, it is considered as an attractive target for cancer therapy. Although molecular mechanisms for oncogenic property of c-Met have been actively investigated, regulatory elements for c-Met endocytosis and its effect on c-Met signaling remain unclear. In this study, we identified a pivotal endocytic motif in c-Met and tested it for selective modulation of HGF-induced c-Met response. Using various chimeric constructs with the cytoplasmic tail of c-Met, we were able to demonstrate that a dileucine motif located in the C-terminus of c-Met acts to regulate its endocytosis. Synthetic peptide Ant-3S, consisting of antennapedia-derived protein transduction domain (designated as Ant) and c-Met-derived 16 amino-acids (designated as 3S, spanning amino-acids 1378 to 1393), rapidly moved into cancer cells and disrupted c-Met trafficking. Importantly, an extension of c-Met retention time on the membrane by Ant-3S peptide significantly decreased phosphorylation-dependent c-Met signal transduction. Additionally, the peptide effectively inhibited HGF-induced cell growth, scattering and migration. The underlying molecular mechanism for these observations has been investigated and revealed that the dileucine motif interacts with endocytic machinery, including adaptin beta and caveolin-1, for sustained and enhanced signal transduction. Finally, Ant-3S peptide specifically blocked internalization of interleukin-2 receptor alpha-subunit/3S chimeric protein, but not the other receptors, including Glut4, Glut8 and transferrin receptor. Such results indicate the presence of a selective endocytic assembly for c-Met. It also suggests a potential for c-Met-specific anti-cancer therapy using the identified endocytic motif in this study. Oncogene (2013) 32, 1018-1029; doi:10.1038/onc.2012.122; published online 23 April 2012	[Cho, K-W; Park, J. H.; Park, C-W; Lee, D.; Lee, E.; Kim, D. J.; Kim, K. J.; Yoon, S. H.; Park, Y.; Kim, E.; Cho, S.; Jang, S.; Park, B-C; Park, Y. W.] Korea Res Inst Biosci & Biotechnol, Aging Res Ctr, Taejon, South Korea; [Park, J. H.; Kim, E.] Chungnam Natl Univ, Coll Biol Sci & Biotechnol, Taejon, South Korea; [Chi, S-W] Korea Res Inst Biosci & Biotechnol, Med Prote Res Ctr, Taejon, South Korea; [Yoo, S. H.; Jang, M. H.; Kim, H. N.] A&R Therapeut, Taejon, South Korea; [Jo, K.] Natl Canc Ctr, Natl OncoVenture, Goyang 410769, Gyeonggi Do, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Cancer Center - Korea (NCC)	Jo, K (corresponding author), Natl Canc Ctr, Natl OncoVenture, 323 Ilsan Ro, Goyang 410769, Gyeonggi Do, South Korea.	kiwonjo@ncc.re.kr; ywpark@kribb.re.kr		Kim, Eunhee/0000-0002-7738-1222	Ministry of Knowledge Economy (Regional R&D Cluster Project) of Korea [B0009735]	Ministry of Knowledge Economy (Regional R&D Cluster Project) of Korea(Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea)	We thank the members of the Kiwon and Young Woo laboratory for their inputs and discussions. We thank Julie Kim and Oh Gordon Chong for editing. This work was supported by the Ministry of Knowledge Economy (Regional R&D Cluster Project B0009735) of Korea.	Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Al-Hasani H, 1999, FEBS LETT, V460, P338, DOI 10.1016/S0014-5793(99)01369-1; Ball LJ, 2000, EMBO J, V19, P4903, DOI 10.1093/emboj/19.18.4903; Branco MC, 2011, CURR OPIN CHEM BIOL, V15, P427, DOI 10.1016/j.cbpa.2011.03.021; Byland R, 2007, MOL BIOL CELL, V18, P414, DOI 10.1091/mbc.E06-06-0535; Cantiani L, 2007, CANCER RES, V67, P7675, DOI 10.1158/0008-5472.CAN-06-4697; Clark SG, 1997, P NATL ACAD SCI USA, V94, P10438, DOI 10.1073/pnas.94.19.10438; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; Craven SE, 2000, J BIOL CHEM, V275, P20045, DOI 10.1074/jbc.M910153199; Czajlik A, 2002, J PEPT SCI, V8, P151, DOI 10.1002/psc.380; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Doray B, 2007, MOL BIOL CELL, V18, P1887, DOI 10.1091/mbc.E07-01-0012; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Flessner LB, 2009, TRAFFIC, V10, P324, DOI 10.1111/j.1600-0854.2008.00866.x; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gomes DA, 2008, J BIOL CHEM, V283, P4344, DOI 10.1074/jbc.M706550200; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Grepin R, 2010, J ONCOL, V2010, DOI 10.1155/2010/835680; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kelly BT, 2008, NATURE, V456, P976, DOI 10.1038/nature07422; Kermorgant S, 2004, EMBO J, V23, P3721, DOI 10.1038/sj.emboj.7600396; Kermorgant S, 2003, J BIOL CHEM, V278, P28921, DOI 10.1074/jbc.M302116200; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; Kirisits A, 2007, INT J BIOCHEM CELL B, V39, P2173, DOI 10.1016/j.biocel.2007.07.012; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Li N, 2007, J BIOL CHEM, V282, P16764, DOI 10.1074/jbc.M610835200; Lindberg M, 2003, EUR J BIOCHEM, V270, P3055, DOI 10.1046/j.1432-1033.2003.03685.x; Lindgren M, 2000, BIOCONJUGATE CHEM, V11, P619, DOI 10.1021/bc990156s; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Lisinski I, 2001, BIOCHEM J, V358, P517, DOI 10.1042/0264-6021:3580517; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Mettlen M, 2009, MOL BIOL CELL, V20, P3251, DOI 10.1091/mbc.E09-03-0256; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Polo S, 2006, CELL, V124, P897, DOI 10.1016/j.cell.2006.02.025; Rosca EV, 2011, CURR PHARM BIOTECHNO, V12, P1101; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; Schmidt U, 2006, J CELL SCI, V119, P2321, DOI 10.1242/jcs.02943; Schroeder B, 2010, EMBO J, V29, P3039, DOI 10.1038/emboj.2010.190; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Singleton PA, 2007, J BIOL CHEM, V282, P30643, DOI 10.1074/jbc.M702573200; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Stein A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002524; Tong JF, 2009, MOL CELL PROTEOMICS, V8, P2131, DOI 10.1074/mcp.M900148-MCP200; Wang W, 2003, J BIOL CHEM, V278, P36848, DOI 10.1074/jbc.M301540200	52	10	10	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					1018	1029		10.1038/onc.2012.122	http://dx.doi.org/10.1038/onc.2012.122			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22525273				2022-12-28	WOS:000316523200009
J	Iida, M; Brand, TM; Campbell, DA; Li, C; Wheeler, DL				Iida, M.; Brand, T. M.; Campbell, D. A.; Li, C.; Wheeler, D. L.			Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor	ONCOGENE			English	Article						nuclear EGFR; SFK; Yes; Lyn	SRC-FAMILY KINASES; SQUAMOUS-CELL CARCINOMA; TYROSINE KINASES; C-SRC; ACQUIRED-RESISTANCE; BREAST-CANCER; EGF RECEPTOR; LUNG-CANCER; SIGNALING NETWORK; PROGNOSTIC VALUE	The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR antibody that has been approved for use in oncology. Previously we investigated mechanisms of resistance to cetuximab using a model derived from the non-small cell lung cancer line NCI-H226. We demonstrated that cetuximab-resistant clones (Ctx(R)) had increased nuclear localization of the EGFR. This process was mediated by Src family kinases (SFKs), and nuclear EGFR had a role in resistance to cetuximab. To better understand SFK-mediated nuclear translocation of EGFR, we investigated which SFK member(s) controlled this process as well as the EGFR tyrosine residues that are involved. Analyses of mRNA and protein expression indicated upregulation of the SFK members Yes (v-Yes-1 yamaguchi sarcoma viral oncogene) and Lyn (v-yes-1 Yamaguchi sarcoma viral-related oncogene homolog) in all Ctx(R) clones. Further, immunoprecipitation analysis revealed that EGFR interacts with Yes and Lyn in Ctx(R) clones, but not in cetuximab-sensitive (Ctx(S)) parental cells. Using RNAi interference, we found that knockdown of either Yes or Lyn led to loss of EGFR translocation to the nucleus. Conversely, overexpression of Yes or Lyn in low nuclear EGFR-expressing Ctx(S) parental cells led to increased nuclear EGFR. Chromatin imnnunoprecipitation (Chip) assays confirmed nuclear EGFR complexes associated with the promoter of the known EGFR target genes B-Myb and iNOS. Further, all Ctx(R) clones exhibited upregulation of B-Myb and iNOS at the mRNA and protein levels. siRNAs directed at Yes or Lyn led to decreased binding of EGFR complexes to the B-Myb and iNOS promoters based on ChIP analyses. SFKs have been shown to phosphorylate EGFR on tyrosines 845 and 1101 (Y845 and Y1101), and mutation of Y1101, but not Y845, impaired nuclear entry of the EGFR. Taken together, our findings demonstrate that Yes and Lyn phosphorylate EGFR at Y1101, which influences EGFR nuclear translocation in this model of cetuximab resistance. Oncogene (2013) 32, 759-767; doi:10.1038/onc.2012.90; published online 19 March 2012	[Iida, M.; Brand, T. M.; Campbell, D. A.; Li, C.; Wheeler, D. L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Wheeler, DL (corresponding author), Univ Wisconsin, Ctr Comprehens Canc, Dept Human Oncol, 1111 Highland Ave,WIMR 3159, Madison, WI 53705 USA.	dlwheeler@wisc.edu	Wheeler, Deric/B-7175-2013	Wheeler, Deric/0000-0001-5915-3675	National Cancer Institute [P30CA014520]; Clinical and Translational Science Award program of the National Center for Research Resources [1UL1RR025011]; National Institutes of Health (DUN) from the American Cancer Society [RSG-10-193-01-TBG]; NIH from Graduate Training in Cellular and Molecular Pathogenesis of Human Diseases [T32 GM08.1061-01A2]; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000428, UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, KL2RR025012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM081061] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Clinical and Translational Science Award program of the National Center for Research Resources; National Institutes of Health (DUN) from the American Cancer Society; NIH from Graduate Training in Cellular and Molecular Pathogenesis of Human Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project was supported, in part, by grant P30CA014520 from the National Cancer Institute, grant 1UL1RR025011 from the Clinical and Translational Science Award program of the National Center for Research Resources and the National Institutes of Health (DUN) by grant RSG-10-193-01-TBG from the American Cancer Society (DLW), and by NIH grant T32 GM08.1061-01A2 from Graduate Training in Cellular and Molecular Pathogenesis of Human Diseases (TMB).	Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Brand TM, 2011, DISCOV MED, V12, P419; Brand TM, 2011, CANCER BIOL THER, V12, P436, DOI 10.4161/cbt.12.5.16394; Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Carpenter G, 2009, EXP CELL RES, V315, P1556, DOI 10.1016/j.yexcr.2008.09.027; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dittmann K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-69; Fu YN, 2008, ONCOGENE, V27, P957, DOI 10.1038/sj.onc.1210684; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hadzisejdic I, 2010, MODERN PATHOL, V23, P392, DOI 10.1038/modpathol.2009.166; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200; Hsu SC, 2009, AM J TRANSL RES, V1, P249; Huang WC, 2011, J BIOL CHEM, V286, P20558, DOI 10.1074/jbc.M111.240796; Hung LY, 2008, NUCLEIC ACIDS RES, V36, P4337, DOI 10.1093/nar/gkn417; Jaganathan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019605; Kasai A, 2005, GENES CELLS, V10, P1175, DOI 10.1111/j.1365-2443.2005.00909.x; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Koppikar P, 2008, CLIN CANCER RES, V14, P4284, DOI 10.1158/1078-0432.CCR-07-5226; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Li CF, 2012, ANN SURG ONCOL, V19, P443, DOI 10.1245/s10434-011-1942-6; Li CR, 2010, RADIOTHER ONCOL, V97, P330, DOI 10.1016/j.radonc.2010.06.010; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Lu KV, 2009, CANCER RES, V69, P6889, DOI 10.1158/0008-5472.CAN-09-0347; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Piccione EC, 2012, ONCOGENE, V31, P2953, DOI 10.1038/onc.2011.465; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; Su T, 2010, NAT CELL BIOL, V12, P1143, DOI 10.1038/ncb2118; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Wang YN, 2010, J BIOL CHEM, V285, P38720, DOI 10.1074/jbc.M110.158659; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Wheeler DL, 2009, CANCER BIOL THER, V8, P696, DOI 10.4161/cbt.8.8.7903; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706; Zhao YT, 2006, J BIOL CHEM, V281, P19501, DOI 10.1074/jbc.M511224200	58	58	60	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					759	767		10.1038/onc.2012.90	http://dx.doi.org/10.1038/onc.2012.90			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430206	Green Accepted			2022-12-28	WOS:000315746700009
J	Wu, J; Lee, SW; Zhang, X; Han, F; Kwan, SY; Yuan, X; Yang, WL; Jeong, YS; Rezaeian, AH; Gao, Y; Zeng, YX; Lin, HK				Wu, J.; Lee, S-W; Zhang, X.; Han, F.; Kwan, S-Y; Yuan, X.; Yang, W-L; Jeong, Y. S.; Rezaeian, A. H.; Gao, Y.; Zeng, Y-X; Lin, H-K			Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex	ONCOGENE			English	Article						Foxo3a; Skp2 SCF complex; ubiquitination	CDK INHIBITOR P27; CELL-CYCLE; UBIQUITIN LIGASE; PROMOTES TUMORIGENESIS; DEPENDENT REGULATION; CANCER PROGRESSION; DEGRADATION; P27(KIP1); SENESCENCE; EXPRESSION	Skp2 (S-phase kinase-associated protein-2) SCF complex displays E3 ligase activity and oncogenic activity by regulating protein ubiquitination and degradation, in turn regulating cell cycle entry, senescence and tumorigenesis. The maintenance of the integrity of Skp2 SCF complex is critical for its E3 ligase activity. The Skp2 F-box protein is a rate-limiting step and key factor in this complex, which binds to its protein substrates and triggers ubiquitination and degradation of its substrates. Skp2 is found to be overexpressed in numerous human cancers, which has an important role in tumorigenesis. The molecular mechanism by which the function of Skp2 and Skp2 SCF complex is regulated remains largely unknown. Here we show that Foxo3a transcription factor is a novel and negative regulator of Skp2 SCF complex. Foxo3a is found to be a transcriptional repressor of Skp2 gene expression by directly binding to the Skp2 promoter, thereby inhibiting Skp2 protein expression. Surprisingly, we found for the first time that Foxo3a also displays a transcription-independent activity by directly interacting with Skp2 and disrupting Skp2 SCF complex formation, in turn inhibiting Skp2 SCF E3 ligase activity and promoting p27 stability. Finally, we show that the oncogenic activity of Skp2 is repressed by Foxo3a overexpression. Our results not only reveal novel insights into how Skp2 SCF complex is regulated, but also establish a new role for Foxo3a in tumor suppression through a transcription-dependent and independent manner. Oncogene (2013) 32, 78-85; doi:10.1038/onc.2012.26; published online 6 February 2012	[Wu, J.; Lee, S-W; Zhang, X.; Han, F.; Kwan, S-Y; Yuan, X.; Yang, W-L; Jeong, Y. S.; Rezaeian, A. H.; Gao, Y.; Lin, H-K] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Wu, J.; Zeng, Y-X] Sun Yat Sen Univ Canc Ctr, Dept Expt Res, Guangzhou, Guangdong, Peoples R China; [Wu, J.; Zeng, Y-X] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol S China, Guangzhou, Guangdong, Peoples R China; [Lee, S-W; Zhang, X.; Han, F.; Kwan, S-Y; Yang, W-L; Jeong, Y. S.; Gao, Y.; Lin, H-K] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA; [Wu, J.] Guangzhou Med Univ, Canc Hosp, Canc Ctr, Guangzhou, Guangdong, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University	Lin, HK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.	hklin@mdanderson.org	kwan, suet yan/AAH-3974-2020; Rezaeian, Abdol-Hossein/AAV-6900-2021; Yang, Wei-Lei/E-2598-2012	Zhang, Xian/0000-0001-9674-7886	MD Anderson Trust Scholar Fund; National Cancer Institute's Prostate Cancer Specialized Program of Research Excellence (SPORE) development grant at the MD Anderson Cancer Center; NIH; CPRIT; DOD; NATIONAL CANCER INSTITUTE [R01CA136787, R01CA149321, P50CA140388] Funding Source: NIH RePORTER	MD Anderson Trust Scholar Fund; National Cancer Institute's Prostate Cancer Specialized Program of Research Excellence (SPORE) development grant at the MD Anderson Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs ME Greenberg, WR Sellers, VA Boussiotis and D Bohmann for providing the reagents. We are grateful to Dr Lin's lab members for their insightful comments and suggestions. We extend our special thanks to S Zhang and Dr Z Han for their technical support. This work was supported by the MD Anderson Trust Scholar Fund, the National Cancer Institute's Prostate Cancer Specialized Program of Research Excellence (SPORE) development grant at the MD Anderson Cancer Center, NIH RO1 grants, CPRIT grant, and DOD New Investigator Award to HKL.	Appleman LJ, 2006, CELL CYCLE, V5, P2123, DOI 10.4161/cc.5.18.3139; Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chan CH, 2011, J MOL MED, V89, P857, DOI 10.1007/s00109-011-0766-y; Chan CH, 2010, THESCIENTIFICWORLDJO, V10, P1001, DOI 10.1100/tsw.2010.89; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Imaki H, 2003, CANCER RES, V63, P4607; Jonason JH, 2007, CELL CYCLE, V6, P951, DOI 10.4161/cc.6.8.4104; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Reichert M, 2007, CANCER RES, V67, P4149, DOI 10.1158/0008-5472.CAN-06-4484; Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559; Schneider G, 2006, EMBO J, V25, P3801, DOI 10.1038/sj.emboj.7601259; Sicinski P, 2007, GENE DEV, V21, P1703, DOI 10.1101/gad.1583207; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; van Duijn PW, 2006, PROSTATE, V66, P749, DOI 10.1002/pros.20398; Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538	44	31	33	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2013	32	1					78	85		10.1038/onc.2012.26	http://dx.doi.org/10.1038/onc.2012.26			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22310285	Green Accepted			2022-12-28	WOS:000313029500008
J	Yoshikawa, S; Kukimoto-Niino, M; Parker, L; Handa, N; Terada, T; Fujimoto, T; Terazawa, Y; Wakiyama, M; Sato, M; Sano, S; Kobayashi, T; Tanaka, T; Chen, L; Liu, ZJ; Wang, BC; Shirouzu, M; Kawa, S; Semba, K; Yamamoto, T; Yokoyama, S				Yoshikawa, S.; Kukimoto-Niino, M.; Parker, L.; Handa, N.; Terada, T.; Fujimoto, T.; Terazawa, Y.; Wakiyama, M.; Sato, M.; Sano, S.; Kobayashi, T.; Tanaka, T.; Chen, L.; Liu, Z-J; Wang, B-C; Shirouzu, M.; Kawa, S.; Semba, K.; Yamamoto, T.; Yokoyama, S.			Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor	ONCOGENE			English	Article						EGFR; T790M; gefitinib; tyrosine kinase inhibitor; NSCLC; drug resistance	EGFR KINASE INHIBITORS; DIFFRACTION DATA; MUTATIONS; GEFITINIB; ACTIVATION; RESISTANT; TRANSFORMATION; REFINEMENT; MECHANISM; SOFTWARE	The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain. The non-small cell lung cancer (NSCLC)-associated EGFR mutants, L858R and G719S, are constitutively active and oncogenic. They display sensitivity to TK inhibitors, including gefitinib and erlotinib. In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants. In this study, our biochemical analyses revealed that the introduction of the T790M mutation confers gefitinib resistance on the G719S mutant. The G719S/T790M double mutant has enhanced activity and retains high gefitinib-binding affinity. The T790M mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant. Structural analyses of the G719S/T790M double mutant, as well as the wild type and the G719S and L858R mutants, revealed that the T790M mutation stabilizes the hydrophobic spine of the active EGFR-TK conformation. The Met790 side chain of the G719S/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands. In the L858R mutant structure, the active-site cleft is expanded by the repositioning of Phe723 within the P-loop. Notably, the introduction of the F723A mutation greatly enhanced the gefitinib sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity. Taken together, our results provide a structural basis for the altered drug sensitivities caused by distinct NSCLC-associated EGFR mutations. Oncogene (2013) 32, 27-38; doi:10.1038/onc.2012.21; published online 20 February 2012	[Yoshikawa, S.; Kukimoto-Niino, M.; Parker, L.; Handa, N.; Terada, T.; Fujimoto, T.; Terazawa, Y.; Wakiyama, M.; Shirouzu, M.; Yokoyama, S.] Yokohama Inst, RIKEN Syst & Struct Biol Ctr, Yokohama, Kanagawa 2300045, Japan; [Yamamoto, T.] Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo 1088639, Japan; [Sato, M.; Sano, S.; Kobayashi, T.; Tanaka, T.] Japan Aerosp Explorat Agcy, Ibaraki, Japan; [Chen, L.; Liu, Z-J; Wang, B-C] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; [Semba, K.] Waseda Univ, Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Tokyo, Japan; [Yamamoto, T.] Okinawa Inst Sci & Technol, Cell Signal Unit, Okinawa, Japan; [Yokoyama, S.] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan	RIKEN; University of Tokyo; Japan Aerospace Exploration Agency (JAXA); University System of Georgia; University of Georgia; Waseda University; Okinawa Institute of Science & Technology Graduate University; University of Tokyo	Yokoyama, S (corresponding author), Yokohama Inst, RIKEN Syst & Struct Biol Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	tyamamot@ims.u-tokyo.ac.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Kukimoto-Niino, Mutsuko/C-6704-2017; Wakiyama, Motoaki/N-6928-2015; Shirouzu, Mikako/A-6521-2016; Liu, Zhi-Jie/A-3946-2012	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kukimoto-Niino, Mutsuko/0000-0002-4178-1611; Wakiyama, Motoaki/0000-0002-8029-4795; Liu, Zhi-Jie/0000-0001-7279-2893; Sano, Satoshi/0000-0001-5909-7474	US Department of Energy, Office of Science, Office of Basic Energy Sciences [W-31-109-Eng-38]; High-quality Protein Crystal Growth Experiment Project in JEM; RIKEN Structural Genomics/Proteomics Initiative; National Project on Protein Structural and Functional Analyses; Targeted Proteins Research Program (TPRP); Ministry of Education, Culture, Sports, Science and Technology of Japan; Japanese Society for the Promotion of Science Fellowship (LJP)	US Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); High-quality Protein Crystal Growth Experiment Project in JEM; RIKEN Structural Genomics/Proteomics Initiative; National Project on Protein Structural and Functional Analyses(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Targeted Proteins Research Program (TPRP)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese Society for the Promotion of Science Fellowship (LJP)	We thank C Takemoto, T Kaminishi, M Kawazoe, Y Fujii and S Kishishita for assisting with the data collection; Y Ishizuka-Katsura, R Akasaka, M Yamaguchi-Hirafuji, T Uchikubo-Kamo, A Urushibata and N Maoka for technical assistance; S Kusano for helpful assistance; and K Murayama for helpful advice. We also thank the beamline staffs of the X06SA (SLS), BL-5A (PF), BL41XU (SPring-8) and BL26B2 (SPring-8) beamlines. Portions of the data were collected at the Southeast Regional Collaborative Access Team (SER-CAT) 22-ID beamline at the Advanced Photon Source, Argonne National Laboratory. Supporting institutions may be found at http://www.ser.anl.gov/. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. W-31-109-Eng-38. This study was supported in part by the 'High-quality Protein Crystal Growth Experiment Project in JEM' promoted by the Japan Aerospace Exploration Agency. The Russian Spacecraft 'Progress' and 'Soyuz', provided by the Russian Federal Space Agency, were used for space transportation. A portion of the crystallization technology for the counter-diffusion method was developed by European Space Agency and University of Granada. This work was supported by the RIKEN Structural Genomics/Proteomics Initiative, the National Project on Protein Structural and Functional Analyses, the Targeted Proteins Research Program (TPRP), the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by a Japanese Society for the Promotion of Science Fellowship (LJP).	Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Azam M, 2008, NAT STRUCT MOL BIOL, V15, P1109, DOI 10.1038/nsmb.1486; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carmi C, 2010, J MED CHEM, V53, P2038, DOI 10.1021/jm901558p; Cha MY, 2012, INT J CANCER, V130, P2445, DOI 10.1002/ijc.26276; Cha MY, 2009, J MED CHEM, V52, P6880, DOI 10.1021/jm901146p; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DeLano WL, 2005, PYMOL V 0 98; Dixit A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007485; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; GARCIARUIZ JM, 1994, ACTA CRYSTALLOGR D, V50, P484, DOI 10.1107/S0907444993014350; Gilmer TM, 2008, CANCER RES, V68, P571, DOI 10.1158/0008-5472.CAN-07-2404; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kobayashi N, 2012, LUNG CANCER, V75, P161, DOI 10.1016/j.lungcan.2011.04.022; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kornev AP, 2006, P NATL ACAD SCI USA, V103, P17783, DOI 10.1073/pnas.0607656103; LESLIE AG, 1992, JOINT CCP4 ESF EAMCB, V26; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Liu Y, 1998, BIOORGAN MED CHEM, V6, P1219, DOI 10.1016/S0968-0896(98)00099-6; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Taube E, 2012, INT J CANCER, V131, P970, DOI 10.1002/ijc.26461; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wakeling AE, 2002, CANCER RES, V62, P5749; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Wu CH, 2010, J MED CHEM, V53, P7316, DOI 10.1021/jm100607r; Yao M, 2006, ACTA CRYSTALLOGR D, V62, P189, DOI 10.1107/S0907444905038965; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhou WJ, 2011, BIOORG MED CHEM LETT, V21, P638, DOI 10.1016/j.bmcl.2010.12.036; Zhou WJ, 2009, NATURE, V462, P1070, DOI 10.1038/nature08622	48	88	91	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					27	38		10.1038/onc.2012.21	http://dx.doi.org/10.1038/onc.2012.21			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22349823				2022-12-28	WOS:000313029500003
J	Kulak, MV; Cyr, AR; Woodfield, GW; Bogachek, M; Spanheimer, PM; Li, T; Price, DH; Domann, FE; Weigel, RJ				Kulak, M. V.; Cyr, A. R.; Woodfield, G. W.; Bogachek, M.; Spanheimer, P. M.; Li, T.; Price, D. H.; Domann, F. E.; Weigel, R. J.			Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer	ONCOGENE			English	Article						TFAP2C; GPX1; breast cancer; oxidative stress	OXIDATIVE STRESS; PRO198LEU POLYMORPHISM; ACTIVATOR PROTEIN-2; CELL-LINES; EXPRESSION; AP-2; RECEPTOR; OVEREXPRESSION; CLONING; FAMILY	The complexity of gene regulation has created obstacles to defining mechanisms that establish the patterns of gene expression characteristic of the different clinical phenotypes of breast cancer. TFAP2C is a transcription factor that has a critical role in the regulation of both estrogen receptor-alpha (ER alpha) and c-ErbB2/HER2 (Her2). Herein, we performed chromatin immunoprecipitation and direct sequencing (ChIP-seq) for TFAP2C in four breast cancer cell lines. Comparing the genomic binding sites for TFAP2C, we identified that glutathione peroxidase (GPX1) is regulated by TFAP2C through an AP-2 regulatory region in the promoter of the GPX1 gene. Knockdown of TFAP2C, but not the related factor TFAP2A, resulted in an abrogation of GPX1 expression. Selenium-dependent GPX activity correlated with endogenous GPX1 expression and overexpression of exogenous GPX1 induced GPX activity and significantly increased resistance to tert-butyl hydroperoxide. Methylation of the CpG island encompassing the AP-2 regulatory region was identified in cell lines where TFAP2C failed to bind the GPX1 promoter and GPX1 expression was unresponsive to TFAP2C. Furthermore, in cell lines where GPX1 promoter methylation was associated with gene silencing, treatment with 5'-aza-2-deoxycytidine (5'-aza-dC) (an inhibitor of DNA methylation) allowed TFAP2C to bind to the GPX1 promoter resulting in the activation of GPX1 RNA and protein expression. Methylation of the GPX1 promoter was identified in similar to 20% of primary breast cancers and a highly significant correlation between the TFAP2C and GPX1 expression was confirmed when considering only those tumors with an unmethylated promoter, whereas the related factor, TFAP2A, failed to demonstrate a correlation. The results demonstrate that TFAP2C regulates the expression of GPX1, which influences the redox state and sensitivity to oxidative stress induced by peroxides. Given the established role of GPX1 in breast cancer, the results provide an important mechanism for TFAP2C to further influence oncogenesis and progression of breast carcinoma cells.	[Kulak, M. V.; Woodfield, G. W.; Bogachek, M.; Spanheimer, P. M.; Weigel, R. J.] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; [Cyr, A. R.; Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; [Li, T.; Price, D. H.; Weigel, R. J.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Weigel, RJ (corresponding author), Univ Iowa, Dept Surg, 200 Hawkins Dr,1516 JCP, Iowa City, IA 52242 USA.	Ronald-Weigel@uiowa.edu	Li, Tiandao/F-4039-2012	Li, Tiandao/0000-0003-1650-0555; Kulak, Mikhail/0000-0002-4307-5868; Price, David/0000-0002-5597-385X; Domann, Frederick/0000-0002-0489-2179; Weigel, Ronald/0000-0002-9249-0793	National Institutes of Health [R01CA109294, R01CA115438, F30 AA019856, T32CA148062]; NATIONAL CANCER INSTITUTE [R01CA109294, T32CA078586, T32CA148062, R01CA115438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F30AA019856] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We appreciate tumor samples provided by Dr Ryan Askeland and Christine Hochstedler (Department of Pathology, University of Iowa) and statistical support from Dr Junlin Liao (Department of Surgery, University of Iowa). This work was supported in part by the National Institutes of Health grants R01CA109294 (PI: RJ Weigel) and R01CA115438 (PI: FE Domann). Anthony Cyr received salary support from NIH F30 AA019856 and Dr Philip Spanheimer was supported by the NIH grant T32CA148062 (PI: RJ Weigel). The work was also supported by a generous gift from the Kristen Olewine Milke Breast Cancer Research Fund.	Allouche A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1851; Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200; Bosher JM, 1996, ONCOGENE, V13, P1701; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Buzdar AU, 2009, ANN ONCOL, V20, P993, DOI 10.1093/annonc/mdn739; Cox DG, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-217; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; Do Jee C, 2009, EUR J CANCER, V45, P1282, DOI 10.1016/j.ejca.2008.12.027; Eckert D, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-246; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Esposito LA, 2000, FREE RADICAL BIO MED, V28, P754, DOI 10.1016/S0891-5849(00)00161-1; Feng WG, 2003, MOL CELL NEUROSCI, V24, P460, DOI 10.1016/S1044-7431(03)00209-4; Gao JP, 2008, BBA-MOL CELL RES, V1783, P2020, DOI 10.1016/j.bbamcr.2008.05.027; Gouaze V, 2001, MOL PHARMACOL, V60, P488; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Hannay JAF, 2007, MOL CANCER THER, V6, P1650, DOI 10.1158/1535-7163.MCT-06-0636; He AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-279; Hu J, 2010, BREAST CANCER RES TR, V124, P425, DOI 10.1007/s10549-010-0841-z; Hu YJ, 2005, J NUTR, V135, p3021S, DOI 10.1093/jn/135.12.3021S; Hu YJ, 2003, CANCER RES, V63, P3347; Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jenssen TK, 2002, HUM GENET, V111, P411, DOI 10.1007/s00439-002-0804-5; Johansson K, 2010, FREE RADICAL BIO MED, V49, P1638, DOI 10.1016/j.freeradbiomed.2010.08.013; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Maiti AK, 2012, INT J CANCER, V130, P1, DOI 10.1002/ijc.26306; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; MOSER M, 1995, DEVELOPMENT, V121, P2779; Pellikainen J, 2004, EUR J CANCER, V40, P1485, DOI 10.1016/j.ejca.2004.02.020; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Ravn-Haren G, 2006, CARCINOGENESIS, V27, P820, DOI 10.1093/carcin/bgi267; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Scibetta AG, 2010, CELL CYCLE, V9, P4525, DOI 10.4161/cc.9.22.13746; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151; Thewes V, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-192; TOWNSEND AJ, 1991, CANCER COMMUN, V3, P265, DOI 10.3727/095535491820873119; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Turner BC, 1998, CANCER RES, V58, P5466; Vibet S, 2008, FREE RADICAL BIO MED, V44, P1483, DOI 10.1016/j.freeradbiomed.2008.01.009; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Woodfield GW, 2009, CLIN CANCER RES, V15, P3672, DOI 10.1158/1078-0432.CCR-08-2343; Yang JW, 2006, FEBS LETT, V580, P6501, DOI 10.1016/j.febslet.2006.10.059; Yu L, 2009, J ONCOL, V2009, DOI 10.1155/2009/780874; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200; Zhuo P, 2009, CANCER RES, V69, P8183, DOI 10.1158/0008-5472.CAN-09-1791	53	35	41	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4043	4051		10.1038/onc.2012.400	http://dx.doi.org/10.1038/onc.2012.400			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22964634	Green Accepted			2022-12-28	WOS:000323748100013
J	Pust, S; Klokk, TI; Musa, N; Jenstad, M; Risberg, B; Erikstein, B; Tcatchoff, L; Liestol, K; Danielsen, HE; van Deurs, B; Sandvig, K				Pust, S.; Klokk, T. I.; Musa, N.; Jenstad, M.; Risberg, B.; Erikstein, B.; Tcatchoff, L.; Liestol, K.; Danielsen, H. E.; van Deurs, B.; Sandvig, K.			Flotillins as regulators of ErbB2 levels in breast cancer	ONCOGENE			English	Article						ErbB2 receptor tyrosine kinase; flotillin; breast cancer; endocytosis; downregulation	SIGNALING NETWORK; EPITHELIAL-CELLS; MAMMALIAN-CELLS; UP-REGULATION; IN-SITU; PHASE-I; RECEPTOR; KINASE; PROTEINS; GELDANAMYCIN	Amplification and overexpression of the receptor tyrosine kinase ErbB2 occur in up to 30% of human breast cancers, and high ErbB2 levels are correlated with poor prognosis for breast cancer patients. In contrast to the epithelial growth factor receptor (ErbB1), ErbB2 is not downregulated by ligand-induced mechanisms. Here we show that flotillins are involved in the stabilization of ErbB2 at the plasma membrane. In SKBR3 breast cancer cells and breast cancer tissue, a positive correlation between flotillin and ErbB2 expression levels could be demonstrated. Moreover, the tissue microarray analyses of biopsies from 194 patients diagnosed with carcinomas of the breast showed that flotillin-2 emerged as a potential predictor of prognosis in breast cancer. Depletion of flotillin-1 and flotillin-2 leads to internalization and degradation of ErbB2. Furthermore, flotillin-1 and -2 were found to be in a molecular complex with ErbB2 and Hsp90. The depletion of one of these proteins results in disruption of this complex, followed by destabilization of ErbB2 at the membrane, and its internalization and degradation. As a consequence, ErbB2-triggered downstream signalling is inhibited. Our data demonstrate a novel mechanism for interfering with ErbB2 signalling, which potentially can have clinical impact.	[Pust, S.; Klokk, T. I.; Musa, N.; Tcatchoff, L.; Sandvig, K.] Oslo Univ Hosp, Inst Canc Res, Dept Biochem, N-0379 Oslo, Norway; [Pust, S.; Klokk, T. I.; Musa, N.; Jenstad, M.; Risberg, B.; Tcatchoff, L.; Liestol, K.; Danielsen, H. E.; Sandvig, K.] Univ Oslo, Fac Med, Ctr Canc Biomed, Oslo, Norway; [Jenstad, M.; Risberg, B.; Danielsen, H. E.] Oslo Univ Hosp, Inst Med Informat, N-0379 Oslo, Norway; [Risberg, B.] Oslo Univ Hosp, Dept Pathol, N-0379 Oslo, Norway; [Erikstein, B.] Oslo Univ Hosp, N-0379 Oslo, Norway; [van Deurs, B.] Univ Copenhagen, Fac Hlth Sci, Dept Cellular & Mol Med, Copenhagen, Denmark; [Sandvig, K.] Univ Oslo, Fac Math & Nat Sci, Dept Mol Biosci, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Copenhagen; University of Oslo	Sandvig, K (corresponding author), Oslo Univ Hosp, Inst Canc Res, Dept Biochem, N-0379 Oslo, Norway.	ksandvig@radium.uio.no	Danielsen, Havard/AAK-8489-2020; Pust, Sascha/M-3201-2013; Danielsen, Havard e/A-7540-2014	Pust, Sascha/0000-0002-0178-2206; Asp, Nagham Theres/0000-0002-2143-1470	South-Eastern Norway Regional Health Authority (Helse Sor-Ost); Norwegian Research Council; Norwegian Cancer Society	South-Eastern Norway Regional Health Authority (Helse Sor-Ost); Norwegian Research Council(Research Council of NorwayEuropean Commission); Norwegian Cancer Society(Norwegian Cancer Society)	We thank Wanja Kildal, Anne-Mari Gjestvang Pedersen and Anne Engen for their expert technical assistance. We thank Gisou van der Goot (EPFL, Lausanne, Switzerland) for providing the polyclonal flotillin-1 antibody used in confocal microscopy. We thank Ornulf Borgan for assistance with the analysis of the results from the breast tissue samples. We thank the South-Eastern Norway Regional Health Authority (Helse Sor-Ost), the Norwegian Research Council and the Norwegian Cancer Society for financial support.	Allred DC, 1998, MODERN PATHOL, V11, P155; Amaddii M, 2012, J BIOL CHEM, V287, P7265, DOI 10.1074/jbc.M111.287599; Arias-Romero LE, 2009, CANCER RES, V69, P4582, DOI 10.1158/0008-5472.CAN-08-4001; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Baulida J, 1996, J BIOL CHEM, V271, P5251; Cicenas J, 2006, EUR J CANCER, V42, P636, DOI 10.1016/j.ejca.2005.11.012; Citri A, 2004, CELL CYCLE, V3, P51; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Glebov OO, 2006, NAT CELL BIOL, V8, P46, DOI 10.1038/ncb1342; Gomez V, 2010, J BIOL CHEM, V285, P20683, DOI 10.1074/jbc.M110.130591; Hazarika P, 2004, CANCER RES, V64, P7361, DOI 10.1158/0008-5472.CAN-04-0823; Jones KL, 2009, LANCET ONCOL, V10, P1179, DOI 10.1016/S1470-2045(09)70315-8; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Langhorst MF, 2005, CELL MOL LIFE SCI, V62, P2228, DOI 10.1007/s00018-005-5166-4; Lerdrup M, 2006, J CELL SCI, V119, P85, DOI 10.1242/jcs.02707; Lin CY, 2011, CLIN CANCER RES, V17, P3089, DOI 10.1158/1078-0432.CCR-10-3068; Marquez DC, 2006, MOL CELL ENDOCRINOL, V246, P91, DOI 10.1016/j.mce.2005.11.020; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Modi S, 2006, CLIN BREAST CANCER, V7, P270, DOI 10.3816/CBC.2006.n.040; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; Pust S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008844; Saslowsky DE, 2010, J CLIN INVEST, V120, P4399, DOI 10.1172/JCI42958; Schulte T, 1997, DEVELOPMENT, V124, P577; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Spears M, 2012, BREAST CANCER RES TR, V132, P463, DOI 10.1007/s10549-011-1606-z; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Tomasovic A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029739; Vassilieva EV, 2009, BIOCHEM BIOPH RES CO, V379, P460, DOI 10.1016/j.bbrc.2008.12.118; Wu YY, 2010, CANCER RES, V70, P5475, DOI 10.1158/0008-5472.CAN-10-0176; Wu YY, 1999, INT J ONCOL, V14, P1021; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhao F, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-479; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	43	50	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2013	32	29					3443	3451		10.1038/onc.2012.357	http://dx.doi.org/10.1038/onc.2012.357			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22869152				2022-12-28	WOS:000322014900005
J	Chander, H; Truesdell, P; Meens, J; Craig, AWB				Chander, H.; Truesdell, P.; Meens, J.; Craig, A. W. B.			Transducer of Cdc42-dependent actin assembly promotes breast cancer invasion and metastasis	ONCOGENE			English	Article						breast cancer; metastasis; invadopodia; F-BAR adaptor Toca-1	CDC42-INTERACTING PROTEIN 4; GROWTH-FACTOR-RECEPTOR; INVADOPODIA FORMATION; TUMOR-CELLS; N-WASP; CARCINOMA CELLS; PCH PROTEINS; BAR; CORTACTIN; SRC	Metastatic breast adenocarcinomas display activation signatures for signaling pathways that trigger cell motility and tissue invasion. Here, we report that the adaptor protein transducer of Cdc42-dependent actin assembly-1 (Toca-1) is expressed in highly invasive breast cancers and regulates their metastatic phenotypes. We show that Toca-1 localizes to the filamentous actin-rich core of invadopodial protrusions actively degrading the extracellular matrix (ECM). Toca-1 colocalizes with Cortactin, and we show that this interaction is mediated by the SH3 domain of Toca-1. Stable knockdown (KD) of Toca-1 expression in MDA-MB-231 cells led to a significant defect in epidermal growth factor (EGF)-induced cell migration and invasion. Toca-1 KD cells also showed significant defects in EGF- and Src-induced ECM digestion and formation of invadopodial membrane protrusions. To test the role of Toca-1 in metastasis, we achieved stable Toca-1 KD in both human and rat metastatic breast adenocarcinoma cell lines. Orthotopic tumor xenografting of control and Toca-1 KD cells in natural-killer /B-/T-cell-deficient mice revealed a significant defect in spontaneous lung metastases with Toca-1 silencing in vivo. In contrast, no defects in primary tumor growth or lung seeding following tail vein injection of Toca-1 KD cells was observed, suggesting that Toca-1 functions at an early step in the dissemination of metastatic breast tumor cells. Taken together, our results identify Toca-1 as a proinvasive protein in breast adenocarcinoma and a potential therapeutic target to limit tumor metastasis.	[Chander, H.; Truesdell, P.; Meens, J.; Craig, A. W. B.] Queens Canc Res Inst, Canc Biol & Genet Div, Kingston, ON, Canada; [Craig, A. W. B.] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Craig, AWB (corresponding author), Queens Univ, 18 Stuart St, Kingston, ON K7L 3N6, Canada.	andrew.craig@queensu.ca	Craig, Andrew/AAC-6923-2019; Craig, Andrew/G-2312-2017	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393	Canadian Breast Cancer Foundation (Ontario, Canada)	Canadian Breast Cancer Foundation (Ontario, Canada)	We greatfully acknowledge Stephanie Everingham, Jinghui Hu and Alka Mukhopadhyay for help in preparing key reagents, and Chandra Tayade for providing mice. Thanks to Sohail Ahmed, Phillipe Chavrier and Alan Mak for providing plasmids, and Leda Raptis and Doris Germain for providing cell lines. This research is supported by a grant from Canadian Breast Cancer Foundation (Ontario, Canada) to AWBC.	Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Aspenstrom P, 2006, TRENDS BIOCHEM SCI, V31, P670, DOI 10.1016/j.tibs.2006.10.001; Aspenstrom P, 2006, EXP CELL RES, V312, P2180, DOI 10.1016/j.yexcr.2006.03.013; Aspenstrom P, 2010, BBA-MOL CELL RES, V1803, P174, DOI 10.1016/j.bbamcr.2009.06.002; Bravo-Cordero JJ, 2011, CURR BIOL, V21, P635, DOI 10.1016/j.cub.2011.03.039; Bu WY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012153; Bu WY, 2009, J BIOL CHEM, V284, P11622, DOI 10.1074/jbc.M805940200; Campellone KG, 2012, J BIOL CHEM, V287, P20613, DOI 10.1074/jbc.M112.363473; Chitu V, 2007, TRENDS CELL BIOL, V17, P145, DOI 10.1016/j.tcb.2007.01.003; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; de Boer M, 2010, J NATL CANCER I, V102, P410, DOI 10.1093/jnci/djq008; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; DesMarais V, 2009, CELL MOTIL CYTOSKEL, V66, P303, DOI 10.1002/cm.20361; Devy L, 2009, CANCER RES, V69, P1517, DOI 10.1158/0008-5472.CAN-08-3255; Eckert MA, 2011, ONCOTARGET, V2, P562; Fricke Robert, 2010, Commun Integr Biol, V3, P89; Fricke R, 2009, CURR BIOL, V19, P1429, DOI 10.1016/j.cub.2009.07.058; Frittoli E, 2011, EUR J CELL BIOL, V90, P108, DOI 10.1016/j.ejcb.2010.04.007; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Giuliani C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000675; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Hu JH, 2011, J CELL SCI, V124, P1739, DOI 10.1242/jcs.078014; Hu JH, 2011, J BIOL CHEM, V286, P2261, DOI 10.1074/jbc.M110.157974; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Le Devedec SE, 2009, CLIN EXP METASTAS, V26, P673, DOI 10.1007/s10585-009-9267-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lizarraga F, 2009, CANCER RES, V69, P2792, DOI 10.1158/0008-5472.CAN-08-3709; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Pichot CS, 2010, CANCER RES, V70, P8347, DOI 10.1158/0008-5472.CAN-09-4149; Rakha EA, 2009, BREAST CANCER RES TR, V113, P411, DOI 10.1007/s10549-008-9952-1; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Rao YJ, 2010, P NATL ACAD SCI USA, V107, P8213, DOI 10.1073/pnas.1003478107; Rucci N, 2006, J PHARMACOL EXP THER, V318, P161, DOI 10.1124/jpet.106.102004; Shimada A, 2010, FEBS LETT, V584, P1111, DOI 10.1016/j.febslet.2010.02.058; Steffen A, 2008, CURR BIOL, V18, P926, DOI 10.1016/j.cub.2008.05.044; Stylli SS, 2008, J CLIN NEUROSCI, V15, P725, DOI 10.1016/j.jocn.2008.03.003; Suetsugu S, 2009, FEBS LETT, V583, P3401, DOI 10.1016/j.febslet.2009.10.019; Sun XL, 2009, CARCINOGENESIS, V30, P2109, DOI 10.1093/carcin/bgp251; Takano K, 2008, EMBO J, V27, P2817, DOI 10.1038/emboj.2008.216; Tsujita K, 2006, J CELL BIOL, V172, P269, DOI 10.1083/jcb.200508091; Valsecchi ME, 2012, CANCER-AM CANCER SOC, V118, P3484, DOI 10.1002/cncr.26661; Van Trappen PO, 2002, LANCET ONCOL, V3, P44, DOI 10.1016/S1470-2045(01)00621-0; Wang Q, 2009, P NATL ACAD SCI USA, V106, P12700, DOI 10.1073/pnas.0902974106; Wang WG, 2007, CANCER RES, V67, P3505, DOI 10.1158/0008-5472.CAN-06-3714; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Webb BA, 2006, EXP CELL RES, V312, P760, DOI 10.1016/j.yexcr.2005.11.032; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamamoto H, 2011, J UROLOGY, V185, P1930, DOI 10.1016/j.juro.2010.12.027	56	28	31	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3080	3090		10.1038/onc.2012.317	http://dx.doi.org/10.1038/onc.2012.317			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22824798				2022-12-28	WOS:000320705700008
J	Maier, HJ; Wagner, M; Schips, TG; Salem, HH; Baumann, B; Wirth, T				Maier, H. J.; Wagner, M.; Schips, T. G.; Salem, H. H.; Baumann, B.; Wirth, T.			Requirement of NEMO/IKK gamma for effective expansion of KRAS-induced precancerous lesions in the pancreas	ONCOGENE			English	Article						pancreatic intraepithelial neoplasia; pancreatic carcinoma; animal model; KRAS; NEMO/IKK gamma	NF-KAPPA-B; CONSTITUTIVE IKK2 ACTIVATION; INTRAEPITHELIAL NEOPLASIA; DUCTAL ADENOCARCINOMA; MOUSE MODEL; CANCER; PROGRESSION; CELLS; MICE; INFLAMMATION	Pancreatic carcinoma, a leading cause of cancer death, is thought to develop out of pancreatic intraepithelial neoplasia (PanIN). PanIN lesions have not yet attained the fully malignant phenotype, but show increased proliferation and dysplasia, and frequently bear an oncogenic KRAS mutation. Pancreatic cancer development is associated with increased activity of the transcription factor NF-kappa B. NEMO (IKK gamma) is a subunit of the IKK complex essential for the activation of canonical NF-kappa B signaling and has been ascribed both oncogenic and tumor-suppressive roles in gastrointestinal tumors. Here, we wanted to address the function of NEMO in pancreatic tumorigenesis. We therefore conditionally ablated NEMO in a mouse model for pancreatic carcinoma based on the expression of oncogenic KRAS in pancreatic precursor cells. Mice were analyzed for PanIN lesions and for the activation of associated signaling pathways. NEMO ablation in the pancreas, while in itself not causing any overt pathology, led to a drastic (>93%) decrease in the prevalence of both low-grade and high-grade PanIN in 10-month-old mice expressing oncogenic KRAS. Also, the inflammatory and fibrotic response associated with KRAS action in the pancreas was virtually abolished, including expression of inflammatory cytokines and activation of the interleukin-6/STAT3 axis. Moreover, the activation of MAPK signaling, Notch and KLF4 signaling normally observed in KRAS-induced PanIN was strongly reduced or absent when NEMO was ablated. Our study suggests that NEMO, an IKK subunit necessary for canonical NF-kappa B activation, is dispensable for normal pancreatic development and function, but essential for the propagation of KRAS-induced PanIN lesions.	[Maier, H. J.; Schips, T. G.; Salem, H. H.; Baumann, B.; Wirth, T.] Univ Ulm, Inst Physiol Chem, D-89081 Ulm, Germany; [Wagner, M.] Univ Ulm, Dept Internal Med 1, Ctr Internal Med, D-89081 Ulm, Germany; [Salem, H. H.] Cairo Univ, Dept Biochem, Fac Pharm, Cairo, Egypt	Ulm University; Ulm University; Egyptian Knowledge Bank (EKB); Cairo University	Wirth, T (corresponding author), Univ Ulm, Inst Physiol Chem, Albert Einstein Allee 11, D-89081 Ulm, Germany.	thomas.wirth@uni-ulm.de	Wirth, Thomas/X-7172-2019	Salem, Heba/0000-0002-3289-5588				Aleksic T, 2007, GUT, V56, P227, DOI 10.1136/gut.2005.084665; Baumann B, 2007, J CLIN INVEST, V117, P1502, DOI 10.1172/JCI30876; Baumgart S, GUT, DOI [10.1136/gutjnl-2011-301008, DOI 10.1136/GUTJNL-2011-301008)]; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; Daniluk J, 2012, J CLIN INVEST, V122, P1519, DOI 10.1172/JCI59743; Fendrich V, 2010, GUT, V59, P630, DOI 10.1136/gut.2009.188961; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Funahashi H, 2007, CANCER RES, V67, P7068, DOI 10.1158/0008-5472.CAN-07-0970; Greer JB, 2009, CURR OPIN PHARMACOL, V9, P411, DOI 10.1016/j.coph.2009.06.011; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hruban Ralph H, 2008, Gastrointest Cancer Res, V2, pS10; Hruban RH, 2008, INT J CLIN EXP PATHO, V1, P306; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Ji H, 2006, ONCOGENE, V25, P2105, DOI 10.1038/sj.onc.1209237; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liptay S, 2003, INT J CANCER, V105, P735, DOI 10.1002/ijc.11081; Lohr M, 2005, NEOPLASIA, V7, P17, DOI 10.1593/neo.04445; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Maier HJ, 2010, CANCER LETT, V295, P214, DOI 10.1016/j.canlet.2010.03.003; Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Vlantis K, 2011, J CLIN INVEST, V121, P2781, DOI 10.1172/JCI45349; Wang WX, 1999, CLIN CANCER RES, V5, P119; Ying HQ, 2011, CANCER DISCOV, V1, P158, DOI 10.1158/2159-8290.CD-11-0031	34	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2690	2695		10.1038/onc.2012.272	http://dx.doi.org/10.1038/onc.2012.272			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22751123				2022-12-28	WOS:000319806700010
J	Laisney, JAGC; Mueller, TD; Schartl, M; Meierjohann, S				Laisney, J. A. G. C.; Mueller, T. D.; Schartl, M.; Meierjohann, S.			Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops	ONCOGENE			English	Article						receptor tyrosine kinase; EGFR ligands; melanoma	EPIDERMAL-GROWTH-FACTOR; RENAL EPITHELIAL-CELLS; EXTRACELLULAR DOMAIN; TYROSINE KINASE; LUNG-CANCER; MONOCLONAL-ANTIBODIES; THERAPEUTIC TARGETS; EXPRESSION ANALYSIS; MALIGNANT-MELANOMA; LIGAND-BINDING	The epidermal growth factor (EGF) receptor (EGFR) has a key role in normal embryonic development, adult tissue homeostasis and many pathological processes, in particular tumour formation. Aberrant EGFR activation occurs in many cancer types, and inhibition of this receptor is a promising anti-tumour strategy. Besides overexpression of the wild-type receptor, mutated oncogenic EGFR variants are often associated with malignant transformation. In human non-small-cell lung cancers, kinase mutants of the EGFR are rather common. Human glioblastoma often express the truncated EGFRvIII version as well as other dimerized and permanently activated mutants of the receptor, which are considered as tumour drivers. Similarly, the mutated and dimerized EGFR variant Xiphophorus melanoma receptor kinase (Xmrk) is causative for the development of malignant pigment cell tumours in medaka and Xiphophorus melanoma models. It is generally believed that oncogenic receptors that are active due to dimerizing mutations are ligand independent. Here, we show that different EGFR variants from fish and human efficiently induce autocrine loops by inducing EGFR ligands such as amphiregulin and HB-EGF. Importantly, the pre-dimerized oncogenic EGFR versions Xmrk from Xiphophorus and human EGFR(C600F), though already active in absence of ligands, respond to ligand stimulation with enhanced oncogenic signalling. In summary, our data show that autocrine or paracrine loops are still acting on pre-dimerized oncogenic EGFRs and contribute to their pro-tumorigenic signalling.	[Laisney, J. A. G. C.; Schartl, M.; Meierjohann, S.] Univ Wurzburg, Dept Physiol Chem Bioctr 1, D-97074 Wurzburg, Germany; [Mueller, T. D.] Univ Wurzburg, Julius Von Sachs Inst, Dept Mol Plant Physiol & Biophys, D-97070 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Laisney, JAGC (corresponding author), Univ Wurzburg, Dept Physiol Chem Bioctr 1, D-97074 Wurzburg, Germany.	juliette.laisney@biozentrum.uni-wuerzburg.de; svenja.meierjohann@biozentrum.uni-wuerzburg.de		Mueller, Thomas/0000-0003-1862-7357; Schartl, Manfred/0000-0001-9882-5948	Deutsche Forschungsgesellschaft [SFB487, Transregio 17]	Deutsche Forschungsgesellschaft(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgesellschaft, SFB487 ('Regulatory membrane proteins') and Transregio 17 ('Ras-dependent pathways in human cancer').	Akslen LA, 2008, MELANOMA RES, V18, P29, DOI 10.1097/CMR.0b013e3282f32517; Amin DN, 2006, CANCER RES, V66, P2173, DOI 10.1158/0008-5472.CAN-05-3387; Astsaturov I, 2007, CURR CANCER DRUG TAR, V7, P650, DOI 10.2174/156800907782418365; Bardeesy N, 2005, MOL CELL BIOL, V25, P4176, DOI 10.1128/MCB.25.10.4176-4188.2005; Bellone S, 2007, GYNECOL ONCOL, V106, P513, DOI 10.1016/j.ygyno.2007.04.028; Berardi R, 2010, CORE EVID, V5, P61, DOI 10.2147/CE.S7035; Boone B, 2011, J CUTAN PATHOL, V38, P492, DOI 10.1111/j.1600-0560.2011.01673.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dawson JP, 2007, STRUCTURE, V15, P942, DOI 10.1016/j.str.2007.06.013; DEWIT PEJ, 1992, J INVEST DERMATOL, V99, P168, DOI 10.1111/1523-1747.ep12616793; Djerf EA, 2009, MELANOMA RES, V19, P156, DOI 10.1097/CMR.0b013e32832c6339; Domingo G, 2010, EXPERT REV ANTICANC, V10, P1577, DOI [10.1586/era.10.141, 10.1586/ERA.10.141]; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Gomez A, 2004, MOL BIOL EVOL, V21, P266, DOI 10.1093/molbev/msh017; Gomez A, 2001, J BIOL CHEM, V276, P3333, DOI 10.1074/jbc.M006574200; Hong YH, 1998, DEV GENES EVOL, V208, P595, DOI 10.1007/s004270050220; Hong YH, 2004, P NATL ACAD SCI USA, V101, P8011, DOI 10.1073/pnas.0308668101; Huang PH, 2007, CELL CYCLE, V6, P2750, DOI 10.4161/cc.6.22.4922; Joy AA, 2009, CLIN LUNG CANCER, V10, pS24, DOI 10.3816/CLC.2009.s.004; Kansra S, 2005, MOL PHARMACOL, V67, P1145, DOI 10.1124/mol.104.004689; Kasahara M, 2007, NATURE, V447, P714, DOI 10.1038/nature05846; Kitamura S, 2001, INT J CANCER, V94, P335, DOI 10.1002/ijc.1470; Krasagakis K, 1995, Recent Results Cancer Res, V139, P169; Laisney JAGC, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-27; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Li CW, 2009, THORAX, V64, P306, DOI 10.1136/thx.2008.106096; Li JX, 2003, ONCOGENE, V22, P211, DOI 10.1038/sj.onc.1206102; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu CF, 2010, MOL CELL BIOL, V30, P5432, DOI 10.1128/MCB.00742-10; MATTEI S, 1994, INT J CANCER, V56, P853, DOI 10.1002/ijc.2910560617; Mattoon D, 2004, P NATL ACAD SCI USA, V101, P923, DOI 10.1073/pnas.0307286101; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Meierjohann S, 2006, CANCER RES, V66, P3145, DOI 10.1158/0008-5472.CAN-05-2667; Meierjohann S, 2004, COMP BIOCHEM PHYS C, V138, P281, DOI 10.1016/j.cca.2004.06.002; Meierjohann S, 2006, ZEBRAFISH, V3, P359, DOI 10.1089/zeb.2006.3.359; Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x; Modjtahedi H, 2009, ANTI-CANCER DRUG, V20, P851, DOI 10.1097/CAD.0b013e3283330590; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Nagy P, 2003, EXP CELL RES, V285, P39, DOI 10.1016/S0014-4827(02)00050-2; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Park JM, 1999, AM J PHYSIOL-CELL PH, V277, pC294, DOI 10.1152/ajpcell.1999.277.2.C294; Pines G, 2010, FEBS LETT, V584, P2699, DOI 10.1016/j.febslet.2010.04.019; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Riese DJ, 2007, BIOESSAYS, V29, P558, DOI 10.1002/bies.20582; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Sakai M, 2001, EXP NEPHROL, V9, P28; Saxon ML, 1999, J BIOL CHEM, V274, P28356, DOI 10.1074/jbc.274.40.28356; Schartl M, 2010, J INVEST DERMATOL, V130, P249, DOI 10.1038/jid.2009.213; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Sihto H, 2005, J MOL MED, V83, P976, DOI 10.1007/s00109-005-0699-4; Singh B, 2009, INT J CANCER, V124, P531, DOI 10.1002/ijc.23974; Sparrow L E, 1999, Australas J Dermatol, V40, P19, DOI 10.1046/j.1440-0960.1999.00310.x; Tao RH, 2008, J CELL SCI, V121, P3207, DOI 10.1242/jcs.033399; Teutschbein J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-386; Tworkoski K, 2011, MOL CANCER RES, V9, P801, DOI 10.1158/1541-7786.MCR-10-0512; Vivanco I, 2010, CURR OPIN ONCOL, V22, P573, DOI 10.1097/CCO.0b013e32833edbdf; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Ward CW, 2007, TRENDS BIOCHEM SCI, V32, P129, DOI 10.1016/j.tibs.2007.01.001; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Winnemoeller D, 2005, INT J CANCER, V117, P723, DOI 10.1002/ijc.21232; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; Wittbrodt J, 2002, NAT REV GENET, V3, P53, DOI 10.1038/nrg704; Yotsumoto F, 2008, BIOCHEM BIOPH RES CO, V365, P555, DOI 10.1016/j.bbrc.2007.11.015; Zhuang S, 2008, AM J PHYSIOL-RENAL, V294, pF459, DOI 10.1152/ajprenal.00473.2007	68	15	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2403	2411		10.1038/onc.2012.267	http://dx.doi.org/10.1038/onc.2012.267			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751127				2022-12-28	WOS:000318694900004
J	Qiu, W; Liu, H; Sebastini, A; Sun, Q; Wang, H; Zhang, L; Yu, J				Qiu, W.; Liu, H.; Sebastini, A.; Sun, Q.; Wang, H.; Zhang, L.; Yu, J.			An apoptosis-independent role of SMAC in tumor suppression	ONCOGENE			English	Article						SMAC; cIAP; NF-kappa B; proliferation; colon cancer	NF-KAPPA-B; DRUG-INDUCED APOPTOSIS; TNF-ALPHA; INTESTINAL TUMORIGENESIS; STEM-CELLS; CANCER; PUMA; SMAC/DIABLO; INFLAMMATION; ACTIVATION	Reduced expression of the pro-apoptotic protein SMAC (second mitochondria-derived activator of caspase) has been reported to correlate with cancer progression, while its significance and underlying mechanisms are poorly understood. In this study, we investigated the role of SMAC in intestinal tumorigenesis using both human samples and animal models. Decreased SMAC expression was found to correlate with increased cIAP2 expression and higher grades of human colon cancer. In mice, SMAC deficiency significantly increased the incidence and size of colon tumors induced by azoxymethane (AOM)/dextran sulfate sodium salt (DSS), and highly enriched beta-catenin hot spot mutations. SMAC deficiency also significantly increased the incidence of spontaneous intestinal polyps in APC(Min/+) mice. Loss of SMAC in mice led to elevated levels of cIAP1 and cIAP2, increased proliferation and activation of the NF-kappa B p65 subunit in normal and tumor tissues. Unexpectedly, SMAC deficiency had little effect on the incidence of precursor lesions, or apoptosis induced by AOM or DSS, or in established tumors in mice. Furthermore, SMAC knockout enhanced TNF alpha-mediated NF-kappa B activation via cIAP2 in HCT 116 colon cancer cells. These results demonstrate an essential and apoptosis-independent function of SMAC in tumor suppression and provide new insights into the biology and targeting of colon cancer.	[Qiu, W.; Liu, H.; Sebastini, A.; Sun, Q.; Wang, H.; Zhang, L.; Yu, J.] Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Qiu, W.; Sun, Q.; Yu, J.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Wang, H.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA; [Zhang, L.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yu, J (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, UPCI Res Pavil,Suite 2-26 H,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	yuj2@upmc.edu	Zhang, Lin/A-7389-2009; Yu, Jian/A-8301-2009	Zhang, Lin/0000-0003-0018-3903; Yu, Jian/0000-0002-4021-1000; Wang, Hong/0000-0003-0477-2908	NIH [CA129829, UO1-DK085570, CA106348, CA121105]; American Cancer Society [RGS-10-124-01-CCE, RSG-07-156-01-CNE]; FAMRI;  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA106348, R01CA121105, P30CA047904, R01CA129829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); FAMRI; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Monica E Buchanan, Matthew F Brown and other members of Zhang and Yu labs for helpful discussion and critical reading, and Laurice A Vance-Carr for editorial assistance. This work is supported in part by NIH grants CA129829, UO1-DK085570, American Cancer Society grant RGS-10-124-01-CCE and FAMRI (JY), NIH grants CA106348, CA121105, and American Cancer Society grant RSG-07-156-01-CNE (LZ). This project used the UPCI shared glassware, animal, and cell and tissue imaging facilities that were supported in part by award P30CA047904.	Bank A, 2008, CANCER RES, V68, P276, DOI 10.1158/0008-5472.CAN-07-5242; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Conze DB, 2005, MOL CELL BIOL, V25, P3348, DOI 10.1128/MCB.25.8.3348-3356.2005; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Endo K, 2009, ONCOL REP, V21, P351, DOI 10.3892/or_00000229; Fingleton B, 2007, CANCER RES, V67, P4800, DOI 10.1158/0008-5472.CAN-06-4473; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gaither A, 2007, CANCER RES, V67, P11493, DOI 10.1158/0008-5472.CAN-07-5173; Geserick P, 2009, J CELL BIOL, V187, P1037, DOI 10.1083/jcb.200904158; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guillen-Ahlers H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009070; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hirose Y, 1996, JPN J CANCER RES, V87, P575, DOI 10.1111/j.1349-7006.1996.tb00262.x; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Leibowitz Brian, 2010, Cancer Biol Ther, V9, P417, DOI 10.4161/cbt.9.6.11392; Leibowitz BJ, 2011, MOL CANCER RES, V9, P616, DOI 10.1158/1541-7786.MCR-11-0052; Mace PD, 2010, J MOL BIOL, V400, P8, DOI 10.1016/j.jmb.2010.04.055; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Martinez-Ruiz G, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-48; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Petersen SL, 2010, P NATL ACAD SCI USA, V107, P11936, DOI 10.1073/pnas.1005667107; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Qiu W, 2008, CELL STEM CELL, V2, P576, DOI 10.1016/j.stem.2008.03.009; Qiu W, 2011, J CLIN INVEST, V121, P1722, DOI 10.1172/JCI42917; Qiu W, 2010, P NATL ACAD SCI USA, V107, P20027, DOI 10.1073/pnas.1010430107; Qiu W, 2009, CANCER RES, V69, P4999, DOI 10.1158/0008-5472.CAN-09-0262; Quante M, 2008, PHYSIOLOGY, V23, P350, DOI 10.1152/physiol.00031.2008; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Stevens RG, 2007, CANCER LETT, V252, P171, DOI 10.1016/j.canlet.2006.11.009; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sun QH, 2011, CLIN CANCER RES, V17, P2361, DOI 10.1158/1078-0432.CCR-10-2262; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Vlantis K, 2011, J CLIN INVEST, V121, P2781, DOI 10.1172/JCI45349; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Wu B, 2007, GUT, V56, P645, DOI 10.1136/gut.2006.101683; Xu Y, 2011, CLIN CANCER RES, V17, P5412, DOI 10.1158/1078-0432.CCR-11-0426; Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2004, CURR OPIN ONCOL, V16, P19, DOI 10.1097/00001622-200401000-00005; Yue W, 2007, CLIN CANCER RES, V13, P4336, DOI 10.1158/1078-0432.CCR-07-0015	50	11	13	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2380	2389		10.1038/onc.2012.265	http://dx.doi.org/10.1038/onc.2012.265			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751125	Green Accepted			2022-12-28	WOS:000318694900002
J	Jafarnejad, SM; Ardekani, GS; Ghaffari, M; Martinka, M; Li, G				Jafarnejad, S. M.; Ardekani, G. S.; Ghaffari, M.; Martinka, M.; Li, G.			Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion	ONCOGENE			English	Article						Sox4; Dicer; melanoma; invasion; miRNA	SOX4 EXPRESSION; PROGNOSTIC-SIGNIFICANCE; TRANSCRIPTION FACTOR; METASTASIS; APOPTOSIS; GENE; IDENTIFICATION; MIGRATION; BIOLOGY; DROSHA	We previously reported reduced expression of Sox4 in metastatic melanoma and its role in suppression of cell migration and invasion through inhibition of nuclear factor (NF)-kappa B p50. Sox4 can also bind to the promoter sequence of Dicer, a microRNA (miRNA) biogenesis factor. Interestingly, altered expression of Dicer was also observed in cancers. However, the potential mechanisms that regulate Dicer expression and its potential significance in melanoma progression are unknown. Here, we studied the regulation of Dicer expression by Sox4 and its role in suppression of melanoma invasion. Our data showed that Sox4 positively regulates Dicer expression by binding to its promoter sequences and enhancing its activity. We found that knockdown of Dicer enhances the matrigel invasion of melanoma cells by at least twofold. In addition, we revealed that overexpression of exogenous Dicer reverts the enhanced melanoma cell invasion upon Sox4 knockdown. Furthermore, we examined the expression of Dicer protein in a large set of melanocytic lesions (n = 514) at different stages by tissue microarray and found that Dicer expression is inversely correlated with melanoma progression (P < 0.0001). Consistently, reduced Dicer expression was correlated with a poorer overall and disease-specific 5-year survival of patients (P = 0.015 and 0.0029, respectively). In addition, we found a significant correlation between expression of Sox4 and Dicer proteins in melanoma biopsies (P = 0.009), further indicating the regulation of Dicer expression by Sox4. Finally, we revealed that knockdown of Sox4 induces a major change in the expression pattern of miRNAs in melanoma cells, mainly due to reduced expression of Dicer. Our results pinpoint the regulation of Dicer expression by Sox4 in melanoma and the critical role of Dicer in suppression of melanoma invasion. Our findings on Sox4-regulated miRNA biogenesis pathway may aid toward the development of novel targeted therapeutic approaches for melanoma. Oncogene (2013) 32, 2131-2139; doi:10.1038/onc.2012.239; published online 11 June 2012	[Jafarnejad, S. M.; Ardekani, G. S.; Li, G.] Univ British Columbia, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver, BC V6H 3Z6, Canada; [Ghaffari, M.] Univ British Columbia, Vancouver Gen Hosp, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; [Martinka, M.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Dept Pathol, Vancouver, BC V6H 3Z6, Canada	University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Li, G (corresponding author), Univ British Columbia, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@mail.ubc.ca		Jafarnejad, Seyed Mehdi/0000-0002-5129-7081	Canadian Institutes of Health Research [MOP-93810, MOP-110974, CCI-117958]; Canadian Dermatology Foundation; University of British Columbia Graduate Fellowship; Canadian Institutes of Health Research-Skin Research Training Centre Trainee Awards	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Dermatology Foundation; University of British Columbia Graduate Fellowship; Canadian Institutes of Health Research-Skin Research Training Centre Trainee Awards(Canadian Institutes of Health Research (CIHR))	The authors would like to thank Dr Ian J MacRae for providing the pCDNA3-Flag-Dicer construct, Stephanie Smith, Kate Orchard, Ronald Wong, Ladan Fazli, Larry Tan, Cecilia Sjoestroem, Liang L Liu and Yabin Cheng for technical assistance and Drs Michael Cox, Aziz Ghahary and Vincent Duronio for helpful discussions. This work was supported by grants from the Canadian Institutes of Health Research (MOP-93810, MOP-110974 and CCI-117958) and the Canadian Dermatology Foundation to GL. SMJ is a recipient of University of British Columbia Graduate Fellowship. SMJ and GSA are recipients of Canadian Institutes of Health Research-Skin Research Training Centre Trainee Awards.	Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456; Ahn SG, 2002, EXP MOL MED, V34, P243, DOI 10.1038/emm.2002.34; Castillo SD, 2012, CANCER RES, V72, P176, DOI 10.1158/0008-5472.CAN-11-3506; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; de Bont JM, 2008, NEURO-ONCOLOGY, V10, P648, DOI 10.1215/15228517-2008-032; Faber C, 2011, EUR J CANCER, V47, P1414, DOI 10.1016/j.ejca.2011.01.006; Faggad A, 2010, J PATHOL, V220, P382, DOI 10.1002/path.2658; Graham JD, 1999, J MOL ENDOCRINOL, V22, P295, DOI 10.1677/jme.0.0220295; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Hur EH, 2004, BIOCHEM BIOPH RES CO, V325, P59, DOI 10.1016/j.bbrc.2004.09.215; Jafarnejad SM, 2010, AM J PATHOL, V177, P2741, DOI 10.2353/ajpath.2010.100377; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lambertz I, 2010, CELL DEATH DIFFER, V17, P633, DOI 10.1038/cdd.2009.202; Levy C, 2010, CELL, V141, P994, DOI 10.1016/j.cell.2010.05.004; Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma ZH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020494; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106; Pramoonjago P, 2006, ONCOGENE, V25, P5626, DOI 10.1038/sj.onc.1209566; Sand M, 2010, CANCER INVEST, V28, P649, DOI 10.3109/07357901003630918; Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415; Sekine S, 2009, GASTROENTEROLOGY, V136, P2304, DOI 10.1053/j.gastro.2009.02.067; Spatz A, 2010, CURR OPIN ONCOL, V22, P163, DOI 10.1097/CCO.0b013e328337fe8f; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang YM, 2006, J BIOL CHEM, V281, P11887, DOI 10.1074/jbc.M511309200; Wong RPC, 2007, MOL CANCER THER, V6, P1692, DOI 10.1158/1535-7163.MCT-07-0134; WOTTON D, 1995, J BIOL CHEM, V270, P7515, DOI 10.1074/jbc.270.13.7515; Wu JF, 2011, MED ONCOL, V28, P804, DOI 10.1007/s12032-010-9520-5	39	50	53	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2131	2139		10.1038/onc.2012.239	http://dx.doi.org/10.1038/onc.2012.239			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689055	Green Accepted			2022-12-28	WOS:000318062800002
J	Gastaldi, S; Sassi, F; Accornero, P; Torti, D; Galimi, F; Migliardi, G; Molyneux, G; Perera, T; Comoglio, PM; Boccaccio, C; Smalley, MJ; Bertotti, A; Trusolino, L				Gastaldi, S.; Sassi, F.; Accornero, P.; Torti, D.; Galimi, F.; Migliardi, G.; Molyneux, G.; Perera, T.; Comoglio, P. M.; Boccaccio, C.; Smalley, M. J.; Bertotti, A.; Trusolino, L.			Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer	ONCOGENE			English	Article						Met tyrosine kinase receptor; mammary stem cells; mammary morphogenesis; basal-like breast cancer; cell-fate determination; mammary tumorigenesis	GLAND DEVELOPMENT; C-MET; DUCTAL MORPHOGENESIS; MOLECULAR PORTRAITS; TYROSINE KINASE; FACTOR RECEPTOR; EGF RECEPTOR; LUNG-CANCER; STEM-CELLS; EXPRESSION	Basal-like breast cancer is an aggressive subtype of mammary carcinoma. Despite expressing basal markers, typical of mammary stem cells, this tumor has been proposed to originate from luminal progenitors, which are downstream of stem cells along the mammary epithelial hierarchy. This suggests that committed luminal progenitors may reacquire basal, stem-like characteristics, but the mechanisms that regulate this transition remain unclear. Using mouse models, we found that luminal progenitors express high levels of the Met receptor for hepatocyte growth factor (HGF), as compared with the other mammary epithelial sub-populations. Constitutive activation of Met led luminal progenitors to attain stem cell properties, including enhanced clonogenic activity in vitro and de novo ability to reconstitute mammary glands in repopulation assays in vivo. Moreover, in response to Met signaling, luminal progenitors gave rise to hyperplastic ductal morphogenesis and preferentially underwent basal lineage commitment at the expense of luminal cell-fate specification. Opposite and symmetric results were produced by systemic pharmacological inhibition of Met. Hence, Met signaling targets luminal progenitors for expansion, impairs their differentiation toward the mature luminal phenotype and enables their commitment toward the basal lineage. These results emphasize a critical role for Met in promoting deregulated proliferation and basal plasticity of normal luminal progenitors in the mammary gland, a complex of events that may be required for sustaining the functional and phenotypic properties of basal-like breast tumors. Oncogene (2013) 32, 1428-1440; doi:10.1038/onc.2012.154; published online 7 May 2012	[Gastaldi, S.; Sassi, F.; Torti, D.; Galimi, F.; Migliardi, G.; Bertotti, A.; Trusolino, L.] Inst Canc Res & Treatment IRCC, Mol Pharmacol Lab, I-10060 Candiolo, Italy; [Gastaldi, S.; Sassi, F.; Torti, D.; Migliardi, G.; Comoglio, P. M.; Boccaccio, C.; Bertotti, A.; Trusolino, L.] Univ Turin, Sch Med, Dept Oncol Sci, Candiolo, Italy; [Accornero, P.] Univ Torino, Sch Vet Med, Dept Vet Morphophysiol, Grugliasco, Italy; [Molyneux, G.; Smalley, M. J.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Perera, T.] Janssen Res & Dev, Beerse, Belgium; [Comoglio, P. M.] Inst Canc Res & Treatment IRCC, Div Mol Clin Oncol, I-10060 Candiolo, Italy; [Boccaccio, C.] Inst Canc Res & Treatment IRCC, Lab Canc Stem Cell Biol, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Johnson & Johnson; Janssen Pharmaceuticals; IRCCS Fondazione del Piemonte per l'Oncologia; IRCCS Fondazione del Piemonte per l'Oncologia	Trusolino, L (corresponding author), Inst Canc Res & Treatment IRCC, Mol Pharmacol Lab, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.	SmalleyMJ@cardiff.ac.uk; livio.trusolino@ircc.it	sassi, francesco/AAB-6844-2020; Smalley, Matthew J/M-7000-2015; Migliardi, Giorgia/AAB-6619-2020; Boccaccio, Carla/AHE-7875-2022	sassi, francesco/0000-0002-4741-0408; Smalley, Matthew J/0000-0001-9540-1146; Boccaccio, Carla/0000-0003-2620-9083; GALIMI, Francesco/0000-0002-5939-6922; Migliardi, Giorgia/0000-0001-5770-8120; Comoglio, Paolo/0000-0002-7056-5328; Trusolino, Livio/0000-0002-6379-3365; Bertotti, Andrea/0000-0001-8196-7608	Janssen pharmaceutical companies; AIRC, Associazione Italiana per la Ricerca sul Cancro (IG project) [10116]; MIUR-FIRB, Fondo per gli Investimenti della Ricerca di Base - Futuro in Ricerca; FPRC, Fondazione Piemontese per la Ricerca sul Cancro; Breakthrough Breast Cancer; United Kingdom National Health Service	Janssen pharmaceutical companies; AIRC, Associazione Italiana per la Ricerca sul Cancro (IG project)(Fondazione AIRC per la ricerca sul cancro); MIUR-FIRB, Fondo per gli Investimenti della Ricerca di Base - Futuro in Ricerca(Ministry of Education, Universities and Research (MIUR)); FPRC, Fondazione Piemontese per la Ricerca sul Cancro; Breakthrough Breast Cancer; United Kingdom National Health Service	T Perera is an employee of Janssen pharmaceutical companies of Johnson & Johnson. PM Comoglio receives research grants from Janssen pharmaceutical companies. The other authors declare no potential conflicts of interest.; We thank Erica Lantelme for help with FACS sorting; Noemi Cavalera, Claudio Isella, Howard Kendrick, Simonetta Leto, Barbara Lupo, Paolo Luraghi, Fiona-Ann Magnay, Barbara Martinoglio, Enzo Medico, Roberta Porporato and Eugenia Zanella for help with experiments, discussion and sharing reagents; Fabrizio Maina, Laura Tarditi and Tuti Werdiningsih for animal husbandry; Raffaella Albano, Stefania Giove and Laura Palmas for technical assistance; Antonella Cignetto, Daniela Gramaglia and Francesca Natale for secretarial assistance. This work was supported by AIRC, Associazione Italiana per la Ricerca sul Cancro (IG project 10116 to LT); MIUR-FIRB, Fondo per gli Investimenti della Ricerca di Base - Futuro in Ricerca (AB); FPRC, Fondazione Piemontese per la Ricerca sul Cancro (LT); Breakthrough Breast Cancer and United Kingdom National Health Service funding to the National Institute for Health Research Biomedical Research Centre (MJS).	Andrechek ER, 2005, ONCOGENE, V24, P932, DOI 10.1038/sj.onc.1208230; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000643; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Bozec A, 2007, BRIT J CANCER, V97, P65, DOI 10.1038/sj.bjc.6603791; Brisken C, 2000, GENE DEV, V14, P650; Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008; Cataldo VD, 2011, NEW ENGL J MED, V364, P947, DOI 10.1056/NEJMct0807960; Cepero V, 2010, CANCER RES, V70, P7580, DOI 10.1158/0008-5472.CAN-10-0436; Chaffer CL, 2010, CELL STEM CELL, V7, P271, DOI 10.1016/j.stem.2010.08.008; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Galimi F, 2011, CLIN CANCER RES, V17, P3146, DOI 10.1158/1078-0432.CCR-10-3377; Garcia S, 2007, HUM PATHOL, V38, P830, DOI 10.1016/j.humpath.2006.11.015; Gastaldi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2617; Gjorevski N, 2011, NAT REV MOL CELL BIO, V12, P581, DOI 10.1038/nrm3168; Graveel CR, 2009, P NATL ACAD SCI USA, V106, P12909, DOI 10.1073/pnas.0810403106; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Jackson-Fisher AJ, 2004, P NATL ACAD SCI USA, V101, P17138, DOI 10.1073/pnas.0407057101; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Kendrick H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-591; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Mackay A, 2011, JNCI-J NATL CANCER I, V103, P662, DOI 10.1093/jnci/djr071; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ponzo MG, 2010, CELL CYCLE, V9, P1043, DOI 10.4161/cc.9.6.11033; Ponzo MG, 2009, P NATL ACAD SCI USA, V106, P12903, DOI 10.1073/pnas.0810402106; Regan JL, 2012, ONCOGENE, V31, P869, DOI 10.1038/onc.2011.289; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shimoyama T, 2006, LUNG CANCER, V53, P13, DOI 10.1016/j.lungcan.2006.03.014; Simian M, 2001, DEVELOPMENT, V128, P3117; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Taddei I, 2008, NAT CELL BIOL, V10, P716, DOI 10.1038/ncb1734; Torti D, 2012, INT J CANCER, V130, P1357, DOI 10.1002/ijc.26137; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wiesen JF, 1999, DEVELOPMENT, V126, P335; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	60	44	45	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1428	1440		10.1038/onc.2012.154	http://dx.doi.org/10.1038/onc.2012.154			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22562252	Green Submitted			2022-12-28	WOS:000316455600009
J	Ozenne, P; Dayde, D; Brambilla, E; Eymin, B; Gazzeri, S				Ozenne, P.; Dayde, D.; Brambilla, E.; Eymin, B.; Gazzeri, S.			p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway	ONCOGENE			English	Article						p14(ARF); mutant EGFR; STAT3; apoptosis; lung cancer	RECEPTOR GENE-MUTATIONS; P53 OVEREXPRESSION; TRANSCRIPTIONAL CONTROL; STAT3 ACTIVATION; CANCER; EXPRESSION; GEFITINIB; PROGNOSIS; PROTEIN; MECHANISMS	Epidermal growth factor receptor (EGFR) stimulates proliferative and survival signals. Activating mutations of EGFR are involved in the aetiology and maintenance of the malignant phenotype of lung tumours. We previously described the frequent association of these mutations with the decreased expression of the p14(ARF) tumour suppressor, another common feature of lung cancer. Based on these data, we postulated that p14(ARF) could protect cells against untimely or excessive mitotic signals induced by mutant EGFR. In this study, we demonstrate that p14(ARF) promotes apoptosis in lung tumour cells harbouring the EGFR L858R mutation through the accumulation of phosphorylated signal transducer and activator of transcription 3 (STAT3) on Tyr 705 residue, which leads to BcI-2 downregulation. Using siRNA against PTP-RT, the phosphatase that specifically targets Tyr 705 residue, we show that accumulation of pSTAT3-Tyr705 promotes EGFR L858R mutant cell death, thereby confirming the existence of a STAT3-dependent pro-apoptotic pathway in these cells. Finally, we show that the expression of the EGFR L858R mutant represses p14(ARF) expression and inhibits STAT3/BcI-2 signalling. These results identify a novel link between the p14(ARF) and EGFR pathways and suggest that EGFR L858R counteracts the pro-apoptotic function of p14(ARF) by downregulating its expression to promote carcinogenesis. Oncogene (2013) 32, 1050-1058; doi:10.1038/onc.2012.107; published online 26 March 2012	[Ozenne, P.; Dayde, D.; Brambilla, E.; Eymin, B.; Gazzeri, S.] Inst Albert Bonniot, INSERM, Equipe Bases Mol Progress Canc Poumon, Ctr Rech,U823, F-38042 Grenoble 09, Isere, France; [Ozenne, P.; Dayde, D.; Brambilla, E.; Eymin, B.; Gazzeri, S.] Univ Grenoble 1, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM, Equipe Bases Mol Progress Canc Poumon, Ctr Rech,U823, BP170, F-38042 Grenoble 09, Isere, France.	Sylvie.Gazzeri@ujf-grenoble.fr	eymin, beatrice/U-4670-2019; gazzeri, sylvie/U-4669-2019; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/M-1961-2013	eymin, beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839	Institut National de la Sante et de la Recherche Medicale [U823]; Association pour la Recherche sur le Cancer; la Fondation de France; AGIR a Dom; Fond de dotation pour la recherche en sante respiratoire	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); la Fondation de France(Fondation de France); AGIR a Dom; Fond de dotation pour la recherche en sante respiratoire	We thank Professor A Gazdar for providing us with the H1975 and H3255 cellular models and Dr P Hainaut for the pcDNA3.1-EGFR-L858R expression vector. We also thank Celine Barrial-Lampreia and Pascal Perron for their technical assistance. This work was supported by Institut National de la Sante et de la Recherche Medicale U823, Association pour la Recherche sur le Cancer and la Fondation de France. PO is supported by AGIR a Dom. DD is supported by the Fond de dotation pour la recherche en sante respiratoire 2010.	Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Gazzeri S, 1998, CANCER RES, V58, P3926; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Hsu HS, 2004, CLIN CANCER RES, V10, P4734, DOI 10.1158/1078-0432.CCR-03-0704; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Mounawar M, 2007, CANCER RES, V67, P5667, DOI 10.1158/0008-5472.CAN-06-4229; Mukohara T, 2003, LUNG CANCER, V41, P123, DOI 10.1016/S0169-5002(03)00225-3; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 2001, MOL CELL BIOL, V21, P6615, DOI 10.1128/MCB.21.19.6615-6625.2001; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Ohsaki Y, 2000, ONCOL REP, V7, P603; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	40	11	11	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					1050	1058		10.1038/onc.2012.107	http://dx.doi.org/10.1038/onc.2012.107			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22450744	Bronze			2022-12-28	WOS:000316523200012
J	Paccez, JD; Vasques, GJ; Correa, RG; Vasconcellos, JF; Duncan, K; Gu, X; Bhasin, M; Libermann, TA; Zerbini, LF				Paccez, J. D.; Vasques, G. J.; Correa, R. G.; Vasconcellos, J. F.; Duncan, K.; Gu, X.; Bhasin, M.; Libermann, T. A.; Zerbini, L. F.			The receptor tyrosine kinase Ax1 is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target	ONCOGENE			English	Article						tyrosine kinase receptor; Ax1; prostate cancer; proliferation; NF-kappa B; IL-6	NF-KAPPA-B; ARREST-SPECIFIC GENE-6; BREAST-CANCER; PROLONGS SURVIVAL; ENDOTHELIAL-CELLS; CARCINOMA CELLS; ACTIVATION; PATHWAY; EXPRESSION; GAS6	Deregulation of the receptor tyrosine kinase Ax1 has been implicated in the progression of several human cancers. However, the role of Ax1 in prostate cancer remains poorly understood, and the therapeutic efficacy of Ax1 targeting remains untested. In this report we identified Ax1 as a new therapeutic target for prostate cancer. Ax1 is consistently overexpressed in prostate cancer cell lines and human prostate tumors. Interestingly, the blockage of Ax1 gene expression strongly inhibits proliferation, migration, invasion and tumor growth. Furthermore, inhibition of Ax1 expression by small interfering RNA regulates a transcriptional program of genes involved in cell survival, strikingly all connected to the nuclear factor-kappa B pathway. Additionally, blockage of Ax1 expression leads to inhibition of Akt, IKK alpha and I kappa B alpha phosphorylation, increasing I kappa B alpha expression and stability. Furthermore, induction of Akt phosphorylation by insulin-like growth factor 1 in Ax1 knockdown cells restores Akt activity and proliferation. Taken together, our results establish an unambiguous role for Ax1 in prostate cancer tumorigenesis with implications for prostate cancer treatment. Oncogene (2013) 32, 689-698; doi:10.1038/onc.2012.89; published online 12 March 2012	[Paccez, J. D.; Vasques, G. J.; Duncan, K.; Zerbini, L. F.] Int Ctr Genet Engn & Biotechnol, Canc Genom Grp, Cape Town, South Africa; [Paccez, J. D.; Zerbini, L. F.] Univ Cape Town, Div Med Biochem, ZA-7925 Cape Town, South Africa; [Correa, R. G.] Sanford Burnham Med Res Inst, La Jolla, CA USA; [Vasconcellos, J. F.; Gu, X.; Bhasin, M.; Libermann, T. A.] Beth Israel Deaconess Med Ctr, BIDMC Genom & Prote Ctr, Boston, MA 02215 USA; [Vasconcellos, J. F.; Gu, X.; Bhasin, M.; Libermann, T. A.] Harvard Univ, Sch Med, Boston, MA USA	International Center for Genetic Engineering & Biotechnology (ICGEB); ICGEB Cape Town; University of Cape Town; Sanford Burnham Prebys Medical Discovery Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Zerbini, LF (corresponding author), Int Ctr Genet Engn & Biotechnol, Canc Genom Grp, Cape Town, South Africa.	luiz.zerbini@uct.ac.za	Correa, Ricardo G/G-7613-2012; Zerbini, Luiz/B-7720-2015; Paccez, Juliano/K-8560-2012	Correa, Ricardo G/0000-0001-6940-7034; Zerbini, Luiz/0000-0003-0736-9508; Paccez, Juliano/0000-0002-1086-4588; Ferreira de Vasconcellos, Jaira/0000-0001-5011-4493; Libermann, Towia/0000-0002-4006-8179; Bhasin, Manoj/0000-0001-5172-420X	ICGEB post-doctoral fellowship; CAPES international fellowship; Department of Defense [PC051217]; NIH [1RO1 CA85467]; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA085467] Funding Source: NIH RePORTER	ICGEB post-doctoral fellowship; CAPES international fellowship; Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	JDP is recipient of the ICGEB post-doctoral fellowship. JFV is recipient of CAPES international fellowship. This study was supported by the Department of Defense grant PC051217 (LFZ), NIH grants 1RO1 CA85467 (TAL) and the Prostate Cancer Foundation (TAL).	Begley LA, 2008, NEOPLASIA, V10, P244, DOI 10.1593/neo.07976; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Gallicchio M, 2005, BLOOD, V105, P1970, DOI 10.1182/blood-2004-04-1469; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Grall F, 2003, ARTHRITIS RHEUM, V48, P1249, DOI 10.1002/art.10942; Haas GP, 2008, CAN J UROL, V15, P3866; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Hasanbasic I, 2004, AM J PHYSIOL-HEART C, V287, pH1207, DOI 10.1152/ajpheart.00020.2004; Healy AM, 2001, AM J PHYSIOL-LUNG C, V280, pL1273, DOI 10.1152/ajplung.2001.280.6.L1273; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Jacob ANK, 1999, CANCER DETECT PREV, V23, P325; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Kobori M, 2004, CELL DEATH DIFFER, V11, P123, DOI 10.1038/sj.cdd.4401325; Koch AE, 2005, ARTHRITIS RHEUM, V52, P710, DOI 10.1002/art.20932; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; Lee WP, 2002, ONCOGENE, V21, P329, DOI 10.1038/sj.onc.1205066; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Okamoto M, 1997, CANCER RES, V57, P141; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Sarker D, 2009, CLIN CANCER RES, V15, P4799, DOI 10.1158/1078-0432.CCR-08-0125; Sawabu T, 2007, MOL CARCINOGEN, V46, P155, DOI 10.1002/mc.20211; Seaton A, 2008, CARCINOGENESIS, V29, P1148, DOI 10.1093/carcin/bgn109; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384; Tobe M, 2003, BIOORGAN MED CHEM, V11, P383, DOI 10.1016/S0968-0896(02)00440-6; Tsai KC, 2009, BIOORG MED CHEM LETT, V19, P5665, DOI 10.1016/j.bmcl.2009.08.021; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Walz A, 1997, J LEUKOCYTE BIOL, V62, P604, DOI 10.1002/jlb.62.5.604; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; Zerbini LF, 2003, CANCER RES, V63, P2206; Zerbini LF, 2006, CANCER RES, V66, P11922, DOI 10.1158/0008-5472.CAN-06-2068; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225	50	88	94	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					689	698		10.1038/onc.2012.89	http://dx.doi.org/10.1038/onc.2012.89			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22410775	Green Accepted			2022-12-28	WOS:000315746700003
J	Chung, S; Yao, J; Suyama, K; Bajaj, S; Qian, X; Loudig, OD; Eugenin, EA; Phillips, GR; Hazan, RB				Chung, S.; Yao, J.; Suyama, K.; Bajaj, S.; Qian, X.; Loudig, O. D.; Eugenin, E. A.; Phillips, G. R.; Hazan, R. B.			N-cadherin regulates mammary tumor cell migration through Akt3 suppression	ONCOGENE			English	Article						adhesion; motility; Akt isoforms; Akt3; breast cancer	BREAST-CANCER; FGF-RECEPTOR; SIGNALING PATHWAY; METASTASIS; ACTIVATION; EXPRESSION; PROGRESSION; PROLIFERATION; ISOFORMS; PROTEIN	N-cadherin is a cell-cell adhesion molecule that plays a role in breast cancer metastasis. Here, we show that in vivo expression of N-cadherin in the PyMT mouse model, which enhances mammary tumor metastasis, results in selective inhibition of Akt3 expression and phosphorylation. Similarly, exogenous expression of N-cadherin in PyMT or MCF-7 mammary tumor cells enhanced cell motility and caused a dramatic reduction in Akt3 expression and phosphorylation. Moreover, knockdown of Akt3 in PyMT tumor cells increased cell motility and disrupted mammary morphogenesis, but had no effect on cell proliferation. Conversely, overexpression of wild-type Akt3 in PyMT-N-cadherin cells inhibited cell motility promoted by N-cadherin. Taken altogether, these findings demonstrate that N-cadherin suppresses Akt3 to promote cell motility and highlight the intricate regulation of Akt isoforms by N-cadherin during metastasis. Oncogene (2013) 32, 422-430; doi:10.1038/onc.2012.65; published online 12 March 2012	[Chung, S.; Yao, J.; Suyama, K.; Bajaj, S.; Qian, X.; Loudig, O. D.; Eugenin, E. A.; Hazan, R. B.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; [Phillips, G. R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA	Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai	Hazan, RB (corresponding author), Albert Einstein Coll Med, Dept Pathol, F529S,1300 Morris Pk Ave, Bronx, NY 10461 USA.	Rachel.hazan@einstein.yu.edu	qian, xia/L-1616-2013; Qian, Xia/D-8255-2014		National Cancer Institute [1R01 CA135061-01A1]; NIH; Breast Cancer Research Foundation; Training Program in Cellular and Molecular Biology and Genetics [T32 GM007491]; NATIONAL CANCER INSTITUTE [R01CA090872, R01CA135061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH096625, K01MH076679] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Training Program in Cellular and Molecular Biology and Genetics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This study was supported by grants from National Cancer Institute (Grant 1R01 CA135061-01A1) the NIH and Breast Cancer Research Foundation (to RB Hazan). Su Chung was partly supported by the Training Program in Cellular and Molecular Biology and Genetics (T32 GM007491).	Agiostratidou G, 2007, J MAMMARY GLAND BIOL, V12, P127, DOI 10.1007/s10911-007-9044-6; Agiostratidou G, 2009, CANCER RES, V69, P5030, DOI 10.1158/0008-5472.CAN-08-4007; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Cavallaro Ugo, 2004, Curr Opin Investig Drugs, V5, P1274; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chin YR, 2010, MOL CELL, V38, P333, DOI 10.1016/j.molcel.2010.02.031; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Nagi C, 2005, BREAST CANCER RES TR, V94, P225, DOI 10.1007/s10549-005-7727-5; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349; Roccaro AM, 2009, BLOOD, V113, P6669, DOI 10.1182/blood-2009-01-198408; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135	27	37	38	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					422	430		10.1038/onc.2012.65	http://dx.doi.org/10.1038/onc.2012.65			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22410780	Green Accepted			2022-12-28	WOS:000315551300003
J	Gao, P; Xing, AY; Zhou, GY; Zhang, TG; Zhang, JP; Gao, C; Li, H; Shi, DB				Gao, P.; Xing, A-Y; Zhou, G-Y; Zhang, T-G; Zhang, J-P; Gao, C.; Li, H.; Shi, D-B			The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer	ONCOGENE			English	Article						gastric carcinoma; miR-145; metastasis; N-cadherin	N-CADHERIN; TUMOR-METASTASIS; BREAST-CANCER; CELL INVASION; COLON-CANCER; EXPRESSION; GROWTH; METALLOPROTEINASES; PROGRESSION; SIGNATURES	Invasion and metastasis are the major features of malignant tumors that are responsible for 90% of cancer-related deaths. Recently, microRNAs have been discovered to have a role in suppressing tumor metastasis. This study's aim was to clarify the roles of miR-145 in gastric carcinomas and its underlying molecular mechanism in regulating tumor metastasis. Here, we demonstrate a stepwise downregulation of miR-145 level in nontumorous gastric mucosa, primary gastric cancers-and their secondary metastases. In vitro analysis of miR-145's ectopic expression and loss-of-function suggests that it suppresses gastric cancer cell migration and invasion. In vivo spontaneous metastasis and experimental metastasis assay further confirm its function in suppressing the invasion-metastasis cascade, including impairing local invasion and inhibiting hematogenous metastasis in gastric cancers. Furthermore, we identified a novel mechanism of miR-145 to suppress metastasis. N-cadherin (CDH2) was proved to be a direct target of miR-145, using luciferase assay and western blot. Re-expressing N-cadherin in miR-145-transfected cells reverses their migration and invasion defects. Although not a direct target of miR-145, matrix metallopeptidase 9 (MMP9), but not MMP2, was also significantly decreased in miR-145-expressing cells. We suggest that miR-145 suppresses tumor metastasis by inhibiting N-cadherin protein translation, and then indirectly downregulates its downstream effector MMP9. Oncogene (2013) 32, 491-501; doi:10.1038/onc.2012.61; published online 27 February 2012	[Gao, P.; Xing, A-Y; Zhou, G-Y; Zhang, T-G; Zhang, J-P; Gao, C.] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Li, H.; Shi, D-B] Shandong Univ, Sch Med, Dept Pathol, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University	Gao, P (corresponding author), Shandong Univ, Qilu Hosp, Dept Pathol, Jinan Wen Hua Xi Rd 107, Jinan 250012, Shandong, Peoples R China.	gaopeng@sdu.edu.cn	邢, 爱艳/AAC-6576-2021		National Natural Science Foundation of China [30972929, 81172351]; Natural Science Foundation of Shandong Province of China [ZR2010HM075]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province of China(Natural Science Foundation of Shandong Province)	This work was supported by the National Natural Science Foundation of China (No. 30972929, 81172351) and the Natural Science Foundation of Shandong Province of China (No. ZR2010HM075). We thank Chun-Ming Wong and Irene Oi-Lin Ng of Department of Pathology, Li Ka Shing Faculty Medicine, University of Hong Kong for useful advice and discussion. Peng Gao was a Cheng Yu Tung Fellow at the University of Hong Kong. The study was approved by the Ethics Committee of Shandong University.	Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Coghlin C, 2010, J PATHOL, V222, P1, DOI 10.1002/path.2727; Crawford M, 2008, BIOCHEM BIOPH RES CO, V373, P607, DOI 10.1016/j.bbrc.2008.06.090; de Krijger I, 2011, J PATHOL, V224, P438, DOI 10.1002/path.2922; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Desiderio MA, 2007, CELL MOL LIFE SCI, V64, P1341, DOI 10.1007/s00018-007-7050-x; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gao P, 2011, J HEPATOL, V54, P1177, DOI 10.1016/j.jhep.2010.09.023; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hartland SN, 2009, LIVER INT, V29, P966, DOI 10.1111/j.1478-3231.2009.02070.x; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Parmo-Cabanas M, 2006, J PATHOL, V208, P108, DOI 10.1002/path.1876; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Song GS, 2009, J BIOL CHEM, V284, P31921, DOI 10.1074/jbc.M109.046862; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406	32	136	144	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					491	501		10.1038/onc.2012.61	http://dx.doi.org/10.1038/onc.2012.61			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22370644				2022-12-28	WOS:000315551300010
J	Derbal-Wolfrom, L; Pencreach, E; Saandi, T; Aprahamian, M; Martin, E; Greferath, R; Tufa, E; Choquet, P; Lehn, JM; Nicolau, C; Duluc, I; Freund, JN				Derbal-Wolfrom, L.; Pencreach, E.; Saandi, T.; Aprahamian, M.; Martin, E.; Greferath, R.; Tufa, E.; Choquet, P.; Lehn, J-M; Nicolau, C.; Duluc, I.; Freund, J-N			Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2	ONCOGENE			English	Article						hypoxia; ITPP; colon cancer; xenograft; MAP kinase; homeobox gene	EXPRESSION; INHIBITOR	Preventing tumor neovascularisation is one of the strategies recently developed to limit the dissemination of cancer cells and apparition of metastases. Although these approaches could improve the existing treatments, a number of unexpected negative effects have been reported, mainly linked to the hypoxic condition and the subsequent induction of the pro-oncogenic hypoxia inducible factor(s) resulting from cancer cells' oxygen starvation. Here, we checked in vivo on colon cancer cells an alternative approach. It is based on treatment with myo-inositol trispyrophosphate (ITPP), a molecule that leads to increased oxygenation of tumors. We provide evidence that ITPP increases the survival of mice in a model of carcinomatosis of human colon cancer cells implanted into the peritoneal cavity. ITPP also reduced the growth of subcutaneous colon cancer cells xenografted in nu/nu mice. In the subcutaneous tumors, ITPP stimulated the expression of the homeobox gene Cdx2 that is crucial for intestinal differentiation and that also has an anti-tumoral function. On this basis, human colon cancer cells were cultured in vitro in hypoxic conditions. Hypoxia was shown to decrease the level of Cdx2 protein, mRNA and the activity of the Cdx2 promoter. This decline was unrelated to the activation of HIF1 alpha and HIF2 alpha by hypoxia. However, it resulted from the activation of a phosphatidylinositol 3-kinases-like mitogen-activated protein kinase pathway, as assessed by the fact that LY294002 and U0126 restored high Cdx2 expression in hypoxia. Corroborating these results, U0126 recapitulated the increase of Cdx2 triggered by ITPP in subcutaneous colon tumor xenografts. The present study provides evidence that a chemical compound that increases oxygen pressure can antagonize the hypoxic setting and reduce the growth of human colon tumors implanted in nu/nu mice.	[Derbal-Wolfrom, L.; Saandi, T.; Aprahamian, M.; Martin, E.; Duluc, I.; Freund, J-N] INSERM, U682, Strasbourg, France; [Pencreach, E.] CHU Hautepierre, Lab Biochim & Biol Mol, EA Physiopathol & Med Translat 4438, F-67098 Strasbourg, France; [Greferath, R.; Tufa, E.; Nicolau, C.] NormOxys Inc, Boston, MA USA; [Choquet, P.] CHU Hautepierre, Serv Biophys & Med Nucl, Fre3240, CNRS, F-67098 Strasbourg, France; [Greferath, R.; Tufa, E.; Lehn, J-M] CNRS, UMR 7006, ISIS, Strasbourg, France; [Nicolau, C.] Tufts Univ, Friedman Sch Nutr Sci, Boston, MA 02111 USA; [Derbal-Wolfrom, L.; Pencreach, E.; Saandi, T.; Aprahamian, M.; Martin, E.; Choquet, P.; Lehn, J-M; Duluc, I.; Freund, J-N] Univ Strasbourg, Fac Med, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; Centre National de la Recherche Scientifique (CNRS); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Tufts University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, JN (corresponding author), Univ Strasbourg, INSERM, U682, 3 Ave Moliere, F-67200 Strasbourg, France.	jean-noel.freund@inserm.fr	Duluc, Isabelle/O-1972-2017; DULUC, Isabelle/AAA-7062-2022; Freund, Jean-Noel/R-4383-2016; CHOQUET, Philippe/H-5868-2019; Pencreach, Erwan/R-3750-2016	Duluc, Isabelle/0000-0001-8396-6385; DULUC, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774; CHOQUET, Philippe/0000-0003-0514-0726; 	INSERM (France); NormOxys Inc (USA); Ligue contre la Cancer du Haut-Rhin (France); AICR (UK); Departement of Mayotte (France)	INSERM (France)(Institut National de la Sante et de la Recherche Medicale (Inserm)); NormOxys Inc (USA); Ligue contre la Cancer du Haut-Rhin (France); AICR (UK); Departement of Mayotte (France)	This work was supported by the INSERM (France), NormOxys Inc (USA) and the Ligue contre la Cancer du Haut-Rhin (France). Ms Saandi was supported by the AICR (UK) and the Departement of Mayotte (France).	Aprahamian M, 2011, CHEMBIOCHEM, V12, P777, DOI 10.1002/cbic.201000619; Benahmed F, 2008, GASTROENTEROLOGY, V135, P1238, DOI 10.1053/j.gastro.2008.06.045; Benahmed F, 2007, AM J PATHOL, V170, P733, DOI 10.2353/ajpath.2007.060696; Biolo A, 2009, P NATL ACAD SCI USA, V106, P1926, DOI 10.1073/pnas.0812381106; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Gross I, 2008, ONCOGENE, V27, P107, DOI 10.1038/sj.onc.1210601; Gross I, 2005, ONCOGENE, V24, P7955, DOI 10.1038/sj.onc.1208945; Hinkel I, 2012, GASTROENTEROLOGY, V142, P875, DOI 10.1053/j.gastro.2011.12.037; Kieda C, 2006, P NATL ACAD SCI USA, V103, P15576, DOI 10.1073/pnas.0607109103; Loges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Marampon F, 2009, MOL CANCER THER, V8, P543, DOI 10.1158/1535-7163.MCT-08-0570; PEARSON JW, 1989, CANCER RES, V49, P3562; Pencreach E, 2009, CLIN CANCER RES, V15, P1297, DOI 10.1158/1078-0432.CCR-08-0889; Renouf B, 2012, NUCLEIC ACIDS RES, V40, P3456, DOI 10.1093/nar/gkr1242; Sihn G, 2007, FEBS LETT, V581, P962, DOI 10.1016/j.febslet.2007.01.079; Stringer EJ, 2012, DEVELOPMENT, V139, P465, DOI 10.1242/dev.070722; Turck N, 2005, EXP CELL RES, V303, P494, DOI 10.1016/j.yexcr.2004.10.025; Verzi MP, 2010, DEV CELL, V19, P713, DOI 10.1016/j.devcel.2010.10.006	19	22	23	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4313	4318		10.1038/onc.2012.445	http://dx.doi.org/10.1038/onc.2012.445			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045284				2022-12-28	WOS:000324168000013
J	Hudson, RS; Yi, M; Esposito, D; Glynn, SA; Starks, AM; Yang, Y; Schetter, AJ; Watkins, SK; Hurwitz, AA; Dorsey, TH; Stephens, RM; Croce, CM; Ambs, S				Hudson, R. S.; Yi, M.; Esposito, D.; Glynn, S. A.; Starks, A. M.; Yang, Y.; Schetter, A. J.; Watkins, S. K.; Hurwitz, A. A.; Dorsey, T. H.; Stephens, R. M.; Croce, C. M.; Ambs, S.			MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer	ONCOGENE			English	Article						prostate cancer; microRNA; apoptosis; disease outcome	MICRORNAS; OVEREXPRESSION; APOPTOSIS; PROFILE; GROWTH; LEADS; MCM7; BIM	The miR-106b-25 microRNA (miRNA) cluster is a candidate oncogene in human prostate cancer. Here, we report that miRNAs encoded by miR-106b-25 are upregulated in both primary tumors and distant metastasis. Moreover, increased tumor miR-106b expression was associated with disease recurrence and the combination of high miR-106b and low CASP7 (caspase-7) expressions in primary tumors was an independent predictor of early disease recurrence (adjusted hazard ratio = 4.1; 95% confidence interval: 1.6-12.3). To identify yet unknown oncogenic functions of miR-106b, we overexpressed it in LNCaP human prostate cancer cells to examine miR-106b-induced global expression changes among protein-coding genes. The approach revealed that CASP7 is a direct target of miR-106b, which was confirmed by western blot analysis and a 3'-untranslated region reporter assay. Moreover, selected phenotypes induced by miR-106b knockdown in DU145 human prostate cancer cells did not develop when both miR-106b and CASP7 expression were inhibited. Further analyses showed that CASP7 is downregulated in primary prostate tumors and metastatic lesions across multiple data sets and is by itself associated with disease recurrence and disease-specific survival. Using bioinformatics, we also observed that miR-106b-25 may specifically influence focal adhesion-related pathways. This observation was experimentally examined using miR-106b-25-transduced 22Rv1 human prostate cancer cells. After infection with a miR-106b-25 lentiviral expression construct, 22Rv1 cells showed increased adhesion to basement membrane-and bone matrix-related filaments and enhanced soft agar growth. In summary, miR-106b-25 was found to be associated with prostate cancer progression and disease outcome and may do so by altering apoptosis-and focal adhesion-related pathways.	[Hudson, R. S.; Glynn, S. A.; Starks, A. M.; Yang, Y.; Schetter, A. J.; Dorsey, T. H.; Ambs, S.] NCI, Human Carcinogenesis Lab, Ctr Canc Res CRC, NIH, Bethesda, MD 20892 USA; [Yi, M.; Stephens, R. M.] NCI, Adv Biomed Comp Ctr, SAIC Frederick Inc, Frederick, MD 21701 USA; [Esposito, D.] NCI, Protein Express Lab, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21701 USA; [Watkins, S. K.; Hurwitz, A. A.] NCI, Mol Immunoregulat Lab, Frederick, MD 21701 USA; [Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Ambs, S (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res CRC, Bldg 37 Room 3050B, Bethesda, MD 20892 USA.	ambss@mail.nih.gov	Young, Richard A/F-6495-2012; Glynn, Sharon A/D-7136-2013	Young, Richard A/0000-0001-8855-8647; Glynn, Sharon A/0000-0003-1459-2580; Ambs, Stefan/0000-0001-7651-9309; Starks, Adrienne/0000-0002-2640-6928; Esposito, Dominic/0000-0002-9987-1687; Yi, Ming/0000-0001-9098-1364	NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [U01CA152758, ZIABC010499, ZIABC010954, ZIABC010886] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Barbara J Taylor at the NCI FACS Core Laboratory for technical help. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Catto JWF, 2011, EUR UROL, V59, P671, DOI 10.1016/j.eururo.2011.01.044; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944; Gocek E, 2011, CANCER RES, V71, P6230, DOI 10.1158/0008-5472.CAN-11-1717; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jalava SE, 2012, ONCOGENE, V31, P4460, DOI 10.1038/onc.2011.624; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Li BQ, 2011, PROSTATE, V71, P567, DOI 10.1002/pros.21272; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Prueitt RL, 2008, PROSTATE, V68, P1152, DOI 10.1002/pros.20786; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Ren B, 2006, ONCOGENE, V25, P1090, DOI 10.1038/sj.onc.1209134; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Sboner A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-8; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Szczyrba J, 2010, MOL CANCER RES, V8, P529, DOI 10.1158/1541-7786.MCR-09-0443; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Trompeter HI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016138; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Yu J, 2006, BIOCHEM BIOPH RES CO, V349, P59, DOI 10.1016/j.bbrc.2006.07.207; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	35	96	99	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4139	4147		10.1038/onc.2012.424	http://dx.doi.org/10.1038/onc.2012.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	22986525	Green Accepted			2022-12-28	WOS:000323748500009
J	Gusenbauer, S; Vlaicu, P; Ullrich, A				Gusenbauer, S.; Vlaicu, P.; Ullrich, A.			HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors	ONCOGENE			English	Article						HGF; EGFR; resistance; gefitinib; kinase-independent	EPIDERMAL-GROWTH-FACTOR; CELL LUNG-CANCER; FACTOR RECEPTOR; ACQUIRED-RESISTANCE; MET AMPLIFICATION; GEFITINIB RESISTANCE; T790M MUTATIONS; C-MET; EXPRESSION; ACTIVATION	The epidermal growth factor receptor (EGFR) is overexpressed and activated in many human cancers and predicts poor patient prognosis. Targeting the kinase domain with specific EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib has been used in anticancer treatments. However, patient response rates in different human cancers were initially low. Only a subgroup of non-small-cell lung cancer (NSCLC) patients harboring EGFR-activating mutations responds to EGFR TKI treatment, but most of these responders relapse and acquire resistance. Recent clinical studies have demonstrated that MET proto-oncogene overexpression correlates with resistance to EGFR TKI treatment. Similarly to MET overexpression, the tumor microenvironment-derived ligand hepatocyte growth factor (HGF) was shown to activate Met and thereby induce short-term resistance to EGFR TKI treatment in gefitinib-sensitive NSCLC cell lines in vitro. However, only little is known about the HGF/Met-induced EGFR TKI resistance mechanism in other human cancer types. Therefore, in order to develop possible new anticancer strategies for diverse human cancers, we screened 12 carcinoma cell lines originating from the breast, kidney, liver and tongue for HGF-induced EGFR tyrosine kinase (TK)-inhibition. In addition, in order to advance our understanding of a TK-inactive EGFR, we used EGFR co-immunoprecipitation, followed by mass spectrometry to identify novel HGF-induced EGFR binding partners, which are potentially involved in tyrosine kinase-independent EGFR signaling mechanisms. Here we show for the first time that HGF-induced EGFR TK-inhibition is a very common mechanism in human cancers, and that the kinase-inactive EGFR directly interacts with and stabilizes several cancer-relevant proteins, including the receptor tyrosine kinases Axl and EphA2, and the CUB domain-containing protein-1. This study has strong implications for the development of new anticancer strategies.	[Gusenbauer, S.; Vlaicu, P.; Ullrich, A.] Max Planck Inst Biochem, Dept Mol Biol, D-85152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18, D-85152 Martinsried, Germany.	ullrich@biochem.mpg.de						Arteaga CL, 2002, ONCOLOGIST, V7, P31; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blagosklonny MV, 2003, CANCER BIOL THER, V2, P137, DOI 10.4161/cbt.2.2.286; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Castillo L, 2004, ANN ONCOL, V15, P1007, DOI 10.1093/annonc/mdh257; Chen HJ, 2009, PATHOL ONCOL RES, V15, P651, DOI 10.1007/s12253-009-9167-8; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Dickler MN, 2009, BREAST CANCER RES TR, V115, P115, DOI 10.1007/s10549-008-0055-9; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Franovic A, 2007, P NATL ACAD SCI USA, V104, P13092, DOI 10.1073/pnas.0702387104; Gordon AN, 2005, INT J GYNECOL CANCER, V15, P785, DOI 10.1111/j.1525-1438.2005.00137.x; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Huang SM, 1999, INVEST NEW DRUG, V17, P259, DOI 10.1023/A:1006384521198; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kawaguchi K, 2009, CARCINOGENESIS, V30, P1097, DOI 10.1093/carcin/bgp097; Laimer K, 2007, ORAL ONCOL, V43, P193, DOI 10.1016/j.oraloncology.2006.02.009; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Liu LB, 2008, J MED CHEM, V51, P3688, DOI 10.1021/jm800401t; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; McDermott U, 2010, CANCER RES, V70, P1625, DOI 10.1158/0008-5472.CAN-09-3620; Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Peghini PL, 2002, CLIN CANCER RES, V8, P2273; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Quesnelle KM, 2007, J CELL BIOCHEM, V102, P311, DOI 10.1002/jcb.21475; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sharma K, 2009, NAT METHODS, V6, P741, DOI [10.1038/NMETH.1373, 10.1038/nmeth.1373]; Spix JK, 2007, EXP CELL RES, V313, P3319, DOI 10.1016/j.yexcr.2007.06.006; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Timpson P, 2007, CANCER RES, V67, P9304, DOI 10.1158/0008-5472.CAN-07-0798; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Twombly R, 2005, J NATL CANCER I, V97, P249, DOI 10.1093/jnci/97.4.249; Wang W, 2009, CLIN CANCER RES, V15, P6630, DOI 10.1158/1078-0432.CCR-09-1001; Weinberger PM, 2005, ARCH OTOLARYNGOL, V131, P707, DOI 10.1001/archotol.131.8.707; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Xu L, 2010, ONCOGENE, V29, P2616, DOI 10.1038/onc.2010.16; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yoshida T, 2010, BIOCHEM PHARMACOL, V80, P613, DOI 10.1016/j.bcp.2010.05.014; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845; Zucali PA, 2008, ANN ONCOL, V19, P1605, DOI 10.1093/annonc/mdn240	53	80	86	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3846	3856		10.1038/onc.2012.396	http://dx.doi.org/10.1038/onc.2012.396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	23045285				2022-12-28	WOS:000323210200007
J	Lai, KC; Liu, CJ; Chang, KW; Lee, TC				Lai, K. C.; Liu, C. J.; Chang, K. W.; Lee, T. C.			Depleting IFIT2 mediates atypical PKC signaling to enhance the migration and metastatic activity of oral squamous cell carcinoma cells	ONCOGENE			English	Article						IFIT2; oral squamous cell carcinoma; epithelial-mesenchymal transition; migration; invasion; atypical PKC	EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOGEN-SYNTHASE KINASE-3; BREAST-CANCER; E-CADHERIN; HEAD; EXPRESSION; SURVIVAL; INVASION; GENES; CDC42	Interferon-induced protein with tetratricopeptide repeats 2 (IFIT2) is one of the most highly responsive interferon-stimulated genes, but its biological functions are poorly understood. In this study, we aimed to explore the underlying mechanisms by which depleting IFIT2 induces the migration of oral squamous cell carcinoma (OSCC) cells. Stable IFIT2-depleted cells underwent epithelial-mesenchymal transition (EMT) and exhibited enhanced cell motility and invasiveness compared with control cells. Furthermore, our results indicated that atypical protein kinase C (aPKC) was activated in IFIT2-depleted cells. Inhibition of aPKC using a specific myristoylated PKC zeta pseudosubstrate or aPKC-targeting small interfering RNA (siRNA) abolished IFIT2 depletion-induced EMT, migration and invasion, indicating that the activation of aPKC has an essential role in regulating the cellular responses induced by IFIT2 depletion. Following tail-vein injection, IFIT2-depleted OSCC cells colonized not only the lungs but also the heart, head and neck, retroperitoneal, and peritoneal cavities; whereas control cells predominantly localized in the lungs. IFIT2 mRNA and protein expression was positively associated with E-cadherin expression in OSCC patient specimens. The loss of E-cadherin and IFIT2 expression was observed at the invasive front of OSCC tumors, suggesting that the loss of IFIT2 may induce EMT and lead to the metastasis of OSCCs. OSCC patients possessing reduced IFIT2-expression levels (IFIT2 <50%) exhibited greater rates of distant metastasis and poor prognoses compared with OSCC patients who expressed greater levels of IFIT2 (IFIT2 >= 50%). These results demonstrate that IFIT2 depletion activates the aPKC pathway and consequently induces EMT, cell migration and invasion. Most importantly, depleting IFIT2 may participate in OSCC tumor progression, particularly during metastasis. Taken together, our study demonstrates that IFIT2, a protein responsible for interferon stimulation, may prevent OSCC metastasis and serve as a valuable prognostic marker.	[Lai, K. C.] Tzu Chi Univ, Dept Pharmacol, Hualien, Taiwan; [Lai, K. C.; Lee, T. C.] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Liu, C. J.] Mackay Mem Hosp, Dept Oral & Maxillofacial Surg, Taipei, Taiwan; [Chang, K. W.] Natl Yang Ming Univ, Sch Dent, Inst Oral Biol, Taipei 112, Taiwan	Tzu Chi University; Academia Sinica - Taiwan; Mackay Memorial Hospital; National Yang Ming Chiao Tung University	Lee, TC (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sect 2,Acad Rd Nankang, Taipei 115, Taiwan.	bmtcl@ibms.sinica.edu.tw	Lee, Te-Chang/B-3245-2011	Lee, Te-Chang/0000-0003-4448-1507	Academia Sinica; National Science Council, Taiwan, ROC [NSC 93-3112-B-001-036, NSC 98-2320-B-001-002-MY3]	Academia Sinica(Academia Sinica - Taiwan); National Science Council, Taiwan, ROC(Ministry of Science and Technology, Taiwan)	We thank the Pathological Core Laboratory supported by Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, ROC for their excellent technical assistance on pathological examination. We also thank Dr Michael Hsiao (Genomics Research Center, Academia Sinica, Taipei, Taiwan, ROC) for providing lentiviral particles and experimental assistance. This work was also supported by the Academia Sinica and grants from the National Science Council, Taiwan, ROC (NSC 93-3112-B-001-036; NSC 98-2320-B-001-002-MY3).	ALBINI A, 1987, CANCER RES, V47, P3239; Bagan JV, 2009, ORAL ONCOL, V45, pE45, DOI 10.1016/j.oraloncology.2008.12.012; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Bell RB, 2007, J ORAL MAXIL SURG, V65, P229, DOI 10.1016/j.joms.2005.11.094; Chang SY, 2009, CYTOKINE, V45, P32, DOI 10.1016/j.cyto.2008.10.013; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Department of Health TEY, 2010, CANC REG ANN REP TAI; Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fan S, 2011, INT J ORAL SCI, V3, P180, DOI 10.4248/IJOS11068; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferlito A, 2001, ORL J OTO-RHINO-LARY, V63, P189, DOI 10.1159/000055738; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gonzalez-Garcia R, 2009, HEAD NECK-J SCI SPEC, V31, P1168, DOI 10.1002/hed.21088; Kim D W, 2001, Exp Mol Med, V33, P101; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Lai KC, 2008, MOL CANCER RES, V6, P1; Leon X, 1999, HEAD NECK-J SCI SPEC, V21, P204, DOI 10.1002/(SICI)1097-0347(199905)21:3<204::AID-HED4>3.0.CO;2-7; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lorusso G, 2012, SEMIN CANCER BIOL, V22, P226, DOI 10.1016/j.semcancer.2012.03.007; Lu X, 2007, J MAMMARY GLAND BIOL, V12, P153, DOI 10.1007/s10911-007-9047-3; Ma C, 2007, CANCER RES, V67, P7756, DOI 10.1158/0008-5472.CAN-06-4665; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Mishra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-144; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rao DN, 1998, BRIT J CANCER, V77, P1514, DOI 10.1038/bjc.1998.249; Rosse C, 2010, NAT REV MOL CELL BIO, V11, P103, DOI 10.1038/nrm2847; Saha S, 2006, J GEN VIROL, V87, P3285, DOI 10.1099/vir.0.82107-0; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Sanjiv K, 2012, INT J CANCER, V130, P1440, DOI 10.1002/ijc.26142; Sano D, 2007, CANCER METAST REV, V26, P645, DOI 10.1007/s10555-007-9082-y; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Shingaki S, 2003, AM J SURG, V185, P278, DOI 10.1016/S0002-9610(02)01378-8; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Terenzi F, 2006, J BIOL CHEM, V281, P34064, DOI 10.1074/jbc.M605771200; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yonezawa Tomo, 2009, Recent Pat DNA Gene Seq, V3, P96	52	44	48	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2013	32	32					3686	3697		10.1038/onc.2012.384	http://dx.doi.org/10.1038/onc.2012.384			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22986528				2022-12-28	WOS:000322904400004
J	Calao, M; Sekyere, EO; Cui, HJ; Cheung, BB; Thomas, WD; Keating, J; Chen, JB; Raif, A; Jankowski, K; Davies, NP; Bekkum, MV; Chen, B; Tan, O; Ellis, T; Norris, MD; Haber, M; Kim, ES; Shohet, JM; Trahair, TN; Liu, T; Wainwright, BJ; Ding, HF; Marshall, GM				Calao, M.; Sekyere, E. O.; Cui, H. J.; Cheung, B. B.; Thomas, W. D.; Keating, J.; Chen, J. B.; Raif, A.; Jankowski, K.; Davies, N. P.; Bekkum, M. V.; Chen, B.; Tan, O.; Ellis, T.; Norris, M. D.; Haber, M.; Kim, E. S.; Shohet, J. M.; Trahair, T. N.; Liu, T.; Wainwright, B. J.; Ding, H. F.; Marshall, G. M.			Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation	ONCOGENE			English	Article						Bmi1; p53; MYCN; neuroblastoma; medulloblastoma; apoptosis	MYC TRANSGENIC MICE; STEM-CELLS; IN-VIVO; NEUROBLASTOMA; MEDULLOBLASTOMA; LINES; AMPLIFICATION; EXPRESSION; MECHANISM; APOPTOSIS	Embryonal cancer can arise from postnatally persistent embryonal remnant or rest cells, which are uniquely characterized by the absence of p53 mutations. Perinatal overexpression of the MycN oncoprotein in embryonal cancer precursor cells causes postnatal rests, and later tumor formation through unknown mechanisms. However, overexpression of Myc in adult tissues normally activates apoptosis and/or senescence signals as an organismal defense mechanism against cancer. Here, we show that perinatal neuroblastoma precursor cells exhibited a transiently diminished p53 response to MycN oncoprotein stress and resistance to trophic factor withdrawal, compared with their adult counterpart cells from the TH-MYCN-/- transgenic mouse model of neuroblastoma. The adult stem cell maintenance factor and Polycomb group protein, Bmi1 (B-cell-specific Moloney murine leukemia virus integration site), had a critical role at neuroblastoma initiation in the model, by repressing p53 responses in precursor cells. We further show in neuroblastoma tumor cells that Bmi1 could directly bind p53 in a complex with other Polycomb complex proteins, Ring1A or Ring1B, leading to increased p53 ubiquitination and degradation. Repressed p53 signal responses were also seen in precursor cells for other embryonal cancer types, medulloblastoma and acute lymphoblastic leukemia. Collectively, these date indicate a general mechanism for p53 inactivation in some embryonal cell types and consequent susceptibility to MycN oncogenesis at the point of embryonal tumor initiation.	[Calao, M.; Sekyere, E. O.; Cheung, B. B.; Thomas, W. D.; Keating, J.; Chen, J. B.; Raif, A.; Jankowski, K.; Davies, N. P.; Bekkum, M. V.; Chen, B.; Tan, O.; Norris, M. D.; Haber, M.; Trahair, T. N.; Liu, T.; Marshall, G. M.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, Sydney, NSW 2031, Australia; [Cui, H. J.] Southwest Univ, Inst Sericulture & Syst Biol, State Key Lab Silkworm Funct Genome Biol, Chongqing, Peoples R China; [Ellis, T.; Wainwright, B. J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Kim, E. S.; Shohet, J. M.] Texas Childrens Hosp, Houston, TX 77030 USA; [Trahair, T. N.; Marshall, G. M.] Sydney Childrens Hosp, Sydney, NSW, Australia; [Ding, H. F.] Med Coll Georgia, Augusta, GA 30912 USA	Children's Cancer Institute; Children's Medical Research Institute - Australia; University of New South Wales Sydney; Southwest University - China; University of Queensland; Baylor College of Medicine; University of Sydney; University System of Georgia; Augusta University	Marshall, GM (corresponding author), Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, Sydney, NSW 2031, Australia.	g.marshall@ccia.unsw.edu.au	Chen, Jinbiao/J-5868-2013; Liu, Tao/A-3922-2015; Chen, Jinbiao/N-9905-2019	Chen, Jinbiao/0000-0003-0339-5880; Chen, Jinbiao/0000-0003-0339-5880; Cheung, Belamy/0000-0001-8784-860X; Ding, Han-Fei/0000-0001-5702-3439; Kim, Eugene/0000-0001-7959-5614; Liu, Tao/0000-0001-6244-7316; Haber, Michelle/0000-0003-2036-8817; Trahair, Toby/0000-0002-3295-228X; Tan, Owen/0000-0002-0303-7138; Wainwright, Brandon/0000-0003-0406-2092	National Health & Medical Research Council of Australia; Cancer Institute New South Wales; Cure for Life Foundation; Cancer Council New South Wales	National Health & Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute New South Wales; Cure for Life Foundation; Cancer Council New South Wales(Cancer Council New South Wales)	We thank W Weiss for the TH-MYCN mice, and D Kaplan for the adenoviral vector MYCN constructs. This work was supported by the National Health & Medical Research Council of Australia, Cancer Institute New South Wales, Cure for Life Foundation and the Cancer Council New South Wales.	Alajez NM, 2009, CELL DEATH DIFFER, V16, P1469, DOI 10.1038/cdd.2009.85; Alchanati I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008104; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Chen LD, 2010, CANCER RES, V70, P1377, DOI 10.1158/0008-5472.CAN-09-2598; Chen ZW, 2009, NEOPLASIA, V11, P753, DOI 10.1593/neo.09466; Cheng AJ, 2007, EUR J CANCER, V43, P1467, DOI 10.1016/j.ejca.2007.03.008; Chesler L, 2008, NEOPLASIA, V10, P1268, DOI 10.1593/neo.08778; CICCARONE V, 1989, CANCER RES, V49, P219; Cohnheim J., 1889, LECT GEN PATHOLOGY; Cui HJ, 2007, AM J PATHOL, V170, P1370, DOI 10.2353/ajpath.2007.060754; Durante F., 1874, ARCH MEMOR OBSERV CH, V11, P217; Ellis T, 2003, GENESIS, V36, P158, DOI 10.1002/gene.10208; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Gilbertson RJ, 2004, LANCET ONCOL, V5, P209, DOI 10.1016/S1470-2045(04)01424-X; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Hansford LM, 2004, P NATL ACAD SCI USA, V101, P12664, DOI 10.1073/pnas.0401083101; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hogarty MD, 2003, CANCER LETT, V197, P173, DOI 10.1016/S0304-3835(03)00103-4; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Jiang LL, 2009, ACTA BIOCH BIOPH SIN, V41, P527, DOI 10.1093/abbs/gmp040; Johnsen J, 2009, APOPTOSIS, V14, P424, DOI 10.1007/s10495-009-0325-y; Kang MK, 2010, CELL CYCLE, V9, P2704, DOI 10.4161/cc.9.14.12322; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Lossi L, 2003, PROG NEUROBIOL, V69, P287, DOI 10.1016/S0301-0082(03)00051-0; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Peirce SK, 2010, CELL HEALTH CYTOSKEL, V2, P49; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Scotting PJ, 2005, NAT REV CANCER, V5, P481, DOI 10.1038/nrc1633; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Taub JW, 2002, BLOOD, V99, P2992, DOI 10.1182/blood.V99.8.2992; Thomas WD, 2009, ONCOGENE, V28, P1605, DOI 10.1038/onc.2009.3; Thomas WD, 2004, INT J BIOCHEM CELL B, V36, P771, DOI 10.1016/S1357-2725(03)00254-1; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wetmore C, 2001, CANCER RES, V61, P513; WHITLOCK CA, 1987, METHOD ENZYMOL, V150, P275; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003	47	46	46	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3616	3626		10.1038/onc.2012.368	http://dx.doi.org/10.1038/onc.2012.368			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22907436	hybrid			2022-12-28	WOS:000322638400006
J	Du, W; Wang, S; Zhou, Q; Li, X; Chu, J; Chang, Z; Tao, Q; Ng, EKW; Fang, J; Sung, JJY; Yu, J				Du, W.; Wang, S.; Zhou, Q.; Li, X.; Chu, J.; Chang, Z.; Tao, Q.; Ng, E. K. W.; Fang, J.; Sung, J. J. Y.; Yu, J.			ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer	ONCOGENE			English	Article						ADAMTS9; tumor suppressor; AKT/mTOR pathway; gastric cancer; prognosis	NASOPHARYNGEAL CARCINOMA; GENE; MTOR; METHYLATION; EXPRESSION; ESOPHAGEAL; APOPTOSIS; THERAPY; CELLS; AKT	Using genome-wide promoter methylation analysis, we identified a disintegrin-like and metalloprotease with thrombospondin type 1 motif 9 (ADAMTS9) is methylated in cancer. We aim to clarify its epigenetic inactivation, biological function and clinical implication in gastric cancer. ADAMTS9 was silenced in 6 out of 8 gastric cancer cell lines. The loss of ADAMTS9 expression was regulated by promoter hypermethylation and could be restored by demethylation agent. Ectopic expression of ADAMTS9 in gastric cancer cell lines (AGS, BGC823) inhibited cell growth curve in both the cell lines (P<0.0001), suppressed colony formation (P<0.01) and induced apoptosis (P<0.001 in AGS, P<0.01 in BGC823). Moreover, conditioned culture medium from ADAMTS9-transfected cell lines significantly disrupted the human umbilical vein endothelial cell tube formation capacity on Matrigel (P<0.01 in AGS, P<0.001 in BGC823). The in vivo growth of ADAMTS9 cells in nude mice was also markedly diminished after stable expression of ADAMTS9 (P<0.001). On the other hand, ADAMTS9 knockdown promoted cell proliferation (P<0.001). We further revealed that ADAMTS9 inhibited tumor growth by blocking activation of Akt and its downstream target the mammalian target of rapamycin (mTOR). ADAMTS9 also reduced phosphorylation of mTOR downstream targets p70 ribosomal S6 kinase, eIF4E-binding protein and downregulated hypoxia-inducible factor-1 alpha. Therefore, this is the first demonstration that ADAMTS9 is a critical tumor suppressor of gastric cancer progression at least in part through suppression of oncogenic AKT/mTOR signaling. Moreover, promoter methylation of ADAMTS9 was detected in 29.2% (21/72) of primary gastric tumors. Multivariate analysis showed that patients with ADAMTS9 methylation had a poorer overall survival (relative risk (RR) = 2.788; 95% confidence interval, 1.474-5.274; P = 0.002). Kaplan-Meier survival curves showed that ADAMTS9 methylation was significantly associated with shortened survival in gastric cancer patients (P = 0.001, log-rank test). In conclusion, ADAMTS9 acts as a functional tumor suppressor in gastric cancer through inhibiting oncogenic AKT/mTOR signaling pathway. Methylation of ADAMTS9 is an independent prognostic factor of gastric cancer.	[Du, W.; Wang, S.; Li, X.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Shatin, Hong Kong, Peoples R China; [Du, W.; Wang, S.; Li, X.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Du, W.; Fang, J.] Shanghai Jiao Tong Univ, Div Gastroenterol, Sch Med,Minist Hlth,State Key Lab Oncogene & Rela, Renji Hosp,Shanghai Inst Digest Disease,Key Lab G, Shanghai 200030, Peoples R China; [Zhou, Q.; Tao, Q.] Chinese Univ Hong Kong, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China; [Chu, J.] Hong Kong Baptist Univ, Sch Chinese Med, Ctr Canc & Inflammat Res, Kowloon, Hong Kong, Peoples R China; [Chang, Z.] Tsinghua Univ, Sch Med, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; [Ng, E. K. W.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Shanghai Jiao Tong University; Chinese University of Hong Kong; Hong Kong Baptist University; Tsinghua University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Shatin, Hong Kong, Peoples R China.	jingyuanfang@yahoo.com; junyu@cuhk.edu.hk	Ng, Enders K.O./F-2787-2010; Li, Xiao-xing/B-9114-2008; Tao, Qian/T-4743-2018; Ng, Enders/T-3881-2019; Sung, Joseph J. Y./R-3203-2018; Yu, Jun/D-8569-2015; Ng, Enders Kwok Wai/E-8276-2016; Chang, Zhijie/AAH-8109-2019	Ng, Enders K.O./0000-0002-6955-0030; Li, Xiao-xing/0000-0001-8791-7505; Tao, Qian/0000-0001-5383-4808; Ng, Enders/0000-0002-6955-0030; Sung, Joseph J. Y./0000-0003-3125-5199; Yu, Jun/0000-0001-5008-2153; Ng, Enders Kai-on/0000-0002-5293-3529	National Basic Research Program of China (973 Program) [2010CB529305]; Shenzhen Basic Research Program [JC20110520111A]; Research Grants Council RGC CERG CUHK [473008]; Group Research Scheme CUHK [3110043]; CUHK Focused Investment Gant [1903026]; RFCID [10090942, 11100022]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); Shenzhen Basic Research Program; Research Grants Council RGC CERG CUHK; Group Research Scheme CUHK; CUHK Focused Investment Gant; RFCID	This project was supported by National Basic Research Program of China (973 Program, 2010CB529305); Shenzhen Basic Research Program (JC20110520111A); Research Grants Council RGC CERG CUHK (473008); Group Research Scheme CUHK (3110043); CUHK Focused Investment Gant (1903026), and RFCID (10090942, 11100022).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Asnaghi L, 2004, ONCOGENE, V23, P5781, DOI 10.1038/sj.onc.1207698; Averous J, 2008, ONCOGENE, V27, P1106, DOI 10.1038/sj.onc.1210715; Cheung KF, 2012, CANCER-AM CANCER SOC, V118, P947, DOI 10.1002/cncr.26189; Cicenas J, 2011, J CANCER RES CLIN, V137, P1409, DOI 10.1007/s00432-011-1039-4; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Jungers KA, 2005, GENE EXPR PATTERNS, V5, P609, DOI 10.1016/j.modgep.2005.03.004; Kern CB, 2010, MATRIX BIOL, V29, P304, DOI 10.1016/j.matbio.2010.01.005; Koo BH, 2006, J BIOL CHEM, V281, P12485, DOI 10.1074/jbc.M511083200; Koo BH, 2010, AM J PATHOL, V176, P1494, DOI 10.2353/ajpath.2010.090655; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Leung WK, 2006, CLIN CANCER RES, V12, P3216, DOI 10.1158/1078-0432.CCR-05-2442; Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124; Liu YJ, 2006, ONCOGENE, V25, P2452, DOI 10.1038/sj.onc.1209287; Lo PHY, 2007, ONCOGENE, V26, P148, DOI 10.1038/sj.onc.1209767; Lo PHY, 2010, CANCER RES, V70, P5567, DOI 10.1158/0008-5472.CAN-09-4510; Lung HL, 2008, INT J CANCER, V123, P401, DOI 10.1002/ijc.23528; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Sepulveda AR, 2010, GASTROENTEROLOGY, V138, P1836, DOI 10.1053/j.gastro.2009.12.042; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Troiano L, 2007, NAT PROTOC, V2, P2719, DOI 10.1038/nprot.2007.405; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yu J, 2009, CANCER-AM CANCER SOC, V115, P49, DOI 10.1002/cncr.23989; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	33	83	90	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2013	32	28					3319	3328		10.1038/onc.2012.359	http://dx.doi.org/10.1038/onc.2012.359			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22907434				2022-12-28	WOS:000321620200002
J	Dong, P; Karaayvaz, M; Jia, N; Kaneuchi, M; Hamada, J; Watari, H; Sudo, S; Ju, J; Sakuragi, N				Dong, P.; Karaayvaz, M.; Jia, N.; Kaneuchi, M.; Hamada, J.; Watari, H.; Sudo, S.; Ju, J.; Sakuragi, N.			Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis	ONCOGENE			English	Article						EMT; cancer; gain-of-function; miRNA; p53 mutation	ENDOMETRIAL CANCER-CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; SUPPRESSES METASTASIS; MICRORNA EXPRESSION; DNA-BINDING; PROMOTES; ZEB1; CONTRIBUTES; REPRESSION	The tumor suppressor gene p53 has been implicated in the regulation of epithelial-mesenchymal transition (EMT) and tumor metastasis by regulating microRNA (miRNA) expression. Here, we report that mutant p53 exerts oncogenic functions and promotes EMT in endometrial cancer (EC) by directly binding to the promoter of miR-130b (a negative regulator of ZEB1) and inhibiting its transcription. We transduced p53 mutants into p53- null EC cells, profiled the miRNA expression by miRNA microarray and identified miR-130b as a potential target of mutant p53. Ectopic expression of p53 mutants repressed the expression of miR-130b and triggered ZEB1-dependent EMT and cancer cell invasion. Loss of an endogenous p53 mutation increased the expression of miR-130b, which resulted in reduced ZEB1 expression and attenuation of the EMT phenotype. Furthermore, re-expression of miR-130b suppressed mutant p53- induced EMT and ZEB1 expression. Importantly, the expression of miR-130 was significantly reduced in EC tissues, and patients with higher expression levels of miR-130b survived longer. These data provide a novel understanding of the roles of p53 gain-of-function mutations in accelerating tumor progression and metastasis through modulation of the miR-130b-ZEB1 axis.	[Dong, P.; Kaneuchi, M.; Watari, H.; Sudo, S.; Sakuragi, N.] Hokkaido Univ, Sch Med, Dept Gynecol, Sapporo, Hokkaido 0608638, Japan; [Karaayvaz, M.; Ju, J.] SUNY Stony Brook, Dept Pathol, Med Ctr, Stony Brook, NY 11794 USA; [Jia, N.] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China; [Hamada, J.] Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Shanghai Jiao Tong University; Hokkaido University	Dong, P (corresponding author), Hokkaido Univ, Sch Med, Dept Gynecol, Sapporo, Hokkaido 0608638, Japan.	dongpeix@yahoo.co.jp; Jingfang.Ju@stonybrookmedicine.edu	Dong, Peixin/M-5592-2015	Dong, Peixin/0000-0002-2335-1394; Ju, Jingfang/0000-0002-4821-7458	Women's Health Educational System; Ministry of Health, Labour and Welfare of Japan; Shanghai Municipal Natural Science Foundation [11ZR1430500]; Stony Brook University Translational Research Laboratory Start-up fund [R01CA155019, R33CA147966]; NATIONAL CANCER INSTITUTE [R33CA147966] Funding Source: NIH RePORTER	Women's Health Educational System; Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Shanghai Municipal Natural Science Foundation; Stony Brook University Translational Research Laboratory Start-up fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate the critical review by Ms Sonya R Lorrain. This work was funded by a grant from Women's Health Educational System, a Grant-in-Aid from the Ministry of Health, Labour and Welfare of Japan, Shanghai Municipal Natural Science Foundation (11ZR1430500) and by Stony Brook University Translational Research Laboratory Start-up fund (J Ju), R01CA155019 (J Ju) and R33CA147966 (J Ju). We thank Dr Zhujie Xu for his technical assistance.	Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chicas A, 2000, BIOCHEM BIOPH RES CO, V279, P383, DOI 10.1006/bbrc.2000.3965; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Clape C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007542; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Dong PX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-99; Dong PX, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-103; Forrest ARR, 2010, LEUKEMIA, V24, P460, DOI 10.1038/leu.2009.246; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Fujisawa T, 2003, Hum Cell, V16, P47, DOI 10.1111/j.1749-0774.2003.tb00128.x; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Kogan-Sakin I, 2011, CELL DEATH DIFFER, V18, P271, DOI 10.1038/cdd.2010.94; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma S, 2010, CELL STEM CELL, V7, P694, DOI 10.1016/j.stem.2010.11.010; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915; Navon R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008003; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh M, 2008, MODERN PATHOL, V21, P912, DOI 10.1038/modpathol.2008.82; Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xi YG, 2006, BIOMARK INSIGHTS, V1, P113; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Yang C, 2012, GYNECOL ONCOL, V124, P325, DOI 10.1016/j.ygyno.2011.10.013; Yip L, 2011, ANN SURG ONCOL, V18, P2035, DOI 10.1245/s10434-011-1733-0; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; ZHANG W, 1993, ONCOGENE, V8, P2555	49	216	227	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3286	3295		10.1038/onc.2012.334	http://dx.doi.org/10.1038/onc.2012.334			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22847613	Green Published, hybrid			2022-12-28	WOS:000321301600008
J	Nayak, BK; Feliers, D; Sudarshan, S; Friedrichs, WE; Day, RT; New, DD; Fitzgerald, JP; Eid, A; DeNapoli, T; Parekh, DJ; Gorin, Y; Block, K				Nayak, B. K.; Feliers, D.; Sudarshan, S.; Friedrichs, W. E.; Day, R. T.; New, D. D.; Fitzgerald, J. P.; Eid, A.; DeNapoli, T.; Parekh, D. J.; Gorin, Y.; Block, K.			Stabilization of HIF-2 alpha through redox regulation of mTORC2 activation and initiation of mRNA translation	ONCOGENE			English	Article						mTOR; Nox oxidase; Rictor; p22(phox); HIF-2 alpha; renal cancer	TUMOR-SUPPRESSOR PROTEIN; CANCER; PHOSPHORYLATION; EXPRESSION; CARCINOMA; COMPLEX; EIF4E; AKT; TRANSFORMATION; CONTRIBUTES	Hypoxia inducible factor-2 alpha (HIF-2 alpha) has a critical role in renal tumorigenesis. HIF-2 alpha is stabilized in von Hippel-Lindau (VHL)-deficient renal cell carcinoma through mechanisms that require ongoing mRNA translation. Mammalian target of rapamycin (mTOR) functions in two distinct complexes: Raptor-associated mTORC1 and Rictor-associated mTORC2. Rictor-associated mTORC2 complex has been linked to maintaining HIF-2 alpha protein in the absence of VHL; however, the mechanisms remain to be elucidated. Although Raptor-associated mTORC1 is a known key upstream regulator of mRNA translation, initiation and elongation, the role of mTORC2 in regulating mRNA translation is not clear. Complex assembly of the mRNA cap protein, eukaryotic translation initiation factor 4 (eIF4)E, with activators (eIF4 gamma (eIF4G)) and inhibitors (eIF4E-binding protein 1 (4E-BP1)) are rate-limiting determinants of mRNA translation. Our laboratory has previously demonstrated that reactive oxygen species, mediated by p22(phox)-based Nox oxidases, are enhanced in VHL-deficient cells and have a role in the activation of Akt on S473, a site phosphorylated by the mTORC2 complex. In this study, we examined the role of Rictor-dependent regulation of HIF-2 alpha through eIF4E-dependent mRNA translation and examined the effects of p22(phox)-based Nox oxidases on TORC2 regulation. We demonstrate for the first time that mTORC2 complex stability and activation is redox sensitive, and further defined a novel role for p22(phox)-based Nox oxidases in eIF4E-dependent mRNA translation through mTORC2. Furthermore, we provide the first evidence that silencing of p22(phox) reduces HIF-2 alpha-dependent gene targeting in vitro and tumor formation in vivo. The clinical relevance of these studies is demonstrated.	[Nayak, B. K.; Feliers, D.; Friedrichs, W. E.; Day, R. T.; New, D. D.; Eid, A.; Gorin, Y.; Block, K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Sudarshan, S.; Fitzgerald, J. P.; Parekh, D. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA; [DeNapoli, T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Block, K.] South Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Block, K (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	block@uthscsa.edu		Feliers, Denis/0000-0003-1952-1386	Veterans Administration; NIH [R01 NCI CA131272, K08 CA138774]; Voelcker Fund Young Investigator Award; Cancer Center Support Grant, National Cancer Institute [5 P30 CA054174-18]; NATIONAL CANCER INSTITUTE [K08CA138774, P30CA054174, R01CA131272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033665] Funding Source: NIH RePORTER	Veterans Administration(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Voelcker Fund Young Investigator Award; Cancer Center Support Grant, National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We acknowledge Dr Goutam Gosh-Choudhury for the HRE responsive element, Cynthia Galindo for technical contributions and Dr Hanna E. Abboud for helpful discussions and critical reading of the manuscript. This study was supported by the Veterans Administration Career Development Award and NIH R01 NCI CA131272 (KB), and NIH K08 CA138774 and Voelcker Fund Young Investigator Award (SS). This study was also supported in part by the Cancer Center Support Grant, National Cancer Institute, 5 P30 CA054174-18 (DJP).	Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Baldewijns MM, 2010, J PATHOL, V221, P125, DOI 10.1002/path.2689; Block K, 2007, J BIOL CHEM, V282, P8019, DOI 10.1074/jbc.M611569200; Block K, 2010, AM J PATHOL, V176, P2447, DOI 10.2353/ajpath.2010.090606; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Feliers D, 2007, AM J PHYSIOL-RENAL, V293, pF607, DOI 10.1152/ajprenal.00497.2006; Foster H, 2010, ANTICANCER RES, V30, P3529; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee HJ, 2009, UROLOGY, V73, P394, DOI 10.1016/j.urology.2008.08.472; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369	28	39	40	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3147	3155		10.1038/onc.2012.333	http://dx.doi.org/10.1038/onc.2012.333			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22869144	Green Accepted			2022-12-28	WOS:000321004600005
J	Li, B; Wang, C; Zhang, Y; Zhao, XY; Huang, B; Wu, PF; Li, Q; Li, H; Liu, YS; Cao, LY; Dai, WM; Fang, WG; Shang, DS; Cao, L; Zhao, WD; Chen, YH				Li, B.; Wang, C.; Zhang, Y.; Zhao, X. Y.; Huang, B.; Wu, P. F.; Li, Q.; Li, H.; Liu, Y. S.; Cao, L. Y.; Dai, W. M.; Fang, W. G.; Shang, D. S.; Cao, L.; Zhao, W. D.; Chen, Y. H.			Elevated PLGF contributes to small-cell lung cancer brain metastasis	ONCOGENE			English	Article						blood-brain barrier; brain metastasis; PLGF; Rho kinase; small-cell lung cancer	ENDOTHELIAL GROWTH-FACTOR; TIGHT JUNCTION PROTEINS; BREAST-CANCER; VASCULAR-PERMEABILITY; DIABETIC-RETINOPATHY; KINASE; OCCLUDIN; BARRIER; PHOSPHORYLATION; ACTIVATION	Brain metastasis (BM) is a major cause of mortality in small-cell lung cancer (SCLC) patients; however, the molecular pathway of SCLC BM remains largely unknown because of a lack of investigation. Here we screen the levels of some candidate-soluble factors in the serum of SCLC patients and find that SCLC patients with high levels of placental growth factor (PLGF) are prone to BM. Using in vitro blood-brain barrier model, we show that PLGF derived from SCLC cells triggers vascular endothelial growth factor receptor1- Rho-extracellular regulated protein kinase 1/2 signaling axis activation, results in disassembly of tight junction in brain endothelial cells and promotes SCLC cell transendothelial migration. Furthermore, the downregulation of PLGF suppresses SCLC cell metastasis to the brain in an experimental BM model. These data suggest that PLGF is a potential signature of SCLC BM and a prospective therapeutic target for SCLC BM.	[Li, B.; Wang, C.; Zhang, Y.; Zhao, X. Y.; Liu, Y. S.; Cao, L. Y.; Dai, W. M.; Fang, W. G.; Shang, D. S.; Zhao, W. D.; Chen, Y. H.] China Med Univ, Dept Dev Biol, Minist Publ Hlth, Key Lab Cell Biol, Shenyang 110001, Peoples R China; [Li, B.; Wang, C.; Zhang, Y.; Zhao, X. Y.; Liu, Y. S.; Cao, L. Y.; Dai, W. M.; Fang, W. G.; Shang, D. S.; Cao, L.; Zhao, W. D.; Chen, Y. H.] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110001, Peoples R China; [Wang, C.] Liaoning Univ Tradit Chinese Med, Dept Cell Biol, Shenyang, Peoples R China; [Zhao, X. Y.] Shenyang Pharmaceut Univ, Dept Cell Biol, Shenyang, Peoples R China; [Huang, B.] Liaoning Canc Hosp & Inst, Dept Pathol, Shenyang, Peoples R China; [Wu, P. F.] China Med Univ, Hosp 1, Dept Neurosurg, Shenyang 110001, Peoples R China; [Li, Q.] China Med Univ, Shengjing Hosp, Dept Med Examinat, Shenyang 110001, Peoples R China; [Li, H.] China Med Univ, Shengjing Hosp, Dept Geriatr Med, Shenyang 110001, Peoples R China; [Cao, L.] China Med Univ, Minist Educ, Minist Publ Hlth, Inst Translat Med,Key Lab Cell Biol, Shenyang 110001, Peoples R China	China Medical University; China Medical University; Liaoning University of Traditional Chinese Medicine; Shenyang Pharmaceutical University; China Medical University; China Medical University; China Medical University; China Medical University	Chen, YH (corresponding author), China Med Univ, Dept Dev Biol, Minist Publ Hlth, Key Lab Cell Biol, 92 Bei Er Rd, Shenyang 110001, Peoples R China.	yhchen@mail.cmu.edu.cn	Liu, Yongshuo/GRX-6416-2022	Liu, Yongshuo/0000-0001-8190-0139	Trans-Century Training Program Foundation for Talents; Ministry of Education of China [JJH2002-48]; Innovation Team Program Foundation of Liaoning Province [2006T131, LT2011011]; National Natural Science Foundation of China [30600270]; Science and Technology Foundation of Liaoning Province [20102291]	Trans-Century Training Program Foundation for Talents; Ministry of Education of China(Ministry of Education, China); Innovation Team Program Foundation of Liaoning Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Foundation of Liaoning Province	We are grateful to Drs Monique Stins and Kwang Sik Kim (Department of Pediatrics, John Hopkins University School of Medicine) for providing HBMEC and Dr Shuh Narumiya (Kyoto University Faculty of Medicine, Kyoto, Japan) for providing pCAGmyc, pCAG-myc-ROCK-WT and pCAG-myc-ROCK-KDIA. This work was supported by the Trans-Century Training Program Foundation for Talents, Ministry of Education of China (JJH2002-48), the Innovation Team Program Foundation of Liaoning Province (2006T131, LT2011011), the National Natural Science Foundation of China (30600270) and the Science and Technology Foundation of Liaoning Province (20102291).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Carbonell WS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005857; CARNEY DN, 1985, CANCER RES, V45, P2913; Casalou C, 2007, LEUKEMIA, V21, P1590, DOI 10.1038/sj.leu.2404668; Castrucci WA, 2008, CANCER J, V14, P138, DOI 10.1097/PPO.0b013e318172d6e1; Chen CN, 2004, CANCER LETT, V213, P73, DOI 10.1016/j.canlet.2004.05.020; Chen JF, 2008, J CELL BIOCHEM, V105, P313, DOI 10.1002/jcb.21831; Cipolla MJ, 2004, FRONT BIOSCI-LANDMRK, V9, P777, DOI 10.2741/1282; Clarke H, 2000, J CELL SCI, V113, P3187; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Dimitri CA, 2005, CURR BIOL, V15, P1319, DOI 10.1016/j.cub.2005.06.037; Dowell JE, 2010, AM J MED SCI, V339, P68, DOI 10.1097/MAJ.0b013e3181bccef5; Eichler AF, 2011, NAT REV CLIN ONCOL, V8, P344, DOI 10.1038/nrclinonc.2011.58; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Francia G, 2011, NAT REV CANCER, V11, P135, DOI 10.1038/nrc3001; FUJIMAKI T, 1993, INT J ONCOL, V3, P789; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Kevil CG, 2000, AM J PHYSIOL-CELL PH, V279, pC21, DOI 10.1152/ajpcell.2000.279.1.C21; Khan NA, 2009, INT J PARASITOL, V39, P1611, DOI 10.1016/j.ijpara.2009.06.004; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Lee BC, 2004, MOL CANCER RES, V2, P327; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Li B, 2006, FEBS LETT, V580, P4252, DOI 10.1016/j.febslet.2006.06.056; Li M, 2009, J IMMUNOL, V182, P5778, DOI 10.4049/jimmunol.0803013; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Lorger M, 2010, AM J PATHOL, V176, P2958, DOI 10.2353/ajpath.2010.090838; Meyer TN, 2003, AM J PHYSIOL-CELL PH, V285, pC1281, DOI 10.1152/ajpcell.00548.2002; Miyamoto N, 2007, DIABETOLOGIA, V50, P461, DOI 10.1007/s00125-006-0539-2; Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766; Parr C, 2005, EUR J CANCER, V41, P2819, DOI 10.1016/j.ejca.2005.07.022; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; Phelps RM, 1996, J CELL BIOCHEM, P32; Ribatti D, 2008, ANGIOGENESIS, V11, P215, DOI 10.1007/s10456-008-9114-4; Rottbauer W, 2005, GENE DEV, V19, P1624, DOI 10.1101/gad.1319405; Schreurs MPH, 2012, FASEB J, V26, P355, DOI 10.1096/fj.11-191916; Stamatovic SM, 2006, J BIOL CHEM, V281, P8379, DOI 10.1074/jbc.M513122200; Taylor AP, 2010, BRIT J CANCER, V103, P82, DOI 10.1038/sj.bjc.6605746; Tsukamoto T, 1999, AM J PHYSIOL-RENAL, V276, pF737, DOI 10.1152/ajprenal.1999.276.5.F737; Vogel C, 2007, J CELL PHYSIOL, V212, P236, DOI 10.1002/jcp.21022; Wang X, 2011, BIOCHEM BIOPH RES CO, V410, P258, DOI 10.1016/j.bbrc.2011.05.128; Wei SC, 2005, GUT, V54, P666, DOI 10.1136/gut.2004.050831; Willis CL, 2010, J CEREBR BLOOD F MET, V30, P1847, DOI 10.1038/jcbfm.2010.119; Zhang CY, 2009, CANCER RES, V69, P828, DOI 10.1158/0008-5472.CAN-08-2588; Zhao WD, 2010, INFECT IMMUN, V78, P4809, DOI 10.1128/IAI.00377-10	47	60	66	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2952	2962		10.1038/onc.2012.313	http://dx.doi.org/10.1038/onc.2012.313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797069				2022-12-28	WOS:000320369700005
J	Lin, PH; Lan, WM; Chau, LY				Lin, P-H; Lan, W-M; Chau, L-Y			TRC8 suppresses tumorigenesis through targeting heme oxygenase-1 for ubiquitination and degradation	ONCOGENE			English	Article						TRC8; heme oxygenase-1; tumor suppressor; ubiquitination	RENAL-CANCER CELLS; TUMOR-SUPPRESSOR; UP-REGULATION; GENE; EXPRESSION; OVEREXPRESSION; RESISTANCE; APOPTOSIS; PATHWAY; GROWTH	The TRC8 gene, which was previously shown to be disrupted by a 3; 8 chromosomal translocation in hereditary kidney cancer, encodes for an endoplasmic reticulum-resident E3 ligase. Studies have shown that TRC8 exhibits a tumor-suppressive effect through its E3-ligase activity. Therefore, the identification of its physiological substrates will provide important insights into the molecular mechanism underlying TRC8-mediated tumor suppression. Here we show that TRC8 targets heme oxygenase-1 (HO-1), an antioxidant enzyme highly expressed in various cancers, for ubiquitination and degradation. Ectopic TRC8 expression suppresses HO-1-induced cancer cell growth and migration/invasion. Conversely, HO-1 depletion reduced the tumorigenic and invasive capacities promoted by TRC8 knockdown. HO-1 downregulation in renal carcinoma cells induces a mitotic delay at G2/M phase by increasing the intracellular reactive oxygen species and the DNA-damage-induced checkpoint activation. These results highlight the tumorigenic role of HO-1 and the importance of TRC8-mediated HO-1 degradation in the control of cancer growth.	[Lin, P-H; Lan, W-M; Chau, L-Y] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan; [Lin, P-H; Lan, W-M; Chau, L-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.	lyc@ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018	Chau, Lee-Young/0000-0002-6316-2328	Academia Sinica Investigatorship; National Science Council of Taiwan [NSC 100-2320-B-100-009MY3]	Academia Sinica Investigatorship(Academia Sinica - Taiwan); National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by an Academia Sinica Investigatorship to LYC and a grant from the National Science Council of Taiwan (NSC 100-2320-B-100-009MY3).	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Alaoui-Jamali MA, 2009, CANCER RES, V69, P8017, DOI 10.1158/0008-5472.CAN-09-0419; Banerjee P, 2011, J BIOL CHEM, V286, P33580, DOI 10.1074/jbc.M111.248401; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; Brauweiler A, 2007, ONCOGENE, V26, P2263, DOI 10.1038/sj.onc.1210017; Chen CY, 2005, BIOCHEM BIOPH RES CO, V331, P993, DOI 10.1016/j.bbrc.2005.03.237; Chen GG, 2004, J CELL BIOCHEM, V92, P1246, DOI 10.1002/jcb.20157; Datta D, 2010, J BIOL CHEM, V285, P36842, DOI 10.1074/jbc.M110.170324; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Fang YJ, 2011, CANCER LETT, V306, P10, DOI 10.1016/j.canlet.2011.02.019; Flad T, 2006, PROTEOMICS, V6, P364, DOI 10.1002/pmic.200500099; Gemmill RM, 2002, ONCOGENE, V21, P3507, DOI 10.1038/sj.onc.1205437; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Gimelli S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-52; Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54; Hill-Kapturczak N, 2003, ARTERIOSCL THROM VAS, V23, P1416, DOI 10.1161/01.ATV.0000081656.76378.A7; Hirsch C, 2009, NATURE, V458, P453, DOI 10.1038/nature07962; Hwang HW, 2009, J BIOL CHEM, V284, P22672, DOI 10.1074/jbc.M109.028001; Irisawa M, 2009, J BIOL CHEM, V284, P28995, DOI 10.1074/jbc.M109.041376; Jozkowicz A, 2007, ANTIOXID REDOX SIGN, V9, P2099, DOI 10.1089/ars.2007.1659; Kocanova S, 2007, APOPTOSIS, V12, P731, DOI 10.1007/s10495-006-0016-x; Koizumi S, 2007, J BIOL CHEM, V282, P8715, DOI 10.1074/jbc.M609427200; Kweon MH, 2006, J BIOL CHEM, V281, P33761, DOI 10.1074/jbc.M604748200; Lee JP, 2010, MOL CANCER RES, V8, P93, DOI 10.1158/1541-7786.MCR-08-0491; Li MY, 2008, EUR RESPIR J, V32, P911, DOI 10.1183/09031936.00064508; Lin PH, 2008, BBA-MOL CELL RES, V1783, P1826, DOI 10.1016/j.bbamcr.2008.05.008; Liu PL, 2010, MOL NUTR FOOD RES, V54, pS196, DOI 10.1002/mnfr.200900550; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Mayerhofer M, 2004, CANCER RES, V64, P3148, DOI 10.1158/0008-5472.CAN-03-1200; Mayerhofer M, 2008, BLOOD, V111, P2200, DOI 10.1182/blood-2006-11-055723; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Otterbein LE, 2011, P NATL ACAD SCI USA, V108, P14491, DOI 10.1073/pnas.1102295108; Poland KS, 2007, GENE CHROMOSOME CANC, V46, P805, DOI 10.1002/gcc.20466; Pouponnot C, 2006, ONCOGENE, V25, P1299, DOI 10.1038/sj.onc.1209171; Sass G, 2008, INT J CANCER, V123, P1269, DOI 10.1002/ijc.23695; Shan Y, 2006, FASEB J, V20, P2651, DOI 10.1096/fj.06-6346fje; Stagg HR, 2009, J CELL BIOL, V186, P685, DOI 10.1083/jcb.200906110; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Tauber S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-200; Was H, 2006, AM J PATHOL, V169, P2181, DOI 10.2353/ajpath.2006.051365; Yang L, 2007, LEUKEMIA, V21, P868, DOI 10.1038/sj.leu.2404624; Yang ZZ, 2001, AM J PHYSIOL-RENAL, V281, pF900, DOI 10.1152/ajprenal.2001.281.5.F900	44	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2325	2334		10.1038/onc.2012.244	http://dx.doi.org/10.1038/onc.2012.244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22689053				2022-12-28	WOS:000318683600009
J	Luo, Y; Tsuchiya, KD; Park, DI; Fausel, R; Kanngurn, S; Welcsh, P; Dzieciatkowski, S; Wang, J; Grady, WM				Luo, Y.; Tsuchiya, K. D.; Park, D. Il; Fausel, R.; Kanngurn, S.; Welcsh, P.; Dzieciatkowski, S.; Wang, J.; Grady, W. M.			RET is a potential tumor suppressor gene in colorectal cancer	ONCOGENE			English	Article						colon neoplasia; methylation; RET	ISLAND METHYLATOR PHENOTYPE; RECEPTOR TYROSINE KINASE; HUMAN-COLON ADENOMAS; TGF-BETA; DNA METHYLATION; CELL LINE; HIRSCHSPRUNG-DISEASE; THYROID-CANCER; MICE LACKING; GDNF FAMILY	Cancer arises as the consequence of mutations and epigenetic alterations that activate oncogenes and inactivate tumor suppressor genes. Through a genome-wide screen for methylated genes in colon neoplasms, we identified aberrantly methylated RET in colorectal cancer. RET, a transmembrane receptor tyrosine kinase and a receptor for the glial cell-derived neurotrophic factor family ligands, was one of the first oncogenes to be identified, and has been shown to be an oncogene in thyroid cancer and pheochromocytoma. However, unexpectedly, we found RET is methylated in 27% of colon adenomas and in 63% of colorectal cancers, and now provide evidence that RET has tumor suppressor activity in colon cancer. The aberrant methylation of RET correlates with decreased RET expression, whereas the restoration of RET in colorectal cancer cell lines results in apoptosis. Furthermore, in support of a tumor suppressor function of RET, mutant RET has also been found in primary colorectal cancer. We now show that these mutations inactivate RET, which is consistent with RET being a tumor suppressor gene in the colon. These findings suggest that the aberrant methylation of RET and the mutational inactivation of RET promote colorectal cancer formation, and that RET can serve as a tumor suppressor gene in the colon. Moreover, the increased frequency of methylated RET in colon cancers compared with adenomas suggests RET inactivation is involved in the progression of colon adenomas to cancer. Oncogene (2013) 32, 2037-2047; doi:10.1038/onc.2012.225; published online 2 July 2012	[Luo, Y.; Wang, J.] Sun Yat Sen Univ, Dept Colorectal Surg, Affiliated Hosp 6, Guangzhou 510275, Guangdong, Peoples R China; [Luo, Y.; Tsuchiya, K. D.; Park, D. Il; Fausel, R.; Kanngurn, S.; Dzieciatkowski, S.; Grady, W. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Tsuchiya, K. D.] Seattle Childrens Hosp, Dept Lab Med & Pathol, Seattle, WA USA; [Tsuchiya, K. D.] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; [Park, D. Il] Sungkyunkwak Univ, Kangbuk Samsung Hosp, Dept Gastroenterol, Seoul, South Korea; [Fausel, R.; Grady, W. M.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA; [Kanngurn, S.] Prince Songkla Univ, Tumor Biol Res Unit, Hat Yai, Thailand; [Kanngurn, S.] Prince Songkla Univ, Dept Pathol, Hat Yai, Thailand; [Welcsh, P.] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA	Sun Yat Sen University; Fred Hutchinson Cancer Center; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Washington; University of Washington Seattle; Prince of Songkla University; Prince of Songkla University; University of Washington; University of Washington Seattle	Grady, WM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave North,D4-100,POB 19024, Seattle, WA 98109 USA.	wgrady@fhcrc.org			NIH [RO1CA115513, P30CA15704, U54CA143862, UO1CA152756]; Burroughs Wellcome Fund Translational Research Award for Clinician Scientist; NATIONAL CANCER INSTITUTE [R01CA115513, P01CA077852, P30CA015704, U01CA152756, U54CA143862] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund Translational Research Award for Clinician Scientist; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support for these studies was provided by the NIH (RO1CA115513, P30CA15704, U54CA143862, UO1CA152756, WMG), and a Burroughs Wellcome Fund Translational Research Award for Clinician Scientist (WMG).	Ahuja N, 1998, CANCER RES, V58, P5489; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Alhopuro P, 2012, INT J CANCER, V130, P1558, DOI 10.1002/ijc.26167; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Arslan-Kirchner M, 2011, EUR J HUM GENET, V19, DOI 10.1038/ejhg.2011.68; Asai N, 2006, PATHOL INT, V56, P164, DOI 10.1111/j.1440-1827.2006.01942.x; Bernet A, 2007, GASTROENTEROLOGY, V133, P1840, DOI 10.1053/j.gastro.2007.08.009; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bogen O, 2008, EUR J NEUROSCI, V28, P12, DOI 10.1111/j.1460-9568.2008.06308.x; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107; Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114; Diaz-Rodriguez E, 2012, ONCOGENE, V31, P2824, DOI 10.1038/onc.2011.458; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, CANCER RES, V60, P5021; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Eskiocak U, 2011, CANCER RES, V71, P4359, DOI 10.1158/0008-5472.CAN-11-0794; Estecio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; Gan FF, 2011, APOPTOSIS, V16, P856, DOI 10.1007/s10495-011-0611-3; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10; Grady WM, 1998, CANCER RES, V58, P3101; HERMAN JG, 1995, CANCER RES, V55, P4525; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jain S, 2010, J CLIN INVEST, V120, P778, DOI 10.1172/JCI41619; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Kang J, 2009, ONCOGENE, V28, P2034, DOI 10.1038/onc.2009.66; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; Mehlen P, 2004, J CLIN ONCOL, V22, P3420, DOI 10.1200/JCO.2004.02.019; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; PARASKEVA C, 1989, CANCER RES, V49, P1282; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Popsueva A, 2003, J CELL BIOL, V161, P119, DOI 10.1083/jcb.200212174; Rojas A, 2008, INT J CANCER, V123, P14, DOI 10.1002/ijc.23608; Rojas A, 2009, BBA-MOL CELL RES, V1793, P1165, DOI 10.1016/j.bbamcr.2009.02.001; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Shen L, 2007, PLOS GENET, V3, P2023, DOI 10.1371/journal.pgen.0030181; Shin SK, 2007, GASTROENTEROLOGY, V133, P1849, DOI 10.1053/j.gastro.2007.08.074; Sipos JA, THER ADV MED ONCOL, V2, P3; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Tang JZ, 2010, MOL CANCER THER, V9, P1697, DOI 10.1158/1535-7163.MCT-09-1077; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wartiovaara K, 1998, J PEDIATR SURG, V33, P1501, DOI 10.1016/S0022-3468(98)90485-7; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wells SA, 2009, CLIN CANCER RES, V15, P7119, DOI 10.1158/1078-0432.CCR-08-2742; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLSON JKV, 1987, CANCER RES, V47, P2704	58	60	70	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2037	2047		10.1038/onc.2012.225	http://dx.doi.org/10.1038/onc.2012.225			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22751117	Green Accepted			2022-12-28	WOS:000317919900005
J	Radulescu, S; Ridgway, RA; Cordero, J; Athineos, D; Salgueiro, P; Poulsom, R; Neumann, J; Jung, A; Patel, S; Woodgett, J; Barker, N; Pritchard, DM; Oien, K; Sansom, OJ				Radulescu, S.; Ridgway, R. A.; Cordero, J.; Athineos, D.; Salgueiro, P.; Poulsom, R.; Neumann, J.; Jung, A.; Patel, S.; Woodgett, J.; Barker, N.; Pritchard, D. M.; Oien, K.; Sansom, O. J.			Acute WNT signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation	ONCOGENE			English	Article						beta-catenin; gastric cancer; APC; GSK3	FAMILIAL ADENOMATOUS POLYPOSIS; FUNDIC GLAND POLYPS; WNT/BETA-CATENIN PATHWAY; E-CADHERIN GENE; BETA-CATENIN; STEM-CELLS; SOMATIC MUTATIONS; GASTRIC-CARCINOMA; APC GENE; FLUORESCENT PROTEIN	A role for WNT signalling in gastric carcinogenesis has been suggested due to two major observations. First, patients with germline mutations in adenomatous polyposis coli (APC) are susceptible to stomach polyps and second, in gastric cancer, WNT activation confers a poor prognosis. However, the functional significance of deregulated WNT signalling in gastric homoeostasis and cancer is still unclear. In this study we have addressed this by investigating the immediate effects of WNT signalling activation within the stomach epithelium. We have specifically activated the WNT signalling pathway within the mouse adult gastric epithelium via deletion of either glycogen synthase kinase 3 (GSK3) or APC or via expression of a constitutively active beta-catenin protein. WNT pathway deregulation dramatically affects stomach homoeostasis at very short latencies. In the corpus, there is rapid loss of parietal cells with fundic gland polyp (FGP) formation and adenomatous change, which are similar to those observed in familial adenomatous polyposis. In the antrum, adenomas occur from 4 days post-WNT activation. Taken together, these data show a pivotal role for WNT signalling in gastric homoeostasis, FGP formation and adenomagenesis. Loss of the parietal cell population and corresponding FGP formation, an early event in gastric carcinogenesis, as well as antral adenoma formation are immediate effects of nuclear beta-catenin translocation and WNT target gene expression. Furthermore, our inducible murine model will permit a better understanding of the molecular changes required to drive tumourigenesis in the stomach. Oncogene (2013) 32, 2048-2057; doi:10.1038/onc.2012.224; published online 4 June 2012	[Radulescu, S.; Ridgway, R. A.; Cordero, J.; Athineos, D.; Salgueiro, P.; Sansom, O. J.] CR UK Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Salgueiro, P.; Barker, N.] ASTAR, Inst Med Biol, Singapore, Singapore; [Poulsom, R.] CR UK London Res Inst, Histopathol Lab, London, England; [Neumann, J.; Jung, A.] Univ Munich, Inst Pathol, D-80539 Munich, Germany; [Patel, S.; Woodgett, J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Pritchard, D. M.] Univ Liverpool, Inst Translat Med, Dept Gastroenterol, Liverpool L69 3BX, Merseyside, England; [Oien, K.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Canc Sci, Glasgow, Lanark, Scotland	Beatson Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); University of Munich; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Liverpool; University of Glasgow	Sansom, OJ (corresponding author), CR UK Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk	Barker, Nick/AAS-2774-2020; Barker, Nick/A-5535-2011; Woodgett, Jim/F-1087-2010; Barker, Nick/AAE-9833-2021; Oien, Karin/AAH-3849-2019	Woodgett, Jim/0000-0003-3731-5797; Barker, Nick/0000-0003-3566-4475; Sansom, Owen J./0000-0001-9540-3010; Athineos, Dimitris/0000-0001-5298-7941; Pritchard, David Mark/0000-0001-7971-3561	CR-UK; AICR [06-0614]; CRUK; Cancer Research UK [12481] Funding Source: researchfish	CR-UK(Cancer Research UK); AICR; CRUK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	This work was funded by the CR-UK project and programme grants and AICR grant 06-0614 to Owen Sansom. Help from Colin Nixon with histology and from Derek Miller and Tom Hamilton with transgenic work was much appreciated. This work was funded by AICR and CRUK grants.	Abraham SC, 2000, AM J PATHOL, V157, P747, DOI 10.1016/S0002-9440(10)64588-9; Abraham SC, 2001, AM J PATHOL, V158, P1005, DOI 10.1016/S0002-9440(10)64047-3; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Barker Nick, 2008, V468, P5, DOI 10.1007/978-1-59745-249-6_1; BECKER KF, 1995, JNCI-J NATL CANCER I, V87, P1082, DOI 10.1093/jnci/87.14.1082; Bianchi LK, 2008, CLIN GASTROENTEROL H, V6, P180, DOI 10.1016/j.cgh.2007.11.018; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Cavard C, 2008, FUTURE ONCOL, V4, P647, DOI 10.2217/14796694.4.5.647; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Clements WM, 2002, CANCER RES, V62, P3503; CORREA P, 1994, CANCER RES, V54, pS1941; CORREA P, 1992, CANCER RES, V52, P6735; Crabtree M, 2003, ONCOGENE, V22, P4257, DOI 10.1038/sj.onc.1206471; de Vries AC, 2008, GASTROENTEROLOGY, V134, P945, DOI 10.1053/j.gastro.2008.01.071; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; FORTE JG, 1983, J CLIN GASTROENTEROL, V5, P17, DOI 10.1097/00004836-198312001-00003; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Freeman HJ, 2008, WORLD J GASTROENTERO, V14, P1318, DOI 10.3748/wjg.14.1318; Garrean S, 2008, AM SURGEON, V74, P79; Gatta G, 2006, LANCET ONCOL, V7, P132, DOI 10.1016/S1470-2045(05)70471-X; Gnad T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-31; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Guillen-Ahlers H, 2008, CURR DRUG TARGETS, V9, P591, DOI 10.2174/138945008784911813; Half E, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-22; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; HORII A, 1992, CANCER RES, V52, P3231; IIDA M, 1985, GASTROENTEROLOGY, V89, P1021, DOI 10.1016/0016-5085(85)90203-3; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Kemp R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh090; Kim B, 2010, PATHOLOGY, V42, P58, DOI 10.3109/00313020903356392; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Luche H, 2007, EUR J IMMUNOL, V37, P43, DOI 10.1002/eji.200636745; Milne AN, 2009, HUM GENET, V126, P615, DOI 10.1007/s00439-009-0722-x; Miyazawa K, 2000, VIRCHOWS ARCH, V437, P508, DOI 10.1007/s004280000283; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Nagase Hiroki, 1992, Human Mutation, V1, P467, DOI 10.1002/humu.1380010603; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; Nakayama M, 2009, J BIOL CHEM, V284, P1612, DOI 10.1074/jbc.M806981200; Ng SW, 2009, J BIOL CHEM, V284, P24767, DOI 10.1074/jbc.M109.011692; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Park DY, 2008, ARCH PATHOL LAB MED, V132, P633, DOI 10.1043/1543-2165(2008)132[633:GPCAM]2.0.CO;2; Park WS, 1999, CANCER RES, V59, P4257; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Patel S, 2008, MOL CELL BIOL, V28, P6314, DOI 10.1128/MCB.00763-08; Przemeck SMC, 2007, AM J PHYSIOL-GASTR L, V292, pG620, DOI 10.1152/ajpgi.00391.2006; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Sekine S, 2002, VIRCHOWS ARCH, V440, P381, DOI 10.1007/s004280100527; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shitashige M, 2008, CANCER SCI, V99, P631, DOI 10.1111/j.1349-7006.2007.00716.x; Smith MG, 2006, WORLD J GASTROENTERO, V12, P2979, DOI 10.3748/wjg.v12.i19.2979; Sokolova O, 2008, J BIOL CHEM, V283, P29367, DOI 10.1074/jbc.M801818200; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Spicer Z, 2000, J BIOL CHEM, V275, P21555, DOI 10.1074/jbc.M001558200; Suzuki M, 2005, J EXP MED, V202, P1235, DOI 10.1084/jem.20051027; Suzuki M, 2009, CELL HOST MICROBE, V5, P23, DOI 10.1016/j.chom.2008.11.010; TAHARA E, 1995, WORLD J SURG, V19, P484, DOI 10.1007/BF00294705; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torbenson M, 2002, MODERN PATHOL, V15, P718, DOI 10.1097/01.MP.0000018976.15044.9B; Tycko B, 2007, CURR MOL MED, V7, P479; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; WATANABE H, 1978, HUM PATHOL, V9, P269, DOI 10.1016/S0046-8177(78)80085-9; Zhang HF, 2008, HEPATO-GASTROENTEROL, V55, P1126; Zhao ZM, 2010, J GENET GENOMICS, V37, P647, DOI 10.1016/S1673-8527(09)60083-7; Zheng HC, 2010, HUM PATHOL, V41, P1255, DOI 10.1016/j.humpath.2010.02.003	75	42	42	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2048	2057		10.1038/onc.2012.224	http://dx.doi.org/10.1038/onc.2012.224			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22665058	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000317919900006
J	Su, B; Gao, L; Meng, F; Guo, LW; Rothschild, J; Gelman, IH				Su, B.; Gao, L.; Meng, F.; Guo, L-W; Rothschild, J.; Gelman, I. H.			Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12	ONCOGENE			English	Article						Src; SSeCKS/Gravin/AKAP12; FAK; caveolin-1; adhesion; actin-based cytoskeleton	RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; HUMAN COLON-CANCER; C-SRC; ONCOGENIC TRANSFORMATION; SIGNAL-TRANSDUCTION; PROSTATE-CANCER; CELL-MIGRATION; BREAST-CANCER; IN-VIVO	Metastatic cell migration and invasion are regulated by altered adhesion-mediated signaling to the actin-based cytoskeleton via activated Src-FAK complexes. Src-suppressed C-kinase substrate (SSeCKS, the rodent orthologue of human Gravin/AKAP12), whose expression is downregulated by oncogenic Src and in many human cancers, antagonizes oncogenic Src pathways including those driving neovascularization at metastatic sites, metastatic cell motility and invasiveness. This is likely manifested through its function as a scaffolder of F-actin and signaling proteins such as cyclins, calmodulin, protein kinase C and A. Here we show that in contrast to its ability to inhibit haptotaxis, SSeCKS increased prostate cancer cell adhesion to fibronectin and type I collagen in a FAK-dependent manner, correlating with a relative increase in FAK(poY397) levels. In contrast, SSeCKS suppressed adhesion-induced Src activation (Src(poY416)) and phosphorylation of FAK at Y925, a known Src substrate site. SSeCKS also induced increased cell spreading, cell flattening, integrin beta 1 clustering and formation of mature focal adhesion plaques. An in silico analysis identified a Src-binding domain on SSeCKS(aa 153-166) that is homologous to the Src-binding domain of caveolin-1, and this region is required for SSeCKS-Src interaction, for SSeCKS-enhanced Src activity and sequestration to lipid rafts and for SSeCKS-enhanced adhesion of MAT-LyLu and CWR22Rv1 prostate cancer cells. Our data suggest a model in which SSeCKS suppresses oncogenic motility by sequestering Src to caveolin-rich lipid rafts, thereby disengaging Src from FAK-associated adhesion and signaling complexes. Oncogene (2013) 32, 2016-2026; doi:10.1038/onc.2012.218; published online 18 June 2012	[Su, B.; Gao, L.; Rothschild, J.; Gelman, I. H.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; [Meng, F.] SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA; [Guo, L-W] Natl Ctr Toxicol Res, Jefferson, AR 72079 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Food & Drug Administration (FDA)	Gelman, IH (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St,CGP L2-309, Buffalo, NY 14263 USA.	irwin.gelman@roswellpark.org			NIH/NCI [CA94108, CA116430]; DoD [PC074228, PC101210]; NCI Comprehensive Cancer funds [P30-CA016056]; NATIONAL CANCER INSTITUTE [R55CA094108, R01CA116430, R01CA094108, P30CA016056] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); NCI Comprehensive Cancer funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Toru Ouchi and Eugene Kandel for critical review of the manuscript, Kalle Saksela and Bruce Mayer for discussions on SH3 interactions and Bruce Mayer, Y Peter Wang and Tom Parsons for reagents. This work is supported by grants (IHG) CA94108, CA116430 (NIH/NCI), PC074228, PC101210 (DoD) and, in part, through NCI Comprehensive Cancer funds (P30-CA016056).	Akakura S, 2010, CELL CYCLE, V9, P4656, DOI 10.4161/cc.9.23.13974; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Bild AH, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2344; Biscardi JS, 1999, ADV CANCER RES, V76, P61; BOS JL, 1989, CANCER RES, V49, P4682; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Bu Y, 2007, J BIOL CHEM, V282, P26725, DOI 10.1074/jbc.M702885200; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Gelman IH, 2006, MOL CANCER RES, V4, P151, DOI 10.1158/1541-7786.MCR-05-0252; Gelman IH, 1998, CELL MOTIL CYTOSKEL, V41, P1; Gelman Irwin H, 2011, Front Biosci (Elite Ed), V3, P801; Gelman Irwin H, 2010, Genes Cancer, V1, P1147, DOI 10.1177/1947601910392984; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Guo LW, 2011, J BIOL CHEM, V286, P38356, DOI 10.1074/jbc.M111.258830; Hiscox S, 2006, ENDOCR-RELAT CANCER, V13, pS53, DOI 10.1677/erc.1.01297; HUMPHRIES MJ, 1998, CURRENT PROTOCOLS CE; Iiizumi M, 2008, BBA-REV CANCER, V1786, P87, DOI 10.1016/j.bbcan.2008.07.002; ILLC D, 1995, NATURE, V377, P539; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ischenko I, 2008, ONCOGENE, V27, P7212, DOI 10.1038/onc.2008.326; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; MACCALMAN CD, 1994, CLIN EXP METASTAS, V12, P101, DOI 10.1007/BF01753976; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Meng FJ, 2012, J CELL SCI, V125, P743, DOI 10.1242/jcs.093104; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Mitra SK, 2006, ONCOGENE, V25, P5969, DOI 10.1038/sj.onc.1209588; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; Moissoglu K, 2003, J BIOL CHEM, V278, P47946, DOI 10.1074/jbc.M302720200; Navarro A, 2004, FASEB J, V18, P1801, DOI 10.1096/fj.04-2516rev; Nethe M, 2011, CELL ADHES MIGR, V5, P59, DOI 10.4161/cam.5.1.13702; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Patra SK, 2008, BBA-REV CANCER, V1785, P182, DOI 10.1016/j.bbcan.2007.11.002; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Ross SH, 2011, J CELL SCI, V124, P1808, DOI 10.1242/jcs.079830; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Seong JY, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1414; Seong JH, 2009, CHEM BIOL, V16, P48, DOI 10.1016/j.chembiol.2008.11.007; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Sieg DJ, 1999, J CELL SCI, V112, P2677; Song KS, 1997, CELL MOL BIOL, V43, P293; Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67; Su B, 2006, CANCER RES, V66, P5599, DOI 10.1158/0008-5472.CAN-05-4123; Su B, 2010, J BIOL CHEM, V285, P4578, DOI 10.1074/jbc.M109.073494; Sverdlov M, 2007, J CELL MOL MED, V11, P1239, DOI 10.1111/j.1582-4934.2007.00127.x; Tao JC, 2007, J BIOL CHEM, V282, P6597, DOI 10.1074/jbc.M608927200; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Wanaski SP, 2003, BIOCHEMISTRY-US, V42, P42, DOI 10.1021/bi012097n; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Xia W, 2001, CANCER RES, V61, P5644; Xia W, 2002, EXP CELL RES, V277, P139, DOI 10.1006/excr.2002.5560; Yan XH, 2009, EXP CELL RES, V315, P1247, DOI 10.1016/j.yexcr.2008.12.026; Yeo MG, 2006, MOL CELL BIOL, V26, P4399, DOI 10.1128/MCB.01147-05; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yoshida T, 2010, CANCER SCI, V101, P167, DOI 10.1111/j.1349-7006.2009.01368.x; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	76	31	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2016	2026		10.1038/onc.2012.218	http://dx.doi.org/10.1038/onc.2012.218			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22710722	Green Accepted			2022-12-28	WOS:000317919900003
J	Tomkiewicz, C; Herry, L; Bui, LC; Metayer, C; Bourdeloux, M; Barouki, R; Coumoul, X				Tomkiewicz, C.; Herry, L.; Bui, L-C; Metayer, C.; Bourdeloux, M.; Barouki, R.; Coumoul, X.			The aryl hydrocarbon receptor regulates focal adhesion sites through a non-genomic FAK/Src pathway	ONCOGENE			English	Article						AhR; cell plasticity; FAK; integrin; Src	PROTEIN-TYROSINE KINASES; AH DIOXIN RECEPTOR; CANCER CELL-LINE; C-SRC; SIGNAL-TRANSDUCTION; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; ENVIRONMENTAL-POLLUTANTS; GENE-EXPRESSION; HUMAN ENHANCER; KNOCKOUT MICE	The aryl hydrocarbon receptor (AhR) is commonly described as a transcription factor, which regulates xenobiotic-metabolizing enzymes. Recent studies have suggested that the binding of ligands to the AhR also activates the Src kinase. In this manuscript, we show that the AhR, through the activation of Src, activates focal adhesion kinase (FAK) and promotes integrin clustering. These effects contribute to cell migration. Further, we show that the activation of the AhR increases the interaction of FAK with the metastatic marker, HEF1/NEDD9/CAS-L, and the expression of several integrins. Xenobiotic exposure, thus, may contribute to novel cell-migratory programs. Oncogene (2013) 32, 1811-1820; doi: 10.1038/onc.2012.197; published online 4 June 2012	[Tomkiewicz, C.; Herry, L.; Bui, L-C; Metayer, C.; Bourdeloux, M.; Barouki, R.; Coumoul, X.] INSERM, UMR S Toxicol Pharmacol & Signalisat Cellulaire 7, Paris, France; [Tomkiewicz, C.; Herry, L.; Bui, L-C; Metayer, C.; Bourdeloux, M.; Barouki, R.; Coumoul, X.] Univ Paris 05, Sorbonne Paris Cite, Ctr Univ St Peres, F-75006 Paris, France; [Herry, L.; Barouki, R.] Hop Necker Enfants Malad, AP HP, Serv Biochim Metab, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Coumoul, X (corresponding author), Univ Paris 05, Sorbonne Paris Cite, 45 Rue St Peres, F-75006 Paris, France.	xavier.coumoul@parisdescartes.fr	COUMOUL, Xavier/AAR-3649-2020	COUMOUL, Xavier/0000-0003-2928-9648	ANSES (Agence Nationale de SEcurite Sanitaire de l'alimentation, de l'environnement et du travail); ANR (Agence Nationale de la Recherche) [06SEST26]; ARC (Association pour la Recherche sur le Cancer) [3927, SFI20101201842]; CNRS (Center Nationale de la recherche scientifique); Fondation pour la Recherche Medicale; Ecole Doctorale du Medicament; Hospitals Europeen Georges Pompidou and Necker Enfants Malade; INSERM (Institut National de la Sante et de la Recherche Medicale); Ligue contre le Cancer; Ministere de l'enseignement superieur et de la recherche; Region Ile de France; Universite Paris Descartes, Paris Sorbonne Cite	ANSES (Agence Nationale de SEcurite Sanitaire de l'alimentation, de l'environnement et du travail)(French National Research Agency (ANR)); ANR (Agence Nationale de la Recherche)(French National Research Agency (ANR)); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer); CNRS (Center Nationale de la recherche scientifique); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Ecole Doctorale du Medicament; Hospitals Europeen Georges Pompidou and Necker Enfants Malade; INSERM (Institut National de la Sante et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ligue contre le Cancer(Ligue nationale contre le cancer); Ministere de l'enseignement superieur et de la recherche; Region Ile de France(Region Ile-de-France); Universite Paris Descartes, Paris Sorbonne Cite	This work was supported by the ANSES (Agence Nationale de SEcurite Sanitaire de l'alimentation, de l'environnement et du travail; all authors), ANR (Agence Nationale de la Recherche, 06SEST26, Oncopop; all authors), ARC (Association pour la Recherche sur le Cancer, 3927 and SFI20101201842; all authors), CNRS (Center Nationale de la recherche scientifique), Fondation pour la Recherche Medicale, 'Ecole Doctorale du Medicament', Hospitals Europeen Georges Pompidou and Necker Enfants Malade, INSERM (Institut National de la Sante et de la Recherche Medicale; all authors), Ligue contre le Cancer (post-doctoral fellowship), Ministere de l'enseignement superieur et de la recherche, Region Ile de France (doctoral fellowship) and Universite Paris Descartes, Paris Sorbonne Cite. The FRNK-expressing vector is a generous gift of Dr Kenneth M Yamada (NIDCR, NIH, USA) and Dr Bernard Rothhut (CNRS UMR 6237, Reims). We warmly thank Dr Lawrence Aggerbeck for his critical reading of this manuscript.	Ahmed S, 2005, FEBS J, V272, P903, DOI 10.1111/j.1742-4658.2004.04519.x; Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Garcia MA, 2010, TOXICOL LETT, V192, P195, DOI 10.1016/j.toxlet.2009.10.026; Ambolet-Camoit A, 2010, TOXICOL SCI, V115, P501, DOI 10.1093/toxsci/kfq082; Ashida H, 2008, EXPERT OPIN DRUG MET, V4, P1429, DOI [10.1517/17425255.4.11.1429, 10.1517/17425255.4.11.1429 ]; Backlund M, 2005, CELL SIGNAL, V17, P39, DOI 10.1016/j.cellsig.2004.05.010; Barouki R, 2007, FEBS LETT, V581, P3608, DOI 10.1016/j.febslet.2007.03.046; Blankenship A, 1997, MOL PHARMACOL, V52, P667, DOI 10.1124/mol.52.4.667; Bui LC, 2009, ONCOGENE, V28, P3642, DOI 10.1038/onc.2009.224; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Roman AC, 2009, J BIOL CHEM, V284, P25135, DOI 10.1074/jbc.M109.013292; Carvajal-Gonzalez JM, 2009, J CELL SCI, V122, P1823, DOI 10.1242/jcs.047274; Carvajal-Gonzalez JM, 2009, MOL BIOL CELL, V20, P1715, DOI 10.1091/mbc.E08-05-0451; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Deramaudt TB, 2011, MOL BIOL CELL, V22, P964, DOI 10.1091/mbc.E10-08-0725; Destaing O, 2011, CURR OPIN CELL BIOL, V23, P597, DOI 10.1016/j.ceb.2011.04.002; Diry M, 2006, ONCOGENE, V25, P5570, DOI 10.1038/sj.onc.1209553; Dong B, 2011, BBA-GEN SUBJECTS, V1810, P427, DOI 10.1016/j.bbagen.2010.11.007; Enan E, 1996, BIOCHEM PHARMACOL, V52, P1599, DOI 10.1016/S0006-2952(96)00566-7; Enan E, 1998, J BIOCHEM MOL TOXIC, V12, P263, DOI 10.1002/(SICI)1099-0461(1998)12:5<263::AID-JBT2>3.0.CO;2-J; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; Gomez-Duran A, 2006, J CELL BIOCHEM, V97, P380, DOI 10.1002/jcb.20637; Hamadi A, 2009, CELL MOL LIFE SCI, V66, P324, DOI 10.1007/s00018-008-8424-4; Hamadi A, 2010, J ONCOL, V2010, DOI 10.1155/2010/932803; Hivert V, 2009, BIOCHEM PHARMACOL, V78, P1017, DOI 10.1016/j.bcp.2009.06.005; Hoelper P, 2005, ARCH TOXICOL, V79, P201, DOI 10.1007/s00204-004-0624-6; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Kim MJ, 2011, ENVIRON HEALTH PERSP, V119, P377, DOI 10.1289/ehp.1002848; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kohle C, 1999, ARCH TOXICOL, V73, P152, DOI 10.1007/s002040050600; Law SF, 1996, MOL CELL BIOL, V16, P3327; Lemaire G, 2004, LIFE SCI, V74, P2265, DOI 10.1016/j.lfs.2003.09.056; Marchand A, 2005, MOL PHARMACOL, V67, P444, DOI 10.1124/mol.104.004010; Matsumura F, 2009, BIOCHEM PHARMACOL, V77, P608, DOI 10.1016/j.bcp.2008.10.013; Mayati A, 2012, J BIOL CHEM, V287, P4041, DOI 10.1074/jbc.M111.319970; McMillan BJ, 2007, MOL PHARMACOL, V72, P487, DOI 10.1124/mol.107.037259; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Mulero-Navarro S, 2005, J BIOL CHEM, V280, P28731, DOI 10.1074/jbc.M504538200; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Pierre S, 2011, BIOCHEM PHARMACOL, V81, P304, DOI 10.1016/j.bcp.2010.10.003; Pontillo CA, 2011, TOXICOL SCI, V120, P284, DOI 10.1093/toxsci/kfq390; Powell-Coffman JA, 1998, P NATL ACAD SCI USA, V95, P2844, DOI 10.1073/pnas.95.6.2844; Provenzano PP, 2009, CELL ADHES MIGR, V3, P347, DOI 10.4161/cam.3.4.9458; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; Puga A, 2009, BIOCHEM PHARMACOL, V77, P713, DOI 10.1016/j.bcp.2008.08.031; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Randi AS, 2008, TOXICOL LETT, V177, P116, DOI 10.1016/j.toxlet.2008.01.003; Ratushny V, 2012, ONCOGENE, V31, P1217, DOI 10.1038/onc.2011.314; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Sciullo EM, 2009, CHEMOSPHERE, V74, P1531, DOI 10.1016/j.chemosphere.2008.11.010; Singh MK, 2007, CELL BIOCHEM BIOPHYS, V48, P54, DOI 10.1007/s12013-007-0036-3; Singh MK, 2010, CANCER RES, V70, P8907, DOI 10.1158/0008-5472.CAN-10-0353; Tikhmyanova N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022102; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Tompkins LM, 2007, J BIOCHEM MOL TOXIC, V21, P176, DOI 10.1002/jbt.20180; Vogel CFA, 2003, J BIOCHEM MOL TOXIC, V17, P305, DOI 10.1002/jbt.10096; Weiss C, 2005, ONCOGENE, V24, P4975, DOI 10.1038/sj.onc.1208679; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	64	57	62	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1811	1820		10.1038/onc.2012.197	http://dx.doi.org/10.1038/onc.2012.197			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22665056				2022-12-28	WOS:000317043900007
J	Rieckmann, T; Kriegs, M; Nitsch, L; Hoffer, K; Rohaly, G; Kocher, S; Petersen, C; Dikomey, E; Dornreiter, I; Dahm-Daphi, J				Rieckmann, T.; Kriegs, M.; Nitsch, L.; Hoffer, K.; Rohaly, G.; Kocher, S.; Petersen, C.; Dikomey, E.; Dornreiter, I.; Dahm-Daphi, J.			p53 modulates homologous recombination at I-SceI-induced double-strand breaks through cell-cycle regulation	ONCOGENE			English	Article						p53; homologous recombination; cell cycle	DNA END RESECTION; MUTANT P53; MAMMALIAN-CELLS; HUMAN RAD51; REPAIR; CTIP; PHOSPHORYLATION; INACTIVATION; DISSOCIATION; SUPPRESSION	Inhibition of homologous recombination (HR) is believed to be a transactivation-independent function of p53 that protects from genetic instability. Misrepair by HR can lead to genetic alterations such as translocations, duplications, insertions and loss of heterozygosity, which all bear the risk of driving oncogenic transformation. Regulation of HR by wild-type p53 (wtp53) should prevent these genomic rearrangements. Mutation of p53 is a frequent event during carcinogenesis. In particular, dominant-negative mutants inhibiting wtp53 expressed from the unperturbed allel can drive oncogenic transformation by disrupting the p53-dependent anticancer barrier. Here, we asked whether the hot spot mutants R175H and R273H relax HR control in p53-proficient cells. Utilizing an I-SceI-based reporter assay, we observed a moderate (1.5 x) stimulation of HR upon expression of the mutant proteins in p53-proficient CV-1, but not in p53-deficient H1299 cells. Importantly, the stimulatory effect was exactly paralleled by an increase in the number of HR competent S- and G2-phase cells, which can well explain the enhanced recombination frequencies. Furthermore, the impact on HR exerted by the transactivation domain double-mutant L22Q/W23S and mutant R273P, both of which were reported to regulate HR independently of G1-arrest execution, is also exactly mirrored by cell-cycle behavior. These results are in contrast to previous concepts stating that the transactivation-independent impact of p53 on HR is a general phenomenon valid for replication-associated and also for directly induced double-strand break. Our data strongly suggest that the latter is largely mediated by cell-cycle regulation, a classical transactivation-dependent function of p53. Oncogene (2013) 32, 968-975; doi:10.1038/onc.2012.123; published online 9 April 2012	[Rieckmann, T.; Kriegs, M.; Nitsch, L.; Hoffer, K.; Kocher, S.; Dikomey, E.; Dahm-Daphi, J.] Univ Med Ctr Hamburg Eppendorf, Lab Radiobiol & Expt Radiooncol, Hamburg, Germany; [Rohaly, G.; Dornreiter, I.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany; [Kocher, S.; Dahm-Daphi, J.] Univ Marburg, Particle Therapy Ctr, Inst Radiobiol & Mol Radiat Oncol, D-35043 Marburg, Hessen, Germany; [Petersen, C.] Univ Med Ctr Hamburg Eppendorf, Dept Radiotherapy & Radiooncol, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute; Philipps University Marburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Dahm-Daphi, J (corresponding author), Univ Marburg, Particle Therapy Ctr, Inst Radiobiol & Mol Radiat Oncol, D-35043 Marburg, Hessen, Germany.	jochen.dahmdaphi@staff.uni-marburg.de	Petersen, Cordula/AAW-9789-2020; Hoffer, Kenneth J/P-6431-2019	Rieckmann, Thorsten/0000-0001-8426-107X	German Cancer Aid (Deutsche Krebshilfe) [107889, 107980]	German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe)	We thank Dr Tom Misteli for the pDsRed-/-Scel-GR vector. This work was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe No. 107889 to JDD and No. 107980 to ID).	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Bunz F, 2002, CANCER RES, V62, P1129; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Eid W, 2010, EMBO REP, V11, P962, DOI 10.1038/embor.2010.157; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; Joerger AC, 2008, ANNU REV BIOCHEM, V77, P557, DOI 10.1146/annurev.biochem.77.060806.091238; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kriegs M, 2010, DNA REPAIR, V9, P889, DOI 10.1016/j.dnarep.2010.05.005; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Linke SP, 2003, CANCER RES, V63, P2596; Mansour WY, 2008, NUCLEIC ACIDS RES, V36, P4088, DOI 10.1093/nar/gkn347; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Restle A, 2008, NUCLEIC ACIDS RES, V36, P5362, DOI 10.1093/nar/gkn503; Roemer K, 1996, ONCOGENE, V12, P2069; Romanova LY, 2004, ONCOGENE, V23, P9025, DOI 10.1038/sj.onc.1207982; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591; Sturzbecher NW, 1996, EMBO J, V15, P1992; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Tang M, 2006, NAT GENET, V38, P395, DOI 10.1038/ng0406-395; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; You ZS, 2009, MOL CELL, V36, P954, DOI 10.1016/j.molcel.2009.12.002; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	37	17	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					968	975		10.1038/onc.2012.123	http://dx.doi.org/10.1038/onc.2012.123			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22484423				2022-12-28	WOS:000316523200004
J	Bompard, G; Rabeharivelo, G; Cau, J; Abrieu, A; Delsert, C; Morin, N				Bompard, G.; Rabeharivelo, G.; Cau, J.; Abrieu, A.; Delsert, C.; Morin, N.			P21-activated kinase 4 (PAK4) is required for metaphase spindle positioning and anchoring	ONCOGENE			English	Article						p21-activated kinase 4; metaphase; spindle orientation; spindle assembly checkpoint	REGULATORY LIGHT-CHAIN; IMPORTIN-BETA; CYTOPLASMIC DYNEIN; CELL-MIGRATION; INDEPENDENT GROWTH; MAMMALIAN-CELLS; MITOTIC SPINDLE; ADHERENT CELLS; MITOSIS; PHOSPHORYLATION	The oncogenic kinase PAK4 was recently found to be involved in the regulation of the G1 phase and the G2/M transition of the cell cycle. We have also identified that PAK4 regulates Ran GTPase activity during mitosis. Here, we show that after entering mitosis, PAK4-depleted cells maintain a prolonged metaphase-like state. In these cells, chromosome congression to the metaphase plate occurs with normal kinetics but is followed by an extended period during which membrane blebbing and spindle rotation are observed. These bipolar PAK4-depleted metaphase-like spindles have a defective astral microtubule MT network and are not centered in the cell but are in close contact with the cell cortex. As the metaphase-like state persists, centrosome fragmentation occurs, chromosomes scatter from the metaphase plate and move toward the spindle poles with an active spindle assembly checkpoint, a phenotype that is reminiscent of cohesion fatigue. PAK4 also regulates the acto-myosin cytoskeleton and we report that PAK4 depletion results in the induction of cortical membrane blebbing during prometaphase arrest. However, we show that membrane blebs, which are strongly enriched in phospho-cofilin, are not responsible for the poor anchoring of the spindle. As PAK4 depletion interferes with the localization of components of the dynein/dynactin complexes at the kinetochores and on the astral MTs, we propose that loss of PAK4 could induce a change in the activities of motor proteins., Oncogene (2013) 32, 910-919; doi:10.1038/onc.2012.98; published online 26 March 2012	[Bompard, G.; Rabeharivelo, G.; Cau, J.; Abrieu, A.; Delsert, C.; Morin, N.] Univ Montpellier 2, Montpellier, France; [Bompard, G.; Rabeharivelo, G.; Cau, J.; Abrieu, A.; Delsert, C.; Morin, N.] Univ Montpellier I, Montpellier, France; [Bompard, G.; Rabeharivelo, G.; Abrieu, A.; Delsert, C.; Morin, N.] CNRS, CRBM, UMR 5237, F-34293 Montpellier, Herault, France; [Cau, J.] CNRS UPR1142, IGH, MRI, Montpellier, France; [Delsert, C.] IFREMER, LGP, La Tremblade, France	Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Ifremer	Morin, N (corresponding author), CNRS, CRBM, UMR 5237, 1919 Route Mende, F-34293 Montpellier, Herault, France.	nathalie.morin@crbm.cnrs.fr	Abrieu, Ariane/P-3307-2019; Abrieu, Ariane/G-6336-2013	Abrieu, Ariane/0000-0002-0942-8877; Bompard, Guillaume/0000-0001-6729-4507; Morin, Nathalie/0000-0001-8677-1401; cau, Julien/0000-0001-6045-6737	Fondation de la Recherche Medicale; MEGAPAK from the ANR (Agence Nationale pour la Recherche) GENOPAT	Fondation de la Recherche Medicale(Fondation pour la Recherche Medicale); MEGAPAK from the ANR (Agence Nationale pour la Recherche) GENOPAT(French National Research Agency (ANR))	We thank Drs Lorca, Castro, Merdes for the gift of reagents. We are indebted to Dr A Desai, Dr K Vaughan and Dr A Musacchio for the kind gifts of reagents. We want to especially thank Dr Dan Fisher (IGMM, UMR5535 CNRS, Montpellier, France) for critical reading and editing of the manuscript, We thank the Montpellier RIO imaging facility. GB is supported by a grant from 'Fondation de la Recherche Medicale'. This work was supported by a grant MEGAPAK to NM from the ANR (Agence Nationale pour la Recherche) GENOPAT.	Ahmed T, 2008, CELL SIGNAL, V20, P1320, DOI 10.1016/j.cellsig.2008.02.021; Bompard G, 2010, J CELL BIOL, V190, P807, DOI 10.1083/jcb.200912056; Bright MD, 2011, INT J BIOCHEM CELL B, V43, P1776, DOI 10.1016/j.biocel.2011.08.015; Brzeska H, 2004, CELL MOTIL CYTOSKEL, V58, P186, DOI 10.1002/cm.20009; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Cau J, 2001, J CELL BIOL, V155, P1029, DOI 10.1083/jcb.200104123; Charras G, 2008, NAT REV MOL CELL BIO, V9, P730, DOI 10.1038/nrm2453; Charras GT, 2006, J CELL BIOL, V175, P477, DOI 10.1083/jcb.200602085; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Ciciarello M, 2004, J CELL SCI, V117, P6511, DOI 10.1242/jcs.01569; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Dasso M, 2006, BIOCHEM SOC T, V34, P711, DOI 10.1042/BST0340711; Daum JR, 2011, CURR BIOL, V21, P1018, DOI 10.1016/j.cub.2011.05.032; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Famulski JK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016494; Fan SL, 2007, J CELL BIOL, V178, P387, DOI 10.1083/jcb.200609096; Gassmann R, 2010, GENE DEV, V24, P957, DOI 10.1101/gad.1886810; Gehmlich K, 2004, EMBO REP, V5, P97, DOI 10.1038/sj.embor.7400046; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; Goshima G, 2005, J CELL BIOL, V171, P229, DOI 10.1083/jcb.200505107; Gundersen GG, 2004, CURR OPIN CELL BIOL, V16, P106, DOI 10.1016/j.ceb.2003.11.010; Kaji N, 2008, J BIOL CHEM, V283, P4983, DOI 10.1074/jbc.M708644200; Kalab P, 2006, NATURE, V440, P697, DOI 10.1038/nature04589; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kobayashi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007827; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li ZL, 2010, MOL BIOL CELL, V21, P3317, DOI 10.1091/mbc.E10-03-0245; Li ZL, 2010, J BIOL CHEM, V285, P23699, DOI 10.1074/jbc.M110.123497; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Mannherz HG, 2005, EUR J CELL BIOL, V84, P503, DOI 10.1016/j.ejcb.2004.11.008; Maroto B, 2008, ONCOGENE, V27, P4900, DOI 10.1038/onc.2008.131; Menzel N, 2007, MECH DEVELOP, V124, P78, DOI 10.1016/j.mod.2006.09.007; Mitsushima M, 2009, MOL CELL BIOL, V29, P2816, DOI 10.1128/MCB.01713-08; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Nekrasova T, 2011, J CELL BIOCHEM, V112, P1795, DOI 10.1002/jcb.23092; Norman L, 2011, EUR J CELL BIOL, V90, P37, DOI 10.1016/j.ejcb.2010.09.013; O'Connell CB, 2000, MOL BIOL CELL, V11, P1765, DOI 10.1091/mbc.11.5.1765; Ozaki Y, 2011, J BIOL CHEM, V286, P5589, DOI 10.1074/jbc.M110.167742; Pearson CG, 2004, NAT REV MOL CELL BIO, V5, P481, DOI 10.1038/nrm1402; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Sillje HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Stevens D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022969; Toyoshima F, 2007, DEV CELL, V13, P796, DOI 10.1016/j.devcel.2007.10.014; Vigneron S, 2009, EMBO J, V28, P2786, DOI 10.1038/emboj.2009.228; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Whale A, 2011, FRONT BIOSCI-LANDMRK, V16, P849, DOI 10.2741/3724; Whyte J, 2008, J CELL BIOL, V183, P819, DOI 10.1083/jcb.200804114; Wong J, 2006, J CELL BIOL, V173, P879, DOI 10.1083/jcb.200511132; Wong LE, 2010, J CELL BIOCHEM, V110, P1244, DOI 10.1002/jcb.22639; Yanase Y, 2010, BIOCHEM J, V425, P179, DOI 10.1042/BJ20091122; Yang ZY, 2007, CURR BIOL, V17, P973, DOI 10.1016/j.cub.2007.04.056; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhou TH, 2006, P NATL ACAD SCI USA, V103, P9039, DOI 10.1073/pnas.0602916103; Zimmerman W, 2000, TRAFFIC, V1, P927, DOI 10.1034/j.1600-0854.2000.011202.x	62	29	29	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2013	32	7					910	919		10.1038/onc.2012.98	http://dx.doi.org/10.1038/onc.2012.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22450748	Green Published			2022-12-28	WOS:000316581100011
J	Zhou, X; Hao, Q; Liao, J; Zhang, Q; Lu, H				Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H.			Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress	ONCOGENE			English	Article						RPS14; p53; MDM2; RPS19; ribosomal stress	DIAMOND-BLACKFAN ANEMIA; N-TERMINAL DOMAIN; P53 ACTIVATION; NUCLEOLAR PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; CELL-PROLIFERATION; ONCOPROTEIN MDM2; UBIQUITIN LIGASE; C-TERMINUS	The MDM2-p53 feedback loop is crucially important for restricting p53 level and activity during normal cell growth and proliferation, and is thus subjected to dynamic regulation in order for cells to activate p53 upon various stress signals. Several ribosomal proteins, such as RPL11, RPL5, RPL23, RPL26 or RPS7, have been shown to have a role in regulation of this feedback loop in response to ribosomal stress. Here, we identify another ribosomal protein S14, which is highly associated with 5q-syndrome, as a novel activator of p53 by inhibiting MDM2 activity. We found that RPS14, but not RPS19, binds to the central acidic domain of MDM2, similar to RPL5 and RPL23, and inhibits its E3 ubiquitin ligase activity toward p53. This RPS14-MDM2 binding was induced upon ribosomal stress caused by actinomycin D or mycophenolic acid. Overexpression of RPS14, but not RPS19, elevated p53 level and activity, leading to G1 or G2 arrest. Conversely, knockdown of RPS14 alleviated p53 induction by these two reagents. Interestingly, knockdown of either RPS14 or RPS19 caused a ribosomal stress that led to p53 activation, which was impaired by further knocking down the level of RPL11 or RPL5. Together, our results demonstrate that RPS14 and RPS19 have distinct roles in regulating the MDM2-p53 feedback loop in response to ribosomal stress. Oncogene (2013) 32, 388-396; doi:10.1038/onc.2012.63; published online 5 March 2012	[Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA; [Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H.] Indiana Univ Sch Med, Ctr Canc, Indianapolis, IN USA; [Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H.] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H.] Tulane Univ, Sch Med, Ctr Canc, New Orleans, LA 70112 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Tulane University; Tulane University	Lu, H (corresponding author), Tulane Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	hlu2@tulane.edu	Zhou, Xiang/J-5046-2017	Zhou, Xiang/0000-0002-1172-7948	NIH-NCI [CA095441, CA 079721, CA129828]; NATIONAL CANCER INSTITUTE [R01CA079721, R01CA095441, R01CA129828] Funding Source: NIH RePORTER	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Steven Ellis for reagents and discussion. This work was supported in part by NIH-NCI Grants CA095441, CA 079721 and CA129828 to HL.	Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Cmejla R, 2009, HUM MUTAT, V30, P321, DOI 10.1002/humu.20874; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2008, MOL CELL BIOL, V28, P4365, DOI 10.1128/MCB.01662-07; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Dutt S, 2011, BLOOD, V117, P2567, DOI 10.1182/blood-2010-07-295238; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Holzel M, 2010, J BIOL CHEM, V285, P6364, DOI 10.1074/jbc.M109.054734; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Llanos S, 2010, CELL CYCLE, V9, P4005, DOI 10.4161/cc.9.19.13299; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; LUNA RMD, 1995, NATURE, V378, P203; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Poyurovsky MV, 2007, EMBO J, V26, P90, DOI 10.1038/sj.emboj.7601465; Poyurovsky MV, 2010, NAT STRUCT MOL BIOL, V17, P982, DOI 10.1038/nsmb.1872; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200; Sun XX, 2011, J BIOL CHEM, V286, P22730, DOI 10.1074/jbc.M111.223651; Sun XX, 2010, J BIOL CHEM, V285, P25812, DOI 10.1074/jbc.M109.098442; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Yadavilli S, 2009, DNA REPAIR, V8, P1215, DOI 10.1016/j.dnarep.2009.07.003; Yu WS, 2011, NUCLEIC ACIDS RES, V39, P2234, DOI 10.1093/nar/gkq1117; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Y, 2010, NUCLEIC ACIDS RES, V38, P6544, DOI 10.1093/nar/gkq536; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	60	110	113	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2013	32	3					388	396		10.1038/onc.2012.63	http://dx.doi.org/10.1038/onc.2012.63			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22391559	Green Accepted			2022-12-28	WOS:000314736600012
J	Bhavsar, PJ; Infante, E; Khwaja, A; Ridley, AJ				Bhavsar, P. J.; Infante, E.; Khwaja, A.; Ridley, A. J.			Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration	ONCOGENE			English	Article						Rho GTPases; acute lymphoblastic leukaemia; Notch1; RhoU; cell migration; cytoskeleton	ACUTE LYMPHOBLASTIC-LEUKEMIA; FAMILY; CANCER; TUMORIGENESIS; INFILTRATION; CYTOSKELETON; INHIBITION; RESISTANCE; REGULATORS; MUTATIONS	NOTCH1 is frequently mutated in T-cell acute lymphoblastic leukaemia (T-ALL), and can stimulate T-ALL cell survival and proliferation. Here we explore the hypothesis that Notch1 also alters T-ALL cell migration. Rho GTPases are well known to regulate cell adhesion and migration. We have analysed the expression levels of Rho GTPases in primary T-ALL samples compared with normal T cells by quantitative PCR. We found that 5 of the 20 human Rho genes are highly and consistently upregulated in T-ALL, and 3 further Rho genes are expressed in T-ALL but not detectable in normal T cells. Of these, RHOU expression is highly correlated with the expression of the Notch1 target DELTEX-1. Inhibition of Notch1 signalling with a gamma-secretase inhibitor (GSI) or Notch1 RNA interference reduced RhoU expression in T-ALL cells, whereas constitutively active Notch1 increased RhoU expression. In addition, Notch1 or RhoU depletion, or GSI treatment, inhibits T-ALL cell adhesion, migration and chemotaxis. These results indicate that NOTCH1 mutation stimulates T-ALL cell migration through RhoU upregulation that could contribute to the leukaemia cell dissemination. Oncogene (2013) 32, 198-208; doi:10.1038/onc.2012.42; published online 20 February 2012	[Bhavsar, P. J.; Infante, E.; Ridley, A. J.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Infante, E.] Guys & St Thomas NHS, Biomed Res Ctr, NIHR, London, England; [Khwaja, A.] UCL, UCL Canc Inst, London, England	University of London; King's College London; University of London; King's College London; University of London; University College London	Ridley, AJ (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	anne.ridley@kcl.ac.uk		Infante, Elvira/0000-0002-9883-8391; Ridley, Anne/0000-0001-8186-5708	Leukaemia and Lymphoma Research UK; Cancer Research UK; King's College London British Heart Foundation Centre of Excellence; Department of Health via National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre; King's College London; King's College Hospital NHS Foundation Trust; Cancer Research UK [15961] Funding Source: researchfish	Leukaemia and Lymphoma Research UK; Cancer Research UK(Cancer Research UK); King's College London British Heart Foundation Centre of Excellence; Department of Health via National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre(National Institute for Health Research (NIHR)); King's College London; King's College Hospital NHS Foundation Trust; Cancer Research UK(Cancer Research UK)	This work was supported by Leukaemia and Lymphoma Research UK, Cancer Research UK and King's College London British Heart Foundation Centre of Excellence. El was supported by the Department of Health via National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre Award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. We are grateful to Sarah Heasman for scientific discussion and guidance; Ritu Garg and Katrina Soderquest for technical assistance; Katherine Lawler for advice on statistical analysis; and Matthew Arno and Estibaliz Aldecoa-otalora Astarloa for assistance and advice on qPCR.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Aspenstrom P, 2007, EXP CELL RES, V313, P3673, DOI 10.1016/j.yexcr.2007.07.022; Aster JC, 2011, J PATHOL, V223, P262, DOI 10.1002/path.2789; Berthold J, 2008, ACTA PHARMACOL SIN, V29, P285, DOI 10.1111/j.1745-7254.2008.00773.x; Berthold J, 2008, EXP CELL RES, V314, P3453, DOI 10.1016/j.yexcr.2008.09.005; Bhojwani D, 2009, CLIN LYMPHOMA MYELOM, V9, pS222, DOI 10.3816/CLM.2009.s.016; Boureux A, 2007, MOL BIOL EVOL, V24, P203, DOI 10.1093/molbev/msl145; Brazier H, 2009, INT J BIOCHEM CELL B, V41, P1391, DOI 10.1016/j.biocel.2008.12.007; Buonamici S, 2009, NATURE, V459, P1000, DOI 10.1038/nature08020; Chang FK, 2006, J MOL BIOL, V364, P302, DOI 10.1016/j.jmb.2006.09.026; Chuang YY, 2007, J CELL SCI, V120, P1927, DOI 10.1242/jcs.03456; Crazzolara R, 2001, BRIT J HAEMATOL, V115, P545, DOI 10.1046/j.1365-2141.2001.03164.x; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Ferrando Adolfo A, 2009, Hematology Am Soc Hematol Educ Program, P353, DOI 10.1182/asheducation-2009.1.353; Fort P, 2011, DEV BIOL, V350, P451, DOI 10.1016/j.ydbio.2010.12.011; Fueller Florian, 2008, Cell Commun Signal, V6, P6, DOI 10.1186/1478-811X-6-6; Graux C, 2006, LEUKEMIA, V20, P1496, DOI 10.1038/sj.leu.2404302; Hayday AC, 2007, NAT IMMUNOL, V8, P137, DOI 10.1038/ni1436; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heasman SJ, 2010, J CELL BIOL, V190, P553, DOI 10.1083/jcb.201002067; Huang M, 2006, HISTOL HISTOPATHOL, V21, P213, DOI 10.14670/HH-21.213; Hubsman MW, 2007, BIOCHEM J, V404, P487, DOI 10.1042/BJ20061696; Infante E, 2011, J LEUKOCYTE BIOL, V89, P577, DOI 10.1189/jlb.0810441; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Palomero T, 2006, BLOOD, V108, P986, DOI 10.1182/blood-2005-08-3482; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Pieters R, 2008, PEDIATR CLIN N AM, V55, P1, DOI 10.1016/j.pcl.2007.11.002; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Riou P, 2010, BIOESSAYS, V32, P986, DOI 10.1002/bies.201000060; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Symons M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-213; Takesono A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008774; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Tybulewicz VLJ, 2009, NAT REV IMMUNOL, V9, P630, DOI 10.1038/nri2606; van Grotel M, 2008, LEUKEMIA, V22, P124, DOI 10.1038/sj.leu.2404957; Van Hennik PB, 2005, ANTIOXID REDOX SIGN, V7, P1440, DOI 10.1089/ars.2005.7.1440; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vicente R, 2010, SEMIN IMMUNOL, V22, P270, DOI 10.1016/j.smim.2010.04.016; Wang H, 2010, CELL SIGNAL, V22, P1022, DOI 10.1016/j.cellsig.2010.02.005; Weerkamp F, 2006, LEUKEMIA, V20, P1197, DOI 10.1038/sj.leu.2404255; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wolfe MS, 2009, SEMIN CELL DEV BIOL, V20, P219, DOI 10.1016/j.semcdb.2008.12.011; Yanez-Mo M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004	53	27	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					198	208		10.1038/onc.2012.42	http://dx.doi.org/10.1038/onc.2012.42			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349824	Green Accepted			2022-12-28	WOS:000314075500008
J	Kumar, SM; Liu, S; Lu, H; Zhang, H; Zhang, PJ; Gimotty, PA; Guerra, M; Guo, W; Xu, X				Kumar, S. M.; Liu, S.; Lu, H.; Zhang, H.; Zhang, P. J.; Gimotty, P. A.; Guerra, M.; Guo, W.; Xu, X.			Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation	ONCOGENE			English	Article						Oct4; cancer stem cell; melanoma; dedifferentiation; hypoxia	MELANOMA-CELLS; INITIATING CELLS; GENE-EXPRESSION; HYPOXIA; DIFFERENTIATION; PROMOTES; OCT4; SUBPOPULATION; PLURIPOTENCY; GENERATION	There is enormous interest to target cancer stem cells (CSCs) for clinical treatment because these cells are highly tumorigenic and resistant to chemotherapy. Oct4 is expressed by CSC-like cells in different types of cancer. However, function of Oct4 in tumor cells is unclear. In this study, we showed that expression of Oct4 gene or transmembrane delivery of Oct4 protein promoted dedifferentiation of melanoma cells to CSC-like cells. The dedifferentiated melanoma cells showed significantly decreased expression of melanocytic markers and acquired the ability to form tumor spheroids. They showed markedly increased resistance to chemotherapeutic agents and hypoxic injury. In the subcutaneous xenograft and tail vein injection assays, these cells had significantly increased tumorigenic capacity. The dedifferentiated melanoma cells acquired features associated with CSCs such as multipotent differentiation capacity and expression of melanoma CSC markers such as ABCB5 and CD271. Mechanistically, Oct4-induced dedifferentiation was associated with increased expression of endogenous Oct4, Nanog and Klf4, and global gene expression changes that enriched for transcription factors. RNAi-mediated knockdown of Oct4 in dedifferentiated cells led to diminished CSC phenotypes. Oct4 expression in melanoma was regulated by hypoxia and its expression was detected in a sub-population of melanoma cells in clinical samples. Our data indicate that Oct4 is a positive regulator of tumor dedifferentiation. The results suggest that CSC phenotype is dynamic and may be acquired through dedifferentiation. Oct4-mediated tumor cell dedifferentiation may have an important role during tumor progression. Oncogene (2012) 31, 4898-4911; doi:10.1038/onc.2011.656; published online 30 January 2012	[Xu, X.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Lu, H.; Guo, W.] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [Gimotty, P. A.; Guerra, M.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Xu, X (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA.	xug@mail.med.upenn.edu	Gimotty, Phyllis/GWZ-4136-2022	Gimotty, Phyllis/0000-0002-3850-9799; Zhang, Hongtao/0000-0001-9173-0049; Liu, Shujing/0000-0002-2958-093X	National Institute of Health [AR-054593, CA-116103, CA-093372]; NATIONAL CANCER INSTITUTE [P50CA093372, R21CA116103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085146] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr M Herlyn (The Wistar Institute) for providing the melanoma cell lines; Dr GQ Daley (Harvard) for providing shRNA to Oct4; Dr W Lee (University of Pennsylvania) for suggestions to manuscript editing. This work was supported by the grants AR-054593, CA-116103 and CA-093372 from National Institute of Health to XX.	Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENNETT DC, 1983, CELL, V34, P445, DOI 10.1016/0092-8674(83)90378-1; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Chan EM, 2009, NAT BIOTECHNOL, V27, P1033, DOI 10.1038/nbt.1580; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Chen Z, 2009, J SURG ONCOL, V99, P414, DOI 10.1002/jso.21270; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Daley GQ, 2008, COLD SH Q B, V73, P171, DOI 10.1101/sqb.2008.73.041; GABBERT H, 1985, CLIN EXP METASTAS, V3, P257, DOI 10.1007/BF01585081; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Helczynska K, 2003, CANCER RES, V63, P1441; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Kang SK, 2006, STEM CELLS DEV, V15, P423, DOI 10.1089/scd.2006.15.423; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Kim JB, 2009, NATURE, V461, P649, DOI 10.1038/nature08436; Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023; Kumar SM, 2007, CANCER RES, V67, P3177, DOI 10.1158/0008-5472.CAN-06-3312; Li WL, 2009, STEM CELLS, V27, P2992, DOI 10.1002/stem.240; Li ZZ, 2010, CURR TOP MICROBIOL, V345, P21, DOI 10.1007/82_2010_75; Liu T, 2010, MOL CELL BIOCHEM, V340, P265, DOI 10.1007/s11010-010-0426-5; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Masuda K, 2006, ONCOGENE, V25, P7740, DOI 10.1038/sj.onc.1209745; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; Morrison SJ, 2000, J NEUROSCI, V20, P7370; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; Strizzi L, 2008, CELL CYCLE, V7, P1931, DOI 10.4161/cc.7.13.6236; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Yu H, 2010, J INVEST DERMATOL, V130, P1227, DOI 10.1038/jid.2009.322; Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482; Zaehres H, 2005, STEM CELLS, V23, P299, DOI 10.1634/stemcells.2004-0252; Zhang XY, 2010, JPN J CLIN ONCOL, V40, P961, DOI 10.1093/jjco/hyq066; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005	46	230	243	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	47					4898	4911		10.1038/onc.2011.656	http://dx.doi.org/10.1038/onc.2011.656			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22286766	Green Accepted			2022-12-28	WOS:000311430200002
J	Li, X; Gao, L; Cui, Q; Gary, BD; Dyess, DL; Taylor, W; Shevde, LA; Samant, RS; Dean-Colomb, W; Piazza, GA; Xi, Y				Li, X.; Gao, L.; Cui, Q.; Gary, B. D.; Dyess, D. L.; Taylor, W.; Shevde, L. A.; Samant, R. S.; Dean-Colomb, W.; Piazza, G. A.; Xi, Y.			Sulindac inhibits tumor cell invasion by suppressing NF-kappa B-mediated transcription of microRNAs	ONCOGENE			English	Article						sulindac; invasion; microRNA; NF-kappa B	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER; BREAST-CANCER; REDUCED EXPRESSION; E-CADHERIN; RT-PCR; APOPTOSIS; INDUCTION; GENES; METASTASIS	Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely reported to display strong efficacy for cancer chemoprevention, although their mechanism of action is poorly understood. The most well-documented effects of NSAIDs include inhibition of tumor cell proliferation and induction of apoptosis, but their effect on tumor cell invasion has not been well studied. Here, we show that the NSAID, sulindac sulfide (SS) can potently inhibit the invasion of human MDA-MB-231 breast and HCT116 colon tumor cells in vitro at concentrations less than those required to inhibit tumor cell growth. To study the molecular basis for this activity, we investigated the involvement of microRNA (miRNA). A total of 132 miRNAs were found to be altered in response to SS treatment, including miR-10b, miR-17, miR-21 and miR-9, which have been previously implicated in tumor invasion and metastasis. We confirmed that these miRNA can stimulate tumor cell invasion and show that SS can attenuate their invasive effects by downregulating their expression. Employing luciferase and chromatin immunoprecipitation assays, NF-kappa B was found to bind the promoters of all four miRNAs to suppress their expression at the transcriptional level. We show that SS can inhibit the translocation of NF-kappa B to the nucleus by decreasing the phosphorylation of IKK beta and I kappa B. Analysis of the promoter sequences of the miRNAs suppressed by SS revealed that 81 of 115 sequences contained NF-kappa B-binding sites. These results show that SS can inhibit tumor cell invasion by suppressing NF-kappa B-mediated transcription of miRNAs. Oncogene (2012) 31, 4979-4986; doi:10.1038/onc.2011.655; published online 30 January 2012	[Li, X.; Gao, L.; Gary, B. D.; Taylor, W.; Shevde, L. A.; Samant, R. S.; Dean-Colomb, W.; Piazza, G. A.; Xi, Y.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36604 USA; [Cui, Q.] Peking Univ, Hlth Sci Ctr, Dept Biomed Informat, Beijing 100871, Peoples R China; [Dyess, D. L.] Univ S Alabama, Dept Surg, Mobile, AL 36604 USA	University of South Alabama; Peking University; University of South Alabama	Xi, Y (corresponding author), Univ S Alabama, Mitchell Canc Inst, 1660 Springhill Ave, Mobile, AL 36604 USA.	xi@usouthal.edu		Xi, Yaguang/0000-0003-3681-9352; Samant, Rajeev/0000-0001-5681-4976; Piazza, Gary/0000-0003-4418-887X	National Cancer Institute [R01CA148817]; NATIONAL CANCER INSTITUTE [R01CA148817, R01CA155638, R01CA140472, R21CA160280, R01CA131378] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the institutional start-up funding (Dr Yaguang Xi) and the National Cancer Institute grant R01CA148817 (Dr Gary A Piazza). We sincerely appreciate Mrs Margaret Sullivan for proof-reading the manuscript.	Agarwal B, 2003, APOPTOSIS, V8, P649, DOI 10.1023/A:1026199929747; ALBERTS DS, 1995, J CELL BIOCHEM, P18; Altuvia Y, 2005, NUCLEIC ACIDS RES, V33, P2697, DOI 10.1093/nar/gki567; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Brown JWS, 2008, TRENDS PLANT SCI, V13, P335, DOI 10.1016/j.tplants.2008.04.010; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Gefen N, 2010, LEUKEMIA, V24, P89, DOI 10.1038/leu.2009.208; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Huang GL, 2009, ONCOL REP, V21, P673, DOI 10.3892/or_00000270; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jiang MC, 2001, BIOCHEM BIOPH RES CO, V282, P671, DOI 10.1006/bbrc.2001.4637; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Kashfi K, 2005, BIOCHEM PHARMACOL, V70, P969, DOI 10.1016/j.bcp.2005.05.004; Lee HC, 2005, J CELL BIOCHEM, V94, P597, DOI 10.1002/jcb.20312; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li HL, 2011, BREAST CANCER RES TR, V126, P565, DOI 10.1007/s10549-010-0954-4; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; LUNDHOLM K, 1994, CANCER RES, V54, P5602; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Piazza GA, 1997, CANCER RES, V57, P2452; Piazza GA, 2009, CANCER PREV RES, V2, P572, DOI 10.1158/1940-6207.CAPR-09-0001; Rigas B, 2000, MED HYPOTHESES, V54, P210, DOI 10.1054/mehy.1999.0023; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Seo AM, 2009, APOPTOSIS, V14, P913, DOI 10.1007/s10495-009-0367-1; Shah SA, 2006, INT J CANCER, V118, P532, DOI 10.1002/ijc.21365; Singh B, 2006, J SURG RES, V131, P267, DOI 10.1016/j.jss.2005.11.582; Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489; Smalley W, 1999, ARCH INTERN MED, V159, P161, DOI 10.1001/archinte.159.2.161; Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29; Stein U, 2011, NEOPLASIA, V13, P131, DOI 10.1593/neo.101172; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Thompson HJ, 1997, CANCER RES, V57, P267; Varkonyi-Gasic E, 2007, PLANT METHODS, V3, DOI 10.1186/1746-4811-3-12; Wang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017167; Xi YG, 2007, RNA, V13, P1668, DOI 10.1261/rna.642907; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zhou R, 2010, NUCLEIC ACIDS RES, V38, P3222, DOI 10.1093/nar/gkq056; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	73	58	60	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					4979	4986		10.1038/onc.2011.655	http://dx.doi.org/10.1038/onc.2011.655			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22286762	Green Accepted			2022-12-28	WOS:000311888600002
J	Lo, PK; Kanojia, D; Liu, X; Singh, UP; Berger, FG; Wang, Q; Chen, H				Lo, P-K; Kanojia, D.; Liu, X.; Singh, U. P.; Berger, F. G.; Wang, Q.; Chen, H.			CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGF beta signaling	ONCOGENE			English	Article						tumor-initiating cells; Her2/neu; mammary tumor; CD49f; CD61; ESA	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; STEM-CELLS; II RECEPTOR; EXPRESSION; MOUSE; GLAND; TUMORIGENESIS; POPULATION; TGF-BETA-1	Human epidermal growth factor receptor 2 (HER2)/Neu is overexpressed in 20-30% of breast cancers and associated with aggressive phenotypes and poor prognosis. For deciphering the role of HER2/Neu in breast cancer, mouse mammary tumor virus (MMTV)-Her2/neu transgenic mice that develop mammary tumors resembling human HER2-subtype breast cancer have been established. Several recent studies have revealed that HER2/Neu is overexpressed in and regulates self renewal of breast tumor-initiating cells (TICs). However, in the MMTV-Her2/neu transgenic mouse model, the identity of TICs remains elusive, despite previous studies showing supportive evidence for existence of TICs in Her2/neu-induced mammary tumors. Through systematic screening and characterization, we identified that surface markers CD49f, CD61 and ESA were aberrantly overexpressed in Her2-overexpressing mammary tumor cells. Analysis of these markers and CD24 detected anomalous expansion of the luminal progenitor population in preneoplastic mammary glands of Her2/neu transgenic mice, indicating that aberrant luminal progenitors originated in Her2-induced mammary tumors. The combined markers, CD49f and CD61, further delineated the CD49f(high)CD61(high)-sorted fraction as a TIC-enriched population, which displayed increased tumorsphere formation ability, enhanced tumorigenicity both in vitro and in vivo and drug resistance to pacitaxel and doxorubicin. Moreover, the TIC-enriched population manifested increased transforming growth factor-beta (TGF beta) signaling and exhibited gene expression signatures of stemness, TGF beta signaling and epithelial-to-mesenchymal transition. Our findings that self-renewal and clonogenicity of TICs were suppressed by pharmacologically inhibiting the TGF beta signaling further indicate that the TGF beta pathway is vital for maintenance of the TIC population. Finally, we showed that the integrin-beta 3 (CD61) signaling pathway was required for sustaining active TGF beta signaling and self-renewal of TICs. We for the first time developed a technique to highly enrich TICs from mammary tumors of Her2/neu transgenic mice, unraveled their properties and identified the cooperative integrin-beta 3-TGF beta signaling axis as a potential therapeutic target for HER2-induced TICs. Oncogene (2012) 31, 2614-2626; doi:10.1038/onc.2011.439; published online 26 September 2011	[Lo, P-K; Kanojia, D.; Berger, F. G.; Chen, H.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; [Lo, P-K; Kanojia, D.; Berger, F. G.; Wang, Q.; Chen, H.] Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA; [Liu, X.] Univ S Carolina, Dept Math, Columbia, SC 29208 USA; [Singh, U. P.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA; [Wang, Q.] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Chen, H (corresponding author), Univ S Carolina, Dept Biol Sci, 715 Sumter St,PSC621, Columbia, SC 29208 USA.	hchen@biol.sc.edu	Kanojia, Deepak/G-5120-2014; chen, hexin/F-1714-2011	Kanojia, Deepak/0000-0003-4295-4972; Wang, Qian/0000-0002-2149-384X; Singh, Udai/0000-0002-7048-4325	Elsa U Pardee Cancer Foundation [B94AFFAA]; American Cancer Society [RSG-10-067-01-TBE]; NIH [3P20RR017698-08]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017698] Funding Source: NIH RePORTER	Elsa U Pardee Cancer Foundation; American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Marai M Pena, Celestia Davis, Sara Johnson and Andrea Daamen for experimental assistance. This work was supported by the Elsa U Pardee Cancer Foundation grant (B94AFFAA), the American Cancer Society Research Award (RSG-10-067-01-TBE) to HC and NIH grant (3P20RR017698-08) to HC and QW.	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Biswas S, 2006, CLIN CANCER RES, V12, P4142, DOI 10.1158/1078-0432.CCR-06-0952; Chen HX, 2010, PROTEOMICS, V10, P3800, DOI 10.1002/pmic.201000297; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524; Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gu Y.B., 2011, J BIOTECH RES, V3, P7; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanker L, 2010, BREAST CANCER RES TR, V122, P765, DOI 10.1007/s10549-009-0608-6; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; Ishikawa Toshihisa, 2009, J Exp Ther Oncol, V8, P5; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kveiborg M., 2001, Journal of Endocrinology, V169, P549, DOI 10.1677/joe.0.1690549; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Margadant C, 2010, EMBO REP, V11, P97, DOI 10.1038/embor.2009.276; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Scaffidi AK, 2004, J BIOL CHEM, V279, P37726, DOI 10.1074/jbc.M403010200; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Welm B, 2003, CELL PROLIFERAT, V36, P17, DOI 10.1046/j.1365-2184.36.s.1.3.x; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yang C, 2007, EXP CELL RES, V313, P1240, DOI 10.1016/j.yexcr.2007.01.011	38	149	155	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2614	2626		10.1038/onc.2011.439	http://dx.doi.org/10.1038/onc.2011.439			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21996747	Green Accepted			2022-12-28	WOS:000304523500002
